RELATION_ID,CONCEPT1_ID,CONCEPT2_ID,RELATION_TYPE,C1_NAME,C2_NAME,WEIGHT,SENTENCE,C1_SEMTYPES,C2_SEMTYPES,C1_MESHTREENUM,C2_MESHTREENUM
064e1ef8-84ce-4a10-97c5-222c84ba00ce,C1422064,C3266262,using large-scale omics ,ACE2 gene,Multiple Chronic Conditions,1,X,[gngm],[dsyn],,C23.550.291.500.500
701f3305-91e3-4d3f-b9df-164e17cebaec,C1422064,omics,using large-scale omics ,ACE2 gene,omics,1,X,[gngm],????,,????
6f54654c-af44-43ac-932a-cf9e03896776,C1422064,C0178784,using data from 30,ACE2 gene,Organ,2,X,[gngm],[bpoc],,
8a31d658-6148-4fce-9b60-22dab732c9c2,C1422064,C0040300,using data from 30,ACE2 gene,Body tissue,2,X,[gngm],[tisu],,A10
8a31d658-6148-4fce-9b60-22dab732c9c2,C1422064,C0040300,were widely disturbed among ,ACE2 gene,Body tissue,5,X,[gngm],[tisu],,A10
cb202232-7470-45a1-9505-adf764b6602e,C1422064,C1175743,receptor for,ACE2 gene,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
cb202232-7470-45a1-9505-adf764b6602e,C1422064,C1175743,point for ,ACE2 gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
831aae73-5c7d-4df9-b86a-e8564d20ab33,C1422064,C0279671,was up-regulated in ,ACE2 gene,Cervical Squamous Cell Carcinoma,2,X,[gngm],[neop],,
d054d0dd-6f78-4e6f-88be-c3ea4d2c5d4d,C1422064,C0008679,patients with common ,ACE2 gene,Chronic disease,1,X,[gngm],[dsyn],,C23.550.291.500
e46af6ac-eeb0-4030-81f2-e179f9a997fa,C0012634,C0012655,could lead to their higher ,Disease,Disease susceptibility,2,X,[dsyn],[clna],C23.550.288,C23.550.291.687;G07.100.250
e46af6ac-eeb0-4030-81f2-e179f9a997fa,C0012634,C0012655,potentially influence ,Disease,Disease susceptibility,2,X,[dsyn],[clna],C23.550.288,C23.550.291.687;G07.100.250
8fe55fdc-1389-4687-947e-fd7e0f26cc29,C0206750,C1825598,reducing ,Coronavirus Infections,IMPACT gene,33,X,[dsyn],[gngm],C02.782.600.550.200,
ca9edbb2-e284-4812-b822-827348ee3aa7,non-at,C0021053,is with ,non-at,Immune System Diseases,2,X,????,[dsyn],????,C20
8a499480-1e53-40c9-b188-84f5f6d4d95a,non-at,C0037274,is with ,non-at,Dermatologic disorders,1,X,????,[dsyn],????,C17.800
b4246223-89d2-4929-9e40-aa6f524ae209,C1609165,C0206750,is under Given its approval investigation in ,tocilizumab,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
b4246223-89d2-4929-9e40-aa6f524ae209,C1609165,C0206750,may may beneficial for severe ,tocilizumab,Coronavirus Infections,2,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
b4246223-89d2-4929-9e40-aa6f524ae209,C1609165,C0206750,has has proposed to ,tocilizumab,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
fd9d79fe-9047-437e-ada8-b8be5d85ee45,C1609165,C1412268,with events is ,tocilizumab,AES gene,2,X,[aapp/imft/phsu],[gngm],x.x.x.x,
38575479-1068-4387-95e8-55fbda51ce03,C1707391,C1412268,with events is ,Choose (action),AES gene,2,X,[acty],[gngm],,
f9184344-a248-4c3b-9846-edaed45c3f65,C1412268,C0369718,as Drug-Induced Liver Disease is,AES gene,N not otherwise specified Antibody,2,X,[gngm],[aapp/imft],,
58fd982a-40cf-4e26-b5c9-04696a0f5afb,C0589104,C1947933,is in ,Process training,care activity,2,X,[topp],[acty],,
878b651a-107e-4036-bc91-6d7ebafa6f2e,C0278996,C0020517,are clinically time ,Malignant Head and Neck Neoplasm,Hypersensitivity,3,X,[neop],[patf],,C20.543
552f1ec3-d3f1-4871-ba71-fafdf9642619,C0543467,C0038952,alter individuals chance of ,Operative Surgical Procedures,Continuance of life,3,X,[topp],[acty],E04,I03.784
45978521-91bc-423a-975b-d11295aada82,C1947933,C0007189,should follow 2019 Update to Society of ,care activity,Cardiology discipline,1,X,[acty],[bmod],,H02.403.429.163
866202b5-77bb-4a89-895f-8d0c95a97c3d,C1947933,C0007203,should follow 2019 Update to Society of ,care activity,Cardiopulmonary Resuscitation,1,X,[acty],[topp],,E02.365.647.110
c9000019-6b0d-4e01-a196-5f3b3635f7fa,C0042769,C0960756,is ,Virus Diseases,factor A,4,X,[dsyn],[orch],C02,x.x.x.x
0ce2a98e-3eca-4f4d-b576-9c2d8641ee52,C0042769,C0032930,is ,Virus Diseases,Precipitating Factors,2,X,[dsyn],[clna],C02,N05.715.350.200.650;N06.850.490.625.500
23029117-848a-4cee-8a74-5b30047f5f2c,C0042769,C0004096,is ,Virus Diseases,Asthma,3,X,[dsyn],[dsyn],C02,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
49747e0a-a616-4196-bf8c-bf4d59971a16,C2348077,C1175175,is with two episodes of ,Date Fruit,Severe Acute Respiratory Syndrome,1,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,C02.782.600.550.200.750;C08.730.730
c2c583a3-ebb7-4946-a72f-bef6ac6a620c,HWC,C1856053,was launched on ,HWC,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,????,[dsyn],????,x.x.x.x
7afc7fea-736e-48a0-bfb3-453248d73f58,HWC,C1706374,was launched on ,HWC,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
f0037dfd-242a-492b-b970-010ee6c2a4d6,C1175743,C0034019,serious threat to global ,SARS coronavirus,public health medicine (field),30,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.720;N01.400.550;N06.850
ced690b8-3a96-4acf-b24d-3679878100c0,C1175743,C2745965,was declared pandemic health ,SARS coronavirus,Emergencies [Disease/Finding],16,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.291.781;N06.230.100.083;N06.850.376
988c519d-c4db-4042-bba1-78d43416e276,C1175743,C0206750,with patients is ,SARS coronavirus,Coronavirus Infections,261,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
75b4a89a-7833-42c4-95c6-d4073239fdb5,C1175743,C0012634,with patients is ,SARS coronavirus,Disease,71,X,[virs],[dsyn],B04.820.504.540.150.113.937,C23.550.288
3ca60640-cb61-4844-8a8f-55179fc78c37,C0319157,C0042765,is hypothesized increased ,AS virus,Virulence,7,X,[virs],[biof],,G06.930
053d817e-24dc-4b7d-b685-530605bca462,C0035736,C1521806,unexpectedly been detected in multiple bodily ,RNA Viral,Body Fluids and Substances,3,X,[nnon],[tisu],D13.444.735.828,
acce62ad-1663-42d0-aa98-b179185d3e9b,C0035736,C0370003,was detected in of ,RNA Viral,Specimen,16,X,[nnon],[sbst],D13.444.735.828,
79b66016-2a2b-4db0-9858-902fff72f9cf,C0319157,C0007634,gains ,AS virus,Cells,1,X,[virs],[cell],,A11
79b66016-2a2b-4db0-9858-902fff72f9cf,C0319157,C0007634,entered ,AS virus,Cells,1,X,[virs],[cell],,A11
17068c0a-2a95-483f-91a4-aa39f267a4c5,C0597357,C0086418,be expressed in different ,receptor,Homo sapiens,1,X,[aapp/rcpt],[humn],,B01.050.150.900.649.313.988.400.112.400.400
17068c0a-2a95-483f-91a4-aa39f267a4c5,C0597357,C0086418,are present in ,receptor,Homo sapiens,3,X,[aapp/rcpt],[humn],,B01.050.150.900.649.313.988.400.112.400.400
e9b12e69-7807-412d-93d6-811738827d30,C0319157,C1422064,gains ,AS virus,ACE2 gene,2,X,[virs],[gngm],,
699374d5-7426-4446-9bfa-0d67eb1f32b7,C0021853,C0009368,is in ,Intestines,Colon structure (body structure),5,X,[bpoc],[bpoc],A03.556.124,A03.556.124.526.356;A03.556.249.249.356
2d6fa999-8b4f-42ff-b4fd-3938cd2994c6,C0598312,C0021853,is in ,DNA Replication,Intestines,4,X,[genf],[bpoc],G02.111.225;G05.226,A03.556.124
ff5fa743-c64b-4ca6-af67-bb56eea8655b,C0206750,C0149978,is with ,Coronavirus Infections,Adenocarcinoma of rectum,7,X,[dsyn],[neop],C02.782.600.550.200,
1723302b-8f96-48e7-ace5-12d4c0368e0f,RT-PCR,C1292533,was performed on rectal ,RT-PCR,Tissue specimen,3,X,????,[tisu],????,
545ba38e-b08b-4df0-8d75-3bfa286a731b,RT-PCR,C0015252,was performed on rectal ,RT-PCR,removal technique,3,X,????,[topp],????,
e118ba1a-c0f3-4b3b-9b7c-129885a7f7be,C1522472,C1175743,were observed for ,section sample,SARS coronavirus,10,X,[sbst],[virs],,B04.820.504.540.150.113.937
79022121-1666-4fd6-a582-127ca391a9bc,C0677043,C0018964,using ,Histopathology,Hematoxylin,8,X,[bmod],[irda/orch],,D03.383.663.283.600;D03.633.100.150.600
ea0ca14e-5150-4d56-bf62-7c18b71b4cd9,C0677043,C0014448,using ,Histopathology,Eosine Yellowish,4,X,[bmod],[chvf/orch],,D02.455.426.779.347.325;D03.633.300.953.275.325;D04.711.347.325
0df0bb1a-523d-4f93-8bcc-015151c4f27f,C0010200,C0206750,was diagnosed with ,Coughing,Coronavirus Infections,7,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200
0df0bb1a-523d-4f93-8bcc-015151c4f27f,C0010200,C0206750,were most common symptoms of ,Coughing,Coronavirus Infections,4,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200
0df0bb1a-523d-4f93-8bcc-015151c4f27f,C0010200,C0206750,including Coronavirus Infections is,Coughing,Coronavirus Infections,2,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200
fadeeea5-c37c-4834-b23c-26d602db2b27,C0028606,C0206750,positive for typical ,Nucleic Acids,Coronavirus Infections,6,X,[bacs/nnon],[dsyn],D13.444,C02.782.600.550.200
58aa45dd-103d-47a2-b3e8-e784df385854,C0028606,C0042760,positive for typical ,Nucleic Acids,Virion,3,X,[bacs/nnon],[celc],D13.444,A21.249;B04.950
c192f266-79b7-4368-ae92-750ce6440f19,C0028606,C0040300,positive for typical ,Nucleic Acids,Body tissue,3,X,[bacs/nnon],[tisu],D13.444,A10
c3d5a935-b2b2-4d15-8745-b3c44c8d30ac,C0206750,C0040300,is in rectal ,Coronavirus Infections,Body tissue,4,X,[dsyn],[tisu],C02.782.600.550.200,A10
c3d5a935-b2b2-4d15-8745-b3c44c8d30ac,C0206750,C0040300,is associated with particularly facultative progenitors of ,Coronavirus Infections,Body tissue,1,X,[dsyn],[tisu],C02.782.600.550.200,A10
d3b2652f-095d-4806-91a7-39f1df98bdde,C0042760,C0040300,is in rectal ,Virion,Body tissue,4,X,[celc],[tisu],A21.249;B04.950,A10
d3b2652f-095d-4806-91a7-39f1df98bdde,C0042760,C0040300,progenitors of ,Virion,Body tissue,1,X,[celc],[tisu],A21.249;B04.950,A10
aa730d74-0682-4f42-8ccc-dfab5edd291f,C0028606,C1175743,positive for ,Nucleic Acids,SARS coronavirus,3,X,[bacs/nnon],[virs],D13.444,B04.820.504.540.150.113.937
aa730d74-0682-4f42-8ccc-dfab5edd291f,C0028606,C1175743,antibodies-based test for ,Nucleic Acids,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.444,B04.820.504.540.150.113.937
db0dbd8a-c5bc-4718-9274-7ecdb18b8994,C1175743,C0040300,is in combination with morphological findings from postmortem ,SARS coronavirus,Body tissue,7,X,[virs],[tisu],B04.820.504.540.150.113.937,A10
6591c4b3-aeb3-4594-afce-1490d3f4fc75,C0598312,C0034896,is in patients ,DNA Replication,Rectum,3,X,[genf],[bpoc],G02.111.225;G05.226,A03.556.124.526.767;A03.556.249.249.767
1d6c6117-724d-40c9-bbc4-631800052ef0,C1175743,C0007634,uses membrane form as,SARS coronavirus,Cells,9,X,[virs],[cell],B04.820.504.540.150.113.937,A11
d325b16f-2e31-41a7-8310-0c5e760a864e,C0086418,C1422064,exhibits greater ,Homo sapiens,ACE2 gene,1,X,[humn],[gngm],B01.050.150.900.649.313.988.400.112.400.400,
4430a78d-b73e-49bc-909a-6c368b4b5feb,C0018787,C1422064,exhibits greater ,Heart,ACE2 gene,1,X,[bpoc],[gngm],A07.541,
4430a78d-b73e-49bc-909a-6c368b4b5feb,C0018787,C1422064,also express ,Heart,ACE2 gene,1,X,[bpoc],[gngm],A07.541,
9162f6cf-fa4b-45f6-9778-41554d6293b6,C0086418,C0024109,exhibits ACE2 gene expression Compared with,Homo sapiens,Lung,2,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.411
9162f6cf-fa4b-45f6-9778-41554d6293b6,C0086418,C0024109,exhibits Peptidyl-Dipeptidase A expression Compared with,Homo sapiens,Lung,1,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.411
9162f6cf-fa4b-45f6-9778-41554d6293b6,C0086418,C0024109,sustained high loads in ,Homo sapiens,Lung,3,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.411
13cd9c8a-2924-4113-a5bc-5e0dfb0bb947,C0018787,C0024109,exhibits ACE2 gene expression Compared with,Heart,Lung,2,X,[bpoc],[bpoc],A07.541,A04.411
13cd9c8a-2924-4113-a5bc-5e0dfb0bb947,C0018787,C0024109,exhibits Peptidyl-Dipeptidase A expression Compared with,Heart,Lung,1,X,[bpoc],[bpoc],A07.541,A04.411
a753eb7d-66f2-41a1-b0b9-42320a934da7,C0018787,C0206750,is in ,Heart,Coronavirus Infections,4,X,[bpoc],[dsyn],A07.541,C02.782.600.550.200
9835bc5f-b864-4b88-ac8a-01fe8df5b68d,C0029896,C0206750,is in ,Otorhinolaryngologic Diseases,Coronavirus Infections,3,X,[dsyn],[dsyn],C09,C02.782.600.550.200
f94c6c49-85a2-42e8-9f38-9753b9f54f57,C1422064,C0024109,is higher than that in ,ACE2 gene,Lung,3,X,[gngm],[bpoc],,A04.411
f94c6c49-85a2-42e8-9f38-9753b9f54f57,C1422064,C0024109,were widely disturbed among ,ACE2 gene,Lung,4,X,[gngm],[bpoc],,A04.411
f94c6c49-85a2-42e8-9f38-9753b9f54f57,C1422064,C0024109,is expressed in ,ACE2 gene,Lung,1,X,[gngm],[bpoc],,A04.411
82d0c645-9bdc-487a-adb4-ddbd653d5746,C1422064,C0018787,is in adult human ,ACE2 gene,Heart,2,X,[gngm],[bpoc],,A07.541
82d0c645-9bdc-487a-adb4-ddbd653d5746,C1422064,C0018787,is relatively more highly expressed in ,ACE2 gene,Heart,1,X,[gngm],[bpoc],,A07.541
82d0c645-9bdc-487a-adb4-ddbd653d5746,C1422064,C0018787,were widely disturbed among ,ACE2 gene,Heart,4,X,[gngm],[bpoc],,A07.541
8bf6f704-2395-4cad-b028-62e741363b40,C4281807,C0018787,is in adult human ,Vitronectin human,Heart,3,X,[aapp/bacs],[bpoc],,A07.541
bbd589bf-eae4-4f05-af86-2e18ee3cfd3d,C0024109,C1175743,may restrict entry of ,Lung,SARS coronavirus,3,X,[bpoc],[virs],A04.411,B04.820.504.540.150.113.937
bbd589bf-eae4-4f05-af86-2e18ee3cfd3d,C0024109,C1175743,are damaged due to presence of ,Lung,SARS coronavirus,1,X,[bpoc],[virs],A04.411,B04.820.504.540.150.113.937
bbd589bf-eae4-4f05-af86-2e18ee3cfd3d,C0024109,C1175743,is in patient with presumed ,Lung,SARS coronavirus,2,X,[bpoc],[virs],A04.411,B04.820.504.540.150.113.937
abb087b6-92f6-44c7-a145-20f03705ec41,C1422064,C0086418,is relatively more highly expressed in ,ACE2 gene,Homo sapiens,1,X,[gngm],[humn],,B01.050.150.900.649.313.988.400.112.400.400
ecaa8073-780e-49bd-95fd-ade27157a74d,C0287990,C1175175,mediate ,paired basic amino acid cleaving enzyme,Severe Acute Respiratory Syndrome,3,X,[aapp/enzy],[dsyn],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,C02.782.600.550.200.750;C08.730.730
44913599-d5f5-4dd9-953d-5a137e810d2b,C0287990,C4281807,may Vitronectin human for S,paired basic amino acid cleaving enzyme,Vitronectin human,2,X,[aapp/enzy],[aapp/bacs],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
c7746c0e-5a4c-4635-b237-80d0a35383f8,C0054871,C4281807,may Vitronectin human for S,Cathepsin L,Vitronectin human,2,X,[aapp/enzy],[aapp/bacs],D08.811.277.656.224.407;D08.811.277.656.262.500.157;D08.811.277.656.300.200.157,
d1f9c01f-02e7-4a0f-bc05-53aedc9ad97f,C0034052,C0206750,are associated with injury in patients with ,Pulmonary artery structure,Coronavirus Infections,2,X,[bpoc],[dsyn],A07.015.114.715,C02.782.600.550.200
d1f9c01f-02e7-4a0f-bc05-53aedc9ad97f,C0034052,C0206750,is independent risk factor for injury in patients with ,Pulmonary artery structure,Coronavirus Infections,3,X,[bpoc],[dsyn],A07.015.114.715,C02.782.600.550.200
80a34bae-03cd-4896-adad-f9a2bff2bba5,C0741923,C0206750,is with ,cardiac event,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
c4e4b0e7-e649-4c63-88c2-e19f6745fa24,C0005775,C0741923,is pivotal pathological cardiac event with,Blood Circulation,cardiac event,5,X,[phsf],[dsyn],G09.330.100,
d2896865-d071-452e-9d33-1020d255da9f,C0005775,C0206750,is pivotal pathological cardiac event with,Blood Circulation,Coronavirus Infections,3,X,[phsf],[dsyn],G09.330.100,C02.782.600.550.200
e4635626-3c41-48a9-ac94-9c95dcaa1b9a,C0009450,C0221423,is associated with neurological ,Communicable Diseases,Illness (finding),3,X,[dsyn],[sosy],C01.539.221,
e4635626-3c41-48a9-ac94-9c95dcaa1b9a,C0009450,C0221423,causes mild ,Communicable Diseases,Illness (finding),1,X,[dsyn],[sosy],C01.539.221,
e4635626-3c41-48a9-ac94-9c95dcaa1b9a,C0009450,C0221423,causing respiratory ,Communicable Diseases,Illness (finding),1,X,[dsyn],[sosy],C01.539.221,
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,was established at National Hospital in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,was established in early ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,with patients is 2020 ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,reached In ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,published in mid ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,was noted third most common stressor in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,be third most common stressor in early ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,opened in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,was declared pandemic on ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,13,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,became on ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,was recorded in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,was reported on ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
76fb118f-3459-4404-811f-a3d73b33df9d,C0206750,C1856053,has had IMPACT gene decreed in Spain on,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
ac958424-9405-452c-94f6-17c5d9a5eaeb,C0012634,C1856053,was recognized by World Health Organization as pandemic on ,Disease,Hydranencephaly with Renal Aplasia-Dysplasia,25,X,[dsyn],[dsyn],C23.550.288,x.x.x.x
7cd427e3-3dc8-4265-bd1d-fe5be7030692,C0206750,C1705178,was established at National Hospital in ,Coronavirus Infections,Order (action),7,X,[dsyn],[acty],C02.782.600.550.200,
6048111b-983f-481d-a85e-f9410f400341,C0012634,C1705178,was established in early ,Disease,Order (action),5,X,[dsyn],[acty],C23.550.288,
6445eed4-15d8-4080-b5f0-04a71488a389,C1856053,C1705178,is in ,Hydranencephaly with Renal Aplasia-Dysplasia,Order (action),2,X,[dsyn],[acty],x.x.x.x,
cfa880fc-d850-4b12-8707-2bca48d938fe,C0014038,C0019080,is with ,Encephalitis,Hemorrhage,2,X,[dsyn],[patf],C10.228.140.430,C23.550.414
111335ec-7bb5-4579-81a6-667340492488,C0019080,C0014059,with Encephalitis is,Hemorrhage,Encephalomyelitis Acute Disseminated,3,X,[patf],[dsyn],C23.550.414,C10.114.375.225;C10.228.140.695.562.225;C10.314.350.225;C20.111.258.250.350
703f43e9-2850-4629-9625-06b8110f8bde,C0019080,C0369718,with Encephalitis is,Hemorrhage,N not otherwise specified Antibody,3,X,[patf],[aapp/imft],C23.550.414,
57e4dca4-34d5-448a-8f88-a9e6ffa2c33e,C0085584,C0011206,is with ,Encephalopathies,Delirium,2,X,[dsyn],[mobd],C10.228.140,C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350
df6a4a38-8511-4fc0-b8d5-12da21c4771a,C0085584,C0033975,is with ,Encephalopathies,Psychotic Disorders,2,X,[dsyn],[mobd],C10.228.140,F03.700.675
7bee9ae3-5ca6-48af-a70b-b340266c290c,C0948008,C0087086,associated with pro ,Ischemic stroke,Thrombus,2,X,[dsyn],[patf],,C14.907.355.830
08e6c3f1-2d92-4bb8-a3ef-b06c346b01cc,C1175175,C0039082,is associated with wide spectrum of neurological ,Severe Acute Respiratory Syndrome,Syndrome,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C23.550.288.500
08e6c3f1-2d92-4bb8-a3ef-b06c346b01cc,C1175175,C0039082,can lead to acute respiratory ,Severe Acute Respiratory Syndrome,Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C23.550.288.500
b60c5e1c-54b7-4bf3-8a08-0ac27ef7b8c4,C0013404,C0206750,should alert clinicians to possibility of ,Dyspnea,Coronavirus Infections,14,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.782.600.550.200
50bd4371-3c3d-42b6-9574-45bb75150a5f,C0857172,C0206750,may play role in severity of hypoxemia in ,persistent dry cough,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
43b18d57-afc5-4fbc-9293-b5cd527521a0,C0015967,C0206750,may play role in severity of hypoxemia in ,Fever,Coronavirus Infections,2,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
43b18d57-afc5-4fbc-9293-b5cd527521a0,C0015967,C0206750,varied spectra of ,Fever,Coronavirus Infections,4,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
43b18d57-afc5-4fbc-9293-b5cd527521a0,C0015967,C0206750,were most common symptoms of ,Fever,Coronavirus Infections,4,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
43b18d57-afc5-4fbc-9293-b5cd527521a0,C0015967,C0206750,shows respectively correlation with total ,Fever,Coronavirus Infections,2,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
43b18d57-afc5-4fbc-9293-b5cd527521a0,C0015967,C0206750,was predominant Symptom:Find:Pt:^Patient:Nom in,Fever,Coronavirus Infections,2,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
43b18d57-afc5-4fbc-9293-b5cd527521a0,C0015967,C0206750,was predominant Symptoms in,Fever,Coronavirus Infections,6,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
43b18d57-afc5-4fbc-9293-b5cd527521a0,C0015967,C0206750,was found in higher number of post ,Fever,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
4da9fc1f-7490-4330-a220-8463c86ae622,C0030054,C0206750,may play role in severity of hypoxemia in ,Oxygen,Coronavirus Infections,2,X,[bacs/elii/phsu],[dsyn],D01.268.185.550;D01.362.670;x.x.x.x,C02.782.600.550.200
4da9fc1f-7490-4330-a220-8463c86ae622,C0030054,C0206750,Red blood cell disorder from,Oxygen,Coronavirus Infections,3,X,[bacs/elii/phsu],[dsyn],D01.268.185.550;D01.362.670;x.x.x.x,C02.782.600.550.200
d6b67455-4dce-4d81-b541-11e156fbdecd,C0598783,C0522534,was observed especially short ,Lipid Metabolism,Saturated,3,X,[moft],[npop],G03.458,
917de261-73bc-4219-ac2e-48ea219c7aa8,C0598783,C0522094,was observed especially short ,Lipid Metabolism,Medium chain fatty acid,3,X,[moft],[bacs/orch],G03.458,
28acfa1d-a1d4-4cee-836f-898b51caa9b3,C0598783,C0368608,was observed especially short ,Lipid Metabolism,acylcarnitine,3,X,[moft],[orch],G03.458,x.x.x.x
79a2e870-35b6-43e9-b598-5c0880b1bb5e,C0598783,C0037900,was observed especially short ,Lipid Metabolism,Sphingolipids,3,X,[moft],[orch],G03.458,D10.570.877
1d27ec34-41c5-462d-8216-aa9678423df1,C0369718,C0428174,responding in ,N not otherwise specified Antibody,Hemoglobin saturation with oxygen,4,X,[aapp/imft],[ortf],,
0a370a3e-b855-4e54-a9cc-5deedf44fc45,C0369718,C0206750,Red blood cell disorder from,N not otherwise specified Antibody,Coronavirus Infections,3,X,[aapp/imft],[dsyn],,C02.782.600.550.200
9ce53b4b-9e9c-44f5-8611-4516c9317eb1,C0040802,C0030054,deliver ,travel,Oxygen,3,X,[dora],[bacs/elii/phsu],I03.883,D01.268.185.550;D01.362.670;x.x.x.x
5106f017-100d-421e-a1a0-c725252f5d4d,C1175175,C0086418,is third zoonotic ,Severe Acute Respiratory Syndrome,Homo sapiens,6,X,[dsyn],[humn],C02.782.600.550.200.750;C08.730.730,B01.050.150.900.649.313.988.400.112.400.400
a2ca30c8-1852-45b2-ba48-54a58b1fa5a9,C1175175,C1185740,using respiratory ,Severe Acute Respiratory Syndrome,Tract,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,
7e54f7c8-ec4d-4b8d-8fe2-08803ac51a51,C1175175,C0370003,using respiratory ,Severe Acute Respiratory Syndrome,Specimen,1,X,[dsyn],[sbst],C02.782.600.550.200.750;C08.730.730,
0c83bc95-daf7-4e0e-a8b0-669ef59308e6,C0206750,C1175743,were positive ,Coronavirus Infections,SARS coronavirus,324,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150.113.937
2bed39c3-1088-4b38-aac9-5cc360171a81,C0012634,C1175743,were positive ,Disease,SARS coronavirus,257,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150.113.937
ba010de6-776d-4c92-8317-efc6acac507a,C0319157,C0746982,rule our ,AS virus,obstructive disease,2,X,[virs],[dsyn],,
55185646-c647-49a3-a92b-4a9c290fdd90,C0319157,C0018787,rule our ,AS virus,Heart,1,X,[virs],[bpoc],,A07.541
02c25d29-67af-40a5-8cd9-7e7c6e12a49a,C0035736,C0302908,unexpectedly been detected in multiple ,RNA Viral,Liquid substance,1,X,[nnon],[sbst],D13.444.735.828,
bba31e47-62f0-473a-b9b8-c99f03c7b34c,C0030054,C0428174,responding in ,Oxygen,Hemoglobin saturation with oxygen,1,X,[bacs/elii/phsu],[ortf],D01.268.185.550;D01.362.670;x.x.x.x,
7427938f-e106-41b3-806e-b5c0a4872d2d,C0221016,C0030054,deliver ,Red blood cell disorder,Oxygen,1,X,[dsyn],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
dfa5a618-5339-443c-a82b-28de59ed1893,C0007222,PCR,were premorbid risk factors present before SARS-CoV-2 PCR ,Cardiovascular Diseases,PCR,4,X,[dsyn],????,C14,????
68daa87d-5921-4ca9-b267-51dc2227b726,C0020538,PCR,were premorbid risk factors present before SARS-CoV-2 PCR ,Hypertensive disease,PCR,4,X,[dsyn],????,C14.907.489,????
2150db98-c299-4dd2-9c1d-812c3dd2b35f,C0022658,PCR,were premorbid risk factors present before SARS-CoV-2 PCR ,Kidney Diseases,PCR,4,X,[dsyn],????,C12.777.419;C13.351.968.419,????
453e1ec0-6af1-4bfb-beea-8e1f164e803d,C0007222,C0206750,were premorbid risk factors present before SARS-CoV-2 PCR ,Cardiovascular Diseases,Coronavirus Infections,3,X,[dsyn],[dsyn],C14,C02.782.600.550.200
453e1ec0-6af1-4bfb-beea-8e1f164e803d,C0007222,C0206750,are at with comorbidities risk of ,Cardiovascular Diseases,Coronavirus Infections,7,X,[dsyn],[dsyn],C14,C02.782.600.550.200
453e1ec0-6af1-4bfb-beea-8e1f164e803d,C0007222,C0206750,were most prevalent comorbidities in ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
453e1ec0-6af1-4bfb-beea-8e1f164e803d,C0007222,C0206750,are Additionally risk factors for ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
453e1ec0-6af1-4bfb-beea-8e1f164e803d,C0007222,C0206750,was associated with critical ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
453e1ec0-6af1-4bfb-beea-8e1f164e803d,C0007222,C0206750,initial considerations of ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
1de69721-4d61-4dcd-9c8e-34798cb54646,C0020538,C0206750,were premorbid risk factors present before SARS-CoV-2 PCR ,Hypertensive disease,Coronavirus Infections,18,X,[dsyn],[dsyn],C14.907.489,C02.782.600.550.200
f0f85e80-1b65-4231-bc62-e1e6fbb8f6fe,C0022658,C0206750,were premorbid risk factors present before SARS-CoV-2 PCR ,Kidney Diseases,Coronavirus Infections,3,X,[dsyn],[dsyn],C12.777.419;C13.351.968.419,C02.782.600.550.200
f0f85e80-1b65-4231-bc62-e1e6fbb8f6fe,C0022658,C0206750,were predominant premorbid risk factors for ,Kidney Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C12.777.419;C13.351.968.419,C02.782.600.550.200
edab9c3f-d39e-4964-8583-1d3ee7de7783,C0002871,C0206750,were predominant premorbid risk factors for ,Anemia,Coronavirus Infections,3,X,[dsyn],[dsyn],C15.378.071,C02.782.600.550.200
3daba207-61f5-4cda-a429-1ad4f42b9977,C0022658,C0022661, includes ,Kidney Diseases,Kidney Failure Chronic,3,X,[dsyn],[dsyn],C12.777.419;C13.351.968.419,C12.777.419.780.750.500;C13.351.968.419.780.750.500
03cddc12-a058-4663-9be8-d9e6ac263499,C0022661,C0206750,were predominant premorbid risk factors for ,Kidney Failure Chronic,Coronavirus Infections,2,X,[dsyn],[dsyn],C12.777.419.780.750.500;C13.351.968.419.780.750.500,C02.782.600.550.200
b73b94c3-262d-4e4e-8177-13990ea0b360,C1706374,C1708476,was associated with ,Tumor Necrosis Factor Ligand Superfamily Member 13,Implementation,2,X,[aapp/bacs],[acty],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,
b133445f-a3b2-4ad4-adba-9976b6f12ceb,C1706374,C1856053,was associated with ,Tumor Necrosis Factor Ligand Superfamily Member 13,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,x.x.x.x
b133445f-a3b2-4ad4-adba-9976b6f12ceb,C1706374,C1856053, with,Tumor Necrosis Factor Ligand Superfamily Member 13,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,x.x.x.x
7741acc1-ce0f-41d8-b030-7eb37fdc1d97,C1706374,C1705178,was associated with ,Tumor Necrosis Factor Ligand Superfamily Member 13,Order (action),1,X,[aapp/bacs],[acty],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,
796ace8f-bfa9-4d1b-b127-28736d4cc91f,C1175175,C0035222,is with ,Severe Acute Respiratory Syndrome,Respiratory Distress Syndrome Adult,4,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.840;C08.618.840
3af7361e-5782-4037-9ecb-7206c5ef1561,C0035222,C0206750,phenotype of ,Respiratory Distress Syndrome Adult,Coronavirus Infections,11,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C02.782.600.550.200
27245edf-de7c-427b-a5c0-b9a23455d515,C0206750,C0225698,is associated with ,Coronavirus Infections,Alveolar Epithelial Cells,2,X,[dsyn],[cell],C02.782.600.550.200,A04.411.715.100;A11.436.081
a9130817-d4fe-408e-a5f8-ff272a0199c9,C0206750,C0042760,is associated with ,Coronavirus Infections,Virion,1,X,[dsyn],[celc],C02.782.600.550.200,A21.249;B04.950
e83a02b5-4d2e-47ec-b022-848b8df5072f,C1537068,C0086418,is in ,Virus Internalization,Homo sapiens,1,X,[biof],[humn],G06.920.881,B01.050.150.900.649.313.988.400.112.400.400
1d8e64ab-d2ed-40b3-902f-e2c029333b5f,C1537068,C1440080,is in ,Virus Internalization,Alveolar,1,X,[biof],[bpoc],G06.920.881,
0316d0dd-9edf-44bc-b444-7fd3a44030ed,C0206750,C1521827,took we ill ,Coronavirus Infections,Preparation,1,X,[dsyn],[acty],C02.782.600.550.200,
0316d0dd-9edf-44bc-b444-7fd3a44030ed,C0206750,C1521827,severe cases of be ,Coronavirus Infections,Preparation,1,X,[dsyn],[acty],C02.782.600.550.200,
6927b0f7-96c4-447f-aeb9-f8968995dfa4,C0204514,C1539905,is in ,Structural analysis,SYNC gene,3,X,[topp],[gngm],,
207fc9b8-d36d-4d60-8999-45f5ff4d57ff,C0206750,C0034019,was declared ,Coronavirus Infections,public health medicine (field),62,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.720;N01.400.550;N06.850
74a52c49-a919-433c-8486-9861986c4440,C1610422,C0597357,was identified as entry ,ACE2 protein human,receptor,1,X,[aapp/enzy],[aapp/rcpt],,
83f46014-c4d2-488f-ba92-b6bade54ea5c,C1610422,C1175743,was identified as entry ,ACE2 protein human,SARS coronavirus,1,X,[aapp/enzy],[virs],,B04.820.504.540.150.113.937
3454c938-a5b1-4dd8-ae53-41ecc2c6c09b,C1175743,C2258685,increased ,SARS coronavirus,angiotensin converting enzyme activity,4,X,[virs],[moft],B04.820.504.540.150.113.937,
d34e010b-4770-44a2-81e5-715f3cb661f5,C0700271,C2258685,increased ,M Protein multiple myeloma,angiotensin converting enzyme activity,4,X,[aapp/imft],[moft],x.x.x.x,
6ba8db03-a25a-4891-8c2c-577c2bc22e18,C0033684,C2258685,increased ,Proteins,angiotensin converting enzyme activity,4,X,[aapp/bacs],[moft],D12.776,
bde0699e-f69c-4f35-84ff-e743a7d961f4,C1175743,C1947941,increased ,SARS coronavirus,Proteolytic Enzyme,2,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,
08da7207-4112-49b9-b2d2-64e08f3bff38,C0700271,C1947941,increased ,M Protein multiple myeloma,Proteolytic Enzyme,2,X,[aapp/imft],[aapp/enzy],x.x.x.x,
b8ef2c31-ead4-4267-9dee-036d04522822,C0033684,C1947941,increased ,Proteins,Proteolytic Enzyme,2,X,[aapp/bacs],[aapp/enzy],D12.776,
91cc6f1f-4271-42af-b300-88a96cf32727,C0006100,C2258685,characterize ,Bradykinin,angiotensin converting enzyme activity,1,X,[aapp/horm],[moft],D12.644.276.812.169;D12.644.400.090;D12.644.456.193;D12.776.467.812.169;D12.776.631.650.090;D23.469.050.375.110;D23.529.812.169;x.x.x.x,
ca24b7a4-a683-4fb2-ba1b-d6d6410dc5f9,C0243071,C2258685,characterize ,Analog,angiotensin converting enzyme activity,1,X,[chvs],[moft],,
334d2c08-6f1a-475d-8eaf-504b25518fc1,C0030956,C2258685,characterize ,Peptides,angiotensin converting enzyme activity,1,X,[aapp/phsu],[moft],D12.644,
dd55dc17-62fd-446f-8e0f-5fcd37450605,C2349975,C0960880,was mediated by ,Enhance (action),angiotensin converting enzyme 2,4,X,[acty],[aapp/enzy],,x.x.x.x
2d566b74-e13a-46d0-9458-250fa4c4a052,C2349975,C1167622,was mediated by ,Enhance (action),Binding (Molecular Function),2,X,[acty],[moft],,
c0ff2609-cbfc-4e2a-881c-6c4f1a71256b,C2349975,C1522002,was mediated by ,Enhance (action),RNA Recognition Motif,2,X,[acty],[aapp/bacs],,G02.111.570.820.709.275.500.869.500
db4ab26a-dc26-4b56-91eb-8ef769e4691b,C2349975,C1175743,was mediated by ,Enhance (action),SARS coronavirus,2,X,[acty],[virs],,B04.820.504.540.150.113.937
a0f38a08-6e71-4bf2-81ca-5f597d3ceb1e,C0030946,C0206750,is attractive drug target as ,Endopeptidases,Coronavirus Infections,2,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300,C02.782.600.550.200
a0f38a08-6e71-4bf2-81ca-5f597d3ceb1e,C0030946,C0206750,is essential for ,Endopeptidases,Coronavirus Infections,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300,C02.782.600.550.200
a0f38a08-6e71-4bf2-81ca-5f597d3ceb1e,C0030946,C0206750,is considered important ,Endopeptidases,Coronavirus Infections,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300,C02.782.600.550.200
d8f13261-8bf9-489f-972b-eadbfa8d602e,C0039902,C0010813,inhibits 2 viral polyprotein ,Thioguanine,Cytokinesis,1,X,[orch/phsu],[celf],D03.633.100.759.854,G04.144.220.250
797a087d-82c8-4c02-b345-f3ea1b7aa3ed,C0039902,C0598312,inhibits ,Thioguanine,DNA Replication,1,X,[orch/phsu],[genf],D03.633.100.759.854,G02.111.225;G05.226
a9d5b1b8-234e-4bee-aaf5-e90b6f166fd7,C0039902,C1175743,inhibits ,Thioguanine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.759.854,B04.820.504.540.150.113.937
46bc2da3-c189-4eab-8dcf-11a69a74ac52,C0039902,C0013227,represents Therapeutic procedure As well-characterized FDA-approved delivered,Thioguanine,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],D03.633.100.759.854,D26
d7c69f69-07e8-40b0-97db-70f53724fbae,C0039902,C0087111,represents promising ,Thioguanine,Therapeutic procedure,2,X,[orch/phsu],[topp],D03.633.100.759.854,E02
a51f8464-c822-4462-9677-cb6d997f142a,C0039902,C0206750,represents promising ,Thioguanine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.759.854,C02.782.600.550.200
c69ba414-80ad-4153-b0d2-f9c7935ab43b,C0013227,C2267219,targets essential ,Pharmaceutical Preparations,Enzymatic Activity,2,X,[phsu],[moft],D26,
7e7858fd-af58-47e0-978c-7ba9e89c3672,C0013227,C1175743,targets essential ,Pharmaceutical Preparations,SARS coronavirus,4,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
7e7858fd-af58-47e0-978c-7ba9e89c3672,C0013227,C1175743,entry of ,Pharmaceutical Preparations,SARS coronavirus,8,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
7e7858fd-af58-47e0-978c-7ba9e89c3672,C0013227,C1175743,have have tested as ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
7e7858fd-af58-47e0-978c-7ba9e89c3672,C0013227,C1175743,may also have risks beyond anti ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
7e7858fd-af58-47e0-978c-7ba9e89c3672,C0013227,C1175743,might might potent to ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
7e7858fd-af58-47e0-978c-7ba9e89c3672,C0013227,C1175743,Therapeutic procedure,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
7e7858fd-af58-47e0-978c-7ba9e89c3672,C0013227,C1175743,exhibited anti ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
60097ace-e0b1-4cc9-bf6e-547f83bc3e2d,C1175743,C0439056,was detected via ,SARS coronavirus,Throat swab sample,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
55b2103f-885d-40a4-9dad-cc9450d1e3da,C0439056,C0206750,is in ,Throat swab sample,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
8f8ffc94-a9b7-4bac-bfd7-4a7613b4c570,C0009450,C0242781,produced For early ,Communicable Diseases,disease transmission,3,X,[dsyn],[patf],C01.539.221,N06.850.310
5e104329-ef41-4d6d-b39d-8bd5262d1d92,C0199176,C0206750,control ,Prophylactic treatment,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
5e104329-ef41-4d6d-b39d-8bd5262d1d92,C0199176,C0206750,became ,Prophylactic treatment,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
5e104329-ef41-4d6d-b39d-8bd5262d1d92,C0199176,C0206750,mitigate ,Prophylactic treatment,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
5e104329-ef41-4d6d-b39d-8bd5262d1d92,C0199176,C0206750,is in severe hospitalized ,Prophylactic treatment,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
fe21ea9e-1266-4354-98ab-2a4250185554,C0199176,C0012634,control pandemic ,Prophylactic treatment,Disease,2,X,[topp],[dsyn],,C23.550.288
3ae1cd83-cdc8-4918-929e-066f0fd87836,C1175743,C0877629,of awareness is mode for ,SARS coronavirus,infection prophylaxis,1,X,[virs],[topp],B04.820.504.540.150.113.937,
4df01c19-bc5d-458e-873d-3a363b81f4f3,C1457887,C0015967,were ,Symptoms,Fever,89,X,[sosy],[sosy],,C23.888.119.344
f5e997d4-6d13-48e0-8e39-534ea3dd053f,C1175743,C1856053,were enrolled From ,SARS coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,29,X,[virs],[dsyn],B04.820.504.540.150.113.937,x.x.x.x
d7d29828-b9d4-40e8-afbf-94d297fe93d6,CoV2,C1856053,rapidly spread all over world becoming in ,CoV2,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,????,[dsyn],????,x.x.x.x
d7d29828-b9d4-40e8-afbf-94d297fe93d6,CoV2,C1856053,rapidly spread over world pandemic in ,CoV2,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,????,[dsyn],????,x.x.x.x
1152cf98-4c84-4e1d-8e9e-0dbb0310f0e1,C0319157,C1819995,uses AS virus spike Glycoproteins domain interact with,AS virus,Host Cell,4,X,[virs],[celc],,
f1590bc3-1ad0-4fe5-8c24-4169abe87b9d,C0319157,C0022709,uses AS virus spike Glycoproteins domain interact with,AS virus,Peptidyl-Dipeptidase A,4,X,[virs],[aapp/enzy/imft],,D08.811.277.656.350.350.687
f1590bc3-1ad0-4fe5-8c24-4169abe87b9d,C0319157,C0022709,also promotes ,AS virus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],,D08.811.277.656.350.350.687
9a712dd1-f99d-4c20-8f23-4b955d0a2a09,C0319157,C0017968,uses ,AS virus,Glycoproteins,2,X,[virs],[aapp/bacs],,D09.400.430;D12.776.395
36bc0a09-67d5-4bb9-bd00-4831af1c8fa6,C0319157,C0597357,uses ,AS virus,receptor,2,X,[virs],[aapp/rcpt],,
27e37225-779c-4289-bccf-a155c37a5021,C0319157,C4689723,uses ,AS virus,glycoprotein binding,2,X,[virs],[moft],,
20d12983-3a13-4f05-86e3-f1b8cf92d826,C0199176,C0013216,repurposing existing ,Prophylactic treatment,Pharmacotherapy,5,X,[topp],[topp],,E02.319
20d12983-3a13-4f05-86e3-f1b8cf92d826,C0199176,C0013216,repurposing Pharmacotherapy as potential,Prophylactic treatment,Pharmacotherapy,3,X,[topp],[topp],,E02.319
88b4f7bd-9a69-464d-bce8-e5fbc3cbed37,C0042210,C0013216,repurposing existing ,Vaccines,Pharmacotherapy,5,X,[aapp/imft/phsu],[topp],D20.215.894,E02.319
88b4f7bd-9a69-464d-bce8-e5fbc3cbed37,C0042210,C0013216,repurposing Pharmacotherapy as potential,Vaccines,Pharmacotherapy,3,X,[aapp/imft/phsu],[topp],D20.215.894,E02.319
48971034-e427-4e7a-bbc6-a87c80843e7c,C0206750,C0012634,with patients is ,Coronavirus Infections,Disease,43,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.288
b2d5f4a6-4a0e-4040-98fc-338b35342a55,C0206419,C1457887,diagnosis of been has challenge in many countries due to ,Genus: Coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150,
b2d5f4a6-4a0e-4040-98fc-338b35342a55,C0206419,C1457887,relating ,Genus: Coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150,
b2d5f4a6-4a0e-4040-98fc-338b35342a55,C0206419,C1457887,could lead to serious of ,Genus: Coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150,
2870163c-9a8e-458f-9077-f601be7b06ec,C0012634,C1457887,diagnosis of been has challenge in many countries due to ,Disease,Symptoms,1,X,[dsyn],[sosy],C23.550.288,
2870163c-9a8e-458f-9077-f601be7b06ec,C0012634,C1457887,relating ,Disease,Symptoms,1,X,[dsyn],[sosy],C23.550.288,
75f631e8-5247-49a2-aad8-2912eab4f0e3,C0030664,C0009368,is in ,Pathology,Colon structure (body structure),2,X,[bmod],[bpoc],H02.403.650,A03.556.124.526.356;A03.556.249.249.356
998edf71-291b-422a-8b72-7c83d988bd83,C1175743,C0021853,is in ,SARS coronavirus,Intestines,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,A03.556.124
eb83dfc6-c2eb-43fe-9c79-59ea375b36e7,C1175743,C0030664,is in ,SARS coronavirus,Pathology,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.650
43bf93bf-5380-4773-8d80-1b3a439ecc00,C0598312,C0030664,is in ,DNA Replication,Pathology,2,X,[genf],[bmod],G02.111.225;G05.226,H02.403.650
1e86260a-21e1-4228-9095-2a29ef35d755,C0206419,C0149978,is with RT-PCR,Genus: Coronavirus,Adenocarcinoma of rectum,3,X,[virs],[neop],B04.820.504.540.150,
b3116977-aad4-4da5-b5a9-745a208bde79,C0206419,RT-PCR,is with RT-PCR,Genus: Coronavirus,RT-PCR,3,X,[virs],????,B04.820.504.540.150,????
ff04183b-3300-4cd4-b7b7-3e068b90e6c8,C0015967,C0206419,was diagnosed with ,Fever,Genus: Coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150
ff04183b-3300-4cd4-b7b7-3e068b90e6c8,C0015967,C0206419,varied spectra of ,Fever,Genus: Coronavirus,1,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150
ff04183b-3300-4cd4-b7b7-3e068b90e6c8,C0015967,C0206419,were most common Symptoms of,Fever,Genus: Coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150
186a7240-a08a-444c-8b67-e961e996e3b1,C0206419,C1856053,was launched in France in ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
186a7240-a08a-444c-8b67-e961e996e3b1,C0206419,C1856053,with patients is 2020 ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
186a7240-a08a-444c-8b67-e961e996e3b1,C0206419,C1856053,was declared pandemic on ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,14,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
186a7240-a08a-444c-8b67-e961e996e3b1,C0206419,C1856053,was noted third common stressor among respondents in ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
186a7240-a08a-444c-8b67-e961e996e3b1,C0206419,C1856053,outbreak of was On ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
eb805f01-7d38-4321-aae1-105d019e40f0,C0206419,C1705178,was established in early ,Genus: Coronavirus,Order (action),5,X,[virs],[acty],B04.820.504.540.150,
cb8d3a12-f5a1-4746-bfb9-ad551e1f03a7,C0007222,C0206419,were premorbid risk factors present before SARS-CoV-2 PCR ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
cb8d3a12-f5a1-4746-bfb9-ad551e1f03a7,C0007222,C0206419,are at higher risk of ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
cb8d3a12-f5a1-4746-bfb9-ad551e1f03a7,C0007222,C0206419,is risk factor for novel ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
cb8d3a12-f5a1-4746-bfb9-ad551e1f03a7,C0007222,C0206419,is associated with more severe manifestations of ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
aca9d427-004f-4947-b721-d1b9e7abf4f4,C0020538,C0206419,were premorbid risk factors present before SARS-CoV-2 PCR ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
aca9d427-004f-4947-b721-d1b9e7abf4f4,C0020538,C0206419,were predictors protective for mortality in hospitalized ,Hypertensive disease,Genus: Coronavirus,5,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
aca9d427-004f-4947-b721-d1b9e7abf4f4,C0020538,C0206419,followed by ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
aca9d427-004f-4947-b721-d1b9e7abf4f4,C0020538,C0206419,are risk factors for morbidity from ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
aca9d427-004f-4947-b721-d1b9e7abf4f4,C0020538,C0206419,is most common comorbidity associated with mortality in current ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
aca9d427-004f-4947-b721-d1b9e7abf4f4,C0020538,C0206419,independent predictors of lethal outcome in ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
c5b3dc43-9fcc-4b61-8421-79e6e7419cac,C0022658,C0206419,were premorbid risk factors present before SARS-CoV-2 PCR ,Kidney Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419;C13.351.968.419,B04.820.504.540.150
c5b3dc43-9fcc-4b61-8421-79e6e7419cac,C0022658,C0206419,were predominant premorbid risk factors for ,Kidney Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419;C13.351.968.419,B04.820.504.540.150
0cb9bb54-9bf2-4a3b-b87b-933ad1c54c7b,C0022661,C0206419,were predominant premorbid risk factors for ,Kidney Failure Chronic,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419.780.750.500;C13.351.968.419.780.750.500,B04.820.504.540.150
d2213ad1-e096-4d85-a315-e6845b7ce6c0,C0002871,C0206419,were predominant premorbid risk factors for ,Anemia,Genus: Coronavirus,1,X,[dsyn],[virs],C15.378.071,B04.820.504.540.150
335acc15-25b7-44aa-ba28-21568ae89d87,C1175175,C0225828,is in ,Severe Acute Respiratory Syndrome,Myocytes Cardiac,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A07.541.704.570;A10.690.552.750.570;A11.620.500
bda22919-3aec-408e-8961-e79e4ca846e7,C0079679,C0017337,selected ,Genus: Lentivirus group,Genes,1,X,[virs],[gngm],B04.820.650.589,G05.360.340.024.340
7f1a9d29-1c73-4673-babf-16465ae66773,C1514559,C0017337,selected ,Protein Overexpression,Genes,1,X,[genf],[gngm],,G05.360.340.024.340
6c147ce5-c07e-437e-b283-20b66055a412,C0079679,C1175743,selected ,Genus: Lentivirus group,SARS coronavirus,1,X,[virs],[virs],B04.820.650.589,B04.820.504.540.150.113.937
6c147ce5-c07e-437e-b283-20b66055a412,C0079679,C1175743,Genes of,Genus: Lentivirus group,SARS coronavirus,1,X,[virs],[virs],B04.820.650.589,B04.820.504.540.150.113.937
dabc518a-ddca-47fa-8f77-914ff369d2cb,C1514559,C1175743,selected ,Protein Overexpression,SARS coronavirus,1,X,[genf],[virs],,B04.820.504.540.150.113.937
dabc518a-ddca-47fa-8f77-914ff369d2cb,C1514559,C1175743,Genes of,Protein Overexpression,SARS coronavirus,1,X,[genf],[virs],,B04.820.504.540.150.113.937
166e0854-9795-4e74-af11-a9d70a95d1a9,C3888108,C0041904,led to ,Import into cell,Up-Regulation (Physiology),1,X,[celf],[moft],,G02.111.905;G05.308.850;G07.690.773.998
ade2627b-6b05-4ec6-ac12-7a768dd71189,C3888108,C0225828,led to ,Import into cell,Myocytes Cardiac,1,X,[celf],[cell],,A07.541.704.570;A10.690.552.750.570;A11.620.500
37dad20d-d841-4428-b79d-34c0bb46ae2e,C0041904,C0225828,is in ,Up-Regulation (Physiology),Myocytes Cardiac,1,X,[moft],[cell],G02.111.905;G05.308.850;G07.690.773.998,A07.541.704.570;A10.690.552.750.570;A11.620.500
cd7b965f-2a1d-425a-8303-3f6b8d2fda9e,C0003451,C0206419,stop ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
cd7b965f-2a1d-425a-8303-3f6b8d2fda9e,C0003451,C0206419,is in older patients with ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
cd7b965f-2a1d-425a-8303-3f6b8d2fda9e,C0003451,C0206419,specific to ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
cd7b965f-2a1d-425a-8303-3f6b8d2fda9e,C0003451,C0206419,are main class of therapeutic agents evaluated against ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
cd7b965f-2a1d-425a-8303-3f6b8d2fda9e,C0003451,C0206419,may prove effective respiratory ,Antiviral Agents,Genus: Coronavirus,3,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
cd7b965f-2a1d-425a-8303-3f6b8d2fda9e,C0003451,C0206419,are are given empirically to patients with ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
0d06fb8e-cc1e-447a-8aab-e10e182a5c49,C0030946,C0282568,is attractive ,Endopeptidases,Drugs Essential,3,X,[aapp/enzy/phsu],[phsu],D08.811.277.656.300,D26.355
13aec5e2-2055-4e58-a3f3-8a79d5bf8501,C0030946,C1160638,is in ,Endopeptidases,Viral life cycle,3,X,[aapp/enzy/phsu],[biof],D08.811.277.656.300,
f57af6d0-ade0-41ea-ae68-5423bde27126,C1516048,C3826426,using newly developed GPU-accelerated implicit-solvent constant pH ,Assessed,Dynamics,1,X,[acty],[npop],,
f57af6d0-ade0-41ea-ae68-5423bde27126,C1516048,C3826426,using newly developed implicit-solvent continuous pH ,Assessed,Dynamics,1,X,[acty],[npop],,
82479d23-d908-496a-b317-d978cb0c26a6,C1516048,C4019011,using newly developed GPU-accelerated implicit-solvent constant pH ,Assessed,Exchange (clinical),1,X,[acty],[clna],,
82479d23-d908-496a-b317-d978cb0c26a6,C1516048,C4019011,using newly developed implicit-solvent continuous pH ,Assessed,Exchange (clinical),1,X,[acty],[clna],,
feda8585-0aa7-449c-9347-00e94f6cbbc3,C3826426,C4019011,is with asynchronous replica ,Dynamics,Exchange (clinical),3,X,[npop],[clna],,
f208cf12-d7ce-4033-ac29-7b31b6a50005,C1441506,C0007382,support ,Calculation,Catalysis,3,X,[acty],[npop],,G02.130
e702c42a-9e4b-4c85-832e-64c5ea38f606,C0034348,C0007382,support ,Pyruvate Kinase,Catalysis,3,X,[aapp/enzy],[npop],D08.811.913.696.620.695,G02.130
f07c4bce-2783-4651-a4ef-d1d8ff558d8b,C1441506,C0010654,support ,Calculation,Cysteine,3,X,[acty],[aapp/bacs],,D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230
72491d4f-d233-4fb5-83d6-2051edbb0728,C0034348,C0010654,support ,Pyruvate Kinase,Cysteine,3,X,[aapp/enzy],[aapp/bacs],D08.811.913.696.620.695,D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230
df3ba7d4-73f8-417a-b6d3-81d82ff1e8bb,C1441506,C0076994,support ,Calculation,Triad Acrylic Resin,3,X,[acty],[bodm/orch],,x.x.x.x
6f8f61fb-56a3-4781-acf2-2f32900fe7d3,C0034348,C0076994,support ,Pyruvate Kinase,Triad Acrylic Resin,3,X,[aapp/enzy],[bodm/orch],D08.811.913.696.620.695,x.x.x.x
e94d8467-802b-4782-b45d-d46b8d89a1db,BL2,C0444626,is coupled to titration of C271/270 in agreement with ,BL2,Crystal Structure,6,X,????,[chvs],????,
72ea0ce6-88f4-4892-88f7-8e2daddc12a5,C3826426,C0444626,is coupled to titration of C271/270 in agreement with ,Dynamics,Crystal Structure,6,X,[npop],[chvs],,
20f8bb80-6d18-4954-a034-9a30ee1c4c8d,BL2,C1175743,is coupled to titration of C271/270 in agreement with ,BL2,SARS coronavirus,6,X,????,[virs],????,B04.820.504.540.150.113.937
154280d9-19a9-4b82-9c6e-9d9d91521dd9,C3826426,C1175743,is coupled to titration of C271/270 in agreement with ,Dynamics,SARS coronavirus,6,X,[npop],[virs],,B04.820.504.540.150.113.937
8afeaa66-19e2-4371-beb3-d8cdb565504f,BL2,C3698360,is in ,BL2,Middle East Respiratory Syndrome Coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.750
ee3932f3-7c62-4fdb-b142-f7684b96f2c5,C0030946,C0206419,is essential for ,Endopeptidases,Genus: Coronavirus,7,X,[aapp/enzy/phsu],[virs],D08.811.277.656.300,B04.820.504.540.150
43512f68-5c24-4157-9a4d-8c6d99016661,C0010813,C1175743,is in cells of ,Cytokinesis,SARS coronavirus,1,X,[celf],[virs],G04.144.220.250,B04.820.504.540.150.113.937
d3baa907-7ccd-4055-9ccf-55eb4e8a5c69,C0039902,C0206419,represents promising ,Thioguanine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.759.854,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,is cause of current ,SARS coronavirus,Genus: Coronavirus,38,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,is causative agent of ,SARS coronavirus,Genus: Coronavirus,15,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,can speculate its stability in ,SARS coronavirus,Genus: Coronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,due to Genus: Coronavirus is,SARS coronavirus,Genus: Coronavirus,3,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,exemplifies general threat to health posed by ,SARS coronavirus,Genus: Coronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,Organism in,SARS coronavirus,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,may trigger severe ,SARS coronavirus,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,due to disease is ,SARS coronavirus,Genus: Coronavirus,4,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,is anew ,SARS coronavirus,Genus: Coronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,is novel ,SARS coronavirus,Genus: Coronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,is indicative of ,SARS coronavirus,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,member of ,SARS coronavirus,Genus: Coronavirus,5,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,recently emerged as responsible for ,SARS coronavirus,Genus: Coronavirus,6,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,environmental surveillance of be Furthermore should priority part of ,SARS coronavirus,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,Pathogenic organism of,SARS coronavirus,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,has led to worldwide pandemic of ,SARS coronavirus,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
5810b9a0-758a-442b-afa0-43c6e3d26c11,C1175743,C0206419,is strain of ,SARS coronavirus,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
b74d9ca5-52fd-482c-9841-af6677f2b34b,C0010340,C0024109,clinical outcomes of are most likely impaired exchange in ,Critical Illness,Lung,1,X,[dsyn],[bpoc],C23.550.291.625,A04.411
a7075398-2c54-4de0-9e5a-7192124703fc,C0032105,C0206419,were applied to severe ,Plasma,Genus: Coronavirus,7,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,B04.820.504.540.150
ec553212-4361-4f6f-a0b7-d438ae11881c,C0206419,C0034019,was controlled with coordinated ,Genus: Coronavirus,public health medicine (field),28,X,[virs],[bmod],B04.820.504.540.150,H02.403.720;N01.400.550;N06.850
c6e355ba-bd16-4521-8313-0785a8070d87,C0012634,27th,has resulted As of May 27th,Disease,27th,2,X,[dsyn],????,C23.550.288,????
db46ada5-fb8d-4414-b01c-d2fcf0205375,C0013216,C0199176,suitable for ,Pharmacotherapy,Prophylactic treatment,3,X,[topp],[topp],E02.319,
0ff37712-f447-4af9-929e-80f57e441c04,C0013216,C0206419,suitable for ,Pharmacotherapy,Genus: Coronavirus,1,X,[topp],[virs],E02.319,B04.820.504.540.150
0cd050f7-c2ed-4c26-abba-8fd0b30e33e2,C0003968,C0042890,is crucial ,Ascorbic Acid,Vitamins,3,X,[orch/phsu/vita],[orch/phsu/vita],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,D27.505.696.377.683.500.600;G07.203.300.681.500.600;J02.500.681.500.600
8bb8aef6-8749-4799-ab5a-e48d408ce9ed,C0003968,C0149784,plays role in ,Ascorbic Acid,biological adaptation to stress,3,X,[orch/phsu/vita],[phsf],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,
3eefb64e-3b79-426b-afaa-0c7becd23d36,C0003968,C0010340,administered to ,Ascorbic Acid,Critical Illness,1,X,[orch/phsu/vita],[dsyn],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,C23.550.291.625
a59f1db0-8cdc-409a-8ff9-3ca4d395d02f,C0034392,C0596577,is well-known ,Quercetin,Flavonoids,3,X,[orch/phsu/vita],[orch],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D03.383.663.283.266.450;D03.633.100.150.266.450
3ca5a808-930c-4a4b-93be-508ab2cc0872,C0003968,C0003451,exerts synergistic ,Ascorbic Acid,Antiviral Agents,2,X,[orch/phsu/vita],[phsu],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,D27.505.954.122.388
df303d11-96ae-4fad-bcc5-b49da734958d,C0003968,C3266814,exerts synergistic ,Ascorbic Acid,Action,1,X,[orch/phsu/vita],[acty],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,
1cbdef8f-5027-4763-b0f0-ac1b755162c9,C0206419,C1175743,successively named ,Genus: Coronavirus,SARS coronavirus,118,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540.150.113.937
4a663bc1-4752-4d44-acd3-7787e4400c23,C0206419,C0012634,with patients is ,Genus: Coronavirus,Disease,29,X,[virs],[dsyn],B04.820.504.540.150,C23.550.288
bba8ffa6-a322-4190-bdb2-64b1c9585eb6,C0206419,C0027051,management of ,Genus: Coronavirus,Myocardial Infarction,4,X,[virs],[dsyn],B04.820.504.540.150,C14.280.647.500;C14.907.585.500
95608874-8e76-449d-81b0-94603a21e151,C1457887,C3714514,is necessary For patients with suspected ,Symptoms,Infection,5,X,[sosy],[patf],,C01.539
95608874-8e76-449d-81b0-94603a21e151,C1457887,C3714514,people with suspected ,Symptoms,Infection,1,X,[sosy],[patf],,C01.539
8032cf92-4632-4c78-ab27-bce88d66d6ba,C0013879,C0042210,is In absence of ,Elements,Vaccines,3,X,[elii],[aapp/imft/phsu],D01.268,D20.215.894
4e2b7380-24a5-4029-831c-3db81aaf1fad,C0024109,C1440080,are damaged due to presence on epithelial ,Lung,Alveolar,3,X,[bpoc],[bpoc],A04.411,
2c5a98c5-14d9-49b0-831d-1cd297a06085,C0024109,C0014597,are damaged due to presence on epithelial ,Lung,Epithelial Cells,5,X,[bpoc],[cell],A04.411,A11.436
0427f019-1078-4ddc-a429-93e66669e6be,C0242656,C0018801, includes ,Disease Progression,Heart failure,3,X,[patf],[dsyn],C23.550.291.656,C14.280.434
692c3289-430c-441d-953d-f5fc59134c40,C0030660,C0242656,strongly associated to atherosclerotic ,Pathologic Processes,Disease Progression,3,X,[patf],[patf],C23.550,C23.550.291.656
d1712103-6b70-4edb-bad8-4f59eec10d2e,C0030660,C0018801,strongly associated to atherosclerotic ,Pathologic Processes,Heart failure,3,X,[patf],[dsyn],C23.550,C14.280.434
664f52f6-5c4c-4fff-b6f8-f93eeb4064fd,C0242656,C0021764,is characterized by immune system dysregulation leading to pro-inflammatory ,Disease Progression,Interleukins,6,X,[patf],[aapp/imft],C23.550.291.656,D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465
8bab9df6-cdc0-445f-860c-5874f3ec1169,C0242656,C1817997,is characterized as ,Disease Progression,chronic inflammatory response,9,X,[patf],[patf],C23.550.291.656,
d44e414e-8ca8-4319-8136-71c7bfffb400,C0004153,C3891814,may may ideal pathogenetic ,Atherosclerosis,Substrate,3,X,[dsyn],[sbst],C14.907.137.126.307,
9bb30993-f4fb-4998-b4e8-fc1452356545,C0004153,C0598312,may may ideal pathogenetic ,Atherosclerosis,DNA Replication,3,X,[dsyn],[genf],C14.907.137.126.307,G02.111.225;G05.226
93e6cbf0-fc8a-4eba-87d4-78f5f8d95298,C0015219,C0079189,exacerbate Biological Evolution due to excessive plasmatic concentration of,Biological Evolution,cytokine,3,X,[genf],[aapp/imft],G05.045;G16.075,D12.644.276.374;D12.776.467.374;D23.529.374
9a987a3a-ef09-4477-a344-178b519de603,C0282580,C3711684,potential B-Lymphocytes of,Epitopes T-Lymphocyte,S protein severe acute respiratory syndrome coronavirus,11,X,[imft],[aapp/bacs],D23.050.550.402,x.x.x.x
b9a6f017-8dcb-4653-9b9d-1e1b75034b74,C0282580,C0030956,potential B-Lymphocytes of,Epitopes T-Lymphocyte,Peptides,1,X,[imft],[aapp/phsu],D23.050.550.402,D12.644
7d951678-87e2-4909-becf-550ac7565c6f,C3711684,C0003320,has ,S protein severe acute respiratory syndrome coronavirus,Antigens,6,X,[aapp/bacs],[imft],x.x.x.x,D23.050
251e2c49-67aa-45e2-a60f-976ea49393d8,C0185027,C0030956,is with fusion ,Imbrication (procedure),Peptides,5,X,[topp],[aapp/phsu],,D12.644
337a5059-f43f-4fe5-a3d3-e85e4a919aed,C0003316,C3711684,is in ,Epitopes,S protein severe acute respiratory syndrome coronavirus,10,X,[imft],[aapp/bacs],D23.050.550,x.x.x.x
4aa02a55-1a59-4c1e-978b-af1ec5973d2d,C0597357,C0319157,Additionally thereby potentiating ,receptor,AS virus,2,X,[aapp/rcpt],[virs],,
93dde51f-a4a0-4e32-a662-455a39cab431,C0597357,C0009450,Additionally thereby potentiating ,receptor,Communicable Diseases,2,X,[aapp/rcpt],[dsyn],,C01.539.221
b72c978d-d575-4cf9-89c4-05ef27d2c181,C0319157,C0086418,started from single ,AS virus,Homo sapiens,12,X,[virs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
3c5331a0-0843-4161-a684-e842d3387805,COVID-19,C0149978,subsequently experienced ,COVID-19,Adenocarcinoma of rectum,11,X,[virs],[neop],C000657245,
b1107286-ff13-4c0d-aaf7-2ce67ac923e8,RT-PCR,C0237820,Rectal mucous membrane after,RT-PCR,Recovery - action,1,X,????,[acty],????,
19a80db9-580a-47ff-8aa5-ce26ccf514cf,C0010200,COVID-19,was diagnosed with ,Coughing,COVID-19,1,X,[sosy],[virs],C08.618.248;C23.888.852.293,C000657245
c3c3779e-c2af-4b37-9df9-4207a5739ae3,C1175743,COVID-19,is responsible for ,SARS coronavirus,COVID-19,20,X,[virs],[virs],B04.820.504.540.150.113.937,C000657245
1879e1d8-4ca4-4858-9b9f-4fd3abac3c56,C0013404,COVID-19,may play role in ,Dyspnea,COVID-19,1,X,[sosy],[virs],C08.618.326;C23.888.852.371,C000657245
9a62deca-0b8a-4e62-9345-4d96ea3b28d7,C0857172,COVID-19,may play role in ,persistent dry cough,COVID-19,1,X,[sosy],[virs],,C000657245
93e6f986-d9b4-48b4-80b1-3b18dc29ffe1,C0015967,COVID-19,may play role in ,Fever,COVID-19,1,X,[sosy],[virs],C23.888.119.344,C000657245
93e6f986-d9b4-48b4-80b1-3b18dc29ffe1,C0015967,COVID-19,varied spectra of ,Fever,COVID-19,1,X,[sosy],[virs],C23.888.119.344,C000657245
93e6f986-d9b4-48b4-80b1-3b18dc29ffe1,C0015967,COVID-19,coryza than,Fever,COVID-19,1,X,[sosy],[virs],C23.888.119.344,C000657245
93e6f986-d9b4-48b4-80b1-3b18dc29ffe1,C0015967,COVID-19,was found in ,Fever,COVID-19,1,X,[sosy],[virs],C23.888.119.344,C000657245
48bfe424-3942-4bda-a1b6-542e39e7b159,C0030054,COVID-19,may play role in ,Oxygen,COVID-19,1,X,[bacs/elii/phsu],[virs],D01.268.185.550;D01.362.670;x.x.x.x,C000657245
48bfe424-3942-4bda-a1b6-542e39e7b159,C0030054,COVID-19,RBCs from ,Oxygen,COVID-19,1,X,[bacs/elii/phsu],[virs],D01.268.185.550;D01.362.670;x.x.x.x,C000657245
f8a7fbde-c657-4d3e-8b7e-18c87a244ed5,C0369718,COVID-19,RBCs from ,N not otherwise specified Antibody,COVID-19,1,X,[aapp/imft],[virs],,C000657245
fb5b88f5-47a4-4f16-b779-2f962e4ea6e9,C1856053,C0230425,between numbers is ,Hydranencephaly with Renal Aplasia-Dysplasia,Structure of right thigh,1,X,[dsyn],[bpoc],x.x.x.x,
dfe5873a-5807-4cc6-854d-7b4e76ff2a1e,C0230425,C1708476,was associated with ,Structure of right thigh,Implementation,2,X,[bpoc],[acty],,
95842a31-7efd-4f1c-9a02-16ff183296f4,C0230425,C1856053,was associated with ,Structure of right thigh,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[bpoc],[dsyn],,x.x.x.x
55d97d0f-3364-4a10-81f7-41eead5e0419,C0230425,C1705178,was associated with ,Structure of right thigh,Order (action),1,X,[bpoc],[acty],,
f3100c9c-0a1a-43c5-9d3f-100093c04dae,C0009450,C1457887,may progress without ,Communicable Diseases,Symptoms,2,X,[dsyn],[sosy],C01.539.221,
fd74c715-30e8-48e6-b01d-5fff1ead9601,C0543467,C0023693,is mandatory in ,Operative Surgical Procedures,Light,6,X,[topp],[npop],E04,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
d487352c-6732-44b1-a8bb-0905d9fe2a2c,C0206750,C1880355,was ,Coronavirus Infections,Discover,1,X,[dsyn],[acty],C02.782.600.550.200,
dd4165fe-8610-4dbd-873b-d7b43c1216f7,C0012634,C1880355,was ,Disease,Discover,1,X,[dsyn],[acty],C23.550.288,
b981bde9-5b24-4129-8de9-ecdb5ea719fd,COVID-19,C0264490,was intubated for ,COVID-19,Acute respiratory failure,1,X,[virs],[dsyn],C000657245,
b981bde9-5b24-4129-8de9-ecdb5ea719fd,COVID-19,C0264490,can lead to ,COVID-19,Acute respiratory failure,1,X,[virs],[dsyn],C000657245,
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,discuss ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,was to COVID19 ,Aim,COVID-19,2,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,evaluate ,Aim,COVID-19,3,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,explore ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,provide ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,identify ,Aim,COVID-19,2,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,better quantify ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,show ,Aim,COVID-19,2,X,[inch/phsu],[virs],,C000657245
07311d75-6509-4faf-9984-ec8e070a117c,C2948600,COVID-19,preserve healthcare resources during ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
61b9ed5a-9f2d-4999-8270-e51c76193020,C2948600,C1521863,discuss ,Aim,estrogen receptor alpha human,1,X,[inch/phsu],[aapp/rcpt],,x.x.x.x
3dcc82db-a2c8-4500-a5c7-894e1bc47b15,C0035668,C0036087,is in ,RNA,saliva,5,X,[nnon],[bdsu],D13.444.735,A12.200.666
6f4a1d5d-26b8-4a02-83e2-1bebae64cfe3,C0003342,C0003320,was detected by rapid ,Antigens Viral,Antigens,4,X,[imft],[imft],D23.050.327,D23.050
6f4a1d5d-26b8-4a02-83e2-1bebae64cfe3,C0003342,C0003320,was Detection by rapid,Antigens Viral,Antigens,1,X,[imft],[imft],D23.050.327,D23.050
c8420caa-c65c-416e-9d99-9c0b9f36e356,C0036087,COVID-19,diagnosing ,saliva,COVID-19,1,X,[bdsu],[virs],A12.200.666,C000657245
f0fedb19-2109-4809-80c8-0211dfea5bc4,C0014507,C3714514,is necessary For patients with ,Epidemiology,Infection,3,X,[bmod],[patf],H02.403.720.500,C01.539
c214c43b-cb3e-458a-8322-d38163e185ba,C0319157,C1856053,was declared pandemic on ,AS virus,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[virs],[dsyn],,x.x.x.x
b7b73952-b46a-4447-bd89-cfadd621a935,C0030946,C0007428, includes ,Endopeptidases,Cathepsins,3,X,[aapp/enzy/phsu],[aapp/enzy],D08.811.277.656.300,D08.811.277.656.224
ecbd3231-be13-471f-860a-086c0371b2a4,C0030946,C1742865, includes ,Endopeptidases,TMPRSS2 protein human,3,X,[aapp/enzy/phsu],[aapp/enzy],D08.811.277.656.300,x.x.x.x
ecbd3231-be13-471f-860a-086c0371b2a4,C0030946,C1742865,as Serine Endopeptidases is,Endopeptidases,TMPRSS2 protein human,1,X,[aapp/enzy/phsu],[aapp/enzy],D08.811.277.656.300,x.x.x.x
bdc3e323-ac79-4471-a370-2c54e0ea411c,C0030946,C0700271,splits up ,Endopeptidases,M Protein multiple myeloma,1,X,[aapp/enzy/phsu],[aapp/imft],D08.811.277.656.300,x.x.x.x
0bfd4e26-f998-4497-bc5d-c765a6682dc2,C0007428,C0700271,splits up ,Cathepsins,M Protein multiple myeloma,1,X,[aapp/enzy],[aapp/imft],D08.811.277.656.224,x.x.x.x
582e3209-b149-4cc0-81e4-92451a99d42d,C1742865,C0700271,splits up ,TMPRSS2 protein human,M Protein multiple myeloma,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,x.x.x.x
582e3209-b149-4cc0-81e4-92451a99d42d,C1742865,C0700271,used for ,TMPRSS2 protein human,M Protein multiple myeloma,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,x.x.x.x
4686c8fd-09dd-4667-9985-f42edf9d9903,C3698360,C1447020,uses ,Middle East Respiratory Syndrome Coronavirus,DPP4 protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.750,x.x.x.x
d11ffe34-626f-4b0c-bad0-f6fbea6d1107,C0079189,COVID-19,was analyzed in ,cytokine,COVID-19,6,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,C000657245
2ab52cbd-00fb-4aaf-9d04-7585a94d80a2,C1861452,COVID-19,was analyzed in ,Storm Syndrome,COVID-19,1,X,[dsyn],[virs],x.x.x.x,C000657245
2ab52cbd-00fb-4aaf-9d04-7585a94d80a2,C1861452,COVID-19,may complicate ,Storm Syndrome,COVID-19,1,X,[dsyn],[virs],x.x.x.x,C000657245
c9685d04-3af2-4407-976f-d2bf555302a2,C0012634,C0087111,pose major ,Disease,Therapeutic procedure,3,X,[dsyn],[topp],C23.550.288,E02
c9685d04-3af2-4407-976f-d2bf555302a2,C0012634,C0087111,seek proper ,Disease,Therapeutic procedure,1,X,[dsyn],[topp],C23.550.288,E02
c9685d04-3af2-4407-976f-d2bf555302a2,C0012634,C0087111,modifying ,Disease,Therapeutic procedure,1,X,[dsyn],[topp],C23.550.288,E02
c9685d04-3af2-4407-976f-d2bf555302a2,C0012634,C0087111,develop ,Disease,Therapeutic procedure,2,X,[dsyn],[topp],C23.550.288,E02
16949d06-b1f7-4fbf-a2a2-74636dbc809a,C0021764,C0021368,play role in ,Interleukins,Inflammation,3,X,[aapp/imft],[patf],D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465,C23.550.470
fe80ceb9-656c-41ca-bddb-b8b191e167d3,C0021764,C3819028,play role in ,Interleukins,Interleukin 6 Receptor Antagonists,1,X,[aapp/imft],[celf],D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465,
f6587a4a-31d4-4fcb-a3c6-b006a36e89f8,C0021368,C1609165,Interleukin 6 Receptor Antagonists such as,Inflammation,tocilizumab,1,X,[patf],[aapp/imft/phsu],C23.550.470,x.x.x.x
2b029095-876d-4452-bbba-04001f925832,COVID-19,C0079189,prevent onset of ,COVID-19,cytokine,1,X,[virs],[aapp/imft],C000657245,D12.644.276.374;D12.776.467.374;D23.529.374
2b029095-876d-4452-bbba-04001f925832,COVID-19,C0079189,can manifest with ,COVID-19,cytokine,1,X,[virs],[aapp/imft],C000657245,D12.644.276.374;D12.776.467.374;D23.529.374
2b029095-876d-4452-bbba-04001f925832,COVID-19,C0079189,are characterized with ,COVID-19,cytokine,1,X,[virs],[aapp/imft],C000657245,D12.644.276.374;D12.776.467.374;D23.529.374
2b029095-876d-4452-bbba-04001f925832,COVID-19,C0079189,leads to ,COVID-19,cytokine,1,X,[virs],[aapp/imft],C000657245,D12.644.276.374;D12.776.467.374;D23.529.374
c1119e1c-6455-458d-8aee-2ed4a6226a12,COVID-19,C1609165,were treated with ,COVID-19,tocilizumab,2,X,[virs],[aapp/imft/phsu],C000657245,x.x.x.x
e994feda-0051-4fdd-ba13-800c1fa59e4f,C0948245,COVID-19,is in ,Cytokine Release Syndrome,COVID-19,8,X,[dsyn],[virs],,C000657245
e6481b65-54ba-46f5-ae59-8b624283b323,C0035253,C0015672,only manifested minor ,Rest,Fatigue,3,X,[dora],[sosy],I03.450.769.647,C23.888.369
5ff7458d-60bf-4e02-8f6c-70dc512a26a2,C0035253,C0015967,only manifested Fatigue with low,Rest,Fever,3,X,[dora],[sosy],I03.450.769.647,C23.888.119.344
c9088198-8210-4ad5-b207-2dbad4408e42,C0030664,C0040145, includes ,Pathology,Thyroidectomy,1,X,[bmod],[topp],H02.403.650,E04.270.856
cee0dd5d-1ce7-4308-991b-7159b4cd7581,C1880355,C0013203,will will paramount for efficient delivery of possible ,Discover,Drug resistance,3,X,[acty],[biof],,G07.690.773.984
7179f577-6ca4-47ba-b236-4c1f045c40a1,C0849867,C0034386,has necessitated self ,Widespread Disease,Quarantine,2,X,[dsyn],[topp],,N06.850.780.200.450.700
6668206f-0331-41cf-abf8-549f5f8528d7,C0206750,C0034386,has necessitated self ,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
6668206f-0331-41cf-abf8-549f5f8528d7,C0206750,C0034386,can can exploited for early ,Coronavirus Infections,Quarantine,2,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
6668206f-0331-41cf-abf8-549f5f8528d7,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
6668206f-0331-41cf-abf8-549f5f8528d7,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
6668206f-0331-41cf-abf8-549f5f8528d7,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
6668206f-0331-41cf-abf8-549f5f8528d7,C0206750,C0034386,using strategies of ,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
6668206f-0331-41cf-abf8-549f5f8528d7,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
50dea9c9-d8bf-45e8-8048-94a51ed49bcb,C0849867,C0012634,so prevent spread of ,Widespread Disease,Disease,6,X,[dsyn],[dsyn],,C23.550.288
e5d5ec99-edd6-48e1-805a-43aa1d044545,C0150593,C0038443,cope with ,game,Stress Psychological,4,X,[dora],[mobd],,F01.145.126.990;F02.830.900
41325649-f922-4245-9f6c-f132c911199b,C0150593,C0849867,cope with ,game,Widespread Disease,8,X,[dora],[dsyn],,
57b08635-f01f-4fea-9bd3-87cdf7dad23a,C0150593,C0206750,cope with ,game,Coronavirus Infections,2,X,[dora],[dsyn],,C02.782.600.550.200
601af10f-50f1-42ea-85dc-fc688aa9e0dc,C1175743,C0278627,is in Italian ,SARS coronavirus,oncology field,1,X,[virs],[bmod],B04.820.504.540.150.113.937,
89cf4eda-2dba-44ba-a7f7-07a3ab503ee5,C0278627,C1175743,is in ,oncology field,SARS coronavirus,4,X,[bmod],[virs],,B04.820.504.540.150.113.937
665b47b4-b71d-4ab9-9dff-fb36f9b6229b,C0086418,C0022709,exhibits greater ,Homo sapiens,Peptidyl-Dipeptidase A,1,X,[humn],[aapp/enzy/imft],B01.050.150.900.649.313.988.400.112.400.400,D08.811.277.656.350.350.687
665b47b4-b71d-4ab9-9dff-fb36f9b6229b,C0086418,C0022709,in Peptidyl-Dipeptidase A is,Homo sapiens,Peptidyl-Dipeptidase A,1,X,[humn],[aapp/enzy/imft],B01.050.150.900.649.313.988.400.112.400.400,D08.811.277.656.350.350.687
665b47b4-b71d-4ab9-9dff-fb36f9b6229b,C0086418,C0022709,Failed have higher percentage of ,Homo sapiens,Peptidyl-Dipeptidase A,1,X,[humn],[aapp/enzy/imft],B01.050.150.900.649.313.988.400.112.400.400,D08.811.277.656.350.350.687
025b653e-9b9a-461c-b92c-dd5be14c7d34,C0018787,C0022709,exhibits greater ,Heart,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.541,D08.811.277.656.350.350.687
025b653e-9b9a-461c-b92c-dd5be14c7d34,C0018787,C0022709,also express ,Heart,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.541,D08.811.277.656.350.350.687
025b653e-9b9a-461c-b92c-dd5be14c7d34,C0018787,C0022709,Failed have higher percentage of ,Heart,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.541,D08.811.277.656.350.350.687
f850e84a-483a-4a93-a175-e3533347a12a,C0022709,C0024109,were widely disturbed among ,Peptidyl-Dipeptidase A,Lung,17,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A04.411
261b4c2b-404f-40d3-8966-333a67d82b63,C0022709,C0018787,is in adult human ,Peptidyl-Dipeptidase A,Heart,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A07.541
261b4c2b-404f-40d3-8966-333a67d82b63,C0022709,C0018787,were widely disturbed among ,Peptidyl-Dipeptidase A,Heart,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A07.541
01f58815-b309-4cfa-98cf-7a16c10bb404,C0010813,C0018787,is in adult human ,Cytokinesis,Heart,1,X,[celf],[bpoc],G04.144.220.250,A07.541
8cdbda1a-93fb-4103-a89a-ce1b98d7128f,C0030946,C0018787,is in adult human ,Endopeptidases,Heart,1,X,[aapp/enzy/phsu],[bpoc],D08.811.277.656.300,A07.541
d6ba5c2d-cbba-4e93-87d7-51f97795b009,C1742865,C0018787,is in adult human ,TMPRSS2 protein human,Heart,1,X,[aapp/enzy],[bpoc],x.x.x.x,A07.541
2898e310-fe39-46ff-9c8e-7e55c153a3e8,C0018787,C1742865,in TMPRSS2 protein human is,Heart,TMPRSS2 protein human,2,X,[bpoc],[aapp/enzy],A07.541,x.x.x.x
72afdffd-da7c-47c3-9f8c-8716ab44ce49,C0018799,C0206750,is in ,Heart Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C14.280,C02.782.600.550.200
5bd25ef6-8fc7-4fb4-8a75-e96c8cfc4a43,C3714514,C1457887,may even progress without ,Infection,Symptoms,1,X,[patf],[sosy],C01.539,
5bd25ef6-8fc7-4fb4-8a75-e96c8cfc4a43,C3714514,C1457887,generally have few ,Infection,Symptoms,1,X,[patf],[sosy],C01.539,
8060b4d4-0fef-4e5e-99ac-74d5ee448eff,C3714514,C0242781,produced For early ,Infection,disease transmission,1,X,[patf],[patf],C01.539,N06.850.310
e2ffc20e-d28c-49a2-a559-ae5921f79f6b,C0013216,C0206750,suitable for ,Pharmacotherapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.319,C02.782.600.550.200
13844d35-2c84-4606-bf5e-ad0f1e73908c,C0003968,C1547282,has ,Ascorbic Acid,Show,1,X,[orch/phsu/vita],[anim],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,
724f705b-d7c6-48b8-b136-421221a064e7,C0003968,C0034392,increasing ,Ascorbic Acid,Quercetin,2,X,[orch/phsu/vita],[orch/phsu/vita],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777
64a0cc8d-e41e-4ee2-8f14-8865d15137ac,C0035736,C1175743,was detected in of ,RNA Viral,SARS coronavirus,6,X,[nnon],[virs],D13.444.735.828,B04.820.504.540.150.113.937
5c520272-0916-49dc-97bc-c9b54b955dde,C0036087,C0206750,diagnosing ,saliva,Coronavirus Infections,3,X,[bdsu],[dsyn],A12.200.666,C02.782.600.550.200
aed50777-3287-4446-ab68-e3cd35f0944f,C0206750,C1547282,has ,Coronavirus Infections,Show,1,X,[dsyn],[anim],C02.782.600.550.200,
cf005e45-9cb2-4166-8d28-6460b30b349c,C0022709,C1819995,is recognized ,Peptidyl-Dipeptidase A,Host Cell,4,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
cf005e45-9cb2-4166-8d28-6460b30b349c,C0022709,C1819995,prevent SARS coronavirus attaching to,Peptidyl-Dipeptidase A,Host Cell,5,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
1321b3a4-f370-479a-8edf-8f40cdaa6c51,C0022709,C0597357,was identified as ,Peptidyl-Dipeptidase A,receptor,27,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,
7d584040-bf0f-42c3-bc8a-5153aee8b7d0,C1819995,C1175743,mediating SARS coronavirus by,Host Cell,SARS coronavirus,8,X,[celc],[virs],,B04.820.504.540.150.113.937
1b8e527f-a483-421e-9ae0-78ce6b4ddb67,C0597357,C1175743,mediating SARS coronavirus by,receptor,SARS coronavirus,8,X,[aapp/rcpt],[virs],,B04.820.504.540.150.113.937
1b8e527f-a483-421e-9ae0-78ce6b4ddb67,C0597357,C1175743,be functional target for spike ,receptor,SARS coronavirus,1,X,[aapp/rcpt],[virs],,B04.820.504.540.150.113.937
1b8e527f-a483-421e-9ae0-78ce6b4ddb67,C0597357,C1175743,prevent ,receptor,SARS coronavirus,6,X,[aapp/rcpt],[virs],,B04.820.504.540.150.113.937
c851d9ce-0095-4314-a305-d0d456297019,C2258685,C1879547,mitigates deleterious effects associated with ,angiotensin converting enzyme activity,Activation action,4,X,[moft],[acty],,
af8a6048-4095-4ebb-a16d-c767e92d7f9b,C2258685,C0035100,mitigates deleterious effects associated with ,angiotensin converting enzyme activity,Chymosin,2,X,[moft],[aapp/enzy],,D08.811.277.656.074.500.200;D08.811.277.656.300.048.200
6011316c-167d-4577-9cc4-42f106ad9f68,C2258685,C0178784,mitigates deleterious effects associated with ,angiotensin converting enzyme activity,Organ,4,X,[moft],[bpoc],,
92a5f297-29dc-40ed-a93e-e66643caa3ba,C0233929,C0034019,affecting ,Emission - Male genitalia finding,public health medicine (field),5,X,[bdsu],[bmod],,H02.403.720;N01.400.550;N06.850
4cecf45e-db03-4d89-a43e-abfc697603b3,C0206750,C0087111,be could applied as ,Coronavirus Infections,Therapeutic procedure,1,X,[dsyn],[topp],C02.782.600.550.200,E02
4cecf45e-db03-4d89-a43e-abfc697603b3,C0206750,C0087111,toxic effect increased of,Coronavirus Infections,Therapeutic procedure,2,X,[dsyn],[topp],C02.782.600.550.200,E02
4cecf45e-db03-4d89-a43e-abfc697603b3,C0206750,C0087111,has IMPACT gene toxic,Coronavirus Infections,Therapeutic procedure,2,X,[dsyn],[topp],C02.782.600.550.200,E02
4cecf45e-db03-4d89-a43e-abfc697603b3,C0206750,C0087111,mobilized institutions worldwide in race towards ,Coronavirus Infections,Therapeutic procedure,3,X,[dsyn],[topp],C02.782.600.550.200,E02
f726272a-63b8-4362-9f3b-210d2a03fbcd,C0020336,C3541371,are Quinoline derivatives antiseptics and disinfectants of,Hydroxychloroquine,Quinoline derivatives antiseptics and disinfectants,2,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180.350,
f547cbbb-3b3c-471a-b3a7-3b3968dfc56f,C0008269,C0019398,are Quinoline derivatives antiseptics and disinfectants of,Chloroquine,Heterocyclic Compounds,4,X,[orch/phsu],[orch],D03.633.100.810.050.180,D03
5975b3ae-6ba9-45a3-9ade-c85ca8ab11b0,C0008269,C0772162,are Quinoline derivatives antiseptics and disinfectants of,Chloroquine,AROMATICS,2,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,
dee71b5f-ab6b-4383-ac7a-694bbc802450,C0008269,C3541371,are Quinoline derivatives antiseptics and disinfectants of,Chloroquine,Quinoline derivatives antiseptics and disinfectants,3,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,
8b12fb66-55a7-440a-affe-0a997bdfaa59,C0020336,C0019398,are Quinoline derivatives antiseptics and disinfectants of,Hydroxychloroquine,Heterocyclic Compounds,2,X,[orch/phsu],[orch],D03.633.100.810.050.180.350,D03
48d92d56-1e51-4b36-a2d3-0465e47b1d47,C0020336,C0772162,are Quinoline derivatives antiseptics and disinfectants of,Hydroxychloroquine,AROMATICS,1,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180.350,
9cad4fdb-5ce9-4c0b-8ebc-9dbedb213a16,C0020336,C1707251,could could used in combination with ,Hydroxychloroquine,Cancer Other,2,X,[orch/phsu],[neop],D03.633.100.810.050.180.350,
23787773-a5c9-40a0-8f95-339e3b3abc3a,C0020336,U.S.,were Recently approved for U.S. ,Hydroxychloroquine,U.S.,1,X,[orch/phsu],????,D03.633.100.810.050.180.350,????
2d3e249d-68dd-4b32-bf48-6d262c6ed6ae,C0020336,C1175743,were Recently approved for U.S. ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
2d3e249d-68dd-4b32-bf48-6d262c6ed6ae,C0020336,C1175743,could potently inhibit ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
2d3e249d-68dd-4b32-bf48-6d262c6ed6ae,C0020336,C1175743,is effective against ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
2d3e249d-68dd-4b32-bf48-6d262c6ed6ae,C0020336,C1175743,is more potent than CQ ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
2d3e249d-68dd-4b32-bf48-6d262c6ed6ae,C0020336,C1175743,exhibited anti ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
760013c9-4ca3-44ef-bf5f-31b373dca97c,C0206750,C1175175,rapidly progresses to ,Coronavirus Infections,Severe Acute Respiratory Syndrome,19,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.600.550.200.750;C08.730.730
577598d4-8f6b-405e-aafb-4b00d0777da4,C0206750,C0022709,is cause with ,Coronavirus Infections,Peptidyl-Dipeptidase A,4,X,[dsyn],[aapp/enzy/imft],C02.782.600.550.200,D08.811.277.656.350.350.687
577598d4-8f6b-405e-aafb-4b00d0777da4,C0206750,C0022709,acts through ,Coronavirus Infections,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C02.782.600.550.200,D08.811.277.656.350.350.687
985cc268-d3ac-47e5-af6b-57e8ff18f8d9,C0206750,C0086418,took 0.39 million ,Coronavirus Infections,Homo sapiens,23,X,[dsyn],[humn],C02.782.600.550.200,B01.050.150.900.649.313.988.400.112.400.400
64721bfc-755d-4b2b-80f3-b773e660ad1a,C0206750,C1167622,is cause with ,Coronavirus Infections,Binding (Molecular Function),2,X,[dsyn],[moft],C02.782.600.550.200,
9e7fb273-e2a7-456c-a544-6f5ee64c4a21,C0206750,C0014597,is cause with ,Coronavirus Infections,Epithelial Cells,4,X,[dsyn],[cell],C02.782.600.550.200,A11.436
d9031b18-b8ca-48e0-9120-88ea0b4493a6,C0206750,C0024109,is cause with ,Coronavirus Infections,Lung,3,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
d9031b18-b8ca-48e0-9120-88ea0b4493a6,C0206750,C0024109,predominantly involves ,Coronavirus Infections,Lung,3,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
d9031b18-b8ca-48e0-9120-88ea0b4493a6,C0206750,C0024109,leading to ,Coronavirus Infections,Lung,1,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
d9031b18-b8ca-48e0-9120-88ea0b4493a6,C0206750,C0024109, includes ,Coronavirus Infections,Lung,1,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
d9031b18-b8ca-48e0-9120-88ea0b4493a6,C0206750,C0024109,directly targets ,Coronavirus Infections,Lung,2,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
13cc03eb-2889-4641-8f18-94cf35aa4072,C0022709,C0086418,is widely expressed in ,Peptidyl-Dipeptidase A,Homo sapiens,14,X,[aapp/enzy/imft],[humn],D08.811.277.656.350.350.687,B01.050.150.900.649.313.988.400.112.400.400
ca6293ce-3775-4f99-bb95-b173caca40e4,C0815017,C2258685,may interfere with ,Angiotensin Receptor Antagonists,angiotensin converting enzyme activity,8,X,[phsu],[moft],D27.505.519.162,
2d9af2a6-d1e0-4c6d-bb9f-07f504c0a05f,C0022709,C2258685,may interfere with ,Peptidyl-Dipeptidase A,angiotensin converting enzyme activity,8,X,[aapp/enzy/imft],[moft],D08.811.277.656.350.350.687,
d1d1402e-2707-4cec-ab5d-1c014aee588f,C0243077,C2258685,may interfere with ,inhibitors,angiotensin converting enzyme activity,8,X,[chvf],[moft],,
299d03df-50f7-4e7f-aacc-3769f83f39f8,nt,C0206750,did affect prognosis in ,nt,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
de600b19-334a-4b66-965b-c18fed2cf9e2,C0206750,C1628999,is caused by single-stranded ,Coronavirus Infections,SARS coronavirus RNA,4,X,[dsyn],[nnon],C02.782.600.550.200,
01785228-8735-406b-b673-9576cfd14c94,C0243077,C0003015, includes ,inhibitors,Angiotensin-Converting Enzyme Inhibitors,3,X,[chvf],[phsu],,D27.505.519.389.745.085
9eb2abe3-eb3f-48ef-b5e1-1212d2932fa7,RAS,C0020538,are widely used in treatment of ,RAS,Hypertensive disease,5,X,????,[dsyn],????,C14.907.489
d3b49e45-80d6-4d2e-9ef4-0e94d268add4,C0243077,C0020538,are widely used in treatment of ,inhibitors,Hypertensive disease,5,X,[chvf],[dsyn],,C14.907.489
448a42fe-8c9b-45d5-83c4-29ff43accdad,C1175743,C0960880,is with ,SARS coronavirus,angiotensin converting enzyme 2,5,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,x.x.x.x
7a877f3d-e889-40b9-a82a-b32cea83d607,C0042731,C0960880,attach ,Viral Matrix Proteins,angiotensin converting enzyme 2,4,X,[aapp/bacs],[aapp/enzy],D12.776.964.970.880.940,x.x.x.x
6cebfb54-cc51-4795-a7e3-a8cb18cd994e,C1175743,C0007603,attach angiotensin converting enzyme 2 on,SARS coronavirus,Plasma membrane,4,X,[virs],[celc],B04.820.504.540.150.113.937,A11.284.149
173b7f3a-49d3-4a02-b63d-f94567df9d62,C0042731,C0007603,attach angiotensin converting enzyme 2 on,Viral Matrix Proteins,Plasma membrane,4,X,[aapp/bacs],[celc],D12.776.964.970.880.940,A11.284.149
a51f00a9-e79d-4445-86d7-57935a388cf1,RAS,C0206750,be maintained during current ,RAS,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
b7bece49-d15e-45ee-bd61-f75a639d30a9,C3540676,C0206750,be maintained during current ,Blockade,Coronavirus Infections,2,X,[elii/phsu],[dsyn],,C02.782.600.550.200
b7bece49-d15e-45ee-bd61-f75a639d30a9,C3540676,C0206750,be maintained in patients with ,Blockade,Coronavirus Infections,1,X,[elii/phsu],[dsyn],,C02.782.600.550.200
579ff1df-ef30-4bb4-b9d0-203189338297,C0013227,C0206750,point for ,Pharmaceutical Preparations,Coronavirus Infections,6,X,[phsu],[dsyn],D26,C02.782.600.550.200
3275e5a8-eb9b-4a03-8ae1-e37f0bf8049e,C2347218,C0206750,be alternative in ,Bronchial Artery Infusion Procedure,Coronavirus Infections,4,X,[topp],[dsyn],,C02.782.600.550.200
1d52cd3e-c59d-4fba-b0fd-0f284cbc3fdf,C2347218,C0304229,be alternative in ,Bronchial Artery Infusion Procedure,Experimental drug,8,X,[topp],[phsu],,
10152eb7-6857-4182-865a-101e8f85ea1d,C2347218,C0392877,be alternative for systemic ,Bronchial Artery Infusion Procedure,infusion of drug,9,X,[topp],[topp],,
a321c0cc-12c3-4d91-9383-190f263bc95a,C0206750,C0304229,is with superadded benefits of high ,Coronavirus Infections,Experimental drug,1,X,[dsyn],[phsu],C02.782.600.550.200,
9d5021d2-9020-442e-9b0e-0de468fbf59f,C0003451,C0206750,stop ,Antiviral Agents,Coronavirus Infections,7,X,[phsu],[dsyn],D27.505.954.122.388,C02.782.600.550.200
e43a4607-0955-4da6-b84d-f6f816e8244f,C0003451,C0309872,stop ,Antiviral Agents,PREVENT (product),1,X,[phsu],[phsu],D27.505.954.122.388,
922e671a-93b1-4ddc-ab94-6dadf4460d39,C0012634,C0206750,was named ,Disease,Coronavirus Infections,42,X,[dsyn],[dsyn],C23.550.288,C02.782.600.550.200
e5c64c9f-f3eb-44d8-9e46-2730716b8574,C4042834,C0206750,gained importance during ,Compassion Fatigue,Coronavirus Infections,2,X,[mobd],[dsyn],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,C02.782.600.550.200
691e39a7-3add-4cff-be04-afa4324b5902,C4042834,C0012634,gained importance during ,Compassion Fatigue,Disease,2,X,[mobd],[dsyn],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,C23.550.288
1124a108-d017-4c1f-a62e-4c689eeb0636,C0042776,C0004391,exploit ,Virus,Autophagy,4,X,[virs],[celf],B04,G04.146.399;G04.417.350.091
a66bc97b-51ae-4e19-b83e-e65cb169e418,C0947647,C0042776,allows ,Manipulation procedure,Virus,4,X,[topp],[virs],,B04
321dbd66-cf05-4349-838e-2272ca48c422,C1704259,C0206750,might play role in ,Biochemical Pathway,Coronavirus Infections,3,X,[moft],[dsyn],,C02.782.600.550.200
321dbd66-cf05-4349-838e-2272ca48c422,C1704259,C0206750,Dysregulation of were proposed mechanisms of ,Biochemical Pathway,Coronavirus Infections,2,X,[moft],[dsyn],,C02.782.600.550.200
7b813c03-f3b8-455d-9397-b91b8a935251,C1704259,C0598312,might play role in ,Biochemical Pathway,DNA Replication,4,X,[moft],[genf],,G02.111.225;G05.226
6e3b1cc3-5473-4c4a-a0b9-6a92d6b5a9dd,C3711684,C0005525,may improve vaccine design diagnosis and ,S protein severe acute respiratory syndrome coronavirus,Biological Response Modifiers,3,X,[aapp/bacs],[imft/phsu],x.x.x.x,D27.505.696.477
2ec8fa8b-0269-4ced-8b73-9ed595dd0a1a,C3711684,C0206750,may improve vaccine design diagnosis and ,S protein severe acute respiratory syndrome coronavirus,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
93e2da52-65e5-4538-81f6-c544186b03bc,COVID,C1175743,are similar to those of ,COVID,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
93e2da52-65e5-4538-81f6-c544186b03bc,COVID,C1175743,is much more than ,COVID,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
60bd7c61-2b6e-48d1-8651-98cfa15116d4,C1552133,C1175743,are similar to those of ,19s,SARS coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150.113.937
a0b43107-40e3-4f85-80c4-e21b70f2649a,C1882932,C0556656,should have Inclusion Bodies in strategic,Representation (action),Meetings,2,X,[acty],[acty],,
53c28bdf-9eff-4d36-9bc1-515c164fdf8f,C1882932,C0007637,should have equal ,Representation (action),Inclusion Bodies,2,X,[acty],[celc],,A11.284.420
4833bb75-7a76-48b1-b938-ed2634015048,C0275524,C0011311,trigger alert for health care professionals in ,Coinfection,Dengue Fever,3,X,[dsyn],[dsyn],C01.539.218;C02.219;C03.202,C02.081.270;C02.782.350.250.214;C02.782.417.214
9399afac-3664-439d-8e4f-63271f431351,C0042769,C0035243,is ,Virus Diseases,Respiratory Tract Infections,1,X,[dsyn],[dsyn],C02,C01.539.739;C08.730
a5cb0ef1-4d23-47df-bd71-9ec0acc8b4b9,C0042769,C0023884,lead to ,Virus Diseases,Liver,1,X,[dsyn],[bpoc],C02,A03.620
e11d47e6-f897-4654-9f02-fa549bf17b43,C1175743,C0015733,was detected in ,SARS coronavirus,Feces,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.459
e11d47e6-f897-4654-9f02-fa549bf17b43,C1175743,C0015733,was isolated from ,SARS coronavirus,Feces,1,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.459
e11d47e6-f897-4654-9f02-fa549bf17b43,C1175743,C0015733,is shed via ,SARS coronavirus,Feces,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.459
d9091779-3e41-4743-bd59-bf8fdfb37c23,CoV2,C0015733,was detected in ,CoV2,Feces,1,X,????,[bdsu],????,A12.459
b712c7fd-d042-4770-a162-10149121cf2f,C0022709,C2699153,enables ,Peptidyl-Dipeptidase A,Cell Invasion,1,X,[aapp/enzy/imft],[patf],D08.811.277.656.350.350.687,
08b99b13-890a-49e6-9154-d3a89c2a45f7,C0022709,C0836205,enables ,Peptidyl-Dipeptidase A,Gut Epithelium,1,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,
9684fec7-3dd9-48de-9f8f-02a48fee98e7,C0022709,vivo,enables Cell Invasion demonstrated and in vivo,Peptidyl-Dipeptidase A,vivo,1,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
dc0afc90-497c-48e7-a4dc-e76cef2d96bf,C4529962,C0016059,is with ,Fatty Liver Disease,Fibrosis,1,X,[dsyn],[patf],,C23.550.355
7df48480-6fb4-4e71-9925-53a9d72d7fb5,C0023890,C0206750,are at high risk for severe ,Liver Cirrhosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.552.630,C02.782.600.550.200
01598c98-c446-4f84-9479-e6385230e288,C0849867,C1825598,has had significant ,Widespread Disease,IMPACT gene,2,X,[dsyn],[gngm],,
f52c6ef5-07e5-471b-8600-c63fcb2b9c9e,C0849867,C0034019,has had significant ,Widespread Disease,public health medicine (field),4,X,[dsyn],[bmod],,H02.403.720;N01.400.550;N06.850
f52c6ef5-07e5-471b-8600-c63fcb2b9c9e,C0849867,C0034019,represents emergent threat to ,Widespread Disease,public health medicine (field),1,X,[dsyn],[bmod],,H02.403.720;N01.400.550;N06.850
e94145a3-01ee-485c-9006-d7462c0a1ee6,C0849867,C1175175,is ,Widespread Disease,Severe Acute Respiratory Syndrome,2,X,[dsyn],[dsyn],,C02.782.600.550.200.750;C08.730.730
4a41215d-aee0-4246-bf25-ade5c32bb895,C1175175,C0032285,causes severe form of ,Severe Acute Respiratory Syndrome,Pneumonia,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.677;C08.730.610
4a41215d-aee0-4246-bf25-ade5c32bb895,C1175175,C0032285,COVID-19 as clinical ,Severe Acute Respiratory Syndrome,Pneumonia,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.677;C08.730.610
24727787-f4f9-4a17-a0eb-3ed34734dc17,C0023870,C1979799,is commonly prescribed ,Lithium,Psychiatric drugs,1,X,[elii/phsu],[phsu],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,
242ce780-d52e-4419-b6c3-4c853cf69108,C0042776,C1819995,uses Virus spike Glycoproteins domain interact with,Virus,Host Cell,5,X,[virs],[celc],B04,
242ce780-d52e-4419-b6c3-4c853cf69108,C0042776,C1819995,mediates altered ,Virus,Host Cell,2,X,[virs],[celc],B04,
242ce780-d52e-4419-b6c3-4c853cf69108,C0042776,C1819995,enter ,Virus,Host Cell,1,X,[virs],[celc],B04,
ab1f15df-5ccd-470b-9474-31b6b4ed0370,C0042776,C0022709,uses Virus spike Glycoproteins domain interact with,Virus,Peptidyl-Dipeptidase A,3,X,[virs],[aapp/enzy/imft],B04,D08.811.277.656.350.350.687
ab1f15df-5ccd-470b-9474-31b6b4ed0370,C0042776,C0022709,exploit ,Virus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04,D08.811.277.656.350.350.687
6cb9cd16-f845-4c52-9fa3-b706e95aa2cc,C0042776,C0017968,uses ,Virus,Glycoproteins,2,X,[virs],[aapp/bacs],B04,D09.400.430;D12.776.395
1c654161-a8ec-43ce-8d4e-ff8ba01372fa,C0042776,C0597357,uses ,Virus,receptor,2,X,[virs],[aapp/rcpt],B04,
1c654161-a8ec-43ce-8d4e-ff8ba01372fa,C0042776,C0597357,recognizes other ,Virus,receptor,1,X,[virs],[aapp/rcpt],B04,
0c19338e-7b75-470e-bab6-83ec9ad5365e,C0042776,C4689723,uses ,Virus,glycoprotein binding,2,X,[virs],[moft],B04,
7a7bbc44-83d1-4500-9dcc-8fa95ad4a050,C0948245,C0960756,be ,Cytokine Release Syndrome,factor A,2,X,[dsyn],[orch],,x.x.x.x
e9e76df3-e87d-4e24-9eb1-8bf57d232eef,C0948245,C1880177,be ,Cytokine Release Syndrome,Contribution,1,X,[dsyn],[acty],,
5f680758-0dcc-47cf-b125-b04b45d6f83f,C3819028,C1609165, includes ,Interleukin 6 Receptor Antagonists,tocilizumab,6,X,[celf],[aapp/imft/phsu],,x.x.x.x
5c8e2983-5fe7-4fb3-bf1b-71286577f7cb,C3819028,C0206419,may Therapeutic procedure,Interleukin 6 Receptor Antagonists,Genus: Coronavirus,1,X,[celf],[virs],,B04.820.504.540.150
31434100-f366-4176-9504-736f2d96a8b5,C1609165,C0206419,may Therapeutic procedure,tocilizumab,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],x.x.x.x,B04.820.504.540.150
31434100-f366-4176-9504-736f2d96a8b5,C1609165,C0206419,may may effective for treatment of severe ,tocilizumab,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],x.x.x.x,B04.820.504.540.150
2d671b90-2c29-4f4a-bcf1-b0583cdf4204,C3819028,C0079189,attenuating ,Interleukin 6 Receptor Antagonists,cytokine,2,X,[celf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
9722d2c9-9b1e-4c99-8754-364162ce1b6e,C1609165,C0079189,attenuating ,tocilizumab,cytokine,2,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,D12.644.276.374;D12.776.467.374;D23.529.374
0aa4bd18-bbe6-41fd-895a-9744eb595588,C0948245,C0206419,is in ,Cytokine Release Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
d4228e68-b39a-4c19-b669-adfaa4194f08,C3711684,C0206419,may improve vaccine design diagnosis and ,S protein severe acute respiratory syndrome coronavirus,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
d9609db7-8a71-4411-87ec-b14a4e768ec2,C2948600,C1947933,define guidelines for safe clinical ,Aim,care activity,1,X,[inch/phsu],[acty],,
d9609db7-8a71-4411-87ec-b14a4e768ec2,C2948600,C1947933,was to COVID19 ,Aim,care activity,1,X,[inch/phsu],[acty],,
d9609db7-8a71-4411-87ec-b14a4e768ec2,C2948600,C1947933,utilize ,Aim,care activity,1,X,[inch/phsu],[acty],,
cc670e56-f555-44ed-a618-7cce1610fc24,C0009450,C0206419,has shown effects in treatment of emerging 2019 ,Communicable Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150
cc670e56-f555-44ed-a618-7cce1610fc24,C0009450,C0206419,is in turn defined by community prevalence of ,Communicable Diseases,Genus: Coronavirus,2,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150
cc670e56-f555-44ed-a618-7cce1610fc24,C0009450,C0206419,is with novel ,Communicable Diseases,Genus: Coronavirus,11,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150
cc670e56-f555-44ed-a618-7cce1610fc24,C0009450,C0206419,should should considered in elderly patients with ,Communicable Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,have emerged with ,Disease,Genus: Coronavirus,2,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,gained importance during ,Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,was named ,Disease,Genus: Coronavirus,13,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,poses substantial threat on front line caring for ,Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,potentially influence Disease susceptibility to,Disease,Genus: Coronavirus,2,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,be redefined during ,Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,have limited knowledge about ,Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,reduce fatality rates during ongoing ,Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
d97d9178-54de-4cb3-bf31-1456819202f9,C0012634,C0206419,otherwise known as ,Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
32b80b6c-f936-450c-8d2a-90856a36bdc5,C0009450,C0012634,has shown effects in treatment of emerging 2019 ,Communicable Diseases,Disease,1,X,[dsyn],[dsyn],C01.539.221,C23.550.288
32b80b6c-f936-450c-8d2a-90856a36bdc5,C0009450,C0012634,has spread worldwide Since December 2019 ,Communicable Diseases,Disease,1,X,[dsyn],[dsyn],C01.539.221,C23.550.288
0ba95591-ffe2-4987-935b-d03c4c291e16,C0032105,C0009450,Therapeutic procedure many types of,Plasma,Communicable Diseases,2,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C01.539.221
9e9a0ca2-2f48-4073-9e86-9985a43c302c,C0032105,C0012634,Therapeutic procedure many types of,Plasma,Disease,2,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C23.550.288
9e9a0ca2-2f48-4073-9e86-9985a43c302c,C0032105,C0012634,is explicit option for ,Plasma,Disease,1,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C23.550.288
9e9a0ca2-2f48-4073-9e86-9985a43c302c,C0032105,C0012634,is potential ,Plasma,Disease,1,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C23.550.288
a3263936-083c-4866-919b-2bb7ebcddad5,C0067430,C0206419,reported cases of ,N-(1-oxyl-2255-tetramethyl-3-pyrrolidinyl)maleimide,Genus: Coronavirus,3,X,[orch],[virs],x.x.x.x,B04.820.504.540.150
c779ff05-12c6-41b4-bdd6-e6a7e350beeb,C0206419,C0015967,usually presents with ,Genus: Coronavirus,Fever,2,X,[virs],[sosy],B04.820.504.540.150,C23.888.119.344
c779ff05-12c6-41b4-bdd6-e6a7e350beeb,C0206419,C0015967,causes severe ,Genus: Coronavirus,Fever,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.119.344
c779ff05-12c6-41b4-bdd6-e6a7e350beeb,C0206419,C0015967,is in patients with ,Genus: Coronavirus,Fever,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.119.344
3171007d-72f4-4110-9668-a943abf7eb78,PINI,C0184661,is low-risk ,PINI,Interventional procedure,1,X,????,[topp],????,
0f6ce67e-8bc7-4063-b2e4-71e93bf295a6,PINI,C0021925,may prevent ,PINI,Intubation,1,X,????,[topp],????,E02.585;E05.497
a9520aff-7a1e-4535-9557-f447c7430ffc,PINI,C0035222,may prevent Intubation in certain patients with,PINI,Respiratory Distress Syndrome Adult,1,X,????,[dsyn],????,C08.381.840;C08.618.840
107f8696-19ec-4d46-bf3b-a5618b0bd5c5,C0206419,C0010200,be transmitted through ,Genus: Coronavirus,Coughing,1,X,[virs],[sosy],B04.820.504.540.150,C08.618.248;C23.888.852.293
107f8696-19ec-4d46-bf3b-a5618b0bd5c5,C0206419,C0010200,share similar fever ,Genus: Coronavirus,Coughing,2,X,[virs],[sosy],B04.820.504.540.150,C08.618.248;C23.888.852.293
2118cf6b-6d58-426d-b18c-607af1a3857f,C1537432,C0020517,performed equally in terms of ,KALRN gene,Hypersensitivity,4,X,[gngm],[patf],,C20.543
ed110d43-98ca-40c0-ba2f-d7cff3e34c11,C1175743,C0020517,performed equally in terms of ,SARS coronavirus,Hypersensitivity,4,X,[virs],[patf],B04.820.504.540.150.113.937,C20.543
ed110d43-98ca-40c0-ba2f-d7cff3e34c11,C1175743,C0020517,generally exhibited ,SARS coronavirus,Hypersensitivity,1,X,[virs],[patf],B04.820.504.540.150.113.937,C20.543
13092c6a-d841-4bdf-8610-a61f856a6bad,C0042210,C0206419,is currently available for treatment of ,Vaccines,Genus: Coronavirus,10,X,[aapp/imft/phsu],[virs],D20.215.894,B04.820.504.540.150
13092c6a-d841-4bdf-8610-a61f856a6bad,C0042210,C0206419,show promise in ,Vaccines,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],D20.215.894,B04.820.504.540.150
13092c6a-d841-4bdf-8610-a61f856a6bad,C0042210,C0206419,prevent person from ,Vaccines,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],D20.215.894,B04.820.504.540.150
6514e4ea-5fd2-4ac8-9bd0-33297f3adb85,C0022709,C0021699,is ,Peptidyl-Dipeptidase A,Integral Membrane Proteins,4,X,[aapp/enzy/imft],[aapp],D08.811.277.656.350.350.687,D12.776.543
6b3f9dc6-186b-41db-bd7a-d4c93db8c4e7,C0022709,C0225698,is ,Peptidyl-Dipeptidase A,Alveolar Epithelial Cells,6,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A04.411.715.100;A11.436.081
640309ff-12ce-4199-9702-f027912f9c84,C0022709,C0682610,is ,Peptidyl-Dipeptidase A,Enterocytes,4,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
51059056-9ab7-4de6-a16c-334bca9bb994,C0022709,C1257792,is ,Peptidyl-Dipeptidase A,Vascular Endothelial Cells,4,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436.275
af776d93-7a2b-48a8-aef9-16ea47f687df,C0022709,C1175743,serves as major entry point into cells for ,Peptidyl-Dipeptidase A,SARS coronavirus,53,X,[aapp/enzy/imft],[virs],D08.811.277.656.350.350.687,B04.820.504.540.150.113.937
16147fbc-a934-40a5-a583-adbaaf1c9414,C0021699,C0024109,expressed by ,Integral Membrane Proteins,Lung,4,X,[aapp],[bpoc],D12.776.543,A04.411
ca036400-6fdf-4fb9-b364-ccdd8c4452f5,C0021699,C0225698,expressed by ,Integral Membrane Proteins,Alveolar Epithelial Cells,4,X,[aapp],[cell],D12.776.543,A04.411.715.100;A11.436.081
539d3662-78c1-4df0-9567-7194060c96a9,C0021699,C0682610,expressed by ,Integral Membrane Proteins,Enterocytes,4,X,[aapp],[cell],D12.776.543,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
ddafed58-519c-462b-a66f-ccb94294b24d,C0021699,C1257792,expressed by ,Integral Membrane Proteins,Vascular Endothelial Cells,4,X,[aapp],[cell],D12.776.543,A11.436.275
579943f4-1938-4b0d-81f2-2752a7c1d112,C0042373,C1175743,is in patients with ,Vascular Diseases,SARS coronavirus,4,X,[dsyn],[virs],C14.907,B04.820.504.540.150.113.937
6802b31b-a2e2-4db1-8e5a-86ed4361065a,C0039082,C1175743,is in patients with ,Syndrome,SARS coronavirus,4,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150.113.937
6802b31b-a2e2-4db1-8e5a-86ed4361065a,C0039082,C1175743,following CoV2 ,Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150.113.937
d7afe158-82de-4733-9238-92f3e2d5befa,C1175175,C0225336,is with focus on ,Severe Acute Respiratory Syndrome,Endothelial Cells,4,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.436.275
d7afe158-82de-4733-9238-92f3e2d5befa,C1175175,C0225336,Severe Acute Respiratory Syndrome of,Severe Acute Respiratory Syndrome,Endothelial Cells,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.436.275
7b1b5213-0aff-449b-90c6-c3c3a63e4ef6,C0206419,C0009450,triggers mechanisms main ,Genus: Coronavirus,Communicable Diseases,27,X,[virs],[dsyn],B04.820.504.540.150,C01.539.221
55b107b5-cffc-4a3c-a514-9db5f6388120,C0032285,C0009450,is very serious ,Pneumonia,Communicable Diseases,3,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C01.539.221
455913bb-8062-4818-8d2a-b43e9c265a89,C0206419,C0008679,is associated with much ,Genus: Coronavirus,Chronic disease,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.500
455913bb-8062-4818-8d2a-b43e9c265a89,C0206419,C0008679,had more WBC CRP ,Genus: Coronavirus,Chronic disease,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.500
455913bb-8062-4818-8d2a-b43e9c265a89,C0206419,C0008679,persons with ,Genus: Coronavirus,Chronic disease,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.500
2d6919a1-7ad2-47a3-b5f0-6280c53e2cc6,C0206419,C0011849,is associated with especially ,Genus: Coronavirus,Diabetes Mellitus,1,X,[virs],[dsyn],B04.820.504.540.150,C18.452.394.750;C19.246
bf0c8b2e-12d2-44a0-b77a-1b697563910e,C0008269,C1819995,blocks entry to ,Chloroquine,Host Cell,3,X,[orch/phsu],[celc],D03.633.100.810.050.180,
bf0c8b2e-12d2-44a0-b77a-1b697563910e,C0008269,C1819995,blocks Virus Attachment to,Chloroquine,Host Cell,3,X,[orch/phsu],[celc],D03.633.100.810.050.180,
38b96950-9dad-473c-bc25-043cab1292fe,C0008269,C1721019,blocks ,Chloroquine,Virus Attachment,3,X,[orch/phsu],[biof],D03.633.100.810.050.180,G06.920.868
0492c3bf-0aea-416a-98bb-cae824b128d2,C0042776,C1175743, includes ,Virus,SARS coronavirus,7,X,[virs],[virs],B04,B04.820.504.540.150.113.937
0492c3bf-0aea-416a-98bb-cae824b128d2,C0042776,C1175743,are responsible for ,Virus,SARS coronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113.937
0492c3bf-0aea-416a-98bb-cae824b128d2,C0042776,C1175743,extrapolating effectiveness on ,Virus,SARS coronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113.937
0492c3bf-0aea-416a-98bb-cae824b128d2,C0042776,C1175743,causes ,Virus,SARS coronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113.937
0492c3bf-0aea-416a-98bb-cae824b128d2,C0042776,C1175743,have However since ,Virus,SARS coronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113.937
11ad2fc4-0e7f-4f8c-97d7-e6d03464ae9d,C0042776,C0206419,agent of ,Virus,Genus: Coronavirus,2,X,[virs],[virs],B04,B04.820.504.540.150
11ad2fc4-0e7f-4f8c-97d7-e6d03464ae9d,C0042776,C0206419, includes ,Virus,Genus: Coronavirus,10,X,[virs],[virs],B04,B04.820.504.540.150
11ad2fc4-0e7f-4f8c-97d7-e6d03464ae9d,C0042776,C0206419,causes ,Virus,Genus: Coronavirus,7,X,[virs],[virs],B04,B04.820.504.540.150
34db4834-1cf9-4639-bb51-6256b542fabf,C0206419,C0035691,are large positive enveloped ,Genus: Coronavirus,RNA Viruses,2,X,[virs],[virs],B04.820.504.540.150,B04.820
34db4834-1cf9-4639-bb51-6256b542fabf,C0206419,C0035691,are group of ,Genus: Coronavirus,RNA Viruses,7,X,[virs],[virs],B04.820.504.540.150,B04.820
34db4834-1cf9-4639-bb51-6256b542fabf,C0206419,C0035691,is caused by ,Genus: Coronavirus,RNA Viruses,1,X,[virs],[virs],B04.820.504.540.150,B04.820
f34f37fe-9aac-406a-95d4-d62e435c97e4,C0042776,C1704259,enter system from different ,Virus,Biochemical Pathway,1,X,[virs],[moft],B04,
f34f37fe-9aac-406a-95d4-d62e435c97e4,C0042776,C1704259,entered CEL gene through different,Virus,Biochemical Pathway,1,X,[virs],[moft],B04,
f34f37fe-9aac-406a-95d4-d62e435c97e4,C0042776,C1704259,entered Cells through different,Virus,Biochemical Pathway,1,X,[virs],[moft],B04,
9def1a1a-cb9a-4faf-916a-7d33df19b419,C0206419,C1704259,enter system from different ,Genus: Coronavirus,Biochemical Pathway,1,X,[virs],[moft],B04.820.504.540.150,
8671592c-f105-4935-b9ee-6bbc5e30e53a,C0042776,C0004457,could In ,Virus,Axis vertebra,2,X,[virs],[bpoc],B04,A02.835.232.834.151.383
313cadae-d8f1-466e-9222-354c9766b2a3,C0021368,C0004457,could In ,Inflammation,Axis vertebra,2,X,[patf],[bpoc],C23.550.470,A02.835.232.834.151.383
db8d50ba-d617-49d0-a6a8-8a822baae116,C0042776,C0235031,could In ,Virus,Neurologic Symptoms,2,X,[virs],[sosy],B04,C10.597;C23.888.592
1369902a-9a91-479d-99c2-450b804c9529,C0021368,C0235031,could In ,Inflammation,Neurologic Symptoms,2,X,[patf],[sosy],C23.550.470,C10.597;C23.888.592
fc26cb35-8f82-47ef-8ed2-bef67da1175a,C0242606,C0004457,could In ,Oxidative Stress,Axis vertebra,2,X,[comd],[bpoc],G03.673;G07.775.750,A02.835.232.834.151.383
035b3456-a29d-454b-b648-f1a0e3e967c8,C0242606,C0235031,could In ,Oxidative Stress,Neurologic Symptoms,2,X,[comd],[sosy],G03.673;G07.775.750,C10.597;C23.888.592
14cf5ce1-c6c3-44b0-afe9-27923e92f180,C1150225,C1879547,mitigates deleterious effects associated with ,angiotensin I-converting enzyme activity,Activation action,8,X,[moft],[acty],,
df1cd9d0-6771-4653-a085-095a8f817bb8,C1150225,C0035100,mitigates deleterious effects associated with ,angiotensin I-converting enzyme activity,Chymosin,4,X,[moft],[aapp/enzy],,D08.811.277.656.074.500.200;D08.811.277.656.300.048.200
269dc4f2-7b4a-490d-b504-def26f1c9b9d,C1167622,C0022709,locate at ,Binding (Molecular Function),Peptidyl-Dipeptidase A,7,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
d9819e2f-055d-48c1-9ea7-aa9e1a9d0fb4,C1167622,C0010813,favors toform ACE2,Binding (Molecular Function),Cytokinesis,1,X,[moft],[celf],,G04.144.220.250
0aafd32e-821c-4ec6-b918-b9c0c444ada9,C1167622,toform,favors toform ACE2,Binding (Molecular Function),toform,1,X,[moft],????,,????
b0cb33b5-fbd1-44e2-8fde-79eac9631ced,C1167622,ACE2,favors toform ACE2,Binding (Molecular Function),ACE2,1,X,[moft],????,,????
26878223-d301-4afa-9f5c-eba19fff7da8,C2745965,COVID-19,were ,Emergencies [Disease/Finding],COVID-19,1,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,C000657245
f70ffdfb-0d27-46d8-9773-99a6ef22a290,C1547282,C0013227,have failed as ,Show,Pharmaceutical Preparations,1,X,[anim],[phsu],,D26
b5bf7147-d292-44fd-b639-35050d4c605f,C0206750,C0015967,usually presents with ,Coronavirus Infections,Fever,4,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
b5bf7147-d292-44fd-b639-35050d4c605f,C0206750,C0015967,Interestingly is characterized by ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
b5bf7147-d292-44fd-b639-35050d4c605f,C0206750,C0015967,could cause wide range of ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
b5bf7147-d292-44fd-b639-35050d4c605f,C0206750,C0015967,must must considered in evaluation of ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
b5bf7147-d292-44fd-b639-35050d4c605f,C0206750,C0015967,was After emergence of novel ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
b5bf7147-d292-44fd-b639-35050d4c605f,C0206750,C0015967,was initially characterized by ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
9a19636e-e6f8-44da-a0f6-955eec2e81ff,C0010813,PRRA,is with inserted sequence of PRRA,Cytokinesis,PRRA,2,X,[celf],????,G04.144.220.250,????
abb95ad0-d61c-425c-8256-a41c4d6cf595,C1175743,C0010813,has polybasic PRRA,SARS coronavirus,Cytokinesis,2,X,[virs],[celf],B04.820.504.540.150.113.937,G04.144.220.250
dde99787-e97f-4359-b592-638942dd4d1b,C1175743,PRRA,has polybasic PRRA,SARS coronavirus,PRRA,2,X,[virs],????,B04.820.504.540.150.113.937,????
ec31f1de-6434-440e-85ad-24609bef3a58,C0036720,C0999626,is in ,Serine,Manidae,2,X,[aapp/bacs/phsu],[mamm],D12.125.154.800,
1ad7a504-012a-413c-bdf0-82170fa1b583,C0036720,RaTG13,were seen in RaTG13,Serine,RaTG13,2,X,[aapp/bacs/phsu],????,D12.125.154.800,????
ca2999ee-f49a-4669-bed1-e8769dce0257,C1175743,C0042776,was only ,SARS coronavirus,Virus,6,X,[virs],[virs],B04.820.504.540.150.113.937,B04
007fc6aa-e86e-466a-98d1-d065b19e2244,C0206750,C0042776,slow spread of ,Coronavirus Infections,Virus,10,X,[dsyn],[virs],C02.782.600.550.200,B04
f3c5984d-471a-4370-b10c-7f3b8b6ef626,C1708476,C0242781,prevent further ,Implementation,disease transmission,2,X,[acty],[patf],,N06.850.310
ec0dfa6d-543d-4380-ba5c-8fb7f14172d3,C0013227,C1547282,have ,Pharmaceutical Preparations,Show,1,X,[phsu],[anim],D26,
497c3a37-d23b-4a89-ab40-510b65936705,C0012634,C3277428,increases ,Disease,Severe viral infections,6,X,[dsyn],[dsyn],C23.550.288,
8829a284-a7a1-4d65-a38d-188e8ab4bc0f,C0206750,C0544633,can Lead to alterations of,Coronavirus Infections,Modulation cellular,6,X,[dsyn],[ortf],C02.782.600.550.200,
99ccdc54-58db-4bb2-82ea-70112190a1c6,C0206750,C1157241,can Lead through,Coronavirus Infections,NAD biosynthetic process,3,X,[dsyn],[moft],C02.782.600.550.200,
3d7d6641-0858-41e1-9ea5-2fbb4ee83cfa,C0206750,C0030012,can Lead to alterations of,Coronavirus Infections,Oxidation-Reduction,2,X,[dsyn],[moft],C02.782.600.550.200,G02.700;G03.295.531
3c33e6c4-b92e-4fb7-9d28-44710800cd5d,C0208355,C0007613,is in ,multicatalytic endopeptidase complex,Cell physiology,3,X,[aapp/enzy],[celf],D05.500.562.500;D08.811.277.656.918;D08.811.600.730,G04
4d57bc4a-d908-4ff9-8f33-03ea7b300038,C0073591,IL-6,can increase IL-6 ,rosoxacin,IL-6,3,X,[antb/orch],????,x.x.x.x,????
ab18871f-e4ae-4868-86b3-ff81dd8f6f99,C0073591,C0599732,can increase IL-6 ,rosoxacin,cell injury,3,X,[antb/orch],[comd],x.x.x.x,
559063d5-eefd-49ed-afb8-825acf6863c8,C0003402,C3538756, includes ,Antioxidants,NLRP1 wt Allele,3,X,[phsu],[gngm],D27.505.519.217;D27.505.696.706.125;D27.720.799.047,
caa138e1-cb40-4b88-90cc-7d050dfc9b58,C1516048,C0009450,is in ,Assessed,Communicable Diseases,3,X,[acty],[dsyn],,C01.539.221
1515a420-9c2b-4dd8-baeb-6c817673873f,14-day,C0009450,prevent spreading in ,14-day,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
1515a420-9c2b-4dd8-baeb-6c817673873f,14-day,C0009450,be sufficient to ,14-day,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
f60b33d7-7372-4c37-aa79-2979a5b0d8ce,C0034386,C0009450,prevent spreading in ,Quarantine,Communicable Diseases,1,X,[topp],[dsyn],N06.850.780.200.450.700,C01.539.221
f60b33d7-7372-4c37-aa79-2979a5b0d8ce,C0034386,C0009450,be sufficient to ,Quarantine,Communicable Diseases,1,X,[topp],[dsyn],N06.850.780.200.450.700,C01.539.221
6ef326a4-43be-4d23-9288-79aec06bd6ef,C2728259,C0009450,prevent spreading in ,Program,Communicable Diseases,1,X,[orch/phsu],[dsyn],V02.355.750,C01.539.221
6ef326a4-43be-4d23-9288-79aec06bd6ef,C2728259,C0009450,be sufficient to ,Program,Communicable Diseases,1,X,[orch/phsu],[dsyn],V02.355.750,C01.539.221
77e3d4b2-4973-4a5d-b0af-b6388aa2333e,14-day,C0206750,prevent spreading in ,14-day,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
279497f7-8fc5-483e-9c9d-5ade4803fa51,C0034386,C0206750,prevent spreading in ,Quarantine,Coronavirus Infections,1,X,[topp],[dsyn],N06.850.780.200.450.700,C02.782.600.550.200
279497f7-8fc5-483e-9c9d-5ade4803fa51,C0034386,C0206750,confront spread of ,Quarantine,Coronavirus Infections,1,X,[topp],[dsyn],N06.850.780.200.450.700,C02.782.600.550.200
e0c31e25-66fa-44d3-a502-8fd5fa3a7834,C2728259,C0206750,prevent spreading in ,Program,Coronavirus Infections,1,X,[orch/phsu],[dsyn],V02.355.750,C02.782.600.550.200
e0c31e25-66fa-44d3-a502-8fd5fa3a7834,C2728259,C0206750,assess its efficacy regarding ,Program,Coronavirus Infections,2,X,[orch/phsu],[dsyn],V02.355.750,C02.782.600.550.200
d0ec119f-bbe7-4505-9a7e-ecd38bbc6a41,C0012656,C1511790,is where determined by community ,Disease Vectors,Detection,4,X,[anim],[topp],N06.850.310.350,
59187de8-e49d-4040-adee-593698c79eda,CPAP,C0087111,is valid ,CPAP,Therapeutic procedure,5,X,????,[topp],????,E02
7397a3dc-1604-43a6-b369-84039258dc7d,CPAP,C0035222,is valid ,CPAP,Respiratory Distress Syndrome Adult,5,X,????,[dsyn],????,C08.381.840;C08.618.840
8ec95668-288a-4a89-bc23-5b4dc3ff92f2,CPAP,C1175743,is valid ,CPAP,SARS coronavirus,5,X,????,[virs],????,B04.820.504.540.150.113.937
2ffa0d25-aae3-45a9-bcc2-7b0fd7d9f95c,C0087111,C0035222,is in mild ,Therapeutic procedure,Respiratory Distress Syndrome Adult,5,X,[topp],[dsyn],E02,C08.381.840;C08.618.840
2ffa0d25-aae3-45a9-bcc2-7b0fd7d9f95c,C0087111,C0035222,have shown first promise in treatment of ,Therapeutic procedure,Respiratory Distress Syndrome Adult,2,X,[topp],[dsyn],E02,C08.381.840;C08.618.840
788f5a62-f442-46d7-8112-7e4df3e7355d,C0087111,C1175743,targeting ,Therapeutic procedure,SARS coronavirus,12,X,[topp],[virs],E02,B04.820.504.540.150.113.937
a78d6b9a-dba8-45c9-929e-b0742531b31d,C2949735,C0024109,detected by ,Recruitment,Lung,1,X,[acty],[bpoc],,A04.411
3aa7dff7-18d1-4098-89c0-6b12f9e88f44,C0024109,C0041621,detected by ,Lung,Ultrasonic Shockwave,1,X,[bpoc],[npop],A04.411,G01.750.770.776.891.500
f6c02cf5-f07f-4701-a5f4-bcd4ac2f98c5,C2949735,C0041621,detected by ,Recruitment,Ultrasonic Shockwave,1,X,[acty],[npop],,G01.750.770.776.891.500
8601e291-acea-4625-ac98-8f869ad9b85f,C0041621,NI-CPAP,underlies therapeutic efficacy of NI-CPAP,Ultrasonic Shockwave,NI-CPAP,5,X,[npop],????,G01.750.770.776.891.500,????
9065e4c1-4857-4acf-8722-fd0f56ee8e45,C0002059,C0006560,were correlated ,Alkaline Phosphatase,C-reactive protein,8,X,[aapp/enzy],[aapp/imft],D08.811.277.352.650.035,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
0706fd43-ade4-4238-a739-a7dd5bf324a3,C0002059,C0035222,were correlated ,Alkaline Phosphatase,Respiratory Distress Syndrome Adult,9,X,[aapp/enzy],[dsyn],D08.811.277.352.650.035,C08.381.840;C08.618.840
445a4ea0-f902-4de7-8330-031708046314,C0630906,C0206750,was in ,vinyltriethoxysilane,Coronavirus Infections,5,X,[orch],[dsyn],x.x.x.x,C02.782.600.550.200
d66fb626-6b92-4e0c-b8ac-a252dd226c4d,C0694549,C0630906,were categorized as high risk for ,Community acquired pneumonia,vinyltriethoxysilane,1,X,[dsyn],[orch],,x.x.x.x
5c222df7-8689-445b-8fc2-2d4494320714,C0630906,C0694549,incidence of was In ,vinyltriethoxysilane,Community acquired pneumonia,1,X,[orch],[dsyn],x.x.x.x,
0ad2b17e-70dd-43d0-85e3-467c707da03c,C0206750,C0694549,is In ,Coronavirus Infections,Community acquired pneumonia,1,X,[dsyn],[dsyn],C02.782.600.550.200,
596a9f0c-2c30-4553-80d2-b39d16dc4cd1,C0206750,C0398623,was associated with ,Coronavirus Infections,Thrombophilia,2,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.925
39e9ff1a-5758-4502-89d8-08483377e9f7,C0700271,C0042776,is ,M Protein multiple myeloma,Virus,2,X,[aapp/imft],[virs],x.x.x.x,B04
c953c375-91f3-4529-b730-961fab13eef4,C0006104,C0206419,different types of ,Brain,Genus: Coronavirus,2,X,[bpoc],[virs],A08.186.211,B04.820.504.540.150
64e12c51-f429-44a1-9ce5-1ffd4bd93ddd,C1457887,C0206750,prognostic of ,Symptoms,Coronavirus Infections,29,X,[sosy],[dsyn],,C02.782.600.550.200
1552176a-95d0-437f-9acb-78f4e6541dd5,C0206750,R0,based on different R0 ,Coronavirus Infections,R0,1,X,[dsyn],????,C02.782.600.550.200,????
1c0bdfac-b7b7-4229-a5f2-df723a31ef4b,C0242781,R0,based on different R0 ,disease transmission,R0,1,X,[patf],????,N06.850.310,????
343ebf27-6b99-4e06-8ae4-88b00f052219,C0035685,C0243052,is in ,RNA-Directed RNA Polymerase,Virus Physiological Phenomena,4,X,[aapp/enzy],[npop],D08.811.913.696.445.735.780,G06.920
da486349-4eab-4ff4-a8ce-3670d7578dc6,C0035685,C0040649,is in ,RNA-Directed RNA Polymerase,Transcription Genetic,4,X,[aapp/enzy],[genf],D08.811.913.696.445.735.780,G02.111.873;G05.297.700
68f60f1d-d4f7-4211-aa89-437377176083,C1152412,C0003451,is good broad-spectrum ,RNA-directed RNA polymerase activity,Antiviral Agents,4,X,[genf],[phsu],,D27.505.954.122.388
b97919ad-088e-4cf3-922f-06b6ecada914,C1706701,C0014544,is with ,Acquisition (action),Epilepsy,2,X,[acty],[dsyn],,C10.228.140.490
98602eba-a54a-48b0-b4e3-772b3a7bb697,C1706701,C0013227,is with ,Acquisition (action),Pharmaceutical Preparations,1,X,[acty],[phsu],,D26
f4e9dab0-c5d6-40cd-955b-68ab764b994d,C0206750,C0036974,could could considered as major ,Coronavirus Infections,Shock,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835
f4e9dab0-c5d6-40cd-955b-68ab764b994d,C0206750,C0036974,challenge to health care systems across world causing at places ,Coronavirus Infections,Shock,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835
f4e9dab0-c5d6-40cd-955b-68ab764b994d,C0206750,C0036974,has produced world-wide ,Coronavirus Infections,Shock,1,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835
27dc1b7a-b416-4a70-8d96-05ff45d4035d,C0206750,C1321919,take its ,Coronavirus Infections,TLR4 protein human,2,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
27dc1b7a-b416-4a70-8d96-05ff45d4035d,C0206750,C1321919,became with potential staggering death ,Coronavirus Infections,TLR4 protein human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
27dc1b7a-b416-4a70-8d96-05ff45d4035d,C0206750,C1321919,is progressing with alarming death ,Coronavirus Infections,TLR4 protein human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
ea880f00-12e7-4ca4-add9-407a59de6a1b,C0206750,C0683278,is taking colossal ,Coronavirus Infections,Mental Suffering,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.145.126.990;F02.830.900
5845f870-c977-44c2-8d37-c1b4a94f365c,C1321919,C0086418,is in ,TLR4 protein human,Homo sapiens,3,X,[aapp/rcpt],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
056f4155-2f68-4718-a415-6080a45c0de4,C1321919,C0683278,is in ,TLR4 protein human,Mental Suffering,3,X,[aapp/rcpt],[mobd],x.x.x.x,F01.145.126.990;F02.830.900
510099f0-7e41-4af9-890a-3549c67e1ae0,LDH,C0206750,is in ,LDH,Coronavirus Infections,3,X,????,[dsyn],????,C02.782.600.550.200
03528073-3c81-49dc-a3d5-7b1690cb7d8d,LDH,C0032285,is in ,LDH,Pneumonia,1,X,????,[dsyn],????,C08.381.677;C08.730.610
448873f4-04dd-4034-b8bd-da155541f239,C0011438,C1175743,becoming source of ,Dentistry,SARS coronavirus,2,X,[bmod],[virs],E06;H02.163,B04.820.504.540.150.113.937
7f601c70-118c-4a3d-85c4-773e1617c263,C0206750,C0011331,has revealed numerous shortcomings in ,Coronavirus Infections,Dental Procedures,2,X,[dsyn],[topp],C02.782.600.550.200,E06.170;N02.421.240.190
75d5a0e4-e63d-4007-8906-575e2bcc3f38,C0394664,C0206750,may play role in patients in ,Acupuncture procedure,Coronavirus Infections,2,X,[topp],[dsyn],E02.190.044,C02.782.600.550.200
75d5a0e4-e63d-4007-8906-575e2bcc3f38,C0394664,C0206750,is effective and safe Interventional procedure for,Acupuncture procedure,Coronavirus Infections,1,X,[topp],[dsyn],E02.190.044,C02.782.600.550.200
ee8ff9eb-dff2-4713-867d-9781f84d0dbc,C0020336,C0013227,has effects Like ,Hydroxychloroquine,Pharmaceutical Preparations,7,X,[orch/phsu],[phsu],D03.633.100.810.050.180.350,D26
c86ad62f-b941-44ef-9cbd-256a018c9a90,C0020336,C0024530,are old ,Hydroxychloroquine,Malaria,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C03.752.530
d61e2fbe-d8de-4f3e-bfff-ebe20f311ea7,C0008269,C0013227,are old ,Chloroquine,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],D03.633.100.810.050.180,D26
cc7d7b8a-38f7-4c7e-9a1e-7e8ac7efb44b,C0008269,C0024530,are old ,Chloroquine,Malaria,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C03.752.530
cc7d7b8a-38f7-4c7e-9a1e-7e8ac7efb44b,C0008269,C0024530,impairs digestion In treatment of ,Chloroquine,Malaria,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C03.752.530
201c074a-c956-40dc-aad0-4c4573b86126,C0013227,C0024530,used in treatment ,Pharmaceutical Preparations,Malaria,2,X,[phsu],[dsyn],D26,C03.752.530
3032a9d4-7c00-4624-bde6-22855361df78,C1706202,C1175743,is very important In current race against time triggered by ,Search - action,SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
3032a9d4-7c00-4624-bde6-22855361df78,C1706202,C1175743,using keywords ,Search - action,SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
f7cd3bfe-2886-4931-9328-457eed2f6cd6,C0520996,C0019134,facilitates activity of low MW ,Anticoagulant effect,heparin,2,X,[ortf],[bacs/orch/phsu],,D09.698.373.400
3b34eab1-ad1e-4a7f-a6b4-78ac95e44c11,C0520996,C0309872,facilitates activity of low MW ,Anticoagulant effect,PREVENT (product),2,X,[ortf],[phsu],,
bd541901-4f7f-4b96-8190-5bf94af02eac,pre,C0005516,is in proinflammatory ,pre,Biological Markers,5,X,????,[clna],????,D23.101
3de53042-aac6-424a-99c6-119a615e0085,C1609165,C0005516,is in proinflammatory ,tocilizumab,Biological Markers,5,X,[aapp/imft/phsu],[clna],x.x.x.x,D23.101
bdcf3532-6a6d-452b-8d4a-c6d9c639cefa,C0282636,C0005516,is in proinflammatory ,Cell Respiration,Biological Markers,5,X,[celf],[clna],G03.197;G04.270,D23.101
e1ba6d83-edbc-4dff-930c-13d9931a5486,C0030858,C0282636,had improvement in their ,Pentaerythritol Tetranitrate,Cell Respiration,5,X,[orch/phsu],[celf],D02.033.455.706.690,G03.197;G04.270
6516aa60-9788-4e56-a41f-7c75a6707709,C0206750,C1257792,also invade ,Coronavirus Infections,Vascular Endothelial Cells,1,X,[dsyn],[cell],C02.782.600.550.200,A11.436.275
6322a01b-5d69-4835-8fd7-0a2dc5375684,C0042373,C0206750,is in ,Vascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907,C02.782.600.550.200
a25ed067-d2ed-45fe-b7fa-161871e26ab7,C0206750,C0543829,is with definitive ,Coronavirus Infections,pneumonia clinical,9,X,[dsyn],[dsyn],C02.782.600.550.200,
3b504f74-7ab4-4e88-9ae9-d11194a3633a,C0023516,C1707455,diagnostic performance of were ,Leukocytes,Comparison,2,X,[cell],[acty],A11.118.637;A15.145.229.637;A15.382.490,
64429f76-9209-4d24-b6b5-3954d3cacb05,C0229671,C0206750,indicated poor outcome in patients with ,Serum,Coronavirus Infections,9,X,[bdsu],[dsyn],A12.207.152.846;A15.145.846,C02.782.600.550.200
07a4bcb8-1768-483e-be38-8d662ced4650,C0079189,C0206750,were elevated in patients with ,cytokine,Coronavirus Infections,27,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C02.782.600.550.200
4bb21419-253e-420f-93c7-df1e4e5d5a59,C0039194,C1514474,was independent ,T-Lymphocyte,Prognostic Factors,4,X,[cell],[clna],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,E01.789
974f9b4b-57b1-458a-acb4-62be441e0a71,C0023516,C0206750,predict clinical outcome of patients with ,Leukocytes,Coronavirus Infections,10,X,[cell],[dsyn],A11.118.637;A15.145.229.637;A15.382.490,C02.782.600.550.200
a9827722-3951-421e-9ffa-04ac8c942a70,C0023516,C0032285,predict clinical outcome of patients with ,Leukocytes,Pneumonia,11,X,[cell],[dsyn],A11.118.637;A15.145.229.637;A15.382.490,C08.381.677;C08.730.610
47491d50-f738-4727-a437-111c7f1df462,C1155266,C1160389,is involved in ,inflammatory response,lung development,12,X,[patf],[ortf],,
6fd96748-af0f-40d6-b582-2484f4c83313,C1150225,C0178784,mitigates deleterious effects associated on ,angiotensin I-converting enzyme activity,Organ,2,X,[moft],[bpoc],,
e3a20d68-780f-45e5-ad58-924d9854fb62,C0277562,C0206750,is with ,Adult disease,Coronavirus Infections,6,X,[dsyn],[dsyn],,C02.782.600.550.200
f670536a-f8e8-4c6d-ae90-e00c3ef978e6,C0242656,C0206750,is with ,Disease Progression,Coronavirus Infections,4,X,[patf],[dsyn],C23.550.291.656,C02.782.600.550.200
d1b9f89c-d46b-4248-be5f-83d3bd2b5f04,C1175743,C1254351,was causative ,SARS coronavirus,Pharmacologic Substance,9,X,[virs],[phsu],B04.820.504.540.150.113.937,
d3976e90-6829-4507-b268-fead2e52c433,C0030231,C0024501,includes ,Palliative Care,Maintenance,1,X,[topp],[acty],E02.760.666;N02.421.585.666,N02.628
090326dd-07b9-43d3-a1a1-bb114ee16a6a,C0030231,C4520800,includes ,Palliative Care,Hydration,1,X,[topp],[phsf],E02.760.666;N02.421.585.666,
090326dd-07b9-43d3-a1a1-bb114ee16a6a,C0030231,C4520800,maintaining ,Palliative Care,Hydration,1,X,[topp],[phsf],E02.760.666;N02.421.585.666,
ca516441-94d0-4a61-8225-4afde2fa105a,C0030231,C0015967,controlling ,Palliative Care,Fever,3,X,[topp],[sosy],E02.760.666;N02.421.585.666,C23.888.119.344
8181785c-a048-44a9-9b99-a2f8baeb0ae8,C0030231,C0010200,controlling ,Palliative Care,Coughing,3,X,[topp],[sosy],E02.760.666;N02.421.585.666,C08.618.248;C23.888.852.293
d178db48-aae2-4195-9107-223294d00fc5,C1276413,C1254351,involve ,Therapeutic regimen,Pharmacologic Substance,3,X,[topp],[phsu],,
6d04205d-70e0-4f2b-9508-5ac3bac2f528,C0067430,C0206750,reported cases of ,N-(1-oxyl-2255-tetramethyl-3-pyrrolidinyl)maleimide,Coronavirus Infections,2,X,[orch],[dsyn],x.x.x.x,C02.782.600.550.200
2e19cecc-cc21-4457-96df-d456d4af25b4,C0003873,C1872427,taking ,Rheumatoid Arthritis,iguratimod,4,X,[dsyn],[orch/phsu],C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199,x.x.x.x
dd687d91-423e-4a67-b249-20d24d303f53,C1511790,C1457887,was observed after resolution of ,Detection,Symptoms,4,X,[topp],[sosy],,
611f9229-a602-44b6-acbd-6272a36ca6cb,C0596448,C0020538,increased mortality with ,dimer,Hypertensive disease,6,X,[chvs],[dsyn],,C14.907.489
f267d44d-7419-46b6-8a41-a29a1665e5cb,C0596448,C0027950,ratio of ,dimer,neutrophil,1,X,[chvs],[cell],,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
a691c2b6-e4d3-4631-bdb8-a3b5b8d3d2f9,C0596448,C0024264,ratio to ,dimer,Lymphocyte,1,X,[chvs],[cell],,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
9a023443-e86e-424b-9f33-64342b8b1285,C0596448,C0206750,is in patients with ,dimer,Coronavirus Infections,3,X,[chvs],[dsyn],,C02.782.600.550.200
9a023443-e86e-424b-9f33-64342b8b1285,C0596448,C0206750,very similar to that of ,dimer,Coronavirus Infections,1,X,[chvs],[dsyn],,C02.782.600.550.200
ff6d9fcc-91f0-4927-bcc0-2a7f8a2439ac,C2948600,C1516048,was to ,Aim,Assessed,2,X,[inch/phsu],[acty],,
bd477618-9c96-4134-9528-4c0e80f74361,C0206750,C0041912,key disease characteristic of is,Coronavirus Infections,Upper Respiratory Infections,1,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.739;C08.730
2c262698-bf34-486b-85bb-626ce14ea200,C0599878,C0041912,key disease characteristic of is,disease characteristic,Upper Respiratory Infections,1,X,[patf],[dsyn],,C01.539.739;C08.730
dd49eac8-d004-49ae-9863-c6b4ebfbeb70,C0041912,C1142578,may may complicated by ,Upper Respiratory Infections,Bilateral pneumonia,1,X,[dsyn],[dsyn],C01.539.739;C08.730,
cb3c9410-29bc-4e60-83c4-1c966d0466b4,C0022709,C0960756,has has identified as ,Peptidyl-Dipeptidase A,factor A,2,X,[aapp/enzy/imft],[orch],D08.811.277.656.350.350.687,x.x.x.x
eacc40a5-12f4-4b98-b09e-afc7f3b6fccc,C0022709,C1167395,is ,Peptidyl-Dipeptidase A,Host (organism),5,X,[aapp/enzy/imft],[orgm],D08.811.277.656.350.350.687,
7fafb5f5-ea3c-459b-adbc-ac8b65a99648,C0022709,C1537068,is ,Peptidyl-Dipeptidase A,Virus Internalization,5,X,[aapp/enzy/imft],[biof],D08.811.277.656.350.350.687,G06.920.881
a2906038-75ed-4072-a553-57ea9920cfc8,C0022709,C0282686,is expressed in ,Peptidyl-Dipeptidase A,Respiratory System Agents,1,X,[aapp/enzy/imft],[phsu],D08.811.277.656.350.350.687,D27.505.954.796
9db75af1-9f9c-479c-83de-1094cb1424c8,C0001625,C0206750,is in patients with severe CD3,Adrenal Glands,Coronavirus Infections,1,X,[bpoc],[dsyn],A06.300.071,C02.782.600.550.200
c76ad3e6-235e-46d1-a310-2ed4d211e7d3,C0001625,C1692321,is in patients with severe CD3,Adrenal Glands,Cellular infiltrate,1,X,[bpoc],[patf],A06.300.071,
f0c31d71-29f5-47fa-b19a-081fc42f804a,C0001625,CD3,is in patients with severe CD3,Adrenal Glands,CD3,1,X,[bpoc],????,A06.300.071,????
891fa513-8973-4b26-b151-59cf18729660,C1175743,C0001621,might impair ,SARS coronavirus,Adrenal Gland Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C19.053
33b6c6c4-32fc-4111-8be9-fb59414f6365,C1175743,C0031843,might impair ,SARS coronavirus,physiological aspects,1,X,[virs],[phsf],B04.820.504.540.150.113.937,x.x.x.x
2e00e6fc-f1c2-4651-92cb-b1e0822340d3,C0001621,C1175743,SARS coronavirus with,Adrenal Gland Diseases,SARS coronavirus,2,X,[dsyn],[virs],C19.053,B04.820.504.540.150.113.937
97ce787b-d19b-4457-a94c-6999853c81bf,C0031843,C1175743,SARS coronavirus with,physiological aspects,SARS coronavirus,2,X,[phsf],[virs],x.x.x.x,B04.820.504.540.150.113.937
97ce787b-d19b-4457-a94c-6999853c81bf,C0031843,C1175743,is in patients with CoV2 ,physiological aspects,SARS coronavirus,2,X,[phsf],[virs],x.x.x.x,B04.820.504.540.150.113.937
d8308d55-2a86-4811-b0a2-67a65b8b522c,C0206750,C0907850,are significantly lower in patients treated with ,Coronavirus Infections,ciclesonide,1,X,[dsyn],[bacs/orch/phsu],C02.782.600.550.200,x.x.x.x
a895f37f-38e9-49e7-8cc6-46feaa4c6369,C0907850,C0032285,is in non-severe ,ciclesonide,Pneumonia,1,X,[bacs/orch/phsu],[dsyn],x.x.x.x,C08.381.677;C08.730.610
439faf59-84e1-4095-8c5f-f89cc69d0db1,C0277548,C1825598,might have certain ,Epidemic disease,IMPACT gene,2,X,[dsyn],[gngm],,
7b6d0ed4-7f38-4735-b7b7-1986f35e96aa,C0277548,C0021390,might have certain ,Epidemic disease,Inflammatory Bowel Diseases,2,X,[dsyn],[dsyn],,C06.405.205.731;C06.405.469.432
5733da3c-c998-40f4-90f3-ceca9dc985f1,C0206750,C0242781,has medium ,Coronavirus Infections,disease transmission,2,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
5733da3c-c998-40f4-90f3-ceca9dc985f1,C0206750,C0242781,is emerging disease transmission with widespread,Coronavirus Infections,disease transmission,10,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
5733da3c-c998-40f4-90f3-ceca9dc985f1,C0206750,C0242781,is mainly ,Coronavirus Infections,disease transmission,2,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
5733da3c-c998-40f4-90f3-ceca9dc985f1,C0206750,C0242781,has attracted attention due to its ,Coronavirus Infections,disease transmission,1,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
5733da3c-c998-40f4-90f3-ceca9dc985f1,C0206750,C0242781,was declared public health medicine (field) Emergencies [Disease/Finding] after Singapores first imported case before,Coronavirus Infections,disease transmission,1,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
5733da3c-c998-40f4-90f3-ceca9dc985f1,C0206750,C0242781,was On January 30 declared after Singapores case before ,Coronavirus Infections,disease transmission,1,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
23cf1d56-bfc7-42e0-b8ec-fc815d208110,C0009450,C0206750,is with ,Communicable Diseases,Coronavirus Infections,26,X,[dsyn],[dsyn],C01.539.221,C02.782.600.550.200
79ea8146-5928-49c3-8683-51c01e4a4513,C0016059,C0012634,characterized late-phase ,Fibrosis,Disease,5,X,[patf],[dsyn],C23.550.355,C23.550.288
7275565f-63ff-4149-98fc-4640848f3f97,C1516048,C0005516,providing visualization compared with non-specific inflammatory ,Assessed,Biological Markers,2,X,[acty],[clna],,D23.101
e0eb1c9e-9d5d-4dc4-b25a-afb7a034e2ca,C0206750,C1514593,know little about broader ,Coronavirus Infections,Psychological Impact,2,X,[dsyn],[clna],C02.782.600.550.200,
86003b6b-a850-4bf0-8fac-f8de48c75791,C0206750,C0233514,develop general ,Coronavirus Infections,Abnormal behavior,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.145.126.972;F01.145.179.750
7c551064-9861-43f2-9034-9e4a60b9349e,C1457887,C0233514,develop general ,Symptoms,Abnormal behavior,2,X,[sosy],[mobd],,F01.145.126.972;F01.145.179.750
99c893e5-e609-407b-be41-d71452729c8e,C1514593,C0233514, includes general ,Psychological Impact,Abnormal behavior,4,X,[clna],[mobd],,F01.145.126.972;F01.145.179.750
8eb3d302-3005-4144-b818-2f5d054eba9b,C0013216,COVID-19,suitable for ,Pharmacotherapy,COVID-19,1,X,[topp],[virs],E02.319,C000657245
a469c334-1f6c-494b-ab7b-062781442b2a,C4042834,C0206419,gained importance during ,Compassion Fatigue,Genus: Coronavirus,1,X,[mobd],[virs],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,B04.820.504.540.150
2fe519fe-4224-4207-af60-f5e59d93df71,COVID-19,C0206419,caused by novel acute ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
2fe519fe-4224-4207-af60-f5e59d93df71,COVID-19,C0206419,is first pandemic caused by ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
2fe519fe-4224-4207-af60-f5e59d93df71,COVID-19,C0206419,know little about broader ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
2fe519fe-4224-4207-af60-f5e59d93df71,COVID-19,C0206419,identify therapeutics with evidence of efficacy for treatment of three ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
2fe519fe-4224-4207-af60-f5e59d93df71,COVID-19,C0206419,is acronym of ,COVID-19,Genus: Coronavirus,2,X,[virs],[virs],C000657245,B04.820.504.540.150
2fe519fe-4224-4207-af60-f5e59d93df71,COVID-19,C0206419,of propagation is ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
2fe519fe-4224-4207-af60-f5e59d93df71,COVID-19,C0206419,is in patients undergoing during ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
dae60463-ebf1-4ad3-b2e4-25ed473a1d8e,COVID-19,C1175743,was diagnosed by ,COVID-19,SARS coronavirus,42,X,[virs],[virs],C000657245,B04.820.504.540.150.113.937
286371dc-8b90-4f2a-a2f2-d6d1feb0efb3,COVID-19,C1456573,has resulted in ,COVID-19,Global Health,1,X,[virs],[bmod],C000657245,H02.403.371;N01.400.337
6681c69a-e1c7-4035-83bc-4d393e1872a8,C3819028,COVID-19,may potentially Therapeutic procedure,Interleukin 6 Receptor Antagonists,COVID-19,1,X,[celf],[virs],,C000657245
00463aba-86bf-40a4-bd71-924aa83a60f7,C1609165,COVID-19,may potentially Therapeutic procedure,tocilizumab,COVID-19,4,X,[aapp/imft/phsu],[virs],x.x.x.x,C000657245
00463aba-86bf-40a4-bd71-924aa83a60f7,C1609165,COVID-19,were reported in ,tocilizumab,COVID-19,1,X,[aapp/imft/phsu],[virs],x.x.x.x,C000657245
f2f49b2e-aee5-4e8a-ae74-e3841a37281e,C2745965,C0206419,were associated with ,Emergencies [Disease/Finding],Genus: Coronavirus,1,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,B04.820.504.540.150
f2f49b2e-aee5-4e8a-ae74-e3841a37281e,C2745965,C0206419,caused by acute viral ,Emergencies [Disease/Finding],Genus: Coronavirus,2,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,B04.820.504.540.150
474266ac-7556-4063-a18e-2e90e49b7610,C0042210,C1160716,contain ,Vaccines,viral transmission,2,X,[aapp/imft/phsu],[celf],D20.215.894,
ed4b5ec1-51ac-401d-a6aa-bd628820c8c7,C0025124,C0304229,is in ,Traditional Chinese Medicine,Experimental drug,3,X,[bmod],[phsu],E02.190.488.585.520;I01.076.201.450.654.558.520,
a5a2b6ef-099f-4ed8-8c1f-64229f93b528,C0184661,C0025124,is with ,Interventional procedure,Traditional Chinese Medicine,4,X,[topp],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
3d50a7c7-c0ff-418d-b838-edd52db5b985,COVID-19,C1829939,were primarily ,COVID-19,{Non-patient},4,X,[virs],[clna],C000657245,
ef81a90a-25f0-4f3f-a741-cdd2ee5a9e10,C1412002,C0015392,has brought public health medicine (field) challenges across,Atypical pneumonia,Eye,1,X,[dsyn],[bpoc],,A01.456.505.420;A09.371
dd37b2aa-8848-45b8-8a85-a9fa2cf4d1b6,C1412002,C0034019,has brought huge ,Atypical pneumonia,public health medicine (field),1,X,[dsyn],[bmod],,H02.403.720;N01.400.550;N06.850
903785e4-eb36-443d-a785-08ae663cb306,C0086418,C0015967,was admitted to hospital for ,Homo sapiens,Fever,2,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.119.344
903785e4-eb36-443d-a785-08ae663cb306,C0086418,C0015967,presented with ,Homo sapiens,Fever,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.119.344
aaa08ad2-21b5-435b-9d93-55c68b660b84,C0022661,C0019004,taking regular ,Kidney Failure Chronic,Hemodialysis,1,X,[dsyn],[topp],C12.777.419.780.750.500;C13.351.968.419.780.750.500,E02.870.300;E02.912.800
b105a296-4cbd-46e1-a97f-0fc56ac5b419,C0019004,C0030054,was treated with ,Hemodialysis,Oxygen,1,X,[topp],[bacs/elii/phsu],E02.870.300;E02.912.800,D01.268.185.550;D01.362.670;x.x.x.x
0169b0a1-f388-4c4a-9525-268002272a35,C0019004,C0003237,was treated with ,Hemodialysis,Antibiotics Antitubercular,1,X,[topp],[antb],E02.870.300;E02.912.800,D27.505.954.122.085.255.135
e9a09f3b-8505-4ed8-bf23-ec2fd289cd86,C0019004,C0003451,was treated with ,Hemodialysis,Antiviral Agents,1,X,[topp],[phsu],E02.870.300;E02.912.800,D27.505.954.122.388
2b35077f-7162-4410-b15f-1f0239ca0dd7,C0019004,C0025815,was treated with ,Hemodialysis,Methylprednisolone,1,X,[topp],[horm/orch/phsu],E02.870.300;E02.912.800,D04.210.500.745.432.769.795.539
4550fc09-183c-47ff-9fdc-f65ebe9c3074,C0019004,C0032285,was discharged recovering from COVID-2019 ,Hemodialysis,Pneumonia,2,X,[topp],[dsyn],E02.870.300;E02.912.800,C08.381.677;C08.730.610
d514254d-06ff-435c-995b-037152de52b5,C0019004,COVID-19,is with ,Hemodialysis,COVID-19,4,X,[topp],[virs],E02.870.300;E02.912.800,C000657245
768d60ac-7cce-4fd9-9ba0-725ecdb4c004,C0005768,COVID-19,supporting ,In Blood,COVID-19,3,X,[bdsu],[virs],x.x.x.x.x,C000657245
13234987-f977-4c8c-9080-9cfffa75c982,C0005768,C0019004,be important option for ,In Blood,Hemodialysis,1,X,[bdsu],[topp],x.x.x.x.x,E02.870.300;E02.912.800
298a246f-63b0-4f34-97fd-06c232ab1bbc,C1706005,C0035222,was correlated with higher incidences of ,CD40LG wt Allele,Respiratory Distress Syndrome Adult,7,X,[gngm],[dsyn],,C08.381.840;C08.618.840
c781d5b0-a747-4935-bbfc-ca3bc26cd54b,titer,C0035222,was correlated with higher incidences of ,titer,Respiratory Distress Syndrome Adult,7,X,????,[dsyn],????,C08.381.840;C08.618.840
d94f03ba-2e3a-4f19-bfb6-4c728cf2b4e0,C0700271,C0319157,is ,M Protein multiple myeloma,AS virus,1,X,[aapp/imft],[virs],x.x.x.x,
4b273fc3-d3d6-4d2e-875f-2e0ff9ca01fa,C1167622,C0700271,Analyzing of ,Binding (Molecular Function),M Protein multiple myeloma,1,X,[moft],[aapp/imft],,x.x.x.x
3c5533af-5d46-4076-87e4-3b3f19d4e6c9,C1167622,C1167395,Analyzing to ,Binding (Molecular Function),Host (organism),1,X,[moft],[orgm],,
97f128a2-2a91-4339-b460-b56c3b7a9e2f,C1167622,C0034787,Analyzing to ,Binding (Molecular Function),Angiotensin Receptor,1,X,[moft],[aapp/rcpt],,D12.776.543.750.695.047;D12.776.543.750.750.130
6b403c28-cc71-49da-81ef-032d633157fa,C0206419,C1257792,invade ,Genus: Coronavirus,Vascular Endothelial Cells,2,X,[virs],[cell],B04.820.504.540.150,A11.436.275
1e5afa73-3cda-42ad-a4b0-3af53592a48d,COVID-19,C0018787,target ,COVID-19,Heart,1,X,[virs],[bpoc],C000657245,A07.541
3b728a93-4184-4bf7-abc6-9556cd14823d,C1707455,C0018787,target ,Comparison,Heart,1,X,[acty],[bpoc],,A07.541
d08b046c-7b8e-4712-99d6-05f104c7196c,IFSO,COVID-19,navigating procedures during ,IFSO,COVID-19,2,X,????,[virs],????,C000657245
2a0d989d-a9c4-4b72-95ab-ab85d5fe2d2d,C0020852,C1175743,cross-reacted with CoV1 ,Immunoglobulin G,SARS coronavirus,2,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,B04.820.504.540.150.113.937
2a0d989d-a9c4-4b72-95ab-ab85d5fe2d2d,C0020852,C1175743,was developed for serological detection of anti ,Immunoglobulin G,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,B04.820.504.540.150.113.937
2a0d989d-a9c4-4b72-95ab-ab85d5fe2d2d,C0020852,C1175743,for assay is ,Immunoglobulin G,SARS coronavirus,3,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,B04.820.504.540.150.113.937
fa69b069-a776-4006-8802-896c5bd31f43,C0020852,CoV1,cross-reacted with CoV1 ,Immunoglobulin G,CoV1,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,????
62773658-6f15-4bfe-b75f-56c7c5191423,C0206419,C0035243,could lead persons with medical conditions to severe ,Genus: Coronavirus,Respiratory Tract Infections,2,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
62773658-6f15-4bfe-b75f-56c7c5191423,C0206419,C0035243,cause ,Genus: Coronavirus,Respiratory Tract Infections,2,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
62773658-6f15-4bfe-b75f-56c7c5191423,C0206419,C0035243,are responsible for ,Genus: Coronavirus,Respiratory Tract Infections,5,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
62773658-6f15-4bfe-b75f-56c7c5191423,C0206419,C0035243,is novel pandemic ,Genus: Coronavirus,Respiratory Tract Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
62773658-6f15-4bfe-b75f-56c7c5191423,C0206419,C0035243,is novel contagious ,Genus: Coronavirus,Respiratory Tract Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
1b63d0cc-8f98-4902-a4ea-d6ef51064c06,C0012634,C0035243,could lead persons with medical conditions to severe ,Disease,Respiratory Tract Infections,2,X,[dsyn],[dsyn],C23.550.288,C01.539.739;C08.730
1b63d0cc-8f98-4902-a4ea-d6ef51064c06,C0012634,C0035243,could lead persons with pre-existing conditions to severe ,Disease,Respiratory Tract Infections,1,X,[dsyn],[dsyn],C23.550.288,C01.539.739;C08.730
1b63d0cc-8f98-4902-a4ea-d6ef51064c06,C0012634,C0035243,is novel pandemic ,Disease,Respiratory Tract Infections,3,X,[dsyn],[dsyn],C23.550.288,C01.539.739;C08.730
d19a03ce-9f88-4f0a-bc43-aad55e989c59,PWT1D,C0015259,reported decrease in ,PWT1D,Exercise,6,X,????,[dora],????,G11.427.410.698.277;I03.350
9acb4004-d978-4870-8fa5-476a9d7aa1c5,PWT1D,C0309872,was inadequate to ,PWT1D,PREVENT (product),1,X,????,[phsu],????,
8b42d5c8-84a1-4c0f-bc05-d42d2071041e,PWT1D,C0005802,was inadequate to ,PWT1D,Blood Glucose,1,X,????,[orch],????,D09.947.875.359.448.500
937bc05b-6744-4ec0-b022-e39913da828b,C4476767,C0012634,is severe ,Diffuse alveolar hemorrhage,Disease,4,X,[dsyn],[dsyn],,C23.550.288
f29220ce-2437-4d32-b4b3-015b77b2e54e,C0019079,C4476767,being key symptome of ,Hemoptysis,Diffuse alveolar hemorrhage,11,X,[sosy],[dsyn],C08.381.348;C23.550.414.896;C23.888.852.430,
4235aebe-2cbb-4d40-8ec9-b0c40a0e851e,C0026691,C0015967,is acute ,Mucocutaneous Lymph Node Syndrome,Fever,2,X,[dsyn],[sosy],C14.907.940.560;C15.604.560;C17.800.862.560,C23.888.119.344
710bdf9f-1210-4701-81c5-f5fc8033e950,C1707455,COVID-19,is with COVID19 ,Comparison,COVID-19,3,X,[acty],[virs],,C000657245
bf92f1b0-e0c5-4507-a6ce-fb9f6f0e678d,C1706374,C0026691,identified rapid increase of ,Tumor Necrosis Factor Ligand Superfamily Member 13,Mucocutaneous Lymph Node Syndrome,2,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,C14.907.940.560;C15.604.560;C17.800.862.560
05005670-892d-435a-924d-ef2438f4de6d,C0026691,C1175743,was related to ,Mucocutaneous Lymph Node Syndrome,SARS coronavirus,2,X,[dsyn],[virs],C14.907.940.560;C15.604.560;C17.800.862.560,B04.820.504.540.150.113.937
0db564fa-f81f-49e6-a119-3fe2595430d6,C1175743,C1706374,was found since ,SARS coronavirus,Tumor Necrosis Factor Ligand Superfamily Member 13,4,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
b3e607e2-de09-4c4f-81ae-3579360beb4c,C1175743,C0030858,was found in eight of ,SARS coronavirus,Pentaerythritol Tetranitrate,4,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,D02.033.455.706.690
c332e03d-c363-4356-b52e-9cd1b0802d2c,C1175743,C0026691,was found in eight ,SARS coronavirus,Mucocutaneous Lymph Node Syndrome,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C14.907.940.560;C15.604.560;C17.800.862.560
7236e6cb-b321-40b9-b74c-9c04bf608d17,C0030858,C0026691,is with ,Pentaerythritol Tetranitrate,Mucocutaneous Lymph Node Syndrome,2,X,[orch/phsu],[dsyn],D02.033.455.706.690,C14.907.940.560;C15.604.560;C17.800.862.560
fec9cf8b-ffe3-4910-ab96-c4c5141496de,C0877203,C4283882, includes ,Viral Respiratory Tract Infection,NR1I2 wt Allele,6,X,[dsyn],[gngm],,
1a6877b5-84a2-454d-b608-ddfe6a184baf,C0877203,C0026691,be Precipitating Factors for,Viral Respiratory Tract Infection,Mucocutaneous Lymph Node Syndrome,2,X,[dsyn],[dsyn],,C14.907.940.560;C15.604.560;C17.800.862.560
b67ddac3-8e90-4acc-a3cc-ead821c1e411,C4283882,C0026691,be Precipitating Factors for,NR1I2 wt Allele,Mucocutaneous Lymph Node Syndrome,2,X,[gngm],[dsyn],,C14.907.940.560;C15.604.560;C17.800.862.560
f93b52d1-fb33-4dd2-a577-5afb0dec72b2,C0877203,C0032930,be ,Viral Respiratory Tract Infection,Precipitating Factors,2,X,[dsyn],[clna],,N05.715.350.200.650;N06.850.490.625.500
9a43a52c-4be6-4e01-ad25-dc908138f45b,C4283882,C0032930,be ,NR1I2 wt Allele,Precipitating Factors,2,X,[gngm],[clna],,N05.715.350.200.650;N06.850.490.625.500
9168f904-3869-4a4e-bd0b-7608d40a0ab0,C0877203,COVID-19,indicates ,Viral Respiratory Tract Infection,COVID-19,1,X,[dsyn],[virs],,C000657245
a5573dd5-cf4f-4178-bb7e-9c4d11cb002c,C4283882,COVID-19,indicates ,NR1I2 wt Allele,COVID-19,1,X,[gngm],[virs],,C000657245
177ee78d-0bbe-4aa9-b60e-ef2378254784,C0036087,C0206419,diagnosing ,saliva,Genus: Coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150
177ee78d-0bbe-4aa9-b60e-ef2378254784,C0036087,C0206419,droplets for ,saliva,Genus: Coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150
b0cf9968-6554-4fe0-b633-c91420295b86,C1704259,C0206419,might play role in ,Biochemical Pathway,Genus: Coronavirus,3,X,[moft],[virs],,B04.820.504.540.150
aab466b4-db55-469a-b437-cc230c0776b3,C0150593,C0206419,cope with ,game,Genus: Coronavirus,2,X,[dora],[virs],,B04.820.504.540.150
2b796ba2-9205-4d1f-92a2-79c01c4f733e,C0206419,C0036974,could could considered as major ,Genus: Coronavirus,Shock,3,X,[virs],[patf],B04.820.504.540.150,C23.550.835
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,has had substantial ,Genus: Coronavirus,IMPACT gene,7,X,[virs],[gngm],B04.820.504.540.150,
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,is having dramatic ,Genus: Coronavirus,IMPACT gene,2,X,[virs],[gngm],B04.820.504.540.150,
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,had limited ,Genus: Coronavirus,IMPACT gene,2,X,[virs],[gngm],B04.820.504.540.150,
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,is now epidemic of proportion with major adverse ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,is causing insurmountable ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,has had profound ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,has daunted world with its ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
32d1a7e2-af92-4dd4-b350-88856fd8a749,C0206419,C1825598,be negatively ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,study ,Aim,Genus: Coronavirus,3,X,[inch/phsu],[virs],,B04.820.504.540.150
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,review growing ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,provide information about ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,Assessed efficacy of Chinese medicine for,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,show changes in tertiary referral ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,introduce our experience based remote patient LTSC,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,summarize prevalence of ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
d61da5cd-a152-49cb-bad5-0418d6078aa6,C2948600,C0206419,describe clinical characteristics of children with ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
e5151095-0c87-4fc1-8a1c-09e55a9a6124,C0042776,C0010076,is in ,Virus,Coronaviridae,10,X,[virs],[virs],B04,B04.820.504.540
08c701ef-4993-4ab1-86fb-e12b32310723,C0003062,C0206419,are involved in current ,Animals,Genus: Coronavirus,3,X,[anim],[virs],B01.050,B04.820.504.540.150
c99f5b48-465b-4033-b75f-97dcb5d0da2d,C0242781,C0325089,has has reported in ,disease transmission,Family Felidae,6,X,[patf],[mamm],N06.850.310,B01.050.150.900.649.313.750.377.750
ac36f440-1fb0-4b73-b200-32dadf7f26e8,C0021017,C0013227,works in antirheumatoid ,Immunoglobulin Isotypes,Pharmaceutical Preparations,3,X,[aapp/imft],[phsu],D12.776.124.486.485.114.619;D12.776.124.790.651.114.619;D12.776.377.715.548.114.619,D26
a0087bd3-c1ce-4f43-9daf-78ebd4d92b6d,C3888108,C1721019,involves ,Import into cell,Virus Attachment,2,X,[celf],[biof],,G06.920.868
8a99534a-0c1b-4951-84b1-ecaaaa1e2335,C3888108,C0007634,involves ,Import into cell,Cells,2,X,[celf],[cell],,A11
a1bc8b20-ab59-4b29-bb23-7fda7e6931e2,C0597357,C0960880,has has identified as ,receptor,angiotensin converting enzyme 2,2,X,[aapp/rcpt],[aapp/enzy],,x.x.x.x
d94466b9-66d5-43e5-bd95-ce68f88269ab,C0007603,C0007634,be involved in ,Plasma membrane,Cells,1,X,[celc],[cell],A11.284.149,A11
c85624df-ad2a-4d80-b55c-c6aabbbc5845,C0021701,C0007634,is involved in ,Integrins,Cells,5,X,[aapp/imft/rcpt],[cell],D12.776.543.750.705.408,A11
bf40a954-6dfa-4fbc-bb1f-7c89975abde3,C0007603,C0507236,be involved in ,Plasma membrane,Anterior bronchopulmonary segment of superior pulmonary vein,1,X,[celc],[bpoc],A11.284.149,
1fd6c514-8994-4cd6-ba57-4d8d7b63f3b0,C0021701,C0507236,be involved in ,Integrins,Anterior bronchopulmonary segment of superior pulmonary vein,1,X,[aapp/imft/rcpt],[bpoc],D12.776.543.750.705.408,
19594c91-262b-4809-a45f-f687641f9572,C0007603,C0206419,be involved in internalization of ,Plasma membrane,Genus: Coronavirus,2,X,[celc],[virs],A11.284.149,B04.820.504.540.150
492d3f38-9b66-48fd-9e93-0f55681291d4,C0021701,C0206419,be involved in internalization of ,Integrins,Genus: Coronavirus,2,X,[aapp/imft/rcpt],[virs],D12.776.543.750.705.408,B04.820.504.540.150
8bdf2029-1e53-49e3-a5c6-096a692f266a,C0507236,C0007634,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Cells,4,X,[bpoc],[cell],,A11
0a095ee7-5cd5-4b57-83b5-9487d86e7ce2,C0021701,C3888108,is involved in ,Integrins,Import into cell,4,X,[aapp/imft/rcpt],[celf],D12.776.543.750.705.408,
97165496-ac6d-4979-9aea-229bb9c24254,C0507236,C3888108,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Import into cell,4,X,[bpoc],[celf],,
00d9e07e-f023-4b43-881f-06e8a5ff0390,C0021701,C0039005,is involved in ,Integrins,Family suidae,2,X,[aapp/imft/rcpt],[mamm],D12.776.543.750.705.408,B01.050.150.900.649.313.500.880
43c75014-4c2c-4171-92b0-34822deedc7e,C0507236,C0039005,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Family suidae,2,X,[bpoc],[mamm],,B01.050.150.900.649.313.500.880
df2571c5-8e2f-45ef-97a6-cdf542b2e212,C0021701,C3310928,is involved in ,Integrins,Enteric coronavirus,4,X,[aapp/imft/rcpt],[virs],D12.776.543.750.705.408,
00011855-62c6-40ba-87c5-7ffa22ae5acc,C0507236,C3310928,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Enteric coronavirus,4,X,[bpoc],[virs],,
b3b3a6b4-eb37-436f-8ad2-486a50beb45b,C3310928,C0086418,causes ,Enteric coronavirus,Homo sapiens,2,X,[virs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
f2a5cf43-99d3-4de6-87f6-01ee892f6b5a,C0960880,C1516359,modulates ,angiotensin converting enzyme 2,Intracellular Signaling Process,2,X,[aapp/enzy],[moft],x.x.x.x,
c897f2a8-9478-476e-ac78-ac617a6175e4,C0960880,C3146294,modulates ,angiotensin converting enzyme 2,Generation (action),2,X,[aapp/enzy],[acty],x.x.x.x,
28ea07d8-d227-47aa-9678-57a3416a2987,C0960880,C0021701,modulates Intracellular Signaling Process Generation (action) by,angiotensin converting enzyme 2,Integrins,2,X,[aapp/enzy],[aapp/imft/rcpt],x.x.x.x,D12.776.543.750.705.408
d6b7a19d-f637-42e3-aaae-22f690115aa7,C1167395,C3888108,Leptocyte,Host (organism),Import into cell,2,X,[orgm],[celf],,
1191a2ee-8b5b-45e3-a233-ac1ce118424b,T4,C3888108,Leptocyte,T4,Import into cell,2,X,????,[celf],????,
1191a2ee-8b5b-45e3-a233-ac1ce118424b,T4,C3888108,does influence ,T4,Import into cell,2,X,????,[celf],????,
1191a2ee-8b5b-45e3-a233-ac1ce118424b,T4,C3888108,possibly restrict ,T4,Import into cell,1,X,????,[celf],????,
c73ac466-1286-42d8-92a8-27fe0a781458,C1167395,C0206419,Leptocyte,Host (organism),Genus: Coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150
c73ac466-1286-42d8-92a8-27fe0a781458,C1167395,C0206419,is in alpha-than beta ,Host (organism),Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
c73ac466-1286-42d8-92a8-27fe0a781458,C1167395,C0206419,more highly constrained for beta ,Host (organism),Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
00bf71de-768f-42e3-8193-81f881c7ae7d,T4,C0206419,Leptocyte,T4,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
00bf71de-768f-42e3-8193-81f881c7ae7d,T4,C0206419,does influence ,T4,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
1bd5f73b-5ceb-42b6-8f28-7c74798d6374,C0007634,C3888108,applies to ,Cells,Import into cell,2,X,[cell],[celf],A11,
738b54eb-e196-4696-8232-c07b2ca261ca,C0007634,C0021701,applies to ,Cells,Integrins,2,X,[cell],[aapp/imft/rcpt],A11,D12.776.543.750.705.408
5bd8b82f-990b-49f6-99f1-bcfaa637a5ed,C0034843,C0021701,is In same locale on ,Thyroid Hormone Receptor,Integrins,2,X,[aapp/rcpt],[aapp/imft/rcpt],D12.776.624.664.700.830;D12.776.826.850,D12.776.543.750.705.408
57da008a-5445-4bd6-a1e4-aed320697412,C0034843,C0507236,is In same locale on ,Thyroid Hormone Receptor,Anterior bronchopulmonary segment of superior pulmonary vein,2,X,[aapp/rcpt],[bpoc],D12.776.624.664.700.830;D12.776.826.850,
2a0534c7-8098-4c0f-9132-d37b16150c0f,T4,C1510827,modulate ,T4,Affinity,2,X,????,[npop],????,
77a5d97b-c27d-4c81-b759-a066b9b9c8a2,T4,C0021701,modulate ,T4,Integrins,2,X,????,[aapp/imft/rcpt],????,D12.776.543.750.705.408
7f4776ec-8268-4bb4-a14e-143d8c05f6f8,T4,C0033684,modulate Affinity for other,T4,Proteins,2,X,????,[aapp/bacs],????,D12.776
d19b4eec-f61b-4ee1-ae79-6b584b26dd4e,T4,C1149503,has By ,T4,Integrin Binding,2,X,????,[moft],????,
fa95e2ae-0bed-4497-9e8e-d422ba1bbc6b,T4,C0221284,does influence Genus: Coronavirus Import into cell by,T4,Leptocyte,1,X,????,[cell],????,
8ef65a3f-719d-4443-9c5a-504bac668f54,T4,triiodo,deaminated 3 5 3 triiodo ,T4,triiodo,2,X,????,????,????,????
49b02192-cb0a-4ab0-82f4-2690c93a4931,T4,C0282364,deaminated 3 5 3 triiodo ,T4,Thyronine,2,X,????,[aapp/bacs],????,D06.472.931.740;D12.125.072.050.767.741
44fbea75-9785-49ff-bc3f-b3ca4ef3d4ae,T4,C0042776,possibly restrict ,T4,Virus,1,X,????,[virs],????,B04
5436e853-69b3-484b-8249-7d53152413e4,C0449867,C0087111,stratified 3-tiered approach of low-intensity ,Use of anticoagulation,Therapeutic procedure,2,X,[topp],[topp],,E02
6d819f48-5055-43fd-b73a-5c998b932f6a,C1175743,C0699748,are dealing with new unknown ,SARS coronavirus,Pathogenesis,1,X,[virs],[patf],B04.820.504.540.150.113.937,
f729e015-3517-4241-8500-4e695d28e635,C3277428,C0242966,are dealing with combination of ,Severe viral infections,Systemic Inflammatory Response Syndrome,1,X,[dsyn],[dsyn],,C23.550.470.790;C23.550.835.900
1951e945-f850-4f20-8b3b-3495f0dbe2ad,C2717961,C0012634,is represented by group of different ,Thrombotic Microangiopathies,Disease,1,X,[dsyn],[dsyn],C15.378.140.855.925,C23.550.288
cd5aa176-f8b4-4866-a12b-54f3f2dfb22a,C0206419,C0684309,proposed possible ,Genus: Coronavirus,Disease model,1,X,[virs],[emod],B04.820.504.540.150,
e6738b2a-7b7e-476f-9fa3-7becc7c7ac2f,C0206419,C0206750,proposed possible ,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
e6738b2a-7b7e-476f-9fa3-7becc7c7ac2f,C0206419,C0206750,etiological Pharmacologic Substance of,Genus: Coronavirus,Coronavirus Infections,3,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
e6738b2a-7b7e-476f-9fa3-7becc7c7ac2f,C0206419,C0206750,etiological Agent of,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
e6738b2a-7b7e-476f-9fa3-7becc7c7ac2f,C0206419,C0206750, includes ,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
e6738b2a-7b7e-476f-9fa3-7becc7c7ac2f,C0206419,C0206750,causes ,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
0f55692a-7c91-431f-85f3-0eb60b4d2c1e,C0684309,C0206750,is in patients with severe new ,Disease model,Coronavirus Infections,1,X,[emod],[dsyn],,C02.782.600.550.200
0f55692a-7c91-431f-85f3-0eb60b4d2c1e,C0684309,C0206750,was constructed in ,Disease model,Coronavirus Infections,2,X,[emod],[dsyn],,C02.782.600.550.200
349a0591-ec84-4ff1-947b-a28f4c6bfb1b,C0206419,C0960880,utilize ,Genus: Coronavirus,angiotensin converting enzyme 2,4,X,[virs],[aapp/enzy],B04.820.504.540.150,x.x.x.x
1edf8c2f-e727-41be-a5c3-c5c258950195,C0206419,C0597357,utilize angiotensin converting enzyme 2 as,Genus: Coronavirus,receptor,3,X,[virs],[aapp/rcpt],B04.820.504.540.150,
b0d79e32-71b0-4ea9-96cd-0b4dc6fd503b,C0206419,C1819995,utilize angiotensin converting enzyme 2 as,Genus: Coronavirus,Host Cell,3,X,[virs],[celc],B04.820.504.540.150,
b0d79e32-71b0-4ea9-96cd-0b4dc6fd503b,C0206419,C1819995,determine Protein Biosynthesis Rating (action) to,Genus: Coronavirus,Host Cell,1,X,[virs],[celc],B04.820.504.540.150,
b0d79e32-71b0-4ea9-96cd-0b4dc6fd503b,C0206419,C1819995,were analyzed determine to ,Genus: Coronavirus,Host Cell,1,X,[virs],[celc],B04.820.504.540.150,
b0d79e32-71b0-4ea9-96cd-0b4dc6fd503b,C0206419,C1819995,are easily adapted to ,Genus: Coronavirus,Host Cell,2,X,[virs],[celc],B04.820.504.540.150,
b0d79e32-71b0-4ea9-96cd-0b4dc6fd503b,C0206419,C1819995,determine adaptation to ,Genus: Coronavirus,Host Cell,1,X,[virs],[celc],B04.820.504.540.150,
8e2910ac-eafe-431d-a578-6af23d2c017e,C0206419,C1175175,may cause serious ,Genus: Coronavirus,Severe Acute Respiratory Syndrome,20,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200.750;C08.730.730
f08d0ab6-9677-4164-bddc-535311f0a91a,C0022709,C0003009,helps in formation of ,Peptidyl-Dipeptidase A,angiotensin II,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
f08d0ab6-9677-4164-bddc-535311f0a91a,C0022709,C0003009,counter pro-inflammatory effects mediated by ,Peptidyl-Dipeptidase A,angiotensin II,1,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
f08d0ab6-9677-4164-bddc-535311f0a91a,C0022709,C0003009,converts proinflammatory effects of ,Peptidyl-Dipeptidase A,angiotensin II,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
f08d0ab6-9677-4164-bddc-535311f0a91a,C0022709,C0003009,proinflammatory and prothrombotic effects of ,Peptidyl-Dipeptidase A,angiotensin II,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
f08d0ab6-9677-4164-bddc-535311f0a91a,C0022709,C0003009,promotes concomitant increase in levels of ,Peptidyl-Dipeptidase A,angiotensin II,1,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
5625f587-ddf1-42f9-a3a2-0a27f2fae2d0,C0022709,C0003006,helps in formation of ,Peptidyl-Dipeptidase A,Angiotensin I,2,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,D06.472.699.094.075;D12.644.400.070.075;D12.644.456.073.021;D12.644.548.058.075;D12.776.631.650.070.075;D23.469.050.050.025;x.x.x.x
dd1da340-bc6b-4b3e-b1ce-030662d27306,C0058362,C0042397,has ,dipeptidyl peptidase II,Vasoconstrictor Agents,4,X,[aapp/enzy],[phsu],x.x.x.x,D27.505.954.411.793
eff1443c-eb06-4365-ae2d-db4741835b96,C0058362,C1439284,has properties via ,dipeptidyl peptidase II,AGTR1 gene,4,X,[aapp/enzy],[gngm],x.x.x.x,
623833fd-b477-4f3f-b085-416ae4495639,C0034787,C0819757,has effects in ,Angiotensin Receptor,Structure of parenchyma of lung,3,X,[aapp/rcpt],[tisu],D12.776.543.750.695.047;D12.776.543.750.750.130,
d5a96e4d-329b-4c94-b1a9-00b071bada7e,C0024115,C0206419,is in ,Lung diseases,Genus: Coronavirus,4,X,[dsyn],[virs],C08.381,B04.820.504.540.150
a29370be-b173-4872-b935-7d8d39defde2,C0024115,C1175743,is in ,Lung diseases,SARS coronavirus,3,X,[dsyn],[virs],C08.381,B04.820.504.540.150.113.937
0a1f51b7-6f8c-4d10-b96a-ae92fc4c21f4,C0016504,1700s,was during 1700s,Foot,1700s,1,X,[bpoc],????,A01.378.610.250,????
1c44f71f-c2af-40b4-8a59-2b0f4b8dbaa2,C0016504,C0037356,was during ,Foot,Smallpox Viruses,1,X,[bpoc],[virs],A01.378.610.250,B04.280.650.160.650.930
f27e68e3-1dc8-4911-ad6f-42a3451a8659,16cases,C0019004,is in ,16cases,Hemodialysis,5,X,????,[topp],????,E02.870.300;E02.912.800
552081ba-16c6-4aba-84c0-e58f56849889,C0206419,C0019004,is in ,Genus: Coronavirus,Hemodialysis,2,X,[virs],[topp],B04.820.504.540.150,E02.870.300;E02.912.800
cad92050-194d-40a7-84e3-e3339d571a70,C1175743,C3694279,by SARS coronavirus is,SARS coronavirus,Middle East Respiratory Syndrome,12,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
cad92050-194d-40a7-84e3-e3339d571a70,C1175743,C3694279,was causative Pharmacologic Substance to that of,SARS coronavirus,Middle East Respiratory Syndrome,4,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
c624898e-130c-4bc5-bc44-54110a5c671e,C3698360,C3694279,by SARS coronavirus is,Middle East Respiratory Syndrome Coronavirus,Middle East Respiratory Syndrome,4,X,[virs],[dsyn],B04.820.504.540.150.113.750,C02.782.600.550.200
2bb38a0f-a2ee-487b-8f76-6e598428b468,C0206419,C0683212,affect ,Genus: Coronavirus,central nervous system function,6,X,[virs],[ortf],B04.820.504.540.150,
57f5e992-b97a-4066-b022-c61ed2f25abe,C0003504,C0012634,tracking ,Aortic Valve Insufficiency,Disease,7,X,[dsyn],[dsyn],C14.280.484.095,C23.550.288
ae70fa9d-7062-447a-9743-9e6c3372961e,C1707391,C0567416,generate shape-based 3D ,Choose (action),Molecule,3,X,[acty],[sbst],,
6195fe86-dc6a-451d-bde8-aa655c11fbb8,C0567416,3D,starting from 3D ,Molecule,3D,7,X,[sbst],????,,????
4758ce14-1acf-4092-b1f0-0c724da47cd2,6LU7,C0206419,is in ,6LU7,Genus: Coronavirus,3,X,????,[virs],????,B04.820.504.540.150
a475c06e-c6c2-48e7-aea7-fc458a0d58c7,C0014964,6LU7,can can qualified as 6LU7 ,Ethambutol,6LU7,7,X,[orch/phsu],????,D02.092.782.258.368.265,????
2e10457c-d867-4528-9c22-5d6c8b3de3ff,C0014964,C0206419,can can qualified as 6LU7 ,Ethambutol,Genus: Coronavirus,3,X,[orch/phsu],[virs],D02.092.782.258.368.265,B04.820.504.540.150
34ed4190-cf61-454c-9269-409bf67b3ae7,C1947904,C0206419,Binding (Molecular Function) of,Attachment (action),Genus: Coronavirus,3,X,[acty],[virs],,B04.820.504.540.150
5346147a-0736-4e3b-a553-eff93e5e863f,C1947904,C0033684,Binding (Molecular Function) of,Attachment (action),Proteins,7,X,[acty],[aapp/bacs],,D12.776
64571f74-195c-47f4-b52a-01ab8b04282d,C1514562,C1707391,using ,Protein Domain,Choose (action),3,X,[amas],[acty],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
64571f74-195c-47f4-b52a-01ab8b04282d,C1514562,C1707391,consisting of ,Protein Domain,Choose (action),3,X,[amas],[acty],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
d5ea0773-7fc7-4337-8866-9f258c71f74b,C1514562,C0206419,was associated with ,Protein Domain,Genus: Coronavirus,2,X,[amas],[virs],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,B04.820.504.540.150
029fbf2a-24c5-4bb6-a17f-07aa95d9937b,C1514562,C0032285,was significantly associated with ,Protein Domain,Pneumonia,3,X,[amas],[dsyn],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,C08.381.677;C08.730.610
07564d79-70e4-4f89-b56d-e200c8fb336d,C0024109,C0960880,are damaged due to presence of ,Lung,angiotensin converting enzyme 2,2,X,[bpoc],[aapp/enzy],A04.411,x.x.x.x
686259fa-ad18-4fc0-b49e-47ed174fb66e,C0024109,C0597358,are damaged due to presence of ,Lung,receptor binding,1,X,[bpoc],[moft],A04.411,
5a4c723d-3219-4cc7-a49a-7e5e3ebb2aa8,C1999230,C0008138,related to ,Providing (action),Chiropractic (field),1,X,[acty],[bmod],,H02.110
4c34c93a-d38f-461b-ad0f-0c4df7bef687,C1999230,C0009450,regarding protecting against ,Providing (action),Communicable Diseases,2,X,[acty],[dsyn],,C01.539.221
4c34c93a-d38f-461b-ad0f-0c4df7bef687,C1999230,C0009450,lead clinical use of ,Providing (action),Communicable Diseases,6,X,[acty],[dsyn],,C01.539.221
2a65f635-2aa2-401d-8198-575bab6f8fcd,C0042210,C0206750,is currently available for treatment of ,Vaccines,Coronavirus Infections,2,X,[aapp/imft/phsu],[dsyn],D20.215.894,C02.782.600.550.200
2a65f635-2aa2-401d-8198-575bab6f8fcd,C0042210,C0206750,are are considered for treatment of ,Vaccines,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],D20.215.894,C02.782.600.550.200
67bff630-973c-4c4b-8e8e-c42bbb9ba1ca,C1175743,C3272452,is positive-sense ,SARS coronavirus,Single-Stranded RNA,6,X,[virs],[nnon],B04.820.504.540.150.113.937,
8e874927-0044-436e-8db3-1c8ecae4a3c2,C1175743,C2717802,is enveloped ,SARS coronavirus,Viral Structures,6,X,[virs],[anst],B04.820.504.540.150.113.937,A21
d00bec5b-6e81-406b-ae0b-224cf32bbdda,C3272452,C2717802,is with spike-like ,Single-Stranded RNA,Viral Structures,3,X,[nnon],[anst],,A21
7d3e93c6-d480-47e6-9ca3-285c0e9ee13e,C0597357,C0024109,were widely disturbed among ,receptor,Lung,12,X,[aapp/rcpt],[bpoc],,A04.411
340d6374-9b18-4b2d-9ea0-158055b1c740,C0042776,C1175175,causes ,Virus,Severe Acute Respiratory Syndrome,5,X,[virs],[dsyn],B04,C02.782.600.550.200.750;C08.730.730
d36dc95c-0b77-48a9-9e3d-215d5d6ec126,C0086418,C0012634,was confirmed for ,Homo sapiens,Disease,10,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C23.550.288
29071e5f-ff01-4377-ac73-e31c3431f907,C0814435,C0920467,may expedite proper management of ,early identification,disorder control (procedure),2,X,[topp],[topp],,
19b4ba0a-9a16-4780-85bb-bebb7b1323d3,C0008679,C0012634,had risk as recommended target ,Chronic disease,Disease,1,X,[dsyn],[dsyn],C23.550.291.500,C23.550.288
9b21f55b-fa91-4ad8-b497-d4761638a4e8,C0008679,C0042196,had risk as recommended target ,Chronic disease,Vaccination,1,X,[dsyn],[topp],C23.550.291.500,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
b472b931-cc4e-4e75-adc6-ed9cca9db1e7,CRE,C0076611,Here investigated possible protective effects of ,CRE,thymoquinone,1,X,????,[orch],????,x.x.x.x
e273c15f-c5c9-428d-a7e9-3481707112e3,CRE,C0025919,Here investigated possible protective effects of ,CRE,Mice Inbred BALB C,1,X,????,[mamm],????,B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338
e273c15f-c5c9-428d-a7e9-3481707112e3,CRE,C0025919,investigated possible effects against kidney damage in ,CRE,Mice Inbred BALB C,1,X,????,[mamm],????,B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338
7e4b391a-6047-423d-89ba-a9533dd17ae3,C0007531,C0076611,was performed after weeks of ,Cecum,thymoquinone,2,X,[bpoc],[orch],A03.556.124.526.209;A03.556.249.249.209,x.x.x.x
498263bc-897b-4479-a3cf-be28322fe2c1,C0007531,C0041281,was performed after weeks of ,Cecum,Tube feeding of patient,2,X,[bpoc],[topp],A03.556.124.526.209;A03.556.249.249.209,
1256ee90-972f-4a27-a235-e683a2f620c2,CRE,C0040300,measured histopathological alterations in kidney ,CRE,Body tissue,1,X,????,[tisu],????,A10
5ca92cf1-f679-4f24-92fc-67a341698f30,CRE,48h,measured alterations After 48h,CRE,48h,1,X,????,????,????,????
fde58878-b220-48ef-92d8-256b48206244,CRE,C2610960,also evaluated ,CRE,Pyroptosis,1,X,????,[celf],????,G04.146.160.530
152bda2e-d289-49d4-bb44-8aae3b52999a,C0076611,C0007531,inhibited CRE,thymoquinone,Cecum,2,X,[orch],[bpoc],x.x.x.x,A03.556.124.526.209;A03.556.249.249.209
152bda2e-d289-49d4-bb44-8aae3b52999a,C0076611,C0007531,also significantly inhibited high levels of ,thymoquinone,Cecum,1,X,[orch],[bpoc],x.x.x.x,A03.556.124.526.209;A03.556.249.249.209
afc4d3d0-7a5e-4247-ab22-5e439913fd18,C0076611,CRE,inhibited CRE,thymoquinone,CRE,2,X,[orch],????,x.x.x.x,????
220b6ef9-1137-4174-be73-d6d2e0648f34,C0076611,C0600137,inhibited ,thymoquinone,Blood Urea Nitrogen,2,X,[orch],[bacs/inch],x.x.x.x,E01.370.225.124.100.115;E01.370.390.400.100;E05.200.124.100.115
18011c61-95dc-46e1-b327-e3379f2677a6,C0076611,C1424250,also significantly inhibited high levels of ,thymoquinone,NLRP3 gene,1,X,[orch],[gngm],x.x.x.x,
aae329c6-77fb-48ae-b581-59f9c6e6466c,NF-B,C0076611,was Furthermore decreased in ,NF-B,thymoquinone,4,X,????,[orch],????,x.x.x.x
373e2b55-80d3-42e2-8740-386a7b73f5a3,NF-B,C0007531,was decreased than than ,NF-B,Cecum,4,X,????,[bpoc],????,A03.556.124.526.209;A03.556.249.249.209
f50e6b5d-45f4-4f90-8c2c-9a9e7e03abfa,C0076611,C0243026,be potential agent for AKI,thymoquinone,Sepsis,2,X,[orch],[dsyn],x.x.x.x,C01.539.757;C23.550.470.790.500
5176b1d7-3717-4908-97b6-cfdb89daa376,C0076611,AKI,be potential agent for AKI,thymoquinone,AKI,2,X,[orch],????,x.x.x.x,????
9aab35a7-38c0-40b3-a786-435fad20a17f,C0920687,C1705178,is in ,cancer care,Order (action),2,X,[topp],[acty],,
d88b53d1-408c-4881-8948-7130a529817b,C0206750,C1456573,presents unprecedented threat to ,Coronavirus Infections,Global Health,27,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.371;N01.400.337
e4a2b1e9-0838-4c12-8c6e-a7bd94b2d6f8,C1140694,C1175743,investigate origin of ,Bio-Informatics,SARS coronavirus,2,X,[bmod],[virs],H01.158.273.180;L01.313.124,B04.820.504.540.150.113.937
369e1cdf-20d1-4e70-88ea-12d03d7a44aa,C1175743,C0015219,exhibited ,SARS coronavirus,Biological Evolution,3,X,[virs],[genf],B04.820.504.540.150.113.937,G05.045;G16.075
b2ecd51a-26f1-4402-bd9f-d0a581668f64,C0206750,C0021403,is unlike ,Coronavirus Infections,Influenza virus vaccine,3,X,[dsyn],[imft/phsu],C02.782.600.550.200,D20.215.894.899.302
d301ca4a-0011-40a3-897c-79057bd4fb73,C0012634,C0021403,having ,Disease,Influenza virus vaccine,5,X,[dsyn],[imft/phsu],C23.550.288,D20.215.894.899.302
21735c51-90a9-4a74-89c5-6210ba8f7bda,C0275524,C0021403,is with ,Coinfection,Influenza virus vaccine,2,X,[dsyn],[imft/phsu],C01.539.218;C02.219;C03.202,D20.215.894.899.302
c7ff032d-fde6-44d5-95da-70fd6e54ca7d,C0275524,C1880177,is with ,Coinfection,Contribution,2,X,[dsyn],[acty],C01.539.218;C02.219;C03.202,
bb877c0b-094b-490f-b428-13ba762e0ee5,C2926735,C0021403,was longer than than those without ,Duration,Influenza virus vaccine,7,X,[orch/phsu],[imft/phsu],,D20.215.894.899.302
88558791-4bc1-4c57-8393-4e4e8698be30,C2926735,C0275524,was longer than than those without ,Duration,Coinfection,14,X,[orch/phsu],[dsyn],,C01.539.218;C02.219;C03.202
d17065c6-1fbe-4ae8-a666-ef094ee304df,C0032285,C0206750,is in ,Pneumonia,Coronavirus Infections,7,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C02.782.600.550.200
361424e0-12b9-478e-9b82-3fc3999a4d20,C0939237,C0748159,eliminated difference of ,lopinavir / Ritonavir,pulmonary involvement,5,X,[phsu],[dsyn],,
52e7e9f6-e6bc-4649-9066-e997bb5f7b04,C0939237,C0021403,eliminated difference between ,lopinavir / Ritonavir,Influenza virus vaccine,2,X,[phsu],[imft/phsu],,D20.215.894.899.302
03e238e9-9b09-4f83-84ad-ab1d9a8a884e,C0939237,C0032285,is associated with ,lopinavir / Ritonavir,Pneumonia,2,X,[phsu],[dsyn],,C08.381.677;C08.730.610
1745b23a-cdab-410b-bbcc-efa946793e67,C0939237,C0206750,treating non-severe ,lopinavir / Ritonavir,Coronavirus Infections,6,X,[phsu],[dsyn],,C02.782.600.550.200
a1a08d7c-4eac-4812-8cfe-1a84e722d266,C0007222,C1824356,are at with comorbidities risk of ,Cardiovascular Diseases,KIAA1551 gene,3,X,[dsyn],[gngm],C14,
c9ba6772-a129-45b9-b16a-c929eab17762,C0017178,C0021079,requiring ,Gastrointestinal Diseases,Therapeutic immunosuppression,12,X,[dsyn],[topp],C06.405,E02.095.465.425.450;E05.478.610
9f1ea4c5-6157-43ce-83ff-1d05d2ac3981,C1516048,C3711684,has ,Assessed,S protein severe acute respiratory syndrome coronavirus,3,X,[acty],[aapp/bacs],,x.x.x.x
3ff8e858-e761-4cb8-a323-92a677723f70,C1516048,C0003320,has ,Assessed,Antigens,1,X,[acty],[imft],,D23.050
1341ef00-549f-4c87-a086-007084ee151a,C0003316,C0027498,is in ,Epitopes,Nausea and vomiting,1,X,[imft],[sosy],D23.050.550,
7a31f3c8-961c-45d3-b6be-3a051bdeb74e,C0282580,C0027498,is in ,Epitopes T-Lymphocyte,Nausea and vomiting,1,X,[imft],[sosy],D23.050.550.402,
e19b26ce-db7a-477f-b304-e6981241c7bd,C0278627,C0206419,is in current ,oncology field,Genus: Coronavirus,1,X,[bmod],[virs],,B04.820.504.540.150
4d000a22-1af3-49e9-9d0d-87e67be5d284,C0003451,C2948600,is with ,Antiviral Agents,Aim,2,X,[phsu],[inch/phsu],D27.505.954.122.388,
192c184e-d016-480a-a4a7-b24bdc5568e8,C0003451,C1999230,is with ,Antiviral Agents,Providing (action),2,X,[phsu],[acty],D27.505.954.122.388,
bc8a1a2b-35ed-4a19-9f9b-b0f110adb71f,C0206419,C1628999,is caused by single-stranded ,Genus: Coronavirus,SARS coronavirus RNA,1,X,[virs],[nnon],B04.820.504.540.150,
8b7560f1-b953-4d2f-8ddf-54ae956e8368,RAS,C0206419,be maintained during current ,RAS,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
765e5a21-5d81-4e5f-a909-37d4d40973cc,C0206419,C1321919,is taking colossal ,Genus: Coronavirus,TLR4 protein human,1,X,[virs],[aapp/rcpt],B04.820.504.540.150,x.x.x.x
f6f80039-4990-42dc-abc6-a1145e1988e0,C0206419,C0086418,took 0.39 million ,Genus: Coronavirus,Homo sapiens,40,X,[virs],[humn],B04.820.504.540.150,B01.050.150.900.649.313.988.400.112.400.400
9c49b47b-81b6-4835-906d-bd8087e33107,C0206419,C0683278,is taking colossal ,Genus: Coronavirus,Mental Suffering,1,X,[virs],[mobd],B04.820.504.540.150,F01.145.126.990;F02.830.900
af7a4a3f-a8ad-4bba-8fa0-6418f4129df1,C0206419,U.S.,has resulted in > 500 000 deaths including > 125 000 deaths in U.S. ,Genus: Coronavirus,U.S.,1,X,[virs],????,B04.820.504.540.150,????
af7a4a3f-a8ad-4bba-8fa0-6418f4129df1,C0206419,U.S.,is placing considerable strain on U.S. ,Genus: Coronavirus,U.S.,1,X,[virs],????,B04.820.504.540.150,????
90eea59c-b9f3-4e75-ab29-95457657aa40,C1516048,C4050231,using Padua prediction ,Assessed,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[acty],[clna],,
90eea59c-b9f3-4e75-ab29-95457657aa40,C1516048,C4050231,using Household ,Assessed,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[acty],[clna],,
a02ea636-149b-4a99-99c1-91e7d5b17d83,C0630906,C1516048,Risks of were ,vinyltriethoxysilane,Assessed,1,X,[orch],[acty],x.x.x.x,
95fa8a97-be09-4eb3-870f-bebc10d4d265,C0630906,C0010076,overall rate of was ,vinyltriethoxysilane,Coronaviridae,6,X,[orch],[virs],x.x.x.x,B04.820.504.540
95fa8a97-be09-4eb3-870f-bebc10d4d265,C0630906,C0010076,incidence of was In patients ,vinyltriethoxysilane,Coronaviridae,6,X,[orch],[virs],x.x.x.x,B04.820.504.540
ca6faf8d-f250-4b6b-a415-88e86639907a,C0630906,C0012634,was in ,vinyltriethoxysilane,Disease,3,X,[orch],[dsyn],x.x.x.x,C23.550.288
1f586e57-392b-45da-ad4b-0665f628975b,COVID,C1882932,have ,COVID,Representation (action),2,X,????,[acty],????,
16907b6d-2b33-4a27-b0b9-fcf851bda35c,C0222045,C1882932,have ,Integumentary scale,Representation (action),2,X,[bpoc],[acty],,
03d5205e-d940-4454-afcf-4bef6eddf7f8,C0206419,C1533724,includes fear coming into contact with ,Genus: Coronavirus,Fomes,1,X,[virs],[fngs],B04.820.504.540.150,B01.300.179.120.174
a9a374d7-461a-477b-9f5c-f582bc4dd34b,C0039082,C0033927,was correlated with preexisting ,Syndrome,Psychopathology,8,X,[dsyn],[bmod],C23.550.288.500,F04.096.670
94544d48-80df-456d-b92d-a92743172fa9,C0039082,C0206419,was correlated with preexisting ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
94544d48-80df-456d-b92d-a92743172fa9,C0039082,C0206419,was correlated with excessive ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
94544d48-80df-456d-b92d-a92743172fa9,C0039082,C0206419,were repeatedly reported after ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
94544d48-80df-456d-b92d-a92743172fa9,C0039082,C0206419,Symptoms of,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
94544d48-80df-456d-b92d-a92743172fa9,C0039082,C0206419,is life-threatening manifestation of ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
94544d48-80df-456d-b92d-a92743172fa9,C0039082,C0206419,seems most common manifestation of ,Syndrome,Genus: Coronavirus,2,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
4d7044b6-5bd4-4e69-b8fa-bdb36976dbe2,C0039082,C0870238,was correlated with preexisting ,Syndrome,buying,6,X,[dsyn],[acty],C23.550.288.500,
403abead-d42a-492f-9517-26a336119cce,C2607914,C0679381,is common ,Allergic rhinitis (disorder),Pediatric Disorder,1,X,[dsyn],[dsyn],C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443,
635d57bf-3fbc-4340-8391-0185a789eb65,C0042776,C1290074,are involved in ,Virus,Chronic mucositis,2,X,[virs],[dsyn],B04,
fc0ac611-00cc-42f6-83cf-cbb3c9d0205a,C0042776,C0028429,are involved in ,Virus,Nose,1,X,[virs],[bpoc],B04,A01.456.505.733;A04.531;A09.531
fc0ac611-00cc-42f6-83cf-cbb3c9d0205a,C0042776,C0028429,Inflammatory disease of mucous membrane of,Virus,Nose,2,X,[virs],[bpoc],B04,A01.456.505.733;A04.531;A09.531
fc0ac611-00cc-42f6-83cf-cbb3c9d0205a,C0042776,C0028429,produce ,Virus,Nose,2,X,[virs],[bpoc],B04,A01.456.505.733;A04.531;A09.531
e006a3d5-fe39-4816-892e-20287cf9512b,C0206419,C0022709,utilize ,Genus: Coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150,D08.811.277.656.350.350.687
7dc5c3e5-6be3-43fb-874b-be4eb36c596f,C1452534,C0003009,helps in formation of ,ACE protein human,angiotensin II,1,X,[aapp/bacs],[aapp/bacs/phsu],x.x.x.x,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
c30299ba-4b7f-42b1-9f89-c2020454bac9,C1452534,C0003006,helps in formation of ,ACE protein human,Angiotensin I,1,X,[aapp/bacs],[aapp/bacs],x.x.x.x,D06.472.699.094.075;D12.644.400.070.075;D12.644.456.073.021;D12.644.548.058.075;D12.776.631.650.070.075;D23.469.050.050.025;x.x.x.x
ae621f94-574a-4d46-aa31-ef1d8d1a729d,C1452534,C0042397,has ,ACE protein human,Vasoconstrictor Agents,1,X,[aapp/bacs],[phsu],x.x.x.x,D27.505.954.411.793
a85b71ad-7663-4ee8-90c3-e5de040aff67,C0003009,C0042397,has ,angiotensin II,Vasoconstrictor Agents,1,X,[aapp/bacs/phsu],[phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D27.505.954.411.793
958084d3-f59f-430e-bf69-fe2f39516347,C1452534,C1439284,has properties via ,ACE protein human,AGTR1 gene,1,X,[aapp/bacs],[gngm],x.x.x.x,
6d421e29-43d4-4f31-a94e-597211213e9f,C0003009,C1439284,has properties via ,angiotensin II,AGTR1 gene,1,X,[aapp/bacs/phsu],[gngm],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
235686bd-7d97-48d3-a45e-7caf35a2c560,C0597357,C0003009,counter pro-inflammatory effects mediated by ,receptor,angiotensin II,2,X,[aapp/rcpt],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
31b017cd-7721-406e-b057-57622eb10b88,C0022709,C0042402,counter pro-inflammatory effects mediated by ,Peptidyl-Dipeptidase A,Vasodilator Agents,1,X,[aapp/enzy/imft],[phsu],D08.811.277.656.350.350.687,D27.505.954.411.918
e5384b08-4254-4630-a468-273a0d5b4aab,C0597357,C0042402,counter pro-inflammatory effects mediated by ,receptor,Vasodilator Agents,2,X,[aapp/rcpt],[phsu],,D27.505.954.411.918
c213b8ed-44e2-4b41-88f9-474f86128a53,C0184661,C0883301,performed procedures on patients arterial ,Interventional procedure,catheter placement,3,X,[topp],[topp],,
0af8a0a7-50fe-43b4-9ec4-efb0e0b26d45,C0740651,C0030193,were ,Abdominal symptom,Pain,1,X,[sosy],[sosy],,C23.888.592.612;F02.830.816.444;G11.561.790.444
43cfc034-b973-402c-88eb-0fa1b631530a,C0052796,C0206419,is in hospitalized patients positive for ,Azithromycin,Genus: Coronavirus,2,X,[antb/orch],[virs],D02.540.576.500.992.050,B04.820.504.540.150
f79de930-cc00-402f-9a0c-3ad890b1c03d,C0020336,C0052796,of Receipt is hydroxychloroquine in combination with ,Hydroxychloroquine,Azithromycin,2,X,[orch/phsu],[antb/orch],D03.633.100.810.050.180.350,D02.540.576.500.992.050
f7010ce5-8b64-4c04-8d88-a728362d7cf8,C1175175,C0184661,is in patient recovering after Hartmanns ,Severe Acute Respiratory Syndrome,Interventional procedure,2,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,
20ef4ca3-f554-4c91-bc96-0b87bdcd85f2,C1175175,C0518989,is in patient recovering after Hartmanns ,Severe Acute Respiratory Syndrome,acute diverticulitis,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,
f9833877-3a03-4214-a4c6-d5fdbed3a611,C1142578,C1175743,confirmed presence of ,Bilateral pneumonia,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
8c0f656c-fa39-47fb-866f-42f4b016174b,C1457887,C0206419,may may attributed to ,Symptoms,Genus: Coronavirus,7,X,[sosy],[virs],,B04.820.504.540.150
4a0a5ca2-0ab6-4602-81ea-713d520306b0,C0206419,C0543467,is in ,Genus: Coronavirus,Operative Surgical Procedures,2,X,[virs],[topp],B04.820.504.540.150,E04
62d9845b-7736-4324-a227-06f92bb4bed1,C0598197,C0543467,is in ,contagion,Operative Surgical Procedures,2,X,[npop],[topp],,E04
e50f96e0-74f8-4dfc-814b-c96cf61259e7,C0003364,ACEI,is with ACEI ,Antihypertensive Agents,ACEI,2,X,[phsu],????,D27.505.954.411.162,????
40225ddc-c5d1-4392-9460-cc8e26796982,C0003364,C3888198,is with ACEI ,Antihypertensive Agents,BESTROPHINOPATHY AUTOSOMAL RECESSIVE,2,X,[phsu],[dsyn],D27.505.954.411.162,
70fb0732-5ac7-4401-9947-ca4871b90368,C0003364,C0683325,is with ACEI ,Antihypertensive Agents,clinical aspects,2,X,[phsu],[clna],D27.505.954.411.162,
d35daffc-a4cd-4801-9a69-ae0e73e6b16c,C1511790,C1175175,is required for ,Detection,Severe Acute Respiratory Syndrome,4,X,[topp],[dsyn],,C02.782.600.550.200.750;C08.730.730
d35daffc-a4cd-4801-9a69-ae0e73e6b16c,C1511790,C1175175,was used for confirmation of ,Detection,Severe Acute Respiratory Syndrome,1,X,[topp],[dsyn],,C02.782.600.550.200.750;C08.730.730
d81bda11-0fe1-42f2-b687-bdd05d1f1370,C0028606,C0206419,is in ,Nucleic Acids,Genus: Coronavirus,3,X,[bacs/nnon],[virs],D13.444,B04.820.504.540.150
611497ff-18e2-48ac-a884-ab145a1a08a5,C1999230,C0028606,effective Complement System Proteins to false-negative results from,Providing (action),Nucleic Acids,3,X,[acty],[bacs/nnon],,D13.444
9130c325-6258-4d80-a55a-38b60e8a4263,C1999230,C1175175,rapidly evaluate ,Providing (action),Severe Acute Respiratory Syndrome,6,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
677fd80d-0a17-4d2c-96f0-a019e390c094,C0185003,C1160716,prevent ,Reparative closure,viral transmission,8,X,[topp],[celf],,
39e709f6-ed1f-4483-b2f5-021ebcd3584f,C0185003,C1825598,prevent its ,Reparative closure,IMPACT gene,5,X,[topp],[gngm],,
e75d9a32-6b93-463c-96dd-7e68495418f4,C0185003,C1705178,is implemented widely in ,Reparative closure,Order (action),5,X,[topp],[acty],,
b5155f93-f9dc-4fa9-b2e6-278719908660,COVID-19,C0015967,usually presents with ,COVID-19,Fever,1,X,[virs],[sosy],C000657245,C23.888.119.344
b5155f93-f9dc-4fa9-b2e6-278719908660,COVID-19,C0015967,is in patients with ,COVID-19,Fever,1,X,[virs],[sosy],C000657245,C23.888.119.344
f67c14eb-66bd-416c-9b76-355c92fd86c4,C0003451,C0086418,should should evaluated for ,Antiviral Agents,Homo sapiens,1,X,[phsu],[humn],D27.505.954.122.388,B01.050.150.900.649.313.988.400.112.400.400
924db9fc-c9f0-486f-9944-d09977282cd9,C0086903,C0032105,had titer at time of ,GTP-Binding Protein alpha Subunits Gs,Plasma,1,X,[aapp/enzy],[bdsu],D08.811.277.040.330.300.200.100.400;D12.644.360.360.100.400;D12.776.157.325.332.100.400;D12.776.476.375.100.400;D12.776.543.325.100.400,A12.207.152.693;A12.207.270.695;A15.145.693
98a736df-032f-44d5-954f-afeb1c0e76c3,C1522002,C0032105,had titer at time of ,RNA Recognition Motif,Plasma,5,X,[aapp/bacs],[bdsu],G02.111.570.820.709.275.500.869.500,A12.207.152.693;A12.207.270.695;A15.145.693
b737100c-5f63-4a75-b3af-890985cb2505,titer,C0032105,had titer at time of ,titer,Plasma,6,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
21379162-0c53-4bdc-81a9-803fe2791eb5,C0086903,titer,had titer ,GTP-Binding Protein alpha Subunits Gs,titer,1,X,[aapp/enzy],????,D08.811.277.040.330.300.200.100.400;D12.644.360.360.100.400;D12.776.157.325.332.100.400;D12.776.476.375.100.400;D12.776.543.325.100.400,????
cbf768c6-2f9f-4c76-a2cf-9cbf70291062,C1522002,titer,had titer ,RNA Recognition Motif,titer,5,X,[aapp/bacs],????,G02.111.570.820.709.275.500.869.500,????
d60b634a-90fd-4f37-97ed-91e4e03826bb,C1457887,COVID-19,reaches levels after 4weeks ,Symptoms,COVID-19,14,X,[sosy],[virs],,C000657245
e494e692-6f63-4b63-9dcb-fc3889bd2d03,C0443640,COVID-19,reaches levels after 4weeks ,Specific antibody,COVID-19,4,X,[aapp/imft],[virs],,C000657245
eaffa30d-ce50-4da5-9dd9-d370865e77ab,C0020852,COVID-19,reaches levels after 4weeks ,Immunoglobulin G,COVID-19,2,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,C000657245
beef2f0e-fa91-48df-a21d-5877cb244e70,C1457887,4weeks,reaches levels after 4weeks ,Symptoms,4weeks,1,X,[sosy],????,,????
63a6a6a2-ebe1-4960-b30e-c32b7a43d29b,C0443640,4weeks,reaches levels after 4weeks ,Specific antibody,4weeks,4,X,[aapp/imft],????,,????
e2ce2bd6-2431-4f6d-b3b7-ca6bf3a9b163,C0020852,4weeks,reaches levels after 4weeks ,Immunoglobulin G,4weeks,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,????
9c5fbc81-7b62-4887-9203-0878c305cba5,COVID-19,C1707455,is with smoking history ,COVID-19,Comparison,1,X,[virs],[acty],C000657245,
9c5fbc81-7b62-4887-9203-0878c305cba5,COVID-19,C1707455,occur among patients on ,COVID-19,Comparison,1,X,[virs],[acty],C000657245,
38c4b1fc-bf54-44a4-9b39-e412bed45523,C0024530,C1456573,remains major ,Malaria,Global Health,3,X,[dsyn],[bmod],C03.752.530,H02.403.371;N01.400.337
7a01eab7-27d6-4772-b8b4-86a86f4d289e,C0024115,C0024530,is with many clinical parallels to ,Lung diseases,Malaria,2,X,[dsyn],[dsyn],C08.381,C03.752.530
af2d8d14-deeb-467e-afdf-3da1192171ea,C0206419,C1456573,is major ,Genus: Coronavirus,Global Health,10,X,[virs],[bmod],B04.820.504.540.150,H02.403.371;N01.400.337
5f2d16e4-8c37-470f-be86-2ee8b3e3889b,C0012634,C1456573,recently appeared as ,Disease,Global Health,13,X,[dsyn],[bmod],C23.550.288,H02.403.371;N01.400.337
027298a7-bfd8-4172-8e25-bc9d64d21ada,MPV,C1707455,was significantly higher as ,MPV,Comparison,4,X,????,[acty],????,
84a2049d-c7e4-4f89-b4a7-50345f80b40c,MPV,C0011849,was significantly higher as ,MPV,Diabetes Mellitus,2,X,????,[dsyn],????,C18.452.394.750;C19.246
84a2049d-c7e4-4f89-b4a7-50345f80b40c,MPV,C0011849,was higher to results from last routine visits of same individuals with ,MPV,Diabetes Mellitus,2,X,????,[dsyn],????,C18.452.394.750;C19.246
84a2049d-c7e4-4f89-b4a7-50345f80b40c,MPV,C0011849,predict Covid ,MPV,Diabetes Mellitus,2,X,????,[dsyn],????,C18.452.394.750;C19.246
efc30971-043a-40a2-9891-f68a741cd964,C0009450,C0011849,is in subjects with ,Communicable Diseases,Diabetes Mellitus,2,X,[dsyn],[dsyn],C01.539.221,C18.452.394.750;C19.246
efc30971-043a-40a2-9891-f68a741cd964,C0009450,C0011849,is in individuals with ,Communicable Diseases,Diabetes Mellitus,1,X,[dsyn],[dsyn],C01.539.221,C18.452.394.750;C19.246
ce6034b9-99be-4a28-8826-0fc88a8df676,MPV,C0009450,predict Covid ,MPV,Communicable Diseases,2,X,????,[dsyn],????,C01.539.221
c5376c51-f9cc-44e9-a589-07110280fc5b,C0040649,C0086418,is in samples of ,Transcription Genetic,Homo sapiens,1,X,[genf],[humn],G02.111.873;G05.297.700,B01.050.150.900.649.313.988.400.112.400.400
bb3d51b0-f368-48c4-8104-6ba1637a75d1,C0040649,C1956101,is in samples of ,Transcription Genetic,Cumulus Cells,1,X,[genf],[cell],G02.111.873;G05.297.700,A05.360.319.114.630.535.200.500;A06.300.312.497.535.300.500;A11.382.812.500;A11.436.329.500
d14f6c2f-47b6-42c0-9725-ee8d11c8f905,C0022709,C0039597,is in ,Peptidyl-Dipeptidase A,Testis,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A05.360.444.849;A05.360.576.782;A06.300.312.782
2cd0abaa-d57f-48d6-90bf-9aa038bedc24,C0029045,C1160716,are associated with very little risk ,Oocytes,viral transmission,1,X,[cell],[celf],A05.360.490.690.680;A11.497.497.600,
14284d9c-e0a9-44a2-81a9-161e2b0d0d66,invitro,C1160716,are associated with very little risk ,invitro,viral transmission,1,X,????,[celf],????,
3218fec0-4639-4b38-9511-1d4c484eb985,C0029045,C2718310,are associated with very little risk ,Oocytes,Gametes,1,X,[cell],[cell],A05.360.490.690.680;A11.497.497.600,A05.360.490;A11.497
fd928317-7dd4-40fc-9882-043e7cc4af3a,invitro,C2718310,are associated with very little risk ,invitro,Gametes,1,X,????,[cell],????,A05.360.490;A11.497
7e36d556-0f44-407d-9d37-04efec17a39b,C0301872,murine,is in murine ,Immune response,murine,1,X,[ortf],????,,????
ee6de103-83e2-4812-901d-51a7f5b955a3,C0301872,C0017260,is in murine ,Immune response,Gene Deletion,1,X,[ortf],[genf],,G05.365.590.762.320;G05.558.800.320
07a943e5-3c16-42ce-ab60-9fa438108f8e,C0021083,C0011627,used in ,Immunotherapy,Dermatology field,1,X,[topp],[bmod],E02.095.465.425,H02.403.225
20ed72bd-1efa-427c-ac37-6d129db33a7a,C0021083,COVID-19,are most likely safe for ,Immunotherapy,COVID-19,1,X,[topp],[virs],E02.095.465.425,C000657245
0fe52f4e-6b9d-4cc2-881e-49ccc7cadbee,C4048329,C0206419,were predictors protective for mortality in hospitalized ,Immunosuppression,Genus: Coronavirus,5,X,[dsyn],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150
0fe52f4e-6b9d-4cc2-881e-49ccc7cadbee,C4048329,C0206419,may may protective in those affected with ,Immunosuppression,Genus: Coronavirus,1,X,[dsyn],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150
0fe52f4e-6b9d-4cc2-881e-49ccc7cadbee,C4048329,C0206419,is largely safe in current ,Immunosuppression,Genus: Coronavirus,1,X,[dsyn],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150
4f32f5a1-a99c-4d8b-8a9f-842fa072f54a,C1175743,C0015392,spread rapidly around ,SARS coronavirus,Eye,42,X,[virs],[bpoc],B04.820.504.540.150.113.937,A01.456.505.420;A09.371
dfbd1b07-1f95-455c-9f46-ef3c400ab7d7,C0042776,COVID-19,could ,Virus,COVID-19,1,X,[virs],[virs],B04,C000657245
dfbd1b07-1f95-455c-9f46-ef3c400ab7d7,C0042776,COVID-19,associated with ,Virus,COVID-19,2,X,[virs],[virs],B04,C000657245
c188fc76-735b-411f-973d-20676d3e0cc8,C0042776,C0013227,could could further explored as potential ,Virus,Pharmaceutical Preparations,5,X,[virs],[phsu],B04,D26
1e147eb7-aff2-4500-ac38-d768b241317b,C0748355,pro-,are result of disruption in balance of pro- ,Acute respiratory distress,pro-,7,X,[dsyn],????,,????
11bfcd58-497c-4bcc-a4b6-357fcc7c5a38,C0748355,C0079189,are result of disruption in balance of pro- ,Acute respiratory distress,cytokine,12,X,[dsyn],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
bb093bfd-c8b5-492d-b43f-e91f04de46ab,C0748355,C0221423,are result Like Like ,Acute respiratory distress,Illness (finding),12,X,[dsyn],[sosy],,
4234db65-31ac-423b-9522-d9ffcb9bd411,COVID-19,C0033860,is with ,COVID-19,Psoriasis,2,X,[virs],[dsyn],C000657245,C17.800.859.675
31d403db-6ed4-4e85-9408-cb1e436e28ed,C1678805,C0011627,could could safer alternative for ,apremilast,Dermatology field,5,X,[orch/phsu],[bmod],x.x.x.x,H02.403.225
12ffa53a-8f67-4b65-9869-ca31ef5f5439,C0206419,C0398623,was associated with ,Genus: Coronavirus,Thrombophilia,2,X,[virs],[dsyn],B04.820.504.540.150,C15.378.925
70496722-5ff4-4bd7-b8c0-8f76b32aff87,C1149313,C0032105,had titer at time of ,IgG binding,Plasma,1,X,[moft],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
4591a51b-17af-404c-8260-e888989fd39c,C1149313,titer,had titer ,IgG binding,titer,1,X,[moft],????,,????
abcf2290-a74d-405f-a1d5-0e04fcbf01ba,C2754943,4weeks,reaches levels after 4weeks ,IgG antibody,4weeks,5,X,[celc],????,,????
8ebf90b3-f67f-4537-8d56-a0b2fa1d027b,C2754943,C0206419,reaches levels after 4weeks ,IgG antibody,Genus: Coronavirus,2,X,[celc],[virs],,B04.820.504.540.150
cbce9491-8cd5-4fd6-84f7-fd841f6787ed,C2754943,C1457887,reaches levels after 4weeks ,IgG antibody,Symptoms,5,X,[celc],[sosy],,
40233edf-80a7-4183-a6ac-9d568d316878,C0206419,3rd,is spreading rapidly as of 3rd ,Genus: Coronavirus,3rd,1,X,[virs],????,B04.820.504.540.150,????
da891ba8-da47-4137-b66b-4dadd0469437,C0747919,COVID-19,is with ,pregnancy related,COVID-19,4,X,[dsyn],[virs],,C000657245
f5be0dab-4065-49e7-ae6b-6419491bfab9,C0206419,C1511790,was first ,Genus: Coronavirus,Detection,2,X,[virs],[topp],B04.820.504.540.150,
0f069355-de13-40c2-bbba-b17b24a771a2,C0042776,C0039082,is responsible for acute respiratory ,Virus,Syndrome,3,X,[virs],[dsyn],B04,C23.550.288.500
02a0262b-5fdc-425a-ac4d-16e3eab94311,C0042776,C0206061,is responsible for acute respiratory ,Virus,Pneumonia Interstitial,6,X,[virs],[dsyn],B04,C08.381.483
39c2eb16-16e4-4f7f-8ff6-a1a93329a2ad,C0206419,C0042776,is new ,Genus: Coronavirus,Virus,10,X,[virs],[virs],B04.820.504.540.150,B04
bbada177-f41c-4073-9235-dea9cb119ee8,C0042776,C0003047,can cause Animal Diseases in,Virus,Animal Diseases,4,X,[virs],[dsyn],B04,C22
df83f311-4dcc-43a1-981e-25189978a708,C0035204,C1175743,caused by highly ,Respiration Disorders,SARS coronavirus,17,X,[dsyn],[virs],C08.618,B04.820.504.540.150.113.937
df83f311-4dcc-43a1-981e-25189978a708,C0035204,C1175743,using much lower dose of ,Respiration Disorders,SARS coronavirus,1,X,[dsyn],[virs],C08.618,B04.820.504.540.150.113.937
91352e1a-5d1d-497b-92e0-474eaa62683a,C0206419,C3713294,39-year-old woman with ,Genus: Coronavirus,MTR protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150,x.x.x.x
d4512e33-5dae-471e-ac20-d46097ade830,C0086418,C3713294,39-year-old woman with ,Homo sapiens,MTR protein human,1,X,[humn],[aapp/enzy],B01.050.150.900.649.313.988.400.112.400.400,x.x.x.x
3da4f81c-fbaf-4735-8a7d-d4196ee64501,C0086418,C0036745,exhibited negative ,Homo sapiens,Study of serum,1,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H02.781
d82ff4ac-fc96-4892-b760-4fd368246d68,C0027183,C0003261,blunt 2 ,NN-Dimethyltryptamine,Antibody Formation,1,X,[bacs/orch],[biof],D02.092.211.215.801.451;D03.633.100.473.914.237,G12.070
62c1bd11-02f3-4581-b88f-1f579b79ca0a,C0030805,C0004364,is most common ,Bullous pemphigoid,Autoimmune Diseases,1,X,[dsyn],[dsyn],C17.800.865.690;C20.111.730,C20.111
284befda-a209-45d0-be3e-1e71d6b97285,C0030805,C0035053,has ,Bullous pemphigoid,Remission Spontaneous,1,X,[dsyn],[npop],C17.800.865.690;C20.111.730,C23.550.291.656.700;G16.767
8b789b4d-67d9-4f43-840e-ad88096759ae,C1825598,C0441516,includes ,IMPACT gene,Demand (clinical),6,X,[gngm],[topp],,
cda34b3f-d720-47b7-8de3-9af832046ef1,C1825598,C1420621,shift towards ,IMPACT gene,TCAP gene,10,X,[gngm],[gngm],,
d736b1c1-34bb-40f7-86d4-2f4030a997c2,C0423866,C1825598,could could anticipated as ,Lanugo,IMPACT gene,7,X,[bpoc],[gngm],A17.360,
a7b59a17-aa59-4a43-b437-8900e7bf99ed,C0032285,C0206419,is in ,Pneumonia,Genus: Coronavirus,6,X,[dsyn],[virs],C08.381.677;C08.730.610,B04.820.504.540.150
0940b866-7627-49fb-80ab-1dcd7c8a6fc7,C0026766,C0206419,are spectrum of ,Multiple Organ Failure,Genus: Coronavirus,4,X,[patf],[virs],C23.550.835.525,B04.820.504.540.150
c44c5235-9e37-4f5b-9da9-d37723956a44,C0013227,C0032285,impairing exacerbation of ,Pharmaceutical Preparations,Pneumonia,3,X,[phsu],[dsyn],D26,C08.381.677;C08.730.610
e70476ac-948a-4a78-9297-c49c34d36b25,C0003374,C0021368,reducing ,Antimalarials,Inflammation,2,X,[phsu],[patf],D27.505.954.122.250.100.085,C23.550.470
838d9137-67f4-4bba-ab3a-038e5d3d157c,C0020336,C0021368,reducing ,Hydroxychloroquine,Inflammation,5,X,[orch/phsu],[patf],D03.633.100.810.050.180.350,C23.550.470
93c59cbc-6290-4e72-8fbf-c079f656f363,C0003374,C0009450,reducing Inflammation to,Antimalarials,Communicable Diseases,2,X,[phsu],[dsyn],D27.505.954.122.250.100.085,C01.539.221
1ddfdf6c-ad90-4b96-bef9-054bb5a73d4a,C0020336,C0009450,reducing Inflammation to,Hydroxychloroquine,Communicable Diseases,5,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.539.221
1ddfdf6c-ad90-4b96-bef9-054bb5a73d4a,C0020336,C0009450,was promoted in ,Hydroxychloroquine,Communicable Diseases,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.539.221
06e2b304-accb-416e-82a4-4ceed614991e,C0013227,C0003374,includes ,Pharmaceutical Preparations,Antimalarials,4,X,[phsu],[phsu],D26,D27.505.954.122.250.100.085
a0645eab-124c-4271-9a53-07e14fcb2335,C0013227,C0020336,includes antimalarial ,Pharmaceutical Preparations,Hydroxychloroquine,5,X,[phsu],[orch/phsu],D26,D03.633.100.810.050.180.350
a0645eab-124c-4271-9a53-07e14fcb2335,C0013227,C0020336,are are tried for treatment of ,Pharmaceutical Preparations,Hydroxychloroquine,1,X,[phsu],[orch/phsu],D26,D03.633.100.810.050.180.350
e67d236c-b945-47f5-ba3a-f46bc4a1c076,C0020336,C0206419,recently reported duration of ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
e67d236c-b945-47f5-ba3a-f46bc4a1c076,C0020336,C0206419,may occur in ,Hydroxychloroquine,Genus: Coronavirus,2,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
e67d236c-b945-47f5-ba3a-f46bc4a1c076,C0020336,C0206419,recently reported as possible therapy for ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
e67d236c-b945-47f5-ba3a-f46bc4a1c076,C0020336,C0206419,are are repurposed for treatment of ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
e67d236c-b945-47f5-ba3a-f46bc4a1c076,C0020336,C0206419,have shown in activity on ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
a2ebfab7-ac51-4bcb-9fb1-1dd31fcefbb7,C0020336,C0441636,recently reported duration as possible therapy for ,Hydroxychloroquine,Surgical shortening - action,5,X,[orch/phsu],[topp],D03.633.100.810.050.180.350,
657a06ab-a24e-4d65-b5c8-5d0556aeca93,C0850149,C0206419,had later ,Dry cough,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
31f91887-1139-4b7c-a9b3-55a882e3d90c,C0850149,2days,had later 2days,Dry cough,2days,5,X,[sosy],????,,????
c78ee2b3-5847-4f59-9f36-dbb9c686ec43,C0850149,C0033771,presented with ,Dry cough,Prurigo,10,X,[sosy],[dsyn],,C17.800.674
30526beb-215b-4685-b7ec-7feaeee614a2,C0000936,DRF,By damage is DRF ,Visual Accommodation,DRF,2,X,[ortf],????,G14.010,????
4867ba62-07d2-4498-8807-c60ccd2b0999,C0000936,C1999230,By damage is DRF ,Visual Accommodation,Providing (action),2,X,[ortf],[acty],G14.010,
3bf120db-59d8-4b48-b8fd-5817860e7376,COVID-19,C0012634,was declared on ,COVID-19,Disease,12,X,[virs],[dsyn],C000657245,C23.550.288
7c16844c-c70b-4302-b0f8-26aa4ed60606,COVID-19,C0042776,refers ,COVID-19,Virus,1,X,[virs],[virs],C000657245,B04
e86e0574-4d27-413f-8b79-3e5dc727fe56,C0184661,C0206074,based on PCR,Interventional procedure,Renal Replacement Therapy,1,X,[topp],[topp],,E02.870
d4911080-fb93-4924-ae1e-ab069d2aa061,C0184661,PCR,based on PCR,Interventional procedure,PCR,1,X,[topp],????,,????
f689f516-8b4c-4be0-8cfe-5da6321c1dc0,C0020538,COVID-19,also increased risk in ,Hypertensive disease,COVID-19,1,X,[dsyn],[virs],C14.907.489,C000657245
f81f03e9-ca03-487f-9e51-298f6e52c992,C0596448,COVID-19,increased mortality in ,dimer,COVID-19,1,X,[chvs],[virs],,C000657245
80cc5d0a-7933-4ca8-8df0-eda2d7aa04e6,C0028084,COVID-19,related to ,Nightmares,COVID-19,1,X,[sosy],[virs],F02.463.188.634.309;F02.830.855.268,C000657245
d350ed8b-95b3-4c9f-ac27-a7e3e63be87c,C0558066,COVID-19,related to ,Intrusive thoughts,COVID-19,1,X,[mobd],[virs],,C000657245
ba690333-6898-4de9-a0c3-5bda6bce10a0,C0521991,COVID-19,associated with ,Symptoms of stress,COVID-19,1,X,[sosy],[virs],,C000657245
f66cf35b-815d-4999-b8b5-f89a9b95ef3f,COVID-19,C1533724,includes fear coming into contact with ,COVID-19,Fomes,1,X,[virs],[fngs],C000657245,B01.300.179.120.174
8d509635-332b-4362-991c-d162b4c51a70,C0039082,COVID-19,was correlated with ,Syndrome,COVID-19,2,X,[dsyn],[virs],C23.550.288.500,C000657245
3788296b-d9bc-4635-8fe0-02612867fa8a,C0747919,C0206419,is with ,pregnancy related,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
71488405-b4e3-431a-b168-122466c20a42,C0151864,C0206419,is with ,Disorder of pregnancy,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
41be3618-b904-4398-b3f7-8dc185d53d42,COVID-19,C1514593,know little about broader ,COVID-19,Psychological Impact,1,X,[virs],[clna],C000657245,
90eb64e0-5f66-438c-9a3c-801a63aab05e,COVID-19,C0233514,develop general ,COVID-19,Abnormal behavior,1,X,[virs],[mobd],C000657245,F01.145.126.972;F01.145.179.750
6e44b128-6754-4d77-ba40-cc43ff3fdffd,C1457887,C0018681,included ,Symptoms,Headache,10,X,[sosy],[sosy],,C23.888.592.612.441
6e44b128-6754-4d77-ba40-cc43ff3fdffd,C1457887,C0018681,can can complicated with ,Symptoms,Headache,3,X,[sosy],[sosy],,C23.888.592.612.441
6e44b128-6754-4d77-ba40-cc43ff3fdffd,C1457887,C0018681,followed by ,Symptoms,Headache,1,X,[sosy],[sosy],,C23.888.592.612.441
a20b3654-6b6f-4c69-bea4-e6ddfda35fc7,C1457887,C0027497, includes ,Symptoms,Nausea,5,X,[sosy],[sosy],,C23.888.821.712
c901ff8c-e3bc-4417-8fee-820e1f092df9,C1457887,C0152027, includes ,Symptoms,Sensory Disorders,5,X,[sosy],[dsyn],,C10.597.751;C23.888.592.763
7e12cdec-8b64-4f0b-a078-a691c9408b8d,COVID,C1457887,may show ,COVID,Symptoms,5,X,????,[sosy],????,
5a60f9d9-892c-4a96-b6bb-db65bc1ef942,COVID,C0018681,may show ,COVID,Headache,5,X,????,[sosy],????,C23.888.592.612.441
b1f258ea-c52c-44cb-8b26-130bdb203ef9,COVID,C0027497,may show ,COVID,Nausea,5,X,????,[sosy],????,C23.888.821.712
8c979f30-7481-45db-b36a-d2afcea4aa64,COVID,C0152027,may show ,COVID,Sensory Disorders,5,X,????,[dsyn],????,C10.597.751;C23.888.592.763
44475756-7c1a-44b0-a8fc-59ab818a2534,C0206419,C3873497,is ,Genus: Coronavirus,Severe acute respiratory infection,1,X,[virs],[dsyn],B04.820.504.540.150,
b0f480b7-2daf-43ac-a1c8-009dd890963b,C0012634,C3873497,is ,Disease,Severe acute respiratory infection,1,X,[dsyn],[dsyn],C23.550.288,
cf34598d-b1e4-47b1-b2f7-c08ea159c417,C1947933,C0023186,include people with ,care activity,Learning Disorders,3,X,[acty],[mobd],,C10.597.606.150.550;C23.888.592.604.150.550;F03.625.562
3e0d0f6b-7671-4121-858d-c239839e6836,COVID-19,C1335737,Currently is affecting life-saving option for patients with ,COVID-19,Recurrent Hematologic Malignancy,2,X,[virs],[neop],C000657245,
a8d2a221-dacf-44ad-ad16-afd3215ade29,COVID-19,C1335724,Currently is affecting life-saving option for patients with ,COVID-19,Refractory Hematologic Malignancy,1,X,[virs],[neop],C000657245,
cb4469fb-8d30-411c-bbee-dab8a7da49c2,C0028756,C0206419,were predictors protective for mortality in hospitalized ,Obesity Morbid,Genus: Coronavirus,4,X,[dsyn],[virs],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,B04.820.504.540.150
cb4469fb-8d30-411c-bbee-dab8a7da49c2,C0028756,C0206419,are associated with greater risk for death with ,Obesity Morbid,Genus: Coronavirus,2,X,[dsyn],[virs],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,B04.820.504.540.150
b257303d-e728-4d9b-8369-d465f0f238ff,C0185003,C0242781,prevent significantly ,Reparative closure,disease transmission,4,X,[topp],[patf],,N06.850.310
f6b02480-eebe-4912-b4a5-37270f1a0da4,C2349975,C0034019,is in ,Enhance (action),public health medicine (field),4,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
f85e9ecb-0a8f-455c-b277-78235cd4bf6b,COVID-19,C0034019,is global ,COVID-19,public health medicine (field),4,X,[virs],[bmod],C000657245,H02.403.720;N01.400.550;N06.850
f85e9ecb-0a8f-455c-b277-78235cd4bf6b,COVID-19,C0034019,unique challenges for ,COVID-19,public health medicine (field),2,X,[virs],[bmod],C000657245,H02.403.720;N01.400.550;N06.850
f85e9ecb-0a8f-455c-b277-78235cd4bf6b,COVID-19,C0034019,admitted to Shanghai ,COVID-19,public health medicine (field),1,X,[virs],[bmod],C000657245,H02.403.720;N01.400.550;N06.850
8dd9ec7b-e360-4351-8667-06d421ce5353,C0012634,C0242781,introduce ,Disease,disease transmission,2,X,[dsyn],[patf],C23.550.288,N06.850.310
8dd9ec7b-e360-4351-8667-06d421ce5353,C0012634,C0242781,is mainly ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
8dd9ec7b-e360-4351-8667-06d421ce5353,C0012634,C0242781,has attracted attention due to its ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
8dd9ec7b-e360-4351-8667-06d421ce5353,C0012634,C0242781,importance of route of ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
8dd9ec7b-e360-4351-8667-06d421ce5353,C0012634,C0242781,understanding temporal course of ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
7204c8cb-366b-4dce-b71f-b849d6e59742,C0012634,COVID-19,was named ,Disease,COVID-19,11,X,[dsyn],[virs],C23.550.288,C000657245
630c18cf-9af5-4d4e-bf2f-924117e05288,R0,C0242781,is critically sensitive to intensity of ,R0,disease transmission,2,X,????,[patf],????,N06.850.310
ad3a86c8-d09f-4e7f-b33f-b6be2c40e39b,C0014544,C0003451,discuss ,Epilepsy,Antiviral Agents,1,X,[dsyn],[phsu],C10.228.140.490,D27.505.954.122.388
39e2ef24-7298-4534-8077-ac6f3dbee76b,C0014544,C1152412,discuss ,Epilepsy,RNA-directed RNA polymerase activity,1,X,[dsyn],[genf],C10.228.140.490,
c7b91ea5-bc8e-434a-a4c9-c0959f4c0239,C0014544,C0243077,discuss ,Epilepsy,inhibitors,1,X,[dsyn],[chvf],C10.228.140.490,
bd4410c7-0f4b-4d5e-931a-d5114228bb91,C0849867,C0036974,could could considered as major ,Widespread Disease,Shock,2,X,[dsyn],[patf],,C23.550.835
3b5f9103-f972-4739-9bf1-9884900a4788,C0003062,C0849867,are involved in ,Animals,Widespread Disease,2,X,[anim],[dsyn],B01.050,
e45b5611-7bc3-4a35-9a92-619483c6cd59,C1865266,C1457887,is common ,RNF217-AS1 gene,Symptoms,3,X,[gngm],[sosy],,
a3eb9e09-bc28-447b-b0a5-5e2bf191dd3b,C1865266,C0206419,is common Symptoms in,RNF217-AS1 gene,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
95a13f01-984f-4b15-92cc-bd2ea532339a,C1865266,C0012634,only Symptoms of,RNF217-AS1 gene,Disease,3,X,[gngm],[dsyn],,C23.550.288
9b1b3931-ae94-4940-aaa9-e7ace04239e2,C0206419,C0543829,is with definitive ,Genus: Coronavirus,pneumonia clinical,3,X,[virs],[dsyn],B04.820.504.540.150,
7fc0fd17-b059-4965-a415-cf3e88358e82,C0229671,C0206419,indicated poor outcome in patients with ,Serum,Genus: Coronavirus,2,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150
7fc0fd17-b059-4965-a415-cf3e88358e82,C0229671,C0206419,were associated with poor outcome in ,Serum,Genus: Coronavirus,2,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150
a581aeab-f749-4fc3-9d94-6d344dfb43a9,C0079189,C0206419,indicated poor outcome in patients with ,cytokine,Genus: Coronavirus,2,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150
a581aeab-f749-4fc3-9d94-6d344dfb43a9,C0079189,C0206419,patients with severe ,cytokine,Genus: Coronavirus,2,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150
a581aeab-f749-4fc3-9d94-6d344dfb43a9,C0079189,C0206419,is emerging as mechanism leading to ,cytokine,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150
31c9dab4-f98e-4261-947f-8b066ff7e630,C0023516,C0206419,predict clinical outcome of patients with ,Leukocytes,Genus: Coronavirus,3,X,[cell],[virs],A11.118.637;A15.145.229.637;A15.382.490,B04.820.504.540.150
e974dbdb-f4b5-4f4d-a667-9828fe9c426a,C0206419,C0037285,has associated ,Genus: Coronavirus,Skin Manifestations,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.885
1d92398d-1f21-4818-ba57-24061f30a5ff,C0206419,C3526598,pose urgent organizational tasks WHO ,Genus: Coronavirus,Psychiatric service,2,X,[virs],[topp],B04.820.504.540.150,
e233ba59-b859-444c-9626-ae6e42698c00,C0206419,C0349725,is in immediate post ,Genus: Coronavirus,Graft infection,1,X,[virs],[patf],B04.820.504.540.150,
90d4e16f-b73e-47f5-af1e-56c9e5398593,C0012634,C0034019,triggering harsh ,Disease,public health medicine (field),32,X,[dsyn],[bmod],C23.550.288,H02.403.720;N01.400.550;N06.850
2e97d303-7462-4c2d-ba4b-794d8f71d802,C0206419,C0221423,may cause serious ,Genus: Coronavirus,Illness (finding),23,X,[virs],[sosy],B04.820.504.540.150,
7f29e497-8ce5-421c-b122-216b55a38f36,C0206419,C0037090,main manifestations of are ,Genus: Coronavirus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
7f29e497-8ce5-421c-b122-216b55a38f36,C0206419,C0037090,present with ,Genus: Coronavirus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
7f29e497-8ce5-421c-b122-216b55a38f36,C0206419,C0037090,causes Signs and Symptoms Respiratory Illness (finding) with,Genus: Coronavirus,Signs and Symptoms Respiratory,4,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
7f29e497-8ce5-421c-b122-216b55a38f36,C0206419,C0037090,clinical manifestations of are ,Genus: Coronavirus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
262688dd-068a-4bc2-b348-4f704ebc9581,C0035222,C1861172,occurred in acute injury in ,Respiratory Distress Syndrome Adult,Venous Thromboembolism,5,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C14.907.355.590.700
d4eacd05-5710-4aa5-bd20-b4217149c76f,C0035222,C0005779,occurred in acute injury in ,Respiratory Distress Syndrome Adult,Blood Coagulation Disorders,5,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C15.378.100
07daba03-057d-489b-9fc6-eb1409fce550,C0003015,C0206419,is in patients with ,Angiotensin-Converting Enzyme Inhibitors,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.519.389.745.085,B04.820.504.540.150
07daba03-057d-489b-9fc6-eb1409fce550,C0003015,C0206419,was associated with higher ,Angiotensin-Converting Enzyme Inhibitors,Genus: Coronavirus,2,X,[phsu],[virs],D27.505.519.389.745.085,B04.820.504.540.150
0b0840a0-13cd-4fa2-ac2f-17a0fa418560,C0597357,C0206419,is in patients with ,receptor,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],,B04.820.504.540.150
0b0840a0-13cd-4fa2-ac2f-17a0fa418560,C0597357,C0206419,is with previous pandemic ,receptor,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],,B04.820.504.540.150
0b0840a0-13cd-4fa2-ac2f-17a0fa418560,C0597357,C0206419,target in ,receptor,Genus: Coronavirus,2,X,[aapp/rcpt],[virs],,B04.820.504.540.150
e9177d0c-002b-449b-852e-64206cb3d1da,C0242781,C0025011,were estimated for ,disease transmission,Measles virus,6,X,[patf],[virs],N06.850.310,B04.820.455.600.650.500.500
e9177d0c-002b-449b-852e-64206cb3d1da,C0242781,C0025011,was modeled for ,disease transmission,Measles virus,6,X,[patf],[virs],N06.850.310,B04.820.455.600.650.500.500
7aac17b7-a437-4790-8263-40cb76af140f,C0035203,C0242781,decrease probability of ,Respiration,disease transmission,4,X,[phsf],[patf],G09.772.705,N06.850.310
a06e3aef-9362-477d-b234-11b76e70f253,C0035203,C0007012,reduces ,Respiration,Carbon Dioxide,2,X,[phsf],[bacs/inch],G09.772.705,D01.200.200;D01.362.150;D01.650.550.200
06d94a1d-18f7-46f4-8462-5f948440a0c9,C0011849,C0206419,know about ,Diabetes Mellitus,Genus: Coronavirus,5,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
06d94a1d-18f7-46f4-8462-5f948440a0c9,C0011849,C0206419,is associated with increased ,Diabetes Mellitus,Genus: Coronavirus,1,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
06d94a1d-18f7-46f4-8462-5f948440a0c9,C0011849,C0206419,showed significant association with ,Diabetes Mellitus,Genus: Coronavirus,2,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
06d94a1d-18f7-46f4-8462-5f948440a0c9,C0011849,C0206419,of history is ,Diabetes Mellitus,Genus: Coronavirus,1,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
52af56bf-aae4-4376-84e5-29d6d7382282,C0948092,C0206419,is in patients with ,diabetes mellitus management,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
7e803abf-7e0c-4e53-a7b2-ece8fdfd20d7,C1706202,C0206419,yielded potential ,Search - action,Genus: Coronavirus,8,X,[acty],[virs],,B04.820.504.540.150
e7ecec5f-6549-4d53-8ac9-dbedcd4241e3,C0020538,C0011849,of Presence is ,Hypertensive disease,Diabetes Mellitus,1,X,[dsyn],[dsyn],C14.907.489,C18.452.394.750;C19.246
e7ecec5f-6549-4d53-8ac9-dbedcd4241e3,C0020538,C0011849,was followed by ,Hypertensive disease,Diabetes Mellitus,4,X,[dsyn],[dsyn],C14.907.489,C18.452.394.750;C19.246
3c1890db-7e21-4041-affc-7d6cfdbda73f,C0622037,C0024117,is with OR ,3'-O-methyl-nordihydroguaiaretic acid,Chronic Obstructive Airway Disease,1,X,[orch/phsu],[dsyn],,C08.381.495.389
845ed1d2-d706-45d0-b806-0054acc7bb95,COVID,p-value,is with p-value ,COVID,p-value,1,X,????,????,????,????
9523d364-15ef-4e9c-830c-69aeeeac8b9c,C0087111,C0206419,is with ,Therapeutic procedure,Genus: Coronavirus,7,X,[topp],[virs],E02,B04.820.504.540.150
cd353a64-ab12-47d3-9a0c-ebdc5f82e735,C0013362,C0206419,is among first cases of ,Dysarthria,Genus: Coronavirus,1,X,[mobd],[virs],C10.597.606.150.500.800.150.200;C23.888.592.604.150.500.800.150.200,B04.820.504.540.150
bba21f7a-b96d-404f-9a7e-d039e9865636,C0018991,C0206419,is among first cases of ,Hemiplegia,Genus: Coronavirus,1,X,[sosy],[virs],C10.597.622.295;C23.888.592.636.312,B04.820.504.540.150
733f06a9-7a50-4d62-9496-4484266ed818,C0394664,C0206419,may play role in patients in ,Acupuncture procedure,Genus: Coronavirus,1,X,[topp],[virs],E02.190.044,B04.820.504.540.150
99ccab05-5cb2-428f-b0d2-de1a3964f165,C0013404,C0206419,is in ,Dyspnea,Genus: Coronavirus,3,X,[sosy],[virs],C08.618.326;C23.888.852.371,B04.820.504.540.150
57b13a4b-94c3-4750-8417-6c2eab83156f,C0034019,C1999230,were ,public health medicine (field),Providing (action),2,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
b612f2b0-f3db-4466-8492-e62256aca049,C2745965,C1999230,is with view to ,Emergencies [Disease/Finding],Providing (action),1,X,[patf],[acty],C23.550.291.781;N06.230.100.083;N06.850.376,
3d3871da-26cf-4740-8051-4659e37a0373,C0034019,C0026636,is with view to ,public health medicine (field),Mouth Diseases,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C07.465
39e0de67-0422-4ecb-8109-cf4fbc25d786,C2745965,C0026636,is with view to ,Emergencies [Disease/Finding],Mouth Diseases,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C07.465
50ad8500-6b87-4e6a-9261-95e9a4b3b573,C2745965,C0034019,is with view to ,Emergencies [Disease/Finding],public health medicine (field),2,X,[patf],[bmod],C23.550.291.781;N06.230.100.083;N06.850.376,H02.403.720;N01.400.550;N06.850
314fdb81-675d-4954-be9c-e60d10011bd3,C0042776,C0242781,track ,Virus,disease transmission,20,X,[virs],[patf],B04,N06.850.310
faec30f6-7764-4d02-8a1f-ea0fc775b35c,C1167395,C0024109,is in ,Host (organism),Lung,1,X,[orgm],[bpoc],,A04.411
41a380b0-4db7-4fe2-b925-c168e8341cb8,C1175743,C0597357,utilize same ,SARS coronavirus,receptor,11,X,[virs],[aapp/rcpt],B04.820.504.540.150.113.937,
41a380b0-4db7-4fe2-b925-c168e8341cb8,C1175743,C0597357,attach to ,SARS coronavirus,receptor,1,X,[virs],[aapp/rcpt],B04.820.504.540.150.113.937,
c3ceaeb6-5bd1-4262-809a-7ccbe66e535c,C1175743,C1514535,uses S1,SARS coronavirus,Protein Binding Motif,2,X,[virs],[amas],B04.820.504.540.150.113.937,
37ea92eb-6b01-4f27-b23a-5dfae5282570,C1707455,C0206419,is with that of other previous ,Comparison,Genus: Coronavirus,4,X,[acty],[virs],,B04.820.504.540.150
11a6c5b5-77c7-4382-a53a-6642efa8b272,C0476236,C2607914,is in ,Developmental symptoms,Allergic rhinitis (disorder),2,X,[sosy],[dsyn],,C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443
564cf803-7f8b-42ea-a2eb-fa2f45029de3,C0476236,C0206419,serve as clues for new-onset ,Developmental symptoms,Genus: Coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150
39aecc93-99e8-4dbb-a75f-b53a21d19c44,C1550600,C0042776,inactivate ,Ingredient,Virus,2,X,[chvf],[virs],,B04
b8d52166-9618-49df-96a2-c27d96e7d1fd,C0006560,C0012634,were good predictors to ,C-reactive protein,Disease,1,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C23.550.288
b8d52166-9618-49df-96a2-c27d96e7d1fd,C0006560,C0012634,were predictors to critical ,C-reactive protein,Disease,1,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C23.550.288
77f438bb-11af-456b-9fb3-506dfd6e67b9,NLR,C0242656,were good predictors of ,NLR,Disease Progression,5,X,????,[patf],????,C23.550.291.656
502eb31c-1e82-4f37-a51f-2a3d5fb53973,NLR,C0012634,were good predictors of ,NLR,Disease,2,X,????,[dsyn],????,C23.550.288
502eb31c-1e82-4f37-a51f-2a3d5fb53973,NLR,C0012634,were predictors to critical ,NLR,Disease,2,X,????,[dsyn],????,C23.550.288
2eeff54f-169c-4656-988a-1b9f27e238dc,C0006560,C0242656,were good predictors of ,C-reactive protein,Disease Progression,1,X,[aapp/imft],[patf],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C23.550.291.656
7179e993-4b7e-4d67-8fd1-fec5e6c22311,C3694279,C0024109,are consequence of multiorgan dysregulation caused by ,Middle East Respiratory Syndrome,Lung,1,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
efd4d1ca-9965-4862-976d-f864510d38ef,C0221423,C1457887,is with ,Illness (finding),Symptoms,1,X,[sosy],[sosy],,
ea7df4e9-97fc-4129-8779-1df8d6cfeece,C0849867,C0042210,may drive interest in ,Widespread Disease,Vaccines,1,X,[dsyn],[aapp/imft/phsu],,D20.215.894
f9c54475-d58e-4aff-83b9-4ee04cfeebb9,C0231239,C0016452,major consequences on potential ,Fluctuation,Food,1,X,[sosy],[food],,G07.203.300;J02.500
88898174-20cf-4ea0-9869-1ea2b76af412,C0206419,C0016452,had on ,Genus: Coronavirus,Food,1,X,[virs],[food],B04.820.504.540.150,G07.203.300;J02.500
8553c30e-50aa-40c6-bb58-92ac533eae1b,GHG,C1825598,complete multivariable ,GHG,IMPACT gene,4,X,????,[gngm],????,
09d70b89-501a-40d4-9124-777b491b29cb,C0233929,C1825598,complete multivariable ,Emission - Male genitalia finding,IMPACT gene,4,X,[bdsu],[gngm],,
2c6b84a9-9472-4b87-82b1-f6dd8746f02d,C0037114,C0040300,applied as ,Silicones,Body tissue,2,X,[bodm/orch],[tisu],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,A10
c6fadea3-78a1-4005-9ae2-fbd8fb8e0d1a,C0278286,C1708715,relieved tissue exposures to ,Dressing of skin or wound,Loading Technique,2,X,[topp],[acty],,
cee930eb-6787-43d8-9f83-0465c986f692,C0718133,C0020517,has ,a & d,Hypersensitivity,2,X,[orch/phsu/vita],[patf],,C20.543
ef32f050-0c63-46e1-b067-4b8521cecced,C0596448,C0020517,has ,dimer,Hypersensitivity,2,X,[chvs],[patf],,C20.543
2be0c6df-33f9-497b-ad20-5454ea0a6df9,CRP,C0206419,were associated with poor outcome in ,CRP,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
c322234a-6863-4820-9602-46e830dc8ce4,C0072027,C0206419,were associated with poor outcome in ,procalcitonin,Genus: Coronavirus,2,X,[aapp/bacs],[virs],D06.472.699.666;D12.644.548.744;D12.776.811.555,B04.820.504.540.150
39bf3bf3-953d-4219-8230-4c9939f765f0,C0060323,C0206419,were related in ,Fibrin fragment D,Genus: Coronavirus,3,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
39bf3bf3-953d-4219-8230-4c9939f765f0,C0060323,C0206419,have have observed in patients with ,Fibrin fragment D,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
39bf3bf3-953d-4219-8230-4c9939f765f0,C0060323,C0206419,were increased in ,Fibrin fragment D,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
39bf3bf3-953d-4219-8230-4c9939f765f0,C0060323,C0206419,were on admission in ,Fibrin fragment D,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
39bf3bf3-953d-4219-8230-4c9939f765f0,C0060323,C0206419,were higher in ,Fibrin fragment D,Genus: Coronavirus,2,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
2578e1e5-6f1a-4889-b93b-772354c9e8f0,C0015879,C0206419,were associated with poor outcome in ,Ferritin,Genus: Coronavirus,2,X,[aapp/bacs/phsu],[virs],D12.776.157.427.249;D12.776.556.579.249;x.x.x.x,B04.820.504.540.150
645bceea-f6d0-41bc-97d8-17c37d2e4ff2,C0042776,C0012634,causes ,Virus,Disease,9,X,[virs],[dsyn],B04,C23.550.288
4d83cda0-8f25-4a35-9ac2-fdba9bd4af82,C3890179,C0007286,is in patients with ,Pulmonary Trunk,Carpal Tunnel Syndrome,3,X,[bpoc],[dsyn],,C10.668.829.500.500.200;C10.668.829.550.200;C26.844.150.206
4d83cda0-8f25-4a35-9ac2-fdba9bd4af82,C3890179,C0007286,was higher than cases with ,Pulmonary Trunk,Carpal Tunnel Syndrome,3,X,[bpoc],[dsyn],,C10.668.829.500.500.200;C10.668.829.550.200;C26.844.150.206
91f57bb5-93ab-496a-929f-a9022f1101ec,C0003062,C0206750,are involved in current ,Animals,Coronavirus Infections,1,X,[anim],[dsyn],B01.050,C02.782.600.550.200
9ff64cbc-f8f3-4b66-940c-2c277176130e,C0243077,C0960880,may increase expression of ,inhibitors,angiotensin converting enzyme 2,3,X,[chvf],[aapp/enzy],,x.x.x.x
bd54aeca-ab07-4e42-a741-aed3bfac0a91,C0960880,C0597357,is receptor for SARSCoV-2 Spike,angiotensin converting enzyme 2,receptor,7,X,[aapp/enzy],[aapp/rcpt],x.x.x.x,
f8a74cb2-b3f1-421d-ad0e-4e421a87f555,C0815017,C0020538,was compatible Among those with ,Angiotensin Receptor Antagonists,Hypertensive disease,3,X,[phsu],[dsyn],D27.505.519.162,C14.907.489
1497f85e-0977-44df-9b26-587525846b22,C0702249,C0087111,C-reactive protein for specific empirical,Infiltration (procedure),Therapeutic procedure,2,X,[topp],[topp],,E02
52797b19-acc3-4245-ba9a-cf2ff1bbe392,C2754943,C0206750,reaches levels after 4weeks ,IgG antibody,Coronavirus Infections,3,X,[celc],[dsyn],,C02.782.600.550.200
9ff84a7e-838e-42d2-9fa3-b94b9b0b3209,C0206750,C0009450,utilizes Angiotensin-converting Enzyme 2 Pathway Angiotensin-converting Enzyme 2 Pathway as means of,Coronavirus Infections,Communicable Diseases,89,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.221
0afe5992-94e9-4323-8df7-b6286de2d663,C1602245,C0009450,lower intra-hospital spread of ,Prompt,Communicable Diseases,2,X,[phsu],[dsyn],,C01.539.221
fd0d20d5-c229-408b-aa2a-5c127251f4fe,C1511790,C0009450,lower intra-hospital spread of ,Detection,Communicable Diseases,2,X,[topp],[dsyn],,C01.539.221
c15ce60c-fae8-42a4-bac8-3edde759c807,C4050231,C4048285,was significantly correlated with ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,C-Reactive Protein human,3,X,[clna],[aapp/imft],,
636e931e-0cc1-4619-a1d2-0c020eabeefc,C1999230,C0005516,visualization compared with non-specific inflammatory ,Providing (action),Biological Markers,7,X,[acty],[clna],,D23.101
449f2e4e-2452-44f6-a4d9-c55f1b21380e,C0085584,C0206750,has has reported for patients including of patients with ,Encephalopathies,Coronavirus Infections,3,X,[dsyn],[dsyn],C10.228.140,C02.782.600.550.200
449f2e4e-2452-44f6-a4d9-c55f1b21380e,C0085584,C0206750,be initial Disease Presentation of,Encephalopathies,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.228.140,C02.782.600.550.200
e20ae8c6-8c2c-42ec-979f-025c50d44192,C0014038,C2348077,has has described in eight patients to ,Encephalitis,Date Fruit,4,X,[dsyn],[food],C10.228.140.430,B01.650.940.800.575.912.250.093.615
818851ca-73ff-4e15-91fb-a083c6edea3d,C1175743,C3540512,has in has ,SARS coronavirus,Circumferential Supracrestal Fiberotomy,4,X,[virs],[topp],B04.820.504.540.150.113.937,
6a71f989-52ed-4050-82b9-0e4ae30026f3,C0810006,C0206750,is emerging of patients hospitalised with ,Acute cerebrovascular disease,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
6a71f989-52ed-4050-82b9-0e4ae30026f3,C0810006,C0206750,has has observed in patients with ,Acute cerebrovascular disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
8420d1ff-a3ac-47ad-a569-fa27e5302b54,C0810006,C0009566,is emerging as important ,Acute cerebrovascular disease,Complication,4,X,[dsyn],[patf],,
afb2873d-a0fc-4189-9f87-52d1821e5aa5,C0398623,C0060323,is with elevated C-reactive protein ,Thrombophilia,Fibrin fragment D,4,X,[dsyn],[aapp/bacs],C15.378.925,x.x.x.x
056191c9-8420-456e-8088-99c46af8c789,C0398623,C0015879,is with elevated C-reactive protein ,Thrombophilia,Ferritin,4,X,[dsyn],[aapp/bacs/phsu],C15.378.925,D12.776.157.427.249;D12.776.556.579.249;x.x.x.x
ac3a9203-3a99-4294-8aa6-3c52cdfdd56d,C0042776,C0009450, includes ,Virus,Communicable Diseases,1,X,[virs],[dsyn],B04,C01.539.221
ac3a9203-3a99-4294-8aa6-3c52cdfdd56d,C0042776,C0009450,is highly ,Virus,Communicable Diseases,2,X,[virs],[dsyn],B04,C01.539.221
ac3a9203-3a99-4294-8aa6-3c52cdfdd56d,C0042776,C0009450,encounter Host (organism) compartment in critical step of,Virus,Communicable Diseases,1,X,[virs],[dsyn],B04,C01.539.221
8370676b-7468-4719-9654-60323ca22d08,C0398623,C0038454,leading to ,Thrombophilia,Cerebrovascular accident,4,X,[dsyn],[dsyn],C15.378.925,C10.228.140.300.775;C14.907.253.855
9af91178-fa6b-457a-b5b6-c198481ea568,C1511790,C0206750,is in current pandemic of ,Detection,Coronavirus Infections,3,X,[topp],[dsyn],,C02.782.600.550.200
9af91178-fa6b-457a-b5b6-c198481ea568,C1511790,C0206750,may play role in development of approaches for ,Detection,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
9af91178-fa6b-457a-b5b6-c198481ea568,C1511790,C0206750,is required for diagnosis of ,Detection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
9af91178-fa6b-457a-b5b6-c198481ea568,C1511790,C0206750,low rates of are indicative ,Detection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
9af91178-fa6b-457a-b5b6-c198481ea568,C1511790,C0206750,understanding overall prevalence of ,Detection,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
1309bed7-6e25-4057-8fc5-5bac3994efaa,C1511790,C0012634,is in current pandemic of ,Detection,Disease,3,X,[topp],[dsyn],,C23.550.288
1309bed7-6e25-4057-8fc5-5bac3994efaa,C1511790,C0012634,is required for diagnosis of ,Detection,Disease,3,X,[topp],[dsyn],,C23.550.288
a94029c2-85dc-46ed-8bec-d37027d475c3,C0370003,C1175743,were tested for ,Specimen,SARS coronavirus,4,X,[sbst],[virs],,B04.820.504.540.150.113.937
a94029c2-85dc-46ed-8bec-d37027d475c3,C0370003,C1175743,remained positive for ,Specimen,SARS coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150.113.937
a94029c2-85dc-46ed-8bec-d37027d475c3,C0370003,C1175743,spiking urine and nasopharyngeal swabs with portion of,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
a94029c2-85dc-46ed-8bec-d37027d475c3,C0370003,C1175743,spiking urine and nasopharyngeal swabs with portion of,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
a94029c2-85dc-46ed-8bec-d37027d475c3,C0370003,C1175743,spiking urine and nasopharyngeal swabs with portion of,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
a94029c2-85dc-46ed-8bec-d37027d475c3,C0370003,C1175743,were analysed for ,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
7fd04cef-ff21-4a8c-8cf3-5dba1e99b066,C1511790,C0036087,was equivalent in ,Detection,saliva,4,X,[topp],[bdsu],,A12.200.666
87964667-80b9-4730-8ac0-69b178ed9627,C3873497,C1175743,caused by ,Severe acute respiratory infection,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
6d14a01b-9332-4c3d-b635-86b9dd6cd805,C0206750,C0349725,is in immediate post ,Coronavirus Infections,Graft infection,1,X,[dsyn],[patf],C02.782.600.550.200,
c2219658-285a-4b49-b6b8-bcf41fa120ab,C0231239,GHG,have GHG ,Fluctuation,GHG,1,X,[sosy],????,,????
7c7a9b42-8911-4f55-bdd3-4db5cd8065de,C0231239,C0233929,have GHG ,Fluctuation,Emission - Male genitalia finding,1,X,[sosy],[bdsu],,
25462380-2c68-4778-a1da-82d3aa40fa9c,C0206750,C0016452,had on ,Coronavirus Infections,Food,1,X,[dsyn],[food],C02.782.600.550.200,G07.203.300;J02.500
0030d749-15c5-4ba9-b64a-d2239798aa4c,C0206750,C0079189,is characterized by excessive proinflammatory ,Coronavirus Infections,cytokine,4,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
0030d749-15c5-4ba9-b64a-d2239798aa4c,C0206750,C0079189,leads to ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
0030d749-15c5-4ba9-b64a-d2239798aa4c,C0206750,C0079189,can manifest with ,Coronavirus Infections,cytokine,2,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
0030d749-15c5-4ba9-b64a-d2239798aa4c,C0206750,C0079189,experience high levels of ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
0030d749-15c5-4ba9-b64a-d2239798aa4c,C0206750,C0079189,may experience ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
0030d749-15c5-4ba9-b64a-d2239798aa4c,C0206750,C0079189,have higher ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
3894381c-62f9-4f05-aa9d-5058f1175f2e,C0206750,C0948245,is with ,Coronavirus Infections,Cytokine Release Syndrome,4,X,[dsyn],[dsyn],C02.782.600.550.200,
77de25b1-cc4f-4906-944c-9bf9b76a4dc4,C1167395,C0597357,maintained by immune systems ,Host (organism),receptor,2,X,[orgm],[aapp/rcpt],,
77de25b1-cc4f-4906-944c-9bf9b76a4dc4,C1167395,C0597357,activate ,Host (organism),receptor,2,X,[orgm],[aapp/rcpt],,
5b931ae1-8e65-4dd9-9d53-7aee7fa03809,C0010340,C0206750,is with ,Critical Illness,Coronavirus Infections,5,X,[dsyn],[dsyn],C23.550.291.625,C02.782.600.550.200
08cbf04e-c0eb-4f02-9c69-d4919c7cecdc,C0030858,C0162578,underwent ,Pentaerythritol Tetranitrate,Thrombectomy,2,X,[orch/phsu],[topp],D02.033.455.706.690,E04.100.814.842
dd0677e2-98d4-4296-b60f-8d5f197a16f9,C0030858,C1856053,underwent ,Pentaerythritol Tetranitrate,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[orch/phsu],[dsyn],D02.033.455.706.690,x.x.x.x
7933ff77-25a2-49c8-8f28-4e3013322ad7,NAAT,C0035736,compare diagnostic values of ,NAAT,RNA Viral,1,X,????,[nnon],????,D13.444.735.828
45cf516e-b0ee-47ba-bfb1-816ca1f3b213,C0036537,C1175743,yielded positive results for ,Bodily secretions,SARS coronavirus,7,X,[bdsu],[virs],A12.200,B04.820.504.540.150.113.937
0e2f571e-a853-43fe-a0f5-c536108aa15c,C0162524,C1175743,were positive for ,Chemiluminescence,SARS coronavirus,1,X,[npop],[virs],G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665,B04.820.504.540.150.113.937
000d7b0e-57fa-43f0-bbad-d66c06e9d8f7,C0162633,C0015733,is in ,Viral Shedding,Feces,8,X,[patf],[bdsu],G07.925,A12.459
fa3f18f8-2282-405c-b923-fdb57a1c4fa3,C0015733,C0242781,highlights potentially increased risk of faeco-oral ,Feces,disease transmission,7,X,[bdsu],[patf],A12.459,N06.850.310
ceeb5acd-ba63-48ad-b187-9f8479d3817b,C0042776,C3697872,belongs to ,Virus,Genus Betacoronavirus,4,X,[virs],[virs],B04,
b7fc7d0d-889f-4c58-b231-3e8b6a8bc525,C0221423,C0206750,with Disease is,Illness (finding),Coronavirus Infections,7,X,[sosy],[dsyn],,C02.782.600.550.200
eae3d6b7-4446-445e-8500-8f6de5b780bd,C0206750,C0221423,is with variable degree of ,Coronavirus Infections,Illness (finding),21,X,[dsyn],[sosy],C02.782.600.550.200,
455fdf05-b9dc-411e-851d-36008766de3f,C0012634,C0221423,is with mild-to-severe respiratory ,Disease,Illness (finding),15,X,[dsyn],[sosy],C23.550.288,
6d8a0404-6b5f-4850-bce1-87e9af4a7694,C0051979,C1550100,is in ,anti-IgG,Specimen Type - Serum,14,X,[aapp/imft],[bdsu],x.x.x.x,
e6fd967d-8191-47cc-ad85-6a90c39240e8,C0051979,C0086418,is in ,anti-IgG,Homo sapiens,4,X,[aapp/imft],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
f3451f11-365b-453c-b59b-762449adbfa0,C1513397,C1175743,is with ,Molecular Medicine,SARS coronavirus,1,X,[bmod],[virs],H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530,B04.820.504.540.150.113.937
fc717c80-8dbd-41f5-b276-c9bfa9f14d5a,C0597357,C1422064,as dipeptidyl peptidase II is,receptor,ACE2 gene,1,X,[aapp/rcpt],[gngm],,
d5a5ccc6-499f-47c3-aa68-8977241dfeb8,C1273412,C0025124,were retrieved from ,Chinese herbal medicine,Traditional Chinese Medicine,1,X,[topp],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
34999dd0-3c06-44a0-837a-5912f70b3602,C0596973,C0025124,were retrieved from ,monomer,Traditional Chinese Medicine,1,X,[chvs],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
ac3f5697-03b6-4973-8e61-95ce2b490396,C1328819,C0242210,have optimal ,Small Molecule,Binding Proteins,2,X,[orch],[aapp/bacs],,D12.776.157
c5708d98-fdbf-4aea-abf1-9917e186b4d2,C0024115,C1704259,is in ,Lung diseases,Biochemical Pathway,1,X,[dsyn],[moft],C08.381,
ae19f2d2-73d2-4e5b-93ce-35a6dcbe9467,C0206750,C1704259,is in ,Coronavirus Infections,Biochemical Pathway,1,X,[dsyn],[moft],C02.782.600.550.200,
ae19f2d2-73d2-4e5b-93ce-35a6dcbe9467,C0206750,C1704259,leads with increasing evidence for ,Coronavirus Infections,Biochemical Pathway,1,X,[dsyn],[moft],C02.782.600.550.200,
ae19f2d2-73d2-4e5b-93ce-35a6dcbe9467,C0206750,C1704259,caused with increasing evidence inflammatory ,Coronavirus Infections,Biochemical Pathway,1,X,[dsyn],[moft],C02.782.600.550.200,
e3d3d66f-d5ae-473a-aa12-2cb3aac8f0a7,C0206750,C0008679,is associated with much ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
e3d3d66f-d5ae-473a-aa12-2cb3aac8f0a7,C0206750,C0008679,had more WBC CRP ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
e3d3d66f-d5ae-473a-aa12-2cb3aac8f0a7,C0206750,C0008679,has caused disruption to patients with ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
e3d3d66f-d5ae-473a-aa12-2cb3aac8f0a7,C0206750,C0008679,persons with ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
1348ab1a-8b87-47dd-b8bf-7e399703b575,C0206750,C0011849,takes course in individuals with ,Coronavirus Infections,Diabetes Mellitus,16,X,[dsyn],[dsyn],C02.782.600.550.200,C18.452.394.750;C19.246
b1368dec-9031-4fdd-9de0-6cfd7d518a9e,C1706202,C1706374,was from establishment of database to ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
b1368dec-9031-4fdd-9de0-6cfd7d518a9e,C1706202,C1706374,identify documents published till ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
b1368dec-9031-4fdd-9de0-6cfd7d518a9e,C1706202,C1706374,were performed until ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,10,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
b1368dec-9031-4fdd-9de0-6cfd7d518a9e,C1706202,C1706374,focused on 10 ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
b1368dec-9031-4fdd-9de0-6cfd7d518a9e,C1706202,C1706374,using terms in first week ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
b1368dec-9031-4fdd-9de0-6cfd7d518a9e,C1706202,C1706374,were conducted in PubMed 4th,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
680e05b3-271c-4e66-a2f7-1110885c9b7d,C0206750,C1511790,was first ,Coronavirus Infections,Detection,8,X,[dsyn],[topp],C02.782.600.550.200,
15475cc4-fb65-4b1e-9c09-fe700705e167,C1516635,C0206750,win battle against ,Clinical Treatment,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
45c4e31e-ff25-44eb-8b0c-1689e0bf225e,C0814435,C0206750,mitigating spread of ,early identification,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
2cf4d3aa-f44c-4f36-ad81-358c60cacc97,C0028756,C0206750,are associated with greater risk for death with ,Obesity Morbid,Coronavirus Infections,6,X,[dsyn],[dsyn],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,C02.782.600.550.200
2cf4d3aa-f44c-4f36-ad81-358c60cacc97,C0028756,C0206750,were predictors protective for mortality in ,Obesity Morbid,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,C02.782.600.550.200
f44b2801-ca91-4e53-ac5a-e64d41a6ff1a,C0028756,C0012634,are associated with greater risk for death with ,Obesity Morbid,Disease,8,X,[dsyn],[dsyn],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,C23.550.288
f64f18fd-0399-4c47-b721-fb03622cf07c,C1167622,C0034800,is with ,Binding (Molecular Function),Receptors Cell Surface,4,X,[moft],[aapp/rcpt],,D12.776.543.750
f391974f-7cc5-4c3a-96c1-380a8db1ee70,C1175743,C1167622,penetrates cells through direct ,SARS coronavirus,Binding (Molecular Function),4,X,[virs],[moft],B04.820.504.540.150.113.937,
f391974f-7cc5-4c3a-96c1-380a8db1ee70,C1175743,C1167622,uses membrane ,SARS coronavirus,Binding (Molecular Function),1,X,[virs],[moft],B04.820.504.540.150.113.937,
f391974f-7cc5-4c3a-96c1-380a8db1ee70,C1175743,C1167622,enters Host Cell by,SARS coronavirus,Binding (Molecular Function),2,X,[virs],[moft],B04.820.504.540.150.113.937,
f391974f-7cc5-4c3a-96c1-380a8db1ee70,C1175743,C1167622,occurs through ,SARS coronavirus,Binding (Molecular Function),1,X,[virs],[moft],B04.820.504.540.150.113.937,
f391974f-7cc5-4c3a-96c1-380a8db1ee70,C1175743,C1167622,enters Cells by,SARS coronavirus,Binding (Molecular Function),2,X,[virs],[moft],B04.820.504.540.150.113.937,
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,penetrates cells through direct ,SARS coronavirus,Peptidyl-Dipeptidase A,4,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,attach to ,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,mediates Cells Virus Internalization through,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,uses membrane-bound form of ,SARS coronavirus,Peptidyl-Dipeptidase A,19,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,capacity through ,SARS coronavirus,Peptidyl-Dipeptidase A,8,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,being internalized with ,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,cause Disease through,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,occurs to ,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,enters Cells by,SARS coronavirus,Peptidyl-Dipeptidase A,2,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
35611592-7e22-4502-9971-2970b4ad043b,C1175743,C0022709,enters Lung through,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
28f0a109-ce53-4c78-92e1-60b13f8eb0a3,C1175743,C0034800,penetrates cells through direct ,SARS coronavirus,Receptors Cell Surface,8,X,[virs],[aapp/rcpt],B04.820.504.540.150.113.937,D12.776.543.750
d2e773fe-8cb7-403c-8733-45f54cf38c53,C0022709,C0001527,is in ,Peptidyl-Dipeptidase A,Adipose tissue,4,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,A10.165.114
5f2d1eaf-eeae-4ffa-9512-9325b4e1f3d1,C0022709,C0819757,was found In ,Peptidyl-Dipeptidase A,Structure of parenchyma of lung,6,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,
91d44138-4c4f-4ba9-b7eb-bbd5cdd02170,C0001527,C0012655,be ,Adipose tissue,Disease susceptibility,4,X,[tisu],[clna],A10.165.114,C23.550.291.687;G07.100.250
89147aea-668c-43f3-8558-491be1f9862f,C0001527,C0206750,be ,Adipose tissue,Coronavirus Infections,3,X,[tisu],[dsyn],A10.165.114,C02.782.600.550.200
bcdafd9a-9a28-4182-aff3-c5cc314ae08a,C0001527,C0009450,be ,Adipose tissue,Communicable Diseases,4,X,[tisu],[dsyn],A10.165.114,C01.539.221
840b660b-4ebf-4632-8e1a-2ad2aa811467,C0009450,C1145670, includes ,Communicable Diseases,Respiratory Failure,8,X,[dsyn],[dsyn],C01.539.221,C08.618.846
c68c7362-6171-41c6-8aeb-0abd01c59ab4,C0028754,C0206750,also have worse outcomes with ,Obesity,Coronavirus Infections,6,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
c68c7362-6171-41c6-8aeb-0abd01c59ab4,C0028754,C0206750,is risk factor for severe ,Obesity,Coronavirus Infections,4,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
c68c7362-6171-41c6-8aeb-0abd01c59ab4,C0028754,C0206750,BACKGROUND/During 2019 ,Obesity,Coronavirus Infections,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
c68c7362-6171-41c6-8aeb-0abd01c59ab4,C0028754,C0206750,develop ,Obesity,Coronavirus Infections,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
c68c7362-6171-41c6-8aeb-0abd01c59ab4,C0028754,C0206750,highlighting role of nutrition in prognosis of ,Obesity,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
c68c7362-6171-41c6-8aeb-0abd01c59ab4,C0028754,C0206750,represents higher risk of ,Obesity,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
c68c7362-6171-41c6-8aeb-0abd01c59ab4,C0028754,C0206750,had increased odds progressing to ,Obesity,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
4bc8e8a0-b299-4ac8-96d9-9d3aade5e12b,C0028754,C0009450,represents higher risk of ,Obesity,Communicable Diseases,7,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C01.539.221
3c8b518b-9053-4393-ae5b-00a72f45060a,C0028754,C1145670,also have worse outcomes with ,Obesity,Respiratory Failure,4,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C08.618.846
1fbc0b1d-0aa5-480e-9dfd-9e72bade1498,C0028754,C0199470,need for ,Obesity,Mechanical ventilation,4,X,[dsyn],[topp],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
2b568159-4779-4102-bb44-b08ba6fae98e,C0567416,C0014964,starting to pharmacophoric features of theoretical compound nCorv ,Molecule,Ethambutol,2,X,[sbst],[orch/phsu],,D02.092.782.258.368.265
7c132d26-965a-46c1-98ab-2051aea08f6c,C0014964,C0206750,can can qualified as 6LU7 ,Ethambutol,Coronavirus Infections,4,X,[orch/phsu],[dsyn],D02.092.782.258.368.265,C02.782.600.550.200
5b86f69f-465e-4574-b1ae-b84dc4597e74,6LU7,C0206750,is in ,6LU7,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
e8104e51-de99-46c6-897a-73dca4449e7f,C1947904,C0206750,Binding (Molecular Function) of,Attachment (action),Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
ecb8e9aa-f454-488d-a468-bc6d32552a87,C0007203,C2926735,limit ,Cardiopulmonary Resuscitation,Duration,2,X,[topp],[orch/phsu],E02.365.647.110,
5b95c493-8633-4033-bd2f-d46b4a1ddb81,C0206750,C1335737,is affecting life-saving option for patients with ,Coronavirus Infections,Recurrent Hematologic Malignancy,2,X,[dsyn],[neop],C02.782.600.550.200,
f25c1dc1-864f-4818-8c7b-b32775def732,C0206750,C1335724,is affecting life-saving option for patients with ,Coronavirus Infections,Refractory Hematologic Malignancy,1,X,[dsyn],[neop],C02.782.600.550.200,
3250b12e-f49d-41d8-b49c-7a78a5f11e50,C4039583,C0206750,has become during current ,Chimeric antigen receptor,Coronavirus Infections,1,X,[aapp/imft/rcpt],[dsyn],D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500,C02.782.600.550.200
36829439-3697-4642-9099-fcff21a437db,C0206750,C0007820,is with new onset of ,Coronavirus Infections,Cerebrovascular Disorders,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300;C14.907.253
2cc8b956-d8cf-4c6e-83c8-e595dca6d178,C0850624,C0020538, includes ,cardiovascular risk factor,Hypertensive disease,4,X,[dsyn],[dsyn],,C14.907.489
01528294-be1b-42e6-929e-2aa3472bbe3e,C0206750,C0850624,have CVD,Coronavirus Infections,cardiovascular risk factor,1,X,[dsyn],[dsyn],C02.782.600.550.200,
01528294-be1b-42e6-929e-2aa3472bbe3e,C0206750,C0850624,is in patients with ,Coronavirus Infections,cardiovascular risk factor,1,X,[dsyn],[dsyn],C02.782.600.550.200,
01528294-be1b-42e6-929e-2aa3472bbe3e,C0206750,C0850624,is emergent ,Coronavirus Infections,cardiovascular risk factor,3,X,[dsyn],[dsyn],C02.782.600.550.200,
2e25b8b4-736d-4cd8-a509-708c504cbe50,C0206750,CVD,have CVD,Coronavirus Infections,CVD,2,X,[dsyn],????,C02.782.600.550.200,????
9f1008ac-5c63-4995-a12a-bcc1dad9578e,C0206750,C0020538,takes course in individuals with ,Coronavirus Infections,Hypertensive disease,3,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.489
00fa2f22-4138-42c6-a47d-1226cc4b705d,C0007820,C1514474,development of is important negative ,Cerebrovascular Disorders,Prognostic Factors,2,X,[dsyn],[clna],C10.228.140.300;C14.907.253,E01.789
33d45b6d-7a98-44d5-bf30-3de719727812,C1706202,MEDLINE,using MEDLINE,Search - action,MEDLINE,2,X,[acty],????,,????
33d45b6d-7a98-44d5-bf30-3de719727812,C1706202,MEDLINE,were performed in MEDLINE ,Search - action,MEDLINE,12,X,[acty],????,,????
1cd81593-079c-47cc-b6f4-61eac0a9c316,C0184661,C0206750,reduce mortality in severe ,Interventional procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
b13c149e-2da3-4007-a133-5632f00947bf,C0087111,C0206750,might higher might mandatory for subset of patients with ,Therapeutic procedure,Coronavirus Infections,9,X,[topp],[dsyn],E02,C02.782.600.550.200
b416264c-c782-4e3c-9bd5-d32952c6cec7,C0087111,C1457887,alleviate ,Therapeutic procedure,Symptoms,4,X,[topp],[sosy],E02,
b416264c-c782-4e3c-9bd5-d32952c6cec7,C0087111,C1457887,lessen ,Therapeutic procedure,Symptoms,2,X,[topp],[sosy],E02,
b14c4944-e6ea-43c7-827c-ccf9654e273b,C0087111,C0003451,were ,Therapeutic procedure,Antiviral Agents,12,X,[topp],[phsu],E02,D27.505.954.122.388
3506a20e-400d-4147-ba21-01f1b18a4cd6,C0596577,C0359916,have attracted attention as ,Flavonoids,Phenolic product,4,X,[orch],[orch/phsu],D03.383.663.283.266.450;D03.633.100.150.266.450,
398dba53-f0b3-4839-9b2e-d55bdef2c2b7,C0068450,C0206750,exert Therapeutic Effect through,naringenin,Coronavirus Infections,9,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
398dba53-f0b3-4839-9b2e-d55bdef2c2b7,C0068450,C0206750,might exert ,naringenin,Coronavirus Infections,3,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
7e45f634-f0fa-499c-ba59-af68613e4465,C0068450,C3463820,exert Therapeutic Effect through,naringenin,Inhibition,4,X,[orch/phsu],[acty],x.x.x.x,F01.145.544;F02.463.425.475;F02.739.794.405
5e796e56-c3e9-4c6a-9b4c-9c524c85c1a9,C0068450,C0030946,exert Therapeutic Effect through,naringenin,Endopeptidases,4,X,[orch/phsu],[aapp/enzy/phsu],x.x.x.x,D08.811.277.656.300
28f0058b-54e3-4be8-a58e-eff0a58785bc,C0068450,C1527144,might exert ,naringenin,Therapeutic Effect,8,X,[orch/phsu],[clna],x.x.x.x,
3b25a625-dcc1-41a3-8577-c356510d6835,C0040732,C0206750,is with ,Transplantation,Coronavirus Infections,9,X,[topp],[dsyn],E04.936,C02.782.600.550.200
7d900866-ae0c-4044-8374-429112bf7c5c,COVID-19,C1321919,is taking colossal ,COVID-19,TLR4 protein human,1,X,[virs],[aapp/rcpt],C000657245,x.x.x.x
ac0392a8-c42b-4918-8942-43be201c2cf3,COVID-19,C0086418,is taking colossal ,COVID-19,Homo sapiens,1,X,[virs],[humn],C000657245,B01.050.150.900.649.313.988.400.112.400.400
ac0392a8-c42b-4918-8942-43be201c2cf3,COVID-19,C0086418,further disease transmission of was,COVID-19,Homo sapiens,1,X,[virs],[humn],C000657245,B01.050.150.900.649.313.988.400.112.400.400
5758b899-8cb0-493f-aef1-037d6e021e7f,COVID-19,C0683278,is taking colossal ,COVID-19,Mental Suffering,1,X,[virs],[mobd],C000657245,F01.145.126.990;F02.830.900
bbee3752-279a-4720-b154-8f2091c5a6aa,C1865266,COVID-19,is common Symptoms in,RNF217-AS1 gene,COVID-19,2,X,[gngm],[virs],,C000657245
ced8e9e2-e12c-4171-8d61-06f011bd4432,C0815017,C0003015,was compatible ,Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,2,X,[phsu],[phsu],D27.505.519.162,D27.505.519.389.745.085
7e0723d2-8b62-486d-9091-d3616110954c,C0003015,C0006560,was associated with lower ,Angiotensin-Converting Enzyme Inhibitors,C-reactive protein,2,X,[phsu],[aapp/imft],D27.505.519.389.745.085,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
f4b65a66-d604-4c5f-8fac-593f39cbc66d,C0003015,C0087111,was associated with lower ,Angiotensin-Converting Enzyme Inhibitors,Therapeutic procedure,2,X,[phsu],[topp],D27.505.519.389.745.085,E02
710631a3-a122-4668-9032-151797f31162,C0003015,C0702249,was associated with milder ,Angiotensin-Converting Enzyme Inhibitors,Infiltration (procedure),1,X,[phsu],[topp],D27.505.519.389.745.085,
14db0cb3-6d8b-4ccd-a829-57362684fc04,C0007634,C1175743,is receptor of,Cells,SARS coronavirus,3,X,[cell],[virs],A11,B04.820.504.540.150.113.937
14db0cb3-6d8b-4ccd-a829-57362684fc04,C0007634,C1175743,infected with ,Cells,SARS coronavirus,2,X,[cell],[virs],A11,B04.820.504.540.150.113.937
2976b32f-b6c6-40f2-9a67-71a6c6c4eb6f,C0007634,C0597357,is ,Cells,receptor,3,X,[cell],[aapp/rcpt],A11,
fe1f426f-d9bc-41ac-9f75-a61b60915ca6,C0012984,C0015219,be Neoplasm Metastasis Host (organism) during,Canis familiaris,Biological Evolution,4,X,[mamm],[genf],B01.050.150.900.649.313.750.250.216.200,G05.045;G16.075
8ab1e621-4a8b-4c3e-8fa5-0061ab7b7599,C0012984,C1175743,be Neoplasm Metastasis Host (organism) during,Canis familiaris,SARS coronavirus,4,X,[mamm],[virs],B01.050.150.900.649.313.750.250.216.200,B04.820.504.540.150.113.937
c0b4c180-6307-4541-a2e5-63ecc9c21765,C0012984,C0027627,be ,Canis familiaris,Neoplasm Metastasis,4,X,[mamm],[neop],B01.050.150.900.649.313.750.250.216.200,C04.697.650;C23.550.727.650
94dd85d2-309d-4c29-bb66-753225a63f40,C0012984,C1167395,be ,Canis familiaris,Host (organism),4,X,[mamm],[orgm],B01.050.150.900.649.313.750.250.216.200,
3c28723d-b529-4d88-a30d-e98703732e7f,C0325089,C1175743,are highly susceptible to ,Family Felidae,SARS coronavirus,4,X,[mamm],[virs],B01.050.150.900.649.313.750.377.750,B04.820.504.540.150.113.937
b67ce32c-c03a-4c71-90eb-964d75251dad,C0015859,C1175743,are susceptible to ,Ferrets,SARS coronavirus,8,X,[mamm],[virs],B01.050.150.900.649.313.750.250.575.350,B04.820.504.540.150.113.937
096f0e07-1e83-45ac-8ac5-9b3683d4c1dc,C0319157,C1175743,are responsible for ,AS virus,SARS coronavirus,1,X,[virs],[virs],,B04.820.504.540.150.113.937
096f0e07-1e83-45ac-8ac5-9b3683d4c1dc,C0319157,C1175743,causes ,AS virus,SARS coronavirus,4,X,[virs],[virs],,B04.820.504.540.150.113.937
78c104fe-5309-4144-a347-d6d3559f9d9e,C0086418,C0275521,showing ,Homo sapiens,Clinical infection,8,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
7f3d8f71-45bc-455a-bed8-9e4ec2a686c9,C0086418,C0037090,showing ,Homo sapiens,Signs and Symptoms Respiratory,8,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.852
ee0c88fb-47a7-42c0-93aa-7e19491f852a,C1175743,C0003062,is in ,SARS coronavirus,Animals,8,X,[virs],[anim],B04.820.504.540.150.113.937,B01.050
5d6c7950-5bd0-4ed0-a1cf-7e80b54622da,C0206074,C0019004,included 30 821 ,Renal Replacement Therapy,Hemodialysis,2,X,[topp],[topp],E02.870,E02.870.300;E02.912.800
d7804f70-b2fd-4f6f-ad84-852405e96af8,C0033414,C0262762,is in ,Promotion (action),crisis management,3,X,[acty],[topp],,
c215f5b6-a3a5-4770-a228-d3f261216ff4,C4048329,C0206750,were predictors protective for mortality in ,Immunosuppression,Coronavirus Infections,1,X,[dsyn],[dsyn],E02.095.465.425.450;E05.478.610,C02.782.600.550.200
c215f5b6-a3a5-4770-a228-d3f261216ff4,C4048329,C0206750,worsen ,Immunosuppression,Coronavirus Infections,2,X,[dsyn],[dsyn],E02.095.465.425.450;E05.478.610,C02.782.600.550.200
581768df-b4e3-4d53-a7b9-c8c09cee2635,C0012634,C1521863,caused morbidity on unprecedented level in ,Disease,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C23.550.288,x.x.x.x
581768df-b4e3-4d53-a7b9-c8c09cee2635,C0012634,C1521863,caused mortality on unprecedented level in ,Disease,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C23.550.288,x.x.x.x
c2549adf-d34d-40c5-98e2-274046326e18,COVID-19,C0009450,is with ,COVID-19,Communicable Diseases,10,X,[virs],[dsyn],C000657245,C01.539.221
7be0d20b-3c3d-40e8-9f02-782c05bdc40e,C0810006,COVID-19,has ,Acute cerebrovascular disease,COVID-19,2,X,[dsyn],[virs],,C000657245
6e532cd0-5102-466d-b741-fb6149d13e5e,COVID-19,C0007820,is with new onset of ,COVID-19,Cerebrovascular Disorders,1,X,[virs],[dsyn],C000657245,C10.228.140.300;C14.907.253
64878ffe-8732-4db1-84ed-aa85ebffd834,COVID-19,C0850624,have CVD,COVID-19,cardiovascular risk factor,1,X,[virs],[dsyn],C000657245,
560ae6e1-ce63-4d03-afd5-906f5649f212,COVID-19,CVD,have CVD,COVID-19,CVD,2,X,[virs],????,C000657245,????
4a089c94-bfef-466c-b62e-4edf77d607f8,COVID-19,C0020538,have CVD,COVID-19,Hypertensive disease,1,X,[virs],[dsyn],C000657245,C14.907.489
274cb61d-3890-41ed-b2ca-cdba3d38f0bc,C0007806,C0151857,were notable for mononuclear ,Cerebrospinal Fluid,Pleocytosis,2,X,[bdsu],[dsyn],A12.207.270.210,C15.378.553.475;C23.550.526
0be85ff9-f210-4531-a4f2-ef2a91fe6be5,C0006104,C0848027,showed bilateral ,Brain,internal lesion,4,X,[bpoc],[dsyn],A08.186.211,
ec64f411-8967-45ce-b340-c7d901aceab4,C0006104,C0228427,showed bilateral ,Brain,Basis pontis,2,X,[bpoc],[bpoc],A08.186.211,
80d4aefc-24aa-4670-98e1-4e2985fd8782,C0013227,C1829939,deferring follow-ups in case of ,Pharmaceutical Preparations,{Non-patient},4,X,[phsu],[clna],D26,
22c9beb4-665e-45b9-8562-8e7039958192,C1947933,C1829939,deferring follow-ups in case of ,care activity,{Non-patient},6,X,[acty],[clna],,
b113af89-ad0e-44ac-997d-2cf6e98610dc,C0013227,COVID-19,is in ,Pharmaceutical Preparations,COVID-19,4,X,[phsu],[virs],D26,C000657245
edde2177-45f7-41ed-8a54-c58e8efafe30,C1947933,COVID-19,is in ,care activity,COVID-19,5,X,[acty],[virs],,C000657245
a6065612-1c22-4e5e-9eca-2dfcdcc28805,C0008679,C0029166,is with ,Chronic disease,Oral Manifestations,6,X,[dsyn],[sosy],C23.550.291.500,C07.465.634;C23.888.619
edf48185-3262-4573-8e57-2d144aa011e5,C0004364,C0029166,is with ,Autoimmune Diseases,Oral Manifestations,3,X,[dsyn],[sosy],C20.111,C07.465.634;C23.888.619
28dbad15-8763-4145-bfd6-9e74cc990a62,C0008679,C0029167,can can exacerbated as result of ,Chronic disease,Oral Medicine,6,X,[dsyn],[bmod],C23.550.291.500,E06.640;H02.163.670
231bc089-256b-4903-be48-418821312f9f,C0004364,C0029167,can can exacerbated as result of ,Autoimmune Diseases,Oral Medicine,3,X,[dsyn],[bmod],C20.111,E06.640;H02.163.670
4a682f88-e57f-4a54-be52-79d810701950,C0035525,C0232910,have ,Ribavirin,Teratogenesis,4,X,[nnon/phsu],[patf],D13.570.800.790,C23.550.863
9801b31f-12e3-4239-9dd3-dd1dd00bdad1,C1138226,C0232910,have ,favipiravir,Teratogenesis,4,X,[orch/phsu],[patf],x.x.x.x,C23.550.863
54a4c679-5839-493c-98e4-ac73397dd394,C1706202,C1856053,was conducted On ,Search - action,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[acty],[dsyn],,x.x.x.x
240b25e6-8e10-4883-bd02-1c6d138c50a0,C0030054,C1947933,individualized ,Oxygen,care activity,1,X,[bacs/elii/phsu],[acty],D01.268.185.550;D01.362.670;x.x.x.x,
c114ab44-29f4-4ee2-b9f8-681979bf81d4,C0599779,C1457887,can reflect clinical ,Animal Model,Symptoms,1,X,[anim],[sosy],E05.598,
5afd4a4f-7ade-4ee5-a559-c6441f907d1b,C0599779,COVID-19,underlying ,Animal Model,COVID-19,1,X,[anim],[virs],E05.598,C000657245
96f6ceb1-90eb-4b93-9501-ecf9b7be400e,C1999230,C0599779,paramount insight into available ,Providing (action),Animal Model,1,X,[acty],[anim],,E05.598
0501734e-86b9-40e3-b8e3-fb527f91fbdc,C1999230,C1175743,paramount insight into available ,Providing (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
0501734e-86b9-40e3-b8e3-fb527f91fbdc,C1999230,C1175743,is with guidance on entry of patients tested for ,Providing (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
0501734e-86b9-40e3-b8e3-fb527f91fbdc,C1999230,C1175743,example for control of CoV2,Providing (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
d5986a94-9517-40eb-abf9-e534438ba750,C3694279,C0206419,were In ,Middle East Respiratory Syndrome,Genus: Coronavirus,2,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150
53ba72a5-3f88-424e-af4b-48ed62a1bfd4,14-day,C0309872,be sufficient to ,14-day,PREVENT (product),1,X,????,[phsu],????,
4ca4e430-a56a-4e05-ab6a-3e041f2cd1c0,C0034386,C0309872,be sufficient to ,Quarantine,PREVENT (product),1,X,[topp],[phsu],N06.850.780.200.450.700,
da693d91-a951-4a0b-8e3f-a56ce788137d,C2728259,C0309872,be sufficient to ,Program,PREVENT (product),1,X,[orch/phsu],[phsu],V02.355.750,
92e91417-f8da-4f0f-a5a0-9d4804dc753e,14-day,C0206419,be sufficient to ,14-day,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
c7aec386-0742-4ee1-93d2-5f596db5905d,C0034386,C0206419,be sufficient to ,Quarantine,Genus: Coronavirus,1,X,[topp],[virs],N06.850.780.200.450.700,B04.820.504.540.150
767cb356-2e7b-43b1-a79b-6c0a2ca7171b,C2728259,C0206419,be sufficient to ,Program,Genus: Coronavirus,1,X,[orch/phsu],[virs],V02.355.750,B04.820.504.540.150
8cad538a-9c85-4209-99b2-b0dc4767494c,C0309872,C0009450,is in ,PREVENT (product),Communicable Diseases,1,X,[phsu],[dsyn],,C01.539.221
a8758620-250b-4a19-b6aa-d54d22c39b6c,C0309872,C0206419,is in ,PREVENT (product),Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
643ce541-171a-4200-b3dd-dcd03bfaff0e,C1334043,C1175743,is with ,Homologous Gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
32431440-95e1-4011-be50-e199dfe3485c,C0087111,COVID-19,might ,Therapeutic procedure,COVID-19,8,X,[topp],[virs],E02,C000657245
618dd31a-8ec8-4ad3-8720-892d01dc546c,C0087111,C1425076,might ,Therapeutic procedure,LIN7B gene,1,X,[topp],[gngm],E02,
680c9087-4267-4d22-a3ce-064c29fe3223,C0206419,C3698360,cause ,Genus: Coronavirus,Middle East Respiratory Syndrome Coronavirus,1,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540.150.113.750
ff4577b2-24e4-432b-b7a9-09bbbea91861,C0087111,C0309872,likely by ,Therapeutic procedure,PREVENT (product),1,X,[topp],[phsu],E02,
ff4577b2-24e4-432b-b7a9-09bbbea91861,C0087111,C0309872,are aimed at ,Therapeutic procedure,PREVENT (product),4,X,[topp],[phsu],E02,
476118ef-1c53-4141-9b22-d8c928af465a,C0087111,C1537068,likely by ,Therapeutic procedure,Virus Internalization,1,X,[topp],[biof],E02,G06.920.881
476118ef-1c53-4141-9b22-d8c928af465a,C0087111,C1537068,immune especially anti-influenza Drugs - dental services due to similarities between,Therapeutic procedure,Virus Internalization,1,X,[topp],[biof],E02,G06.920.881
e29c2e03-435f-4a52-be74-7c1af21b7183,C0087111,C0014597,likely by ,Therapeutic procedure,Epithelial Cells,1,X,[topp],[cell],E02,A11.436
4fec938b-627a-471b-a9c9-f4cf683d16a0,C0108225,C0087111,has shown ,camostate-mesilate,Therapeutic procedure,1,X,[orch/phsu],[topp],,E02
6868d1dc-841b-44b1-8449-ac2c578ec2ad,C0108225,C0309872,has shown ,camostate-mesilate,PREVENT (product),1,X,[orch/phsu],[phsu],,
5a80ac4f-697a-4b35-832d-8a1257c78682,C0108225,C1537068,has shown ,camostate-mesilate,Virus Internalization,1,X,[orch/phsu],[biof],,G06.920.881
72047f22-1e93-42ff-959b-ae2a3419eca3,C0108225,C0014597,has shown ,camostate-mesilate,Epithelial Cells,1,X,[orch/phsu],[cell],,A11.436
bab83e9a-1771-493a-840f-37f35a24bf12,C4044947,C0309872,improve mortality by ,baricitinib,PREVENT (product),1,X,[orch/phsu],[phsu],x.x.x.x,
9349b5da-b98e-4189-9249-62771cdea42f,C0206419,C0002808,has had on teaching of ,Genus: Coronavirus,Science of Anatomy,1,X,[virs],[bmod],B04.820.504.540.150,H01.158.100
6a83f586-d309-48d8-8627-6ba093468f74,C1175743,C0242821,is in ,SARS coronavirus,Human body,3,X,[virs],[humn],B04.820.504.540.150.113.937,I01.076.201.450.560;K01.093.378
fbaaa2be-9da8-478f-922e-740876c0647f,C0206419,C1422064,utilize ,Genus: Coronavirus,ACE2 gene,1,X,[virs],[gngm],B04.820.504.540.150,
f9445a45-0086-45da-bb85-dc03037f5ca1,C0022709,C0220781,helps in ,Peptidyl-Dipeptidase A,Anabolism,1,X,[aapp/enzy/imft],[biof],D08.811.277.656.350.350.687,G03
648894ef-ccc4-4895-95b8-23c1b97e29a4,C1422064,C0003009,counter pro-inflammatory effects mediated by ,ACE2 gene,angiotensin II,1,X,[gngm],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
28faf15e-f107-4690-baaf-a6b780d7a978,C1422064,C0042402,counter pro-inflammatory effects mediated by ,ACE2 gene,Vasodilator Agents,1,X,[gngm],[phsu],,D27.505.954.411.918
8d17beb7-9224-4b1d-b69a-117fc01628c8,C0232741,C0206419,been have reported in ,Liver function,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
66d24cd9-fbae-4746-b640-516e242200ea,C0232741,C0012634,have have reported in ,Liver function,Disease,2,X,[ortf],[dsyn],,C23.550.288
90ca038d-3dc3-427d-8c3a-442e9e230d4f,SMD,C1707455,is in severe as ,SMD,Comparison,1,X,????,[acty],????,
4349dba2-ed11-4c02-ad02-bb81f41875f6,C0239981,C0017040,followed by derangements ,Hypoalbuminemia,Gamma-glutamyl transferase,1,X,[dsyn],[aapp/enzy],C15.378.147.607.500,D08.811.913.050.200.500
772e4d17-22ec-4bbb-8382-e284c14fef68,C0206419,C0073187,are depicted in ,Genus: Coronavirus,Blood group antigen D,1,X,[virs],[aapp/imft],B04.820.504.540.150,x.x.x.x
2ea826d5-0cea-4a33-a380-f4d7bb5f96de,C0011849,C0005802,is in Brazil ,Diabetes Mellitus,Blood Glucose,1,X,[dsyn],[orch],C18.452.394.750;C19.246,D09.947.875.359.448.500
c8dbfce2-f4e5-4997-8419-c357a5e6ac74,C2936405,C0013227,can facilitate Drug Repositioning Discover process by,Drug Repositioning,Pharmaceutical Preparations,2,X,[topp],[phsu],E05.290.875,D26
c8dbfce2-f4e5-4997-8419-c357a5e6ac74,C2936405,C0013227,is widely used for rapid identification of potential ,Drug Repositioning,Pharmaceutical Preparations,3,X,[topp],[phsu],E05.290.875,D26
c8dbfce2-f4e5-4997-8419-c357a5e6ac74,C2936405,C0013227,is In scenario widely used for identification of potential ,Drug Repositioning,Pharmaceutical Preparations,2,X,[topp],[phsu],E05.290.875,D26
edf9b124-7944-4234-8f55-a66db1d8455b,C2936405,C0087111,can facilitate Drug Repositioning Discover process by,Drug Repositioning,Therapeutic procedure,2,X,[topp],[topp],E05.290.875,E02
edf9b124-7944-4234-8f55-a66db1d8455b,C2936405,C0087111,novel Agent as,Drug Repositioning,Therapeutic procedure,1,X,[topp],[topp],E05.290.875,E02
9338fe21-f2a6-42af-9005-b145773e8b47,C2936405,C0221423,can facilitate Drug Repositioning Discover process by,Drug Repositioning,Illness (finding),2,X,[topp],[sosy],E05.290.875,
ee057235-8e40-4890-aa4b-e2af0c3d8f83,C2936405,C1880355,may facilitate rapid drug ,Drug Repositioning,Discover,4,X,[topp],[acty],E05.290.875,
290ed57e-fbe1-402d-9adf-27bd871dfdc4,C0034019,C0024128,has drastically changed markedly so for ,public health medicine (field),Lung Transplantation,4,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,E04.928.600.495;E04.936.450.495
b736ac83-f4de-42a6-81a0-928a79817e94,C2745965,C0024128,has drastically changed markedly so for ,Emergencies [Disease/Finding],Lung Transplantation,4,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E04.928.600.495;E04.936.450.495
4b45b961-4625-4c0e-864b-6abac6e5d7f8,C0034019,C0029216,has drastically changed practices in solid ,public health medicine (field),Organ Transplantation,2,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,E04.936.450
4530971d-4940-4e13-9f1c-09ce8a0e033c,C2745965,C0029216,has drastically changed practices in solid ,Emergencies [Disease/Finding],Organ Transplantation,2,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E04.936.450
d80f5bba-0c1d-485a-b1eb-b3cfb7b45c3d,C0034019,C0040732,has drastically changed practices in solid ,public health medicine (field),Transplantation,2,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,E04.936
53bd290b-ac0a-431d-9328-242679cd24fd,C2745965,C0040732,has drastically changed practices in solid ,Emergencies [Disease/Finding],Transplantation,2,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E04.936
48f3210d-4fc5-47b0-b21f-d64175df17f2,C0034019,C0206419,caused by acute viral ,public health medicine (field),Genus: Coronavirus,2,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
48f3210d-4fc5-47b0-b21f-d64175df17f2,C0034019,C0206419,should report country-specific ,public health medicine (field),Genus: Coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
48f3210d-4fc5-47b0-b21f-d64175df17f2,C0034019,C0206419,curtail ,public health medicine (field),Genus: Coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
48f3210d-4fc5-47b0-b21f-d64175df17f2,C0034019,C0206419,would reduce risk of ,public health medicine (field),Genus: Coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
edd48703-d2b6-486b-b2d1-f59570f1c9b4,C0034019,C1443953,caused by acute viral ,public health medicine (field),Acute viral disease,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,
34bf9461-d2f4-4fc7-86bf-180012ef9a6c,C2745965,C1443953,caused by acute viral ,Emergencies [Disease/Finding],Acute viral disease,2,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,
55e0c8e6-5d23-43fe-862e-1e2a06afda6c,C0024128,C0319157,target of ,Lung Transplantation,AS virus,2,X,[topp],[virs],E04.928.600.495;E04.936.450.495,
59336d7a-0936-4c93-b49a-f2f6f35667cf,C1254351,C0206419,cause ,Pharmacologic Substance,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
cfc7f4ca-60f4-4a8f-9dda-2e7f9d3bc4ae,C1254351,C0012634,cause ,Pharmacologic Substance,Disease,2,X,[phsu],[dsyn],,C23.550.288
cfc7f4ca-60f4-4a8f-9dda-2e7f9d3bc4ae,C1254351,C0012634,may have role in treatment of ,Pharmacologic Substance,Disease,1,X,[phsu],[dsyn],,C23.550.288
c12f75a9-3756-499d-9393-2328c1d6f998,C1175743,C0087086,potentially increasing ,SARS coronavirus,Thrombus,1,X,[virs],[patf],B04.820.504.540.150.113.937,C14.907.355.830
843aa0a2-b4a9-4d7b-9c40-7cb832d410cc,C1175743,C0022646,can develop into severe condition with ,SARS coronavirus,Kidney,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,A05.810.453
dbe08868-8e36-46bc-b91c-b33bafa4e535,C1160716,C1280903,argue for more thorough ,viral transmission,Exploration procedure,1,X,[celf],[topp],,
9fea941e-f8ab-4218-ae10-a91d3deec09c,C1160716,C1825598,argue for more thorough ,viral transmission,IMPACT gene,1,X,[celf],[gngm],,
9703f6e6-fa98-42cb-b0fb-5c69c2ca2dcd,C1160716,C0185003,argue for more thorough ,viral transmission,Reparative closure,1,X,[celf],[topp],,
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,deferring follow-ups because of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,have Show promise for treatment of,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,are under currently investigation for treatment of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,have performed well in ,Pharmaceutical Preparations,Genus: Coronavirus,2,X,[phsu],[virs],D26,B04.820.504.540.150
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,has has experimentally used for ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,are are tried for treatment of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,be re-purposed for prevention of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
dd255983-fa81-476e-8164-3bc87072e53a,C0013227,C0206419,be Therefore may developed for future ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
848ea422-346a-4e9c-ba5d-d294bb92d4c8,C1947933,C0206419,deferring follow-ups because of ,care activity,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
848ea422-346a-4e9c-ba5d-d294bb92d4c8,C1947933,C0206419,were undertaken as result of ,care activity,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
a4703e3c-c5e0-4ac4-bdd6-b52646d9c6cc,C0206419,CBRN,can in respects can viewed as CBRN ,Genus: Coronavirus,CBRN,1,X,[virs],????,B04.820.504.540.150,????
64948f3c-921a-47bf-b4a2-3bc16840118a,C0010356,PPE,minimizing Demand (clinical) for PPE,Cross Infection,PPE,3,X,[patf],????,C01.539.248;C23.550.291.875.500,????
ab7609e0-30cc-4aa4-979e-c19b2909eb59,C0010356,C0441516,minimizing ,Cross Infection,Demand (clinical),3,X,[patf],[topp],C01.539.248;C23.550.291.875.500,
61ddc4cf-d275-4f39-976e-ff43a7cb26a9,C0010051,C0021308,is potential cause of ,Coronary Aneurysm,Infarction,2,X,[dsyn],[patf],C14.280.647.250.250;C14.907.055.395;C14.907.585.250.250,C23.550.513.355;C23.550.717.489
5c501693-48c2-439d-813c-4a800a5e783c,C0010051,C2745965,was visualized in ,Coronary Aneurysm,Emergencies [Disease/Finding],1,X,[dsyn],[patf],C14.280.647.250.250;C14.907.055.395;C14.907.585.250.250,C23.550.291.781;N06.230.100.083;N06.850.376
d8474d69-3ac9-4a00-9927-13b427b24174,C0010051,CAG,was visualized in CAG,Coronary Aneurysm,CAG,1,X,[dsyn],????,C14.280.647.250.250;C14.907.055.395;C14.907.585.250.250,????
2b7c20e8-dcce-4e35-8e47-98c6017fc765,C0009450,C0035554,of Institute is de ,Communicable Diseases,Ribostamycin,2,X,[dsyn],[antb/orch],C01.539.221,D09.408.051.623.800
2b7c20e8-dcce-4e35-8e47-98c6017fc765,C0009450,C0035554,reproducing data of confirmed cases in de ,Communicable Diseases,Ribostamycin,1,X,[dsyn],[antb/orch],C01.539.221,D09.408.051.623.800
17de5afa-d16e-4e16-8561-3c4062512c6a,C0697125,C0035554,of Institute is de ,Inonotus obliquus preparation,Ribostamycin,2,X,[phsu],[antb/orch],,D09.408.051.623.800
e181fbfd-14d0-4259-90e8-ff5e575fecc7,C0009450,de,of Institute is de ,Communicable Diseases,de,2,X,[dsyn],????,C01.539.221,????
e181fbfd-14d0-4259-90e8-ff5e575fecc7,C0009450,de,reproducing data of confirmed cases in de ,Communicable Diseases,de,1,X,[dsyn],????,C01.539.221,????
11cae0b2-0a0e-42c9-a1d0-bd08561149f0,C0697125,de,of Institute is de ,Inonotus obliquus preparation,de,2,X,[phsu],????,,????
6f612a8e-ed6c-42d7-b801-a83781ba8d16,C0034602,C0206419,is in ,Interventional radiology,Genus: Coronavirus,1,X,[bmod],[virs],H02.403.740.675,B04.820.504.540.150
b8addac4-dc56-48f4-929c-f21c7cd982f8,C0441655,C0206419,is in ,Activities,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
f07e842e-c83c-495c-bae1-fe336efc81fb,C0034602,C1521863,is in ,Interventional radiology,estrogen receptor alpha human,3,X,[bmod],[aapp/rcpt],H02.403.740.675,x.x.x.x
98b51c01-9747-4bda-8c2b-05de1e81463f,C0441655,C1521863,is in ,Activities,estrogen receptor alpha human,2,X,[acty],[aapp/rcpt],,x.x.x.x
5d43babc-f248-4a96-9bf8-0d90f9d9d3da,C0206419,C0034602,changed ,Genus: Coronavirus,Interventional radiology,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.740.675
5d43babc-f248-4a96-9bf8-0d90f9d9d3da,C0206419,C0034602,reduction of ,Genus: Coronavirus,Interventional radiology,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.740.675
71f03734-56cd-426f-87bf-a1d59e0162b2,C0012634,C0034602,reduction of ,Disease,Interventional radiology,3,X,[dsyn],[bmod],C23.550.288,H02.403.740.675
ff9a22b0-4803-4bc0-a35c-031c848012dd,C0034602,C0747973,were prioritized opposed to ,Interventional radiology,Elective procedure,6,X,[bmod],[topp],H02.403.740.675,
c31b367c-1736-4463-945b-ff9bcaa4c160,C0012634,C0032285,may progress to ,Disease,Pneumonia,2,X,[dsyn],[dsyn],C23.550.288,C08.381.677;C08.730.610
c31b367c-1736-4463-945b-ff9bcaa4c160,C0012634,C0032285,associated with severe ,Disease,Pneumonia,1,X,[dsyn],[dsyn],C23.550.288,C08.381.677;C08.730.610
c31b367c-1736-4463-945b-ff9bcaa4c160,C0012634,C0032285,can lead to serious problems like ,Disease,Pneumonia,1,X,[dsyn],[dsyn],C23.550.288,C08.381.677;C08.730.610
c5a71d91-e344-460b-a28c-0124673b4131,C1155099,C0960756,was suggested as ,cytokine biosynthesis,factor A,4,X,[moft],[orch],,x.x.x.x
d0b4bec4-ddc6-4687-86f9-6c5cdf340315,C1155099,C0024109,exacerbating ,cytokine biosynthesis,Lung,2,X,[moft],[bpoc],,A04.411
2ee41c1d-3812-4ea6-b247-7d5de6fde6ed,C1155099,C0206419,is in ,cytokine biosynthesis,Genus: Coronavirus,1,X,[moft],[virs],,B04.820.504.540.150
4e655d61-77bd-45c5-b596-3f4568e4e8c6,C1155099,C0012634,is in ,cytokine biosynthesis,Disease,2,X,[moft],[dsyn],,C23.550.288
859ff7d6-44d5-4314-b2b5-e4fb054229b0,C0678951,C0079189,is in ,gene polymorphism,cytokine,2,X,[genf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
c012fcca-15b7-4e2e-9f85-cb6c7869c027,C1522002,4weeks,reaches levels after 4weeks ,RNA Recognition Motif,4weeks,3,X,[aapp/bacs],????,G02.111.570.820.709.275.500.869.500,????
51563876-8806-4da5-a2af-42d7d4842740,C1522002,C0206750,reaches levels after 4weeks ,RNA Recognition Motif,Coronavirus Infections,2,X,[aapp/bacs],[dsyn],G02.111.570.820.709.275.500.869.500,C02.782.600.550.200
a73978f4-99f8-4c0e-a2f0-f4d7530081aa,C1522002,C1457887,reaches levels after 4weeks ,RNA Recognition Motif,Symptoms,3,X,[aapp/bacs],[sosy],G02.111.570.820.709.275.500.869.500,
e538b21c-94e6-4304-a4f3-855a4a5360ea,C0042776,C0086418,is supposed spread to ,Virus,Homo sapiens,16,X,[virs],[humn],B04,B01.050.150.900.649.313.988.400.112.400.400
e538b21c-94e6-4304-a4f3-855a4a5360ea,C0042776,C0086418,has appeared as new ,Virus,Homo sapiens,3,X,[virs],[humn],B04,B01.050.150.900.649.313.988.400.112.400.400
e538b21c-94e6-4304-a4f3-855a4a5360ea,C0042776,C0086418,Owing to high rate of ,Virus,Homo sapiens,2,X,[virs],[humn],B04,B01.050.150.900.649.313.988.400.112.400.400
9cdbcbb5-e2c0-4459-af26-50178145422e,C0015859,C0042776,can transmit or indirectly ,Ferrets,Virus,2,X,[mamm],[virs],B01.050.150.900.649.313.750.250.575.350,B04
7768c252-1dc1-49fe-b20f-a802c0f1503d,C1707455,C0206750,related to ,Comparison,Coronavirus Infections,13,X,[acty],[dsyn],,C02.782.600.550.200
ee79126d-9d40-482e-968a-236a6fbb694d,C1707455,C0009450,is with data from ,Comparison,Communicable Diseases,1,X,[acty],[dsyn],,C01.539.221
c275270f-2f40-415e-949f-47ad6869bf23,C1707455,C0027712,is with data from ,Comparison,Nephrology Speciality,1,X,[acty],[bmod],,H02.403.429.580
81a7c5e8-7a9e-41ab-a2fa-8761f54dee02,C0206750,C0019004,were less common in patients on ,Coronavirus Infections,Hemodialysis,9,X,[dsyn],[topp],C02.782.600.550.200,E02.870.300;E02.912.800
6b7a1262-2d4d-4dbf-82dd-4884db89e75c,C1707391,C0014964,generate shape-based ,Choose (action),Ethambutol,1,X,[acty],[orch/phsu],,D02.092.782.258.368.265
5721b353-c45d-4dfd-8664-3edac225fbac,C0032105,COVID-19,was applied to ,Plasma,COVID-19,5,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,C000657245
5721b353-c45d-4dfd-8664-3edac225fbac,C0032105,COVID-19,is explicit option for ,Plasma,COVID-19,1,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,C000657245
9b8bfc55-ac78-498f-b2fa-8bee8dba5aa9,C0032105,C1999230,has potential to ,Plasma,Providing (action),3,X,[bdsu],[acty],A12.207.152.693;A12.207.270.695;A15.145.693,
c4337800-e63c-49db-8f20-889ddae439ad,C1276305,COVID-19,is In ,Curative - procedure intent,COVID-19,4,X,[topp],[virs],,C000657245
c87bc5f5-da3f-4c5f-89ce-1c84349d73e2,C0032105,C1276305,may may ,Plasma,Curative - procedure intent,5,X,[bdsu],[topp],A12.207.152.693;A12.207.270.695;A15.145.693,
28773444-6d2d-4a60-b610-8e349dff7a18,remdesivir,C1175743,is broad spectrum antiviral with in ,remdesivir,SARS coronavirus,3,X,[clnd],[virs],,B04.820.504.540.150.113.937
28773444-6d2d-4a60-b610-8e349dff7a18,remdesivir,C1175743,potentially act as ,remdesivir,SARS coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150.113.937
28773444-6d2d-4a60-b610-8e349dff7a18,remdesivir,C1175743,exhibited anti ,remdesivir,SARS coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150.113.937
f1c65f44-065e-4ebe-81a0-ab29be5e3e7d,C0230425,C0032105,is in ,Structure of right thigh,Plasma,4,X,[bpoc],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
b2fb0159-c914-442c-88a0-7c43831a7775,C0444263,C1175743,were positive for ,Plasma specimen,SARS coronavirus,4,X,[bdsu],[virs],,B04.820.504.540.150.113.937
0a916034-a268-4422-be7c-dfe82822b594,remdesivir,C1266129,was interrupted for side effects among four patients including ,remdesivir,Atypical Lipoma,4,X,[clnd],[neop],,C04.557.450.550.400
ef8594ae-5fbb-45ff-9aec-6a2dd8aa8d23,C0036658,C0015385,is in distal ,Esthesia,Limb structure,4,X,[ortf],[bpoc],F02.830.816;G11.561.790,A01.378
75cca671-d9e4-4df1-9460-f06967011658,C0007806,C0086168,revealed albuminocytologic ,Cerebrospinal Fluid,Dissociation,4,X,[bdsu],[mobd],A12.207.270.210,F03.300
85660c3c-a136-4944-8458-0b0e163d9ea9,C0035078,C1302112,requiring ,Kidney Failure,Kidney replacement procedure,1,X,[dsyn],[topp],C12.777.419.780;C13.351.968.419.780,
2dca134f-bc7d-4b3c-a47b-8d0436edd2ef,C0235031,C0012634,were reported in early phase of 3days,Neurologic Symptoms,Disease,7,X,[sosy],[dsyn],C10.597;C23.888.592,C23.550.288
3927fe82-e54a-42d5-a162-6f3032ada42d,C0235031,3days,were reported in early phase of 3days,Neurologic Symptoms,3days,1,X,[sosy],????,C10.597;C23.888.592,????
3927fe82-e54a-42d5-a162-6f3032ada42d,C0235031,3days,were reported with median onset ranging from to 3days,Neurologic Symptoms,3days,1,X,[sosy],????,C10.597;C23.888.592,????
07492482-d6bd-45be-92cd-d7678e5b9c9c,C0018681,C0233494,showed ,Headache,Tension,1,X,[sosy],[mobd],C23.888.592.612.441,
ecfd202a-4c56-4f17-bb4f-741265c230e0,C0231528,C0003862,was more frequently associated with ,Myalgia,Arthralgia,1,X,[sosy],[sosy],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C05.550.091;C23.888.592.612.094;F02.830.816.444.350;G11.561.790.444.350
fc5489bf-05d2-471c-9b7c-3d266e33bb56,C0553757,C0206750,were early Symptoms of,Olfaction Disorders,Coronavirus Infections,5,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C02.782.600.550.200
6bc840d6-2d50-464c-b4c5-f8a505ea861b,C0553757,C1457887,were In cohort of ,Olfaction Disorders,Symptoms,1,X,[dsyn],[sosy],C10.597.751.600;C23.888.592.763.550,
aeaa963f-5c2a-4808-96f5-0428c7278537,C0553757,C0012634,were In cohort of ,Olfaction Disorders,Disease,1,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C23.550.288
aeaa963f-5c2a-4808-96f5-0428c7278537,C0553757,C0012634,more frequently reported by patients with milder forms of ,Olfaction Disorders,Disease,1,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C23.550.288
aaf885b7-0b52-4060-9f8d-fcd8e39f8814,C0018681,C1457887,reflect common ,Headache,Symptoms,1,X,[sosy],[sosy],C23.888.592.612.441,
aaf885b7-0b52-4060-9f8d-fcd8e39f8814,C0018681,C1457887,were most prevalent ,Headache,Symptoms,2,X,[sosy],[sosy],C23.888.592.612.441,
aaf885b7-0b52-4060-9f8d-fcd8e39f8814,C0018681,C1457887,are main ,Headache,Symptoms,1,X,[sosy],[sosy],C23.888.592.612.441,
aaf885b7-0b52-4060-9f8d-fcd8e39f8814,C0018681,C1457887,seems leader on ,Headache,Symptoms,2,X,[sosy],[sosy],C23.888.592.612.441,
cca51476-1466-4325-8d9d-776b11f73075,C0018681,C0039082,reflect common ,Headache,Syndrome,1,X,[sosy],[dsyn],C23.888.592.612.441,C23.550.288.500
0c4abe7d-4b8a-42ee-a563-5b118eb8f3cf,C0018681,C0003862,is in association with ,Headache,Arthralgia,1,X,[sosy],[sosy],C23.888.592.612.441,C05.550.091;C23.888.592.612.094;F02.830.816.444.350;G11.561.790.444.350
4bb3f967-d860-4248-ac8c-86b684d1af4a,C0017428,C0206750,was detected in South African patient with ,Genome,Coronavirus Infections,1,X,[gngm],[dsyn],G05.360.340,C02.782.600.550.200
4482b79b-738a-41a7-be74-b5979804f965,C0017428,C0012634,was detected in South African patient with ,Genome,Disease,1,X,[gngm],[dsyn],G05.360.340,C23.550.288
4482b79b-738a-41a7-be74-b5979804f965,C0017428,C0012634,diagnose possible ,Genome,Disease,1,X,[gngm],[dsyn],G05.360.340,C23.550.288
9a2f056f-3e38-49a2-b8bf-e74bc405c3f3,C1175743,C0036087,is near ubiquitously present in ,SARS coronavirus,saliva,4,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.200.666
57b45aca-72dc-4fb1-aad1-ea98ae3c02db,C0302908,C0039082,relevant in terms of diagnosis of ,Liquid substance,Syndrome,1,X,[sbst],[dsyn],,C23.550.288.500
1b7b9656-b9f5-4c5c-8cd2-2a2e800c4834,C0302908,C0242781,relevant in terms of diagnosis of ,Liquid substance,disease transmission,1,X,[sbst],[patf],,N06.850.310
da4fdf64-a7ae-4ef4-be2b-f5460cdc0bdf,C1511790,C0302908,has made biological ,Detection,Liquid substance,1,X,[topp],[sbst],,
4e4b5502-26de-47c1-a6b5-80f2a881a23c,C1511790,C0039082,has made biological ,Detection,Syndrome,1,X,[topp],[dsyn],,C23.550.288.500
040e697f-0c57-4169-881f-54d2ac25e40f,C1511790,C0242781,has made biological ,Detection,disease transmission,2,X,[topp],[patf],,N06.850.310
040e697f-0c57-4169-881f-54d2ac25e40f,C1511790,C0242781,low rates of are indicative ,Detection,disease transmission,3,X,[topp],[patf],,N06.850.310
7087c870-b66b-45a4-9832-63ae90a93c07,C0003615,C0206750,proportion of were ,Appendicitis,Coronavirus Infections,3,X,[dsyn],[dsyn],C01.539.463.099;C06.405.205.099;C06.405.469.110.207,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,is in phase of ongoing ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,manage ,Providing (action),Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,may affect ,Providing (action),Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,lead clinical use of ,Providing (action),Coronavirus Infections,5,X,[acty],[dsyn],,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,is with advantageous protection against ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,is in hospital due to ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,Facing shortage during ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
831ec805-1503-481b-986c-927913e363dc,C1999230,C0206750,insight into treatment of ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
b1d10852-d6a8-47df-9492-2d0d65f2927c,C1527398,C0206750,is in phase of ongoing ,Emergency Care,Coronavirus Infections,1,X,[topp],[dsyn],N02.421.297,C02.782.600.550.200
e8785575-548b-43f2-a469-5b7519ea9a74,C1947933,C0206750,is in phase of ongoing ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
e8785575-548b-43f2-a469-5b7519ea9a74,C1947933,C0206750,deferring follow-ups because of ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
e8785575-548b-43f2-a469-5b7519ea9a74,C1947933,C0206750,were undertaken as result of ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
e8785575-548b-43f2-a469-5b7519ea9a74,C1947933,C0206750,are of Up of patients admitted to ICU with confirmed ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
e8785575-548b-43f2-a469-5b7519ea9a74,C1947933,C0206750,are reorganizing resources to ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
e82136ab-c80c-4ecd-90d1-663b2d1a6d33,C0037090,C0850149, includes ,Signs and Symptoms Respiratory,Dry cough,5,X,[sosy],[sosy],C23.888.852,
ad72f05d-9c55-4e31-ad8f-73be7d871c8a,C0206750,C0037090,causes Signs and Symptoms Respiratory Illness (finding) with,Coronavirus Infections,Signs and Symptoms Respiratory,5,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
ad72f05d-9c55-4e31-ad8f-73be7d871c8a,C0206750,C0037090,main manifestations of are ,Coronavirus Infections,Signs and Symptoms Respiratory,3,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
ad72f05d-9c55-4e31-ad8f-73be7d871c8a,C0206750,C0037090,is principally defined by its ,Coronavirus Infections,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
ad72f05d-9c55-4e31-ad8f-73be7d871c8a,C0206750,C0037090,is predominantly defined by ,Coronavirus Infections,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
ad72f05d-9c55-4e31-ad8f-73be7d871c8a,C0206750,C0037090,is with only mild ,Coronavirus Infections,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
7842296d-365e-4aba-a4e1-56477a1027c3,C0206750,C0850149,causes Signs and Symptoms Respiratory Illness (finding) with,Coronavirus Infections,Dry cough,2,X,[dsyn],[sosy],C02.782.600.550.200,
07a90627-ae5c-430c-bd69-2c9c24c3bfe0,C0221423,C0037090,is with ,Illness (finding),Signs and Symptoms Respiratory,2,X,[sosy],[sosy],,C23.888.852
94b975d0-6973-4761-8e50-009d9f4d3e1f,C0221423,C0850149,is with ,Illness (finding),Dry cough,1,X,[sosy],[sosy],,
5225de1e-8f6d-4b4e-9f63-329dfddb98ef,C0073020,C0012634,have allowed better ,recombinase,Disease,3,X,[aapp/enzy],[dsyn],D08.811.739,C23.550.288
449e4131-95ba-45f5-9e4c-c1b3094821f1,C1335439,C0012634,have allowed better ,Polymerase,Disease,4,X,[aapp/enzy],[dsyn],,C23.550.288
5fd6af71-2446-4ee6-9b99-108ede1ebfb0,C3658200,C0012634,have allowed better ,Clustered Regularly Interspaced Short Palindromic Repeats,Disease,1,X,[nnon],[dsyn],G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069,C23.550.288
c8ad9d4d-2c66-4a81-b982-2743f267fc99,C0041199,C0858277,was mildly elevated without ,Troponin,angina symptom,7,X,[aapp/bacs],[sosy],D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825,
965e8be0-2c0c-4b45-8136-e8e91781ceca,C0031039,C0036974,piercing Structure of apex of right ventricle Structure of apex of right ventricle alongside early diastolic,Pericardial effusion,Shock,6,X,[dsyn],[patf],C14.280.695,C23.550.835
a55b2ec0-47e8-49be-96a1-140783a3d197,C0031039,C0445242,piercing Structure of apex of right ventricle Structure of apex of right ventricle alongside early diastolic,Pericardial effusion,Structure of apex of right ventricle,20,X,[dsyn],[bpoc],C14.280.695,
ef757c70-833a-4459-a0f4-a0d0ba307972,C0023175,C1707455,were confirmed on ,Lead,Comparison,7,X,[elii/hops],[acty],D01.268.556.435;D01.552.544.435;x.x.x.x,
84910dfe-babc-4773-b3b4-cf5bf3b24ec7,C0191234,C0185115,was performed with ,Pericardiocentesis,Extraction,2,X,[topp],[topp],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,
d9f2209c-5148-4566-beb0-d1edba9cdaa8,C0191234,C0008318,was performed with ,Pericardiocentesis,Cholecalciferol,7,X,[topp],[orch/phsu/vita],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,D04.210.500.247.222.159;D04.210.500.247.808.146;D04.210.500.812.768.196;D10.570.938.146
78456a5a-3512-48ec-85f8-c4da717e2096,C0191234,C0015388,was performed with ,Pericardiocentesis,Exudate,7,X,[topp],[bdsu],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,A12.383
38d2c8bf-d0b0-4828-bdd0-683e9d1809a1,C0008679,C0920467,requiring Adrenal Cortex Hormones for,Chronic disease,disorder control (procedure),6,X,[dsyn],[topp],C23.550.291.500,
38d2c8bf-d0b0-4828-bdd0-683e9d1809a1,C0008679,C0920467,requiring Therapeutic immunosuppression for,Chronic disease,disorder control (procedure),6,X,[dsyn],[topp],C23.550.291.500,
dcdc3bf2-0fb5-448c-aef8-0fff6b09eff7,C0017178,C0920467,requiring Adrenal Cortex Hormones for,Gastrointestinal Diseases,disorder control (procedure),4,X,[dsyn],[topp],C06.405,
dcdc3bf2-0fb5-448c-aef8-0fff6b09eff7,C0017178,C0920467,requiring Therapeutic immunosuppression for,Gastrointestinal Diseases,disorder control (procedure),4,X,[dsyn],[topp],C06.405,
3bb2c40e-a835-473c-b946-3a59ee46e7c9,C1262481,C0008679,are ,Eosinophilic gastroenteritis,Chronic disease,8,X,[dsyn],[dsyn],,C23.550.291.500
5f62add7-52ff-4d9e-a5e2-7bb3750dbb55,C1262481,C0017178,are ,Eosinophilic gastroenteritis,Gastrointestinal Diseases,4,X,[dsyn],[dsyn],,C06.405
e190cbed-7754-47ce-a0c8-63770723ba87,C0008679,C0021079,requiring ,Chronic disease,Therapeutic immunosuppression,6,X,[dsyn],[topp],C23.550.291.500,E02.095.465.425.450;E05.478.610
f935a7de-df16-40bc-84c2-e1a19e194e44,C0008679,C0001617,requiring ,Chronic disease,Adrenal Cortex Hormones,6,X,[dsyn],[horm/orch/phsu],C23.550.291.500,D06.472.040
c879880a-5d73-43c0-a2fb-803b697c75dd,C0017178,C0001617,requiring ,Gastrointestinal Diseases,Adrenal Cortex Hormones,4,X,[dsyn],[horm/orch/phsu],C06.405,D06.472.040
683a53c6-3310-4039-9703-a9664b6017f2,C0012634,EGID,is in EGID ,Disease,EGID,2,X,[dsyn],????,C23.550.288,????
cf73dec3-dd1d-4930-b8ab-50659664d3d3,USC,C2346906,highlight experiences at ,USC,Lupus Anticoagulant Antibody,2,X,????,[aapp/imft],????,
e8b302ea-89d9-4e4d-a968-d46e49ee94ff,USC,C0023749,experiences at largest single provider of healthcare in ,USC,Linoleic Acid,1,X,????,[bacs/orch/phsu],????,D10.251.355.310.515.500;D10.251.355.343.500.500
8d04e538-7c26-416e-a550-8cb977b4bb32,C2346906,C0023749,provider in ,Lupus Anticoagulant Antibody,Linoleic Acid,1,X,[aapp/imft],[bacs/orch/phsu],,D10.251.355.310.515.500;D10.251.355.343.500.500
688abb71-8d58-404f-a5b2-42678336a780,USC,C0242781,reduce risk of ,USC,disease transmission,1,X,????,[patf],????,N06.850.310
fb887b3d-b019-4413-893b-dd416f66e5d5,IFSO,C0028754,navigating bariatric procedures in patients with ,IFSO,Obesity,3,X,????,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
ed9dcfae-92df-4157-bd2e-473d0eff116a,C0012634,C0009450,is ominous ,Disease,Communicable Diseases,36,X,[dsyn],[dsyn],C23.550.288,C01.539.221
5ebcefc8-bd80-41ec-a41e-741f74c43d4b,C0042762,COVID-19,IMPACT gene on,Science of Virology,COVID-19,1,X,[bmod],[virs],H01.158.273.540.859,C000657245
9c51b47e-7940-4b60-a2ae-4c68f0c238b9,COVID-19,C0011849,is with ,COVID-19,Diabetes Mellitus,4,X,[virs],[dsyn],C000657245,C18.452.394.750;C19.246
d7196a20-964a-48e2-9823-87dc522898cd,C0042762,C0011849,IMPACT gene of,Science of Virology,Diabetes Mellitus,1,X,[bmod],[dsyn],H01.158.273.540.859,C18.452.394.750;C19.246
6f2e94d7-5c2c-46a1-a7e0-4e525d18dc49,C0254211,C1707455,is PCR ,arbidol,Comparison,3,X,[orch/phsu],[acty],x.x.x.x,
3b2254eb-7e69-4012-856b-d5b179770066,C0254211,PCR,is associated with higher negative rate of PCR,arbidol,PCR,6,X,[orch/phsu],????,x.x.x.x,????
15019aa1-da22-4b3b-8642-0e3d96921b0a,C0319157,C0012222,has ,AS virus,Diffusion,3,X,[virs],[npop],,G01.202;G02.196
ab3e9d3c-42e9-4a7f-93d8-7a3c2cc5fdcb,C0319157,C0040802,closely followed ,AS virus,travel,2,X,[virs],[dora],,I03.883
8c4b7ae7-9d5b-4d5b-bc73-11bf86a7bf81,C0263237,C1880022,are In particular ,Vesicular eruption,Characterization,2,X,[dsyn],[acty],,
6f04b3e2-a240-4e4c-bce4-010e5b58b00e,C0263237,C1457887,occasionally preceding other ,Vesicular eruption,Symptoms,2,X,[dsyn],[sosy],,
98d1bc26-749e-40c0-80e9-743bf61e0b22,C2348077,C1175743,have had four patients with ,Date Fruit,SARS coronavirus,2,X,[food],[virs],B01.650.940.800.575.912.250.093.615,B04.820.504.540.150.113.937
98d1bc26-749e-40c0-80e9-743bf61e0b22,C2348077,C1175743,have have postulated for ,Date Fruit,SARS coronavirus,1,X,[food],[virs],B01.650.940.800.575.912.250.093.615,B04.820.504.540.150.113.937
daf77ee2-a8f0-4fcf-bc91-5bd2955729fd,C3272275,C0242781,block ,Urgent Procedure,disease transmission,2,X,[topp],[patf],,N06.850.310
730f0dfb-de5f-4891-ac3e-55997eff06a7,C0029341,C0206750,is in ,Orthomyxoviridae,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.545,C02.782.600.550.200
e7b73e7b-064f-4494-8b39-27d87335a364,C0029341,C0547605,is in ,Orthomyxoviridae,prevention of infection,1,X,[virs],[topp],B04.820.545,
bbd2fb11-70ef-4627-9782-ceaa8390d119,C1254351,C1510827,is in currently use for predicted ,Pharmacologic Substance,Affinity,7,X,[phsu],[npop],,
4b4f1a92-dd0f-4d62-9e34-bf92536f9d83,C0242210,C0033684,is in ,Binding Proteins,Proteins,7,X,[aapp/bacs],[aapp/bacs],D12.776.157,D12.776
eda01009-1ae0-4d6d-95d8-3b44da57fe20,C0042760,C1254351,bind ,Virion,Pharmacologic Substance,1,X,[celc],[phsu],A21.249;B04.950,
d2750cde-8269-4afb-883b-2d7e473b5a6b,C0597358,C0022709,must move interact with ,receptor binding,Peptidyl-Dipeptidase A,10,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
053d1b24-773c-48e0-b0d4-d52496a28065,C1254351,C0086418,may act interfere with movements prior to ,Pharmacologic Substance,Homo sapiens,1,X,[phsu],[humn],,B01.050.150.900.649.313.988.400.112.400.400
053d1b24-773c-48e0-b0d4-d52496a28065,C1254351,C0086418,already approved for use ,Pharmacologic Substance,Homo sapiens,4,X,[phsu],[humn],,B01.050.150.900.649.313.988.400.112.400.400
a33de306-ea95-44f7-b267-3bc919e824bf,C1254351,C0022709,may act interfere with movements prior to ,Pharmacologic Substance,Peptidyl-Dipeptidase A,1,X,[phsu],[aapp/enzy/imft],,D08.811.277.656.350.350.687
33538ced-79b0-4b11-bfc2-19d5b6401ce3,C1254351,C0033684,may act interfere with movements prior to ,Pharmacologic Substance,Proteins,7,X,[phsu],[aapp/bacs],,D12.776
5141eaa8-1847-47b8-b846-e46049371b9c,C1254351,C0745283,may act interfere with movements prior to ,Pharmacologic Substance,INFECTIOUS PROCESS,7,X,[phsu],[patf],,
123dc6d8-c9a8-41b7-948d-10df5cfb43ea,C0020336,COVID-19,was promoted in ,Hydroxychloroquine,COVID-19,5,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,C000657245
c596c093-32ef-460c-84ca-6d007cbebb98,COVID-19,C0036202,is in patient with ,COVID-19,Sarcoidosis,1,X,[virs],[dsyn],C000657245,C15.604.515.827
35fb24b5-f1d9-4543-a529-d028cb2cb5c0,BMJ,C0087111,are facing disaster without available ,BMJ,Therapeutic procedure,1,X,????,[topp],????,E02
3fb7bfdf-c22f-4bf8-bd2c-2a7504c98901,BMJ,C0206419,are facing unprecedented disaster of ,BMJ,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
cade9ab3-816b-4d0e-b273-ec9e34f42247,BMJ,C0012634,are facing unprecedented disaster of ,BMJ,Disease,1,X,????,[dsyn],????,C23.550.288
10008a01-e508-405a-80aa-ea7d3cb5d789,COVID-19,C0087111,seek proper ,COVID-19,Therapeutic procedure,1,X,[virs],[topp],C000657245,E02
a7cce3ed-aa02-426c-99ac-71fefaf7782b,C0206419,C0087111,seek proper ,Genus: Coronavirus,Therapeutic procedure,1,X,[virs],[topp],B04.820.504.540.150,E02
a7cce3ed-aa02-426c-99ac-71fefaf7782b,C0206419,C0087111,requires ,Genus: Coronavirus,Therapeutic procedure,1,X,[virs],[topp],B04.820.504.540.150,E02
18701fd7-1a03-45e9-a066-02b52d3daf63,C0008269,remdesivir, includes ,Chloroquine,remdesivir,17,X,[orch/phsu],[clnd],D03.633.100.810.050.180,
ec3a4f1f-4ddb-4f35-8d6e-03391453e28b,C3652465,remdesivir, includes ,Interferon,remdesivir,17,X,[aapp/imft/phsu],[clnd],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
c901f7f7-23e8-492c-92da-568381be23a2,C0003451,remdesivir, includes ,Antiviral Agents,remdesivir,17,X,[phsu],[clnd],D27.505.954.122.388,
c3790273-98d9-4c44-a354-bc5e16148800,C0008269,C0674432, includes ,Chloroquine,lopinavir,17,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,D03.383.742.698.553
19681173-ab15-477b-b24d-bd52df525f6f,C3652465,C0674432, includes ,Interferon,lopinavir,17,X,[aapp/imft/phsu],[orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D03.383.742.698.553
1089f3cc-a7a0-4c23-bec7-d299d98795eb,C0003451,C0674432, includes ,Antiviral Agents,lopinavir,17,X,[phsu],[orch/phsu],D27.505.954.122.388,D03.383.742.698.553
0d872482-fb72-4211-8bdb-bfc9aacc4c7f,C0008269,C0292818, includes ,Chloroquine,Ritonavir,17,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,D02.886.675.653;D03.383.129.708.653
5b89d64b-be45-4f2a-bab1-a773d4aa6c1b,C3652465,C0292818, includes ,Interferon,Ritonavir,17,X,[aapp/imft/phsu],[orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D02.886.675.653;D03.383.129.708.653
476d2cbc-cc4f-48b0-9512-32a4f6fc26bc,C0003451,C0292818, includes ,Antiviral Agents,Ritonavir,17,X,[phsu],[orch/phsu],D27.505.954.122.388,D02.886.675.653;D03.383.129.708.653
78037c41-70fb-46ee-962a-81bb1c84f9ee,C0008269,C1875319,are INVESTIGATIONAL AGENTS under,Chloroquine,INVESTIGATIONAL AGENTS,17,X,[orch/phsu],[phsu],D03.633.100.810.050.180,
e632a800-10e7-491a-a859-40882d12992b,C3652465,C1875319,are INVESTIGATIONAL AGENTS under,Interferon,INVESTIGATIONAL AGENTS,17,X,[aapp/imft/phsu],[phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
b5317180-8649-4053-90d3-a17e7751ce35,C0003451,C1875319,are INVESTIGATIONAL AGENTS under,Antiviral Agents,INVESTIGATIONAL AGENTS,17,X,[phsu],[phsu],D27.505.954.122.388,
f6ffa7ce-e830-42f0-9b12-7e993d58b24b,remdesivir,C1875319,are INVESTIGATIONAL AGENTS under,remdesivir,INVESTIGATIONAL AGENTS,17,X,[clnd],[phsu],,
12611b63-db79-4541-a707-0eb940fd90e2,C0674432,C1875319,are INVESTIGATIONAL AGENTS under,lopinavir,INVESTIGATIONAL AGENTS,17,X,[orch/phsu],[phsu],D03.383.742.698.553,
239c7b02-6a39-4bef-8841-1b11d530ebf2,C0292818,C1875319,are INVESTIGATIONAL AGENTS under,Ritonavir,INVESTIGATIONAL AGENTS,17,X,[orch/phsu],[phsu],D02.886.675.653;D03.383.129.708.653,
85cecda6-ea38-47af-a9bb-d8681274cb7d,C0005525,C0021081,using due ,Biological Response Modifiers,Immunosuppressive Agents,4,X,[imft/phsu],[imft/phsu],D27.505.696.477,D27.505.696.477.656
c631d542-9673-4b0a-a41e-a7efafcd24a9,C1175743,C0319157,with patients is ,SARS coronavirus,AS virus,11,X,[virs],[virs],B04.820.504.540.150.113.937,
2ef43098-3b27-4846-95d9-408b56fc6c41,genomic,C0282688,enable understanding of ,genomic,Evolution Molecular,1,X,????,[biof],????,G05.045.250;G16.075.250
e322528c-71e6-467a-a46c-c054dc6b942e,genomic,C0319157,enable understanding of ,genomic,AS virus,1,X,????,[virs],????,
5b3cd83d-67b1-4c34-89e2-9e67c4bd6f6f,C0013227,C1254351,is in already use as ,Pharmaceutical Preparations,Pharmacologic Substance,3,X,[phsu],[phsu],D26,
5b3cd83d-67b1-4c34-89e2-9e67c4bd6f6f,C0013227,C1254351,may act as ,Pharmaceutical Preparations,Pharmacologic Substance,3,X,[phsu],[phsu],D26,
aa450608-3f05-4f24-af86-3f683142d7f8,C0022709,C0174990,coronavirus receptor for,Peptidyl-Dipeptidase A,coronavirus receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
aa450608-3f05-4f24-af86-3f683142d7f8,C0022709,C0174990,is In addition ,Peptidyl-Dipeptidase A,coronavirus receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
aa450608-3f05-4f24-af86-3f683142d7f8,C0022709,C0174990,may may ,Peptidyl-Dipeptidase A,coronavirus receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
57230829-26d2-456a-a17e-a5263e09055b,C1175743,C0225336,is with focus on ,SARS coronavirus,Endothelial Cells,1,X,[virs],[cell],B04.820.504.540.150.113.937,A11.436.275
57230829-26d2-456a-a17e-a5263e09055b,C1175743,C0225336,infect ,SARS coronavirus,Endothelial Cells,1,X,[virs],[cell],B04.820.504.540.150.113.937,A11.436.275
54422de1-525b-494e-ad2b-7022f963069f,C0206419,C0021403,having ,Genus: Coronavirus,Influenza virus vaccine,1,X,[virs],[imft/phsu],B04.820.504.540.150,D20.215.894.899.302
f50f381c-a6cb-42ed-8389-88c3bad030da,C0939237,C0206419,is associated with ,lopinavir / Ritonavir,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
f50f381c-a6cb-42ed-8389-88c3bad030da,C0939237,C0206419,are are repurposed for treatment of ,lopinavir / Ritonavir,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
7e71721f-b99f-4135-ae13-390da605ba3e,C0037088,C0042769,right Virus Diseases for,Signs and Symptoms,Virus Diseases,1,X,[sosy],[dsyn],C23.888,C02
663637f8-b8bd-4283-823c-a52a1ae9d6cf,C0319157,C0013227,could could explored as potential ,AS virus,Pharmaceutical Preparations,1,X,[virs],[phsu],,D26
7b12acd3-2ad1-4e92-bf87-8a7ebcdbff37,C2349975,C0024501,was recommended to ,Enhance (action),Maintenance,1,X,[acty],[acty],,N02.628
07801f0a-fa49-42e5-ab2a-f12471699571,C0024109,C0006145,are ,Lung,Breast Diseases,3,X,[bpoc],[dsyn],A04.411,C17.800.090
bc8ad9ed-a778-489f-8c7f-a1c74ed72eff,C0024109,C0206419,involved in ,Lung,Genus: Coronavirus,3,X,[bpoc],[virs],A04.411,B04.820.504.540.150
8693a1cb-8c81-4d88-8ea9-c1b20c5a71f7,C0024109,GGO,distributed GGO,Lung,GGO,1,X,[bpoc],????,A04.411,????
89e73130-f674-48bd-ac17-ec8e6ce7a836,C0282515,C0020336,is with daily dosing of ,Chemoprevention,Hydroxychloroquine,3,X,[topp],[orch/phsu],E02.319.162,D03.633.100.810.050.180.350
89001e4f-a421-4896-b423-c8686135dd27,C0282515,C0206419,time to contracting ,Chemoprevention,Genus: Coronavirus,5,X,[topp],[virs],E02.319.162,B04.820.504.540.150
ec2cafea-3d95-4197-916a-e21feb6e7810,C0282515,C0012634,is with increases time to contracting ,Chemoprevention,Disease,2,X,[topp],[dsyn],E02.319.162,C23.550.288
f46116c3-7043-4fed-9727-fd187be13e75,C0020336,C0032042,dosed weekly with daily ,Hydroxychloroquine,Placebos,2,X,[orch/phsu],[topp],D03.633.100.810.050.180.350,D26.660;E02.785
72e6af36-1643-41f1-9059-92d6ca9b1c78,C0319157,C0206419,causes ,AS virus,Genus: Coronavirus,6,X,[virs],[virs],,B04.820.504.540.150
72e6af36-1643-41f1-9059-92d6ca9b1c78,C0319157,C0206419,responsible for novel ,AS virus,Genus: Coronavirus,2,X,[virs],[virs],,B04.820.504.540.150
72e6af36-1643-41f1-9059-92d6ca9b1c78,C0319157,C0206419,is with specific roles in ,AS virus,Genus: Coronavirus,2,X,[virs],[virs],,B04.820.504.540.150
2b1b7751-3c28-4e49-b2e4-00eaa9bb7057,C0319157,C0012634,causing 2019 ,AS virus,Disease,10,X,[virs],[dsyn],,C23.550.288
2b1b7751-3c28-4e49-b2e4-00eaa9bb7057,C0319157,C0012634,responsible for novel ,AS virus,Disease,1,X,[virs],[dsyn],,C23.550.288
2b1b7751-3c28-4e49-b2e4-00eaa9bb7057,C0319157,C0012634,prevent ,AS virus,Disease,1,X,[virs],[dsyn],,C23.550.288
e0598f13-0dc1-47fd-9544-04b03aa294ec,C0009450,C0309872,been effective in ,Communicable Diseases,PREVENT (product),4,X,[dsyn],[phsu],C01.539.221,
1fcb085d-efb9-4621-9b6b-ef08aecd17e7,C1602245,C0412786,Ensure (product),Prompt,Protection of patient,8,X,[phsu],[topp],,
9c39eec9-d762-443f-a127-5f3fb666c425,C0206419,C3694279,shows ,Genus: Coronavirus,Middle East Respiratory Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
9c39eec9-d762-443f-a127-5f3fb666c425,C0206419,C3694279,may cause ,Genus: Coronavirus,Middle East Respiratory Syndrome,9,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
01eefbc3-5728-4d90-adec-12e41c40c467,C0814033,C0319157,are potentially affected by ,neural circuits,AS virus,1,X,[bpoc],[virs],,
143e85f7-d956-4f67-b5e6-75c3f7b83e64,C0206419,C4284302,is with ,Genus: Coronavirus,EHD1 wt Allele,3,X,[virs],[gngm],B04.820.504.540.150,
7e6f18ed-49b3-4907-9f2c-baaa196d5b07,C0012634,C4284302,affecting ~ 9 million people in ,Disease,EHD1 wt Allele,1,X,[dsyn],[gngm],C23.550.288,
4135e39b-ac6a-489d-acae-72fd70ebaea6,C0019638,C0225695,thickened ,Histology,Alveolar wall,2,X,[bmod],[bpoc],H01.158.100.656,
481640dc-b5a9-43f1-aac7-bf82809b367e,C0019638,C0015982,showed changes with ,Histology,Fibrin,2,X,[bmod],[aapp/bacs/phsu],H01.158.100.656,D12.776.124.270
4ba9e972-cf14-4299-98f0-0e28bf8f50ea,C0019638,C0596898,showed changes with ,Histology,membrane biogenesis,2,X,[bmod],[celf],H01.158.100.656,
f67d7e20-57c8-474a-9006-61dc2d3baba4,C0019638,C2328510,thickened ,Histology,Interstitium,2,X,[bmod],[bpoc],H01.158.100.656,
da2fefba-d78d-4aad-992e-9ecd9843e4de,C0019638,C0333386,thickened Alveolar wall with,Histology,Chronic lymphocytic inflammation,2,X,[bmod],[patf],H01.158.100.656,
da2fefba-d78d-4aad-992e-9ecd9843e4de,C0019638,C0333386,thickened Interstitium with,Histology,Chronic lymphocytic inflammation,2,X,[bmod],[patf],H01.158.100.656,
e6434e94-4f8f-44f0-a402-fa705ab806ac,C0699748,C1175175,is in aftermath of 2002 2003 ,Pathogenesis,Severe Acute Respiratory Syndrome,5,X,[patf],[dsyn],,C02.782.600.550.200.750;C08.730.730
a2c82d8f-e03b-4ee1-b7fc-c049a2af9ddf,C2806453,C0013227,of features is potential ,Betacoronavirus,Pharmaceutical Preparations,5,X,[virs],[phsu],B04.820.504.540.150.113,D26
de6b4d73-42de-45b3-a52f-434611f9fbd6,C0012634,C1175175,rapidly progresses to ,Disease,Severe Acute Respiratory Syndrome,18,X,[dsyn],[dsyn],C23.550.288,C02.782.600.550.200.750;C08.730.730
3fdd171f-4faf-44c5-9f82-8d1be93ae3c7,C0206419,C0013404,share similar fever ,Genus: Coronavirus,Dyspnea,2,X,[virs],[sosy],B04.820.504.540.150,C08.618.326;C23.888.852.371
51d6a0d1-f174-4acb-9a96-4e4b8be8b1cc,C1175743,C0277548,were However ,SARS coronavirus,Epidemic disease,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
51d6a0d1-f174-4acb-9a96-4e4b8be8b1cc,C1175743,C0277548,is responsible for ,SARS coronavirus,Epidemic disease,4,X,[virs],[dsyn],B04.820.504.540.150.113.937,
af16bdc3-e7b7-4b67-b073-d7531a38342a,C3714514,C0277548,were However ,Infection,Epidemic disease,1,X,[patf],[dsyn],C01.539,
8da6ff72-be0b-4503-ab53-7d8b6cadafa2,C1175743,11th,had spread on 11th,SARS coronavirus,11th,6,X,[virs],????,B04.820.504.540.150.113.937,????
37de494e-8249-4ce2-a5e7-0788126f2c28,C0007682,C0497327, includes Alzheimers-like ,CNS disorder,Dementia,6,X,[dsyn],[mobd],C10.228,C10.228.140.380;F03.615.400
d4e012c6-3e57-4165-9d15-c4fb30ff8c08,COVID-19,C0008679,is associated with much ,COVID-19,Chronic disease,1,X,[virs],[dsyn],C000657245,C23.550.291.500
21ca59f5-5f0e-4a13-a781-e03e9bcc917f,C1707455,C1516048,was ,Comparison,Assessed,1,X,[acty],[acty],,
39da4f28-75d3-466e-bca3-6c035cadc5b7,C0034386,C1516048,was ,Quarantine,Assessed,1,X,[topp],[acty],N06.850.780.200.450.700,
9b0544e3-13c0-4004-8b67-4bc415e28e80,C0206419,C0024109,are consequence of multiorgan dysregulation caused by ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
9b0544e3-13c0-4004-8b67-4bc415e28e80,C0206419,C0024109,can affect ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
9b0544e3-13c0-4004-8b67-4bc415e28e80,C0206419,C0024109,can can suggested on ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
9b0544e3-13c0-4004-8b67-4bc415e28e80,C0206419,C0024109, includes ,Genus: Coronavirus,Lung,4,X,[virs],[bpoc],B04.820.504.540.150,A04.411
9b0544e3-13c0-4004-8b67-4bc415e28e80,C0206419,C0024109,colocalized in ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
ee839a01-201e-4339-a120-2114b9265ca4,C0012634,C0024109,are consequence of multiorgan dysregulation caused by ,Disease,Lung,1,X,[dsyn],[bpoc],C23.550.288,A04.411
ee839a01-201e-4339-a120-2114b9265ca4,C0012634,C0024109,is in patients with pattern of ,Disease,Lung,2,X,[dsyn],[bpoc],C23.550.288,A04.411
ee839a01-201e-4339-a120-2114b9265ca4,C0012634,C0024109,is In symptomatic individuals mild immune-mediated ,Disease,Lung,2,X,[dsyn],[bpoc],C23.550.288,A04.411
68ba226e-ee5a-4894-87eb-f43698a297ca,C0007222,COVID-19,are at ,Cardiovascular Diseases,COVID-19,1,X,[dsyn],[virs],C14,C000657245
39ee64ba-49b9-487c-8e2b-de95e2163c86,C0028606,COVID-19,is in ,Nucleic Acids,COVID-19,1,X,[bacs/nnon],[virs],D13.444,C000657245
2205d41b-5dd3-49e3-a7c6-2abe88ac77a9,C0206419,11th,was characterized as global pandemic by the WHO on 11th,Genus: Coronavirus,11th,2,X,[virs],????,B04.820.504.540.150,????
2205d41b-5dd3-49e3-a7c6-2abe88ac77a9,C0206419,11th,has has announced by World Health Organization Director General on 11th,Genus: Coronavirus,11th,1,X,[virs],????,B04.820.504.540.150,????
1c610123-07ed-4e82-bd91-8ad47e3d7781,C0012634,11th,was characterized as global pandemic by the WHO on 11th,Disease,11th,2,X,[dsyn],????,C23.550.288,????
5cf58a7c-6999-4992-9bfb-28c29e611062,C0206419,C1155266,is associated with severe ,Genus: Coronavirus,inflammatory response,1,X,[virs],[patf],B04.820.504.540.150,
5cf58a7c-6999-4992-9bfb-28c29e611062,C0206419,C1155266,triggering ,Genus: Coronavirus,inflammatory response,2,X,[virs],[patf],B04.820.504.540.150,
5cf58a7c-6999-4992-9bfb-28c29e611062,C0206419,C1155266,direct systemic ,Genus: Coronavirus,inflammatory response,1,X,[virs],[patf],B04.820.504.540.150,
f6986ff3-b0dc-441a-bc07-608d3a788fc2,C0012634,C1155266,is associated with severe ,Disease,inflammatory response,2,X,[dsyn],[patf],C23.550.288,
986692fb-dab9-4107-946d-a0010eefe5a3,C0021368,C2936350,affects ,Inflammation,Plaque Atherosclerotic,2,X,[patf],[bdsu],C23.550.470,C23.300.823
986692fb-dab9-4107-946d-a0010eefe5a3,C0021368,C2936350,may result in rupture of vulnerable ,Inflammation,Plaque Atherosclerotic,3,X,[patf],[bdsu],C23.550.470,C23.300.823
345c4d21-2089-48e6-81ab-6e3dad471b79,COVID-19,C1511790,was diagnosed by ,COVID-19,Detection,1,X,[virs],[topp],C000657245,
56344065-256b-407e-b6f3-13277cff1d42,C0021368,COVID-19,related to ,Inflammation,COVID-19,7,X,[patf],[virs],C23.550.470,C000657245
1d3a7628-2c90-4ee3-8649-4dd7ebe5f5dd,C0021368,C0302148,resulting in ,Inflammation,Blood Clot,3,X,[patf],[patf],C23.550.470,C14.907.355.830
9e329ba5-cd7c-4dff-96c1-711b37031369,C0026140,RT-PCR,was tested by real-time RT-PCR,Milk Human,RT-PCR,1,X,[bdsu],????,A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500,????
0fdfb167-7b4a-4c89-af95-513d3bd72bb5,C0026140,C1175743,was positive for ,Milk Human,SARS coronavirus,1,X,[bdsu],[virs],A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500,B04.820.504.540.150.113.937
0fdfb167-7b4a-4c89-af95-513d3bd72bb5,C0026140,C1175743,tested for ,Milk Human,SARS coronavirus,1,X,[bdsu],[virs],A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500,B04.820.504.540.150.113.937
03ea5d07-4229-4e0c-a497-91211a696d13,C1175743,C0026140,is in ,SARS coronavirus,Milk Human,1,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500
135d10af-357f-4326-bb18-57d4bdc1333c,C1457887,C0010200,were ,Symptoms,Coughing,40,X,[sosy],[sosy],,C08.618.248;C23.888.852.293
d37e8b52-92a1-445e-91b5-8541d2c05f62,C1457887,C0231218,include ,Symptoms,Malaise,2,X,[sosy],[sosy],,
5f869896-6607-44b4-828b-d1ea9cbad320,C0030946,C0872147,using ,Endopeptidases,DNA Library,5,X,[aapp/enzy/phsu],[gngm/nnon],D08.811.277.656.300,G05.360.325
88104475-7b6c-48c7-9fbe-a326d8486604,C0030946,C1566558,using ,Endopeptidases,Natural Products,5,X,[aapp/enzy/phsu],[bacs],D08.811.277.656.300,D20.215
cfa08e00-13f1-49fe-a51f-30a6cfc985e8,MDS,C0023688,were performed on ,MDS,Ligands,5,X,????,[chem],????,D27.720.470.480
1300c88d-5998-4bb6-9baa-b73590de1415,MDS,C1180347,were performed on ,MDS,Protein complex,5,X,????,[aapp/bacs],????,
83e4599a-b155-4363-91dc-7664e2686de1,MDS,C1167622,verify their ,MDS,Binding (Molecular Function),10,X,????,[moft],????,
779086be-9890-44d8-81c2-6d665aeee333,C0034386,COVID-19,recommended due to ,Quarantine,COVID-19,1,X,[topp],[virs],N06.850.780.200.450.700,C000657245
779086be-9890-44d8-81c2-6d665aeee333,C0034386,COVID-19,significantly reduced ,Quarantine,COVID-19,1,X,[topp],[virs],N06.850.780.200.450.700,C000657245
866809f1-ed26-4b57-9889-a396abaf74d4,C0004610,C0035243,were attributed to non ,Bacteremia,Respiratory Tract Infections,2,X,[dsyn],[dsyn],C01.252.100;C01.539.757.100;C23.550.470.790.500.100,C01.539.739;C08.730
de303f53-09dc-4f1e-b719-1c4ddfe3f8bb,C0023237,C1511790,was ,Legionella,Detection,1,X,[bact],[topp],B03.440.400.425.450.450;B03.660.250.460.460,
4f98d768-299f-475c-93d0-7bebb263e296,C4267729,C0033808,isolated with ,Respiratory pathogens,Pseudomonas,1,X,[orgm],[bact],,B03.440.400.425.625.625;B03.660.250.580.590
f1a0c80d-a66d-46f1-aeaa-12054a71190d,C4267729,C0009450,isolated with ,Respiratory pathogens,Communicable Diseases,1,X,[orgm],[dsyn],,C01.539.221
511a8be5-bee2-420e-9b04-41d26010c0f0,C4267729,C0275524,isolated in community-acquired ,Respiratory pathogens,Coinfection,1,X,[orgm],[dsyn],,C01.539.218;C02.219;C03.202
2f21af25-a25b-42fd-9127-09bc3c055a09,C1262313,C3714514,were attributed to line related ,Invasive Fungal Infections,Infection,2,X,[dsyn],[patf],C01.703.492,C01.539
9688107e-7c88-4bfc-b1c9-49389a0f5fa2,C4086266,C0230425,reduction in ,Escalation,Structure of right thigh,5,X,[acty],[bpoc],,
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,analyze existing research works in relation to prevalence during ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,quantify effect of ,Aim,Coronavirus Infections,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,explore effect on outcomes of patients with ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,present epidemiological analysis of first two months of ,Aim,Coronavirus Infections,11,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,confirmed ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,analyze and stress during,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,investigate whether ,Aim,Coronavirus Infections,5,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,report radiological ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,evaluate results of protocol established in advanced ,Aim,Coronavirus Infections,7,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,determine maximum number of ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,estimate basic reproduction number of ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,summarize data on treatment of ,Aim,Coronavirus Infections,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,analyze known comorbidities of ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,review typical CT findings in ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,discuss emergent repair in patients affected by ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
bc359e4e-efc8-4e85-8151-cdad5577a681,C2948600,C0206750,is with following patients during ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
82df1abc-f20c-421e-90c7-32f6fbe6aa30,C0042776,C0206750,agent of ,Virus,Coronavirus Infections,2,X,[virs],[dsyn],B04,C02.782.600.550.200
82df1abc-f20c-421e-90c7-32f6fbe6aa30,C0042776,C0206750,causing current ,Virus,Coronavirus Infections,53,X,[virs],[dsyn],B04,C02.782.600.550.200
82df1abc-f20c-421e-90c7-32f6fbe6aa30,C0042776,C0206750,triggered ,Virus,Coronavirus Infections,2,X,[virs],[dsyn],B04,C02.782.600.550.200
82df1abc-f20c-421e-90c7-32f6fbe6aa30,C0042776,C0206750,is potentially more lethal than ,Virus,Coronavirus Infections,2,X,[virs],[dsyn],B04,C02.782.600.550.200
7173d02d-ba3d-4b7b-85bb-55579f73f8c7,C0039082,C2717865,are known Besides ,Syndrome,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,2,X,[dsyn],[dsyn],C23.550.288.500,C14.907.940.897.249;C20.111.193
7757f2b6-4e9f-44df-927d-54fff4c1be98,C0024109,C2717865,are known Besides ,Lung,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,2,X,[bpoc],[dsyn],A04.411,C14.907.940.897.249;C20.111.193
11e53383-c734-495d-bbcd-0d121bd72351,C0003204,C2717865,are known Besides ,Anti-Infective Agents,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,2,X,[phsu],[dsyn],D27.505.954.122,C14.907.940.897.249;C20.111.193
2c701883-e449-4770-ac36-75c8fcd4d01b,C0004364,C0103647, includes ,Autoimmune Diseases,Antineutrophil Cytoplasmic Antibodies,2,X,[dsyn],[imft],C20.111,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
c24ff573-02eb-4b47-a860-0904b09916f6,C2717865,C0004364,are known Besides ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,Autoimmune Diseases,2,X,[dsyn],[dsyn],C14.907.940.897.249;C20.111.193,C20.111
3d6fc272-4cdb-4e15-9a59-5db0421d4a25,C0039082,C0004364,are known Besides ,Syndrome,Autoimmune Diseases,2,X,[dsyn],[dsyn],C23.550.288.500,C20.111
82870fca-b116-4abb-baf5-e1ebee66f3b7,C0024109,C0004364,are known Besides ,Lung,Autoimmune Diseases,2,X,[bpoc],[dsyn],A04.411,C20.111
83a1c22a-636e-413b-89b5-58c5a9ddb9e9,C0003204,C0004364,are known Besides ,Anti-Infective Agents,Autoimmune Diseases,2,X,[phsu],[dsyn],D27.505.954.122,C20.111
201db2eb-bc94-4076-a0a8-182642c3c67c,C2717865,C0103647,are known Besides ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,Antineutrophil Cytoplasmic Antibodies,2,X,[dsyn],[imft],C14.907.940.897.249;C20.111.193,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
f60d9c34-06c7-4d43-975d-0e20979c9939,C0039082,C0103647,are known Besides ,Syndrome,Antineutrophil Cytoplasmic Antibodies,2,X,[dsyn],[imft],C23.550.288.500,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
251e1a9c-48f6-4b76-8aa9-f5c665ea1617,C0024109,C0103647,are known Besides ,Lung,Antineutrophil Cytoplasmic Antibodies,2,X,[bpoc],[imft],A04.411,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
2f6e89a7-29a1-4479-835b-6459a934f5bc,C0003204,C0103647,are known Besides ,Anti-Infective Agents,Antineutrophil Cytoplasmic Antibodies,2,X,[phsu],[imft],D27.505.954.122,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
8b158308-a3a0-40e5-a26b-1e7c37a349a6,C2717865,C4476767,be culprits of ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,Diffuse alveolar hemorrhage,4,X,[dsyn],[dsyn],C14.907.940.897.249;C20.111.193,
fe569f2b-c50c-4e84-aef2-d61794568621,C0039082,C4476767,be culprits of ,Syndrome,Diffuse alveolar hemorrhage,4,X,[dsyn],[dsyn],C23.550.288.500,
6f0ebd4c-6ff8-425d-9676-ad871c390ed6,C0024109,C4476767,be culprits of ,Lung,Diffuse alveolar hemorrhage,4,X,[bpoc],[dsyn],A04.411,
9256f236-5678-4d0d-84c7-966a2ec7f564,C0003204,C4476767,be culprits of ,Anti-Infective Agents,Diffuse alveolar hemorrhage,4,X,[phsu],[dsyn],D27.505.954.122,
ab061600-fdf7-4184-a982-4c74e420fa85,C0567416,C0036563,starting to pharmacophoric features of its ,Molecule,Plant seeds,4,X,[sbst],[plnt],,A18.024.500.750;G07.203.300.775;J02.500.775
edd98f37-c262-4cc4-8b84-405c6048f330,C0206750,C0033860,is with ,Coronavirus Infections,Psoriasis,5,X,[dsyn],[dsyn],C02.782.600.550.200,C17.800.859.675
cb7fc6b6-4ca9-4884-9a75-8f48f9c9652d,C0026766,C0206750,are spectrum of ,Multiple Organ Failure,Coronavirus Infections,4,X,[patf],[dsyn],C23.550.835.525,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,recently reported duration of ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,may occur in ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,was empirically recommended as prophylaxis by National ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,is under evaluation as possible ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,have recently become because of ongoing ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,reduce death risk of ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,should Therefore should prescribed as part of treatment for ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,offered efficacy in treatment of ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,has has proposed as possible treatment for ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,decreases inflammatory response storm In patients with,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
24a1b447-3095-4187-bdc2-7d7be65d5859,C0020336,C0206750,clinical symptoms of ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
3106a4dd-44b7-42bc-89ae-64e5ff160ad5,C0850149,C0206750,had ,Dry cough,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
bdc448b9-acfb-4919-8223-160945b66c81,C0086418,C0042762,Institute of ,Homo sapiens,Science of Virology,2,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H01.158.273.540.859
3d32703f-e32a-44ba-8e78-efe0e58b2b74,C0021400,C0042762,Institute of ,Influenza,Science of Virology,2,X,[dsyn],[bmod],C02.782.620.365;C08.730.310,H01.158.273.540.859
ce45861f-e77b-44a5-bbd1-573ea255f911,CN,C1705178,is in alphabetical ,CN,Order (action),4,X,????,[acty],????,
c7f8ca9a-de44-4004-82e4-e9245b0083a7,ICMR,C1705178,is In alphabetical ,ICMR,Order (action),1,X,????,[acty],????,
5588f1e3-77da-4a79-9c3e-bd61d11145bb,COVID,C1705178,is in alphabetical ,COVID,Order (action),4,X,????,[acty],????,
1f6b9a71-ef86-4db9-874f-5282f856b8dd,C0014507,C1705178,is in alphabetical ,Epidemiology,Order (action),3,X,[bmod],[acty],H02.403.720.500,
069c528d-0820-4bb1-869b-745b8d546e47,C0376576,C1705178,is in alphabetical ,gb virus,Order (action),2,X,[virs],[acty],,
b0b5343d-8631-456a-aff5-f2b9b2381a83,C0018939,C0002871, includes ,Hematological Disease,Anemia,6,X,[dsyn],[dsyn],C15.378,C15.378.071
9983e4f2-4088-4e0b-acba-369f98a83c97,C0018939,C0005779, includes ,Hematological Disease,Blood Coagulation Disorders,6,X,[dsyn],[dsyn],C15.378,C15.378.100
a35059a8-2116-4505-b9ff-f6dc6c1c482e,C0018939,C0040034, includes ,Hematological Disease,Thrombocytopenia,6,X,[dsyn],[dsyn],C15.378,C15.378.140.855
a35059a8-2116-4505-b9ff-f6dc6c1c482e,C0018939,C0040034,exhibits ,Hematological Disease,Thrombocytopenia,2,X,[dsyn],[dsyn],C15.378,C15.378.140.855
1f6606ca-6604-43cc-a059-905abbeaf614,C0206750,C0010200,was initially characterized by ,Coronavirus Infections,Coughing,11,X,[dsyn],[sosy],C02.782.600.550.200,C08.618.248;C23.888.852.293
e2700867-8058-451f-9f6e-88920de7cbb4,C0206750,C0013404,was initially characterized by ,Coronavirus Infections,Dyspnea,10,X,[dsyn],[sosy],C02.782.600.550.200,C08.618.326;C23.888.852.371
06ec30a1-9503-49db-8d80-4fdad36dc802,C0012634,C0370003,is in ,Disease,Specimen,1,X,[dsyn],[sbst],C23.550.288,
86e61b35-e62e-4203-aa24-2146ce18444e,C3274800,C0012634,was observed higher in patients with co morbid ,Disease Presentation,Disease,8,X,[clna],[dsyn],,C23.550.288
86e61b35-e62e-4203-aa24-2146ce18444e,C3274800,C0012634,characteristics of ,Disease Presentation,Disease,1,X,[clna],[dsyn],,C23.550.288
29ae40c1-c56c-454e-b310-d3bd4baac328,HRCT,C0206750,is in ,HRCT,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
f0fa0e82-609f-4ee9-9dcc-15a5903506ee,C0549646,C0206750,is in ,chest disorders,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
29aef13a-8c9f-4b1b-96bf-924eb892010c,C0024312,C0596448,raised D ,Lymphopenia,dimer,3,X,[dsyn],[chvs],C15.378.553.546.605;C20.673.627,
cdde8a1a-7f3b-4d34-b2f9-dda7f74819d9,C2347218,C0206419,be alternative in ,Bronchial Artery Infusion Procedure,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
934e4c08-2a78-4214-994b-073c86c9aee9,C0206419,C0304229,is with superadded benefits of high ,Genus: Coronavirus,Experimental drug,1,X,[virs],[phsu],B04.820.504.540.150,
751110a5-d62e-42eb-ba5d-44447acc1bc9,C0282686,C0206419,different types of ,Respiratory System Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.796,B04.820.504.540.150
ad3cbdc5-669a-4dc1-a6c2-f31a72ecda17,C0206419,C1514593,know little about ,Genus: Coronavirus,Psychological Impact,1,X,[virs],[clna],B04.820.504.540.150,
888caa0c-317b-4940-8708-8b5e3faaab52,C0877203,C0206419,indicates potential timing of increase in incidence of disease in ,Viral Respiratory Tract Infection,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
9bba38bf-f7ff-477d-a5e0-4aa8f3395588,C4283882,C0206419,indicates potential timing of increase in incidence of disease in ,NR1I2 wt Allele,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
ef9ee9e3-8bd3-499f-9747-106e0c42845e,C0242781,C0012655,combining age-stratified contact frequencies with age-dependent ,disease transmission,Disease susceptibility,1,X,[patf],[clna],N06.850.310,C23.550.291.687;G07.100.250
78d52380-40c4-4afd-b784-c9e3f2f34f47,C4553629,C0242781,estimate age-stratified ,MATRix Regimen,disease transmission,1,X,[topp],[patf],,N06.850.310
799cf159-5dcf-4195-ab05-6cf8240bc51e,C0037386,C1705178,was followed in ,snow - weather,Order (action),4,X,[npop],[acty],G16.500.175.867;G16.500.275.063.725.480;G16.500.750.775.480;N06.230.300.100.725.480,
bd014dc8-84d3-4471-aea6-5645ef4f6e98,C1706202,C1705178,was followed in ,Search - action,Order (action),4,X,[acty],[acty],,
ca864caa-5cf6-4e45-aa1e-c28be4ea381e,C0039195,C1175175,is in ,Cytotoxic T-Lymphocytes,Severe Acute Respiratory Syndrome,4,X,[cell],[dsyn],A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200,C02.782.600.550.200.750;C08.730.730
b7af086e-45bc-4cb3-91b5-f1a29c93d811,C1175175,C2699153,can can partially explained by direct ,Severe Acute Respiratory Syndrome,Cell Invasion,4,X,[dsyn],[patf],C02.782.600.550.200.750;C08.730.730,
cbeef4cf-e3f8-4478-bd2e-379866e55fc5,C1175175,C0039194,can can partially explained by direct ,Severe Acute Respiratory Syndrome,T-Lymphocyte,3,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
f381fb17-aa06-4ed4-ae56-bd97ec68123a,C1175175,C1175743,can can partially explained by direct ,Severe Acute Respiratory Syndrome,SARS coronavirus,4,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
f381fb17-aa06-4ed4-ae56-bd97ec68123a,C1175175,C1175743,diagnostic performance of ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
f381fb17-aa06-4ed4-ae56-bd97ec68123a,C1175175,C1175743,is third zoonotic ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
f381fb17-aa06-4ed4-ae56-bd97ec68123a,C1175175,C1175743,caused by ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
f381fb17-aa06-4ed4-ae56-bd97ec68123a,C1175175,C1175743,in injury is specific presentations of cardiovascular involvement by ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
b18e2f81-5ee4-4434-8065-a1e230e01a1f,C0005778,C0206419,is in ,Blood coagulation,Genus: Coronavirus,1,X,[ortf],[virs],G09.188.390.150,B04.820.504.540.150
51d4835b-f832-4b49-be6c-62db1446c1e1,C0042071,C0005778,Dysregulation of were proposed mechanisms of ,Urokinase,Blood coagulation,4,X,[aapp/enzy/phsu],[ortf],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,G09.188.390.150
bbda42f8-6d5a-4e3b-8263-eb2a127220ff,C1704259,C0005778,Dysregulation of were proposed mechanisms of ,Biochemical Pathway,Blood coagulation,4,X,[moft],[ortf],,G09.188.390.150
0159bd6e-81a5-4fb3-905e-9f871c3c794c,C0042071,C0206419,Dysregulation of were proposed mechanisms of ,Urokinase,Genus: Coronavirus,1,X,[aapp/enzy/phsu],[virs],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,B04.820.504.540.150
8407e737-9279-4868-876c-1f3b5d0d428e,C0013404,C1457887,were most common clinical ,Dyspnea,Symptoms,26,X,[sosy],[sosy],C08.618.326;C23.888.852.371,
9505c678-3dbf-4ab6-acfe-78f3d7375a6b,C0015967,C1457887,were major ,Fever,Symptoms,2,X,[sosy],[sosy],C23.888.119.344,
9505c678-3dbf-4ab6-acfe-78f3d7375a6b,C0015967,C1457887,were most common clinical ,Fever,Symptoms,15,X,[sosy],[sosy],C23.888.119.344,
9505c678-3dbf-4ab6-acfe-78f3d7375a6b,C0015967,C1457887,were most prevalent ,Fever,Symptoms,6,X,[sosy],[sosy],C23.888.119.344,
9505c678-3dbf-4ab6-acfe-78f3d7375a6b,C0015967,C1457887,Regarding ,Fever,Symptoms,1,X,[sosy],[sosy],C23.888.119.344,
9505c678-3dbf-4ab6-acfe-78f3d7375a6b,C0015967,C1457887,was most frequent ,Fever,Symptoms,1,X,[sosy],[sosy],C23.888.119.344,
d3116dc9-c6b5-4a58-b9ef-8712d3e887d6,C0010200,C1457887,were major ,Coughing,Symptoms,2,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
d3116dc9-c6b5-4a58-b9ef-8712d3e887d6,C0010200,C1457887,were most common clinical ,Coughing,Symptoms,13,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
d3116dc9-c6b5-4a58-b9ef-8712d3e887d6,C0010200,C1457887,were most prevalent ,Coughing,Symptoms,3,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
34ea771e-d9e8-4c1d-9ba7-3ba3fa2c1e09,C0031350,C1457887,were major ,Pharyngitis,Symptoms,2,X,[dsyn],[sosy],C07.550.781;C08.730.561;C09.775.649,
cdd1b849-2726-4a8b-a75e-07fb43caa279,C0233401,C0206419,rates of were During ,Psychiatric symptom,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
cdd1b849-2726-4a8b-a75e-07fb43caa279,C0233401,C0206419,been common during ,Psychiatric symptom,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
43a5da8e-e8be-4335-b9cf-7abc6578d170,C0233401,C0011570,rates of were During ,Psychiatric symptom,Mental Depression,6,X,[sosy],[mobd],,F01.145.126.350
b3e03fce-8a44-480a-a21d-b4c7ac607ba1,C0233401,C0917801,rates of were During ,Psychiatric symptom,Sleeplessness,6,X,[sosy],[sosy],,C10.886.425.800.800;F03.870.400.800.800
ab0d5d35-f99d-4402-bde6-e59d38926ea8,C0233401,C0009450,people with suspected ,Psychiatric symptom,Communicable Diseases,2,X,[sosy],[dsyn],,C01.539.221
c00c31a5-27e1-45f8-b5bd-2dc57de4bbcd,C1457887,C0009450,people with suspected ,Symptoms,Communicable Diseases,2,X,[sosy],[dsyn],,C01.539.221
c00c31a5-27e1-45f8-b5bd-2dc57de4bbcd,C1457887,C0009450,prognostic of ,Symptoms,Communicable Diseases,1,X,[sosy],[dsyn],,C01.539.221
c00c31a5-27e1-45f8-b5bd-2dc57de4bbcd,C1457887,C0009450,were present mostly in early stages of ,Symptoms,Communicable Diseases,3,X,[sosy],[dsyn],,C01.539.221
c00c31a5-27e1-45f8-b5bd-2dc57de4bbcd,C1457887,C0009450,arise during course of ,Symptoms,Communicable Diseases,1,X,[sosy],[dsyn],,C01.539.221
1a4741c2-5e4b-4add-95f5-5dfe7dadb1cc,on-site,C1319405,is with Department of ,on-site,Clinical microbiology,2,X,????,[bmod],????,
d03b5afd-4cdf-4f8a-b96d-7a7f0465de48,C0003451,C0042774,inhibit ,Antiviral Agents,Virus Replication,1,X,[phsu],[celf],D27.505.954.122.388,G06.920.925
d03b5afd-4cdf-4f8a-b96d-7a7f0465de48,C0003451,C0042774,could could related to ,Antiviral Agents,Virus Replication,2,X,[phsu],[celf],D27.505.954.122.388,G06.920.925
6dabb8cd-2172-4826-9f1b-e000620e7409,C0013227,C0003451,were ,Pharmaceutical Preparations,Antiviral Agents,8,X,[phsu],[phsu],D26,D27.505.954.122.388
e958578f-5d52-4077-bdcb-16d100b2a97c,C0567416,C0079189,mitigated inflammatory ,Molecule,cytokine,1,X,[sbst],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
9fa04cb9-f425-4521-97cd-3d8c6dfa2303,C0567416,C0118522,mitigated inflammatory ,Molecule,GA-Binding Protein Transcription Factor,1,X,[sbst],[aapp/bacs],,D12.776.260.615.249;D12.776.930.618.249
5f3312ef-baab-498b-a9d9-f8f57bcac2ba,C0118522,C0032310,are useful in management of ,GA-Binding Protein Transcription Factor,Pneumonia Viral,1,X,[aapp/bacs],[dsyn],D12.776.260.615.249;D12.776.930.618.249,C02.705;C08.381.677.807;C08.730.610.763
2c578b8b-5d8c-41e7-94fe-ff97853888ed,C0242781,HK,importation in HK,disease transmission,HK,3,X,[patf],????,N06.850.310,????
902f8124-155a-4e74-8d64-eaf69d3c5bb5,C0206419,HK,importation in HK,Genus: Coronavirus,HK,1,X,[virs],????,B04.820.504.540.150,????
528cb62e-f90b-4965-8528-7b042cd89c1e,C0010340,C0206419,is with ,Critical Illness,Genus: Coronavirus,5,X,[dsyn],[virs],C23.550.291.625,B04.820.504.540.150
79a64912-b62f-4df1-9626-bce1089615ef,C0012634,C0042776,is caused by very small ,Disease,Virus,7,X,[dsyn],[virs],C23.550.288,B04
eb7448af-1259-41c5-8bce-59004d9e7137,C0009450,C0042776,caused by new ,Communicable Diseases,Virus,2,X,[dsyn],[virs],C01.539.221,B04
b39eeb6b-ac64-4ad0-9664-0952991a8b79,C0042776,C0035204,causes ,Virus,Respiration Disorders,2,X,[virs],[dsyn],B04,C08.618
2bacded6-94a6-4801-8052-067d821477e7,C0042776,C0010200,causes Respiration Disorders with,Virus,Coughing,5,X,[virs],[sosy],B04,C08.618.248;C23.888.852.293
2bacded6-94a6-4801-8052-067d821477e7,C0042776,C0010200,is spreading through ,Virus,Coughing,1,X,[virs],[sosy],B04,C08.618.248;C23.888.852.293
0ee22e44-0718-4930-bf5e-f410f02194c1,COVID-19,C0206750,of propagation is ,COVID-19,Coronavirus Infections,10,X,[virs],[dsyn],C000657245,C02.782.600.550.200
7ee08724-a52f-405d-9b2b-f4efaefc291b,C0010076,COVID-19,reaches levels after 4weeks ,Coronaviridae,COVID-19,1,X,[virs],[virs],B04.820.504.540,C000657245
7ee08724-a52f-405d-9b2b-f4efaefc291b,C0010076,COVID-19,was named ,Coronaviridae,COVID-19,2,X,[virs],[virs],B04.820.504.540,C000657245
e099c7da-c844-41e4-92ae-43144c089281,C0010076,4weeks,reaches levels after 4weeks ,Coronaviridae,4weeks,1,X,[virs],????,B04.820.504.540,????
8030da89-c59d-49e4-ac1c-248d006abb9e,COVID-19,C0037090,main manifestations of are ,COVID-19,Signs and Symptoms Respiratory,1,X,[virs],[sosy],C000657245,C23.888.852
8030da89-c59d-49e4-ac1c-248d006abb9e,COVID-19,C0037090,is defined by its ,COVID-19,Signs and Symptoms Respiratory,1,X,[virs],[sosy],C000657245,C23.888.852
02418f7d-505c-4533-9e96-b5f7e4b185d3,C0206750,C0948008,is with ,Coronavirus Infections,Ischemic stroke,11,X,[dsyn],[dsyn],C02.782.600.550.200,
7124d2bb-0ef2-4cca-9531-a1fd4fc86798,C0012634,C0948008,is associated with higher risk of ,Disease,Ischemic stroke,2,X,[dsyn],[dsyn],C23.550.288,
052e445e-460e-49c2-aa02-db7626d25a5a,C0206750,C0729531,is associated would expected from ,Coronavirus Infections,Viral respiratory infection,8,X,[dsyn],[dsyn],C02.782.600.550.200,
9c0f194d-e91d-4422-b5b7-5f0d553ed18b,C0012634,C0729531,is associated would expected from ,Disease,Viral respiratory infection,4,X,[dsyn],[dsyn],C23.550.288,
48128aad-f575-4500-b659-1374a7ad5ed2,C1707455,C2062441,included adults with emergency department visits with ,Comparison,Influenza A,5,X,[acty],[dsyn],,
64d3cdd5-de94-4190-a9ff-6bcffde20274,C1175743,C0027442,is in ,SARS coronavirus,Nasopharynx,6,X,[virs],[bpoc],B04.820.504.540.150.113.937,A04.623.557;A14.724.557
d8f6a26f-5d49-489a-9161-e21fa6018da6,C0948008,C0021403,higher rate with cohort of patients with ,Ischemic stroke,Influenza virus vaccine,4,X,[dsyn],[imft/phsu],,D20.215.894.899.302
2a8aacde-1ec8-46e5-92bd-6f441fd93f21,C0948008,C0038454,higher rate of ,Ischemic stroke,Cerebrovascular accident,5,X,[dsyn],[dsyn],,C10.228.140.300.775;C14.907.253.855
c6ffaa37-1ca3-4be8-8c73-f614773d0c48,C0948008,C1707455,higher rate of ,Ischemic stroke,Comparison,5,X,[dsyn],[acty],,
e92e569b-7171-45dd-a910-ff9b0c06c056,C0011121,C0026051,is with ,Decontamination,microwave electromagnetic radiation,2,X,[topp],[npop],N06.850.780.325,G01.358.500.505.810.500;G01.750.250.810.500;G01.750.770.721.500
8abccfa5-6dd4-4ea7-89b7-dd38f4598390,C0011121,C0018837,is with ,Decontamination,Heat (physical force),2,X,[topp],[npop],N06.850.780.325,
d3de5ab6-65ab-4bd8-b583-33b77085c269,C3811133,C0011121,be options for successful ,Ethylene Oxide Sterilization,Decontamination,3,X,[acty],[topp],,N06.850.780.325
9d0313a8-580b-4479-b34a-3ae1085ebb10,C0038225,C0011121,appear viable options for successful ,Steam,Decontamination,2,X,[inch],[topp],D01.045.250.875.800;D01.248.497.158.459.650.800;D01.650.550.925.800;G16.500.887;N06.230.650,N06.850.780.325
427a9007-a835-4c34-a723-8177ae64f89d,C0041625,C0011121,appear viable options for ,Ultraviolet Rays,Decontamination,2,X,[npop],[topp],G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600,N06.850.780.325
6796e000-aa51-4d79-9900-074c99903363,C0018837,C0011121,appear viable options for successful ,Heat (physical force),Decontamination,2,X,[npop],[topp],,N06.850.780.325
33454d0b-8042-47fe-9f2b-66b275e2cb33,COVID-19,C1160716,owing to nature ,COVID-19,viral transmission,1,X,[virs],[celf],C000657245,
b71dd91d-830c-4280-bdec-e32b102f6c6f,COVID-19,C0458578,owing to nature possible airborne transmission ,COVID-19,Upper respiratory tract,2,X,[virs],[bpoc],C000657245,
1d7bfe8b-7d10-4917-abcc-de7b6ffc61e2,C1160716,C0458578,is in ,viral transmission,Upper respiratory tract,2,X,[celf],[bpoc],,
4dd48a0a-a0aa-40fa-8235-772650b13842,C0032105,C0017082,resembled that of monosialodihexosyl ,Plasma,Gangliosides,1,X,[bdsu],[orch/phsu],A12.207.152.693;A12.207.270.695;A15.145.693,D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475
90b5fbdf-21b2-41fc-9067-4389647a5443,C0032105,C0037906,resembled that of monosialodihexosyl ,Plasma,Sphingomyelins,1,X,[bdsu],[bacs/orch],A12.207.152.693;A12.207.270.695;A15.145.693,D09.400.410.420.525.870;D10.390.470.675.870;D10.570.755.893;D10.570.877.360.612.870
d8869ed2-217e-4804-bbfd-819bf1ceaa4a,C0017082,C0037906,is with enhanced levels of ,Gangliosides,Sphingomyelins,1,X,[orch/phsu],[bacs/orch],D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475,D09.400.410.420.525.870;D10.390.470.675.870;D10.570.755.893;D10.570.877.360.612.870
ef182115-5059-4dc6-982e-21532dfff625,C2350332,COVID-19,should ,Exosomes,COVID-19,4,X,[celc],[virs],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,C000657245
ca61c186-47b8-4189-b31d-a509261e61ba,C2350332,C0030660,may partake in ,Exosomes,Pathologic Processes,1,X,[celc],[patf],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,C23.550
1e576002-3a13-474b-bc47-fcec50b6f44d,C2350332,C0699748,may partake in ,Exosomes,Pathogenesis,1,X,[celc],[patf],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
f87fb016-bc5b-4448-97d5-dd838d4444cf,C2350332,C0032105,presents ,Exosomes,Plasma,1,X,[celc],[bdsu],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A12.207.152.693;A12.207.270.695;A15.145.693
0e7c8492-24e5-4a62-9a31-2cf56f470150,C1175743,C1550100,is in matched ,SARS coronavirus,Specimen Type - Serum,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
29a01c7f-ac25-4c1c-8aec-e6c5ee8775b6,C1175743,C0521839,is in matched ,SARS coronavirus,Influenza-like illness,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
50a366d6-6f6a-4893-882f-6acd9a9b5178,C1175743,C0033727,is with interval of at least ,SARS coronavirus,Protons,2,X,[virs],[elii],B04.820.504.540.150.113.937,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
8a786a95-d3ed-4b15-95ec-4b5608f46604,C0319924,C1265415,is ,Aspergillus versicolor,Endophytes,1,X,[fngs],[fngs],,B05.237
195e4aa4-bd19-431d-bd7c-c060a8f1c4e3,CMS,C0013227,suspend utilization review requirements related to ,CMS,Pharmaceutical Preparations,4,X,????,[phsu],????,D26
196f3ccf-4383-4c1a-a9e8-f127dcd8f92a,CMS,C1999230,suspend utilization review requirements related to ,CMS,Providing (action),4,X,????,[acty],????,
4c7d5c5b-18d8-45bf-b7be-2e032031278c,C2948600,C0080078,quantify effect of ,Aim,Range of Motion Articular,3,X,[inch/phsu],[clna],,E01.370.600.700;G11.427.760
94f7d9e6-4229-48e7-82bd-1c7d269e8230,C2745965,C0319157,AS virus as for possible future returns of,Emergencies [Disease/Finding],AS virus,8,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,
ee681684-a817-4d73-a66c-70ac676d7c03,C0079189,C0021753, includes ,cytokine,Interleukin-1 beta,7,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600
7e8a54e1-dc54-48f1-a36e-a55726209ec0,C1721019,C0021753,can determine release of pro ,Virus Attachment,Interleukin-1 beta,2,X,[biof],[aapp/imft],G06.920.868,D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600
821374ad-df4f-4d67-b3d0-2956cfea730c,C1721019,C1879547,can determine release with successive ,Virus Attachment,Activation action,5,X,[biof],[acty],G06.920.868,
52097ec8-6e49-4039-a11a-8bf01a8264af,C1721019,C0032285,can determine release with successive ,Virus Attachment,Pneumonia,5,X,[biof],[dsyn],G06.920.868,C08.381.677;C08.730.610
999b91bf-335f-4180-ba2b-926872385822,C1175175,C0206750,was common during ,Severe Acute Respiratory Syndrome,Coronavirus Infections,14,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C02.782.600.550.200
71ca8d0f-cbbe-44d4-9b98-af4db410e7b2,CoV-2,C0206750,due to illness is ,CoV-2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
72c9480a-cde1-4d1f-bf5f-113caaecfb14,C0003451,C0178784,limiting viral-induced ,Antiviral Agents,Organ,1,X,[phsu],[bpoc],D27.505.954.122.388,
5c1bb022-a4da-444d-9756-ab405c1ee0c7,48h,C0040300,measured histopathological alterations in kidney ,48h,Body tissue,1,X,????,[tisu],????,A10
eb7fd2ea-0e45-4770-9eed-7c028d4676ae,C0206750,C0235031,exhibit ,Coronavirus Infections,Neurologic Symptoms,1,X,[dsyn],[sosy],C02.782.600.550.200,C10.597;C23.888.592
eb7fd2ea-0e45-4770-9eed-7c028d4676ae,C0206750,C0235031,patients with ,Coronavirus Infections,Neurologic Symptoms,1,X,[dsyn],[sosy],C02.782.600.550.200,C10.597;C23.888.592
02fb2feb-75fc-443e-bcca-28043c3ac0f4,C0037090,C0206750,is in critical ,Signs and Symptoms Respiratory,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.852,C02.782.600.550.200
02fb2feb-75fc-443e-bcca-28043c3ac0f4,C0037090,C0206750,are typically found during ,Signs and Symptoms Respiratory,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.852,C02.782.600.550.200
614a9aee-43eb-462a-92bf-2b8a97939ceb,C0206750,C1145670,is with ,Coronavirus Infections,Respiratory Failure,5,X,[dsyn],[dsyn],C02.782.600.550.200,C08.618.846
6eabacc6-a643-462f-81de-7cec0075c3e1,C1706202,C1273412,evaluate efficacy of ,Search - action,Chinese herbal medicine,2,X,[acty],[topp],,
86083010-398c-4863-b39f-1fa69fcee48a,C1706202,C0206750,yielded potential ,Search - action,Coronavirus Infections,12,X,[acty],[dsyn],,C02.782.600.550.200
b3457ea5-57d1-4a98-9cca-d641f4cada6f,C1273412,C0206750,could could used as potential candidates for ,Chinese herbal medicine,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
61317e35-8411-4713-91c4-eeb390f26fd8,C0206750,C3873497,is ,Coronavirus Infections,Severe acute respiratory infection,1,X,[dsyn],[dsyn],C02.782.600.550.200,
ec701b99-8d9b-4476-a8df-0d6bcbb3748e,C0204027,C0032285,minimise ,Short wave diathermy,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
98e00b45-29c4-49a7-a139-fcaf26b1603a,C0204027,C0012634,shorten Duration to positive-to-negative conversion of,Short wave diathermy,Disease,2,X,[topp],[dsyn],,C23.550.288
811195a2-51a2-48e1-b6f5-a8f4b4a34003,C0204027,C0028606,shorten Duration to positive-to-negative conversion of,Short wave diathermy,Nucleic Acids,2,X,[topp],[bacs/nnon],,D13.444
ac3bb5a1-cee2-42da-b1ad-6df857c9fbfd,C0204027,C2926735,shorten ,Short wave diathermy,Duration,2,X,[topp],[orch/phsu],,
47c68e3e-b2e5-461a-9ea9-e7fef628a2ad,C0450254,C0041296, includes ,Pathogenic organism,Tuberculosis,2,X,[orgm],[dsyn],,C01.252.410.040.552.846
85973309-6bbd-491f-9faa-bc1a12cc40ee,C0036974,C0005779,have ,Shock,Blood Coagulation Disorders,2,X,[patf],[dsyn],C23.550.835,C15.378.100
4fb1c04c-1300-49d1-b70c-4ac949ff881b,C0028606,C1457887,Recovery - action from,Nucleic Acids,Symptoms,1,X,[bacs/nnon],[sosy],D13.444,
c4151661-c7c4-43c6-a20a-ecc0b755813e,C0871208,C1457887,Recovery - action from,Rating (action),Symptoms,1,X,[acty],[sosy],,
e01c95af-2489-40f5-9a56-82997759570f,C0206750,C1706374,continues As of ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
e01c95af-2489-40f5-9a56-82997759570f,C0206750,C1706374,were registered As of ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,4,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
e01c95af-2489-40f5-9a56-82997759570f,C0206750,C1706374,has spread worldwide over 80 000 deaths reported by end of ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
e01c95af-2489-40f5-9a56-82997759570f,C0206750,C1706374,has caused IMPACT gene after especially declaration of state of,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
e01c95af-2489-40f5-9a56-82997759570f,C0206750,C1706374,will will enrolled in trial from 6th 31st ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
e01c95af-2489-40f5-9a56-82997759570f,C0206750,C1706374,occurred as of 30 ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
6de2f272-804c-4055-9ad0-e83c7fcd2248,C3714514,C1416797,is With longer ,Infection,STMN1 gene,1,X,[patf],[gngm],C01.539,
9791e943-01f4-4f5f-b11e-ea78f553c710,C1706701,C1035167,Search - action After registration on,Acquisition (action),Prospero,2,X,[acty],[plnt],,
cd948378-da07-46c7-952c-360f4acee42c,C0004933,C0042024,is in ,Behavior Therapy,Urinary Incontinence,2,X,[topp],[patf],F04.754.137,C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
211a2a0c-80b1-4439-8575-da25ce17d0e8,C0932441,C0042024,is in ,Muscle of pelvic diaphragm,Urinary Incontinence,2,X,[bpoc],[patf],,C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
3b4e22d0-6387-429b-99f8-d3820d29048c,C1707391,C0042024,is with PCa ,Choose (action),Urinary Incontinence,2,X,[acty],[patf],,C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
ab48492a-d10f-48b1-b549-3a8183ba8984,C1707391,C0877015,is with PCa ,Choose (action),Pelvic Organ Prolapse,2,X,[acty],[dsyn],,C23.300.842.624
10684504-2fbc-4113-8e07-035a26a4cb16,C1707391,C0042018,is with PCa ,Choose (action),Urinary Calculi,2,X,[acty],[bdsu],,C12.777.967.500;C13.351.968.967.500;C23.300.175.850
d0f97ecc-f850-4ece-b6b7-6b995b0bc6cb,C1707391,C0042029,is with PCa ,Choose (action),Urinary tract infection,2,X,[acty],[dsyn],,C01.539.895;C12.777.892;C13.351.968.892
79526439-0d87-4e25-836c-f96d505bcd60,C0042075,C0376358, includes ,Urologic Diseases,Malignant neoplasm of prostate,4,X,[dsyn],[neop],C12.777;C13.351.968,
e8346517-7088-45ec-ba88-00ff994a03f1,C1707391,C0042075,is with several common clinical ,Choose (action),Urologic Diseases,2,X,[acty],[dsyn],,C12.777;C13.351.968
5d11cde7-390e-4f94-a20a-517622cc6ece,C1707391,C0376358,is with several common clinical ,Choose (action),Malignant neoplasm of prostate,2,X,[acty],[neop],,
3581978b-e669-4fcb-9e34-2c9da25e7ed5,C0605411,C0010200,is with ,austin,Coughing,2,X,[orch],[sosy],x.x.x.x,C08.618.248;C23.888.852.293
4d1e99f1-6284-40ad-b6ba-6556748dc488,UTHA,C1856053,conducted contact during ,UTHA,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,????,[dsyn],????,x.x.x.x
67db4567-ba11-439f-99a3-2ced5529d6e9,C1175743,U.S.,is in outpatient settings at U.S. ,SARS coronavirus,U.S.,2,X,[virs],????,B04.820.504.540.150.113.937,????
983666f6-b9cf-4e0d-a7cb-b1639e9adf88,C0008679,C2348077,experienced on ,Chronic disease,Date Fruit,2,X,[dsyn],[food],C23.550.291.500,B01.650.940.800.575.912.250.093.615
73ece165-d6aa-4258-9d58-7195bd0da101,C0163275,C0018939,were In ,Fibrin split products,Hematological Disease,2,X,[aapp/bacs],[dsyn],D12.776.124.270.300;D12.776.811.300.290,C15.378
bda6a8fe-a126-4819-966d-9dc1f3bf8c86,C1175175,C0040132,can affect ,Severe Acute Respiratory Syndrome,Thyroid Gland,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A06.300.900
76ce79fb-eae7-4253-bb32-388fe0878f54,C1175175,C0030518,can affect ,Severe Acute Respiratory Syndrome,Parathyroid gland,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A06.300.560
25761146-8d80-4f2c-b37a-2d5bfb67ae07,C1175175,C0016017,can affect ,Severe Acute Respiratory Syndrome,Fibrinolysis,1,X,[dsyn],[phsf],C02.782.600.550.200.750;C08.730.730,G09.188.390.150.390
7a766905-6e75-4784-a0e0-485f0dd60ca0,C1175175,C0596204,can affect ,Severe Acute Respiratory Syndrome,bone metabolism,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,
b35c22cb-d970-4c31-9248-e2e7dcd79476,C1175175,C0023884,can affect ,Severe Acute Respiratory Syndrome,Liver,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A03.620
c90df298-5c04-45e7-9e16-43f0659b9c09,C1175175,C0017420,can affect ,Severe Acute Respiratory Syndrome,Genitalia,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A05.360
6c83a427-2048-422d-8a3f-19c7f490ccf3,C1175175,C0019116,can affect ,Severe Acute Respiratory Syndrome,Hemostatic function,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,G09.188.390
6c83a427-2048-422d-8a3f-19c7f490ccf3,C1175175,C0019116,triggers ,Severe Acute Respiratory Syndrome,Hemostatic function,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,G09.188.390
a70bdaab-3d4a-46fc-a326-91b9cb3db1f5,C1175175,C0005778,can affect ,Severe Acute Respiratory Syndrome,Blood coagulation,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,G09.188.390.150
5dda5387-f5e1-4580-8f97-485380223abe,C0032285,C0035222,may rapidly progress to ,Pneumonia,Respiratory Distress Syndrome Adult,7,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C08.381.840;C08.618.840
20c16dc9-dbef-4ace-88a4-f7e2c28233e6,C0071216,C0040861,could serve as quick ,Urokinase Plasminogen Activator Receptor,Triage,6,X,[aapp/imft/rcpt],[topp],D12.776.395.550.448.813;D12.776.543.484.500.813;D12.776.543.550.418.813;D12.776.543.750.815,N02.421.297.900
ceb8d4cb-efa0-449a-a60d-cef421ac6a84,C0206750,ICMR,maintained by ICMR,Coronavirus Infections,ICMR,2,X,[dsyn],????,C02.782.600.550.200,????
0eb2b752-0978-411e-8532-e891df71ca24,C0023895,ICMR,maintained by ICMR,Liver diseases,ICMR,2,X,[dsyn],????,C06.552,????
0fbb199e-5c00-4cf1-8bf4-ea86b041d5e6,C0678790,C4554533,existed between frequency of exposure for ,dose-response relationship,Trend:Type:Point in time:^Patient:Nominal,2,X,[biof],[clna],,
f1d4ba7d-3404-47f5-b9ba-98aefa89105c,C0021966,C0871208,predict range of contact ,Iodides,Rating (action),1,X,[inch],[acty],D01.248.497.158.490;D01.475.410,
be43b476-6535-4c59-941d-06340a812952,C0021966,C0012634,predict number of ,Iodides,Disease,1,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C23.550.288
51b4485d-d21c-455f-ad85-cfc7cb6f12e1,C2986522,C0376358,is ,Laparoscopic Prostatectomy,Malignant neoplasm of prostate,9,X,[topp],[neop],,
149c552f-5ae8-465a-bc77-8fd4d5e0ced3,C1175743,C1145670,may cause severe ,SARS coronavirus,Respiratory Failure,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.618.846
877cb106-7154-4334-a5c8-29c080881632,C1175743,C0999626,is related to ,SARS coronavirus,Manidae,1,X,[virs],[mamm],B04.820.504.540.150.113.937,
b6cd64d1-1ea8-4cc3-915a-cad6c0f2782b,C1622204,C1512488,is with ,envelope,Homologous Protein,1,X,[celc],[aapp],,
7cc600e5-54b0-40d3-9f17-abf86dc854c2,C1142652,C1512488,is with ,NR4A2 protein human,Homologous Protein,1,X,[aapp/bacs],[aapp],x.x.x.x,
b8e26c12-dfea-4af1-a38f-874848375e1b,C1707455,C1175743,timing in relation to timing of ,Comparison,SARS coronavirus,7,X,[acty],[virs],,B04.820.504.540.150.113.937
0534e49a-ac91-40a0-8fce-9a1b0917bb6d,C0630906,COVID-19,was in ,vinyltriethoxysilane,COVID-19,4,X,[orch],[virs],x.x.x.x,C000657245
b58b409c-e47c-484d-aec5-6c4290c24742,C0630906,C0032285,overall rate of was ,vinyltriethoxysilane,Pneumonia,1,X,[orch],[dsyn],x.x.x.x,C08.381.677;C08.730.610
b58b409c-e47c-484d-aec5-6c4290c24742,C0630906,C0032285,incidence of was ,vinyltriethoxysilane,Pneumonia,1,X,[orch],[dsyn],x.x.x.x,C08.381.677;C08.730.610
8501c5ab-2b28-4b0c-b835-02a407972661,COVID-19,C0398623,was associated with ,COVID-19,Thrombophilia,1,X,[virs],[dsyn],C000657245,C15.378.925
c89ff7f7-6514-4633-881f-ff324678f594,C0032285,C0398623,was associated with ,Pneumonia,Thrombophilia,1,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C15.378.925
c07ecc6a-4a55-488e-9d54-59f57495bcf9,C0038454,C0398623,frequently had events in context of pro-inflammatory ,Cerebrovascular accident,Thrombophilia,3,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C15.378.925
2fb88654-3b42-46d5-8481-486e3ea972b7,C0038454,C0060323,frequently had events in context of pro-inflammatory ,Cerebrovascular accident,Fibrin fragment D,3,X,[dsyn],[aapp/bacs],C10.228.140.300.775;C14.907.253.855,x.x.x.x
d25b720a-abcd-4d98-a366-6ba973e70b0a,C0038454,C0015879,frequently had events in context of pro-inflammatory ,Cerebrovascular accident,Ferritin,3,X,[dsyn],[aapp/bacs/phsu],C10.228.140.300.775;C14.907.253.855,D12.776.157.427.249;D12.776.556.579.249;x.x.x.x
09a9f4a5-cecd-4b30-a6fe-e2a880983246,remdesivir,C0441655,is broad spectrum antiviral with in ,remdesivir,Activities,2,X,[clnd],[acty],,
09a9f4a5-cecd-4b30-a6fe-e2a880983246,remdesivir,C0441655,demonstrated potent ,remdesivir,Activities,1,X,[clnd],[acty],,
5b60ae9a-022a-4c88-b50c-9abaf5ca779f,C0026766,COVID-19,are spectrum of ,Multiple Organ Failure,COVID-19,2,X,[patf],[virs],C23.550.835.525,C000657245
2c0b3209-add1-43fb-9e0d-8827d9c4abb0,C0032285,COVID-19,is in ,Pneumonia,COVID-19,4,X,[dsyn],[virs],C08.381.677;C08.730.610,C000657245
c49e3365-0c47-4c82-8a92-e05aabd883fc,C0850149,COVID-19,had ,Dry cough,COVID-19,1,X,[sosy],[virs],,C000657245
7a7a119e-ae86-43ce-8acf-5177035a0118,C1254373,C1175743,is ,etiologic agent,SARS coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150.113.937
37c25108-afdc-4ce7-adb5-87c7265ec8df,C0301872,C0242656,are implicated in ,Immune response,Disease Progression,4,X,[ortf],[patf],,C23.550.291.656
37c25108-afdc-4ce7-adb5-87c7265ec8df,C0301872,C0242656,prevent its ,Immune response,Disease Progression,1,X,[ortf],[patf],,C23.550.291.656
37c25108-afdc-4ce7-adb5-87c7265ec8df,C0301872,C0242656,contribute to ,Immune response,Disease Progression,2,X,[ortf],[patf],,C23.550.291.656
b9628870-42e0-4dbd-865d-1d91a45fbfb0,C1301856,C1155266,center on loss of regulation between protective ,All critical points,inflammatory response,4,X,[clna],[patf],,
d06291f6-be45-4998-8d92-5adf8eac81f2,C0960880,C0024109,is in ,angiotensin converting enzyme 2,Lung,1,X,[aapp/enzy],[bpoc],x.x.x.x,A04.411
6c1c7cce-5ac5-4f24-ba58-8eb8d16a462a,C1413931,C1422064,may stimulate ,ACE gene,ACE2 gene,1,X,[gngm],[gngm],,
2790bc73-4dfb-47b5-b287-6b761ff1fc3a,C0815017,C1422064,may stimulate ,Angiotensin Receptor Antagonists,ACE2 gene,1,X,[phsu],[gngm],D27.505.519.162,
618e058e-7372-43e3-ad09-409f8454dd59,C0021440,C1422064,increase numbers of ,Intravenous infusion procedures,ACE2 gene,1,X,[topp],[gngm],E02.319.267.082.500;E02.319.267.510.590,
e77aefef-5f36-4645-a86c-9eeb9629af01,C0021440,C0597357,increase numbers of ,Intravenous infusion procedures,receptor,1,X,[topp],[aapp/rcpt],E02.319.267.082.500;E02.319.267.510.590,
0bb563da-48c5-48da-83bc-88708d7c4260,C0021440,C0003064,is in ,Intravenous infusion procedures,Animals Laboratory,1,X,[topp],[anim],E02.319.267.082.500;E02.319.267.510.590,B01.050.050.199
f78bce6f-67a4-4b63-8cdd-5f72ac5a41be,COVID-19,C0242656,is with spectrum ,COVID-19,Disease Progression,1,X,[virs],[patf],C000657245,C23.550.291.656
b70f8bf1-3c38-4015-9d24-13a440d82913,COVID-19,C0748168,is with spectrum ,COVID-19,Pulmonary Pathology,1,X,[virs],[dsyn],C000657245,
0b14c8e2-3513-42f8-aa66-31dd40b59848,C0035736,C0042760,is encountered with ,RNA Viral,Virion,2,X,[nnon],[celc],D13.444.735.828,A21.249;B04.950
8b3fc992-91ab-4191-9592-024306dc5f25,C0035736,C0225336,is encountered with ,RNA Viral,Endothelial Cells,2,X,[nnon],[cell],D13.444.735.828,A11.436.275
c954f3b8-e68c-4d64-9505-633fcc667d20,C0035736,C0024109,was ,RNA Viral,Lung,3,X,[nnon],[bpoc],D13.444.735.828,A04.411
c42bd383-015e-4a45-9079-50d697fcbdb6,C0042760,C0225336,is in ,Virion,Endothelial Cells,1,X,[celc],[cell],A21.249;B04.950,A11.436.275
c1da0e0a-e5d4-4da1-8751-e0417eebcd32,C0026766,C0151763,is with severe ,Multiple Organ Failure,Liver damage,1,X,[patf],[patf],C23.550.835.525,
358e14b8-ca18-4ba5-9e13-74d816d010a2,C0026766,C0079189,is in finally possibly as consequence of early-onset pro-inflammatory ,Multiple Organ Failure,cytokine,1,X,[patf],[aapp/imft],C23.550.835.525,D12.644.276.374;D12.776.467.374;D23.529.374
358e14b8-ca18-4ba5-9e13-74d816d010a2,C0026766,C0079189,also known as ,Multiple Organ Failure,cytokine,1,X,[patf],[aapp/imft],C23.550.835.525,D12.644.276.374;D12.776.467.374;D23.529.374
abcf0970-41fe-4474-9800-cf1c876857d8,C1175743,C0023693,can speculate its stability in ,SARS coronavirus,Light,2,X,[virs],[npop],B04.820.504.540.150.113.937,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
17d53377-8003-4f9f-b50b-af1022909c84,C0599705,COVID-19,observed as ,perfusion (blood),COVID-19,1,X,[ortf],[virs],,C000657245
ebef811c-bc81-4f4a-86d3-82c913beafe5,C0027746,COVID-19,observed as ,Nerve Degeneration,COVID-19,1,X,[comd],[virs],C23.550.737,C000657245
492efccb-7061-46a6-9aff-746db61bf29e,C0021368,C0544688,observed as long-term ,Inflammation,complication of disease,5,X,[patf],[patf],C23.550.470,
055d34aa-6539-491a-a540-1835d156ae5c,C0599705,C0544688,observed as long-term ,perfusion (blood),complication of disease,5,X,[ortf],[patf],,
c7739507-dfb6-475e-8b8b-0bffadaf4e75,C0027746,C0544688,observed as long-term ,Nerve Degeneration,complication of disease,5,X,[comd],[patf],C23.550.737,
89b6f937-738d-4378-bfb6-6a043f4c0348,C1171208,C1999230,for Older adult care is current article,Older adult care,Providing (action),4,X,[topp],[acty],,
ba1da551-d062-496c-947d-240300dadf04,C0020452,COVID-19,were reported in ,Hyperemia,COVID-19,1,X,[dsyn],[virs],C14.907.474,C000657245
9be37525-6ab9-4da7-b08e-736509a160e8,C0264545,COVID-19,were reported in ,Thickening of pleura,COVID-19,1,X,[dsyn],[virs],,C000657245
9be37525-6ab9-4da7-b08e-736509a160e8,C0264545,COVID-19,were common in ,Thickening of pleura,COVID-19,1,X,[dsyn],[virs],,C000657245
492d5f59-0026-4a60-aeee-b720bd9d0b4f,C0025062,C0021403,were In contrast reported only in studies on ,Mediastinal Emphysema,Influenza virus vaccine,5,X,[dsyn],[imft/phsu],C08.846.187.290;C23.550.325.250,D20.215.894.899.302
4aa5b0f8-47a0-402b-9c34-ae41886571fe,C0022709,Cov2,are associated with greater risk of Cov2 ,Peptidyl-Dipeptidase A,Cov2,1,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
98080ffd-2a60-42bf-898b-e0d172f6bbb1,C0004153,C0086418,Society of ,Atherosclerosis,Homo sapiens,6,X,[dsyn],[humn],C14.907.137.126.307,B01.050.150.900.649.313.988.400.112.400.400
105a272a-a3c0-4ad1-a058-d0b7fee804ad,C0009450,COVID-19,is case for ,Communicable Diseases,COVID-19,2,X,[dsyn],[virs],C01.539.221,C000657245
105a272a-a3c0-4ad1-a058-d0b7fee804ad,C0009450,COVID-19,are obtaining ,Communicable Diseases,COVID-19,1,X,[dsyn],[virs],C01.539.221,C000657245
105a272a-a3c0-4ad1-a058-d0b7fee804ad,C0009450,COVID-19,overall prevalence of ,Communicable Diseases,COVID-19,1,X,[dsyn],[virs],C01.539.221,C000657245
33749510-a1b2-4fab-8563-403a8e122a30,C0031268,C1175743,are responsible for ,Pet Animal,SARS coronavirus,2,X,[anim],[virs],B01.050.050.116.600,B04.820.504.540.150.113.937
ff49cd03-9567-40f2-8aa5-95ce4a7a9866,C0206750,C0035243,is novel ,Coronavirus Infections,Respiratory Tract Infections,5,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.739;C08.730
8f2002bc-37a5-46ef-8f6f-97092c18f3f7,C0042776,C0450254,has appeared as new ,Virus,Pathogenic organism,3,X,[virs],[orgm],B04,
19e59263-018e-4892-8d55-0deef7765167,C0020974,C0042776,hold back mysterious ,passive immunization procedure,Virus,3,X,[topp],[virs],E02.095.465.425.400.330;E05.478.550.520,B04
a24b3717-fd11-4e1f-a8b3-f146702f5122,C0020974,20th,has in has use since early 20th ,passive immunization procedure,20th,3,X,[topp],????,E02.095.465.425.400.330;E05.478.550.520,????
45f5f891-6bfe-4ce4-aece-fd708396666c,C0027651,C0029355,be how ,Neoplasms,Orthopedics,2,X,[neop],[bmod],C04,H02.403.810.494
72466165-2ab3-4e17-8f58-6631dafe288c,C0042762,C1512717,Division of ,Science of Virology,Infectious Disease Epidemiology,1,X,[bmod],[bmod],H01.158.273.540.859,
57c6e853-c426-4da5-8191-c7d6d3999c0c,C0206750,C0035691,is caused by highly contagious ,Coronavirus Infections,RNA Viruses,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820
57c6e853-c426-4da5-8191-c7d6d3999c0c,C0206750,C0035691,is enveloped ,Coronavirus Infections,RNA Viruses,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820
10d7966a-73bd-4bee-879f-470179236ba7,C0012634,C0035691,is caused by highly contagious ,Disease,RNA Viruses,2,X,[dsyn],[virs],C23.550.288,B04.820
e1ed1ea9-a0b1-4078-8df3-c79107f89f86,C1272248,C0206750,is unnecessary for ,Retinal screening,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
04cdda56-77b4-4fb7-8ce7-d4ac405967b1,C1175743,C0370003,causes COVID-19 in ,SARS coronavirus,Specimen,1,X,[virs],[sbst],B04.820.504.540.150.113.937,
04cdda56-77b4-4fb7-8ce7-d4ac405967b1,C1175743,C0370003,is in simulated patient ,SARS coronavirus,Specimen,3,X,[virs],[sbst],B04.820.504.540.150.113.937,
c7e63788-4c90-4838-9c45-90d1d01eb741,C0032285,C1175743,positive for CoV2,Pneumonia,SARS coronavirus,4,X,[dsyn],[virs],C08.381.677;C08.730.610,B04.820.504.540.150.113.937
f1780d63-5f5c-48f8-a512-d8ec414bd035,C1706374,C0006145,were hospitalized in ,Tumor Necrosis Factor Ligand Superfamily Member 13,Breast Diseases,2,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,C17.800.090
ed50a4d2-c018-42b0-adbd-b64ad82bde3f,C1539372,C0013404,defined Asthma deterioration as onset of,EXOSC10 gene,Dyspnea,1,X,[gngm],[sosy],,C08.618.326;C23.888.852.371
c2763e8c-8a32-420a-8287-040b1388367a,C1539372,C0004096,defined severe ,EXOSC10 gene,Asthma,1,X,[gngm],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
2b05a758-18d1-490c-bf73-5000b02417c5,C4053960,C2987634,inhaled beta 2 ,Systemic Corticosteroid Therapy,Agonist,1,X,[topp],[phsu],,
6ab6bd60-c6e7-4132-8daf-fe7a0c90d927,C0040034,C0022917,raised ,Thrombocytopenia,Lactate Dehydrogenase,4,X,[dsyn],[aapp/enzy],C15.378.140.855,D08.811.682.047.551.400;D08.811.682.047.820.493
961b0c00-5dd6-489b-903f-57d144adeafd,C0028630,C1707455,is in ,Nucleotides,Comparison,3,X,[nnon],[acty],D09.408.620;D13.695,
667b312f-12c4-45c4-b586-2449e4012458,C3494870,C0026882,harbor common ,Viral isolate,Mutation,6,X,[bacs],[genf],,G05.365.590
6b5f1797-c437-4cd0-a0c1-eb6b4af0b3c5,C14408,C0028630,be most common ,C14408,Nucleotides,1,X,????,[nnon],????,D09.408.620;D13.695
d4061f32-f9af-43bb-8dd8-eb3b83a4682e,C14408,C3494870,be most common ,C14408,Viral isolate,1,X,????,[bacs],????,
c8c8a954-cd32-4af7-9bc7-340177e837a6,C0206750,C1533724,includes fear coming into contact with ,Coronavirus Infections,Fomes,1,X,[dsyn],[fngs],C02.782.600.550.200,B01.300.179.120.174
8b5ccf85-7561-46de-8dd7-1e2f40d4099d,C0039082,C0206750,was correlated with preexisting ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8b5ccf85-7561-46de-8dd7-1e2f40d4099d,C0039082,C0206750,was correlated with excessive ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8b5ccf85-7561-46de-8dd7-1e2f40d4099d,C0039082,C0206750,have have described in patients with ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8b5ccf85-7561-46de-8dd7-1e2f40d4099d,C0039082,C0206750,seems most common manifestation of ,Syndrome,Coronavirus Infections,4,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8b5ccf85-7561-46de-8dd7-1e2f40d4099d,C0039082,C0206750,were repeatedly reported after ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8b5ccf85-7561-46de-8dd7-1e2f40d4099d,C0039082,C0206750,epicenter of ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
7a80b79c-3f45-49df-9c46-0fc3b3e453bf,C2948600,C1705178,review typical CT findings in ,Aim,Order (action),3,X,[inch/phsu],[acty],,
7761761d-7004-4879-80eb-90264887057f,C2948600,C1999230,was to COVID19 ,Aim,Providing (action),4,X,[inch/phsu],[acty],,
83d11a11-c590-474e-8392-7c081301e4f5,C0206750,C0037285,has associated ,Coronavirus Infections,Skin Manifestations,2,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.885
6d365252-51b3-4168-bedc-f03592347463,C0444192,C0370003,are widely accepted as ,Nasopharyngeal swab (specimen),Specimen,2,X,[bdsu],[sbst],,
cf8f58d3-43f3-4ed6-b7b5-890b8970c64e,C0444192,C1511790,are widely accepted as ,Nasopharyngeal swab (specimen),Detection,2,X,[bdsu],[topp],,
51ea1366-4127-4d0f-a18f-07b577e13c2a,C0444192,C1175743,are widely accepted as ,Nasopharyngeal swab (specimen),SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
dcdcbbda-4853-4a8d-bc1a-c3a10c3d4e25,C0444192,C0206750,are widely accepted as ,Nasopharyngeal swab (specimen),Coronavirus Infections,2,X,[bdsu],[dsyn],,C02.782.600.550.200
b421a557-c947-405e-9043-e2e29fd3418c,C0444192,C0012634,are widely accepted as ,Nasopharyngeal swab (specimen),Disease,2,X,[bdsu],[dsyn],,C23.550.288
62bb2ba4-46ae-46c3-99cc-70b6be6f2170,C0751142,C0015385,is in distal ,Facial Palsy Lower Motor Neuron,Limb structure,3,X,[sosy],[bpoc],C07.465.327;C10.597.622.214;C23.888.592.636.214,A01.378
e7dd5398-16b1-4153-8503-06d2d86d9267,C0234170,C0015385,is in distal ,General areflexia,Limb structure,3,X,[dsyn],[bpoc],,A01.378
543a3127-df14-4928-bd75-2bc57ae3430c,C0030946,C0243052,attractive pharmacological target due to its involvement in ,Endopeptidases,Virus Physiological Phenomena,1,X,[aapp/enzy/phsu],[npop],D08.811.277.656.300,G06.920
988435c8-2edd-4a8b-bc82-8516c6dc09b8,C1882932,C0243052,attractive pharmacological target due to its involvement in ,Representation (action),Virus Physiological Phenomena,1,X,[acty],[npop],,G06.920
b5fff8d9-5f7f-4f10-9c7e-a6fd380b8a1e,C0444626,C1433062,shows large structural resemblance with ,Crystal Structure,3C-like protease SARS coronavirus,2,X,[chvs],[aapp/enzy],,x.x.x.x
cdd5e3ad-92be-4f6c-ba45-2f349f10571d,C0020517,C0010654,is located around exactly catalytic site ,Hypersensitivity,Cysteine,1,X,[patf],[aapp/bacs],C20.543,D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230
9e18274e-090a-49ca-b65b-688c4ef361c7,C0020517,C1167622,coincides with ,Hypersensitivity,Binding (Molecular Function),1,X,[patf],[moft],C20.543,
c8739933-86ae-4592-8e2b-48e27ce56d2d,C0020517,C0243077,coincides with ,Hypersensitivity,inhibitors,1,X,[patf],[chvf],C20.543,
a6dfa157-a4cc-4673-9abe-3a19fefae43b,C0012634,C1707455,is in India ,Disease,Comparison,4,X,[dsyn],[acty],C23.550.288,
734bbf84-84f5-40ec-8035-14a0f0b7f55a,C4551660,intra,heavily rely on intra ,Virus Host Interactions,intra,1,X,[npop],????,G06.373;G16.527,????
c3e97eaa-4a4b-4363-b6a9-2967b94e581e,C4551660,C1167395,heavily rely on intra ,Virus Host Interactions,Host (organism),1,X,[npop],[orgm],G06.373;G16.527,
b288ed4d-d1cf-48b2-bbd1-2eef466a53ef,C4551660,C3826426,heavily rely on intra ,Virus Host Interactions,Dynamics,1,X,[npop],[npop],G06.373;G16.527,
1cf44b61-66ee-4495-a004-4ec5dc764155,C0444241,C1175743,is in clinical ,Genetic sample,SARS coronavirus,2,X,[celc],[virs],,B04.820.504.540.150.113.937
f3c4c111-3abb-48ef-a768-d1be3aad0ceb,C0038317,C0206750,worsen outcomes in ,Steroids,Coronavirus Infections,5,X,[orch/phsu],[dsyn],D04.210.500,C02.782.600.550.200
6798eb62-26fe-4629-8c12-32baa109f1cd,C0206750,HK,importation in HK,Coronavirus Infections,HK,2,X,[dsyn],????,C02.782.600.550.200,????
97aeea09-ff8f-4b41-b87b-bc0250d90d39,C1441506,C0206750,can predict critical outcomes in patients with ,Calculation,Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
578ee5e3-4bcc-4b65-b817-74956fc235fc,C2948600,C1167622,investigate together ,Aim,Binding (Molecular Function),3,X,[inch/phsu],[moft],,
d15fd274-698b-47f6-8c3e-30d179967c1a,C2948600,C0682997,investigate together ,Aim,Monoterpenes,3,X,[inch/phsu],[orch],,D02.455.849.575
04d92550-15b8-4aa1-9b05-3a9991bac817,C2948600,C0030946,investigate Binding (Molecular Function) together with,Aim,Endopeptidases,2,X,[inch/phsu],[aapp/enzy/phsu],,D08.811.277.656.300
04d92550-15b8-4aa1-9b05-3a9991bac817,C2948600,C0030946,investigate Binding (Molecular Function) with cellular,Aim,Endopeptidases,1,X,[inch/phsu],[aapp/enzy/phsu],,D08.811.277.656.300
c2aa42a2-f2c7-4494-bb59-865e477a7561,C0054837,C0567416,was found most effective ,carvone,Molecule,4,X,[orch],[sbst],x.x.x.x,
018d1119-0d4e-473d-9506-01d14a47dd93,LD50,C0034721,is in ,LD50,Rattus,4,X,????,[mamm],????,B01.050.150.900.649.313.992.635.505.700
5b2adab0-64b1-43ff-afe0-59934c8b43fb,C0054837,mol/kg,dose of was In addition 1.707 mol/kg,carvone,mol/kg,4,X,[orch],????,x.x.x.x,????
70af12d1-c8df-4a44-a790-c1e0f6503bc6,LD50,mol/kg,was In addition 1.707 mol/kg,LD50,mol/kg,4,X,????,????,????,????
c9d2ab87-45c2-40ad-b61c-a0db5bc17082,C1254351,C0872152,is in ,Pharmacologic Substance,Drug Development,4,X,[phsu],[bmod],,E05.290;H01.158.703.007.338;H01.181.466.338
346e7a67-3550-47a0-9f40-31e39e2d3d7f,C0054837,C1254351,be considered as alternative ,carvone,Pharmacologic Substance,4,X,[orch],[phsu],x.x.x.x,
bc15deb7-853a-4588-b489-02707ebbd7fd,C0054837,C0872152,be considered as alternative ,carvone,Drug Development,4,X,[orch],[bmod],x.x.x.x,E05.290;H01.158.703.007.338;H01.181.466.338
b356e666-0718-4240-a6c0-8778771a781c,C0032310,GGO,Most frequent findings of were predominantly mixed pattern of GGO GGO,Pneumonia Viral,GGO,8,X,[dsyn],????,C02.705;C08.381.677.807;C08.730.610.763,????
bee1dc86-fb3b-4705-8a2f-831f394b87d2,C0206750,C0032310,involvement with non-COVID ,Coronavirus Infections,Pneumonia Viral,3,X,[dsyn],[dsyn],C02.782.600.550.200,C02.705;C08.381.677.807;C08.730.610.763
bee1dc86-fb3b-4705-8a2f-831f394b87d2,C0206750,C0032310,typically presents as ,Coronavirus Infections,Pneumonia Viral,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.705;C08.381.677.807;C08.730.610.763
bee1dc86-fb3b-4705-8a2f-831f394b87d2,C0206750,C0032310,emerged as ,Coronavirus Infections,Pneumonia Viral,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.705;C08.381.677.807;C08.730.610.763
7adde680-af45-4a19-9f8d-c770f632d32b,C0206750,C1707455,represents variant by ,Coronavirus Infections,Comparison,8,X,[dsyn],[acty],C02.782.600.550.200,
1badccdb-c97c-49fc-8180-209b4f5cbc26,C0031090,C0012634,comprises group of ,Periodontal Diseases,Disease,2,X,[dsyn],[dsyn],C07.465.714,C23.550.288
a5e9ab52-cb44-4a91-b18c-2348dc8aa656,C0221423,C1175743,caused by ,Illness (finding),SARS coronavirus,3,X,[sosy],[virs],,B04.820.504.540.150.113.937
b865ba59-ec57-4060-bfa4-7e9072095cf4,C0031090,C0206750,is associated with severe ,Periodontal Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C07.465.714,C02.782.600.550.200
fb7b87ea-eacf-41be-925f-2fa8a30df1a8,C0162633,C0206750,clinical course of consecutive symptomatic ,Viral Shedding,Coronavirus Infections,4,X,[patf],[dsyn],G07.925,C02.782.600.550.200
fb7b87ea-eacf-41be-925f-2fa8a30df1a8,C0162633,C0206750,may pose threat to ,Viral Shedding,Coronavirus Infections,1,X,[patf],[dsyn],G07.925,C02.782.600.550.200
1081d8c6-a1a0-4ecd-9729-d7c77fbc3a1c,C0035668,C0206750,clinical course of consecutive symptomatic ,RNA,Coronavirus Infections,1,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
1081d8c6-a1a0-4ecd-9729-d7c77fbc3a1c,C0035668,C0206750,play roles in multiple aspects of ,RNA,Coronavirus Infections,4,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
1081d8c6-a1a0-4ecd-9729-d7c77fbc3a1c,C0035668,C0206750,are pervasive throughout ,RNA,Coronavirus Infections,4,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
1081d8c6-a1a0-4ecd-9729-d7c77fbc3a1c,C0035668,C0206750,isolated from nasopharyngeal swabs collected from ,RNA,Coronavirus Infections,2,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
ecbe83a3-2042-4dfd-93c3-a1fb0a61312b,C0001617,C0162633,is associated with prolonged ,Adrenal Cortex Hormones,Viral Shedding,6,X,[horm/orch/phsu],[patf],D06.472.040,G07.925
d41518d7-b49e-471d-b20c-7e27ec73b249,C0001617,C0035668,is associated with prolonged ,Adrenal Cortex Hormones,RNA,3,X,[horm/orch/phsu],[nnon],D06.472.040,D13.444.735
068f7245-998c-405f-9870-71398c897d22,C0939237,C0162633,may may associated with prolonged ,lopinavir / Ritonavir,Viral Shedding,6,X,[phsu],[patf],,G07.925
1a17b01d-dbcf-433a-95e2-88134ca82ef1,C0939237,C0035668,may may associated with prolonged ,lopinavir / Ritonavir,RNA,3,X,[phsu],[nnon],,D13.444.735
9902fb3e-2bb0-4365-b69c-322567268b3b,C0939237,C1829939,may may associated with prolonged ,lopinavir / Ritonavir,{Non-patient},5,X,[phsu],[clna],,
fe6870ca-bbf7-4437-8484-4f6ee84319fb,C0162633,C1829939,is in ,Viral Shedding,{Non-patient},12,X,[patf],[clna],G07.925,
97879d4b-6b1c-4602-91ce-e297469776b3,C0035668,C1829939,is in ,RNA,{Non-patient},6,X,[nnon],[clna],D13.444.735,
d9d34fd6-0370-4f35-97b7-920a255ef682,C1175743,C0206061,was characterized by ,SARS coronavirus,Pneumonia Interstitial,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.483
6f84e5ce-3e81-4b2e-a735-8ddfa4a0dc27,C0206061,C0597404,is in mainly ,Pneumonia Interstitial,Respiratory viruses,2,X,[dsyn],[virs],C08.381.483,
0cbcbf67-c6d7-4b61-a1a0-ee787bf907b5,C0024400,C0237820,reinfected during early ,Macaca mulatta,Recovery - action,1,X,[mamm],[acty],B01.050.150.900.649.313.988.400.112.199.120.510.550,
f17967b7-9e47-4980-bc54-8e7ae370e373,C0024400,C1175743,reinfected during early ,Macaca mulatta,SARS coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.988.400.112.199.120.510.550,B04.820.504.540.150.113.937
f17967b7-9e47-4980-bc54-8e7ae370e373,C0024400,C1175743,reinfected with identical ,Macaca mulatta,SARS coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.988.400.112.199.120.510.550,B04.820.504.540.150.113.937
41909b9c-9d15-404d-86a4-7b2d62b27eeb,C0301872,humoral,Comparing humoral ,Immune response,humoral,1,X,[ortf],????,,????
40638611-294e-41af-8b83-40d6b9ad7ffa,C0301872,C0948192,Comparing humoral ,Immune response,primary infection nos,1,X,[ortf],[dsyn],,
f5e9231a-1685-4fa2-8d07-85fddcd6c13b,C1175743,C0024400,protects in ,SARS coronavirus,Macaca mulatta,1,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.988.400.112.199.120.510.550
a5612523-4ec2-45a4-af79-9f8c9cea77bb,C1175743,C0008679,represents unprecedented ,SARS coronavirus,Chronic disease,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C23.550.291.500
234c53c8-378a-4446-af01-a121736cdfc6,C0068450,C0055673,exert Therapeutic Effect through,naringenin,Chymase,3,X,[orch/phsu],[aapp/enzy],x.x.x.x,D08.811.277.656.300.760.103;D08.811.277.656.959.350.103
4ad37f0d-700c-46d2-9f1e-9d23bf251338,C0068450,C2258685,exert Therapeutic Effect through,naringenin,angiotensin converting enzyme activity,6,X,[orch/phsu],[moft],x.x.x.x,
3331707c-0623-49bb-b29e-c7ac369c4819,C0068450,C0597357,exert Therapeutic Effect through,naringenin,receptor,3,X,[orch/phsu],[aapp/rcpt],x.x.x.x,
e87ece37-2e39-47ba-9407-8812c2494e02,C1175743,C0221423,causes ,SARS coronavirus,Illness (finding),4,X,[virs],[sosy],B04.820.504.540.150.113.937,
e87ece37-2e39-47ba-9407-8812c2494e02,C1175743,C0221423,is novel ,SARS coronavirus,Illness (finding),2,X,[virs],[sosy],B04.820.504.540.150.113.937,
e87ece37-2e39-47ba-9407-8812c2494e02,C1175743,C0221423,is etiological Agent of highly contagious,SARS coronavirus,Illness (finding),1,X,[virs],[sosy],B04.820.504.540.150.113.937,
c0fa59de-7e4c-4a8f-9bf3-06fb4dd3567c,C0042776,C0042542,is in ,Virus,Vero Cells,1,X,[virs],[cell],B04,A11.251.210.955;A11.436.955
6e1b9c7f-4cd3-4ac3-9bad-b330a03fc77e,C0042776,C0007537,is in ,Virus,Cefaclor,1,X,[virs],[antb/orch],B04,D02.065.589.099.249.200.155;D02.886.665.074.200.155;D03.633.100.300.249.200.155
9ccded7e-c741-48b5-9c05-1dc497b26c3d,C0003320,C0042776,propagating ,Antigens,Virus,1,X,[imft],[virs],D23.050,B04
9bf77783-46f0-4701-b1e9-c3895b4d0341,C0003320,C0042542,propagating ,Antigens,Vero Cells,2,X,[imft],[cell],D23.050,A11.251.210.955;A11.436.955
a05ece6e-8683-4576-90eb-bdc2b20585da,C0003320,C0007537,propagating ,Antigens,Cefaclor,2,X,[imft],[antb/orch],D23.050,D02.065.589.099.249.200.155;D02.886.665.074.200.155;D03.633.100.300.249.200.155
0f9f3679-acb2-44b9-be78-f6e07825fe18,C0020852,C1550100,was developed for serological detection of anti ,Immunoglobulin G,Specimen Type - Serum,1,X,[aapp/imft/phsu],[bdsu],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,
5a0eb0b9-9d1b-4dd2-954a-aa72507e1572,C0020852,C0020517,was found ,Immunoglobulin G,Hypersensitivity,2,X,[aapp/imft/phsu],[patf],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,C20.543
979f0e3f-f0a5-4a96-9371-c0ccd7d2de44,C1175743,C0086418,uses ,SARS coronavirus,Homo sapiens,21,X,[virs],[humn],B04.820.504.540.150.113.937,B01.050.150.900.649.313.988.400.112.400.400
675320b7-5afd-4071-a967-2eb9e7696e7c,C0034019,C0597404,spread of common ,public health medicine (field),Respiratory viruses,2,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,
bc1f1b3a-3339-4f48-87de-0ae5021854b5,C0009450,C1856053,was declared pandemic on ,Communicable Diseases,Hydranencephaly with Renal Aplasia-Dysplasia,13,X,[dsyn],[dsyn],C01.539.221,x.x.x.x
bc1f1b3a-3339-4f48-87de-0ae5021854b5,C0009450,C1856053,was reported in ,Communicable Diseases,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[dsyn],[dsyn],C01.539.221,x.x.x.x
82922d47-9cf1-455e-bf36-6aaac7fd60fc,C0037088,C1457887,has has reported cases despite lack of ,Signs and Symptoms,Symptoms,1,X,[sosy],[sosy],C23.888,
82922d47-9cf1-455e-bf36-6aaac7fd60fc,C0037088,C1457887,has has cases of infectivity despite lack of ,Signs and Symptoms,Symptoms,1,X,[sosy],[sosy],C23.888,
5ac9b40f-461b-4177-add8-976490bce2ff,C1175743,C1456573,is cause of ,SARS coronavirus,Global Health,3,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
5ac9b40f-461b-4177-add8-976490bce2ff,C1175743,C1456573,has rapidly become ,SARS coronavirus,Global Health,9,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
5ac9b40f-461b-4177-add8-976490bce2ff,C1175743,C1456573,is emerging ,SARS coronavirus,Global Health,3,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
5ac9b40f-461b-4177-add8-976490bce2ff,C1175743,C1456573,is new ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
5ac9b40f-461b-4177-add8-976490bce2ff,C1175743,C1456573,has led to ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
5ac9b40f-461b-4177-add8-976490bce2ff,C1175743,C1456573,recently appeared as ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
5ac9b40f-461b-4177-add8-976490bce2ff,C1175743,C1456573,is evolving rapidly at present with unprecedented ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
92fca2ed-d63f-4ba8-8d4f-650b83e3c556,C0605290,C1819995,interact enter into ,SAS,Host Cell,2,X,[orch],[celc],x.x.x.x,
24ddb087-2bca-4455-9ac8-05f840024870,C0605290,C1721019,interact for initial ,SAS,Virus Attachment,2,X,[orch],[biof],x.x.x.x,G06.920.868
08322f4f-26ee-4819-9b5a-fb4199269ec9,C0605290,C0023206,interact with ,SAS,Lectin,1,X,[orch],[aapp/bacs],x.x.x.x,D12.776.503
dca775c5-5d82-4bb7-ab01-a5e6579f9403,C0605290,C1415188,interact with ,SAS,GP2 gene,2,X,[orch],[gngm],x.x.x.x,
f605f4c9-b461-49d8-af3f-4a224dbb61f1,C0605290,C1175743,interact with ,SAS,SARS coronavirus,1,X,[orch],[virs],x.x.x.x,B04.820.504.540.150.113.937
18bac10f-e84b-427c-b979-1c63f740b6ee,C1175743,C1148583,acts as classical ,SARS coronavirus,polysaccharide binding,1,X,[virs],[moft],B04.820.504.540.150.113.937,
cfe585f7-f6ca-4185-a9cb-33a1aed043e3,C0062154,C1148583,acts as classical ,hemagglutinin esterase,polysaccharide binding,1,X,[aapp],[moft],x.x.x.x,
409e9d72-bec0-4338-b0f3-109a67f5d471,C1175743,C0023206,acts as classical ,SARS coronavirus,Lectin,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.776.503
168300d8-9ba9-41a5-a96e-b304715fb0ef,C0062154,C0023206,acts as classical ,hemagglutinin esterase,Lectin,1,X,[aapp],[aapp/bacs],x.x.x.x,D12.776.503
2ff2b3cc-4bb0-4015-8fb5-28a0b6683e07,C0062154,C0214192,is specific for ,hemagglutinin esterase,9-aminocamptothecin,2,X,[aapp],[orch/phsu],x.x.x.x,x.x.x.x
2ff2b3cc-4bb0-4015-8fb5-28a0b6683e07,C0062154,C0214192,prefers 7 di ,hemagglutinin esterase,9-aminocamptothecin,2,X,[aapp],[orch/phsu],x.x.x.x,x.x.x.x
a62309d5-dbc5-467c-aa4e-9aaf657e09cb,C0062154,C0605290,is specific for ,hemagglutinin esterase,SAS,1,X,[aapp],[orch],x.x.x.x,x.x.x.x
a62309d5-dbc5-467c-aa4e-9aaf657e09cb,C0062154,C0605290,prefers 7 di ,hemagglutinin esterase,SAS,1,X,[aapp],[orch],x.x.x.x,x.x.x.x
414fae04-a5f6-4dae-b620-efb047f3972b,C1333471,C0242781,was C/D,Esterase Gene,disease transmission,1,X,[gngm],[patf],,N06.850.310
ddd8d87a-2200-428e-9f6e-72254d11d2f5,C0017337,C0242781,was C/D,Genes,disease transmission,1,X,[gngm],[patf],G05.360.340.024.340,N06.850.310
06312bc7-bcef-4f94-add5-1c202bf4fb98,C1333471,C0887912,was C/D,Esterase Gene,Gene Transfer Horizontal,1,X,[gngm],[genf],,G05.728.390
f7a7042f-c8cf-434d-b57e-821df6fb413a,C0017337,C0887912,was C/D,Genes,Gene Transfer Horizontal,1,X,[gngm],[genf],G05.360.340.024.340,G05.728.390
448fc4d7-fc47-443e-b37e-269da9fdd94b,C1333471,C0029341,was C/D,Esterase Gene,Orthomyxoviridae,1,X,[gngm],[virs],,B04.820.545
3e25b834-6745-4eb0-8da3-d8ef8960d503,C0017337,C0029341,was C/D,Genes,Orthomyxoviridae,1,X,[gngm],[virs],G05.360.340.024.340,B04.820.545
ab27ebcf-989a-440b-9b01-b18abdc18551,C1333471,C/D,was C/D,Esterase Gene,C/D,1,X,[gngm],????,,????
9368cfdc-668a-4a6c-8ed7-29fd479a6efa,C0017337,C/D,was C/D,Genes,C/D,1,X,[gngm],????,G05.360.340.024.340,????
09244301-17ca-4e57-97c9-8d4620d1c0dd,C0062154,C0242781,takes place by cross-species ,hemagglutinin esterase,disease transmission,1,X,[aapp],[patf],x.x.x.x,N06.850.310
a471a354-c2dd-4e40-b172-4e199ef3b08b,C1706701,C0242781,takes place by cross-species ,Acquisition (action),disease transmission,1,X,[acty],[patf],,N06.850.310
33ab43ad-2048-43ad-b23e-bc3ff6d94bc7,C1706701,C0062154,takes place over ,Acquisition (action),hemagglutinin esterase,1,X,[acty],[aapp],,x.x.x.x
b305b8c0-0773-4093-8965-46ffcc7ed0c0,C0062154,C0015219,takes place over ,hemagglutinin esterase,Biological Evolution,1,X,[aapp],[genf],x.x.x.x,G05.045;G16.075
b305b8c0-0773-4093-8965-46ffcc7ed0c0,C0062154,C0015219,precedes ,hemagglutinin esterase,Biological Evolution,2,X,[aapp],[genf],x.x.x.x,G05.045;G16.075
a3102970-f879-4766-b6c7-a519da5810dc,C1706701,C0015219,takes place over ,Acquisition (action),Biological Evolution,1,X,[acty],[genf],,G05.045;G16.075
a6dcc2c2-417c-48fb-9608-c1de54961be9,C0062154,C0042776,precedes ,hemagglutinin esterase,Virus,2,X,[aapp],[virs],x.x.x.x,B04
b3649957-9d81-4437-84d4-71faf407008c,C0597357,C0042776,precedes ,receptor,Virus,2,X,[aapp/rcpt],[virs],,B04
b3649957-9d81-4437-84d4-71faf407008c,C0597357,C0042776,considered ,receptor,Virus,3,X,[aapp/rcpt],[virs],,B04
de459aa6-8a87-4e8b-8c5f-84de7aa3bc38,C0597357,C0015219,precedes ,receptor,Biological Evolution,2,X,[aapp/rcpt],[genf],,G05.045;G16.075
573a51d6-33ee-4be9-b978-c1db9513c51e,C0062154,C0067762,precedes ,hemagglutinin esterase,N-Acetylneuraminic Acid,2,X,[aapp],[bacs/orch],x.x.x.x,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
c9a248af-ac48-4f81-92a2-6669d79c9718,C0597357,C0067762,precedes ,receptor,N-Acetylneuraminic Acid,2,X,[aapp/rcpt],[bacs/orch],,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
63470eb5-d7d9-435c-88ab-13e75b6db645,C0062154,C0032594,precedes ,hemagglutinin esterase,Polysaccharides,2,X,[aapp],[orch/phsu],x.x.x.x,D09.698
954af3f5-2647-4079-8028-f8fe5b71e44b,C0597357,C0032594,precedes ,receptor,Polysaccharides,2,X,[aapp/rcpt],[orch/phsu],,D09.698
361f0ddf-708a-45d8-a3f9-af82e4660bbd,C0062154,C1167395,precedes ,hemagglutinin esterase,Host (organism),2,X,[aapp],[orgm],x.x.x.x,
5d2eb7c9-dc7b-4185-84b6-c7bf49ba5a28,C0597357,C1167395,precedes ,receptor,Host (organism),2,X,[aapp/rcpt],[orgm],,
63136817-88eb-4a1b-b5b9-782bd088fe93,C3536948,C0023206,potentiates switch by simple conformational shift of,Stereochemistry (Molecular Function),Lectin,1,X,[moft],[aapp/bacs],,D12.776.503
b8af2e44-0b02-4abb-9141-cd161e613ae2,C1514527,C0023206,potentiates switch by simple conformational shift of,Protein-Carbohydrate Interaction,Lectin,1,X,[moft],[aapp/bacs],,D12.776.503
ecb5915c-d258-44b0-a55b-6d7b4ad2d319,C0023206,C0067762,potentiates ,Lectin,N-Acetylneuraminic Acid,1,X,[aapp/bacs],[bacs/orch],D12.776.503,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
f2c49686-fc0c-4209-95fa-206e91f852ef,C3536948,C0067762,potentiates ,Stereochemistry (Molecular Function),N-Acetylneuraminic Acid,1,X,[moft],[bacs/orch],,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
2491df51-85e9-45ad-8b0c-420dbf6490c3,C0023206,C0023688,potentiates ,Lectin,Ligands,1,X,[aapp/bacs],[chem],D12.776.503,D27.720.470.480
0b8e1a72-6e18-4ef9-a79f-bac262ec6aa4,C3536948,C0023688,potentiates ,Stereochemistry (Molecular Function),Ligands,1,X,[moft],[chem],,D27.720.470.480
edd78b84-5b9d-48aa-899b-8d792b6fc25a,C1514527,C0067762,potentiates ,Protein-Carbohydrate Interaction,N-Acetylneuraminic Acid,1,X,[moft],[bacs/orch],,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
148e4661-2369-4c5b-852d-91af18ab82fe,C1514527,C0023688,potentiates ,Protein-Carbohydrate Interaction,Ligands,1,X,[moft],[chem],,D27.720.470.480
1559eb5c-381a-484a-b626-e773e0422c45,C4321457,C0042776,Therefore can lead to better understanding of ,Examination,Virus,1,X,[acty],[virs],,B04
9e9f59c5-1b62-49e5-b3dc-3a76b4feb650,C4321457,C0015219,Therefore can lead to better understanding of ,Examination,Biological Evolution,1,X,[acty],[genf],,G05.045;G16.075
5f91cc69-160c-4da1-8652-997417ffd158,C4321457,C4277517,Therefore can lead to better understanding of ,Examination,Host Tropism,1,X,[acty],[phsf],,G06.099.925;G06.920.863
83a070c8-56d0-461e-ac0b-839102d54094,C1257646,C0062154,is found in BCoV ,PON1 protein human,hemagglutinin esterase,1,X,[aapp/enzy],[aapp],x.x.x.x,x.x.x.x
c6f5fcfd-8d4e-4ae3-bb1a-fde027f79f5f,C0062154,di,prefers 7 di ,hemagglutinin esterase,di,1,X,[aapp],????,x.x.x.x,????
790d73d4-cd55-43f0-800b-9a2ed9043cdf,C2247147,C0214192,is with two different subtypes of typical ,sialic acid binding,9-aminocamptothecin,2,X,[moft],[orch/phsu],,x.x.x.x
71ecd773-e546-44eb-b309-7f9b10752369,C0033684,C4277517,Virus Biological Evolution toward,Proteins,Host Tropism,1,X,[aapp/bacs],[phsf],D12.776,G06.099.925;G06.920.863
b58ad640-2109-4767-9c8e-96a21ef797fb,C0567416,C4277517,Virus Biological Evolution toward,Molecule,Host Tropism,1,X,[sbst],[phsf],,G06.099.925;G06.920.863
0891406e-03cc-419b-a8c8-9ee4c9adada1,C0033684,C0015219,Virus,Proteins,Biological Evolution,1,X,[aapp/bacs],[genf],D12.776,G05.045;G16.075
73c8ece5-b29c-4052-944f-8e59e05e2034,C0567416,C0015219,Virus,Molecule,Biological Evolution,1,X,[sbst],[genf],,G05.045;G16.075
70674712-3718-49e9-8992-7391cd3ee034,C0255558,C0087111,are are currently targeted for ,nonstructural protein coronavirus,Therapeutic procedure,1,X,[aapp],[topp],x.x.x.x,E02
7222113f-1fc5-4162-b4e6-62edbe24d6fe,C0206750,C0028606,cases of ,Coronavirus Infections,Nucleic Acids,6,X,[dsyn],[bacs/nnon],C02.782.600.550.200,D13.444
7222113f-1fc5-4162-b4e6-62edbe24d6fe,C0206750,C0028606,is with negative ,Coronavirus Infections,Nucleic Acids,1,X,[dsyn],[bacs/nnon],C02.782.600.550.200,D13.444
1d3a7cf8-b94d-4ea0-83a0-ac1146988769,C0206750,C1316572,false negative cases of are worth ,Coronavirus Infections,Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider},2,X,[dsyn],[clna],C02.782.600.550.200,
faaf3431-9d87-43fd-8ae8-478c38f74d6e,C0815172,C0206750,is with confirmed ,patient characteristics,Coronavirus Infections,17,X,[clna],[dsyn],,C02.782.600.550.200
29f0effd-32b3-45c8-a1fb-7285f094bf28,C0815172,C0012634,is with confirmed ,patient characteristics,Disease,15,X,[clna],[dsyn],,C23.550.288
05a87564-2258-4443-afd6-e9a2d13c0da3,C0162595,C0005779,contribute to ,Antiphospholipid Antibodies,Blood Coagulation Disorders,1,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,C15.378.100
07f52789-62f1-40a0-8d0e-c0ef9933d279,C0017968,C2825347,was most common aPL present in critically ill patients followed by ,Glycoproteins,Immunoglobulin A Human,1,X,[aapp/bacs],[imft/phsu],D09.400.430;D12.776.395,
07f52789-62f1-40a0-8d0e-c0ef9933d279,C0017968,C2825347,was For multiple aPLs type followed by ,Glycoproteins,Immunoglobulin A Human,2,X,[aapp/bacs],[imft/phsu],D09.400.430;D12.776.395,
10c20046-2db7-4f1c-8414-8bc09666a7b9,C0206750,C0008073,may trigger ,Coronavirus Infections,Developmental Disabilities,1,X,[dsyn],[mobd],C02.782.600.550.200,F03.625.421
b362ad9d-8c43-4b28-bfea-b4ff470f0eaf,C0206750,C0001468,may trigger ,Coronavirus Infections,Adenosine Phosphosulfate,1,X,[dsyn],[bacs/nnon],C02.782.600.550.200,D03.633.100.759.646.138.180.080;D13.695.667.138.180.080;D13.695.827.068.180.080
7b09ddb1-22fd-432f-8d31-e6e17f070856,C0206750,C0039082,may trigger ,Coronavirus Infections,Syndrome,7,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.288.500
513771e6-c1c8-441f-b356-b5d7f4acec03,C0206750,C0042077,is in also ,Coronavirus Infections,Urology,4,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.810.860
513771e6-c1c8-441f-b356-b5d7f4acec03,C0206750,C0042077,published by American Confederation ,Coronavirus Infections,Urology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.810.860
e268fb71-9b03-4375-b5a0-ffa223633747,C1175743,C1819995,enters ,SARS coronavirus,Host Cell,5,X,[virs],[celc],B04.820.504.540.150.113.937,
e268fb71-9b03-4375-b5a0-ffa223633747,C1175743,C1819995,infects ,SARS coronavirus,Host Cell,3,X,[virs],[celc],B04.820.504.540.150.113.937,
e268fb71-9b03-4375-b5a0-ffa223633747,C1175743,C1819995,Viral Components of,SARS coronavirus,Host Cell,2,X,[virs],[celc],B04.820.504.540.150.113.937,
2ad5b681-b7df-4bb2-90a2-2d2db1490095,C0003015,C0870392,role of is ,Angiotensin-Converting Enzyme Inhibitors,debate,1,X,[phsu],[acty],D27.505.519.389.745.085,
c5877dc1-82cf-4df1-bd1e-7181b95896c9,RAAS,C0206750,be maintained in patients with ,RAAS,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
667814b0-a057-4201-b04b-2ec69cefe44e,C0027950,C1514474,was independent ,neutrophil,Prognostic Factors,2,X,[cell],[clna],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,E01.789
667814b0-a057-4201-b04b-2ec69cefe44e,C0027950,C1514474,were selected as final ,neutrophil,Prognostic Factors,1,X,[cell],[clna],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,E01.789
0c580f4b-8aef-4220-8a08-8f6f4d5da56c,C0006938,COVID-19,was applied to ,Captopril,COVID-19,1,X,[aapp/phsu],[virs],D12.125.072.401.623.270,C000657245
d054088e-8690-4e57-bdc3-09dd7383e09b,C0006938,C1999230,has potential to ,Captopril,Providing (action),1,X,[aapp/phsu],[acty],D12.125.072.401.623.270,
339baa7c-7a46-41da-8b10-ae534f21e214,C1825598,C1184743,includes development ,IMPACT gene,bony process,1,X,[gngm],[bpoc],,
55546868-8bcf-4c41-a1c1-9f2dccaa531f,C0441516,C0206419,Short-term IMPACT gene of,Demand (clinical),Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
8c335025-f55a-4d65-8370-179ca8ec5063,C0441516,C1420621,shift towards ,Demand (clinical),TCAP gene,1,X,[topp],[gngm],,
50ef1213-e398-464f-a220-cba4c4187bea,C0242781,C0026926,was modeled for ,disease transmission,Mycobacterium tuberculosis,6,X,[patf],[bact],N06.850.310,B03.510.024.049.525.500.702;B03.510.460.400.410.552.552.702
50ef1213-e398-464f-a220-cba4c4187bea,C0242781,C0026926,were estimated for ,disease transmission,Mycobacterium tuberculosis,5,X,[patf],[bact],N06.850.310,B03.510.024.049.525.500.702;B03.510.460.400.410.552.552.702
5a97cdee-89aa-4ccb-b7d9-636755d4681c,C0242781,C0023238,was modeled for ,disease transmission,Legionella pneumophila,6,X,[patf],[bact],N06.850.310,B03.440.400.425.450.450.500;B03.660.250.460.460.580
446f1012-9741-4480-a1fc-4b34caf47dce,C0242781,C0029341,was modeled for ,disease transmission,Orthomyxoviridae,6,X,[patf],[virs],N06.850.310,B04.820.545
446f1012-9741-4480-a1fc-4b34caf47dce,C0242781,C0029341,were estimated for ,disease transmission,Orthomyxoviridae,5,X,[patf],[virs],N06.850.310,B04.820.545
744ac083-5577-4054-8452-e31f5d9c7e5a,C0242781,C0206419,was modeled for ,disease transmission,Genus: Coronavirus,6,X,[patf],[virs],N06.850.310,B04.820.504.540.150
744ac083-5577-4054-8452-e31f5d9c7e5a,C0242781,C0206419,were estimated for ,disease transmission,Genus: Coronavirus,5,X,[patf],[virs],N06.850.310,B04.820.504.540.150
744ac083-5577-4054-8452-e31f5d9c7e5a,C0242781,C0206419,involving droplets for ,disease transmission,Genus: Coronavirus,2,X,[patf],[virs],N06.850.310,B04.820.504.540.150
744ac083-5577-4054-8452-e31f5d9c7e5a,C0242781,C0206419,be main route ,disease transmission,Genus: Coronavirus,6,X,[patf],[virs],N06.850.310,B04.820.504.540.150
744ac083-5577-4054-8452-e31f5d9c7e5a,C0242781,C0206419,was reconstructed from 9 120 ,disease transmission,Genus: Coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150
744ac083-5577-4054-8452-e31f5d9c7e5a,C0242781,C0206419,was respectively fitted to reported data for ,disease transmission,Genus: Coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150
6a963759-54f2-4393-baa6-bd5aa0cbe388,C0242781,C0020517,is strongly driven From ,disease transmission,Hypersensitivity,12,X,[patf],[patf],N06.850.310,C20.543
f53f1205-7bb0-4e10-b9e9-372cc8bb4548,C1879547,C1397014,induces prothrombotic state resulting from ,Activation action,Imbalance,2,X,[acty],[sosy],,
b5a41017-d692-4c38-9954-34ec7c52f47e,C1879547,C0005778,induces prothrombotic state resulting from ,Activation action,Blood coagulation,1,X,[acty],[ortf],,G09.188.390.150
b5a41017-d692-4c38-9954-34ec7c52f47e,C1879547,C0005778,participate in dysfunctional ,Activation action,Blood coagulation,2,X,[acty],[ortf],,G09.188.390.150
5bf65b56-60fb-4b62-bc03-81fb746465ac,C0003009,C0567416,is central effector ,angiotensin II,Molecule,2,X,[aapp/bacs/phsu],[sbst],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
2739fdcf-9318-4414-8dcb-e07d11701a7f,C0003009,C1879547,is central effector ,angiotensin II,Activation action,2,X,[aapp/bacs/phsu],[acty],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
0e8c5e87-4f41-447c-bf02-d1783cbfc5b1,C0003009,C0022709,is degraded by ,angiotensin II,Peptidyl-Dipeptidase A,2,X,[aapp/bacs/phsu],[aapp/enzy/imft],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D08.811.277.656.350.350.687
85bc81f7-edbb-4003-b436-fb8f75c6066d,C0003009,C0103306,is degraded by ,angiotensin II,angiotensin I (1-7),2,X,[aapp/bacs/phsu],[aapp/phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,x.x.x.x
594608f4-0289-44b0-b4ad-3b302b5233a9,C0206750,C0206419,is in same ,Coronavirus Infections,Genus: Coronavirus,3,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150
73c176b1-7828-4e36-9aee-8d7485cf156c,C0206750,C1155266,is characterized by exaggerated ,Coronavirus Infections,inflammatory response,2,X,[dsyn],[patf],C02.782.600.550.200,
73c176b1-7828-4e36-9aee-8d7485cf156c,C0206750,C1155266,triggers uncontrolled aberrant ,Coronavirus Infections,inflammatory response,3,X,[dsyn],[patf],C02.782.600.550.200,
73c176b1-7828-4e36-9aee-8d7485cf156c,C0206750,C1155266,is associated with severe ,Coronavirus Infections,inflammatory response,1,X,[dsyn],[patf],C02.782.600.550.200,
73c176b1-7828-4e36-9aee-8d7485cf156c,C0206750,C1155266,is associated with systemic ,Coronavirus Infections,inflammatory response,1,X,[dsyn],[patf],C02.782.600.550.200,
73c176b1-7828-4e36-9aee-8d7485cf156c,C0206750,C1155266,features preeminent ,Coronavirus Infections,inflammatory response,2,X,[dsyn],[patf],C02.782.600.550.200,
47c6ec5d-34bf-4303-8ee8-fda3cee44504,C1155266,C0035222,can lead patients to severe ,inflammatory response,Respiratory Distress Syndrome Adult,2,X,[patf],[dsyn],,C08.381.840;C08.618.840
47c6ec5d-34bf-4303-8ee8-fda3cee44504,C1155266,C0035222,due to Respiratory Distress Syndrome Adult is,inflammatory response,Respiratory Distress Syndrome Adult,1,X,[patf],[dsyn],,C08.381.840;C08.618.840
db3ffbab-d445-4275-8a2e-e1feaa5c4f1b,C1155266,C0243026,is in ,inflammatory response,Sepsis,3,X,[patf],[dsyn],,C01.539.757;C23.550.470.790.500
db8e7c0f-994e-43f1-a15b-ff36c57c7d6d,C0022709,C1879547,resulting in ,Peptidyl-Dipeptidase A,Activation action,2,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
8f3df4cb-c55c-4854-b7eb-d191f84bc99e,C0597357,C1879547,resulting in ,receptor,Activation action,2,X,[aapp/rcpt],[acty],,
6610cf30-d111-49e7-9672-977fd311cc93,C0042397,C0960880,downregulating ,Vasoconstrictor Agents,angiotensin converting enzyme 2,2,X,[phsu],[aapp/enzy],D27.505.954.411.793,x.x.x.x
0e60b66f-d102-4b22-a521-b37320551001,C0003009,C0960880,downregulating ,angiotensin II,angiotensin converting enzyme 2,2,X,[aapp/bacs/phsu],[aapp/enzy],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,x.x.x.x
321dc5ac-90ec-422d-bfb6-6c702b2e131c,C0003009,C0040018,increases ,angiotensin II,Thrombin,2,X,[aapp/bacs/phsu],[aapp/enzy/phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960
bc7ffe3c-e7ab-4cd6-a27b-105eaa633331,C0003009,C0220781,increases ,angiotensin II,Anabolism,1,X,[aapp/bacs/phsu],[biof],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,G03
91bbe2e0-5f69-43ec-a3a0-9ceb06faf8d6,C0003009,C0016017,impairs ,angiotensin II,Fibrinolysis,2,X,[aapp/bacs/phsu],[phsf],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,G09.188.390.150.390
30be21d7-30b0-439f-b781-e34adf72bc18,C0034019,C0042776,prevent spread of ,public health medicine (field),Virus,3,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04
30be21d7-30b0-439f-b781-e34adf72bc18,C0034019,C0042776,has changed target of ,public health medicine (field),Virus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04
1df08ac7-4f2c-479e-86ba-bf1ac82417ed,C0034019,C1705178,have have introduced in ,public health medicine (field),Order (action),3,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
be9da18b-87a6-4ec3-974e-57d942df02e8,C0015967,C0031350,was most common ,Fever,Pharyngitis,2,X,[sosy],[dsyn],C23.888.119.344,C07.550.781;C08.730.561;C09.775.649
9b58e7f1-f915-4cb1-bc21-b751a41978d9,C0015620,silico,was recently identified in in silico ,Famotidine,silico,2,X,[orch/phsu],????,D02.886.675.215;D03.383.129.708.215,????
86ef5fab-99b5-417b-b997-90e5b6ce17e3,C0682972,C0017168,used for treatment ,G-Protein-Coupled Receptors,Gastroesophageal reflux disease,2,X,[aapp/rcpt],[dsyn],D12.776.543.750.695,C06.405.117.119.500.484
3f172173-bc21-4235-b818-d0267f49ed98,C0231491,C0017168,used for treatment ,Antagonist muscle action,Gastroesophageal reflux disease,2,X,[ortf],[dsyn],,C06.405.117.119.500.484
6e51b938-5bd2-4bbe-b7ad-be48e28ba6be,C0015620,1990s,was described In 1990s,Famotidine,1990s,4,X,[orch/phsu],????,D02.886.675.215;D03.383.129.708.215,????
829eede7-a3ac-44e8-bfc6-848cd8746a83,C0015620,C0003451,was In 1990s ,Famotidine,Antiviral Agents,2,X,[orch/phsu],[phsu],D02.886.675.215;D03.383.129.708.215,D27.505.954.122.388
829eede7-a3ac-44e8-bfc6-848cd8746a83,C0015620,C0003451,was described as ,Famotidine,Antiviral Agents,2,X,[orch/phsu],[phsu],D02.886.675.215;D03.383.129.708.215,D27.505.954.122.388
829eede7-a3ac-44e8-bfc6-848cd8746a83,C0015620,C0003451,likely be achieved in only combination with ,Famotidine,Antiviral Agents,2,X,[orch/phsu],[phsu],D02.886.675.215;D03.383.129.708.215,D27.505.954.122.388
32a57a75-e34f-4097-94d4-b188131a4185,C0015620,C0019682,was In 1990s ,Famotidine,HIV,2,X,[orch/phsu],[virs],D02.886.675.215;D03.383.129.708.215,B04.820.650.589.650.350
32a57a75-e34f-4097-94d4-b188131a4185,C0015620,C0019682,was described as ,Famotidine,HIV,2,X,[orch/phsu],[virs],D02.886.675.215;D03.383.129.708.215,B04.820.650.589.650.350
82d11930-68bf-4ad1-8fbe-91a3c67cb1f0,C2756991,C1175743,being Interestingly are presently used against CoV2,HIV Protease Inhibitors [MoA],SARS coronavirus,2,X,[moft],[virs],,B04.820.504.540.150.113.937
095d66cf-144a-4615-8d72-5bbbdd4e204b,C2756991,CoV2,being Interestingly are presently used against CoV2,HIV Protease Inhibitors [MoA],CoV2,2,X,[moft],????,,????
d5e0b7ee-2f54-4b5e-a39e-01b628c1f874,C0003451,C3463820,could could related to ,Antiviral Agents,Inhibition,2,X,[phsu],[acty],D27.505.954.122.388,F01.145.544;F02.463.425.475;F02.739.794.405
65bda260-3dfe-47ae-8832-77982db89699,C0003451,C0030946,could could related to ,Antiviral Agents,Endopeptidases,2,X,[phsu],[aapp/enzy/phsu],D27.505.954.122.388,D08.811.277.656.300
ca0f8ba5-2584-4c8f-b64a-228767249d0e,C0015620,C0007382,interact within CoV2 ,Famotidine,Catalysis,2,X,[orch/phsu],[npop],D02.886.675.215;D03.383.129.708.215,G02.130
908c29d2-87de-4ae8-85f5-375556bd5ceb,C0015620,C0030946,interact within CoV2 ,Famotidine,Endopeptidases,2,X,[orch/phsu],[aapp/enzy/phsu],D02.886.675.215;D03.383.129.708.215,D08.811.277.656.300
a11376fa-b874-4599-bbb7-666612ca2bb7,C0015620,C1175743,interact within CoV2 ,Famotidine,SARS coronavirus,2,X,[orch/phsu],[virs],D02.886.675.215;D03.383.129.708.215,B04.820.504.540.150.113.937
a117087c-5371-4e18-90f0-954c259af7c9,C0015620,CoV2,interact within CoV2 ,Famotidine,CoV2,2,X,[orch/phsu],????,D02.886.675.215;D03.383.129.708.215,????
e751289c-828e-4736-bb0c-15b4d9791934,C0015620,C0598312,interact within CoV2 ,Famotidine,DNA Replication,2,X,[orch/phsu],[genf],D02.886.675.215;D03.383.129.708.215,G02.111.225;G05.226
99520e0f-0e4d-46b9-90d6-05729d716b44,C0599878,C0206419,key Epidemiology of,disease characteristic,Genus: Coronavirus,6,X,[patf],[virs],,B04.820.504.540.150
4947e4a3-7aab-4e0d-8e23-971663317de3,C0008058,C0041834,is with ,Chilblains,Erythema,7,X,[dsyn],[dsyn],C26.212.500.217;C26.417.217,C17.800.229;C23.888.885.328
fd28852d-c00c-49e5-9b32-eb034c38b532,C0032105,C0002055,has On ,Plasma,Alkalies,4,X,[bdsu],[inch],A12.207.152.693;A12.207.270.695;A15.145.693,D01.045
dba44d9a-806f-41e5-8dcf-3c26014f636d,C0032105,C0087111,is potential ,Plasma,Therapeutic procedure,4,X,[bdsu],[topp],A12.207.152.693;A12.207.270.695;A15.145.693,E02
d71768be-8292-41be-abaf-821cf27c13d9,C0032105,C0029345,had had used previously for treatment of ,Plasma,Orthomyxovirus Type A Porcine,4,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,B04.820.545.405.400
d60bfdb8-450b-4d23-a8ca-6322b197ccf6,C1999230,C0206419,lead clinical use for treatment of patients with severe ,Providing (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
d60bfdb8-450b-4d23-a8ca-6322b197ccf6,C1999230,C0206419,realistic scheme for healthcare systems in ,Providing (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
d60bfdb8-450b-4d23-a8ca-6322b197ccf6,C1999230,C0206419,assist communities caring for people affected by ,Providing (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
b5a94ace-dbcb-4262-ae66-3f71a4c05ae4,C1184743,C1706214,is thought crucial for ,bony process,Creation,3,X,[bpoc],[acty],,
a320673b-e1d6-4f59-a4af-a551a9800bbf,C0022709,C0009450,serving as portal ,Peptidyl-Dipeptidase A,Communicable Diseases,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C01.539.221
a320673b-e1d6-4f59-a4af-a551a9800bbf,C0022709,C0009450,is downregulated after CoV2 ,Peptidyl-Dipeptidase A,Communicable Diseases,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C01.539.221
a320673b-e1d6-4f59-a4af-a551a9800bbf,C0022709,C0009450,enable CoV2,Peptidyl-Dipeptidase A,Communicable Diseases,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C01.539.221
364fab2f-047c-4781-9bb2-77517246267a,C0040044,C1536220,reasonable option for relatively stable ,Thrombolytic Therapy,ST segment elevation myocardial infarction,1,X,[topp],[dsyn],E02.319.913,C14.280.647.500.875;C14.907.585.500.875
9a2b42f5-9647-4cc0-b6f8-1eb7fcf05e83,C0949266,C0087111,have been in absence of ,Therapies Investigational,Therapeutic procedure,1,X,[topp],[topp],E02.931,E02
ca502058-3049-40c3-961d-e88f3402bfaa,C1175743,C1709595,retrospectively tested ,SARS coronavirus,Pooled Sample,2,X,[virs],[sbst],B04.820.504.540.150.113.937,
0c6fbbba-51b9-412b-b06f-de590c983797,C1175743,C0037090,retrospectively tested ,SARS coronavirus,Signs and Symptoms Respiratory,2,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.852
0c6fbbba-51b9-412b-b06f-de590c983797,C1175743,C0037090,rapidly spread worldwide with vast majority of confirmed cases presenting with ,SARS coronavirus,Signs and Symptoms Respiratory,2,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.852
e0ca1b8c-b34c-46a0-8589-87780ed08e95,C0009450,C0010200,is with common presenting symptoms of fever ,Communicable Diseases,Coughing,4,X,[dsyn],[sosy],C01.539.221,C08.618.248;C23.888.852.293
e0ca1b8c-b34c-46a0-8589-87780ed08e95,C0009450,C0010200,mainly presents as ,Communicable Diseases,Coughing,2,X,[dsyn],[sosy],C01.539.221,C08.618.248;C23.888.852.293
d8ed17e2-4a32-43e9-a344-bdf278b7f948,C0009450,C0015672,is with common presenting symptoms of fever ,Communicable Diseases,Fatigue,4,X,[dsyn],[sosy],C01.539.221,C23.888.369
6a3e668d-e23d-4ccb-8161-0873baab65ef,C0206750,C0015672,is highly Communicable Diseases respiratory Communicable Diseases with common symptoms of fever ,Coronavirus Infections,Fatigue,6,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.369
bf49fc3f-ccf0-4ed8-90e7-76a7a36ee9fe,C1511790,C0005889,has made biological ,Detection,Body Fluids,1,X,[topp],[bdsu],,A12.207
6d00e8d4-cd71-4b87-a0d8-4104cc3e6eeb,C0005889,C0242781,relevant in terms of diagnosis of ,Body Fluids,disease transmission,1,X,[bdsu],[patf],A12.207,N06.850.310
d7d6b6bc-5114-46b5-82e0-683278a17301,C0042776,C0242943,can generate ,Virus,Molecular Mimicry,2,X,[virs],[moft],B04,G02.111.560;G05.545;G16.012.750.500
6135cbab-1ec6-4f01-a0b6-97d3d9837b7a,C0042776,C1167395,can generate Molecular Mimicry phenomena within their,Virus,Host (organism),2,X,[virs],[orgm],B04,
6135cbab-1ec6-4f01-a0b6-97d3d9837b7a,C0042776,C1167395,encounter endosomal/lysosomal ,Virus,Host (organism),1,X,[virs],[orgm],B04,
94e73285-2ef7-406c-b31b-556d9b3451e5,C0042776,C0040300,thus eliciting autoimmune phenomena withdevasting consequences in ,Virus,Body tissue,2,X,[virs],[tisu],B04,A10
7f46787d-2cce-44ba-b2ae-ae06e85eefef,C2188405,C0206750,suspected for ,urgent Operation,Coronavirus Infections,6,X,[topp],[dsyn],,C02.782.600.550.200
86e0e626-9d54-48db-b05e-7f92c795bac2,C0002085,C0042776,Affinity to S,Alleles,Virus,1,X,[gngm],[virs],G05.360.340.024.340.030,B04
710a7735-10e1-451b-b589-35f4172b94eb,C0002085,C0022709,Affinity of,Alleles,Peptidyl-Dipeptidase A,1,X,[gngm],[aapp/enzy/imft],G05.360.340.024.340.030,D08.811.277.656.350.350.687
0864d3db-9bfa-46e1-abb9-050f35dc384b,C1155099,C0206750,is in ,cytokine biosynthesis,Coronavirus Infections,1,X,[moft],[dsyn],,C02.782.600.550.200
ce134a46-a602-4365-8980-b396d8d01a43,C0021760,ng/ml,were 55.98 ng/ml ,Interleukin-6,ng/ml,2,X,[aapp/imft],????,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,????
abc0b0b5-8c42-4e18-b228-a2cafa36f09b,C0623362,ng/ml,were 55.98 ng/ml ,Matrix Metalloproteinases,ng/ml,2,X,[aapp/enzy],????,D08.811.277.656.300.480.525;D08.811.277.656.675.374.525,????
7c83d175-0708-4346-882e-5eb90b6153cb,C2948600,C1825598,identify ,Aim,IMPACT gene,2,X,[inch/phsu],[gngm],,
7c83d175-0708-4346-882e-5eb90b6153cb,C2948600,C1825598,investigate ,Aim,IMPACT gene,1,X,[inch/phsu],[gngm],,
7c83d175-0708-4346-882e-5eb90b6153cb,C2948600,C1825598,evaluate ,Aim,IMPACT gene,1,X,[inch/phsu],[gngm],,
7c83d175-0708-4346-882e-5eb90b6153cb,C2948600,C1825598,model ,Aim,IMPACT gene,1,X,[inch/phsu],[gngm],,
bf0b3ace-84b8-48d4-9f18-1fca49b92d58,C1825598,C2700061,particularly affecting ,IMPACT gene,Transition (action),2,X,[gngm],[acty],,
210aa704-9496-411b-b23f-e5eaf98e1176,C0206750,C0027651,has resulted in unprecedented challenges for ,Coronavirus Infections,Neoplasms,2,X,[dsyn],[neop],C02.782.600.550.200,C04
210aa704-9496-411b-b23f-e5eaf98e1176,C0206750,C0027651,is in oral ,Coronavirus Infections,Neoplasms,1,X,[dsyn],[neop],C02.782.600.550.200,C04
ead1270a-0775-4905-91cf-d0a81c55a409,C0000936,C1140680,Women with current diagnosis ,Visual Accommodation,Malignant neoplasm of ovary,3,X,[ortf],[neop],G14.010,
8a4ee97a-16e0-47bb-a3ea-35a9cc7e1573,C0030858,C0920425,experienced participants scheuled for ,Pentaerythritol Tetranitrate,cancer therapy,3,X,[orch/phsu],[topp],D02.033.455.706.690,
e295fd58-1311-4da6-9856-038890f629c8,C0040811,C1175743,is with globally obtained 15 277 ,Trees (plant),SARS coronavirus,4,X,[plnt],[virs],B01.650.915,B04.820.504.540.150.113.937
e295fd58-1311-4da6-9856-038890f629c8,C0040811,C1175743,analyze phylogeny of ,Trees (plant),SARS coronavirus,1,X,[plnt],[virs],B01.650.915,B04.820.504.540.150.113.937
58c73b5e-c514-404e-b7fc-f47a69cc70ea,C1293116,C0009450,is earlier than first reported case of ,Introduction procedure,Communicable Diseases,3,X,[topp],[dsyn],,C01.539.221
6146326f-5e31-45d8-8441-9c7a3eaaac77,C0042720,C0040811,are dispersed among most types in phylogenetic ,Viral Genome,Trees (plant),3,X,[gngm],[plnt],G05.360.340.358.840,B01.650.915
dab21926-9834-46fe-aac6-65dfa5eafe28,C1175743,C0024109,uses attach in,SARS coronavirus,Lung,12,X,[virs],[bpoc],B04.820.504.540.150.113.937,A04.411
9de39367-65d1-4e8b-ba77-9f116ba68f18,C1175743,C0597358,uses S1,SARS coronavirus,receptor binding,1,X,[virs],[moft],B04.820.504.540.150.113.937,
9de39367-65d1-4e8b-ba77-9f116ba68f18,C1175743,C0597358,has regions in ,SARS coronavirus,receptor binding,2,X,[virs],[moft],B04.820.504.540.150.113.937,
9de39367-65d1-4e8b-ba77-9f116ba68f18,C1175743,C0597358,affects specific ,SARS coronavirus,receptor binding,2,X,[virs],[moft],B04.820.504.540.150.113.937,
9de39367-65d1-4e8b-ba77-9f116ba68f18,C1175743,C0597358,belongs in terms of ,SARS coronavirus,receptor binding,1,X,[virs],[moft],B04.820.504.540.150.113.937,
accae85f-8349-4529-a709-161c503e7b1c,C1175743,S1,uses S1,SARS coronavirus,S1,1,X,[virs],????,B04.820.504.540.150.113.937,????
6d017220-1c21-4566-9765-38e99f68f638,C1175743,C1167395,attach to ,SARS coronavirus,Host (organism),1,X,[virs],[orgm],B04.820.504.540.150.113.937,
6d017220-1c21-4566-9765-38e99f68f638,C1175743,C1167395,mediates Cells Virus Internalization through,SARS coronavirus,Host (organism),1,X,[virs],[orgm],B04.820.504.540.150.113.937,
6d017220-1c21-4566-9765-38e99f68f638,C1175743,C1167395,producing excessive reaction in ,SARS coronavirus,Host (organism),5,X,[virs],[orgm],B04.820.504.540.150.113.937,
6d017220-1c21-4566-9765-38e99f68f638,C1175743,C1167395,utilize same ,SARS coronavirus,Host (organism),7,X,[virs],[orgm],B04.820.504.540.150.113.937,
6d017220-1c21-4566-9765-38e99f68f638,C1175743,C1167395,caused ,SARS coronavirus,Host (organism),1,X,[virs],[orgm],B04.820.504.540.150.113.937,
eddad453-d2a3-43fa-8d3b-ad78aacd1354,C0476236,C0206750,serve as clues for new-onset ,Developmental symptoms,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
dacdbf0a-78fd-4e1b-826f-037251a2078a,C0733529,cut-off,is with cut-off mg/l,CI-825,cut-off,1,X,[nnon/phsu],????,D03.383.742.680.350.200.700;D13.570.230.677;D13.570.685.350.200.700,????
7665f50e-1d69-4ab6-9d9a-af1181b967d6,C0733529,mg/l,is with cut-off mg/l,CI-825,mg/l,1,X,[nnon/phsu],????,D03.383.742.680.350.200.700;D13.570.230.677;D13.570.685.350.200.700,????
b8fd721a-c3bc-4719-9f5e-bce7552afa10,C4048285,C0242656,were predictors of ,C-Reactive Protein human,Disease Progression,2,X,[aapp/imft],[patf],,C23.550.291.656
5eb18e7e-9458-4bfa-869d-2227c5d4575d,C4048285,C0012634,were predictors to critical ,C-Reactive Protein human,Disease,1,X,[aapp/imft],[dsyn],,C23.550.288
5eb18e7e-9458-4bfa-869d-2227c5d4575d,C4048285,C0012634,were good predictors of ,C-Reactive Protein human,Disease,1,X,[aapp/imft],[dsyn],,C23.550.288
f6232709-a7d3-4a32-ac6b-0292c6f4a7e7,C1292459,C0206750,is with ,Specimen from patient,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
d2ef99a6-98c1-4c88-a04b-62bb38e9b237,C1292459,C0012634,is with ,Specimen from patient,Disease,3,X,[bdsu],[dsyn],,C23.550.288
082bb5f4-d7a8-494e-9354-2fff4e1700af,C0026691,C0442893,suggest here hypothesis of new post-viral ,Mucocutaneous Lymph Node Syndrome,Systemic disease,10,X,[dsyn],[dsyn],C14.907.940.560;C15.604.560;C17.800.862.560,
3c778b4a-7dc4-4814-84a7-bc776a37b725,C0026691,C1290884,suggest here hypothesis of new post-viral ,Mucocutaneous Lymph Node Syndrome,Inflammatory disorder,8,X,[dsyn],[dsyn],C14.907.940.560;C15.604.560;C17.800.862.560,
3d993b81-a6a4-4078-b44b-ca6c9d252a01,C0086418,C0035222,ventilated due to ,Homo sapiens,Respiratory Distress Syndrome Adult,8,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C08.381.840;C08.618.840
133e7626-4e9a-47d6-bb1b-ce7d3bb230ef,C0086418,C0206750,was confirmed for ,Homo sapiens,Coronavirus Infections,18,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C02.782.600.550.200
86b5ad54-1c5d-474b-9ee5-4232912c7178,C0035239,hoc,were started in ad hoc ,Respiratory Therapy,hoc,2,X,[topp],????,E02.880,????
0a439680-d71a-45f5-9366-c32aa778246c,C0013459,hoc,were started in ad hoc ,Early Mobilization,hoc,2,X,[topp],????,E02.760.169.063.500.335;E02.831.335,????
6fc0aee0-b160-413c-94b5-1a2a310c4f9a,C2985393,hoc,were started in ad hoc ,Neuromuscular Electrical Stimulation,hoc,2,X,[topp],????,,????
99b90962-2699-45b1-95e4-fe36bfc8119b,C0231484,C3714552,was consistent with intensive care unit-acquired ,Muscle function,Weakness,4,X,[ortf],[sosy],,
4b3ceb60-ca30-4386-b0cd-927de916123e,C0035668,C0596402,is with minimal ,RNA,cytotoxicity,1,X,[nnon],[comd],D13.444.735,
fc9d6417-614a-4b64-9553-58f168dfecf0,C0035668,C1550101,is in cell culture ,RNA,Supernatant,1,X,[nnon],[bdsu],D13.444.735,
865a4ec0-99b2-423b-984c-6770170fba73,C3271951,C1550101,similarly decreased RNA Viral in,macropinocytosis,Supernatant,1,X,[celf],[bdsu],,
30f779b2-9542-47ee-8397-e6a02ac2f541,C0059831,C1550101,similarly decreased RNA Viral in,ethylisopropylamiloride,Supernatant,1,X,[orch/phsu],[bdsu],x.x.x.x,
5cb6f87a-0ff5-4e31-8cc5-31c3dd860d21,C3271951,C0035736,Surprisingly similarly decreased ,macropinocytosis,RNA Viral,2,X,[celf],[nnon],,D13.444.735.828
155f8b46-3c9c-4afe-a282-25a1960eef74,C0059831,C0035736,Surprisingly similarly decreased ,ethylisopropylamiloride,RNA Viral,2,X,[orch/phsu],[nnon],x.x.x.x,D13.444.735.828
fec4b47f-73c8-4b57-88fb-6a5d34858100,C0754188,C0019704,inhibited SARS coronavirus much higher than that required for,Amprenavir,HIV-1,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.650.589.650.350.400
c1b1234d-66b4-4d5b-a9ad-30729928ccc1,IC,C0019704,were higher than that required for ,IC,HIV-1,1,X,????,[virs],????,B04.820.650.589.650.350.400
4c96c5e9-d009-4f7e-be42-b6c2a35b6da4,C4045453,C0019704,inhibited SARS coronavirus much higher than that required for,ALLINI-2,HIV-1,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.650.589.650.350.400
c6f07b0f-ba42-4b54-a480-a6d021bf9344,C0019704,C1175743,inhibited ,HIV-1,SARS coronavirus,1,X,[virs],[virs],B04.820.650.589.650.350.400,B04.820.504.540.150.113.937
a36deef9-8569-4723-858e-8352c5b3ae79,C0243077,C1175743,shown in case of ,inhibitors,SARS coronavirus,5,X,[chvf],[virs],,B04.820.504.540.150.113.937
d2051244-5d12-4478-a6e8-0c2baa0f8055,C0132326,C1175743,inhibited ,Nevirapine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.383.725.506,B04.820.504.540.150.113.937
c1d864c5-9a86-4a2f-9d09-da7fee0caf5c,C4045453,C1175743,inhibited ,ALLINI-2,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
28c865e4-7c7a-4042-86bb-be920fb06d39,C0754188,C1175743,inhibited ,Amprenavir,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
372f537d-f1d6-4587-b3bc-9f9b05cfa26f,C0243077,C0019704,inhibited SARS coronavirus much higher than that required for,inhibitors,HIV-1,1,X,[chvf],[virs],,B04.820.650.589.650.350.400
cb68d772-9577-470b-9059-288f9c676744,C0132326,C0019704,inhibited SARS coronavirus much higher than that required for,Nevirapine,HIV-1,1,X,[orch/phsu],[virs],D03.383.725.506,B04.820.650.589.650.350.400
dd2ee526-d0ea-4b89-afdc-9b29aa10bd44,C0206750,C0441655,impairing course of routine ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
dd2ee526-d0ea-4b89-afdc-9b29aa10bd44,C0206750,C0441655,screened compounds for their ,Coronavirus Infections,Activities,2,X,[dsyn],[acty],C02.782.600.550.200,
dd2ee526-d0ea-4b89-afdc-9b29aa10bd44,C0206750,C0441655,halting worldwide principal income ,Coronavirus Infections,Activities,2,X,[dsyn],[acty],C02.782.600.550.200,
dd2ee526-d0ea-4b89-afdc-9b29aa10bd44,C0206750,C0441655,implementing preemptive ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
dd2ee526-d0ea-4b89-afdc-9b29aa10bd44,C0206750,C0441655,include population confinement with consequent isolation of their ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
dd2ee526-d0ea-4b89-afdc-9b29aa10bd44,C0206750,C0441655,resume ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
6b263dc0-18ab-4bfd-886e-56f8da52affd,C1443867,C1175743,of SARS coronavirus is,Standard precautions,SARS coronavirus,3,X,[topp],[virs],,B04.820.504.540.150.113.937
d70037ef-99f2-4e87-80c5-11f6d5a36cfd,C1157562,C0751973,determining composition of ,translational elongation,Proteome,3,X,[genf],[aapp/bacs],,D12.776.817
70838b14-e0ea-4286-9c1e-113c2dc78428,C0206750,C1819995,determine adaptation of ,Coronavirus Infections,Host Cell,1,X,[dsyn],[celc],C02.782.600.550.200,
70838b14-e0ea-4286-9c1e-113c2dc78428,C0206750,C1819995,are adapted to ,Coronavirus Infections,Host Cell,1,X,[dsyn],[celc],C02.782.600.550.200,
70838b14-e0ea-4286-9c1e-113c2dc78428,C0206750,C1819995,also induces severe attack on ,Coronavirus Infections,Host Cell,2,X,[dsyn],[celc],C02.782.600.550.200,
cb76f80b-9d5c-4d64-9926-0e0e90edb30c,C0206750,C0597295,determine ,Coronavirus Infections,Protein Biosynthesis,1,X,[dsyn],[moft],C02.782.600.550.200,G02.111.660.871;G03.734.871;G05.297.670
d56bcd22-497b-4f61-b5e1-4c22357045d5,C1175743,C0597295,have faster ,SARS coronavirus,Protein Biosynthesis,3,X,[virs],[moft],B04.820.504.540.150.113.937,G02.111.660.871;G03.734.871;G05.297.670
f8deadb9-d77c-4bf6-a222-d73fbe837798,C0206750,RSCU,have high RSCU ,Coronavirus Infections,RSCU,1,X,[dsyn],????,C02.782.600.550.200,????
c718bd5a-9bf4-44ff-9e2c-94731efd6af0,C0206750,C0206422,have high RSCU ,Coronavirus Infections,Human coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200,
f60c2ffa-9e86-4ef5-8521-7dc821c5b46e,C4698072,C0042333,shows evidence for ,NL63,Variation (Genetics),3,X,[virs],[npop],,G05.365
88ad4f01-a7c3-4bff-8bc2-bf8539e23a10,C1167395,C0682447,portrays relation between ,Host (organism),virus by host,3,X,[orgm],[virs],,
110e20b3-2f5f-41e7-a0c9-2bd4674ddede,C0206750,C0278996,potentially disproportionate IMPACT gene on,Coronavirus Infections,Malignant Head and Neck Neoplasm,10,X,[dsyn],[neop],C02.782.600.550.200,
6b648c38-a9f9-4bdc-b331-e775856ab88f,C0206750,C0595938,has IMPACT gene toxic,Coronavirus Infections,effect increased,4,X,[dsyn],[patf],C02.782.600.550.200,
bc26e7aa-7c5e-4ab0-af24-a60d29318b9d,C1825598,C0087111,toxic effect increased of,IMPACT gene,Therapeutic procedure,2,X,[gngm],[topp],,E02
d6f3444b-0dcf-4c10-9613-b9fcbcd4398c,C0021055,C0206750,is in patients with ,Immunologic Memory,Coronavirus Infections,1,X,[ortf],[dsyn],G12.450.050.500,C02.782.600.550.200
756faa44-dc38-414d-8adc-ffea8728c6c4,C0021760,C0018681,was found significantly higher in patients with ,Interleukin-6,Headache,2,X,[aapp/imft],[sosy],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C23.888.592.612.441
338ce4b5-cbba-4e6e-adc8-2f1ada5a3ebf,C0235031,C0206750,are seen in patients with ,Neurologic Symptoms,Coronavirus Infections,2,X,[sosy],[dsyn],C10.597;C23.888.592,C02.782.600.550.200
338ce4b5-cbba-4e6e-adc8-2f1ada5a3ebf,C0235031,C0206750,have Recently have noticed in patients with ,Neurologic Symptoms,Coronavirus Infections,2,X,[sosy],[dsyn],C10.597;C23.888.592,C02.782.600.550.200
338ce4b5-cbba-4e6e-adc8-2f1ada5a3ebf,C0235031,C0206750,be initial Disease Presentation of,Neurologic Symptoms,Coronavirus Infections,2,X,[sosy],[dsyn],C10.597;C23.888.592,C02.782.600.550.200
d98b9d13-199e-4755-be29-8e88f1b53abc,C1457887,C0012634,is in ,Symptoms,Disease,2,X,[sosy],[dsyn],,C23.550.288
c97e4c52-3a12-4b9c-9d79-9584a14657e5,C0235031,C0042776,prohibit ,Neurologic Symptoms,Virus,1,X,[sosy],[virs],C10.597;C23.888.592,B04
18956e77-db89-4867-87d3-9ca998c9d466,C3272452,C1622204,is with spike-like ,Single-Stranded RNA,envelope,1,X,[nnon],[celc],,
dd6462ce-8513-456b-b148-5a74131bbdcd,C2717802,C1622204,is with spike-like ,Viral Structures,envelope,1,X,[anst],[celc],A21,
baead955-83ef-4ff1-916c-951e795da6cb,C1175743,C1622204,is enveloped ,SARS coronavirus,envelope,1,X,[virs],[celc],B04.820.504.540.150.113.937,
d9b50a52-7d89-4bb1-92e4-b22b6effc2c2,C1622204,C0010813,can interact after ,envelope,Cytokinesis,1,X,[celc],[celf],,G04.144.220.250
f7ef2126-f49f-4b67-b183-18da9f77f3ab,C1622204,C0022709,can interact with ,envelope,Peptidyl-Dipeptidase A,1,X,[celc],[aapp/enzy/imft],,D08.811.277.656.350.350.687
2f129cdc-1a92-4503-8ae2-bab49952166b,C1622204,C0597357,can interact with ,envelope,receptor,1,X,[celc],[aapp/rcpt],,
9a7ab6e7-6571-4e08-8e48-b4cf67caa537,C0025118,C0206750,deferring follow-ups because of ,Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403,C02.782.600.550.200
be47d114-57c6-4699-8865-668f487067c8,C0025118,C1829939,deferring follow-ups in case of ,Medicine,{Non-patient},2,X,[bmod],[clna],H02.403,
38a589fa-9b30-4a9d-947e-6c4af75e518e,C0015967,C1175743,led to testing for ,Fever,SARS coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
38a589fa-9b30-4a9d-947e-6c4af75e518e,C0015967,C1175743,stands for ,Fever,SARS coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
38a589fa-9b30-4a9d-947e-6c4af75e518e,C0015967,C1175743,are most prevalent Symptoms of adults infected by,Fever,SARS coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
38a589fa-9b30-4a9d-947e-6c4af75e518e,C0015967,C1175743,can facilitate ,Fever,SARS coronavirus,1,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
4fbe6912-060a-42c4-a3bd-1a9a77731f17,C0029235,C0206750,was identified in January 2020 as novel ,Organism,Coronavirus Infections,9,X,[orgm],[dsyn],,C02.782.600.550.200
23f14483-c65b-4efa-bd74-f02607685ae1,C0019682,C0024312,demonstrated severe ,HIV,Lymphopenia,1,X,[virs],[dsyn],B04.820.650.589.650.350,C15.378.553.546.605;C20.673.627
cf6b72e7-1d3a-49f1-a042-d2804049371c,C0019682,COVID-19,remain at ,HIV,COVID-19,2,X,[virs],[virs],B04.820.650.589.650.350,C000657245
7dc6b719-9920-43df-8fa2-b824001466af,C0019682,CD4,decreased CD4 ,HIV,CD4,1,X,[virs],????,B04.820.650.589.650.350,????
c0dde7f8-2a86-4d55-8043-5a1795ba7af6,C0086418,1week,was admitted due to right limb weakness for 1day 1week,Homo sapiens,1week,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
c0dde7f8-2a86-4d55-8043-5a1795ba7af6,C0086418,1week,was admitted to Hubei Provincial 1day 1week,Homo sapiens,1week,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
69b15d62-abf1-461f-a09c-b17cb1004ece,C0086418,C0025118,was admitted to Hubei Provincial Hospital of TraditionalChinese ,Homo sapiens,Medicine,1,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H02.403
d6ed21ec-4c62-45de-bf6a-5f924dc8cb3a,C0070166,C0087111,were administered to ,clopidogrel,Therapeutic procedure,3,X,[orch/phsu],[topp],D02.886.778.823.500.500;D03.383.725.849.500.500;D03.383.903.830.500.500;D03.633.100.928.500.500,E02
307d83b7-8ea8-41a6-93bc-61023aec6d78,C0070166,C0751956,were administered to ,clopidogrel,Acute Cerebrovascular Accidents,6,X,[orch/phsu],[dsyn],D02.886.778.823.500.500;D03.383.725.849.500.500;D03.383.903.830.500.500;D03.633.100.928.500.500,C10.228.140.300.775;C14.907.253.855
2e32abbd-0a5b-4b0b-9617-5b8f8d2b648b,C1175175,C1327414,caused hypoxemia of ,Severe Acute Respiratory Syndrome,cytokine secretion,4,X,[dsyn],[celf],C02.782.600.550.200.750;C08.730.730,
94f2d4cb-4082-40b8-9688-8d9f930afc3c,C1327414,C0948008,contribute to occurrence of ,cytokine secretion,Ischemic stroke,3,X,[celf],[dsyn],,
a483bc17-2849-4b14-a71b-6f213cea3372,C0206750,C0751956,show ,Coronavirus Infections,Acute Cerebrovascular Accidents,8,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
a483bc17-2849-4b14-a71b-6f213cea3372,C0206750,C0751956,be may complicated with ,Coronavirus Infections,Acute Cerebrovascular Accidents,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
a483bc17-2849-4b14-a71b-6f213cea3372,C0206750,C0751956,simultaneously diagnosed with ,Coronavirus Infections,Acute Cerebrovascular Accidents,2,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
e2b039e7-0722-473b-bad9-6cff02d9895c,C0206750,C0000768,induce ,Coronavirus Infections,Congenital Abnormality,2,X,[dsyn],[cgab],C02.782.600.550.200,C16.131
c761d1b4-cd6d-4154-8ccf-b156fec139ac,C0206750,C1705764,induces ,Coronavirus Infections,Doubling,1,X,[dsyn],[acty],C02.782.600.550.200,
1a34be00-e473-4f14-a7d4-12415e065c51,C1882509,C2741673,is With ,put - instruction imperative,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[acty],[clna],,
0dcc2888-e31c-463f-8ecc-92da9d424931,C1704330,C0221423,Coronavirus Infections,Dental Diseases,Illness (finding),2,X,[dsyn],[sosy],C07,
3a1267df-2f7c-448d-b92f-4968a3742a6d,C0004002,C0001899,was present ,Aspartate Transaminase,Alanine Transaminase,7,X,[aapp/enzy],[aapp/enzy],D08.811.913.477.700.225,D08.811.913.477.700.100
7c2f36bc-1a2f-49a7-ae6e-dd210fb26302,C0596402,C0022917, includes ,cytotoxicity,Lactate Dehydrogenase,12,X,[comd],[aapp/enzy],,D08.811.682.047.551.400;D08.811.682.047.820.493
e184603a-f965-4217-80ff-f06936d863ba,C0596402,C0266258,is in ,cytotoxicity,Congenital absence of liver,10,X,[comd],[cgab],,
3833d95f-7093-44f5-bdad-b775974d51f0,remdesivir,C0206750,received emergency use authorization for use in patients hospitalized with ,remdesivir,Coronavirus Infections,2,X,[clnd],[dsyn],,C02.782.600.550.200
3833d95f-7093-44f5-bdad-b775974d51f0,remdesivir,C0206750,demonstrated powerful ,remdesivir,Coronavirus Infections,1,X,[clnd],[dsyn],,C02.782.600.550.200
3833d95f-7093-44f5-bdad-b775974d51f0,remdesivir,C0206750,showed faster time to clinical improvement in severe ,remdesivir,Coronavirus Infections,1,X,[clnd],[dsyn],,C02.782.600.550.200
3833d95f-7093-44f5-bdad-b775974d51f0,remdesivir,C0206750,Therapeutic procedure,remdesivir,Coronavirus Infections,1,X,[clnd],[dsyn],,C02.782.600.550.200
0c897550-0d08-4b43-ba48-f82cf03bac3d,C0304229,C0036658,therefore have created ,Experimental drug,Esthesia,2,X,[phsu],[ortf],,F02.830.816;G11.561.790
872f95f6-7bc5-4fa0-8f14-d7109a91161e,C0025118,C0544688,is in ,Medicine,complication of disease,1,X,[bmod],[patf],H02.403,
f659b8c5-3a11-48fa-8ca8-508978c504f7,C1175743,C1511790,was first ,SARS coronavirus,Detection,5,X,[virs],[topp],B04.820.504.540.150.113.937,
5a1fdb49-a0d9-4a4b-b3be-b19d5e6bbd92,C0012634,C0003451,are away from still target ,Disease,Antiviral Agents,4,X,[dsyn],[phsu],C23.550.288,D27.505.954.122.388
5a1fdb49-a0d9-4a4b-b3be-b19d5e6bbd92,C0012634,C0003451,associated with specific ,Disease,Antiviral Agents,2,X,[dsyn],[phsu],C23.550.288,D27.505.954.122.388
b85212f3-4bd2-425e-9719-5327fde4b600,C0393706,C1175743,improves accuracy of ,Early infantile epileptic encephalopathy with suppression bursts,SARS coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150.113.937
a811c02a-8c59-410e-bde1-5a660bc1b40b,C0206750,C2348077,have spread to ,Coronavirus Infections,Date Fruit,5,X,[dsyn],[food],C02.782.600.550.200,B01.650.940.800.575.912.250.093.615
2f18a823-5f9a-4855-8fc4-4f30f5223ffc,C0206074,C1185740,performed on respiratory ,Renal Replacement Therapy,Tract,4,X,[topp],[bpoc],E02.870,
13bcc1f1-b785-4462-9117-036c83db8947,C0032521,C1185740,performed on respiratory ,Polymers,Tract,1,X,[bodm/chvs],[bpoc],D05.750;D25.720;J01.637.051.720,
88f1aca6-2a56-410c-af15-c2ae275e2c53,C0206074,C0370003,performed on respiratory ,Renal Replacement Therapy,Specimen,2,X,[topp],[sbst],E02.870,
b1daa068-bad1-478d-8ee2-c9ee90e10bc0,C0032521,C0370003,performed on respiratory ,Polymers,Specimen,1,X,[bodm/chvs],[sbst],D05.750;D25.720;J01.637.051.720,
684897b3-08f4-4a80-bd1e-21cb1c3efc21,C3858690,C1609165,included ,adjunctive treatment,tocilizumab,4,X,[topp],[aapp/imft/phsu],,x.x.x.x
a88a9823-de80-42f0-8c09-15d430164ad4,C3858690,C0087111,included ,adjunctive treatment,Therapeutic procedure,4,X,[topp],[topp],,E02
617ab551-a929-4445-b7b6-4ec6111676d7,C3858690,C0001617,included ,adjunctive treatment,Adrenal Cortex Hormones,4,X,[topp],[horm/orch/phsu],,D06.472.040
2693e2ae-4958-4732-8e5c-9e557eb7f3fa,C1160716,intra,heavily rely on intra ,viral transmission,intra,1,X,[celf],????,,????
3c795345-0a3b-48d0-9015-ab24d90e01f3,C1160716,C1167395,heavily rely on intra ,viral transmission,Host (organism),1,X,[celf],[orgm],,
5c11175e-725d-4e85-a8e2-41c482150d5c,C1160716,C3826426,heavily rely on intra ,viral transmission,Dynamics,1,X,[celf],[npop],,
cde656ef-b90b-4fb9-901a-9e1f0b4a0364,C0035253,C0206750,have have particularly hit during crisis due ,Rest,Coronavirus Infections,1,X,[dora],[dsyn],I03.450.769.647,C02.782.600.550.200
4d7015c6-9bfb-4f9b-9eb4-6bf3a0dcffe2,C0242781,C0042776,is easy in context of highly contagious ,disease transmission,Virus,1,X,[patf],[virs],N06.850.310,B04
8cf3a1b2-54c9-4721-8bf3-aa8f6c0e05ca,C0032521,C1175743,is in first days for detection of ,Polymers,SARS coronavirus,2,X,[bodm/chvs],[virs],D05.750;D25.720;J01.637.051.720,B04.820.504.540.150.113.937
92752456-ce1c-4150-83e7-9be15da75971,C0032285,C0034019,outbreak of was major ,Pneumonia,public health medicine (field),2,X,[dsyn],[bmod],C08.381.677;C08.730.610,H02.403.720;N01.400.550;N06.850
22dcdba8-4e16-4f3e-9167-bc882ede004c,C0032285,C2745965,outbreak of was major ,Pneumonia,Emergencies [Disease/Finding],2,X,[dsyn],[patf],C08.381.677;C08.730.610,C23.550.291.781;N06.230.100.083;N06.850.376
76f8809d-20be-47f2-9b7c-e62c3e38fcc1,C0032285,C0086418,outbreak of was major ,Pneumonia,Homo sapiens,2,X,[dsyn],[humn],C08.381.677;C08.730.610,B01.050.150.900.649.313.988.400.112.400.400
6c01c69d-6f46-4d7b-b194-66e4dc8d45a0,C0034019,C0086418,is with substantive ,public health medicine (field),Homo sapiens,5,X,[bmod],[humn],H02.403.720;N01.400.550;N06.850,B01.050.150.900.649.313.988.400.112.400.400
4e766229-07cb-42ad-b433-2df049ef28a7,C2745965,C0086418,is in ,Emergencies [Disease/Finding],Homo sapiens,2,X,[patf],[humn],C23.550.291.781;N06.230.100.083;N06.850.376,B01.050.150.900.649.313.988.400.112.400.400
0730335e-efb1-4015-8a4e-a3069655a776,C0282682,C1175743,primarily target S protein among structural elements of ,Antibodies Blocking,SARS coronavirus,1,X,[aapp/imft/irda],[virs],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,B04.820.504.540.150.113.937
170ac3c1-0742-493e-8e9e-2e8021e9e0e1,C1175743,C1537068,mediates ,SARS coronavirus,Virus Internalization,2,X,[virs],[biof],B04.820.504.540.150.113.937,G06.920.881
170ac3c1-0742-493e-8e9e-2e8021e9e0e1,C1175743,C1537068,occurs through ,SARS coronavirus,Virus Internalization,1,X,[virs],[biof],B04.820.504.540.150.113.937,G06.920.881
00b30e71-c70c-4e28-92cf-197f996426c4,C1175743,C1514760,mediates Cells Virus Internalization through,SARS coronavirus,Receptor Cell,2,X,[virs],[cell],B04.820.504.540.150.113.937,
00b30e71-c70c-4e28-92cf-197f996426c4,C1175743,C1514760,uses membrane form as,SARS coronavirus,Receptor Cell,3,X,[virs],[cell],B04.820.504.540.150.113.937,
00b30e71-c70c-4e28-92cf-197f996426c4,C1175743,C1514760,caused ,SARS coronavirus,Receptor Cell,2,X,[virs],[cell],B04.820.504.540.150.113.937,
5b22a1cc-6289-43c1-a26e-c632e07b2aad,C0206750,C1947933,transmissible to medical professionals involved in their ,Coronavirus Infections,care activity,3,X,[dsyn],[acty],C02.782.600.550.200,
5b22a1cc-6289-43c1-a26e-c632e07b2aad,C0206750,C1947933,prioritize ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
5b22a1cc-6289-43c1-a26e-c632e07b2aad,C0206750,C1947933,provides opportunity for health care planners of organizations across India for reformation of disabilities ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
5b22a1cc-6289-43c1-a26e-c632e07b2aad,C0206750,C1947933,Indeed provides opportunity for reformation of disabilities ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
5b22a1cc-6289-43c1-a26e-c632e07b2aad,C0206750,C1947933,profound global IMPACT gene on urological,Coronavirus Infections,care activity,2,X,[dsyn],[acty],C02.782.600.550.200,
5b22a1cc-6289-43c1-a26e-c632e07b2aad,C0206750,C1947933,has created unprecedented challenges for ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
1c1388b8-726e-48a4-b992-d887fb7ad4d6,C0009450,C1947933,transmissible to medical professionals involved in their ,Communicable Diseases,care activity,3,X,[dsyn],[acty],C01.539.221,
aceb8d19-e466-4204-84cc-5a26f93cd445,C0751956,C0206750,may have undiagnosed ,Acute Cerebrovascular Accidents,Coronavirus Infections,9,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C02.782.600.550.200
fe0bb32f-abb4-4df3-9ab8-2beaa5da1412,C0751956,C0009450,may have undiagnosed ,Acute Cerebrovascular Accidents,Communicable Diseases,5,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C01.539.221
f17f6532-bfd1-4b1f-8580-134c9aa5c717,C0751956,C1947933,may have undiagnosed ,Acute Cerebrovascular Accidents,care activity,5,X,[dsyn],[acty],C10.228.140.300.775;C14.907.253.855,
a6c6d2d7-22f9-45eb-ad45-62313a487bf2,C1167622,C0086418,is with ,Binding (Molecular Function),Homo sapiens,9,X,[moft],[humn],,B01.050.150.900.649.313.988.400.112.400.400
b6ece6e2-ffb8-487e-a188-ee348557e7ff,C1510827,C0507236,control internalization of ,Affinity,Anterior bronchopulmonary segment of superior pulmonary vein,1,X,[npop],[bpoc],,
80d27355-a665-4088-8210-049c5dcd9241,C0319157,C3888108,possibly restrict ,AS virus,Import into cell,1,X,[virs],[celf],,
4f199579-3ddb-49cf-81f1-80ec7812aa47,C0009450,C1323511,into Pneumonia is,Communicable Diseases,N-carbamoylputrescine amidase activity,1,X,[dsyn],[moft],C01.539.221,
64478bdf-02ac-4916-b7b9-bd83b88cc265,C0029167,C1705178,is in ,Oral Medicine,Order (action),1,X,[bmod],[acty],E06.640;H02.163.670,
b48fd2c1-a79c-4623-ab77-c5edbbbabb38,C0029167,C1999230,is in ,Oral Medicine,Providing (action),1,X,[bmod],[acty],E06.640;H02.163.670,
4b0e4e64-771c-4267-87b0-db442c420458,C0029167,C1290071,is in ,Oral Medicine,Disorder of oral mucous membrane,1,X,[bmod],[dsyn],E06.640;H02.163.670,
d85e4269-67e1-4a50-9af0-78bf055b47e6,C1516048,C0206419,effect on ,Assessed,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
d85e4269-67e1-4a50-9af0-78bf055b47e6,C1516048,C0206419,changes during ,Assessed,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
0198ddab-8927-47d1-87a4-cd79e3792f8d,C0080078,C0206419,are correlated with decreased ,Range of Motion Articular,Genus: Coronavirus,1,X,[clna],[virs],E01.370.600.700;G11.427.760,B04.820.504.540.150
0198ddab-8927-47d1-87a4-cd79e3792f8d,C0080078,C0206419,are strongly correlated with ,Range of Motion Articular,Genus: Coronavirus,1,X,[clna],[virs],E01.370.600.700;G11.427.760,B04.820.504.540.150
903669e3-1284-4558-afef-b0fe481789c6,C0030858,C0206419,infected with ,Pentaerythritol Tetranitrate,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.033.455.706.690,B04.820.504.540.150
2c7731b4-eff4-4d73-a5a8-6c696b9b965c,C1547282,C0024109,is in ,Show,Lung,2,X,[anim],[bpoc],,A04.411
5b731cc3-36aa-4da9-a93e-29d2ae2b0d02,GGO,C0024109,is in ,GGO,Lung,2,X,????,[bpoc],????,A04.411
c159ffab-6b53-4520-a4e8-9776d11c9408,C1547282,C1265876,is with reduction in density of lesions of linear ,Show,Abnormally opaque structure (morphologic abnormality),1,X,[anim],[patf],,
c01e0b93-fbcc-40ba-a020-9a4f4f9f31ca,C0242656,C1265876,is with reduction in density of lesions of linear ,Disease Progression,Abnormally opaque structure (morphologic abnormality),1,X,[patf],[patf],C23.550.291.656,
382c3383-8eba-4771-bd08-667e5ff1cc05,C1880355,C0032285,is in patients with serious ,Discover,Pneumonia,1,X,[acty],[dsyn],,C08.381.677;C08.730.610
4348e11a-cd76-466b-a83a-828ec74cc126,C1160638,C1537068,targets during ,Viral life cycle,Virus Internalization,1,X,[biof],[biof],,G06.920.881
e9dd8c0a-eb71-4b40-bdb3-2823f4ec9742,C1160638,C0598312,targets during ,Viral life cycle,DNA Replication,1,X,[biof],[genf],,G02.111.225;G05.226
8f8d4dc2-9fe2-443d-9a17-97235ddd5960,C1160638,C1706853,targets during ,Viral life cycle,Assembly (construction),1,X,[biof],[acty],,
a260a0c8-2c6d-4265-9740-7ba6b15af3f6,C0019240,C0319157,are awaiting assessment for therapeutic use against ,Herb,AS virus,2,X,[plnt],[virs],,
13da8b1e-1ffd-4e61-a6cc-9712bf024b87,C0019240,C0206419,are awaiting assessment for therapeutic use against ,Herb,Genus: Coronavirus,1,X,[plnt],[virs],,B04.820.504.540.150
ed0582ef-8e6c-4887-8769-307796a5e12c,C0577749,C0319157,are awaiting assessment for therapeutic use against ,Phytochemicals,AS virus,2,X,[bacs/orch],[virs],D23.704,
557b4920-41df-4b74-b9b2-22ea7f650502,C0577749,C0206419,are awaiting assessment for therapeutic use against ,Phytochemicals,Genus: Coronavirus,1,X,[bacs/orch],[virs],D23.704,B04.820.504.540.150
c345573d-2721-47bb-8ac2-2e6d1a270ade,C0577749,C1547282,are awaiting assessment As review ,Phytochemicals,Show,1,X,[bacs/orch],[anim],D23.704,
f5e632b9-4c15-48d7-b6cf-9cb339737a63,C0019240,C1547282,are awaiting assessment As review ,Herb,Show,1,X,[plnt],[anim],,
f9e805bd-7bd2-4390-8276-2a0755364416,C0021400,C1449759,was shadowed under consequences of ,Influenza,World War I,1,X,[dsyn],[acty],C02.782.620.365;C08.730.310,I01.880.735.950.250.968;K01.400.504.968.900
90c6d624-a2e3-4f59-9597-f95b3011ba50,C0021400,C1825598,had similar ,Influenza,IMPACT gene,1,X,[dsyn],[gngm],C02.782.620.365;C08.730.310,
fb4471a5-589b-4010-b91c-f849e32986b1,C1511790,C2598152,is in ,Detection,Pulmonary Function Tests:-:Point in time:^Patient:-,1,X,[topp],[clna],,
feb7f894-f0bf-4a2a-b8c5-2dbb7d08383a,C1511790,C0206419,is in more half of ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
feb7f894-f0bf-4a2a-b8c5-2dbb7d08383a,C1511790,C0206419,may play role in development of therapeutic approaches for ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
feb7f894-f0bf-4a2a-b8c5-2dbb7d08383a,C1511790,C0206419,is required for diagnosis of ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
feb7f894-f0bf-4a2a-b8c5-2dbb7d08383a,C1511790,C0206419,low rates of are indicative ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
fc5a86e9-d29b-4ccf-8aee-426ca4b1c81b,C0158644,C0206419,were Detection in half of,Congenital anomaly of lung,Genus: Coronavirus,2,X,[cgab],[virs],,B04.820.504.540.150
6ead5185-2ae7-447d-8f21-2dd9b1c4a97a,C0035231,C1511790,were ,Respiratory Muscles,Detection,1,X,[bpoc],[topp],A02.633.567.900,
348c5867-fb83-4c5f-a40d-7d6581232068,C0517349,C1511790,were ,Muscle Strength,Detection,1,X,[ortf],[topp],E01.370.600.425;G11.427.560,
cfacb4bb-52af-4b48-a3ed-f77fab111fc3,C0035231,C0206419,were Detection in half of,Respiratory Muscles,Genus: Coronavirus,2,X,[bpoc],[virs],A02.633.567.900,B04.820.504.540.150
962f8f09-a852-4dc4-84b3-daaa6079f627,C0517349,C0206419,were Detection in half of,Muscle Strength,Genus: Coronavirus,2,X,[ortf],[virs],E01.370.600.425;G11.427.560,B04.820.504.540.150
29c1f21f-1673-4265-8c7e-49d70bce354c,C4050231,C0230425,effectively predicts SARS-CoV-2 PCR ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Structure of right thigh,1,X,[clna],[bpoc],,
cded34a7-1c45-4500-a9a1-b47d9da9a42c,C4050231,PCR,effectively predicts SARS-CoV-2 PCR ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,PCR,1,X,[clna],????,,????
3abe3875-6364-444e-b1c3-8186eaf1c790,C2948600,COVID19,was to COVID19 ,Aim,COVID19,2,X,[inch/phsu],????,,????
27c9c1cf-22a2-49d5-9e9f-9464934463e6,C1825598,C0011331,viral transmission on,IMPACT gene,Dental Procedures,2,X,[gngm],[topp],,E06.170;N02.421.240.190
2ddddc27-7bb0-4b7a-a3a4-a4ba3bc0d807,C1175743,C0026766,can evolve into ,SARS coronavirus,Multiple Organ Failure,2,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.835.525
f9cfd81c-872b-4ef2-a242-3647b12b6e3c,C0005516,C0599878,reflecting main pathophysiological ,Biological Markers,disease characteristic,4,X,[clna],[patf],D23.101,
601491a0-fb5a-4fe4-9701-4d8247293683,C0024312,C0012634,represents hallmark of ,Lymphopenia,Disease,2,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C23.550.288
601491a0-fb5a-4fe4-9701-4d8247293683,C0024312,C0012634,suggested ,Lymphopenia,Disease,2,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C23.550.288
e6038041-155a-4a09-8c53-e175c75d250d,C0009450,C0020964,produce ,Communicable Diseases,Immunity,2,X,[dsyn],[phsf],C01.539.221,G12.450
916a595c-2c7a-4042-adbe-bd572315a458,C1963758,C0678812,is often considered for ,Immunomodulation,systemic administration,3,X,[topp],[topp],E02.095.465;G12.535,
95d70f49-0aa8-4938-964e-e1bd838d16b7,C1963758,C0007634,is often considered for ,Immunomodulation,Cells,1,X,[topp],[cell],E02.095.465;G12.535,A11
fa1de9b2-0b06-400a-9f69-a6c4de931ae6,C0001617,C0042164,is in patients with ,Adrenal Cortex Hormones,Uveitis,3,X,[horm/orch/phsu],[dsyn],D06.472.040,C11.941.879
871bda30-2b3f-4da2-ad7c-d058e80b89af,C0027950,C0039194,percentage to ,neutrophil,T-Lymphocyte,1,X,[cell],[cell],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
a8b23412-05e7-4f0f-8511-44f0d0988490,C1947904,C0048243,Binding (Molecular Function) of 6LU7,Attachment (action),4-dichlorobenzene,2,X,[acty],[hops/orch],,x.x.x.x
8e8681c6-528b-4513-85d6-16128c7be0b6,C1947904,C0009450,Binding (Molecular Function) of 6LU7,Attachment (action),Communicable Diseases,2,X,[acty],[dsyn],,C01.539.221
6ec294cd-0929-415b-b8d2-3c29d929ce6b,C1947904,6LU7,Binding (Molecular Function) of 6LU7,Attachment (action),6LU7,2,X,[acty],????,,????
cb5c1fbc-1711-470f-a141-9c1802b1ee53,C0206750,C1443869,should take ,Coronavirus Infections,Airborne precautions,3,X,[dsyn],[topp],C02.782.600.550.200,
f38b8607-0a74-471a-a6cc-1f6c01e48225,C0191234,C0728940,was performed with ,Pericardiocentesis,Excision,4,X,[topp],[topp],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,
820f70b5-d2eb-44ff-9169-109fc15a4506,C0206750,C0319157,occur through exposure to ,Coronavirus Infections,AS virus,3,X,[dsyn],[virs],C02.782.600.550.200,
499da6cd-3906-4fc6-9621-5fbc47962fa6,C0012634,C0319157,is in ,Disease,AS virus,4,X,[dsyn],[virs],C23.550.288,
fd74720d-46ff-4e29-bdb7-77506fc50bf2,C0009450,C0319157,caused by new ,Communicable Diseases,AS virus,1,X,[dsyn],[virs],C01.539.221,
ed9f33ae-c29c-4652-824a-325bd4596e01,C0319157,C0010200,causes Respiration Disorders with,AS virus,Coughing,2,X,[virs],[sosy],,C08.618.248;C23.888.852.293
ed9f33ae-c29c-4652-824a-325bd4596e01,C0319157,C0010200,is spreading through ,AS virus,Coughing,3,X,[virs],[sosy],,C08.618.248;C23.888.852.293
ed9f33ae-c29c-4652-824a-325bd4596e01,C0319157,C0010200,survive in droplets of ,AS virus,Coughing,1,X,[virs],[sosy],,C08.618.248;C23.888.852.293
829eb30c-fca3-47c9-8373-7f6b3aa1310b,C0319157,C0035204,causes ,AS virus,Respiration Disorders,1,X,[virs],[dsyn],,C08.618
9b2ae03e-29ba-4daf-8c59-4f6d6cf0df08,C0319157,C1707455,is in ,AS virus,Comparison,3,X,[virs],[acty],,
ae50d517-45dc-46cc-a377-440bdc5290fe,C0319157,C0017428,is in full ,AS virus,Genome,3,X,[virs],[gngm],,G05.360.340
500df061-ebf3-449f-b601-785917103704,C0310367,C0206750,is rapid outbreak of ,Today,Coronavirus Infections,11,X,[antb/orch],[dsyn],,C02.782.600.550.200
d6beff20-e521-4fef-937b-099e7a3d0d18,C0599732,C1155357,serve through purinergic ,cell injury,cell surface receptor signaling pathway,7,X,[comd],[moft],,
27151a60-9bbd-4799-ae0f-ada17bb82b15,C0599732,C0243042,serve as ,cell injury,Inflammation Mediators,7,X,[comd],[phsu],,D23.469
085b5c79-abea-4b7e-a4d8-d32305fb6839,C0001443,C0087111,is seen as major obstacle to efficacy of immune ,Adenosine,Therapeutic procedure,7,X,[bacs/nnon/phsu],[topp],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,E02
260b3016-9fb0-4ece-b9e0-5aad3202f24c,C1325584,C0087111,are critical ,lateral element,Therapeutic procedure,7,X,[celc],[topp],,E02
a2a928bc-5f61-4626-a7d9-cf18fb4cb9cf,C1704259,C0445623,is in ,Biochemical Pathway,Microorganism,1,X,[moft],[orgm],,
f7dd6da8-41f8-4d47-954c-0601c273e3cb,C0243077,C1704259,specific to adenosinergic ,inhibitors,Biochemical Pathway,7,X,[chvf],[moft],,
f7dd6da8-41f8-4d47-954c-0601c273e3cb,C0243077,C1704259,is in endosomal ,inhibitors,Biochemical Pathway,1,X,[chvf],[moft],,
e3c9eaf7-1b5c-4fa9-a228-70a45ca72ed8,C0243077,C0445623,specific to adenosinergic ,inhibitors,Microorganism,1,X,[chvf],[orgm],,
996bda34-7d0c-4f91-a1ff-a18d930ed3b5,C2745965,C0445623,were ,Emergencies [Disease/Finding],Microorganism,5,X,[patf],[orgm],C23.550.291.781;N06.230.100.083;N06.850.376,
2cc246c1-8a35-4dc5-b79d-157b0cf04e7a,C2745965,C0022568,were ,Emergencies [Disease/Finding],Keratitis,5,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C11.204.564
359decbe-da83-49cb-b95a-8153f293b9a4,C1764827,C1175175,is with ,Isolate - microorganism,Severe Acute Respiratory Syndrome,1,X,[bacs],[dsyn],,C02.782.600.550.200.750;C08.730.730
64adea50-69b5-41b9-b8f2-06af7ad2fde5,C0034019,C1764827,recommend ,public health medicine (field),Isolate - microorganism,1,X,[bmod],[bacs],H02.403.720;N01.400.550;N06.850,
69379b89-b50a-466f-9074-c7cbc23f2edf,C0034019,C1175175,recommend ,public health medicine (field),Severe Acute Respiratory Syndrome,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200.750;C08.730.730
69379b89-b50a-466f-9074-c7cbc23f2edf,C0034019,C1175175,isolating patients with ,public health medicine (field),Severe Acute Respiratory Syndrome,5,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200.750;C08.730.730
d2b311ea-a14b-4d4f-b238-73d85df5ead2,C1880177,C3810578,is in terms of ,Contribution,Gigaxonin human,1,X,[acty],[aapp],,
71b94575-393a-498c-ba3c-3cea8b70e38f,C0042870,C0206750,play role in ,Vitamin D Deficiency,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.521.500.133.770,C02.782.600.550.200
320d718c-394b-4b28-86ed-c9e614ccb9b2,C0042870,C0012634,play role in ,Vitamin D Deficiency,Disease,1,X,[dsyn],[dsyn],C18.654.521.500.133.770,C23.550.288
c7f2b8d8-d01b-4c78-8562-9f9169f27c28,ITU,C0220853,had 25 ,ITU,Hydroxide Ion,1,X,????,[elii],????,x.x.x.x
dfbbe015-58e1-49ca-a45f-41b984053a8d,C1513397,C0087111,is with ,Molecular Medicine,Therapeutic procedure,1,X,[bmod],[topp],H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530,E02
de9c7820-c332-4124-acf7-b3920c543786,C0687133,C0087111,is with emerging ,Drug Interactions,Therapeutic procedure,4,X,[patf],[topp],G07.690.773.968,E02
5ac21abc-0e42-487b-8e08-f67d6e8f3642,C1513397,C0206750,is with ,Molecular Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530,C02.782.600.550.200
5d556b8c-00b6-43cb-9814-d9153c5d2b98,C0687133,C0206750,is with emerging ,Drug Interactions,Coronavirus Infections,4,X,[patf],[dsyn],G07.690.773.968,C02.782.600.550.200
08048c31-328a-4ec1-b109-0c1f560d8fb9,2-item,C0344315,measure ,2-item,Depressed mood,2,X,????,[mobd],????,
3f8f0b40-abd1-4a87-b97a-9e01e65263d4,2-item,pre,measure Depressed mood level respectively for pre,2-item,pre,4,X,????,????,????,????
b291c947-f2d7-4d0b-b5d8-b5df0263b3ff,2-item,C0206750,measure Depressed mood level respectively for pre,2-item,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
5b21c5b3-6a4f-40c2-9571-2bdb5c1f8f57,C2364111,PHQ-2,also exhibited similar associations with PHQ-2 ,Ageusia,PHQ-2,2,X,[sosy],????,C10.597.751.861.184;C23.888.592.763.861.184,????
90a5bee7-cd92-43a2-9726-9cb90bd83cbf,C0301630,C1824356,is in odds of ,Reduction (chemical),KIAA1551 gene,1,X,[npop],[gngm],,
566e2ab4-d14f-4b38-9c4f-b3999baa6edd,C0301630,C1175743,is in odds of ,Reduction (chemical),SARS coronavirus,1,X,[npop],[virs],,B04.820.504.540.150.113.937
566e2ab4-d14f-4b38-9c4f-b3999baa6edd,C0301630,C1175743,have have implemented in countries with outbreaks of CoV2,Reduction (chemical),SARS coronavirus,4,X,[npop],[virs],,B04.820.504.540.150.113.937
bb6e7d3b-0296-433b-975d-4deb17786e97,C0029250,C1175743,engage in first comprehensive analysis of ,Organoids,SARS coronavirus,2,X,[tisu],[virs],A10.802,B04.820.504.540.150.113.937
f4583398-5dff-4bd3-80db-5d3f7179ad61,C0086418,C1175175,is with severe ,Homo sapiens,Severe Acute Respiratory Syndrome,8,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C02.782.600.550.200.750;C08.730.730
4d0e7369-f34c-4bd2-aa18-afefd4128975,C0042769,C0021745,elicits extremely robust intrinsic ,Virus Diseases,Interferon Type II,2,X,[dsyn],[aapp/imft/phsu],C02,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
0d8a50ed-b952-476b-923e-8f3fd046292b,C0021745,de,controlling de ,Interferon Type II,de,1,X,[aapp/imft/phsu],????,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,????
b22a75ce-9bcf-4de6-95dc-4a2c1937f73b,C0021745,C0319157,controlling de ,Interferon Type II,AS virus,1,X,[aapp/imft/phsu],[virs],D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,
c68ec5bd-e5bc-4f7f-84f7-6b3dff246149,C0021745,C1175743,controlling ,Interferon Type II,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,B04.820.504.540.150.113.937
583c7e88-ce1a-4c69-907f-d701777c7478,C0021745,C0598312,controlling ,Interferon Type II,DNA Replication,1,X,[aapp/imft/phsu],[genf],D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,G02.111.225;G05.226
11759e9b-a8e5-4720-84b4-cf6b29d33acc,C0086418,C1175743,are productive site of ,Homo sapiens,SARS coronavirus,2,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
11759e9b-a8e5-4720-84b4-cf6b29d33acc,C0086418,C1175743,be functional target for spike ,Homo sapiens,SARS coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
11759e9b-a8e5-4720-84b4-cf6b29d33acc,C0086418,C1175743,were productively infected with ,Homo sapiens,SARS coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
11759e9b-a8e5-4720-84b4-cf6b29d33acc,C0086418,C1175743,has has identified as functional ,Homo sapiens,SARS coronavirus,3,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
59ed64eb-e251-44e2-b321-b2d5cd958849,C0087111,C1825598,limiting ,Therapeutic procedure,IMPACT gene,2,X,[topp],[gngm],E02,
0b21646c-52c6-487c-806a-658d7a65d64a,C0087111,C0042774,are aimed at ,Therapeutic procedure,Virus Replication,2,X,[topp],[celf],E02,G06.920.925
0b21646c-52c6-487c-806a-658d7a65d64a,C0087111,C0042774,reducing effects rather than ,Therapeutic procedure,Virus Replication,1,X,[topp],[celf],E02,G06.920.925
c88520e6-9018-42a4-a6ce-68c168bb4852,C3273807,C0022646,protect ,Sodium-Glucose Transporter 2 Inhibitors,Kidney,6,X,[orch/phsu],[bpoc],D27.505.519.936;D27.505.696.422.750,A05.810.453
bd87831d-da15-40b3-8e9a-d82730ee406c,C3273807,C0018787,protect ,Sodium-Glucose Transporter 2 Inhibitors,Heart,6,X,[orch/phsu],[bpoc],D27.505.519.936;D27.505.696.422.750,A07.541
7af78198-eea1-4220-8c7e-c091ef38cc6b,remdesivir,C0003451,demonstrated powerful ,remdesivir,Antiviral Agents,2,X,[clnd],[phsu],,D27.505.954.122.388
2cdccd9d-dc2a-4cbd-9f06-4304193d8230,C0475647,C0206750,produce in patients infected with ,Home exercise program,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
599c629a-ead7-4156-b634-129d5ede5508,C0042769,C0206750,is in ,Virus Diseases,Coronavirus Infections,5,X,[dsyn],[dsyn],C02,C02.782.600.550.200
28df03f6-eb0f-4975-8769-cd92c2998764,C1175743,C1452534,being internalized with ,SARS coronavirus,ACE protein human,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,x.x.x.x
28df03f6-eb0f-4975-8769-cd92c2998764,C1175743,C1452534,binding ,SARS coronavirus,ACE protein human,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,x.x.x.x
d5d9d7f4-aa0f-4d74-b42e-e4ccb739da6e,C1175743,C0024264,being internalized with ,SARS coronavirus,Lymphocyte,2,X,[virs],[cell],B04.820.504.540.150.113.937,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
0c8179cb-a628-4703-bd3d-29f7018ad2e3,C1413931,C0242298,modulate protein protein interaction by,ACE gene,Fostering,1,X,[gngm],[dora],,E02.760.352;I01.880.787.416;N02.421.143.452;N02.421.585.352
14584d2e-1a18-460e-ad5b-81ae8164a49f,C0032529,C0242298,modulate protein protein interaction by,Genetic Polymorphism,Fostering,1,X,[genf],[dora],G05.365.795,E02.760.352;I01.880.787.416;N02.421.143.452;N02.421.585.352
14584d2e-1a18-460e-ad5b-81ae8164a49f,C0032529,C0242298,contribute by ,Genetic Polymorphism,Fostering,1,X,[genf],[dora],G05.365.795,E02.760.352;I01.880.787.416;N02.421.143.452;N02.421.585.352
4e7f79a6-7675-4e3f-863e-0659900f9b14,C1413931,C0042396,modulate protein protein interaction by,ACE gene,Vascular constriction (function),1,X,[gngm],[ortf],,G09.330.380.925
0cde2c0b-9124-4bb6-8062-006b41301b50,C0032529,C0042396,modulate protein protein interaction by,Genetic Polymorphism,Vascular constriction (function),1,X,[genf],[ortf],G05.365.795,G09.330.380.925
0cde2c0b-9124-4bb6-8062-006b41301b50,C0032529,C0042396,contribute by ,Genetic Polymorphism,Vascular constriction (function),1,X,[genf],[ortf],G05.365.795,G09.330.380.925
b10030f8-48d1-40ba-875f-b71dfda02bdf,C0032529,C1413931,is in ,Genetic Polymorphism,ACE gene,4,X,[genf],[gngm],G05.365.795,
4945be2c-6332-4a4d-bd6d-7d72f82b8804,C1413931,C0872079,modulate intermolecular ,ACE gene,protein protein interaction,1,X,[gngm],[moft],,
4945be2c-6332-4a4d-bd6d-7d72f82b8804,C1413931,C0872079,modulate protein protein interaction with spike,ACE gene,protein protein interaction,1,X,[gngm],[moft],,
20ae37f6-fbf1-42c8-86c6-060d6ee38e63,C0032529,C0872079,modulate intermolecular ,Genetic Polymorphism,protein protein interaction,1,X,[genf],[moft],G05.365.795,
20ae37f6-fbf1-42c8-86c6-060d6ee38e63,C0032529,C0872079,modulate protein protein interaction with spike,Genetic Polymorphism,protein protein interaction,1,X,[genf],[moft],G05.365.795,
5e6c5be6-025b-4e46-969c-43968c3ea7ce,C1413931,C1175743,modulate protein protein interaction with spike,ACE gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
94965b80-4eef-415b-b1aa-07cb0ae5e9bc,C0032529,C1175743,modulate protein protein interaction with spike,Genetic Polymorphism,SARS coronavirus,1,X,[genf],[virs],G05.365.795,B04.820.504.540.150.113.937
faac07ce-59a4-410e-89be-d80a4c489617,PPE,C2699153,prevent ,PPE,Cell Invasion,2,X,????,[patf],????,
0eeb589e-f004-492e-99bb-85669b97678e,PPE,C0042760,prevent ,PPE,Virion,2,X,????,[celc],????,A21.249;B04.950
d317d200-664b-4d0c-bab3-3d28fd83860d,C0003015,C0206750,could influence ,Angiotensin-Converting Enzyme Inhibitors,Coronavirus Infections,6,X,[phsu],[dsyn],D27.505.519.389.745.085,C02.782.600.550.200
d317d200-664b-4d0c-bab3-3d28fd83860d,C0003015,C0206750,make patients susceptible to ,Angiotensin-Converting Enzyme Inhibitors,Coronavirus Infections,2,X,[phsu],[dsyn],D27.505.519.389.745.085,C02.782.600.550.200
6c1dee4c-5f2f-439d-8d61-d14469ca2be8,C0003015,C0012634,could influence ,Angiotensin-Converting Enzyme Inhibitors,Disease,2,X,[phsu],[dsyn],D27.505.519.389.745.085,C23.550.288
6c1dee4c-5f2f-439d-8d61-d14469ca2be8,C0003015,C0012634,make patients susceptible to ,Angiotensin-Converting Enzyme Inhibitors,Disease,1,X,[phsu],[dsyn],D27.505.519.389.745.085,C23.550.288
0b750dd0-f604-49bf-9849-5a2d6817e887,C0815017,C0206750,could influence ,Angiotensin Receptor Antagonists,Coronavirus Infections,6,X,[phsu],[dsyn],D27.505.519.162,C02.782.600.550.200
0b750dd0-f604-49bf-9849-5a2d6817e887,C0815017,C0206750,are Essential Hypertension in,Angiotensin Receptor Antagonists,Coronavirus Infections,1,X,[phsu],[dsyn],D27.505.519.162,C02.782.600.550.200
1ad1f2cd-d36f-4eeb-b437-ea0e40773333,C0815017,C0012634,could influence ,Angiotensin Receptor Antagonists,Disease,2,X,[phsu],[dsyn],D27.505.519.162,C23.550.288
0a06c270-6369-421a-981d-25add1c6d36e,C0003451,C0022709,Top results for ,Antiviral Agents,Peptidyl-Dipeptidase A,2,X,[phsu],[aapp/enzy/imft],D27.505.954.122.388,D08.811.277.656.350.350.687
6ddf5cc8-43bb-4c35-bfc2-6ecc61d7036c,C0003451,C1167622,Top results for ,Antiviral Agents,Binding (Molecular Function),2,X,[phsu],[moft],D27.505.954.122.388,
799a3be0-73bf-47ec-b8e1-cee5454ec977,C0012634,C0012644,was run on ,Disease,Animal Disease Models,2,X,[dsyn],[emod],C23.550.288,C22.232;E05.598.500;E05.599.395.080
fe7b3512-38d8-483e-a571-030c50bcdea3,C0206074,C0031139,included ,Renal Replacement Therapy,Peritoneal Dialysis,1,X,[topp],[topp],E02.870,E02.870.300.650;E02.912.800.650
ed59ee73-790f-44fa-99f2-10a3d64a898c,C0032105,C0206750,is potential ,Plasma,Coronavirus Infections,8,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C02.782.600.550.200
da92be84-f65d-45ef-8589-da379f0fc535,C0042776,C1707455,is in ,Virus,Comparison,1,X,[virs],[acty],B04,
fce594cf-8ff1-4257-84a2-649eff6bcf3a,C0042776,C0017428,is with positive-polarity ,Virus,Genome,2,X,[virs],[gngm],B04,G05.360.340
a703c6d1-1a76-4296-bd52-f528160c489c,C0917801,C0206750,experiencing high degree of threat from ,Sleeplessness,Coronavirus Infections,1,X,[sosy],[dsyn],C10.886.425.800.800;F03.870.400.800.800,C02.782.600.550.200
83b1ad15-9d59-4fd7-babd-1194787ce58f,C0206750,C1880022,performed RNA sequencing from clinically well ,Coronavirus Infections,Characterization,1,X,[dsyn],[acty],C02.782.600.550.200,
cb8cce21-7992-43fd-8f9d-87b4b6d5e379,C0014597,C1175743,showed average three-fold increase in expression of ,Epithelial Cells,SARS coronavirus,2,X,[cell],[virs],A11.436,B04.820.504.540.150.113.937
1d635eb5-1532-4d51-a909-1547a61f8dde,C0014597,C0206750,showed increase In patients with ,Epithelial Cells,Coronavirus Infections,2,X,[cell],[dsyn],A11.436,C02.782.600.550.200
a6e713f3-2778-4c97-8014-8ebdfc5c89b2,C0022709,C3652465,correlated with ,Peptidyl-Dipeptidase A,Interferon,2,X,[aapp/enzy/imft],[aapp/imft/phsu],D08.811.277.656.350.350.687,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
247f64e0-4e00-4f4f-a95f-69d4d8136bb7,C0022709,C0037083,correlated with ,Peptidyl-Dipeptidase A,Signal Transduction,4,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,G02.111.820;G04.835
3ba287e3-78b6-4043-b288-43d6f66d7cdc,C4330475,C0024432, includes inflammatory ,Immune Cell,macrophage,2,X,[cell],[cell],,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
e1da344f-4291-4bc8-9c1d-0e8a330fa273,C3463820,C0021053,might suppress ,Inhibition,Immune System Diseases,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C20
5c5e609a-3669-4309-91a8-85396c61c6bb,C3463820,C0206750,might suppress Immune System Diseases hyperactivation in critical,Inhibition,Coronavirus Infections,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C02.782.600.550.200
5c5e609a-3669-4309-91a8-85396c61c6bb,C3463820,C0206750,is likely part of mechanisms leading to lung injury in ,Inhibition,Coronavirus Infections,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C02.782.600.550.200
e880f00c-e7c5-4342-b9de-c0dedb7b3661,C0042109,C0085077,Erythema Nodosum like,Urticaria,Sweet Syndrome,3,X,[dsyn],[dsyn],C17.800.862.945;C20.543.480.904,C17.800.229.800
c9c0f44d-d5e1-4ee5-bd48-4bd4ee0b26d3,C0012634,C0751956,had significant independent association with ,Disease,Acute Cerebrovascular Accidents,6,X,[dsyn],[dsyn],C23.550.288,C10.228.140.300.775;C14.907.253.855
c9c0f44d-d5e1-4ee5-bd48-4bd4ee0b26d3,C0012634,C0751956,is significantly associated with imaging confirmation of ,Disease,Acute Cerebrovascular Accidents,6,X,[dsyn],[dsyn],C23.550.288,C10.228.140.300.775;C14.907.253.855
b17eaec2-a4e1-4813-9fa0-5445490e5f12,C0003451,C1175743,were independent factors associated with ,Antiviral Agents,SARS coronavirus,21,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150.113.937
7bf4b44c-dee6-497e-8d2c-07f172c35d8a,C0003241,C1175743,can block entry of ,Antibodies,SARS coronavirus,5,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
7bf4b44c-dee6-497e-8d2c-07f172c35d8a,C0003241,C1175743,could trigger immunopathogenic events in ,Antibodies,SARS coronavirus,2,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
7bf4b44c-dee6-497e-8d2c-07f172c35d8a,C0003241,C1175743,showed performance in detection of ,Antibodies,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
7bf4b44c-dee6-497e-8d2c-07f172c35d8a,C0003241,C1175743,inhibit ,Antibodies,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
ba19f61f-8511-4596-9066-0d87091ffbee,C0035736,C2676137,was detected in additional ,RNA Viral,Diamond-Blackfan Anemia 1,4,X,[nnon],[dsyn],D13.444.735.828,x.x.x.x
f088d266-c7f4-4751-a167-ffb49339915c,C0035736,C3887642,yielding ,RNA Viral,Hippocampus Proper,4,X,[nnon],[bpoc],D13.444.735.828,A08.186.211.180.405;A08.186.211.200.885.287.500.345
c6aecb97-85af-47bd-a1ae-ea4ab3b2cff7,C0035736,C0042776,yielding Hippocampus Proper with evidence of,RNA Viral,Virus,2,X,[nnon],[virs],D13.444.735.828,B04
69e2ee84-6a1b-453a-afef-23158a79d59e,C0042769,C1175743,is caused by novel ,Virus Diseases,SARS coronavirus,15,X,[dsyn],[virs],C02,B04.820.504.540.150.113.937
5edc7316-cf84-47ea-bf9a-f64f3a1e8d48,C0545747,C0024109,are at also risk of severe ,pulmonary artery and pulmonary artery,Lung,3,X,[bpoc],[bpoc],,A04.411
b13ef1ef-34f7-43c0-a473-c9fb56602213,C0086707,C0042776,is possible mode of transmission for ,Nicotiana,Virus,3,X,[plnt],[virs],B01.650.940.800.575.912.250.908.500.900,B04
722ad44c-d7c9-4ddf-afc5-993485590eb6,C0035222,C0027950,fueled by exaggerated ,Respiratory Distress Syndrome Adult,neutrophil,7,X,[dsyn],[cell],C08.381.840;C08.618.840,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
a60d2a7c-f75e-4639-a9cb-d19e4dddeee5,C0035222,C0024109,fueled by exaggerated ,Respiratory Distress Syndrome Adult,Lung,7,X,[dsyn],[bpoc],C08.381.840;C08.618.840,A04.411
c438a52a-0c56-4c5a-9a37-4f6c32f3d0bf,C0004561,C0003241,represent unique subpopulation of B lymphocytes critical for natural ,B-Lymphocytes,Antibodies,13,X,[cell],[aapp/imft/phsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
040013b1-610d-4427-8248-4fd82d293253,1a,C0003241,represent unique subpopulation of B lymphocytes critical for natural ,1a,Antibodies,8,X,????,[aapp/imft/phsu],????,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
8631e8b2-f9eb-482e-a5ac-3ff2bcea605f,C1706005,C0042776,neutralizes ,CD40LG wt Allele,Virus,8,X,[gngm],[virs],,B04
cf937fd9-d31b-45ef-915f-d68ede06ee54,C0314597,C1292101,induces IgM B lymphocyte production by,Colony-stimulating factor granulocyte-monocyte,IgM B lymphocyte,12,X,[aapp/bacs],[cell],,
cbaf94c8-b1dc-43d8-8a66-7586ccbe6ec7,C1706005,C0004611,opsonizes ,CD40LG wt Allele,Bacteria,7,X,[gngm],[bact],,B03
9f331526-ff85-4ce2-9633-2bea6e10920e,C0085295,C0079189,attenuates ,Interleukin-10,cytokine,7,X,[aapp/imft],[aapp/imft],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D12.644.276.374;D12.776.467.374;D23.529.374
aaa9cbad-666e-431e-a357-ee8946a5543d,C0004561,C0029341,ameliorate ,B-Lymphocytes,Orthomyxoviridae,16,X,[cell],[virs],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,B04.820.545
c918d738-2355-4fdb-b8e7-51a1c83adf14,1a,C0029341,ameliorate ,1a,Orthomyxoviridae,8,X,????,[virs],????,B04.820.545
df0779d2-4104-4e9f-81ce-056edc2cf786,C0004561,C0243026,ameliorate ,B-Lymphocytes,Sepsis,16,X,[cell],[dsyn],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,C01.539.757;C23.550.470.790.500
b69028d3-f306-4bbc-9648-7c5b72fa0d1b,1a,C0243026,ameliorate ,1a,Sepsis,8,X,????,[dsyn],????,C01.539.757;C23.550.470.790.500
05f10f47-a570-4bef-8245-8ecff813a62d,C0004561,C0032285,ameliorate ,B-Lymphocytes,Pneumonia,16,X,[cell],[dsyn],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,C08.381.677;C08.730.610
1a81a63f-7353-419e-a1e7-4568a00ee3fb,1a,C0032285,ameliorate ,1a,Pneumonia,8,X,????,[dsyn],????,C08.381.677;C08.730.610
83e75883-2cd0-4966-adf3-b8f198e8dd16,C1880355,C0039082,further reinforces their role against ,Discover,Syndrome,2,X,[acty],[dsyn],,C23.550.288.500
839ace3c-c9a4-44e0-8c87-907f7cd65858,C1880355,C0086418,is in ,Discover,Homo sapiens,8,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
660d104d-1abf-4afa-bd6c-daab6b527dc0,C0004561,C0003261,protect via ,B-Lymphocytes,Antibody Formation,15,X,[cell],[biof],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,G12.070
0aeb0174-bce5-439b-af54-492ed38140ad,1a,C0035222,protect against ,1a,Respiratory Distress Syndrome Adult,8,X,????,[dsyn],????,C08.381.840;C08.618.840
d339cc82-cfdb-49cb-81e3-81ccea3d4deb,C0004561,C0035222,protect against ,B-Lymphocytes,Respiratory Distress Syndrome Adult,15,X,[cell],[dsyn],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,C08.381.840;C08.618.840
54c35984-2f1c-4073-bd49-fb97aa41cfb8,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
54c35984-2f1c-4073-bd49-fb97aa41cfb8,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
54c35984-2f1c-4073-bd49-fb97aa41cfb8,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
54c35984-2f1c-4073-bd49-fb97aa41cfb8,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
54c35984-2f1c-4073-bd49-fb97aa41cfb8,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
357385ba-f445-42f5-a05f-6ec33cfbb549,1a,C0003261,protect via ,1a,Antibody Formation,8,X,????,[biof],????,G12.070
9923bbda-2db5-48f3-a7bb-1e8e3e8fb7f0,C0036770,C0039082,suggests potential vulnerability of male reproductive system to ,Structure of sertoli cell,Syndrome,1,X,[cell],[dsyn],A05.360.444.849.789;A11.382.952;A11.436.837,C23.550.288.500
19071ed8-7d79-4c75-ac08-1b09804140e7,C0035668,C2756969,is in ,RNA,Semen,2,X,[nnon],[bdsu],D13.444.735,A12.200.732
74d622a8-3cf5-47ae-ad3e-8b335e12c5b0,C0035668,C0444176,is in ,RNA,Seminal fluid specimen,3,X,[nnon],[bdsu],D13.444.735,
014f448d-e6b8-458b-8c31-94ea30e7ad83,C0444176,C0036563,indicates unlikely possibility of transmission through ,Seminal fluid specimen,Plant seeds,2,X,[bdsu],[plnt],,A18.024.500.750;G07.203.300.775;J02.500.775
3980e19a-c2a6-4842-9d0f-009d6942fb43,C1265876,C0032310,suspicious for ,Abnormally opaque structure (morphologic abnormality),Pneumonia Viral,3,X,[patf],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
d8b46bfe-647c-4c40-bbdb-ccee8ca5e9de,C0264490,C0206750,secondary to ,Acute respiratory failure,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
d8b46bfe-647c-4c40-bbdb-ccee8ca5e9de,C0264490,C0206750,efficient Injury care for,Acute respiratory failure,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
d8b46bfe-647c-4c40-bbdb-ccee8ca5e9de,C0264490,C0206750,associated with ,Acute respiratory failure,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
1ef98bdf-6e21-4bab-be40-e9340c0dfda5,C0013227,C0042776,approved for prevention of ,Pharmaceutical Preparations,Virus,2,X,[phsu],[virs],D26,B04
1ef98bdf-6e21-4bab-be40-e9340c0dfda5,C0013227,C0042776,are active against ,Pharmaceutical Preparations,Virus,1,X,[phsu],[virs],D26,B04
1ef98bdf-6e21-4bab-be40-e9340c0dfda5,C0013227,C0042776,eradicate ,Pharmaceutical Preparations,Virus,1,X,[phsu],[virs],D26,B04
666c70ad-b567-4a8a-9d52-150621fc1bcd,C0012634,C0003062,is in ,Disease,Animals,7,X,[dsyn],[anim],C23.550.288,B01.050
84776ad1-e36c-45b9-8951-0a19444a8205,C0012634,C0005595,is in ,Disease,Aves,7,X,[dsyn],[bird],C23.550.288,B01.050.150.900.248
59382612-8038-41f6-b8f7-25da82f4bf9b,C0012634,C0086418,threatens health of ,Disease,Homo sapiens,31,X,[dsyn],[humn],C23.550.288,B01.050.150.900.649.313.988.400.112.400.400
1624e225-cef1-444f-92fe-7b63185b3de0,C0035691,C0012634,are associated with different ,RNA Viruses,Disease,7,X,[virs],[dsyn],B04.820,C23.550.288
510ff7ea-4776-4603-b65b-6e4d9f0113a8,C0035691,C0003062,are associated with different ,RNA Viruses,Animals,7,X,[virs],[anim],B04.820,B01.050
510ff7ea-4776-4603-b65b-6e4d9f0113a8,C0035691,C0003062,can infect ,RNA Viruses,Animals,1,X,[virs],[anim],B04.820,B01.050
aabe6466-f62d-4386-a518-406a51af950e,C0035691,C0005595,are associated with different ,RNA Viruses,Aves,7,X,[virs],[bird],B04.820,B01.050.150.900.248
60c36e2a-1072-40e2-84b9-f811c763fa83,C0035691,C0086418,are associated with different ,RNA Viruses,Homo sapiens,7,X,[virs],[humn],B04.820,B01.050.150.900.649.313.988.400.112.400.400
60c36e2a-1072-40e2-84b9-f811c763fa83,C0035691,C0086418,can infect ,RNA Viruses,Homo sapiens,1,X,[virs],[humn],B04.820,B01.050.150.900.649.313.988.400.112.400.400
6995314d-47c5-4bf1-b7b8-9c752d5bf3fd,C0206422,C0221423,be causative agents of mild respiratory ,Human coronavirus,Illness (finding),7,X,[virs],[sosy],,
f350461c-0b0b-4973-9474-4d7ea5ad931c,C0003451,C0039082,described for ,Antiviral Agents,Syndrome,7,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288.500
f350461c-0b0b-4973-9474-4d7ea5ad931c,C0003451,C0039082,may prove effective respiratory ,Antiviral Agents,Syndrome,2,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288.500
f350461c-0b0b-4973-9474-4d7ea5ad931c,C0003451,C0039082,may prove effective againstsevere acute ,Antiviral Agents,Syndrome,2,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288.500
b219b1a6-0a19-4291-9612-c54fd5e65b70,C0008058,C0206750,are associated with ,Chilblains,Coronavirus Infections,2,X,[dsyn],[dsyn],C26.212.500.217;C26.417.217,C02.782.600.550.200
55b50726-affd-4907-a980-7d54c4f1ef41,C1706005,C0039082,were negative for ,CD40LG wt Allele,Syndrome,1,X,[gngm],[dsyn],,C23.550.288.500
90a0266c-1ca6-4fe9-81ab-a54324397cdb,titers,C0039082,were negative for ,titers,Syndrome,1,X,????,[dsyn],????,C23.550.288.500
d6f4778f-109a-424e-bbe8-588a50e5583b,C0012634,C0007222,is In ,Disease,Cardiovascular Diseases,13,X,[dsyn],[dsyn],C23.550.288,C14
289f1474-bc41-4105-a0e8-4482a6438090,C0012634,C0017178, includes ,Disease,Gastrointestinal Diseases,7,X,[dsyn],[dsyn],C23.550.288,C06.405
1daddf67-4682-4c04-a383-ec9b5e0e2e29,C1457887,C0242104,were ,Symptoms,Sputum production,7,X,[sosy],[ortf],,
7a9089bf-0566-4302-97ed-68a5b09097b4,C0036087,C0039082,detecting ,saliva,Syndrome,1,X,[bdsu],[dsyn],A12.200.666,C23.550.288.500
4b80b6aa-9888-45eb-97d5-0238541923f6,C0232741,C0206750,have have reported in ,Liver function,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
4b80b6aa-9888-45eb-97d5-0238541923f6,C0232741,C0206750,is imperative in ,Liver function,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
bfec0d8a-95cd-4f6b-b6cb-d9220bba8a16,C0206750,C0073187,are depicted in ,Coronavirus Infections,Blood group antigen D,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,x.x.x.x
f3feb51a-6519-49e5-a0f9-8f9f1c18bb4e,C0206750,C0013227, includes promising approved ,Coronavirus Infections,Pharmaceutical Preparations,1,X,[dsyn],[phsu],C02.782.600.550.200,D26
f3feb51a-6519-49e5-a0f9-8f9f1c18bb4e,C0206750,C0013227,screened approximately 250 ,Coronavirus Infections,Pharmaceutical Preparations,2,X,[dsyn],[phsu],C02.782.600.550.200,D26
f3feb51a-6519-49e5-a0f9-8f9f1c18bb4e,C0206750,C0013227,sparks fear of ,Coronavirus Infections,Pharmaceutical Preparations,1,X,[dsyn],[phsu],C02.782.600.550.200,D26
35ec3acb-66b8-4a0b-9615-50430296dd6d,C0021368,C0206750,related to ,Inflammation,Coronavirus Infections,12,X,[patf],[dsyn],C23.550.470,C02.782.600.550.200
9a6f47a9-a9e6-414a-bf31-1a52bf598448,C0042071,C0206750,Dysregulation of were proposed mechanisms of ,Urokinase,Coronavirus Infections,2,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,C02.782.600.550.200
a6e1b793-799a-4cee-93db-26d83a4b5abf,C0005778,C0206750,is in patients with ,Blood coagulation,Coronavirus Infections,5,X,[ortf],[dsyn],G09.188.390.150,C02.782.600.550.200
03c45e6f-7db9-4fd9-a87f-85b1989fca19,C0030755,C0206750,is with ,Pediatrics,Coronavirus Infections,5,X,[bmod],[dsyn],H02.403.670,C02.782.600.550.200
74415c5c-ed7f-4e3f-976e-3678936c8d72,C0034602,C0206750,is in ,Interventional radiology,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.740.675,C02.782.600.550.200
09b03261-5692-45a2-a786-88d961b9ded1,C0206750,C0034602,changed ,Coronavirus Infections,Interventional radiology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.740.675
09b03261-5692-45a2-a786-88d961b9ded1,C0206750,C0034602,reduction of ,Coronavirus Infections,Interventional radiology,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.740.675
b06ea714-5606-4500-af1e-bcb8ae3cf40f,C0008139,C1167395,serve as reservoir ,Chiroptera,Host (organism),5,X,[mamm],[orgm],B01.050.150.900.649.313.937,
b06ea714-5606-4500-af1e-bcb8ae3cf40f,C0008139,C1167395,are considered as reservoir ,Chiroptera,Host (organism),2,X,[mamm],[orgm],B01.050.150.900.649.313.937,
e54eee5e-2596-442c-b605-c2cee93c2909,C0014507,C0028606,absence of be Thus may potential risk factors for false ,Epidemiology,Nucleic Acids,2,X,[bmod],[bacs/nnon],H02.403.720.500,D13.444
f45b31bf-6a3f-45a9-9585-6afa67d890ee,ECDC,C1426785,was present in 25 526 of ,ECDC,FCF1 gene,1,X,????,[gngm],????,
28553181-5c23-4d58-8f30-7b1cba632227,C0035448,C1426785,was present in 25 526 of ,Rheumatoid Factor,FCF1 gene,1,X,[aapp/imft],[gngm],D12.776.124.486.485.114.323.732;D12.776.124.790.651.114.323.732;D12.776.377.715.548.114.323.732,
e033f402-ead8-4066-ab72-ec7cdb90f7e4,C1426785,C1829939,were significantly more likely than ,FCF1 gene,{Non-patient},2,X,[gngm],[clna],,
f1bcf43a-22c2-419b-92ce-1b8d1b1bc008,C1426785,ECDC,present with at least one ECDC ,FCF1 gene,ECDC,1,X,[gngm],????,,????
bd2169a8-c702-4856-9e32-2de38571964f,C1426785,C0035448,present with at least one ECDC ,FCF1 gene,Rheumatoid Factor,1,X,[gngm],[aapp/imft],,D12.776.124.486.485.114.323.732;D12.776.124.790.651.114.323.732;D12.776.377.715.548.114.323.732
0c3a46fd-17b7-4e71-b4d1-02caddb22014,C0282682,C3711684,primarily target ,Antibodies Blocking,S protein severe acute respiratory syndrome coronavirus,2,X,[aapp/imft/irda],[aapp/bacs],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,x.x.x.x
5044ebe2-7755-40ea-ab33-48508cbd594c,C3711684,C0022709,mediates CEL gene Virus Internalization through,S protein severe acute respiratory syndrome coronavirus,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],x.x.x.x,D08.811.277.656.350.350.687
ef9b695d-1afd-47b5-84e3-366705da7644,C3711684,C1514760,mediates CEL gene Virus Internalization through,S protein severe acute respiratory syndrome coronavirus,Receptor Cell,2,X,[aapp/bacs],[cell],x.x.x.x,
2caf1e32-fd53-404d-8e60-f35886211b71,C3711684,C1167395,mediates CEL gene Virus Internalization through,S protein severe acute respiratory syndrome coronavirus,Host (organism),1,X,[aapp/bacs],[orgm],x.x.x.x,
58307c79-2000-4f51-9e82-9b28d1ee12e5,C3711684,C1413336,mediates ,S protein severe acute respiratory syndrome coronavirus,CEL gene,1,X,[aapp/bacs],[gngm],x.x.x.x,
41ea31f3-0628-422e-bd3f-f21b68788f6a,C3711684,C1537068,mediates ,S protein severe acute respiratory syndrome coronavirus,Virus Internalization,2,X,[aapp/bacs],[biof],x.x.x.x,G06.920.881
c63a056a-e754-472d-b7a5-72ec00bcf7ad,C0206750,C1413336,performed single ,Coronavirus Infections,CEL gene,1,X,[dsyn],[gngm],C02.782.600.550.200,
8305456a-0bca-449e-87c6-ba7f05191c4a,C0021390,C0206750,is risk factor for novel ,Inflammatory Bowel Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
8305456a-0bca-449e-87c6-ba7f05191c4a,C0021390,C0206750,should continue during ,Inflammatory Bowel Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
8305456a-0bca-449e-87c6-ba7f05191c4a,C0021390,C0206750,focused ,Inflammatory Bowel Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
8305456a-0bca-449e-87c6-ba7f05191c4a,C0021390,C0206750,is with confirmed ,Inflammatory Bowel Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
bd7253c5-1f15-4906-bbad-edf79b4d5003,C0021390,C0013227,should continue their usual ,Inflammatory Bowel Diseases,Pharmaceutical Preparations,1,X,[dsyn],[phsu],C06.405.205.731;C06.405.469.432,D26
db6a53c8-943f-4720-8449-fe3797b4ccce,C1305957,C0038952,were associated with poor ,Cardiac troponin I,Continuance of life,3,X,[aapp/bacs],[acty],,I03.784
e1beae1c-9ee4-45ba-98d2-4f0783f80c63,U.S.,C1511790,was ,U.S.,Detection,2,X,????,[topp],????,
2d726313-caf8-4b06-9166-2df0a00b5b6b,C0012634,C0011849,is In ,Disease,Diabetes Mellitus,7,X,[dsyn],[dsyn],C23.550.288,C18.452.394.750;C19.246
ab50b39b-9666-407a-9174-2a3abb715570,C0012634,C0020538, includes ,Disease,Hypertensive disease,6,X,[dsyn],[dsyn],C23.550.288,C14.907.489
ab50b39b-9666-407a-9174-2a3abb715570,C0012634,C0020538,was observed in of patients with ,Disease,Hypertensive disease,4,X,[dsyn],[dsyn],C23.550.288,C14.907.489
3c874025-a6ec-49e1-b49b-7daf95ccd179,C0012634,C0028754, includes ,Disease,Obesity,2,X,[dsyn],[dsyn],C23.550.288,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
3c874025-a6ec-49e1-b49b-7daf95ccd179,C0012634,C0028754,involve severe inflammation in people with ,Disease,Obesity,1,X,[dsyn],[dsyn],C23.550.288,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
e52c7fbe-3bf8-473c-862b-b35e97a5f812,C0012634,C1561643, includes ,Disease,Chronic Kidney Diseases,2,X,[dsyn],[dsyn],C23.550.288,C12.777.419.780.750;C13.351.968.419.780.750
049cacbe-a3af-4d87-b877-d1685fa4e359,C0012634,C0264220, includes ,Disease,Chronic disease of respiratory system,2,X,[dsyn],[dsyn],C23.550.288,
4d15f8be-4ee2-4ec4-aa46-6345a7c21305,C0011849,C0028754,lack of insurance male sex smoking and ,Diabetes Mellitus,Obesity,2,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
d4122bd1-3b2c-461a-8663-e4281e117e62,C3714514,C0042776,is with closely related ,Infection,Virus,4,X,[patf],[virs],C01.539,B04
7dfe0f8c-384e-42b0-b2c3-0dfa6ccfe575,C0003241,C0009450,even enhance ,Antibodies,Communicable Diseases,5,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,C01.539.221
1cc9d11a-286f-46cf-aa41-cdb2959137e7,C1175743,C0242656,is in ,SARS coronavirus,Disease Progression,3,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.291.656
4c20235c-cf73-407c-8bc9-649bc90079ea,C0206750,sera,is with convalescent sera,Coronavirus Infections,sera,3,X,[dsyn],????,C02.782.600.550.200,????
89a3f612-d66b-4aab-aca6-60374340ba42,C0206750,C0340515,more severely involve Lung with multiple organ-system,Coronavirus Infections,Myocardial dysfunction,2,X,[dsyn],[patf],C02.782.600.550.200,
89a3f612-d66b-4aab-aca6-60374340ba42,C0206750,C0340515,involve Myocardial dysfunction with multiple organ-system,Coronavirus Infections,Myocardial dysfunction,1,X,[dsyn],[patf],C02.782.600.550.200,
a7f75c6f-fa86-4ea0-b36a-33775b5cec53,C3714514,C0340515,more severely involve Lung with multiple organ-system,Infection,Myocardial dysfunction,2,X,[patf],[patf],C01.539,
a7f75c6f-fa86-4ea0-b36a-33775b5cec53,C3714514,C0340515,involve Myocardial dysfunction with multiple organ-system,Infection,Myocardial dysfunction,1,X,[patf],[patf],C01.539,
a4fe2a6d-6abb-440c-974d-85240a932919,C3714514,C0024109,more severely involve ,Infection,Lung,1,X,[patf],[bpoc],C01.539,A04.411
a4fe2a6d-6abb-440c-974d-85240a932919,C3714514,C0024109,mainly involve ,Infection,Lung,2,X,[patf],[bpoc],C01.539,A04.411
9becd984-0548-4377-be08-0aa859b16757,C0026691,C0036974,was defined by presence of ,Mucocutaneous Lymph Node Syndrome,Shock,2,X,[dsyn],[patf],C14.907.940.560;C15.604.560;C17.800.862.560,C23.550.835
002c475b-e13d-4821-a1e3-98980d0635dd,C1706374,C0521982,fits description course and ,Tumor Necrosis Factor Ligand Superfamily Member 13,Response to treatment,1,X,[aapp/bacs],[clna],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,
34c541b5-47c6-4842-97d5-b22e3d1ac56c,C0206419,C0034386,Mortality of is major concern for ,Genus: Coronavirus,Quarantine,1,X,[virs],[topp],B04.820.504.540.150,N06.850.780.200.450.700
b4616777-daaa-430c-ae0c-b87b6abf064c,C1825598,C0042077,is in ,IMPACT gene,Urology,3,X,[gngm],[bmod],,H02.403.810.860
2cf926d0-aece-4c8c-81e4-ff9b7d008f7d,C0012634,C1641588,is in medical ,Disease,Urological oncology,1,X,[dsyn],[bmod],C23.550.288,
ce82a905-8c3b-419c-bc50-3a7f4f2ebd41,C0012634,C0027651,is in medical ,Disease,Neoplasms,1,X,[dsyn],[neop],C23.550.288,C04
1d839db8-b8ad-4c17-be93-31a1738f5405,C1515090,C0871208,had low cancellation ,Surgical Oncology specialty,Rating (action),1,X,[bmod],[acty],H02.403.429.515.750;H02.403.810.796,
e262537e-2b6e-49ed-b1be-fce01bb2b0c4,C0206419,C0871208,had higher total cancellation ,Genus: Coronavirus,Rating (action),1,X,[virs],[acty],B04.820.504.540.150,
e262537e-2b6e-49ed-b1be-fce01bb2b0c4,C0206419,C0871208,determine ,Genus: Coronavirus,Rating (action),1,X,[virs],[acty],B04.820.504.540.150,
269d9509-3e76-490e-b04e-e82edb4c34ff,C0206419,C0199939,had higher total cancellation ,Genus: Coronavirus,Oncologic procedure NOS,1,X,[virs],[topp],B04.820.504.540.150,
4fc0f2c8-4df2-4208-bb64-b7609be540f8,C0871208,C0030231,is in adjuvant ,Rating (action),Palliative Care,1,X,[acty],[topp],,E02.760.666;N02.421.585.666
7f535069-a536-43a2-b498-9cf360b96a24,C0086418,C0033684,be functional target for spike ,Homo sapiens,Proteins,1,X,[humn],[aapp/bacs],B01.050.150.900.649.313.988.400.112.400.400,D12.776
ce7c9084-58c5-4120-8ae6-814a086510aa,C0022709,C0033684,be functional target for spike ,Peptidyl-Dipeptidase A,Proteins,1,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,D12.776
4b5d0c8d-46bd-4a68-a183-586dbe160c65,C0014442,C0033684,be functional target for spike ,Enzymes,Proteins,1,X,[aapp/enzy],[aapp/bacs],D08.811,D12.776
d96efa21-67cb-4774-8b26-d932351aa904,C0597357,C0033684,be functional target for spike ,receptor,Proteins,1,X,[aapp/rcpt],[aapp/bacs],,D12.776
6d43d67b-9f13-4bc0-9b60-a4da50c2fc50,C0014442,C1175743,be functional target for spike ,Enzymes,SARS coronavirus,1,X,[aapp/enzy],[virs],D08.811,B04.820.504.540.150.113.937
b1514e97-9d99-4f9f-ab47-40132e3f6230,C0003015,C0011860,are currently used for treatment of patients with ,Angiotensin-Converting Enzyme Inhibitors,Diabetes Mellitus Non-Insulin-Dependent,1,X,[phsu],[dsyn],D27.505.519.389.745.085,C18.452.394.750.149;C19.246.300
ed814c12-2add-401c-b920-2bf96d35c022,C0087111,C1175175,favorably alter clinical course of ,Therapeutic procedure,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],E02,C02.782.600.550.200.750;C08.730.730
ed814c12-2add-401c-b920-2bf96d35c022,C0087111,C1175175,Symptoms of,Therapeutic procedure,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],E02,C02.782.600.550.200.750;C08.730.730
b74fe16d-445a-470a-8b94-605e3c0a8cff,IBT,C0011860,is in patients with ,IBT,Diabetes Mellitus Non-Insulin-Dependent,1,X,????,[dsyn],????,C18.452.394.750.149;C19.246.300
29b05e6a-b44b-46b1-92d0-3bfebf79982f,IBT,C0206419,is in patients with ,IBT,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
e06556f3-06ab-4b7e-9d06-885144be7906,C0024264,CD3, includes total CD3,Lymphocyte,CD3,6,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
d76f6d7a-c740-4b45-b4ca-beac68de1538,C0206419,C0027926,is with ,Genus: Coronavirus,Science of neurosurgery,2,X,[virs],[bmod],B04.820.504.540.150,H02.403.810.425
9644b844-ad4b-4583-915f-a4739d8daf3c,pre,C0242781,is proposed based on risk of ,pre,disease transmission,2,X,????,[patf],????,N06.850.310
aaa1238b-6531-41c0-be66-9ea03c9f5ca3,C0543467,C0242781,is proposed based on risk of ,Operative Surgical Procedures,disease transmission,2,X,[topp],[patf],E04,N06.850.310
c312f296-8e21-4d40-973e-205169668c2e,C4050231,C0242781,is proposed based on risk of ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,disease transmission,2,X,[clna],[patf],,N06.850.310
5d02a5b7-17f5-42e3-bdaa-a4c6c244b109,C0206419,C0450254,is caused by highly ,Genus: Coronavirus,Pathogenic organism,1,X,[virs],[orgm],B04.820.504.540.150,
5d02a5b7-17f5-42e3-bdaa-a4c6c244b109,C0206419,C0450254,are severe ,Genus: Coronavirus,Pathogenic organism,3,X,[virs],[orgm],B04.820.504.540.150,
a30f85cf-2980-489c-b201-d54413907c5f,C0265267,C0206419,is with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,Genus: Coronavirus,3,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
bf0b9a2e-39e4-40f4-a50e-6d6d49feb2d6,C0265267,C0559758,is with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,MULTISYSTEM DISORDER,1,X,[dsyn],[dsyn],x.x.x.x,
5f36d88c-d08a-4d47-b8f9-08fb2de01360,C1457887,C0742038,included ,Symptoms,Cerebellar signs,1,X,[sosy],[sosy],,
966af61b-6f05-429a-bfe0-59c2e239582a,C1457887,C0151786,included ,Symptoms,Muscle Weakness,1,X,[sosy],[sosy],,C05.651.515;C10.597.613.593;C23.550.695;C23.888.592.608.593
05c23633-0ac7-4aff-bf57-12fac2a4c4c7,C1457887,C0085584,included ,Symptoms,Encephalopathies,1,X,[sosy],[dsyn],,C10.228.140
8d77267e-a3d8-478d-9536-5a3b26578c25,C1457887,C0006121,included ,Symptoms,Brain Stem,1,X,[sosy],[bpoc],,A08.186.211.132
1f6fcb2f-bf7a-42e1-a9f7-542a869249e7,C0206419,C3272452,are group with ,Genus: Coronavirus,Single-Stranded RNA,8,X,[virs],[nnon],B04.820.504.540.150,
1a45e1b7-eaaf-4cd2-8c29-d43a22c08506,C0206419,C0036658,are group with ,Genus: Coronavirus,Esthesia,2,X,[virs],[ortf],B04.820.504.540.150,F02.830.816;G11.561.790
7ea2f50b-f06c-4318-ae72-bc4f0c4b9c85,C0206419,C0017428,are group with ,Genus: Coronavirus,Genome,4,X,[virs],[gngm],B04.820.504.540.150,G05.360.340
463fcf7b-5d57-4419-a74f-3087028fe66f,C0018787,C0206419,is in convalescent phase for patients recovered from ,Heart,Genus: Coronavirus,1,X,[bpoc],[virs],A07.541,B04.820.504.540.150
463fcf7b-5d57-4419-a74f-3087028fe66f,C0018787,C0206419,is in patients hospitalized with ,Heart,Genus: Coronavirus,1,X,[bpoc],[virs],A07.541,B04.820.504.540.150
463fcf7b-5d57-4419-a74f-3087028fe66f,C0018787,C0206419,are potential targets in ,Heart,Genus: Coronavirus,2,X,[bpoc],[virs],A07.541,B04.820.504.540.150
d321d8af-ad0d-4265-8a76-4148ada956ba,dataset,C0442540,provides four kinds of data ,dataset,Streams,4,X,????,[npop],????,G01.311.750;G16.500.275.280.650;N06.230.232.650
1c432eb7-18d1-47be-a389-7545f31f3c91,dataset,C1882932,provides four kinds of data ,dataset,Representation (action),2,X,????,[acty],????,
d5b6f190-4e86-40fa-bc7b-f3c18a421f5e,dataset,C1175743,provides four kinds of data ,dataset,SARS coronavirus,8,X,????,[virs],????,B04.820.504.540.150.113.937
d5b6f190-4e86-40fa-bc7b-f3c18a421f5e,dataset,C1175743,presents dataset ,dataset,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
0cecfa2b-bd45-4453-88c0-4fcd9ee405b0,C0597357,C0022567,was found expressed on skin mainly on ,receptor,keratinocyte,3,X,[aapp/rcpt],[cell],,A11.409.500;A11.436.397
7e5b87bb-449f-4193-9653-b42b0ce5e563,C0206419,C0597295,determine ,Genus: Coronavirus,Protein Biosynthesis,2,X,[virs],[moft],B04.820.504.540.150,G02.111.660.871;G03.734.871;G05.297.670
3fa5b37b-f943-4413-b06b-09c5f2dbb7a9,C1175743,C0871208,have faster ,SARS coronavirus,Rating (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
7e362827-5ab8-403d-ab20-e3bc588d699c,C0206419,RSCU,have high RSCU ,Genus: Coronavirus,RSCU,2,X,[virs],????,B04.820.504.540.150,????
d5df2e35-ae35-4c84-beab-dc8c90d42f6b,C0206419,C0206422,have high RSCU ,Genus: Coronavirus,Human coronavirus,2,X,[virs],[virs],B04.820.504.540.150,
d5df2e35-ae35-4c84-beab-dc8c90d42f6b,C0206419,C0206422,caused by novel ,Genus: Coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150,
6671227c-be6c-4393-8348-566393ee5777,C0871208,C1157569,is in zoonotic ,Rating (action),viral translation,1,X,[acty],[celf],,
de8edee0-a64d-49fe-a5d7-46ae28c03ee7,C0004651,C0031676,has ,Bacteriophages,Phospholipids,4,X,[virs],[bacs/orch],B04.123,D10.570.755
56b303be-bdd7-46e0-91f1-77dd0797d41f,C2975867,C0031676,has ,GPI protein human,Phospholipids,4,X,[aapp/enzy],[bacs/orch],x.x.x.x,D10.570.755
427fb428-ded5-47c2-aca6-c0be9bf55661,C0004651,C1622204,has ,Bacteriophages,envelope,4,X,[virs],[celc],B04.123,
93acda1d-c840-4362-826a-be74993561df,C2975867,C1622204,has ,GPI protein human,envelope,4,X,[aapp/enzy],[celc],x.x.x.x,
d9e10137-314e-44a9-ac32-eca8e79fdd5b,C2975867,C0086418,is used as surrogate for ,GPI protein human,Homo sapiens,8,X,[aapp/enzy],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
a0e9ea62-7746-47ce-8abc-f205cd8d309d,C2975867,C0005889,was suspended in ,GPI protein human,Body Fluids,4,X,[aapp/enzy],[bdsu],x.x.x.x,A12.207
e3ab4ad7-3537-4871-b686-48ce4775921b,C2975867,C0038239,inoculated onto cm coupons of ,GPI protein human,Steel,4,X,[aapp/enzy],[bodm/inch],x.x.x.x,D01.490.800;D01.552.033.847;D25.058.807;J01.637.051.058.807;x.x.x.x
c05b7feb-30eb-45e0-a03f-de55b24a170e,C0337007,C0700308,declined compared to higher AH ,High humidity,Protium,5,X,[npop],[elii],,
08be6cf8-5a8b-44b5-b0d9-93c95714088d,C0337007,C0012634,declined under ,High humidity,Disease,4,X,[npop],[dsyn],,C23.550.288
d777aa95-ee09-4a11-b2ae-e0f4e1bd6c92,C0337007,C0337008,declined under ,High humidity,Low humidity,1,X,[npop],[npop],,
ab80dd55-7b64-48d1-8af6-ce84bc0ed183,C0337007,C0871208,declined at slower ,High humidity,Rating (action),1,X,[npop],[acty],,
ba946f04-e955-4617-84c8-ebdb34b0564e,C0337007,C0520510,declined at slower rate on ,High humidity,Materials,4,X,[npop],[sbst],,
c8bbbd0c-87b0-4f50-827b-f652952afd7f,C0949892,C0012634,is in similar AH ,Ebolavirus,Disease,2,X,[virs],[dsyn],B04.820.455.300.200,C23.550.288
42c6326c-74c7-4af2-8677-fad7882bf39c,C2975867,C0949892,was found conservative surrogate for ,GPI protein human,Ebolavirus,18,X,[aapp/enzy],[virs],x.x.x.x,B04.820.455.300.200
42c6326c-74c7-4af2-8677-fad7882bf39c,C2975867,C0949892,was used as surrogate for persistence research related to ,GPI protein human,Ebolavirus,2,X,[aapp/enzy],[virs],x.x.x.x,B04.820.455.300.200
42c6326c-74c7-4af2-8677-fad7882bf39c,C2975867,C0949892,assess suitability as surrogate for persistence research related to enveloped ,GPI protein human,Ebolavirus,3,X,[aapp/enzy],[virs],x.x.x.x,B04.820.455.300.200
fd24ad8c-18ba-41fb-abc4-696dd711c840,C2975867,C0337008,was found conservative surrogate under ,GPI protein human,Low humidity,12,X,[aapp/enzy],[npop],x.x.x.x,
c8385e8f-7bd0-4b74-9bf8-28108939bf65,C2975867,C0012634,was found conservative surrogate under ,GPI protein human,Disease,14,X,[aapp/enzy],[dsyn],x.x.x.x,C23.550.288
c8385e8f-7bd0-4b74-9bf8-28108939bf65,C2975867,C0012634,was found Under laboratory-simulated ,GPI protein human,Disease,4,X,[aapp/enzy],[dsyn],x.x.x.x,C23.550.288
713c1a41-9d67-46bb-a964-1efecbdcbf14,C0042776,C0949892, includes ,Virus,Ebolavirus,3,X,[virs],[virs],B04,B04.820.455.300.200
63813509-2128-4a8d-b8e8-27a9149657b8,C2975867,C0042776,was used as surrogate for persistence research related to ,GPI protein human,Virus,2,X,[aapp/enzy],[virs],x.x.x.x,B04
63813509-2128-4a8d-b8e8-27a9149657b8,C2975867,C0042776,assess suitability as surrogate for environmental persistence research related to ,GPI protein human,Virus,1,X,[aapp/enzy],[virs],x.x.x.x,B04
d338f763-2649-4849-b9ff-ce10b5e085a8,C2975867,C1516048,was used to ,GPI protein human,Assessed,1,X,[aapp/enzy],[acty],x.x.x.x,
0d9506fd-ff54-4807-a86f-ca0d3e1aca98,C0012634,C0015392,has spread across ,Disease,Eye,1,X,[dsyn],[bpoc],C23.550.288,A01.456.505.420;A09.371
5f22f5d0-70d5-466e-aac1-ac0929cef349,C0012634,C0006826,are common among older ,Disease,Malignant Neoplasms,1,X,[dsyn],[neop],C23.550.288,C04
5f22f5d0-70d5-466e-aac1-ac0929cef349,C0012634,C0006826, includes ,Disease,Malignant Neoplasms,1,X,[dsyn],[neop],C23.550.288,C04
37b4531e-08d3-4de6-898d-6405e3a830e6,C0012634,C1290884,are common among older ,Disease,Inflammatory disorder,2,X,[dsyn],[dsyn],C23.550.288,
36c3de8c-4037-4668-87ad-5cc9da2923aa,C0015259,C0021053,could result in ,Exercise,Immune System Diseases,2,X,[dora],[dsyn],G11.427.410.698.277;I03.350,C20
78d06e14-4941-4bc3-8d6d-f3f199479b07,C2598152,C1516048,are performed in routine ,Pulmonary Function Tests:-:Point in time:^Patient:-,Assessed,2,X,[clna],[acty],,
9ab685f5-1aea-4a0e-9e0b-3bde154588af,C2598152,C0034060,are performed in routine ,Pulmonary Function Tests:-:Point in time:^Patient:-,Pulmonary Medicine,2,X,[clna],[bmod],,H02.403.429.675
2b73e1a5-6b0a-459f-ae43-2b7de41207a4,C2598152,C1707391,should should restricted to small patient population with ,Pulmonary Function Tests:-:Point in time:^Patient:-,Choose (action),1,X,[clna],[acty],,
2b73e1a5-6b0a-459f-ae43-2b7de41207a4,C2598152,C1707391,should should performed in ,Pulmonary Function Tests:-:Point in time:^Patient:-,Choose (action),1,X,[clna],[acty],,
a1e9a582-4f9f-47a7-abda-57122ea470e4,C2598152,C0007018,Diffusion capacity of lung function for,Pulmonary Function Tests:-:Point in time:^Patient:-,Carbon Monoxide,2,X,[clna],[hops/inch],,D01.200.250;D01.362.200;D01.650.550.250
f32a60e0-6fd3-4379-949b-7051d59703ce,C0026766,C0679215,are very serious ,Multiple Organ Failure,health and disease,2,X,[patf],[npop],C23.550.835.525,
7fafc60b-9c28-43fc-a98c-b92f8a4f705a,C2350332,C0024432,inducing anti-inflammatory ,Exosomes,macrophage,2,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
0e91e327-439d-4b13-91de-e9757765fb52,C2350332,C4330475,can affect ,Exosomes,Immune Cell,2,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
c290db9d-86cb-4f6d-8696-6cafef80a42c,C1257975,C4330475,can affect ,Mesenchymal Stem Cells,Immune Cell,2,X,[cell],[cell],A11.329.830.500;A11.872.590.500,
6ffb892e-6d57-4858-b163-f46ce797e3cc,C2350332,C0004561,inducing ,Exosomes,B-Lymphocytes,2,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562
d76b26b1-4ec1-488c-94b1-ab00cd3b5c00,C1257975,C0039194,can inactivate ,Mesenchymal Stem Cells,T-Lymphocyte,1,X,[cell],[cell],A11.329.830.500;A11.872.590.500,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
74e67958-aec7-40e5-bcd2-d919b993475b,C0087111,C0553757,identify evidence in scientific literature about ,Therapeutic procedure,Olfaction Disorders,3,X,[topp],[dsyn],E02,C10.597.751.600;C23.888.592.763.550
e1a95d8a-2e19-4dbf-8e6d-f64b802ac23c,C0237820,C0206419,usually happened after ,Recovery - action,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
2b5dcf3d-d3ba-4470-9e2b-132e8d39e720,C0553757,C1175743,are strong predictors of ,Olfaction Disorders,SARS coronavirus,12,X,[dsyn],[virs],C10.597.751.600;C23.888.592.763.550,B04.820.504.540.150.113.937
7ece1df2-ec2d-49c7-a615-b7a52848c0a8,C0553757,C0009450,is in ,Olfaction Disorders,Communicable Diseases,20,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C01.539.221
81889a76-f1a7-446e-afe2-b17277acc764,C0553757,C0599878,be should considered as part of ,Olfaction Disorders,disease characteristic,1,X,[dsyn],[patf],C10.597.751.600;C23.888.592.763.550,
8a866d39-21d4-4a92-80d2-f3522e6565dc,C0553757,C0206419,be should considered as part of ,Olfaction Disorders,Genus: Coronavirus,1,X,[dsyn],[virs],C10.597.751.600;C23.888.592.763.550,B04.820.504.540.150
ef41d702-e83d-41f8-b9be-2877eb228eef,C0009262,C0432616,combines Action with,Colchicine,Blood group antibody A,2,X,[orch/phsu],[aapp/imft],D03.132.225,
9cd20797-5105-4b59-bbbf-f813d547bd92,C0009262,C3266814,combines ,Colchicine,Action,1,X,[orch/phsu],[acty],D03.132.225,
269212b4-8a92-4dd3-9587-165a23c0f260,C0018787,C0012634,is in patients hospitalized with ,Heart,Disease,1,X,[bpoc],[dsyn],A07.541,C23.550.288
c5b918b1-5e8f-4603-951c-1de874e160c9,C0011991,C0009262,was more frequent with ,Diarrhea,Colchicine,2,X,[sosy],[orch/phsu],C23.888.821.214,D03.132.225
1c661497-b420-430d-8329-84e5dcc2234c,C1522002,C0206419,reaches levels after 4weeks ,RNA Recognition Motif,Genus: Coronavirus,1,X,[aapp/bacs],[virs],G02.111.570.820.709.275.500.869.500,B04.820.504.540.150
1c661497-b420-430d-8329-84e5dcc2234c,C1522002,C0206419,counter effect of ,RNA Recognition Motif,Genus: Coronavirus,1,X,[aapp/bacs],[virs],G02.111.570.820.709.275.500.869.500,B04.820.504.540.150
f81115a2-8da0-4bf4-a4b0-0562f6ef611f,C1707391,3D,generate shape-based 3D ,Choose (action),3D,1,X,[acty],????,,????
1c27c863-8eec-4d09-b878-a04e649ffcbe,C1707391,C0036563,generate shape-based 3D ,Choose (action),Plant seeds,1,X,[acty],[plnt],,A18.024.500.750;G07.203.300.775;J02.500.775
729b0f13-f101-4624-85c1-7cb07edd63ec,C0013227,C0033684,may act interfere with movements within ,Pharmaceutical Preparations,Proteins,6,X,[phsu],[aapp/bacs],D26,D12.776
5133639a-4d3c-4934-92d6-39ebc01162d5,C0013227,C0745283,may act interfere with movements within ,Pharmaceutical Preparations,INFECTIOUS PROCESS,6,X,[phsu],[patf],D26,
cadcec00-0d1a-4f08-b56f-378d3b841c71,C0013227,C0086418,already approved for use ,Pharmaceutical Preparations,Homo sapiens,3,X,[phsu],[humn],D26,B01.050.150.900.649.313.988.400.112.400.400
c407c8e8-d023-459e-aa0e-33ab7cc61234,C0206419,C0242781,is emerging disease transmission with widespread,Genus: Coronavirus,disease transmission,2,X,[virs],[patf],B04.820.504.540.150,N06.850.310
c407c8e8-d023-459e-aa0e-33ab7cc61234,C0206419,C0242781,shows higher ,Genus: Coronavirus,disease transmission,1,X,[virs],[patf],B04.820.504.540.150,N06.850.310
1a9ba20a-af68-47bd-a2fd-8a2395c61ba5,C1880355,C1175743,reinforces their potentially critical role in ,Discover,SARS coronavirus,5,X,[acty],[virs],,B04.820.504.540.150.113.937
c7ae2afb-e8a9-4317-acf0-3359e8a3e38f,C1825598,C0206419,is essential Given pandemic of ,IMPACT gene,Genus: Coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150
2d591556-3eb6-4f91-9762-e3c32cb4d61f,C0162765,C1704259,is in endosomal ,Isoprenylation,Biochemical Pathway,1,X,[celf],[moft],G02.111.672;G03.804,
176e2f4f-e399-4583-a3cd-a0467a23e0c2,C0007595,C0024109,important in acute response in ,cell growth,Lung,1,X,[celf],[bpoc],,A04.411
19348de7-0d11-4776-acbd-de39e70d2a19,C0206419,C0014597,was found highly expressed in GI ,Genus: Coronavirus,Epithelial Cells,1,X,[virs],[cell],B04.820.504.540.150,A11.436
ef6a2dde-43c2-454a-9106-b32af5b386d1,C0476288,C0206419,is in patients with ,Digestive symptom,Genus: Coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150
3099d66e-c10c-47b3-a382-af44a21508cf,C0815172,C0206419,is with ,patient characteristics,Genus: Coronavirus,3,X,[clna],[virs],,B04.820.504.540.150
cad25dde-e204-4f8b-bbc2-026662519d2d,C1175743,C0038013,is with ,SARS coronavirus,Ankylosing spondylitis,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850
1cd8ba51-32db-4c8b-bb96-dc99d622457d,C1175743,C3179547,is with ,SARS coronavirus,secukinumab,2,X,[virs],[imft/phsu],B04.820.504.540.150.113.937,x.x.x.x
d5b67071-75a4-4ede-841b-63afaab78515,C0242656,C0035436,is in patients with ,Disease Progression,Rheumatic Fever,4,X,[patf],[dsyn],C23.550.291.656,C01.252.410.890.731;C05.550.114.843;C05.799.825
d4c81601-9b1b-4e35-b3a3-c033c4ac88a9,C0206419,C0035436,is in patients with ,Genus: Coronavirus,Rheumatic Fever,2,X,[virs],[dsyn],B04.820.504.540.150,C01.252.410.890.731;C05.550.114.843;C05.799.825
0b721d89-3ad2-4628-aef9-b5017c4180fa,61-year,C0038013,is with ,61-year,Ankylosing spondylitis,2,X,????,[dsyn],????,C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850
2e1a0041-3ee8-42ec-8ca3-48322a351d51,C0384648,C0206419,has has related in ,Interleukin-17,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.517;D12.776.467.374.465.517;D23.529.374.465.517,B04.820.504.540.150
f20bb853-e900-4d89-b26d-4f439b6970bc,C3653320,C0021368,were presented as promising targets for prevention of ,Interleukin inhibitors,Inflammation,1,X,[phsu],[patf],,C23.550.470
fbe98ac5-f012-425d-8413-553ba3aa6f5b,C3653320,C0206419,were presented as promising targets for prevention of ,Interleukin inhibitors,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
ae98c83e-764c-441b-813c-9e70dbab2ba7,C3653320,C1175743,is in ,Interleukin inhibitors,SARS coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150.113.937
78fc658e-f252-4db6-afda-16a2c523a2d8,C0206422,C0032285,causing pandemic of severe ,Human coronavirus,Pneumonia,2,X,[virs],[dsyn],,C08.381.677;C08.730.610
78fc658e-f252-4db6-afda-16a2c523a2d8,C0206422,C0032285,study ,Human coronavirus,Pneumonia,2,X,[virs],[dsyn],,C08.381.677;C08.730.610
539469b8-305c-4821-a378-d57780928989,C1175743,C0206422,is novel ,SARS coronavirus,Human coronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.937,
539469b8-305c-4821-a378-d57780928989,C1175743,C0206422,to SARS coronavirus is,SARS coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
539469b8-305c-4821-a378-d57780928989,C1175743,C0206422,cause of ,SARS coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
539469b8-305c-4821-a378-d57780928989,C1175743,C0206422,is emerging ,SARS coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
74946d60-b8bb-4ca1-ba1d-254b0e56050d,C0524816,C1167395,were potential inhibitors of key component for response of,Nucleocapsid Proteins,Host (organism),2,X,[aapp/bacs],[orgm],D12.776.964.970.600,
3cd56c04-5db6-477d-9caa-e4bbcf61f902,ORF8,C1167395,were potential inhibitors of key component for antiviral response of,ORF8,Host (organism),2,X,????,[orgm],????,
e6e1e1ba-15be-4cc3-9fc0-10a531e4b7d2,ORF8,C2610474,were potential inhibitors of,ORF8,type I interferon signaling pathway,2,X,????,[celf],????,
e6e1e1ba-15be-4cc3-9fc0-10a531e4b7d2,ORF8,C2610474,were In study potential ,ORF8,type I interferon signaling pathway,2,X,????,[celf],????,
7f90e746-34c8-4626-9522-7244d2178ac1,C2610474,C1167395,component for antiviral response of ,type I interferon signaling pathway,Host (organism),2,X,[celf],[orgm],,
d8ffebea-1818-457e-9cb2-7c4bcbc1fcd1,C0524816,C2610474,were potential inhibitors of,Nucleocapsid Proteins,type I interferon signaling pathway,2,X,[aapp/bacs],[celf],D12.776.964.970.600,
d8ffebea-1818-457e-9cb2-7c4bcbc1fcd1,C0524816,C2610474,were In study potential ,Nucleocapsid Proteins,type I interferon signaling pathway,2,X,[aapp/bacs],[celf],D12.776.964.970.600,
b0c0e6b7-d4ab-4a93-ac71-a00c2bac40a9,ORF8,C0243077,were In study potential ,ORF8,inhibitors,2,X,????,[chvf],????,
dcb2be66-8fb0-4b04-9858-ca03ad72cee2,C0524816,C0243077,were In study potential ,Nucleocapsid Proteins,inhibitors,2,X,[aapp/bacs],[chvf],D12.776.964.970.600,
5de7b3f9-3584-4c7b-a142-8f19a8c9f9b1,ORF6,ISRE,inhibit ISRE,ORF6,ISRE,1,X,????,????,????,????
98d5208f-729a-41e1-9642-90e64f2fad13,C0033684,C1319860,inhibit Response Elements after,Proteins,Sendai virus infection,2,X,[aapp/bacs],[dsyn],D12.776,
98d5208f-729a-41e1-9642-90e64f2fad13,C0033684,C1319860,inhibit Response Elements after,Proteins,Sendai virus infection,2,X,[aapp/bacs],[dsyn],D12.776,
30b0f1e3-1a5e-42ab-ba57-47e6650e7fb8,ORF6,C0015980,inhibit ISRE after treatment with ,ORF6,Interferon-beta,1,X,????,[aapp/imft/phsu],????,D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275
595d3d1f-a7e9-42c5-b381-52b8c8c7b960,C0033684,C3463820,showed strong ,Proteins,Inhibition,2,X,[aapp/bacs],[acty],D12.776,F01.145.544;F02.463.425.475;F02.739.794.405
595d3d1f-a7e9-42c5-b381-52b8c8c7b960,C0033684,C3463820,could could direct targets for ,Proteins,Inhibition,1,X,[aapp/bacs],[acty],D12.776,F01.145.544;F02.463.425.475;F02.739.794.405
eea933e6-a382-4959-be78-3ebf4dd6a10e,C0033684,C0021743,showed strong ,Proteins,Interferon Type I,2,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890
59299077-7a3c-456f-852b-911e56033d24,C0033684,C3652465,inhibit ,Proteins,Interferon,4,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
05254137-2b01-4a2e-9f41-cc52b5fd304b,C0033684,C1948023,inhibit ,Proteins,Stimulation (motivation),2,X,[aapp/bacs],[npop],D12.776,
7525e613-c807-466b-b558-e5c0788a4f76,C0033684,C0600508,inhibit ,Proteins,Response Elements,2,X,[aapp/bacs],[bacs/nnon],D12.776,G02.111.570.080.689.330.700;G02.111.570.080.689.675.700;G05.360.080.689.330.700;G05.360.080.689.675.700;G05.360.340.024.340.137.750.249.765;G05.360.340.024.340.137.750.680.765
c51d235f-3eb3-451c-b761-54e5e139b199,C1707455,C0225386,is with current protective ,Comparison,Breath,3,X,[acty],[bdsu],,
4bc99fc9-97fc-4adb-a690-94737728067f,C0206750,C0035204,is viral ,Coronavirus Infections,Respiration Disorders,11,X,[dsyn],[dsyn],C02.782.600.550.200,C08.618
5b4b4cd9-fde8-4ef5-9689-e1d788b84721,C0231528,C1457887,were most common clinical ,Myalgia,Symptoms,8,X,[sosy],[sosy],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,
60b81b64-f4d8-4e5a-9595-a0bb5fb1b50c,C0038454,C0748159,extent of ,Cerebrovascular accident,pulmonary involvement,6,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,
fe2d564e-870f-4a33-8e2e-1b36bc20ad48,C1175743,C1175175,caused ,SARS coronavirus,Severe Acute Respiratory Syndrome,6,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
fe2d564e-870f-4a33-8e2e-1b36bc20ad48,C1175743,C1175175,was causative Pharmacologic Substance of,SARS coronavirus,Severe Acute Respiratory Syndrome,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
fe2d564e-870f-4a33-8e2e-1b36bc20ad48,C1175743,C1175175,stands for ,SARS coronavirus,Severe Acute Respiratory Syndrome,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
fe2d564e-870f-4a33-8e2e-1b36bc20ad48,C1175743,C1175175,belonging as ,SARS coronavirus,Severe Acute Respiratory Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
9ed56d84-0a73-442d-869b-6e15367ddaa7,C0206419,C0035222,triggers mechanisms main ,Genus: Coronavirus,Respiratory Distress Syndrome Adult,4,X,[virs],[dsyn],B04.820.504.540.150,C08.381.840;C08.618.840
ce6a15bf-4a14-462b-9183-a16a36ee6284,C0007222,C0242656,are at higher risk of ,Cardiovascular Diseases,Disease Progression,4,X,[dsyn],[patf],C14,C23.550.291.656
ce6a15bf-4a14-462b-9183-a16a36ee6284,C0007222,C0242656,are Additionally risk factors for ,Cardiovascular Diseases,Disease Progression,1,X,[dsyn],[patf],C14,C23.550.291.656
1d62670f-a903-4e6b-a131-974a41a61cba,C0007222,C0035204,are at higher risk to severe ,Cardiovascular Diseases,Respiration Disorders,4,X,[dsyn],[dsyn],C14,C08.618
78fdbc6d-cd76-44ad-9406-3342f6d6a963,C0007222,C0035222,are at higher risk to severe respiratory manifestations of ,Cardiovascular Diseases,Respiratory Distress Syndrome Adult,6,X,[dsyn],[dsyn],C14,C08.381.840;C08.618.840
b239a3a4-9d49-4fd2-969f-6fb7596175d9,C0699748,C1705178,is in ,Pathogenesis,Order (action),6,X,[patf],[acty],,
8cad32fb-fe94-4911-83b8-69bd89efc3e5,C0699748,C1999230,is in ,Pathogenesis,Providing (action),1,X,[patf],[acty],,
7605d518-6d7b-4374-9639-7fd6fd79b65f,C1704259,C0012655,potentially links cardiovascular ,Biochemical Pathway,Disease susceptibility,6,X,[moft],[clna],,C23.550.291.687;G07.100.250
180a1af4-9d2c-4e7a-b49b-fe5dc57fdcb4,C1704259,C1175743,links outcome to ,Biochemical Pathway,SARS coronavirus,6,X,[moft],[virs],,B04.820.504.540.150.113.937
180a1af4-9d2c-4e7a-b49b-fe5dc57fdcb4,C1704259,C1175743,potentially links Disease susceptibility to,Biochemical Pathway,SARS coronavirus,6,X,[moft],[virs],,B04.820.504.540.150.113.937
180a1af4-9d2c-4e7a-b49b-fe5dc57fdcb4,C1704259,C1175743,support Organ Transplantation in even,Biochemical Pathway,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
180a1af4-9d2c-4e7a-b49b-fe5dc57fdcb4,C1704259,C1175743,are engaged by ,Biochemical Pathway,SARS coronavirus,2,X,[moft],[virs],,B04.820.504.540.150.113.937
5aed08cf-3d03-4ad8-8f4c-fe5da185fa27,C0009450,C1175175,results in moderate to ,Communicable Diseases,Severe Acute Respiratory Syndrome,11,X,[dsyn],[dsyn],C01.539.221,C02.782.600.550.200.750;C08.730.730
a9257f64-a9bd-43e5-87b7-5b370bc00161,C0042776,C0032285,was identified in outbreak of ,Virus,Pneumonia,1,X,[virs],[dsyn],B04,C08.381.677;C08.730.610
a9257f64-a9bd-43e5-87b7-5b370bc00161,C0042776,C0032285,leading to ,Virus,Pneumonia,3,X,[virs],[dsyn],B04,C08.381.677;C08.730.610
e4956e4a-5a3b-4404-a427-361b7e1dcc80,C0017428,C0035668,is inscribed on single strand of ,Genome,RNA,5,X,[gngm],[nnon],G05.360.340,D13.444.735
0f1f0d14-8af0-49a3-9bc5-bb378ab9ff5f,C0035243,C0086418,is in ,Respiratory Tract Infections,Homo sapiens,5,X,[dsyn],[humn],C01.539.739;C08.730,B01.050.150.900.649.313.988.400.112.400.400
b952c68d-e27a-4191-95d2-e11cfbb91c35,C0221423,C1175175, includes ,Illness (finding),Severe Acute Respiratory Syndrome,5,X,[sosy],[dsyn],,C02.782.600.550.200.750;C08.730.730
b952c68d-e27a-4191-95d2-e11cfbb91c35,C0221423,C1175175,is similar to high ,Illness (finding),Severe Acute Respiratory Syndrome,1,X,[sosy],[dsyn],,C02.782.600.550.200.750;C08.730.730
14be61e6-30c9-4abc-9e23-8a649c5cdeac,C0178784,C0030054,suffer through lack of ,Organ,Oxygen,9,X,[bpoc],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
6b6878c4-2226-42d1-accf-b9ba8b81527a,C0178784,C1880287,suffer through ,Organ,Deregulation,10,X,[bpoc],[acty],,
8241fa32-2885-40eb-bc90-b482b6c0c174,C0178784,C0021368,suffer through ,Organ,Inflammation,10,X,[bpoc],[patf],,C23.550.470
94f48791-6da5-4096-942c-c3e79d522566,C0042769,C0009450,is ,Virus Diseases,Communicable Diseases,4,X,[dsyn],[dsyn],C02,C01.539.221
17f54974-8e74-44a6-bc43-fa93632a9484,C0599878,C1707455,is in ,disease characteristic,Comparison,2,X,[patf],[acty],,
f30bfe62-b41f-4ae7-ba9e-26410da2df16,C0599878,C4522312,is in ,disease characteristic,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,2,X,[patf],[gngm],,
65348f19-6895-41ce-a3d7-dff93c7f33d5,C1707455,C4522312,is with SN ,Comparison,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,4,X,[acty],[gngm],,
fecf4045-9ea3-4a8a-a252-d2ab03182ca2,C0206419,WBC,had more WBC CRP ,Genus: Coronavirus,WBC,1,X,[virs],????,B04.820.504.540.150,????
bcdfb5b1-8ec0-4ac7-beb8-616557b902cd,C0206419,C0027950,had more WBC CRP ,Genus: Coronavirus,neutrophil,1,X,[virs],[cell],B04.820.504.540.150,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
2de6b377-f27a-43dc-b7e3-6d52d79044fc,C0206419,CRP,had more WBC CRP ,Genus: Coronavirus,CRP,1,X,[virs],????,B04.820.504.540.150,????
2fc08201-1120-4862-8d1b-733b760ac7c6,C4522312,C0021368,showed more ,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Inflammation,2,X,[gngm],[patf],,C23.550.470
018c4158-7633-4d47-bb03-1360e6315524,C4522312,C0206419,showed more ,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
018c4158-7633-4d47-bb03-1360e6315524,C4522312,C0206419,more Inflammation than,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
146c93b3-cae3-4ba0-8b4a-b672a1dc810d,C0024264,COVID-19,were ,Lymphocyte,COVID-19,8,X,[cell],[virs],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C000657245
4a0fae36-4411-41ec-8d34-2613a69322cd,C0027950,COVID-19,are important indicators for ,neutrophil,COVID-19,1,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C000657245
4a0fae36-4411-41ec-8d34-2613a69322cd,C0027950,COVID-19,predict independently ,neutrophil,COVID-19,2,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C000657245
50c64d7e-5058-4153-9a43-806146e900c2,C0006560,COVID-19,were ,C-reactive protein,COVID-19,4,X,[aapp/imft],[virs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C000657245
288077c6-81c9-4203-af5e-63a7a5b2b5ce,NLR,COVID-19,are important indicators for ,NLR,COVID-19,1,X,????,[virs],????,C000657245
fb898dd8-ff8d-4514-9d17-dd9aa7db869f,C0077401,COVID-19,are important indicators for ,Troponin I,COVID-19,1,X,[aapp/bacs],[virs],D05.500.945.925;D05.750.078.730.825.925;D12.776.210.500.910.925;D12.776.220.525.825.925,C000657245
41ab05da-153f-4b68-be2d-62c85bbdce63,C0010294,COVID-19,are important indicators for ,Creatinine,COVID-19,1,X,[bacs/orch],[virs],D03.383.129.308.207,C000657245
79855ccd-aab5-4179-9718-ac23adad539e,C0600137,COVID-19,are important indicators for ,Blood Urea Nitrogen,COVID-19,1,X,[bacs/inch],[virs],E01.370.225.124.100.115;E01.370.390.400.100;E05.200.124.100.115,C000657245
8f847042-8469-4d3b-92cc-85ce3020d400,C0233697,C0003467,Anxiety about future sadness and,Obsessions,Anxiety,2,X,[mobd],[mobd],F01.145.126.950,F01.470.132
f989b877-283a-4249-b65c-d060ec57d3cd,C0011570,C1707455,were lower ,Mental Depression,Comparison,1,X,[mobd],[acty],F01.145.126.350,
35793fa6-d6fb-4a77-ad04-5300618cfa14,C4050231,C1707455,were lower ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Comparison,1,X,[clna],[acty],,
a82705fb-77b5-4e2f-8f39-a96c1aa2a68c,C0206419,C0588006,caused mild-level ,Genus: Coronavirus,Mild depression,1,X,[virs],[mobd],B04.820.504.540.150,
7e67a7cf-950a-4b7f-b81b-5f0707c1dc25,C0426576,C0206419,are are recognized in ,Gastrointestinal symptom,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
7e67a7cf-950a-4b7f-b81b-5f0707c1dc25,C0426576,C0206419,could could used for prognostication in hospitalized patients with ,Gastrointestinal symptom,Genus: Coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150
ac93206a-5587-4832-9784-1bbaef21e8bc,C0426576,C0012634,have have recognized as part of ,Gastrointestinal symptom,Disease,7,X,[sosy],[dsyn],,C23.550.288
ac93206a-5587-4832-9784-1bbaef21e8bc,C0426576,C0012634,frequently reported in ,Gastrointestinal symptom,Disease,1,X,[sosy],[dsyn],,C23.550.288
8fbac65f-616c-42a1-8ef1-6d87756376b0,C1856053,COVID-19,is with ,Hydranencephaly with Renal Aplasia-Dysplasia,COVID-19,1,X,[dsyn],[virs],x.x.x.x,C000657245
adadf8f2-0fd8-4862-8aeb-dfdb8216f3bb,C0206419,C0426576,were Comparison with,Genus: Coronavirus,Gastrointestinal symptom,4,X,[virs],[sosy],B04.820.504.540.150,
01959204-0438-45bf-b2ce-8472c9a75dde,C1707455,C0426576,is with ,Comparison,Gastrointestinal symptom,1,X,[acty],[sosy],,
487f8540-8a80-4924-8f1e-2f6824150496,C0206419,COVID-19,designated as ,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
487f8540-8a80-4924-8f1e-2f6824150496,C0206419,COVID-19,causing ,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
487f8540-8a80-4924-8f1e-2f6824150496,C0206419,COVID-19,supporting Nucleoside Analogs as,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
487f8540-8a80-4924-8f1e-2f6824150496,C0206419,COVID-19,is causative Agent of,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
487f8540-8a80-4924-8f1e-2f6824150496,C0206419,COVID-19,was found in COVID19,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
f53b9876-9acb-42de-a088-6bda7a384615,C1706853,C0206419,minimize risk of exposure to ,Assembly (construction),Genus: Coronavirus,2,X,[acty],[virs],,B04.820.504.540.150
f08c1cc8-8359-4503-9971-a4b42090b4b9,C1706853,C0012634,minimize risk of exposure to ,Assembly (construction),Disease,2,X,[acty],[dsyn],,C23.550.288
04f04a40-94cf-4ca1-b8e9-b6d47bb1de0c,C0027651,COVID-19,managing Neoplasms patients during,Neoplasms,COVID-19,2,X,[neop],[virs],C04,C000657245
51d333c8-676d-4818-a616-272d6641e02d,SOPA,C0024501,ultimately contribute in ,SOPA,Maintenance,6,X,????,[acty],????,N02.628
d5db19d9-3fe2-4b05-ad99-78364293da34,SOPA,C0920425,ultimately contribute in ,SOPA,cancer therapy,6,X,????,[topp],????,
6e997102-f71d-40ba-ae5e-533c9a64bfcf,C0319157,COVID-19,causes ,AS virus,COVID-19,3,X,[virs],[virs],,C000657245
6e997102-f71d-40ba-ae5e-533c9a64bfcf,C0319157,COVID-19,led ,AS virus,COVID-19,1,X,[virs],[virs],,C000657245
197982e4-9ded-471d-a46b-021331744382,C0017428,C0033684,encodes numerous ,Genome,Proteins,3,X,[gngm],[aapp/bacs],G05.360.340,D12.776
aea4c528-d6eb-4b4f-b40b-7f3617f09776,C0033684,C0003451,might might targets for ,Proteins,Antiviral Agents,3,X,[aapp/bacs],[phsu],D12.776,D27.505.954.122.388
a39c7060-3ed1-41c9-a544-7bfeee9fdaab,C0002520,C1175743,is in ,Amino Acids,SARS coronavirus,3,X,[aapp/bacs/phsu],[virs],D12.125,B04.820.504.540.150.113.937
b3d55caf-d8fe-49df-9356-dce31cd4dddc,C0001461,C0206419,is important characteristic of beta ,Adenosine Diphosphate Ribose,Genus: Coronavirus,3,X,[bacs/nnon],[virs],D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125,B04.820.504.540.150
7c503c2b-1a40-42b3-a7b0-eceb404d8c36,C0683325,C0206419,were analyzed in relation to severity of ,clinical aspects,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
210876c5-767e-49fc-9251-dda16a5e46e9,C0026764,COVID-19,diagnosed with ,Multiple Myeloma,COVID-19,2,X,[neop],[virs],C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650,C000657245
5569b344-c3e3-43ca-9afb-f92560091d1c,C0020538,C1136084,was significantly associated In entire series of patients with ,Hypertensive disease,Plasma cell dyscrasia,4,X,[dsyn],[dsyn],C14.907.489,
4b74d966-5c1d-41a8-a468-8ab347147fac,C0026764,C0012634,compromised system due to ,Multiple Myeloma,Disease,3,X,[neop],[dsyn],C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650,C23.550.288
180c6c2c-c6ef-4b52-86f1-6c5d4d9a6f3b,C2348077,C1707455,to cohort is ,Date Fruit,Comparison,2,X,[food],[acty],B01.650.940.800.575.912.250.093.615,
a7c68447-d9fd-4ceb-9170-62cad623319a,C0812426,C0206750,may happen in patients with severe ,Kidney problem,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
9a32780a-9512-4efe-81fc-0b94296dfb15,C0014544,C0206750,have ,Epilepsy,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.490,C02.782.600.550.200
2169bcce-d679-403d-8b77-3fba6d53a6a5,andit,C1831732,could could explained by ,andit,Blood-Brain Barrier Disruption,6,X,????,[topp],????,
274016bb-e24c-4638-ac92-f894fb31c39d,andit,C0856169,could could explained by ,andit,endothelial dysfunction,3,X,????,[dsyn],????,
7e9ab3b9-d4ed-49c5-a250-16a09585bcd5,andit,C1175743,could could explained by ,andit,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
21f1f75c-138d-4fbf-a251-2a2f4229c15e,64-year,COVID-19,is with COVID19 ,64-year,COVID-19,3,X,????,[virs],????,C000657245
a9ec7833-8f20-4732-86a8-ed68dee5cd7b,64-year,COVID19,is with COVID19 ,64-year,COVID19,3,X,????,????,????,????
2867a7c3-cda8-443e-a40c-44c963c81307,64-year,C0009450,is with COVID19 ,64-year,Communicable Diseases,3,X,????,[dsyn],????,C01.539.221
1520f50c-ff75-43fe-b2ad-2e58021adece,C0011849,C0012634,is ,Diabetes Mellitus,Disease,9,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C23.550.288
e2fb5d73-b84b-4f56-a2df-112395969084,C0022671,C0206750,thought symptomatic for ,Kidney Transplantation,Coronavirus Infections,8,X,[topp],[dsyn],E02.870.500;E04.936.450.485;E04.950.774.400,C02.782.600.550.200
c0a7eb02-58a0-4c83-9ed9-cbbb43457e03,C0012634,C0037285,has associated ,Disease,Skin Manifestations,1,X,[dsyn],[sosy],C23.550.288,C23.888.885
ed95bc9f-6745-4c71-a89d-6dbe08243c23,C0007203,C1175743,is in patients with ,Cardiopulmonary Resuscitation,SARS coronavirus,1,X,[topp],[virs],E02.365.647.110,B04.820.504.540.150.113.937
db2a8b18-c223-494a-b773-4ec47b3d9c80,C0948008,C0021400,higher rate with cohort of patients with ,Ischemic stroke,Influenza,1,X,[dsyn],[dsyn],,C02.782.620.365;C08.730.310
d6daffb9-005e-4745-bf77-f580d9a10ce4,IJMR,C0009450,trend of ,IJMR,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
d51328d2-2bf1-4de3-a12b-c921009757c3,C1825598,C0206750,is essential Given pandemic of ,IMPACT gene,Coronavirus Infections,3,X,[gngm],[dsyn],,C02.782.600.550.200
d51328d2-2bf1-4de3-a12b-c921009757c3,C1825598,C0206750,demographic characteristics of ,IMPACT gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
d51328d2-2bf1-4de3-a12b-c921009757c3,C1825598,C0206750,is in severe ,IMPACT gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
da2658d6-dc95-46fe-bc99-f5f15621b5c2,C0032098,C0012634,developing effective remedies against novel ,Plants,Disease,2,X,[plnt],[dsyn],B01.650,C23.550.288
3348861d-8489-4281-96cf-d3bc0e711844,C0439861,C0012634,developing effective remedies against novel ,Substance,Disease,2,X,[sbst],[dsyn],,C23.550.288
7cabfdf7-a707-4349-bac7-55e932af9f8f,C0035452,C0206750,be at high risk from ,Rheumatology specialty,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.429.730,C02.782.600.550.200
7cabfdf7-a707-4349-bac7-55e932af9f8f,C0035452,C0206750,received national ,Rheumatology specialty,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.429.730,C02.782.600.550.200
d8ec1ec1-e3d8-4791-98e9-b2fc2c526bfc,C0035452,C1875400,are considered hence have self ,Rheumatology specialty,ISOLATE COMPOUND,3,X,[bmod],[phsu],H02.403.429.730,
0c68ac6f-7cb1-411c-bc24-ceb6ad3d0ba1,C1175743,C0010076,members of ,SARS coronavirus,Coronaviridae,3,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540
0c68ac6f-7cb1-411c-bc24-ceb6ad3d0ba1,C1175743,C0010076,are emerged ,SARS coronavirus,Coronaviridae,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540
0c68ac6f-7cb1-411c-bc24-ceb6ad3d0ba1,C1175743,C0010076,belongs to genus ,SARS coronavirus,Coronaviridae,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540
aff27629-22fe-4b2c-99c6-11f72efdc0bf,C2754943,C1175743,directed against ,IgG antibody,SARS coronavirus,2,X,[celc],[virs],,B04.820.504.540.150.113.937
5e716a04-9574-4257-8950-06f5a7281660,C0069228,C0033110,Group for Health of Italian Society of Hygiene ,O-(glucuronic acid 2-sulfate)-(1--4)-O-(25)-anhydromannitol 6-sulfate,preventive medicine specialty,3,X,[orch],[bmod],x.x.x.x,H02.403.720.750
7d2d29e8-9b10-4d28-8e44-8bcd0431ab48,C0343844,C0033110,Group for Health of Italian Society of Hygiene ,Siti,preventive medicine specialty,3,X,[dsyn],[bmod],,H02.403.720.750
0ae28f61-f54f-458b-b7bd-6bac86170573,C0026809,C0206750,exhibit pathologic findings found in ,Mus,Coronavirus Infections,4,X,[mamm],[dsyn],B01.050.150.900.649.313.992.635.505.500,C02.782.600.550.200
f4484b69-92cd-416c-b460-42627a0cfec9,C0042774,C0206750,is often followed In severe ,Virus Replication,Coronavirus Infections,11,X,[celf],[dsyn],G06.920.925,C02.782.600.550.200
c1a2f579-f6db-4ce4-80ee-afae16ac387e,C0003261,C0206750,exhibit pathologic findings found in ,Antibody Formation,Coronavirus Infections,2,X,[biof],[dsyn],G12.070,C02.782.600.550.200
0cc55452-83e4-45ee-ac90-6a83e18a1fe6,C0021743,C1175743,control CoV2 ,Interferon Type I,SARS coronavirus,6,X,[aapp/imft/phsu],[virs],D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890,B04.820.504.540.150.113.937
085a244a-ffdf-414d-9d85-f33f62308875,C0021743,CoV2,control CoV2 ,Interferon Type I,CoV2,6,X,[aapp/imft/phsu],????,D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890,????
ca968472-65e3-4d66-b579-49f9efa28d5e,C0021743,C0598312,control CoV2 ,Interferon Type I,DNA Replication,6,X,[aapp/imft/phsu],[genf],D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890,G02.111.225;G05.226
93af7da7-3edd-4f98-af84-e014b5161b0f,hACE2,C1175175,enables Deploy for in-depth analysis following robust,hACE2,Severe Acute Respiratory Syndrome,3,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
93af7da7-3edd-4f98-af84-e014b5161b0f,hACE2,C1175175,Thus enables Deploy for in-depth analysis following,hACE2,Severe Acute Respiratory Syndrome,2,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
6c9a1101-eb2d-4e42-9156-426a2222d52f,C1564874,C1175175,enables Deploy for in-depth analysis following robust,Adeno-Associated Virus,Severe Acute Respiratory Syndrome,3,X,[virs],[dsyn],B04.280.580.650.170,C02.782.600.550.200.750;C08.730.730
6c9a1101-eb2d-4e42-9156-426a2222d52f,C1564874,C1175175,Thus enables Deploy for in-depth analysis following,Adeno-Associated Virus,Severe Acute Respiratory Syndrome,2,X,[virs],[dsyn],B04.280.580.650.170,C02.782.600.550.200.750;C08.730.730
058f83e8-b167-44c8-80fa-6cdfd6a78d11,C2986594,C1175175,enables Deploy for in-depth analysis following robust,Mouse Model,Severe Acute Respiratory Syndrome,3,X,[emod],[dsyn],,C02.782.600.550.200.750;C08.730.730
058f83e8-b167-44c8-80fa-6cdfd6a78d11,C2986594,C1175175,Thus enables Deploy for in-depth analysis following,Mouse Model,Severe Acute Respiratory Syndrome,2,X,[emod],[dsyn],,C02.782.600.550.200.750;C08.730.730
618a123c-c724-4bb2-af37-ea06204b3017,C1175175,C0319157,is with authentic patient-derived ,Severe Acute Respiratory Syndrome,AS virus,4,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,
67029a46-2e4e-453b-bcc1-59e8030e76b0,C1175175,C0026809,is in ,Severe Acute Respiratory Syndrome,Mus,5,X,[dsyn],[mamm],C02.782.600.550.200.750;C08.730.730,B01.050.150.900.649.313.992.635.505.500
8a5daed4-dc12-4322-a011-5e8634ff4fdb,hACE2,C2825812,enables rapid ,hACE2,Deploy,12,X,????,[acty],????,
549a8de8-b503-4f1f-9cf0-dfe5dcd9c942,C1564874,C2825812,enables rapid ,Adeno-Associated Virus,Deploy,12,X,[virs],[acty],B04.280.580.650.170,
8a146470-752d-4b02-b4ed-aa83e69f6943,C2986594,C2825812,enables rapid ,Mouse Model,Deploy,12,X,[emod],[acty],,
bb140fd9-3f78-400c-9883-9b18865aebb9,C0036537,C0028606,yielded positive results for ,Bodily secretions,Nucleic Acids,1,X,[bdsu],[bacs/nnon],A12.200,D13.444
f0f0ebe1-34f4-4296-9b8a-b5bf2add440e,C0599705,C0206750,observed as long-term ,perfusion (blood),Coronavirus Infections,3,X,[ortf],[dsyn],,C02.782.600.550.200
25dae9eb-9210-4c06-9f46-ffcd3dcb4a80,C0027746,C0206750,observed as long-term ,Nerve Degeneration,Coronavirus Infections,3,X,[comd],[dsyn],C23.550.737,C02.782.600.550.200
d9761daa-bf9d-4b6b-90ff-55331dd69679,C0013227,C0003364,stratified by ,Pharmaceutical Preparations,Antihypertensive Agents,6,X,[phsu],[phsu],D26,D27.505.954.411.162
1b37a8a0-d2ae-4e0e-a210-cf7337b9800e,C0003364,C0206750,risk of ,Antihypertensive Agents,Coronavirus Infections,3,X,[phsu],[dsyn],D27.505.954.411.162,C02.782.600.550.200
0fa239d3-e5f4-4315-a381-bf4cf7ab2f66,C0012655,C0850624,is in patients with ,Disease susceptibility,cardiovascular risk factor,2,X,[clna],[dsyn],C23.550.291.687;G07.100.250,
2e11c727-1d69-4e73-b7a3-09f4eeb14eaf,C0087111,C0013227,is with non-specific ,Therapeutic procedure,Pharmaceutical Preparations,1,X,[topp],[phsu],E02,D26
356a4cf9-03bd-4a88-9700-b1df362126ad,C0087111,C0678420,is with non-specific ,Therapeutic procedure,Cocktail,1,X,[topp],[food],E02,
5b27b3b5-0cca-4e27-a7fa-3856678b364b,C0025598,C0002055,seems as strong ,Metformin,Alkalies,1,X,[orch/phsu],[inch],D02.078.370.141.450,D01.045
5e7f8ef6-578f-4a49-848a-d73ec8e6feb1,C0074785,C0034069,Pharmacologic Substance for,Sodium-Hydrogen Antiporter,Pulmonary Fibrosis,1,X,[aapp/bacs],[dsyn],D12.776.157.530.450.162.775;D12.776.157.530.937.703;D12.776.543.550.190.775;D12.776.543.585.450.162.775;D12.776.543.585.937.828,C08.381.765
9df8fde9-3a1a-445b-9fa3-0d2b9a83f86b,C0206750,C0872315,is ,Coronavirus Infections,Communicable Diseases Emerging,4,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.221.500
e75868a0-05e0-43b8-a6a1-47bfa6b0e426,C0032113,C0079189,significantly reduced inflammatory ,Plasma Exchange,cytokine,1,X,[topp],[aapp/imft],E02.095.135.750,D12.644.276.374;D12.776.467.374;D23.529.374
feee99c3-8773-4745-a6e7-b4fb33262710,C0344211,C2919552,extend patients ,Supportive care,Survival time,1,X,[topp],[clna],,
62c75c45-cfbc-4612-bc45-a21dbfe9fa8f,C0344211,C0087111,increase chance of ,Supportive care,Therapeutic procedure,1,X,[topp],[topp],,E02
1a9e7dc2-7629-46f5-940e-47fd5c0441c1,C0206750,C0278348,occurred amid ,Coronavirus Infections,Immunotherapy for cancer,1,X,[dsyn],[topp],C02.782.600.550.200,
39130ec0-9d40-4537-80a4-b9155e381440,C4684977,C0346429,standard for ,Immune Checkpoint Inhibitor,Multiple malignancy,4,X,[imft/phsu],[neop],,
ec34d2b7-d6c3-4b0d-b963-32648d80896c,C4684977,C0032285,are associated with peculiar ,Immune Checkpoint Inhibitor,Pneumonia,1,X,[imft/phsu],[dsyn],,C08.381.677;C08.730.610
1d5757b3-4414-4650-b065-aa40f030e0a4,C0319157,C0206750,causing 2019 ,AS virus,Coronavirus Infections,34,X,[virs],[dsyn],,C02.782.600.550.200
1d5757b3-4414-4650-b065-aa40f030e0a4,C0319157,C0206750,is named as novel 2019-nCoV ,AS virus,Coronavirus Infections,2,X,[virs],[dsyn],,C02.782.600.550.200
1d5757b3-4414-4650-b065-aa40f030e0a4,C0319157,C0206750,remained in ,AS virus,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
1d5757b3-4414-4650-b065-aa40f030e0a4,C0319157,C0206750,underlying risk factors for ,AS virus,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
ee2056c4-3aa2-4b8c-864a-1c7ee433c1c6,C0024264,C0206750,predict classification of ,Lymphocyte,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
ee2056c4-3aa2-4b8c-864a-1c7ee433c1c6,C0024264,C0206750,are important indicators for severity grading in ,Lymphocyte,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
ee2056c4-3aa2-4b8c-864a-1c7ee433c1c6,C0024264,C0206750,are vital in ,Lymphocyte,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
ee2056c4-3aa2-4b8c-864a-1c7ee433c1c6,C0024264,C0206750,comprehensive decrease of are In conclusion reliable indicators of ,Lymphocyte,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
ef80eb70-f9d2-4dcf-89f7-1b15d2d241bc,C0279328,C0206750,improve hypoxemia for ,Hyperbaric Oxygen (substance),Coronavirus Infections,2,X,[phsu],[dsyn],,C02.782.600.550.200
8955c4dd-b147-4ccd-8ecd-f598bc093d8c,C0020431,C0206750,improve hypoxemia for ,Hyperbaric oxygenation therapy,Coronavirus Infections,2,X,[topp],[dsyn],E02.880.690.490,C02.782.600.550.200
08856821-4b67-450c-aabd-35638e592b96,C0279328,C0032285,improve hypoxemia for ,Hyperbaric Oxygen (substance),Pneumonia,3,X,[phsu],[dsyn],,C08.381.677;C08.730.610
1c12c77e-4a22-4b72-baf2-5dddb3e41323,C0020431,C0032285,improve hypoxemia for ,Hyperbaric oxygenation therapy,Pneumonia,3,X,[topp],[dsyn],E02.880.690.490,C08.381.677;C08.730.610
8d6ed266-cc93-405a-b87c-3d5c00a87674,C0013404,C0020431,remarkably relieved after seven days of ,Dyspnea,Hyperbaric oxygenation therapy,2,X,[sosy],[topp],C08.618.326;C23.888.852.371,E02.880.690.490
0ac8de2a-052d-4e1b-bd21-c20ae8b08941,C0060323,C0728936,corresponding to peripheral ,Fibrin fragment D,Disorder of circulatory system,3,X,[aapp/bacs],[dsyn],x.x.x.x,
caa6a1d7-ff87-46cc-981d-f7c623e55a92,C0060323,C0012634,corresponding to peripheral ,Fibrin fragment D,Disease,3,X,[aapp/bacs],[dsyn],x.x.x.x,C23.550.288
54a84ea7-ab4b-412d-ae84-78b3faa8c9a1,C0206750,CBRN,can in respects can viewed as CBRN ,Coronavirus Infections,CBRN,1,X,[dsyn],????,C02.782.600.550.200,????
0b518e18-1cd5-4c7d-ae81-aa657457cbd8,FDP,C0030054,needed ,FDP,Oxygen,1,X,????,[bacs/elii/phsu],????,D01.268.185.550;D01.362.670;x.x.x.x
d10d3556-ee7b-40cd-9d0b-910e5e645bd2,C0060323,C0030054,needed ,Fibrin fragment D,Oxygen,1,X,[aapp/bacs],[bacs/elii/phsu],x.x.x.x,D01.268.185.550;D01.362.670;x.x.x.x
97052375-41c9-4970-ad40-03dfcded6c96,C0024312,COVID-19,were significantly common than ,Lymphopenia,COVID-19,4,X,[dsyn],[virs],C15.378.553.546.605;C20.673.627,C000657245
9817e732-b78d-4868-90c7-1e3bd23536eb,C0003467,C0206750,expected to ,Anxiety,Coronavirus Infections,2,X,[mobd],[dsyn],F01.470.132,C02.782.600.550.200
9817e732-b78d-4868-90c7-1e3bd23536eb,C0003467,C0206750,were common in patients with ,Anxiety,Coronavirus Infections,2,X,[mobd],[dsyn],F01.470.132,C02.782.600.550.200
22f74074-ec39-4229-b2c9-ecd0317d1a0c,C0011570,C0206750,expected to ,Mental Depression,Coronavirus Infections,2,X,[mobd],[dsyn],F01.145.126.350,C02.782.600.550.200
22f74074-ec39-4229-b2c9-ecd0317d1a0c,C0011570,C0206750,has has observed in ,Mental Depression,Coronavirus Infections,1,X,[mobd],[dsyn],F01.145.126.350,C02.782.600.550.200
5a4b7e05-bf2f-402a-9112-7bfc036a8a73,C0003467,C0001546,expected to ,Anxiety,Adjustment Disorders,2,X,[mobd],[mobd],F01.470.132,F03.950.500
59734d1c-2aa9-4a94-8aad-80bd20983325,C0011570,C0001546,expected to ,Mental Depression,Adjustment Disorders,2,X,[mobd],[mobd],F01.145.126.350,F03.950.500
0d2c7d7c-1d8d-4c89-b0b6-0be815f23553,C0161816,C0003811,include ,Cardiac complication,Cardiac Arrhythmia,4,X,[patf],[dsyn],,C14.280.067;C23.550.073
7d239d8c-d3be-409c-a203-e6fc5d3722df,C0161816,C0011071,include even ,Cardiac complication,Sudden death,2,X,[patf],[patf],,C23.550.260.322
d16dd4b2-a1e0-4d28-8d92-dde85faebd41,C0161816,C0036980,include ,Cardiac complication,Shock Cardiogenic,2,X,[patf],[patf],,C14.280.647.500.750;C14.907.585.500.750;C23.550.835.550
2e3f98af-1b86-41d0-add8-970a7a742601,C0687133,C0003811,may place patient at risk for ,Drug Interactions,Cardiac Arrhythmia,2,X,[patf],[dsyn],G07.690.773.968,C14.280.067;C23.550.073
92ce600e-aefe-4844-ab43-77d601da944b,C0674607,C0015733,is in ,detox adjuvant,Feces,2,X,[aapp/imft/phsu],[bdsu],x.x.x.x,A12.459
2ab032b9-9d93-408f-8b9c-91dbc55b78dd,C0206750,C0038454,lower Lymphocyte than those without history of,Coronavirus Infections,Cerebrovascular accident,14,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
a5457749-ce89-4228-905f-ed1a04edf718,C0032310,C0038454,had ,Pneumonia Viral,Cerebrovascular accident,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C10.228.140.300.775;C14.907.253.855
e4ddd7d1-8ed5-4003-b78e-048378ce75c9,C0032310,C0011849,had ,Pneumonia Viral,Diabetes Mellitus,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C18.452.394.750;C19.246
75d14691-0983-4bab-9bb1-8c685f7755a1,C0032310,C0020538,had ,Pneumonia Viral,Hypertensive disease,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C14.907.489
9cc1e254-fc78-4fb1-bbfb-7085a8f165c5,C0206750,C0085096,had ,Coronavirus Infections,Peripheral Vascular Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.617
a28cb0d9-c9e5-4e8d-9397-0e315b256c35,C0032310,C0085096,had ,Pneumonia Viral,Peripheral Vascular Diseases,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C14.907.617
5af2887e-1603-429d-8b07-2cf03944768e,C0038454,C0011849,is with neurological deficits ,Cerebrovascular accident,Diabetes Mellitus,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C18.452.394.750;C19.246
0f9bb958-302e-4e28-94d7-e7dcd1c2cd9b,C0038454,C0020538,is with neurological deficits ,Cerebrovascular accident,Hypertensive disease,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C14.907.489
bb53fa27-e5a7-4045-861d-dd515d8ddfad,C0038454,C0085096,is with neurological deficits ,Cerebrovascular accident,Peripheral Vascular Diseases,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C14.907.617
9f84e701-1a51-4628-81e1-22ed471f21bd,C1856053,COVID,is with mild symptoms in Pediatric COVID ,Hydranencephaly with Renal Aplasia-Dysplasia,COVID,1,X,[dsyn],????,x.x.x.x,????
61c1ccec-2ac7-4b74-8c93-f4e3f927d8e0,C0042029,C1856053,is in 6-week-old child admitted on ,Urinary tract infection,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C01.539.895;C12.777.892;C13.351.968.892,x.x.x.x
36b3b4c0-0250-4841-a208-bb0bc90c00b9,C4048329,C0040732,leaves ,Immunosuppression,Transplantation,1,X,[dsyn],[topp],E02.095.465.425.450;E05.478.610,E04.936
31f85808-58ed-4349-95a8-95b3b070f773,C4048329,C1175175,leaves ,Immunosuppression,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],E02.095.465.425.450;E05.478.610,C02.782.600.550.200.750;C08.730.730
95d9a860-57bf-49bd-8f99-e4f5c016a311,C0024109,C0030858,intubate after ,Lung,Pentaerythritol Tetranitrate,1,X,[bpoc],[orch/phsu],A04.411,D02.033.455.706.690
163fa778-d1df-4167-ae5d-437c3ab05772,C1155266,C0040732,was attenuated in ,inflammatory response,Transplantation,2,X,[patf],[topp],,E04.936
db12dbbc-f0c0-4d56-9977-5a78a1535fd1,C0040732,C0009450,be might susceptible to ,Transplantation,Communicable Diseases,1,X,[topp],[dsyn],E04.936,C01.539.221
1cda414e-be40-4184-b124-429848f6f938,C0040732,C1175743,be might susceptible to ,Transplantation,SARS coronavirus,1,X,[topp],[virs],E04.936,B04.820.504.540.150.113.937
42298794-0114-4522-a71b-8220a7a8efd1,C0009450,C1175743,prioritize clinical questions related to use of ,Communicable Diseases,SARS coronavirus,64,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150.113.937
1d1ba2f6-2746-4807-bd79-140042d9ce86,C0003241,C0085278,is in ,Antibodies,Antiphospholipid Syndrome,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,C20.111.197
ed6f6758-afe8-4772-826c-a630c62b3b01,C0030858,C0032105,were prospectively treated with ,Pentaerythritol Tetranitrate,Plasma,4,X,[orch/phsu],[bdsu],D02.033.455.706.690,A12.207.152.693;A12.207.270.695;A15.145.693
83041721-5e28-452f-97d9-da3b7760a92e,C0030858,C0206750,were prospectively treated with ,Pentaerythritol Tetranitrate,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.033.455.706.690,C02.782.600.550.200
83041721-5e28-452f-97d9-da3b7760a92e,C0030858,C0206750,distinguish ,Pentaerythritol Tetranitrate,Coronavirus Infections,6,X,[orch/phsu],[dsyn],D02.033.455.706.690,C02.782.600.550.200
6007efa8-286f-4694-9f43-0e16a967e46f,hotspot,C0009450,different probability of ,hotspot,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
8bbf4a42-60a6-4b50-ad5a-7e26974aa3bf,C1515417,C0024109,has developed recommendations to guide decisions in ,Thoracic Oncology,Lung,3,X,[bmod],[bpoc],,A04.411
c7186d9d-d1da-4b92-a721-8cf9b45a2dc8,C1515417,C0920425,has developed recommendations to guide decisions in ,Thoracic Oncology,cancer therapy,3,X,[bmod],[topp],,
028789cf-e341-47a0-9a4e-d8a94873d111,C1515417,C1175743,has developed recommendations during ,Thoracic Oncology,SARS coronavirus,3,X,[bmod],[virs],,B04.820.504.540.150.113.937
21384132-262e-4bca-844b-924259ddb865,C4281807,C1167622,mediates Host Cell entry by,Vitronectin human,Binding (Molecular Function),3,X,[aapp/bacs],[moft],,
e7e644d2-4e9f-4a91-a2d7-a129632368a0,C4281807,C0022709,mediates Host Cell entry by,Vitronectin human,Peptidyl-Dipeptidase A,5,X,[aapp/bacs],[aapp/enzy/imft],,D08.811.277.656.350.350.687
886862f3-d9d9-419a-b6cf-800862afcc83,C4281807,C1819995,mediates ,Vitronectin human,Host Cell,3,X,[aapp/bacs],[celc],,
cbe11198-e803-43d3-9543-7e77b4834cb4,C2987482,C0087111,may may exploited by ,Animal Coat,Therapeutic procedure,3,X,[bpoc],[topp],,E02
033cbfee-b128-463e-92a6-18d39de7c146,C1175743,C0035668,2-positive at RT-PCR ,SARS coronavirus,RNA,2,X,[virs],[nnon],B04.820.504.540.150.113.937,D13.444.735
17527545-ed2e-4119-b4e2-8cab6a3c06dd,C1175743,RT-PCR,2-positive at RT-PCR ,SARS coronavirus,RT-PCR,2,X,[virs],????,B04.820.504.540.150.113.937,????
17527545-ed2e-4119-b4e2-8cab6a3c06dd,C1175743,RT-PCR,for Hypersensitivity is topic of particular importance given insufficient quantity of RT-PCR,SARS coronavirus,RT-PCR,3,X,[virs],????,B04.820.504.540.150.113.937,????
25743fbf-c454-41ca-ab28-9949f1514f8e,C0036745,C0035668,performed after RT-PCR ,Study of serum,RNA,3,X,[bmod],[nnon],H02.781,D13.444.735
95371f1a-7b49-422b-a00d-392d7cee912e,C0036745,RT-PCR,performed after RT-PCR ,Study of serum,RT-PCR,3,X,[bmod],????,H02.781,????
87c4ef8f-7f0c-4c0e-ad8a-86f3dcbc7089,C0275518,C0009450,caused by ,Acute infectious disease,Communicable Diseases,1,X,[dsyn],[dsyn],,C01.539.221
7f4bf610-27ea-483c-8bca-8290f7bac17e,C0275518,C1175743,caused by ,Acute infectious disease,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
f212bd4d-c23a-4f97-9ef6-87a5f40b6a41,C0206750,C0719214,is in ,Coronavirus Infections,century,1,X,[dsyn],[phsu/vita],C02.782.600.550.200,
a8a36eb6-3d87-45e1-9a0b-15da1f3bd7de,C0275518,C0206750,caused by ,Acute infectious disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
065e2cc4-d870-4107-a1ad-d14b7d07a8c6,C0275518,C0719214,caused by ,Acute infectious disease,century,1,X,[dsyn],[phsu/vita],,
a221abfc-1765-40f3-a111-e309583a7cb0,C0012634,C0035222,often evolves into ,Disease,Respiratory Distress Syndrome Adult,4,X,[dsyn],[dsyn],C23.550.288,C08.381.840;C08.618.840
ce6415f2-a83c-47c3-a588-55c0a07ecaef,C0206419,C0850149,causes Signs and Symptoms Respiratory Illness (finding) with,Genus: Coronavirus,Dry cough,2,X,[virs],[sosy],B04.820.504.540.150,
ab90ec85-e8ff-4792-be56-78a8af599b4d,HRCT,C0206419,is in ,HRCT,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
4f02e8b4-009d-462a-8480-5c153599f501,C0549646,C0206419,is in ,chest disorders,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
c9d2af20-8c55-4754-99c2-f43cb5458528,C0850624,C0011849, includes ,cardiovascular risk factor,Diabetes Mellitus,2,X,[dsyn],[dsyn],,C18.452.394.750;C19.246
223a9193-ab75-4658-bdf1-e02c688ac806,C0850624,C0010054, includes ,cardiovascular risk factor,Coronary Arteriosclerosis,2,X,[dsyn],[dsyn],,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260
f542eb90-6160-4fa3-b867-e9bf25aa1727,C3260929,C0206419,associated with ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Genus: Coronavirus,2,X,[clna],[virs],,B04.820.504.540.150
043a0f17-1bbd-47e8-96c1-29b5f6987114,C0520510,C1705178,required in ,Materials,Order (action),3,X,[sbst],[acty],,
b0244b5b-e4a5-47b8-b86b-05efaa95eb99,C0037285,C0206419,is in ,Skin Manifestations,Genus: Coronavirus,2,X,[sosy],[virs],C23.888.885,B04.820.504.540.150
dbfea87d-393b-42e1-9bf0-be6561ff28ca,C0235267,C0043047,was commonest presenting complaint followed by ,Redness of eye,Water,3,X,[sosy],[inch/phsu],,D01.045.250.875;D01.248.497.158.459.650;D01.650.550.925;x.x.x.x
df36af9a-2f25-496e-9948-d218755a19f3,C0039082,C0009763,was commonest diagnosis followed by ,Syndrome,Conjunctivitis,3,X,[dsyn],[dsyn],C23.550.288.500,C11.187.183
5bc36bf1-b44a-463d-a954-624316fb5948,2weeks,4weeks,patients operated in 4weeks,2weeks,4weeks,1,X,????,????,????,????
d0a45c3a-bac3-467c-b26d-65f8b2ca52ea,C1829939,C0038952,were older Compared with ,{Non-patient},Continuance of life,6,X,[clna],[acty],,I03.784
e78d28dd-a65e-40f0-8bdb-4103ce98486a,C1829939,C0199470,received more ,{Non-patient},Mechanical ventilation,3,X,[clna],[topp],,
191cdd30-eb7b-4be9-b59e-955602c27807,C0012634,C0010054,is with ,Disease,Coronary Arteriosclerosis,3,X,[dsyn],[dsyn],C23.550.288,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260
3843a7a6-5e0b-4424-bf3c-02cb6f27184f,C0040034,C0206419,is in ,Thrombocytopenia,Genus: Coronavirus,3,X,[dsyn],[virs],C15.378.140.855,B04.820.504.540.150
dcbcab51-7e02-4ead-9061-c1d572751c72,C1708476,C0206419,is discussed as model against ,Implementation,Genus: Coronavirus,3,X,[acty],[virs],,B04.820.504.540.150
dcbcab51-7e02-4ead-9061-c1d572751c72,C1708476,C0206419,will reduce ,Implementation,Genus: Coronavirus,3,X,[acty],[virs],,B04.820.504.540.150
dcbcab51-7e02-4ead-9061-c1d572751c72,C1708476,C0206419,convey level for ,Implementation,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
b1cda3f2-c182-441b-9b57-d182ffe81a1d,C0011682,C0012222,using sessile wetted ,Desiccation,Diffusion,3,X,[npop],[npop],E05.196.335;G02.176,G01.202;G02.196
92a29059-7f96-4917-a64d-20488088d4bb,C0011682,C0596539,using sessile wetted ,Desiccation,evaporation,3,X,[npop],[npop],E05.196.335;G02.176,
8b2a2c21-8b97-4e31-b37a-757d842e2e89,C0011682,sessile,using sessile wetted ,Desiccation,sessile,3,X,[npop],????,E05.196.335;G02.176,????
babe8ed8-d584-4205-8705-dcf662100f98,IFSO,C0206750,navigating bariatric procedures in patients with ,IFSO,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
9c18ed54-c1ae-4f5c-89e7-e833b9fdaa4f,C0003308,C0206750,is in Iranian ,Antifungal Agents,Coronavirus Infections,2,X,[phsu],[dsyn],D27.505.954.122.136,C02.782.600.550.200
797fa319-876a-4a6e-a112-fad5a6b105cd,C0012655,C0206750,is in Iranian ,Disease susceptibility,Coronavirus Infections,6,X,[clna],[dsyn],C23.550.291.687;G07.100.250,C02.782.600.550.200
a7cb029e-204a-4b87-bde4-634f0c14fff9,C0206750,C0919659,is with ,Coronavirus Infections,oropharyngeal candidiasis,5,X,[dsyn],[dsyn],C02.782.600.550.200,
e5b42490-c0d8-45ab-a253-76257d085f1d,C0206750,C0007222,is with ,Coronavirus Infections,Cardiovascular Diseases,6,X,[dsyn],[dsyn],C02.782.600.550.200,C14
53677b59-68be-4b48-a71b-37ba57b96244,C0012634,C0919659,is In ,Disease,oropharyngeal candidiasis,2,X,[dsyn],[dsyn],C23.550.288,
83c0cfa8-89f1-4295-a0a5-d7b163d0507b,C0006837,C.,followed by C. ,Candida albicans,C.,2,X,[fngs],????,B01.300.107.795.095.326;B01.300.381.147.326;B01.300.930.176.326,????
eaf9e7c6-a0db-4b92-8606-4284b6429951,C0006837,C1010126,followed by ,Candida albicans,Candida dubliniensis,2,X,[fngs],[fngs],B01.300.107.795.095.326;B01.300.381.147.326;B01.300.930.176.326,
febba5c4-7219-4b01-bedb-414984213f1e,C0960880,C1175743,is Receptor Cell for,angiotensin converting enzyme 2,SARS coronavirus,3,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
febba5c4-7219-4b01-bedb-414984213f1e,C0960880,C1175743,been has identified as ,angiotensin converting enzyme 2,SARS coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
55524636-dd60-44a3-af4b-b8f80ac29e84,C0960880,C1514760,is ,angiotensin converting enzyme 2,Receptor Cell,3,X,[aapp/enzy],[cell],x.x.x.x,
9ee81a61-bc93-40ce-8122-a660c9e9127b,C1515670,C0017471,was expressed in ,mRNA Expression,Germ Cells,3,X,[genf],[cell],,A05.360.490;A11.497
47853539-31ce-4e1e-ae40-317f4435e8df,C1175743,C1704259,cause Disease through,SARS coronavirus,Biochemical Pathway,3,X,[virs],[moft],B04.820.504.540.150.113.937,
47853539-31ce-4e1e-ae40-317f4435e8df,C1175743,C1704259,were similar to target ,SARS coronavirus,Biochemical Pathway,1,X,[virs],[moft],B04.820.504.540.150.113.937,
525e6a0b-86ff-4149-b02d-30ece87c066c,C1175743,C1422064,cause Disease through,SARS coronavirus,ACE2 gene,2,X,[virs],[gngm],B04.820.504.540.150.113.937,
525e6a0b-86ff-4149-b02d-30ece87c066c,C1175743,C1422064,use Complement Factor B in addition to,SARS coronavirus,ACE2 gene,2,X,[virs],[gngm],B04.820.504.540.150.113.937,
525e6a0b-86ff-4149-b02d-30ece87c066c,C1175743,C1422064,use Proteasome Pathway in addition to,SARS coronavirus,ACE2 gene,2,X,[virs],[gngm],B04.820.504.540.150.113.937,
65977c28-b1f5-4bea-ade7-e6c0c9639a8b,C1704259,C1422064,activated by ,Biochemical Pathway,ACE2 gene,1,X,[moft],[gngm],,
c3cfb36d-72f9-4f71-80b6-844e82e99a09,C0236099,C0206750,induced by ,Disorder of male reproductive system,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
1d01b838-a2e4-4ce5-84f5-f99a3bb9dd9c,C1424188,C1421479,is in ,PPP1R2C gene,WASF1 gene,1,X,[gngm],[gngm],,
c5696011-eebb-4332-ad6a-6c90a789dd7b,C1421479,C4082587,is in ,WASF1 gene,HLA Class II Histocompatibility Antigen Gamma Chain human,1,X,[gngm],[aapp/imft],,
94c02dc6-4cd7-4dc8-bd5b-f3b4283de9a7,C1424188,C4082587,is in ,PPP1R2C gene,HLA Class II Histocompatibility Antigen Gamma Chain human,1,X,[gngm],[aapp/imft],,
d73a7350-883b-44ce-a209-13ee51d47918,C0040300,C0349410,is main cause of multi ,Body tissue,Single organ dysfunction,5,X,[tisu],[sosy],A10,
a4d43132-d5ba-4f23-bf2c-44fb1d6e42d6,C0242184,C0349410,is main cause of multi ,Hypoxia,Single organ dysfunction,5,X,[patf],[sosy],C23.888.852.079,
b5a5409f-3e43-43fa-8dbe-055a82a12dd6,C0040300,C0243026,is main cause of multi ,Body tissue,Sepsis,4,X,[tisu],[dsyn],A10,C01.539.757;C23.550.470.790.500
427b2d86-396e-43ae-8479-4e162573513d,C0242184,C0243026,is main cause of multi ,Hypoxia,Sepsis,4,X,[patf],[dsyn],C23.888.852.079,C01.539.757;C23.550.470.790.500
510ab872-d648-4c9e-a2db-66d6c4b2c396,C0040135,C0040300,has effects on immune system in infected ,Thyroid Hormones,Body tissue,2,X,[horm],[tisu],D06.472.931,A10
3d9fccd2-db6a-492d-a1de-2aba8009fc09,C0015190,C0243026,is common in ,Euthyroid Sick Syndromes,Sepsis,2,X,[dsyn],[dsyn],C19.874.255,C01.539.757;C23.550.470.790.500
aa5b9872-9f6c-4c8b-a299-53efc31326a5,C0040135,C0010340,may Thus may treatment in setting of ,Thyroid Hormones,Critical Illness,2,X,[horm],[dsyn],D06.472.931,C23.550.291.625
b4c0c552-d507-40f3-b9ea-196c6589d40c,C0040135,C0042769,may Thus may treatment in setting of ,Thyroid Hormones,Virus Diseases,2,X,[horm],[dsyn],D06.472.931,C02
bc39d234-b45d-4f78-97a6-12b88ce4b3fb,C0010340,C0700366,requiring Extra ,Critical Illness,body membrane,2,X,[dsyn],[tisu],C23.550.291.625,
181283d0-a4da-410a-b061-2bcac8eb1f4b,C0206750,C0700366,requiring Extra ,Coronavirus Infections,body membrane,2,X,[dsyn],[tisu],C02.782.600.550.200,
63f4e540-f3bc-4c0d-b4d0-d7c4305bf258,C0010340,C0282636,requiring Extra ,Critical Illness,Cell Respiration,2,X,[dsyn],[celf],C23.550.291.625,G03.197;G04.270
dbc6ff3e-affd-4cb7-b729-b77168e6b27f,C0206750,C0282636,requiring Extra ,Coronavirus Infections,Cell Respiration,2,X,[dsyn],[celf],C02.782.600.550.200,G03.197;G04.270
5d1f4937-8c1b-49e8-8705-13c55f342b16,C0013230,C0001617,of trial is ,Investigational New Drugs,Adrenal Cortex Hormones,2,X,[phsu],[horm/orch/phsu],D26.371,D06.472.040
708fed30-a8d7-43d7-a81c-168655854b9f,C0304229,C0001617,of trial is ,Experimental drug,Adrenal Cortex Hormones,2,X,[phsu],[horm/orch/phsu],,D06.472.040
bd5c27dd-4187-4a0a-9f77-62744dadb6d1,C0032042,C0439861,is with composition identical apart from active ,Placebos,Substance,2,X,[topp],[sbst],D26.660;E02.785,
74603a9f-bf9d-4d25-a433-a382dc97f3f2,C0772289,IWRS,incorporating IWRS,corticotropin-releasing factor human,IWRS,2,X,[horm/orch/phsu],????,,????
94e5e7ef-9897-4937-b476-e6ef4bf25b37,C0772289,C1705178,incorporating IWRS in ,corticotropin-releasing factor human,Order (action),2,X,[horm/orch/phsu],[acty],,
e72f7572-867c-44d1-beeb-f2fa60076fb8,C0012634,C1704259,leads with increasing evidence for ,Disease,Biochemical Pathway,1,X,[dsyn],[moft],C23.550.288,
e72f7572-867c-44d1-beeb-f2fa60076fb8,C0012634,C1704259,may Lead to activated,Disease,Biochemical Pathway,1,X,[dsyn],[moft],C23.550.288,
e72f7572-867c-44d1-beeb-f2fa60076fb8,C0012634,C1704259,may lead to activated immune-inflammatory ,Disease,Biochemical Pathway,1,X,[dsyn],[moft],C23.550.288,
c1e5c84f-8fe1-4cfe-a5af-8f04899f25e3,C2931926,C4054044,proven in treatment of ,ruxolitinib,Secondary Hemophagocytic Lymphohistiocytosis,2,X,[orch/phsu],[dsyn],,
11cf9c90-df99-47e2-ba86-289906bd3e6e,C0450442,C1175175,appear promising in fight against ,Agent,Severe Acute Respiratory Syndrome,2,X,[chvf],[dsyn],,C02.782.600.550.200.750;C08.730.730
5564736b-ed34-4e80-9058-53327eb9a9bb,C0027078,C0206750,were selected by multivariate analysis as candidates for prediction of disease severity in ,Myoglobin,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D12.776.210.500.588;D12.776.422.316.940,C02.782.600.550.200
d0beaadd-642b-4e6f-bba3-bebf7b83ace9,C0282682,C0597358,is with most against ,Antibodies Blocking,receptor binding,4,X,[aapp/imft/irda],[moft],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,
86d9dc6b-c55a-4fa0-87f6-68bf972902d6,C0032105,C0597358,differed in their degree of focus on ,Plasma,receptor binding,4,X,[bdsu],[moft],A12.207.152.693;A12.207.270.695;A15.145.693,
4765f31e-4a6b-4691-b773-ce1553675745,C0032105,C0003316,differed in their degree of focus on ,Plasma,Epitopes,4,X,[bdsu],[imft],A12.207.152.693;A12.207.270.695;A15.145.693,D23.050.550
d5af57a4-97c2-4ffd-955c-1a155fe5fdf8,C0524865,S1,showed recognition of S1,Reconstructive Surgical Procedures,S1,4,X,[topp],????,E04.680,????
716a8ad9-390d-4452-a3a9-8fb9aa2832ad,C0003316,C1422064,blocks ,Epitopes,ACE2 gene,2,X,[imft],[gngm],D23.050.550,
4576e4cd-97cf-47d4-9616-72b0b38efbbc,C0003316,C0597358,blocks ,Epitopes,receptor binding,4,X,[imft],[moft],D23.050.550,
26b29ead-2f63-4050-bcc1-6cdae3940cbc,C0003316,C1522002,blocks ACE2 gene receptor binding on,Epitopes,RNA Recognition Motif,1,X,[imft],[aapp/bacs],D23.050.550,G02.111.570.820.709.275.500.869.500
26b29ead-2f63-4050-bcc1-6cdae3940cbc,C0003316,C1522002,blocks Peptidyl-Dipeptidase A receptor binding on,Epitopes,RNA Recognition Motif,2,X,[imft],[aapp/bacs],D23.050.550,G02.111.570.820.709.275.500.869.500
e4ab9c8f-be0a-4a98-b150-6aabd84acde7,C0206750,H1N1,has spread rapidly like just H1N1 ,Coronavirus Infections,H1N1,4,X,[dsyn],????,C02.782.600.550.200,????
c3f66d0c-f0ec-4e79-a517-3c2ae6535e1b,C0012634,H1N1,has spread rapidly like just H1N1 ,Disease,H1N1,4,X,[dsyn],????,C23.550.288,????
c55ef38c-1e45-4aaf-b256-e2d58e610c33,C0206750,C1135183,has spread rapidly like just H1N1 ,Coronavirus Infections,Sus scrofa,4,X,[dsyn],[mamm],C02.782.600.550.200,B01.050.150.900.649.313.500.880.399
a670ca9b-7177-4785-9e9a-2f0201395e3a,C0012634,C1135183,has spread rapidly like just H1N1 ,Disease,Sus scrofa,4,X,[dsyn],[mamm],C23.550.288,B01.050.150.900.649.313.500.880.399
7f409a6a-972b-4091-b3e1-3912a7bd3d9a,C0206750,C2076600,has spread rapidly like just H1N1 ,Coronavirus Infections,Influenza due to Influenza A virus subtype H1N1,4,X,[dsyn],[dsyn],C02.782.600.550.200,
7f409a6a-972b-4091-b3e1-3912a7bd3d9a,C0206750,C2076600,is severe than 2009 ,Coronavirus Infections,Influenza due to Influenza A virus subtype H1N1,2,X,[dsyn],[dsyn],C02.782.600.550.200,
07c49d02-f2e9-4d63-842d-ccf0a92ec7d0,C0012634,C2076600,has spread rapidly like just H1N1 ,Disease,Influenza due to Influenza A virus subtype H1N1,4,X,[dsyn],[dsyn],C23.550.288,
3d1295ee-0999-4893-beb3-5e57fe8e761c,C0242648,C0206750,using Medical Subject terms ,Vertical Disease Transmission,Coronavirus Infections,4,X,[patf],[dsyn],N06.850.310.425,C02.782.600.550.200
002ad4c5-cbdc-4436-b861-1db0786a2fec,C0439056,C0033727,were collected at ,Throat swab sample,Protons,6,X,[bdsu],[elii],,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
763fe6c4-1e0b-4298-adf8-8ea39b01d409,C1511790,C0229671,is in neonates ,Detection,Serum,8,X,[topp],[bdsu],,A12.207.152.846;A15.145.846
144fc16d-7a46-4989-9db3-acbf25050973,C0039082,C0282686,concern only ,Syndrome,Respiratory System Agents,2,X,[dsyn],[phsu],C23.550.288.500,D27.505.954.796
682528c2-ef72-4e62-8a23-4db5474d4263,COVID,C0242821,numerous areas of ,COVID,Human body,4,X,????,[humn],????,I01.076.201.450.560;K01.093.378
1064dfd9-8e72-49c6-a52c-1653f742e600,C1999230,C1707455,direct visualization of anatomic injury ,Providing (action),Comparison,1,X,[acty],[acty],,
ced834ab-d32d-4226-8556-1c94b9de31f8,C0319157,C3697872,belongs to ,AS virus,Genus Betacoronavirus,3,X,[virs],[virs],,
ff2a9ce6-5ffd-4a57-ba47-0b3fcfef1db8,C0319157,C0010076,belongs to ,AS virus,Coronaviridae,3,X,[virs],[virs],,B04.820.504.540
31378422-312a-4521-9b3a-df36b004e39e,C0221423,C0206419,with Genus: Coronavirus is,Illness (finding),Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
31378422-312a-4521-9b3a-df36b004e39e,C0221423,C0206419,caused by ,Illness (finding),Genus: Coronavirus,3,X,[sosy],[virs],,B04.820.504.540.150
ba806708-09fb-4fb9-8f02-953bceee02ef,C1628478,C1550100,is in ,SARS coronavirus IgG,Specimen Type - Serum,2,X,[aapp/imft],[bdsu],,
a57633f9-248e-44eb-bb0c-16dae5ba6d1b,C1628478,C0086418,is in ,SARS coronavirus IgG,Homo sapiens,1,X,[aapp/imft],[humn],,B01.050.150.900.649.313.988.400.112.400.400
e036f427-6dad-4c82-984d-7cbf61fa2155,C0191234,C1883720,was performed with ,Pericardiocentesis,Removing (action),1,X,[topp],[acty],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,
910e1c09-5c7b-4da5-a7d6-4eedded4276b,C0020452,C0206419,were reported in ,Hyperemia,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.474,B04.820.504.540.150
244ce586-f748-4bbb-89df-1d29e9ab5fb3,C0264545,C0206419,were reported in ,Thickening of pleura,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
972064ec-a783-4b8f-b313-52318eaed116,C0206419,C0032310,involvement with non-COVID ,Genus: Coronavirus,Pneumonia Viral,2,X,[virs],[dsyn],B04.820.504.540.150,C02.705;C08.381.677.807;C08.730.610.763
972064ec-a783-4b8f-b313-52318eaed116,C0206419,C0032310,emerged as ,Genus: Coronavirus,Pneumonia Viral,1,X,[virs],[dsyn],B04.820.504.540.150,C02.705;C08.381.677.807;C08.730.610.763
d95853ff-0874-4af6-8df8-ff3cc3a1a156,C0206419,C1707455,involvement of upper ,Genus: Coronavirus,Comparison,2,X,[virs],[acty],B04.820.504.540.150,
7ac06d02-fa1e-407a-bf07-ccbea3651feb,C0019682,C0206419,is with ,HIV,Genus: Coronavirus,3,X,[virs],[virs],B04.820.650.589.650.350,B04.820.504.540.150
95d4aec0-a4a9-4c2b-a926-d350e472ee8f,C0019682,C1963724,had proportions on ,HIV,Antiretroviral therapy,1,X,[virs],[topp],B04.820.650.589.650.350,
a78f3fec-4c81-4fdb-b738-066a1dce33b2,C2948600,C0242821,review growing ,Aim,Human body,1,X,[inch/phsu],[humn],,I01.076.201.450.560;K01.093.378
dc44b2c7-f947-496e-b204-63b79271d967,C2948600,C0242656,review growing ,Aim,Disease Progression,2,X,[inch/phsu],[patf],,C23.550.291.656
c72b6208-ceca-4d68-87fb-a0565fcad04d,C2948600,C0035436,review growing ,Aim,Rheumatic Fever,1,X,[inch/phsu],[dsyn],,C01.252.410.890.731;C05.550.114.843;C05.799.825
e843d400-e51f-4b00-84b0-b7449f264841,C1701790,C0206419,has has related to hyperinflammatory state in ,IL17A protein human,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
15b8114d-e091-442e-8abb-8f95a2a83751,C2364111,C1457887,was reported less frequently than other ,Ageusia,Symptoms,3,X,[sosy],[sosy],C10.597.751.861.184;C23.888.592.763.861.184,
d9d5d4c0-80d6-4396-b7db-0d81eb91cf0a,C1457887,C1175743,predicting ,Symptoms,SARS coronavirus,3,X,[sosy],[virs],,B04.820.504.540.150.113.937
d9d5d4c0-80d6-4396-b7db-0d81eb91cf0a,C1457887,C1175743,met in older adults infected with ,Symptoms,SARS coronavirus,4,X,[sosy],[virs],,B04.820.504.540.150.113.937
d9d5d4c0-80d6-4396-b7db-0d81eb91cf0a,C1457887,C1175743,conduct surveillance for ,Symptoms,SARS coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150.113.937
e33900a7-26e1-42a4-b96b-38776d312584,C0013879,C0871208,promote similar -1 PRF ,Elements,Rating (action),2,X,[elii],[acty],D01.268,
e2892089-9cc2-47ed-928d-b021abfce7b4,C0013879,C1538187,promote similar ,Elements,ZNF395 gene,1,X,[elii],[gngm],D01.268,
e2892089-9cc2-47ed-928d-b021abfce7b4,C0013879,C1538187,similar Rating (action) of,Elements,ZNF395 gene,1,X,[elii],[gngm],D01.268,
a48dbbaa-0c40-4d3f-a540-f1f6a603f6f5,C1519323,C1186763,is in three ,Silent Mutation,Stem of Organ,6,X,[genf],[bpoc],G05.365.590.803,
03f9e2ba-8462-4ac1-84ae-f103369bc081,C1538187,C1175743,is in ,ZNF395 gene,SARS coronavirus,9,X,[gngm],[virs],,B04.820.504.540.150.113.937
2152c216-4a6a-41b4-b8a8-abdd89b1501a,C0243077,C0303231,Providing (action) promising,inhibitors,Lead compound,1,X,[chvf],[chvs],,
aa3b60a2-7496-4c5e-9cee-778819f9fc67,PRF,C1538187,was similarly effective against ,PRF,ZNF395 gene,6,X,????,[gngm],????,
43d8de43-f002-45dd-8616-7bf902e3a28e,PRF,C1175743,was similarly effective against ,PRF,SARS coronavirus,6,X,????,[virs],????,B04.820.504.540.150.113.937
76d29dec-da6f-4126-9de5-6d16c2526cdb,C0444279,C0206419,collected from confirmed ,Respiratory sample,Genus: Coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150
e52faf0f-74d9-43c0-8d45-546ff2b465d7,C2985398,C1167395,regulating ,Intestinal Microbiome,Host (organism),1,X,[orgm],[orgm],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,
fddc923d-11ca-4bfc-94c6-567c6ff0a69b,C2985398,C0019868,regulating ,Intestinal Microbiome,Homeostasis,1,X,[orgm],[biof],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,G07.410
d340ced1-4267-41f9-81d1-036bf1b8c017,C2985398,C0024501,is closely related to ,Intestinal Microbiome,Maintenance,1,X,[orgm],[acty],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,N02.628
b0658d42-8649-4ab0-a963-f4c15434e3c9,C2985398,C0024109,is closely related to ,Intestinal Microbiome,Lung,1,X,[orgm],[bpoc],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,A04.411
3b0de3d4-d30e-4c10-9a90-9424c3f556f2,C0012155,C0870883,improving proportion of its ,Diet,Metabolite,1,X,[food],[bacs],G07.203.650.240,
b2a39aac-7022-4551-820c-8378cd3b8cfc,C0012155,C0525033,improving proportion of its ,Diet,Probiotics,1,X,[food],[bact],G07.203.650.240,G07.203.300.456.500;J02.500.456.500
4ac251de-1b17-4746-a219-b317364ef2eb,C0012155,C2985398,improving composition of ,Diet,Intestinal Microbiome,1,X,[food],[orgm],G07.203.650.240,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
06a4b9f5-ba19-49f2-a43d-0f09f76ad695,C0012155,C0206419,prevent ,Diet,Genus: Coronavirus,1,X,[food],[virs],G07.203.650.240,B04.820.504.540.150
2de87c95-2059-4202-9681-bcddfcb27f0d,C0022671,C0206419,thought symptomatic for ,Kidney Transplantation,Genus: Coronavirus,6,X,[topp],[virs],E02.870.500;E04.936.450.485;E04.950.774.400,B04.820.504.540.150
1592894b-ba6d-439d-a156-302fc285c954,C0027950,C0206419,predict independently classification of ,neutrophil,Genus: Coronavirus,1,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,B04.820.504.540.150
af4ef424-0b28-486b-a5fb-2356de0bc474,C1175743,C0035691,is new ,SARS coronavirus,RNA Viruses,5,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820
550340dc-a146-4a89-b0ea-16ea8b206539,C1412002,C0026766,can progress to ,Atypical pneumonia,Multiple Organ Failure,5,X,[dsyn],[patf],,C23.550.835.525
2cc3e0c9-80b1-45cd-b15d-74546883efdd,C0206419,C0024291,simulate ,Genus: Coronavirus,Lymphohistiocytosis Hemophagocytic,2,X,[virs],[dsyn],B04.820.504.540.150,C15.604.250.410.575
7239e2ca-fa5c-4d68-850b-f03a33261575,C1624602,C1609165, includes ,Anti-Antibodies,tocilizumab,4,X,[aapp/imft],[aapp/imft/phsu],D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071,x.x.x.x
9f08b43a-cb8e-4a18-bd80-211caaf0d842,C1624602,C1175743,play role in treatment with ,Anti-Antibodies,SARS coronavirus,6,X,[aapp/imft],[virs],D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071,B04.820.504.540.150.113.937
7d9c979e-8e8a-40f1-bffe-a5300632563e,C0063717,C1175743,play role in treatment with ,Interleukin 6 Receptor,SARS coronavirus,4,X,[aapp/imft/rcpt],[virs],D12.776.543.750.705.852.420.400,B04.820.504.540.150.113.937
1ebea2bf-b7ff-4c19-98f0-015793aa7571,C1609165,C1175743,play role in treatment with ,tocilizumab,SARS coronavirus,5,X,[aapp/imft/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
19328f8d-a628-4711-9ee0-69d6391c7e84,C0035243,C1175743,is with ,Respiratory Tract Infections,SARS coronavirus,1,X,[dsyn],[virs],C01.539.739;C08.730,B04.820.504.540.150.113.937
e3735de5-8771-4d39-8e6d-01251a508cb6,C1292459,C0206419,is with ,Specimen from patient,Genus: Coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150
dd9aaf47-0b36-4d3e-ab3a-e6a70de1e415,C0026691,C0042769,suggest here hypothesis of new post-viral ,Mucocutaneous Lymph Node Syndrome,Virus Diseases,6,X,[dsyn],[dsyn],C14.907.940.560;C15.604.560;C17.800.862.560,C02
cc1d23b7-3a82-4fe7-906a-bba80f8c153d,C1550661,C1175743,became for ,Specimen Type - Stool = Fecal,SARS coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150.113.937
edfd26d7-d10d-483e-a514-391f363cc2c6,C1550661,C0444279,15days after first positive ,Specimen Type - Stool = Fecal,Respiratory sample,3,X,[bdsu],[bdsu],,
5ec756ba-8319-4baa-a183-4f0f896adce8,C0265267,C0012634,is associated with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,Disease,3,X,[dsyn],[dsyn],x.x.x.x,C23.550.288
942fe0c4-51a2-49ec-a910-2e00415276e5,NYSDOH,C0265267,definition for ,NYSDOH,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,2,X,????,[dsyn],????,x.x.x.x
e4753225-cdb0-4eb8-a3a6-c7aaf2b5f74a,NYSDOH,C1856053,definition for ,NYSDOH,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,????,[dsyn],????,x.x.x.x
24f1060f-6924-4b87-b6e9-63e947813825,C0426576,C1761613,had ,Gastrointestinal symptom,Conjunctival hyperemia,3,X,[sosy],[dsyn],,
bac02e8d-1fda-4082-a428-4e00517fd553,C0426576,C0015230,had ,Gastrointestinal symptom,Exanthema,3,X,[sosy],[sosy],,C17.800.257
2736adc2-96ab-4e7b-aed0-893090b89b21,C0007430,C0206419,was compared ,Catheterization,Genus: Coronavirus,1,X,[topp],[virs],E02.148;E05.157,B04.820.504.540.150
1f55607a-398d-43f4-b9fa-bcb8f2dd4853,C0917801,C0206419,experiencing high degree of threat from ,Sleeplessness,Genus: Coronavirus,1,X,[sosy],[virs],C10.886.425.800.800;F03.870.400.800.800,B04.820.504.540.150
f4bb8397-af89-430b-84de-3dd03ddd67ad,C0683325,C0026769,is in patients with ,clinical aspects,Multiple Sclerosis,1,X,[clna],[dsyn],,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
56be0ba8-53c4-4686-985d-a24b96307b16,C0387382,C0206419,were independent risk factors for ,CI 4,Genus: Coronavirus,1,X,[aapp/phsu],[virs],,B04.820.504.540.150
3d51787f-b60b-4fdf-ab48-6d7d2065b1bb,C0028754,C0206419,were independent risk factors for ,Obesity,Genus: Coronavirus,1,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
3d51787f-b60b-4fdf-ab48-6d7d2065b1bb,C0028754,C0206419,also have worse outcomes with ,Obesity,Genus: Coronavirus,2,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
3d51787f-b60b-4fdf-ab48-6d7d2065b1bb,C0028754,C0206419,BACKGROUND/During 2019 ,Obesity,Genus: Coronavirus,4,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
3d51787f-b60b-4fdf-ab48-6d7d2065b1bb,C0028754,C0206419,may contribute to ,Obesity,Genus: Coronavirus,2,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
f15243af-fbbc-45b1-ae87-ab446b386a75,EDSS,C0206419,was associated with highest variability of ,EDSS,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
30a06fe2-6198-4a60-87b0-d148b310502c,C1415900,C0007600,is in ,IFNA1 gene,Cultured Cell Line,3,X,[gngm],[cell],,A11.251.210
c531f0e0-a568-4e99-bd5c-ac457f5be4fe,C2931926,C1175743,boosted ,ruxolitinib,SARS coronavirus,6,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
8bc93b18-604e-46ca-b446-4531882e1813,C0007590,C1413097,is in IFN-competent ,Cell division,CALU gene,1,X,[celf],[gngm],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,
23dc65e6-bd1f-408a-a64a-0edfa2b44a38,C2931926,C3854325,Janus kinase inhibitor of IFN-triggered,ruxolitinib,Janus kinase inhibitor,3,X,[orch/phsu],[phsu],,D27.505.519.389.755.500
15f7d287-029d-4a92-b4ef-7a9da38fa255,C0020598,C0206419,were independent risk factors associated with long-term hospitalization in patients with ,Hypocalcemia,Genus: Coronavirus,4,X,[dsyn],[virs],C18.452.174.509;C18.452.950.509,B04.820.504.540.150
c8c3bc6a-9ff5-43a9-8f98-860910ca1b6f,C0085680,C0206419,were independent risk factors associated with long-term hospitalization in patients with ,Hypochloremia (disorder),Genus: Coronavirus,4,X,[dsyn],[virs],,B04.820.504.540.150
1b0a2103-8666-424d-8938-ef7c78ea22a2,C1142578,C0206419,were independent risk factors associated with long-term hospitalization in patients with ,Bilateral pneumonia,Genus: Coronavirus,4,X,[dsyn],[virs],,B04.820.504.540.150
ec50f347-e2fe-4feb-8c74-90f04d69471e,studys,C0206419,apply morphoproteomics from forensic autopsy of untreated ,studys,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
162de50f-cc27-4dca-9735-62f9626f7c7d,studys,C0545747,apply morphoproteomics to ,studys,pulmonary artery and pulmonary artery,4,X,????,[bpoc],????,
835f2ec0-d556-4579-9961-a2dfadd5e823,C0225698,C2328510,is in ,Alveolar Epithelial Cells,Interstitium,4,X,[cell],[bpoc],A04.411.715.100;A11.436.081,
414a6b23-9fac-4c5d-9d21-7dbb581ab333,C0387583,C0225698,is in alveolar ,cyclooxygenase 2,Alveolar Epithelial Cells,4,X,[aapp/enzy],[cell],D08.811.600.720.750,A04.411.715.100;A11.436.081
6318d754-6c66-4449-bbef-24870d5730c2,C2985566,C0024115,could address ,Targeted Therapy,Lung diseases,4,X,[topp],[dsyn],,C08.381
f5f8d81d-4ba7-4190-b864-8994a5fd4823,C2985566,C0005532,could address ,Targeted Therapy,biology (field),4,X,[topp],[bmod],,H01.158.273
6cd95f43-9ea6-4d71-85a6-5e3ef03fef91,C2985566,C0206419,could address ,Targeted Therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
7bc2c120-e009-41a6-9d18-d868830dda34,C0033684,C0042776,collectively reveal map of ,Proteins,Virus,1,X,[aapp/bacs],[virs],D12.776,B04
2033a299-ffb2-449c-b334-e6c5e01d9f1e,C1167408,C0597357,is with ,immunoglobulin complex location,receptor,2,X,[celc],[aapp/rcpt],,
41e77d88-a3da-4c63-b96c-9d91971e790e,C1167408,C1328819,is with ,immunoglobulin complex location,Small Molecule,2,X,[celc],[orch],,
7bd87fc5-b79b-41e9-853c-5f44b06eb9da,C0017968,C0376322,is with modeled ,Glycoproteins,Protein Glycosylation,2,X,[aapp/bacs],[moft],D09.400.430;D12.776.395,G02.111.158.812;G02.607.299;G03.191.812
644b00a8-9fce-4bf3-8529-d2fa9219aa04,C0206419,C0264219,is causative agent of ,Genus: Coronavirus,Acute respiratory disease,2,X,[virs],[dsyn],B04.820.504.540.150,
644b00a8-9fce-4bf3-8529-d2fa9219aa04,C0206419,C0264219,could cause ,Genus: Coronavirus,Acute respiratory disease,1,X,[virs],[dsyn],B04.820.504.540.150,
4287eb50-85de-4db6-8b2e-1e16dc539eaf,C1175743,C0264219,is causative agent of ,SARS coronavirus,Acute respiratory disease,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,
4287eb50-85de-4db6-8b2e-1e16dc539eaf,C1175743,C0264219,induces severe ,SARS coronavirus,Acute respiratory disease,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,
4287eb50-85de-4db6-8b2e-1e16dc539eaf,C1175743,C0264219,commonly presents as severe ,SARS coronavirus,Acute respiratory disease,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
669bcfa8-5001-43b1-ab0c-3f95e5a24dd5,C0035668,C1511790,can can used for ,RNA,Detection,2,X,[nnon],[topp],D13.444.735,
669bcfa8-5001-43b1-ab0c-3f95e5a24dd5,C0035668,C1511790,was After resolution of ,RNA,Detection,1,X,[nnon],[topp],D13.444.735,
8a86833c-b7ac-4fa7-95b3-900386b6328e,C0035668,C1764827,can can used for ,RNA,Isolate - microorganism,2,X,[nnon],[bacs],D13.444.735,
96e6e37d-a594-4a8a-81b4-a4041d94af0a,C0035668,SYBR,using low-cost SYBR ,RNA,SYBR,2,X,[nnon],????,D13.444.735,????
ab1d4d3d-9c9c-45b5-a1be-3d76fdc6f515,C1175743,C0599638,is in ,SARS coronavirus,Drinking Water,1,X,[virs],[sbst],B04.820.504.540.150.113.937,D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418
524ce8ff-797b-4d79-a752-efde2735df1e,C1514562,C0206750,was significantly associated with ,Protein Domain,Coronavirus Infections,1,X,[amas],[dsyn],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,C02.782.600.550.200
6eabb206-01dc-45bd-8c69-a98756e95b1e,DRF,C0206750,understand ,DRF,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
e45974cd-64a2-412e-a495-41fd2cc7bfd3,DRF,C0699748,understand ,DRF,Pathogenesis,1,X,????,[patf],????,
67c5233b-37dd-4f54-a5ac-46e661066ded,DRF,C0023317,provides ,DRF,Lens Crystalline,1,X,????,[bpoc],????,A09.371.060.500
a503989b-b0ef-4631-8e55-67334eb5ab0c,C0011849,C0206750,were most prevalent comorbidities in ,Diabetes Mellitus,Coronavirus Infections,10,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C02.782.600.550.200
bbd7d504-7c53-4180-84b4-b4226eb8fccf,C0011849,C0948092,provides guidance recommendations for ,Diabetes Mellitus,diabetes mellitus management,4,X,[dsyn],[topp],C18.452.394.750;C19.246,
884eee8c-9376-466e-a186-8c09d9207c4d,C0948092,C0206750,is in patients with ,diabetes mellitus management,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
df86f3c4-40b3-423a-872f-513158197ce0,C0037633,C0206750,literature on infection control practices in health care facilities against ,Solutions,Coronavirus Infections,1,X,[sbst],[dsyn],D26.776,C02.782.600.550.200
44d715b9-9416-445a-b592-461db2a336ba,C0206750,C0030664,has complex ,Coronavirus Infections,Pathology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.650
44d715b9-9416-445a-b592-461db2a336ba,C0206750,C0030664,is in children with underlying chronic renal ,Coronavirus Infections,Pathology,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.650
44d715b9-9416-445a-b592-461db2a336ba,C0206750,C0030664,have course in children with underlying chronic ,Coronavirus Infections,Pathology,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.650
805c6c83-eb1f-4313-b439-2950ed08cbc6,C0012644,C1457887,can reflect clinical ,Animal Disease Models,Symptoms,1,X,[emod],[sosy],C22.232;E05.598.500;E05.599.395.080,
6adf6054-e793-4a5a-b98e-e185fe585e31,C0012644,C0206750,underlying etiopathogenesis similar to ,Animal Disease Models,Coronavirus Infections,1,X,[emod],[dsyn],C22.232;E05.598.500;E05.599.395.080,C02.782.600.550.200
c16153b0-6f47-4fee-8c71-fa84aeb028a5,C0003015,C1175743,are associated with risk of Cov2 ,Angiotensin-Converting Enzyme Inhibitors,SARS coronavirus,2,X,[phsu],[virs],D27.505.519.389.745.085,B04.820.504.540.150.113.937
57dbbf63-0ad8-4d6a-aa63-bea234310a14,C0003015,Cov2,are associated with risk of Cov2 ,Angiotensin-Converting Enzyme Inhibitors,Cov2,2,X,[phsu],????,D27.505.519.389.745.085,????
7dcc1448-90f4-43c6-b25d-248bf470da53,C2948600,C0700201,investigate prevalence of ,Aim,Dyssomnias,3,X,[inch/phsu],[mobd],,C10.886.425;F03.870.400
2be75239-e79b-459e-8704-39a5438a029c,C0086132,C0860603,reported ,Depressive Symptoms,Anxiety symptoms,2,X,[sosy],[sosy],F01.145.126.350,
2be75239-e79b-459e-8704-39a5438a029c,C0086132,C0860603,were related to ,Depressive Symptoms,Anxiety symptoms,6,X,[sosy],[sosy],F01.145.126.350,
0073ee87-4c03-453f-bf39-66aa91df6d35,C0086132,C0700201,were associated with poor sleep quality ,Depressive Symptoms,Dyssomnias,3,X,[sosy],[mobd],F01.145.126.350,C10.886.425;F03.870.400
60935032-9ed2-40eb-9838-8a9da21a68e0,C0086132,C0011570,were associated with poor sleep quality ,Depressive Symptoms,Mental Depression,3,X,[sosy],[mobd],F01.145.126.350,F01.145.126.350
edc63674-b3a7-493f-9761-3da209a75e70,C0206750,C0006145,Available information on ,Coronavirus Infections,Breast Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C17.800.090
fe62f699-cc1c-418b-bf68-9b797fb0aca7,C0012634,C0006145,Available information on ,Disease,Breast Diseases,1,X,[dsyn],[dsyn],C23.550.288,C17.800.090
5932774f-d02c-4d72-bfb1-7ff429390e5d,C0206750,C0242656,is in ,Coronavirus Infections,Disease Progression,4,X,[dsyn],[patf],C02.782.600.550.200,C23.550.291.656
55fe0d54-f727-4605-ace4-d6bab179fb00,C0003015,C1422064,Top results for ,Angiotensin-Converting Enzyme Inhibitors,ACE2 gene,1,X,[phsu],[gngm],D27.505.519.389.745.085,
9cd5cd2e-9553-4793-ac9b-f6befade7abb,C0003015,C1167622,Top results for ,Angiotensin-Converting Enzyme Inhibitors,Binding (Molecular Function),1,X,[phsu],[moft],D27.505.519.389.745.085,
7fb13204-c0f0-498d-b2b3-eeb0897db26f,C1305855,kg/m,was 29.00 kg/m,Body mass index,kg/m,1,X,[clna],????,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,????
db025e26-3ab7-4b63-9505-c92cee904183,C1305855,C0028754,was used as indicator of overall ,Body mass index,Obesity,2,X,[clna],[dsyn],E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
41fa062f-57fb-4f3e-85c9-4bd679d5f3b8,C1136170,C0012634,include lack of understanding of ,Virulence Factors,Disease,1,X,[bacs/hops/orch],[dsyn],D23.946.896,C23.550.288
ff30a981-b782-44dd-b363-4297a93729d6,C0024312,C0225730,is in ,Lymphopenia,Left lung,2,X,[dsyn],[bpoc],C15.378.553.546.605;C20.673.627,
3a9015ac-df8c-45ba-b49f-40e9f10b33d6,C0030054,C0020431,remarkably relieved after seven days of ,Oxygen,Hyperbaric oxygenation therapy,1,X,[bacs/elii/phsu],[topp],D01.268.185.550;D01.362.670;x.x.x.x,E02.880.690.490
b8b2e8b9-97a2-4fb5-a8a7-3ff8ec0fd39c,C0206750,C0024291,simulate ,Coronavirus Infections,Lymphohistiocytosis Hemophagocytic,2,X,[dsyn],[dsyn],C02.782.600.550.200,C15.604.250.410.575
037bc539-93dd-47db-9ccb-9100ad24c591,C1624602,C3873497,play role in treatment of ,Anti-Antibodies,Severe acute respiratory infection,3,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071,
465541cb-72d8-4158-b1f7-97a070f9b2fd,C0063717,C3873497,play role in treatment of ,Interleukin 6 Receptor,Severe acute respiratory infection,2,X,[aapp/imft/rcpt],[dsyn],D12.776.543.750.705.852.420.400,
1f2800bb-3454-49f6-9367-18ba9a92da42,C1609165,C3873497,play role in treatment of ,tocilizumab,Severe acute respiratory infection,4,X,[aapp/imft/phsu],[dsyn],x.x.x.x,
207e04b0-e199-40f2-8a00-a5ac52451870,C1175743,C0003451,was refractory to ,SARS coronavirus,Antiviral Agents,9,X,[virs],[phsu],B04.820.504.540.150.113.937,D27.505.954.122.388
44b7a939-1052-4c2a-bf56-76f63a3d0600,C1175743,C0021755,was refractory with favourable outcome after treatment with anti ,SARS coronavirus,Interleukin-1,2,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374.465.010;D12.644.276.374.500.400;D12.776.467.374.465.010;D12.776.467.374.500.400;D23.529.374.465.131;D23.529.374.500.400
f2944489-a8c6-4755-af75-2dbe88abb418,C0052796,C0206750,is in hospitalized patients positive for ,Azithromycin,Coronavirus Infections,1,X,[antb/orch],[dsyn],D02.540.576.500.992.050,C02.782.600.550.200
ed9a3da3-e19f-42c1-9447-47f106984ffa,C0206750,C3146294,has ,Coronavirus Infections,Generation (action),1,X,[dsyn],[acty],C02.782.600.550.200,
1eca333e-2973-44de-8c2c-dcfaf8990589,C0040038,C0206750,are of utmost importance in ,Thromboembolism,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.590,C02.782.600.550.200
1eca333e-2973-44de-8c2c-dcfaf8990589,C0040038,C0206750,have Despite severity of ,Thromboembolism,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.590,C02.782.600.550.200
60a4760b-eb28-4a31-a3ed-ce945d766fbf,C0005779,C0206750,is in ,Blood Coagulation Disorders,Coronavirus Infections,7,X,[dsyn],[dsyn],C15.378.100,C02.782.600.550.200
fd63b176-ed1d-4cbc-abbe-66355264e435,C0206750,C0199242,severe cases of be ,Coronavirus Infections,Anticoagulant prophylaxis,2,X,[dsyn],[topp],C02.782.600.550.200,
a333383b-306d-48fc-9538-ec8a3baa749b,C0199242,C0019139,using ,Anticoagulant prophylaxis,Heparin Low-Molecular-Weight,1,X,[topp],[orch/phsu],,D09.698.373.400.300
a413f976-e933-4c10-bbcd-7520b74f1105,C0014507,C1825598,been For analysis of ,Epidemiology,IMPACT gene,1,X,[bmod],[gngm],H02.403.720.500,
a413f976-e933-4c10-bbcd-7520b74f1105,C0014507,C1825598,Considering ,Epidemiology,IMPACT gene,1,X,[bmod],[gngm],H02.403.720.500,
e651dcc7-8256-4222-a500-b2979599e2a1,C0030956,C1167622,provide highly specific ,Peptides,Binding (Molecular Function),1,X,[aapp/phsu],[moft],D12.644,
78295378-9210-4b9b-9f5b-d65343d944eb,C0030956,C1175743,provide highly specific ,Peptides,SARS coronavirus,8,X,[aapp/phsu],[virs],D12.644,B04.820.504.540.150.113.937
6e85b6a3-533e-4d1e-a618-aead8efc9875,C0700271,C0960880,is with ,M Protein multiple myeloma,angiotensin converting enzyme 2,1,X,[aapp/imft],[aapp/enzy],x.x.x.x,x.x.x.x
07469ce0-1e5c-4aa6-8325-847caf983f58,C0030956,C0960880,could inhibit ,Peptides,angiotensin converting enzyme 2,2,X,[aapp/phsu],[aapp/enzy],D12.644,x.x.x.x
5fe447e0-9342-4d46-ae60-ae12fc298909,C0030956,C0700271,could inhibit ,Peptides,M Protein multiple myeloma,1,X,[aapp/phsu],[aapp/imft],D12.644,x.x.x.x
56a49509-8668-4671-be97-b6676fd70509,C0030956,C1537068,thereby blocking cellular ,Peptides,Virus Internalization,2,X,[aapp/phsu],[biof],D12.644,G06.920.881
dcb6cbbd-9ff0-4392-a243-b54e2f6078ac,C3463820,C1175743,be developed as anti ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
dcb6cbbd-9ff0-4392-a243-b54e2f6078ac,C3463820,C1175743,caused by ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
dcb6cbbd-9ff0-4392-a243-b54e2f6078ac,C3463820,C1175743,serving as ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
dcb6cbbd-9ff0-4392-a243-b54e2f6078ac,C3463820,C1175743,may impair viral ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
b16f410b-4c15-4925-9782-d9d39af5a6cf,C3463820,C1254351,be developed as anti ,Inhibition,Pharmacologic Substance,1,X,[acty],[phsu],F01.145.544;F02.463.425.475;F02.739.794.405,
4df14dfc-7016-4124-84fc-4656ff0a0483,C0030956,C1254351,be developed as anti ,Peptides,Pharmacologic Substance,1,X,[aapp/phsu],[phsu],D12.644,
b032498f-78ac-417f-8379-880f309d3070,C3463820,C1175175,be developed as anti ,Inhibition,Severe Acute Respiratory Syndrome,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C02.782.600.550.200.750;C08.730.730
ec85c8c5-542e-4812-aa89-993339ea5f84,C0030956,C1175175,be developed as anti ,Peptides,Severe Acute Respiratory Syndrome,1,X,[aapp/phsu],[dsyn],D12.644,C02.782.600.550.200.750;C08.730.730
b582e785-791f-45d3-b8dd-cb8aaebb8c63,C0206750,C0035222,presents as ,Coronavirus Infections,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
b582e785-791f-45d3-b8dd-cb8aaebb8c63,C0206750,C0035222,resulting in ,Coronavirus Infections,Respiratory Distress Syndrome Adult,3,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
b582e785-791f-45d3-b8dd-cb8aaebb8c63,C0206750,C0035222, includes ,Coronavirus Infections,Respiratory Distress Syndrome Adult,5,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
b582e785-791f-45d3-b8dd-cb8aaebb8c63,C0206750,C0035222,may challenge so-called ,Coronavirus Infections,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
b582e785-791f-45d3-b8dd-cb8aaebb8c63,C0206750,C0035222,can manifest with ,Coronavirus Infections,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
938ef6b2-79bd-4604-9c45-7ecb0377a55f,C0185112,C0543419,counter negative ,Therapeutic Mobilization,Sequela of disorder,1,X,[topp],[patf],,
3aeaaf29-140b-40e8-95cb-0dfae617af9a,C4505065,C0206750,risk of ,Noncommunicable Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.500.750,C02.782.600.550.200
3aeaaf29-140b-40e8-95cb-0dfae617af9a,C4505065,C0206750,may influence Host (organism) Immune System Diseases to,Noncommunicable Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.500.750,C02.782.600.550.200
08aa4c7f-4648-4a19-9809-7d685bad2c6a,C0206750,C1170730,is ,Coronavirus Infections,wake ups,1,X,[dsyn],[orch/phsu],C02.782.600.550.200,
afed8693-0db3-42b8-9fe5-8a04b3b06cd2,C0035668,C0598312,play roles in multiple aspects of ,RNA,DNA Replication,4,X,[nnon],[genf],D13.444.735,G02.111.225;G05.226
35b479a6-7be0-497e-bf7e-6afa7ea047a4,C0035668,C0017428,are pervasive throughout ,RNA,Genome,4,X,[nnon],[gngm],D13.444.735,G05.360.340
3e36336b-5486-4a46-a75d-01cd3f6d6e8e,C0035668,C0042211,disruption of be Thus could strategy for generation of ,RNA,Vaccines Attenuated,4,X,[nnon],[imft/phsu],D13.444.735,D20.215.894.811
44ede95f-deb7-4e6a-9dfc-7e9e6506f7f0,C0035668,C1175743,disruption of be Thus could strategy for generation of ,RNA,SARS coronavirus,4,X,[nnon],[virs],D13.444.735,B04.820.504.540.150.113.937
44ede95f-deb7-4e6a-9dfc-7e9e6506f7f0,C0035668,C1175743,was However since ,RNA,SARS coronavirus,2,X,[nnon],[virs],D13.444.735,B04.820.504.540.150.113.937
1fc5fd15-6332-47c4-bed8-ca0dbfae3d44,C0005768,C0206750,is in hospitalized ,In Blood,Coronavirus Infections,3,X,[bdsu],[dsyn],x.x.x.x.x,C02.782.600.550.200
1fc5fd15-6332-47c4-bed8-ca0dbfae3d44,C0005768,C0206750,was statistically significantly more frequent among those infected with ,In Blood,Coronavirus Infections,1,X,[bdsu],[dsyn],x.x.x.x.x,C02.782.600.550.200
06e7f5e3-1c1f-465a-88f6-65ee7de49a67,4weeks,C0206750,had 305 ,4weeks,Coronavirus Infections,3,X,????,[dsyn],????,C02.782.600.550.200
b054b2b1-98b9-4384-b627-b89cc6534eaa,C0206750,C0005841,had significantly lower ,Coronavirus Infections,Blood Transfusion,2,X,[dsyn],[topp],C02.782.600.550.200,E02.095.135
b054b2b1-98b9-4384-b627-b89cc6534eaa,C0206750,C0005841,required many fewer ,Coronavirus Infections,Blood Transfusion,3,X,[dsyn],[topp],C02.782.600.550.200,E02.095.135
8d316374-afc0-4930-abe0-920f7dcb2cb7,C0242656,C0032285,is in ,Disease Progression,Pneumonia,1,X,[patf],[dsyn],C23.550.291.656,C08.381.677;C08.730.610
e0746884-c4a2-472c-b584-77f94bb3029f,C0206750,C0032285,leading to ,Coronavirus Infections,Pneumonia,13,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.677;C08.730.610
8ebac324-2ce1-4494-9d83-f59763642945,HRCT,C0032285,were when reached in ,HRCT,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
95936555-61fe-405c-8ae5-0d7fc8f169a4,HRCT,C0012634,is Demand (clinical) Given values of HRCT,HRCT,Disease,1,X,????,[dsyn],????,C23.550.288
3988b7ff-8ca7-4195-8148-bb2c36e3a0be,HRCT,C0441516,is highly ,HRCT,Demand (clinical),1,X,????,[topp],????,
d1a8a4c3-7463-4327-aec6-87f1e1947dcf,C0444190,C0009763,were collected from patients without ,Conjunctival swab (specimen),Conjunctivitis,8,X,[bdsu],[dsyn],,C11.187.183
ffb2468e-d47e-45b0-9f4f-65eff596b93d,C0444190,C1175743,detecting ,Conjunctival swab (specimen),SARS coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150.113.937
4057b0ba-4028-4ad4-8af6-096482b6382f,C0444190,C0035668,detecting ,Conjunctival swab (specimen),RNA,2,X,[bdsu],[nnon],,D13.444.735
f076aea8-f724-4d84-9bf6-bfced6c02bc3,C0035668,C0009763,was detected in one patient without ,RNA,Conjunctivitis,2,X,[nnon],[dsyn],D13.444.735,C11.187.183
b99e87c6-a232-47eb-90f7-f5708c6e39fb,C1175743,C1521806,is in ,SARS coronavirus,Body Fluids and Substances,2,X,[virs],[tisu],B04.820.504.540.150.113.937,
410f73ca-c803-4f40-8ea7-bb34f115fe76,C0337050,C0319157,stop spread of ,Rivers,AS virus,2,X,[npop],[virs],G01.311.750;G16.500.275.280.650;N06.230.232.650,
845645c8-3bc7-4714-8ffb-3f2bd4786de9,C0337050,C0034019,implemented first-level ,Rivers,public health medicine (field),2,X,[npop],[bmod],G01.311.750;G16.500.275.280.650;N06.230.232.650,H02.403.720;N01.400.550;N06.850
7dd43135-cfd7-4f15-972b-ef0e0576d5cc,C0337050,C2745965,implemented first-level ,Rivers,Emergencies [Disease/Finding],2,X,[npop],[patf],G01.311.750;G16.500.275.280.650;N06.230.232.650,C23.550.291.781;N06.230.100.083;N06.850.376
7eedd67f-3a96-4b1a-b080-1bd3de95fd15,C0683325,C0032310,could differentiate between two types of ,clinical aspects,Pneumonia Viral,3,X,[clna],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
9276e5a0-f2e8-4a0e-b4d1-2f9c20243d5c,C0038056,C0206750,were most common symptoms of ,Sputum,Coronavirus Infections,4,X,[bdsu],[dsyn],A12.200.808,C02.782.600.550.200
ffee4788-4afb-4a68-bc9a-8189ec62d4ac,C0231528,C0206750,were most common symptoms of ,Myalgia,Coronavirus Infections,3,X,[sosy],[dsyn],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C02.782.600.550.200
0754af3f-60ab-4b70-8315-76b781afd156,C0006560,C1615607,Elevation of was more common phenomenon than that in patients with ,C-reactive protein,Influenza A Virus H1N1 Subtype,3,X,[aapp/imft],[virs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,B04.820.545.405.400.214
d55a316a-1bee-4c49-a487-14686447b4c6,C0006560,C0032285,Elevation of was more common phenomenon than that in patients with ,C-reactive protein,Pneumonia,3,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C08.381.677;C08.730.610
249e7844-6a0c-4715-a162-e8f4d8749540,C0026473,C0206750,was increased in ,Monocytes,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,C02.782.600.550.200
9cb20d62-ceac-4ca7-9811-8db270349a8d,C2676739,C0206750,is typical sign of ,Chromosome 2q32-Q33 Deletion Syndrome,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
00840932-1d2c-4ea8-94bd-59601ff38936,C0311437,C0206750,is typical sign of ,Exudation,Coronavirus Infections,2,X,[ortf],[dsyn],,C02.782.600.550.200
c034819c-7974-453a-9ce6-795c18f89ebc,C0376537,C0029355,is in ,Evidence-Based Medicine,Orthopedics,2,X,[bmod],[bmod],H02.249.750;H02.403.200.400,H02.403.810.494
e5a147b7-41cd-40bb-9e0e-4fede5d19cfa,C0032285,C0021368,often occurs in setting of increased ,Pneumonia,Inflammation,3,X,[dsyn],[patf],C08.381.677;C08.730.610,C23.550.470
601cac31-3174-4dd7-bd27-f453fa80dc32,TOCI,C0006560,had higher baseline ,TOCI,C-reactive protein,2,X,????,[aapp/imft],????,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
25aab517-d4ec-4dd8-b68f-3d00ef075a67,TOCI,C0021760,had ,TOCI,Interleukin-6,3,X,????,[aapp/imft],????,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
d9d6600e-c658-49b9-b32e-2a4fa14eb526,C0027950,TOCI,is with TOCI ,neutrophil,TOCI,3,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
db0ef187-dc1e-4b06-80f9-3936b3f769b9,TOCI,C0027950,had higher TOCI ,TOCI,neutrophil,3,X,????,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
8a16d85f-2f34-468c-a7a2-22dd84e82bfa,C1516048,C1706374,is in late ,Assessed,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
844b1aab-ca3f-409d-ba50-7e3bff84521f,C0022709,C0242821,is In addition ,Peptidyl-Dipeptidase A,Human body,1,X,[aapp/enzy/imft],[humn],D08.811.277.656.350.350.687,I01.076.201.450.560;K01.093.378
844b1aab-ca3f-409d-ba50-7e3bff84521f,C0022709,C0242821,is coronavirus receptor for,Peptidyl-Dipeptidase A,Human body,1,X,[aapp/enzy/imft],[humn],D08.811.277.656.350.350.687,I01.076.201.450.560;K01.093.378
66441b59-5059-44f7-9a2e-d237d5351c00,C0206419,C0033860,is with ,Genus: Coronavirus,Psoriasis,1,X,[virs],[dsyn],B04.820.504.540.150,C17.800.859.675
32fbb6e7-3800-41ba-8cd2-100021ba5810,C1706005,C0085295,opsonizes ,CD40LG wt Allele,Interleukin-10,1,X,[gngm],[aapp/imft],,D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510
7fbabc1e-40bb-4cdb-b0e4-6fcbc9151ca9,C1706005,C0599946,opsonizes ,CD40LG wt Allele,Attenuation,1,X,[gngm],[acty],,
92ba5c76-9731-49b2-af8f-663468e4b1f6,C1706005,C0314597,opsonizes ,CD40LG wt Allele,Colony-stimulating factor granulocyte-monocyte,2,X,[gngm],[aapp/bacs],,
3f4f3964-e1c3-4bb2-87a1-0ace70e7b627,C1880355,C0301872,reinforces their potentially critical role in ,Discover,Immune response,4,X,[acty],[ortf],,
3f9591ef-13f8-4cee-927f-94fb4f78c64e,C0450254,C0206419,due to Genus: Coronavirus is,Pathogenic organism,Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
3f9591ef-13f8-4cee-927f-94fb4f78c64e,C0450254,C0206419, includes ,Pathogenic organism,Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
3f9591ef-13f8-4cee-927f-94fb4f78c64e,C0450254,C0206419,was soon identified as novel ,Pathogenic organism,Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
60aab2c4-2724-4785-be70-97057104373f,C0080078,14days,commonly set at 14days,Range of Motion Articular,14days,2,X,[clna],????,E01.370.600.700;G11.427.760,????
66b6d22e-2fbb-43c6-aedb-e833018af0b2,C0034386,14days,commonly set at 14days,Quarantine,14days,2,X,[topp],????,N06.850.780.200.450.700,????
8096ba36-2b61-4856-965e-93eaea867ef2,C0080078,C0014507,defined according only incubation-based ,Range of Motion Articular,Epidemiology,2,X,[clna],[bmod],E01.370.600.700;G11.427.760,H02.403.720.500
e51cbfad-b9a4-47ab-bce5-df0975b0f52c,C0034386,C0014507,defined according only incubation-based ,Quarantine,Epidemiology,2,X,[topp],[bmod],N06.850.780.200.450.700,H02.403.720.500
81164d3a-5dff-40ad-ac5e-94b0be7fea96,C0036576,C1706202,were identified during electronic database ,Genetic Selection,Search - action,3,X,[genf],[acty],G05.783,
4b78e759-ddcf-41cf-83df-1e081d6e82c6,C2348077,19th,until Publications is 19th ,Date Fruit,19th,6,X,[food],????,B01.650.940.800.575.912.250.093.615,????
181664ec-036c-4b3f-8b68-56193de9e9ad,C2348077,C1856053,until Publications is 19th ,Date Fruit,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,x.x.x.x
df46460a-dc14-4ed9-90a9-76f9d8ef8454,acral,C0206419,have received attention worldwide Given their potential association with ,acral,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
16894a99-c863-4e19-9e24-13e0ac5df841,C1175743,C0002199,generally exhibited ,SARS coronavirus,Interferon-alpha,2,X,[virs],[aapp/imft/phsu],B04.820.504.540.150.113.937,D12.644.276.374.440.890.250;D12.776.467.374.440.890.250;D23.529.374.440.890.250
8bba04c2-fe30-4468-a2cf-9dd473dc8821,C2931926,C0007590,boosted ,ruxolitinib,Cell division,4,X,[orch/phsu],[celf],,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
8f98e5f3-c8b7-467b-b3cd-4aa006ac82c8,C0025124,C0280118,has has applied in ,Traditional Chinese Medicine,infection prophylaxis/management,2,X,[bmod],[topp],E02.190.488.585.520;I01.076.201.450.654.558.520,
2e59e386-fe79-4c9c-ac49-8f7e2373f22c,C0025124,C0003237,reduce use of ,Traditional Chinese Medicine,Antibiotics Antitubercular,2,X,[bmod],[antb],E02.190.488.585.520;I01.076.201.450.654.558.520,D27.505.954.122.085.255.135
9db64a0e-84c7-493e-b7af-4a338c6c2fc1,C1963758,C1155266, includes targeting ,Immunomodulation,inflammatory response,2,X,[topp],[patf],E02.095.465;G12.535,
6ac0ea7d-1176-4a4a-9f21-2dc0c20aba20,C1963758,C0301872, includes targeting ,Immunomodulation,Immune response,2,X,[topp],[ortf],E02.095.465;G12.535,
61c0ab8a-0ac1-47d1-9595-a27d1a51a7a6,C1167395,C0280274,are In absence of ,Host (organism),Antiviral Therapy,2,X,[orgm],[topp],,
5bbbee33-cf3b-43f7-a1b7-ff2f2eaab409,C1963758,C0280274,are In absence of ,Immunomodulation,Antiviral Therapy,1,X,[topp],[topp],E02.095.465;G12.535,
5f985f27-63cf-4f6f-875f-6d5d60a0eae3,C1155266,C0280274,are In absence of ,inflammatory response,Antiviral Therapy,1,X,[patf],[topp],,
d5b354b7-e359-4a07-bec4-8541f101831d,C0301872,C0280274,are In absence of ,Immune response,Antiviral Therapy,1,X,[ortf],[topp],,
8abd7f03-f920-42f9-847f-cb5c21566047,C0087111,C1167395,may affect clearance essential component of ,Therapeutic procedure,Host (organism),5,X,[topp],[orgm],E02,
111e9fc4-967d-4a06-98a5-9227bf21067b,C0021368,C1167395,is essential component of ,Inflammation,Host (organism),5,X,[patf],[orgm],C23.550.470,
a94c523e-b6de-4d64-9c9d-c1aec13acdda,C0021368,C0003451,is essential component of ,Inflammation,Antiviral Agents,4,X,[patf],[phsu],C23.550.470,D27.505.954.122.388
1cf508ac-da45-466f-b311-7e5d7ab52d06,C0087111,C0021368,targeting ,Therapeutic procedure,Inflammation,5,X,[topp],[patf],E02,C23.550.470
1cf508ac-da45-466f-b311-7e5d7ab52d06,C0087111,C0021368,have shown first promise in treatment of ,Therapeutic procedure,Inflammation,2,X,[topp],[patf],E02,C23.550.470
1cf508ac-da45-466f-b311-7e5d7ab52d06,C0087111,C0021368,could attenuate ,Therapeutic procedure,Inflammation,2,X,[topp],[patf],E02,C23.550.470
ed50a340-7162-4fbc-89f9-ead8b909fe72,C4086768,C0042769,is associated with ,Reactivation,Virus Diseases,5,X,[acty],[dsyn],,C02
2d0692e3-e1a5-4c1f-ad59-028f0721ab2e,C4086768,C0597177,is associated with ,Reactivation,Particle,5,X,[acty],[chvs],,
3882a173-7a9e-4f1d-a262-e99346e3b9ca,C1175743,C0282686,primarily targets ,SARS coronavirus,Respiratory System Agents,6,X,[virs],[phsu],B04.820.504.540.150.113.937,D27.505.954.796
3882a173-7a9e-4f1d-a262-e99346e3b9ca,C1175743,C0282686,might attack ,SARS coronavirus,Respiratory System Agents,2,X,[virs],[phsu],B04.820.504.540.150.113.937,D27.505.954.796
17378d63-6e9f-406e-8f69-4c3e0ab66c20,C0042776,C0007610,may enter system in nasal cavity in brainstem ,Virus,Cell Nucleus,5,X,[virs],[celc],B04,A11.284.430.106;A11.284.430.214.190.875.117
60a7bafc-ff23-4ed4-bb15-4ab03fa1d2a5,C0042776,C1656385,may enter system in nasal cavity in brainstem ,Virus,regulation of cellular respiration,5,X,[virs],[celf],B04,
21ca01d4-a87b-4dfd-aede-ff6f22ef471d,C0042776,C0028938,may enter system through ,Virus,Olfactory Nerve,5,X,[virs],[bpoc],B04,A08.800.800.120.640
69c6b7a6-f3e6-4b0c-b48b-60843ade118a,C1880019,C0007758,put - instruction imperative,Cessation,Cerebellar Ataxia,6,X,[acty],[dsyn],,C10.228.140.252.190;C10.597.350.090.500;C23.888.592.350.090.200
3c9a2bb7-fe72-47fe-a37f-1a9ef383af5b,C0206419,C1171362,control relative ,Genus: Coronavirus,protein expression,2,X,[virs],[genf],B04.820.504.540.150,
415be79a-2a5a-4d51-a24d-af20dcb3540b,C0013879,PRF,promote similar -1 PRF ,Elements,PRF,5,X,[elii],????,D01.268,????
fe57e687-c888-421e-b7f6-04cd88ae5d36,C1519323,PRF,strongly ablate -1 PRF ,Silent Mutation,PRF,9,X,[genf],????,G05.365.590.803,????
a70e45db-6418-47ec-8eeb-5ad6339d6a55,C0079380,C0206419,combat current ,Frameshift Mutation function,Genus: Coronavirus,1,X,[comd],[virs],G05.365.590.265,B04.820.504.540.150
ff22f444-ed95-48a4-9a74-fc3cfd64c330,C0243077,C0206419,combat current ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
ff22f444-ed95-48a4-9a74-fc3cfd64c330,C0243077,C0206419,also have high ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
ff22f444-ed95-48a4-9a74-fc3cfd64c330,C0243077,C0206419,Furthermore interact with catalytic dyad ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
ff22f444-ed95-48a4-9a74-fc3cfd64c330,C0243077,C0206419,have shown ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
ae09c653-c86f-4278-8bec-749bfb1d699f,C0004936,C0009450,public awareness for ,Mental disorders,Communicable Diseases,4,X,[mobd],[dsyn],F03,C01.539.221
54b4d2d6-235c-417d-ae11-818d97f7c820,C0013227,C0010357,are running in various stages of trials with ,Pharmaceutical Preparations,Cross Reactions,1,X,[phsu],[moft],D26,G12.122.281
059f4c4a-6884-432a-b3cf-0eb464eb91a5,C0042210,C0010357,are running in various stages of trials with ,Vaccines,Cross Reactions,1,X,[aapp/imft/phsu],[moft],D20.215.894,G12.122.281
1539aa13-0070-4f5b-b06d-2087d58b99d1,C0003241,C0010357,are running in various stages of preclinical/clinical trials with ,Antibodies,Cross Reactions,1,X,[aapp/imft/phsu],[moft],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,G12.122.281
8efc9630-db80-4ad6-9ebf-1579c1d0afec,xe,C0010357,are running in various stages of preclinical/clinical trials with ,xe,Cross Reactions,1,X,????,[moft],????,G12.122.281
c841eaea-735d-459d-98e1-b47f3a833303,ntity33,C0010357,are running in various stages of preclinical/clinical trials with ,ntity33,Cross Reactions,1,X,????,[moft],????,G12.122.281
87796856-676c-4f43-8da4-1189e0d42a63,C0087111,C0010357,are running in various stages of preclinical/clinical trials with ,Therapeutic procedure,Cross Reactions,1,X,[topp],[moft],E02,G12.122.281
25c92665-e39c-4a16-8236-ad87fec21df5,C0010357,COVID-19,may ,Cross Reactions,COVID-19,1,X,[moft],[virs],G12.122.281,C000657245
65c9b489-94c6-4bf5-bfe9-b3b22a2526d8,C0206750,C0450254,is newly discovered highly ,Coronavirus Infections,Pathogenic organism,1,X,[dsyn],[orgm],C02.782.600.550.200,
8e1f4dfc-7be8-4617-b92a-8025491cd98f,C0450254,C1856053,was declared in ,Pathogenic organism,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[orgm],[dsyn],,x.x.x.x
f93d9329-5f01-43da-8644-c6eaa0cd2e8a,C0042776,C0282686,affects ,Virus,Respiratory System Agents,1,X,[virs],[phsu],B04,D27.505.954.796
43d52c88-bbeb-4860-b53c-376278cb0e8f,C1263722,C0028754, includes ,Chronic metabolic disorder,Obesity,2,X,[dsyn],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
0ee01a6f-73b1-4eb8-9848-75aa04985d6d,C1263722,C0011849, includes ,Chronic metabolic disorder,Diabetes Mellitus,4,X,[dsyn],[dsyn],,C18.452.394.750;C19.246
3d1ef59e-afd8-4ec0-a83d-31dd3ecd17c3,C1263722,C0020538, includes ,Chronic metabolic disorder,Hypertensive disease,2,X,[dsyn],[dsyn],,C14.907.489
3fc32033-6d1a-4c62-89e2-3ef3dd4cf384,C0206750,C1263722,takes course in individuals with ,Coronavirus Infections,Chronic metabolic disorder,1,X,[dsyn],[dsyn],C02.782.600.550.200,
b5a400d7-86f4-477c-8fb4-380f08060c63,C0206750,C0028754,takes course in individuals with ,Coronavirus Infections,Obesity,7,X,[dsyn],[dsyn],C02.782.600.550.200,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
905a4e8a-80a3-4267-bf78-bbc539766c73,C0025219,C0019932,is multifunctional signaling ,Melatonin,Hormones,1,X,[horm/orch/phsu],[horm],D03.633.100.473.914.481;D06.472.506,D06.472;D27.505.696.399.472
a066d6ae-3dd8-4612-ac73-28c73081b2b3,C0025219,C0031939,secreted primarily by ,Melatonin,Pineal gland,1,X,[horm/orch/phsu],[bpoc],D03.633.100.473.914.481;D06.472.506,A06.300.635;A06.688.733;A08.186.211.180.200.680;A08.186.211.200.317.200.620;A08.713.733
9524b1bd-c133-4d7f-a911-0636d2e83c66,C0003402,C0001272,is with immunomodulatory ,Antioxidants,Action Potentials,1,X,[phsu],[celf],D27.505.519.217;D27.505.696.706.125;D27.720.799.047,G04.580.100;G07.265.675.100;G11.561.570.100
a76ac2c3-aea4-45b3-b214-3a66bac2174a,C0012634,C0003402,involve inflammation as powerful ,Disease,Antioxidants,1,X,[dsyn],[phsu],C23.550.288,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
a0a50577-2f05-44d5-b86a-61221cefafc6,C0242606,C0028754,severe inflammation in people with ,Oxidative Stress,Obesity,1,X,[comd],[dsyn],G03.673;G07.775.750,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
0d9df028-b7d1-4118-a68d-1bd70448ba37,C0011849,C0007637,anticipated ,Diabetes Mellitus,Inclusion Bodies,1,X,[dsyn],[celc],C18.452.394.750;C19.246,A11.284.420
44ad7e85-7dde-45fa-a48c-3cdd09368a2a,C0011849,C0025219,anticipated ,Diabetes Mellitus,Melatonin,1,X,[dsyn],[horm/orch/phsu],C18.452.394.750;C19.246,D03.633.100.473.914.481;D06.472.506
118e26a4-a5f6-4f86-a1c2-77396dd06f06,C0025219,C1254351,is potential ,Melatonin,Pharmacologic Substance,1,X,[horm/orch/phsu],[phsu],D03.633.100.473.914.481;D06.472.506,
d8f85472-06bc-4ff0-9a90-18d6ff712c65,C0003865,C0206750,is in ,Arthritis Adjuvant-Induced,Coronavirus Infections,1,X,[emod],[dsyn],C05.550.114.015;E05.598.500.249,C02.782.600.550.200
cb23962b-3c87-4dcc-918a-34d9561e8653,C0003865,C0011849,is in ,Arthritis Adjuvant-Induced,Diabetes Mellitus,1,X,[emod],[dsyn],C05.550.114.015;E05.598.500.249,C18.452.394.750;C19.246
26795c4f-0e75-4946-951b-910a65137236,C0233401,COVID-19,rates of were ,Psychiatric symptom,COVID-19,8,X,[sosy],[virs],,C000657245
d69175b7-d3de-4bfa-994e-93ff47132463,C0233401,C0003467,rates of were ,Psychiatric symptom,Anxiety,4,X,[sosy],[mobd],,F01.470.132
c1b39190-d332-4ff3-ae91-b1cf82cf9e34,COVID-19,C0086132,had risk for ,COVID-19,Depressive Symptoms,2,X,[virs],[sosy],C000657245,F01.145.126.350
ccc2ab0b-4db8-4f92-9dd0-7a5aa70c57d5,COVID-19,C0917801,had ,COVID-19,Sleeplessness,1,X,[virs],[sosy],C000657245,C10.886.425.800.800;F03.870.400.800.800
bb6068ff-8f0e-4434-ab59-4f657c666dbb,C0086132,C0069590,of Depressive Symptoms is,Depressive Symptoms,ORALIT,1,X,[sosy],[inch/phsu],F01.145.126.350,x.x.x.x
611c0c05-9359-4aef-bbe3-613b800e407c,C0233401,C3714514,people with suspected ,Psychiatric symptom,Infection,1,X,[sosy],[patf],,C01.539
f37d8d9e-b5d9-42ad-8691-c6f0613bb6a2,C0221423,C0015967,leading to age of ,Illness (finding),Fever,1,X,[sosy],[sosy],,C23.888.119.344
3b011318-ca09-42cd-99a7-46da221bd80c,C0015967,C0021368,lasted laboratory evidence of ,Fever,Inflammation,2,X,[sosy],[patf],C23.888.119.344,C23.550.470
8967ce01-85ab-4f49-9357-8efa131c81eb,C3714514,C1175743,is with ,Infection,SARS coronavirus,4,X,[patf],[virs],C01.539,B04.820.504.540.150.113.937
a34e2e4c-4e0e-4bc2-b857-512860fbd35a,C0085297,C0017710,was used in ,Immunoglobulins Intravenous,Glucocorticoids,2,X,[aapp/imft/phsu],[horm/orch],D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632,D06.472.040.543;D27.505.696.399.472.488
a136e368-8588-4302-b144-a15cb5074a87,C0265267,C1175743,is in ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,SARS coronavirus,2,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150.113.937
22d8e7e1-cc1f-4c53-9425-0bb4c038cdfb,C0028040,C0009324,is used in ,Nicotine,Ulcerative Colitis,2,X,[hops/orch],[dsyn],D03.132.760.570;D03.383.725.518,C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
61fadacd-07f1-44fa-9e67-232a7d3945cf,C0028040,C0021368,counteract ,Nicotine,Inflammation,2,X,[hops/orch],[patf],D03.132.760.570;D03.383.725.518,C23.550.470
efd1e8b6-9dcb-46e4-b56f-591c8e9b4112,C0028040,C0948245,constitute novel potential ,Nicotine,Cytokine Release Syndrome,1,X,[hops/orch],[dsyn],D03.132.760.570;D03.383.725.518,
99840642-44bd-452a-83a3-f676577dbba7,C0028040,C1175743,constitute novel potential CRS ,Nicotine,SARS coronavirus,2,X,[hops/orch],[virs],D03.132.760.570;D03.383.725.518,B04.820.504.540.150.113.937
8d07f761-0308-4476-9921-637a5f844adc,C0948245,C1175743,is in severe ,Cytokine Release Syndrome,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
8c6cfa0b-5841-4e22-9d7f-704ff63c2cac,C0191275,C0079850,undertaking ,Operation on skin,Mohs Surgery,2,X,[topp],[topp],,E04.494.575;E04.680.275.580
6e86c1e3-32ae-47e0-970b-8c17fb582209,C0035222,C0398623,can predispose patients to ,Respiratory Distress Syndrome Adult,Thrombophilia,2,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C15.378.925
ba1a75aa-1069-4ab2-9d44-31697bba79dc,C0035222,C0042487,can predispose patients with ,Respiratory Distress Syndrome Adult,Venous Thrombosis,2,X,[dsyn],[patf],C08.381.840;C08.618.840,C14.907.355.830.925
8b41d297-d9c8-43d9-87ef-8ad0ddcf4ec2,C0012655,C1184743,presents multifactorial physiopathology related to severe ,Disease susceptibility,bony process,1,X,[clna],[bpoc],C23.550.291.687;G07.100.250,
3a8ad91c-aff6-41e8-bf56-edaa1594c21b,C0012655,C0005789,presents multifactorial physiopathology related to severe ,Disease susceptibility,Blood Coagulation Factor,1,X,[clna],[aapp/bacs/phsu],C23.550.291.687;G07.100.250,D12.776.124.125;D23.119
c667d176-febb-4229-8d36-7c4d78e0c05c,C0021368,C0079189,accompanied by ,Inflammation,cytokine,2,X,[patf],[aapp/imft],C23.550.470,D12.644.276.374;D12.776.467.374;D23.529.374
c667d176-febb-4229-8d36-7c4d78e0c05c,C0021368,C0079189,caused by ,Inflammation,cytokine,1,X,[patf],[aapp/imft],C23.550.470,D12.644.276.374;D12.776.467.374;D23.529.374
c667d176-febb-4229-8d36-7c4d78e0c05c,C0021368,C0079189,sustained by ,Inflammation,cytokine,1,X,[patf],[aapp/imft],C23.550.470,D12.644.276.374;D12.776.467.374;D23.529.374
ad59ded6-7de3-4854-85aa-ee54fd124c05,C0003209,C0023821,changes in quantity of ,Anti-Inflammatory Agents,High Density Lipoproteins,2,X,[phsu],[aapp/bacs],D27.505.954.158,D10.532.432;D12.776.521.479
e3dc34de-44d7-4762-910d-7926e761eee0,C0003209,COVID-19,changes ,Anti-Inflammatory Agents,COVID-19,1,X,[phsu],[virs],D27.505.954.158,C000657245
140efa02-6ddf-4ecc-a54a-ef285902fc7f,C0023820,C0178784,lead to virus-associated ,Lipoproteins,Organ,2,X,[aapp/bacs],[bpoc],D10.532;D12.776.521,
5b2905d8-7fbe-4e22-b535-f6849e558115,C0023820,C0074129,lead to virus-associated ,Lipoproteins,scavenger receptor,2,X,[aapp/bacs],[aapp/rcpt],D10.532;D12.776.521,D12.776.543.750.705.940;D12.776.543.750.710.450.750
e6e03b3b-e255-4986-8b51-0fcc96f9c9d6,C0023820,C0030011,is with ,Lipoproteins,Oxidation,2,X,[aapp/bacs],[moft],D10.532;D12.776.521,
534c47c0-cfb1-45cd-935c-b77d3cfe0406,C0023820,C0031676,is with ,Lipoproteins,Phospholipids,2,X,[aapp/bacs],[bacs/orch],D10.532;D12.776.521,D10.570.755
cb6e896f-0928-4556-a145-8769219c5f30,C1254351,C0475463,blocking scavenger receptor with,Pharmacologic Substance,Antibodies Neutralizing,1,X,[phsu],[aapp/imft],,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
3ae10007-aad2-439e-863d-0023f9976a33,C0085201,C1254351,raising ,Apolipoprotein A-I,Pharmacologic Substance,2,X,[aapp/bacs],[phsu],D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100,
60c6b956-c53f-4100-adde-24a82e6eefbc,C1254351,C0074129,blocking relevant ,Pharmacologic Substance,scavenger receptor,1,X,[phsu],[aapp/rcpt],,D12.776.543.750.705.940;D12.776.543.750.710.450.750
31c2b265-2129-45cf-8a48-8cca75775a7e,C0000936,C1947933,is in older adult ,Visual Accommodation,care activity,1,X,[ortf],[acty],G14.010,
eadf0a6e-0fba-41b3-af53-93f284057161,C0419193,COVID-19,is with ,Care of aged,COVID-19,4,X,[topp],[virs],,C000657245
53296b44-1b5b-4d89-9b5c-2d9ec2ac5fef,C1947933,amidst,would fit particular needs of older adults in settings amidst ,care activity,amidst,1,X,[acty],????,,????
53296b44-1b5b-4d89-9b5c-2d9ec2ac5fef,C1947933,amidst,would Seizures particular needs in settings amidst,care activity,amidst,1,X,[acty],????,,????
8459cd85-c67b-4783-a2f3-3bdcc99ba838,CMH,C0011438,Institute of ,CMH,Dentistry,1,X,????,[bmod],????,E06;H02.163
a0ce8501-e825-49dc-8448-69da517b43a0,C2948600,C0041621,explore ,Aim,Ultrasonic Shockwave,1,X,[inch/phsu],[npop],,G01.750.770.776.891.500
3d751731-918b-4213-a70d-8dbc1c7072b4,C0032285,C0041621,underwent bedside ,Pneumonia,Ultrasonic Shockwave,1,X,[dsyn],[npop],C08.381.677;C08.730.610,G01.750.770.776.891.500
1537b8d6-76b2-4321-b0ba-44f22867fd5e,C0041621,COVID-19,valid diagnostic aid in ,Ultrasonic Shockwave,COVID-19,3,X,[npop],[virs],G01.750.770.776.891.500,C000657245
ec308c29-a1e4-4783-9fa5-869af3c3d2b6,C0041621,C0032285,valid diagnostic aid in ,Ultrasonic Shockwave,Pneumonia,1,X,[npop],[dsyn],G01.750.770.776.891.500,C08.381.677;C08.730.610
ec308c29-a1e4-4783-9fa5-869af3c3d2b6,C0041621,C0032285,could represent ,Ultrasonic Shockwave,Pneumonia,1,X,[npop],[dsyn],G01.750.770.776.891.500,C08.381.677;C08.730.610
fa9b6ddd-466a-492c-be64-b04431809a97,C2985398,C0026809,is in ,Intestinal Microbiome,Mus,2,X,[orgm],[mamm],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,B01.050.150.900.649.313.992.635.505.500
2c23184d-e0cb-4b33-ac6e-666bbf6ebf4e,C0030664,C2985398,is in ,Pathology,Intestinal Microbiome,1,X,[bmod],[orgm],H02.403.650,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
89e0ae30-f692-4ff6-909b-6d8807c40a4b,C3888108,C0030664,cause ,Import into cell,Pathology,1,X,[celf],[bmod],,H02.403.650
d18199c3-0f6b-4085-8762-1456ab7c855c,C3888108,C2985398,cause pathological changes in ,Import into cell,Intestinal Microbiome,2,X,[celf],[orgm],,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
307d99e6-26b3-43c7-a2f4-eddb08c5fac0,C3888108,C0026809,cause pathological changes in ,Import into cell,Mus,2,X,[celf],[mamm],,B01.050.150.900.649.313.992.635.505.500
3a9bfa6c-5233-4e5a-a023-ac917cb3c2c8,C0450254,C3536832,are typically sparse in ,Pathogenic organism,Air,2,X,[orgm],[inch/phsu],,G16.500.275.063.150;N06.230.300.100.150
2d85b029-869c-4810-ae36-21f9e0d24f55,C0038029,C0020517,may exacerbate ,Spores Fungal,Hypersensitivity,2,X,[fngs],[patf],A11.870.710;A19.374.500;B05.775.710,C20.543
f7c48580-4564-4443-8bd8-9d8a5ad72404,C0038029,C0004096,may exacerbate ,Spores Fungal,Asthma,2,X,[fngs],[dsyn],A11.870.710;A19.374.500;B05.775.710,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
8d238906-4230-40dd-8045-e5443d8246b6,C0042776,C0004651, includes ,Virus,Bacteriophages,1,X,[virs],[virs],B04,B04.123
64f0c032-51f2-4225-8709-f04d7daa269f,C0012634,C1145670,can lead to severe ,Disease,Respiratory Failure,1,X,[dsyn],[dsyn],C23.550.288,C08.618.846
0a470276-05fb-4a52-816a-c3f73938275d,C0025124,C0199176,bringing new hope for ,Traditional Chinese Medicine,Prophylactic treatment,1,X,[bmod],[topp],E02.190.488.585.520;I01.076.201.450.654.558.520,
8b684789-9308-44fb-8d6a-e5cd357943b2,C0025124,C0206419,bringing new hope for ,Traditional Chinese Medicine,Genus: Coronavirus,1,X,[bmod],[virs],E02.190.488.585.520;I01.076.201.450.654.558.520,B04.820.504.540.150
8b684789-9308-44fb-8d6a-e5cd357943b2,C0025124,C0206419,is in Novel ,Traditional Chinese Medicine,Genus: Coronavirus,1,X,[bmod],[virs],E02.190.488.585.520;I01.076.201.450.654.558.520,B04.820.504.540.150
0273c3b9-b10f-4c23-9117-f0a5cdc0f61a,C1879848,C0024109,improvements in several clinical ,Biomedicine,Lung,2,X,[bmod],[bpoc],,A04.411
11e08825-53e2-4468-b05c-4e4def220e6a,C1707455,C0024109,has improvements in several ,Comparison,Lung,1,X,[acty],[bpoc],,A04.411
a59189ae-89fa-45b1-aed5-a1d26f117d10,C1273412,C0024109,has improvements in several ,Chinese herbal medicine,Lung,1,X,[topp],[bpoc],,A04.411
7657238b-d21f-45a2-bf04-f6495b38dfb7,C1273412,C0206419,could could used as potential candidates for ,Chinese herbal medicine,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
e91925c0-b3ce-4a79-b18b-46bf884ac5ab,C0036974,C0026766,have Patients with ,Shock,Multiple Organ Failure,1,X,[patf],[patf],C23.550.835,C23.550.835.525
c7afa999-4142-46a5-ae15-67025ae059ab,C0242966,C1457887,Recovery - action from,Systemic Inflammatory Response Syndrome,Symptoms,1,X,[dsyn],[sosy],C23.550.470.790;C23.550.835.900,
f26af73b-d28c-4465-a3bc-79176630eb26,C0605411,C0031350,is with ,austin,Pharyngitis,1,X,[orch],[dsyn],x.x.x.x,C07.550.781;C08.730.561;C09.775.649
19fa5d8e-7520-48bf-b62b-212af0606edb,C0605411,C0013404,is with ,austin,Dyspnea,1,X,[orch],[sosy],x.x.x.x,C08.618.326;C23.888.852.371
df83b49f-68f6-461f-83cd-0430424f498a,C0028677,C0037633,offering guidance for ,Discipline of Nursing,Solutions,2,X,[bmod],[sbst],H02.478;N04.452.758.377,D26.776
5068ce2f-1c42-48ed-9db9-aa0e99f09824,C0520510,C0003451,were found more ,Materials,Antiviral Agents,6,X,[sbst],[phsu],,D27.505.954.122.388
26ea47c9-29b2-4a78-b1e4-dd4eca0724bd,C0520510,C3698360,were found more ,Materials,Middle East Respiratory Syndrome Coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150.113.750
26ea47c9-29b2-4a78-b1e4-dd4eca0724bd,C0520510,C3698360,be more Antiviral Agents activity than other morphologies against,Materials,Middle East Respiratory Syndrome Coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150.113.750
6a275759-46e7-44ac-9002-e3d6f9626ff6,C0520510,C0206419,are positive affect against ,Materials,Genus: Coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150
6a275759-46e7-44ac-9002-e3d6f9626ff6,C0520510,C0206419,included patients with diagnosis of ,Materials,Genus: Coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150
c37c606d-b673-423b-81bb-f9ecce1d23ae,C0271355,C0086418,is in previously healthy young ,Abducens Nerve Diseases,Homo sapiens,2,X,[dsyn],[humn],C10.292.150,B01.050.150.900.649.313.988.400.112.400.400
dfd8a23e-4576-4bbb-b7c2-89be2413755e,C0934029,C0011307,consistent with ,Left lateral rectus,Denervation,2,X,[bpoc],[topp],,E04.525.210
93008d5d-c9d5-44d4-98a9-322d27180676,C0934029,T2,was hyperintense on T2 ,Left lateral rectus,T2,2,X,[bpoc],????,,????
b2f17433-ed09-439a-aff7-4812b8478c39,C0262576,C0042769,is suspected related to his ,Nerve palsy,Virus Diseases,4,X,[dsyn],[dsyn],,C02
65023d36-5f09-4b7f-93d2-3bfb5a2dcff5,C0151311,C0027765,may represent part ,Cranial nerve palsies,nervous system disorder,1,X,[dsyn],[dsyn],,C10
bbc31f3f-1478-47fa-954e-2154cdc9032b,C0151311,C0206419,may represent part ,Cranial nerve palsies,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
90e0552d-a08d-48f0-9c4d-401a6bef5c03,C0028128,C0042774,inhibit early stage in ,Nitric Oxide,Virus Replication,2,X,[bacs/inch/phsu],[celf],D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600,G06.920.925
83b683d3-6678-4cfc-87d9-8c0751cda340,C0028128,C1175743,inhibits replication cycle of ,Nitric Oxide,SARS coronavirus,1,X,[bacs/inch/phsu],[virs],D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600,B04.820.504.540.150.113.937
4c920b54-e48b-4f8d-85ad-9cbc54bd7929,C0239059,C1707455,contains Nitric Oxide as 160ppm,Cigarette smoke (substance),Comparison,1,X,[hops],[acty],,
78af00e6-01b1-4bfd-ab61-3444fdb5ddf7,C0239059,160ppm,contains Nitric Oxide as 160ppm,Cigarette smoke (substance),160ppm,1,X,[hops],????,,????
eab08d0f-b499-439b-8bd6-59f37d1cdf37,C0239059,C0028128,contains ,Cigarette smoke (substance),Nitric Oxide,1,X,[hops],[bacs/inch/phsu],,D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
6cad613a-729f-4605-9802-cc7450de0eaf,C0028167,C0037366,is in mainstream ,Nitrogen Oxides,Smoke,1,X,[inch],[hops],D01.362.635;D01.625.550;D01.650.550.587,D20.633.937
3f5b6324-39fe-45c9-866f-7e15e3d30900,C0028167,C0028128,is ,Nitrogen Oxides,Nitric Oxide,1,X,[inch],[bacs/inch/phsu],D01.362.635;D01.625.550;D01.650.550.587,D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
efc0868c-bab5-441e-af8f-6f6deffc3f2f,C0021528,C0013227,provide ,Inosine,Pharmaceutical Preparations,1,X,[nnon/phsu],[phsu],D03.633.100.759.590.616;D13.570.583.616;D13.570.800.573;x.x.x.x,D26
b3ab1f48-a0d1-40c8-aab2-de8f6d9d735f,C0021528,C0079483,provide Pharmaceutical Preparations without,Inosine,health hazards,1,X,[nnon/phsu],[hops],D03.633.100.759.590.616;D13.570.583.616;D13.570.800.573;x.x.x.x,
b53c3f86-4ff5-49c2-b311-187cdaf93e02,C0920687,C0206419,is impacted by ,cancer care,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
820cd3b9-935b-4748-9c2d-db24c1b4f51e,C0920687,C0012634,is impacted by ,cancer care,Disease,1,X,[topp],[dsyn],,C23.550.288
38a20257-ac85-4c7e-9b32-63989e1b015b,C0023688,C0007382,conformation of ,Ligands,Catalysis,1,X,[chem],[npop],D27.720.470.480,G02.130
63619265-ec7d-4412-a1a1-bd421111f5ae,C0023688,C0011334,conformation of ,Ligands,Dental caries,1,X,[chem],[dsyn],D27.720.470.480,C07.793.720.210
6f2cd453-9f1a-48dc-8198-6a1778d5db61,C1707455,C0023688,is with previously reported low-temperature ,Comparison,Ligands,1,X,[acty],[chem],,D27.720.470.480
37bd0b68-8183-4fc8-8fcf-a086993131a6,C0450254,C1175743,relative of ,Pathogenic organism,SARS coronavirus,4,X,[orgm],[virs],,B04.820.504.540.150.113.937
37bd0b68-8183-4fc8-8fcf-a086993131a6,C0450254,C1175743,established ,Pathogenic organism,SARS coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150.113.937
37bd0b68-8183-4fc8-8fcf-a086993131a6,C0450254,C1175743,develop Communicable Diseases after intranasal,Pathogenic organism,SARS coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150.113.937
ef70d112-1068-4a49-a612-b8cebcf4f61c,C1947933,C0031843,inferring ,care activity,physiological aspects,4,X,[acty],[phsf],,x.x.x.x
13a63ee2-49eb-4b0e-b36b-50582251c4a5,C0243083,C0087111,requires ,associated disease,Therapeutic procedure,1,X,[patf],[topp],,E02
b8928765-7161-4b61-8b6f-454fe76680e4,C0087111,C1947933,be can translated to ,Therapeutic procedure,care activity,1,X,[topp],[acty],E02,
405d69bd-d626-4fa2-bedb-bcd1edc79c76,C0022942,C1175175,is effective inhibitor of ,Lactoferrin,Severe Acute Respiratory Syndrome,1,X,[aapp/bacs],[dsyn],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,C02.782.600.550.200.750;C08.730.730
5e87a7b5-268a-4711-a653-0b5487ed3683,C1175175,IC,is with IC ,Severe Acute Respiratory Syndrome,IC,1,X,[dsyn],????,C02.782.600.550.200.750;C08.730.730,????
7f662a96-364f-406a-9798-2203e71570e7,C1175175,C0312860,is with IC ,Severe Acute Respiratory Syndrome,Neutrophil migration function,1,X,[dsyn],[celf],C02.782.600.550.200.750;C08.730.730,
70603ca5-b508-48c9-b8cd-0d0627dc5c7d,C0022942,C1819995,also stimulates antiviral ,Lactoferrin,Host Cell,1,X,[aapp/bacs],[celc],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,
d778d7aa-7e03-4a61-b939-acc67a46d392,C0022942,C3463820,retains ,Lactoferrin,Inhibition,1,X,[aapp/bacs],[acty],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,F01.145.544;F02.463.425.475;F02.739.794.405
dda9609d-a656-4fc8-af63-3c03197cc4e7,C0022942,C0225698,retains ,Lactoferrin,Alveolar Epithelial Cells,1,X,[aapp/bacs],[cell],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,A04.411.715.100;A11.436.081
b6a94629-1798-4751-a376-e399e3107879,C3463820,C2717959,is in ,Inhibition,Induced Pluripotent Stem Cells,1,X,[acty],[cell],F01.145.544;F02.463.425.475;F02.739.794.405,A11.872.040.500;A11.872.700.500
23018259-4534-4505-ae80-19de1552bb8b,C3463820,C0225698,is in ,Inhibition,Alveolar Epithelial Cells,1,X,[acty],[cell],F01.145.544;F02.463.425.475;F02.739.794.405,A04.411.715.100;A11.436.081
b4e18713-b0f1-4d78-80cb-81f2a5260bfc,C2717959,C0948192,model for ,Induced Pluripotent Stem Cells,primary infection nos,2,X,[cell],[dsyn],A11.872.040.500;A11.872.700.500,
226c31cf-20b2-46f7-b885-db2cfcfbf02c,C0225698,C0948192,model for ,Alveolar Epithelial Cells,primary infection nos,2,X,[cell],[dsyn],A04.411.715.100;A11.436.081,
79e5026f-44b0-48a3-9c96-e4f7393c6e56,C3166216,C0042769,exacerbate ,Prescribed medications,Virus Diseases,1,X,[phsu],[dsyn],,C02
68fc17b4-5ffe-4510-91ac-5e473e008d11,C0003451,C1533157,is with potential to ,Antiviral Agents,Block Specimens,1,X,[phsu],[bdsu],D27.505.954.122.388,
d0eb5fa5-5757-4a5b-a6e2-666ef77cb25c,C0013227,C0087111,used to ,Pharmaceutical Preparations,Therapeutic procedure,11,X,[phsu],[topp],D26,E02
9a3501ff-fc84-406e-a352-f89170c75a24,C0003250,C0079189,targeting pro-inflammatory ,Monoclonal Antibodies,cytokine,2,X,[aapp/imft],[aapp/imft],D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224,D12.644.276.374;D12.776.467.374;D23.529.374
38a92863-f204-4826-960a-4d289af38d39,C0087111,C0035245,could ameliorate ,Therapeutic procedure,Respiratory physiology,4,X,[topp],[phsf],E02,G09.772
e1f762c1-a1ad-4f22-9e1b-b83e6248ad50,C0184661,C0013227,is with ,Interventional procedure,Pharmaceutical Preparations,1,X,[topp],[phsu],,D26
95bc3a2c-7a85-4f73-ae42-e34929a1d955,C0206419,C0035204,is primarily ,Genus: Coronavirus,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618
95bc3a2c-7a85-4f73-ae42-e34929a1d955,C0206419,C0035204,is newly emerging life-threatening ,Genus: Coronavirus,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618
b5b68435-d8cb-4818-8a3b-21906c0ea718,2D,C0206419,diagnose ,2D,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
063649ad-f981-43c9-b16a-a8d45f027038,C0001527,C0206419,be ,Adipose tissue,Genus: Coronavirus,1,X,[tisu],[virs],A10.165.114,B04.820.504.540.150
38f483a6-eebc-41d3-a43c-7039be9e0139,C1511790,C1175743,However is required for ,Detection,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
38f483a6-eebc-41d3-a43c-7039be9e0139,C1511790,C1175743,is in CoV2,Detection,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
38f483a6-eebc-41d3-a43c-7039be9e0139,C1511790,C1175743,was used for confirmation of ,Detection,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
64833663-5eea-42e5-9c0b-57f4957ca4ed,C1628478,C0206419,is in ,SARS coronavirus IgG,Genus: Coronavirus,1,X,[aapp/imft],[virs],,B04.820.504.540.150
6cdda81b-1976-4742-82db-ba8b17f3e4d4,C0871208,RT-PCR,was severe In RT-PCR ,Rating (action),RT-PCR,1,X,[acty],????,,????
f50b6c77-15db-4691-9703-8b6104f4fd31,C0871208,C1511790,was severe In RT-PCR ,Rating (action),Detection,1,X,[acty],[topp],,
faf907d8-6436-444c-9a7a-2eadd0481f1a,C0020517,C0871208,produce probability ,Hypersensitivity,Rating (action),1,X,[patf],[acty],C20.543,
aae5dc4d-8c1c-4cf4-9b7a-fa2583b8f8dc,C0206419,C1443869,should take ,Genus: Coronavirus,Airborne precautions,1,X,[virs],[topp],B04.820.504.540.150,
3e5818ab-b27c-4819-b9f6-c4776e20a3b3,C2188405,C0206419,suspected for ,urgent Operation,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
ded0dc38-5de2-49b7-bd63-2f0dd0574d8a,C2948600,C0018837,compare ,Aim,Heat (physical force),2,X,[inch/phsu],[npop],,
765a58c5-71ec-44aa-a3da-67ab08039bea,C2948600,C0806140,compare ,Aim,Flow,2,X,[inch/phsu],[npop],,
0ce5402c-9503-461a-86e5-5f32e919a62d,C0020336,C1321301,is in target ,Hydroxychloroquine,Peripheral blood mononuclear cell (cell),2,X,[orch/phsu],[cell],D03.633.100.810.050.180.350,
d784a319-17d5-4ae1-879e-5eff9a848df1,C0057223,C0026056,using ,Cytochrome P-450 CYP2D6,Midazolam,2,X,[aapp/enzy],[orch/phsu],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D03.633.100.079.080.575
bfcb8f5f-438f-440a-a16e-70f6818fb0b3,C0057223,C0724441,using ,Cytochrome P-450 CYP2D6,yohimbine,2,X,[aapp/enzy],[orch/phsu],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D03.132.436.681.933;D03.633.100.473.402.681.933
ebbf8e74-36d1-443f-bd13-970c6659ab25,C0057223,C0014442,using Midazolam as,Cytochrome P-450 CYP2D6,Enzymes,2,X,[aapp/enzy],[aapp/enzy],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D08.811
ebbf8e74-36d1-443f-bd13-970c6659ab25,C0057223,C0014442,using yohimbine as,Cytochrome P-450 CYP2D6,Enzymes,2,X,[aapp/enzy],[aapp/enzy],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D08.811
30ef464d-cee2-4fa1-977c-2357805518dd,C0057223,C1513396,using Midazolam as,Cytochrome P-450 CYP2D6,Molecular Marker Activity,2,X,[aapp/enzy],[phsf],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,
30ef464d-cee2-4fa1-977c-2357805518dd,C0057223,C1513396,using yohimbine as,Cytochrome P-450 CYP2D6,Molecular Marker Activity,2,X,[aapp/enzy],[phsf],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,
b67e0db3-3b39-4894-9e02-180a75dff877,C0029456,C0206419,showed significant association with ,Osteoporosis,Genus: Coronavirus,2,X,[dsyn],[virs],C05.116.198.579;C18.452.104.579,B04.820.504.540.150
d8041dc0-5a57-4c30-a86f-f51faf376aee,C0003873,C0206419,showed significant association with ,Rheumatoid Arthritis,Genus: Coronavirus,2,X,[dsyn],[virs],C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199,B04.820.504.540.150
d621dcf9-001d-4000-8e5a-076ca2ee9495,C0237123,C0206419,showed significant association with ,Alcohol or Other Drugs use,Genus: Coronavirus,2,X,[mobd],[virs],,B04.820.504.540.150
5f2ec3cd-9846-4fc8-8b56-25c330b9b7a0,C0036341,C0206419,showed significant association with ,Schizophrenia,Genus: Coronavirus,2,X,[mobd],[virs],F03.700.750,B04.820.504.540.150
9b88e5f9-ca30-4007-8dbf-2e43beb4b4be,RAAS,C0206419,be maintained in patients with ,RAAS,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
db3823f4-6dd4-4b79-b130-805a1da0b46e,C0035452,C0206419,be at high risk from ,Rheumatology specialty,Genus: Coronavirus,6,X,[bmod],[virs],H02.403.429.730,B04.820.504.540.150
36963ad3-7d63-4c28-a770-fcd71a44c915,C0015230,C1609165,persisted despite ,Exanthema,tocilizumab,4,X,[sosy],[aapp/imft/phsu],C17.800.257,x.x.x.x
81e4f8c8-1007-490e-8929-60fce341f905,C0015230,C1533734,persisted despite ,Exanthema,Administration procedure,3,X,[sosy],[topp],C17.800.257,
fd4a5da9-0918-49dd-ae7f-d0672e04d29a,C0015230,C0206419,highly suggestive for ,Exanthema,Genus: Coronavirus,2,X,[sosy],[virs],C17.800.257,B04.820.504.540.150
305ef4b8-84be-4977-8974-d25b66878ae0,C0206419,C0795934,has opened new ,Genus: Coronavirus,Digitorenocerebral Syndrome,3,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
8e96fed6-24eb-4958-875f-ef0e99a5aa47,C0206419,C0003504,has opened new ,Genus: Coronavirus,Aortic Valve Insufficiency,3,X,[virs],[dsyn],B04.820.504.540.150,C14.280.484.095
fafae156-0ea8-40a5-a843-35137928b9d7,C0206419,C0013227,screened approximately 250 existing ,Genus: Coronavirus,Pharmaceutical Preparations,1,X,[virs],[phsu],B04.820.504.540.150,D26
6afc0c78-d2bf-483d-95af-6f54bc4af3f9,C0206419,C0441655,screened compounds for their ,Genus: Coronavirus,Activities,1,X,[virs],[acty],B04.820.504.540.150,
6afc0c78-d2bf-483d-95af-6f54bc4af3f9,C0206419,C0441655,halting worldwide principal income ,Genus: Coronavirus,Activities,2,X,[virs],[acty],B04.820.504.540.150,
68a420c2-2423-4947-90a5-f551ad843286,C0206419,C0085306,screened compounds for their ,Genus: Coronavirus,Feline infectious peritonitis,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200.360;C22.180.440
3d9eb250-3ec7-4ce4-9dd3-785d348e184e,C0206419,C0472699,was proliferated in feline Fcwf-4cells in ,Genus: Coronavirus,Hemopoietic stem cell transplant,1,X,[virs],[topp],B04.820.504.540.150,E02.095.147.500.500.500;E04.936.225.687.500
210bd3b7-f763-4937-83e1-ef37ec6d03e3,C0524816,C0472699,is in ,Nucleocapsid Proteins,Hemopoietic stem cell transplant,3,X,[aapp/bacs],[topp],D12.776.964.970.600,E02.095.147.500.500.500;E04.936.225.687.500
d8dfdc9a-6025-482e-9fc4-86c852941ab9,C0013227,C1948030,of concentrations is ,Pharmaceutical Preparations,EC Regimen (Etoposide-Carboplatin),3,X,[phsu],[topp],D26,
c8c01cbf-e3ce-413d-afa7-f7a140aeb4b9,8cells,C0017440,were measured by ,8cells,Gentian Violet,3,X,????,[irda/orch/phsu],????,D02.092.146.400
ba29b455-0005-4fc4-95c5-c68d4cff0606,C0319157,C0009450, includes ,AS virus,Communicable Diseases,1,X,[virs],[dsyn],,C01.539.221
ba29b455-0005-4fc4-95c5-c68d4cff0606,C0319157,C0009450,is highly ,AS virus,Communicable Diseases,3,X,[virs],[dsyn],,C01.539.221
c48d715e-82d3-493f-bb26-bf1a86f22fae,C0035736,C0009450,Amplification of is current gold test for confirmation of ,RNA Viral,Communicable Diseases,2,X,[nnon],[dsyn],D13.444.735.828,C01.539.221
fb892e88-f654-4094-95b3-ed1dfea7f4ef,PCR,C1185740,performed on respiratory ,PCR,Tract,3,X,????,[bpoc],????,
38a81c6a-4606-4aea-944e-6f08c161b99c,C0206074,C0444279,performed on respiratory ,Renal Replacement Therapy,Respiratory sample,2,X,[topp],[bdsu],E02.870,
ecfea4c4-3321-4f31-b33d-7d945d2e543f,PCR,C0444279,performed on respiratory ,PCR,Respiratory sample,2,X,????,[bdsu],????,
ecfea4c4-3321-4f31-b33d-7d945d2e543f,PCR,C0444279,detect Coronavirus Infections in,PCR,Respiratory sample,1,X,????,[bdsu],????,
17aad59e-d455-48e3-9f3f-aecab49cd1a3,C0020452,C0206750,were reported in ,Hyperemia,Coronavirus Infections,3,X,[dsyn],[dsyn],C14.907.474,C02.782.600.550.200
e15b0190-c9c3-4522-a07a-6799fde8c5c3,C0264545,C0206750,were reported in ,Thickening of pleura,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
0b825485-5138-4b8c-b0f9-d27c974d5dfc,C2825977,C1947933,predispose dental ,Dental Retraction (procedure),care activity,2,X,[topp],[acty],,
cd1d6330-46f6-4e34-8e28-0ba9ec2beb1e,C0012682,C1947933,predispose dental ,Disinfectants,care activity,2,X,[sbst],[acty],D27.505.954.122.425;D27.720.274,
e1ad3016-dcc6-4e44-8d8c-0cb96f815f3f,C1947933,C0005889,consistent exposure to ,care activity,Body Fluids,2,X,[acty],[bdsu],,A12.207
292e9085-7554-4b5e-9dcf-aa0b210ef344,C0242781,C3826466,is in ,disease transmission,Dentistry--Practice,2,X,[patf],[bmod],N06.850.310,
a33ee81a-3597-4e06-978b-0fec2212c2c3,C3826426,C3826466,is in ,Dynamics,Dentistry--Practice,2,X,[npop],[bmod],,
5b544eda-cf15-489b-934f-48764d35f558,C0189573,hoc,were prioritized ad hoc,Cardiovascular procedures,hoc,2,X,[topp],????,,????
62f06421-3f7d-4218-9fcc-ea695fc3a052,C0189573,C0040861,be useful for fair ,Cardiovascular procedures,Triage,12,X,[topp],[topp],,N02.421.297.900
ddce8192-d8b3-4979-a0a5-a2d60e880038,C1293116,C0206750,aiding ,Introduction procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
08116fed-abfa-4302-b492-293ac53534d5,C1293116,C0012634,aiding ,Introduction procedure,Disease,1,X,[topp],[dsyn],,C23.550.288
20969368-fdb9-4194-b1f6-402375e4d3ae,C1293116,C1511790,aiding ,Introduction procedure,Detection,1,X,[topp],[topp],,
b986e887-7f16-4feb-95b3-926876a08d45,C0005818,C0206750,significantly lower Leukocytes in,Blood Platelet Disorders,Coronavirus Infections,2,X,[dsyn],[dsyn],C15.378.140,C02.782.600.550.200
d6d33867-ebcc-4152-a1f2-91dddb5f0f69,C0005818,C0032285,significantly lower Leukocytes in,Blood Platelet Disorders,Pneumonia,2,X,[dsyn],[dsyn],C15.378.140,C08.381.677;C08.730.610
f441b702-16e1-4583-a7c5-87028d1971b1,C0700635,C0206750,is in severe ,Strudwick syndrome,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
144acabd-1ce4-46d6-9f73-dbecce525daf,C0023516,C0009450,are markers of ,Leukocytes,Communicable Diseases,2,X,[cell],[dsyn],A11.118.637;A15.145.229.637;A15.382.490,C01.539.221
0bec289c-ea28-4468-aa06-79a379b260eb,C1706374,C0206750,related to ,Tumor Necrosis Factor Ligand Superfamily Member 13,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,C02.782.600.550.200
08ce86fd-4502-43a2-9217-bb4bcacb932c,C1706374,C0242667,related to ,Tumor Necrosis Factor Ligand Superfamily Member 13,Reproductive Health,1,X,[aapp/bacs],[bmod],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,N01.400.625
8f776d47-459e-453a-a773-e26db8a79e65,C0206750,C0242667,is in ,Coronavirus Infections,Reproductive Health,1,X,[dsyn],[bmod],C02.782.600.550.200,N01.400.625
84d07c0b-e801-452f-bd16-bda31a44834b,C1825598,C0015491,bathing ,IMPACT gene,factor IX,1,X,[gngm],[aapp/bacs/phsu],,D08.622.355;D12.776.124.125.375;D23.119.375
ff5aa6bb-dca3-4c5c-9dc2-52e054f52fdd,C0006141,babys,Symptoms of their babys,Breast,babys,1,X,[bpoc],????,A01.236,????
c58002cd-ab43-43e5-a923-a46fb9499dd0,C0006141,C0009450,Symptoms of their babys,Breast,Communicable Diseases,1,X,[bpoc],[dsyn],A01.236,C01.539.221
af20b992-ca56-458a-85cb-5dcb28e4fb82,C1871526,C0074558,are more effective drug candidates than ,raltegravir,sinefungin,3,X,[nnon/phsu],[antb/orch],,x.x.x.x
af20b992-ca56-458a-85cb-5dcb28e4fb82,C1871526,C0074558,Binding (Molecular Function) strongly to active site to,raltegravir,sinefungin,1,X,[nnon/phsu],[antb/orch],,x.x.x.x
2b4d0194-0ca2-452e-9221-5f2dec557a60,C1871526,C3463820,are more effective drug candidates than ,raltegravir,Inhibition,3,X,[nnon/phsu],[acty],,F01.145.544;F02.463.425.475;F02.739.794.405
08d0dcfe-b0a0-4971-b48f-9361a9143d85,C1667052,C0074558,are more effective drug candidates than ,maraviroc,sinefungin,3,X,[orch/phsu],[antb/orch],D02.455.426.392.368.367.726;D03.383.129.799.682,x.x.x.x
08d0dcfe-b0a0-4971-b48f-9361a9143d85,C1667052,C0074558,Binding (Molecular Function) strongly to active site to,maraviroc,sinefungin,1,X,[orch/phsu],[antb/orch],D02.455.426.392.368.367.726;D03.383.129.799.682,x.x.x.x
524653da-8a35-4499-8c8b-2c4922ef10c4,C1667052,C3463820,are more effective drug candidates than ,maraviroc,Inhibition,3,X,[orch/phsu],[acty],D02.455.426.392.368.367.726;D03.383.129.799.682,F01.145.544;F02.463.425.475;F02.739.794.405
ffd36e24-548e-4c00-a5ad-e4edb9f055a0,C1667052,C0206750,may may used in treatment of ,maraviroc,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D02.455.426.392.368.367.726;D03.383.129.799.682,C02.782.600.550.200
72447c84-c4d4-42c3-9398-458a052670c6,C1761613,C0271298,had ,Conjunctival hyperemia,Chemosis of conjunctiva,4,X,[dsyn],[patf],,
d4a21728-061e-4866-b403-9b698b9a5274,C0184904,C0011884,showed ,Slitting,Diabetic Retinopathy,4,X,[topp],[dsyn],,C11.768.257;C14.907.320.382;C19.246.099.500.382
1a001615-3115-4097-8606-e58ebc4a4833,C4321457,C0011884,showed ,Examination,Diabetic Retinopathy,4,X,[acty],[dsyn],,C11.768.257;C14.907.320.382;C19.246.099.500.382
c6cbb30c-a664-46c4-9afd-cdacefb58a52,C0184904,C0086543,showed ,Slitting,Cataract,4,X,[topp],[acab],,C11.510.245
854e7b84-6a9e-41dd-90da-723770e93935,C4321457,C0086543,showed ,Examination,Cataract,4,X,[acty],[acab],,C11.510.245
1fa692cf-0ad6-4ec3-a59a-5f9b3c814649,C0184904,C1761613,showed ,Slitting,Conjunctival hyperemia,4,X,[topp],[dsyn],,
3f016a1f-63d4-48a7-93d0-872a1bb20376,C4321457,C1761613,showed ,Examination,Conjunctival hyperemia,4,X,[acty],[dsyn],,
e35000a1-dac9-48f8-8e81-5dba96e64144,C0184904,C0271298,showed ,Slitting,Chemosis of conjunctiva,4,X,[topp],[patf],,
8ab6a0c5-9d47-4734-bf05-3864993a38e1,C4321457,C0271298,showed ,Examination,Chemosis of conjunctiva,4,X,[acty],[patf],,
8abf50eb-a209-488e-a191-83b69954c3c3,C0239981,C1829939,occurred in ,Hypoalbuminemia,{Non-patient},8,X,[dsyn],[clna],C15.378.147.607.500,
7e7a39dc-5ccc-43ee-a0f0-fa85f341dc02,C0239981,C1155266,are associated with exacerbation of disease-associated ,Hypoalbuminemia,inflammatory response,5,X,[dsyn],[patf],C15.378.147.607.500,
220b4bdb-02c9-4f7b-a6f9-8acb176cadb8,C0239981,C0242656,are associated with exacerbation of disease-associated ,Hypoalbuminemia,Disease Progression,5,X,[dsyn],[patf],C15.378.147.607.500,C23.550.291.656
644c5e9c-fab4-4cd8-93b3-0c87cddd8739,C1290884,C0302189,have have described in context of ,Inflammatory disorder,Cell Therapy,3,X,[dsyn],[topp],,E02.095.147
97930828-4c68-4a44-ab2d-64b78fc6e6d9,C1619738,COVID-19,have COVID19,Immune Reconstitution Inflammatory Syndrome,COVID-19,6,X,[dsyn],[virs],C20.608,C000657245
3fdc0748-bd27-4dbe-a1d7-8ea42bd420a4,C4054044,COVID-19,have COVID19,Secondary Hemophagocytic Lymphohistiocytosis,COVID-19,6,X,[dsyn],[virs],,C000657245
cc488447-b86f-4dee-9dee-3f05f1a099df,C0948245,COVID19,have COVID19,Cytokine Release Syndrome,COVID19,6,X,[dsyn],????,,????
0e9e6f74-13e7-4fe8-8a82-834809de5d8d,C1619738,COVID19,have COVID19,Immune Reconstitution Inflammatory Syndrome,COVID19,6,X,[dsyn],????,C20.608,????
bf77a813-1b2d-45d8-8ed7-566dc9967dce,C4054044,COVID19,have COVID19,Secondary Hemophagocytic Lymphohistiocytosis,COVID19,6,X,[dsyn],????,,????
c0aae4af-daa2-40c6-8a26-362d92444c8f,C2827774,C0206750,are are evaluated for treatment of ,Current Therapy,Coronavirus Infections,3,X,[topp],[dsyn],,C02.782.600.550.200
be71e050-ae07-4181-b699-d3c1d2cc8705,genomic,C0042776,enable understanding of characteristics of ,genomic,Virus,1,X,????,[virs],????,B04
b4160483-d0df-4fd6-9d57-6202794fc631,humoral,C0301872,revealed ,humoral,Immune response,1,X,????,[ortf],????,
187c4d10-245c-46bf-9e3f-b60b77d4e3a5,humoral,C0282682,revealed notably enhanced ,humoral,Antibodies Blocking,1,X,????,[aapp/imft/irda],????,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
e9a909d6-73c8-4552-9857-392c2a1d51fc,C0086418,C0009450,sustained loads upon intranasal ,Homo sapiens,Communicable Diseases,7,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C01.539.221
8a55e54b-6110-4ca3-b9bc-6ffaafd7573b,C0305052,C0013227,can can considered as potential candidates for ,Gamma globulin serum,Pharmaceutical Preparations,2,X,[aapp/imft/phsu],[phsu],,D26
cde0b9e1-73dd-43db-a2a0-7a0dc14e5043,C0305052,C0087111,can can considered as potential candidates for ,Gamma globulin serum,Therapeutic procedure,2,X,[aapp/imft/phsu],[topp],,E02
68cfea48-d325-443e-8543-bbfbad331e4d,C0305052,C0206750,can can considered as potential candidates for ,Gamma globulin serum,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],,C02.782.600.550.200
30ba456a-fb27-4e6d-8394-439072ace999,C2936405,C0206750,stands out as promising strategy for response in fight against novel ,Drug Repositioning,Coronavirus Infections,3,X,[topp],[dsyn],E05.290.875,C02.782.600.550.200
15020db6-dbd6-45f7-8035-125dc1d73b33,TLR3,C0013227,be considered as potential ,TLR3,Pharmaceutical Preparations,2,X,????,[phsu],????,D26
17b231c5-5e50-42ee-a525-023caedf2dcd,C0243192,C0013227,be considered as potential ,agonists,Pharmaceutical Preparations,2,X,[phsu],[phsu],x.x.x,D26
7e3bc69f-d7b2-4050-9342-4cde72d939bf,TLR3,C2936405,be considered as potential ,TLR3,Drug Repositioning,2,X,????,[topp],????,E05.290.875
8b152412-6bef-42a8-ba64-764eea73fe58,C0243192,C2936405,be considered as potential ,agonists,Drug Repositioning,2,X,[phsu],[topp],x.x.x,E05.290.875
cb10ace4-f065-4c22-9507-98d4f685db3e,TLR3,C0206750,be considered as potential ,TLR3,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
04dc8b2f-09ad-4a9e-85b5-6fdbb0457599,C0243192,C0206750,be considered as potential ,agonists,Coronavirus Infections,1,X,[phsu],[dsyn],x.x.x,C02.782.600.550.200
ed0b3a49-bba5-478a-8c48-faed879acbf2,C0206419,C0597404,are group of well-known ,Genus: Coronavirus,Respiratory viruses,3,X,[virs],[virs],B04.820.504.540.150,
ed0b3a49-bba5-478a-8c48-faed879acbf2,C0206419,C0597404,are large family of respiratory ,Genus: Coronavirus,Respiratory viruses,3,X,[virs],[virs],B04.820.504.540.150,
2b2820a9-2f07-4c46-9a73-4884fea77288,C0597404,C0339901,can cause ,Respiratory viruses,Acute respiratory infections,3,X,[virs],[dsyn],,
ca196797-6961-4859-88bb-8ef6cc93f221,C0206750,C1254351,is cited as most worldwide problematic ,Coronavirus Infections,Pharmacologic Substance,4,X,[dsyn],[phsu],C02.782.600.550.200,
201ea248-c1ff-40c6-8653-3a7251248ca2,C0206750,C0282686,is cited as most worldwide problematic ,Coronavirus Infections,Respiratory System Agents,6,X,[dsyn],[phsu],C02.782.600.550.200,D27.505.954.796
201ea248-c1ff-40c6-8653-3a7251248ca2,C0206750,C0282686,was initially characterized by mainly manifestations of ,Coronavirus Infections,Respiratory System Agents,1,X,[dsyn],[phsu],C02.782.600.550.200,D27.505.954.796
c7fe4b7d-6700-4768-8467-0d3e68b673ab,KCDC,C0242656,clearly distinguished improvement Coronaviridae from,KCDC,Disease Progression,1,X,????,[patf],????,C23.550.291.656
406f6ec9-27b9-4acc-a545-52d3c96dcfc6,C0021966,C0242656,clearly distinguished improvement Coronaviridae from,Iodides,Disease Progression,1,X,[inch],[patf],D01.248.497.158.490;D01.475.410,C23.550.291.656
69631e9e-5a75-4eab-ae34-a3cb99aec696,KCDC,C0010076,clearly distinguished improvement Coronaviridae from,KCDC,Coronaviridae,1,X,????,[virs],????,B04.820.504.540
69631e9e-5a75-4eab-ae34-a3cb99aec696,KCDC,C0010076,clearly distinguished improvement ,KCDC,Coronaviridae,1,X,????,[virs],????,B04.820.504.540
f7f68285-3866-44c4-8ae9-ddad9853b35d,C0021966,C0010076,clearly distinguished improvement Coronaviridae from,Iodides,Coronaviridae,1,X,[inch],[virs],D01.248.497.158.490;D01.475.410,B04.820.504.540
f7f68285-3866-44c4-8ae9-ddad9853b35d,C0021966,C0010076,clearly distinguished improvement ,Iodides,Coronaviridae,1,X,[inch],[virs],D01.248.497.158.490;D01.475.410,B04.820.504.540
0b751c45-8427-4eb8-9581-e50f91664f15,KCDC,C1293130,clearly distinguished improvement ,KCDC,Stabilization,1,X,????,[topp],????,
3f3b1a57-da90-414d-aad0-fafec76b00a6,C0021966,C1293130,clearly distinguished improvement ,Iodides,Stabilization,1,X,[inch],[topp],D01.248.497.158.490;D01.475.410,
f11538f0-ec75-4705-86e3-0e82053aab3a,C0040861,C1521827,was ,Triage,Preparation,1,X,[topp],[acty],N02.421.297.900,
a654a1af-eff5-4756-8d98-916ca820334c,C0040861,C0206750,identify potential ,Triage,Coronavirus Infections,1,X,[topp],[dsyn],N02.421.297.900,C02.782.600.550.200
dd9c13de-40e1-4db6-a033-5141b5b4d77c,C1283174,C0206750,identify potential ,Checking (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
04628c7e-9ca9-460c-9bdf-5ea233a0f853,C0333557,C0206750,is in patient with ,Watershed infarct,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
421a0a18-3bcd-4198-91c6-8371e27a5c10,C0039259,C0521530,is with focal distribution subpleural pleural ,Tail,Lung consolidation,1,X,[bpoc],[dsyn],A13.895,
c7621b57-d52a-48a7-8f05-6301560cb93d,C0039259,pleural,is with focal distribution subpleural pleural ,Tail,pleural,1,X,[bpoc],????,A13.895,????
458d212a-dcbe-4539-a0ae-1cc4d421ada1,C0017428,C0226993,characterized by ,Genome,Tooth Crowns,3,X,[gngm],[bpoc],G05.360.340,A14.549.167.900.710
bfa543e8-78c5-4ee9-9036-47dc5dfbd64a,C0036658,C0226993,characterized by ,Esthesia,Tooth Crowns,3,X,[ortf],[bpoc],F02.830.816;G11.561.790,A14.549.167.900.710
8bcc9ffd-d0a9-4fb3-8bde-2dd5973da211,C0035691,C0226993,characterized by ,RNA Viruses,Tooth Crowns,3,X,[virs],[bpoc],B04.820,A14.549.167.900.710
8bcc9ffd-d0a9-4fb3-8bde-2dd5973da211,C0035691,C0226993,containing ,RNA Viruses,Tooth Crowns,1,X,[virs],[bpoc],B04.820,A14.549.167.900.710
26addab4-bbe3-4515-bbb2-bcb5df7f6138,6LU7,C1519126,identity with ,6LU7,SARS Coronavirus Protease Pathway,2,X,????,[moft],????,
dbb15cb3-13af-4118-a8c5-8fd2f2bb46cc,6LU7,C0598312,are playing role in ,6LU7,DNA Replication,3,X,????,[genf],????,G02.111.225;G05.226
6aaed045-d461-4f26-aa50-05a2534cab1c,C1167622,kcal,is with -8.2 kcal ,Binding (Molecular Function),kcal,3,X,[moft],????,,????
6aaed045-d461-4f26-aa50-05a2534cab1c,C1167622,kcal,was calculated -2.80 0.84 kcal ,Binding (Molecular Function),kcal,4,X,[moft],????,,????
09f02ee2-3b36-4d00-9d15-9484a0ca71d4,C1510827,kcal,is with -8.2 kcal ,Affinity,kcal,3,X,[npop],????,,????
9d6b6c25-798a-4b8e-a0d1-adb505608356,C1167622,C0324740,is with -8.2 kcal ,Binding (Molecular Function),Talpidae,3,X,[moft],[mamm],,B01.050.150.900.649.473.450
9d6b6c25-798a-4b8e-a0d1-adb505608356,C1167622,C0324740,was calculated -2.80 0.84 kcal ,Binding (Molecular Function),Talpidae,4,X,[moft],[mamm],,B01.050.150.900.649.473.450
497c0d55-adaf-49c6-bf2e-206b94c3aba9,C1510827,C0324740,is with -8.2 kcal ,Affinity,Talpidae,3,X,[npop],[mamm],,B01.050.150.900.649.473.450
75d5ec22-bb6d-414d-9118-28309e9bceab,remdesivir,C1167622,having better ,remdesivir,Binding (Molecular Function),3,X,[clnd],[moft],,
f157adfd-16c7-4026-a985-09043bbe76cb,remdesivir,C1510827,having better ,remdesivir,Affinity,3,X,[clnd],[npop],,
8402ae4c-c101-4515-80d5-f1ec34481ace,remdesivir,C0035253,having better ,remdesivir,Rest,3,X,[clnd],[dora],,I03.450.769.647
fd71a929-f9ad-41e6-8755-97f56bb1f614,remdesivir,C0033607,having better ,remdesivir,Protease Inhibitors,3,X,[clnd],[phsu],,D27.505.519.389.745
3c610b5f-3b18-4669-8528-8e8c58fe1608,remdesivir,C0087111,is potent ,remdesivir,Therapeutic procedure,3,X,[clnd],[topp],,E02
39f8ac6d-5b1a-4125-8be8-9d95fd18bc15,C1145670,C0206750,lethal manifestation of ,Respiratory Failure,Coronavirus Infections,3,X,[dsyn],[dsyn],C08.618.846,C02.782.600.550.200
92ca88ba-3d04-4dd4-9538-09dc020e8b95,C0035222,C0281169,propose entity as remedy to ,Respiratory Distress Syndrome Adult,pulmonary complications,6,X,[dsyn],[patf],C08.381.840;C08.618.840,
06a32d00-95bf-404a-9fa9-a72b6b572767,C0002986,C0234221,include ,Fabry Disease,Acroparesthesia,2,X,[dsyn],[dsyn],C10.228.140.163.100.435.825.200;C10.228.140.300.275.374;C14.907.253.329.374;C16.320.322.124;C16.320.565.189.435.825.200;C16.320.565.398.641.803.300;C16.320.565.595.554.825.200;C18.452.132.100.435.825.200;C18.452.584.687.803.300;C18.452.648.189.435.825.200;C18.452.648.398.641.803.300;C18.452.648.595.554.825.200,
a22bddfa-e030-4e43-8e1e-f22ec3dfea70,C0002986,C0391845,is X-linked Fabry Disease due to,Fabry Disease,Lysosomal enzyme,2,X,[dsyn],[aapp/enzy],C10.228.140.163.100.435.825.200;C10.228.140.300.275.374;C14.907.253.329.374;C16.320.322.124;C16.320.565.189.435.825.200;C16.320.565.398.641.803.300;C16.320.565.595.554.825.200;C18.452.132.100.435.825.200;C18.452.584.687.803.300;C18.452.648.189.435.825.200;C18.452.648.398.641.803.300;C18.452.648.595.554.825.200,
1de9d1b2-11e8-473d-b96f-7103c6850c6f,C0002986,C1457887,is X-linked Fabry Disease due to,Fabry Disease,Symptoms,2,X,[dsyn],[sosy],C10.228.140.163.100.435.825.200;C10.228.140.300.275.374;C14.907.253.329.374;C16.320.322.124;C16.320.565.189.435.825.200;C16.320.565.398.641.803.300;C16.320.565.595.554.825.200;C18.452.132.100.435.825.200;C18.452.584.687.803.300;C18.452.648.189.435.825.200;C18.452.648.398.641.803.300;C18.452.648.595.554.825.200,
9b2a6bff-91aa-4ece-9e39-47018c539679,C0319157,C0450254,has appeared as new ,AS virus,Pathogenic organism,1,X,[virs],[orgm],,
9b2a6bff-91aa-4ece-9e39-47018c539679,C0319157,C0450254,exerts its ,AS virus,Pathogenic organism,2,X,[virs],[orgm],,
bfb2c830-e81b-4333-844d-82bc8021e024,C0020974,C0319157,hold back mysterious ,passive immunization procedure,AS virus,1,X,[topp],[virs],E02.095.465.425.400.330;E05.478.550.520,
1a31b056-ded3-4708-b26d-a7ad185b9521,C0871189,C0206750,have have related to ,Psychotic symptom,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
b951b5b5-e7d2-4e89-b7bb-2ab6002581f9,C0338614,C0206750,is in ,Psychotic episodes,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
2bde04fb-f11a-4dae-93af-55dd4a20cc13,C0206750,C0960756,can develop as ,Coronavirus Infections,factor A,2,X,[dsyn],[orch],C02.782.600.550.200,x.x.x.x
2bde04fb-f11a-4dae-93af-55dd4a20cc13,C0206750,C0960756,was related with ,Coronavirus Infections,factor A,6,X,[dsyn],[orch],C02.782.600.550.200,x.x.x.x
2bde04fb-f11a-4dae-93af-55dd4a20cc13,C0206750,C0960756,combines multiplex ,Coronavirus Infections,factor A,1,X,[dsyn],[orch],C02.782.600.550.200,x.x.x.x
a1215d53-0488-43c5-8b9d-a4156e4902e6,C0003018,C0225336,is expressed in ,Angiotensins,Endothelial Cells,2,X,[aapp/bacs/phsu],[cell],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,A11.436.275
c438c960-1165-4bf4-b2bd-4c57d7ba27fc,C0003018,C0162772,could could implicated in production of ,Angiotensins,Reactive Oxygen Species,2,X,[aapp/bacs/phsu],[bacs/elii],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,D01.339.431;D01.650.775
9b7d6fde-c99f-472d-b422-ae65c001c637,C0003018,C0856169,could could implicated in production of ,Angiotensins,endothelial dysfunction,2,X,[aapp/bacs/phsu],[dsyn],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,
2ae90798-5537-46d4-aa7d-93aa1a89872b,A23403,C0028630,be most common ,A23403,Nucleotides,2,X,????,[nnon],????,D09.408.620;D13.695
89f43817-17b7-4c7f-acf0-52bde3e9f4b1,A23403,C3494870,be most common ,A23403,Viral isolate,2,X,????,[bacs],????,
8507bbd1-2cd7-4ff7-b66c-2e2a41fd7830,C0020598,C0206750,were independent risk factors associated with long-term hospitalization in patients with ,Hypocalcemia,Coronavirus Infections,6,X,[dsyn],[dsyn],C18.452.174.509;C18.452.950.509,C02.782.600.550.200
fa359533-d8d9-465c-b911-aafe9a2682c6,C0085680,C0206750,were independent risk factors associated with long-term hospitalization in patients with ,Hypochloremia (disorder),Coronavirus Infections,8,X,[dsyn],[dsyn],,C02.782.600.550.200
321f9375-dbba-4e79-a3b0-aa9c5df9fe28,C1142578,C0206750,were independent risk factors associated with long-term hospitalization in patients with ,Bilateral pneumonia,Coronavirus Infections,7,X,[dsyn],[dsyn],,C02.782.600.550.200
e88ba3ca-e6dc-476e-a45d-2e82a1950840,C3649547,C0178784,has become effective ,Continuous renal replacement therapy,Organ,1,X,[topp],[bpoc],,
1d750e42-2692-4d43-bd4d-6d1202b5e967,C3649547,C0206074,has become effective ,Continuous renal replacement therapy,Renal Replacement Therapy,1,X,[topp],[topp],,E02.870
1d750e42-2692-4d43-bd4d-6d1202b5e967,C3649547,C0206074,has become instead of single ,Continuous renal replacement therapy,Renal Replacement Therapy,1,X,[topp],[topp],,E02.870
4557c70c-678e-41db-95fb-b94970020701,C0012634,C3649547, includes ,Disease,Continuous renal replacement therapy,1,X,[dsyn],[topp],C23.550.288,
154d5422-5561-4f86-8760-d26c61e3fe83,C3649547,C0206750,is in ,Continuous renal replacement therapy,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
d665aa32-1dd4-4083-9625-f60f5859c605,C0553741,C3649547,elaborate similarities between ,Fluid Management,Continuous renal replacement therapy,1,X,[topp],[topp],,
49d5134f-c2ea-44bd-99bd-e448b1e23e5e,C0553741,C0206750,elaborate similarities between ,Fluid Management,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
1341dfea-47e7-4399-b778-c9c8c50fafb5,C2745965,C0009450,is characterized by high ,Emergencies [Disease/Finding],Communicable Diseases,3,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C01.539.221
1341dfea-47e7-4399-b778-c9c8c50fafb5,C2745965,C0009450,is Characterization by high,Emergencies [Disease/Finding],Communicable Diseases,2,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C01.539.221
27414122-236f-4663-85c7-8a1b96b94e3a,C0002520,C0206750,may affect ,Amino Acids,Coronavirus Infections,3,X,[aapp/bacs/phsu],[dsyn],D12.125,C02.782.600.550.200
039ed766-0b1b-4a72-8763-21db21d3523d,C0282575,C0206750,may affect ,Micronutrients,Coronavirus Infections,3,X,[bacs],[dsyn],D27.505.696.377.683.500;G07.203.300.681.500;J02.500.681.500,C02.782.600.550.200
2f2b4028-4c1f-4f70-9c92-5ddd2c069bc2,C0319157,C0006255,is in lower ,AS virus,Bronchi,3,X,[virs],[bpoc],,A04.411.125
fc7cba09-e7c5-4784-a0af-6600b93624b3,C0225700,C0006255,is in lower ,Type-II Pneumocytes,Bronchi,5,X,[cell],[bpoc],A04.411.715.100;A11.436.081,A04.411.125
21bbb475-5c38-48c0-80ee-d99bba5a7cfa,C0014442,C0040300,is widely expressed in numerous ,Enzymes,Body tissue,4,X,[aapp/enzy],[tisu],D08.811,A10
f7e2c9a6-8ed2-4714-8c03-7a3e26b23a1d,C1706079,C0206061,causes severe primary ,Arrival - action,Pneumonia Interstitial,10,X,[acty],[dsyn],,C08.381.483
daa2c73e-d723-4965-9ca1-f23678d38bd0,C0206061,C0079189,can lead to ,Pneumonia Interstitial,cytokine,5,X,[dsyn],[aapp/imft],C08.381.483,D12.644.276.374;D12.776.467.374;D23.529.374
d1fb848b-964d-49a8-bf15-8197e99323d1,C0206061,C1861452,can lead to ,Pneumonia Interstitial,Storm Syndrome,5,X,[dsyn],[dsyn],C08.381.483,x.x.x.x
b79805cb-56b5-4ffc-bcc5-1722f5fe6efc,C0206061,C1155266,can lead to deadly uncontrolled systemic ,Pneumonia Interstitial,inflammatory response,5,X,[dsyn],[patf],C08.381.483,
c8678785-523b-4e0e-a1f2-d3e43c3f6e25,C0206061,C1512853,can lead to deadly uncontrolled systemic ,Pneumonia Interstitial,Interleukin Signaling Process,10,X,[dsyn],[phsf],C08.381.483,
b4819303-3013-4308-a694-2aecc0eb190b,C0012739,C0206750,are life-threatening for patients with ,Disseminated Intravascular Coagulation,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.100.220;C15.378.463.250;C15.378.925.220,C02.782.600.550.200
03b29f39-07cf-4230-a27a-2d9e0323b38a,C0597404,C0009264,replicate at ,Respiratory viruses,Cold Temperature,4,X,[virs],[npop],,G01.906.595.272;G16.500.275.063.725.710.300;G16.500.750.775.710.300;N06.230.300.100.725.154;N06.230.300.100.725.710.300
3b0c9bcc-6e5c-4f39-b5d6-b803e3f9126e,C0042774,C0015219,risk of ,Virus Replication,Biological Evolution,5,X,[celf],[genf],G06.920.925,G05.045;G16.075
b9bd2271-4300-41cc-908e-6e5bea0a2620,C0597571,C2030271,is in ,thermostability,Humid heat,5,X,[npop],[topp],,
8dcbc0c7-d7a4-44a2-84a4-19a3f9604307,C0597571,C0348007,is in ,thermostability,Laser ablation,5,X,[npop],[topp],,
8c31a1b7-f560-44da-b878-c8551ce4f5c6,C0042210,C0678544,affect first ,Vaccines,wave - physical agent,1,X,[aapp/imft/phsu],[npop],D20.215.894,
165f6fb6-77d6-4d19-b914-946b73aba7a5,C2926735,C0206419,is in children with ,Duration,Genus: Coronavirus,1,X,[orch/phsu],[virs],,B04.820.504.540.150
165f6fb6-77d6-4d19-b914-946b73aba7a5,C2926735,C0206419,is in patients infected with ,Duration,Genus: Coronavirus,2,X,[orch/phsu],[virs],,B04.820.504.540.150
12ff01b7-0fdf-4634-9229-02905de59463,vis,C0028754,is with multiple ,vis,Obesity,1,X,????,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
ea4f99c6-34ac-4c43-be68-711a010fa4bc,C0038454,C0206419,is serious neurological comorbidity observed during ,Cerebrovascular accident,Genus: Coronavirus,2,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150
52a0739a-464b-40cb-8e7c-541969a3fc92,C0038454,C2937358,includes ,Cerebrovascular accident,Cerebral Hemorrhage,2,X,[dsyn],[patf],C10.228.140.300.775;C14.907.253.855,C10.228.140.300.535.200;C14.907.253.573.200;C23.550.414.913.100
a3541dbc-24b6-48b4-97b8-eda125339fcc,C0038454,C0948008,includes ,Cerebrovascular accident,Ischemic stroke,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,
36a80361-a426-4fdb-938b-fbee58ad5202,C0038454,C0151945,includes ,Cerebrovascular accident,Thrombosis of cerebral veins,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,
8f5a83a0-9b53-430c-b2ce-18d23b48432d,C0206419,C0043047,is in ,Genus: Coronavirus,Water,1,X,[virs],[inch/phsu],B04.820.504.540.150,D01.045.250.875;D01.248.497.158.459.650;D01.650.550.925;x.x.x.x
3a4ebca5-b2b1-45bc-a9b7-1f4f62394500,C0038443,C1825598,may have adverse ,Stress Psychological,IMPACT gene,2,X,[mobd],[gngm],F01.145.126.990;F02.830.900,
3a4ebca5-b2b1-45bc-a9b7-1f4f62394500,C0038443,C1825598,have negative ,Stress Psychological,IMPACT gene,2,X,[mobd],[gngm],F01.145.126.990;F02.830.900,
aa3a6af1-8693-486b-b156-7d191c25a9ef,C0038443,C2700061,surrounding ,Stress Psychological,Transition (action),2,X,[mobd],[acty],F01.145.126.990;F02.830.900,
a70aeffe-f6fe-426c-aab8-6c10748a3504,C0038443,C1457887,was associated with levels of vocal ,Stress Psychological,Symptoms,2,X,[mobd],[sosy],F01.145.126.990;F02.830.900,
a303a2a5-5547-454a-a6bd-230f45145568,C0162836,C0206419,capture data on risks clinical course and outcomes of ,Hidradenitis Suppurativa,Genus: Coronavirus,2,X,[dsyn],[virs],C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320,B04.820.504.540.150
4726d6f6-9430-4bc2-b281-f6427d09d89d,C0206419,C1145670,is easily Communicable Diseases in its form characterized by,Genus: Coronavirus,Respiratory Failure,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618.846
4726d6f6-9430-4bc2-b281-f6427d09d89d,C0206419,C1145670,may cause ,Genus: Coronavirus,Respiratory Failure,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618.846
4726d6f6-9430-4bc2-b281-f6427d09d89d,C0206419,C1145670,is with severe ,Genus: Coronavirus,Respiratory Failure,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618.846
b425e5b3-38db-4948-ad3e-67da227becef,C0206419,C0079189,is easily Communicable Diseases in its form characterized by,Genus: Coronavirus,cytokine,3,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
b425e5b3-38db-4948-ad3e-67da227becef,C0206419,C0079189,inducing ,Genus: Coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
b425e5b3-38db-4948-ad3e-67da227becef,C0206419,C0079189,leads to ,Genus: Coronavirus,cytokine,3,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
b425e5b3-38db-4948-ad3e-67da227becef,C0206419,C0079189,manifest ,Genus: Coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
fef397c5-040d-4ff6-a94e-0959ff0207c1,C0369718,C0002520,found highly conserved surface ,N not otherwise specified Antibody,Amino Acids,6,X,[aapp/imft],[aapp/bacs/phsu],,D12.125
7dc77cd2-5632-4191-a7e6-d3e2b691f4f8,C0017428,C1175743,is in ,Genome,SARS coronavirus,13,X,[gngm],[virs],G05.360.340,B04.820.504.540.150.113.937
6dbea3ad-169b-4867-b8e1-b126af1df5d0,C4553629,C0022709,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6dbea3ad-169b-4867-b8e1-b126af1df5d0,C4553629,C0022709,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6dbea3ad-169b-4867-b8e1-b126af1df5d0,C4553629,C0022709,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6dbea3ad-169b-4867-b8e1-b126af1df5d0,C4553629,C0022709,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6dbea3ad-169b-4867-b8e1-b126af1df5d0,C4553629,C0022709,elucidated potential missense variants from population databases within ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6dbea3ad-169b-4867-b8e1-b126af1df5d0,C4553629,C0022709,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6dbea3ad-169b-4867-b8e1-b126af1df5d0,C4553629,C0022709,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
ae7833c6-0f46-4c9d-a6c6-d608f6b57660,C4553629,xentit,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,xentit,1,X,[topp],????,,????
ae7833c6-0f46-4c9d-a6c6-d608f6b57660,C4553629,xentit,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,xentit,1,X,[topp],????,,????
ae7833c6-0f46-4c9d-a6c6-d608f6b57660,C4553629,xentit,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,xentit,1,X,[topp],????,,????
ae7833c6-0f46-4c9d-a6c6-d608f6b57660,C4553629,xentit,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,xentit,1,X,[topp],????,,????
ae7833c6-0f46-4c9d-a6c6-d608f6b57660,C4553629,xentit,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,xentit,1,X,[topp],????,,????
ae7833c6-0f46-4c9d-a6c6-d608f6b57660,C4553629,xentit,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,xentit,1,X,[topp],????,,????
96b79878-555f-4e5f-b5a5-efbb22604ae4,C4553629,y384,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,y384,1,X,[topp],????,,????
c6a3859c-c5d6-41a5-ae2d-2bce9f9a072c,C4553629,C0036734,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
c6a3859c-c5d6-41a5-ae2d-2bce9f9a072c,C4553629,C0036734,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
c6a3859c-c5d6-41a5-ae2d-2bce9f9a072c,C4553629,C0036734,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
c6a3859c-c5d6-41a5-ae2d-2bce9f9a072c,C4553629,C0036734,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
c6a3859c-c5d6-41a5-ae2d-2bce9f9a072c,C4553629,C0036734,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
c6a3859c-c5d6-41a5-ae2d-2bce9f9a072c,C4553629,C0036734,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
771268ec-327b-46db-bb7b-4ff788c93e63,C3266262,C0206419,Cytomegalovirus Infections of only,Multiple Chronic Conditions,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.291.500.500,B04.820.504.540.150
c61c214a-0de3-451e-b1af-4d7ba52bcb48,C0020517,C0801658,have ,Hypersensitivity,Diagnosis.primary:Impression/interpretation of study:Point in time:^Patient:Nominal,3,X,[patf],[clna],C20.543,
1ad5ba37-d2e4-41b9-9918-f535c139d37e,C0020517,C0206419,was affected by increased resource use on ,Hypersensitivity,Genus: Coronavirus,4,X,[patf],[virs],C20.543,B04.820.504.540.150
f123bc41-038d-45a3-92c9-18c1605b1456,C0013227,C0030946,were investigated against ,Pharmaceutical Preparations,Endopeptidases,1,X,[phsu],[aapp/enzy/phsu],D26,D08.811.277.656.300
94ed2c3c-2f56-411a-b77c-36ba00c60583,C0013227,C0012634,were investigated against ,Pharmaceutical Preparations,Disease,5,X,[phsu],[dsyn],D26,C23.550.288
c5b18cff-9cf4-4d3e-87ff-9f82afae03ba,C0030576,C1167622,have strong ,Paromomycin,Binding (Molecular Function),2,X,[antb/orch],[moft],D09.408.051.706,
56bcb906-05a8-4ad2-ad2c-0fd7789e5a91,C0030576,C1510827,have strong ,Paromomycin,Affinity,2,X,[antb/orch],[npop],D09.408.051.706,
acf214ea-6555-4bbd-abde-391eb5941a98,C0030576,C0206419,have strong ,Paromomycin,Genus: Coronavirus,1,X,[antb/orch],[virs],D09.408.051.706,B04.820.504.540.150
b377a160-781f-4047-ab69-629b9dbda477,C0016452,C0012634,suppressing ,Food,Disease,4,X,[food],[dsyn],G07.203.300;J02.500,C23.550.288
abc9eb5e-c310-42da-a687-9e3a1f9ce749,C1516924,C0206419,are important part of pathophysiology of ,Epigenetic Process,Genus: Coronavirus,1,X,[genf],[virs],G05.308.203,B04.820.504.540.150
89af419e-aba8-40e2-aa24-6bd8cefcf08f,MEDLINE,C1856053,Web for literature on use from their inception ,MEDLINE,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,????,[dsyn],????,x.x.x.x
34461d2e-0a7c-4c9c-9b13-62f99424cf3e,C0301872,C0079189,trigger ,Immune response,cytokine,2,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
34461d2e-0a7c-4c9c-9b13-62f99424cf3e,C0301872,C0079189,dysregulates ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
34461d2e-0a7c-4c9c-9b13-62f99424cf3e,C0301872,C0079189,developing ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
34461d2e-0a7c-4c9c-9b13-62f99424cf3e,C0301872,C0079189,orchestrated by inflammatory ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
34461d2e-0a7c-4c9c-9b13-62f99424cf3e,C0301872,C0079189,embodies in decrease of ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
3fed6752-1f50-41ed-8c4d-30296355ce61,C0012634,C0393022,is with ,Disease,rituximab,2,X,[dsyn],[aapp/imft/phsu],C23.550.288,D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
5166c7f7-fb71-4736-96c9-882a0f660cd9,C0432618,C1254351,depleting ,Blood group antibody B,Pharmacologic Substance,2,X,[aapp/imft],[phsu],,
4c4a3cd6-7451-430c-aacd-1814758a485d,CD20,C1254351,depleting ,CD20,Pharmacologic Substance,1,X,????,[phsu],????,
da5734b9-45c6-4987-b4fe-3145bb3dfbb2,C1413336,C1254351,depleting ,CEL gene,Pharmacologic Substance,1,X,[gngm],[phsu],,
99a69570-7a44-4d7d-92e7-ce17e7c4d570,C0393022,C0432618,with treatment is CD20 ,rituximab,Blood group antibody B,4,X,[aapp/imft/phsu],[aapp/imft],D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,
59db0761-4e37-49f0-ae28-fc9599ad35ab,C0393022,CD20,with treatment is CD20 ,rituximab,CD20,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,????
d69cc350-746b-4ca8-ad43-aac393cf1f6a,C0393022,C1413336,with treatment is CD20 ,rituximab,CEL gene,1,X,[aapp/imft/phsu],[gngm],D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,
fcd7e6b8-10ea-4745-8f7f-902636fcd474,C0026769,C0432618,for treatment is CD20 ,Multiple Sclerosis,Blood group antibody B,4,X,[dsyn],[aapp/imft],C10.114.375.500;C10.314.350.500;C20.111.258.250.500,
55a3d017-5fca-4d36-ae85-e3ed96116535,C0026769,CD20,for treatment is CD20 ,Multiple Sclerosis,CD20,2,X,[dsyn],????,C10.114.375.500;C10.314.350.500;C20.111.258.250.500,????
8e08be11-b76c-4245-8d04-fa76bf80b84a,C0026769,C1413336,for treatment is CD20 ,Multiple Sclerosis,CEL gene,1,X,[dsyn],[gngm],C10.114.375.500;C10.314.350.500;C20.111.258.250.500,
b623541e-4d3a-4f97-87ae-56a0dd90e8e5,C1457887,C0426576,were ,Symptoms,Gastrointestinal symptom,2,X,[sosy],[sosy],,
73dc9754-d9f6-40cd-b575-a3c3af60919c,EMBASE,C1706202,were ,EMBASE,Search - action,1,X,????,[acty],????,
6cf08236-b1e9-4bc2-ab5f-e28fc54af69e,MEDLINE,C1706202,were electronically ,MEDLINE,Search - action,2,X,????,[acty],????,
12a4e8d8-138d-455d-b898-575a364206b6,MEDLINE,C1706374,were Search - action through,MEDLINE,Tumor Necrosis Factor Ligand Superfamily Member 13,4,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
fc9e1189-d78f-4176-bf52-b2d299266a87,EMBASE,C1706374,were Search - action through,EMBASE,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
425e77b7-2b3b-4bcb-a8df-ed6108dcb96f,C0319157,C0242781,is ,AS virus,disease transmission,4,X,[virs],[patf],,N06.850.310
53ca5474-69d0-4ab3-9138-e4034177eaa9,C0036974,C0042397,resistant to ,Shock,Vasoconstrictor Agents,2,X,[patf],[phsu],C23.550.835,D27.505.954.411.793
53ca5474-69d0-4ab3-9138-e4034177eaa9,C0036974,C0042397,requiring ,Shock,Vasoconstrictor Agents,1,X,[patf],[phsu],C23.550.835,D27.505.954.411.793
ed1c038b-4c6d-4569-abf4-2698f48617fe,C0032604,C0079189,has has shown to adsorb ,Polystyrenes,cytokine,2,X,[bodm/orch],[aapp/imft],D02.455.426.559.389.150.750.800.830;D05.750.716.579;D25.720.716.579;J01.637.051.720.716.579,D12.644.276.374;D12.776.467.374;D23.529.374
07ae0dd4-9894-4059-9540-1628a765b856,C0019010,C0010340,extracorporeal Excretory function in,Hemodynamics,Critical Illness,2,X,[ortf],[dsyn],G09.330.380,C23.550.291.625
3208edf6-fcc3-44a8-a0e4-082f26ff0cae,C0019010,C0206750,extracorporeal Excretory function in,Hemodynamics,Coronavirus Infections,1,X,[ortf],[dsyn],G09.330.380,C02.782.600.550.200
57e068c2-1054-49c6-868d-fda6ca5e8192,C0221102,C0019010,stabilize ,Excretory function,Hemodynamics,2,X,[phsf],[ortf],,G09.330.380
ec0ea7af-4970-42f8-8ada-dffbb9785691,C0221102,C0010340,is in ,Excretory function,Critical Illness,2,X,[phsf],[dsyn],,C23.550.291.625
400f7ea6-add4-46df-9c5c-fd8bd8ebdeed,C0221102,C0206750,is in ,Excretory function,Coronavirus Infections,1,X,[phsf],[dsyn],,C02.782.600.550.200
f9382ea1-a4d5-46e6-878a-a0285b13145d,C0019010,C0079189,extracorporeal Excretory function of,Hemodynamics,cytokine,2,X,[ortf],[aapp/imft],G09.330.380,D12.644.276.374;D12.776.467.374;D23.529.374
1f9f0d9a-1081-4f9a-ae1e-c25cb5a10610,C1516048,C0007637,is done after ,Assessed,Inclusion Bodies,1,X,[acty],[celc],,A11.284.420
f34875fe-9326-4151-9272-bdbf4d9a3ea3,C0310367,C0036658,rebuild ,Today,Esthesia,2,X,[antb/orch],[ortf],,F02.830.816;G11.561.790
dbbd39ac-6c20-4ae0-8d8d-b6cf5883a706,C1175743,C1268456,Viral Components of,SARS coronavirus,Viral Components,2,X,[virs],[celc],B04.820.504.540.150.113.937,A21
5338a634-e8f2-49f3-9068-859da64b18f7,C1175743,C2752522,site on ,SARS coronavirus,host cell surface,2,X,[virs],[celc],B04.820.504.540.150.113.937,
83345f67-9212-40b5-9106-3a5ee5f0a0b1,C1704241,C0597358,is with ,complex (molecular entity),receptor binding,1,X,[chvs],[moft],,
e55c9d9e-00a3-4592-b9ce-1d7a0260432b,C0206750,C0015392,has radically shifted healthcare operations across ,Coronavirus Infections,Eye,1,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
e55c9d9e-00a3-4592-b9ce-1d7a0260432b,C0206750,C0015392,spread across ,Coronavirus Infections,Eye,5,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
e55c9d9e-00a3-4592-b9ce-1d7a0260432b,C0206750,C0015392,is sweeping ,Coronavirus Infections,Eye,2,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
e55c9d9e-00a3-4592-b9ce-1d7a0260432b,C0206750,C0015392,is currently impacting life around ,Coronavirus Infections,Eye,1,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
e55c9d9e-00a3-4592-b9ce-1d7a0260432b,C0206750,C0015392,has impacted research around ,Coronavirus Infections,Eye,1,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
91bdb9a7-88f8-4cec-8120-5f3b7866f8c8,C0013230,C1152412,having spectrum Antiviral Agents RNA-directed RNA polymerase activity with its target,Investigational New Drugs,RNA-directed RNA polymerase activity,4,X,[phsu],[genf],D26.371,
3e95a937-1152-4482-83f4-0568b57c60c5,remdesivir,C0013230,is ,remdesivir,Investigational New Drugs,2,X,[clnd],[phsu],,D26.371
d4054415-ac8b-4a39-9562-93e54fdab3af,C0013230,C0003451,having broad spectrum ,Investigational New Drugs,Antiviral Agents,2,X,[phsu],[phsu],D26.371,D27.505.954.122.388
f50ac691-a4cc-43e6-864c-c4d070e80f44,remdesivir,vitro,had promising in vitro vivo,remdesivir,vitro,2,X,[clnd],????,,????
14d5b01d-08c3-4e14-86bd-c85c2193012a,remdesivir,vivo,had promising in vitro vivo,remdesivir,vivo,2,X,[clnd],????,,????
81910207-b65e-446b-a5e4-14f87a46c7d0,C0518766,C0543467,were stable on first day after ,Vital signs,Operative Surgical Procedures,6,X,[clna],[topp],E01.370.600.875,E04
88b81127-05e5-4e19-8b86-27918a362e28,C0206750,C2359945,raised questions in patients about use of ,Coronavirus Infections,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[dsyn],[clna],C02.782.600.550.200,
6ef19b02-2644-4b96-824f-7f4934449050,C2745965,C0042776,has changed target of ,Emergencies [Disease/Finding],Virus,1,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,B04
8b0f2989-f21f-4973-a90c-83e39a0bc43a,C0024128,C0042776,target of ,Lung Transplantation,Virus,2,X,[topp],[virs],E04.928.600.495;E04.936.450.495,B04
a241162b-00a6-4a4e-ac99-167d8a0a38f0,C0673477,C0019134,is with end point-attached ,ultra-high molecular weight polyethylene,heparin,1,X,[orch],[bacs/orch/phsu],x.x.x.x,D09.698.373.400
f30ae654-8669-47a3-b437-540a971ea23d,C0004611,C0699040,Binding (Molecular Function) in similar way to interaction on,Bacteria,Cell surface,1,X,[bact],[celc],B03,
a6320e81-8678-4ca9-852e-8c9893ea5b24,C0016832,C0699040,Binding (Molecular Function) in similar way to interaction on,Fungi,Cell surface,1,X,[fngs],[celc],B01.300,
81c19dac-665d-444f-9796-eaf2afe4328d,C0040549,C0699040,Binding (Molecular Function) in similar way to interaction on,Toxin,Cell surface,1,X,[bacs/hops],[celc],D23.946,
d8669a7c-47be-47a1-946e-ac040f75e9af,C0004611,C0019134,Binding (Molecular Function) to immobilized,Bacteria,heparin,1,X,[bact],[bacs/orch/phsu],B03,D09.698.373.400
4d576b96-c881-4020-8029-936150b65b65,C0016832,C0019134,Binding (Molecular Function) to immobilized,Fungi,heparin,1,X,[fngs],[bacs/orch/phsu],B01.300,D09.698.373.400
845abb7b-0c0d-423a-ac32-388b13d82659,C0040549,C0019134,Binding (Molecular Function) to immobilized,Toxin,heparin,1,X,[bacs/hops],[bacs/orch/phsu],D23.946,D09.698.373.400
2cd72a8f-b28e-48a8-b055-f6a1a20f012b,C0450254,C0005775,are removed from ,Pathogenic organism,Blood Circulation,2,X,[orgm],[phsf],,G09.330.100
89aa4224-427d-4eaa-91de-eab89e52a0c2,C0042071,COVID-19,Dysregulation of were ,Urokinase,COVID-19,1,X,[aapp/enzy/phsu],[virs],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,C000657245
ec7f3f01-9aed-4d25-a684-b5eead59a123,C1704259,COVID-19,is in ,Biochemical Pathway,COVID-19,2,X,[moft],[virs],,C000657245
61c3e145-1e95-4502-bfae-107fcd50aac3,C0005778,COVID-19,is in ,Blood coagulation,COVID-19,2,X,[ortf],[virs],G09.188.390.150,C000657245
fd97cebe-62b5-4026-869f-3f33004de2e7,C4521503,10th,Delhi between 10th ,CCDC26 wt Allele,10th,1,X,[gngm],????,,????
d18b491c-5a9c-489e-a19c-7bf17beadff9,C4521503,C1706374,Delhi between 10th ,CCDC26 wt Allele,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[gngm],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
3c202559-e171-49b7-b7c0-904c687fa7ab,C0011849,C0221423,were most common co-existing ,Diabetes Mellitus,Illness (finding),1,X,[dsyn],[sosy],C18.452.394.750;C19.246,
00a4daa6-7af7-4489-947a-d786a283e427,C0020538,C0221423,were most common co-existing ,Hypertensive disease,Illness (finding),1,X,[dsyn],[sosy],C14.907.489,
85bb0081-79ee-474d-bc31-77ca7213c960,C0024117,C0221423,were most common co-existing ,Chronic Obstructive Airway Disease,Illness (finding),1,X,[dsyn],[sosy],C08.381.495.389,
0399619b-e25c-44b1-83b7-13538fb4607d,C1457887,C0013404,were ,Symptoms,Dyspnea,12,X,[sosy],[sosy],,C08.618.326;C23.888.852.371
5e819a89-e062-4386-b217-0de1c093cb76,C0023530,C0024312,was present with majority of patients presenting with ,Leukopenia,Lymphopenia,1,X,[dsyn],[dsyn],C15.378.553.546,C15.378.553.546.605;C20.673.627
1ba3d206-bfb3-443b-babc-7bcbc24e3f9d,C0040034,C0030312,was seen in ,Thrombocytopenia,Pancytopenia,1,X,[dsyn],[dsyn],C15.378.140.855,C15.378.700
4dffc7b3-3ea0-45d4-86c3-c06744cb430f,C0036974,C0476273,is in higher ,Shock,Respiratory distress,1,X,[patf],[sosy],C23.550.835,
77cdd47a-2961-4d91-aa43-d07db407287e,C0206419,C0032285,presented in severe ,Genus: Coronavirus,Pneumonia,11,X,[virs],[dsyn],B04.820.504.540.150,C08.381.677;C08.730.610
580dc66e-8c7d-4259-b3aa-ca8948383148,C0699748,COVID-19,is in ,Pathogenesis,COVID-19,3,X,[patf],[virs],,C000657245
94122ca0-b9f9-4366-92cc-9f5c2ec3e367,C2267116,C0017110,is in ,Vascular Alterations,Gases,3,X,[phsf],[chvs],,D01.362
86be4420-255f-41dd-b4b2-1c2fd89e16a1,C3694279,C4284302,were In ,Middle East Respiratory Syndrome,EHD1 wt Allele,7,X,[dsyn],[gngm],C02.782.600.550.200,
ac7b5dd4-327f-465e-bfd0-437b782dbaa6,C0035203,C0007610,is with ,Respiration,Cell Nucleus,3,X,[phsf],[celc],G09.772.705,A11.284.430.106;A11.284.430.214.190.875.117
e631d8cf-9a1f-4ab3-bfa4-99ce19b2a4c2,C0028754,C0022709,develop COVID-19 outcome due to role of ,Obesity,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D08.811.277.656.350.350.687
e631d8cf-9a1f-4ab3-bfa4-99ce19b2a4c2,C0028754,C0022709,generally led to higher expression of ,Obesity,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D08.811.277.656.350.350.687
1a4b0bac-f85f-4495-a54d-daf9193da8f3,C0028754,C0042769,develop COVID-19 outcome due to role of ,Obesity,Virus Diseases,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02
1a4b0bac-f85f-4495-a54d-daf9193da8f3,C0028754,C0042769,develop Coronavirus Infections outcome due to role in,Obesity,Virus Diseases,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02
f54264cb-0b31-4f9a-b6e0-6f176991843c,C0028754,COVID-19,may Contribution to,Obesity,COVID-19,7,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C000657245
c90bf009-a05d-447a-bd39-dcca3b61a7ba,C0022709,C0017337,is regulated in human cells by ,Peptidyl-Dipeptidase A,Genes,6,X,[aapp/enzy/imft],[gngm],D08.811.277.656.350.350.687,G05.360.340.024.340
ef9df517-ee0e-4264-9538-fa8b3d94db9f,C0022709,C0042774,decreased ,Peptidyl-Dipeptidase A,Virus Replication,3,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,G06.920.925
d574b464-6e69-4bce-ac1b-e05eab393613,C0022709,C1423053,decreased ,Peptidyl-Dipeptidase A,TAS2R13 gene,3,X,[aapp/enzy/imft],[gngm],D08.811.277.656.350.350.687,
9b981678-cea4-4a74-911e-675495ee1a9f,C0206131,C0017337, includes ,Adipocytes,Genes,6,X,[cell],[gngm],A11.329.114,G05.360.340.024.340
47b60455-d355-435d-8768-1c70505d8243,C0017337,C0086418,expressed in ,Genes,Homo sapiens,6,X,[gngm],[humn],G05.360.340.024.340,B01.050.150.900.649.313.988.400.112.400.400
5358f8ca-1d30-4a35-a1ae-9c66ef7ea1ae,C0017337,C0206131,expressed in ,Genes,Adipocytes,3,X,[gngm],[cell],G05.360.340.024.340,A11.329.114
9106f52d-5bd4-4a87-910d-c53bbc7c5af3,C0035668,C0017337,revealed ,RNA,Genes,9,X,[nnon],[gngm],D13.444.735,G05.360.340.024.340
9106f52d-5bd4-4a87-910d-c53bbc7c5af3,C0035668,C0017337,identified ,RNA,Genes,4,X,[nnon],[gngm],D13.444.735,G05.360.340.024.340
167d4540-4495-4721-a558-5df96b457812,C0035668,C0086418,revealed ,RNA,Homo sapiens,6,X,[nnon],[humn],D13.444.735,B01.050.150.900.649.313.988.400.112.400.400
89a9575e-e2fe-480a-8e2c-759aecb6d801,C0035668,C0206131,revealed ,RNA,Adipocytes,3,X,[nnon],[cell],D13.444.735,A11.329.114
a3011288-e5be-480d-8bc7-7570da1c3e55,C1426803,3-fold,increased by 3-fold ,FNDC5 gene,3-fold,3,X,[gngm],????,,????
6f34078b-7e23-4136-94a3-23ac722e7481,C1426803,C1423053,increased by 3-fold ,FNDC5 gene,TAS2R13 gene,3,X,[gngm],[gngm],,
4a7f8686-fe18-47b7-a132-ad2c84fb77c5,C1426803,C1519595,increased by 3-fold ,FNDC5 gene,Transcript,3,X,[gngm],[nnon],,
c36c6f00-a6d6-4e3f-ad1f-568e6dfa3eee,C0042769,C0001527,is in ,Virus Diseases,Adipose tissue,2,X,[dsyn],[tisu],C02,A10.165.114
edb2ee3c-5482-49e6-b293-ece1395e10e6,C0003504,C0206419,identify ,Aortic Valve Insufficiency,Genus: Coronavirus,1,X,[dsyn],[virs],C14.280.484.095,B04.820.504.540.150
0718bc5a-422e-4098-95c5-681b66676a73,studys,COVID-19,apply morphoproteomics from ,studys,COVID-19,2,X,????,[virs],????,C000657245
386ff2b3-02f0-47fc-a8e6-478c8ca21398,PD-1,C1570089,abundance of intra-alveolar interstitial ,PD-1,CD163 protein human,1,X,????,[aapp/imft],????,
88bba033-1255-4608-b7af-1a7b8879d9b6,PD-1,C0041484,nuclear expression of ,PD-1,MONOPHENOL MONOOXYGENASE,1,X,????,[aapp/enzy],????,D08.811.682.690.708.125.500
fe4275a2-c30b-496a-a639-b862e5c946de,PD-1,C0253050,nuclear expression of p ,PD-1,Stat3 protein,1,X,????,[aapp/bacs],????,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
5fe049f3-7207-4ea1-b261-66f2043f6155,PD-1,C4322733,absence of ,PD-1,CD56+ NK cell,2,X,????,[cell],????,
fbfdfd83-28ad-431d-b669-c5b94a71ea6d,PD-1,C0242629,relative paucity of ,PD-1,CD8-Positive T-Lymphocytes,2,X,????,[cell],????,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
7b7122ab-c4f3-4201-987c-7a03f283bc4b,C2985566,COVID-19,could address ,Targeted Therapy,COVID-19,2,X,[topp],[virs],,C000657245
e9c95e93-dc58-4c03-8f35-a4c25d14e5ee,C2985566,C0032285,could address ,Targeted Therapy,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
5278286d-53b8-4059-80b8-6d4f122983a1,C2985566,C0242656,prevent its ,Targeted Therapy,Disease Progression,2,X,[topp],[patf],,C23.550.291.656
7c171006-84db-476a-9e16-9224287c5174,C0278347,C0815172,radiologic patient characteristics of 1 568,Transfusion of plasma,patient characteristics,2,X,[topp],[clna],,
4dabd379-22d4-48b9-8647-0d469d23ccc7,C0028754,renin,is associated with dysregulated renin ,Obesity,renin,2,X,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,????
526ada42-4553-4c6a-a5ec-e8f7d22f597e,C0028754,C0003018,is associated with dysregulated renin ,Obesity,Angiotensins,2,X,[dsyn],[aapp/bacs/phsu],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
0906430a-1e60-4f09-931d-cba706046453,C0028754,C0004457,is associated with dysregulated renin ,Obesity,Axis vertebra,2,X,[dsyn],[bpoc],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,A02.835.232.834.151.383
de1b2c46-4e80-4b80-8026-4295ff74fb79,CoV2,C1167622,uses membrane ,CoV2,Binding (Molecular Function),1,X,????,[moft],????,
308e5e83-0b3c-40ae-a5bc-a4be58d2e87a,CoV2,C0022709,uses membrane-bound form of ,CoV2,Peptidyl-Dipeptidase A,5,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
bbc36601-3196-4b33-acb0-45e58f0f25de,CoV2,C1514760,uses membrane form as,CoV2,Receptor Cell,3,X,????,[cell],????,
464afc93-9d37-4a82-bff7-11440db8cadd,CoV2,C0007634,uses membrane form as,CoV2,Cells,1,X,????,[cell],????,A11
6cfadb00-6824-4a9b-9103-7ba1ca56be41,C0022709,C1325584,is protective lateral element of,Peptidyl-Dipeptidase A,lateral element,4,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
3f600011-c6c9-4fda-903d-9f8ac7a91eda,C0022709,C0003018,is protective lateral element of,Peptidyl-Dipeptidase A,Angiotensins,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
2882256d-3019-4807-89db-4c3fbf776020,C0022709,CoV2,is downregulated after CoV2 ,Peptidyl-Dipeptidase A,CoV2,2,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
2882256d-3019-4807-89db-4c3fbf776020,C0022709,CoV2,enable CoV2,Peptidyl-Dipeptidase A,CoV2,1,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
952af649-79e2-49d4-9b85-726bf79b66f3,C0003018,C0028754,could could link between ,Angiotensins,Obesity,2,X,[aapp/bacs/phsu],[dsyn],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
5fe8c68a-b526-47ab-a486-2d3b6ed7451d,C0004457,C0028754,could could link between ,Axis vertebra,Obesity,2,X,[bpoc],[dsyn],A02.835.232.834.151.383,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
039f27a5-ece1-4b98-a971-618c90576804,C1145670,C0206419,is with ,Respiratory Failure,Genus: Coronavirus,4,X,[dsyn],[virs],C08.618.846,B04.820.504.540.150
86e0f3bf-27b6-4346-ad34-32ccd41ddc46,DCPEM,C1319405,initiated surveillance program in close collaboration with Department of ,DCPEM,Clinical microbiology,1,X,????,[bmod],????,
1754e4e7-07d8-415f-9917-a1ef891143f6,DOH,C1319405,initiated surveillance program in close collaboration with Department of ,DOH,Clinical microbiology,3,X,????,[bmod],????,
218d4aa9-db1a-4c6c-9b47-2b1e06b92717,COVID-19,C0221423,can cause severe respiratory ,COVID-19,Illness (finding),1,X,[virs],[sosy],C000657245,
218d4aa9-db1a-4c6c-9b47-2b1e06b92717,COVID-19,C0221423,is new clinical syndrome from upper respiratory ,COVID-19,Illness (finding),1,X,[virs],[sosy],C000657245,
218d4aa9-db1a-4c6c-9b47-2b1e06b92717,COVID-19,C0221423,is new syndrome from mild upper respiratory ,COVID-19,Illness (finding),1,X,[virs],[sosy],C000657245,
23f5a603-98d7-4adb-a94c-0db9dcb8d8cd,C0319157,C0042542,is in ,AS virus,Vero Cells,1,X,[virs],[cell],,A11.251.210.955;A11.436.955
3fb468d0-690c-4a33-9812-0157f57bc8e5,C0319157,C0007537,is in ,AS virus,Cefaclor,1,X,[virs],[antb/orch],,D02.065.589.099.249.200.155;D02.886.665.074.200.155;D03.633.100.300.249.200.155
0d91b2e0-f75c-4465-bd62-f7aea2ea96dc,C0003320,C0319157,propagating ,Antigens,AS virus,1,X,[imft],[virs],D23.050,
9ed00f69-de90-452e-89e5-2a50744e24c3,C1511790,C1550100,is in ,Detection,Specimen Type - Serum,2,X,[topp],[bdsu],,
3ed30198-27a1-46a4-baf5-805b780824f5,C1511790,C0086418,is in ,Detection,Homo sapiens,1,X,[topp],[humn],,B01.050.150.900.649.313.988.400.112.400.400
e80c0fd5-1fbc-45b3-8cc8-7d7c116e0e9d,C0450254,C0206750,due to Coronavirus Infections is,Pathogenic organism,Coronavirus Infections,2,X,[orgm],[dsyn],,C02.782.600.550.200
e80c0fd5-1fbc-45b3-8cc8-7d7c116e0e9d,C0450254,C0206750,has has recently recognized as cause of ,Pathogenic organism,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
63e35f9e-bf7b-4193-9dd0-a7b976f6e9a8,C0063034,C2745965,guarantee ,huperzine B,Emergencies [Disease/Finding],5,X,[orch/phsu],[patf],x.x.x.x,C23.550.291.781;N06.230.100.083;N06.850.376
9ce3bf04-f3df-4fdc-aef7-f565f57ca314,C0063034,C0038897,guarantee ,huperzine B,Cardiovascular Surgical Procedures,5,X,[orch/phsu],[topp],x.x.x.x,E04.100
e4ced91d-a786-4a14-a817-9b31e979bfb0,C0063034,C2188405,guarantee ,huperzine B,urgent Operation,5,X,[orch/phsu],[topp],x.x.x.x,
ead2006d-b866-4aba-9382-8755def7c7d8,C0063034,C0018787,efficiently safeguards access to ,huperzine B,Heart,9,X,[orch/phsu],[bpoc],x.x.x.x,A07.541
2d5db4bf-64fe-485b-a644-2c4f24f0c740,C0206422,C0206750,has has recognized as cause of ,Human coronavirus,Coronavirus Infections,2,X,[virs],[dsyn],,C02.782.600.550.200
2d5db4bf-64fe-485b-a644-2c4f24f0c740,C0206422,C0206750,latest version of be ,Human coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
4ce86a4a-7ee5-4569-a3c9-ddf78314170b,C0014507,C0007222,suggest association between ,Epidemiology,Cardiovascular Diseases,2,X,[bmod],[dsyn],H02.403.720.500,C14
b12cbf4e-9b04-4dde-a53f-8c92d4d15905,C0014507,C0683325,suggest association between ,Epidemiology,clinical aspects,2,X,[bmod],[clna],H02.403.720.500,
34cbc5af-c4bb-454c-99f3-39a28e565ea7,C0018787,C0007222,outcome for patients with underlying ,Heart,Cardiovascular Diseases,1,X,[bpoc],[dsyn],A07.541,C14
706f2449-64df-498c-b371-000ceb53d4dc,C1853193,C1290884,followed by ,Recurrent skin infections,Inflammatory disorder,1,X,[dsyn],[dsyn],,
eb632b81-607b-45f4-ad5d-b7b42ba95476,C1947933,C0037274,improves diagnostic accuracy in ,care activity,Dermatologic disorders,1,X,[acty],[dsyn],,C17.800
ba5a891f-e85d-461f-9a2a-05677e9a4fd9,C4321457,C0037274,improves diagnostic accuracy in ,Examination,Dermatologic disorders,1,X,[acty],[dsyn],,C17.800
4a1362d3-055b-4565-81b2-6e16a4d0045b,C0206750,C0085593,presenting with ,Coronavirus Infections,Chills,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.208
126baa58-e1e7-412c-87ca-3c6d45598fd5,C1829939,C0037090,is with ,{Non-patient},Signs and Symptoms Respiratory,2,X,[clna],[sosy],,C23.888.852
a74bb732-93ae-4ebe-95e8-8cf89231e956,C1829939,C0206750,have ,{Non-patient},Coronavirus Infections,2,X,[clna],[dsyn],,C02.782.600.550.200
84e87402-309c-470b-8c6b-5a804b2324d6,C0277554,C0184893,required ,primary disorders,Emergency operation,2,X,[dsyn],[topp],,
5755278c-c564-4863-adf1-0b3128531c72,C0883468,CD3,numbers of CD3,CD16+CD56+ cell,CD3,4,X,[cell],????,,????
5f318bc4-a5ed-43b4-81ca-1e8fef543b26,C2709199,CD3,numbers of CD3,Natural killer,CD3,2,X,[cell],????,,????
1543e119-e05f-401a-ad11-21ed823e695a,C0020639,C0005778,of presence is abnormal ,Hypoproteinemia,Blood coagulation,2,X,[dsyn],[ortf],C15.378.147.607,G09.188.390.150
004b295c-b262-4f1f-b1ef-d2e4e72e114b,C0020625,C0005778,of presence is abnormal ,Hyponatremia,Blood coagulation,2,X,[dsyn],[ortf],C18.452.950.620,G09.188.390.150
7f1775cf-d999-4f65-9969-1803c53d5d43,C0020598,C0005778,of presence is abnormal ,Hypocalcemia,Blood coagulation,2,X,[dsyn],[ortf],C18.452.174.509;C18.452.950.509,G09.188.390.150
851ba594-dc22-4756-9d1e-6b1491434f71,C0020639,C0031843,of presence is abnormal ,Hypoproteinemia,physiological aspects,2,X,[dsyn],[phsf],C15.378.147.607,x.x.x.x
68d6541e-81cc-4c99-9e9e-5f1c6885fdbf,C0020625,C0031843,of presence is abnormal ,Hyponatremia,physiological aspects,2,X,[dsyn],[phsf],C18.452.950.620,x.x.x.x
fea4c7ce-9305-4f75-b1ed-416960608c03,C0020598,C0031843,of presence is abnormal ,Hypocalcemia,physiological aspects,2,X,[dsyn],[phsf],C18.452.174.509;C18.452.950.509,x.x.x.x
e34d80f9-5b5e-45ac-9637-ada318eaced1,C1856053,C0206750,included attitudes toward ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
e34d80f9-5b5e-45ac-9637-ada318eaced1,C1856053,C0206750,is in World Health Organization ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
e34d80f9-5b5e-45ac-9637-ada318eaced1,C1856053,C0206750,established ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
e34d80f9-5b5e-45ac-9637-ada318eaced1,C1856053,C0206750,2020 during ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
e34d80f9-5b5e-45ac-9637-ada318eaced1,C1856053,C0206750,lowered compound growth rate of ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
7565792d-9819-4451-b187-7192a16af8c5,C1422064,C0034800,is in conveyor ,ACE2 gene,Receptors Cell Surface,4,X,[gngm],[aapp/rcpt],,D12.776.543.750
7e560d2c-bc09-4e9c-a999-7faad788e9c0,C0004096,C0206750,constitutes risk factor for ,Asthma,Coronavirus Infections,4,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C02.782.600.550.200
7e560d2c-bc09-4e9c-a999-7faad788e9c0,C0004096,C0206750,is in 11/46 children hospitalized for ,Asthma,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C02.782.600.550.200
019521fb-5a57-4f70-b1c7-fd863a778ed9,C1175743,C0679381,is in ,SARS coronavirus,Pediatric Disorder,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,
d8929162-5f9e-448f-8f4a-d80d3f61de88,C0679381,C1175743,in SARS coronavirus is,Pediatric Disorder,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
1da2c775-92f2-4984-84a8-a4793171b993,C1155266,C0035243,occurs in addition to ,inflammatory response,Respiratory Tract Infections,3,X,[patf],[dsyn],,C01.539.739;C08.730
a63df19e-9ba8-4e62-aa87-42a6fad5295f,C1155266,C0005779,leads to ,inflammatory response,Blood Coagulation Disorders,3,X,[patf],[dsyn],,C15.378.100
296494df-a89d-42b9-bb4f-67e857a15baa,C0242781,C1708476,was documented before ,disease transmission,Implementation,1,X,[patf],[acty],N06.850.310,
a9c7c704-a0aa-457d-8661-da65c3320cb0,C1999230,C0020405,importance of rigorous ,Providing (action),Hygiene,1,X,[acty],[bmod],,E02.547;N06.850.670
2e54c44b-156b-4e69-aa05-ee0d98f8a03f,PWH,C0005516,had higher levels of ,PWH,Biological Markers,1,X,????,[clna],????,D23.101
e488ff96-5120-47d7-9ba5-4ab5c7a57b21,PWH,COVID-19,remain at ,PWH,COVID-19,1,X,????,[virs],????,C000657245
c0734a6e-0740-4787-9422-743d831af2a3,C1707455,C1742865,is with positive control ,Comparison,TMPRSS2 protein human,1,X,[acty],[aapp/enzy],,x.x.x.x
013e1870-5965-42bc-8317-5cde8f0fdcad,C1742865,C0385178,as compound is ,TMPRSS2 protein human,benzquercin,1,X,[aapp/enzy],[orch/phsu],x.x.x.x,x.x.x.x
25af2c44-bf92-4aaa-a188-f2148219018d,C0243052,C1175743, includes ,Virus Physiological Phenomena,SARS coronavirus,1,X,[npop],[virs],G06.920,B04.820.504.540.150.113.937
62230b9f-991f-4507-92b2-635cfba83026,C0243052,C0086418, includes ,Virus Physiological Phenomena,Homo sapiens,1,X,[npop],[humn],G06.920,B01.050.150.900.649.313.988.400.112.400.400
683f1cf1-4a45-42e7-b996-cead8a5db706,C0061751,C0243052,has shown ,Glycyrrhizic Acid,Virus Physiological Phenomena,5,X,[orch/phsu],[npop],D02.455.849.919.530.466,G06.920
e8e3c208-3be2-469f-9ec8-339e4836b70c,C0061751,C1175743,has shown ,Glycyrrhizic Acid,SARS coronavirus,2,X,[orch/phsu],[virs],D02.455.849.919.530.466,B04.820.504.540.150.113.937
e8e3c208-3be2-469f-9ec8-339e4836b70c,C0061751,C1175743,good candidate tested against ,Glycyrrhizic Acid,SARS coronavirus,8,X,[orch/phsu],[virs],D02.455.849.919.530.466,B04.820.504.540.150.113.937
d43263c2-da93-4b53-9c1d-9a52a998895a,C0061751,C0086418,has shown ,Glycyrrhizic Acid,Homo sapiens,2,X,[orch/phsu],[humn],D02.455.849.919.530.466,B01.050.150.900.649.313.988.400.112.400.400
6d1dc0d8-ec58-4f5a-9706-c087080d28ca,C0061751,C0520481,is non-hemolytic ,Glycyrrhizic Acid,Saponin,2,X,[orch/phsu],[orch],D02.455.849.919.530.466,D09.408.782
606ceb72-78b2-43df-998d-bb15b64b62b1,C0061751,C0008377,induces ,Glycyrrhizic Acid,Cholesterol,2,X,[orch/phsu],[bacs/orch],D02.455.849.919.530.466,D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208
ba91e31c-324a-4a9a-a3bc-468c51ae01db,C0061751,C1167250,induces ,Glycyrrhizic Acid,lipid raft,2,X,[orch/phsu],[celc],D02.455.849.919.530.466,
93c74239-51a9-47db-963a-a24fb419ba11,C0061751,C0596901,induces disorganization At ,Glycyrrhizic Acid,Membrane,2,X,[orch/phsu],[celc],D02.455.849.919.530.466,A10.615
dffd7912-ea90-4683-8ff2-61f7c70856bc,C0061751,C0019534,can CD40LG wt Allele,Glycyrrhizic Acid,High Mobility Group Proteins,2,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.660.235.400;D12.776.664.235.400
dffd7912-ea90-4683-8ff2-61f7c70856bc,C0061751,C0019534,can trap ,Glycyrrhizic Acid,High Mobility Group Proteins,2,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.660.235.400;D12.776.664.235.400
5395aa0b-b42c-4382-a325-9476a3a80bef,C0061751,C3891560,thus blocks ,Glycyrrhizic Acid,Alarmins,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D23.035
5395aa0b-b42c-4382-a325-9476a3a80bef,C0061751,C3891560,thus Obstruction,Glycyrrhizic Acid,Alarmins,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D23.035
c45e722b-a7c9-4732-a29d-3481d94313d7,C0061751,C0019796,thus blocks ,Glycyrrhizic Acid,HMGB1 Protein,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.260.356.300;D12.776.660.235.400.600.300;D12.776.664.235.400.600.300
c45e722b-a7c9-4732-a29d-3481d94313d7,C0061751,C0019796,thus Obstruction,Glycyrrhizic Acid,HMGB1 Protein,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.260.356.300;D12.776.660.235.400.600.300;D12.776.664.235.400.600.300
ac4a7b77-d217-4ff2-93f3-b62358429c90,C3540027,C0008269,is with ,Adrenergic and dopaminergic agents combinations,Chloroquine,2,X,[phsu],[orch/phsu],,D03.633.100.810.050.180
6945d6de-ef7d-498e-8f4e-2ba56234da3a,COVID-19,C1947933,opportunity for reformation of disabilities ,COVID-19,care activity,2,X,[virs],[acty],C000657245,
6945d6de-ef7d-498e-8f4e-2ba56234da3a,COVID-19,C1947933,has dramatically changed practice in favor of ,COVID-19,care activity,1,X,[virs],[acty],C000657245,
6945d6de-ef7d-498e-8f4e-2ba56234da3a,COVID-19,C1947933,presented for ,COVID-19,care activity,1,X,[virs],[acty],C000657245,
4cc60817-6dd3-4875-80aa-7e50a0f84407,C1999230,C1947933,opportunity for reformation of disabilities ,Providing (action),care activity,2,X,[acty],[acty],,
4cc60817-6dd3-4875-80aa-7e50a0f84407,C1999230,C1947933,is essential ,Providing (action),care activity,2,X,[acty],[acty],,
b533e3ce-a2e2-4617-9919-26a1261712d1,C0020517,COVID-19,is with ,Hypersensitivity,COVID-19,2,X,[patf],[virs],C20.543,C000657245
04cced13-86f7-4399-bf07-15eb97080e8b,COVID-19,C0278996,has altered healthcare environment for management ,COVID-19,Malignant Head and Neck Neoplasm,4,X,[virs],[neop],C000657245,
2156df6c-f554-443f-85bc-663d065f143b,C0206419,C0035920,is ,Genus: Coronavirus,Rubella,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.930.700.700
9cf83f59-cc50-4c2d-9e2a-e3e95293763b,C0012634,C0035920,is ,Disease,Rubella,1,X,[dsyn],[dsyn],C23.550.288,C02.782.930.700.700
723dcdca-31f8-4985-84b1-1c66ffdfd6d4,C0237820,C1628327,is ,Recovery - action,Zoonotic pathogen,1,X,[acty],[orgm],,
6f9d9920-6daa-4e90-ae67-0fa33e0bd15c,C0237820,C3694279,is ,Recovery - action,Middle East Respiratory Syndrome,1,X,[acty],[dsyn],,C02.782.600.550.200
c9f460de-c7e8-4430-8639-f8e191f24ab9,C0025241,C1504389,is with autologous ,Melphalan,Stem cell transplant,1,X,[aapp/phsu],[topp],D02.455.526.728.650.594;D12.125.072.050.685.500,E02.095.147.500.500;E04.936.225.687
5a8c894c-f0f2-4ecc-9228-902db0deff32,C0034019,C0719214,is in ,public health medicine (field),century,1,X,[bmod],[phsu/vita],H02.403.720;N01.400.550;N06.850,
4c9bee6a-b1e2-413d-9f89-f6550b2a2749,C0341073,COVID-19,is useful for ,Percutaneous cholecystostomy,COVID-19,1,X,[topp],[virs],,C000657245
3d21d215-9f1a-4f81-9cad-d8f4b5e5bc23,C0341073,C0149520,is useful for ,Percutaneous cholecystostomy,Acute Cholecystitis,1,X,[topp],[dsyn],,C06.130.564.263.500
a10ec20c-1b3a-47ed-a0e6-fe84dcd72a4b,C0149520,COVID-19,is in ,Acute Cholecystitis,COVID-19,1,X,[dsyn],[virs],C06.130.564.263.500,C000657245
bff75357-2655-4afa-9726-68247e881bed,dataset,C0028630,determine separately ,dataset,Nucleotides,1,X,????,[nnon],????,D09.408.620;D13.695
e83c9b09-9ca0-44ca-9c5a-1922b5c8b462,dataset,C0026882,determine separately ,dataset,Mutation,1,X,????,[genf],????,G05.365.590
e83c9b09-9ca0-44ca-9c5a-1922b5c8b462,dataset,C0026882,determine codon ,dataset,Mutation,1,X,????,[genf],????,G05.365.590
05d2bcfa-f1f2-4ab2-9354-114dbb1ddfcd,C0040034,C1175743,were significantly more common in ,Thrombocytopenia,SARS coronavirus,4,X,[dsyn],[virs],C15.378.140.855,B04.820.504.540.150.113.937
3420afd4-e379-42a7-bdad-a677990e9d76,et,C0018943,conducted meta-analysis In recent paper published in Journal of ,et,Hematology (discipline),2,X,????,[bmod],????,H02.403.429.445
6ac9d4b3-f63d-41c0-9d02-fe2fda001447,al,C0018943,conducted meta-analysis In recent paper published in Journal of ,al,Hematology (discipline),2,X,????,[bmod],????,H02.403.429.445
072fa36b-5a23-4487-ab9c-14292dbb0abd,C0235029,C0038454,include ,neurological complication,Cerebrovascular accident,2,X,[patf],[dsyn],,C10.228.140.300.775;C14.907.253.855
aa7207f0-a223-414d-9fa7-449ff2baf47d,C0235029,C0009450,associated with ,neurological complication,Communicable Diseases,2,X,[patf],[dsyn],,C01.539.221
2d4d6c89-620b-4124-8f2d-4fa684e16d0f,C0235029,C1175743,associated with ,neurological complication,SARS coronavirus,2,X,[patf],[virs],,B04.820.504.540.150.113.937
d70969a4-b916-4100-9ea3-bc6074261d15,C0038454,C1155266,may result from dysregulated ,Cerebrovascular accident,inflammatory response,2,X,[dsyn],[patf],C10.228.140.300.775;C14.907.253.855,
fbd4ea64-1d73-4c9a-94b4-0cfdd7bcdcfe,C0038454,C0009450,may result from dysregulated ,Cerebrovascular accident,Communicable Diseases,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C01.539.221
fbd4ea64-1d73-4c9a-94b4-0cfdd7bcdcfe,C0038454,C0009450,should closely Assessed lung apices,Cerebrovascular accident,Communicable Diseases,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C01.539.221
ba519872-85c8-438a-a787-aa8a8c4a7b46,C1276305,C0206419,is In early stage ,Curative - procedure intent,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
3a415283-e275-4ddb-8017-e4a06b4a597f,C0012634,C0037090,causes Signs and Symptoms Respiratory Illness (finding) with,Disease,Signs and Symptoms Respiratory,4,X,[dsyn],[sosy],C23.550.288,C23.888.852
79f5b3b5-1d8b-40b4-b6a9-79a9b6332666,C0012634,C0850149,causes Signs and Symptoms Respiratory Illness (finding) with,Disease,Dry cough,2,X,[dsyn],[sosy],C23.550.288,
8810f9de-916b-4e0e-ac22-486958b9017c,C0022709,C0225336,is expressed in ,Peptidyl-Dipeptidase A,Endothelial Cells,3,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436.275
ea46b4a3-8436-400d-a99f-d8a80b5269e8,C0022709,C0162772,could could implicated in production of ,Peptidyl-Dipeptidase A,Reactive Oxygen Species,3,X,[aapp/enzy/imft],[bacs/elii],D08.811.277.656.350.350.687,D01.339.431;D01.650.775
4071a550-fa4f-468b-8592-f371d0b440ff,C0022709,C0856169,could could implicated in production of ,Peptidyl-Dipeptidase A,endothelial dysfunction,3,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,
f5b43e1b-1bf6-4ed4-a4ab-31a20046be7f,C0751956,C0206419,may have undiagnosed ,Acute Cerebrovascular Accidents,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150
d1fa7422-624b-460b-b980-8cefad4d18a2,C0206419,C0275522,can cause spectrum of presentations ranging from ,Genus: Coronavirus,Asymptomatic Infections,5,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.187.500
92f9baac-dca0-4e05-ba8f-a89855bee932,C0949880,C0041912,typically cause mild ,Human coronavirus 229E,Upper Respiratory Infections,5,X,[virs],[dsyn],B04.820.504.540.150.075.750,C01.539.739;C08.730
19613bcc-50e4-410e-94df-f9ed452ebbf0,C1412384,C0265267,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects in,AMH gene,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,1,X,[gngm],[dsyn],,x.x.x.x
0104e007-600b-4874-a24a-fc15cec8de28,C0054943,C0030755,Academy of ,ALANINE AMINOPEPTIDASE,Pediatrics,5,X,[aapp/enzy/imft],[bmod],D08.811.277.656.350.100.160;D08.811.277.656.350.555.100;D08.811.277.656.675.555.100;D23.050.301.264.894.113;D23.101.100.894.113,H02.403.670
e4f27361-7135-4103-adeb-9757f29417e6,C0034019,C0699680,should report country-specific ,public health medicine (field),Metric,1,X,[bmod],[orch/phsu],H02.403.720;N01.400.550;N06.850,D02.640.672.500;D03.383.129.308.658.500
20d7d6b0-06a6-4f1d-a061-3d2b0c11f6fb,C0086418,C0035804,is in ,Homo sapiens,Rodent,2,X,[humn],[mamm],B01.050.150.900.649.313.988.400.112.400.400,B01.050.150.900.649.313.992
27b6cf80-1d05-4ac3-a42c-f9ce09d09c28,C0004626,C1521863,were conducted in pre-antibiotic ,Pneumonia Bacterial,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C01.252.620;C08.381.677.540;C08.730.610.540,x.x.x.x
53447754-02e4-41d0-95e6-0332c55f5140,C1518010,C0029408,is when applied to subacute ,Low Dose Radiation Therapy,Degenerative polyarthritis,4,X,[topp],[dsyn],,C05.550.114.606;C05.799.613
9fb2a761-6a0c-4879-b054-b5d1a2866da9,C1518010,C0024109,produces effects in inflamed ,Low Dose Radiation Therapy,Lung,2,X,[topp],[bpoc],,A04.411
ef620036-ae38-4632-b544-405ddd7facf8,C1518010,COVID-19,exacerbates ,Low Dose Radiation Therapy,COVID-19,2,X,[topp],[virs],,C000657245
26eb71da-f589-4238-ab1d-c8ef330e4b22,COVID-19,C0042769,is new ,COVID-19,Virus Diseases,1,X,[virs],[dsyn],C000657245,C02
26eb71da-f589-4238-ab1d-c8ef330e4b22,COVID-19,C0042769,is due to mainly ,COVID-19,Virus Diseases,1,X,[virs],[dsyn],C000657245,C02
bd03ac34-2be6-4f30-bffb-1ac03f5cb6c0,COVID-19,C0458827,can affect ,COVID-19,Airway structure,1,X,[virs],[bpoc],C000657245,
947e6687-6f2b-4389-980a-44cacea7c44c,COVID-19,C0024109,can affect ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
947e6687-6f2b-4389-980a-44cacea7c44c,COVID-19,C0024109,cause severe ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
947e6687-6f2b-4389-980a-44cacea7c44c,COVID-19,C0024109,is new clinical syndrome from upper respiratory ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
947e6687-6f2b-4389-980a-44cacea7c44c,COVID-19,C0024109,aggravated in ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
947e6687-6f2b-4389-980a-44cacea7c44c,COVID-19,C0024109,directly targets ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
d322933d-444a-429d-a79b-9ac8c0b1971a,C0040300,C0024109, includes ,Body tissue,Lung,6,X,[tisu],[bpoc],A10,A04.411
cbc39e1b-b464-4804-b0a5-9cbdc502f25b,C0040300,C0022646, includes ,Body tissue,Kidney,6,X,[tisu],[bpoc],A10,A05.810.453
fe98ab0f-910d-4eab-9d6e-1ae45f9c02d3,C0040300,C0021852, includes ,Body tissue,Intestines Small,6,X,[tisu],[bpoc],A10,A03.556.124.684
1c2fdbdf-fe0d-4b15-a3eb-85470f09680b,C0040300,C0018787, includes ,Body tissue,Heart,6,X,[tisu],[bpoc],A10,A07.541
f7a078a0-fd05-4fb8-86a2-42947b7e1643,C0022709,C0040300,were widely disturbed among ,Peptidyl-Dipeptidase A,Body tissue,7,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,A10
e11189b8-2f9a-4204-b487-b1dbd4499db4,C0597357,C0040300,were widely disturbed among ,receptor,Body tissue,9,X,[aapp/rcpt],[tisu],,A10
e11189b8-2f9a-4204-b487-b1dbd4499db4,C0597357,C0040300,is present on ,receptor,Body tissue,1,X,[aapp/rcpt],[tisu],,A10
e11189b8-2f9a-4204-b487-b1dbd4499db4,C0597357,C0040300,is widely expressed in numerous ,receptor,Body tissue,1,X,[aapp/rcpt],[tisu],,A10
ffb1543f-6fb9-45a0-834f-53e05a9482bd,C0022709,C0022646,were widely disturbed among ,Peptidyl-Dipeptidase A,Kidney,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A05.810.453
ffb1543f-6fb9-45a0-834f-53e05a9482bd,C0022709,C0022646,effect on ,Peptidyl-Dipeptidase A,Kidney,6,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A05.810.453
26986c3f-c160-4a4c-9835-2129409b4d66,C0597357,C0022646,were widely disturbed among ,receptor,Kidney,6,X,[aapp/rcpt],[bpoc],,A05.810.453
26986c3f-c160-4a4c-9835-2129409b4d66,C0597357,C0022646,is present on ,receptor,Kidney,1,X,[aapp/rcpt],[bpoc],,A05.810.453
7546ac3c-19b4-46f4-aaa3-6878d9b3179b,C0022709,C0021852,were widely disturbed among ,Peptidyl-Dipeptidase A,Intestines Small,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A03.556.124.684
fa1bfa5e-800a-4aad-ad63-d1ad3f339f17,C0597357,C0021852,were widely disturbed among ,receptor,Intestines Small,6,X,[aapp/rcpt],[bpoc],,A03.556.124.684
f64608e3-1c48-42de-9b27-df299b5473fa,C0597357,C0018787,were widely disturbed among ,receptor,Heart,6,X,[aapp/rcpt],[bpoc],,A07.541
f64608e3-1c48-42de-9b27-df299b5473fa,C0597357,C0018787,is present on ,receptor,Heart,1,X,[aapp/rcpt],[bpoc],,A07.541
e8071f80-16bb-4585-b665-34fb2f90dd14,C0597357,COVID-19,considered ,receptor,COVID-19,3,X,[aapp/rcpt],[virs],,C000657245
dfcf0c47-1e91-4d8b-96b3-0c8e6616744b,C0127400,NF-B,Up-Regulation (Physiology) of NF-B,Mediator brand of benfluorex hydrochloride,NF-B,3,X,[orch/phsu],????,,????
b3ec0890-d237-43cb-b54f-d3243f84efd2,C0127400,C1704259,Up-Regulation (Physiology) of NF-B,Mediator brand of benfluorex hydrochloride,Biochemical Pathway,3,X,[orch/phsu],[moft],,
e680d0f6-0357-4a9c-9c60-466d8c3105ae,C0118522,C0432616,was TRANSCRIPTION FACTOR play,GA-Binding Protein Transcription Factor,Blood group antibody A,6,X,[aapp/bacs],[aapp/imft],D12.776.260.615.249;D12.776.930.618.249,
285bb755-a12b-487f-a406-fcd3e9881b86,C0118522,C0085403,was TRANSCRIPTION FACTOR play,GA-Binding Protein Transcription Factor,Oxidants,3,X,[aapp/bacs],[chvf],D12.776.260.615.249;D12.776.930.618.249,D27.720.642;D27.888.569.540
1835bf2b-29b6-475d-ba5c-e91195cc212e,C0118522,C0014442,was TRANSCRIPTION FACTOR play,GA-Binding Protein Transcription Factor,Enzymes,2,X,[aapp/bacs],[aapp/enzy],D12.776.260.615.249;D12.776.930.618.249,D08.811
74b2436d-309b-4629-b4d3-2da758f1075a,C0118522,C0040648,was ,GA-Binding Protein Transcription Factor,TRANSCRIPTION FACTOR,6,X,[aapp/bacs],[aapp/bacs],D12.776.260.615.249;D12.776.930.618.249,D12.776.930
18c8993c-f1f3-4b88-975d-e593dd160844,C0432616,C0085403,is in generation of ,Blood group antibody A,Oxidants,3,X,[aapp/imft],[chvf],,D27.720.642;D27.888.569.540
c44563d1-89f5-4eb6-b64f-275f20b0a96f,C0432616,C0014442,is in generation of ,Blood group antibody A,Enzymes,2,X,[aapp/imft],[aapp/enzy],,D08.811
6cd6b5bb-0168-45d5-928d-731943b43398,C0127400,C1310468, includes ,Mediator brand of benfluorex hydrochloride,DDX58 protein human,2,X,[orch/phsu],[aapp/enzy],,x.x.x.x
fc472bef-5c72-4b22-a395-2d16f6d6eebd,TRMPSS2,C0085403,induce anti ,TRMPSS2,Oxidants,1,X,????,[chvf],????,D27.720.642;D27.888.569.540
9d17f8f5-9ff0-4fad-9214-2f85f8857c72,TRMPSS2,C0014442,induce anti ,TRMPSS2,Enzymes,1,X,????,[aapp/enzy],????,D08.811
c52e0049-764d-4b13-910e-b7df3612994d,TRMPSS2,C1160700,induce ,TRMPSS2,viral gene expression,2,X,????,[celf],????,
791b1a92-48be-473e-97e4-51e34954ccb9,TRMPSS2,C0127400,induce ,TRMPSS2,Mediator brand of benfluorex hydrochloride,1,X,????,[orch/phsu],????,
4095d060-5bd7-47b1-a71a-ac0abffc3361,TRMPSS2,C1310468,induce ,TRMPSS2,DDX58 protein human,1,X,????,[aapp/enzy],????,x.x.x.x
49805d6d-685e-436a-928f-c39b9a1c1a3e,TRMPSS2,C0022709,Up-Regulation (Physiology) of,TRMPSS2,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
a1822928-92a2-4872-baf6-fd66147fc5e2,C0017262,C1336763,Apoptosis Regulatory Proteins of,Gene Expression,Toll-Like Receptor Family Gene,1,X,[genf],[gngm],G05.297,
a0206cce-9784-4897-8708-6b7886eccb9e,TRMPSS2,C1564881,inhibit ,TRMPSS2,Apoptosis Regulatory Proteins,1,X,????,[aapp/bacs],????,D12.644.360.075;D12.776.476.075
526f3ad8-c2f3-4a44-a831-b70e0f3d181c,TRMPSS2,C1336763,inhibit ,TRMPSS2,Toll-Like Receptor Family Gene,1,X,????,[gngm],????,
b1848f19-f9ea-48ee-8ce1-e412d087788b,C0058218,COVID-19,is in ,dimethyl fumarate,COVID-19,3,X,[imft/orch/phsu],[virs],D02.241.081.337.302.500,C000657245
99eab2ff-21d9-4203-a439-67ead417fe3b,COVID-19,C0009528,could therefore could caused by overactivation of ,COVID-19,Complement Activation,1,X,[virs],[moft],C000657245,G12.274
d302b92a-06f7-4d34-8ab7-c56005e15454,C0302148,C0009528,could therefore could caused by overactivation of ,Blood Clot,Complement Activation,1,X,[patf],[moft],C14.907.355.830,G12.274
a2657aea-1015-4977-abb6-12fccd876a5a,C0009528,C0206750,is in ,Complement Activation,Coronavirus Infections,2,X,[moft],[dsyn],G12.274,C02.782.600.550.200
5d4a53fb-d917-49a3-aa13-2a9e6169f966,C0009498,C0005821,Activation action,Complement System Proteins,Blood Platelets,2,X,[aapp/imft],[cell],D12.776.124.486.274,A11.118.188;A15.145.229.188
e09594f2-c531-444f-a169-0f0d160da0ce,C0009498,C0005778,Activation action,Complement System Proteins,Blood coagulation,2,X,[aapp/imft],[ortf],D12.776.124.486.274,G09.188.390.150
235d48c1-96b1-4d29-8f09-3ceeb485ce31,C1452534,C3655548,is Height Kidney in,ACE protein human,Height Kidney,15,X,[aapp/bacs],[clna],x.x.x.x,
8486863b-940b-47e7-b4b0-fbe309e43c2f,C1452534,C0026809,is Height Kidney with female,ACE protein human,Mus,7,X,[aapp/bacs],[mamm],x.x.x.x,B01.050.150.900.649.313.992.635.505.500
9a4d8537-131d-4908-823a-4b4e8ac8dee0,C0574032,C1439284,reduced glomerular ,Infusion procedures,AGTR1 gene,2,X,[topp],[gngm],,
2cb78055-0fe7-4849-bcf4-4dc9e352cc64,C0574032,C1167622,reduced glomerular ,Infusion procedures,Binding (Molecular Function),2,X,[topp],[moft],,
769efd54-11a5-48a2-b6d1-7c3102e4db54,C0574032,C1883559,reduced AGTR1 gene Binding (Molecular Function) in,Infusion procedures,Wild Type,2,X,[topp],[gngm],,
ed21e022-791c-4a3e-81df-8e0cf7d6c900,C0574032,C0026809,reduced AGTR1 gene Binding (Molecular Function) in,Infusion procedures,Mus,2,X,[topp],[mamm],,B01.050.150.900.649.313.992.635.505.500
6035d26c-979a-43dd-99c0-f8fce5809c55,C0574032,C0533668,effect of ,Infusion procedures,ANGPT1 protein human,5,X,[topp],[aapp/bacs],,x.x.x.x
6538d09c-a5e1-4434-a428-4ef8777fa6bf,C0022709,C1171362,effect on ,Peptidyl-Dipeptidase A,protein expression,6,X,[aapp/enzy/imft],[genf],D08.811.277.656.350.350.687,
71e51daf-d68f-41d1-83a7-ef1238361047,C0022709,C0025250,effect on ,Peptidyl-Dipeptidase A,Neprilysin,6,X,[aapp/enzy/imft],[aapp/enzy],D08.811.277.656.350.350.687,D08.811.277.656.300.480.600;D08.811.277.656.675.374.600;D23.050.285.550;D23.101.140.500
7d387244-3156-4646-855f-8684f417bd14,C0022709,C3887624,effect on ,Peptidyl-Dipeptidase A,Human Neprilysin,6,X,[aapp/enzy/imft],[aapp/enzy],D08.811.277.656.350.350.687,
716a5d02-c9f2-44b5-9003-ee46c393d01c,C0014442,C0533668,catabolizes precursor of ,Enzymes,ANGPT1 protein human,6,X,[aapp/enzy],[aapp/bacs],D08.811,x.x.x.x
5056bb64-7701-492d-a457-0fbd712c9951,C3887624,C1883559,is in ,Human Neprilysin,Wild Type,6,X,[aapp/enzy],[gngm],,
0ee1446c-9107-47cf-85dd-2e9b89697ec2,C3887624,C0026809,is in ,Human Neprilysin,Mus,6,X,[aapp/enzy],[mamm],,B01.050.150.900.649.313.992.635.505.500
a3843c2b-8b3f-4df8-8144-02029875bc2d,C1511760,C3887624,resulted in lowered ,Deletion Mutation,Human Neprilysin,6,X,[comd],[aapp/enzy],G05.365.590.762;G05.558.800,
b9395ffd-5ba7-4fb4-836f-dc1483beb3c3,C1511760,C0533668,resulted in lowered ,Deletion Mutation,ANGPT1 protein human,6,X,[comd],[aapp/bacs],G05.365.590.762;G05.558.800,x.x.x.x
027ecbb5-9727-470d-94e6-af91163e282c,C0022709,C0533668,contributes to female protection from ,Peptidyl-Dipeptidase A,ANGPT1 protein human,3,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,x.x.x.x
bf3ecbc5-ce18-430b-9345-f79ae92acbac,C0041912,C0009443, includes ,Upper Respiratory Infections,Common Cold,8,X,[dsyn],[dsyn],C01.539.739;C08.730,C02.782.687.207;C08.730.162
773e9e5d-cdeb-47f3-a64f-75f3d9b51a89,C0206419,C0041912,were assumed associated with mild ,Genus: Coronavirus,Upper Respiratory Infections,10,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
aa3837f5-ff5e-4cd4-b8e6-d4dd6036b444,C0206419,C0009443,were assumed associated with mild ,Genus: Coronavirus,Common Cold,8,X,[virs],[dsyn],B04.820.504.540.150,C02.782.687.207;C08.730.162
801a9424-c6df-478c-9b5d-2c618932b86e,C3694279,C3698360,caused by ,Middle East Respiratory Syndrome,Middle East Respiratory Syndrome Coronavirus,5,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150.113.750
0c012e5c-7069-42af-85fb-d89c799e6815,C0032310,C0242656,is with risk of ,Pneumonia Viral,Disease Progression,6,X,[dsyn],[patf],C02.705;C08.381.677.807;C08.730.610.763,C23.550.291.656
21e76b5d-af2c-4334-a1d1-76a83c61c2e6,C0032310,C1145670,is with risk of ,Pneumonia Viral,Respiratory Failure,6,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C08.618.846
07e3063f-6311-40be-a6dd-d195786b0310,C0419787,C0304066,is in ,Surveillance of contact,Cork,4,X,[topp],[orch],,
bbabd123-871b-43df-9191-20ff161eb773,C1457887,C0019159, includes ,Symptoms,Hepatitis A,4,X,[sosy],[dsyn],,C02.440.420;C02.782.687.359.500;C06.552.380.705.422
eda9c072-0808-4f54-899e-2c6d2c04986c,C1457887,C0014038,extrapulmonary signs ,Symptoms,Encephalitis,1,X,[sosy],[dsyn],,C10.228.140.430
11b91941-1943-4558-aed9-23d40e22aeba,C0019159,C0014038,extrapulmonary signs ,Hepatitis A,Encephalitis,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C10.228.140.430
dc01f815-eda0-4a00-b852-cddeb9f897b6,C1457887,C0027121,extrapulmonary signs ,Symptoms,Myositis,1,X,[sosy],[dsyn],,C05.651.594;C10.668.491.562
92f52edc-7465-4955-af15-48943eb8d936,C0019159,C0027121,extrapulmonary signs ,Hepatitis A,Myositis,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C05.651.594;C10.668.491.562
c3929257-afac-4e00-8b09-34b94f376081,C1457887,C0017160,extrapulmonary signs ,Symptoms,Gastroenteritis,1,X,[sosy],[dsyn],,C06.405.205
739d4226-f498-4032-987f-7dbe037b7ae6,C0019159,C0017160,extrapulmonary signs ,Hepatitis A,Gastroenteritis,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C06.405.205
8670ce50-6f8d-4408-9bc1-8ec10aba26f5,C1457887,C0022660,extrapulmonary signs ,Symptoms,Kidney Failure Acute,1,X,[sosy],[dsyn],,C12.777.419.780.050;C13.351.968.419.780.050
22820f13-efaf-4cf2-a391-7c77ab28d324,C0019159,C0022660,extrapulmonary signs ,Hepatitis A,Kidney Failure Acute,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C12.777.419.780.050;C13.351.968.419.780.050
74ab90fa-09c0-4e63-bfd9-69acb0084b1f,C0011682,C0011121,appear viable options for successful ,Desiccation,Decontamination,1,X,[npop],[topp],E05.196.335;G02.176,N06.850.780.325
6f9a0b71-10d3-4b72-b339-43d87b05e76a,C0206419,C1160716,owing to nature ,Genus: Coronavirus,viral transmission,1,X,[virs],[celf],B04.820.504.540.150,
7649f802-6088-439e-aa02-7d66e94b7630,C0206419,C0458578,owing to nature possible airborne transmission ,Genus: Coronavirus,Upper respiratory tract,2,X,[virs],[bpoc],B04.820.504.540.150,
159a53dd-0b24-4dba-8249-571bec866ada,C0001617,C0677850,are commonly used as ,Adrenal Cortex Hormones,adjuvant therapy,2,X,[horm/orch/phsu],[topp],D06.472.040,
a45ef269-73df-4666-83c1-82c9d98078d8,C0001617,C0032310,However is controversial for patients with severe ,Adrenal Cortex Hormones,Pneumonia Viral,2,X,[horm/orch/phsu],[dsyn],D06.472.040,C02.705;C08.381.677.807;C08.730.610.763
d2655511-7872-44b5-b26d-cb3ce3d3bc2b,C0001617,C0021403,was associated with increased mortality for ,Adrenal Cortex Hormones,Influenza virus vaccine,2,X,[horm/orch/phsu],[imft/phsu],D06.472.040,D20.215.894.899.302
44087ef9-ff67-4d7b-8874-05eb23184ad6,C0024312,C0206419,might might factors associated with severity of from ,Lymphopenia,Genus: Coronavirus,2,X,[dsyn],[virs],C15.378.553.546.605;C20.673.627,B04.820.504.540.150
004aa8a7-e26f-47b8-bcff-49f78088022d,C1155266,C0206419,might might factors associated with severity of from ,inflammatory response,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
004aa8a7-e26f-47b8-bcff-49f78088022d,C1155266,C0206419,are hallmarks of severe ,inflammatory response,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
347a6049-1b86-40c7-b845-d5d6b67d5497,C1527344,4-point,were self-assessed through 4-point ,Dysphonia,4-point,1,X,[mobd],????,C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,????
d157ac04-b825-46a1-974c-237979dd81c4,C1527344,C0206419,may may encountered in quarter of patients with ,Dysphonia,Genus: Coronavirus,1,X,[mobd],[virs],C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,B04.820.504.540.150
447257a1-a351-4b72-b839-07f87f291294,C1527344,C1457887,be should considered as ,Dysphonia,Symptoms,1,X,[mobd],[sosy],C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,
65e08791-dd9e-41bb-9f8f-cfeb6b0990b0,C1527344,C0009450,be should considered as ,Dysphonia,Communicable Diseases,1,X,[mobd],[dsyn],C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,C01.539.221
80cacfdb-3da9-449e-b923-89cd5d0da266,C0036087,C0242781,is hence potential source for infection given possible ,saliva,disease transmission,2,X,[bdsu],[patf],A12.200.666,N06.850.310
f0ff3472-113e-4050-93df-7f3b8d24810a,C0242781,C0036087,is through ,disease transmission,saliva,9,X,[patf],[bdsu],N06.850.310,A12.200.666
d2853a35-4da7-4315-ab43-2da28dbaf897,ity224,C0036087,is near ubiquitously present in ,ity224,saliva,1,X,????,[bdsu],????,A12.200.666
bb16be5f-e33f-4f9d-9e96-97119d65d1be,C2598130,C0031765, includes ,Major Treatments,Phototherapy,2,X,[topp],[topp],,E02.774
e1728fd4-08bc-42ff-a67f-b291a2bf2c82,C0206419,C2598130,has ,Genus: Coronavirus,Major Treatments,6,X,[virs],[topp],B04.820.504.540.150,
f71132af-68b1-459c-93ac-3bcc4bd8fe40,C0206419,C0011627,has ,Genus: Coronavirus,Dermatology field,4,X,[virs],[bmod],B04.820.504.540.150,H02.403.225
95c0a1be-26c1-4789-99dc-21351cde69c1,C0206419,C0031765,has ,Genus: Coronavirus,Phototherapy,2,X,[virs],[topp],B04.820.504.540.150,E02.774
cd01d4aa-dfbf-4ff4-b5f3-40a672e33a64,C1184743,C0206419,understanding public response to ,bony process,Genus: Coronavirus,2,X,[bpoc],[virs],,B04.820.504.540.150
9e195939-2cf6-4f76-937e-3fb9f86a51aa,C0450254,C0949892, includes ,Pathogenic organism,Ebolavirus,1,X,[orgm],[virs],,B04.820.455.300.200
eb648ef2-8797-4acd-b7ff-cf3d3ac90e39,C0450254,C0318793, includes ,Pathogenic organism,Zika Virus,1,X,[orgm],[virs],,B04.820.250.350.995
d31dd916-7abb-4fc3-816c-4c947631b984,C0450254,C0751673, includes ,Pathogenic organism,Nipah Virus,1,X,[orgm],[virs],,B04.820.455.600.650.400.550
0b604125-263d-4c90-8768-cfefe18df476,C0012634,C0450254,have emerged with ,Disease,Pathogenic organism,1,X,[dsyn],[orgm],C23.550.288,
a5355376-d90d-4d7c-a406-b31e492ca2de,C0012634,C0949892,have emerged with ,Disease,Ebolavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.455.300.200
25e477ba-bae5-4b1c-a5b2-43410f9e41f7,C0012634,C0318793,have emerged with ,Disease,Zika Virus,1,X,[dsyn],[virs],C23.550.288,B04.820.250.350.995
f9e0c4dd-bd73-4108-8514-9cbfdd1b8b0d,C0012634,C0751673,have emerged with ,Disease,Nipah Virus,1,X,[dsyn],[virs],C23.550.288,B04.820.455.600.650.400.550
695b26c7-1ef6-41f9-b8dd-1cc68296cd5a,C0042776,C0003062,has has transferred from ,Virus,Animals,2,X,[virs],[anim],B04,B01.050
695b26c7-1ef6-41f9-b8dd-1cc68296cd5a,C0042776,C0003062, includes ,Virus,Animals,2,X,[virs],[anim],B04,B01.050
3c2485f3-91ce-42d2-9141-c1136b71a39c,C0042776,C0008139,has has transferred from ,Virus,Chiroptera,1,X,[virs],[mamm],B04,B01.050.150.900.649.313.937
c4717c5b-4254-4faa-8ded-c44c6e77d150,C0003451,C0087111,prevent potential ,Antiviral Agents,Therapeutic procedure,1,X,[phsu],[topp],D27.505.954.122.388,E02
c4717c5b-4254-4faa-8ded-c44c6e77d150,C0003451,C0087111,could Also could guide for potential ,Antiviral Agents,Therapeutic procedure,3,X,[phsu],[topp],D27.505.954.122.388,E02
4a349e4b-cb52-4433-a289-cd596fdceb16,C0038056,C1457887,were most common ,Sputum,Symptoms,1,X,[bdsu],[sosy],A12.200.808,
9f568f83-6bd1-45cd-a6e4-be32232e4853,C0038056,C0206419,were most common Symptoms of,Sputum,Genus: Coronavirus,2,X,[bdsu],[virs],A12.200.808,B04.820.504.540.150
d025d07d-a358-4940-8c37-e30a42adbaa7,C0231528,C0206419,were most common Symptoms of,Myalgia,Genus: Coronavirus,2,X,[sosy],[virs],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,B04.820.504.540.150
c0ac5820-2b29-4765-a7da-a0c2f533e682,C0010200,C0206419,were most common Symptoms of,Coughing,Genus: Coronavirus,1,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150
c0ac5820-2b29-4765-a7da-a0c2f533e682,C0010200,C0206419,were correlated with hospitalizations for ,Coughing,Genus: Coronavirus,1,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150
da254117-5fd1-4729-b047-c81de7d61e7e,C0006560,C0206419,Elevation of was more common phenomenon in patients with ,C-reactive protein,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,B04.820.504.540.150
f7b3473c-533d-410a-95ed-58026f3b62d5,C0026473,C0206419,was increased in ,Monocytes,Genus: Coronavirus,1,X,[cell],[virs],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,B04.820.504.540.150
4437234b-493d-4e0d-8afa-fe7dd9b1de29,C2676739,C0206419,is typical sign of ,Chromosome 2q32-Q33 Deletion Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
3352aaf3-e17c-44be-a9a4-7cca30b6632d,C0311437,C0206419,is typical sign of ,Exudation,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
dac7356e-53e5-4d55-837f-71c86063dad2,C1175743,C0277554,Organism in,SARS coronavirus,primary disorders,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
071368ad-08b6-43e2-a5bd-7719bf8b0b27,C0087162,C0040808,should Hence should incorporated in ,Vitamin B6,Treatment Protocols,2,X,[orch/phsu/vita],[topp],D03.383.725.676.925,E02.183;N05.715.360.330.125
cbe9c382-f624-4a63-96fc-6b61adc9c03d,C0016410,C0040808,should Hence should incorporated in ,Folic Acid,Treatment Protocols,2,X,[orch/phsu/vita],[topp],D03.633.100.733.631.400,E02.183;N05.715.360.330.125
25cae9ff-a1d3-4bcc-a2d3-595878a5dcd4,C0042845,C0040808,should Hence should incorporated in ,Vitamin B 12,Treatment Protocols,2,X,[orch/phsu/vita],[topp],D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777,E02.183;N05.715.360.330.125
cb251899-eda6-4af8-b8a8-cb913cad55f9,C0087162,C1175175,should Hence should incorporated in ,Vitamin B6,Severe Acute Respiratory Syndrome,1,X,[orch/phsu/vita],[dsyn],D03.383.725.676.925,C02.782.600.550.200.750;C08.730.730
320564b0-c5c1-4d74-a5b0-4f15c916f6c0,C0016410,C1175175,should Hence should incorporated in ,Folic Acid,Severe Acute Respiratory Syndrome,1,X,[orch/phsu/vita],[dsyn],D03.633.100.733.631.400,C02.782.600.550.200.750;C08.730.730
0aaae30c-e768-403f-9245-43b880ae3291,C0042845,C1175175,should Hence should incorporated in ,Vitamin B 12,Severe Acute Respiratory Syndrome,1,X,[orch/phsu/vita],[dsyn],D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777,C02.782.600.550.200.750;C08.730.730
ba38a349-183d-4111-9e7f-a88646536d8f,C0042776,C3826603,mediates altered ,Virus,Cell metabolism,2,X,[virs],[cell],B04,
9afc131a-5cf6-4c0e-8aa3-655a4863ad6b,C0206419,C1305430,activate multiple ,Genus: Coronavirus,complement pathway,2,X,[virs],[moft],B04.820.504.540.150,
db9af651-d109-4b6f-a8ab-6fbe77e596a2,C0206419,C2806453,is ,Genus: Coronavirus,Betacoronavirus,3,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540.150.113
dddd3916-c5d0-41b5-b8ef-6904ad9a8af2,C4506270,C2806453,have anti ,Gene-Eden-VIR,Betacoronavirus,4,X,[phsu],[virs],x.x.x.x,B04.820.504.540.150.113
6d10f524-28e9-4dae-8d66-9a39eb697cf8,C1550600,C2806453,have anti ,Ingredient,Betacoronavirus,2,X,[chvf],[virs],,B04.820.504.540.150.113
d9b6993c-9688-4de5-85fa-b0b22d24b832,C0040038,C0012634,Disseminated Intravascular Coagulation represent causes during,Thromboembolism,Disease,1,X,[patf],[dsyn],C14.907.355.590,C23.550.288
c06f70a9-2f51-44e9-8b51-c6f272ddd7cf,C0012655,C0005778,is due to multiple derangements of ,Disease susceptibility,Blood coagulation,8,X,[clna],[ortf],C23.550.291.687;G07.100.250,G09.188.390.150
34c7383e-4aa7-4fed-8d45-a40292fc3658,C0012655,C0060323,is due to multiple derangements of ,Disease susceptibility,Fibrin fragment D,8,X,[clna],[aapp/bacs],C23.550.291.687;G07.100.250,x.x.x.x
d326b15d-e7d4-471c-aeb8-c4c1846bc640,C0060323,C0038952,correlate with ,Fibrin fragment D,Continuance of life,4,X,[aapp/bacs],[acty],x.x.x.x,I03.784
c626156c-becd-40c1-9e5b-ffd996d97e06,C0409983,C0012739,eventually development of ,Secondary antiphospholipid syndrome,Disseminated Intravascular Coagulation,4,X,[dsyn],[dsyn],,C15.378.100.220;C15.378.463.250;C15.378.925.220
cbaa3bca-e4bd-4c47-a11e-14177a0cc20d,C0409983,C0009450,eventually development of ,Secondary antiphospholipid syndrome,Communicable Diseases,4,X,[dsyn],[dsyn],,C01.539.221
cbaa3bca-e4bd-4c47-a11e-14177a0cc20d,C0409983,C0009450,is responsible for ,Secondary antiphospholipid syndrome,Communicable Diseases,4,X,[dsyn],[dsyn],,C01.539.221
9fc9737a-ad92-4b20-b681-d3ebcd2dffa0,C0040038,C0409983,represent ,Thromboembolism,Secondary antiphospholipid syndrome,4,X,[patf],[dsyn],C14.907.355.590,
c8329168-af4a-4e42-8dce-187cd0b61934,C0040038,C0012739,eventually development of ,Thromboembolism,Disseminated Intravascular Coagulation,4,X,[patf],[dsyn],C14.907.355.590,C15.378.100.220;C15.378.463.250;C15.378.925.220
c8329168-af4a-4e42-8dce-187cd0b61934,C0040038,C0012739,may lead to ,Thromboembolism,Disseminated Intravascular Coagulation,3,X,[patf],[dsyn],C14.907.355.590,C15.378.100.220;C15.378.463.250;C15.378.925.220
bd19e970-7050-4a8c-8613-ebf46f6125f1,C0040038,C0009450,eventually development of ,Thromboembolism,Communicable Diseases,4,X,[patf],[dsyn],C14.907.355.590,C01.539.221
55ea5d1d-a602-444d-8dbc-01403b859db9,C0409983,C0005779,is responsible for ,Secondary antiphospholipid syndrome,Blood Coagulation Disorders,4,X,[dsyn],[dsyn],,C15.378.100
3de68db2-35c8-4d3e-ae69-16a5aa9f911b,C0409983,C0242656,is responsible for ,Secondary antiphospholipid syndrome,Disease Progression,4,X,[dsyn],[patf],,C23.550.291.656
f055892c-f9cf-47df-8d72-c57d130ddb37,C0409983,C0206750,is responsible for ,Secondary antiphospholipid syndrome,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
dd36ef79-fd93-4dc5-a9b0-43874420b50c,C0009450,C4287874,may have ,Communicable Diseases,Droplet Transmission,2,X,[dsyn],[patf],C01.539.221,
41c5c3af-2f41-4603-9ecb-0f8fa61cf887,C0035222,COVID-19,is leading cause of ,Respiratory Distress Syndrome Adult,COVID-19,4,X,[dsyn],[virs],C08.381.840;C08.618.840,C000657245
107770d3-31a3-4f99-adca-46f2eafebd20,C0035222,C0021368,characterized by rapid onset of generalized ,Respiratory Distress Syndrome Adult,Inflammation,1,X,[dsyn],[patf],C08.381.840;C08.618.840,C23.550.470
6ede924b-7a1e-44e4-b212-5a505eea7e8d,C0242656,COVID-19,is in ,Disease Progression,COVID-19,1,X,[patf],[virs],C23.550.291.656,C000657245
eb0ecb91-332e-4b0d-bb31-0fe55ab7829a,C0072027,COVID-19,were ,procalcitonin,COVID-19,6,X,[aapp/bacs],[virs],D06.472.699.666;D12.644.548.744;D12.776.811.555,C000657245
d602ca86-09dc-4eb1-86f0-6434009a963b,C0072027,C0242656,were associated with risk for ,procalcitonin,Disease Progression,3,X,[aapp/bacs],[patf],D06.472.699.666;D12.644.548.744;D12.776.811.555,C23.550.291.656
e294433d-7037-481d-846c-74b622031a31,C0024264,C0005516,Furthermore can also help as novel ,Lymphocyte,Biological Markers,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,D23.101
82919e0f-b30a-4466-b9e8-d2b8556f6de4,C0024264,C1155266,Furthermore can also help as novel ,Lymphocyte,inflammatory response,1,X,[cell],[patf],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
6e71f3ed-93d4-4cb4-a2c7-7aa9dd4b3f2f,C0023516,COVID-19,is with ,Leukocytes,COVID-19,2,X,[cell],[virs],A11.118.637;A15.145.229.637;A15.382.490,C000657245
b928d7cd-5bf9-4f73-9102-77d0c8463743,C0024264,C0027950,has taken levels of ,Lymphocyte,neutrophil,1,X,[cell],[cell],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
adc1ba5c-15ff-47dd-8d1b-9adaea6e14d3,C0024264,C2741673,has taken levels of ,Lymphocyte,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
e4a913bf-b643-40f9-8ba7-95cf0d65053b,C0206750,C0029216,has evolved into abdominal ,Coronavirus Infections,Organ Transplantation,1,X,[dsyn],[topp],C02.782.600.550.200,E04.936.450
107e44b7-8485-40cc-8ff6-9dcfc9de483d,C0012634,C0029216,has evolved into abdominal ,Disease,Organ Transplantation,1,X,[dsyn],[topp],C23.550.288,E04.936.450
f1e0e11c-6ebe-4919-91a7-65680f0d79b5,C0206750,C0040732,has evolved into abdominal ,Coronavirus Infections,Transplantation,1,X,[dsyn],[topp],C02.782.600.550.200,E04.936
f1e0e11c-6ebe-4919-91a7-65680f0d79b5,C0206750,C0040732,had fatality rate Among ,Coronavirus Infections,Transplantation,2,X,[dsyn],[topp],C02.782.600.550.200,E04.936
f1e0e11c-6ebe-4919-91a7-65680f0d79b5,C0206750,C0040732,poses increasing challenge for ,Coronavirus Infections,Transplantation,1,X,[dsyn],[topp],C02.782.600.550.200,E04.936
f8b391f4-0706-4bbb-8e91-50ac0d7ba781,C0012634,C0040732,has evolved into abdominal ,Disease,Transplantation,1,X,[dsyn],[topp],C23.550.288,E04.936
e8135329-7d1b-481d-9253-b88587a04bd8,C0029216,COVID-19,is in ,Organ Transplantation,COVID-19,1,X,[topp],[virs],E04.936.450,C000657245
b08c7819-4678-4e79-86c8-1020392e19e1,C0040732,COVID-19,was ,Transplantation,COVID-19,3,X,[topp],[virs],E04.936,C000657245
12b5fbd8-d4c5-4c63-b72a-e6d3b3d42942,C0029216,C1521863,is in ,Organ Transplantation,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04.936.450,x.x.x.x
2106f2a0-32b5-4e0c-8e4a-e4d5858f5ff4,C0040732,C1521863,is in ,Transplantation,estrogen receptor alpha human,2,X,[topp],[aapp/rcpt],E04.936,x.x.x.x
87bfb862-fd25-4907-8c58-0a25492522a9,C0597357,C0225336,is present on ,receptor,Endothelial Cells,1,X,[aapp/rcpt],[cell],,A11.436.275
34dffe26-743d-475f-937c-e4cbd9a4dded,C0225336,C0024109,is in ,Endothelial Cells,Lung,1,X,[cell],[bpoc],A11.436.275,A04.411
a82ee1d2-faf4-4c3a-970e-48cdca7a75f1,C0225336,C0018787,is in ,Endothelial Cells,Heart,1,X,[cell],[bpoc],A11.436.275,A07.541
7e63af03-d39a-4b77-b619-c94a282c8c78,C0225336,C0022646,is in ,Endothelial Cells,Kidney,1,X,[cell],[bpoc],A11.436.275,A05.810.453
8cccba0a-60d6-4df1-b02e-3c525fc756d5,C0225336,C0040300,is in ,Endothelial Cells,Body tissue,1,X,[cell],[tisu],A11.436.275,A10
6e6560d0-f828-444d-b647-38802dda9b1e,C1175175,C0024109,is in ,Severe Acute Respiratory Syndrome,Lung,5,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A04.411
4b3e53f7-491c-41ee-b26e-061ebb89d68d,C1175175,C0031001,has component of ,Severe Acute Respiratory Syndrome,Perfusion (procedure),2,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,E05.680
9dbca946-a5bb-4014-8fd8-63f4ab6844cf,C0087111,C0022709,increase ,Therapeutic procedure,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],E02,D08.811.277.656.350.350.687
c3333954-f7ec-41ba-943d-6f8f94350afb,C0020517,C0450254,is with other ,Hypersensitivity,Pathogenic organism,1,X,[patf],[orgm],C20.543,
77badc70-3dc2-49c3-9dcf-bc7bbcbf4c30,C0033860,C1290884,is systemic immune-mediated ,Psoriasis,Inflammatory disorder,2,X,[dsyn],[dsyn],C17.800.859.675,
510452db-001b-4741-9296-fd51a22ee0b0,C0033860,C0442893,is systemic immune-mediated ,Psoriasis,Systemic disease,2,X,[dsyn],[dsyn],C17.800.859.675,
f851fe1f-69cf-46b8-82e9-56803c85e289,C0010076,C0035204,causes ,Coronaviridae,Respiration Disorders,2,X,[virs],[dsyn],B04.820.504.540,C08.618
f7f7ca4b-4c73-4702-a4ea-c6ce10514041,C0079189,C0032285,can induce ,cytokine,Pneumonia,8,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.677;C08.730.610
60e724f3-28d2-4a18-a336-d905bd0fc0f1,C2248778,C0021368,suppress ,cyclic nucleotide-gated mechanosensitive ion channel activity,Inflammation,2,X,[moft],[patf],,C23.550.470
fbffd5ad-67c0-43a4-8a89-34b1e232faa8,nt,C1516348,have problems associated to ,nt,Cell Maintenance,2,X,????,[celf],????,
f1d616b6-9fe0-4ab3-a8cb-39c9b28e3e82,C2350332,C2248778,apply same repair effects of ,Exosomes,cyclic nucleotide-gated mechanosensitive ion channel activity,2,X,[celc],[moft],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
ae01c55f-5ff9-4cb7-b47a-0ef0b70426f7,C2350332,C1550101,should Then should isolated from ,Exosomes,Supernatant,2,X,[celc],[bdsu],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
e5434dd2-54e4-4782-b9c8-a7723dcd8a65,C2350332,C0003069,should ,Exosomes,Animals Transgenic,2,X,[celc],[anim],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,B01.050.050.136;B05.620.136
696b6175-f54e-4c0b-b23e-d2a3fdbc3578,C0699748,C0035222,can cause lung injury with ,Pathogenesis,Respiratory Distress Syndrome Adult,2,X,[patf],[dsyn],,C08.381.840;C08.618.840
c47784bf-4160-456e-bf4e-d6cb6a6a5ee5,C0035222,C0087111,finding novel ,Respiratory Distress Syndrome Adult,Therapeutic procedure,2,X,[dsyn],[topp],C08.381.840;C08.618.840,E02
d1e66ee0-fd80-4443-8973-0c69a998a5c1,C0035222,C0012634,finding novel ,Respiratory Distress Syndrome Adult,Disease,2,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C23.550.288
63c9238b-fbff-4686-a1d3-dd6e4718d336,C4061114,C0035222,varies from mild to life-threatening ,Acute illness,Respiratory Distress Syndrome Adult,2,X,[patf],[dsyn],,C08.381.840;C08.618.840
b014ceec-a45f-4324-83d6-ebcd203bfa2d,C0009498,C0172217,is part of innate ,Complement System Proteins,arsenal,2,X,[aapp/imft],[orch/phsu],D12.776.124.486.274,
17d43fb1-8dd4-4b97-ad94-7d7391ab1512,C0009498,C0450254,is part of innate ,Complement System Proteins,Pathogenic organism,2,X,[aapp/imft],[orgm],D12.776.124.486.274,
adf5f7a4-505b-4f14-b426-cb025712371e,C0042776,C0007634,mediate ,Virus,Cells,1,X,[virs],[cell],B04,A11
adf5f7a4-505b-4f14-b426-cb025712371e,C0042776,C0007634,entered ,Virus,Cells,1,X,[virs],[cell],B04,A11
adf5f7a4-505b-4f14-b426-cb025712371e,C0042776,C0007634,are taken up into ,Virus,Cells,1,X,[virs],[cell],B04,A11
1232c517-0559-4be4-a608-428a74daaa9e,C0596756,C1879547,can can directly ,immunopathology specialty,Activation action,2,X,[bmod],[acty],,
a745bb13-8e25-4290-8e7b-c0a92d6da4d4,C0596756,C0312743,can can directly ,immunopathology specialty,Complement component,1,X,[bmod],[aapp/imft],,
d893fa75-1345-4d55-85c2-08736d83ee90,C0596756,C0079189,can can directly ,immunopathology specialty,cytokine,2,X,[bmod],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
dc647a6e-01dc-4538-bddc-1d00b880e01d,C0398623,C0009450,related to ,Thrombophilia,Communicable Diseases,2,X,[dsyn],[dsyn],C15.378.925,C01.539.221
221ee826-464c-4dc4-8ce5-da407b724c7e,C1175743,C0009450,is responsible for ,SARS coronavirus,Communicable Diseases,4,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.221
221ee826-464c-4dc4-8ce5-da407b724c7e,C1175743,C0009450,is etiological Agent of highly contagious,SARS coronavirus,Communicable Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.221
221ee826-464c-4dc4-8ce5-da407b724c7e,C1175743,C0009450,has become pandemic ,SARS coronavirus,Communicable Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.221
581e3538-03b4-41a5-8164-722f9737b7f0,C2948600,C0023884,provide information in healthy ,Aim,Liver,2,X,[inch/phsu],[bpoc],,A03.620
581e3538-03b4-41a5-8164-722f9737b7f0,C2948600,C0023884,illustrate clinical implications on ,Aim,Liver,2,X,[inch/phsu],[bpoc],,A03.620
f8004b95-839b-48ce-9cb6-820fefba286a,C0023890,C0020964,has recognized ,Liver Cirrhosis,Immunity,6,X,[dsyn],[phsf],C06.552.630,G12.450
c694ca8e-dab3-4d2c-a13d-72d0d7e13b8f,C0020964,C1175175,making more susceptible to ,Immunity,Severe Acute Respiratory Syndrome,2,X,[phsf],[dsyn],G12.450,C02.782.600.550.200.750;C08.730.730
443826a9-61ba-4a99-a5a4-da652a768793,C0020964,C0021051,includes ,Immunity,Immunologic Deficiency Syndromes,3,X,[phsf],[dsyn],G12.450,C20.673
63b4125e-eb96-4cb1-8229-6c0261a20f0d,C0020964,C0021368,includes ,Immunity,Inflammation,3,X,[phsf],[patf],G12.450,C23.550.470
aafd382f-1efe-454f-9ac5-12db6ddae846,C2364082,COVID-19,can ,Sense of smell impaired,COVID-19,1,X,[sosy],[virs],,C000657245
52dd677d-07d4-4e52-95b9-406a11f21582,C2364082,C0018563,can ,Sense of smell impaired,Hand,1,X,[sosy],[bpoc],,A01.378.800.667
e72fd44d-31be-4fea-8dd1-3a1fc1a15d37,C2364082,C1457887,have have identified as highly prevalent ,Sense of smell impaired,Symptoms,2,X,[sosy],[sosy],,
dae9773e-3197-4e37-8638-6474c05ae653,COVID-19,C0014038,is with ,COVID-19,Encephalitis,1,X,[virs],[dsyn],C000657245,C10.228.140.430
3310352d-3b6a-454c-ae32-82bce4053a38,C0068450,COVID-19,exert Therapeutic Effect through,naringenin,COVID-19,3,X,[orch/phsu],[virs],x.x.x.x,C000657245
3310352d-3b6a-454c-ae32-82bce4053a38,C0068450,COVID-19,might exert ,naringenin,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
3310352d-3b6a-454c-ae32-82bce4053a38,C0068450,COVID-19,could ,naringenin,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
a73a233d-e4aa-4dfc-a73d-834c28128e8f,C0683325,COVID-19,key Epidemiology of,clinical aspects,COVID-19,3,X,[clna],[virs],,C000657245
fe443706-2869-4e83-aad7-3320c8136ca4,C0310367,C0206419,is rapid outbreak of ,Today,Genus: Coronavirus,3,X,[antb/orch],[virs],,B04.820.504.540.150
b2d32c18-751d-476c-b7dd-1e59b55ed889,C0545747,COVID-19,are at ,pulmonary artery and pulmonary artery,COVID-19,1,X,[bpoc],[virs],,C000657245
be111415-8374-4e61-a667-eaad63737abb,C0545747,C0009450,are at also risk of severe ,pulmonary artery and pulmonary artery,Communicable Diseases,2,X,[bpoc],[dsyn],,C01.539.221
f68a20da-436f-4f88-b566-dd673a04147a,C1175175,COVID-19,is in ,Severe Acute Respiratory Syndrome,COVID-19,3,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,C000657245
754a8b24-ba24-48ce-8405-e0f00bbe5a7c,C0008139,C0206419,are presumed reservoirs of diverse ,Chiroptera,Genus: Coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.937,B04.820.504.540.150
052dd61b-19b0-4329-9f6c-40526a62df7f,C0008139,C1175175,are presumed reservoirs of diverse ,Chiroptera,Severe Acute Respiratory Syndrome,1,X,[mamm],[dsyn],B01.050.150.900.649.313.937,C02.782.600.550.200.750;C08.730.730
90e6d852-71be-47f9-bf10-f2c248dbe5c8,C1175743,C1265469,is in ,SARS coronavirus,Rhinolophus,1,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.937
b8af3da1-5876-4af0-b45e-efb998d032fe,C1175743,C0074992,is in ,SARS coronavirus,sphingosine 1-phosphate,1,X,[virs],[orch],B04.820.504.540.150.113.937,x.x.x.x
d96ad37a-bca9-489b-8bb8-3eb75683d1ae,C0235031,24h,greater than 24h,Neurologic Symptoms,24h,2,X,[sosy],????,C10.597;C23.888.592,????
4b567145-6a6c-4f9c-b480-82cf4ea75b62,COVID-19,C0035298,is in ,COVID-19,Retina,1,X,[virs],[bpoc],C000657245,A09.371.729
f11e17ff-178d-4ba2-acd1-000cfe5f1645,C0242781,C0015392,is in ,disease transmission,Eye,1,X,[patf],[bpoc],N06.850.310,A01.456.505.420;A09.371
6890aa87-286f-4ce5-ab7c-f560f31ab8cf,IRB,C0085076,was conducted to detail novel same-day ,IRB,Mammaplasty,2,X,????,[topp],????,E02.218.565;E04.680.500
ed59dfd6-7dbe-4ab4-a113-053c428d40c1,C0085076,C0184661,can can definitive ,Mammaplasty,Interventional procedure,2,X,[topp],[topp],E02.218.565;E04.680.500,
e96e9d4b-2391-4f8b-afd3-e10dff34bbeb,C0085076,C0524865,be used as bridge to autologous ,Mammaplasty,Reconstructive Surgical Procedures,2,X,[topp],[topp],E02.218.565;E04.680.500,E04.680
de69b7f1-5ee6-4932-b287-12d4bfcf333b,C1000689,C1175743,M of ,Clerodendrum,SARS coronavirus,5,X,[plnt],[virs],B01.650.940.800.575.912.250.583.520.121,B04.820.504.540.150.113.937
71013b64-21d5-4607-980c-eda686ede6e6,C0075816,C1167622,exhibited better ,taraxerol,Binding (Molecular Function),6,X,[orch/phsu],[moft],x.x.x.x,
a55498d4-6c74-42f4-8ea4-bdca63b496f8,C0075816,C0042736,exhibited Binding (Molecular Function) energy scores with concerned,taraxerol,Viral Proteins,6,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.964
21fdfb22-1156-4582-8e78-ab9bf43f0a6e,C0075816,C3687832,exhibited Binding (Molecular Function) energy scores with concerned,taraxerol,Drugs - dental services,3,X,[orch/phsu],[topp],x.x.x.x,
2ab97397-d9ad-4757-ab0b-694737e859f7,COVID-19,C0543467,underwent ,COVID-19,Operative Surgical Procedures,2,X,[virs],[topp],C000657245,E04
2ab97397-d9ad-4757-ab0b-694737e859f7,COVID-19,C0543467,has dramatically changed practice in favor of ,COVID-19,Operative Surgical Procedures,1,X,[virs],[topp],C000657245,E04
186ccba8-b21b-4568-ba21-19c3729c5548,COVID-19,C1856053,underwent Operative Surgical Procedures during,COVID-19,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[virs],[dsyn],C000657245,x.x.x.x
186ccba8-b21b-4568-ba21-19c3729c5548,COVID-19,C1856053,was declared by World Health Organization as global pandemic in ,COVID-19,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[virs],[dsyn],C000657245,x.x.x.x
186ccba8-b21b-4568-ba21-19c3729c5548,COVID-19,C1856053,is pandemic surface with case fatality rate of estimated by WHO up to ,COVID-19,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[virs],[dsyn],C000657245,x.x.x.x
29a29dc8-148f-4f79-a604-e8c33d46009a,C2936287,C1533734,requiring prolonged ,Chemical Oxygen Demand,Administration procedure,3,X,[biof],[topp],N06.850.460.350.080.500;N06.850.780.375.349,
e36426b9-9e95-45d1-99f1-cde332ac64e1,C2936287,C0184633,requiring prolonged ,Chemical Oxygen Demand,Oxygen Therapy Care,3,X,[biof],[topp],N06.850.460.350.080.500;N06.850.780.375.349,E02.880.690
671881d5-bf64-403e-9488-aa57e5218058,C0086418,C0206419,ventilated due to ,Homo sapiens,Genus: Coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150
671881d5-bf64-403e-9488-aa57e5218058,C0086418,C0206419,is with severe ,Homo sapiens,Genus: Coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150
671881d5-bf64-403e-9488-aa57e5218058,C0086418,C0206419,is in development of vaccine against ,Homo sapiens,Genus: Coronavirus,2,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150
36a5c727-4e44-4975-91d3-71c3148e36a4,C1999230,COVID-19,is in ,Providing (action),COVID-19,1,X,[acty],[virs],,C000657245
59026cd6-da07-4566-af49-d9768c021dcd,C0034991,COVID-19,is in ,Rehabilitation therapy,COVID-19,1,X,[topp],[virs],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C000657245
0e81857a-eb7f-4dc8-8dea-1108cf35f52f,C0034991,C1175175,is in ,Rehabilitation therapy,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200.750;C08.730.730
b5fbb88b-421a-4d7b-8f47-9fa1510e67e3,C0005802,COVID-19,increase ,Blood Glucose,COVID-19,1,X,[orch],[virs],D09.947.875.359.448.500,C000657245
4728c22c-362d-4272-8f06-9e1afbc02348,C0011849,COVID-19,is in ,Diabetes Mellitus,COVID-19,3,X,[dsyn],[virs],C18.452.394.750;C19.246,C000657245
4ddfb395-4bd6-48c3-b2d6-a3566ddab402,C0021440,C3669205,is with hourly ,Intravenous infusion procedures,Blood glucose monitoring (regime/therapy),4,X,[topp],[topp],E02.319.267.082.500;E02.319.267.510.590,
812b7e82-12c0-4902-bd15-a1a26dd67bd6,C0021641,C3669205,is with hourly ,Insulin,Blood glucose monitoring (regime/therapy),2,X,[aapp/horm/phsu],[topp],D06.472.699.587.200.500.625;D12.644.548.586.200.500.625,
21502bd6-b746-40b5-b83f-180b574c2eab,C0007430,COVID-19,was ,Catheterization,COVID-19,1,X,[topp],[virs],E02.148;E05.157,C000657245
5c613aea-efe7-42d1-bc7b-4fa4aca01638,C4553629,y245,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,y245,1,X,[topp],????,,????
af4fed49-4d27-49ab-811a-d3a183056ebb,C0369718,C0010340,had ,N not otherwise specified Antibody,Critical Illness,2,X,[aapp/imft],[dsyn],,C23.550.291.625
e09fa900-084f-4309-8abf-5b1b31343a90,C3887843,COVID-19,is in ,Microbiota (environment),COVID-19,1,X,[orgm],[virs],G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500,C000657245
1b024562-3a8f-49c8-9b72-34269d94b5ff,COVID-19,C0683325,share similar ,COVID-19,clinical aspects,1,X,[virs],[clna],C000657245,
675f99fc-1900-4fea-a5b5-747e611028bf,C1175743,C0683325,share similar ,SARS coronavirus,clinical aspects,1,X,[virs],[clna],B04.820.504.540.150.113.937,
f3e0e278-713d-4a42-acec-0b13516cca0b,C0022709,C4018878,regulates ,Peptidyl-Dipeptidase A,Gastrointestinal Microbiome,1,X,[aapp/enzy/imft],[orgm],D08.811.277.656.350.350.687,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
65e5af2c-fbff-4346-92a3-25972932e82a,C0022709,C1819788,indirectly controlling ,Peptidyl-Dipeptidase A,antimicrobial peptide secretion,2,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,
5d6478c4-e0dd-4475-b670-e7cfceb22817,C4018878,C0003451,enhances ,Gastrointestinal Microbiome,Antiviral Agents,2,X,[orgm],[phsu],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,D27.505.954.122.388
204a5bee-7613-40d4-88d9-cd2370f5d7ab,C4018878,C0678209,enhances Antiviral Agents Adaptive Immunity by,Gastrointestinal Microbiome,Adaptive Immunity,3,X,[orgm],[phsf],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,G12.450.050
ba43709a-ead9-4d53-825e-343800489474,C0597404,C0024109,influence composition in ,Respiratory viruses,Lung,1,X,[virs],[bpoc],,A04.411
5dbd493c-ab6a-4e0c-9b5f-795dc7b3fc3a,C1457887,C1260880, includes ,Symptoms,Rhinorrhea,4,X,[sosy],[sosy],,
d28f34f4-c998-4fbf-9b03-c572cd96b645,C1457887,C0012833, includes ,Symptoms,Dizziness,6,X,[sosy],[sosy],,C23.888.592.763.237
b48d6fe4-0791-41fd-b093-0b6817bcecf0,C1457887,C0085593, includes ,Symptoms,Chills,4,X,[sosy],[sosy],,C23.888.208
26e1b6d3-7e49-43bb-a716-609c7fac4718,C0242656,C0009566,was most common ,Disease Progression,Complication,4,X,[patf],[patf],C23.550.291.656,
45213ec7-755a-49a3-a460-3ba140d3a458,C0005525,C4524578,is with ,Biological Response Modifiers,Recovered Plasma,4,X,[imft/phsu],[phsu],D27.505.696.477,
bc0accfe-bb4a-424d-8d05-e08f8ed93404,C1292533,C1510711,were obtained during emergent ,Tissue specimen,Abdominal Surgical Procedure,3,X,[tisu],[topp],,
2d29c9be-c92b-46be-9380-d66b80c131e1,C1292533,C0206419,were obtained during emergent ,Tissue specimen,Genus: Coronavirus,1,X,[tisu],[virs],,B04.820.504.540.150
f4117dfd-6574-4b66-a3e3-cd5d04ddc10b,C1510711,C0206419,is in four patients with ,Abdominal Surgical Procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
430c4a17-bdd3-4f55-9f8a-d06711605d29,C1292533,C0040300,were obtained examine for ,Tissue specimen,Body tissue,6,X,[tisu],[tisu],,A10
bc7596a4-a58f-4a9e-8a54-105f4047a825,C1292533,C1175743,were obtained examine for ,Tissue specimen,SARS coronavirus,6,X,[tisu],[virs],,B04.820.504.540.150.113.937
42ec067f-e4ef-4d6c-8636-35386adb2ab5,C0149725,C0041912,occurs in ,Lower respiratory tract infection,Upper Respiratory Infections,6,X,[dsyn],[dsyn],,C01.539.739;C08.730
c493677a-0288-4e8f-b64c-d5bddeeb289a,C1511790,C0006279,is in ,Detection,Bronchoalveolar Lavage Fluid,6,X,[topp],[bdsu],,E05.927.100.500
f7570cba-d696-4398-b943-07deec1ba96d,C0041912,C0456204,is with clinical testing ,Upper Respiratory Infections,Specimen type,6,X,[dsyn],[clna],C01.539.739;C08.730,
9396f441-3a5f-4bae-a1c0-8b351a0acbd9,C0149725,C0006279,Detection in,Lower respiratory tract infection,Bronchoalveolar Lavage Fluid,3,X,[dsyn],[bdsu],,E05.927.100.500
b133f6aa-0d7c-465b-982e-11a8ab1b4613,C1175743,C0024115,may trigger severe ,SARS coronavirus,Lung diseases,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381
151be363-e732-49f7-b3c5-d0ef33a2b1e8,C0751982,C0024109,is in ,Neutrophil Infiltration,Lung,1,X,[phsf],[bpoc],G12.632,A04.411
ada49b11-d03f-4a86-9617-316f0c5c5821,C1879547,C3850088,releasing ,Activation action,Neutrophil Extracellular Traps,2,X,[acty],[celc],,A11.284.295.495
ea83cb7a-b89c-47f5-b3c4-3140818883c6,C0027950,C3850088,releasing ,neutrophil,Neutrophil Extracellular Traps,2,X,[cell],[celc],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,A11.284.295.495
3751fc33-1696-4ef6-b09c-7f0ba03d7886,C1879547,C0021368,induce ,Activation action,Inflammation,2,X,[acty],[patf],,C23.550.470
3751fc33-1696-4ef6-b09c-7f0ba03d7886,C1879547,C0021368,protecting system from ,Activation action,Inflammation,1,X,[acty],[patf],,C23.550.470
3b05f860-2de8-4e9d-9506-e528a9044b69,C0027950,C0021368,induce ,neutrophil,Inflammation,2,X,[cell],[patf],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C23.550.470
da6a873b-fb53-4b40-92ce-a03e4b2516dc,C1135662,C0010674,is FDA-approved for ,Dornase Alfa,Cystic Fibrosis,3,X,[aapp/enzy/phsu],[dsyn],x.x.x.x,C06.689.202;C08.381.187;C16.320.190;C16.614.213
f4406995-7512-454f-95cb-a3ecc5447747,C1135662,C0225698,reducing -induced toxicity on alveolar,Dornase Alfa,Alveolar Epithelial Cells,2,X,[aapp/enzy/phsu],[cell],x.x.x.x,A04.411.715.100;A11.436.081
18af4356-2139-4503-a2d5-44dded7dc5a5,C1135662,C3850088,reducing ,Dornase Alfa,Neutrophil Extracellular Traps,2,X,[aapp/enzy/phsu],[celc],x.x.x.x,A11.284.295.495
18af4356-2139-4503-a2d5-44dded7dc5a5,C1135662,C3850088,targeting ,Dornase Alfa,Neutrophil Extracellular Traps,1,X,[aapp/enzy/phsu],[celc],x.x.x.x,A11.284.295.495
0204d624-1a81-4b87-a664-f88b73d964ab,C0010674,C4289789,may break up ,Cystic Fibrosis,Cell-Free DNA,2,X,[dsyn],[bacs/nnon],C06.689.202;C08.381.187;C16.320.190;C16.614.213,D13.444.154
b650f4da-7bb5-47b8-b1b2-f3bc3ee4c84a,COVID-19,C0035222,is with large number of ,COVID-19,Respiratory Distress Syndrome Adult,3,X,[virs],[dsyn],C000657245,C08.381.840;C08.618.840
7792c0e7-8a2e-4ae5-bb9a-c28cb4499a75,C0013227,C1960499,promoting improved ,Pharmaceutical Preparations,Clearance of secretions of respiratory tract,4,X,[phsu],[topp],D26,
09fd8b2a-d0f2-47cc-9720-7d7ec42bee30,C0013227,C0024109,might make ,Pharmaceutical Preparations,Lung,2,X,[phsu],[bpoc],D26,A04.411
09fd8b2a-d0f2-47cc-9720-7d7ec42bee30,C0013227,C0024109,preventing further damage to ,Pharmaceutical Preparations,Lung,1,X,[phsu],[bpoc],D26,A04.411
02796ed1-211d-42f8-817c-d91ec65f525d,C0013227,C0026727,might make ,Pharmaceutical Preparations,Mucous body substance,2,X,[phsu],[bdsu],D26,A12.200.503
5cb5a894-7460-4ff7-8875-9f41e0c39fc9,C0026727,C1515933,reduce extracellular hyperinflammation in ,Mucous body substance,Alveolus,3,X,[bdsu],[bpoc],A12.200.503,
e5060994-3d4e-4d25-b11d-31ed78927656,C0012854,C1515933,is in ,DNA,Alveolus,2,X,[bacs/nnon],[bpoc],D13.444.308,
b61d4186-322f-40d6-b446-fae1fd6a7809,C0026727,C0024109,preventing further damage to ,Mucous body substance,Lung,1,X,[bdsu],[bpoc],A12.200.503,A04.411
1d054ed7-627f-4117-8c03-f54c8a6b9ede,C0850149,C0032310,can progress to severe ,Dry cough,Pneumonia Viral,3,X,[sosy],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
f0fc2a24-3f60-44c1-b6f9-6189f3a3f4f4,C0013404,C0032310,can progress to severe ,Dyspnea,Pneumonia Viral,3,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.705;C08.381.677.807;C08.730.610.763
f0fc2a24-3f60-44c1-b6f9-6189f3a3f4f4,C0013404,C0032310,were main Symptoms in groups with,Dyspnea,Pneumonia Viral,1,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.705;C08.381.677.807;C08.730.610.763
75c761c3-2811-4561-b88c-2e2f4ed74dd4,C4287874,C0242781,be main route ,Droplet Transmission,disease transmission,6,X,[patf],[patf],,N06.850.310
8cc79cff-2c0f-4c2b-a515-1b093d2844cb,C4287874,C0206419,be main route ,Droplet Transmission,Genus: Coronavirus,6,X,[patf],[virs],,B04.820.504.540.150
84f13159-2b64-434a-8e31-938bd94d5a4b,C0206750,WBC,had more WBC CRP ,Coronavirus Infections,WBC,1,X,[dsyn],????,C02.782.600.550.200,????
ab340d47-02c8-48af-8ffe-1fceda53d81a,C0206750,C0027950,had more WBC CRP ,Coronavirus Infections,neutrophil,1,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
31013fca-16ad-49f6-b418-0f726b498cb9,C0206750,CRP,had more WBC CRP ,Coronavirus Infections,CRP,1,X,[dsyn],????,C02.782.600.550.200,????
a9785334-6473-48ad-8c7d-4779f58932a4,C4522312,C0206750,showed more ,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
a9785334-6473-48ad-8c7d-4779f58932a4,C4522312,C0206750,more Inflammation than,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
3c7bda35-6c4b-426c-bfcb-b575ad9438f9,C0027950,C0206750,are important indicators for severity grading in ,neutrophil,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02.782.600.550.200
3c7bda35-6c4b-426c-bfcb-b575ad9438f9,C0027950,C0206750,predicting ,neutrophil,Coronavirus Infections,3,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02.782.600.550.200
3c7bda35-6c4b-426c-bfcb-b575ad9438f9,C0027950,C0206750,were significantly associated with outcomes of ,neutrophil,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02.782.600.550.200
8aa1f6c7-fca1-42ff-8345-1fca8e9a4a9b,C0006560,C0206750,are important indicators for severity grading in ,C-reactive protein,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C02.782.600.550.200
89c72c8f-77d8-4b72-96f4-9e216a6a320f,NLR,C0206750,are important indicators for severity grading in ,NLR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
89c72c8f-77d8-4b72-96f4-9e216a6a320f,NLR,C0206750,may serve as useful ,NLR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
920e609a-e8d2-4658-ad72-bc16ae8adf07,C0077401,C0206750,are important indicators for severity grading in ,Troponin I,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D05.500.945.925;D05.750.078.730.825.925;D12.776.210.500.910.925;D12.776.220.525.825.925,C02.782.600.550.200
10053a2e-491a-43ff-b915-4a4f34dc7f8e,C0010294,C0206750,are important indicators for severity grading in ,Creatinine,Coronavirus Infections,1,X,[bacs/orch],[dsyn],D03.383.129.308.207,C02.782.600.550.200
8a35288c-e4d0-47a8-90d3-bb19a6f0279a,C0600137,C0206750,are important indicators for severity grading in ,Blood Urea Nitrogen,Coronavirus Infections,1,X,[bacs/inch],[dsyn],E01.370.225.124.100.115;E01.370.390.400.100;E05.200.124.100.115,C02.782.600.550.200
2b3df4a3-7d1d-463b-b73c-a89b54d0ff68,C0314732,C0206750,responsible for ,Infectious agent,Coronavirus Infections,2,X,[orgm],[dsyn],,C02.782.600.550.200
de3a2445-4c50-4c15-96c3-87ea7034fc74,C3037,C0028630,were found most common ,C3037,Nucleotides,3,X,????,[nnon],????,D09.408.620;D13.695
b3e8a10e-0c9b-4cd9-b1b7-e8872f9c8c6b,C3037,C3494870,were found most common ,C3037,Viral isolate,3,X,????,[bacs],????,
d37e285c-92d3-4bc7-8493-6230b3908525,C0035736,C0319157,yielding Hippocampus Proper with evidence of,RNA Viral,AS virus,2,X,[nnon],[virs],D13.444.735.828,
eb031a0a-0675-42a3-9806-149621a349f6,C1720950,C0206750,identify possible ,Gene Regulatory Networks,Coronavirus Infections,3,X,[moft],[dsyn],G05.360.080.689.360,C02.782.600.550.200
375019c9-ab5e-4772-a7d5-0c4902c0e6e2,C1720950,C0017337,identify bioactive ,Gene Regulatory Networks,Genes,3,X,[moft],[gngm],G05.360.080.689.360,G05.360.340.024.340
6189f612-ccd3-41bc-92cc-ede25d12291d,C0007634,C0041904,identified ,Cells,Up-Regulation (Physiology),8,X,[cell],[moft],A11,G02.111.905;G05.308.850;G07.690.773.998
cf18ca4a-7851-42c8-83ec-7273f567614e,C0035668,C0041904,identified ,RNA,Up-Regulation (Physiology),4,X,[nnon],[moft],D13.444.735,G02.111.905;G05.308.850;G07.690.773.998
1fbefdfc-3c61-4a15-a250-b6e1457abcf4,C0007634,C0027950,identified ,Cells,neutrophil,8,X,[cell],[cell],A11,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
1fbefdfc-3c61-4a15-a250-b6e1457abcf4,C0007634,C0027950,expressed ,Cells,neutrophil,1,X,[cell],[cell],A11,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
5a217ec6-dd20-4824-9ba0-7211f8b181bd,C0035668,C0027950,identified ,RNA,neutrophil,4,X,[nnon],[cell],D13.444.735,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
dd8d9701-1556-49b4-a7ac-fec34223c712,C0007634,C0017337,identified ,Cells,Genes,8,X,[cell],[gngm],A11,G05.360.340.024.340
b65ff0f6-db49-484f-a598-13300be216e3,C1175743,C1533724,be acquired by exposure to ,SARS coronavirus,Fomes,1,X,[virs],[fngs],B04.820.504.540.150.113.937,B01.300.179.120.174
ece842fd-4320-4e4e-aeda-9427819ddd6f,C3710940,C1705178,must implement form in ,STS protein human,Order (action),3,X,[aapp/enzy],[acty],x.x.x.x,
e8faeec2-4cd7-4ae6-9307-faca5f9f7f83,C0206750,C0026882,form escape ,Coronavirus Infections,Mutation,2,X,[dsyn],[genf],C02.782.600.550.200,G05.365.590
5ef4f1d4-fc93-4a21-8f6b-e0a60252392c,C0026882,C1149306,may correspond to reduction in ,Mutation,immunoglobulin binding,4,X,[genf],[moft],G05.365.590,
c4d2c598-3343-481b-8b08-7711a5feb0b1,C0301872,C0682639,is with formation of CD8,Immune response,Memory T-Lymphocyte,4,X,[ortf],[cell],,
dd248d56-f3c7-41f3-931d-74e829fd6332,C0301872,CD8,is with formation of CD8,Immune response,CD8,4,X,[ortf],????,,????
cad4a63d-d3b6-49e1-868d-b15267cfd54f,C0599878,C0037090,is with non ,disease characteristic,Signs and Symptoms Respiratory,1,X,[patf],[sosy],,C23.888.852
f7ad2d61-97ed-4f9d-82df-9defd7bb3bd1,C2948600,C1175175,describe demographic baseline clinical characteristics of cohort with ,Aim,Severe Acute Respiratory Syndrome,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
f7ad2d61-97ed-4f9d-82df-9defd7bb3bd1,C2948600,C1175175,summarize data on treatment of ,Aim,Severe Acute Respiratory Syndrome,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
f7ad2d61-97ed-4f9d-82df-9defd7bb3bd1,C2948600,C1175175,emphasize mechanism due to ,Aim,Severe Acute Respiratory Syndrome,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
f7ad2d61-97ed-4f9d-82df-9defd7bb3bd1,C2948600,C1175175,systematically review main ,Aim,Severe Acute Respiratory Syndrome,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
ea1c77de-0465-4bdf-a45f-b692956c8498,C0206750,C0871208,was associated with overall fatality ,Coronavirus Infections,Rating (action),2,X,[dsyn],[acty],C02.782.600.550.200,
ea1c77de-0465-4bdf-a45f-b692956c8498,C0206750,C0871208,assess ,Coronavirus Infections,Rating (action),1,X,[dsyn],[acty],C02.782.600.550.200,
4cfa4e59-a650-48a4-a55f-fb2403eda6c6,C1708476,C1706374,is in specific community setting among community-dwelling individuals exposed to from January to ,Implementation,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
4cfa4e59-a650-48a4-a55f-fb2403eda6c6,C1708476,C1706374,of weeks is ,Implementation,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
424bf7c8-c220-4de4-bbde-45101bd6eb34,C0439056,C1175743,were positive for ,Throat swab sample,SARS coronavirus,3,X,[bdsu],[virs],,B04.820.504.540.150.113.937
2dcb6daa-3741-44ac-820c-1e59d94ce152,C3274800,C0206750,prevalence of ,Disease Presentation,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
03bef63c-43dd-4926-9b52-37e11533adc7,C0010340,C0199470,requiring ,Critical Illness,Mechanical ventilation,2,X,[dsyn],[topp],C23.550.291.625,
4cfb6cd8-c07c-4235-a9fe-8bf53a274737,C0010340,C0015357,requiring ,Critical Illness,Extracorporeal Membrane Oxygenation,2,X,[dsyn],[topp],C23.550.291.625,E02.880.301;E04.292.451
1a8658ba-0192-4f46-bb54-9088568c8367,C0871208,C1175743,was low In large cohort of patients tested for ,Rating (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
da8766de-8942-456e-ad5c-c8325c782abc,C0206750,C0851312,may exacerbate delays in time to ,Coronavirus Infections,Breast surgery specialty,6,X,[dsyn],[bmod],C02.782.600.550.200,
006fe408-170b-4f27-91d7-b44b7c27b380,C0042774,C0079189,is often followed by ,Virus Replication,cytokine,3,X,[celf],[aapp/imft],G06.920.925,D12.644.276.374;D12.776.467.374;D23.529.374
6913bb56-9808-4562-9de8-38cb23d427a9,C0042774,C1861452,is often followed by ,Virus Replication,Storm Syndrome,3,X,[celf],[dsyn],G06.920.925,x.x.x.x
fa76fd92-9c07-41b4-82fb-891826eb4db2,C0032310,C0206750, includes ,Pneumonia Viral,Coronavirus Infections,6,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C02.782.600.550.200
1985aa6c-dcc3-41ce-82d2-908acb58381a,C0042774,C0032310,is often followed In severe ,Virus Replication,Pneumonia Viral,6,X,[celf],[dsyn],G06.920.925,C02.705;C08.381.677.807;C08.730.610.763
319b7869-219b-4d95-9d5a-6b21ef93ea81,C0042774,C0012634,is often followed In severe ,Virus Replication,Disease,12,X,[celf],[dsyn],G06.920.925,C23.550.288
fc45ce4d-ccff-400f-ba2a-9f45a679ec53,C1861452,C0035222,leads to ,Storm Syndrome,Respiratory Distress Syndrome Adult,3,X,[dsyn],[dsyn],x.x.x.x,C08.381.840;C08.618.840
169f24a2-0b53-4ba3-8853-0006c574a96f,C0725685,C0841874,is with provisions for ,Compleat Liquid Nutrition,dental emergency,2,X,[food],[topp],,
4c58f8fe-4bf6-4448-9fe1-48b8cfe6befb,C1704330,C1999230,Coronavirus Infections,Dental Diseases,Providing (action),1,X,[dsyn],[acty],C07,
fd605f96-d6f7-44f5-b721-8d25c295fed3,C1999230,C0087111,update on ,Providing (action),Therapeutic procedure,2,X,[acty],[topp],,E02
57356013-8bc7-4701-9c22-bd8960757245,C2754943,C0039082,directed against ,IgG antibody,Syndrome,1,X,[celc],[dsyn],,C23.550.288.500
4fd651c4-1fa5-4715-8001-b575cd2b55d6,C0007876,C0028773,is in our ,Cesarean section,Discipline of obstetrics,1,X,[topp],[bmod],E04.520.252.500,H02.403.810.450
b86bbbda-9a37-460c-bb5a-acad7035a803,C0039082,C0028429,is in asymptomatic woman with positive ,Syndrome,Nose,1,X,[dsyn],[bpoc],C23.550.288.500,A01.456.505.733;A04.531;A09.531
9a905791-47a0-46d5-bd26-86d3e32bac03,C0039082,C0439056,is in asymptomatic woman with positive ,Syndrome,Throat swab sample,1,X,[dsyn],[bdsu],C23.550.288.500,
55c3682b-742d-4876-8c05-dc2a32878307,C0206750,C1521863,is now global pandemic with highest number of affected individuals in modern ,Coronavirus Infections,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
55c3682b-742d-4876-8c05-dc2a32878307,C0206750,C1521863,self-protection and prompt diagnosis in ,Coronavirus Infections,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
55c3682b-742d-4876-8c05-dc2a32878307,C0206750,C1521863,ensure self-protection diagnosis in ,Coronavirus Infections,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
3e35603d-72b9-4b94-8c10-e22942c0a36f,C0018787,C0155686,include ,Heart,Acute myocarditis,1,X,[bpoc],[dsyn],A07.541,
3db7f78e-06d7-4c2e-b29a-af43d05441e5,C0018787,C0027051,include ,Heart,Myocardial Infarction,1,X,[bpoc],[dsyn],A07.541,C14.280.647.500;C14.907.585.500
1c2bb774-d927-4544-89f4-d6a5ab9791e7,C0018787,C0003811,include ,Heart,Cardiac Arrhythmia,1,X,[bpoc],[dsyn],A07.541,C14.280.067;C23.550.073
bb8a56ba-1a5d-4cb1-b627-187bed38ce8e,C0027765,C0206750,nervous system disorder,nervous system disorder,Coronavirus Infections,5,X,[dsyn],[dsyn],C10,C02.782.600.550.200
d57c8074-a1fc-44bb-ac5d-eaebc8445c63,C0206750,C3542961,attack ,Coronavirus Infections,NERVOUS SYSTEM DRUGS,1,X,[dsyn],[phsu],C02.782.600.550.200,
1723f546-1dfb-4134-b436-4be808b1c797,C1327414,C3542961,are among most possible routes into ,cytokine secretion,NERVOUS SYSTEM DRUGS,2,X,[celf],[phsu],,
ac331a3f-126f-478d-b63b-ef5a61e06a7d,C0005775,C3542961,are among most possible routes into ,Blood Circulation,NERVOUS SYSTEM DRUGS,2,X,[phsf],[phsu],G09.330.100,
8ded3a26-86b3-42ec-855d-4dbe4f95d53a,C1825598,C0948089,is in particularly field of ,IMPACT gene,Acute Coronary Syndrome,3,X,[gngm],[dsyn],,C14.280.647.124;C14.907.585.124
cd7bd939-758c-4801-a3f4-8d496ee44de9,C4554533,C0206750,is in ,Trend:Type:Point in time:^Patient:Nominal,Coronavirus Infections,2,X,[clna],[dsyn],,C02.782.600.550.200
3656b257-15d1-4864-bf03-8d7851cad790,C4554533,C2348077,analyzed literature data published since beginning to ,Trend:Type:Point in time:^Patient:Nominal,Date Fruit,2,X,[clna],[food],,B01.650.940.800.575.912.250.093.615
1b0d4372-7d5c-4d21-961c-77c950b8d049,C2806453,C0450254,is ,Betacoronavirus,Pathogenic organism,7,X,[virs],[orgm],B04.820.504.540.150.113,
88350ec4-df8e-43c8-bfbc-4757e8b95155,C2806453,C0009450,has has recognized as ,Betacoronavirus,Communicable Diseases,5,X,[virs],[dsyn],B04.820.504.540.150.113,C01.539.221
d6079996-d44d-4f27-b699-1a6364984e97,C1422064,C0030664,is in various neoplastic ,ACE2 gene,Pathology,2,X,[gngm],[bmod],,H02.403.650
fea583b5-87c9-4630-a633-0478f283cebb,C0034848,C0030664,is in various neoplastic ,Receptors Virus,Pathology,4,X,[aapp/rcpt],[bmod],D12.776.543.750.830,H02.403.650
a9a2b837-99d0-4433-bade-62bd29105da7,C0079189,C0009450,could have in vulnerability to ,cytokine,Communicable Diseases,6,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C01.539.221
802b4c35-ebe7-4675-87cb-392947e85bfb,C0025268,C0042542,is in ,Multiple Endocrine Neoplasia Type 2a,Vero Cells,2,X,[neop],[cell],C04.588.322.400.505;C04.651.600.505;C04.700.630.505;C16.320.700.630.505;C19.344.400.505,A11.251.210.955;A11.436.955
4a8e2f0c-9a0e-465f-9ffc-fefd2f9f20b4,C0003451,C0042542,is in ,Antiviral Agents,Vero Cells,2,X,[phsu],[cell],D27.505.954.122.388,A11.251.210.955;A11.436.955
cf640bac-6956-4d1b-93ce-964d9fb88fda,C0025268,C1335332,is in ,Multiple Endocrine Neoplasia Type 2a,Papillomavirus Transforming Protein E6,1,X,[neop],[aapp/bacs],C04.588.322.400.505;C04.651.600.505;C04.700.630.505;C16.320.700.630.505;C19.344.400.505,
0a2e05b2-62f9-44d6-b970-299fe5b3fb41,C0003451,C1335332,is in ,Antiviral Agents,Papillomavirus Transforming Protein E6,1,X,[phsu],[aapp/bacs],D27.505.954.122.388,
b459562c-0476-463a-baf0-218faaa2a463,C0206750,C0275518,is novel ,Coronavirus Infections,Acute infectious disease,5,X,[dsyn],[dsyn],C02.782.600.550.200,
f9ccf873-ab41-49a9-96e1-95dd998b9c83,C0064906,C1167622,affirmed ,Nafarelin,Binding (Molecular Function),1,X,[aapp/phsu],[moft],D06.472.699.327.740.320.580;D12.644.400.400.740.320.580;D12.644.456.460.600;D12.644.548.365.740.320.580;D12.776.631.650.405.740.320.580,
5a6e0703-1533-4b91-b725-ac8eefb22ff0,C0064906,C0324740,affirmed ,Nafarelin,Talpidae,1,X,[aapp/phsu],[mamm],D06.472.699.327.740.320.580;D12.644.400.400.740.320.580;D12.644.456.460.600;D12.644.548.365.740.320.580;D12.776.631.650.405.740.320.580,B01.050.150.900.649.473.450
21f41c0f-645d-48a9-8899-b4171ac1f126,C0246269,C1167622,affirmed ,icatibant,Binding (Molecular Function),1,X,[aapp/phsu],[moft],x.x.x.x,
5925a8c2-8a7a-4449-a8a9-6e177009a81f,C0246269,C0324740,affirmed ,icatibant,Talpidae,1,X,[aapp/phsu],[mamm],x.x.x.x,B01.050.150.900.649.473.450
40a8de50-d69c-4356-98ff-db8a7044d52f,C0936079,C0242402,mentioning ,Cannabis,Opioids,1,X,[plnt],[hops/orch/phsu],B01.650.940.800.575.912.250.859.937.055.500,D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
511e45e1-a187-4de2-b427-eea5c1e9675c,C0936079,C0206750,mentioning Opioids from,Cannabis,Coronavirus Infections,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.859.937.055.500,C02.782.600.550.200
b251a2b9-601f-46cd-b9eb-a1f4a75ce796,C0936079,C0227813,mentioning Opioids from,Cannabis,Body of uterus,1,X,[plnt],[bpoc],B01.650.940.800.575.912.250.859.937.055.500,
039cd04a-84dc-496e-842b-dbed1bf87551,C2948600,C0086132,analyze ,Aim,Depressive Symptoms,1,X,[inch/phsu],[sosy],,F01.145.126.350
e97ec934-fa08-4a90-b6e3-c4a404bbf63f,C2948600,C0003467,analyze ,Aim,Anxiety,1,X,[inch/phsu],[mobd],,F01.470.132
e97ec934-fa08-4a90-b6e3-c4a404bbf63f,C2948600,C0003467,enhancing ,Aim,Anxiety,1,X,[inch/phsu],[mobd],,F01.470.132
4cd86a0e-7799-4e1f-be41-add877649043,C0206750,C0042769,is viral ,Coronavirus Infections,Virus Diseases,12,X,[dsyn],[dsyn],C02.782.600.550.200,C02
3d81c848-fb69-4e68-a738-fc833d05af9f,C0086418,C1292533,Lacking clear information about load on ,Homo sapiens,Tissue specimen,2,X,[humn],[tisu],B01.050.150.900.649.313.988.400.112.400.400,
c37a3c5d-1c4a-4c1a-abcd-48fd093e0019,C0370003,C1292533,Lacking clear information about load on ,Specimen,Tissue specimen,2,X,[sbst],[tisu],,
e5e41239-517a-43a7-bbf4-a7696cf05ff0,C1947904,C1328821,determining ,Attachment (action),tissue tropism,1,X,[acty],[phsf],,
ed26b520-b546-46e4-87b7-7a17534ed38f,C1947904,C1167395,determining ,Attachment (action),Host (organism),1,X,[acty],[orgm],,
72b6f681-09eb-4c6e-bfce-2e4a987eb087,C0009450,C0025255,fusion of viral ,Communicable Diseases,Tissue membrane,1,X,[dsyn],[tisu],C01.539.221,A10.615
0707f1e8-89ad-4cdc-adb3-369db1638a52,C1175743,C0475463,is main target of ,SARS coronavirus,Antibodies Neutralizing,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
9669e146-6ccb-4577-9960-23523d7a29ac,C3826426,C0475463,are limiting factors main target of ,Dynamics,Antibodies Neutralizing,1,X,[npop],[aapp/imft],,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
b2c45959-92d6-4f65-9801-5af08243ae7f,C0020964,C0206750,is in ,Immunity,Coronavirus Infections,1,X,[phsf],[dsyn],G12.450,C02.782.600.550.200
69823006-0719-4ac7-966e-d94e2deb3f16,C0020964,C0024264,count of ,Immunity,Lymphocyte,1,X,[phsf],[cell],G12.450,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
db940d95-1044-4037-beb4-dfdf4bf66ba2,C0024264,C1879547,lead to compensatory CD8 ,Lymphocyte,Activation action,1,X,[cell],[acty],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
8a5b014f-bbea-4dfb-a5f9-dff26137f271,C0024264,CD8,lead to compensatory CD8 ,Lymphocyte,CD8,1,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
8a5b014f-bbea-4dfb-a5f9-dff26137f271,C0024264,CD8,increased CD8 ,Lymphocyte,CD8,1,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
ca6f43db-4c82-4baf-9c55-2f461591ab6f,C0024264,C2603360,lead to compensatory CD8 ,Lymphocyte,T prime,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
4e069744-f614-477e-95c9-d83d11fea8f2,MAFLD,C0206750,is with ,MAFLD,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
fe0a249d-21cc-42f4-936b-694e85881765,C0243077,C0042774,reduce ,inhibitors,Virus Replication,1,X,[chvf],[celf],,G06.920.925
7bc5e693-cb37-41eb-803b-af2716982fb6,C0205721,C0206750,accounted for ,Infections Hospital,Coronavirus Infections,1,X,[dsyn],[dsyn],C01.539.248;C23.550.291.875.500,C02.782.600.550.200
f3a581f0-fab6-4ba7-8813-35b0eec7cd72,C0032105,C3277428,increase survival rates in other ,Plasma,Severe viral infections,2,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,
eaec7cc2-96c6-40db-b267-47c15c706366,C0034535,C0206750,is in ,Radiation Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,C02.782.600.550.200
acf6936e-2fe2-49c4-b855-662cd214309f,C0027651,C0206750,is in ,Neoplasms,Coronavirus Infections,1,X,[neop],[dsyn],C04,C02.782.600.550.200
bf35ef30-fdd8-45c8-b22d-ed841dee4d33,C0034535,C0012634,is in ,Radiation Syndrome,Disease,2,X,[dsyn],[dsyn],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,C23.550.288
97b3363f-99a3-4a85-a53e-d09f8451721b,C0027651,C0012634,was converted into 22-inpatient bedcoronavirus ,Neoplasms,Disease,4,X,[neop],[dsyn],C04,C23.550.288
43088594-aec5-4d63-8dc4-df2b6cce0e3f,C0278996,C0034535,is in ,Malignant Head and Neck Neoplasm,Radiation Syndrome,2,X,[neop],[dsyn],,C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360
ff754830-5789-49c8-82d0-7a7017fe9e7f,C0278996,C0027651,is in ,Malignant Head and Neck Neoplasm,Neoplasms,2,X,[neop],[neop],,C04
e533fb70-05ba-4fcc-99b5-1a3efc49c884,C3887461,C0206750,were proven as ,Head and Neck Carcinoma,Coronavirus Infections,1,X,[neop],[dsyn],,C02.782.600.550.200
e533fb70-05ba-4fcc-99b5-1a3efc49c884,C3887461,C0206750,is high risk ,Head and Neck Carcinoma,Coronavirus Infections,2,X,[neop],[dsyn],,C02.782.600.550.200
135f1ee4-34d3-4ba5-8be9-3e617a9e7375,C0025242,C1422064,may decrease ,Memantine,ACE2 gene,1,X,[orch/phsu],[gngm],D02.455.426.100.050.035.500,
f4283e9c-012b-42cf-b5ae-409633ac0fc4,C0025242,C0597360,may decrease ,Memantine,receptor expression,2,X,[orch/phsu],[genf],D02.455.426.100.050.035.500,
14eb173e-9b0e-4cf4-874f-945f0f57f7ec,C0025242,C0231491,may decrease ACE2 gene receptor expression as,Memantine,Antagonist muscle action,1,X,[orch/phsu],[ortf],D02.455.426.100.050.035.500,
14eb173e-9b0e-4cf4-874f-945f0f57f7ec,C0025242,C0231491,may decrease Peptidyl-Dipeptidase A receptor expression as,Memantine,Antagonist muscle action,1,X,[orch/phsu],[ortf],D02.455.426.100.050.035.500,
db75f7ff-3aee-4949-81ed-2fde443d34bd,C0025242,C1148665,may decrease ACE2 gene receptor expression as,Memantine,nicotinic acetylcholine-activated cation-selective channel activity,1,X,[orch/phsu],[moft],D02.455.426.100.050.035.500,
db75f7ff-3aee-4949-81ed-2fde443d34bd,C0025242,C1148665,may decrease Peptidyl-Dipeptidase A receptor expression as,Memantine,nicotinic acetylcholine-activated cation-selective channel activity,1,X,[orch/phsu],[moft],D02.455.426.100.050.035.500,
be313c58-780c-4e92-9d17-cb4ef453c128,C0231491,C0021368,reduce ,Antagonist muscle action,Inflammation,1,X,[ortf],[patf],,C23.550.470
b5b84df9-73a8-45ad-8ad7-98a58a456753,C0231491,C0242606,reduce ,Antagonist muscle action,Oxidative Stress,1,X,[ortf],[comd],,G03.673;G07.775.750
ad539d5a-813f-4db6-bdd3-f0f9587e9cba,C0025242,C1175743,may reduce ,Memantine,SARS coronavirus,2,X,[orch/phsu],[virs],D02.455.426.100.050.035.500,B04.820.504.540.150.113.937
a2260d95-0870-4bff-be6e-e32d6523102e,C1096155,C0012634,is in pandemic ,Macrophage Activation Syndrome,Disease,5,X,[dsyn],[dsyn],C20.683.515.800,C23.550.288
b85a7ae3-444b-4f85-a6dc-ca08ae3444bf,C1096155,C0206750,is in pandemic ,Macrophage Activation Syndrome,Coronavirus Infections,2,X,[dsyn],[dsyn],C20.683.515.800,C02.782.600.550.200
433ec68b-4037-42b2-a133-c8d6d352bb28,C1707455,C1175175,is with other pandemic strains such that of ,Comparison,Severe Acute Respiratory Syndrome,2,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
07a0e63a-cdab-4fd3-975e-c8d3ee32315a,C0033873,C0206750,effectively provided care services during early phase of New York Citys ,Psychiatry Specialty,Coronavirus Infections,1,X,[bmod],[dsyn],F04.096.544;H02.403.690,C02.782.600.550.200
6b6e35d8-661b-4f5c-bd14-49c329dce483,C4300185,C0206750,effectively provided care services during early phase of New York Citys ,Palliative care.team,Coronavirus Infections,2,X,[bmod],[dsyn],,C02.782.600.550.200
52883719-a5fe-491a-8998-92516e4efa4a,C4300185,C1273400,thereby enabling ,Palliative care.team,Specialist palliative care,1,X,[bmod],[bmod],,
b87116ce-5b58-4f92-b82e-92f5a3cc2063,C0033873,C0557533,is in specific ,Psychiatry Specialty,Hospice and Palliative Care Nursing,1,X,[bmod],[bmod],F04.096.544;H02.403.690,H02.478.676.350;N02.421.533.390
4b33f865-6d35-49ff-9221-eff47e050f8c,C0206419,C2348077,has ,Genus: Coronavirus,Date Fruit,1,X,[virs],[food],B04.820.504.540.150,B01.650.940.800.575.912.250.093.615
8355374d-d4a3-4a77-b25f-8fde1c619edd,C0206419,C2745965,was declared global health ,Genus: Coronavirus,Emergencies [Disease/Finding],9,X,[virs],[patf],B04.820.504.540.150,C23.550.291.781;N06.230.100.083;N06.850.376
acd3d5ab-8d95-4d6d-93a2-6c6acb9448ed,C0264361,C0796494,is with over ,Traction bronchiectasis,lobe,4,X,[dsyn],[bpoc],,
1f9e11ff-e590-4786-b61c-058284d2670e,ANCC,C2700061,is in Practice ,ANCC,Transition (action),1,X,????,[acty],????,
4530dfe2-7dde-4f37-8a56-6e712d920492,C0206419,C0042769,is new ,Genus: Coronavirus,Virus Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C02
f70722b7-d959-4ec2-b7fd-ab673e11ff8b,C1422064,C0022646,were widely disturbed among ,ACE2 gene,Kidney,4,X,[gngm],[bpoc],,A05.810.453
f70722b7-d959-4ec2-b7fd-ab673e11ff8b,C1422064,C0022646,effect on ,ACE2 gene,Kidney,6,X,[gngm],[bpoc],,A05.810.453
c81d8352-7d23-41e0-bbe4-4c4e7bb2343b,C1422064,C0021852,were widely disturbed among ,ACE2 gene,Intestines Small,4,X,[gngm],[bpoc],,A03.556.124.684
d610a586-036a-4a3e-959e-db242cc3eaf6,TRMPSS2,C1422064,Up-Regulation (Physiology) of,TRMPSS2,ACE2 gene,2,X,????,[gngm],????,
8b9484ad-6e95-4e70-9140-ef69be69a781,C0162633,C0005768,is in ,Viral Shedding,In Blood,1,X,[patf],[bdsu],G07.925,x.x.x.x.x
6e1e3840-4856-4181-92f2-ee2288d76da0,C0031843,C0206419,thus seem important to ,physiological aspects,Genus: Coronavirus,6,X,[phsf],[virs],x.x.x.x,B04.820.504.540.150
6411307f-6103-40c0-88cd-fb70a44a97b4,C0013982,C1175743,inhibit ,Emodin,SARS coronavirus,2,X,[bacs/orch/phsu],[virs],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,B04.820.504.540.150.113.937
ff0dd49e-f5e3-4f06-9dac-4012bae31047,C0013982,C1167622,inhibit SARS coronavirus entry by apparently,Emodin,Binding (Molecular Function),1,X,[bacs/orch/phsu],[moft],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,
59aa2545-ee58-4cbb-98c1-049ae4f8ff67,C0013982,C1422064,inhibit SARS coronavirus entry by apparently,Emodin,ACE2 gene,1,X,[bacs/orch/phsu],[gngm],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,
c477319e-448b-4e55-82a3-a71e1f66da8d,C0014442,C0599740,is argued convenient model ,Enzymes,pharmacophore,4,X,[aapp/enzy],[rcpt],D08.811,
977aa247-d1e8-41dd-a726-928b4f4156f8,C0044707,C0599740,is argued convenient model ,11-beta-Hydroxysteroid Dehydrogenases,pharmacophore,4,X,[aapp/enzy],[rcpt],D08.811.682.047.436.174;D08.811.682.047.820.100,
b3be1a26-551f-4b4d-a46f-e7e35161d03f,C0009450,C0038454,represents independent ,Communicable Diseases,Cerebrovascular accident,2,X,[dsyn],[dsyn],C01.539.221,C10.228.140.300.775;C14.907.253.855
b0995562-8250-4d4e-8a4a-de8c83f87abc,C0042776,C0333355,Inflammatory disease of mucous membrane of,Virus,Inflammatory disease of mucous membrane,2,X,[virs],[patf],B04,C06.405.205.798;C07.465.584
b0995562-8250-4d4e-8a4a-de8c83f87abc,C0042776,C0333355,produce ,Virus,Inflammatory disease of mucous membrane,4,X,[virs],[patf],B04,C06.405.205.798;C07.465.584
1f18f1bc-b410-41e1-9fa6-fa3794cfe578,C0039336,C1175743,is in ,Taste Perception,SARS coronavirus,2,X,[ortf],[virs],F02.830.816.724;G11.561.790.724,B04.820.504.540.150.113.937
0574fb30-3d1a-413a-a23d-05bd8d7da618,C1175743,C1825598,is having profound ,SARS coronavirus,IMPACT gene,8,X,[virs],[gngm],B04.820.504.540.150.113.937,
b0697ed0-8b95-4849-a724-2cbe0a3e835e,C0441655,C0018563,studying on other ,Activities,Hand,1,X,[acty],[bpoc],,A01.378.800.667
eb59500e-d91c-4057-9f2a-3a3099b38792,C1457887,C0562483,was ,Symptoms,Persistent cough,4,X,[sosy],[sosy],,
446c3821-31c2-4572-b2a8-3860ad01c297,C0010200,C0015967,was more common than ,Coughing,Fever,4,X,[sosy],[sosy],C08.618.248;C23.888.852.293,C23.888.119.344
05b66360-a311-4aed-8bf3-ac7129fe8c25,C3825816,C0206419,is with ,Pneumonia in children,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
5f13968e-5abd-4623-bf79-8d3cafdd0c81,C3825816,C0012634,is with ,Pneumonia in children,Disease,3,X,[dsyn],[dsyn],,C23.550.288
52c5c76c-dd52-44f2-a2a8-ea595fd60ce5,C0021054,C0206419,is in children with ,Immunologic Factors,Genus: Coronavirus,1,X,[imft],[virs],D27.505.696.477,B04.820.504.540.150
52c5c76c-dd52-44f2-a2a8-ea595fd60ce5,C0021054,C0206419,participate in ,Immunologic Factors,Genus: Coronavirus,2,X,[imft],[virs],D27.505.696.477,B04.820.504.540.150
f96eeb26-6098-4521-87da-a97cc1cb7f2e,C0021054,C0699748,participate in ,Immunologic Factors,Pathogenesis,6,X,[imft],[patf],D27.505.696.477,
aa09dec7-9108-4b18-8ec5-7d8d3e150814,C0021054,C0032285,participate in ,Immunologic Factors,Pneumonia,6,X,[imft],[dsyn],D27.505.696.477,C08.381.677;C08.730.610
85c10a6d-1f0a-47ec-a377-7bdb9462b5cc,C0699748,C0206419,is in children with ,Pathogenesis,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
056de6d5-7d46-4d4b-b84b-2afcc4441bef,C0597357,C0206750,make patients susceptible to ,receptor,Coronavirus Infections,2,X,[aapp/rcpt],[dsyn],,C02.782.600.550.200
6f58cff4-64df-412e-aea6-c069dce0764a,C1999230,C0032105,lead clinical use of ,Providing (action),Plasma,3,X,[acty],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
17c8233c-d0d0-476f-8d57-ef8bbe468f8d,C4554533,C2745965,seen in ,Trend:Type:Point in time:^Patient:Nominal,Emergencies [Disease/Finding],4,X,[clna],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
61b03bbc-184d-4c44-b04f-e5fb26623b9b,C1706005,C1175743,were negative for ,CD40LG wt Allele,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
61b03bbc-184d-4c44-b04f-e5fb26623b9b,C1706005,C1175743,for assay is ,CD40LG wt Allele,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
61b03bbc-184d-4c44-b04f-e5fb26623b9b,C1706005,C1175743,be useful test for diagnosis of active ,CD40LG wt Allele,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
0abf15d7-fde1-43c0-bfd6-8333162ca6f6,titers,C1175743,were negative for ,titers,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
31053367-543b-42cc-bb22-c8f5a49cb8ac,C0319157,C0598197,is highly ,AS virus,contagion,1,X,[virs],[npop],,
a7fc0694-a711-4cdf-8675-c14e94fcd7d8,C0162429,C0039082,of Lung is,Malnutrition,Syndrome,1,X,[dsyn],[dsyn],C18.654.521,C23.550.288.500
ca340ffa-6504-4805-bace-520e6abd52eb,C0024109,C0042740,Viral syndrome of epidemic,Lung,Viral syndrome,2,X,[bpoc],[dsyn],A04.411,
8a7543be-763a-4acd-abb6-6176bb6233dc,C0039082,C3891560,Syndrome of,Syndrome,Alarmins,2,X,[dsyn],[aapp/bacs],C23.550.288.500,D23.035
6e881fc1-46b3-46e9-86a5-8b2f6df63c72,C0039082,C0018837,Syndrome of,Syndrome,Heat (physical force),2,X,[dsyn],[npop],C23.550.288.500,
8d105eee-8289-43fe-b47f-69d146555788,C0162429,C0042740,of Lung is,Malnutrition,Viral syndrome,1,X,[dsyn],[dsyn],C18.654.521,
11b1a9b0-d8b4-4544-98e1-4530f2ed4804,C0042740,C0018837,Syndrome of pathogenic,Viral syndrome,Heat (physical force),1,X,[dsyn],[npop],,
4776d88f-2244-440c-b80d-422a5e548fc7,C0024109,C0018837,Syndrome of pathogenic,Lung,Heat (physical force),3,X,[bpoc],[npop],A04.411,
fa0b8629-a025-4dcf-8805-5df15737c6dd,C1457887,C0042740,were clustered including ,Symptoms,Viral syndrome,2,X,[sosy],[dsyn],,
53d53aa1-f07f-4e3e-a584-9853e7a0396d,C1457887,C0024109,were clustered including ,Symptoms,Lung,1,X,[sosy],[bpoc],,A04.411
53d53aa1-f07f-4e3e-a584-9853e7a0396d,C1457887,C0024109,stagnating in ,Symptoms,Lung,1,X,[sosy],[bpoc],,A04.411
1dd675cd-e71c-4082-884f-c84a9dc6c0e5,C0039082,C0042740,Viral syndrome of epidemic,Syndrome,Viral syndrome,1,X,[dsyn],[dsyn],C23.550.288.500,
581943a3-ccbe-4e21-806c-12806367c82c,C0039082,C0024109,Viral syndrome of epidemic,Syndrome,Lung,1,X,[dsyn],[bpoc],C23.550.288.500,A04.411
581943a3-ccbe-4e21-806c-12806367c82c,C0039082,C0024109,is with limited damage to ,Syndrome,Lung,2,X,[dsyn],[bpoc],C23.550.288.500,A04.411
42cf0c4e-cd72-4eea-9bfb-dbd797c339d1,C0729650,C0039082,with Syndrome is,Constituents,Syndrome,1,X,[sbst],[dsyn],,C23.550.288.500
2689d0ff-1c22-4ac7-905a-54ef5430baa0,C0729650,C3891560,with Syndrome is,Constituents,Alarmins,1,X,[sbst],[aapp/bacs],,D23.035
85825bb9-b478-4774-838c-9a3a6db005ec,C0729650,C0018837,with Syndrome is,Constituents,Heat (physical force),1,X,[sbst],[npop],,
d4ca15f2-cc86-4d5b-8963-de4c5ab6dc02,C0039082,C0729650,is with ,Syndrome,Constituents,1,X,[dsyn],[sbst],C23.550.288.500,
353f20b1-59f9-4539-841e-1aad406e6b9d,C0729650,C0042740,with Syndrome is,Constituents,Viral syndrome,2,X,[sbst],[dsyn],,
096db281-57d7-4e48-83bb-f81370699d0a,C0729650,C0024109,with Syndrome is,Constituents,Lung,1,X,[sbst],[bpoc],,A04.411
dc35fbc3-8ab6-42ca-929e-489ab395714b,C0024109,C0162429,Syndrome of Qi,Lung,Malnutrition,1,X,[bpoc],[dsyn],A04.411,C18.654.521
6adb60d8-1903-4628-9623-3d85ac73ad34,C0009264,C0242821,to Aversion is,Cold Temperature,Human body,2,X,[npop],[humn],G01.906.595.272;G16.500.275.063.725.710.300;G16.500.750.775.710.300;N06.230.300.100.725.154;N06.230.300.100.725.710.300,I01.076.201.450.560;K01.093.378
3bdfefea-91bf-4d5a-b195-cbd1bac6fa24,C0687681,C0682477,is in ,Feeling feverish,Arecaceae,1,X,[sosy],[plnt],,B01.650.940.800.575.912.250.093
7d2c620c-96df-4d84-8365-09432add21be,C0024109,C0009264,Syndrome of,Lung,Cold Temperature,1,X,[bpoc],[npop],A04.411,G01.906.595.272;G16.500.275.063.725.710.300;G16.500.750.775.710.300;N06.230.300.100.725.154;N06.230.300.100.725.710.300
51961878-792d-446b-829a-cb13051ca131,C0024109,C3891560,Syndrome of,Lung,Alarmins,2,X,[bpoc],[aapp/bacs],A04.411,D23.035
7b53ffe9-756b-4052-be79-20477d36ce89,C0370003,C0033727,were collected at ,Specimen,Protons,1,X,[sbst],[elii],,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
8f50fa41-4016-4807-a21e-cab3759b47d6,C1175743,C0015296,is seventh in ,SARS coronavirus,Exonuclease,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.277.352.365
28b427ab-8217-4ce0-b6be-1997976d3990,C1175743,C0440471,repairing mismatches in newly transcribed ,SARS coronavirus,Genetic Materials,1,X,[virs],[gngm],B04.820.504.540.150.113.937,G05.360.340.024.340
5e2e9aea-8662-4e2b-b075-29eb9a073a4d,C0206750,C0015296,is with unique ,Coronavirus Infections,Exonuclease,1,X,[dsyn],[aapp/enzy],C02.782.600.550.200,D08.811.277.352.365
21128082-d7bf-4ce9-8d84-674709298181,C0920474,C0319157,eliminate ,drug mechanism,AS virus,1,X,[patf],[virs],,
8d9aa667-773f-491d-9193-5a4813526925,C0596957,C0013227,concluded three ,Molecular Dynamics,Pharmaceutical Preparations,2,X,[moft],[phsu],E05.599.595.500;G02.111.570.895;L01.224.160.500,D26
c2520244-3686-45f2-8ceb-fff7382e34cb,C0013227,C1167622,is from PubChem database with docking scores with its ,Pharmaceutical Preparations,Binding (Molecular Function),1,X,[phsu],[moft],D26,
c2520244-3686-45f2-8ceb-fff7382e34cb,C0013227,C1167622,shows good ,Pharmaceutical Preparations,Binding (Molecular Function),3,X,[phsu],[moft],D26,
0b822489-6d77-4e4f-a38a-efd4bfcdb3b4,C0013227,C0678591,is from PubChem database with docking scores with its ,Pharmaceutical Preparations,free energy,1,X,[phsu],[npop],D26,
a123493b-91e7-45a8-8915-5b8ec734fd43,C1947933,C0012634,preventing further health outcomes from ,care activity,Disease,1,X,[acty],[dsyn],,C23.550.288
a123493b-91e7-45a8-8915-5b8ec734fd43,C1947933,C0012634,are added ,care activity,Disease,2,X,[acty],[dsyn],,C23.550.288
7b87d3d6-d837-458a-aa9c-8f870ccde29d,C0206750,C0010356,is in ,Coronavirus Infections,Cross Infection,1,X,[dsyn],[patf],C02.782.600.550.200,C01.539.248;C23.550.291.875.500
474e874d-240f-4195-98bb-4a20e9a2d7b0,C0036087,C1511790,is acceptable Specimen to nasopharyngeal specimen for,saliva,Detection,2,X,[bdsu],[topp],A12.200.666,
808bd5d9-626e-410b-ae59-2dfdaf4f0511,C0036087,C1175743,is acceptable Specimen to nasopharyngeal specimen for,saliva,SARS coronavirus,2,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
808bd5d9-626e-410b-ae59-2dfdaf4f0511,C0036087,C1175743,detecting ,saliva,SARS coronavirus,2,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
808bd5d9-626e-410b-ae59-2dfdaf4f0511,C0036087,C1175743,were sufficient for use in tests of ,saliva,SARS coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
808bd5d9-626e-410b-ae59-2dfdaf4f0511,C0036087,C1175743,are suitable for testing for ,saliva,SARS coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
e0d92c7e-821e-4789-9f80-dd3706c79810,C0036087,C0370003,is acceptable ,saliva,Specimen,2,X,[bdsu],[sbst],A12.200.666,
bf7273d2-4ffa-4693-bc7b-8191b9fe3ebb,C1708476,C0162429,rapid diagnosis of ,Implementation,Malnutrition,5,X,[acty],[dsyn],,C18.654.521
382e76ae-4026-4cca-9298-de197e3dc1fb,C0441655,C0030547,are crucial According to specialists from Chinese Medical Association for ,Activities,Parenteral Nutrition,5,X,[acty],[topp],,E02.421.505;E02.642.500.505
a13132b5-22f0-439a-8582-e625565fb47c,C0013879,C0206750,is in patients with ,Elements,Coronavirus Infections,6,X,[elii],[dsyn],D01.268,C02.782.600.550.200
702f6508-4859-4f03-b042-991ab3fd2b1a,COVID19,C0206750,of propagation is ,COVID19,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
563c151e-17ed-4666-96ab-7b83730b18e0,COVID19,C0012634,of propagation is ,COVID19,Disease,3,X,????,[dsyn],????,C23.550.288
2d50c9c2-5e59-427e-a142-01409c968e17,C0018581,C0042210,represent weapons in absence of ,Handwashing,Vaccines,2,X,[acty],[aapp/imft/phsu],N06.850.670.150.500,D20.215.894
331f4b78-a822-4559-8305-31d7ce0019db,C0020405,C0042210,represent weapons in absence of ,Hygiene,Vaccines,1,X,[bmod],[aapp/imft/phsu],E02.547;N06.850.670,D20.215.894
b67e3c94-fd1a-4ac7-878c-47fab6ea284c,C0086418,C3658340,was admitted to Hubei Provincial 1day 1week,Homo sapiens,Hospital Medicine,3,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H02.403.377
a7b6ec3a-17c3-400d-9966-7f65c8996115,C0086418,C0013227,was admitted to Hubei Provincial 1day 1week,Homo sapiens,Pharmaceutical Preparations,3,X,[humn],[phsu],B01.050.150.900.649.313.988.400.112.400.400,D26
29815356-280c-4927-8db1-4c9bfdfe2505,C0086418,1day,was admitted to Hubei Provincial 1day 1week,Homo sapiens,1day,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
29815356-280c-4927-8db1-4c9bfdfe2505,C0086418,1day,was admitted due to right limb weakness for 1day 1week,Homo sapiens,1day,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
89f20a19-8bb2-4ecb-b0f8-3ff482021131,C0428692,COVID-19,have effect on ,Ambient temperature,COVID-19,1,X,[npop],[virs],,C000657245
e0aeb0c8-4526-4ad3-85e7-db6315cfb99a,C0428692,C0242781,have effect on ,Ambient temperature,disease transmission,1,X,[npop],[patf],,N06.850.310
4f789338-d092-4845-9a1d-89cccdd58144,C1963758,C0015967,is often considered for ,Immunomodulation,Fever,1,X,[topp],[sosy],E02.095.465;G12.535,C23.888.119.344
ba5b4866-45e9-40d6-9f35-1bca5f9f5a98,C0042164,C1963758,generated consensus statements for ,Uveitis,Immunomodulation,1,X,[dsyn],[topp],C11.941.879,E02.095.465;G12.535
e2b0cd1d-5888-4590-a1e5-eac42ef26ee6,C2825347,C0020517,was demonstrated ,Immunoglobulin A Human,Hypersensitivity,8,X,[imft/phsu],[patf],,C20.543
b4edddab-55f0-4329-904a-8b126381fd81,C2825347,C0005516,was demonstrated ,Immunoglobulin A Human,Biological Markers,8,X,[imft/phsu],[clna],,D23.101
a59fff68-6ce3-4a9f-bfab-bca9eda6971f,C2825347,C0009450,was demonstrated ,Immunoglobulin A Human,Communicable Diseases,8,X,[imft/phsu],[dsyn],,C01.539.221
3e66fa74-c5f5-4def-9cd1-b9f94f0645f8,studys,C0152060,apply morphoproteomics to ,studys,Transection (procedure),2,X,????,[topp],????,
53247620-06d6-4927-821f-4f0f3c897831,C0387583,C1440080,is in ,cyclooxygenase 2,Alveolar,1,X,[aapp/enzy],[bpoc],D08.811.600.720.750,
eef093f6-232f-42bc-b7d5-b4426c09381b,C0152060,C0242629,rare PD-1 as ,Transection (procedure),CD8-Positive T-Lymphocytes,2,X,[topp],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
eef093f6-232f-42bc-b7d5-b4426c09381b,C0152060,C0242629,relative paucity of ,Transection (procedure),CD8-Positive T-Lymphocytes,2,X,[topp],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
fa9f37b1-5a84-4198-858b-18cb530b9402,C0032285,C1457887,appeared with clinical ,Pneumonia,Symptoms,2,X,[dsyn],[sosy],C08.381.677;C08.730.610,
4f19888d-680d-48e5-aa53-4c813e3b3380,C0032285,C0543829,appeared with clinical ,Pneumonia,pneumonia clinical,2,X,[dsyn],[dsyn],C08.381.677;C08.730.610,
c42e0bf7-0797-49b2-b02c-b6cecf810e39,WONCA,C0015607,is in ,WONCA,family medicine (field),2,X,????,[bmod],????,H02.403.340.500
c53145e6-f269-456d-96ea-91106dac1474,C1705648,C1824356,be concerns than ,Dropping,KIAA1551 gene,4,X,[acty],[gngm],,
710612a4-51f9-4547-b18f-e2336f97e51d,C0376637,C0023175,was described as ,Indinavir,Lead,2,X,[orch/phsu],[elii/hops],D03.383.725.385,D01.268.556.435;D01.552.544.435;x.x.x.x
625acdb2-7c9c-44e6-b793-1b4ea7a9684f,C0376637,C0013227,was described as ,Indinavir,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],D03.383.725.385,D26
e3b106b1-a57a-447b-9165-4443a3dc5fc0,C0376637,C4050231,was described as ,Indinavir,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[orch/phsu],[clna],D03.383.725.385,
f8de6cf2-18a4-47a5-a61d-f0931aaad684,C0023175,C4050231,is with docking ,Lead,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[elii/hops],[clna],D01.268.556.435;D01.552.544.435;x.x.x.x,
9f53f74d-5069-45ec-af18-dad5d549a88a,C0013227,C4050231,is with docking ,Pharmaceutical Preparations,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[phsu],[clna],D26,
06416715-fefa-4cde-a3b5-6f7581737ee5,C0376637,C0599740,possesses important ,Indinavir,pharmacophore,2,X,[orch/phsu],[rcpt],D03.383.725.385,
a0cde3d6-3cc0-44c0-b655-83183bb4abf4,C4082587,COVID-19,suggesting ,HLA Class II Histocompatibility Antigen Gamma Chain human,COVID-19,1,X,[aapp/imft],[virs],,C000657245
4118c0c6-8f31-47f5-9f90-5ec162a2df75,C4082587,C0087111,suggesting ,HLA Class II Histocompatibility Antigen Gamma Chain human,Therapeutic procedure,1,X,[aapp/imft],[topp],,E02
03e122fb-a1f0-4728-ba86-7c00156b14ed,C4082587,C1880355,suggesting ,HLA Class II Histocompatibility Antigen Gamma Chain human,Discover,1,X,[aapp/imft],[acty],,
bf8c1174-e02d-4922-b75e-92e1016ff374,C0206750,C1516048,were ,Coronavirus Infections,Assessed,2,X,[dsyn],[acty],C02.782.600.550.200,
c22def03-ae6d-46c8-b610-9ed08b153cce,C0547605,C0042769,is in corona ,prevention of infection,Virus Diseases,1,X,[topp],[dsyn],,C02
031419e3-dd65-4db1-a8ed-8f92a6101e81,C0596197,COVID-19,is in ,blood treatment,COVID-19,2,X,[topp],[virs],,C000657245
357ba808-8e89-4bf9-a912-f470ec6e61d6,C0030693,C0596197,received bedside ,Patient Isolation,blood treatment,3,X,[topp],[topp],E02.770;N06.850.780.200.450.650,
00192c21-901d-42a2-b68a-8a0708c80bd5,C0030693,C0005768,received ,Patient Isolation,In Blood,1,X,[topp],[bdsu],E02.770;N06.850.780.200.450.650,x.x.x.x.x
765ec2e4-63fb-4731-b9f4-ad2b0f7b1696,C0439056,COVID-19,is in ,Throat swab sample,COVID-19,1,X,[bdsu],[virs],,C000657245
e9e44f27-ab59-4a94-83ec-75fd59428aaf,C0439056,C0319157,is in ,Throat swab sample,AS virus,1,X,[bdsu],[virs],,
d118252c-1721-455c-ae80-c289d8d83312,C0439056,C0028606,is in ,Throat swab sample,Nucleic Acids,1,X,[bdsu],[bacs/nnon],,D13.444
92c54b61-2699-4df8-97f7-5fc10b474350,C0005768,C0009450,control of patients in ,In Blood,Communicable Diseases,1,X,[bdsu],[dsyn],x.x.x.x.x,C01.539.221
e944916a-3983-4eb7-9488-cfee9faa46a2,COVID-19,C0010356,in treatment is occurrence of ,COVID-19,Cross Infection,1,X,[virs],[patf],C000657245,C01.539.248;C23.550.291.875.500
8f0a254a-d919-4033-8646-e02cec72cff1,C0005768,C0010356,occurrence of ,In Blood,Cross Infection,1,X,[bdsu],[patf],x.x.x.x.x,C01.539.248;C23.550.291.875.500
27ff5bf6-bb73-4921-9bc8-52e10e8c941f,C0949880,C0035204,cause mild ,Human coronavirus 229E,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150.075.750,C08.618
2cc0fd7e-62d0-4887-b2ff-b4749ea0f1e3,C0206750,C0021400,has emerged Like severe ,Coronavirus Infections,Influenza,2,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.620.365;C08.730.310
43744e7c-06ec-4db2-9987-3b6ddc3471c9,C0012634,C2350530,predisposes patients to secondary ,Disease,Bronchopulmonary Aspergillosis,2,X,[dsyn],[dsyn],C23.550.288,C01.703.080.768;C08.381.472.850
abf33708-0703-44ba-a9b2-d4a496144cff,C1290884,C2350530,are predisposing risk factors for ,Inflammatory disorder,Bronchopulmonary Aspergillosis,2,X,[dsyn],[dsyn],,C01.703.080.768;C08.381.472.850
0c1cbe36-866b-48bb-a81e-29928e448cd4,C1175743,C1145701,may challenge use of ,SARS coronavirus,amphotericin B liposomal,2,X,[virs],[antb/orch],B04.820.504.540.150.113.937,x.x.x.x
77134f50-3be9-480e-8bac-faf73bb191a3,C0597357,C0014597,was found highly expressed in GI ,receptor,Epithelial Cells,2,X,[aapp/rcpt],[cell],,A11.436
8d07b529-47e9-4740-9e62-197068f74190,C0022709,C0014597,was found highly expressed in GI ,Peptidyl-Dipeptidase A,Epithelial Cells,2,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
8d07b529-47e9-4740-9e62-197068f74190,C0022709,C0014597,are differentially expressed in respiratory ,Peptidyl-Dipeptidase A,Epithelial Cells,2,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
8d07b529-47e9-4740-9e62-197068f74190,C0022709,C0014597,identified on ,Peptidyl-Dipeptidase A,Epithelial Cells,1,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
8d07b529-47e9-4740-9e62-197068f74190,C0022709,C0014597,is in primary ,Peptidyl-Dipeptidase A,Epithelial Cells,1,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
2f8e841d-d5fa-473f-9266-2cafb780504b,C0597357,C1999230,be highly expressed in ,receptor,Providing (action),1,X,[aapp/rcpt],[acty],,
9a6eab63-1102-4dee-9de9-15507d5946d9,C0022709,C1999230,be highly expressed in ,Peptidyl-Dipeptidase A,Providing (action),1,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
7aed56ec-58de-4b71-89d7-3a3f142de490,C0476288,C0206750,is in patients with ,Digestive symptom,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
4b0f6087-9608-437f-8d8e-84641087ab68,C0030664,C0815172,is in ,Pathology,patient characteristics,1,X,[bmod],[clna],H02.403.650,
3c29f329-53a9-4738-b49c-9424dbc50f1e,C0030664,C0206750,is in ,Pathology,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.650,C02.782.600.550.200
ac4083d5-247e-46c4-ba7d-cd28adb4a1ef,C0020311,C0012634,affect main manifestations of ,Hydrotherapy,Disease,2,X,[topp],[dsyn],E02.779.492;E02.831.535.492,C23.550.288
b2f85876-65c6-408b-bdb4-99b7fd5c8fa3,C0014507,C0337005,is in ,Epidemiology,Cold weather,1,X,[bmod],[npop],H02.403.720.500,
93d38229-77c5-4385-9a70-52ffc59c1e39,C2745965,C0023693,trends brought to ,Emergencies [Disease/Finding],Light,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
93d38229-77c5-4385-9a70-52ffc59c1e39,C2745965,C0023693,attitudes brought to ,Emergencies [Disease/Finding],Light,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
fcb0629d-9a3e-4e0c-919d-850e3259948e,cov,C0206750,is member of ,cov,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
cbacd179-bf60-45a5-b39b-5447609b9eac,COVID-19,C3536832,could have ,COVID-19,Air,2,X,[virs],[inch/phsu],C000657245,G16.500.275.063.150;N06.230.300.100.150
83c652ce-febc-4914-a188-9562471db20a,COVID-19,C0242781,could have ,COVID-19,disease transmission,2,X,[virs],[patf],C000657245,N06.850.310
3b46d5b7-ec97-4b2e-add0-c24967a750ee,COVID-19,C1720884,could have atmospheric ,COVID-19,Particulate Matter,2,X,[virs],[sbst],C000657245,D20.633
54e92a10-7163-4007-9830-7c4a36c2710f,C1720884,C0032285,induces Pneumonia in,Particulate Matter,Pneumonia,6,X,[sbst],[dsyn],D20.633,C08.381.677;C08.730.610
d5ab5d9c-6526-4996-84e1-3f74c6b24bd5,C0012634,C0719214,is in twentieth ,Disease,century,1,X,[dsyn],[phsu/vita],C23.550.288,
d5ab5d9c-6526-4996-84e1-3f74c6b24bd5,C0012634,C0719214,has emerged as once in a ,Disease,century,1,X,[dsyn],[phsu/vita],C23.550.288,
d5ab5d9c-6526-4996-84e1-3f74c6b24bd5,C0012634,C0719214,is considered as major health ,Disease,century,1,X,[dsyn],[phsu/vita],C23.550.288,
fc2861a7-5add-434a-bcd5-f87f46db77c0,C0206750,C1457887,results after resolution of ,Coronavirus Infections,Symptoms,10,X,[dsyn],[sosy],C02.782.600.550.200,
49d057a5-be29-42aa-88ed-583041d7dfcd,C0024115,C1457887,could lead to serious of clinical ,Lung diseases,Symptoms,2,X,[dsyn],[sosy],C08.381,
4e51f00c-5f2e-455e-b022-9b135e79c4f3,C0748168,C0206750,is in ,Pulmonary Pathology,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
13a9efdc-e197-4d20-b585-ca4b53452601,C0002808,C0451610,were Patient review on,Science of Anatomy,Patient review,6,X,[bmod],[topp],H01.158.100,
33c0149d-d6f0-46ca-a4bd-0263999955a0,C0001933,C0026727,were performed for examinations of ,Alcian Blue,Mucous body substance,1,X,[irda/orch],[bdsu],D03.633.100.473.050;x.x.x.x,A12.200.503
c605e61a-6b09-4066-a914-381fb39d9c61,C0001933,C0819757,were performed for examinations of ,Alcian Blue,Structure of parenchyma of lung,2,X,[irda/orch],[tisu],D03.633.100.473.050;x.x.x.x,
9414b5cb-5992-40e5-9718-b97e0e7c10a9,PCR,C1175743,detect ,PCR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
9414b5cb-5992-40e5-9718-b97e0e7c10a9,PCR,C1175743,by SARS coronavirus is,PCR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
9414b5cb-5992-40e5-9718-b97e0e7c10a9,PCR,C1175743,positive for CoV2,PCR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
9414b5cb-5992-40e5-9718-b97e0e7c10a9,PCR,C1175743,is currently standard for ,PCR,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
003ce48c-75bb-48e1-bcf1-c3c581bccb43,C0030664,C0024109,is in ,Pathology,Lung,1,X,[bmod],[bpoc],H02.403.650,A04.411
d6aed4a7-ddbb-47cd-8278-ce0d64aab72a,C0333977,C0021966,extensive impairment of type ,Atypical hyperplasia,Iodides,2,X,[patf],[inch],,D01.248.497.158.490;D01.475.410
92a86da3-5b16-4022-bcce-ba785d0855ea,C0333977,C1440080,extensive impairment of type ,Atypical hyperplasia,Alveolar,2,X,[patf],[bpoc],,
64b25328-c9d6-4ea0-af46-7d1a44925674,C0026727,C0015388,is with fibrinous ,Mucous body substance,Exudate,2,X,[bdsu],[bdsu],A12.200.503,A12.383
0b09639a-dcc5-47ba-b3e8-4f5796e7270e,C0225700,C1175743,were infected by ,Type-II Pneumocytes,SARS coronavirus,2,X,[cell],[virs],A04.411.715.100;A11.436.081,B04.820.504.540.150.113.937
368ab9aa-9348-4022-b6f3-313565743889,C0225700,C0085236,is in ,Type-II Pneumocytes,Macrophages Alveolar,2,X,[cell],[cell],A04.411.715.100;A11.436.081,A11.329.372.600;A11.627.482.600;A11.733.397.600;A15.382.670.522.600;A15.382.680.397.600
8ce38104-b478-413e-afbe-b3f9f86a496d,C0206750,C1254373,emerged as ,Coronavirus Infections,etiologic agent,1,X,[dsyn],[sbst],C02.782.600.550.200,
53e556cb-82e2-41bf-9d34-46c73db38ae2,C0020517,C0206750,were conducted to ,Hypersensitivity,Coronavirus Infections,6,X,[patf],[dsyn],C20.543,C02.782.600.550.200
e7ae1ee4-5ab1-4f38-8c53-c283ff6f5fd6,C0206750,C0085306,screened compounds for their ,Coronavirus Infections,Feline infectious peritonitis,2,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.600.550.200.360;C22.180.440
6123b90a-756f-420b-af7c-e8542b302d91,C0206750,C0472699,was proliferated in feline Fcwf-4cells in human ,Coronavirus Infections,Hemopoietic stem cell transplant,2,X,[dsyn],[topp],C02.782.600.550.200,E02.095.147.500.500.500;E04.936.225.687.500
58171a6f-d8f5-4a6e-985f-6de284578254,C2741673,C0012634,is in response of patients to ,Account number:Identifier:Point in time:^Patient:Nominal,Disease,2,X,[clna],[dsyn],,C23.550.288
ca3badba-9f50-471a-9743-3f3835f902e7,C0023895,C0010827,could could multifactorial related to any of ,Liver diseases,Cytopathogenic Effect Viral,2,X,[dsyn],[comd],C06.552,E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190
3ed43e50-9aef-4574-8b3f-33bb56c1859b,C0023895,C0206750,is in ,Liver diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C06.552,C02.782.600.550.200
fb1ba53a-90bd-4771-9195-db49312be5fe,C0022709,C1440080,are present in type ,Peptidyl-Dipeptidase A,Alveolar,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
d1cf54d4-4267-46a2-b121-93a276360ac0,C0597360,C0023884,were identified in gastrointestinal tract of ,receptor expression,Liver,2,X,[genf],[bpoc],,A03.620
6210f37d-cba6-4d65-b7b5-c7aab7ddda39,C2717801,C1537068,govern ,Viral Tropism,Virus Internalization,2,X,[phsf],[biof],G06.099.925;G06.920.863,G06.920.881
a3562f2f-1cc8-41ad-ac0d-1fe9e693b361,C2717801,C0284778,govern Virus Internalization in,Viral Tropism,RNA Small Cytoplasmic,2,X,[phsf],[bacs/nnon],G06.099.925;G06.920.863,D13.444.735.790.552.750
ebb53a30-d79d-417a-a43a-f9609e8ec3ae,C0022709,C0284778,govern Virus Internalization in,Peptidyl-Dipeptidase A,RNA Small Cytoplasmic,2,X,[aapp/enzy/imft],[bacs/nnon],D08.811.277.656.350.350.687,D13.444.735.790.552.750
00b9c468-81e5-4e72-90fb-10b1b18da209,C2717801,C0007634,govern Virus Internalization in single,Viral Tropism,Cells,2,X,[phsf],[cell],G06.099.925;G06.920.863,A11
b85fcca0-4a9f-405d-86dd-e60f1ba6a2af,C0022709,C0007634,was expressed in ,Peptidyl-Dipeptidase A,Cells,12,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11
e4d825f2-859f-48e7-a508-013326652e54,C0014597,C0022709,display highest ,Epithelial Cells,Peptidyl-Dipeptidase A,2,X,[cell],[aapp/enzy/imft],A11.436,D08.811.277.656.350.350.687
0f0a8401-95f1-4128-8e3e-c6bf0187f3dc,C0206750,C0275522,investigate prevalence in ,Coronavirus Infections,Asymptomatic Infections,3,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.187.500
0f0a8401-95f1-4128-8e3e-c6bf0187f3dc,C0206750,C0275522,vary from ,Coronavirus Infections,Asymptomatic Infections,2,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.187.500
1b59aaa5-e834-47a9-aa15-b6c79c651f34,C0002871,C0596448,increased D ,Anemia,dimer,2,X,[dsyn],[chvs],C15.378.071,
09845180-12c5-4ca4-9931-b52c4b78438c,C0002871,C0021760,increased ,Anemia,Interleukin-6,2,X,[dsyn],[aapp/imft],C15.378.071,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
c14c955c-b9eb-445e-979e-d023bd7d9ab5,C1704241,RBD,is with RBD,complex (molecular entity),RBD,1,X,[chvs],????,,????
a0066a82-2231-43f6-8e4e-78a585731e19,C0013982,C1149286,inhibit SARS coronavirus entry by apparently,Emodin,enzyme binding,1,X,[bacs/orch/phsu],[moft],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,
7d96240b-78fa-4191-a951-dd2ae50abe16,C0013982,C0003018,inhibit SARS coronavirus entry by apparently,Emodin,Angiotensins,1,X,[bacs/orch/phsu],[aapp/bacs/phsu],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
e829bea4-41c2-4039-90f5-9008073ae0e9,C0920687,C0023693,is in ,cancer care,Light,2,X,[topp],[npop],,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
5cfb373a-8c79-456f-9a1f-b4fd3c913777,C0014442,C0597357,activate ,Enzymes,receptor,2,X,[aapp/enzy],[aapp/rcpt],D08.811,
bd004cd2-f8ee-4c5c-9770-033db373c0df,C0287990,C0597357,activate ,paired basic amino acid cleaving enzyme,receptor,2,X,[aapp/enzy],[aapp/rcpt],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
9413cef0-67b4-4a1b-ba16-64e11cd25886,C1167395,C1514535,activate ,Host (organism),Protein Binding Motif,2,X,[orgm],[amas],,
10cdcc98-a471-4bb3-bb8d-8389442d26ef,C0014442,C1514535,activate ,Enzymes,Protein Binding Motif,2,X,[aapp/enzy],[amas],D08.811,
3a6be8a1-53de-4f73-9cd4-8e4b45eca42f,C0287990,C1514535,activate ,paired basic amino acid cleaving enzyme,Protein Binding Motif,2,X,[aapp/enzy],[amas],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
10903636-b6b6-47bb-adee-9caec6043b0f,C1167395,C0597358,activate ,Host (organism),receptor binding,2,X,[orgm],[moft],,
d389b2e6-f0fb-4626-929a-492ee4906ddd,C0014442,C0597358,activate ,Enzymes,receptor binding,2,X,[aapp/enzy],[moft],D08.811,
468eae83-cc41-40fc-80ff-3312487f7f2b,C0287990,C0597358,activate ,paired basic amino acid cleaving enzyme,receptor binding,2,X,[aapp/enzy],[moft],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
88c6d0c5-55c3-4729-9c1e-e979ff3045f2,C0040300,C0287990,higher expression of ,Body tissue,paired basic amino acid cleaving enzyme,6,X,[tisu],[aapp/enzy],A10,D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353
3fe0a3bf-ac66-47c0-adac-a15ea264cee0,C0220641,C0287990,exhibit higher expression of ,Lip and Oral Cavity Carcinoma,paired basic amino acid cleaving enzyme,2,X,[neop],[aapp/enzy],,D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353
5cbe0ef9-fdb9-4f5d-ba78-be5a021af5ff,C0220641,C0206750,require attention during ,Lip and Oral Cavity Carcinoma,Coronavirus Infections,1,X,[neop],[dsyn],,C02.782.600.550.200
51bb5592-88bc-4a36-b938-6f2e6246c565,C0220641,C0027651,require attention during ,Lip and Oral Cavity Carcinoma,Neoplasms,2,X,[neop],[neop],,C04
c3358d2d-9993-4b48-8014-01a10026e596,C0075816,C0013227,exhibited Binding (Molecular Function) energy scores with concerned,taraxerol,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],x.x.x.x,D26
40f993f3-a001-42da-b8ee-caa073197a6b,C1707455,C1275589,were distributed in fewer ,Comparison,Lobular pneumonia,1,X,[acty],[dsyn],,
266a06e1-0cb8-44a6-bf7b-c9f09ff9df07,C0599878,GGO,are multiple areas of GGO ,disease characteristic,GGO,2,X,[patf],????,,????
7c7882a1-72ee-4819-afc1-9ffbd74ad67b,C1175743,C1879547,cause Disease through,SARS coronavirus,Activation action,1,X,[virs],[acty],B04.820.504.540.150.113.937,
c1cf8862-3a9d-4990-8275-0ee2099a301f,C0236099,C0206419,induced by ,Disorder of male reproductive system,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
898bde64-3710-4327-8302-bbffa785831a,C1707391,C1706202,were identified during electronic database ,Choose (action),Search - action,3,X,[acty],[acty],,
1eed53ae-a49f-4a5b-8b97-062adb43fb46,C2948600,C0063034,analyse results of ,Aim,huperzine B,2,X,[inch/phsu],[orch/phsu],,x.x.x.x
14805e9c-6d10-46c8-8e12-f39a926d3438,C0301630,C0012634,are among consequences of ,Reduction (chemical),Disease,2,X,[npop],[dsyn],,C23.550.288
0a0e03e2-cc5c-453a-9eba-5a159cb3b6cf,C0028754,C0012634,BACKGROUND/During 2019 ,Obesity,Disease,4,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
0a0e03e2-cc5c-453a-9eba-5a159cb3b6cf,C0028754,C0012634,has In addition has correlated with mortality rates after ,Obesity,Disease,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
0a0e03e2-cc5c-453a-9eba-5a159cb3b6cf,C0028754,C0012634,increase chances of ,Obesity,Disease,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
0a0e03e2-cc5c-453a-9eba-5a159cb3b6cf,C0028754,C0012634,risk in patients with ,Obesity,Disease,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
a5b3723a-a064-44dc-bf3a-6ed4d1467ae8,ALF,C0001899,was determined as 40U/L,ALF,Alanine Transaminase,4,X,????,[aapp/enzy],????,D08.811.913.477.700.100
4cbb04e9-3bd1-465e-86d8-c10030a87296,ALF,40U/L,was determined as 40U/L,ALF,40U/L,4,X,????,????,????,????
205343ac-d9b9-4bff-b689-ce4da9c40549,C0028754,C1305855,was determined as 24kg/m,Obesity,Body mass index,5,X,[dsyn],[clna],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175
f4d5138a-8ab8-4f29-b202-31c0edd82dd0,C0028754,24kg/m,was determined as 24kg/m,Obesity,24kg/m,3,X,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,????
83fa051a-6171-4ddf-96b9-2bb02c2e8e44,C2926735,C0028754,was increased to those with overweight ,Duration,Obesity,20,X,[orch/phsu],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
623bcd5b-9723-4aca-b01c-9ccfce2ee4fe,ALF,C0012634,predicting probability of prolonged hospitalization in patients with ,ALF,Disease,2,X,????,[dsyn],????,C23.550.288
cbc6e5d2-4632-46c2-a371-50c83b35aa37,C2948600,C0242781,reducing ,Aim,disease transmission,1,X,[inch/phsu],[patf],,N06.850.310
cbc6e5d2-4632-46c2-a371-50c83b35aa37,C2948600,C0242781,slow ,Aim,disease transmission,2,X,[inch/phsu],[patf],,N06.850.310
85f4e91a-5027-4a83-afb4-44d4384fdf7c,C1706202,C1330330,succinctly summarize primary active ingredients of action of ,Search - action,Hand Sanitizers,2,X,[acty],[phsu],,D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650
1a18f605-51bc-4840-a72b-4d1d06a86eb4,C0001962,C1175743,be effective against ,Ethanol,SARS coronavirus,20,X,[orch/phsu],[virs],D02.033.375;x.x.x.x,B04.820.504.540.150.113.937
d2f97f9b-0758-4c76-b02c-fc5a102b675b,C0242781,C1175743,be effective against ,disease transmission,SARS coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150.113.937
d2f97f9b-0758-4c76-b02c-fc5a102b675b,C0242781,C1175743,are responsible for three disease outbreaks since 2002 caused by ,disease transmission,SARS coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150.113.937
d2f97f9b-0758-4c76-b02c-fc5a102b675b,C0242781,C1175743,Zoonotically are responsible for three disease outbreaks caused by ,disease transmission,SARS coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150.113.937
55fe1d29-e86a-4fb7-9fa1-ba701246bbd4,C1330330,C1175743,be effective against ,Hand Sanitizers,SARS coronavirus,2,X,[phsu],[virs],D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650,B04.820.504.540.150.113.937
b5120ece-5152-40ee-a444-c908be007941,C0360714,C1537068,modulating ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Virus Internalization,2,X,[orch/phsu],[biof],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,G06.920.881
783d2d57-09c4-41c9-81a0-462d67f8d79f,C0360714,C1175743,could act acting on ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,SARS coronavirus,4,X,[orch/phsu],[virs],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,B04.820.504.540.150.113.937
2302bc1a-c0e3-465b-ab94-9626e04e689b,C0360714,C0174990,acting on ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,coronavirus receptor,2,X,[orch/phsu],[aapp/rcpt],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,x.x.x.x
0bf0dea6-6bcd-49b8-bfdd-0db874a9237b,C0360714,C0042774,could regulate ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Virus Replication,2,X,[orch/phsu],[celf],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,G06.920.925
c653df2a-3e3f-4249-9373-c579d8973323,C0360714,C0004391,inducing ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Autophagy,2,X,[orch/phsu],[celf],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,G04.146.399;G04.417.350.091
17dfc9cf-7716-4eb2-8d0f-53ea56f027d2,C0360714,C1879547,inducing ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Activation action,2,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
07e64115-722c-41e1-9de0-dfc6f573a82e,C0360714,C0206419,improve ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Genus: Coronavirus,1,X,[orch/phsu],[virs],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,B04.820.504.540.150
b59d2184-71ef-4a92-947d-5a3debcad4fa,C2259033,C0206419,improve ,activation of coagulation,Genus: Coronavirus,2,X,[phsf],[virs],,B04.820.504.540.150
f89c71c0-9a1e-4677-b1e9-7eb2405284c2,C0233514,C0440283,consuming ,Abnormal behavior,Citrus limon plant,3,X,[mobd],[plnt],F01.145.126.972;F01.145.179.750,
6ccc167b-ab83-4f3e-9a4b-f7d2aee1fcfe,C0233514,C0017102,consuming ,Abnormal behavior,Allium sativum,3,X,[mobd],[plnt],F01.145.126.972;F01.145.179.750,B01.650.940.800.575.912.250.618.100.050.060.300
17bd4818-b825-4d5d-868b-dde8c1d4322e,C0233514,C0019240,consuming ,Abnormal behavior,Herb,3,X,[mobd],[plnt],F01.145.126.972;F01.145.179.750,
32cf5b9a-7d90-4f74-9b05-66e89da9c5d0,C0233514,C0439861,consuming ,Abnormal behavior,Substance,3,X,[mobd],[sbst],F01.145.126.972;F01.145.179.750,
7322d61a-0171-4cdd-9776-93ef17865740,C0301630,CoV2,have have implemented in countries with outbreaks of CoV2,Reduction (chemical),CoV2,4,X,[npop],????,,????
1426921f-aa52-4ecc-945d-0499212fed99,C0038164,C0699748,gain insights into mechanism of ,Staphylococcal Protein A,Pathogenesis,4,X,[aapp/imft/irda],[patf],D12.776.097.820;D23.050.161.821,
8a04862e-7ae9-495a-98cf-5c8451e5a5f1,C0204514,C0699748,gain insights into mechanism of ,Structural analysis,Pathogenesis,4,X,[topp],[patf],,
a4d2ba72-a32e-4bdb-8c60-9465b3ddaddb,C0037083,C1175743,are different in case of ,Signal Transduction,SARS coronavirus,4,X,[celf],[virs],G02.111.820;G04.835,B04.820.504.540.150.113.937
b9fd8859-378a-435f-abf3-45bdab0a97d2,C0042333,C0017428,is in ,Variation (Genetics),Genome,4,X,[npop],[gngm],G05.365,G05.360.340
cfb23ad4-ba9d-4184-a72a-204fab0655e0,C0042333,C1175743,is in ,Variation (Genetics),SARS coronavirus,4,X,[npop],[virs],G05.365,B04.820.504.540.150.113.937
5f20d6c5-6081-4ab3-924a-bf30491e9935,C0006786,C0001272,have IC ,Calpain II,Action Potentials,2,X,[aapp/bacs],[celf],D08.811.277.656.262.500.120;D08.811.277.656.300.200.120,G04.580.100;G07.265.675.100;G11.561.570.100
969f8e40-cc8a-4ef1-8146-19d783f48160,C0243077,C0001272,have IC ,inhibitors,Action Potentials,1,X,[chvf],[celf],,G04.580.100;G07.265.675.100;G11.561.570.100
c5186337-ca3c-485f-b0b7-00f91d4bb2ee,C0006786,IC,have IC ,Calpain II,IC,2,X,[aapp/bacs],????,D08.811.277.656.262.500.120;D08.811.277.656.300.200.120,????
39cab7f5-2ed4-4069-9609-593aacd34da5,C0243077,IC,have IC ,inhibitors,IC,1,X,[chvf],????,,????
894e44ce-7836-4661-b162-2ae568620c30,C0001272,IC,is with single-digit to submicromolar IC ,Action Potentials,IC,4,X,[celf],????,G04.580.100;G07.265.675.100;G11.561.570.100,????
221309e5-79b8-4adc-b5ed-4b9b0a6237aa,C0007590,C0040676,is with ,Cell division,Transferase,3,X,[celf],[aapp/enzy],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,D08.811.913
1f31b89b-334e-4f05-9bb7-313ed415777b,C1175743,C0007590,is in ,SARS coronavirus,Cell division,3,X,[virs],[celf],B04.820.504.540.150.113.937,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
570abaf1-5738-46c3-ae83-4f5a25af60f8,C0040676,C0007590,is in ,Transferase,Cell division,6,X,[aapp/enzy],[celf],D08.811.913,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
ecc3b2a0-d751-493f-bc75-aebb2058e56f,C1175743,C0040676,is in ,SARS coronavirus,Transferase,3,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.913
f7c143b9-5955-4afc-9402-da88d013e53a,C3891814,C1175743,provide points for further development of ,Substrate,SARS coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150.113.937
9b1fba00-1ae1-41e6-8fd5-716bbefd7313,C1167622,C1175743,provide points for further development of ,Binding (Molecular Function),SARS coronavirus,7,X,[moft],[virs],,B04.820.504.540.150.113.937
75c495e1-8a81-424b-a1c0-c76c0acdc9a2,C0235029,C0206419,is in patients with ,neurological complication,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
3023dccd-d1b6-4dc9-86db-aa625e08cc70,C0497552,C1175743,are caused by Cov2 ,Congenital neurologic anomalies,SARS coronavirus,3,X,[cgab],[virs],C10.500;C16.131.666,B04.820.504.540.150.113.937
6a08319a-7038-479d-9a1e-c5c76bc3ad7b,C0497552,Cov2,are caused by Cov2 ,Congenital neurologic anomalies,Cov2,3,X,[cgab],????,C10.500;C16.131.666,????
5981e38e-02c1-4446-9df8-cd9ee2158382,C0497552,C0206419,is in ,Congenital neurologic anomalies,Genus: Coronavirus,1,X,[cgab],[virs],C10.500;C16.131.666,B04.820.504.540.150
f0180677-881f-43d4-9280-35f689b43763,C0206419,C0011570, includes ,Genus: Coronavirus,Mental Depression,1,X,[virs],[mobd],B04.820.504.540.150,F01.145.126.350
7588da58-21ab-4c92-9eaa-4576c3d32644,C0030567,C0206419,long-term sequalae of ,Parkinson Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,B04.820.504.540.150
800fc750-40b8-46f6-baa1-76329d93ff49,C0002395,C0206419,long-term sequalae of ,Alzheimer's Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,B04.820.504.540.150
5d8987be-7b72-475f-9a19-b19adb919654,C0030567,C0011570,long-term sequalae of ,Parkinson Disease,Mental Depression,2,X,[dsyn],[mobd],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,F01.145.126.350
e306dde4-d4e7-4f90-b711-3cb5a332cc55,C0002395,C0011570,long-term sequalae of ,Alzheimer's Disease,Mental Depression,2,X,[dsyn],[mobd],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,F01.145.126.350
bd26727f-d318-446a-95c4-ad647179938d,C0021747,C1175743,controlling ,Interferons,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04.820.504.540.150.113.937
89b21e2d-00cb-4b37-9633-253cbc5b87eb,C0021747,C0598312,controlling ,Interferons,DNA Replication,1,X,[aapp/imft],[genf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G02.111.225;G05.226
9821535f-0342-4851-baf8-e68ea071b451,C0021747,de,controlling de ,Interferons,de,1,X,[aapp/imft],????,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,????
44599e5b-b79b-4448-a940-35cf51c1cb25,C0021747,C0042776,controlling de ,Interferons,Virus,1,X,[aapp/imft],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04
574816be-0117-4d08-91eb-6ee6540f0088,C3273807,C1547282,were recently ,Sodium-Glucose Transporter 2 Inhibitors,Show,3,X,[orch/phsu],[anim],D27.505.519.936;D27.505.696.422.750,
50707ba3-0080-43c0-b25e-b9b5e3f6e902,C0178784,C0206750,may explain pulmonary deficits seen in ,Organ,Coronavirus Infections,9,X,[bpoc],[dsyn],,C02.782.600.550.200
9afd240d-9adf-4f8d-85e1-243510a98b48,C1547282,C1819995,could could potential ,Show,Host Cell,1,X,[anim],[celc],,
9cf89fa5-087f-412b-a702-d7494a353a15,C1547282,C1175743,could could potential ,Show,SARS coronavirus,1,X,[anim],[virs],,B04.820.504.540.150.113.937
de14ccb9-3905-4daa-80de-49ee6e8adebb,C0007600,C1819995,are genetically and phenotypically different from ,Cultured Cell Line,Host Cell,6,X,[cell],[celc],A11.251.210,
ae4e77ee-5f67-43c4-be50-b95467a13a3f,C0178708,C1819995,are genetically and phenotypically different from ,immortalized cell,Host Cell,2,X,[cell],[celc],,
bd3e6896-19e0-4b17-be28-eac9a0a8c44e,C1182792,2D,is in 2D,Epithelial cell of proximal tubule,2D,4,X,[cell],????,,????
53a79621-cffb-422f-ad56-c17bed499666,C0086418,2D,is in 2D,Homo sapiens,2D,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
5b326873-a69f-4b8f-afec-8467e02158cc,C0022646,2D,is in 2D,Kidney,2D,2,X,[bpoc],????,A05.810.453,????
22ba3c55-0e03-4bf5-acdf-f307c60b000e,C0022677,C0596902,Importantly maintained lineage physiological aspects with expression of,Kidney Tubules Proximal,Membrane Transport Proteins,1,X,[bpoc],[aapp/bacs],A05.810.453.736.560.570,D12.776.157.530;D12.776.543.585
22ba3c55-0e03-4bf5-acdf-f307c60b000e,C0022677,C0596902,maintained lineage physiological aspects with expression of specific,Kidney Tubules Proximal,Membrane Transport Proteins,1,X,[bpoc],[aapp/bacs],A05.810.453.736.560.570,D12.776.157.530;D12.776.543.585
dcfa1ebe-2f06-4f71-8ef7-783afe361585,C0022677,C0031843,maintained lineage ,Kidney Tubules Proximal,physiological aspects,4,X,[bpoc],[phsf],A05.810.453.736.560.570,x.x.x.x
c986ad17-900b-48be-aef0-70a45a7a71aa,C1452534,C1175743,receptor for,ACE protein human,SARS coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150.113.937
c986ad17-900b-48be-aef0-70a45a7a71aa,C1452534,C1175743,is entry ,ACE protein human,SARS coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150.113.937
41aa6787-ae97-49e3-9df2-047b7d53261d,C1452534,2DCR,was Very interestingly twofold higher in 3Dorganoids culture 2DCR ,ACE protein human,2DCR,3,X,[aapp/bacs],????,x.x.x.x,????
ef7c873c-61bd-4307-9460-bf9c3a08a316,C1452534,C0012634,was Very interestingly twofold higher in 3Dorganoids culture 2DCR ,ACE protein human,Disease,3,X,[aapp/bacs],[dsyn],x.x.x.x,C23.550.288
b705a5a4-b332-475a-876b-cbf9d3e88ee2,C1452534,C1707455,was Very interestingly twofold higher in 3Dorganoids culture 2DCR ,ACE protein human,Comparison,5,X,[aapp/bacs],[acty],x.x.x.x,
33f8ccf7-ce49-4dc8-98c9-98a63486bdde,C4281807,C0024075,enter Cellular Reprogramming with,Vitronectin human,Luciferases,2,X,[aapp/bacs],[aapp/enzy/irda],,D08.811.682.517;D12.776.532.510
cc743da5-8e4f-4d1c-bd32-5732b645c9c4,C4281807,C3850096,enter ,Vitronectin human,Cellular Reprogramming,2,X,[aapp/bacs],[celf],,G04.152.262;G05.135
531d7397-dfa6-47a0-9a20-fcc0743a81aa,C0017428,C0042765,decrease its inocula,Genome,Virulence,2,X,[gngm],[biof],G05.360.340,G06.930
d8a8da97-1cde-4864-accd-e2ce54de291b,C0017428,C0319157,decrease its inocula,Genome,AS virus,3,X,[gngm],[virs],G05.360.340,
d37fb62d-4541-46ae-abec-dab079f3c723,C0017428,inocula,decrease its inocula,Genome,inocula,2,X,[gngm],????,G05.360.340,????
42652fe6-1da8-43a2-8dbb-20894aa9cfab,C1707455,C1452534,demonstrated moderately lower risk with ,Comparison,ACE protein human,2,X,[acty],[aapp/bacs],,x.x.x.x
fc1212af-92f1-4ce3-891c-e894ed680403,C3888198,C1452534,demonstrated moderately lower risk with ,BESTROPHINOPATHY AUTOSOMAL RECESSIVE,ACE protein human,2,X,[dsyn],[aapp/bacs],,x.x.x.x
4e57d5e6-104e-4523-bdc1-a1784755a3e2,nt,C1167395,would of would threat to ,nt,Host (organism),3,X,????,[orgm],????,
a0b45d9d-9d3c-4479-8b1a-7ab368779324,C0042776,C0023779,interacting with ,Virus,Lipids,6,X,[virs],[orch],B04,D10
91b52b88-4a33-443c-9dba-32fa92a2cfb3,C0042776,C0596901,interacting with ,Virus,Membrane,6,X,[virs],[celc],B04,A10.615
29be8cb0-2843-4f44-9d08-281eec1966c1,C0042776,C0178784,could also affect human internal ,Virus,Organ,3,X,[virs],[bpoc],B04,
7f28f595-e40f-4fac-8699-2b7ada60bdbc,C1175743,C0025249,is in case detrimentally dependent on integrity of its ,SARS coronavirus,Membrane Lipids,6,X,[virs],[orch],B04.820.504.540.150.113.937,D10.570
e22e0c70-5a0f-4af6-b9ea-92f190de216a,C0206750,C0043528,is new ,Coronavirus Infections,Zoonoses,1,X,[dsyn],[dsyn],C02.782.600.550.200,C01.908;C02.968;C03.908;C22.969
9a00672e-faca-475a-ba29-ca99102275e3,C0012634,C0043528,is new ,Disease,Zoonoses,1,X,[dsyn],[dsyn],C23.550.288,C01.908;C02.968;C03.908;C22.969
a716f905-64d3-48ea-8240-4f93a5c65087,C0012634,C0282686,IMPACT gene of be may,Disease,Respiratory System Agents,1,X,[dsyn],[phsu],C23.550.288,D27.505.954.796
a716f905-64d3-48ea-8240-4f93a5c65087,C0012634,C0282686,was initially characterized by mainly manifestations of ,Disease,Respiratory System Agents,1,X,[dsyn],[phsu],C23.550.288,D27.505.954.796
1a368516-aa26-4e26-8e07-4d167b39f8fe,C1825598,C0282686,may beyond may ,IMPACT gene,Respiratory System Agents,1,X,[gngm],[phsu],,D27.505.954.796
cfca3464-c9bf-4569-815b-c4c6aabc2ae1,C0042774,C0301872,are when prevalent under insufficient ,Virus Replication,Immune response,8,X,[celf],[ortf],G06.920.925,
17c80c5b-a7c8-47f6-ac2a-aef2593fa70a,C0072393,C1537068,allowing ,Protein S,Virus Internalization,2,X,[aapp/bacs],[biof],D12.776.124.670;D12.776.395.642;D23.113.725,G06.920.881
eee57ff0-296e-4b4a-8771-7f02c4c021b9,C2249699,C1537068,allowing ,activation of proteolysis,Virus Internalization,2,X,[moft],[biof],,G06.920.881
d0dccd1c-cf45-4af1-945d-6eff57cddad8,C0072393,C0221284,allowing Virus Internalization into,Protein S,Leptocyte,2,X,[aapp/bacs],[cell],D12.776.124.670;D12.776.395.642;D23.113.725,
422f9854-56eb-484c-ab26-32121ecde99a,C2249699,C0221284,allowing Virus Internalization into,activation of proteolysis,Leptocyte,2,X,[moft],[cell],,
f744b2fc-af9c-4c0f-9091-124d145bf484,C0243077,C0007634,is in ,inhibitors,Cells,1,X,[chvf],[cell],,A11
a0d69a11-81ee-4fa4-b8cf-34e9f99e6e63,C1160657,C0007634,is in ,Virus Uncoating,Cells,1,X,[celf],[cell],G06.920.950,A11
8b0f272e-2887-4467-ae52-1a242768116b,C0243077,C0034850,is in cellular ,inhibitors,Endosomes,2,X,[chvf],[celc],,A11.284.430.214.190.875.190.880.337
24fdd460-4b0e-4b58-a66f-0994f10dd3bf,C1160657,C0034850,is in cellular ,Virus Uncoating,Endosomes,2,X,[celf],[celc],G06.920.950,A11.284.430.214.190.875.190.880.337
07bed3f9-64a8-4e42-b8de-e75db41c8ec5,C0206750,C2745965,was declared ,Coronavirus Infections,Emergencies [Disease/Finding],24,X,[dsyn],[patf],C02.782.600.550.200,C23.550.291.781;N06.230.100.083;N06.850.376
dbda6313-2d3b-4ca1-9e0c-5ca18e2041fb,C0012634,C2745965,is serious ,Disease,Emergencies [Disease/Finding],8,X,[dsyn],[patf],C23.550.288,C23.550.291.781;N06.230.100.083;N06.850.376
a8e573e4-a030-42d9-a699-b0d04496d26d,C1824986,C2945744,is in ,DUOXA1 gene,Bud - CHV concept,1,X,[gngm],[anst],,
7e4a409b-c901-444e-9794-f8d646d9dfe5,C0206750,C2945744,is in ,Coronavirus Infections,Bud - CHV concept,1,X,[dsyn],[anst],C02.782.600.550.200,
6d938cdc-48fa-485b-a0b7-54c2f92e421d,C1706202,C0022671,included ,Search - action,Kidney Transplantation,2,X,[acty],[topp],,E02.870.500;E04.936.450.485;E04.950.774.400
6d938cdc-48fa-485b-a0b7-54c2f92e421d,C1706202,C0022671,was performed ,Search - action,Kidney Transplantation,1,X,[acty],[topp],,E02.870.500;E04.936.450.485;E04.950.774.400
b3fa819d-9860-4182-95ed-d2bde49a3c7f,C0022671,C4048329,potential risk for infection non-negligible comorbidity and exposure to long-term ,Kidney Transplantation,Immunosuppression,2,X,[topp],[dsyn],E02.870.500;E04.936.450.485;E04.950.774.400,E02.095.465.425.450;E05.478.610
6df1ca6c-13de-4d42-b098-97182dc40a40,C1457887,C0022671,is in ,Symptoms,Kidney Transplantation,2,X,[sosy],[topp],,E02.870.500;E04.936.450.485;E04.950.774.400
0fd83fc6-a457-416f-9157-f7e8ea6b30ab,C0024109,C0178784,are main ,Lung,Organ,2,X,[bpoc],[bpoc],A04.411,
e7852e0c-e11b-40de-9172-37ba3e3332cf,C0024109,C0035222,are main ,Lung,Respiratory Distress Syndrome Adult,2,X,[bpoc],[dsyn],A04.411,C08.381.840;C08.618.840
e7852e0c-e11b-40de-9172-37ba3e3332cf,C0024109,C0035222,involved in ,Lung,Respiratory Distress Syndrome Adult,1,X,[bpoc],[dsyn],A04.411,C08.381.840;C08.618.840
e7852e0c-e11b-40de-9172-37ba3e3332cf,C0024109,C0035222,can can used only in patients with L phenotype ,Lung,Respiratory Distress Syndrome Adult,1,X,[bpoc],[dsyn],A04.411,C08.381.840;C08.618.840
d0c755de-c375-48ad-a9c4-4f5d007d24a6,C0024109,C0206750,is with acute lung injury post ,Lung,Coronavirus Infections,5,X,[bpoc],[dsyn],A04.411,C02.782.600.550.200
ddbd1cf4-5c2b-4323-a867-a20178c0f653,C0013227,C0939237,include ,Pharmaceutical Preparations,lopinavir / Ritonavir,2,X,[phsu],[phsu],D26,
e0f95791-e667-403b-a36f-8b11e21f3ea8,C0013227,C0021747,include ,Pharmaceutical Preparations,Interferons,1,X,[phsu],[aapp/imft],D26,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
e87a3dff-329e-41e8-800a-4379b496b730,C0013227,C0032105,include ,Pharmaceutical Preparations,Plasma,2,X,[phsu],[bdsu],D26,A12.207.152.693;A12.207.270.695;A15.145.693
6b09bc17-7fda-4c69-a93b-5ed6b152109e,C0013227,C0003250,include ,Pharmaceutical Preparations,Monoclonal Antibodies,2,X,[phsu],[aapp/imft],D26,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
ee9836c5-e3d8-4c9d-83d2-39e7487e4401,C0939237,C0021747,combined with ,lopinavir / Ritonavir,Interferons,1,X,[phsu],[aapp/imft],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
dc5c29df-2b86-4230-bd56-080167758ab7,C0939237,C0032105,combined with ,lopinavir / Ritonavir,Plasma,2,X,[phsu],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
264b6c54-7a93-4098-85e5-6d9153446add,C0939237,C0003250,combined with ,lopinavir / Ritonavir,Monoclonal Antibodies,2,X,[phsu],[aapp/imft],,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
6099ace4-b26a-4ec0-b890-2fe66a0fe949,C0007820,C0871208,has disability ,Cerebrovascular Disorders,Rating (action),1,X,[dsyn],[acty],C10.228.140.300;C14.907.253,
6099ace4-b26a-4ec0-b890-2fe66a0fe949,C0007820,C0871208,has fatality ,Cerebrovascular Disorders,Rating (action),1,X,[dsyn],[acty],C10.228.140.300;C14.907.253,
e62e894a-6c62-4619-96b0-f3e649b0e25a,C0206750,EGID,is in EGID ,Coronavirus Infections,EGID,1,X,[dsyn],????,C02.782.600.550.200,????
d4500659-c3bf-4c91-a7d1-db457e223903,C0206419,C0230425,is in patients with first negative PCR ,Genus: Coronavirus,Structure of right thigh,1,X,[virs],[bpoc],B04.820.504.540.150,
459f7cbc-b99c-443b-9688-9b6391ffb5ec,C0206419,PCR,is in patients with first negative PCR ,Genus: Coronavirus,PCR,1,X,[virs],????,B04.820.504.540.150,????
36acf23b-fa82-415f-b632-48c807f95b23,remdesivir,C0206419,received emergency use authorization recently for use in patients hospitalized with ,remdesivir,Genus: Coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150
36acf23b-fa82-415f-b632-48c807f95b23,remdesivir,C0206419,have shown ,remdesivir,Genus: Coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150
9b7a873d-3fb4-47c6-89ba-ac026006b65e,C1742865,C0319157,used by ,TMPRSS2 protein human,AS virus,1,X,[aapp/enzy],[virs],x.x.x.x,
fee3d695-0026-47b4-ab48-d7d38b64b89d,C1742865,C1175743,are Proteins to,TMPRSS2 protein human,SARS coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
fee3d695-0026-47b4-ab48-d7d38b64b89d,C1742865,C1175743,are key ,TMPRSS2 protein human,SARS coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
fee3d695-0026-47b4-ab48-d7d38b64b89d,C1742865,C1175743,chemical cofactor for CoV2,TMPRSS2 protein human,SARS coronavirus,2,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
25698019-94b4-4c68-be6b-b555c7b95638,C1742865,C0033684,are key ,TMPRSS2 protein human,Proteins,1,X,[aapp/enzy],[aapp/bacs],x.x.x.x,D12.776
2e8bd3a0-5230-4df8-9cd6-8ca77f540a41,C0033147,C1175175,be also susceptible to ,Primates,Severe Acute Respiratory Syndrome,2,X,[mamm],[dsyn],B01.050.150.900.649.313.988,C02.782.600.550.200.750;C08.730.730
140384ef-13f1-4f9c-8e92-7a9e5a0f8262,C0033147,C0012634,be also susceptible to ,Primates,Disease,2,X,[mamm],[dsyn],B01.050.150.900.649.313.988,C23.550.288
d1eebf0f-d7bd-4a3f-bc0f-120aa5f66f7f,C0086418,C1254351,is with well-established potential as bi-directional zoonotic/anthroponotic ,Homo sapiens,Pharmacologic Substance,1,X,[humn],[phsu],B01.050.150.900.649.313.988.400.112.400.400,
eb78bd64-94de-4a81-9af2-9ed2925b5714,C0033147,C1254351,is with well-established potential as bi-directional zoonotic/anthroponotic ,Primates,Pharmacologic Substance,1,X,[mamm],[phsu],B01.050.150.900.649.313.988,
2bd2cbc5-b0f0-48c5-98d7-c5a2aa3d8cb1,C0033147,C0086418,is with well-established potential as bi-directional zoonotic/anthroponotic ,Primates,Homo sapiens,1,X,[mamm],[humn],B01.050.150.900.649.313.988,B01.050.150.900.649.313.988.400.112.400.400
d37359fc-794c-4e7f-bb2c-1cbecfe90273,C4045971,C0026447, includes wild ,Savannah Monkey,Monkeys,1,X,[mamm],[mamm],B01.050.150.900.649.313.988.400.112.199.120.126.110,B01.050.150.900.649.313.988.400
404e3b97-76c5-4e1c-add4-05b932f2f73e,C1742865,C0017428,inspected recently published ,TMPRSS2 protein human,Genome,2,X,[aapp/enzy],[gngm],x.x.x.x,G05.360.340
2cb95df4-b4f8-45c7-9704-0215b985bfca,C1742865,C4045971,inspected recently published ,TMPRSS2 protein human,Savannah Monkey,1,X,[aapp/enzy],[mamm],x.x.x.x,B01.050.150.900.649.313.988.400.112.199.120.126.110
42757a2a-3770-4f7b-a94b-0497b851bff8,C1742865,C0026447,inspected recently published ,TMPRSS2 protein human,Monkeys,1,X,[aapp/enzy],[mamm],x.x.x.x,B01.050.150.900.649.313.988.400
a7cbd583-3e1a-42f2-8f82-320f3d6e03a5,sabaeus,VRC,are present in VRC,sabaeus,VRC,1,X,????,????,????,????
c91768bc-d388-48eb-943c-db61ad27bdc7,C0277548,C0086418,is in communities with frequent ,Epidemic disease,Homo sapiens,1,X,[dsyn],[humn],,B01.050.150.900.649.313.988.400.112.400.400
8ae664c7-84dc-449e-aaf3-0dc2dbdfb951,C0206419,C0033147,is in communities with frequent ,Genus: Coronavirus,Primates,1,X,[virs],[mamm],B04.820.504.540.150,B01.050.150.900.649.313.988
2f175a7e-f1f8-4110-afec-792c42f233b4,C0277548,C0033147,is in communities with frequent ,Epidemic disease,Primates,1,X,[dsyn],[mamm],,B01.050.150.900.649.313.988
b0c2f18b-d1f2-4b4b-be3c-6e70598008e9,C0017710,C0024115,are used in treatment of ,Glucocorticoids,Lung diseases,2,X,[horm/orch],[dsyn],D06.472.040.543;D27.505.696.399.472.488,C08.381
e4398d93-a582-4dac-b551-3fb7a651d515,C0744425,C0206419,be considered for patients with ,glucocorticoid therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
b6a18646-961b-42f5-aa6f-40480549c71c,C1515119,C0206419,be considered for patients with ,systemic therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
af839ba6-2d05-4472-a98a-d138693be383,C0744425,C0012634,be considered for patients with ,glucocorticoid therapy,Disease,1,X,[topp],[dsyn],,C23.550.288
5b9f729a-2d2b-4db5-953b-a0e644fb2fb6,C1515119,C0012634,be considered for patients with ,systemic therapy,Disease,1,X,[topp],[dsyn],,C23.550.288
4c9329ed-512d-432b-b3ff-799fab0d3377,C0319157,C0037090,causes severe ,AS virus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],,C23.888.852
aa7a7f8f-93d9-451a-8b32-4b4657b95976,C0206419,C0003451,great need for ,Genus: Coronavirus,Antiviral Agents,1,X,[virs],[phsu],B04.820.504.540.150,D27.505.954.122.388
96a4c83a-c670-4f8c-a0f4-1d9eaed1d07d,C0042210,C0009426,show promise in ,Vaccines,Combat Disorders,1,X,[aapp/imft/phsu],[mobd],D20.215.894,F03.950.750.249
d813e5f0-4234-44dd-8964-597aee8215d2,C1175175,C0042542,is in ,Severe Acute Respiratory Syndrome,Vero Cells,8,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.251.210.955;A11.436.955
3f5bfc3e-d76f-4ffa-a34a-d84200767738,C1175175,C1335332,is in ,Severe Acute Respiratory Syndrome,Papillomavirus Transforming Protein E6,4,X,[dsyn],[aapp/bacs],C02.782.600.550.200.750;C08.730.730,
91ffe199-d856-4d94-9b28-031a7c2dd799,COVID19,C0206419,of propagation is ,COVID19,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
e7939b58-c8d9-4328-8ccf-8550451b4860,C0006145,C0206419,thin-section CT of ,Breast Diseases,Genus: Coronavirus,2,X,[dsyn],[virs],C17.800.090,B04.820.504.540.150
32c94850-9807-487f-8feb-4c781042b5c4,COVID-19,C0003018,Peptidyl-Dipeptidase A,COVID-19,Angiotensins,1,X,[virs],[aapp/bacs/phsu],C000657245,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
6981a9c5-5b13-4fe0-85a0-62660852e2ad,C0042776,C0003018,Peptidyl-Dipeptidase A,Virus,Angiotensins,1,X,[virs],[aapp/bacs/phsu],B04,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
a32948fb-fc4f-4047-812b-4df5d65beb0f,COVID-19,C0751956,had significant independent association with ,COVID-19,Acute Cerebrovascular Accidents,2,X,[virs],[dsyn],C000657245,C10.228.140.300.775;C14.907.253.855
a32948fb-fc4f-4047-812b-4df5d65beb0f,COVID-19,C0751956,is significantly associated with imaging confirmation of ,COVID-19,Acute Cerebrovascular Accidents,2,X,[virs],[dsyn],C000657245,C10.228.140.300.775;C14.907.253.855
006cad50-a298-4302-9979-b2479fcc69fa,C0009450,C0751956,had significant independent association with ,Communicable Diseases,Acute Cerebrovascular Accidents,2,X,[dsyn],[dsyn],C01.539.221,C10.228.140.300.775;C14.907.253.855
006cad50-a298-4302-9979-b2479fcc69fa,C0009450,C0751956,is significantly associated with imaging confirmation of ,Communicable Diseases,Acute Cerebrovascular Accidents,2,X,[dsyn],[dsyn],C01.539.221,C10.228.140.300.775;C14.907.253.855
e4872fb9-c539-4da0-972a-ab26d1200ca8,C0333557,COVID-19,is in ,Watershed infarct,COVID-19,1,X,[patf],[virs],,C000657245
ebd7afbd-a69b-44ba-b1ac-3cf6fed3c7a2,C1292533,C0206750,were obtained during emergent ,Tissue specimen,Coronavirus Infections,2,X,[tisu],[dsyn],,C02.782.600.550.200
19cc8ac5-4328-487e-aaa3-6c5ae76fade8,C1510711,C0206750,is in four patients with ,Abdominal Surgical Procedure,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
68b4341a-6ec0-4d8e-b168-fa4f4973d9a8,C0042776,C1267213,is disease transmission through directly or,Virus,Upper aerodigestive tract,1,X,[virs],[bpoc],B04,
197b8e78-4a2f-4e4a-a206-c2db2404d793,C0220641,COVID-19,require attention during ,Lip and Oral Cavity Carcinoma,COVID-19,1,X,[neop],[virs],,C000657245
7567591f-43f8-4566-afdf-8d317d29fae3,COVID-19,C0027651,is in oral ,COVID-19,Neoplasms,1,X,[virs],[neop],C000657245,C04
756aca12-a49c-4ea4-8f93-6aa254d4753d,C0232741,C0341439,is in patients with ,Liver function,Chronic liver disease,2,X,[ortf],[dsyn],,
8ea40bde-d0ea-4f3e-acfb-ad2f3bfb0f41,COVID-19,C0524909,is with ,COVID-19,Hepatitis B Chronic,4,X,[virs],[dsyn],C000657245,C02.256.430.400.100;C02.440.435.100;C06.552.380.350.100;C06.552.380.705.437.100
539f957a-eee5-4442-9c4a-afbec4b3f39a,COVID-19,C1825598,is having significant ,COVID-19,IMPACT gene,2,X,[virs],[gngm],C000657245,
539f957a-eee5-4442-9c4a-afbec4b3f39a,COVID-19,C1825598,has demonstrated ,COVID-19,IMPACT gene,1,X,[virs],[gngm],C000657245,
84b9102d-377b-48ad-9572-f10129cb9281,COVID-19,C0700431,is having significant ,COVID-19,Cardiac rehabilitation,1,X,[virs],[topp],C000657245,E02.760.169.063.500.185;E02.831.185;H02.403.680.600.250;N02.421.784.244
b9876a44-06c1-44f1-8554-c7577d8c47ee,C0206750,C0040038,is known associated with risk of ,Coronavirus Infections,Thromboembolism,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.590
b9876a44-06c1-44f1-8554-c7577d8c47ee,C0206750,C0040038,be associated with heightened risk of ,Coronavirus Infections,Thromboembolism,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.590
28c6e054-0639-4878-90da-c238a488416a,C0598197,C3826426,understand ,contagion,Dynamics,4,X,[npop],[npop],,
71a64963-f911-46a8-86b1-675fc38960ea,C0598197,C0012634,understand ,contagion,Disease,4,X,[npop],[dsyn],,C23.550.288
c0c815d8-c32d-4325-a51f-8179ebbac0d1,C1457887,C0015672,were ,Symptoms,Fatigue,10,X,[sosy],[sosy],,C23.888.369
1fd12d76-a7ab-481b-bca6-662746fcfe5f,C1457887,C0850149,were ,Symptoms,Dry cough,5,X,[sosy],[sosy],,
83e51966-01f3-4881-b468-0ee0b4c0e234,C1457887,C0031350,can can complicated with ,Symptoms,Pharyngitis,3,X,[sosy],[dsyn],,C07.550.781;C08.730.561;C09.775.649
2afe66d1-0321-427c-9793-f222ddb594f1,C0231918,C1260880, includes stuffy ,Nose symptoms,Rhinorrhea,1,X,[sosy],[sosy],,
39b2f302-f1a7-4078-aa9d-ba0f1bc37af9,C0231918,C0011991, includes stuffy ,Nose symptoms,Diarrhea,1,X,[sosy],[sosy],,C23.888.821.214
ac918e60-3417-4259-8fea-3cf3e46ec6c9,C0206061,C3489532, includes fibrous ,Pneumonia Interstitial,Cone-Rod Dystrophy 2,2,X,[dsyn],[dsyn],C08.381.483,C11.270.152;C11.768.585.658.250;C16.320.290.152
2c7f83f3-bb33-475f-a380-6de62d937d12,posedan,C3714514,is with more eight million ,posedan,Infection,1,X,????,[patf],????,C01.539
af2556c8-1c5c-49e1-9b55-d3813cfddb50,C0086418,C0043031,is with history of atrial fibrillation on ,Homo sapiens,Warfarin,1,X,[humn],[hops/orch/phsu],B01.050.150.900.649.313.988.400.112.400.400,D03.383.663.283.446.520.914;D03.633.100.150.446.520.914
709818a3-16d4-4e8d-a2fd-8a3cd01c5a7d,C1145670,C1265800,is with ,Respiratory Failure,Multiple emboli,2,X,[dsyn],[patf],C08.618.846,
1aab1b54-47d0-454c-907c-0483105a5d35,C1145670,C0024109,is with ,Respiratory Failure,Lung,1,X,[dsyn],[bpoc],C08.618.846,A04.411
44b6e219-c533-4f2d-a542-0372b46947fe,C0199470,C0038317,was started on ,Mechanical ventilation,Steroids,1,X,[topp],[orch/phsu],,D04.210.500
51639a61-2d62-45c8-b0ac-a1e0b74ded6f,C0013404,C0037088,were most frequent ,Dyspnea,Signs and Symptoms,1,X,[sosy],[sosy],C08.618.326;C23.888.852.371,C23.888
3a1c9378-fe64-4b1e-a4f2-4fd1e4785821,C0015967,C0037088,were most frequent ,Fever,Signs and Symptoms,1,X,[sosy],[sosy],C23.888.119.344,C23.888
468d0f28-f239-490f-add8-cec43ba02d2c,C0010200,C0037088,were most frequent ,Coughing,Signs and Symptoms,1,X,[sosy],[sosy],C08.618.248;C23.888.852.293,C23.888
3d9de1c3-ec4b-4aeb-868e-6f09b88cc6a4,C0020517,C1705178,is in ,Hypersensitivity,Order (action),1,X,[patf],[acty],C20.543,
cd412d62-fd03-4c06-aa5c-7a9ec5b33318,C0020517,C1457887,considering diversity of ,Hypersensitivity,Symptoms,1,X,[patf],[sosy],C20.543,
cd412d62-fd03-4c06-aa5c-7a9ec5b33318,C0020517,C1457887,improved in patients with longer existing ,Hypersensitivity,Symptoms,2,X,[patf],[sosy],C20.543,
30a2caad-bb27-4414-a69a-d4fb0c208ed4,C1880355,C0206419,is in ,Discover,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
9c8a420e-b413-4f57-a300-2f90fd317aa2,C0035253,C0206419,have have hit during crisis due ,Rest,Genus: Coronavirus,1,X,[dora],[virs],I03.450.769.647,B04.820.504.540.150
1634d504-9142-4b0d-81e1-cfe6aef94503,C0242781,C0319157,is easy in context of contagious ,disease transmission,AS virus,1,X,[patf],[virs],N06.850.310,
9d170608-8a6c-4932-b8e1-4aaa240eaf6e,C0206419,C0034991,is essential for their ,Genus: Coronavirus,Rehabilitation therapy,2,X,[virs],[topp],B04.820.504.540.150,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
c98c8c7b-5862-4cb5-8dd6-e6d2c8be8042,C1158478,C1999230,was effective in ,DNA Integration,Providing (action),2,X,[genf],[acty],,
7f0b5ed9-1a7e-476e-ba20-93df088001fd,C0206419,C0004364,is with ,Genus: Coronavirus,Autoimmune Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C20.111
e2092fce-ca0c-49e4-824b-9b30d73f9ade,C0221102,C0206419,is in ,Excretory function,Genus: Coronavirus,1,X,[phsf],[virs],,B04.820.504.540.150
663c6a8a-7036-4d78-99f5-c04310939890,C0019010,C0206419,extracorporeal Excretory function in,Hemodynamics,Genus: Coronavirus,1,X,[ortf],[virs],G09.330.380,B04.820.504.540.150
fe63d117-3ea9-49f1-ac5c-ef968ae78568,C1175743,C0006560,for test is mg/l,SARS coronavirus,C-reactive protein,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
ecc17248-673a-413a-9832-42f63d337712,C1175743,mg/l,for test is mg/l,SARS coronavirus,mg/l,1,X,[virs],????,B04.820.504.540.150.113.937,????
d1519c94-72b3-411f-b018-0f5544e908d2,C0318793,C4035700,tested health systems for particularly ,Zika Virus,Maternal-Child Health,2,X,[virs],[bmod],B04.820.250.350.995,
c6ccb511-e682-403c-bd5d-05c271b9d9c8,C0700271,C1175743,development for ,M Protein multiple myeloma,SARS coronavirus,4,X,[aapp/imft],[virs],x.x.x.x,B04.820.504.540.150.113.937
c6ccb511-e682-403c-bd5d-05c271b9d9c8,C0700271,C1175743,is Homologous Protein of,M Protein multiple myeloma,SARS coronavirus,1,X,[aapp/imft],[virs],x.x.x.x,B04.820.504.540.150.113.937
0f205368-6389-4ef7-bfc7-9862c0ba4ffd,C0038164,C1175743,development for ,Staphylococcal Protein A,SARS coronavirus,4,X,[aapp/imft/irda],[virs],D12.776.097.820;D23.050.161.821,B04.820.504.540.150.113.937
dc74ee7c-f77a-4b71-aa66-a77c37597e19,C1273412,C1947933,is in than standard ,Chinese herbal medicine,care activity,1,X,[topp],[acty],,
e53654d9-589b-4406-a1eb-992c00ac6f5a,C1433062,C1268456,Viral Components of,3C-like protease SARS coronavirus,Viral Components,3,X,[aapp/enzy],[celc],x.x.x.x,A21
0a713511-dd5c-4ebe-9716-a085cadea988,C1433062,C0598312,Viral Components of,3C-like protease SARS coronavirus,DNA Replication,3,X,[aapp/enzy],[genf],x.x.x.x,G02.111.225;G05.226
1f0a07d8-8efd-4f3a-a48f-c80d5b578a47,C1433062,C0206419,is considered as prime target for anti ,3C-like protease SARS coronavirus,Genus: Coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150
09528aed-b0ae-4fbc-be31-18b42bff3f21,C1433062,C0872152,is considered as prime target for anti ,3C-like protease SARS coronavirus,Drug Development,3,X,[aapp/enzy],[bmod],x.x.x.x,E05.290;H01.158.703.007.338;H01.181.466.338
9c3e89b6-66db-427c-9f7d-252a655f9fbd,C0071649,C1621837,exhibit good ,polyphenols,protease binding,3,X,[orch/phsu],[moft],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
cd086c75-9888-49e6-bebb-1d80bf26a1f5,C0071649,C1510827,exhibit good ,polyphenols,Affinity,3,X,[orch/phsu],[npop],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
321d25ed-8a6f-4fba-bbbf-ca5ce1e3e079,C0071649,C0013227,possess favorable ,polyphenols,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,D26
dfe54e2a-8c1d-469b-acfe-790404a541b5,C0071649,C3469597,are promising ,polyphenols,Administration of medication,4,X,[orch/phsu],[topp],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
784a2242-7959-45a2-a3d9-a70b18cd9e0b,C0071649,C0206419,are promising ,polyphenols,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,B04.820.504.540.150
44c93f14-1250-4de2-b884-8a3df222f15d,C0071649,C0243077,can Altogether can used as potential ,polyphenols,inhibitors,3,X,[orch/phsu],[chvf],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
55a04e15-0201-4f23-9119-9355b952a0a7,C0071649,C1433062,can Altogether can used as potential ,polyphenols,3C-like protease SARS coronavirus,3,X,[orch/phsu],[aapp/enzy],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,x.x.x.x
706086bc-11af-4ced-b1ab-5f46cd9c3f61,C0230425,C0242781,has raised possibility of ,Structure of right thigh,disease transmission,1,X,[bpoc],[patf],,N06.850.310
bbcd2360-33eb-49d0-982f-8687a6398fad,C0032521,C0242781,has raised possibility of ,Polymers,disease transmission,1,X,[bodm/chvs],[patf],D05.750;D25.720;J01.637.051.720,N06.850.310
14aa2102-3d6d-4cc2-b73f-a15e9c2ccc12,C0230425,C0015733,is in ,Structure of right thigh,Feces,1,X,[bpoc],[bdsu],,A12.459
ecf50324-849a-40c6-b7e7-d38199fe652e,C0032521,C0015733,is in ,Polymers,Feces,1,X,[bodm/chvs],[bdsu],D05.750;D25.720;J01.637.051.720,A12.459
5a445a72-0d15-49ca-85f6-124c47a950b2,C0599779,C2936609,demonstrate strong anti-inflammatory effects of ,Animal Model,Phosphodiesterase 4 Inhibitors,2,X,[anim],[phsu],E05.598,D27.505.519.389.735.374
9ccf9f07-7e7d-4e8c-b3a0-55c8e6952435,C2936609,C0206419,is in ,Phosphodiesterase 4 Inhibitors,Genus: Coronavirus,2,X,[phsu],[virs],D27.505.519.389.735.374,B04.820.504.540.150
4cef9765-37d3-406d-a812-4977b28bacbb,C2936609,C0242634,is in ,Phosphodiesterase 4 Inhibitors,Primate Diseases,2,X,[phsu],[dsyn],D27.505.519.389.735.374,C22.735
4ee224e2-c3a0-4495-b27f-926c8834384a,C1704259,C0242634,is in ,Biochemical Pathway,Primate Diseases,2,X,[moft],[dsyn],,C22.735
66f19ad4-4d99-473c-8b00-face8db51ef5,C0003451,C0038952,may pose risk to patient ,Antiviral Agents,Continuance of life,1,X,[phsu],[acty],D27.505.954.122.388,I03.784
310aa04d-a570-4a78-b58e-3b859d576b3e,C0301872,C0038952,may pose risk to patient ,Immune response,Continuance of life,1,X,[ortf],[acty],,I03.784
708a7c6a-23f3-4f1b-a2b9-57599e5c73a4,C0003451,C0021368,may pose risk to patient ,Antiviral Agents,Inflammation,1,X,[phsu],[patf],D27.505.954.122.388,C23.550.470
4696d1c6-7f7f-48e2-9420-2efdaeb6222d,C0301872,C0021368,may pose risk to patient ,Immune response,Inflammation,1,X,[ortf],[patf],,C23.550.470
83fec74f-73fd-4f56-8fdb-a18b901a7111,C0003451,C2936609,may pose risk to patient ,Antiviral Agents,Phosphodiesterase 4 Inhibitors,1,X,[phsu],[phsu],D27.505.954.122.388,D27.505.519.389.735.374
69788230-e3f0-4bd7-bff1-583806be6466,C0301872,C2936609,may pose risk to patient ,Immune response,Phosphodiesterase 4 Inhibitors,1,X,[ortf],[phsu],,D27.505.519.389.735.374
711c4c0c-8228-4363-ba8a-b16f1dc7ec41,C0301872,C0206419,is in older patients with ,Immune response,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
230985ca-ccc7-47db-9b46-becdc66eae96,C0301872,C0003451,may pose risk with especially ,Immune response,Antiviral Agents,1,X,[ortf],[phsu],,D27.505.954.122.388
da0e0527-f898-46ce-a936-004b72b51e27,C0021368,C2936609,is with ,Inflammation,Phosphodiesterase 4 Inhibitors,1,X,[patf],[phsu],C23.550.470,D27.505.519.389.735.374
24d1b718-b633-406e-a89a-f1846d157254,C0041625,C0003451,has well-known ,Ultraviolet Rays,Antiviral Agents,1,X,[npop],[phsu],G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600,D27.505.954.122.388
bf513e1a-b287-417a-8230-17a4e71d7101,C0206419,C0041625,is with ,Genus: Coronavirus,Ultraviolet Rays,3,X,[virs],[npop],B04.820.504.540.150,G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600
ff152a27-26e0-460a-9207-5db35db87ac7,C0206419,C2169144,determine ,Genus: Coronavirus,Radiation dose,1,X,[virs],[topp],B04.820.504.540.150,
cd12ebcc-8f48-4204-b551-68ff652bf4ce,C0206419,C0319157,determine ,Genus: Coronavirus,AS virus,1,X,[virs],[virs],B04.820.504.540.150,
f988b178-8278-4df2-b618-36f4e4c67e39,C0206419,C0035668,have similar ,Genus: Coronavirus,RNA,1,X,[virs],[nnon],B04.820.504.540.150,D13.444.735
f988b178-8278-4df2-b618-36f4e4c67e39,C0206419,C0035668,are large family of respiratory ,Genus: Coronavirus,RNA,3,X,[virs],[nnon],B04.820.504.540.150,D13.444.735
c2144793-2789-4abb-b44e-8c1e4fa71cb3,C0206419,C0020517,seems ,Genus: Coronavirus,Hypersensitivity,4,X,[virs],[patf],B04.820.504.540.150,C20.543
fd2a0e18-e6a5-476d-bf02-5a1e9db7e7d6,C0035204,C0206419,caused by novel ,Respiration Disorders,Genus: Coronavirus,2,X,[dsyn],[virs],C08.618,B04.820.504.540.150
86b6eb72-81d2-43ce-894e-fbeb70ce8a4a,C0042210,C1824356,prevent person from ,Vaccines,KIAA1551 gene,1,X,[aapp/imft/phsu],[gngm],D20.215.894,
35d04837-af7b-4c23-84a6-f7fe7d3ac92a,C0596957,C0040300,predict macrocyclic ,Molecular Dynamics,Body tissue,2,X,[moft],[tisu],E05.599.595.500;G02.111.570.895;L01.224.160.500,A10
95a64dde-610a-49d0-a5db-339987b57ddc,C0596957,C0015505,predict macrocyclic ,Molecular Dynamics,Factor VIIa,4,X,[moft],[aapp/enzy/phsu],E05.599.595.500;G02.111.570.895;L01.224.160.500,D08.811.277.656.300.760.300;D08.811.277.656.959.350.300;D12.776.124.125.325.300;D23.119.325.300
00ebfd7d-4425-4e1e-bc0b-cdc1430394e5,C0596957,C0030946,predict macrocyclic ,Molecular Dynamics,Endopeptidases,1,X,[moft],[aapp/enzy/phsu],E05.599.595.500;G02.111.570.895;L01.224.160.500,D08.811.277.656.300
3166934e-d49e-4993-a54d-87fd87c5342c,C4048299,C0005778,prevent ,Tissue Factor,Blood coagulation,4,X,[aapp/imft],[ortf],D12.776.124.125.900;D23.119.965,G09.188.390.150
4c2adaf8-f77b-471d-8b20-573ceb57c276,C0243077,C0005778,prevent ,inhibitors,Blood coagulation,4,X,[chvf],[ortf],,G09.188.390.150
0f7fb283-4a1c-43b5-a7d2-cb32f1a3b9ef,C0243077,C0003451,have ,inhibitors,Antiviral Agents,1,X,[chvf],[phsu],,D27.505.954.122.388
dd32c17e-dc01-40b4-85ae-4942978e491a,C0243077,C1510827,also have high ,inhibitors,Affinity,2,X,[chvf],[npop],,
0e23b91b-291b-454a-aab4-106c3c07af77,C0243077,C0030946,also have high ,inhibitors,Endopeptidases,2,X,[chvf],[aapp/enzy/phsu],,D08.811.277.656.300
0e23b91b-291b-454a-aab4-106c3c07af77,C0243077,C0030946,Furthermore interact with dyad ,inhibitors,Endopeptidases,2,X,[chvf],[aapp/enzy/phsu],,D08.811.277.656.300
17a02f39-808a-41b0-b6b5-13330d6c22c1,C0243077,dyad,Furthermore interact with dyad ,inhibitors,dyad,2,X,[chvf],????,,????
427a8f1e-11a8-42c8-9b6b-eedccf8e8d16,dyad,C0206419,is in active site of ,dyad,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
53531db0-6e3b-48b5-b1a6-c5f2340b7832,dyad,C0030946,is in active site of ,dyad,Endopeptidases,2,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
81c491c5-a95f-4382-95ed-023f85bfda4e,C0030946,C0042774,is important in ,Endopeptidases,Virus Replication,2,X,[aapp/enzy/phsu],[celf],D08.811.277.656.300,G06.920.925
2e353fee-4086-4511-8bfa-3acf6f8d15e9,C0086168,C0033607,are found very similar to experimental ,Dissociation,Protease Inhibitors,2,X,[mobd],[phsu],F03.300,D27.505.519.389.745
5dc47831-612d-4590-b4fb-21e4f6d9c14a,C0034019,C0242781,curtail ,public health medicine (field),disease transmission,2,X,[bmod],[patf],H02.403.720;N01.400.550;N06.850,N06.850.310
5dc47831-612d-4590-b4fb-21e4f6d9c14a,C0034019,C0242781,significantly reduced ,public health medicine (field),disease transmission,1,X,[bmod],[patf],H02.403.720;N01.400.550;N06.850,N06.850.310
a94b5e51-13ce-4280-9eea-b3cc74c1ac4e,C0020517,C0699680,were test ,Hypersensitivity,Metric,1,X,[patf],[orch/phsu],C20.543,D02.640.672.500;D03.383.129.308.658.500
f841de90-e752-4e57-a1e9-c6453ec2bea9,C0012634,C0039082,is caused by ,Disease,Syndrome,4,X,[dsyn],[dsyn],C23.550.288,C23.550.288.500
091e22b2-64c1-4e8e-a121-46a2b670bee2,1a,C0032105,anti effects of convalescent,1a,Plasma,1,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
091e22b2-64c1-4e8e-a121-46a2b670bee2,1a,C0032105,anti effects of convalescent,1a,Plasma,1,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
091e22b2-64c1-4e8e-a121-46a2b670bee2,1a,C0032105,anti effects of convalescent,1a,Plasma,1,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
89841f8d-7124-4422-a902-621e24f0172a,C0206750,C0040802,leading to widespread ,Coronavirus Infections,travel,7,X,[dsyn],[dora],C02.782.600.550.200,I03.883
fabc5ba5-3618-47c3-9944-6e1b1a38f5ec,C0683325,C0206750,were analyzed in relation to severity of ,clinical aspects,Coronavirus Infections,7,X,[clna],[dsyn],,C02.782.600.550.200
1a6108a1-52a6-4e39-8ad9-277672dbabf9,C0013404,C0012634,was only ,Dyspnea,Disease,14,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C23.550.288
e7a2286c-af45-401a-8542-a39d98c48c5e,C0035473,C0039082,are typically explained in case of ,Rhinovirus,Syndrome,2,X,[virs],[dsyn],B04.820.565.775,C23.550.288.500
45b55165-fd87-461e-9409-5cdcf2fab947,C0029341,C0039082,are typically explained in case of ,Orthomyxoviridae,Syndrome,2,X,[virs],[dsyn],B04.820.545,C23.550.288.500
42e40e36-e40e-4d98-a160-2990078a89ea,C0302507,C0039082,are typically explained in case of ,Parainfluenza Virus Infections,Syndrome,2,X,[dsyn],[dsyn],C02.782.580.600,C23.550.288.500
10ab4acb-107c-4dfb-b96b-ba252558291b,C0035473,C0026727,are typically explained by nasal obstruction with ,Rhinovirus,Mucous body substance,9,X,[virs],[bdsu],B04.820.565.775,A12.200.503
1062df8e-152d-4206-8462-2305690c9ecf,C0029341,C0026727,are typically explained by nasal obstruction with ,Orthomyxoviridae,Mucous body substance,9,X,[virs],[bdsu],B04.820.545,A12.200.503
021a2fd3-7941-4d3d-8bd9-841059176cc7,C0302507,C0026727,are typically explained by nasal obstruction with ,Parainfluenza Virus Infections,Mucous body substance,9,X,[dsyn],[bdsu],C02.782.580.600,A12.200.503
96c408ee-c1b2-4681-b47e-c0c9776743c5,C0039082,C1705178,is in ,Syndrome,Order (action),1,X,[dsyn],[acty],C23.550.288.500,
4e24868e-3218-4b86-a057-11368fd931d9,C0036563,C0441655,restarting endoscopic ,Plant seeds,Activities,1,X,[plnt],[acty],A18.024.500.750;G07.203.300.775;J02.500.775,
6d0d5d5a-1ac6-4921-b824-8811b2de1b60,C1550100,C0806140,using four point-of-care ,Specimen Type - Serum,Flow,1,X,[bdsu],[npop],,
6d0d5d5a-1ac6-4921-b824-8811b2de1b60,C1550100,C0806140,using four lateral ,Specimen Type - Serum,Flow,1,X,[bdsu],[npop],,
fb588290-11aa-4359-8b57-b8634195e42e,C1550100,C0003261,tested for ,Specimen Type - Serum,Antibody Formation,2,X,[bdsu],[biof],,G12.070
6745d5f2-25db-43b1-9a7b-d210afbeedd4,POC,LFIA,based on LFIA,POC,LFIA,2,X,????,????,????,????
8900ef0c-e827-4006-99a2-d9849947e93f,C0003241,LFIA,based on LFIA,Antibodies,LFIA,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,????
bf03d2e8-ea51-4278-b928-668487988a4c,POC,C0039082,showed performance in detection of ,POC,Syndrome,1,X,????,[dsyn],????,C23.550.288.500
76399706-2b60-4eb2-9a53-a464506a002b,C0003241,C0039082,showed performance in detection of ,Antibodies,Syndrome,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,C23.550.288.500
89cb5ac3-3916-4f19-b282-74b6a6e3af4e,C0206750,C0003242,exhibited earlier ,Coronavirus Infections,Antibodies Anti-Idiotypic,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071
948aa9c8-63fa-444c-9d71-48712803fc10,C1999230,C0302148,is in field of ,Providing (action),Blood Clot,4,X,[acty],[patf],,C14.907.355.830
9b1df293-7eb1-45ec-955d-ca95bfd62e70,C0005779,C0596448,includes exceptionally high levels of D ,Blood Coagulation Disorders,dimer,5,X,[dsyn],[chvs],C15.378.100,
bd03cb41-dc44-4f32-8e9e-7966b6091c1b,C0060323,C0005516,were related with ,Fibrin fragment D,Biological Markers,9,X,[aapp/bacs],[clna],x.x.x.x,D23.101
ea5dd7da-e839-4bde-ba01-08e983c74586,C0040044,C0012634,might offer hope for patients with ,Thrombolytic Therapy,Disease,5,X,[topp],[dsyn],E02.319.913,C23.550.288
5f712f1a-9879-4c56-b31c-afdef287649e,C0016016,C0206750,can where can deleterious in ,Plasmin,Coronavirus Infections,4,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.330;D08.811.277.656.959.350.330,C02.782.600.550.200
1a6918fd-0f8b-4fce-95df-8c8488f05acc,C0220781,C0206750,can where can deleterious in ,Anabolism,Coronavirus Infections,1,X,[biof],[dsyn],G03,C02.782.600.550.200
1ac59f48-963c-4a76-a8d5-22f4993f032e,C0012634,C0524850,is in department of ,Disease,Neurosurgical Procedures,1,X,[dsyn],[topp],C23.550.288,E04.525
cbbf09a2-9720-4cbd-8bca-6d4d1f78d205,C0087111,C1705178,is in ,Therapeutic procedure,Order (action),2,X,[topp],[acty],E02,
4b8bf2fe-926a-437d-9447-dbd27a58000e,C0206750,C0017181,is with ,Coronavirus Infections,Gastrointestinal Hemorrhage,3,X,[dsyn],[patf],C02.782.600.550.200,C06.405.227;C23.550.414.788
3754ae54-420d-41ab-ba10-ae53115ac950,C1175175,C1880022,was ,Severe Acute Respiratory Syndrome,Characterization,1,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
79b30977-aa63-40f7-b352-b0e9b9911048,C1175175,C0206061,was ,Severe Acute Respiratory Syndrome,Pneumonia Interstitial,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.483
02e2ab75-29bd-42c2-bcd3-dfec233fbf6a,C2349975,humoral,Comparing humoral ,Enhance (action),humoral,1,X,[acty],????,,????
c8c8eef2-7b8a-4cb5-8b1a-f20adc0c81c0,C0282682,humoral,Comparing humoral ,Antibodies Blocking,humoral,1,X,[aapp/imft/irda],????,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,????
a7712ae3-06f6-427e-89a0-5e7fc0e98715,COVID-19,C0010200,share similar fever ,COVID-19,Coughing,1,X,[virs],[sosy],C000657245,C08.618.248;C23.888.852.293
1561fca3-869f-4882-863a-0911ae2461f5,COVID-19,C0013404,share similar fever ,COVID-19,Dyspnea,1,X,[virs],[sosy],C000657245,C08.618.326;C23.888.852.371
66885aa1-6e52-40be-8c57-e98d45915a99,C0026056,C0011744,of AUC is ,Midazolam,Deuterium,2,X,[orch/phsu],[elii],D03.633.100.079.080.575,D01.268.406.500;D01.362.340.500;D01.496.289;x.x.x.x
76e43d07-6c05-4b9c-9bfd-aa516cd91e10,C0185112,C0087111,is in worldwide race towards ,Therapeutic Mobilization,Therapeutic procedure,1,X,[topp],[topp],,E02
8a6b58db-8f1d-4521-96e2-625ebd99fb01,C0037633,C0242781,reduce further ,Solutions,disease transmission,1,X,[sbst],[patf],D26.776,N06.850.310
2d84f17c-7a0c-489d-8448-9818c691f45c,C0037633,C0086418,reduce ,Solutions,Homo sapiens,1,X,[sbst],[humn],D26.776,B01.050.150.900.649.313.988.400.112.400.400
bd429473-64b4-4afe-85c6-678d97e1c167,C3463820,C2931926,is with ,Inhibition,ruxolitinib,2,X,[acty],[orch/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,
71bfe2e2-beee-4ebd-b069-15ae697572ce,C2931926,C0079189,reduce ,ruxolitinib,cytokine,2,X,[orch/phsu],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
7bcd6fde-cf47-4320-99a5-3ca87a9193d5,COVID-19,C1175175,is caused by ,COVID-19,Severe Acute Respiratory Syndrome,1,X,[virs],[dsyn],C000657245,C02.782.600.550.200.750;C08.730.730
ad4fe50c-8b46-4ec5-b378-07442491bbd5,COVID-19,C3272452,is caused by ,COVID-19,Single-Stranded RNA,1,X,[virs],[nnon],C000657245,
b3498b66-5286-4b5e-99f2-e795eeab443a,COVID-19,C0017428,is caused by ,COVID-19,Genome,1,X,[virs],[gngm],C000657245,G05.360.340
1291fc62-23e5-4f5b-ad4c-d6b0a02d30b8,C0042736,C0034800,interact with ,Viral Proteins,Receptors Cell Surface,3,X,[aapp/bacs],[aapp/rcpt],D12.776.964,D12.776.543.750
3256a263-4c2e-41cf-8778-69129ad96ee4,C0023688,C0034800,interact with ,Ligands,Receptors Cell Surface,3,X,[chem],[aapp/rcpt],D27.720.470.480,D12.776.543.750
773ccbc7-c5bf-4d5e-85b4-bd2253af5e24,C0042736,C0042776,interact with ,Viral Proteins,Virus,2,X,[aapp/bacs],[virs],D12.776.964,B04
3c0102bf-3450-4742-bea4-2e9d50153865,C0023688,C0042776,interact with ,Ligands,Virus,2,X,[chem],[virs],D27.720.470.480,B04
4e784d69-9aae-4550-a17f-6d66d8b6e762,C0024109,C0038952,affect ,Lung,Continuance of life,3,X,[bpoc],[acty],A04.411,I03.784
5cb093b6-32aa-4562-9d0e-d9fc8031c6d7,C1167395,C0038952,affect ,Host (organism),Continuance of life,3,X,[orgm],[acty],,I03.784
f8eb6b90-5e6f-4806-8bba-ee8a4f661c43,C0022942,C0678695,is ,Lactoferrin,Nutrients,3,X,[aapp/bacs],[food],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,D27.505.696.377.683;G07.203.300.681;J02.500.681
ee7584ba-d7ee-4534-9738-b58c50a1c7f0,C0022942,C0026131,is ,Lactoferrin,Milk (body substance),3,X,[aapp/bacs],[bdsu],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,A12.200.455;G07.203.100.700;G07.203.300.350.525;J02.200.700;J02.500.350.525
35e8b439-3dd3-4a31-8467-abad35ddffb0,C1175743,C0441655,Heparan Sulfate Proteoglycans based on other,SARS coronavirus,Activities,3,X,[virs],[acty],B04.820.504.540.150.113.937,
6eaee8a7-ef3a-40b2-8055-59d8d3f8fd9d,C1175743,C0022942,Heparan Sulfate Proteoglycans based on other,SARS coronavirus,Lactoferrin,3,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
d091ecca-fba1-4788-9358-4359ca24fe0f,C0062503,C1819995,prevent SARS coronavirus attaching to,Heparan Sulfate Proteoglycans,Host Cell,4,X,[aapp/bacs],[celc],D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350,
4e89b931-3dbb-40c0-a5fb-94f492a376dc,C1167395,C1175743,prevent ,Host (organism),SARS coronavirus,6,X,[orgm],[virs],,B04.820.504.540.150.113.937
4e89b931-3dbb-40c0-a5fb-94f492a376dc,C1167395,C1175743,utilizing publicly available high throughput ,Host (organism),SARS coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150.113.937
4cee72c4-5eeb-4164-812e-0ca6106d1644,C1167395,C1819995,prevent SARS coronavirus attaching to,Host (organism),Host Cell,5,X,[orgm],[celc],,
f2d91987-5f8e-448d-85ee-8c9185e45bbe,C0597357,C1819995,prevent SARS coronavirus attaching to,receptor,Host Cell,5,X,[aapp/rcpt],[celc],,
f2007c9c-5931-4a2d-b5f0-50cd534b8c8c,C1167395,C0441655,Heparan Sulfate Proteoglycans based on,Host (organism),Activities,2,X,[orgm],[acty],,
bf0b3425-e741-4af9-a0c9-de170cc1a9ec,C0597357,C0441655,Heparan Sulfate Proteoglycans based on,receptor,Activities,2,X,[aapp/rcpt],[acty],,
b07e9eab-7ccc-4c75-91d2-85f71746005c,C0022709,C0441655,Heparan Sulfate Proteoglycans based on,Peptidyl-Dipeptidase A,Activities,2,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
b909035b-2677-48eb-aa45-834addbb4e09,C1167395,C0022942,Heparan Sulfate Proteoglycans based on,Host (organism),Lactoferrin,2,X,[orgm],[aapp/bacs],,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
40870f95-8946-49d6-84e7-b118d9956da0,C0597357,C0022942,Heparan Sulfate Proteoglycans based on,receptor,Lactoferrin,2,X,[aapp/rcpt],[aapp/bacs],,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
35b88324-4d21-40da-bb27-ec91e9005a04,C0022709,C0022942,Heparan Sulfate Proteoglycans based on,Peptidyl-Dipeptidase A,Lactoferrin,2,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
71e4d6e6-1f3e-41a0-b921-2c4f1d6103a0,C0062503,C1175743,prevent ,Heparan Sulfate Proteoglycans,SARS coronavirus,6,X,[aapp/bacs],[virs],D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350,B04.820.504.540.150.113.937
9cc6c905-5f48-46d2-ab22-1b70e77cbaa3,C0022942,COVID-19,may of ,Lactoferrin,COVID-19,2,X,[aapp/bacs],[virs],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,C000657245
d1804def-7a85-4bcf-995e-93a1fde1c6f0,C0151942,CAC,are more frequent in CAC,Arterial thrombosis,CAC,1,X,[patf],????,,????
52e548ce-b49d-4cba-aa06-a4bdc4efc0b5,C1861172,CAC,are more frequent in CAC,Venous Thromboembolism,CAC,2,X,[dsyn],????,C14.907.355.590.700,????
37d6830c-b510-4b24-b2eb-7ea7f44b9f22,C0151942,C0005779,are frequent compared to ,Arterial thrombosis,Blood Coagulation Disorders,1,X,[patf],[dsyn],,C15.378.100
4f2fc8ff-bc07-4911-9e18-000ff3bf8dc3,C0151942,C0012739,are frequent compared to ,Arterial thrombosis,Disseminated Intravascular Coagulation,1,X,[patf],[dsyn],,C15.378.100.220;C15.378.463.250;C15.378.925.220
96bb78c4-550c-4ad3-9560-fe3ca0dc8988,C1861172,C0005779,are frequent compared to ,Venous Thromboembolism,Blood Coagulation Disorders,1,X,[dsyn],[dsyn],C14.907.355.590.700,C15.378.100
c306d419-f07a-41c7-bf08-4c041984bde1,C1861172,C0012739,are frequent compared to ,Venous Thromboembolism,Disseminated Intravascular Coagulation,1,X,[dsyn],[dsyn],C14.907.355.590.700,C15.378.100.220;C15.378.463.250;C15.378.925.220
dd8fa888-062d-4a1b-8b61-9b73e8b9b82e,C0042769,C0011311, includes ,Virus Diseases,Dengue Fever,3,X,[dsyn],[dsyn],C02,C02.081.270;C02.782.350.250.214;C02.782.417.214
a07eb900-cb01-4c8c-b2a6-d0d3f14c2a6e,C0206750,C0011311,is with false-positive ,Coronavirus Infections,Dengue Fever,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.081.270;C02.782.350.250.214;C02.782.417.214
71edf548-071a-472e-ac45-949650c8e607,C0206750,C0036745,is with false-positive ,Coronavirus Infections,Study of serum,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.781
fa536fc6-2b6b-44d3-9024-650624919137,C0024109,COVID-19,is with ,Lung,COVID-19,4,X,[bpoc],[virs],A04.411,C000657245
e6919fe2-5a0b-44b6-ad75-57ac2efe314e,C0009450,C0034019,has become serious ,Communicable Diseases,public health medicine (field),3,X,[dsyn],[bmod],C01.539.221,H02.403.720;N01.400.550;N06.850
a8c3dda7-95f7-4f5d-a60f-1de799431649,C1512523,C3854325,is broad spectrum ,hydrochloride,Janus kinase inhibitor,1,X,[inch/phsu],[phsu],,D27.505.519.389.755.500
54cbc5cd-ffbd-4dff-9ec6-558084b3d893,C1512523,C0206750,has great potential for treatment of patients with ,hydrochloride,Coronavirus Infections,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200
99e2f0f0-17e8-4062-971b-69199d06ee3b,C1512523,C0012634,has great potential for treatment of patients with ,hydrochloride,Disease,3,X,[inch/phsu],[dsyn],,C23.550.288
30b99506-937a-4a18-87ac-9f9cb0c3156a,C0441655,C0206750,is in ,Activities,Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
77f4a5c7-4cf0-4bfd-8b13-f415de9f1027,C0699748,C0206750,may behind may ,Pathogenesis,Coronavirus Infections,4,X,[patf],[dsyn],,C02.782.600.550.200
ad5bda95-7e71-4363-bae1-7f3a44adc4da,C2267116,C0206750,is in ,Vascular Alterations,Coronavirus Infections,2,X,[phsf],[dsyn],,C02.782.600.550.200
90e6fd61-d352-4739-8832-771b2cf74868,C0035216,C0007682,is in ,Respiratory Center,CNS disorder,4,X,[bpoc],[dsyn],A08.186.211.132.772.646,C10.228
31e25468-b4b6-4437-9acc-bebeac8befba,C0003316,C1114743,outshine Among ,Epitopes,Type:ID:Pt:Vaccine:Nom,6,X,[imft],[clna],D23.050.550,
3044c1ec-70f5-432b-a922-c7a6509fd879,C0599934,C1114743,outshine Among ,Vaccines Peptide,Type:ID:Pt:Vaccine:Nom,6,X,[imft/phsu],[clna],D20.215.894.860,
c8a9569a-bf8f-4a4c-a34b-a68819eff54d,C0042760,C0599444,were found in ,Virion,Cell body of neuron,1,X,[celc],[celc],A21.249;B04.950,
d74f4cdc-a7d0-4b23-9264-db2e40a4ddba,C0042760,C0085103,were found in ,Virion,Neurites,1,X,[celc],[celc],A21.249;B04.950,A08.675.256.500;A08.675.542.145.500;A11.284.180.610;A11.671.501.145.500;A11.671.543
021ba3f4-afdb-4f89-9103-a76ea2dd3801,PCR,C0042776,suggesting at least increase in ,PCR,Virus,1,X,????,[virs],????,B04
cf2e1672-f080-46fd-a12d-26e30946f81b,PCR,C0042774,corroborated ,PCR,Virus Replication,2,X,????,[celf],????,G06.920.925
18450cd2-6850-49c6-b44c-db9e011d41c5,C0003504,C0206750,identify ,Aortic Valve Insufficiency,Coronavirus Infections,3,X,[dsyn],[dsyn],C14.280.484.095,C02.782.600.550.200
191ccbe5-adda-40a9-aa18-0264d969f20c,C1175175,C0349410,causes multiple ,Severe Acute Respiratory Syndrome,Single organ dysfunction,4,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,
6c49ebdb-28d3-4f77-bcf1-b1478c018836,C0034019,C0018563,have on other ,public health medicine (field),Hand,2,X,[bmod],[bpoc],H02.403.720;N01.400.550;N06.850,A01.378.800.667
522cadcd-8cc8-41ee-9546-075385a06702,C0242821,C0018563,have on other ,Human body,Hand,2,X,[humn],[bpoc],I01.076.201.450.560;K01.093.378,A01.378.800.667
d20007f7-8b14-4ff9-9159-0b866d6f2332,C0034386,C1705178,is in ,Quarantine,Order (action),1,X,[topp],[acty],N06.850.780.200.450.700,
073c6020-77a4-42e3-be9f-c0c1f23583d6,C0037633,C0012634,address mental health issues of patients affected by ,Solutions,Disease,1,X,[sbst],[dsyn],D26.776,C23.550.288
a3196225-7f8e-48b3-b99a-dca9ed587659,C0037633,C1882509,have in have ,Solutions,put - instruction imperative,2,X,[sbst],[acty],D26.776,
9c7ab02a-f05d-47e8-a8d4-b1c1b56f10e7,C0206750,C2806453,is ,Coronavirus Infections,Betacoronavirus,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150.113
1eb8c472-e455-47c5-9937-754b8a92267f,C0206750,C3272275,created ,Coronavirus Infections,Urgent Procedure,1,X,[dsyn],[topp],C02.782.600.550.200,
bc1b550c-2741-4aca-8657-8291e507bcd9,C0683325,C0015967,is in ,clinical aspects,Fever,3,X,[clna],[sosy],,C23.888.119.344
835eec49-56ba-475d-ac11-cac0cfee7004,C0014507,C0206750,were compared between ,Epidemiology,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
835eec49-56ba-475d-ac11-cac0cfee7004,C0014507,C0206750,include data on sociodemographic ,Epidemiology,Coronavirus Infections,3,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
835eec49-56ba-475d-ac11-cac0cfee7004,C0014507,C0206750,include number of recovered ,Epidemiology,Coronavirus Infections,6,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
835eec49-56ba-475d-ac11-cac0cfee7004,C0014507,C0206750,Considering ,Epidemiology,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
da8049e5-6949-4aba-a20d-166ff27f0d00,C1175743,C0015967,is in outpatients from our ,SARS coronavirus,Fever,3,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.119.344
0590376a-6cf7-4f99-8644-27e0b829e253,C0015967,C0010200,followed by ,Fever,Coughing,4,X,[sosy],[sosy],C23.888.119.344,C08.618.248;C23.888.852.293
0590376a-6cf7-4f99-8644-27e0b829e253,C0015967,C0010200,42-year-old male patient with ,Fever,Coughing,1,X,[sosy],[sosy],C23.888.119.344,C08.618.248;C23.888.852.293
4a67bf97-7bff-4171-8e4c-871ae165c18d,C0015967,C0012634,are probably valuable indicator of ,Fever,Disease,3,X,[sosy],[dsyn],C23.888.119.344,C23.550.288
f4933ab8-aabc-4696-848c-a869c6a8590a,C2948600,C0220781,provide rapid ,Aim,Anabolism,1,X,[inch/phsu],[biof],,G03
54fba74f-4b27-4863-ad25-78ad944c58d4,C1175743,C0242781,was obtained given rampant community ,SARS coronavirus,disease transmission,4,X,[virs],[patf],B04.820.504.540.150.113.937,N06.850.310
77871d60-6d88-4c86-9491-5ce16b12aa80,CoV2,C0242781,is ,CoV2,disease transmission,2,X,????,[patf],????,N06.850.310
2e613626-b321-4508-a310-0f27817ea351,C4284286,C0041612,Evacuation procedure through,C2 wt Allele,Ultrafiltration (procedure),2,X,[gngm],[topp],,E04.292.975;E05.196.454.807;G01.280.807;G02.263.807
9db34c94-ae15-4b62-a72a-c8844775e584,C0441655,C3272275,specific recommendations for most frequent ,Activities,Urgent Procedure,4,X,[acty],[topp],,
fcf23249-f367-478c-84cf-91773d940e8e,C0152097,C0028768, includes ,Disease of diaphragm,Obsessive-Compulsive Disorder,3,X,[dsyn],[mobd],,F03.080.600
68b52ddd-f8af-4e71-8c65-a0734d51c57e,C0034386,C0028768,were significantly associated with more elevated ,Quarantine,Obsessive-Compulsive Disorder,3,X,[topp],[mobd],N06.850.780.200.450.700,F03.080.600
4e393bb3-b4ef-43ec-aa8c-2ade13818769,C0034386,C1457887,were significantly associated with more elevated ,Quarantine,Symptoms,3,X,[topp],[sosy],N06.850.780.200.450.700,
a1bc0340-30e0-4e33-93b0-56bdcfdc53f9,C0009450,C0302113,should should considered in elderly patients with ,Communicable Diseases,Fragility,1,X,[dsyn],[comd],C01.539.221,
4aa8264a-4c6f-48ba-b586-71af3cf44bfb,C1004593,C1856053,were Search - action up up,Scopus,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[bird],[dsyn],,x.x.x.x
5a53682d-a2ef-49ec-9c19-a19aaa08c6c6,C0872147,C1856053,were Search - action up up,DNA Library,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[gngm/nnon],[dsyn],G05.360.325,x.x.x.x
15729735-2684-43ae-87f6-a5fe8460e5cd,C0872147,C1706202,were ,DNA Library,Search - action,3,X,[gngm/nnon],[acty],G05.360.325,
572afc5e-a226-40a7-9897-b24cf3397c9e,C1004593,C1706202,were ,Scopus,Search - action,2,X,[bird],[acty],,
368f4f10-f9d9-4322-ab23-93168b81fc8a,C0024109,C0015982,often reveals ,Lung,Fibrin,3,X,[bpoc],[aapp/bacs/phsu],A04.411,D12.776.124.270
339c3bf0-7ebf-4796-8687-d0f9ef266946,C0024109,C0011382,often reveals ,Lung,Dental Occlusion,3,X,[bpoc],[ortf],A04.411,E06.276;G10.549.208
33bf4291-23e3-4232-a7b2-cc1a2425e76d,C0024109,C1096458,often reveals ,Lung,Vascular occlusion,2,X,[bpoc],[dsyn],A04.411,
927e0d4c-1ca9-4efa-9751-09fdb250e55d,C0085278,C0398623,is acquired ,Antiphospholipid Syndrome,Thrombophilia,3,X,[dsyn],[dsyn],C20.111.197,C15.378.925
35bd506e-3f2f-4c47-99a8-17b2d3a92359,C0021053,C0178784,is in severe multi ,Immune System Diseases,Organ,1,X,[dsyn],[bpoc],C20,
910ba154-1bd9-4647-9949-f71ac9951afd,C0178784,C0024109, includes ,Organ,Lung,1,X,[bpoc],[bpoc],,A04.411
910ba154-1bd9-4647-9949-f71ac9951afd,C0178784,C0024109,may explain ,Organ,Lung,4,X,[bpoc],[bpoc],,A04.411
41bbd2a9-6a54-4bc8-bcd8-71e60d079b7f,C0023693,C0440744,efficiently kills Pathogenic organism without harm to,Light,Human tissue,3,X,[npop],[tisu],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,
4f84dc7d-6dd2-4e08-994c-87bccaf2e240,C0023693,C0450254,efficiently kills potentially ,Light,Pathogenic organism,3,X,[npop],[orgm],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,
ca7d2128-0f70-4e2c-a22f-efe03f42d505,C0312860,C0029341,efficiently kills airborne ,Neutrophil migration function,Orthomyxoviridae,3,X,[celf],[virs],,B04.820.545
87431a42-c1ab-491c-80e1-cf826da64146,C0023693,C0029341,efficiently kills airborne ,Light,Orthomyxoviridae,3,X,[npop],[virs],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,B04.820.545
f6ff558c-f5ac-48a4-9f6b-f85e69e47c5f,C0206422,genomic,have similar genomic ,Human coronavirus,genomic,1,X,[virs],????,,????
a6e315fc-e5c5-427f-9a19-65f466458d31,C0206422,C1175743, includes ,Human coronavirus,SARS coronavirus,3,X,[virs],[virs],,B04.820.504.540.150.113.937
bad1beae-6375-4a94-8865-9c1df4ef1699,C0023693,C0206422,show similar inactivation efficiency against other ,Light,Human coronavirus,3,X,[npop],[virs],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,
2885d61b-cb19-4e31-8d0a-0f3c9a8b2bf2,C0023693,C1175743,show similar inactivation efficiency against other ,Light,SARS coronavirus,3,X,[npop],[virs],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,B04.820.504.540.150.113.937
dfcb7171-90fb-47d7-9947-7487e384dacf,C0206419,C1861452,are characterized with ,Genus: Coronavirus,Storm Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
9c1c3075-7344-4732-a440-bb982e9b592d,C1861452,C0178784,can cause severe damage to ,Storm Syndrome,Organ,4,X,[dsyn],[bpoc],x.x.x.x,
fb63d367-3d25-401f-a62e-b9ee14125309,C1861452,C0026766,can cause severe damage to ,Storm Syndrome,Multiple Organ Failure,3,X,[dsyn],[patf],x.x.x.x,C23.550.835.525
b34ebf25-2a08-4839-9aa6-1a5b6d95b25b,C0424295,C0206419,is in ,Hyperactive behavior,Genus: Coronavirus,2,X,[mobd],[virs],,B04.820.504.540.150
bfde826e-c544-4ba5-a3fd-7daede259520,C1285338,C0206419,is in ,Inflammatory disorder of immune system,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
b0a65751-86ac-4e88-b85f-e2a1b39b31bd,C0004897,C0042105,is rich in ,Ursidae Family,Ursodiol,4,X,[mamm],[bacs/orch/phsu],B01.050.150.900.649.313.750.250.761,D04.210.500.105.225.272.962;D04.210.500.221.430.342.925
aa7e6cc6-054f-4dfb-86f1-511d46590774,C0005388,C0042105,is rich in ,Bile fluid,Ursodiol,4,X,[bdsu],[bacs/orch/phsu],A12.200.087,D04.210.500.105.225.272.962;D04.210.500.221.430.342.925
d0c2aacd-393b-4507-94b8-440a3c0bb017,C0042105,C0035139,is logical ,Ursodiol,Surgical Replantation,4,X,[bacs/orch/phsu],[topp],D04.210.500.105.225.272.962;D04.210.500.221.430.342.925,E04.936.494
24bd1cca-5799-4a7b-a8d7-3438cd2d32f8,C0042105,C0004897,is logical and attainable Surgical Replantation for,Ursodiol,Ursidae Family,4,X,[bacs/orch/phsu],[mamm],D04.210.500.105.225.272.962;D04.210.500.221.430.342.925,B01.050.150.900.649.313.750.250.761
174a74b8-5cce-4dc0-b2b5-4355bea98f9d,C0042105,C0005388,is logical and attainable Surgical Replantation for,Ursodiol,Bile fluid,4,X,[bacs/orch/phsu],[bdsu],D04.210.500.105.225.272.962;D04.210.500.221.430.342.925,A12.200.087
013055e8-a2eb-4ae0-a9be-33ffdbc49070,C0005388,C0009905,is available in ,Bile fluid,Contraceptives Oral,4,X,[bdsu],[phsu],A12.200.087,D27.505.696.875.360.276.210;D27.505.954.705.360.276.210
109c97cf-40c3-41bf-90ea-e1ed182b46c0,MAFLD,C0206419,is with ,MAFLD,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
cfb14dcc-092d-44fe-8c5a-7ed0aec9eb6e,C0206277,C0221423,characteristics of highly ,Fatal Outcome,Illness (finding),3,X,[patf],[sosy],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,
5936a30a-b904-48c1-8941-73c64ac87aa4,C0206419,C0022661,brought challenges to patients with ,Genus: Coronavirus,Kidney Failure Chronic,1,X,[virs],[dsyn],B04.820.504.540.150,C12.777.419.780.750.500;C13.351.968.419.780.750.500
6b087e64-1a20-4088-becd-a0791e930a59,C2720167,COVID-19,is in ,Sirtuin 1,COVID-19,1,X,[aapp/enzy],[virs],D08.811.277.087.520.200.650.100;D12.776.476.900.100,C000657245
6cee401d-2e6e-4991-b86d-f26ee6a0719a,C3463820,COVID-19,is in ,Inhibition,COVID-19,3,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,C000657245
1229c4ea-bb05-4a24-a971-1e687bcef9ad,C2720167,C0206419,is in ,Sirtuin 1,Genus: Coronavirus,1,X,[aapp/enzy],[virs],D08.811.277.087.520.200.650.100;D12.776.476.900.100,B04.820.504.540.150
c5f6683e-6bcc-4fb6-a5d0-65221ae7393b,C3463820,C0206419,is in ,Inhibition,Genus: Coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150
c40fa1f8-3cd0-4270-bdbb-0e9ec8a3015f,C2720167,C0012634,is in ,Sirtuin 1,Disease,1,X,[aapp/enzy],[dsyn],D08.811.277.087.520.200.650.100;D12.776.476.900.100,C23.550.288
af1dc7ce-4596-4d46-854f-52c89d87b050,C3463820,C0012634,is in ,Inhibition,Disease,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C23.550.288
355a2d8c-64d6-44c3-9295-e6c0094a894a,C2720167,CD8,reduces CD8 ,Sirtuin 1,CD8,1,X,[aapp/enzy],????,D08.811.277.087.520.200.650.100;D12.776.476.900.100,????
66a70654-898b-4b76-9f86-8a23e343e0d9,C3463820,CD8,reduces CD8 ,Inhibition,CD8,1,X,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405,????
65379e9f-7d66-483e-9d0b-67974a229b21,C2720167,C0039195,reduces CD8 ,Sirtuin 1,Cytotoxic T-Lymphocytes,1,X,[aapp/enzy],[cell],D08.811.277.087.520.200.650.100;D12.776.476.900.100,A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
25010c3e-d2e9-4e4e-9475-c90b0c27905d,C3463820,C0039195,reduces CD8 ,Inhibition,Cytotoxic T-Lymphocytes,1,X,[acty],[cell],F01.145.544;F02.463.425.475;F02.739.794.405,A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
22e02d1a-269f-4697-a6dd-588a23c84d29,C2720167,C0024131,reduces CD8 Cytotoxic T-Lymphocytes in patients with systemic erythematosus,Sirtuin 1,Lupus Vulgaris,1,X,[aapp/enzy],[dsyn],D08.811.277.087.520.200.650.100;D12.776.476.900.100,C01.252.410.040.552.846.583.470;C01.252.825.820.470;C01.539.800.720.820.470;C17.800.838.765.820.470
6d9a555e-868a-4f8d-9fb8-4e9ed3df6132,C3463820,C0024131,reduces CD8 Cytotoxic T-Lymphocytes in patients with systemic erythematosus,Inhibition,Lupus Vulgaris,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.252.410.040.552.846.583.470;C01.252.825.820.470;C01.539.800.720.820.470;C17.800.838.765.820.470
1f58a9fd-9e69-4bb6-9f8d-5e1d685fda88,C2720168,C0014467,is regulated by ,Sirtuin 2,eosinophil,2,X,[aapp/enzy],[cell],D08.811.277.087.520.200.650.200;D08.811.913.400.725.115.961.200;D12.776.476.900.200,A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251
51253159-d559-403d-95bd-ad2dda8bedfe,C2720168,C3156663,is regulated by ,Sirtuin 2,interleukin-4 secretion,4,X,[aapp/enzy],[celf],D08.811.277.087.520.200.650.200;D08.811.913.400.725.115.961.200;D12.776.476.900.200,
6880af47-9cbf-4317-a959-46fd46835d47,C2720169,C0302600,promotes ,Sirtuin 3,Angiogenic Process,1,X,[aapp/enzy],[ortf],D08.811.277.087.520.200.650.600;D08.811.913.400.725.115.961.600;D12.776.476.900.600;D12.776.575.875,
96c986ab-4def-4b6e-bdc8-197ff9be6267,C1423064,C1423065,is Tumor Suppressor Genes in contrastto,SIRT4 gene,SIRT5 gene,1,X,[gngm],[gngm],,
0a61e93b-2459-4bb4-8364-bbf767e5efaf,C0079427,C1423065,is in contrastto ,Tumor Suppressor Genes,SIRT5 gene,1,X,[gngm],[gngm],G05.360.340.024.340.375.249;G05.360.340.024.340.415.400,
9474dfcc-d5ea-4b45-8257-d21862e58d0d,C1423064,C0079427,is ,SIRT4 gene,Tumor Suppressor Genes,1,X,[gngm],[gngm],,G05.360.340.024.340.375.249;G05.360.340.024.340.415.400
bc96429c-d897-4a38-9d69-3e97184cb462,C0596290,C1527249,causing ,Cell Proliferation,Colorectal Cancer,1,X,[celf],[neop],G04.161.750;G07.345.249.410.750,C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180
03eb7c10-8f46-4ed6-b1c7-c0d39a41a753,C1423066,C0206558,attenuates ,SIRT6 gene,Simplexvirus,1,X,[gngm],[virs],,B04.280.382.100.750
cd692af3-9a28-4b15-a152-cf3846b7f306,C1423066,C0036220,attenuates ,SIRT6 gene,Kaposi Sarcoma,1,X,[gngm],[neop],,C02.256.466.860;C04.557.450.795.850;C04.557.645.750
68d2f8e7-9691-4154-b3aa-be391218cb8d,C1423065,C0596290,promotes ,SIRT5 gene,Cell Proliferation,1,X,[gngm],[celf],,G04.161.750;G07.345.249.410.750
e2209bad-89be-415b-8c29-df7e415be1ab,C0206558,C0036220,associated with ,Simplexvirus,Kaposi Sarcoma,1,X,[virs],[neop],B04.280.382.100.750,C02.256.466.860;C04.557.450.795.850;C04.557.645.750
211ef185-f72f-471d-94fa-7fbdbd17ba13,C0206558,C0376526,associated with ,Simplexvirus,human herpesvirus 8,1,X,[virs],[virs],B04.280.382.100.750,B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330
fe0873d4-337c-4e83-bfd8-634b12d68a13,C0598312,C0334227,Apoptosis of,DNA Replication,Tumor cells malignant,1,X,[genf],[cell],G02.111.225;G05.226,
3e258998-6463-4b9a-83b5-91ae1caefee4,C0162638,C0598312,attenuates ,Apoptosis,DNA Replication,1,X,[celf],[genf],G04.146.160,G02.111.225;G05.226
53e0dc1b-343c-41f0-accd-ec771d65c1be,C0162638,C0376526,attenuates ,Apoptosis,human herpesvirus 8,1,X,[celf],[virs],G04.146.160,B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330
ff026a1c-a3d0-49b6-b8ee-50a15cf89bb5,C0598312,C3463820,is associated with ,DNA Replication,Inhibition,1,X,[genf],[acty],G02.111.225;G05.226,F01.145.544;F02.463.425.475;F02.739.794.405
b3e18167-dd79-4352-8e34-0f2cc2025a21,C0598312,C2720167,is associated with ,DNA Replication,Sirtuin 1,1,X,[genf],[aapp/enzy],G02.111.225;G05.226,D08.811.277.087.520.200.650.100;D12.776.476.900.100
2a54c189-808f-404c-a0c5-6c9307a62c4f,C0162638,C3463820,is associated with ,Apoptosis,Inhibition,1,X,[celf],[acty],G04.146.160,F01.145.544;F02.463.425.475;F02.739.794.405
844346ec-4be2-45e5-8999-dadf6f3e56b9,C0162638,C2720167,is associated with ,Apoptosis,Sirtuin 1,1,X,[celf],[aapp/enzy],G04.146.160,D08.811.277.087.520.200.650.100;D12.776.476.900.100
de1e1855-59d0-445d-92a8-f1db01e3dd7c,C0162638,C0206419,attenuates DNA Replication in addition to molecular pathology pathway of,Apoptosis,Genus: Coronavirus,1,X,[celf],[virs],G04.146.160,B04.820.504.540.150
8f2b83ba-ced0-4426-bfdd-0737353e79f1,C1175743,C0596756,is driving ,SARS coronavirus,immunopathology specialty,1,X,[virs],[bmod],B04.820.504.540.150.113.937,
380dcac5-a1c9-4e30-8609-cb85508d636d,C0596756,C0002390,strongly resembles severe form of ,immunopathology specialty,Extrinsic allergic alveolitis,2,X,[bmod],[dsyn],,C08.381.483.125;C08.674.055;C20.543.480.680.075
3ac651dc-4542-4a9a-bf84-c76eed685310,C0596756,C0032285,strongly resembles severe form of ,immunopathology specialty,Pneumonia,2,X,[bmod],[dsyn],,C08.381.677;C08.730.610
daeb87ec-e9f4-467c-88d3-d71def082694,C0600327,C1175743,is in setting of ,Toxic Shock Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712,B04.820.504.540.150.113.937
0dfdb2cd-014f-4600-acea-ce544b4f563f,C1175743,C0032285,led to outbreak of ,SARS coronavirus,Pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.677;C08.730.610
0dfdb2cd-014f-4600-acea-ce544b4f563f,C1175743,C0032285,causes novel ,SARS coronavirus,Pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.677;C08.730.610
0dfdb2cd-014f-4600-acea-ce544b4f563f,C1175743,C0032285,include ,SARS coronavirus,Pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.677;C08.730.610
b491bf37-bbb2-4e8e-a066-f5950688d718,C1185738,C0003467,focuses on neurobiological explanations for ,Column (anatomic),Anxiety,1,X,[bpoc],[mobd],,F01.470.132
9606daa9-680e-416f-99cf-e39e132e7c58,COVID-19,C0011991,been associated disease with,COVID-19,Diarrhea,1,X,[virs],[sosy],C000657245,C23.888.821.214
618e6a13-d83b-4d27-8463-dcef1bed0983,COVID-19,C0243083,been associated disease with,COVID-19,associated disease,2,X,[virs],[patf],C000657245,
5ee60099-a66c-4953-854f-6f079253bef6,CBLL,C0037284,accounted for for ,CBLL,Skin lesion,2,X,????,[dsyn],????,
89ebcfd3-3f3b-409d-81e3-8c2a11c3ef0f,CBLL,C0242656,appear late in ,CBLL,Disease Progression,2,X,????,[patf],????,C23.550.291.656
16bbe870-daad-47b8-b848-7a8a169475cf,C1175743,C0035242,has has identified as agent of global outbreak of ,SARS coronavirus,Respiratory Tract Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08
0aaa4f6a-3d6f-4d41-b6e0-878a2a2a4c69,C0009450,C0035222,results in moderate to ,Communicable Diseases,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C01.539.221,C08.381.840;C08.618.840
17370f90-87b4-40e1-8605-bab50dbe770a,C0009450,C1868981,requiring ,Communicable Diseases,Invasive mechanical ventilation NOS,1,X,[dsyn],[topp],C01.539.221,
4bfae462-d5dc-4bc7-93d6-099de019abeb,C1175743,C0010357,is indicative of ,SARS coronavirus,Cross Reactions,1,X,[virs],[moft],B04.820.504.540.150.113.937,G12.122.281
6448d631-d94a-4026-aaff-b84eca0a642f,C1175743,C0009443,is indicative of ,SARS coronavirus,Common Cold,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.687.207;C08.730.162
c82a1d2f-a82a-4cf4-af45-15486457c323,C0039194,C0025248,were directed to spike ,T-Lymphocyte,Membrane Glycoproteins,1,X,[cell],[aapp/bacs],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,D12.776.395.550;D12.776.543.550
f8be32a8-5700-4dcf-82f6-957aff739b4a,C1175743,C0079189,predominantly produced effector ,SARS coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374;D12.776.467.374;D23.529.374
f8be32a8-5700-4dcf-82f6-957aff739b4a,C1175743,C0079189,is characterized by overwhelming ,SARS coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374;D12.776.467.374;D23.529.374
f8be32a8-5700-4dcf-82f6-957aff739b4a,C1175743,C0079189,may cause reaction through release of ,SARS coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374;D12.776.467.374;D23.529.374
8b518794-5ce1-4d2d-88c9-ff28959feb4a,C0039194,C0079189,predominantly produced effector ,T-Lymphocyte,cytokine,1,X,[cell],[aapp/imft],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,D12.644.276.374;D12.776.467.374;D23.529.374
9620deb8-5c5e-4f1c-a023-c03280d74f25,C0553757,COVID-19,beginning before ,Olfaction Disorders,COVID-19,2,X,[dsyn],[virs],C10.597.751.600;C23.888.592.763.550,C000657245
b0b970cb-9ebc-4645-91c8-b91811f6eaf8,C0553757,C0037088,beginning before ,Olfaction Disorders,Signs and Symptoms,2,X,[dsyn],[sosy],C10.597.751.600;C23.888.592.763.550,C23.888
26f6959c-3c34-4ee0-8d03-58a5ce28900d,C0237820,COVID-19,usually happened after ,Recovery - action,COVID-19,2,X,[acty],[virs],,C000657245
82f2b5f6-12f4-4d08-b28d-460188bc79be,C0149783,C0395797,is in ,Steroid therapy,Ear nose and throat disorder,6,X,[topp],[dsyn],,
d01ec128-4615-4f79-aa60-716f789e2f0b,C1523273,C0062503,Viral Interference with,protein complex oligomerization,Heparan Sulfate Proteoglycans,2,X,[moft],[aapp/bacs],,D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350
af636f98-c0d4-42fc-be32-6bd22fda5847,C1523273,C0042730,Viral Interference with,protein complex oligomerization,Viral Interference,2,X,[moft],[npop],,G06.920.800
787388be-71b4-443c-b252-3c022bda33b5,C1523273,C4551660,outcompeting ,protein complex oligomerization,Virus Host Interactions,4,X,[moft],[npop],,G06.373;G16.527
8de6752c-ea05-4185-b43c-a1d59e8e3939,C1523273,C0032594,outcompeting ,protein complex oligomerization,Polysaccharides,2,X,[moft],[orch/phsu],,D09.698
3a0c7c3e-2226-4eda-9e5d-cd41ba48fe19,C0042730,C0062503,is with ,Viral Interference,Heparan Sulfate Proteoglycans,2,X,[npop],[aapp/bacs],G06.920.800,D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350
cb9ec0eb-62ea-4f1d-92e6-5b68d53a6b0f,C1609165,C0035222,were reported in ,tocilizumab,Respiratory Distress Syndrome Adult,1,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C08.381.840;C08.618.840
c3e4ead1-859c-4054-87a3-c02541def406,C0229671,C1609165,were assayed at time of first ,Serum,tocilizumab,1,X,[bdsu],[aapp/imft/phsu],A12.207.152.846;A15.145.846,x.x.x.x
68258127-1eff-4221-bf44-f3ba5e1c21a5,C0024312,C4019050,was reversed at_time days after ,Lymphopenia,tocilizumab Injection,1,X,[dsyn],[clnd],C15.378.553.546.605;C20.673.627,
95cdb312-a745-430d-b1e4-76cb80c76934,COVID-19,C0011945,occur among patients on ,COVID-19,Physical Dialysis,1,X,[virs],[npop],C000657245,E05.196.353;G02.186
92fa747a-209a-416e-9b87-236ae1bb972f,C0009450,C0011945,occur among patients on ,Communicable Diseases,Physical Dialysis,2,X,[dsyn],[npop],C01.539.221,E05.196.353;G02.186
8a380c3a-cbeb-41e0-af34-6e6393b5c3dc,C0009450,C1707455,occur among patients on ,Communicable Diseases,Comparison,1,X,[dsyn],[acty],C01.539.221,
0b77a158-acd3-47a4-a156-d5277ee82943,C0034535,C0206419,is in ,Radiation Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,B04.820.504.540.150
e7fe5d30-5f52-48fe-91c1-26d3cc92d1ed,C0027651,C0206419,managing Neoplasms patients during,Neoplasms,Genus: Coronavirus,4,X,[neop],[virs],C04,B04.820.504.540.150
723d56f7-af1a-4065-b4f3-5569214235fa,C0034535,C1521863,is in ,Radiation Syndrome,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,x.x.x.x
00e6d4a7-0e2e-4f91-933b-ff7a352de6cf,C0027651,C1521863,is in ,Neoplasms,estrogen receptor alpha human,1,X,[neop],[aapp/rcpt],C04,x.x.x.x
7c13e352-7592-4787-84c7-ac777234fc29,C0232741,COVID-19,should ,Liver function,COVID-19,1,X,[ortf],[virs],,C000657245
22dac978-bc88-4f0c-84c5-6ce3f7546354,C1179870,C0032930,inflammatory damage of are possible ,Nodal myocyte,Precipitating Factors,1,X,[cell],[clna],,N05.715.350.200.650;N06.850.490.625.500
41349fa9-dc34-4109-85c7-a66e335f9729,C0003130,C0032930,are possible ,Anoxia,Precipitating Factors,1,X,[patf],[clna],C23.888.852.079,N05.715.350.200.650;N06.850.490.625.500
d8133153-6081-41c9-9df3-68f43d6ee8db,C0037088,C0206419,is in inpatient ,Signs and Symptoms,Genus: Coronavirus,1,X,[sosy],[virs],C23.888,B04.820.504.540.150
c1fe57d0-2a97-431d-b1e3-592e3040768a,C0037088,C0012634,is in inpatient ,Signs and Symptoms,Disease,2,X,[sosy],[dsyn],C23.888,C23.550.288
0e3b5745-f7a9-4192-8b50-64e752b36e35,C0024115,COVID-19,is in ,Lung diseases,COVID-19,3,X,[dsyn],[virs],C08.381,C000657245
7cb4a851-00c9-4817-9ad1-f42ff9b13d49,C0032529,C0017337,is in ,Genetic Polymorphism,Genes,2,X,[genf],[gngm],G05.365.795,G05.360.340.024.340
912d321e-2332-4e1e-8f6a-88ccbc167f97,C0032529,C1422064,is in ,Genetic Polymorphism,ACE2 gene,1,X,[genf],[gngm],G05.365.795,
6b722c38-4cdb-4320-9044-f0daeabe7047,C0032529,C0678951,is in ,Genetic Polymorphism,gene polymorphism,1,X,[genf],[genf],G05.365.795,
0560428b-7e0b-4665-8a74-def63e5ab37a,C0032529,C0598312,could affect ,Genetic Polymorphism,DNA Replication,2,X,[genf],[genf],G05.365.795,G02.111.225;G05.226
3d14cc58-5992-45a8-84db-785be39ad7c5,C0032529,C1537068,could affect ,Genetic Polymorphism,Virus Internalization,2,X,[genf],[biof],G05.365.795,G06.920.881
aec5b2a5-5e15-435d-b0b4-ca360c7f0fc5,C0020167,C0301872,can influence ,Humidity,Immune response,4,X,[npop],[ortf],G16.500.275.063.725.310;G16.500.750.775.310;N06.230.150.372;N06.230.300.100.725.310,
f2870c8f-1771-494f-a3de-f6d0660cdbf9,C0020167,C0038952,can influence viral ,Humidity,Continuance of life,2,X,[npop],[acty],G16.500.275.063.725.310;G16.500.750.775.310;N06.230.150.372;N06.230.300.100.725.310,I03.784
7deed52a-c4c0-41de-86fb-3255ab8067a7,C1708476,C0012634,has also Contribution to less,Implementation,Disease,2,X,[acty],[dsyn],,C23.550.288
b0cb7d29-2bb9-43a5-94e1-60ed99fd312a,C1335439,C0003451,is promising ,Polymerase,Antiviral Agents,1,X,[aapp/enzy],[phsu],,D27.505.954.122.388
c655fb95-10b2-429d-bc39-20bb6724b5fb,C0005516,C0229671, includes ,Biological Markers,Serum,1,X,[clna],[bdsu],D23.101,A12.207.152.846;A15.145.846
5cec8fc6-2be3-4e0e-aa77-4ce8eba4dc35,C0854532,C0009450,remains prominent ,Myopericarditis,Communicable Diseases,4,X,[dsyn],[dsyn],,C01.539.221
ab22fbd8-cace-4dc3-a2eb-b108ada61447,C1520005,C0854532,be leading contributors ,Viral Pathogenesis,Myopericarditis,2,X,[patf],[dsyn],,
0c1bcfe9-d4b5-47d1-8166-23bc27240337,NYSDOH,C0282624,definition for ,NYSDOH,Minimally Invasive Surgical Procedures,1,X,????,[topp],????,E04.502
bb887515-9997-49c1-820d-700a6adabc89,C0751973,C1175743,dynamicome-level understanding of ,Proteome,SARS coronavirus,4,X,[aapp/bacs],[virs],D12.776.817,B04.820.504.540.150.113.937
4109095f-ae05-497d-ae52-3274753f9fbc,C4553629,y216,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,y216,1,X,[topp],????,,????
532a9b76-7c08-4362-8406-388b3f68b99d,C0009450,C1880355,caused by newly ,Communicable Diseases,Discover,1,X,[dsyn],[acty],C01.539.221,
532a9b76-7c08-4362-8406-388b3f68b99d,C0009450,C1880355,has spread worldwide Since December 2019 ,Communicable Diseases,Discover,1,X,[dsyn],[acty],C01.539.221,
5359a639-770f-4f58-93f3-05dcf19c3063,C0033684,C0319157,collectively reveal map of ,Proteins,AS virus,1,X,[aapp/bacs],[virs],D12.776,
81d61647-e41e-4002-848c-9259f51bb3ce,C0162595,C0850624,are considered as ,Antiphospholipid Antibodies,cardiovascular risk factor,2,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,
464e2a5a-0d71-4dd6-adb4-cd1251ec85c1,C0162595,C0005516,are essential ,Antiphospholipid Antibodies,Biological Markers,2,X,[aapp/imft],[clna],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,D23.101
e8e28954-1dd7-4bce-ae8a-d92412fcbe52,C0162595,C0085278,are essential Biological Markers for,Antiphospholipid Antibodies,Antiphospholipid Syndrome,2,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,C20.111.197
141ce102-9f76-47bd-a8aa-cff3dda69e8d,C0003209,C0001617, includes ,Anti-Inflammatory Agents,Adrenal Cortex Hormones,4,X,[phsu],[horm/orch/phsu],D27.505.954.158,D06.472.040
b77c5149-624d-429e-8929-a4e612772634,C0003209,C0079189,effectively reduce effect of ,Anti-Inflammatory Agents,cytokine,2,X,[phsu],[aapp/imft],D27.505.954.158,D12.644.276.374;D12.776.467.374;D23.529.374
4d86a11f-4102-406b-a174-97cdcac009f8,C0001617,C0079189,effectively reduce effect of ,Adrenal Cortex Hormones,cytokine,2,X,[horm/orch/phsu],[aapp/imft],D06.472.040,D12.644.276.374;D12.776.467.374;D23.529.374
4d86a11f-4102-406b-a174-97cdcac009f8,C0001617,C0079189,is In other very similar ,Adrenal Cortex Hormones,cytokine,2,X,[horm/orch/phsu],[aapp/imft],D06.472.040,D12.644.276.374;D12.776.467.374;D23.529.374
c2f75bcd-a16e-4a85-b8c3-7dd789765bdd,C1533734,C0010340,reduce effect of ,Administration procedure,Critical Illness,2,X,[topp],[dsyn],,C23.550.291.625
25f35b7f-39e9-4fc7-b258-f207afffa25c,C1533734,C0021027,is in combination with IV ,Administration procedure,Immunoglobulins,2,X,[topp],[aapp/imft],,D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548
388f563f-2ec9-4b7f-aeb7-1fc3fa96247f,C1879547,C0319157,causes in addition to direct injury from se,Activation action,AS virus,1,X,[acty],[virs],,
6dabf101-b0a2-4038-b61f-9cc987375571,C1879547,se,causes in addition to direct injury from se,Activation action,se,1,X,[acty],????,,????
60fe059b-b4c9-4eeb-b3e8-c874e8c251f8,C0079189,C0319157,causes in addition to direct injury from se,cytokine,AS virus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,
3ccda438-5c02-4ba3-a344-c9b3482677ca,C0079189,se,causes in addition to direct injury from se,cytokine,se,2,X,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374,????
3288371f-be48-4103-a7a0-6e9b58d1d882,C1175743,C2348077,are warranted To ,SARS coronavirus,Date Fruit,1,X,[virs],[food],B04.820.504.540.150.113.937,B01.650.940.800.575.912.250.093.615
3288371f-be48-4103-a7a0-6e9b58d1d882,C1175743,C2348077,2-positive results to ,SARS coronavirus,Date Fruit,1,X,[virs],[food],B04.820.504.540.150.113.937,B01.650.940.800.575.912.250.093.615
b959c0b6-8c3a-4d26-b2bd-0737b49bd942,C0087111,C2348077,are warranted To ,Therapeutic procedure,Date Fruit,2,X,[topp],[food],E02,B01.650.940.800.575.912.250.093.615
692908bc-00ed-4084-bee2-3507d8031943,C3687832,C1175743,However may have risks beyond anti ,Drugs - dental services,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
692908bc-00ed-4084-bee2-3507d8031943,C3687832,C1175743,have have tested as new ,Drugs - dental services,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
692908bc-00ed-4084-bee2-3507d8031943,C3687832,C1175743,entry of ,Drugs - dental services,SARS coronavirus,2,X,[topp],[virs],,B04.820.504.540.150.113.937
76ed04ac-26c8-428a-bc12-3c8278038269,C3687832,C0232217,especially altering ,Drugs - dental services,Cardiac conduction,1,X,[topp],[ortf],,
46a734b4-ec16-4f76-b0df-0da47e1e1c50,C0035204,C0206061,occurred with ,Respiration Disorders,Pneumonia Interstitial,3,X,[dsyn],[dsyn],C08.618,C08.381.483
8b1262dc-acc7-4bad-8aee-7c2069471b00,C0035668,C0178784,is in ,RNA,Organ,3,X,[nnon],[bpoc],D13.444.735,
b6a283ed-c2aa-43ac-b958-81b2f4ab4f72,C0035204,C0026179,occurred in ,Respiration Disorders,Mink,3,X,[dsyn],[mamm],C08.618,B01.050.150.900.649.313.750.250.575.500
7925b8dc-93c4-4f06-8a74-838b0524af17,C0013330,C0035736,contained ,Dust,RNA Viral,3,X,[sbst],[nnon],D20.633.222,D13.444.735.828
adf4db0b-4a73-4a86-ab9b-af5cd9e6f3a0,C4321457,C0024115,rule out incidental finding ,Examination,Lung diseases,1,X,[acty],[dsyn],,C08.381
227aea51-2025-40f0-83e7-2299c64958cc,C4321457,C0156149,rule out ,Examination,Gastrointestinal tract vascular insufficiency,1,X,[acty],[dsyn],,
d903070a-adeb-461c-9a4a-7e2cacd07033,C0282624,C4283938,is associated with shorter hospital stay than ,Minimally Invasive Surgical Procedures,Open Surgical Procedure,3,X,[topp],[topp],E04.502,
d903070a-adeb-461c-9a4a-7e2cacd07033,C0282624,C4283938,reconverted to ,Minimally Invasive Surgical Procedures,Open Surgical Procedure,3,X,[topp],[topp],E04.502,
d01fcb17-4893-4c48-a99e-5b6ff797e47a,C1175743,C1705178,recommended in ,SARS coronavirus,Order (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
a6c475ad-d9db-4aba-b681-5452fc657b4e,C1175743,C3714514,prevent professional ,SARS coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150.113.937,C01.539
a6c475ad-d9db-4aba-b681-5452fc657b4e,C1175743,C3714514,has caused about million ,SARS coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150.113.937,C01.539
5772e2c3-4b4e-45dd-ae7b-6ea77704483b,C0282624,C0206419,reconverted during ,Minimally Invasive Surgical Procedures,Genus: Coronavirus,1,X,[topp],[virs],E04.502,B04.820.504.540.150
82cbbcbb-06cb-443c-a9f8-3a90405a8483,C1175743,C0189341,is in anticipation of ,SARS coronavirus,Planned tracheostomy,2,X,[virs],[topp],B04.820.504.540.150.113.937,
1452be4c-0bd1-430b-8338-3c8b9ffc1dae,C3176469,silico,readily bind in silico,Over the counter medications,silico,1,X,[phsu],????,,????
085c6d81-8bf2-4a0a-aaa2-f9006f510d83,C0020538,C1707455,occurred more commonly in elderly group ,Hypertensive disease,Comparison,1,X,[dsyn],[acty],C14.907.489,
3beb2f97-103d-4a94-9d44-2e9887c65de8,C0011849,C1707455,occurred commonly in elderly group ,Diabetes Mellitus,Comparison,1,X,[dsyn],[acty],C18.452.394.750;C19.246,
3beb2f97-103d-4a94-9d44-2e9887c65de8,C0011849,C1707455,frequency of was ,Diabetes Mellitus,Comparison,1,X,[dsyn],[acty],C18.452.394.750;C19.246,
dd8b8abf-7c52-4212-bbbc-9eeea3ad60a5,C0006560,C4551752,percentage of ,C-reactive protein,Abnormal Lymphocyte cell,1,X,[aapp/imft],[cell],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,
a2cb6b95-d1aa-4e06-a2d5-b68b8004dd2c,C1704259,C0233514,are associated with major ,Biochemical Pathway,Abnormal behavior,5,X,[moft],[mobd],,F01.145.126.972;F01.145.179.750
f7ae2ea1-d917-4ee2-b23b-13bd54f87d47,C1817997,C0012634,be crucially involved in manifestation in individuals with ,chronic inflammatory response,Disease,2,X,[patf],[dsyn],,C23.550.288
36a726c1-657d-4754-9fb2-97bcb6aa0ab2,C0206750,C0004936,is with prior ,Coronavirus Infections,Mental disorders,2,X,[dsyn],[mobd],C02.782.600.550.200,F03
36a726c1-657d-4754-9fb2-97bcb6aa0ab2,C0206750,C0004936,could specially affect people with ,Coronavirus Infections,Mental disorders,1,X,[dsyn],[mobd],C02.782.600.550.200,F03
36a726c1-657d-4754-9fb2-97bcb6aa0ab2,C0206750,C0004936,is with its subsequent ,Coronavirus Infections,Mental disorders,1,X,[dsyn],[mobd],C02.782.600.550.200,F03
36a726c1-657d-4754-9fb2-97bcb6aa0ab2,C0206750,C0004936,possesses challenges for individuals with preexisting ,Coronavirus Infections,Mental disorders,1,X,[dsyn],[mobd],C02.782.600.550.200,F03
07688ba1-8e4e-469d-97a3-5ad34bf304cd,C0013227,C0030664,already used in clinical setting for ,Pharmaceutical Preparations,Pathology,1,X,[phsu],[bmod],D26,H02.403.650
4446cf0c-cda7-45d7-894d-45e969dd197b,C1856053,C1845118,as of Institute is ,Hydranencephaly with Renal Aplasia-Dysplasia,SHORT STATURE IDIOPATHIC X-LINKED,1,X,[dsyn],[cgab],x.x.x.x,x.x.x.x
12531f6b-382c-4a3e-bb9a-eae3e8e1e7eb,DCC19,C0206750,assist GPs for patients with suspected ,DCC19,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
09e4a47a-1122-49c5-9bc8-f5e636aa98fe,DCC19,C1999230,assist GPs in ,DCC19,Providing (action),5,X,????,[acty],????,
2a91c0de-0cf6-4869-938c-439c1bf2ff26,C0301630,C0004610,is in rates of ,Reduction (chemical),Bacteremia,4,X,[npop],[dsyn],,C01.252.100;C01.539.757.100;C23.550.470.790.500.100
1254dd91-5f8d-4a17-a349-f726b6a58519,C0743841,C0301630,continues Despite dramatic 1980s,Disorder characterized by fever,Reduction (chemical),4,X,[dsyn],[npop],,
0d81c836-43cf-4d28-ae1a-f834b4ef50d5,C0743841,C0004610,continues Despite dramatic 1980s,Disorder characterized by fever,Bacteremia,2,X,[dsyn],[dsyn],,C01.252.100;C01.539.757.100;C23.550.470.790.500.100
ac113753-f2f0-4076-98df-e3eba557fd0b,C0743841,1980s,continues Despite dramatic 1980s,Disorder characterized by fever,1980s,4,X,[dsyn],????,,????
e345e8b5-ffed-4b9a-83f4-07dde7bfa876,C0009450,C0425716,include delayed ,Communicable Diseases,Capillary filling function (observable entity),2,X,[dsyn],[ortf],C01.539.221,
17a9285a-5f23-4124-92bf-3c541115eeb5,C0009450,C1516048,include overall physician ,Communicable Diseases,Assessed,3,X,[dsyn],[acty],C01.539.221,
a51cc09f-b7ad-4106-9e1c-53c3581ec583,C0009450,C0241144,include ,Communicable Diseases,Petechiae of skin,2,X,[dsyn],[sosy],C01.539.221,
787de500-6b7f-4663-811c-d4334aa8c461,C0042029,C3826128,are most common serious bacterial ,Urinary tract infection,Infection in children,4,X,[dsyn],[dsyn],C01.539.895;C12.777.892;C13.351.968.892,
6e61ae08-de89-4a96-9ca9-e60b4ac1e66b,C0003237,C0007561,include ,Antibiotics Antitubercular,Ceftriaxone,4,X,[antb],[antb/orch],D27.505.954.122.085.255.135,D02.065.589.099.249.190.190.155;D02.886.665.074.190.190.155;D03.633.100.300.249.190.190.155
6856c667-c91c-495b-9780-948e76ec05cf,C0002680,C0007554,is with ,Ampicillin,Cefotaxime,4,X,[antb/orch],[antb/orch],D02.065.589.099.750.750.050;D02.886.108.750.750.050;D03.633.100.300.750.750.050,D02.065.589.099.249.190.190;D02.886.665.074.190.190;D03.633.100.300.249.190.190
a9c13abf-0f49-47e2-8921-26fd3eec8a2b,C0002680,C3854019,is with ,Ampicillin,Gentamicin,4,X,[antb/orch],[antb/orch],D02.065.589.099.750.750.050;D02.886.108.750.750.050;D03.633.100.300.750.750.050,D09.408.051.374
7d092b5c-4598-4605-a061-2d503634ed7c,C0003237,C0060400,are ,Antibiotics Antitubercular,Cefixime,5,X,[antb],[antb/orch],D27.505.954.122.085.255.135,D02.065.589.099.249.190.190.115;D02.886.665.074.190.190.115;D03.633.100.300.249.190.190.115
bd82ad8b-006b-474f-a2e9-75491dcf3015,C0003237,C0054066,are ,Antibiotics Antitubercular,Amoxicillin / Clavulanate,3,X,[antb],[phsu],D27.505.954.122.085.255.135,D02.065.589.099.374.160.060;D02.065.589.099.750.750.050.050.060;D02.886.108.750.750.050.050.060;D03.633.100.300.374.160.060;D03.633.100.300.750.750.050.050.500;D26.310.102
1e604362-fa83-40df-83bc-3cf5df600ecc,C0003237,C0041044,are ,Antibiotics Antitubercular,Trimethoprim-Sulfamethoxazole Combination,3,X,[antb],[phsu],D27.505.954.122.085.255.135,D02.065.884.725.867.500;D02.092.146.807.867.500;D02.886.590.700.725.867.500;D03.383.742.906.500;D26.310.875
bc3b82d3-bc06-4eaf-9f02-07bc5feb8dd5,C0206750,C0877373,patients with ,Coronavirus Infections,advanced cancer,4,X,[dsyn],[neop],C02.782.600.550.200,
2954029c-a377-4404-8d3d-3b0c47a1798f,C0206750,C0751569,patients with ,Coronavirus Infections,Genitourinary Cancer,2,X,[dsyn],[neop],C02.782.600.550.200,C04.588.945;C12.758;C13.351.937
2e82ba45-8679-4a7f-9d1f-170d0de70fb3,C1537068,C0242821,is in ,Virus Internalization,Human body,4,X,[biof],[humn],G06.920.881,I01.076.201.450.560;K01.093.378
518433c9-df3f-42bb-8a9b-f4f06014ee54,C0206750,C0857828,is in ,Coronavirus Infections,infection in the elderly,2,X,[dsyn],[dsyn],C02.782.600.550.200,
2a8d3961-7263-4681-abe1-20c79bda262e,C0206750,C0277562,is in young ,Coronavirus Infections,Adult disease,3,X,[dsyn],[dsyn],C02.782.600.550.200,
f283fe2e-0894-476a-a90d-e9e990bd35e0,C0857828,C0277562,is in ,infection in the elderly,Adult disease,3,X,[dsyn],[dsyn],,
68cbf335-7bc5-4647-8b56-3e9fc5925036,C0206750,C0023175,is in ,Coronavirus Infections,Lead,2,X,[dsyn],[elii/hops],C02.782.600.550.200,D01.268.556.435;D01.552.544.435;x.x.x.x
0d30daee-66b7-4f7d-a2ed-fcd27f8b4c3f,C0857828,C0023175,is in ,infection in the elderly,Lead,1,X,[dsyn],[elii/hops],,D01.268.556.435;D01.552.544.435;x.x.x.x
618c741c-be2d-497b-8b62-1e17c1572ee0,C0079189,C0035222,can induce ,cytokine,Respiratory Distress Syndrome Adult,4,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.840;C08.618.840
618c741c-be2d-497b-8b62-1e17c1572ee0,C0079189,C0035222,leading to ,cytokine,Respiratory Distress Syndrome Adult,4,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.840;C08.618.840
618c741c-be2d-497b-8b62-1e17c1572ee0,C0079189,C0035222,followed by ,cytokine,Respiratory Distress Syndrome Adult,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.840;C08.618.840
5b3c3e3b-a46f-4dd8-884c-7f3e2fb4b606,C0079189,C0026766,can induce ,cytokine,Multiple Organ Failure,4,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.835.525
5b3c3e3b-a46f-4dd8-884c-7f3e2fb4b606,C0079189,C0026766,lead to ,cytokine,Multiple Organ Failure,1,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.835.525
354ebeef-e29c-4917-a796-ced0f8fda8d8,C0206750,C0007682,is in ,Coronavirus Infections,CNS disorder,2,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228
f5c8849d-de59-4106-bd20-17d043f946fb,C0011849,C0301889,has ,Diabetes Mellitus,Immune defect,1,X,[dsyn],[patf],C18.452.394.750;C19.246,
c342408e-f1ab-430a-880c-9e0416f090d8,covid,C0342303,Also can cause ,covid,Metabolic stress hyperglycemia,1,X,????,[patf],????,
a7c3ea7a-d89e-4cb7-9207-e49da7ce3b96,C0024115,C0206750,is in ,Lung diseases,Coronavirus Infections,7,X,[dsyn],[dsyn],C08.381,C02.782.600.550.200
5e6b438d-e787-4374-a543-53e66787e74c,C0024115,C0012634,be associated with higher risk of hospitalization with ,Lung diseases,Disease,1,X,[dsyn],[dsyn],C08.381,C23.550.288
a864923c-43c3-4e5a-9e5d-94e1eaeee297,C0013227,C0004096,is in patients with ,Pharmaceutical Preparations,Asthma,1,X,[phsu],[dsyn],D26,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
5be4982d-0fcc-47c9-b189-1a81fc7545f5,C0001617,C0013227,are most commonly used controller ,Adrenal Cortex Hormones,Pharmaceutical Preparations,3,X,[horm/orch/phsu],[phsu],D06.472.040,D26
02bdbd7b-484c-49eb-bb68-c4ed1b8cf338,C0001617,C0004096,are most commonly used controller ,Adrenal Cortex Hormones,Asthma,1,X,[horm/orch/phsu],[dsyn],D06.472.040,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
de49aed1-f170-4483-b6bb-3151941c710e,C0232804,C0020538,independently predicted mortality at_time ,Renal function,Hypertensive disease,1,X,[ortf],[dsyn],,C14.907.489
172e1eab-2130-4eaf-a91d-49b165dfb6f3,C0282687,C0318793,is with ,Hemorrhagic Fever Ebola,Zika Virus,1,X,[dsyn],[virs],C02.782.417.415;C02.782.580.250.400,B04.820.250.350.995
d8a824ba-bf55-4de8-9369-6c4d2935503e,C0003451,C1705178,be integrated into control measures in ,Antiviral Agents,Order (action),2,X,[phsu],[acty],D27.505.954.122.388,
a4121189-9c59-4a98-80ce-5800ec3e3dd9,C0003451,C0034386,result in combination with contact tracing ,Antiviral Agents,Quarantine,2,X,[phsu],[topp],D27.505.954.122.388,N06.850.780.200.450.700
11e156cf-7b7c-4171-8d84-e53fb05bf1f0,C1533734,C0034386,is shown together ,Administration procedure,Quarantine,2,X,[topp],[topp],,N06.850.780.200.450.700
6f482453-8869-4992-ace3-592b6f97e2eb,C0444190,C1628999,detecting ,Conjunctival swab (specimen),SARS coronavirus RNA,1,X,[bdsu],[nnon],,
2593e0c0-b03b-47d9-beb0-e83c6b678947,C1628999,C0009763,Likewise was detected in one patient without ,SARS coronavirus RNA,Conjunctivitis,1,X,[nnon],[dsyn],,C11.187.183
355a447e-7489-4704-aace-aa8fd3ae9086,C0596448,C0012634,is in patients with ,dimer,Disease,1,X,[chvs],[dsyn],,C23.550.288
d165bdbb-8690-48c0-9f9a-a5f67fe4b1c5,C1707455,C0596448,is with normal D ,Comparison,dimer,1,X,[acty],[chvs],,
621195c6-a3a3-4c56-b0a1-16d8bc34f2f4,C0060323,C1416903,was related with ,Fibrin fragment D,LPO gene,1,X,[aapp/bacs],[gngm],x.x.x.x,
c47e8919-8819-489d-99a8-3896e6201d18,C0060323,C0232117,was negatively related with ,Fibrin fragment D,Pulse Rate,2,X,[aapp/bacs],[clna],x.x.x.x,E01.370.600.875.500;G09.330.380.500
83b7258c-13e9-4981-af9e-0eff39223a7c,C0060323,C0369768,was negatively related with ,Fibrin fragment D,Molecular oxygen saturation,2,X,[aapp/bacs],[moft],x.x.x.x,
64790566-820e-43af-824b-11e3a549dcc4,C0060323,C0522534,was negatively related with ,Fibrin fragment D,Saturated,2,X,[aapp/bacs],[npop],x.x.x.x,
35a86ea1-a1b8-428f-bd20-3bd2cf141ba2,C0060323,C0231832,was related with ,Fibrin fragment D,Respiratory rate,2,X,[aapp/bacs],[clna],x.x.x.x,E01.370.600.875.875;G09.772.705.730
378e15eb-cc07-4a06-9fe6-b3c0ed1fc5f8,C0060323,C0206750,were related in ,Fibrin fragment D,Coronavirus Infections,7,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
26f362e2-07fe-4dac-ba3e-a7f5b0175d40,MSC,C0035222,have shown first promise in treatment of ,MSC,Respiratory Distress Syndrome Adult,2,X,????,[dsyn],????,C08.381.840;C08.618.840
14a71426-cbf2-45d8-adf4-1085d6850a80,MSC,C0032285,have shown first promise in treatment of ,MSC,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
616ce00c-e02f-4a2f-9263-771f8a253e26,C0087111,C0032285,have shown first promise in treatment of ,Therapeutic procedure,Pneumonia,2,X,[topp],[dsyn],E02,C08.381.677;C08.730.610
f99662e2-6a05-46b7-b04f-bb051e62f194,MSC,C0021368,have shown first promise in treatment of ,MSC,Inflammation,2,X,????,[patf],????,C23.550.470
5bb7ba85-4291-4aac-9584-9bfba312f9f2,MSC,C0243026,have shown first promise in treatment of ,MSC,Sepsis,2,X,????,[dsyn],????,C01.539.757;C23.550.470.790.500
28d1da7b-8d2d-4713-bf9c-8671b42d0fc2,C0087111,C0243026,have shown first promise in treatment of ,Therapeutic procedure,Sepsis,2,X,[topp],[dsyn],E02,C01.539.757;C23.550.470.790.500
9e45e35f-a6db-44c0-a890-5dc04a2b72b7,C0243026,C0206750,are among leading causes of mortality in ,Sepsis,Coronavirus Infections,2,X,[dsyn],[dsyn],C01.539.757;C23.550.470.790.500,C02.782.600.550.200
6f54c242-4e33-4311-9aa0-799d3561bf69,C1880022,C4048299,is with unchecked CD142 ,Characterization,Tissue Factor,2,X,[acty],[aapp/imft],,D12.776.124.125.900;D23.119.965
54863cc4-98e0-43ca-88f0-9ffbbd3a5b21,MSC,C4048299,is with unchecked CD142 ,MSC,Tissue Factor,2,X,????,[aapp/imft],????,D12.776.124.125.900;D23.119.965
9c04dc8c-b3ba-4dc1-aa74-a08913133ecf,C1880022,CD142,is with unchecked CD142 ,Characterization,CD142,2,X,[acty],????,,????
0ebea281-997e-4e18-a775-f2a51fee8f3d,MSC,CD142,is with unchecked CD142 ,MSC,CD142,2,X,????,????,????,????
0588933d-9c70-427c-93ce-2b125fa0135e,C1880022,C0178784,inducing ,Characterization,Organ,2,X,[acty],[bpoc],,
29053579-58e7-4021-868c-930e2a2bef20,MSC,C0206750,is in ,MSC,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
c753f58e-b38f-4b7a-a5a0-ed2f90349bf0,C0872315,C1175743,caused by ,Communicable Diseases Emerging,SARS coronavirus,1,X,[dsyn],[virs],C01.539.221.500,B04.820.504.540.150.113.937
68a2edf9-db76-4d46-b82a-b9523056d586,C0079189,C1175743,is in asymptomatic ,cytokine,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150.113.937
68a2edf9-db76-4d46-b82a-b9523056d586,C0079189,C1175743,were seen in ,cytokine,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150.113.937
eb8dee4f-3a1c-4bf6-baa7-01b33bc52d78,C0012634,C0679215,became reportable ,Disease,health and disease,2,X,[dsyn],[npop],C23.550.288,
eb8dee4f-3a1c-4bf6-baa7-01b33bc52d78,C0012634,C0679215,reportable health and disease of public,Disease,health and disease,1,X,[dsyn],[npop],C23.550.288,
eb8dee4f-3a1c-4bf6-baa7-01b33bc52d78,C0012634,C0679215,can lead to serious problems like ,Disease,health and disease,1,X,[dsyn],[npop],C23.550.288,
1e633d20-f4c6-44df-b8c1-4dc396884faa,C0034019,C1175743,were Providing (action) with guidance on entry of patients tested for,public health medicine (field),SARS coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150.113.937
370e4723-ac79-4958-9209-9d946bb4e65a,C0441655,C0018837,protect health during periods of ,Activities,Heat (physical force),1,X,[acty],[npop],,
1b39d715-a6a5-4ce3-a052-02d6b6bd579f,C0319157,C0678568,causes Coronavirus Infections into,AS virus,Cool - action,1,X,[virs],[npop],,
696953bf-1408-4eef-a376-c33ff44e825d,C1186763,C2828389,got ,Stem of Organ,Exclusion,1,X,[bpoc],[acty],,
17cec68a-67ce-4d2c-8106-f1bba65bb41d,C1184743,C2828389,got ,bony process,Exclusion,1,X,[bpoc],[acty],,
ed8d277b-55a4-4353-aa5e-2d9efb3cbea2,C1186763,C0012634,got ,Stem of Organ,Disease,1,X,[bpoc],[dsyn],,C23.550.288
88a4b1f9-7037-4fa1-ba66-72dc34716198,C1184743,C0012634,got ,bony process,Disease,1,X,[bpoc],[dsyn],,C23.550.288
9d0bab62-c752-42b0-8f2c-fc2ef9a2e6cb,RT-PCR,C0206750,detect ,RT-PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
8238b473-3ed7-4897-9ffd-7988e6946297,C0012634,C0014338,is in ,Disease,Coronavirus Turkey,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150.400.500
5c44e6e6-e59e-4616-84fb-c1acea892044,C1280903,C0206750,is in severe ,Exploration procedure,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
a7fec595-b33f-45cd-b4fa-2606c94cd0d6,C0024264,C4048285,is with higher levels of ,Lymphocyte,C-Reactive Protein human,1,X,[cell],[aapp/imft],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
57f33478-d646-4f0d-b33f-0dfc3e8979f3,C0021368,C0744673,is with induced ,Inflammation,heart inflammation,3,X,[patf],[dsyn],C23.550.470,
b8af27cd-83f0-46ae-8cd1-0d85a411ccd5,C0751956,C2745965,continues treatable medical ,Acute Cerebrovascular Accidents,Emergencies [Disease/Finding],8,X,[dsyn],[patf],C10.228.140.300.775;C14.907.253.855,C23.550.291.781;N06.230.100.083;N06.850.376
c897fb55-d796-4059-acd0-9825e646150d,C0751956,C1175743,be treatable medical Emergencies [Disease/Finding] also during,Acute Cerebrovascular Accidents,SARS coronavirus,4,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150.113.937
c897fb55-d796-4059-acd0-9825e646150d,C0751956,C1175743,continues treatable medical ,Acute Cerebrovascular Accidents,SARS coronavirus,4,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150.113.937
350dd787-e211-490a-8db0-11036ab318d0,C0009566,C0206750,is in severe cases of ,Complication,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
350dd787-e211-490a-8db0-11036ab318d0,C0009566,C0206750,is in patients with severe ,Complication,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
350dd787-e211-490a-8db0-11036ab318d0,C0009566,C0206750,associated with ,Complication,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
350dd787-e211-490a-8db0-11036ab318d0,C0009566,C0206750,were found during ,Complication,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
049ce9bf-591b-401a-9946-9c1f8509502d,C0699748,C0948008,may behind may ,Pathogenesis,Ischemic stroke,2,X,[patf],[dsyn],,
12da144e-2480-4a6e-a5bd-574f39feb470,C0948008,C0206750,may result from ,Ischemic stroke,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
9fbfa147-ef75-487e-a357-a26f4fa045f8,C0079189,C0729531,frequently exacerbates Lung tissue damage during,cytokine,Viral respiratory infection,2,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,
99f6ccb4-3883-4e84-874d-2b2d675f9aed,C0037083,C0729531,frequently exacerbates Lung tissue damage during,Signal Transduction,Viral respiratory infection,2,X,[celf],[dsyn],G02.111.820;G04.835,
44b8d848-3a68-40eb-a23a-32be1ae254ea,C0079189,C0024109,frequently exacerbates ,cytokine,Lung,2,X,[aapp/imft],[bpoc],D12.644.276.374;D12.776.467.374;D23.529.374,A04.411
ae5c64cc-3f9a-492a-99fe-d670e9a157e4,C0037083,C0024109,frequently exacerbates ,Signal Transduction,Lung,2,X,[celf],[bpoc],G02.111.820;G04.835,A04.411
84b3c709-4a38-4035-b1ad-e64df69e5d02,C0021747,C1167395,are ,Interferons,Host (organism),2,X,[aapp/imft],[orgm],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
c5888b84-31f8-4cd9-b412-848d19ae390a,C0021747,C0003451,are ,Interferons,Antiviral Agents,2,X,[aapp/imft],[phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D27.505.954.122.388
6f3feb48-2856-4647-8e5d-e8998600e1e4,C0021747,C0079189,are ,Interferons,cytokine,2,X,[aapp/imft],[aapp/imft],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D12.644.276.374;D12.776.467.374;D23.529.374
913220da-7cde-476b-885a-b067c886d73a,IFN,C0014609,is in ,IFN,Epithelium,2,X,????,[tisu],????,A10.272
aa7622da-13ff-45ca-8c6e-a3ac05373704,IFN,C0003451,inducing localized ,IFN,Antiviral Agents,2,X,????,[phsu],????,D27.505.954.122.388
66c32c9f-6f34-4d52-a6f8-13c8fbe2aac8,IFN,C0020964,inducing localized ,IFN,Immunity,2,X,????,[phsf],????,G12.450
70521cba-04bf-4f61-9c81-2405b719fa65,C0037083,IFN,interferes with IFN,Signal Transduction,IFN,2,X,[celf],????,G02.111.820;G04.835,????
6c433cd2-c233-4b21-a2a0-9b195796582d,C0037083,C0021403,interferes during ,Signal Transduction,Influenza virus vaccine,2,X,[celf],[imft/phsu],G02.111.820;G04.835,D20.215.894.899.302
0ed95e9d-8d8e-4149-b01b-32e48d3cabe6,C0037083,C0237820,interferes during ,Signal Transduction,Recovery - action,2,X,[celf],[acty],G02.111.820;G04.835,
df4694d7-ca7d-44de-851b-4fcb244ddd8e,C0037083,C0189537,interferes with ,Signal Transduction,Repair of lung,2,X,[celf],[topp],G02.111.820;G04.835,
e195c2ae-6109-4029-844a-cc24e121143f,C0079419,C0038826,Disease susceptibility to bacterial,TP53 gene,Superinfection,2,X,[gngm],[dsyn],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,C01.539.597.880;C02.597.880;C03.684.880
7a4600d5-3cda-4e3a-bec0-5e73090b4b71,C0079419,C0007589,directly reduces ,TP53 gene,Cell Differentiation process,2,X,[gngm],[celf],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,G04.152
60f97490-255e-487c-872a-8a496a760ec8,C0079419,C0334097,directly reduces ,TP53 gene,Epithelial proliferation,2,X,[gngm],[patf],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,
ac1ee2ab-3980-4f28-b9d5-4b93b3b1be8e,C2926735,IFN,are Therefore parameters of IFN ,Duration,IFN,3,X,[orch/phsu],????,,????
ac1ee2ab-3980-4f28-b9d5-4b93b3b1be8e,C2926735,IFN,be considered for IFN ,Duration,IFN,1,X,[orch/phsu],????,,????
e6e1ce67-2e65-4571-99bb-e74e9ff67c30,C0206750,C0588006,caused mild-level ,Coronavirus Infections,Mild depression,1,X,[dsyn],[mobd],C02.782.600.550.200,
38d845b9-b48e-4126-875e-76e9d4f48903,C0029456,C0206750,showed significant association with ,Osteoporosis,Coronavirus Infections,2,X,[dsyn],[dsyn],C05.116.198.579;C18.452.104.579,C02.782.600.550.200
38d845b9-b48e-4126-875e-76e9d4f48903,C0029456,C0206750,pose challenge during ,Osteoporosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C05.116.198.579;C18.452.104.579,C02.782.600.550.200
ab33e6d1-6303-4b76-9a19-e4b42100fc9a,C0003873,C0206750,showed significant association with ,Rheumatoid Arthritis,Coronavirus Infections,2,X,[dsyn],[dsyn],C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199,C02.782.600.550.200
53ab8292-fc04-48ae-b682-31619f1d45d2,C0237123,C0206750,showed significant association with ,Alcohol or Other Drugs use,Coronavirus Infections,2,X,[mobd],[dsyn],,C02.782.600.550.200
2bfee11e-627b-44bc-94c1-fae5b6a25a3f,C0036341,C0206750,showed significant association with ,Schizophrenia,Coronavirus Infections,2,X,[mobd],[dsyn],F03.700.750,C02.782.600.550.200
e9b27039-3aa2-41b9-bbd2-c102fb087a16,C0032227,C3536832,reversed ,Pleural effusion disorder,Air,1,X,[dsyn],[inch/phsu],C08.528.652,G16.500.275.063.150;N06.230.300.100.150
4b1fc24c-5a40-41e6-9df5-959a216d762f,C0032227,C0011334,reversed ,Pleural effusion disorder,Dental caries,1,X,[dsyn],[dsyn],C08.528.652,C07.793.720.210
801c62f6-b004-4607-97ff-96ec82e4dac2,C0032227,C0235593,reversed ,Pleural effusion disorder,Thoracic lymphadenopathy,1,X,[dsyn],[dsyn],C08.528.652,
e2e37161-405a-43e9-82b7-0174eeb56d9d,C0032227,C1868833,reversed ,Pleural effusion disorder,Bronchial wall thickening,1,X,[dsyn],[dsyn],C08.528.652,
401cba13-6378-4fca-80bb-e732e275f52c,C0032227,C0233205,reversed ,Pleural effusion disorder,Halo sign,4,X,[dsyn],[sosy],C08.528.652,
a1274abd-a080-41a5-bfda-e7001e11d950,C1514593,C1306597,has has additionally documented together with most relevant ,Psychological Impact,Psychiatric problem,1,X,[clna],[mobd],,
7c17975d-af50-45ce-9974-b77dd838b65a,C1306597,C0206750,is in general population related to ,Psychiatric problem,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
e34511ed-beae-4fd9-a754-980c90c266ee,C2077218,C0264490,induced ,Injury care,Acute respiratory failure,1,X,[topp],[dsyn],,
5c2d3b11-5006-47da-bde8-9d79605ef15b,C2077218,C0024115,induced ,Injury care,Lung diseases,1,X,[topp],[dsyn],,C08.381
1ac2d689-da0c-41df-94e7-656e1dc55826,C3463820,C0700271,caused by ,Inhibition,M Protein multiple myeloma,1,X,[acty],[aapp/imft],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
2df92106-5c89-419b-a9c7-b87adfbcbe29,C3260929,C0206750,is in patients with ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Coronavirus Infections,5,X,[clna],[dsyn],,C02.782.600.550.200
96959700-001d-4a06-ba4e-bde21374a898,C0221284,C2937290,is in HCC515 ,Leptocyte,COL-3,1,X,[cell],[antb/orch],,
c400b5d9-0ef4-4eaa-9df8-720e90b84baa,C0221284,HCC515,is in HCC515 ,Leptocyte,HCC515,1,X,[cell],????,,????
8e5a7263-34e9-427d-81c2-d76e25313f86,C1704259,C0221284,are Leptocyte in HCC515,Biochemical Pathway,Leptocyte,2,X,[moft],[cell],,
0e91e9a6-3235-4853-8293-c9b1cfca7064,C1704259,C2937290,are Leptocyte in HCC515,Biochemical Pathway,COL-3,1,X,[moft],[antb/orch],,
62a7d3ea-ee6b-4339-b1e3-1531cb31589e,C1704259,HCC515,are Leptocyte in HCC515,Biochemical Pathway,HCC515,1,X,[moft],????,,????
b96cdafb-86c2-4544-86f5-69910d8cf4c6,C1332838,C0084340, includes ,Candidate Disease Gene,rhoA GTP-Binding Protein,1,X,[gngm],[aapp/enzy],,D08.811.277.040.330.300.400.700.200;D12.644.360.525.700.200;D12.776.157.325.515.700.200;D12.776.476.525.700.200
e0ea1ad4-1dc3-40cb-a0ae-bdabd92896f0,C2937290,C1332838,is with common ,COL-3,Candidate Disease Gene,1,X,[antb/orch],[gngm],,
9fe3d29c-8169-4dc2-985c-75ba09458db6,C2937290,C0084340,is with common ,COL-3,rhoA GTP-Binding Protein,1,X,[antb/orch],[aapp/enzy],,D08.811.277.040.330.300.400.700.200;D12.644.360.525.700.200;D12.776.157.325.515.700.200;D12.776.476.525.700.200
cf3b2d4a-57d9-4b4f-aa37-65040b26c14b,C1571058,C2937290,is with ,CGP 60474,COL-3,1,X,[orch],[antb/orch],,
6dea6230-4f37-408d-94b7-fea5e1a3a163,C0017337,C1413096,related to lung ,Genes,CALR gene,1,X,[gngm],[gngm],G05.360.340.024.340,
3bb89d0d-8ff4-4581-8aed-a6939659a527,C1571058,C0013227,have potential as ,CGP 60474,Pharmaceutical Preparations,1,X,[orch],[phsu],,D26
e36d7fed-659d-4e6d-b304-a43d212a5506,C2937290,C0013227,have potential as ,COL-3,Pharmaceutical Preparations,2,X,[antb/orch],[phsu],,D26
fa14cee3-dcfe-4e63-82f3-372d13d77597,C0022709,C0206750,is likely part of mechanisms leading to lung injury in ,Peptidyl-Dipeptidase A,Coronavirus Infections,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
fa14cee3-dcfe-4e63-82f3-372d13d77597,C0022709,C0206750,was increased in demographic with incidence of severe ,Peptidyl-Dipeptidase A,Coronavirus Infections,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
fa14cee3-dcfe-4e63-82f3-372d13d77597,C0022709,C0206750,causing ,Peptidyl-Dipeptidase A,Coronavirus Infections,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
fa14cee3-dcfe-4e63-82f3-372d13d77597,C0022709,C0206750,underlying risk factors for ,Peptidyl-Dipeptidase A,Coronavirus Infections,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
93986016-6046-4b02-aa88-5d07a1c6e288,C0150126,C0184661,is aerosol-producing high-risk ,Airway Management,Interventional procedure,3,X,[topp],[topp],E02.041,
e60f7548-2328-4c55-92be-a3b25d73d5ca,C1512523,C0597721,is broad spectrum ,hydrochloride,Janus kinase,2,X,[inch/phsu],[aapp/enzy],,D08.811.913.696.620.682.725.124;D12.776.476.393
4e0c87e8-0d70-4e4e-a743-ca8fc03cbc01,C0031336,veryday,required for patients veryday ,Pharmacy (field),veryday,3,X,[bmod],????,H02.646,????
6dc5ee63-12ab-48dd-a51f-9ce96da97ec2,C0035028,C0003467,may Representation (action) Exercise cope with,Relaxation,Anxiety,2,X,[acty],[mobd],I03.450.769,F01.470.132
5486e68f-ff52-4ee9-9fce-df9c6c78ebe6,C0035028,C0015259,may Representation (action) helpful,Relaxation,Exercise,1,X,[acty],[dora],I03.450.769,G11.427.410.698.277;I03.350
4cc2c974-81ed-4adc-8f5d-a9ede16d97e4,C0037709,C2984554,improved ,Sound - physical agent,Emotional Well-being,1,X,[npop],[clna],G01.750.770.776,
84e54485-5aa6-43e2-99b6-a45211cd9d93,C0037709,C0206750,reduce preoccupation related to ,Sound - physical agent,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776,C02.782.600.550.200
d73e8a86-64a6-4a15-be62-f49a1a4a9ab8,C0037709,C0012634,reduce preoccupation related to ,Sound - physical agent,Disease,1,X,[npop],[dsyn],G01.750.770.776,C23.550.288
9c387ccb-b8f0-48e0-bc89-3ba34dd3ce04,C0037709,C1879547,reduce psychomotor ,Sound - physical agent,Activation action,1,X,[npop],[acty],G01.750.770.776,
6546162a-544c-4ce6-a643-9489e421d6d5,C0547605,C0206750,is with risk of ,prevention of infection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
6546162a-544c-4ce6-a643-9489e421d6d5,C0547605,C0206750,prevent spread of ,prevention of infection,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
6546162a-544c-4ce6-a643-9489e421d6d5,C0547605,C0206750,becoming independent ,prevention of infection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
24b00d37-03fd-4794-9b0e-07122a25e5b5,C0441655,C1175743,are needed for ,Activities,SARS coronavirus,3,X,[acty],[virs],,B04.820.504.540.150.113.937
d8cac2f0-e9be-4b4e-bc26-d965cd83b7eb,C0598312,C1175743,entry of ,DNA Replication,SARS coronavirus,3,X,[genf],[virs],G02.111.225;G05.226,B04.820.504.540.150.113.937
49c74135-acef-46f5-ae00-b2c96d8caec6,C0035078,C0599878,are among gravest ,Kidney Failure,disease characteristic,3,X,[dsyn],[patf],C12.777.419.780;C13.351.968.419.780,
ba53d1e6-565c-4a62-b3c9-3de4b529d9ed,C0035078,C0206750,are among gravest ,Kidney Failure,Coronavirus Infections,2,X,[dsyn],[dsyn],C12.777.419.780;C13.351.968.419.780,C02.782.600.550.200
f1d046ed-98af-410c-b5b7-4f60cbbc92af,C0079613,C0178784,is in other target ,Adoptive Immunotherapy,Organ,3,X,[topp],[bpoc],E02.095.465.425.400.330.050.400;E05.478.550.520.050.400,
efc117f3-6cc2-4efa-a531-13d226af7c03,C0022709,C4689723,also serves as ,Peptidyl-Dipeptidase A,glycoprotein binding,5,X,[aapp/enzy/imft],[moft],D08.811.277.656.350.350.687,
d6a443df-e4c9-41be-80ae-c5f5cdb6f9b3,C0022709,C0034848,is regarded as ,Peptidyl-Dipeptidase A,Receptors Virus,8,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,D12.776.543.750.830
bfc6dbc6-d81a-4923-ace0-e30cb99119b9,C0022709,C1947904,enabling its ,Peptidyl-Dipeptidase A,Attachment (action),3,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
971b2a29-de2c-42ab-97f9-e6f8d6beddda,ity212,C0022709,widely expressing ,ity212,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
161427db-69b2-4146-adc5-068728f3cca1,C0887869,C0022709,widely expressing ,Cell-Matrix Junction,Peptidyl-Dipeptidase A,3,X,[celc],[aapp/enzy/imft],A11.284.149.165.165,D08.811.277.656.350.350.687
b2e48859-d557-49f3-9320-3bbca8b08699,C0024432,C0003451,play role in ,macrophage,Antiviral Agents,2,X,[cell],[phsu],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,D27.505.954.122.388
2768bb85-792c-4f80-bae6-2301ac072cd9,C0225385,C0227261,Small intestine mucous membrane,Structure of respiratory epithelium,Small intestine mucous membrane,5,X,[tisu],[tisu],,
0c27ee5b-0d41-418f-8e4f-8ccdc76e3c67,C1175743,C2699153,capacity for ,SARS coronavirus,Cell Invasion,8,X,[virs],[patf],B04.820.504.540.150.113.937,
8010ab89-6510-491f-a041-ef8baf9d244b,C0033684,C1819995,enable Virus Internalization into,Proteins,Host Cell,5,X,[aapp/bacs],[celc],D12.776,
8010ab89-6510-491f-a041-ef8baf9d244b,C0033684,C1819995,may use same ,Proteins,Host Cell,2,X,[aapp/bacs],[celc],D12.776,
8010ab89-6510-491f-a041-ef8baf9d244b,C0033684,C1819995,entering ,Proteins,Host Cell,2,X,[aapp/bacs],[celc],D12.776,
9dae7857-d049-42e3-b4c2-9ab28dbe8eee,C0033684,C1537068,enable ,Proteins,Virus Internalization,10,X,[aapp/bacs],[biof],D12.776,G06.920.881
de55c5db-a013-4942-99a1-3a926bf82566,C0033684,C0042210,synthesize ,Proteins,Vaccines,5,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D20.215.894
4c1ccf4f-d923-4868-b5fb-31d9a321078f,C0033684,C0003250,synthesize ,Proteins,Monoclonal Antibodies,5,X,[aapp/bacs],[aapp/imft],D12.776,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
ffa4dcff-9db7-4928-a3c3-5a561f7c7fc9,C0040300,C0022709,express ,Body tissue,Peptidyl-Dipeptidase A,5,X,[tisu],[aapp/enzy/imft],A10,D08.811.277.656.350.350.687
ad22485d-d12f-468a-99d6-3845c65a878a,C0040300,C0700271,performed in-depth analysis like sequence alignments of ,Body tissue,M Protein multiple myeloma,5,X,[tisu],[aapp/imft],A10,x.x.x.x
993d3c50-02a0-43b1-992d-4356dbbf7271,C0040300,C1175743,performed in-depth analysis like sequence alignments of ,Body tissue,SARS coronavirus,5,X,[tisu],[virs],A10,B04.820.504.540.150.113.937
ec86ad5d-0a84-423e-a5d5-41339f3aca5e,C0034788,C0003250,synthesize ,Receptors Antigen,Monoclonal Antibodies,5,X,[aapp/imft/rcpt],[aapp/imft],D12.776.543.750.705.816,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
365cf14c-9104-4fd9-b424-4c75b39b59d2,C0034788,C0042210,synthesize ,Receptors Antigen,Vaccines,5,X,[aapp/imft/rcpt],[aapp/imft/phsu],D12.776.543.750.705.816,D20.215.894
53b6ebab-0b6e-4cf3-afd8-195bfcbc39f3,C0022709,C0178784,is widely expressed in ,Peptidyl-Dipeptidase A,Organ,5,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
53b6ebab-0b6e-4cf3-afd8-195bfcbc39f3,C0022709,C0178784,plays role in practically ,Peptidyl-Dipeptidase A,Organ,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
7f410100-7578-4b45-8d81-60185ca6a020,C3711684,C0597358,has regions in ,S protein severe acute respiratory syndrome coronavirus,receptor binding,3,X,[aapp/bacs],[moft],x.x.x.x,
e6c22baa-17b7-4b7d-a0ab-4852c4b15480,C0030956,C0597358,is in ,Peptides,receptor binding,5,X,[aapp/phsu],[moft],D12.644,
8e584da0-bd4b-4a79-891c-ba3cfb1621c7,C1175743,C4049595,can Binding (Molecular Function) to,SARS coronavirus,HLA Complex,4,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,
998c3077-deea-48c2-9e0e-021e9deca644,C1175743,C0002085,can Binding (Molecular Function) to,SARS coronavirus,Alleles,4,X,[virs],[gngm],B04.820.504.540.150.113.937,G05.360.340.024.340.030
a85b19b3-6805-496b-aeeb-7ec2075b7dbb,C1175743,C0003316,serve as effective ,SARS coronavirus,Epitopes,4,X,[virs],[imft],B04.820.504.540.150.113.937,D23.050.550
3c1df9c2-a9b6-4249-a988-66d0ed307328,C1175743,C0042210,serve as effective ,SARS coronavirus,Vaccines,4,X,[virs],[aapp/imft/phsu],B04.820.504.540.150.113.937,D20.215.894
91c58383-b654-434a-acd1-d2026c51e275,C0030858,COVID-19,distinguish Coronavirus Infections from,Pentaerythritol Tetranitrate,COVID-19,1,X,[orch/phsu],[virs],D02.033.455.706.690,C000657245
a11d67d3-4f5e-41c1-a043-d1590bc25815,C0162429,COVID-19,treating ,Malnutrition,COVID-19,1,X,[dsyn],[virs],C18.654.521,C000657245
560e84f7-f7b5-4c78-b558-964d25d35640,C1533734,C0543419,serve as preventive measure against ,Administration procedure,Sequela of disorder,2,X,[topp],[patf],,
71995035-3755-4775-8a23-dab8b6f44997,C1533734,C0206750,serve as preventive measure against ,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
71995035-3755-4775-8a23-dab8b6f44997,C1533734,C0206750,improves clinical outcome of patients with ,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
71995035-3755-4775-8a23-dab8b6f44997,C1533734,C0206750,is safe treatment option for those with ,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
71995035-3755-4775-8a23-dab8b6f44997,C1533734,C0206750,optimize Biochemical Pathway during current,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
50beaf3d-efd1-4725-880b-3e6bcdda82ec,C0042211,C1819995,inducing trained ,Vaccines Attenuated,Host Cell,6,X,[imft/phsu],[celc],D20.215.894.811,
6d6cb976-2f68-411c-af98-954ab60165b2,C0042211,C3714514,inducing trained ,Vaccines Attenuated,Infection,3,X,[imft/phsu],[patf],D20.215.894.811,C01.539
aa9f5056-97db-4ed2-9f57-05e72b452057,C0042211,C0150259,nonspecific Infection protection against lethal,Vaccines Attenuated,Infection protection,3,X,[imft/phsu],[topp],D20.215.894.811,
aa9f5056-97db-4ed2-9f57-05e72b452057,C0042211,C0150259,provide nonspecific ,Vaccines Attenuated,Infection protection,6,X,[imft/phsu],[topp],D20.215.894.811,
3e4a8ff3-9c1d-463a-9dcf-b20f18b50969,C0042211,C0450254,nonspecific Infection protection against lethal,Vaccines Attenuated,Pathogenic organism,3,X,[imft/phsu],[orgm],D20.215.894.811,
20ba34a7-f18b-4039-ae0d-987c535b5c60,C0042211,C0042210,nonspecific Infection protection against lethal,Vaccines Attenuated,Vaccines,3,X,[imft/phsu],[aapp/imft/phsu],D20.215.894.811,D20.215.894
9f50ebff-12cb-495a-b7d1-9cbed9146521,C2926735,C3687742,is in nasopharyngeal ,Duration,Oropharyngeal swab,2,X,[orch/phsu],[bdsu],,
988350c3-7597-4383-9538-44ed12728fd4,C0031740,C0309872,mitigate Coronavirus Infections to either,Photochemotherapy,PREVENT (product),1,X,[topp],[phsu],E02.186.500;E02.319.685;E02.774.722,
4fec6205-e576-43fe-af11-4d2ca04cf85b,C0031740,C3714514,mitigate Coronavirus Infections to either,Photochemotherapy,Infection,1,X,[topp],[patf],E02.186.500;E02.319.685;E02.774.722,C01.539
f912abf6-5b8a-4e45-be33-c8506a669c94,C0031740,C0206750,mitigate ,Photochemotherapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.186.500;E02.319.685;E02.774.722,C02.782.600.550.200
391f6cc4-6b3c-422e-a78b-a052100d24ba,C0035253,C1705178,is in ,Rest,Order (action),3,X,[dora],[acty],I03.450.769.647,
2bb81b24-dd12-4305-9d37-95900eeac8ba,71-year,C1175743,was hospitalized at University of Bologna for ,71-year,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
fd4b0458-44b8-4721-b1fb-f282845f2996,71-year,C0009450,was hospitalized at ,71-year,Communicable Diseases,2,X,????,[dsyn],????,C01.539.221
c11d1218-7534-4a47-814d-87380481cb7b,71-year,C0003842,is with history of ,71-year,Arteries,2,X,????,[bpoc],????,A07.015.114
8bfe09c0-28b2-4e90-952f-371e3653ffb1,C1696945,C0543467,showing statistically significant reduction in ,Burnout Psychological,Operative Surgical Procedures,1,X,[mobd],[topp],F01.145.126.990.367;F02.830.900.333,E04
cad8b88e-f6d2-4910-a63b-f0c36cae84b7,C0599878,C0206750,is in early phase of ,disease characteristic,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
cad8b88e-f6d2-4910-a63b-f0c36cae84b7,C0599878,C0206750,on data is number of recovered ,disease characteristic,Coronavirus Infections,8,X,[patf],[dsyn],,C02.782.600.550.200
78785b57-297f-4893-97f2-34c68107051b,C1167622,C0542479,were found by molecular docking approaches with ,Binding (Molecular Function),Energy Physics,2,X,[moft],[npop],,
636e4f3b-5a40-44bd-97a2-1b1189dd4829,C0206750,C0795934,has opened new ,Coronavirus Infections,Digitorenocerebral Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
04b24a90-841c-454b-a4af-7fbcb0e1a732,C0206750,C0003504,has opened new ,Coronavirus Infections,Aortic Valve Insufficiency,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.280.484.095
f7f1ce10-e487-4973-84ad-4efa13d57cd9,C0243077,C0206750,are related to ,inhibitors,Coronavirus Infections,1,X,[chvf],[dsyn],,C02.782.600.550.200
f7f1ce10-e487-4973-84ad-4efa13d57cd9,C0243077,C0206750,combat current ,inhibitors,Coronavirus Infections,3,X,[chvf],[dsyn],,C02.782.600.550.200
21d99a97-ac3e-4836-9d16-c3cf843fb6d5,C1533734,C0079189,reduce effect of ,Administration procedure,cytokine,1,X,[topp],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
80f6584a-058d-46fc-b59c-c7f8fa4a6184,C3266262,C0206655,is with three parallel ,Multiple Chronic Conditions,Alveolar rhabdomyosarcoma,1,X,[dsyn],[neop],C23.550.291.500.500,C04.557.450.590.550.660.665;C04.557.450.795.550.660.665
1536d4f2-5768-4405-a558-fd8bd0489025,C0021361,C3839507,is with ,Female infertility,Diminished ovarian reserve,3,X,[patf],[dsyn],C13.351.500.365.700,
81a730a4-fdb2-463a-a4df-8cc56321d9ed,C0404268,C0013938,is with planned fresh ,Oocyte Retrieval,Embryo transfer (procedure),3,X,[topp],[topp],E02.875.800.976;E04.936.537.625;E05.820.800.976,E02.875.800.500;E05.820.800.500
73060f10-0cc4-4da3-8ce1-8df3322c1299,C2751898,C3839507,is in patients with ,Ventricular Fibrillation Paroxysmal Familial 1,Diminished ovarian reserve,3,X,[dsyn],[dsyn],x.x.x.x,
685b3433-e256-4a0a-9e8f-00faf3b0678e,C2948600,C0028754,investigate whether ,Aim,Obesity,1,X,[inch/phsu],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
a406e1e7-6b81-4c03-9cda-409ab67a5960,C0005516,C0369718,were higher than ,Biological Markers,N not otherwise specified Antibody,8,X,[clna],[aapp/imft],D23.101,
3e532ee1-d5e1-41d6-a131-23d0970fe316,C0079189,C0544688,is serious ,cytokine,complication of disease,4,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,
385b0375-ecc1-4818-86a8-486b69281838,C1861452,C0544688,is serious ,Storm Syndrome,complication of disease,4,X,[dsyn],[patf],x.x.x.x,
ec9b7106-f915-4f42-bbbe-9d694779871f,C1861452,C0206750,is serious ,Storm Syndrome,Coronavirus Infections,4,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
ec9b7106-f915-4f42-bbbe-9d694779871f,C1861452,C0206750,is considered as leading cause of mortality in ,Storm Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
9c9814ff-21cb-43b4-8b01-8cbdbc51a6cf,C0001617,C1096155,is In other very similar ,Adrenal Cortex Hormones,Macrophage Activation Syndrome,4,X,[horm/orch/phsu],[dsyn],D06.472.040,C20.683.515.800
f9cadd84-43db-4de0-978a-abfb53fb94e3,C1700396,C0017710,early use of ,CCL21 protein human,Glucocorticoids,4,X,[aapp/bacs],[horm/orch],x.x.x.x,D06.472.040.543;D27.505.696.399.472.488
d94125b1-f525-4550-b869-773ed6d35383,C0040038,C0947751,is highly suspected through COV2,Thromboembolism,vascular inflammations,8,X,[patf],[dsyn],C14.907.355.590,
f1cc331a-c7e3-4205-b25d-4798ccf82c47,C0040038,C1175743,is highly suspected through COV2,Thromboembolism,SARS coronavirus,8,X,[patf],[virs],C14.907.355.590,B04.820.504.540.150.113.937
dc95a0f7-1121-451e-8342-55b4fb1848f8,C0040038,COV2,is highly suspected through COV2,Thromboembolism,COV2,8,X,[patf],????,C14.907.355.590,????
e82354d2-4109-4e82-a579-a73abace20b5,LTCF,C0206750,are why resilient to ,LTCF,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
f7073bfb-06d9-4e3f-b024-2269a39c1928,C1175743,7days,showed sensitivity before 7days,SARS coronavirus,7days,1,X,[virs],????,B04.820.504.540.150.113.937,????
49eb3675-a6ac-4c2c-a9f2-3beff5dab827,C0683174,COVID-19,provides ,topical application,COVID-19,1,X,[topp],[virs],,C000657245
619b9f30-c4d5-41a8-9a37-82c2bc559b62,C0683174,C0184661,provides ,topical application,Interventional procedure,1,X,[topp],[topp],,
f97b5f1c-2d89-4252-b6da-8c386edf38d7,C3714514,C0012634,enter phase of control of spread of ,Infection,Disease,1,X,[patf],[dsyn],C01.539,C23.550.288
cc371e02-7995-4e09-b3db-b664b1a24cb8,C0242781,C0037778,is in specific context of development of our ,disease transmission,Medical Specialities,1,X,[patf],[bmod],N06.850.310,H02.403
ebaf72d1-d3a8-4d08-bc64-8e753a6f11f2,C0040590,C0184661,is aerosol-generating ,Tracheostomy procedure,Interventional procedure,1,X,[topp],[topp],E02.041.750;E04.579.935;E04.580.900;E04.928.780,
961f73a9-93f8-4734-b442-b96d34f23dcb,C0040590,C1160716,poses significant risk ,Tracheostomy procedure,viral transmission,1,X,[topp],[celf],E02.041.750;E04.579.935;E04.580.900;E04.928.780,
f92688a4-330c-441a-bf67-2505a0e9f2a8,C0040590,14th,was carried out on 14th ,Tracheostomy procedure,14th,1,X,[topp],????,E02.041.750;E04.579.935;E04.580.900;E04.928.780,????
39bed995-a278-4c89-9471-aaee3536f449,C0040590,C0021925,was carried out on 14th ,Tracheostomy procedure,Intubation,1,X,[topp],[topp],E02.041.750;E04.579.935;E04.580.900;E04.928.780,E02.585;E05.497
3fc546cd-3efa-4cd9-abfd-5a7cc4c09af1,C0022709,C0034987,is key counter ,Peptidyl-Dipeptidase A,Regulatory Sequences Nucleic Acid,2,X,[aapp/enzy/imft],[bacs/nnon],D08.811.277.656.350.350.687,G02.111.570.080.689;G05.360.080.689
86aa79f2-9405-4179-9dd3-c080c7262584,C0103306,C0003009,proinflammatory and prothrombotic effects of ,angiotensin I (1-7),angiotensin II,1,X,[aapp/phsu],[aapp/bacs/phsu],x.x.x.x,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
b733edac-f298-428a-888c-4d562268e7f2,C4082587,C0003009,proinflammatory and prothrombotic effects of ,HLA Class II Histocompatibility Antigen Gamma Chain human,angiotensin II,1,X,[aapp/imft],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
bd7496b2-8206-4efa-aea6-58d9384a2e99,C0022709,C0103306,converts ,Peptidyl-Dipeptidase A,angiotensin I (1-7),2,X,[aapp/enzy/imft],[aapp/phsu],D08.811.277.656.350.350.687,x.x.x.x
21b2b771-6c55-4911-b444-e6bc20c5d128,C0022709,C4082587,converts ,Peptidyl-Dipeptidase A,HLA Class II Histocompatibility Antigen Gamma Chain human,2,X,[aapp/enzy/imft],[aapp/imft],D08.811.277.656.350.350.687,
db0acc2f-eb9e-4e7b-8712-f5078ab4768a,C0022709,C1656555,also facilitates ,Peptidyl-Dipeptidase A,viral entry into host cell,2,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,
dce03d6e-bf87-44ee-bbd8-9aaccba4ecd7,C3687832,COVID-19,may IMPACT gene,Drugs - dental services,COVID-19,1,X,[topp],[virs],,C000657245
fb699418-e692-4a77-b43f-b266c29520f4,C3687832,C0699748,may IMPACT gene,Drugs - dental services,Pathogenesis,1,X,[topp],[patf],,
283d98d7-2d03-4268-b69b-fb363157afe4,C3687832,C0022709,may IMPACT gene,Drugs - dental services,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
283d98d7-2d03-4268-b69b-fb363157afe4,C3687832,C0022709,targeting ,Drugs - dental services,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
2dce049a-072f-4478-8f5b-f3f432e89115,COVID-19,C0023530,showed ,COVID-19,Leukopenia,1,X,[virs],[dsyn],C000657245,C15.378.553.546
c6b28ba4-557d-4d7d-afdb-a2884adf7514,C0028754,C0242781,may Contribution to,Obesity,disease transmission,2,X,[dsyn],[patf],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,N06.850.310
c77c0b05-63b2-46d7-86c2-18a1f046890f,C2926735,COVID-19,were similar in ,Duration,COVID-19,3,X,[orch/phsu],[virs],,C000657245
3addf0c0-0348-47b6-8a8b-08aa01b41caf,COVID-19,C0344211,Management of is mainly ,COVID-19,Supportive care,1,X,[virs],[topp],C000657245,
8bd923dd-3ea4-4fbf-a2d6-5c19c430231b,C0035222,C0079189,is characterized by severe ,Respiratory Distress Syndrome Adult,cytokine,1,X,[dsyn],[aapp/imft],C08.381.840;C08.618.840,D12.644.276.374;D12.776.467.374;D23.529.374
8bd923dd-3ea4-4fbf-a2d6-5c19c430231b,C0035222,C0079189,sustained by uncontrolled inflammatory ,Respiratory Distress Syndrome Adult,cytokine,1,X,[dsyn],[aapp/imft],C08.381.840;C08.618.840,D12.644.276.374;D12.776.467.374;D23.529.374
5e1a6dd7-c132-4bee-890b-5dad98d43203,C0151467,C0001623,is in patients with ,Addisonian crisis,Adrenal gland hypofunction,1,X,[dsyn],[dsyn],,C19.053.500
ec471a7e-d537-4479-95e3-abd4f744f322,C0151467,C2745965,is medical ,Addisonian crisis,Emergencies [Disease/Finding],1,X,[dsyn],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
dd31e184-e96c-4953-9db8-39bbaccf70c3,C0001623,C0017710,with patients is dose of ,Adrenal gland hypofunction,Glucocorticoids,1,X,[dsyn],[horm/orch],C19.053.500,D06.472.040.543;D27.505.696.399.472.488
b83d683b-bb82-411d-8a44-13ba51042e0e,C0001623,C0279033,with patients is dose of ,Adrenal gland hypofunction,Replacement therapy,1,X,[dsyn],[topp],C19.053.500,
305381b6-bd57-498c-9cf6-3ede5c3d879f,C0001623,C0744425,with patients is dose of ,Adrenal gland hypofunction,glucocorticoid therapy,1,X,[dsyn],[topp],C19.053.500,
a2a315f7-f3b6-4126-8327-f8eeb9a24d0d,C0015967,C0073187,was On 8 ,Fever,Blood group antigen D,3,X,[sosy],[aapp/imft],C23.888.119.344,x.x.x.x
f04673c0-eb33-4e2e-9c33-dfd82ab22a93,C0369768,C2964138,was despite high ,Molecular oxygen saturation,Inspiratory flow,6,X,[moft],[clna],,
0f4308c9-6f64-4c5a-a3d5-5c08c4de6dd8,C0369768,C0030054,was despite high ,Molecular oxygen saturation,Oxygen,3,X,[moft],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
f35a6f8c-96c6-473c-8cdb-a2a3e6ff15d7,C0003451,C0030054,were used In addition to nasal catheter ,Antiviral Agents,Oxygen,3,X,[phsu],[bacs/elii/phsu],D27.505.954.122.388,D01.268.185.550;D01.362.670;x.x.x.x
39996e6c-9341-49b2-8255-8af7873ab8b9,C4720089,C0073187,were given orally for ,Oseltamivir Phosphate Capsules,Blood group antigen D,6,X,[clnd],[aapp/imft],,x.x.x.x
89b0dc0f-e8d3-4d92-a6af-7da846e9a986,C0021027,C0021440,was administered by intravenous drip ,Immunoglobulins,Intravenous infusion procedures,3,X,[aapp/imft],[topp],D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548,E02.319.267.082.500;E02.319.267.510.590
3b645762-dd06-4f12-8f08-2a470155422d,C0025815,C0033727,was given once ,Methylprednisolone,Protons,3,X,[horm/orch/phsu],[elii],D04.210.500.745.432.769.795.539,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
a356a5fb-4060-4b4c-94b9-1e52194ea0cc,C0040106,C0005525,once daily combined with ,Thymosin,Biological Response Modifiers,3,X,[aapp/horm],[imft/phsu],D06.472.910.850;D12.644.548.869;D12.776.922;x.x.x.x,D27.505.696.477
0ad8672f-de53-4824-a505-e0871f5b119b,C0031354,C0206750,were negative for novel ,Pharyngeal structure,Coronavirus Infections,1,X,[bpoc],[dsyn],A03.556.750;A04.623;A14.724,C02.782.600.550.200
b7e0063d-81fe-4cf9-a2fd-b17cff0799fa,C0031354,C0028606,were negative for novel ,Pharyngeal structure,Nucleic Acids,1,X,[bpoc],[bacs/nnon],A03.556.750;A04.623;A14.724,D13.444
d1ef141f-52d8-4c39-bfcb-b5bbe3c241aa,C0072027,C1175743,determining severity of patients infected with ,procalcitonin,SARS coronavirus,3,X,[aapp/bacs],[virs],D06.472.699.666;D12.644.548.744;D12.776.811.555,B04.820.504.540.150.113.937
9d0cabe2-6e28-4563-a8a0-921912b9139c,C0037633,C1955980,proposed in ,Solutions,Disaster Medicine,1,X,[sbst],[bmod],D26.776,H02.403.230
a687f23a-8700-4c30-a410-836ca34228ea,C0040861,C0806140,manage Emergency Department ,Triage,Flow,1,X,[topp],[npop],N02.421.297.900,
ad46fe8f-d1a0-45d2-bb27-991a317a1830,C1856053,C0040861,established ,Hydranencephaly with Renal Aplasia-Dysplasia,Triage,1,X,[dsyn],[topp],x.x.x.x,N02.421.297.900
a91ca63f-5f0c-4df8-a08d-deb3fa1e26d8,C0040861,C1829939,prevent spread among ,Triage,{Non-patient},2,X,[topp],[clna],N02.421.297.900,
007c14eb-a3ce-409c-8920-b148154e56b4,C0557061,C3203533,will focus lockdown policies on ,Discussion (procedure),Psychological Trauma,1,X,[topp],[mobd],,F03.950.750.375
a6498f4d-fcb6-4ff2-9f89-039e7983fc20,C0557061,C0206750,will focus poorly equipped health care system dealing with spread of ,Discussion (procedure),Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
37cda547-6fb1-4b73-826f-e065502f2224,C3203533,C0020701,types of were social withdrawal ,Psychological Trauma,Hysteria,1,X,[mobd],[mobd],F03.950.750.375,F03.675.400.500
e36a7684-bfab-428c-bd3a-04dcf993f514,C3203533,C0042693,types of were social withdrawal ,Psychological Trauma,Violence,2,X,[mobd],[mobd],F03.950.750.375,I01.198.240.856;I01.880.735.900
4dcae139-8b29-454b-9036-0b5c7f4c916e,C2948600,C0007634,investigate Binding (Molecular Function) together with,Aim,Cells,1,X,[inch/phsu],[cell],,A11
e00c98a4-c2e9-4349-921c-5bf9262dbc55,C3266262,C0265267,is in ,Multiple Chronic Conditions,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,1,X,[dsyn],[dsyn],C23.550.291.500.500,x.x.x.x
ce304ae3-953b-4319-ae39-69c33e35833e,C0027424,C0026727,is with ,Nasal congestion (finding),Mucous body substance,1,X,[sosy],[bdsu],,A12.200.503
5f31a241-dbb1-4948-b696-6c235dc02303,C0035473,C1175743,are typically explained in case of ,Rhinovirus,SARS coronavirus,8,X,[virs],[virs],B04.820.565.775,B04.820.504.540.150.113.937
e9ac059e-1797-4dc8-82dd-64ec3d5b0701,C0029341,C1175743,are typically explained in case of ,Orthomyxoviridae,SARS coronavirus,8,X,[virs],[virs],B04.820.545,B04.820.504.540.150.113.937
b10b6f75-84fb-475e-bbd0-1a039dfae53e,C0302507,C1175743,are typically explained in case of ,Parainfluenza Virus Infections,SARS coronavirus,8,X,[dsyn],[virs],C02.782.580.600,B04.820.504.540.150.113.937
001ca0e9-14c3-4df1-8f5d-4fb434f22c67,C1175175,C1705178,is in ,Severe Acute Respiratory Syndrome,Order (action),4,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
dbae22f6-0506-495b-9a8f-43897d7898be,C0018943,C0206750,is in patients with ,Hematology (discipline),Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.429.445,C02.782.600.550.200
6caf63d7-2a39-43a7-bf91-e1aefd48149d,C2948600,C0018943,investigate characteristics of ,Aim,Hematology (discipline),1,X,[inch/phsu],[bmod],,H02.403.429.445
321cb296-3f7c-4196-8468-ae5346b3d111,C0020517,C0024264,followed by combined parameter ,Hypersensitivity,Lymphocyte,1,X,[patf],[cell],C20.543,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
3fb41fd3-e387-4599-b186-7b617a3182fd,C0024264,C0018943,is best ,Lymphocyte,Hematology (discipline),1,X,[cell],[bmod],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,H02.403.429.445
d246e216-dafb-4ab2-b049-a53da0e1f5e2,RDW-SD,C0018943,is best ,RDW-SD,Hematology (discipline),1,X,????,[bmod],????,H02.403.429.445
9c8e5ab5-d9e5-43cd-881c-ddd32b57147a,C0014507,C0150638,should should focused on ,Epidemiology,Preventing injury,2,X,[bmod],[topp],H02.403.720.500,
ac16de04-10b1-48e3-8dde-c078cac67435,C0597357,C0012634,make patients susceptible to ,receptor,Disease,1,X,[aapp/rcpt],[dsyn],,C23.550.288
109796a0-5ca8-407f-9287-253dffc19da9,C0206750,C0012655,is In nested case-control ,Coronavirus Infections,Disease susceptibility,2,X,[dsyn],[clna],C02.782.600.550.200,C23.550.291.687;G07.100.250
109796a0-5ca8-407f-9287-253dffc19da9,C0206750,C0012655,raised many questions about higher ,Coronavirus Infections,Disease susceptibility,1,X,[dsyn],[clna],C02.782.600.550.200,C23.550.291.687;G07.100.250
4bad86bd-f3c1-4d64-8179-daaa3d7157c5,C1707455,C0012655,is In nested case-control analysis of ,Comparison,Disease susceptibility,2,X,[acty],[clna],,C23.550.291.687;G07.100.250
b01f4b01-28b4-460b-a6c8-7a42031be1c0,C4288399,C0206750,are indicated in context of ,Pharmacotherapy Discontinuation,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
d73af617-1ac8-41ec-989d-9e9a6c33bad1,C0020517,RT-PCR,topic given insufficient quantity of RT-PCR ,Hypersensitivity,RT-PCR,3,X,[patf],????,C20.543,????
6c88a8ff-a295-4ed1-8fa7-b0f013fc90f4,C0020517,C1707455,was For chest CT ,Hypersensitivity,Comparison,4,X,[patf],[acty],C20.543,
d5edf9bd-8e59-4b7f-a66c-f5a34d68b0b8,RT-PCR,C1707455,Hypersensitivity of was,RT-PCR,Comparison,2,X,????,[acty],????,
77f272f1-91f5-492e-a7b6-b5899db22884,C0947647,C0242781,increase likelihood of ,Manipulation procedure,disease transmission,2,X,[topp],[patf],,N06.850.310
533e537d-3331-456d-817a-7e682523713f,C0947647,C0184661,therefore is considered high-risk ,Manipulation procedure,Interventional procedure,2,X,[topp],[topp],,
71649c0d-4684-4b36-95b3-6eac5f4d8068,C0038056,C1175743,was positive for PCR,Sputum,SARS coronavirus,2,X,[bdsu],[virs],A12.200.808,B04.820.504.540.150.113.937
70d07bbe-1f56-4570-80ac-71e04485a6e7,C0038056,PCR,was positive for PCR,Sputum,PCR,2,X,[bdsu],????,A12.200.808,????
6619b5d7-fb96-40a9-8ff1-49c1220b859d,C1532372,C0028606,were tested for ,Respiratory secretion,Nucleic Acids,4,X,[bdsu],[bacs/nnon],,D13.444
37f76ee0-5bd3-4e6a-baa7-c2e88600325e,C4050231,C1861172,identify patients at risk for ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Venous Thromboembolism,2,X,[clna],[dsyn],,C14.907.355.590.700
08a215f2-5ffc-4aaa-b714-f7e6a6d4de26,C1707455,C0694549,is with ,Comparison,Community acquired pneumonia,2,X,[acty],[dsyn],,
f03f5810-c72d-4d2d-86c3-06861f5136b7,C0060323,C0694549,Comparison with,Fibrin fragment D,Community acquired pneumonia,2,X,[aapp/bacs],[dsyn],x.x.x.x,
b285b8d7-9e5d-44b1-9a93-e639f16fa6cd,C0060323,C0021368,were related with ,Fibrin fragment D,Inflammation,3,X,[aapp/bacs],[patf],x.x.x.x,C23.550.470
4408f406-cbb8-49f4-a078-e9380e746cf6,C4050231,C0206750,is in ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
f9c9b772-7e52-422f-8bdd-91b02ab70404,C0040590,C1145670,were performed on patients with ,Tracheostomy procedure,Respiratory Failure,1,X,[topp],[dsyn],E02.041.750;E04.579.935;E04.580.900;E04.928.780,C08.618.846
9e0b4989-15e1-4cb6-ae6f-e773b5c9c859,C0040590,C1175175,were performed on patients with ,Tracheostomy procedure,Severe Acute Respiratory Syndrome,1,X,[topp],[dsyn],E02.041.750;E04.579.935;E04.580.900;E04.928.780,C02.782.600.550.200.750;C08.730.730
4bcbe4db-0531-47ff-9e1a-ddc46f80a838,C0206419,C0015392,is rapidly spreading across ,Genus: Coronavirus,Eye,1,X,[virs],[bpoc],B04.820.504.540.150,A01.456.505.420;A09.371
4bcbe4db-0531-47ff-9e1a-ddc46f80a838,C0206419,C0015392,is sweeping ,Genus: Coronavirus,Eye,1,X,[virs],[bpoc],B04.820.504.540.150,A01.456.505.420;A09.371
8d9f278c-82a2-4c2e-ba73-2804772611a6,C0206419,C2825812,has posed barriers to communication ,Genus: Coronavirus,Deploy,1,X,[virs],[acty],B04.820.504.540.150,
0b54457d-8209-4cb8-be67-e9130bbf0db1,C0206419,C0003467,has posed barriers to communication ,Genus: Coronavirus,Anxiety,1,X,[virs],[mobd],B04.820.504.540.150,F01.470.132
dace6038-f7cb-4e2d-b368-d4ebf0c9bd51,C0079460,C1440080,plays role in ,Granulocyte-Macrophage Colony-Stimulating Factor,Alveolar,2,X,[aapp/imft],[bpoc],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,
646519a2-7116-40a9-ae54-61e8017810cc,C0079460,C3820859,plays role in ,Granulocyte-Macrophage Colony-Stimulating Factor,macrophage homeostasis,2,X,[aapp/imft],[celf],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,
51f68e1f-3353-475d-90b7-b3eee083bbd0,C0079460,C0019868,plays role in ,Granulocyte-Macrophage Colony-Stimulating Factor,Homeostasis,2,X,[aapp/imft],[biof],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,G07.410
b20e4983-d5d2-4708-b991-e98822f57c4f,C4684977,C0007131,have revolutionized management of fit patients with ,Immune Checkpoint Inhibitor,Non-Small Cell Lung Carcinoma,1,X,[imft/phsu],[neop],,C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500
8b7ea35f-9228-49e6-8bab-d5f104ee113e,C0279025,C0206419,acts during ,Hormone Therapy,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
c69c5b03-d367-406a-8678-731fe2783f55,coldand,C0042776,transmitting ,coldand,Virus,1,X,????,[virs],????,B04
cdaa2376-43d1-4ea9-b78f-35f5b3c1d282,C0206419,C0017968,presents with S ,Genus: Coronavirus,Glycoproteins,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D09.400.430;D12.776.395
6d18a29e-d466-421f-9609-d2a1d2a4e00b,C0206419,C0596901,presents with S ,Genus: Coronavirus,Membrane,1,X,[virs],[celc],B04.820.504.540.150,A10.615
a19b5202-fe2d-4b4a-b8d6-b51f6387ce8a,C0596901,C0022709,plays role with ,Membrane,Peptidyl-Dipeptidase A,1,X,[celc],[aapp/enzy/imft],A10.615,D08.811.277.656.350.350.687
b564020a-8039-4297-83c1-ef56f62f8965,C0596901,C0597357,plays role with ,Membrane,receptor,1,X,[celc],[aapp/rcpt],A10.615,
adce980e-1cfd-42e5-8e50-232f91620c30,C0596901,C1721019,plays role in ,Membrane,Virus Attachment,1,X,[celc],[biof],A10.615,G06.920.868
4fd328f2-a1d1-4858-96ee-886076a2ee1d,C0042776,C1824356,replicate after ,Virus,KIAA1551 gene,1,X,[virs],[gngm],B04,
f368e504-073f-47d8-85e6-e723f016b23d,C0042776,C0010834,replicate after ,Virus,Cytoplasm,1,X,[virs],[celc],B04,A11.284.430.214
414ea629-c1c9-4736-8a91-dc5be3835b54,C0022709,C0225700,is intramembrane receptor on,Peptidyl-Dipeptidase A,Type-II Pneumocytes,1,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A04.411.715.100;A11.436.081
35355499-0f80-4208-9eec-bd4a9adaa564,C0597357,C0225700,is intramembrane receptor on,receptor,Type-II Pneumocytes,1,X,[aapp/rcpt],[cell],,A04.411.715.100;A11.436.081
585c244f-4315-4523-a3d4-1a5f7b5bddfd,C2936405,C1175743,is widely used for rapid identification of potential ,Drug Repositioning,SARS coronavirus,3,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
585c244f-4315-4523-a3d4-1a5f7b5bddfd,C2936405,C1175743,is In scenario widely used for identification of potential ,Drug Repositioning,SARS coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
585c244f-4315-4523-a3d4-1a5f7b5bddfd,C2936405,C1175743,utilizing publicly available high throughput ,Drug Repositioning,SARS coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
585c244f-4315-4523-a3d4-1a5f7b5bddfd,C2936405,C1175743,stands out Due to evidence of ,Drug Repositioning,SARS coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
585c244f-4315-4523-a3d4-1a5f7b5bddfd,C2936405,C1175743,is In scenario used for rapid identification against ,Drug Repositioning,SARS coronavirus,1,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
45fefdbd-92b6-43e9-8b6b-07b85af792c2,C1167395,C0017262,utilizing publicly available high throughput ,Host (organism),Gene Expression,2,X,[orgm],[genf],,G05.297
ca00945c-d66a-4285-be82-f362a44b5b8e,C2936405,C0017262,utilizing publicly available high throughput ,Drug Repositioning,Gene Expression,2,X,[topp],[genf],E05.290.875,G05.297
ddc2dba6-eff0-46dd-9077-bce2da7538e6,C1333327,C0009450,were identified in early ,TYMP gene,Communicable Diseases,3,X,[gngm],[dsyn],,C01.539.221
6edd6b2f-86ee-453e-93f0-0167e85d31a3,C0387583,C0009450,were identified in early ,cyclooxygenase 2,Communicable Diseases,3,X,[aapp/enzy],[dsyn],D08.811.600.720.750,C01.539.221
0f9c44dc-5c4c-4050-ab00-c081d08854c6,C1412937,C0009450,were identified in early ,C1S gene,Communicable Diseases,3,X,[gngm],[dsyn],,C01.539.221
b3476afa-3376-4c67-bf78-f6d085605687,C0009002,C0009450,were identified in early ,Clofibrate,Communicable Diseases,3,X,[orch/phsu],[dsyn],D02.241.081.114.968.500.500.195;D02.355.726.305.500.195;D02.455.426.559.389.657.654.305.500.195,C01.539.221
c0300c17-3c9c-4734-a521-457d484899e6,C1424650,C0009450,were identified in early ,IFI44 gene,Communicable Diseases,3,X,[gngm],[dsyn],,C01.539.221
0f47b845-8c76-4211-9765-a418350f2623,C1447833,C0009450,were identified in early ,HSXIAPAF1 protein human,Communicable Diseases,3,X,[aapp/bacs],[dsyn],x.x.x.x,C01.539.221
1ca14191-a15e-423a-8638-a8671c461cfa,CXCL2,C0009450,were identified in early ,CXCL2,Communicable Diseases,3,X,????,[dsyn],????,C01.539.221
8d7c5da3-8c60-43ec-858b-fd97b3e7b6c4,CXCL3,C0009450,were identified in early ,CXCL3,Communicable Diseases,3,X,????,[dsyn],????,C01.539.221
1b61efbf-1c7c-43a3-9bcb-37915bb48458,C1333327,C1175743,were identified in early ,TYMP gene,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
939ce3b5-49b7-4686-8013-c35b10ad23f7,C0387583,C1175743,were identified in early ,cyclooxygenase 2,SARS coronavirus,3,X,[aapp/enzy],[virs],D08.811.600.720.750,B04.820.504.540.150.113.937
3b7f65ca-1640-4c1c-803e-7f8370b69cf4,C1412937,C1175743,were identified in early ,C1S gene,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
64044c94-dfb1-48fa-971d-37d6cdb5f14d,C0009002,C1175743,were identified in early ,Clofibrate,SARS coronavirus,3,X,[orch/phsu],[virs],D02.241.081.114.968.500.500.195;D02.355.726.305.500.195;D02.455.426.559.389.657.654.305.500.195,B04.820.504.540.150.113.937
de305dd5-07cb-4e42-a6aa-bf2f76c2dd7c,C1424650,C1175743,were identified in early ,IFI44 gene,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
bfe72756-3ab8-4a49-84ae-72d8291f95d7,C1447833,C1175743,were identified in early ,HSXIAPAF1 protein human,SARS coronavirus,3,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150.113.937
11b7a72d-d705-49c0-a0fe-dae9ce6f02ee,CXCL2,C1175743,were identified in early ,CXCL2,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
1fd39698-d30c-43dd-aba2-963ea87042c6,CXCL3,C1175743,were identified in early ,CXCL3,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
9769892e-a26e-4a4d-8839-6df941ecfbc0,C1880157,C0206419,could propose candidate drugs against ,Computation (action),Genus: Coronavirus,2,X,[acty],[virs],,B04.820.504.540.150
2197b4c9-e1c0-4f0f-a7d4-a244e1ea0b77,C0028630,C1175743,inhibit ,Nucleotides,SARS coronavirus,1,X,[nnon],[virs],D09.408.620;D13.695,B04.820.504.540.150.113.937
8c8ea033-61b2-49f9-b1e5-4ccf9e41ff51,C0243071,C1175743,inhibit ,Analog,SARS coronavirus,1,X,[chvs],[virs],,B04.820.504.540.150.113.937
1c8858d2-7446-40f0-ad71-c149436d7beb,C0028630,C0035685,inhibit ,Nucleotides,RNA-Directed RNA Polymerase,1,X,[nnon],[aapp/enzy],D09.408.620;D13.695,D08.811.913.696.445.735.780
8f3bbee7-55d4-4893-8b2b-57f0fe29a943,C0243071,C0035685,inhibit ,Analog,RNA-Directed RNA Polymerase,1,X,[chvs],[aapp/enzy],,D08.811.913.696.445.735.780
12c4924f-5397-4752-8957-22d4d0d88415,C0028630,C0146894,inhibit ,Nucleotides,triphosphate,1,X,[nnon],[inch],D09.408.620;D13.695,
d005f4f1-4d14-4e89-be8c-83003bac0b3d,C0243071,C0146894,inhibit ,Analog,triphosphate,1,X,[chvs],[inch],,
bfd9f2cc-b2d3-4d76-bc96-f3d8438d1417,C0028630,C2976303,inhibit ,Nucleotides,sofosbuvir,1,X,[nnon],[nnon/phsu],D09.408.620;D13.695,D03.383.742.686.850.877.500;D13.695.740.850.877.500;D13.695.827.919.877.500
69ca11ea-85e2-4ef8-bdac-339715899308,C0243071,C2976303,inhibit ,Analog,sofosbuvir,1,X,[chvs],[nnon/phsu],,D03.383.742.686.850.877.500;D13.695.740.850.877.500;D13.695.827.919.877.500
943f65f3-d61e-470a-9bcf-4505ea7b0a05,C0146894,C1152412,including RNA-Directed RNA Polymerase is,triphosphate,RNA-directed RNA polymerase activity,1,X,[inch],[genf],,
ff485403-c694-46a8-8c10-cb5ed44e5256,C1328948,C0206419,catalyzed by ,RNA biosynthesis,Genus: Coronavirus,1,X,[moft],[virs],,B04.820.504.540.150
e23b8cb1-f642-42ed-831a-644aea22c525,C1328948,C1152412,catalyzed by ,RNA biosynthesis,RNA-directed RNA polymerase activity,1,X,[moft],[genf],,
508ecf56-b85e-4e1e-b89f-1297b46ce2c9,C1152412,C1335439,is in ,RNA-directed RNA polymerase activity,Polymerase,1,X,[genf],[aapp/enzy],,
ab25ea9b-1d25-48ac-9154-258257bcfd66,C1335439,C0081912,carbovir triphosphate of,Polymerase,carbovir triphosphate,1,X,[aapp/enzy],[nnon/phsu],,x.x.x.x
60645009-0619-4f80-88ed-0ceea1561de4,C0206419,C0015296,possess ,Genus: Coronavirus,Exonuclease,1,X,[virs],[aapp/enzy],B04.820.504.540.150,D08.811.277.352.365
5bd60a3e-9170-471a-96d8-20ea38f29c88,C0015296,C0220853,apparently requires 2 ,Exonuclease,Hydroxide Ion,1,X,[aapp/enzy],[elii],D08.811.277.352.365,x.x.x.x
77c4a94e-05b0-4b8d-95af-450a787ab921,C0015296,C0035668,apparently requires 2 ,Exonuclease,RNA,1,X,[aapp/enzy],[nnon],D08.811.277.352.365,D13.444.735
06c97153-3fe0-42dc-b046-8e97a2af9789,C0028630,C0220853,lack 2 ,Nucleotides,Hydroxide Ion,1,X,[nnon],[elii],D09.408.620;D13.695,x.x.x.x
e0a53538-8262-45ca-aa96-d53fe1c1a15e,C0243071,C0220853,lack 2 ,Analog,Hydroxide Ion,1,X,[chvs],[elii],,x.x.x.x
00f43643-0039-4226-b5c0-fe684b155f18,C0033262,C3469597,are Administration of medication for,Prodrugs,Administration of medication,1,X,[chvf],[topp],D26.675,
00f43643-0039-4226-b5c0-fe684b155f18,C0033262,C3469597,are FDA-approved ,Prodrugs,Administration of medication,1,X,[chvf],[topp],D26.675,
db6f616a-e4fd-4681-9d97-e3ed1a4d57aa,C0033262,C0042769,are Administration of medication for,Prodrugs,Virus Diseases,1,X,[chvf],[dsyn],D26.675,C02
d876c8b1-7839-4479-ac4a-0572e0ce536f,C0567416,C0087111,can can evaluated as potential ,Molecule,Therapeutic procedure,1,X,[sbst],[topp],,E02
16bf52ef-051e-4781-a48d-4584018ada56,C0567416,C0206419,can can evaluated as potential ,Molecule,Genus: Coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150
4bd15a8d-2c0c-4a0f-85b7-02fb8fe19a74,C0567416,C3463820,demonstrating potency in ,Molecule,Inhibition,1,X,[sbst],[acty],,F01.145.544;F02.463.425.475;F02.739.794.405
e5595601-1c7b-4608-97c0-25d3f9100e75,C0567416,C0007590,demonstrating potency in ,Molecule,Cell division,2,X,[sbst],[celf],,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
2dedbb7f-ae38-47de-a553-ac26ac88f8ca,C0150593,C0040210,was modeled after ,game,Tidal Volume,2,X,[dora],[clna],,E01.370.386.700.485.750.900.350.750;G09.772.850.970.500.700
57007d10-760f-494a-bfdc-83c242b785ee,C0150593,C2350169,was modeled with ,game,Warm-Up Exercise,2,X,[dora],[dora],,G11.427.410.698.277.968;I03.350.968
f6e1e148-4942-4294-a1d1-ac52b08ea9d4,C0018799,C0235974,Heart Diseases ischemic,Heart Diseases,Pancreatic carcinoma,1,X,[dsyn],[neop],C14.280,x.x.x.x
8147a17b-6077-485b-8e13-f4c631e4227d,C0018799,C0023418,Heart Diseases ischemic,Heart Diseases,leukemia,1,X,[dsyn],[neop],C14.280,C04.557.337
0e45073b-d2d3-4fac-bf13-9bf1384009e7,C0206419,C0729531,is acute ,Genus: Coronavirus,Viral respiratory infection,1,X,[virs],[dsyn],B04.820.504.540.150,
9b12273c-b649-4fc8-bfb4-b0072e23c266,C0206419,C0339901,is acute ,Genus: Coronavirus,Acute respiratory infections,1,X,[virs],[dsyn],B04.820.504.540.150,
ec8f422f-2388-4998-8a6b-675be0d8237e,C0729531,C1175743,caused by ,Viral respiratory infection,SARS coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150.113.937
c9b14e40-2470-4aa1-8d8b-d3d6c7263b9f,C0339901,C1175743,caused by ,Acute respiratory infections,SARS coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150.113.937
8041ce17-a754-4677-8f13-0c66bd0204d9,C2986592,C0042210,are uncovered such as ,Definitive Treatment,Vaccines,3,X,[topp],[aapp/imft/phsu],,D20.215.894
5a1e90a5-afc9-43a6-bdc9-4dace39a6932,C3274800,C0035243,is common to other ,Disease Presentation,Respiratory Tract Infections,2,X,[clna],[dsyn],,C01.539.739;C08.730
15525762-cb45-4027-be67-97ed4bcf90b1,C0599878,C2676739,were grand ,disease characteristic,Chromosome 2q32-Q33 Deletion Syndrome,2,X,[patf],[dsyn],,x.x.x.x
1ab9f785-2f2f-4624-bc19-ca07064c2399,C0599878,C1265876,were grand ,disease characteristic,Abnormally opaque structure (morphologic abnormality),2,X,[patf],[patf],,
d426596e-d4f0-4e9f-ba8d-56d0daea065f,C0012634,C1825598,has had substantial ,Disease,IMPACT gene,4,X,[dsyn],[gngm],C23.550.288,
d426596e-d4f0-4e9f-ba8d-56d0daea065f,C0012634,C1825598,is causing insurmountable psychosocial ,Disease,IMPACT gene,2,X,[dsyn],[gngm],C23.550.288,
d426596e-d4f0-4e9f-ba8d-56d0daea065f,C0012634,C1825598,is now epidemic of proportion with major adverse ,Disease,IMPACT gene,1,X,[dsyn],[gngm],C23.550.288,
d426596e-d4f0-4e9f-ba8d-56d0daea065f,C0012634,C1825598,has had extraordinary ,Disease,IMPACT gene,1,X,[dsyn],[gngm],C23.550.288,
d0c572c1-8749-4681-88e6-a987150ef8bc,C0206419,C0039082,is acute ,Genus: Coronavirus,Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.288.500
d0c572c1-8749-4681-88e6-a987150ef8bc,C0206419,C0039082,caused by ,Genus: Coronavirus,Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.288.500
1050773b-b2fd-4968-90d6-bab32ffc49ff,C0013227,C0034991,promote ,Pharmaceutical Preparations,Rehabilitation therapy,5,X,[phsu],[topp],D26,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
ddc19e73-6f55-4662-8710-530bc78dbdab,C0206750,C1706214,is ,Coronavirus Infections,Creation,2,X,[dsyn],[acty],C02.782.600.550.200,
23e719d0-b216-42c0-87c1-adb3631db6cf,C3241973,C0027651, includes ,Pediatric Surgical Procedures,Neoplasms,2,X,[topp],[neop],,C04
3dcdac21-308c-4169-be25-269d2a02b8fe,C0020336,C0559546,causing cardiovascular ,Hydroxychloroquine,Adverse reactions,1,X,[orch/phsu],[patf],D03.633.100.810.050.180.350,
5f26a805-9958-4010-8a93-fcd7db5d11bf,C0020336,C0162770,was associated with higher reporting of ,Hydroxychloroquine,Right Ventricular Hypertrophy,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C14.280.195.410;C23.300.775.250.401
55748cd9-2cae-4f36-baa3-a10172d4cb33,C0040479,C0206750,are relevant to ,Torsades de Pointes,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700,C02.782.600.550.200
51f869c5-21d8-4c86-a2b3-dfbbf0627b51,C0040479,C2348331,are relevant to ,Torsades de Pointes,Dose Regimen,1,X,[dsyn],[topp],C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700,
0dacbc3e-f668-4571-891f-c051f5b7648f,30-day,C0035222,is in ,30-day,Respiratory Distress Syndrome Adult,1,X,????,[dsyn],????,C08.381.840;C08.618.840
50eb269f-f2b6-40f2-9619-4c4c40bc3f37,C0207682,C3698360,effectively blocked ,nafamostat mesilate,Middle East Respiratory Syndrome Coronavirus,2,X,[orch/phsu],[virs],,B04.820.504.540.150.113.750
50eb269f-f2b6-40f2-9619-4c4c40bc3f37,C0207682,C3698360,inhibited ,nafamostat mesilate,Middle East Respiratory Syndrome Coronavirus,4,X,[orch/phsu],[virs],,B04.820.504.540.150.113.750
df9d42f0-f6c6-41ef-bec5-30887a4a2fc8,C0207682,C0072330,effectively blocked ,nafamostat mesilate,protease S,4,X,[orch/phsu],[aapp/enzy],,x.x.x.x
df9d42f0-f6c6-41ef-bec5-30887a4a2fc8,C0207682,C0072330,targeting ,nafamostat mesilate,protease S,4,X,[orch/phsu],[aapp/enzy],,x.x.x.x
3729a007-cf0a-4b0b-bf75-486050091af4,C0207682,C0021699,effectively blocked ,nafamostat mesilate,Integral Membrane Proteins,5,X,[orch/phsu],[aapp],,D12.776.543
3729a007-cf0a-4b0b-bf75-486050091af4,C0207682,C0021699,targeting ,nafamostat mesilate,Integral Membrane Proteins,4,X,[orch/phsu],[aapp],,D12.776.543
ae06f258-f129-4f8f-a382-0fc8b83ce7a3,C0207682,C1742865,targeting ,nafamostat mesilate,TMPRSS2 protein human,4,X,[orch/phsu],[aapp/enzy],,x.x.x.x
c9476530-d4c6-4671-8a36-cbc55ef665e1,C0013227,C0012739,used for ,Pharmaceutical Preparations,Disseminated Intravascular Coagulation,4,X,[phsu],[dsyn],D26,C15.378.100.220;C15.378.463.250;C15.378.925.220
09dc75f8-faa9-48ec-82bd-c170b6fb0de2,C0207682,C0036720,targeting ,nafamostat mesilate,Serine,4,X,[orch/phsu],[aapp/bacs/phsu],,D12.125.154.800
5e1a6afe-3e93-4ddf-b405-34cbd5b68028,C0207682,C0024109,inhibited ,nafamostat mesilate,Lung,4,X,[orch/phsu],[bpoc],,A04.411
5fec0fa6-281e-4591-9387-a8b5257b6040,C0207682,C0014609,inhibited ,nafamostat mesilate,Epithelium,3,X,[orch/phsu],[tisu],,A10.272
5d6b0ca0-5e15-4f8a-8970-7cc4c7b2e7c3,C0207682,C1413097,inhibited ,nafamostat mesilate,CALU gene,4,X,[orch/phsu],[gngm],,
5d6b0ca0-5e15-4f8a-8970-7cc4c7b2e7c3,C0207682,C1413097,blocked 2 ,nafamostat mesilate,CALU gene,4,X,[orch/phsu],[gngm],,
3e415d49-a173-4559-9b15-ee32fb7b05fd,C0108225,10-fold,was about 10-fold ,camostate-mesilate,10-fold,6,X,[orch/phsu],????,,????
677040a6-972a-4dd7-ac5f-ff4124f2ce8a,C0207682,10-fold,potently inhibited fusion about 10-fold ,nafamostat mesilate,10-fold,4,X,[orch/phsu],????,,????
31102c0a-b56f-497f-8f3c-b1e00be95b5d,C0207682,C1175743,blocked ,nafamostat mesilate,SARS coronavirus,8,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
31102c0a-b56f-497f-8f3c-b1e00be95b5d,C0207682,C1175743,potently inhibits ,nafamostat mesilate,SARS coronavirus,7,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
31102c0a-b56f-497f-8f3c-b1e00be95b5d,C0207682,C1175743,also inhibits 2 ,nafamostat mesilate,SARS coronavirus,3,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
4d59c5a5-416d-436d-8acf-59bc34539a23,C0312860,C0005768,is below its average ,Neutrophil migration function,In Blood,4,X,[celf],[bdsu],,x.x.x.x.x
d1f0c562-cc59-4631-9e54-0a7008310651,C0312860,C1511497,is below its average ,Neutrophil migration function,Continuous Intravenous Infusion,8,X,[celf],[topp],,
9963e4d1-95e2-4a0e-8dc3-c7155011148f,C0312860,C0574032,is below its average ,Neutrophil migration function,Infusion procedures,4,X,[celf],[topp],,
fb2bad9b-87a7-492a-b888-e5b288717864,C0009450,C0020405,of spread is greater attention to endoscopic room ,Communicable Diseases,Hygiene,4,X,[dsyn],[bmod],C01.539.221,E02.547;N06.850.670
0d0cea86-8681-451a-aa76-bfb47fceac17,C0596577,C0005532,have attracted attention due to their various ,Flavonoids,biology (field),1,X,[orch],[bmod],D03.383.663.283.266.450;D03.633.100.150.266.450,H01.158.273
a0cbeeaa-2863-4eed-bfee-f9d8ff1bf21b,C0015230,C0206750,highly suggestive for ,Exanthema,Coronavirus Infections,2,X,[sosy],[dsyn],C17.800.257,C02.782.600.550.200
6faafd9c-6f67-45ff-a720-99994d1e1533,C0206750,C4321457,diagnosed in our hospital ,Coronavirus Infections,Examination,3,X,[dsyn],[acty],C02.782.600.550.200,
c5e9cc34-0a99-4723-adcd-75851c1ad1e4,C0009450,C4321457,diagnosed in our hospital ,Communicable Diseases,Examination,3,X,[dsyn],[acty],C01.539.221,
c5e9cc34-0a99-4723-adcd-75851c1ad1e4,C0009450,C4321457,can can used as ,Communicable Diseases,Examination,2,X,[dsyn],[acty],C01.539.221,
0ac4b26a-be9c-44e5-8c79-2a64c6ebe283,C0009429,C0206750,be considered as preferred treatment approach to severe ,Combined Modality Therapy,Coronavirus Infections,3,X,[topp],[dsyn],E02.186,C02.782.600.550.200
0ac4b26a-be9c-44e5-8c79-2a64c6ebe283,C0009429,C0206750,affect ,Combined Modality Therapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.186,C02.782.600.550.200
88738f4e-e5a6-4ac8-87d0-0b874ec1b284,C0033972,C0206750,is in patients with ,Psychotherapy Multiple,Coronavirus Infections,3,X,[topp],[dsyn],F04.754.766,C02.782.600.550.200
c8f969b7-92e9-4ace-99c1-b7f9c72a7328,C0001962,C0042776,inactivating enveloped ,Ethanol,Virus,1,X,[orch/phsu],[virs],D02.033.375;x.x.x.x,B04
8aa41301-cc97-4922-a23f-8fd5c78a1c2e,C1330330,C0042776,inactivating enveloped ,Hand Sanitizers,Virus,1,X,[phsu],[virs],D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650,B04
46ac46ad-199d-4f51-b140-366f45db9211,C0001962,C0206419,inactivating enveloped ,Ethanol,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.033.375;x.x.x.x,B04.820.504.540.150
0d630bd2-9fa6-40ba-b31b-fd3f7f79bcfc,C1330330,C0206419,inactivating enveloped ,Hand Sanitizers,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650,B04.820.504.540.150
1226b4d3-1052-40bd-8566-e96c3ef839bb,C0042776,C2717802,extrapolating effectiveness on ,Virus,Viral Structures,2,X,[virs],[anst],B04,A21
07d8a1ce-e545-4c14-ac1d-59ccd7a94d78,C0042776,C1330330,extrapolating effectiveness of ,Virus,Hand Sanitizers,1,X,[virs],[phsu],B04,D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650
a6338b92-e95e-404b-9cfc-39b417a8d4d1,C0079189,C0042776,causes in addition to direct injury from se,cytokine,Virus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04
a6338b92-e95e-404b-9cfc-39b417a8d4d1,C0079189,C0042776,are responsible for poor humoral ,cytokine,Virus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04
88af4092-609c-4f00-833b-7b55e599ab19,C0013227,C0232217,especially altering ,Pharmaceutical Preparations,Cardiac conduction,1,X,[phsu],[ortf],D26,
d0853210-8b99-411c-b485-1f2801b6e645,C0015967,C0013404,stuffed ,Fever,Dyspnea,1,X,[sosy],[sosy],C23.888.119.344,C08.618.326;C23.888.852.371
ccddce19-7e79-44dc-81b1-d2d3ca58ea30,C0015672,C0206750,were identified as prognostic symptoms of ,Fatigue,Coronavirus Infections,2,X,[sosy],[dsyn],C23.888.369,C02.782.600.550.200
a002c249-7ab4-4536-bc1e-1c639c42644f,C0028429,C0206750,were identified as prognostic symptoms of ,Nose,Coronavirus Infections,2,X,[bpoc],[dsyn],A01.456.505.733;A04.531;A09.531,C02.782.600.550.200
fc3d35ec-47c5-4ceb-9668-ee86023c9c3f,C0038056,C1514474,was sole ,Sputum,Prognostic Factors,2,X,[bdsu],[clna],A12.200.808,E01.789
e74c7c89-fe04-4c9a-b7e5-e9e5b154c3de,C0161816,C0020538, includes ,Cardiac complication,Hypertensive disease,4,X,[patf],[dsyn],,C14.907.489
34247d76-623c-49e0-9825-cead0810a4ca,C0038056,C0161816,was sole Prognostic Factors for patients with,Sputum,Cardiac complication,2,X,[bdsu],[patf],A12.200.808,
b12443de-f60c-4435-96fc-ad93e798f4c5,C0038056,C0020538,was sole Prognostic Factors for patients with,Sputum,Hypertensive disease,2,X,[bdsu],[dsyn],A12.200.808,C14.907.489
271fbb87-acde-4244-ae89-19d11b63fa11,C0007222,C0020538, includes ,Cardiovascular Diseases,Hypertensive disease,2,X,[dsyn],[dsyn],C14,C14.907.489
854f43a2-27c2-4531-9d16-7bb3bde92169,C0013404,C0009450,is prognostic of severe ,Dyspnea,Communicable Diseases,2,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C01.539.221
f5d63cf0-08c7-40f4-97c7-3533f9cd251b,C0027497,C1514474,are favorable ,Nausea,Prognostic Factors,2,X,[sosy],[clna],C23.888.821.712,E01.789
aec3b747-31d1-44e2-9f45-fe43f2ec871d,C0027497,C0009450,are favorable Prognostic Factors of severe,Nausea,Communicable Diseases,4,X,[sosy],[dsyn],C23.888.821.712,C01.539.221
09f621ba-51f2-4415-ba81-73b9fc38e5ff,C0028429,C1514474,are favorable ,Nose,Prognostic Factors,2,X,[bpoc],[clna],A01.456.505.733;A04.531;A09.531,E01.789
8ced1f88-ca84-48da-9fe6-cb37ac35607c,C0028429,C0009450,are favorable Prognostic Factors of severe,Nose,Communicable Diseases,3,X,[bpoc],[dsyn],A01.456.505.733;A04.531;A09.531,C01.539.221
d49daa5d-b4d4-4314-ad34-f71592fc38dd,C0264219,C0086418,is threat to ,Acute respiratory disease,Homo sapiens,2,X,[dsyn],[humn],,B01.050.150.900.649.313.988.400.112.400.400
a0c9fe50-23fc-41f4-a5ad-27e09884b708,C3698360,C3697872,belong to same ,Middle East Respiratory Syndrome Coronavirus,Genus Betacoronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.750,
3e86f0be-195d-42a1-90c4-b0d2b108f702,C0030946,C0598312,is essential for ,Endopeptidases,DNA Replication,2,X,[aapp/enzy/phsu],[genf],D08.811.277.656.300,G02.111.225;G05.226
86ec0fa6-9a59-48d6-a545-e5352223263b,C0030946,C0087111,is considered important ,Endopeptidases,Therapeutic procedure,4,X,[aapp/enzy/phsu],[topp],D08.811.277.656.300,E02
d278c9f6-8962-4e9b-a8d6-57f73efbfc96,C0030946,C0012634,is considered important ,Endopeptidases,Disease,4,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300,C23.550.288
e2cd3bf7-7591-4a11-a52c-fc163bf06b86,C0031843,C0206750,makes ,physiological aspects,Coronavirus Infections,5,X,[phsf],[dsyn],x.x.x.x,C02.782.600.550.200
ffbd6931-dab0-4070-a282-95d9475d1103,C0031843,C0598312,is in ,physiological aspects,DNA Replication,2,X,[phsf],[genf],x.x.x.x,G02.111.225;G05.226
5b0b1f12-2a74-48b9-a4bd-a38db3b475b1,C0206058,C1705178,is in ,Elective Surgical Procedures,Order (action),8,X,[topp],[acty],E04.249,
25abe3a0-6f8d-4e78-8709-6c59ef0b9eda,C0018821,C1705178,have have postponed in ,Cardiac Surgery procedures,Order (action),3,X,[topp],[acty],E04.100.376;E04.928.220,
81d092d3-459c-4c3d-9050-fdfba0f78b66,C0206058,C0242781,reduce ,Elective Surgical Procedures,disease transmission,6,X,[topp],[patf],E04.249,N06.850.310
6c9f8c55-837d-4c4c-9628-cbaa6048d5e3,C0018821,C0242781,reduce ,Cardiac Surgery procedures,disease transmission,3,X,[topp],[patf],E04.100.376;E04.928.220,N06.850.310
b2e612b3-fcfc-4125-a620-13b4ab25d1a2,C0012634,C0018799,is in setting of emergent ,Disease,Heart Diseases,4,X,[dsyn],[dsyn],C23.550.288,C14.280
6f05265a-7317-4530-b335-e093b2bc841c,C3272275,C0206750,is with active/recent ,Urgent Procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
64088998-60d5-45f9-830b-6c2b628150ee,22nd,C0374505,divided into routine ,22nd,Group Therapies,2,X,????,[topp],????,
65b86b47-467d-4f54-9880-98a3cd0aab68,22nd,C1415068,divided by ,22nd,GJA1 gene,2,X,????,[gngm],????,
a09af7a8-4e6d-4e70-9220-8af999d8dbb1,C0052432,C0559546,eliminate Pathogenic organism with fewer,artesunate,Adverse reactions,2,X,[orch/phsu],[patf],D01.248.497.158.685.750.212.500;D01.339.431.374.212.500;D01.650.550.750.200.500;D02.389.338.055.500;D02.455.849.765.211.500,
c2fe57e0-ad59-402e-b1d1-820b65f136a2,C0052432,C0450254,eliminate ,artesunate,Pathogenic organism,2,X,[orch/phsu],[orgm],D01.248.497.158.685.750.212.500;D01.339.431.374.212.500;D01.650.550.750.200.500;D02.389.338.055.500;D02.455.849.765.211.500,
82004066-ad73-4594-977d-ef404bd56050,C0021966,C0206750,emphasize significance due to previous exposure to seasonal ,Iodides,Coronavirus Infections,2,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C02.782.600.550.200
82004066-ad73-4594-977d-ef404bd56050,C0021966,C0206750,is in completo isolamento durante da ,Iodides,Coronavirus Infections,1,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C02.782.600.550.200
88761c26-7bf0-4f5b-96e5-f45601dd843d,C0021966,C0178575,emphasize significance of ,Iodides,cross immunity,2,X,[inch],[moft],D01.248.497.158.490;D01.475.410,
c1a1ac00-d6e2-4522-bd64-f9d1f0035898,COVID-19,CBRN,can in certain respects can viewed as CBRN ,COVID-19,CBRN,1,X,[virs],????,C000657245,????
14fa090c-756e-43a0-94ea-14c9547613dc,C2948600,7-day,evaluate 7-day HCP ,Aim,7-day,2,X,[inch/phsu],????,,????
8aa458c0-7f0d-4cfe-929c-1c0671771ee9,C2948600,C2828389,evaluate 7-day HCP ,Aim,Exclusion,2,X,[inch/phsu],[acty],,
2fd323c9-4f6d-42e5-8416-68d133729f71,C2948600,HCP,evaluate 7-day HCP ,Aim,HCP,1,X,[inch/phsu],????,,????
db750ee3-2f37-4e16-838e-abefbd98c3b6,COVID-19,C1521863,is in burgeoning ,COVID-19,estrogen receptor alpha human,2,X,[virs],[aapp/rcpt],C000657245,x.x.x.x
37f217b2-4181-42b3-bb37-733a045e52e6,C0032285,C1521863,is in burgeoning ,Pneumonia,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C08.381.677;C08.730.610,x.x.x.x
2ef0b2c2-55eb-4650-a2c6-1fed305c42f8,COVID-19,C2718059,is in burgeoning ,COVID-19,Precision Medicine,2,X,[virs],[topp],C000657245,E02.574;H02.403.200.700
e4aad492-c816-465f-b342-a53959e77bf2,C0032285,C2718059,is in burgeoning ,Pneumonia,Precision Medicine,2,X,[dsyn],[topp],C08.381.677;C08.730.610,E02.574;H02.403.200.700
b7d1edd9-7ccd-4046-a007-dbfda873aef6,COVID-19,C0037054,is in ,COVID-19,Sickle Cell Trait,2,X,[virs],[dsyn],C000657245,C15.378.071.141.150.150.670;C15.378.420.155.668;C16.320.070.150.670;C16.320.365.155.668
a1e3294f-0a2f-4a31-ac6a-206610d5058a,C0032285,C0037054,is in ,Pneumonia,Sickle Cell Trait,2,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C15.378.071.141.150.150.670;C15.378.420.155.668;C16.320.070.150.670;C16.320.365.155.668
a9fad601-402b-4b63-934c-d2b665812393,C0005821,C1175743,is in patients infected with ,Blood Platelets,SARS coronavirus,2,X,[cell],[virs],A11.118.188;A15.145.229.188,B04.820.504.540.150.113.937
0e5e46fd-0e46-4c79-bca3-817a37e138ff,C0017262,C1175743,is in patients infected with ,Gene Expression,SARS coronavirus,2,X,[genf],[virs],G05.297,B04.820.504.540.150.113.937
382a1b96-505b-407e-a1fe-1540c9143850,C3641730,COVID-19,demonstrated ,Cell-Free RNA,COVID-19,1,X,[nnon],[virs],D13.444.154,C000657245
0d9b7c20-13ad-49dd-ac98-f0ca0cee472d,C3641730,C0005821,demonstrated ,Cell-Free RNA,Blood Platelets,1,X,[nnon],[cell],D13.444.154,A11.118.188;A15.145.229.188
56ed2992-a56b-4191-a440-30b805ef9f5d,C1519516,C1704259,is in ,Tissue-Specific Gene Expression,Biochemical Pathway,2,X,[genf],[moft],,
f66a589a-916f-4b98-986a-cba46457f5cd,C1519516,C1519751,is in ,Tissue-Specific Gene Expression,Ubiquitination,2,X,[genf],[moft],,G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831
229c561a-6517-4350-ac76-c5661dd0d367,C0005821,C0134835,had increased ,Blood Platelets,P-Selectin,1,X,[cell],[aapp/imft],A11.118.188;A15.145.229.188,D12.776.395.550.200.700.775;D12.776.395.550.625.905;D12.776.503.843.775;D12.776.543.550.200.700.775;D12.776.543.550.625.905;D23.050.301.350.700.775
35396843-3326-4f1f-9ad9-a9e229893afc,C0039194,COVID-19,were significantly elevated in ,T-Lymphocyte,COVID-19,1,X,[cell],[virs],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,C000657245
c06ec8e2-7819-4f7b-94a4-122aa8edf3d0,C0051979,C0009359,is with ,anti-IgG,Gold Colloid,2,X,[aapp/imft],[inch/phsu],x.x.x.x,D01.379.400
cb67b231-f3a0-445f-90fe-761e7342567d,C0086418,C0009359,is with ,Homo sapiens,Gold Colloid,1,X,[humn],[inch/phsu],B01.050.150.900.649.313.988.400.112.400.400,D01.379.400
537e6567-5379-4cfe-ab31-8770f221d6fe,C1511790,C1524029,took 15 20 ,Detection,Mouse MIN NOS,2,X,[topp],[neop],,
40432ed7-e738-4fd5-8626-36c165abb7d5,C0034019,COVID-19,would reduce ,public health medicine (field),COVID-19,3,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,C000657245
b7f6efa6-e39e-4f53-85ff-c4345cbae1fd,C0034019,C1521827,is in ,public health medicine (field),Preparation,1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
ee9d307e-1ca3-4033-80b8-9fb7c7cf8e48,C0034019,C1421479,is in ,public health medicine (field),WASF1 gene,1,X,[bmod],[gngm],H02.403.720;N01.400.550;N06.850,
f709ee23-be0f-4ca5-aa5c-ab0c7592cffa,C0023530,C0086418,is in 65-year-old Chinese ,Leukopenia,Homo sapiens,1,X,[dsyn],[humn],C15.378.553.546,B01.050.150.900.649.313.988.400.112.400.400
344151c4-02a0-457c-902a-f728ea0a1463,C0086418,COVID-19,was diagnosed with ,Homo sapiens,COVID-19,4,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,C000657245
9941d8f3-42d2-4317-990d-3aa9697997f4,C0030069,CP,decreased on day after CP ,Oxyhemoglobin,CP,1,X,[aapp/bacs],????,D12.776.124.400.707;D12.776.422.316.762.687,????
011bf57f-aec8-4c91-b28f-94043af82c23,C0522534,CP,decreased on day after CP ,Saturated,CP,1,X,[npop],????,,????
3549ee9b-d917-4b94-8d6e-fdeaa34c9f6a,C0064582,C0030069,remained arterial CP ,Lactic acid,Oxyhemoglobin,1,X,[bacs/orch/phsu],[aapp/bacs],D02.241.511.459.450,D12.776.124.400.707;D12.776.422.316.762.687
02daebf7-22f0-4784-8725-75a636b125c4,C0064582,C0522534,remained arterial CP ,Lactic acid,Saturated,1,X,[bacs/orch/phsu],[npop],D02.241.511.459.450,
4cf37fe3-6f8a-40ab-80d9-4d29db946087,C0064582,CP,remained arterial CP ,Lactic acid,CP,1,X,[bacs/orch/phsu],????,D02.241.511.459.450,????
5d0f04d9-0954-4195-a6bc-acdbfa04c6c8,C0035668,C0439056,remained in ,RNA,Throat swab sample,3,X,[nnon],[bdsu],D13.444.735,
f6cef500-17e1-4baa-9901-0d063573457f,C1175743,MEO,was performed in MEO,SARS coronavirus,MEO,2,X,[virs],????,B04.820.504.540.150.113.937,????
a6eb3b01-347e-4307-bb87-ae06169a74fe,C1450224,COVID-19,successfully navigating ,forensic pathology discipline,COVID-19,1,X,[bmod],[virs],H02.403.330.300;H02.403.650.249;I01.198.780.937.460,C000657245
3645bd3f-7308-4f5f-89bd-42d7f992fd7e,C1450224,C0012634,successfully navigating emerging ,forensic pathology discipline,Disease,2,X,[bmod],[dsyn],H02.403.330.300;H02.403.650.249;I01.198.780.937.460,C23.550.288
c0d68b1f-7977-4529-ba69-ed8799c2ff20,COVID-19,C0036974,cause economic ,COVID-19,Shock,1,X,[virs],[patf],C000657245,C23.550.835
d7260a3e-7fef-4adb-bf6c-fc40989ccf43,C0011570,1930s,is in 1930s,Mental Depression,1930s,1,X,[mobd],????,F01.145.126.350,????
7043fed9-eb62-4dbf-9665-0f984a9a0fbd,C0012634,C2806453,caused by ,Disease,Betacoronavirus,2,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150.113
a82282d2-3af1-4d5d-968d-7eb0965ac5b0,C0012634,C0020517,was shown temperature ,Disease,Hypersensitivity,4,X,[dsyn],[patf],C23.550.288,C20.543
1e3b6dbd-21ed-4071-987f-6ad26574f72e,C1160716,C0015392,are proposed with highlight on system as conduit between ,viral transmission,Eye,2,X,[celf],[bpoc],,A01.456.505.420;A09.371
4dd7db7d-fc29-43ca-bbab-fa312c54c731,C1511790,C0036537,is in ocular ,Detection,Bodily secretions,1,X,[topp],[bdsu],,A12.200
e2218417-ca1b-4918-aba0-59e91b87bb92,C0024109,C0079189,is key target of ,Lung,cytokine,1,X,[bpoc],[aapp/imft],A04.411,D12.644.276.374;D12.776.467.374;D23.529.374
75cbfe01-79d9-4cfd-a793-3108dcdb9baf,C2755994,C0079189,heavy burden of ,intracellular signal transduction pathway,cytokine,1,X,[celf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
4fbe14da-815c-4607-a14a-be332d2280c9,C1511617,C0079189,heavy burden of ,Cytokine Signaling,cytokine,1,X,[moft],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
4da8ad5c-34dc-4dea-8b92-093203614f5f,C0079189,C2985566,can Therefore can ,cytokine,Targeted Therapy,2,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,
2825db32-72f6-4643-bb0d-e0994e5345df,C0079189,C2948600,can Therefore can ,cytokine,Aim,1,X,[aapp/imft],[inch/phsu],D12.644.276.374;D12.776.467.374;D23.529.374,
a1fd0321-e87e-4c99-84b3-72379dbb0583,C0013227,C1521827,be ,Pharmaceutical Preparations,Preparation,1,X,[phsu],[acty],D26,
2f5d77dd-f21c-46be-a55a-a25501a9626c,hadto,C1521827,be ,hadto,Preparation,1,X,????,[acty],????,
f39dacfc-c5b6-4bc4-94ab-f464a57796d2,C0037778,COVID-19,is In ,Medical Specialities,COVID-19,1,X,[bmod],[virs],H02.403,C000657245
42d113e1-b1f4-4dbe-8ddf-dfe85693030b,C0037778,C1521863,is In ,Medical Specialities,estrogen receptor alpha human,1,X,[bmod],[aapp/rcpt],H02.403,x.x.x.x
23131650-0f56-463a-a49f-e0939e3a8597,C0815172,C0015967,is in ,patient characteristics,Fever,3,X,[clna],[sosy],,C23.888.119.344
a9fb7d92-9149-497a-b3b2-f7f08ff60f7a,C2348077,C1705178,was defined In ,Date Fruit,Order (action),2,X,[food],[acty],B01.650.940.800.575.912.250.093.615,
9fe89e72-b5c8-46d4-b691-bbca9994661c,C2348077,C2741673,was defined In ,Date Fruit,Account number:Identifier:Point in time:^Patient:Nominal,2,X,[food],[clna],B01.650.940.800.575.912.250.093.615,
e1d40e9d-9acb-4704-858a-5ed3ef83a10d,C0442886,C0206750,occurred in in critical ill patients with ,Secondary Infections,Coronavirus Infections,1,X,[dsyn],[dsyn],C01.539.218;C02.219;C03.202,C02.782.600.550.200
e0f889d6-6f8e-4c42-867e-d44e144696c6,C0042487,C0206750,was identified in patients with critically ill ,Venous Thrombosis,Coronavirus Infections,3,X,[patf],[dsyn],C14.907.355.830.925,C02.782.600.550.200
e0f889d6-6f8e-4c42-867e-d44e144696c6,C0042487,C0206750,is in intensive care unit with severe ,Venous Thrombosis,Coronavirus Infections,2,X,[patf],[dsyn],C14.907.355.830.925,C02.782.600.550.200
6ca295e6-2ce4-480e-853e-0260d84ad657,C0042487,C0199242,is in critically ill ,Venous Thrombosis,Anticoagulant prophylaxis,1,X,[patf],[topp],C14.907.355.830.925,
b7527c2a-88d1-47d6-963f-3616ffd6e847,C0042487,C0679698,is in critically ill ,Venous Thrombosis,disease prevention,1,X,[patf],[topp],C14.907.355.830.925,
2cc0dca9-d66a-4107-ac85-757f49f5f62e,C0206750,C0679698,is with ,Coronavirus Infections,disease prevention,1,X,[dsyn],[topp],C02.782.600.550.200,
3d6b254f-3ec7-43c8-9ff0-1960feb83818,C0042487,C0149871,occurred in distal ,Venous Thrombosis,Deep Vein Thrombosis,2,X,[patf],[dsyn],C14.907.355.830.925,C14.907.355.830.925
433ac0d8-a1fa-49dc-9d97-8eeb270e6cec,DVT,C0149871,occurred in distal ,DVT,Deep Vein Thrombosis,2,X,????,[dsyn],????,C14.907.355.830.925
2dc071dd-3ace-4b4f-b385-cea8e7c8eae0,C0239981,C0149871,presence of were significantly independent risk factors of ,Hypoalbuminemia,Deep Vein Thrombosis,1,X,[dsyn],[dsyn],C15.378.147.607.500,C14.907.355.830.925
01099f02-5458-4428-9a09-4e6ace731f47,C0036770,C1175175,suggests potential vulnerability to ,Structure of sertoli cell,Severe Acute Respiratory Syndrome,1,X,[cell],[dsyn],A05.360.444.849.789;A11.382.952;A11.436.837,C02.782.600.550.200.750;C08.730.730
2f2825a0-6104-48ab-90ad-d27259e1dc0e,C1511790,C0444176,is in ,Detection,Seminal fluid specimen,1,X,[topp],[bdsu],,
87f597ab-e7e9-403d-a586-ee1ca1338e39,C0149871,C0206750,is in patients with ,Deep Vein Thrombosis,Coronavirus Infections,2,X,[dsyn],[dsyn],C14.907.355.830.925,C02.782.600.550.200
aec0b300-2e80-40d8-b69f-15e6c2c902d1,C0206750,C0149871,is with ,Coronavirus Infections,Deep Vein Thrombosis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.355.830.925
2cd35e0f-2bcd-4d0b-a93e-992698f0be25,C0206750,C0596448,had average in-hospital D ,Coronavirus Infections,dimer,1,X,[dsyn],[chvs],C02.782.600.550.200,
2cd35e0f-2bcd-4d0b-a93e-992698f0be25,C0206750,C0596448,= 3D ,Coronavirus Infections,dimer,1,X,[dsyn],[chvs],C02.782.600.550.200,
d8c86260-cf8f-495d-b298-32b97c26878c,C0204819,C0700184,can also cause ,Intubation Nasogastric,Throat irritation,2,X,[topp],[sosy],E02.585.412;E05.497.412,
aa21635e-b371-4c0c-a1ed-06ed8d21cf69,C0204819,C0010200,resulting in ,Intubation Nasogastric,Coughing,2,X,[topp],[sosy],E02.585.412;E05.497.412,C08.618.248;C23.888.852.293
0ddf4035-ff7e-4c61-bede-b9347c64932c,C0444279,C0206750,collected from confirmed ,Respiratory sample,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
ffa7a1ff-9b0c-4730-b3bb-3d2126999486,C2948600,C0422833,investigate transversally ,Aim,ENT symptoms,4,X,[inch/phsu],[sosy],,
fa1a6d62-6664-4497-a409-8bc71f0bc3d2,C2948600,C0012634,investigate transversally ,Aim,Disease,2,X,[inch/phsu],[dsyn],,C23.550.288
fa1a6d62-6664-4497-a409-8bc71f0bc3d2,C2948600,C0012634,report radiological ,Aim,Disease,1,X,[inch/phsu],[dsyn],,C23.550.288
fa1a6d62-6664-4497-a409-8bc71f0bc3d2,C2948600,C0012634,evaluate Clinical Treatment implications with ACEI,Aim,Disease,2,X,[inch/phsu],[dsyn],,C23.550.288
fa1a6d62-6664-4497-a409-8bc71f0bc3d2,C2948600,C0012634,evaluate results of protocol established in advanced ,Aim,Disease,1,X,[inch/phsu],[dsyn],,C23.550.288
fa1a6d62-6664-4497-a409-8bc71f0bc3d2,C2948600,C0012634,describe clinical presentation of patients aged 80 years with ,Aim,Disease,2,X,[inch/phsu],[dsyn],,C23.550.288
fa1a6d62-6664-4497-a409-8bc71f0bc3d2,C2948600,C0012634,investigate correlations between serum calcium in patients with ,Aim,Disease,1,X,[inch/phsu],[dsyn],,C23.550.288
cc50636f-46c0-4c4f-8b52-b74338d30372,C0004093,C1457887,were most prevalent ,Asthenia,Symptoms,2,X,[sosy],[sosy],C23.888.089,
2a6be344-c38b-4921-b47c-43d1b662d855,C1457887,C1518304,probably linked to ,Symptoms,Neurotropism,2,X,[sosy],[patf],,
8eecfdd7-0921-4e01-a0f3-7d8a8538994a,C1457887,C0319157,probably linked to ,Symptoms,AS virus,1,X,[sosy],[virs],,
7a183588-630a-4067-a814-d38af211207c,anosmia,C1457887,are Furthermore ,anosmia,Symptoms,2,X,????,[sosy],????,
7a183588-630a-4067-a814-d38af211207c,anosmia,C1457887,have have identified as highly prevalent ,anosmia,Symptoms,1,X,????,[sosy],????,
bfeab608-3a28-48da-9814-2bd5acda50f5,anosmia,C0206750,are early Symptoms of,anosmia,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
bfeab608-3a28-48da-9814-2bd5acda50f5,anosmia,C0206750,are frequent early symptoms of ,anosmia,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
bfeab608-3a28-48da-9814-2bd5acda50f5,anosmia,C0206750,are Furthermore ,anosmia,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
baf3877a-9ca4-41e0-8ccc-dfc8722aae0b,C0199529,C0206750,is in patients with ,Pulmonary rehabilitation (procedure),Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
9a7a0c37-0dd4-4266-a810-5c8121209c46,C0206750,C0344211,Management of is mainly ,Coronavirus Infections,Supportive care,1,X,[dsyn],[topp],C02.782.600.550.200,
06749e1d-bd8d-4e45-bb28-924ba960464e,C0476474,C0206750,is with suspected association to ,persistent fever,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
c3189710-2de5-40cc-9bf2-82272529f952,C2948600,C0815172,report radiological ,Aim,patient characteristics,1,X,[inch/phsu],[clna],,
e7d34df2-66b1-447e-afea-d028433f383c,C0036658,C0017428,is with largest RNA ,Esthesia,Genome,2,X,[ortf],[gngm],F02.830.816;G11.561.790,G05.360.340
b5d523e3-3562-4b62-a734-619094fae8b7,C3272452,C0017428,is with largest RNA ,Single-Stranded RNA,Genome,2,X,[nnon],[gngm],,G05.360.340
e1de3c8e-3348-45a9-b935-99282fdc628d,C0567416,C0003451,exhibit significant ,Molecule,Antiviral Agents,1,X,[sbst],[phsu],,D27.505.954.122.388
e1de3c8e-3348-45a9-b935-99282fdc628d,C0567416,C0003451,is with well-known broad-spectrum ,Molecule,Antiviral Agents,1,X,[sbst],[phsu],,D27.505.954.122.388
e1de3c8e-3348-45a9-b935-99282fdc628d,C0567416,C0003451,elicit ,Molecule,Antiviral Agents,1,X,[sbst],[phsu],,D27.505.954.122.388
be476ced-676d-4799-8129-06fe022a7fb5,C0567416,C1175743,exhibit significant ,Molecule,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
be476ced-676d-4799-8129-06fe022a7fb5,C0567416,C1175743,prevent ,Molecule,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
c9e611a1-34d8-4a12-8265-7db24127891b,C0567416,C1705178,are In present review discussed in ,Molecule,Order (action),1,X,[sbst],[acty],,
48a14342-a97c-47c5-adb6-a00ccc20b350,C0032081,C0441655,is with mentioned ,Plant Extracts,Activities,1,X,[bacs/phsu],[acty],D20.215.784.500;D26.667,
c4f2055e-48e1-47f4-8015-3443b9075206,C0600558,C0280220,is in advanced ,Neoadjuvant Therapy,stage ovarian epithelial cancer,2,X,[topp],[neop],E02.186.450,
9f419f60-d621-4730-8ee9-832ec3f4bbcd,C0677962,C0195495,is with ,Total hysterectomy (procedure),Bilateral salpingectomy with oophorectomy,2,X,[topp],[topp],,
38fb3268-b62a-4e1f-990e-f4a601dbb0a5,C0035124,C1947933,is measure of ,Reperfusion Therapy,care activity,2,X,[topp],[acty],E04.100.700;E05.680.730,
f7ef3d17-e801-4976-90eb-8c939ed72e12,C0035124,C1536220,is measure of ,Reperfusion Therapy,ST segment elevation myocardial infarction,2,X,[topp],[dsyn],E04.100.700;E05.680.730,C14.280.647.500.875;C14.907.585.500.875
60e60101-12fa-48ea-a08c-3003a0558e8e,C1947933,C1536220,is in patients with ,care activity,ST segment elevation myocardial infarction,2,X,[acty],[dsyn],,C14.280.647.500.875;C14.907.585.500.875
5c609450-303c-4cba-9cce-127c02bde048,C0035124,C0040044,is focused on ,Reperfusion Therapy,Thrombolytic Therapy,2,X,[topp],[topp],E04.100.700;E05.680.730,E02.319.913
5c609450-303c-4cba-9cce-127c02bde048,C0035124,C0040044,is in patients with ,Reperfusion Therapy,Thrombolytic Therapy,2,X,[topp],[topp],E04.100.700;E05.680.730,E02.319.913
b3280b7f-0c05-42a2-b586-11c73cd150f3,C0035124,C1175175,is in patients with ,Reperfusion Therapy,Severe Acute Respiratory Syndrome,4,X,[topp],[dsyn],E04.100.700;E05.680.730,C02.782.600.550.200.750;C08.730.730
793a7105-a805-4dc7-95e1-0468a8ff8113,PCR,C0370003,also remained from lower respiratory tract ,PCR,Specimen,2,X,????,[sbst],????,
793a7105-a805-4dc7-95e1-0468a8ff8113,PCR,C0370003,performed on respiratory ,PCR,Specimen,1,X,????,[sbst],????,
d98dc8c7-6c23-4940-a473-59e304048ab8,PCR,C0444159,qualified ,PCR,Sputum specimen,2,X,????,[bdsu],????,
26626cc1-f9b3-4055-81ba-060e24a254e1,C0003451,C0199848,are needed for ,Antiviral Agents,Coronavirus vaccination,2,X,[phsu],[topp],D27.505.954.122.388,
4e06e005-9a33-48d4-9c28-0ca745448685,C0441655,C0199848,are needed for ,Activities,Coronavirus vaccination,1,X,[acty],[topp],,
1eead9a1-f257-4d56-9ecd-2627f40ace14,C1708476,C0206750,is discussed as model against ,Implementation,Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
1eead9a1-f257-4d56-9ecd-2627f40ace14,C1708476,C0206750,will reduce ,Implementation,Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
f750271e-4e33-464b-9bee-efdb7e6f18de,C0282572,C1171362,control relative ,Frameshifting Ribosomal,protein expression,8,X,[genf],[genf],G02.111.660.871.200;G03.734.871.200;G05.308.215,
1e9babd3-f859-461e-b0cc-3b7a0ca080e9,C0042774,PRF,Altering -1 PRF ,Virus Replication,PRF,2,X,[celf],????,G06.920.925,????
cd651cb0-4453-4489-a876-8c4a3b687f4b,C0042774,C0441655,Altering -1 PRF ,Virus Replication,Activities,2,X,[celf],[acty],G06.920.925,
bb6862d8-8346-457d-a28f-18737c89e467,C1519323,C0441655,strongly ablate -1 PRF ,Silent Mutation,Activities,3,X,[genf],[acty],G05.365.590.803,
82205a3e-43ba-4c1c-b364-bdf7db4da885,C0441655,C0042776,is also retained in ,Activities,Virus,4,X,[acty],[virs],,B04
6edba27a-cf04-485f-babb-baace72138fa,C0034019,C2745965,is in ,public health medicine (field),Emergencies [Disease/Finding],1,X,[bmod],[patf],H02.403.720;N01.400.550;N06.850,C23.550.291.781;N06.230.100.083;N06.850.376
dcd08590-4a5a-47ac-a4b6-ef59923eb424,C0010200,C1175175,stands for ,Coughing,Severe Acute Respiratory Syndrome,2,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200.750;C08.730.730
2ead7e08-dbd5-4317-b850-08ef4f4de856,C0015967,C1175175,stands for ,Fever,Severe Acute Respiratory Syndrome,2,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200.750;C08.730.730
2eed58fe-5540-4ffe-93d7-fe16fb644753,C0013404,C1175175,stands for ,Dyspnea,Severe Acute Respiratory Syndrome,2,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.782.600.550.200.750;C08.730.730
4da5de58-6afb-4c5d-9674-905a34dfaa7f,C0010200,C1175743,stands for ,Coughing,SARS coronavirus,2,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150.113.937
4da5de58-6afb-4c5d-9674-905a34dfaa7f,C0010200,C1175743,are most prevalent Symptoms of adults infected by,Coughing,SARS coronavirus,1,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150.113.937
1fecff7b-3c24-41f5-9400-0e182f6d1bdf,C0013404,C1175743,stands for ,Dyspnea,SARS coronavirus,2,X,[sosy],[virs],C08.618.326;C23.888.852.371,B04.820.504.540.150.113.937
c774073a-257f-4137-af1c-995875a6869e,hisskin,sclera,was jaundiced with sclera ,hisskin,sclera,4,X,????,????,????,????
13104674-4f45-4209-9e8d-df711fc26ddd,hisskin,C0004002,was jaundiced with sclera ,hisskin,Aspartate Transaminase,2,X,????,[aapp/enzy],????,D08.811.913.477.700.225
13104674-4f45-4209-9e8d-df711fc26ddd,hisskin,C0004002,was jaundiced with very high levels of ,hisskin,Aspartate Transaminase,2,X,????,[aapp/enzy],????,D08.811.913.477.700.225
1839a5d1-8cd4-4b30-9b5c-30d355658049,hisskin,icteric,was jaundiced with icteric sclera ,hisskin,icteric,3,X,????,????,????,????
17252363-db48-4ba1-b2da-7ded764a343e,C0118522,C0003451,regulates expression of wide array of genes including ,GA-Binding Protein Transcription Factor,Antiviral Agents,1,X,[aapp/bacs],[phsu],D12.776.260.615.249;D12.776.930.618.249,D27.505.954.122.388
def134e2-02f8-4056-b02c-a9507bf3c145,C0118522,C0030012,regulates cellular ,GA-Binding Protein Transcription Factor,Oxidation-Reduction,3,X,[aapp/bacs],[moft],D12.776.260.615.249;D12.776.930.618.249,G02.700;G03.295.531
88538fbc-d0d8-490f-a81d-c8ca6d76737e,C0118522,C0012634,making elderly susceptible to ,GA-Binding Protein Transcription Factor,Disease,3,X,[aapp/bacs],[dsyn],D12.776.260.615.249;D12.776.930.618.249,C23.550.288
3812d52d-d248-4aab-8146-3c57be9a6abb,C0441655,C0012634,making elderly susceptible to ,Activities,Disease,2,X,[acty],[dsyn],,C23.550.288
c9eae3e9-eadb-49d2-bb2e-51d32a9c7abe,C0012634,C0021376,include type diabetes ,Disease,Chronic inflammation,3,X,[dsyn],[patf],C23.550.288,
9cdf5806-bb3d-4cb2-85f7-0ff9e61443d7,C0012634,C0042769,is viral ,Disease,Virus Diseases,6,X,[dsyn],[dsyn],C23.550.288,C02
22663478-ca89-47cd-aaae-d178f5b2e8aa,C0118522,C1422064,downregulates ,GA-Binding Protein Transcription Factor,ACE2 gene,2,X,[aapp/bacs],[gngm],D12.776.260.615.249;D12.776.930.618.249,
9bdd9a1c-4d6a-41a2-a91a-4805b56b338c,C1879547,C1422064,downregulates ,Activation action,ACE2 gene,2,X,[acty],[gngm],,
210728de-c7fa-4eca-8a4d-bf5bc80a4cdc,PB125,C1422064,downregulates ,PB125,ACE2 gene,2,X,????,[gngm],????,
6126ce3c-c212-4cb7-bd87-6436d35dfed4,C0118522,C1515670,downregulates ,GA-Binding Protein Transcription Factor,mRNA Expression,3,X,[aapp/bacs],[genf],D12.776.260.615.249;D12.776.930.618.249,
abe8f927-5d33-4e35-89a7-d615e1c2fe3c,C1879547,C1515670,downregulates ,Activation action,mRNA Expression,3,X,[acty],[genf],,
e230cf26-73df-45e7-b02a-a38f14db16ae,PB125,C1515670,downregulates ,PB125,mRNA Expression,3,X,????,[genf],????,
f780ab25-b025-4a60-aaf4-700663627924,C0118522,C0086418,downregulates ACE2 gene mRNA Expression in,GA-Binding Protein Transcription Factor,Homo sapiens,2,X,[aapp/bacs],[humn],D12.776.260.615.249;D12.776.930.618.249,B01.050.150.900.649.313.988.400.112.400.400
f780ab25-b025-4a60-aaf4-700663627924,C0118522,C0086418,downregulates Peptidyl-Dipeptidase A mRNA Expression in,GA-Binding Protein Transcription Factor,Homo sapiens,1,X,[aapp/bacs],[humn],D12.776.260.615.249;D12.776.930.618.249,B01.050.150.900.649.313.988.400.112.400.400
dabff8fb-8f7c-46e2-9130-7be0a12bc999,C1879547,C0086418,downregulates ACE2 gene mRNA Expression in,Activation action,Homo sapiens,2,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
dabff8fb-8f7c-46e2-9130-7be0a12bc999,C1879547,C0086418,downregulates Peptidyl-Dipeptidase A mRNA Expression in,Activation action,Homo sapiens,1,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
e6c79682-0376-467b-8b2e-52cae0c504ea,PB125,C0086418,downregulates ACE2 gene mRNA Expression in,PB125,Homo sapiens,2,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
e6c79682-0376-467b-8b2e-52cae0c504ea,PB125,C0086418,downregulates Peptidyl-Dipeptidase A mRNA Expression in,PB125,Homo sapiens,1,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
8210e89c-a32e-4710-9200-331ae82a88cf,C0118522,C0023884,downregulates ACE2 gene mRNA Expression in,GA-Binding Protein Transcription Factor,Liver,1,X,[aapp/bacs],[bpoc],D12.776.260.615.249;D12.776.930.618.249,A03.620
8210e89c-a32e-4710-9200-331ae82a88cf,C0118522,C0023884,downregulates Peptidyl-Dipeptidase A mRNA Expression in,GA-Binding Protein Transcription Factor,Liver,1,X,[aapp/bacs],[bpoc],D12.776.260.615.249;D12.776.930.618.249,A03.620
ef46e39e-6bb3-4242-b33f-e53259308a4d,C1879547,C0023884,downregulates ACE2 gene mRNA Expression in,Activation action,Liver,1,X,[acty],[bpoc],,A03.620
ef46e39e-6bb3-4242-b33f-e53259308a4d,C1879547,C0023884,downregulates Peptidyl-Dipeptidase A mRNA Expression in,Activation action,Liver,1,X,[acty],[bpoc],,A03.620
7d894214-a906-43b6-ba8c-a0639ccd8e6b,PB125,C0023884,downregulates ACE2 gene mRNA Expression in,PB125,Liver,1,X,????,[bpoc],????,A03.620
7d894214-a906-43b6-ba8c-a0639ccd8e6b,PB125,C0023884,downregulates Peptidyl-Dipeptidase A mRNA Expression in,PB125,Liver,1,X,????,[bpoc],????,A03.620
8f892767-51e5-4fe7-99aa-8b50cd690c62,C0118522,C2717940,downregulates ACE2 gene mRNA Expression in,GA-Binding Protein Transcription Factor,Hep G2 Cells,2,X,[aapp/bacs],[cell],D12.776.260.615.249;D12.776.930.618.249,A11.251.860.180.432;A11.436.348.500
8f892767-51e5-4fe7-99aa-8b50cd690c62,C0118522,C2717940,downregulates Peptidyl-Dipeptidase A mRNA Expression in,GA-Binding Protein Transcription Factor,Hep G2 Cells,1,X,[aapp/bacs],[cell],D12.776.260.615.249;D12.776.930.618.249,A11.251.860.180.432;A11.436.348.500
803d0b40-0e29-42c3-89df-31643412b423,C1879547,C2717940,downregulates ACE2 gene mRNA Expression in,Activation action,Hep G2 Cells,2,X,[acty],[cell],,A11.251.860.180.432;A11.436.348.500
803d0b40-0e29-42c3-89df-31643412b423,C1879547,C2717940,downregulates Peptidyl-Dipeptidase A mRNA Expression in,Activation action,Hep G2 Cells,1,X,[acty],[cell],,A11.251.860.180.432;A11.436.348.500
ab4f838f-38ec-4f8f-8310-7f5c80ea3924,PB125,C2717940,downregulates ACE2 gene mRNA Expression in,PB125,Hep G2 Cells,2,X,????,[cell],????,A11.251.860.180.432;A11.436.348.500
ab4f838f-38ec-4f8f-8310-7f5c80ea3924,PB125,C2717940,downregulates Peptidyl-Dipeptidase A mRNA Expression in,PB125,Hep G2 Cells,1,X,????,[cell],????,A11.251.860.180.432;A11.436.348.500
add6b37c-33ff-4285-8a95-4da2a66b9235,C1422064,C0597357,is surface ,ACE2 gene,receptor,2,X,[gngm],[aapp/rcpt],,
cb7f9390-f1b9-42f9-b73f-1ce758dc7e33,C0028606,C0020538,is with ,Nucleic Acids,Hypertensive disease,2,X,[bacs/nnon],[dsyn],D13.444,C14.907.489
a2e7efaa-3069-49a1-a9fc-e210717e9239,C0206750,C0034819,In age is low lymphocyte count myocardial injury and abnormal increase of ,Coronavirus Infections,Interleukin 2 Receptor,2,X,[dsyn],[aapp/imft/rcpt],C02.782.600.550.200,D12.776.543.750.705.852.420.320
744ee276-1184-4783-a8d3-b890878581e1,C0206750,C0021760,In age is low lymphocyte count myocardial injury and abnormal increase of ,Coronavirus Infections,Interleukin-6,2,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
a911d99f-c9a5-4f38-8b98-4091409ce181,C0206750,C0085295,In age is low lymphocyte count myocardial injury and abnormal increase of ,Coronavirus Infections,Interleukin-10,2,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510
94802aff-1ea4-4d1a-88c7-f593c7722461,C0013404,C0010200,followed by ,Dyspnea,Coughing,5,X,[sosy],[sosy],C08.618.326;C23.888.852.371,C08.618.248;C23.888.852.293
fcf89507-5d29-4100-b85f-d37221339822,C0030193,C0005768,factors elevated ,Pain,In Blood,1,X,[sosy],[bdsu],C23.888.592.612;F02.830.816.444;G11.561.790.444,x.x.x.x.x
fcf89507-5d29-4100-b85f-d37221339822,C0030193,C0005768,associated elevated white ,Pain,In Blood,1,X,[sosy],[bdsu],C23.888.592.612;F02.830.816.444;G11.561.790.444,x.x.x.x.x
009baf48-e965-4176-9967-dd2468735282,C0030193,C0013404,factors ,Pain,Dyspnea,1,X,[sosy],[sosy],C23.888.592.612;F02.830.816.444;G11.561.790.444,C08.618.326;C23.888.852.371
009baf48-e965-4176-9967-dd2468735282,C0030193,C0013404,associated ,Pain,Dyspnea,1,X,[sosy],[sosy],C23.888.592.612;F02.830.816.444;G11.561.790.444,C08.618.326;C23.888.852.371
860220e0-9679-4586-958f-69d89f7dc0fe,C0023884,C0206419,were common in ,Liver,Genus: Coronavirus,2,X,[bpoc],[virs],A03.620,B04.820.504.540.150
e41df191-db6d-4796-ac1a-b027b33f908e,C0030193,C0023884,associated with elevated ,Pain,Liver,1,X,[sosy],[bpoc],C23.888.592.612;F02.830.816.444;G11.561.790.444,A03.620
7898a3e1-052a-471d-b34f-90163518569c,C0030193,C0206419,associated with elevated ,Pain,Genus: Coronavirus,1,X,[sosy],[virs],C23.888.592.612;F02.830.816.444;G11.561.790.444,B04.820.504.540.150
0b14129b-2a2e-4587-9a8f-7e62922c162b,C0174990,C0206419,Agent of,coronavirus receptor,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],x.x.x.x,B04.820.504.540.150
b24927cb-6e02-4ff4-a8b7-e1a883125375,C1452534,C0174990,is entry ,ACE protein human,coronavirus receptor,2,X,[aapp/bacs],[aapp/rcpt],x.x.x.x,x.x.x.x
7ecde4a9-0beb-46bc-9ac7-8461266e68a4,C1452534,C0206419,decreases during ,ACE protein human,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
66cbbce9-4b9d-4e45-bc86-9961b2ea0803,C1452534,C0035222,leads to ,ACE protein human,Respiratory Distress Syndrome Adult,1,X,[aapp/bacs],[dsyn],x.x.x.x,C08.381.840;C08.618.840
c639002b-3528-4ca0-9116-fe421267421d,C0277564,C1882509,are ,Acquired disease,put - instruction imperative,1,X,[dsyn],[acty],,
ab562e9f-74bf-4fc7-8e64-b31dc3215b03,C0222045,C0960756,is in ,Integumentary scale,factor A,2,X,[bpoc],[orch],,x.x.x.x
d4665070-9600-44cf-91c6-74682d2098e0,C1177210,8-fold,is with 8-fold ,cupric cation,8-fold,2,X,[inch/phsu],????,,????
febd56ec-121a-487b-b832-41a440f0ba05,C2700061,8-fold,is with 8-fold ,Transition (action),8-fold,2,X,[acty],????,,????
49f6ee18-a89c-4a4b-b498-fba506c4c696,C1177210,C0002055,is with 8-fold ,cupric cation,Alkalies,2,X,[inch/phsu],[inch],,D01.045
80b5e899-c92b-4102-bda7-e9a16038cd25,C2700061,C0002055,is with 8-fold ,Transition (action),Alkalies,2,X,[acty],[inch],,D01.045
5b0f1878-1196-4820-9e1f-7beccce99713,C1177210,C1175743,underpinned almost one-half of amino acid differences between ,cupric cation,SARS coronavirus,2,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
be71ac45-64e6-4813-b0b7-e90f7adb1b9b,C2700061,C1175743,underpinned almost one-half of amino acid differences between ,Transition (action),SARS coronavirus,2,X,[acty],[virs],,B04.820.504.540.150.113.937
8e3a92fb-7bbb-486c-b4ec-6970f4add3f5,C2700061,U/A,occurred preferentially in U/A ,Transition (action),U/A,2,X,[acty],????,,????
26c2b797-edf5-4850-90bf-bf79ea07c747,C2700061,C1514562,occurred preferentially in U/A ,Transition (action),Protein Domain,2,X,[acty],[amas],,G02.111.570.820.709.275.750;G02.111.570.820.709.610.500
143e80be-686b-40b7-99df-3ee403ca91e3,C2700061,C1609158,occurred preferentially in U/A ,Transition (action),APOBEC3 protein human,2,X,[acty],[aapp/enzy],,x.x.x.x
2cdd08a4-e7de-470c-9bc9-1b665018c9e5,C0002055,C1177210,may represent long-term effects of prolonged ,Alkalies,cupric cation,2,X,[inch],[inch/phsu],D01.045,
60bed18d-a8a8-48cf-ba07-e4f860aab89f,C0002055,C1167395,may represent effects in their ,Alkalies,Host (organism),2,X,[inch],[orgm],D01.045,
d6ea8f60-8ec4-46d7-bb40-15bfd0fea71f,C0002055,C0206422,observed in nonpandemic ,Alkalies,Human coronavirus,2,X,[inch],[virs],D01.045,
8c7d217d-08dc-470c-bcf8-89b680e8eb7d,C0002520,C0042776,is with adaptive value for ,Amino Acids,Virus,1,X,[aapp/bacs/phsu],[virs],D12.125,B04
d5b12ebd-f9f7-451c-804c-c9824852c821,C1177210,C1167395,is in ,cupric cation,Host (organism),2,X,[inch/phsu],[orgm],,
2cc10ade-29bb-4e5a-acfa-c8afa79d75ff,C0026882,C1167395,is in ,Mutation,Host (organism),2,X,[genf],[orgm],G05.365.590,
00071659-80a3-4b90-bf4a-edafa2773975,C1177210,C1325696,is in ,cupric cation,apolipoprotein B mRNA editing enzyme complex,2,X,[inch/phsu],[celc],,
c1566fa2-075c-41fe-9b81-17b0c3da34ee,C0026882,C1325696,is in ,Mutation,apolipoprotein B mRNA editing enzyme complex,2,X,[genf],[celc],G05.365.590,
d0d79b97-41ad-4061-bbdf-7a727b521b8d,C0886515,C0087111,more recently are emerging as new promising ,Secretory Vesicles,Therapeutic procedure,4,X,[celc],[topp],A11.284.430.214.190.875.190.880.810,E02
1535e5d9-c850-4291-9694-e8f807efa0c3,C3894683,C0087111,more recently are emerging as new promising ,Extracellular Vesicles,Therapeutic procedure,2,X,[celc],[topp],A11.284.295.588,E02
22b26b85-bb21-45a3-ab3c-abd76bbb2f4d,C0087111,C0024109,also regenerate ,Therapeutic procedure,Lung,2,X,[topp],[bpoc],E02,A04.411
22b26b85-bb21-45a3-ab3c-abd76bbb2f4d,C0087111,C0024109,diminished ,Therapeutic procedure,Lung,1,X,[topp],[bpoc],E02,A04.411
8c22c747-0f28-4fa3-8b44-f32ae47f37e3,C0038250,C1527144,exert their immunomodulatory ,Stem cells,Therapeutic Effect,2,X,[cell],[clna],A11.872,
b1c6e824-7e81-4b1f-a2bd-b751b9e9a805,C0699748,C0237820,seems most effective way for patients ,Pathogenesis,Recovery - action,2,X,[patf],[acty],,
01df2e28-8bd4-4406-a8a1-57f8c11e369a,C0087111,C0237820,seems most effective way for patients ,Therapeutic procedure,Recovery - action,2,X,[topp],[acty],E02,
cc6314cf-e0a6-407c-8831-1465121b7107,C0282636,C0237820,seems most effective way for patients ,Cell Respiration,Recovery - action,2,X,[celf],[acty],G03.197;G04.270,
52eb1f8e-c91c-4e56-8a74-e2dd46a737b9,C0003209,C0237820,seems most effective way for patients ,Anti-Inflammatory Agents,Recovery - action,2,X,[phsu],[acty],D27.505.954.158,
b0db2079-81be-46ef-b1a5-406ce90926de,C1261096,C0237820,seems most effective way for patients ,Extracorporeal blood,Recovery - action,1,X,[bdsu],[acty],,
0e65211a-ac0e-4bfd-ac1d-4713ed7c9055,C0013227,HPLC,using validated HPLC ,Pharmaceutical Preparations,HPLC,2,X,[phsu],????,D26,????
e27d0627-4317-499d-bbe4-d9c019078e3a,C0008269,C0206419,were removed by treatment with Seraph dose adjustments in ,Chloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180,B04.820.504.540.150
e27d0627-4317-499d-bbe4-d9c019078e3a,C0008269,C0206419,are are repurposed for treatment of ,Chloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180,B04.820.504.540.150
2bc6c57c-4c4f-46dd-bdcf-008d273cd0af,C0026652,C0203597,were higher than than ,Moxibustion,hyperthermia treatment,5,X,[topp],[topp],E02.190.044.588,
2bc6c57c-4c4f-46dd-bdcf-008d273cd0af,C0026652,C0203597,were lower than than ,Moxibustion,hyperthermia treatment,10,X,[topp],[topp],E02.190.044.588,
c0f9693a-1c63-4a48-acc3-916d09bbc68d,C0026652,C0020517,were higher than than ,Moxibustion,Hypersensitivity,4,X,[topp],[patf],E02.190.044.588,C20.543
c0f9693a-1c63-4a48-acc3-916d09bbc68d,C0026652,C0020517,were lower than than ,Moxibustion,Hypersensitivity,4,X,[topp],[patf],E02.190.044.588,C20.543
28c3798e-5940-43eb-82b2-ac24892fad59,C0026652,C0018837,was higher than than ,Moxibustion,Heat (physical force),2,X,[topp],[npop],E02.190.044.588,
262808e1-e9ff-4d6b-b389-b5fd6ec999c6,C0026652,C1457887,improve ,Moxibustion,Symptoms,3,X,[topp],[sosy],E02.190.044.588,
5a70c3ea-a608-44da-84cf-bf67edb8cfe5,C0026652,C0206419,improve Symptoms with,Moxibustion,Genus: Coronavirus,1,X,[topp],[virs],E02.190.044.588,B04.820.504.540.150
7d6829f9-b124-4a59-8173-86e2e8a9412b,C0700271,C1707455,is in ,M Protein multiple myeloma,Comparison,1,X,[aapp/imft],[acty],x.x.x.x,
c5dade31-be4a-4180-887c-44bb9246288e,C0042776,C1422064,recognizes other ,Virus,ACE2 gene,1,X,[virs],[gngm],B04,
0eea1088-5832-4222-b052-9181d330c7c7,C0027794,C0597358,contains ,Neural Tube Defects,receptor binding,1,X,[cgab],[moft],C10.500.680;C16.131.666.680,
68ad903c-45b1-444c-9a83-8e8e0fbb5fc3,C0027794,C1175743,contains ,Neural Tube Defects,SARS coronavirus,1,X,[cgab],[virs],C10.500.680;C16.131.666.680,B04.820.504.540.150.113.937
a97cd839-c9f4-42a6-af07-b14e1124ad3d,C0597358,C1175743,Protein Domain different from that of,receptor binding,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
bf64a8a9-2368-438f-8de6-b02a5012dc0a,C1514562,C0042738,been In particular have found in ,Protein Domain,Viral Structural Proteins,2,X,[amas],[aapp/bacs],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,D12.776.964.970
cf4495b6-edb4-451e-937e-b5220fd71992,C1457887,C0231528,were ,Symptoms,Myalgia,7,X,[sosy],[sosy],,C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500
61770394-1f18-41e4-a4ba-253d75b6abbe,C1457887,C0038056,was ,Symptoms,Sputum,3,X,[sosy],[bdsu],,A12.200.808
29c77533-b72e-429a-a197-d02f9d93ec66,C0206419,C4552744,has enforced dramatic changes to ,Genus: Coronavirus,Daily Living,1,X,[virs],[dora],B04.820.504.540.150,
0cb8a8c2-b970-4667-9743-39d63cbcc456,C0243082,C0206750,were reported During ,associated conditions,Coronavirus Infections,3,X,[patf],[dsyn],,C02.782.600.550.200
63d1d2c3-aba9-40e7-a031-04f90f855b6e,C0012655,C0596448,is with high D ,Disease susceptibility,dimer,3,X,[clna],[chvs],C23.550.291.687;G07.100.250,
1cc7418e-6114-4079-aea7-7e9d80c09e8d,C0005779,C0012634,are associated with ,Blood Coagulation Disorders,Disease,1,X,[dsyn],[dsyn],C15.378.100,C23.550.288
1cc7418e-6114-4079-aea7-7e9d80c09e8d,C0005779,C0012634,induced by ,Blood Coagulation Disorders,Disease,2,X,[dsyn],[dsyn],C15.378.100,C23.550.288
1cc7418e-6114-4079-aea7-7e9d80c09e8d,C0005779,C0012634,has recently emerged as major component of ,Blood Coagulation Disorders,Disease,3,X,[dsyn],[dsyn],C15.378.100,C23.550.288
ec1a7764-4a3d-4019-a5ac-06d95653c54c,C0005779,C1175743,are associated with ,Blood Coagulation Disorders,SARS coronavirus,1,X,[dsyn],[virs],C15.378.100,B04.820.504.540.150.113.937
b498260b-0f43-4d7e-9a3f-920d396d635d,C0302148,C2586211,is in small ,Blood Clot,Thrombosis of blood vessel,3,X,[patf],[patf],C14.907.355.830,
4b81566c-a206-449f-bd20-6685406e93ed,C2350571,C0024109,is in ,Microvascular Network,Lung,3,X,[bpoc],[bpoc],A07.015.461,A04.411
122e7eee-761c-4f2c-909a-c2eda8e3c82b,C1861172,C0206750,is in hospitalised ,Venous Thromboembolism,Coronavirus Infections,3,X,[dsyn],[dsyn],C14.907.355.590.700,C02.782.600.550.200
122e7eee-761c-4f2c-909a-c2eda8e3c82b,C1861172,C0206750,has has frequently reported in patients with ,Venous Thromboembolism,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907.355.590.700,C02.782.600.550.200
122e7eee-761c-4f2c-909a-c2eda8e3c82b,C1861172,C0206750,has emerged as important consideration in management of patients with ,Venous Thromboembolism,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907.355.590.700,C02.782.600.550.200
c87367d7-e737-4149-b2f0-d99091e33ba5,C2348077,C1947933,personalized ,Date Fruit,care activity,2,X,[food],[acty],B01.650.940.800.575.912.250.093.615,
b0c3b8e9-6a28-45b7-b913-2e1979db93f2,PCR,C0242781,has raised possibility of feco-oral ,PCR,disease transmission,3,X,????,[patf],????,N06.850.310
db7ebf62-3339-4697-aa3b-ed18fa5617ef,PCR,C0015733,is in ,PCR,Feces,3,X,????,[bdsu],????,A12.459
a1e0de0f-9f8f-40b7-9f82-b131d9e1448d,C0360714,C0206750,improve ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,C02.782.600.550.200
288845ef-d103-4835-be52-b943a6353053,C2259033,C0206750,improve ,activation of coagulation,Coronavirus Infections,2,X,[phsf],[dsyn],,C02.782.600.550.200
c6e69a5a-0103-4789-9fbc-7f047bff8057,C1511790,C0038056,is in ,Detection,Sputum,1,X,[topp],[bdsu],,A12.200.808
2117337f-26e9-4d1b-9f99-0024e772073b,C0206750,C1608239,was found in ,Coronavirus Infections,Specimen Type - Bile fluid,2,X,[dsyn],[bdsu],C02.782.600.550.200,
84b56c17-9340-4eea-abf0-c3013ea44383,C0206750,RTPCR,was In case report found in RTPCR,Coronavirus Infections,RTPCR,1,X,[dsyn],????,C02.782.600.550.200,????
84b56c17-9340-4eea-abf0-c3013ea44383,C0206750,RTPCR,was found by realtime RTPCR,Coronavirus Infections,RTPCR,1,X,[dsyn],????,C02.782.600.550.200,????
172afd04-cce9-44d4-a2a5-699500152b8d,C0086312,C1705178,predict compound growth rate after SIP ,Forests,Order (action),2,X,[npop],[acty],G16.500.275.157.437;N06.230.124.343,
ddd93f28-8ae0-44b0-9cc0-7d7b9c6e260b,C0948245,C3714514,is systemic inflammatory response can triggered by,Cytokine Release Syndrome,Infection,2,X,[dsyn],[patf],,C01.539
5f9e1049-08cc-4139-82d5-6fcf54abe55b,C0948245,C1155266,is systemic ,Cytokine Release Syndrome,inflammatory response,4,X,[dsyn],[patf],,
531b94a6-7c39-495f-a73e-d219b8ae9b1c,C0948245,C0206750,is in patients with ,Cytokine Release Syndrome,Coronavirus Infections,6,X,[dsyn],[dsyn],,C02.782.600.550.200
eb56813e-0e3a-4d8c-a00a-7afda0c5f607,C0948245,C0012634,is in patients with ,Cytokine Release Syndrome,Disease,2,X,[dsyn],[dsyn],,C23.550.288
b152976c-a060-493e-8346-8e65e06d3d53,C1155266,C0206750,can can triggered by ,inflammatory response,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
b152976c-a060-493e-8346-8e65e06d3d53,C1155266,C0206750,are hallmarks of severe ,inflammatory response,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
b152976c-a060-493e-8346-8e65e06d3d53,C1155266,C0206750,has direct ,inflammatory response,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
993bf939-9b12-4182-aba1-bcbeb319f783,C1155266,C0948245,can can triggered by ,inflammatory response,Cytokine Release Syndrome,2,X,[patf],[dsyn],,
d7a4437a-6010-4b74-95d1-7af093ce3264,C0206277,C0032962,is in ,Fatal Outcome,Pregnancy Complications,1,X,[patf],[patf],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,C13.703
c07984f1-59e7-4ed7-9e08-ea3e7e2c7864,C1817959,C0035222,will reduce frequency of ,tolerance induction,Respiratory Distress Syndrome Adult,1,X,[biof],[dsyn],,C08.381.840;C08.618.840
ae85f9fc-6770-4673-9c44-154bbd3a4de9,C0389003,C0041755,is known as ideal target for next generation without ,cyclooxygenase 1,Adverse reaction to drug,2,X,[aapp/enzy],[patf],D08.811.600.720.500,C25.100
59667f21-3bcd-4be2-8799-e6af4cf098c9,C1412677,C0041755,is known as ideal target for next generation without ,ATP6V1E1 gene,Adverse reaction to drug,1,X,[gngm],[patf],,C25.100
223819be-82b8-4713-bfae-1f1fd52ac407,C1506770,C1424489,using DREAM in ,lapatinib,BCAP31 gene,1,X,[orch/phsu],[gngm],D03.633.100.786.516,
0d33b988-018d-4d03-9820-846846d16365,C1506770,C0033555,has has identified as ,lapatinib,Prostaglandins A,2,X,[orch/phsu],[orch/phsu],D03.633.100.786.516,D10.251.355.255.550.100;D23.469.050.175.725.100
aaa39ec4-e81e-4685-aa96-4bc95220f42d,C1424489,C1718097,repurpose New medications for various,BCAP31 gene,New medications,1,X,[gngm],[phsu],,
aaa39ec4-e81e-4685-aa96-4bc95220f42d,C1424489,C1718097,repurpose FDA-approved ,BCAP31 gene,New medications,1,X,[gngm],[phsu],,
d9f3d729-9ce0-4c30-ab55-0b54664a4f7d,C1424489,C0087111,repurpose New medications for various,BCAP31 gene,Therapeutic procedure,1,X,[gngm],[topp],,E02
e622de1f-00d8-4727-902f-05fd6fadd5a1,C0036974,COVID-19,is known as ,Shock,COVID-19,2,X,[patf],[virs],C23.550.835,C000657245
f352870c-4e2d-4695-b895-9838a2a81537,C3714634,C0242781,underpin ,Biological Processes,disease transmission,2,X,[biof],[patf],G16,N06.850.310
1b14f665-0d51-4721-a70c-9359a8c597a3,C3714634,C0012634,underpin population-level dynamics of ,Biological Processes,Disease,2,X,[biof],[dsyn],G16,C23.550.288
836fab54-7094-49f9-a792-c67c3bdf6622,C0031843,C0014442,makes ,physiological aspects,Enzymes,3,X,[phsf],[aapp/enzy],x.x.x.x,D08.811
881351d9-dbe7-4a7b-adc9-b1a2c85e7e4b,C0031843,C0243077,makes ,physiological aspects,inhibitors,2,X,[phsf],[chvf],x.x.x.x,
9b3928df-5e6e-4f5a-bc87-a1f8b369bed9,C0031843,C0087111,makes ,physiological aspects,Therapeutic procedure,3,X,[phsf],[topp],x.x.x.x,E02
8be36b77-f01e-4f51-bb15-f1caa741422c,C0014442,C0243077,promising target for ,Enzymes,inhibitors,3,X,[aapp/enzy],[chvf],D08.811,
7fb0b07c-4d28-4959-8ddc-d9dc8c061030,C0014442,C0087111,promising target to ,Enzymes,Therapeutic procedure,3,X,[aapp/enzy],[topp],D08.811,E02
38168dd2-2751-46cb-8a8e-45eee26fd2cb,C0014442,C0206750,promising target to ,Enzymes,Coronavirus Infections,3,X,[aapp/enzy],[dsyn],D08.811,C02.782.600.550.200
9f31b244-cd98-4af3-996a-1d521e73ec67,C0031843,C0042774,is in ,physiological aspects,Virus Replication,3,X,[phsf],[celf],x.x.x.x,G06.920.925
9258dd6e-1724-4e16-bc6c-94907d6fa2bc,C1510827,C1175743,is in ,Affinity,SARS coronavirus,3,X,[npop],[virs],,B04.820.504.540.150.113.937
8cb577e7-51cd-4719-b5c3-f46d22515189,C0319157,C0008139,is related to SL ,AS virus,Chiroptera,2,X,[virs],[mamm],,B01.050.150.900.649.313.937
82ae14b1-4ec3-4d4d-9c73-34fac153f4bb,C0319157,SL,is related to SL ,AS virus,SL,2,X,[virs],????,,????
3ec1b9db-8344-40b3-993f-b062c9046be5,C0030858,C0013227,shows Binding (Molecular Function) Affinity among,Pentaerythritol Tetranitrate,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],D02.033.455.706.690,D26
40a94690-eb4d-4e2d-b68c-ccc9b9a89413,C0030858,C1167622,shows good ,Pentaerythritol Tetranitrate,Binding (Molecular Function),3,X,[orch/phsu],[moft],D02.033.455.706.690,
b2b823b5-d244-407b-9b23-7662bab11921,C0030858,C1510827,shows good ,Pentaerythritol Tetranitrate,Affinity,3,X,[orch/phsu],[npop],D02.033.455.706.690,
f5568eed-d75d-414d-a7d0-7b5ca41bee4c,C0013227,C1510827,shows good ,Pharmaceutical Preparations,Affinity,3,X,[phsu],[npop],D26,
f5568eed-d75d-414d-a7d0-7b5ca41bee4c,C0013227,C1510827,evaluate ,Pharmaceutical Preparations,Affinity,1,X,[phsu],[npop],D26,
fd1589a7-9c02-49e6-99cb-a827631263ed,C1167622,C1433062,is with ,Binding (Molecular Function),3C-like protease SARS coronavirus,6,X,[moft],[aapp/enzy],,x.x.x.x
45de2e6f-3e26-4b98-a133-c9ef3fb3786b,C1175743,C0021368,leads to ,SARS coronavirus,Inflammation,1,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.470
e3ad6621-5ade-4bbe-8ed1-92a724644639,C0085405,C0032143,is with ,Salvage Therapy,alteplase,1,X,[topp],[aapp/enzy/phsu],E02.895,D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970
1965ff25-7fa8-42f3-97e2-6117f063d7e0,C2370955,C0089147,using ,Smell function,butyl alcohol,1,X,[phsf],[orch],,D02.033.415.110.175;D10.289.110.175
80d9b30c-2a09-4442-a618-c8eebe23e46a,C0003342,COVID-19,contribute to ,Antigens Viral,COVID-19,1,X,[imft],[virs],D23.050.327,C000657245
6bafca73-12ad-407d-9a60-fac900fb4287,C0450254,C0020517,established ,Pathogenic organism,Hypersensitivity,2,X,[orgm],[patf],,C20.543
4ab535db-cb20-4fb2-a8d2-858b255c37ee,C0450254,C0206415,screened ,Pathogenic organism,Oligonucleotide Primers,2,X,[orgm],[nnon],,D13.695.578.424.450.275;D27.720.470.530.600.223.600
9a0050fc-2193-485f-ba51-0acafe4e9597,LOD,C1175743,Using two fold diluted ,LOD,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
9a0050fc-2193-485f-ba51-0acafe4e9597,LOD,C1175743,reported in RealTime ,LOD,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
49f513e3-857d-4fec-beea-556773864a71,C0017337,C1511790,be used for rapid ,Genes,Detection,2,X,[gngm],[topp],G05.360.340.024.340,
49f513e3-857d-4fec-beea-556773864a71,C0017337,C1511790,could With advantage of CoV2 ,Genes,Detection,2,X,[gngm],[topp],G05.360.340.024.340,
6e4565f2-b1d7-439b-b48c-c38a67da7d1d,C0017337,C1175743,be used for rapid ,Genes,SARS coronavirus,2,X,[gngm],[virs],G05.360.340.024.340,B04.820.504.540.150.113.937
6e4565f2-b1d7-439b-b48c-c38a67da7d1d,C0017337,C1175743,could With advantage of CoV2 ,Genes,SARS coronavirus,2,X,[gngm],[virs],G05.360.340.024.340,B04.820.504.540.150.113.937
eabd2de9-312d-417c-b4d1-6c6bfa96e81d,C0017337,CoV2,could With advantage of CoV2 ,Genes,CoV2,2,X,[gngm],????,G05.360.340.024.340,????
a0f3eca7-907e-4d0c-aefb-129d6b10b652,C0812928,COVID-19,uniquely exposes providers to ,Oral and maxillofacial surgery (qualifier value),COVID-19,1,X,[topp],[virs],,C000657245
49898777-beb8-4bf6-a4c5-7a7fc63db8a4,C0035452,COVID-19,received ,Rheumatology specialty,COVID-19,1,X,[bmod],[virs],H02.403.429.730,C000657245
aa68d276-09ff-47a8-8c15-785f53851cff,C0007430,C0543467,maintain their ,Catheterization,Operative Surgical Procedures,1,X,[topp],[topp],E02.148;E05.157,E04
0b05a41c-f32e-4f3f-9329-d80f673ce254,C1829939,C0679225,showed frequently several ,{Non-patient},multiple pathologies,4,X,[clna],[dsyn],,
7cf2f505-072c-4f6e-9834-1de03a90735a,C1829939,C0020538,showed frequently several ,{Non-patient},Hypertensive disease,2,X,[clna],[dsyn],,C14.907.489
5f33db8f-45a9-4139-90c2-bf9ec52fcbf0,C0679225,C0020538,is with ,multiple pathologies,Hypertensive disease,2,X,[dsyn],[dsyn],,C14.907.489
65096b07-2c99-420a-97d9-d15d90df9853,C0020538,C0679225,was most common ,Hypertensive disease,multiple pathologies,1,X,[dsyn],[dsyn],C14.907.489,
a9b0d6b9-38d9-4cff-a220-4062a8dd04c7,C3887642,C0319157,is with evidence of ,Hippocampus Proper,AS virus,2,X,[bpoc],[virs],A08.186.211.180.405;A08.186.211.200.885.287.500.345,
9e577d9f-063e-45d0-9029-727e58775188,C0039082,C0302189,have have described in context of ,Syndrome,Cell Therapy,1,X,[dsyn],[topp],C23.550.288.500,E02.095.147
b3c50990-8914-4e90-abad-c52e32b6d083,C1619738,C0206750,have disease characteristic in common with,Immune Reconstitution Inflammatory Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C20.608,C02.782.600.550.200
09c23406-0b6f-4c6f-ac3c-8a1c72baf8b3,C4054044,C0206750,have disease characteristic in common with,Secondary Hemophagocytic Lymphohistiocytosis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
8ce0dc5c-0940-4144-aecc-9593e5dd96c1,C0948245,C0599878,have clinical ,Cytokine Release Syndrome,disease characteristic,2,X,[dsyn],[patf],,
57c57acc-d2b9-4730-99eb-ec72ebf7b695,C1619738,C0599878,have clinical ,Immune Reconstitution Inflammatory Syndrome,disease characteristic,2,X,[dsyn],[patf],C20.608,
abdcf20f-dcbb-42c0-bf7e-edabbbe9ff5b,C4054044,C0599878,have clinical ,Secondary Hemophagocytic Lymphohistiocytosis,disease characteristic,2,X,[dsyn],[patf],,
b39a7bca-1682-4bc7-a656-1b2792d121a6,C0086418,C1856053,China until ,Homo sapiens,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,x.x.x.x
b39a7bca-1682-4bc7-a656-1b2792d121a6,C0086418,C1856053,was diagnosed with ,Homo sapiens,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,x.x.x.x
b2e60f29-c177-4bf3-b784-6ff22a8ed498,C0206750,C0439056,was positive for ,Coronavirus Infections,Throat swab sample,1,X,[dsyn],[bdsu],C02.782.600.550.200,
126587e3-1e02-479f-a090-1fb675450a3e,C3687832,C0087111,have have tested as new ,Drugs - dental services,Therapeutic procedure,1,X,[topp],[topp],,E02
91aab90c-11cd-42dd-b2a5-b42e21dcf3af,C3687832,C0030664,already used in clinical setting for ,Drugs - dental services,Pathology,1,X,[topp],[bmod],,H02.403.650
742ad3f9-1a7d-431a-a9a2-679721c67900,C0019682,C1175743,tested positive for ,HIV,SARS coronavirus,2,X,[virs],[virs],B04.820.650.589.650.350,B04.820.504.540.150.113.937
db744f4c-afbd-4696-b86a-0549b3dc9a8b,C0019682,C0444192,tested positive for ,HIV,Nasopharyngeal swab (specimen),2,X,[virs],[bdsu],B04.820.650.589.650.350,
f9dfa190-9a21-446f-8e6f-7f3440b953ad,C0235029,C0206750,is in patients with ,neurological complication,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
0a4cf844-3642-454f-9525-129d2a062ee5,C0497552,C0206750,is in ,Congenital neurologic anomalies,Coronavirus Infections,1,X,[cgab],[dsyn],C10.500;C16.131.666,C02.782.600.550.200
789f897c-8eaa-4bcc-a698-22d80f35dde4,C0206750,C0011570, includes ,Coronavirus Infections,Mental Depression,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.145.126.350
12d34b7c-632c-4ef5-bbe8-21250882b8fd,C0030567,C0206750,long-term sequalae of ,Parkinson Disease,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,C02.782.600.550.200
2be35c07-c249-4c39-8375-efaab6d427d4,C0002395,C0206750,long-term sequalae of ,Alzheimer's Disease,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,C02.782.600.550.200
373ccf80-1930-4845-b3b9-f050754284f1,C0815107,C0206750,people with ,psychological distress,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
84507adb-fd56-47fa-a544-9dd125e4d8fd,C0683587,COVID-19,are ,tourism,COVID-19,1,X,[dora],[virs],,C000657245
7007dfae-80ae-40c1-83e2-d73246efbebd,C0683587,C0025874,are worldwide research gap ,tourism,Metrorrhagia,3,X,[dora],[patf],,C13.351.500.852.691.622;C23.550.414.993.700
eb2ee336-0a74-4a9d-9124-9ff5cf2e782f,C0008151,C0035243,importantly reduce healthcare worker exposure to ,Chlamydia trachomatis,Respiratory Tract Infections,1,X,[bact],[dsyn],B03.440.190.190.190.750,C01.539.739;C08.730
4d77c38f-ac85-4a4e-9197-20126d30dbfb,C1175175,C0598197,is highly ,Severe Acute Respiratory Syndrome,contagion,1,X,[dsyn],[npop],C02.782.600.550.200.750;C08.730.730,
490bbe92-1126-4012-8c9d-206abc58c99c,C1999230,C1424721,structured information on prevention in ,Providing (action),FAIM2 gene,1,X,[acty],[gngm],,
61cfa60a-d44c-407f-8f74-fb35ec5fdd7e,C0009450,C0015967,mainly presents as ,Communicable Diseases,Fever,2,X,[dsyn],[sosy],C01.539.221,C23.888.119.344
7b90c14d-5e41-4f41-9e4d-9689d80c6353,C0009450,C0013404,mainly presents as ,Communicable Diseases,Dyspnea,2,X,[dsyn],[sosy],C01.539.221,C08.618.326;C23.888.852.371
c1401aab-1d79-4cef-97e6-075f166edff9,AKI,COVID-19,is in ,AKI,COVID-19,3,X,????,[virs],????,C000657245
3b9f8732-ff0b-4e04-be95-6664d022ebd2,AKI,C0009450,is in ,AKI,Communicable Diseases,2,X,????,[dsyn],????,C01.539.221
45810d7e-4815-48ff-ad6a-7a1cf47bba2b,C3649547,C0005768,is most used ,Continuous renal replacement therapy,In Blood,2,X,[topp],[bdsu],,x.x.x.x.x
3f355a40-1640-4f60-8445-46fc65601b4f,COVID-19,C0870392,is under In addition still ,COVID-19,debate,2,X,[virs],[acty],C000657245,
66facc18-7f79-4d2a-a707-f40d8e8f21d1,C0024501,C0870392,is under In addition ,Maintenance,debate,2,X,[acty],[acty],N02.628,
b875174c-dbf6-4322-b6a0-89823edf6ec3,C0021079,C0870392,is under In addition ,Therapeutic immunosuppression,debate,1,X,[topp],[acty],E02.095.465.425.450;E05.478.610,
a99903d6-e9ba-4977-91d0-5bdc206bde53,C1175175,C0022646,is in ,Severe Acute Respiratory Syndrome,Kidney,2,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A05.810.453
85c54e09-39ec-486d-9dfa-4c09ec0b8ab6,C1175175,C0206277,is in ,Severe Acute Respiratory Syndrome,Fatal Outcome,2,X,[dsyn],[patf],C02.782.600.550.200.750;C08.730.730,E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325
dbdd28ee-9a5a-4bf6-90ae-8935abf28e52,PCR,C0206750,analyzing DNA during especially now,PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
dbdd28ee-9a5a-4bf6-90ae-8935abf28e52,PCR,C0206750,development of positive ,PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
dbdd28ee-9a5a-4bf6-90ae-8935abf28e52,PCR,C0206750,detect new ,PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
7a7cc711-1a05-4c45-bc1a-cd94e0cb6d90,PCR,C0012854,analyzing ,PCR,DNA,1,X,????,[bacs/nnon],????,D13.444.308
1a44b807-f17e-485c-b6e4-423c9b73495e,C0042720,C0065827,contains distinctive features including fragment within spike ,Viral Genome,Measles Virus Nucleoprotein,1,X,[gngm],[aapp/bacs],G05.360.340.358.840,x.x.x.x
7a91fe6a-163f-42e7-b68a-a99aea33d5a3,C0065827,C0206750,allows ,Measles Virus Nucleoprotein,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
7a91fe6a-163f-42e7-b68a-a99aea33d5a3,C0065827,C0206750,is important Antigens for,Measles Virus Nucleoprotein,Coronavirus Infections,2,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
23b58a72-d3fb-445b-900a-7e982269b568,C0065827,C1947904,allows ,Measles Virus Nucleoprotein,Attachment (action),1,X,[aapp/bacs],[acty],x.x.x.x,
d44e953c-ba11-438c-8a4a-02d7efe27cf9,C0206750,C3536832,might might ongoing during summer ,Coronavirus Infections,Air,1,X,[dsyn],[inch/phsu],C02.782.600.550.200,G16.500.275.063.150;N06.230.300.100.150
0ed22f54-a34a-457d-818c-5d49635eb5c2,COVID-19,C0009079,suggest continuing with ,COVID-19,Clozapine,2,X,[virs],[orch/phsu],C000657245,D03.633.300.240.220
40abc20a-8c5a-4441-bcef-93f4160a7a0d,C0035243,C0009079,recommend use in ,Respiratory Tract Infections,Clozapine,1,X,[dsyn],[orch/phsu],C01.539.739;C08.730,D03.633.300.240.220
db1e7ce2-0311-4489-91aa-dc37cea3b374,C0543467,C0751429,collected during different ,Operative Surgical Procedures,Surgical Procedures Laparoscopic,1,X,[topp],[topp],E04,E01.370.388.250.520;E04.502.250.520
636ca239-d07f-491d-913f-aa485cc4a0f4,C0037366,C0751429,collected during different ,Smoke,Surgical Procedures Laparoscopic,1,X,[hops],[topp],D20.633.937,E01.370.388.250.520;E04.502.250.520
f2873c56-a0ec-46c5-8a7d-5c4daaee8880,C0019169,C0042776,was identified About other ,Hepatitis B Virus,Virus,2,X,[virs],[virs],B04.280.375.650.425;B04.450.390.650.425,B04
38ebcf5a-0063-4851-bb57-5e59cf040a24,C0019169,C0543467,was identified in ,Hepatitis B Virus,Operative Surgical Procedures,2,X,[virs],[topp],B04.280.375.650.425;B04.450.390.650.425,E04
61f3ad7b-a95c-409d-a1a2-7af7221387dc,C0019169,C0037366,was identified in ,Hepatitis B Virus,Smoke,2,X,[virs],[hops],B04.280.375.650.425;B04.450.390.650.425,D20.633.937
5443c54d-75c5-44ba-bf7b-d951c2cb4f45,C0019169,C0751429,was identified in ,Hepatitis B Virus,Surgical Procedures Laparoscopic,2,X,[virs],[topp],B04.280.375.650.425;B04.450.390.650.425,E01.370.388.250.520;E04.502.250.520
683b0624-e7e4-4d4f-8947-527ef41197a7,C0343641,C0543467,is in ,Human papilloma virus infection,Operative Surgical Procedures,1,X,[dsyn],[topp],C02.256.650;C02.928.725,E04
8a23c2b8-1328-4cbb-9195-132ba2b70e8e,C0021344,C0242781,have high risk of ,Human Papillomavirus,disease transmission,1,X,[virs],[patf],,N06.850.310
255a2b60-239f-4801-80a1-74949cf02c62,C0298067,C1254351,is recognized as antifibrotic ,pirfenidone,Pharmacologic Substance,2,X,[orch/phsu],[phsu],x.x.x.x,
d1357e76-68d1-4c53-8235-298d06ab2ee1,C0298067,C1800706,is recognized as antifibrotic ,pirfenidone,Idiopathic Pulmonary Fibrosis,2,X,[orch/phsu],[dsyn],x.x.x.x,C08.381.483.487.500;C08.381.765.500
384e853a-50ef-49b2-aea7-37d3db806fd1,C0298067,C0206750,has Recently has launched for treatment of ,pirfenidone,Coronavirus Infections,2,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
6da7405c-235e-46b3-a764-ee1bcd8c9aa5,C0298067,C0012634,has Recently has launched for treatment of ,pirfenidone,Disease,2,X,[orch/phsu],[dsyn],x.x.x.x,C23.550.288
3d9f6ad8-740b-4162-b72e-c1e68cd2d22e,C0011570,C0665820,is in amplitude of ,Mental Depression,DMBT1 protein human,2,X,[mobd],[aapp/bacs],F01.145.126.350,x.x.x.x
a30d2101-7794-46fd-afe2-b1d810f2968f,C0298067,C0162585,perturbing specific ,pirfenidone,Ion Transport,2,X,[orch/phsu],[celf],x.x.x.x,G03.143.500
d1ffa12e-6cf0-4ad8-a820-1c55c95bc48f,COVID-19,C2745965,is world health ,COVID-19,Emergencies [Disease/Finding],2,X,[virs],[patf],C000657245,C23.550.291.781;N06.230.100.083;N06.850.376
d1ffa12e-6cf0-4ad8-a820-1c55c95bc48f,COVID-19,C2745965,has demonstrated ,COVID-19,Emergencies [Disease/Finding],1,X,[virs],[patf],C000657245,C23.550.291.781;N06.230.100.083;N06.850.376
d1ffa12e-6cf0-4ad8-a820-1c55c95bc48f,COVID-19,C2745965,IMPACT gene of large-scale health,COVID-19,Emergencies [Disease/Finding],1,X,[virs],[patf],C000657245,C23.550.291.781;N06.230.100.083;N06.850.376
8d2a8de1-bd1d-4c2f-8298-7a8db1dbb0da,C0036421,C1947933,need ,Systemic Scleroderma,care activity,3,X,[dsyn],[acty],C17.300.799;C17.800.784,
d5f6d9a2-01ef-4e4c-8666-7876a8aaf9a7,COVID-19,C0024115,might complicate ,COVID-19,Lung diseases,6,X,[virs],[dsyn],C000657245,C08.381
ad8229c3-a319-4ec2-beda-523e6071ae51,C0009450,C0024115,might complicate ,Communicable Diseases,Lung diseases,6,X,[dsyn],[dsyn],C01.539.221,C08.381
13351460-b033-4e80-ac84-039426b78c09,COVID-19,C0036421,might complicate Lung diseases scenario Lung diseases Lung diseases in,COVID-19,Systemic Scleroderma,2,X,[virs],[dsyn],C000657245,C17.300.799;C17.800.784
8df8acb2-8c1c-455a-9e3d-62af065e512a,C0009450,C0036421,might complicate Lung diseases scenario Lung diseases Lung diseases in,Communicable Diseases,Systemic Scleroderma,2,X,[dsyn],[dsyn],C01.539.221,C17.300.799;C17.800.784
f01a9a81-3085-4caf-8bf0-d6c57f4a3639,COVID-19,C1705178,is in ,COVID-19,Order (action),2,X,[virs],[acty],C000657245,
e8d2c75f-f032-4ede-87cb-420610c7a8df,C0009450,C1705178,is in ,Communicable Diseases,Order (action),2,X,[dsyn],[acty],C01.539.221,
47818f66-3936-4d24-8509-a92a22c1ca6e,COVID-19,C0206062,distinguish from ,COVID-19,Lung Diseases Interstitial,2,X,[virs],[dsyn],C000657245,C08.381.483
c3625f7f-c577-474c-99aa-995f821075cc,C1550661,C1628999,became for ,Specimen Type - Stool = Fecal,SARS coronavirus RNA,1,X,[bdsu],[nnon],,
4e89ccee-a354-4393-9d34-e2547a9827aa,C0370003,C0035668,remained positive for ,Specimen,RNA,1,X,[sbst],[nnon],,D13.444.735
8e2b56a6-8a89-4249-86c3-47918e28295a,C2948600,C1516635,evaluate ,Aim,Clinical Treatment,4,X,[inch/phsu],[topp],,
50b21a1a-c3ce-449b-bf23-6f42004f69ed,C2948600,ACEI,evaluate Clinical Treatment implications with ACEI,Aim,ACEI,1,X,[inch/phsu],????,,????
68cd9937-47d8-4368-9853-e79accbc745e,C2948600,C3888198,evaluate Clinical Treatment implications with ACEI,Aim,BESTROPHINOPATHY AUTOSOMAL RECESSIVE,1,X,[inch/phsu],[dsyn],,
607d3d04-b5e2-4bcb-bfc8-3ef4a0b428fd,C0007430,C1707455,was ,Catheterization,Comparison,1,X,[topp],[acty],E02.148;E05.157,
7bff9b10-28e9-4cf8-83dc-d7f75ff20185,C0007430,C0206750,was ,Catheterization,Coronavirus Infections,1,X,[topp],[dsyn],E02.148;E05.157,C02.782.600.550.200
efe77dd5-d33c-43ef-901f-331e8ba248d6,C4553629,y144,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,y144,1,X,[topp],????,,????
857e473b-c17a-4882-a71f-409b6bce95d7,C0026780,C0282682,provide broad ,Mumps,Antibodies Blocking,4,X,[dsyn],[aapp/imft/irda],C02.782.580.600.680.500;C07.465.815.470.800.630,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
c9c893ab-90e9-4e61-a4a4-77c5e42e32eb,C0026780,C0012634,provide broad ,Mumps,Disease,2,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C23.550.288
c9c893ab-90e9-4e61-a4a4-77c5e42e32eb,C0026780,C0012634,broad Antibodies Blocking against numbers of,Mumps,Disease,1,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C23.550.288
d167f542-bebb-40c6-9176-73f95dabc646,C0026780,C0206750,provide broad ,Mumps,Coronavirus Infections,2,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C02.782.600.550.200
d167f542-bebb-40c6-9176-73f95dabc646,C0026780,C0206750,broad Antibodies Blocking against numbers of,Mumps,Coronavirus Infections,1,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C02.782.600.550.200
e7900174-91b0-447f-890e-f48ec25a599c,C0025007,C0282682,provide broad ,Measles,Antibodies Blocking,4,X,[dsyn],[aapp/imft/irda],C02.782.580.600.500.500,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
b018a09a-da3a-4a65-ab7b-68c8cc49276d,C0025007,C0012634,provide broad ,Measles,Disease,2,X,[dsyn],[dsyn],C02.782.580.600.500.500,C23.550.288
b018a09a-da3a-4a65-ab7b-68c8cc49276d,C0025007,C0012634,broad Antibodies Blocking against numbers of,Measles,Disease,1,X,[dsyn],[dsyn],C02.782.580.600.500.500,C23.550.288
aa09b2e6-05f4-43b9-92b6-340bfa002551,C0025007,C0206750,provide broad ,Measles,Coronavirus Infections,2,X,[dsyn],[dsyn],C02.782.580.600.500.500,C02.782.600.550.200
aa09b2e6-05f4-43b9-92b6-340bfa002551,C0025007,C0206750,broad Antibodies Blocking against numbers of,Measles,Coronavirus Infections,1,X,[dsyn],[dsyn],C02.782.580.600.500.500,C02.782.600.550.200
5816fcef-d894-4d10-ad75-9cda1227fc36,C0035923,C0012634,broad Antibodies Blocking against numbers of,Rubella virus vaccine,Disease,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C23.550.288
5816fcef-d894-4d10-ad75-9cda1227fc36,C0035923,C0012634,provide broad ,Rubella virus vaccine,Disease,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C23.550.288
622fd4b7-45d8-46f4-86bd-1e7171083d27,C0035923,C0206750,broad Antibodies Blocking against numbers of,Rubella virus vaccine,Coronavirus Infections,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C02.782.600.550.200
622fd4b7-45d8-46f4-86bd-1e7171083d27,C0035923,C0206750,provide broad ,Rubella virus vaccine,Coronavirus Infections,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C02.782.600.550.200
b388eb20-439a-4d1f-bbae-a1880d0ccf22,C0035923,C0282682,provide broad ,Rubella virus vaccine,Antibodies Blocking,8,X,[aapp/imft/phsu],[aapp/imft/irda],D20.215.894.899.779,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
ab7e7402-6b7f-4e82-9b7c-84bb8bf5f769,C0003316,C0025007,is in ,Epitopes,Measles,2,X,[imft],[dsyn],D23.050.550,C02.782.580.600.500.500
d1b8ca3c-8336-4d95-8edd-184c75c1df49,humoral,C0206750,children with advantageous protection against ,humoral,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
aadfc83b-0289-4e25-89a5-db0493292b0d,C1175743,C0849867,cause ,SARS coronavirus,Widespread Disease,7,X,[virs],[dsyn],B04.820.504.540.150.113.937,
aadfc83b-0289-4e25-89a5-db0493292b0d,C1175743,C0849867,is responsible for unprecedented ,SARS coronavirus,Widespread Disease,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
f7204854-016e-444c-bb53-ce150fd76514,C0055673,C0042774,Enzymes for,Chymase,Virus Replication,4,X,[aapp/enzy],[celf],D08.811.277.656.300.760.103;D08.811.277.656.959.350.103,G06.920.925
2d967aa0-a024-425b-aed9-1c618d32d632,C0596391,C0038734,is with reactive Cys145,covalent bond,Sulfhydryl Compounds,4,X,[npop],[orch],,D02.886.489
7de50c87-9f09-4d57-85f9-cb8ad03a5df1,C0596391,Cys145,is with reactive Cys145,covalent bond,Cys145,4,X,[npop],????,,????
1cf33234-dee6-4b86-a535-67257c2784d2,C3864824,C0243077,were Moreover identified as potential ,paritaprevir,inhibitors,4,X,[orch/phsu],[chvf],,
8177f34b-d191-462f-b80a-b2cdb8f17165,C3864824,C1175743,were Moreover identified as potential ,paritaprevir,SARS coronavirus,4,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
2d3baf1c-e905-4b3a-a96a-91e4bf968c57,C0432626,C0087111,could Importantly could ready for trials to ,Blood group antibody c,Therapeutic procedure,6,X,[aapp/imft],[topp],,E02
5520af48-6870-4993-9cfc-0ec678d779ab,C0019159,C0087111,could Importantly could ready for trials to ,Hepatitis A,Therapeutic procedure,3,X,[dsyn],[topp],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,E02
986491b4-71b4-4537-8ff7-77a247df61b3,C0319157,C0087111,could Importantly could ready for trials to ,AS virus,Therapeutic procedure,3,X,[virs],[topp],,E02
f467ee62-55e4-43d7-be10-80cb96da1b36,C0206750,C0264219,is causative agent of ,Coronavirus Infections,Acute respiratory disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,
f467ee62-55e4-43d7-be10-80cb96da1b36,C0206750,C0264219,could In cases could complicated by ,Coronavirus Infections,Acute respiratory disease,3,X,[dsyn],[dsyn],C02.782.600.550.200,
68230ca3-177a-474b-887a-c12a965e3f76,RT-PCR,C2347609,using ,RT-PCR,Chemical Probe,2,X,????,[chvf],????,
ee6d8875-0279-438b-b7cf-96accfcf349b,RT-PCR,C0206415,using multiple ,RT-PCR,Oligonucleotide Primers,2,X,????,[nnon],????,D13.695.578.424.450.275;D27.720.470.530.600.223.600
ba0963a0-19d4-4c6e-ae87-434d801cbf1a,C1628999,SYBR,using low-cost SYBR ,SARS coronavirus RNA,SYBR,1,X,[nnon],????,,????
01512912-4c3c-4f6d-b272-a51b48053bf6,C1628999,C1511790,can can used for ,SARS coronavirus RNA,Detection,1,X,[nnon],[topp],,
51d353b0-e4fb-444b-bf68-9a6067600326,C1628999,C1764827,can can used for ,SARS coronavirus RNA,Isolate - microorganism,1,X,[nnon],[bacs],,
275ef395-8953-4d5d-92a3-cd3b1402a350,C0597404,C4284302,can cause Infection we have seen in,Respiratory viruses,EHD1 wt Allele,3,X,[virs],[gngm],,
86dcbb65-bae3-495f-9bd4-0166b8cd0fcc,C0597404,C3714514,can cause severe ,Respiratory viruses,Infection,3,X,[virs],[patf],,C01.539
25e09c96-c18b-4bd6-93e9-9155fc626a4d,C0597404,C0458827,can cause severe ,Respiratory viruses,Airway structure,3,X,[virs],[bpoc],,
80ffe00c-8708-4bca-acfa-3c476153f7b2,C0242781,C0234856,produced by ,disease transmission,Speaking (activity),9,X,[patf],[dora],N06.850.310,
18d931b1-dfc5-4954-bf6e-7b92ce172028,C0030106,C0242656,could of could help in control of ,Ozone,Disease Progression,3,X,[chem],[patf],D01.362.670.600;x.x.x.x,C23.550.291.656
0087e194-3f8d-4930-a586-dd8317c3093c,U.S.,remdesivir,has granted Emergency Use Authorization for ,U.S.,remdesivir,1,X,????,[clnd],????,
9c291fed-76a4-44cc-aed4-fd1164425e17,U.S.,C0087111,has granted Emergency Use Authorization for ,U.S.,Therapeutic procedure,1,X,????,[topp],????,E02
e9157684-e1b3-4fc7-940c-9a6b6673d3f0,U.S.,C0206750,has granted Emergency Use Authorization for ,U.S.,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
e9157684-e1b3-4fc7-940c-9a6b6673d3f0,U.S.,C0206750,onboard developed ,U.S.,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
c5c745b6-4239-4398-9002-7aa87c4ffef1,C0019134,C0003280,may Given complications may choice of ,heparin,Anticoagulants,1,X,[bacs/orch/phsu],[phsu],D09.698.373.400,D27.505.954.502.119
c5c745b6-4239-4398-9002-7aa87c4ffef1,C0019134,C0003280,may Given complications specific to ,heparin,Anticoagulants,1,X,[bacs/orch/phsu],[phsu],D09.698.373.400,D27.505.954.502.119
780ff500-e887-46d6-ba14-250bd2753b1e,C0003280,C0522794,is discussed as possible potentiate for ,Anticoagulants,Heparin therapy,2,X,[phsu],[topp],D27.505.954.502.119,
18eccd48-188a-4b74-96c5-1a624c691448,C0206750,C0021368,aggravates ,Coronavirus Infections,Inflammation,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.470
235747cd-34f8-4b39-8034-b630dca98358,C0206750,C0003130,aggravates ,Coronavirus Infections,Anoxia,2,X,[dsyn],[patf],C02.782.600.550.200,C23.888.852.079
235747cd-34f8-4b39-8034-b630dca98358,C0206750,C0003130,Affinity to,Coronavirus Infections,Anoxia,1,X,[dsyn],[patf],C02.782.600.550.200,C23.888.852.079
fd1f65f0-3150-4a13-bf82-608aa93e846b,C0028754,C0221423,can lead to severe ,Obesity,Illness (finding),2,X,[dsyn],[sosy],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
882bf738-36bc-440b-b169-c1e169707c88,C0021760,C0242656,play role in ,Interleukin-6,Disease Progression,2,X,[aapp/imft],[patf],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C23.550.291.656
882bf738-36bc-440b-b169-c1e169707c88,C0021760,C0242656,were associated with ,Interleukin-6,Disease Progression,1,X,[aapp/imft],[patf],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C23.550.291.656
d950d150-03f6-4ebc-a51f-5274c444248f,C0021760,C0206750,were elevated in patients with ,Interleukin-6,Coronavirus Infections,9,X,[aapp/imft],[dsyn],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C02.782.600.550.200
ba12881a-eb5b-47bf-b31d-3fc38b934bdf,C0079189,C0242656,play role in ,cytokine,Disease Progression,2,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.291.656
ba12881a-eb5b-47bf-b31d-3fc38b934bdf,C0079189,C0242656,is in female patients associated with worse ,cytokine,Disease Progression,3,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.291.656
e8c42fd0-d513-4e21-b827-c2d0a7d22fb0,C0028754,C0011849, includes ,Obesity,Diabetes Mellitus,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C18.452.394.750;C19.246
c128b8e5-bf19-472a-af94-669337bfe017,C1155266,C0028754,may predispose to complications of ,inflammatory response,Obesity,2,X,[patf],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
a17a7143-d3e7-4381-b921-586fe25a4c56,C1155266,C0011849,may predispose to complications of ,inflammatory response,Diabetes Mellitus,2,X,[patf],[dsyn],,C18.452.394.750;C19.246
b92a80a2-937b-4925-974a-55cfd6ba277e,C0026652,C0920467,has wealth in prevention of ,Moxibustion,disorder control (procedure),3,X,[topp],[topp],E02.190.044.588,
221d05a6-ffeb-4de1-973f-49b2a00a589d,C0394664,C0920467,has wealth in prevention of epidemic ,Acupuncture procedure,disorder control (procedure),3,X,[topp],[topp],E02.190.044,
78cea5e5-8b31-46f4-9dcc-34c76fa1dc7e,C0020164,C0185451,was During period third most common ,Bone structure of humerus,Osteoclasis,3,X,[bpoc],[topp],A02.835.232.087.090.400,
78cea5e5-8b31-46f4-9dcc-34c76fa1dc7e,C0020164,C0185451,was third most common Osteoclasis for,Bone structure of humerus,Osteoclasis,2,X,[bpoc],[topp],A02.835.232.087.090.400,
7e4f8819-ba51-4b3c-a2ca-3d161ecdf656,C0016641,C0185451,was During period third most common ,Fracture Fixation,Osteoclasis,3,X,[topp],[topp],E04.555.300,
7e4f8819-ba51-4b3c-a2ca-3d161ecdf656,C0016641,C0185451,was third most common Osteoclasis for,Fracture Fixation,Osteoclasis,2,X,[topp],[topp],E04.555.300,
4d3cb48b-dd88-4192-88b9-0301d23818f9,C0185023,C0185451,was During period third most common ,Fixation - action,Osteoclasis,3,X,[topp],[topp],,
4d3cb48b-dd88-4192-88b9-0301d23818f9,C0185023,C0185451,was third most common Osteoclasis for,Fixation - action,Osteoclasis,2,X,[topp],[topp],,
1c1f6719-d031-4dda-b566-2a8a6efb1e72,C0039194,C0301872,induce Immune response in,T-Lymphocyte,Immune response,2,X,[cell],[ortf],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,
1c1f6719-d031-4dda-b566-2a8a6efb1e72,C0039194,C0301872,induce protective ,T-Lymphocyte,Immune response,2,X,[cell],[ortf],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,
1c1f6719-d031-4dda-b566-2a8a6efb1e72,C0039194,C0301872,suggesting dysregulated ,T-Lymphocyte,Immune response,1,X,[cell],[ortf],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,
00817467-0504-4d96-9fa6-452daf626baa,C1167622,C0024518,is with ,Binding (Molecular Function),Major Histocompatibility Complex,2,X,[moft],[gngm],,G05.360.340.024.340.610;G05.360.340.024.380.500;G12.500.500
c544f403-2e87-4fdc-aa97-dc3e08bec59c,C0079600,C0003241,could enable generation of ,Immunodominant Epitopes,Antibodies,2,X,[imft],[aapp/imft/phsu],D23.050.550.500,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
743cb707-f38b-4a9c-af7a-cf53a1a4b19f,C1265876,15days,increase beyond 15days ,Abnormally opaque structure (morphologic abnormality),15days,4,X,[patf],????,,????
3726910c-4ec3-4b0a-a5ec-b1e12f188ade,C1265876,C0010340,increase beyond 15days ,Abnormally opaque structure (morphologic abnormality),Critical Illness,2,X,[patf],[dsyn],,C23.550.291.625
790e5a1a-ae04-459d-9a61-75033773b32b,15days,C0010340,is in severe ,15days,Critical Illness,1,X,????,[dsyn],????,C23.550.291.625
49fe7106-ebc0-4b18-8da8-0529b4111eb2,C1265876,C0231218,drop for moderately ,Abnormally opaque structure (morphologic abnormality),Malaise,2,X,[patf],[sosy],,
8a8e3cee-eb56-4fbe-a77b-00af84b5f309,C0015219,C0206750,varied with disease severity in ,Biological Evolution,Coronavirus Infections,1,X,[genf],[dsyn],G05.045;G16.075,C02.782.600.550.200
b78b87fb-8982-438b-b859-05c5a87ab79d,C0206750,C0440790,is in ,Coronavirus Infections,Solid organ,2,X,[dsyn],[bpoc],C02.782.600.550.200,
f37ac853-b747-4b12-997a-c24eb1146a3a,C1537065,C0440790,is in ,transplantation infection,Solid organ,2,X,[patf],[bpoc],,
7890c13b-1397-4599-a2a4-94b01e0524b1,C0206750,C1537065,is in ,Coronavirus Infections,transplantation infection,2,X,[dsyn],[patf],C02.782.600.550.200,
f6c76bb4-de5a-43dd-9813-b0526ec2573d,C1706374,RT-PCR,indicated nasopharyngeal swab RT-PCR ,Tumor Necrosis Factor Ligand Superfamily Member 13,RT-PCR,2,X,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,????
4500797e-98f0-4306-a8a4-b3c4d3394a94,C1706374,C0029355,indicated nasopharyngeal swab RT-PCR ,Tumor Necrosis Factor Ligand Superfamily Member 13,Orthopedics,2,X,[aapp/bacs],[bmod],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,H02.403.810.494
f806a449-2eda-4ff1-9e3f-27de466b3f47,C0086418,C0011991,is with ,Homo sapiens,Diarrhea,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.821.214
61c7a752-9b95-4471-bbc9-41a630b109bb,C0086418,C0018787,is with ,Homo sapiens,Heart,1,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A07.541
12b16e2f-3e71-44ea-ae46-89225e58be4a,C0206419,C0018787,Homo sapiens with,Genus: Coronavirus,Heart,1,X,[virs],[bpoc],B04.820.504.540.150,A07.541
12b16e2f-3e71-44ea-ae46-89225e58be4a,C0206419,C0018787, includes ,Genus: Coronavirus,Heart,2,X,[virs],[bpoc],B04.820.504.540.150,A07.541
bda377b9-43ee-41c3-aef5-9d6dfa9f0bc9,C2939465,C0026882,is common X-linked ,Deficiency of glucose-6-phosphate dehydrogenase,Mutation,4,X,[dsyn],[genf],C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402,G05.365.590
ac4ad2fb-4720-4071-b2c4-8fe857e6f691,C0206419,C0302110,may cause ,Genus: Coronavirus,Hemolytic crisis,1,X,[virs],[comd],B04.820.504.540.150,
4325a6ea-a2ca-4266-b9c4-cfc028c112e1,C0042769,C0302110,may cause ,Virus Diseases,Hemolytic crisis,2,X,[dsyn],[comd],C02,
a6de2dff-b9c6-4c4f-8f34-5d5da1745a64,C0206750,C0302110,may cause ,Coronavirus Infections,Hemolytic crisis,4,X,[dsyn],[comd],C02.782.600.550.200,
2cdc6922-0ea4-4b4d-b499-51467900dd26,C0206419,C2939465,may cause outcome in presence ,Genus: Coronavirus,Deficiency of glucose-6-phosphate dehydrogenase,1,X,[virs],[dsyn],B04.820.504.540.150,C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402
6485e049-dda0-4930-bb27-63676d238622,C0042769,C2939465,may cause outcome in presence ,Virus Diseases,Deficiency of glucose-6-phosphate dehydrogenase,2,X,[dsyn],[dsyn],C02,C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402
d8f013c6-b08c-4f9d-b353-e4fee50dde61,C0206750,C2939465,may cause outcome in presence ,Coronavirus Infections,Deficiency of glucose-6-phosphate dehydrogenase,4,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402
009be84c-7492-46a6-940f-d4332e1e7c83,C2939465,C0206419,is in ,Deficiency of glucose-6-phosphate dehydrogenase,Genus: Coronavirus,1,X,[dsyn],[virs],C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402,B04.820.504.540.150
132271aa-de9a-4fb3-af18-f1b902964601,C0013879,C0206419,is in ,Elements,Genus: Coronavirus,1,X,[elii],[virs],D01.268,B04.820.504.540.150
bdd8e656-78b9-43db-a7d6-cd4727fed207,C1707455,C0700308,is with decay rate of 0.65 logPFU ,Comparison,Protium,4,X,[acty],[elii],,
47c26cd0-6cbe-4f44-ae23-f8fd989c14f2,C0337007,C1707455,declined as ,High humidity,Comparison,2,X,[npop],[acty],,
25381e92-1a4b-4623-81f2-b72d7f2fe946,C0852312,C0206419,is in ,gender disorders,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
e754a788-fa1c-4b28-92a2-b8200371764e,C0185117,C0024109,is in ,Expression procedure,Lung,2,X,[topp],[bpoc],,A04.411
17c3c89a-e5ff-4b93-bb7e-84df6e0ecde6,C0748168,C0206419,is in ,Pulmonary Pathology,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
914c3813-fee9-4161-a6fd-78c084d566fc,PCR,C1175175,detect ,PCR,Severe Acute Respiratory Syndrome,2,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
1f226437-5957-4d74-926d-eb84563fe2e1,C0185117,C0242210,direct Binding Proteins of S,Expression procedure,Binding Proteins,1,X,[topp],[aapp/bacs],,D12.776.157
dae4c7c9-5465-4849-8caf-dc328b33d39d,C0009450,C0026766,leading to ,Communicable Diseases,Multiple Organ Failure,2,X,[dsyn],[patf],C01.539.221,C23.550.835.525
90dae631-30fc-45bf-935e-35cef22bc8d5,C0003018,C0206419,has attracted interest as potential regulator of ,Angiotensins,Genus: Coronavirus,1,X,[aapp/bacs/phsu],[virs],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,B04.820.504.540.150
d80ac5ac-e727-4c7f-87fd-eb02eb7e4a31,C0206419,C0740766,is acute viral ,Genus: Coronavirus,acute pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150,
f66734e5-50a7-4577-a0e0-cb76a23dfb62,C0743841,C0037090,is with ,Disorder characterized by fever,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],,C23.888.852
f613ac4f-613c-464b-90c3-6c28f84f8600,C0042776,C1707391,Outpatient management of ,Virus,Choose (action),1,X,[virs],[acty],B04,
32489fb9-f15d-447c-af07-003611ff1083,POC,C1175743,showed performance in detection of ,POC,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
c83158b1-553d-466b-af79-485658272531,C0206419,C0003242,exhibited earlier ,Genus: Coronavirus,Antibodies Anti-Idiotypic,1,X,[virs],[aapp/imft],B04.820.504.540.150,D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071
afaaa800-5277-4671-89bd-557814d9023a,C0243077,remdesivir, includes ,inhibitors,remdesivir,3,X,[chvf],[clnd],,
2ce4f13c-f4fa-4498-a7c0-14ed4d439770,C0597107,C0035685,have shown this despite understanding of viral nsp12 ,nucleotide analog,RNA-Directed RNA Polymerase,2,X,[nnon],[aapp/enzy],,D08.811.913.696.445.735.780
c43427d1-e513-4e98-9060-eb4a9e1a3556,C0243077,C0035685,have shown this despite understanding of viral nsp12 ,inhibitors,RNA-Directed RNA Polymerase,1,X,[chvf],[aapp/enzy],,D08.811.913.696.445.735.780
33e2828b-f439-486e-afd9-425000ab7e5a,C0597107,nsp12,have shown this despite understanding of viral nsp12 ,nucleotide analog,nsp12,2,X,[nnon],????,,????
439ef1c4-a706-45e3-901d-b61a7c4b4598,C0243077,nsp12,have shown this despite understanding of viral nsp12 ,inhibitors,nsp12,1,X,[chvf],????,,????
98c7cf56-0170-4e63-ac66-090da1ea45e9,C0597107,C0687133,have shown this despite understanding of viral nsp12 ,nucleotide analog,Drug Interactions,2,X,[nnon],[patf],,G07.690.773.968
2077773a-3a7b-4a84-a40d-87ddf7e42c59,C0243077,C0687133,have shown this despite understanding of viral nsp12 ,inhibitors,Drug Interactions,1,X,[chvf],[patf],,G07.690.773.968
3e66067e-51c1-44dc-806c-b2cb242a6caf,remdesivir,C0035685,have shown this despite understanding of viral nsp12 ,remdesivir,RNA-Directed RNA Polymerase,1,X,[clnd],[aapp/enzy],,D08.811.913.696.445.735.780
4b051264-064e-42a9-9155-4129b260e20c,remdesivir,nsp12,have shown this despite understanding of viral nsp12 ,remdesivir,nsp12,1,X,[clnd],????,,????
d9e101ae-92d4-429c-bf5d-731597820d01,remdesivir,C0687133,have shown this despite understanding of viral nsp12 ,remdesivir,Drug Interactions,1,X,[clnd],[patf],,G07.690.773.968
0dcf7326-a215-429a-8a4d-e7680282ac92,C1138226,C0035685,have shown this despite mechanistic understanding of viral nsp12 ,favipiravir,RNA-Directed RNA Polymerase,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,D08.811.913.696.445.735.780
b59b3097-603a-439d-9175-6eb975a667a9,C1138226,nsp12,have shown this despite mechanistic understanding of viral nsp12 ,favipiravir,nsp12,1,X,[orch/phsu],????,x.x.x.x,????
63654719-4328-4ccc-9495-75d44b6ca0b8,C1138226,C0687133,have shown this despite mechanistic understanding of viral nsp12 ,favipiravir,Drug Interactions,1,X,[orch/phsu],[patf],x.x.x.x,G07.690.773.968
2cbdc679-a900-4c12-8428-4f2f650ee9d2,C0597107,invitro,have shown promise in invitro ,nucleotide analog,invitro,2,X,[nnon],????,,????
ca52cadf-40e8-499b-9d73-da4bc4c9925a,C0243077,invitro,have shown promise in invitro ,inhibitors,invitro,1,X,[chvf],????,,????
e358d6c6-898d-4a96-b89d-ff597454df5f,remdesivir,invitro,have shown promise in invitro ,remdesivir,invitro,1,X,[clnd],????,,????
bdf0e98a-30fb-4d37-9fd1-67c8765479de,C1138226,C1516635,have shown ,favipiravir,Clinical Treatment,2,X,[orch/phsu],[topp],x.x.x.x,
3f11e492-940e-4556-a0ea-43da89465fd0,C1138226,C0206419,have shown ,favipiravir,Genus: Coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150
3f11e492-940e-4556-a0ea-43da89465fd0,C1138226,C0206419,has has experimentally used for ,favipiravir,Genus: Coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150
61c489a2-7f07-45c1-91a0-14f1ec9017ea,C0597107,C1516635,have shown ,nucleotide analog,Clinical Treatment,4,X,[nnon],[topp],,
c6f9635a-7cb4-4f2e-8513-8c1a72725f28,C0243077,C1516635,have shown ,inhibitors,Clinical Treatment,2,X,[chvf],[topp],,
d47de3d1-c061-47be-9776-4d93c2177723,C0597107,C0206419,have shown ,nucleotide analog,Genus: Coronavirus,2,X,[nnon],[virs],,B04.820.504.540.150
43bda827-6a9d-44fe-b0c8-70b4be3b19d0,remdesivir,C1516635,have shown ,remdesivir,Clinical Treatment,2,X,[clnd],[topp],,
2a21cef5-40af-434a-a72d-2f2252051712,C1138226,invitro,have shown promise in invitro ,favipiravir,invitro,1,X,[orch/phsu],????,x.x.x.x,????
58205cc2-8852-4ade-be72-e798fc574d1e,C1707455,apo,is with apo ,Comparison,apo,1,X,[acty],????,,????
3f4780cb-21f1-407f-b35e-ef6acb75eac8,C1707455,C1704241,is with apo ,Comparison,complex (molecular entity),1,X,[acty],[chvs],,
cc6cc0bd-2bb8-4a50-a150-20c2f824a7a4,C2700061,C0206419,provide clues for understanding of ,Transition (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
ea970e01-32dd-4cc4-842a-11c1e68229d2,C2700061,C0040649,provide clues for understanding of ,Transition (action),Transcription Genetic,1,X,[acty],[genf],,G02.111.873;G05.297.700
a00447e3-438f-4e59-8101-c587e9503d90,C0021760,C0206419,are elevated In ,Interleukin-6,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,B04.820.504.540.150
a00447e3-438f-4e59-8101-c587e9503d90,C0021760,C0206419,is in patients with ,Interleukin-6,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,B04.820.504.540.150
c52eb0a1-8d6e-4138-a520-85e0b8c23893,C1514562,C1175743,can can related to pathogenicity of ,Protein Domain,SARS coronavirus,1,X,[amas],[virs],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,B04.820.504.540.150.113.937
50dd7061-6c67-4975-b7fc-1cff23532880,C1175743,C1707391,were similar to target ,SARS coronavirus,Choose (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
9212ee0f-433e-4923-ba8a-70a6457a6bb5,C1101610,C0206419,may constitute potential therapeutic approaches in ,MicroRNAs,Genus: Coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150
30fcf8bf-b79f-4920-9e2f-cc003ade8839,C0037633,C0206419,literature on infection control practices in health care facilities against ,Solutions,Genus: Coronavirus,1,X,[sbst],[virs],D26.776,B04.820.504.540.150
c4cb96ef-7da1-4bbc-a861-dff41ccc1108,C0545747,C0206419,are at also risk of severe ,pulmonary artery and pulmonary artery,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
2174e00d-56f9-4596-8d09-0298d36c06f2,C0279328,C0206419,improve hypoxemia for ,Hyperbaric Oxygen (substance),Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
9067dfe6-1ca6-46b1-9ada-ed234fd79508,C0020431,C0206419,improve hypoxemia for ,Hyperbaric oxygenation therapy,Genus: Coronavirus,1,X,[topp],[virs],E02.880.690.490,B04.820.504.540.150
eb18e9d8-a53c-4503-9d61-6b326a1475db,C4086508,C1609165, includes ,IL6 Receptor Antibody,tocilizumab,6,X,[aapp/imft],[aapp/imft/phsu],,x.x.x.x
7d91b988-afed-4256-bde6-90c9f851ae61,C4086508,C3873497,play role in treatment of ,IL6 Receptor Antibody,Severe acute respiratory infection,3,X,[aapp/imft],[dsyn],,
b0a3e3dd-108a-44b6-8916-4003aa00417e,C4086508,C1175743,play role in treatment of ,IL6 Receptor Antibody,SARS coronavirus,3,X,[aapp/imft],[virs],,B04.820.504.540.150.113.937
6dc6af62-1329-418f-ab4d-2454e7a95c50,C0034386,C1160716,prevent onward viral transmission during,Quarantine,viral transmission,2,X,[topp],[celf],N06.850.780.200.450.700,
f186f715-fc8e-42d0-aabc-394118f8168c,C0206419,C2359945,raised questions in patients about use of ,Genus: Coronavirus,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[virs],[clna],B04.820.504.540.150,
891e2dd2-e1de-41fe-8e51-a0044dc165f8,C1511790,C0009359,evaluate differences between ,Detection,Gold Colloid,2,X,[topp],[inch/phsu],,D01.379.400
8bb53aed-3872-4d0f-9076-9e9e5bb3d5e7,C1706005,C0206419,is in patients with ,CD40LG wt Allele,Genus: Coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150
8bb53aed-3872-4d0f-9076-9e9e5bb3d5e7,C1706005,C0206419,were negative for ,CD40LG wt Allele,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
e7ab07d2-ce2f-46fd-95f7-5eb847cad75a,C1706005,C0012634,is in patients with ,CD40LG wt Allele,Disease,2,X,[gngm],[dsyn],,C23.550.288
bd2eeddb-3195-489d-9fac-ef87f4bdb335,C0162524,C2584300,showed positive rate ,Chemiluminescence,Climbing,2,X,[npop],[dora],G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665,
a15472fa-0baf-4ad7-90ce-6086450d9236,C0162524,C0009359,showed positive rate ,Chemiluminescence,Gold Colloid,2,X,[npop],[inch/phsu],G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665,D01.379.400
21d3e36b-52eb-43ad-9039-ae9405103e2c,C0162524,C2754943,showed rate Climbing For,Chemiluminescence,IgG antibody,1,X,[npop],[celc],G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665,
d25e82a7-d669-4a95-ac90-78e865b330be,C0009359,C0162524,is less Hypersensitivity than,Gold Colloid,Chemiluminescence,2,X,[inch/phsu],[npop],D01.379.400,G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665
e305d626-8751-4a95-8d2b-c65d727c05af,C0009359,C0020517,is generally less ,Gold Colloid,Hypersensitivity,2,X,[inch/phsu],[patf],D01.379.400,C20.543
55530b9b-3275-4ec2-ba6d-a9b7a9ffc50e,C0010200,C0040590,increases aerosol production via particularly ,Coughing,Tracheostomy procedure,1,X,[sosy],[topp],C08.618.248;C23.888.852.293,E02.041.750;E04.579.935;E04.580.900;E04.928.780
5f01f0d3-03e6-450b-8840-a5afe6f6b169,C1880355,C0042769,repurposing those already in use for other ,Discover,Virus Diseases,1,X,[acty],[dsyn],,C02
8c5b0957-edba-409c-ab99-f226ac92d414,C1175743,C0920283,over non is,SARS coronavirus,DNA Helicases,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.277.040.025.159;D08.811.399.340
e17f64fd-cc9e-406c-a9f8-07fcf0c90ed6,C0683949,C0022322,revealed broad range of antiviral effects of ,animal study,Ivermectin,2,X,[anim],[orch/phsu],,D02.540.576.500.997;x.x.x.x
272f2e0f-c919-4f1b-a02b-cf46e84b88ca,LTCF,C0206419,are why resilient to ,LTCF,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
1275d609-df26-453b-925e-8bdb0c9eb4bd,C1516048,C0012634,is important component of diagnosis of ,Assessed,Disease,3,X,[acty],[dsyn],,C23.550.288
ab0f1732-e912-4ac0-961c-f7b07d4a9417,C3714798,C0724441,using ,Cytochrome P-450 CYP3A4,yohimbine,1,X,[aapp/enzy],[orch/phsu],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D03.132.436.681.933;D03.633.100.473.402.681.933
032d4301-6fa4-4389-ac9e-10683a5c51a7,C3714798,C0014442,using yohimbine as,Cytochrome P-450 CYP3A4,Enzymes,1,X,[aapp/enzy],[aapp/enzy],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D08.811
032d4301-6fa4-4389-ac9e-10683a5c51a7,C3714798,C0014442,using Midazolam as,Cytochrome P-450 CYP3A4,Enzymes,1,X,[aapp/enzy],[aapp/enzy],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D08.811
52a66793-02f6-4d4f-8183-f68efd842391,C3714798,C1513396,using yohimbine as,Cytochrome P-450 CYP3A4,Molecular Marker Activity,1,X,[aapp/enzy],[phsf],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,
52a66793-02f6-4d4f-8183-f68efd842391,C3714798,C1513396,using Midazolam as,Cytochrome P-450 CYP3A4,Molecular Marker Activity,1,X,[aapp/enzy],[phsf],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,
a09a0d2c-d9ed-424a-8b0d-9fedf00f8f20,C3714798,C0026056,using ,Cytochrome P-450 CYP3A4,Midazolam,1,X,[aapp/enzy],[orch/phsu],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D03.633.100.079.080.575
828398cd-52e2-419f-8813-53cda2909aa3,C0035078,C0206419,are among gravest ,Kidney Failure,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419.780;C13.351.968.419.780,B04.820.504.540.150
d2a65710-30e0-4a0a-a944-1c80133bec08,C0022709,C1325834,also serves as ,Peptidyl-Dipeptidase A,viral glycoprotein,1,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
be483c51-6156-495b-9d2d-d6c849125d5a,ity164,C0022709,widely expressing ,ity164,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
8899b72e-66a8-4eaf-8ef2-52c04c331ff7,C0039082,C0597357,utilize same ,Syndrome,receptor,1,X,[dsyn],[aapp/rcpt],C23.550.288.500,
1e437841-a010-4573-b21c-12c465b3d184,C0039082,C1167395,utilize same ,Syndrome,Host (organism),1,X,[dsyn],[orgm],C23.550.288.500,
36068178-3316-476f-a355-417abfd305b3,COVID-19,C0039082,caused by ,COVID-19,Syndrome,1,X,[virs],[dsyn],C000657245,C23.550.288.500
524237f6-2901-46a2-a9ae-1299855a9fc7,C3540469,silico,of in silico ,AICDA wt Allele,silico,2,X,[gngm],????,,????
8adf5da9-1c5c-4ebe-9e71-0026d044e519,C0872152,C0206419,combat ,Drug Development,Genus: Coronavirus,1,X,[bmod],[virs],E05.290;H01.158.703.007.338;H01.181.466.338,B04.820.504.540.150
51dcca2a-f651-478c-b331-a306bf6475d7,C0872152,C0012634,combat ,Drug Development,Disease,2,X,[bmod],[dsyn],E05.290;H01.158.703.007.338;H01.181.466.338,C23.550.288
d8865cf9-f897-4715-b85f-cd39337673ce,C1704259,C3813209,discuss ,Biochemical Pathway,PROS1 wt Allele,2,X,[moft],[gngm],,
1fad2c60-325c-4cd0-91c3-07f7b1686aab,C0221423,C0009450,caused by ,Illness (finding),Communicable Diseases,2,X,[sosy],[dsyn],,C01.539.221
a4d617b0-07d9-4b85-bbc3-5e176b7c3847,C0221423,C0039082,caused by ,Illness (finding),Syndrome,1,X,[sosy],[dsyn],,C23.550.288.500
e26ecc82-f367-4054-8239-a11d03a49352,C0009450,C0039082,is with novel ,Communicable Diseases,Syndrome,1,X,[dsyn],[dsyn],C01.539.221,C23.550.288.500
4196f9ff-30cd-4e85-b04b-89764cea08ce,C0243052,C0206419,candidate against ,Virus Physiological Phenomena,Genus: Coronavirus,6,X,[npop],[virs],G06.920,B04.820.504.540.150
f872c964-f0a8-4c4d-a791-c8faaf9206db,C0243052,C0039082,candidate against ,Virus Physiological Phenomena,Syndrome,2,X,[npop],[dsyn],G06.920,C23.550.288.500
aa0894bc-823e-40fa-a523-f227e9b2d5f9,C0600334,C0206419,of Virus Physiological Phenomena is potential drug candidate against,silybin,Genus: Coronavirus,3,X,[orch/phsu],[virs],D03.383.663.283.266.450.268.777.500;D03.633.100.150.266.450.268.777.500,B04.820.504.540.150
4e94c986-a225-4da1-bd44-b33ef6a263a2,C0600334,C0039082,of Virus Physiological Phenomena is potential drug candidate against,silybin,Syndrome,1,X,[orch/phsu],[dsyn],D03.383.663.283.266.450.268.777.500;D03.633.100.150.266.450.268.777.500,C23.550.288.500
32cea308-0cc1-4a4e-9f10-ac6b48489b3b,C1325583,C0035685,is expected As computationally predicted inhibitor of ,central element,RNA-Directed RNA Polymerase,2,X,[celc],[aapp/enzy],,D08.811.913.696.445.735.780
d0bf22dc-1615-4867-8c26-1deec1f1455d,C2936405,C0206419,stands out as promising strategy for short-term response in fight against ,Drug Repositioning,Genus: Coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150
d0bf22dc-1615-4867-8c26-1deec1f1455d,C2936405,C0206419,novel Agent as,Drug Repositioning,Genus: Coronavirus,1,X,[topp],[virs],E05.290.875,B04.820.504.540.150
7237abf9-cad6-47a5-aa8e-7d73922e7d19,C2936405,C0040616,stands out Due to evidence of ,Drug Repositioning,Anti-Anxiety Agents,4,X,[topp],[phsu],E05.290.875,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
d3c91c27-79cf-4ed5-95ac-1d911cc31fda,C2936405,C0039082,stands out Due to evidence of ,Drug Repositioning,Syndrome,2,X,[topp],[dsyn],E05.290.875,C23.550.288.500
a40f1da1-72b9-4b05-85e6-2922915fc0f5,C0010340,C1868981,associated with high frequency ,Critical Illness,Invasive mechanical ventilation NOS,1,X,[dsyn],[topp],C23.550.291.625,
dddceafd-9af7-447e-98bc-8b423f4a11c3,C0206750,C0151763,induce some ,Coronavirus Infections,Liver damage,4,X,[dsyn],[patf],C02.782.600.550.200,
7660f8b6-5c6d-40ce-99af-535be7a618d9,C0206750,C0031843,induce some ,Coronavirus Infections,physiological aspects,2,X,[dsyn],[phsf],C02.782.600.550.200,x.x.x.x
c317d2ae-8e42-40a3-822b-7ab44084ba7d,C1706214,C0009676,is in our ,Creation,Confusion,1,X,[acty],[mobd],,C10.597.606.337;C23.888.592.604.339;F01.700.250
347b483a-4838-4ec2-b3e8-73585b960397,C0003451,C0013227,are among ,Antiviral Agents,Pharmaceutical Preparations,3,X,[phsu],[phsu],D27.505.954.122.388,D26
1f066795-f4a2-4c97-994a-3051f129722e,C0018939,C0206750,is in ,Hematological Disease,Coronavirus Infections,3,X,[dsyn],[dsyn],C15.378,C02.782.600.550.200
549718a0-51da-4899-89ba-233a1ccbef72,C0237873,C0206750,is in ,Physiological Sexual Disorders,Coronavirus Infections,3,X,[patf],[dsyn],C12.294.644;C13.351.500.665,C02.782.600.550.200
f81c6f67-ec6b-4256-ad2f-a3b2ec0dbb16,C2948600,C0010356,simultaneously prevent ,Aim,Cross Infection,1,X,[inch/phsu],[patf],,C01.539.248;C23.550.291.875.500
97dd083b-7aa4-4867-a326-51eedec6c8a2,C0815172,C1175743,is with ,patient characteristics,SARS coronavirus,1,X,[clna],[virs],,B04.820.504.540.150.113.937
aadf8b15-d9df-44ee-bb2c-f467d7eaa839,C0086418,7days,developed fever after 7days ,Homo sapiens,7days,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
aadf8b15-d9df-44ee-bb2c-f467d7eaa839,C0086418,7days,developed Coughing after 7days,Homo sapiens,7days,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
1be54bea-f531-476c-ab3e-7f5e95db8e19,C0040802,7days,developed fever after 7days ,travel,7days,1,X,[dora],????,I03.883,????
1be54bea-f531-476c-ab3e-7f5e95db8e19,C0040802,7days,developed Coughing after 7days,travel,7days,1,X,[dora],????,I03.883,????
76750845-9b47-45bf-b373-171af66799a7,C0086418,C4275242,developed fever after 7days ,Homo sapiens,Sudden sensorineural hearing loss,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
76750845-9b47-45bf-b373-171af66799a7,C0086418,C4275242,developed Coughing after 7days,Homo sapiens,Sudden sensorineural hearing loss,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
da271f91-9651-4468-886f-d61fa14e76c9,C0040802,C4275242,developed fever after 7days ,travel,Sudden sensorineural hearing loss,1,X,[dora],[dsyn],I03.883,
da271f91-9651-4468-886f-d61fa14e76c9,C0040802,C4275242,developed Coughing after 7days,travel,Sudden sensorineural hearing loss,1,X,[dora],[dsyn],I03.883,
9b3d88c8-7f50-41ac-91fa-9d742ad6ae92,C0086418,C0013404,developed ,Homo sapiens,Dyspnea,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.326;C23.888.852.371
9b3d88c8-7f50-41ac-91fa-9d742ad6ae92,C0086418,C0013404,presented with ,Homo sapiens,Dyspnea,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.326;C23.888.852.371
7d58045c-f087-48b1-9d41-a2ee5ed97926,C0040802,C0013404,developed ,travel,Dyspnea,1,X,[dora],[sosy],I03.883,C08.618.326;C23.888.852.371
3489eeba-671d-4730-a9d9-921403d9f3ca,C0086418,C0010200,developed ,Homo sapiens,Coughing,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.248;C23.888.852.293
3489eeba-671d-4730-a9d9-921403d9f3ca,C0086418,C0010200,presented with ,Homo sapiens,Coughing,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.248;C23.888.852.293
3489eeba-671d-4730-a9d9-921403d9f3ca,C0086418,C0010200,was brought with 3-week ,Homo sapiens,Coughing,2,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.248;C23.888.852.293
881ec798-ce5f-49a4-9a3a-356c3cf39388,C0040802,C0010200,developed ,travel,Coughing,1,X,[dora],[sosy],I03.883,C08.618.248;C23.888.852.293
f3d8faad-2972-4e83-b9cd-1274050a35f8,C0086418,C0149783,developed Coughing after 7days,Homo sapiens,Steroid therapy,1,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,
35cb35d8-f652-415c-8367-aaabb9a65a89,C0040802,C0149783,developed Coughing after 7days,travel,Steroid therapy,1,X,[dora],[topp],I03.883,
88e4040d-de34-4f9d-a052-4c1d6278fc83,C0035203,C0087111,deteriorated despite ,Respiration,Therapeutic procedure,1,X,[phsf],[topp],G09.772.705,E02
12852e49-3c5e-494d-a144-7b32a5b497ac,C0035203,C0939237,deteriorated despite ,Respiration,lopinavir / Ritonavir,1,X,[phsf],[phsu],G09.772.705,
d1535be0-e6cd-48a8-ba41-864f7536989a,C0087111,C0939237,is with ,Therapeutic procedure,lopinavir / Ritonavir,1,X,[topp],[phsu],E02,
1e584430-d13c-43d4-a619-484da9f613f4,C4058719,C0280274,enhance ,interferon beta-1b Injection,Antiviral Therapy,2,X,[clnd],[topp],,
2c20e970-b06a-4022-a57c-0b16ea82572e,C0242656,C0028351,necessitated inhalation Nitrogen Oxides for,Disease Progression,Norepinephrine,1,X,[patf],[horm/orch/phsu],C23.550.291.656,D02.033.100.291.502;D02.092.063.480;D02.092.211.215.746;D02.092.311.830;D02.455.426.559.389.657.166.175.830
62428331-963d-446e-9c4b-0be260f471ef,C0242656,C0028167,necessitated inhalation ,Disease Progression,Nitrogen Oxides,1,X,[patf],[inch],C23.550.291.656,D01.362.635;D01.625.550;D01.650.550.587
7450afd4-de29-4c5a-9b2e-39445cfbbdb4,C0178913,C0042749,indicating IL-6 ,Blood specimen,Viremia,1,X,[bdsu],[dsyn],,C02.937;C23.550.470.790.500.900
5a4b7e8e-4322-4181-8a07-80e1d1431442,PCR,C0042749,indicating IL-6 ,PCR,Viremia,1,X,????,[dsyn],????,C02.937;C23.550.470.790.500.900
38cc400a-d2b2-417d-abfb-97b59cad9db5,C0178913,IL-6,indicating IL-6 ,Blood specimen,IL-6,1,X,[bdsu],????,,????
0f06f1db-cf98-4525-ab33-3ad18feaff21,PCR,IL-6,indicating IL-6 ,PCR,IL-6,1,X,????,????,????,????
4b2500f1-33bb-4dad-be7f-5a9803c11219,C0042216,C0282636,maintain ,Vaccinia virus,Cell Respiration,1,X,[virs],[celf],B04.280.650.160.650.900,G03.197;G04.270
a03c76d1-d3fb-4e0b-b6a6-035c25405ade,C0015357,C0282636,maintain ,Extracorporeal Membrane Oxygenation,Cell Respiration,1,X,[topp],[celf],E02.880.301;E04.292.451,G03.197;G04.270
d2d88776-6efe-4dd9-a45c-27a6840963e7,C0079189,C0178784,requiring vigorous ,cytokine,Organ,1,X,[aapp/imft],[bpoc],D12.644.276.374;D12.776.467.374;D23.529.374,
51e2db5f-351a-4659-b338-64a9dc5dece3,C0079189,C0087111,requiring vigorous ,cytokine,Therapeutic procedure,1,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,E02
d6ed9522-a34c-476e-bad0-7e09e42e916b,C0178784,C0038952,allow for ,Organ,Continuance of life,1,X,[bpoc],[acty],,I03.784
be1d19d2-03e3-4080-b5d4-2c555c64c6b5,C0087111,C0038952,allow for ,Therapeutic procedure,Continuance of life,1,X,[topp],[acty],E02,I03.784
be1d19d2-03e3-4080-b5d4-2c555c64c6b5,C0087111,C0038952,could increase ,Therapeutic procedure,Continuance of life,1,X,[topp],[acty],E02,I03.784
a0f8b05b-3cd0-45cd-8177-b9ff8f9bf95d,C0178784,C0349410,allow for ,Organ,Single organ dysfunction,1,X,[bpoc],[sosy],,
8dc76b71-42c5-442a-8512-4920895d89f8,C0087111,C0349410,allow for ,Therapeutic procedure,Single organ dysfunction,1,X,[topp],[sosy],E02,
5723f8e9-a5a7-4619-a280-82552e020c05,C0563597,C1874964,is in ,Momentum,DELIVER (Dietary Supplement),1,X,[npop],[phsu],,
fc884d13-8566-4136-a1ea-0a1216e3e1c1,C0206750,C0023693,is important to high ,Coronavirus Infections,Light,1,X,[dsyn],[npop],C02.782.600.550.200,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
1e9e9d5a-9183-4829-bea3-ea8a5407a6a3,C0009450,C0683325,resulting in wide range ,Communicable Diseases,clinical aspects,1,X,[dsyn],[clna],C01.539.221,
525197e8-2d27-40e5-b89a-2ebf3183ff73,C1511790,C0225778,is in ,Detection,Pleural fluid,1,X,[topp],[bdsu],,
dc352c8f-49a8-47d7-a817-b96cce7e227a,C0027950,C0319157,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,AS virus,1,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,
49fc28b2-d093-42cf-9bc5-4171dc24227e,C0027950,2weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,2weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
2e67299f-5390-44e9-88ed-b3d027873900,C0027950,3weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,3weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
c3998274-aa2e-42fe-905d-69f519c080a2,C0027950,4weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,4weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
ebaabbaa-8d59-4ba8-902d-036b7594dba8,C0027950,5weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,5weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
96ceeee5-bb09-4743-ae0e-7e53a8c76baf,C0027950,C0042769,predicting ,neutrophil,Virus Diseases,1,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02
7bc76ab4-2e2f-4e49-92d2-4e45bc41ca38,et,COVID-19,reviewed COVID19 ,et,COVID-19,1,X,????,[virs],????,C000657245
c082b18b-e3a9-4faf-9750-e7d275a0fb0c,al,COVID-19,reviewed COVID19 ,al,COVID-19,1,X,????,[virs],????,C000657245
c7e4ed21-e246-4770-aa43-6c69e835561f,et,C1160716,reviewed COVID19 ,et,viral transmission,2,X,????,[celf],????,
de4f6ccf-a818-417d-a457-73061ced3edf,al,C1160716,reviewed COVID19 ,al,viral transmission,2,X,????,[celf],????,
e5c456d4-9ad6-4482-9884-1d4454764b3a,et,COVID19,reviewed COVID19 ,et,COVID19,1,X,????,????,????,????
a3a6278b-eed2-40f9-a97a-bb5cbfde1ce8,al,COVID19,reviewed COVID19 ,al,COVID19,1,X,????,????,????,????
bd64c643-4c95-454e-aa97-b6c7dd49af12,C0013879,C1175743,have become universal besides ,Elements,SARS coronavirus,2,X,[elii],[virs],D01.268,B04.820.504.540.150.113.937
f4a5ede4-3672-4a19-aba6-1464113124a7,C1414683,C3B6,is in C3B6 ,FOXJ1 gene,C3B6,1,X,[gngm],????,,????
db0438e2-8a96-4c98-967f-92cac92ebcbb,C0086418,C3B6,is in C3B6 ,Homo sapiens,C3B6,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
b6cef646-da10-4df5-ae2f-b2d914cc0e17,C1414683,C0026809,is in C3B6 ,FOXJ1 gene,Mus,1,X,[gngm],[mamm],,B01.050.150.900.649.313.992.635.505.500
7501154e-42b5-41c1-98b0-01d0fb409f0a,C0086418,C0026809,is in C3B6 ,Homo sapiens,Mus,1,X,[humn],[mamm],B01.050.150.900.649.313.988.400.112.400.400,B01.050.150.900.649.313.992.635.505.500
cbcc5017-922d-4f48-bea5-b2e87990eeb8,C0026809,C1800706,generated ,Mus,Idiopathic Pulmonary Fibrosis,1,X,[mamm],[dsyn],B01.050.150.900.649.313.992.635.505.500,C08.381.483.487.500;C08.381.765.500
5ee5f958-69db-407d-950b-df722c3ec8a9,C0035736,C0015392,could could found in ,RNA Viral,Eye,1,X,[nnon],[bpoc],D13.444.735.828,A01.456.505.420;A09.371
4aac6d03-492f-4291-b139-071b886332e2,C0035736,C0018787,could could found in ,RNA Viral,Heart,1,X,[nnon],[bpoc],D13.444.735.828,A07.541
fe098fb7-0ace-4455-a6b0-db94d1261a76,C0035736,C1521713,could could found in ,RNA Viral,CNS - Brain (MMHCC),2,X,[nnon],[tisu],D13.444.735.828,
722af28c-bc9e-4416-af0d-797d597fc3fa,C0035435,C0024432, includes ,Rheumatism,macrophage,4,X,[dsyn],[cell],C05.799;C17.300.775,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
3410317f-e8dc-4bed-a0ca-ec9042c971f1,C0005522,C0035435,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,Rheumatism,2,X,[bacs/phsu],[dsyn],D20.215,C05.799;C17.300.775
6571e0a0-7128-463f-a690-2ab5bc3fe069,C0005522,C0039082,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,Syndrome,4,X,[bacs/phsu],[dsyn],D20.215,C23.550.288.500
66e87944-f52f-4108-bb31-f595416a6cc4,C0005522,C0024432,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,macrophage,2,X,[bacs/phsu],[cell],D20.215,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
604a4403-a8c9-4adf-a699-75d23b4d3790,C1155266,C1175743,induced by ,inflammatory response,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
42f201fb-4e43-4d0b-bc05-1695b303872f,C0038952,C1565830,followed by ,Continuance of life,PTGS1 protein human,1,X,[acty],[aapp/enzy],I03.784,x.x.x.x
f7056e8a-33c0-4e19-9209-40373440941f,C0021368,C0012634,adjusting for ,Inflammation,Disease,1,X,[patf],[dsyn],C23.550.470,C23.550.288
f7056e8a-33c0-4e19-9209-40373440941f,C0021368,C0012634,is in severe ,Inflammation,Disease,2,X,[patf],[dsyn],C23.550.470,C23.550.288
d674469a-91bc-4690-a482-f8c2b205aad3,C0021368,C4050231,adjusting for ,Inflammation,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[patf],[clna],C23.550.470,
4c285b1a-0d2d-4cb0-bfc9-7042262dea44,C3540676,C0012634,is in ,Blockade,Disease,1,X,[elii/phsu],[dsyn],,C23.550.288
8b7e1b14-674c-4d36-a191-4add73cb9ad9,C0007634,C0282554,expressed ,Cells,chemokine,1,X,[cell],[aapp/imft],A11,D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200
f5625140-8b52-4a42-b6ac-3639e8a4e2d5,C0206750,C3272452,is caused by ,Coronavirus Infections,Single-Stranded RNA,1,X,[dsyn],[nnon],C02.782.600.550.200,
9b7d9b0a-46bb-493c-b3ac-41abc92c5cb0,C0206750,C0017428,is caused by enveloped ,Coronavirus Infections,Genome,2,X,[dsyn],[gngm],C02.782.600.550.200,G05.360.340
b654d749-36c4-4287-b032-c2435184c75e,C0042736,C0319157,interact with ,Viral Proteins,AS virus,1,X,[aapp/bacs],[virs],D12.776.964,
ae711a2b-d92a-46e8-a012-d1f9edc48fea,C0023688,C0319157,interact with ,Ligands,AS virus,1,X,[chem],[virs],D27.720.470.480,
cfb8165c-2ec0-4560-8824-b66010d5fdc0,C1514593,C0206750,has has additionally documented together with relevant reactions in population related to ,Psychological Impact,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
ff1284a3-8288-4cbf-9bf4-6a7165376239,C0001924,C0369768,more likely ,Albumins,Molecular oxygen saturation,8,X,[aapp/bacs],[moft],D12.776.034,
163dde88-d64d-4b30-8e78-636a2f97d00f,C0001924,C0024264,low levels of ,Albumins,Lymphocyte,3,X,[aapp/bacs],[cell],D12.776.034,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
12f21a2b-2063-4c77-99e3-124a3d481689,C1947933,C0815172,were collected on key ,care activity,patient characteristics,4,X,[acty],[clna],,
43ea23ec-f350-4134-bc51-5d1d2d341b00,C1704259,C0815172,were collected on key ,Biochemical Pathway,patient characteristics,4,X,[moft],[clna],,
4700eb24-31b0-4d96-bcd8-4210e56a4a4f,centre,C1704259,effectively managed Emergency treatment with appropriate patient,centre,Biochemical Pathway,1,X,????,[moft],????,
4700eb24-31b0-4d96-bcd8-4210e56a4a4f,centre,C1704259,effectively managed Emergency Care with appropriate patient,centre,Biochemical Pathway,1,X,????,[moft],????,
b7c7e417-84c8-4e2d-aa23-09f248f176a8,centre,C0013969,effectively managed urgent ,centre,Emergency treatment,1,X,????,[topp],????,E02.365
d2eef72e-3397-43bd-8bfd-aa1e8f43730a,C0005779,C0021368,is common abnormality in patients with ,Blood Coagulation Disorders,Inflammation,2,X,[dsyn],[patf],C15.378.100,C23.550.470
67f85b19-ffb8-4f9d-8c0f-45fe66f627c6,C0040038,C0524702, includes ,Thromboembolism,Pulmonary Thromboembolisms,2,X,[patf],[dsyn],C14.907.355.590,C08.381.746;C14.907.355.350.700
c3024ec0-8bd4-4d49-967d-79e2c37ea6cd,C1175743,C1550661,was detected in their nasopharyngeal swabs ,SARS coronavirus,Specimen Type - Stool = Fecal,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
07687bd3-b3e0-4579-9f35-2470d7a00d72,C1175743,C3687742,was detected in their nasopharyngeal swabs ,SARS coronavirus,Oropharyngeal swab,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
679ae2f4-cd76-4169-8740-e95837b4889a,C0029892,C0037778,producing resources for ,Otolaryngology specialty,Medical Specialities,2,X,[bmod],[bmod],H02.403.810.526,H02.403
344e1407-35fc-4930-bc73-8daffb6fc360,ACE2,C0007634,of levels is ,ACE2,Cells,1,X,????,[cell],????,A11
34d639e5-96b5-4cbd-8ba3-4f78f5fb9872,ACE2,C0206750,of levels is ,ACE2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
687561fb-6a81-446b-b6e0-437f07917861,ACE2,C1175743,point for ,ACE2,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
3363d17f-b1e3-46c2-b9ab-14d0528816e2,AGES-RS,C0003015,was stratified by ,AGES-RS,Angiotensin-Converting Enzyme Inhibitors,3,X,????,[phsu],????,D27.505.519.389.745.085
1e902f41-7f19-4f50-93f6-be7ec298c672,C0035100,C0229671,were significantly raised in ,Chymosin,Serum,3,X,[aapp/enzy],[bdsu],D08.811.277.656.074.500.200;D08.811.277.656.300.048.200,A12.207.152.846;A15.145.846
1a55d429-b883-4660-8a1d-ee167d946035,C0035100,C0003015,were significantly raised in ,Chymosin,Angiotensin-Converting Enzyme Inhibitors,3,X,[aapp/enzy],[phsu],D08.811.277.656.074.500.200;D08.811.277.656.300.048.200,D27.505.519.389.745.085
c0950786-65a7-49b7-a07c-2e6ba3f78efa,C1422064,C1171362,effect on ,ACE2 gene,protein expression,6,X,[gngm],[genf],,
294e0dfe-df6a-4085-a192-ab2864d091cf,C1422064,C0025250,effect on ,ACE2 gene,Neprilysin,6,X,[gngm],[aapp/enzy],,D08.811.277.656.300.480.600;D08.811.277.656.675.374.600;D23.050.285.550;D23.101.140.500
6864a641-5eb3-48ec-9d05-88a0fa39ec0c,C1422064,C3887624,effect on ,ACE2 gene,Human Neprilysin,6,X,[gngm],[aapp/enzy],,
46661bb0-2b03-4889-96eb-42c194aabd21,C0574032,C3887624,downregulated ,Infusion procedures,Human Neprilysin,2,X,[topp],[aapp/enzy],,
7ad57226-bafd-4bfa-abe1-b1341b0a5806,C0574032,C1171362,downregulated ,Infusion procedures,protein expression,2,X,[topp],[genf],,
134c563d-caf2-4c97-82f8-50e3582318c1,C1422064,C0533668,contributes to female protection from ,ACE2 gene,ANGPT1 protein human,3,X,[gngm],[aapp/bacs],,x.x.x.x
2f257c9e-16a3-4e60-bb63-c2157d97e552,C0151864,C0206750,is in ,Disorder of pregnancy,Coronavirus Infections,5,X,[dsyn],[dsyn],,C02.782.600.550.200
17e34101-b714-4482-9541-9353bb457bfe,C0151864,C1521863,is in ,Disorder of pregnancy,estrogen receptor alpha human,5,X,[dsyn],[aapp/rcpt],,x.x.x.x
ff3d348e-d082-4ac1-83de-2a42d6b32fb4,C0010200,GLCM,was negatively correlated with GLCM offset4,Coughing,GLCM,5,X,[sosy],????,C08.618.248;C23.888.852.293,????
806245df-1826-4589-a578-b34a7d3adbea,C0010200,offset4,was negatively correlated with GLCM offset4,Coughing,offset4,5,X,[sosy],????,C08.618.248;C23.888.852.293,????
51c5b511-5a52-4125-91fb-5077cc10e280,C0006560,C2699239,offset 4 _ ,C-reactive protein,SD Rat Strain,5,X,[aapp/imft],[mamm],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,
4b7d491a-12d4-4a7d-a9b3-f6772b9b2121,C1514562,C0024109,changes of ,Protein Domain,Lung,5,X,[amas],[bpoc],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,A04.411
49536967-64e2-4469-9f71-d2c5a2332f16,C0028754,C0061355, includes ,Obesity,Glucagon-Like Peptide 1,2,X,[dsyn],[aapp],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D06.472.317.680.500.500
853ae585-8adc-49c8-b0aa-38ef0a2cc2b1,C0087111,C0028754,is with ,Therapeutic procedure,Obesity,1,X,[topp],[dsyn],E02,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
d9e807df-45f9-4021-954b-df2654fcdf1d,C0087111,C0243071,is with ,Therapeutic procedure,Analog,2,X,[topp],[chvs],E02,
ee8f4d7e-cff2-45b9-8833-61d4eee07206,C0087111,C0360714,is with ,Therapeutic procedure,Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[topp],[orch/phsu],E02,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
fafb3d25-ca41-442b-bef3-106bb76651f7,C0087111,C0085826,is with ,Therapeutic procedure,Antiplatelet Agents,2,X,[topp],[phsu],E02,D27.505.954.502.780
d4ada089-db37-45e2-9ac5-8a45842295db,C0087111,C0061355,is with ,Therapeutic procedure,Glucagon-Like Peptide 1,1,X,[topp],[aapp],E02,D06.472.317.680.500.500
f13279d1-d19d-4223-9d88-64ec5723a765,C0013227,C0028754,used to ,Pharmaceutical Preparations,Obesity,1,X,[phsu],[dsyn],D26,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
ae461bcf-20da-4cf0-80ea-aad48443e2fb,C0013227,C0243071,used to ,Pharmaceutical Preparations,Analog,2,X,[phsu],[chvs],D26,
2bdd43b2-192f-4d0c-be6f-932687b60312,C0013227,C0360714,used to ,Pharmaceutical Preparations,Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[phsu],[orch/phsu],D26,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
c68db7f6-a496-4102-999c-ef070c4692fe,C0013227,C0085826,used to ,Pharmaceutical Preparations,Antiplatelet Agents,2,X,[phsu],[phsu],D26,D27.505.954.502.780
367e9f98-71ac-40ac-b5ba-06f957a50416,C0013227,C0061355,used to ,Pharmaceutical Preparations,Glucagon-Like Peptide 1,1,X,[phsu],[aapp],D26,D06.472.317.680.500.500
ad2058cd-b3a3-477d-8bc1-17d5952e6818,C1706202,11th,has increased significantly since February 11th,Search - action,11th,1,X,[acty],????,,????
1a85ae54-45c8-4d0d-98cd-e2ad97855dea,C1175743,C0013227,have far-reaching ,SARS coronavirus,Pharmaceutical Preparations,6,X,[virs],[phsu],B04.820.504.540.150.113.937,D26
473a47c3-a33d-4472-8c91-00fe9e31845a,C0021966,C0042776,was aware of my risk of exposure to ,Iodides,Virus,3,X,[inch],[virs],D01.248.497.158.490;D01.475.410,B04
50fc49a9-d86f-418c-b136-aec85046e0bb,C0021966,C4048158,assumed that as ,Iodides,Convulsions,2,X,[inch],[sosy],D01.248.497.158.490;D01.475.410,C10.597.742;C23.888.592.742
b0f2adc5-b1b6-4800-9750-06cdfeebb82c,C0021966,C0021932,necessitating ,Iodides,Intubation Intratracheal,3,X,[inch],[topp],D01.248.497.158.490;D01.475.410,E02.041.500;E02.585.578;E05.497.578
955779f0-f3c4-4db7-80af-10f966ef1f89,C0021966,C0199470,necessitating ,Iodides,Mechanical ventilation,3,X,[inch],[topp],D01.248.497.158.490;D01.475.410,
ce7e64d5-8d38-4c0a-b0f5-e14299740611,C0021966,C0034991,was discharged home After two further days of ,Iodides,Rehabilitation therapy,3,X,[inch],[topp],D01.248.497.158.490;D01.475.410,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
f4700433-ce31-4221-af39-f90b21542396,C0524816,C0017968,is in spike ,Nucleocapsid Proteins,Glycoproteins,3,X,[aapp/bacs],[aapp/bacs],D12.776.964.970.600,D09.400.430;D12.776.395
c043d2f3-4c7a-45d7-a18f-245363b159b2,C0525021,C0524816,is in ,Nuclear Localization Signals,Nucleocapsid Proteins,3,X,[amas],[aapp/bacs],D12.644.770.610;G02.111.570.060.670.610,D12.776.964.970.600
b94133e8-c596-4ce2-b799-0469fff4b726,C0017968,C0206419,be associated with high case fatality rate of ,Glycoproteins,Genus: Coronavirus,6,X,[aapp/bacs],[virs],D09.400.430;D12.776.395,B04.820.504.540.150
7a6cb1e8-ffb4-4959-a912-bac422c0682c,C0035243,C1856053,be ultimately declared pandemic by World Health Organization on ,Respiratory Tract Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C01.539.739;C08.730,x.x.x.x
00f66036-6cb9-4963-aee7-f0cc2ab7e694,C0035243,C0015392,has since spread across ,Respiratory Tract Infections,Eye,1,X,[dsyn],[bpoc],C01.539.739;C08.730,A01.456.505.420;A09.371
c5eee0aa-439a-4cb7-b03a-ed26134f70bf,C1267213,C0242781,is portal of ,Upper aerodigestive tract,disease transmission,2,X,[bpoc],[patf],,N06.850.310
3ba53fae-c7d7-480f-9830-4b15c41571f0,C1267213,C0042774,is portal of ,Upper aerodigestive tract,Virus Replication,4,X,[bpoc],[celf],,G06.920.925
54957a03-ee8e-4f4d-83fe-a024bca790c1,C2745965,C0029892,is in ,Emergencies [Disease/Finding],Otolaryngology specialty,2,X,[patf],[bmod],C23.550.291.781;N06.230.100.083;N06.850.376,H02.403.810.526
6a2689ce-ee03-4335-905b-209f10ade4f2,C1533734,C0237798,is in ,Administration procedure,Nonhuman primate,2,X,[topp],[mamm],,
9cb2cb8f-6cba-4751-a22b-2a42da25a0be,C1533734,C0003261,is in ,Administration procedure,Antibody Formation,3,X,[topp],[biof],,G12.070
b1a45fa2-6374-4ca3-a7ce-afe51156824a,C0003261,C1175743,potently neutralized ,Antibody Formation,SARS coronavirus,2,X,[biof],[virs],G12.070,B04.820.504.540.150.113.937
77ac3485-adf8-4332-afe8-9309b2fd7a40,C0012655,C0012634,are associated with ,Disease susceptibility,Disease,1,X,[clna],[dsyn],C23.550.291.687;G07.100.250,C23.550.288
5ce13291-25d9-46ef-8ebd-c8bddfb52f4a,C0012655,C1175743,are associated with ,Disease susceptibility,SARS coronavirus,1,X,[clna],[virs],C23.550.291.687;G07.100.250,B04.820.504.540.150.113.937
76bda8b6-2562-4e05-b6a4-e5155224e5bf,C0007222,C0683325,is in term of ,Cardiovascular Diseases,clinical aspects,1,X,[dsyn],[clna],C14,
bdef5b60-8dc5-4686-96c4-a5ee98c3f84b,C2948600,C0599878,describe cardiological ,Aim,disease characteristic,4,X,[inch/phsu],[patf],,
764e4dbc-5161-4ad4-b389-80eb918212f2,C2948600,C0007222,describe clinical outcome for patients with ,Aim,Cardiovascular Diseases,1,X,[inch/phsu],[dsyn],,C14
56f8fde0-6e67-4f14-a7bd-e6136729bb89,C0596197,C0206750,is in patients with ,blood treatment,Coronavirus Infections,3,X,[topp],[dsyn],,C02.782.600.550.200
ff702abc-e50d-4019-aec6-c3145f13bdc5,C0152025,C0225990,Occlusive stroke from,Polyneuropathy,Large blood vessel structure,1,X,[dsyn],[bpoc],C10.668.829.800,
60a7cebd-79b6-4cfa-b280-b1e56b90b185,C0152025,C1298680,Occlusive stroke from,Polyneuropathy,Occlusive stroke,1,X,[dsyn],[dsyn],C10.668.829.800,
6c62bc85-d469-4e4f-8d03-d6a592947661,C0079102,C0206750,may complicate initial clinical presentation of ,Cerebral Thrombosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.300.525.425;C14.907.253.566.350;C14.907.355.590.213.350,C02.782.600.550.200
d19709bd-49da-4360-bd7a-21b2876a8fee,C0035668,C0037088,was Detection After resolution of,RNA,Signs and Symptoms,2,X,[nnon],[sosy],D13.444.735,C23.888
22d1d89d-41ea-419d-bbb0-11d707f151d1,C0524865,C2700061,initiate great green ,Reconstructive Surgical Procedures,Transition (action),1,X,[topp],[acty],E04.680,
8f4a154f-e051-4294-ba0d-04ec11bda733,C2728259,C2700061,initiate great green ,Program,Transition (action),1,X,[orch/phsu],[acty],V02.355.750,
f6a294f0-942b-486a-afbc-404c4d2e6400,C0694549,C1175743, includes CoV2,Community acquired pneumonia,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
f45eebb5-61f8-463a-a8f2-3cd49bbb9f31,C0694549,CoV2, includes CoV2,Community acquired pneumonia,CoV2,1,X,[dsyn],????,,????
c13beded-1e4e-4542-8c05-ff67880a29e2,C0857828,C0079189,leads to ,infection in the elderly,cytokine,3,X,[dsyn],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
e65434b0-08dc-4c21-9e93-cb5817f5e9ad,C0206750,CD8,characterize CD8 ,Coronavirus Infections,CD8,1,X,[dsyn],????,C02.782.600.550.200,????
e65434b0-08dc-4c21-9e93-cb5817f5e9ad,C0206750,CD8,decreased CD8 ,Coronavirus Infections,CD8,2,X,[dsyn],????,C02.782.600.550.200,????
8eee7175-f05d-499b-bdb9-044bdcaa34e1,CD8,C1175743,is in ,CD8,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
fd81488e-69b9-49d2-9b10-be66692fe62c,C0282580,C1175743,CD8 in ,Epitopes T-Lymphocyte,SARS coronavirus,1,X,[imft],[virs],D23.050.550.402,B04.820.504.540.150.113.937
0c2a3d70-5a67-4557-81ef-9cad97f4a679,C0043309,3D,derive physically realistic 3D ,Roentgen Rays,3D,1,X,[npop],????,G01.358.500.505.970;G01.750.250.970;G01.750.750.918,????
0fdfa983-4fe8-4f55-b3ae-c89d8e74c57d,C0043309,C1175743,derive physically realistic 3D ,Roentgen Rays,SARS coronavirus,1,X,[npop],[virs],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,B04.820.504.540.150.113.937
412cbfb4-08df-430f-ad55-e364fa22039f,C0206419,C1947932,later identified as quickly ,Genus: Coronavirus,Smear - instruction imperative,1,X,[virs],[acty],B04.820.504.540.150,
55a40b99-0f4a-4324-a24f-c0f41d9fe1cc,C1175743,C1947932,has worldwide ,SARS coronavirus,Smear - instruction imperative,2,X,[virs],[acty],B04.820.504.540.150.113.937,
f13360d6-d5ec-4831-ac04-83234c67e2b1,C0018787,C0960880,caused by ,Heart,angiotensin converting enzyme 2,2,X,[bpoc],[aapp/enzy],A07.541,x.x.x.x
f13360d6-d5ec-4831-ac04-83234c67e2b1,C0018787,C0960880,have have direct ,Heart,angiotensin converting enzyme 2,1,X,[bpoc],[aapp/enzy],A07.541,x.x.x.x
d37a2f18-7c3a-4b02-8436-5f5a1d6b308e,C3260929,C0960880,caused by ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,angiotensin converting enzyme 2,1,X,[clna],[aapp/enzy],,x.x.x.x
d37a2f18-7c3a-4b02-8436-5f5a1d6b308e,C3260929,C0960880,have have direct ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,angiotensin converting enzyme 2,1,X,[clna],[aapp/enzy],,x.x.x.x
d10a83c9-59b2-4252-b1ae-4e99c78723e5,C3260929,C0018787,have have direct ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Heart,1,X,[clna],[bpoc],,A07.541
0831a663-0017-4ef4-8d36-a072a6ea2739,C0011389,C0005779,is with ,Dental Plaque,Blood Coagulation Disorders,2,X,[dsyn],[dsyn],C07.793.208.377,C15.378.100
c374524f-6328-4aab-90db-29f777f9e9b3,C1719472,C0264714,can lead to ,Stress induced cardiomyopathy,Acute heart failure,2,X,[dsyn],[dsyn],,
d5dc99df-36c5-402b-b473-1c96ddd63d6c,C1719472,C0018787,can lead with further ,Stress induced cardiomyopathy,Heart,1,X,[dsyn],[bpoc],,A07.541
df02cd18-75eb-42fd-8e24-e19991e66cd4,C1719472,C0012634,is in critically ill ,Stress induced cardiomyopathy,Disease,2,X,[dsyn],[dsyn],,C23.550.288
2f495b96-d594-4503-aa8a-6cef1ed7fff9,C0206419,C0026882,form escape ,Genus: Coronavirus,Mutation,2,X,[virs],[genf],B04.820.504.540.150,G05.365.590
6518c9cc-aef1-42ae-b336-7369846b05a8,C1527075,C0226658,followed by specific considerations in ,Revision procedure,Structure of valve of coronary sinus,1,X,[topp],[bpoc],,
b63fd747-1fd1-4686-a4a9-599afcca33f5,C0206419,C0010076,is ,Genus: Coronavirus,Coronaviridae,4,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540
26e51189-efcb-4192-a744-8d2e921a9562,C0012634,C0010076,is ,Disease,Coronaviridae,2,X,[dsyn],[virs],C23.550.288,B04.820.504.540
0897ab59-b89b-4c12-a2be-4c0d6350a9e2,C1422064,C1440080,are present in type ,ACE2 gene,Alveolar,1,X,[gngm],[bpoc],,
78082782-76a3-481f-a1eb-6ced54ba9658,C2316160,C0206419,is in critically ill patients with ,Infection of bloodstream,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
d6efcbdd-9d10-4da9-9550-3f5e5b4107a3,C0003209,C2316160,was independently associated with development ,Anti-Inflammatory Agents,Infection of bloodstream,4,X,[phsu],[patf],D27.505.954.158,
d1245836-42fa-4738-a098-6461fda9f93c,C1457887,C0458578,are those of ,Symptoms,Upper respiratory tract,2,X,[sosy],[bpoc],,
57d9d8a9-8180-414c-ace1-9cb2f9377413,C0034019,C0450254,Increasingly are using genomic ,public health medicine (field),Pathogenic organism,1,X,[bmod],[orgm],H02.403.720;N01.400.550;N06.850,
51f16386-fc48-404b-8a04-374aea4a1751,C0034019,genomic,Increasingly are using genomic ,public health medicine (field),genomic,1,X,[bmod],????,H02.403.720;N01.400.550;N06.850,????
a75bb0b4-7c13-41b9-8e6d-d549f1f35a12,C0450254,C0034019,is in ,Pathogenic organism,public health medicine (field),1,X,[orgm],[bmod],,H02.403.720;N01.400.550;N06.850
ee7c110e-64f6-4131-8e6e-d41bf8571a48,genomic,C0034019,is in ,genomic,public health medicine (field),1,X,????,[bmod],????,H02.403.720;N01.400.550;N06.850
75213f7c-e38c-4bc0-a5ab-c2e99901f88d,COVID-19,C1527075,has drawn attention experts calling for its ,COVID-19,Revision procedure,1,X,[virs],[topp],C000657245,
8539644d-5a27-42b9-b497-2705fce19322,COVID-19,C1334294,performs on PCR,COVID-19,JTB gene,1,X,[virs],[gngm],C000657245,
7e282aa2-158e-4110-98c6-f2f06b85305c,COVID-19,C0230425,performs on PCR,COVID-19,Structure of right thigh,1,X,[virs],[bpoc],C000657245,
cbcc0484-0399-4850-8bb1-8609abad259c,COVID-19,PCR,performs on PCR,COVID-19,PCR,1,X,[virs],????,C000657245,????
b2b2db5f-c269-4886-b561-bc15a27703c4,C1334294,COVID-19,is with PCR,JTB gene,COVID-19,1,X,[gngm],[virs],,C000657245
6965f2e0-fe0f-417e-ab50-a6254ff7bcb7,C1334294,C0230425,is with PCR,JTB gene,Structure of right thigh,1,X,[gngm],[bpoc],,
411276ec-71d0-4375-bbdd-9616cb58edc6,C1334294,PCR,is with PCR,JTB gene,PCR,1,X,[gngm],????,,????
dac43ec0-b495-45f6-ab65-a0d3f98b82f9,COVID-19,C0020517,has ,COVID-19,Hypersensitivity,2,X,[virs],[patf],C000657245,C20.543
16b72b31-2a3f-4cad-8c52-6d2424fb80fb,C0872079,C1413931,Genetic Polymorphism in,protein protein interaction,ACE gene,1,X,[moft],[gngm],,
79ee06b7-1b93-4e50-9385-d3367de48822,C0032529,C0024109,contribute to ,Genetic Polymorphism,Lung,1,X,[genf],[bpoc],G05.365.795,A04.411
83389350-fdfb-4e7f-bb85-7f6c697d552b,C0206750,60-year,with patient is 60-year ,Coronavirus Infections,60-year,2,X,[dsyn],????,C02.782.600.550.200,????
bb01afc0-5940-4178-af38-bdd3fce4f48a,C0012634,60-year,with patient is 60-year ,Disease,60-year,2,X,[dsyn],????,C23.550.288,????
0bfc05c8-d0e9-4fa5-a8ba-9caedfe3b10a,C0024432,C0950580,are ,macrophage,sentinel,2,X,[cell],[hops/orch],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,
9f86193f-166f-4eb1-baf6-f52e1d5d8626,C0011306,C0950580,are ,Dendritic Cells,sentinel,2,X,[cell],[hops/orch],A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260,
65d6d363-138b-4b0c-b31c-02122b4bff0c,C0678209,C0699748,affect ,Adaptive Immunity,Pathogenesis,2,X,[phsf],[patf],G12.450.050,
a4329637-a1ba-470d-a829-55634f2ec62d,C0678209,C1175743,affect ,Adaptive Immunity,SARS coronavirus,2,X,[phsf],[virs],G12.450.050,B04.820.504.540.150.113.937
d70b1efa-da97-4408-b6cc-bf13413f0083,C0026473,C1175175,were permissive to ,Monocytes,Severe Acute Respiratory Syndrome,4,X,[cell],[dsyn],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,C02.782.600.550.200.750;C08.730.730
454a8143-d05c-440b-8d84-3138a1c1b575,C0066350,C1175175,were permissive to ,methylene dimethanesulfonate,Severe Acute Respiratory Syndrome,2,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200.750;C08.730.730
f0f6b565-7642-4dcf-9d4e-640767780791,C3652465,C0007634,is in ,Interferon,Cells,2,X,[aapp/imft/phsu],[cell],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,A11
c31359bf-d2b5-4be9-9e8d-fea6b968e21a,C1721019,C0022709,locate at ,Virus Attachment,Peptidyl-Dipeptidase A,1,X,[biof],[aapp/enzy/imft],G06.920.868,D08.811.277.656.350.350.687
2b8d0be9-bc14-45cb-8e60-69bc30113b59,C1721019,C0034987,locate at ,Virus Attachment,Regulatory Sequences Nucleic Acid,1,X,[biof],[bacs/nnon],G06.920.868,G02.111.570.080.689;G05.360.080.689
78848d71-0395-40c3-a2dc-fdb6c914b438,C0022709,C0011860,is reduced in ,Peptidyl-Dipeptidase A,Diabetes Mellitus Non-Insulin-Dependent,6,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C18.452.394.750.149;C19.246.300
bd2f7492-625d-47c3-bad1-e28bcc28f553,C0022709,C0079189,is reduced with inflammatory ,Peptidyl-Dipeptidase A,cytokine,6,X,[aapp/enzy/imft],[aapp/imft],D08.811.277.656.350.350.687,D12.644.276.374;D12.776.467.374;D23.529.374
bd2f7492-625d-47c3-bad1-e28bcc28f553,C0022709,C0079189,was significantly negatively associated with type ,Peptidyl-Dipeptidase A,cytokine,1,X,[aapp/enzy/imft],[aapp/imft],D08.811.277.656.350.350.687,D12.644.276.374;D12.776.467.374;D23.529.374
5e2caf0c-1606-45f1-a16c-f78c69d43194,C3649547,C4547399,was required in ,Continuous renal replacement therapy,CI-2,1,X,[topp],[aapp/phsu],,
8ad9be38-c566-46f2-ad0e-1e591f2da5ff,AKI,C0206750,is associated with severity of ,AKI,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
cac938c5-9754-457c-80fc-860bd86da089,C0034019,C0275518,was classified as pandemic of ,public health medicine (field),Acute infectious disease,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,
880e25da-12d4-417f-9dc7-7a2a7baa202f,C0034019,C0206750,has has declared worldwide since ,public health medicine (field),Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200
880e25da-12d4-417f-9dc7-7a2a7baa202f,C0034019,C0206750,started following ,public health medicine (field),Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200
880e25da-12d4-417f-9dc7-7a2a7baa202f,C0034019,C0206750,mitigate spread of ,public health medicine (field),Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200
c7f0fb51-d25c-44ac-9ed3-4334a4bd2794,C0034019,C0012634,has has declared worldwide since ,public health medicine (field),Disease,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C23.550.288
c7f0fb51-d25c-44ac-9ed3-4334a4bd2794,C0034019,C0012634,was key disproportionately affected by ,public health medicine (field),Disease,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C23.550.288
c7f0fb51-d25c-44ac-9ed3-4334a4bd2794,C0034019,C0012634,mitigate spread of ,public health medicine (field),Disease,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C23.550.288
1283805a-a886-459a-8ce7-1b1892b1ee98,C0206750,C1704330,is in ,Coronavirus Infections,Dental Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C07
9d358b45-4ea0-42ab-9406-9103fafa1655,C0040034,C1511790,was ,Thrombocytopenia,Detection,2,X,[dsyn],[topp],C15.378.140.855,
fffd9143-8805-457d-8d13-642829c9f7e1,C0040034,C0206750,was Detection of patients with,Thrombocytopenia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.140.855,C02.782.600.550.200
8a84bd84-b048-45e3-b982-23c1cd5d2bd1,C1706202,C1707391,resulted in ,Search - action,Choose (action),3,X,[acty],[acty],,
81a8437b-c725-4748-9fac-b723c71d699c,C2948600,C0016059,evaluate efficacy in treatment of ,Aim,Fibrosis,2,X,[inch/phsu],[patf],,C23.550.355
215f847c-5e3b-4bcf-97ba-4f1619712717,C0016059,C0206750,is in patients with severe ,Fibrosis,Coronavirus Infections,2,X,[patf],[dsyn],C23.550.355,C02.782.600.550.200
215f847c-5e3b-4bcf-97ba-4f1619712717,C0016059,C0206750,direct future efforts towards its potential role in ,Fibrosis,Coronavirus Infections,1,X,[patf],[dsyn],C23.550.355,C02.782.600.550.200
1536dfb1-1706-4400-a659-7ee57752f421,C0014898,C0016059,used other anti ,Esters,Fibrosis,2,X,[orch],[patf],D02.241.400,C23.550.355
9fd3fa7f-877c-45ad-9885-9c2fa0e2876a,C0004482,C0016059,used other anti ,Azathioprine,Fibrosis,2,X,[hops/orch/phsu],[patf],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,C23.550.355
e67624d9-0c99-44ee-97e2-fae3a1a512f7,C0010583,C0016059,used other anti ,Cyclophosphamide,Fibrosis,2,X,[orch/phsu],[patf],D02.455.526.728.650.730.243;D02.705.672.500.243,C23.550.355
ce60d03c-60b9-4c63-9de5-f86a0ef40720,C3652465,C0016059,used other anti ,Interferon,Fibrosis,2,X,[aapp/imft/phsu],[patf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,C23.550.355
61b04631-6eab-4749-abde-e7181b35cf6d,C0025124,C0016059,used other anti ,Traditional Chinese Medicine,Fibrosis,2,X,[bmod],[patf],E02.190.488.585.520;I01.076.201.450.654.558.520,C23.550.355
739edc6c-ef21-4c09-94e5-d9cb66c71a69,C0014898,C0034060,used other anti ,Esters,Pulmonary Medicine,2,X,[orch],[bmod],D02.241.400,H02.403.429.675
517cb1d0-0ed5-47b4-90b9-98987297c2dc,C0004482,C0034060,used other anti ,Azathioprine,Pulmonary Medicine,2,X,[hops/orch/phsu],[bmod],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,H02.403.429.675
9f6c6862-1093-474d-9a0c-b850bd80e4e0,C0010583,C0034060,used other anti ,Cyclophosphamide,Pulmonary Medicine,2,X,[orch/phsu],[bmod],D02.455.526.728.650.730.243;D02.705.672.500.243,H02.403.429.675
1b43dc7c-b84d-4259-9910-96f85c4cdffd,C3652465,C0034060,used other anti ,Interferon,Pulmonary Medicine,2,X,[aapp/imft/phsu],[bmod],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,H02.403.429.675
bbc10aca-a5e4-49d8-a9a5-e35398bc1e45,C0025124,C0034060,used other anti ,Traditional Chinese Medicine,Pulmonary Medicine,2,X,[bmod],[bmod],E02.190.488.585.520;I01.076.201.450.654.558.520,H02.403.429.675
307f0026-48d6-4cc2-8efc-a0c76155e87a,C0014898,C2930789,consider in past ,Esters,nintedanib,2,X,[orch],[orch/phsu],D02.241.400,x.x.x.x
0b13cfec-bcf6-46d8-b8f8-5a102788e8f3,C0004482,C2930789,consider in past ,Azathioprine,nintedanib,2,X,[hops/orch/phsu],[orch/phsu],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,x.x.x.x
ab69aac0-30c1-46f9-a7d9-0d763aebb284,C0010583,C2930789,consider in past ,Cyclophosphamide,nintedanib,2,X,[orch/phsu],[orch/phsu],D02.455.526.728.650.730.243;D02.705.672.500.243,x.x.x.x
293e3df8-f508-4ab9-bbf4-8154e0bc4a93,C3652465,C2930789,consider in past ,Interferon,nintedanib,2,X,[aapp/imft/phsu],[orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,x.x.x.x
8fba1e11-9cd2-4c08-bc61-d58d6aa33a7f,C0025124,C2930789,consider in past ,Traditional Chinese Medicine,nintedanib,2,X,[bmod],[orch/phsu],E02.190.488.585.520;I01.076.201.450.654.558.520,x.x.x.x
a46be3c4-7a3e-4555-bb0f-37baf2163aea,C1254351,C0009905,is Anluohuaxian ,Pharmacologic Substance,Contraceptives Oral,1,X,[phsu],[phsu],,D27.505.696.875.360.276.210;D27.505.954.705.360.276.210
4ef88b6c-6f84-43d3-8014-a87d82df43c3,C1254351,C1136140,is Anluohuaxian ,Pharmacologic Substance,Long-Term Synaptic Depression,1,X,[phsu],[ortf],,G11.561.638.355
1563d022-419c-4eb3-b8a3-66db36f0be43,C1417168,HC,0.12 in HC,MID2 gene,HC,2,X,[gngm],????,,????
7e38108f-a307-4b62-8e91-f7f7f3fe8f17,C1268822,HC,0.12 in HC,Optical density function,HC,2,X,[clna],????,,????
95c98610-49fc-4f3f-a556-d2ed8c0f6b25,C1417167,HC,is in HC S1 ,MID1 gene,HC,4,X,[gngm],????,,????
c8c30dd5-09a0-4d54-8a83-144ee3c02b2e,C1417167,C0051980,is in HC S1 ,MID1 gene,anti-IgM,6,X,[gngm],[aapp/imft],,x.x.x.x
be16fa58-29bc-43b5-9b2f-f49306babb16,C1417167,S1,is in HC S1 ,MID1 gene,S1,1,X,[gngm],????,,????
bed80830-58ab-4933-a36a-e7d2c3a8ed99,C0254211,C0001551,combined with ,arbidol,Immunologic Adjuvants,1,X,[orch/phsu],[imft/phsu],x.x.x.x,D27.505.696.477.067
eea48d02-87d0-4d36-8b4c-b17ea5721091,C0254211,C0033972,combined with ,arbidol,Psychotherapy Multiple,1,X,[orch/phsu],[topp],x.x.x.x,F04.754.766
a3ec188c-b6ec-47bc-ad39-3fd1b4130380,C0254211,C0743841,relieve ,arbidol,Disorder characterized by fever,1,X,[orch/phsu],[dsyn],x.x.x.x,
1094d62e-5a3b-4b19-9f6f-8a63dcec0905,C0254211,C0206750,relieve ,arbidol,Coronavirus Infections,1,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
4adb6a34-be14-400a-b162-9296c73bfaa3,C0520510,C0441655,were found more ,Materials,Activities,3,X,[sbst],[acty],,
3e9d43f1-5ac6-4c85-9d3d-48724f33b941,C0151311,COVID-19,may Representation (action),Cranial nerve palsies,COVID-19,1,X,[dsyn],[virs],,C000657245
2c4042cf-d523-414e-914a-4b9ff1714ade,C0151311,C1518256,may Representation (action),Cranial nerve palsies,Nervous System Part,2,X,[dsyn],[bpoc],,
72228b40-7272-4320-a8c8-b3af49f504de,C0677043,C0015982,often reveals ,Histopathology,Fibrin,1,X,[bmod],[aapp/bacs/phsu],,D12.776.124.270
af470293-786f-40de-9180-c3b2e8ed7f2d,C0677043,C0011382,often reveals ,Histopathology,Dental Occlusion,1,X,[bmod],[ortf],,E06.276;G10.549.208
37984109-cbe0-49dd-a0fc-0359729a1889,C0005841,C0005821,Comparison to non-COVID wards for RBCs ,Blood Transfusion,Blood Platelets,2,X,[topp],[cell],E02.095.135,A11.118.188;A15.145.229.188
de1cf24f-8a40-4732-a409-b3cd1898e202,C0005841,C0032105,Comparison to non-COVID wards for RBCs ,Blood Transfusion,Plasma,2,X,[topp],[bdsu],E02.095.135,A12.207.152.693;A12.207.270.695;A15.145.693
44551954-5fa5-48bb-afe5-697c4f753b30,COVID-19,C0007189,brings changes For ,COVID-19,Cardiology discipline,1,X,[virs],[bmod],C000657245,H02.403.429.163
7dfc03d9-4d68-4098-9f17-0448267f3877,COVID-19,C1861452,are characterized with ,COVID-19,Storm Syndrome,1,X,[virs],[dsyn],C000657245,x.x.x.x
47aa850d-b746-4730-988e-fe24f71caa7e,C0424295,COVID-19,is in ,Hyperactive behavior,COVID-19,1,X,[mobd],[virs],,C000657245
332c2431-3093-42e4-9ce8-2ee5c3265d1a,C0301872,COVID-19,is in ,Immune response,COVID-19,2,X,[ortf],[virs],,C000657245
ef5a2446-2d20-4433-a0f8-aded4da4bb69,C1155266,COVID-19,is in ,inflammatory response,COVID-19,2,X,[patf],[virs],,C000657245
aff14535-1447-43b9-a2a8-0365dee20571,COVID-19,C0035204,is primarily ,COVID-19,Respiration Disorders,1,X,[virs],[dsyn],C000657245,C08.618
aff14535-1447-43b9-a2a8-0365dee20571,COVID-19,C0035204,can result in severe ,COVID-19,Respiration Disorders,1,X,[virs],[dsyn],C000657245,C08.618
7e31192f-c62c-4eb5-993c-4f9e4e6e4a64,COVID-19,C1880355,is primarily ,COVID-19,Discover,1,X,[virs],[acty],C000657245,
bcf361b8-387f-45cd-9a1a-f09f7501185b,C4554533,COVID-19,is in ,Trend:Type:Point in time:^Patient:Nominal,COVID-19,1,X,[clna],[virs],,C000657245
75353c50-9c3f-4cb4-a735-65b1f7bdc182,C0012634,C0008679,persons with ,Disease,Chronic disease,2,X,[dsyn],[dsyn],C23.550.288,C23.550.291.500
e99c087c-836f-46b5-9e22-e3af993382f8,C1262020,C1292533,was main finding in lung ,diffuse alveolar damage,Tissue specimen,1,X,[dsyn],[tisu],,
74277f34-82db-42b8-a9c3-8637ded951d8,C0700148,C0677043,were ,Congestion,Histopathology,1,X,[patf],[bmod],,
49ad1545-e412-46d9-8d7c-0b4839ff8b62,C0225698,C0333865,in Alveolar Epithelial Cells is,Alveolar Epithelial Cells,Cytologic atypia,2,X,[cell],[comd],A04.411.715.100;A11.436.081,
037e8633-c526-4feb-8658-e3636f64e18a,C0005847,C0677043,Congestion of were other,Blood Vessel,Histopathology,1,X,[bpoc],[bmod],A07.015,
bae8feab-a4df-4cb6-984f-5af8f2db86c4,C0005847,C0024109,Congestion of were other,Blood Vessel,Lung,1,X,[bpoc],[bpoc],A07.015,A04.411
bae8feab-a4df-4cb6-984f-5af8f2db86c4,C0005847,C0024109,amount of was In ,Blood Vessel,Lung,2,X,[bpoc],[bpoc],A07.015,A04.411
f78e504c-245e-4418-adc0-5d66850c3a18,C0024432,C0677043,accumulation of were ,macrophage,Histopathology,1,X,[cell],[bmod],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,
b21cdf9e-aca4-49d0-85d4-127a12932b2a,C0225698,C0677043,were ,Alveolar Epithelial Cells,Histopathology,1,X,[cell],[bmod],A04.411.715.100;A11.436.081,
670c16a5-4234-4214-8afc-bb83b19fa849,C0010054,C0018787,is most probable justification of observed pathologic changes in ,Coronary Arteriosclerosis,Heart,1,X,[dsyn],[bpoc],C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260,A07.541
b66411d2-fe49-454d-880e-c352109111e1,C1706202,C0599416,were performed in MEDLINE,Search - action,ovid,1,X,[acty],[mamm],,
2cd1b8ae-0051-4594-8bad-9484415d05e2,C4086266,C0184633,invasive ventilation of ,Escalation,Oxygen Therapy Care,1,X,[acty],[topp],,E02.880.690
3775d400-6718-4045-97ff-4d99eb98135e,HFNC,C1145670,reduce ventilation in patients with ,HFNC,Respiratory Failure,1,X,????,[dsyn],????,C08.618.846
7213f9cf-2320-453f-877a-be3215815292,HFNC,C0184633,reduce invasive ventilation of ,HFNC,Oxygen Therapy Care,2,X,????,[topp],????,E02.880.690
b4caaf8d-7a9d-47d9-a712-742faefc6e40,C0806140,COVID-19,need with ,Flow,COVID-19,1,X,[npop],[virs],,C000657245
56dce07d-9bdb-4bcb-b3c8-eff145770ace,cannula,COVID-19,need with ,cannula,COVID-19,1,X,????,[virs],????,C000657245
65e03567-88cf-4606-ac23-da0010ed9005,C0806140,C0184633,need with ,Flow,Oxygen Therapy Care,1,X,[npop],[topp],,E02.880.690
e695b9b2-dc68-4bad-a02f-f3073e7b127e,cannula,C0184633,need with ,cannula,Oxygen Therapy Care,1,X,????,[topp],????,E02.880.690
de41a461-c056-4ca8-b7a0-3ea4eb88ae4f,C0806140,C4039867,need with ,Flow,Acute hypoxemic respiratory failure,1,X,[npop],[dsyn],,
3676e35b-f29e-41e0-9f7d-9bed16e0c164,cannula,C4039867,need with ,cannula,Acute hypoxemic respiratory failure,1,X,????,[dsyn],????,
f2c969ff-663c-4f06-876f-d57a74ea24b3,COVID-19,C4039867,is with ,COVID-19,Acute hypoxemic respiratory failure,1,X,[virs],[dsyn],C000657245,
2360df6d-7cbf-4297-85b9-ef3fc855bcc3,C0184633,COVID-19,is in ,Oxygen Therapy Care,COVID-19,1,X,[topp],[virs],E02.880.690,C000657245
d88b7a51-4591-4c97-9188-819a676d1ca2,C0184633,C4039867,is in ,Oxygen Therapy Care,Acute hypoxemic respiratory failure,1,X,[topp],[dsyn],E02.880.690,
df568d23-e43c-4aea-9a63-cd9cd9e82734,C3714514,C4042908,were accounting to ,Infection,Seroconversion,2,X,[patf],[npop],C01.539,G12.800
6623b0fe-12e0-4b46-b4b3-3ae4473416ec,C0917707,C1708476,arguably Representation (action) key steps for,Cannulation,Implementation,1,X,[topp],[acty],E02.148;E05.157,
d85c5c84-3774-4de8-bf2b-19d82c0d4f74,C0917707,C0015357,arguably Representation (action) key steps for,Cannulation,Extracorporeal Membrane Oxygenation,1,X,[topp],[topp],E02.148;E05.157,E02.880.301;E04.292.451
a07c9973-87e1-4bd1-a33f-b2de8ab95617,C0917707,cannula,ensuring appropriate cannula ,Cannulation,cannula,1,X,[topp],????,E02.148;E05.157,????
2f12cd3d-694f-4d87-8bfb-f471e31303c9,C0005528,C0015357,implemented protocol for bedside ,Biological Transport,Extracorporeal Membrane Oxygenation,1,X,[celf],[topp],G03.143,E02.880.301;E04.292.451
33ecf0c3-fffa-4564-87a6-a3cf9c5bfdb0,C0005528,C0917707,implemented protocol for bedside ,Biological Transport,Cannulation,1,X,[celf],[topp],G03.143,E02.148;E05.157
c7617694-4f76-415a-80b8-87f1d9ddd750,C0023870,C0087111,is used to ,Lithium,Therapeutic procedure,1,X,[elii/phsu],[topp],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,E02
be3aa87a-80f0-407f-84b4-40aeb592e881,C0023870,C0005586,is used to ,Lithium,Bipolar Disorder,1,X,[elii/phsu],[mobd],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,F03.084.500
3c7a603f-ab2a-433c-8f42-52ad751d989b,C1861452,C0206419,patients with severe ,Storm Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
1ac464cc-6640-48f4-9286-573bbaca1b2b,C2700061,C0441655,restrictions on non-essential ,Transition (action),Activities,1,X,[acty],[acty],,
c0b19092-44c5-4e9e-8033-e44cd648e2a8,C4082587,C0441655,restrictions on non-essential ,HLA Class II Histocompatibility Antigen Gamma Chain human,Activities,1,X,[aapp/imft],[acty],,
77ef28ef-dec3-4c76-9596-242da2b41db2,C0012634,U.S.,is placing considerable strain on U.S. ,Disease,U.S.,1,X,[dsyn],????,C23.550.288,????
af48619d-d633-4d80-917c-311a07d7b48d,C0038952,COVID-19,is in ,Continuance of life,COVID-19,3,X,[acty],[virs],I03.784,C000657245
ba9a9d38-cf6e-46c5-91b2-23bfd5c6a032,C0007203,C0032285,is in cohort of similar critically ill patients with ,Cardiopulmonary Resuscitation,Pneumonia,3,X,[topp],[dsyn],E02.365.647.110,C08.381.677;C08.730.610
d66fd352-dadc-4ab8-acd4-47013a944512,C0030738,C0042397,were receiving ,Peas - dietary,Vasoconstrictor Agents,3,X,[food],[phsu],B01.650.940.800.575.912.250.401.630,D27.505.954.411.793
90507d5e-23d7-4fc5-933e-6a7e90b2672c,C0450254,C0036974,caused ,Pathogenic organism,Shock,1,X,[orgm],[patf],,C23.550.835
a117ce7d-6812-4d64-8e79-afec2fdbdaf0,C0450254,C0003467,caused nationwide ,Pathogenic organism,Anxiety,1,X,[orgm],[mobd],,F01.470.132
00e09b33-3cca-48c3-84d3-4fae62f490f8,C0072027,C0206750,be indicator of disease severity in ,procalcitonin,Coronavirus Infections,2,X,[aapp/bacs],[dsyn],D06.472.699.666;D12.644.548.744;D12.776.811.555,C02.782.600.550.200
a5833e60-201a-4df3-a6b9-4525c0cd6695,C0229671,C1175743,collected from ,Serum,SARS coronavirus,1,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150.113.937
a5833e60-201a-4df3-a6b9-4525c0cd6695,C0229671,C1175743,was significantly higher in ,Serum,SARS coronavirus,2,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150.113.937
606da1a5-075d-42f3-af46-6df2386e5336,C0022709,C0028429,is in ,Peptidyl-Dipeptidase A,Nose,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A01.456.505.733;A04.531;A09.531
9acb2801-074d-4969-b1aa-d1dc17882c11,C0035668,C0022709,revealed ,RNA,Peptidyl-Dipeptidase A,1,X,[nnon],[aapp/enzy/imft],D13.444.735,D08.811.277.656.350.350.687
b1eec715-ef24-4382-8fcc-c7fa8dfeb75e,C0009450,C0024109,is in proximal ,Communicable Diseases,Lung,1,X,[dsyn],[bpoc],C01.539.221,A04.411
b1eec715-ef24-4382-8fcc-c7fa8dfeb75e,C0009450,C0024109,requires collaboration of ,Communicable Diseases,Lung,2,X,[dsyn],[bpoc],C01.539.221,A04.411
a6206ad8-29be-4320-9b5e-1ac62ad98f18,C0024109,C0012634,identified focal ,Lung,Disease,1,X,[bpoc],[dsyn],A04.411,C23.550.288
b0f029fe-7d47-49b9-b2b8-3ad7d7bcfb73,C0700198,C1175743,is in ,Pulmonary aspiration,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
39269c48-e785-4939-94d7-208e587f776f,C1175743,C0700198,is with likely subsequent ,SARS coronavirus,Pulmonary aspiration,2,X,[virs],[patf],B04.820.504.540.150.113.937,
8f88f249-d2a1-4082-b643-f58f4a841016,C0011777,C0027497,delayed ,Dexamethasone,Nausea,2,X,[orch/phsu],[sosy],D04.210.500.745.432.769.344;D04.210.500.908.238,C23.888.821.712
1b9df7db-e8c6-438a-a33e-c91c830f22c5,C0011777,C0042963,delayed ,Dexamethasone,Vomiting,2,X,[orch/phsu],[sosy],D04.210.500.745.432.769.344;D04.210.500.908.238,C23.888.821.937
68a1770e-a413-487e-a51f-f4224afa2f1a,C0677960,C4048329,may augment ,T-Cell Depletion Therapy,Immunosuppression,2,X,[topp],[dsyn],,E02.095.465.425.450;E05.478.610
3bf067f2-654f-4c4c-9719-c17cca31c0a5,C0024264,C0301872,are vital in ,Lymphocyte,Immune response,2,X,[cell],[ortf],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
46a21ae4-edc7-4ad5-86a0-f0a9dd003fca,C0003297,C0206750,are available during ,Antiemetics,Coronavirus Infections,1,X,[phsu],[dsyn],D27.505.696.663.050.030;D27.505.954.427.095;D27.505.954.483.200,C02.782.600.550.200
c034de6f-0208-41ee-999b-1bdb4e311498,C2948600,C0015397,describe demographics of patients with ,Aim,Disorder of eye,1,X,[inch/phsu],[dsyn],,C11
197d8e6e-ea8a-4d78-8f30-8a0da2aab018,C0242781,C4287874,mainly occurs by ,disease transmission,Droplet Transmission,4,X,[patf],[patf],N06.850.310,
f0d7313d-07d8-4727-a93f-57c0d9c89eec,C0032105,FFP2,Reprocess FFP2,Plasma,FFP2,2,X,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693,????
f0d7313d-07d8-4727-a93f-57c0d9c89eec,C0032105,FFP2,allows to FFP2,Plasma,FFP2,1,X,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693,????
ddd9e992-58af-4b53-b9bf-50a10d7cd2af,C0038280,FFP2,Reprocess FFP2,Sterilization for infection control,FFP2,2,X,[topp],????,N06.850.780.200.450.850,????
ddd9e992-58af-4b53-b9bf-50a10d7cd2af,C0038280,FFP2,allows to FFP2,Sterilization for infection control,FFP2,1,X,[topp],????,N06.850.780.200.450.850,????
99ed0586-fe2b-469f-b99c-6145e4cb6ad6,C0011121,C0017110,were further checked by single ,Decontamination,Gases,4,X,[topp],[chvs],N06.850.780.325,D01.362
99ed0586-fe2b-469f-b99c-6145e4cb6ad6,C0011121,C0017110,were further checked for residual ,Decontamination,Gases,1,X,[topp],[chvs],N06.850.780.325,D01.362
51ffbb00-8664-495b-be56-c9ba0696971f,C0011121,C0011744,were further checked for residual ,Decontamination,Deuterium,8,X,[topp],[elii],N06.850.780.325,D01.268.406.500;D01.362.340.500;D01.496.289;x.x.x.x
10ae127e-ad0a-4527-8b99-ad73a258f2f1,C0011121,C0389006,were further checked for residual ,Decontamination,Growth Arrest-Specific Protein 2,8,X,[topp],[aapp/bacs],N06.850.780.325,
c089659a-6bfb-487e-b70b-9019e7e33c81,C0011121,C0031180,were further checked for residual ,Decontamination,Peroxides,12,X,[topp],[inch],N06.850.780.325,D01.248.497.158.685.750;D01.339.431.374;D01.650.550.750;D02.389.338
b5af827a-37c6-4b34-835a-1095e9f7e2a7,C0015376,C0004178,was quantitatively tested with 10 test persons in ,Extravasation,Atmosphere planetary,4,X,[patf],[npop],,G16.500.275.063;N06.230.300.100
acf5c251-2428-4d15-aeb1-bbaea4bad097,C0015376,C0030415,was quantitatively tested with 10 test persons in ,Extravasation,Paraffin,4,X,[patf],[bodm/orch],,D02.455.612
eec28e0a-d2e0-440d-8067-b57b78af97b2,C0036572,C0015376,was calculated as inverse of total inward ,Seizures,Extravasation,1,X,[sosy],[patf],C10.597.742;C23.888.592.742,
6b3601f3-e6c3-4ee1-8ec4-68f91102ed66,C0118522,C0020964,regulates expression of wide array of genes involved in ,GA-Binding Protein Transcription Factor,Immunity,2,X,[aapp/bacs],[phsf],D12.776.260.615.249;D12.776.930.618.249,G12.450
e1b6b99e-1f2e-49f0-abd3-35bdb3f41d1f,C0118522,C0007634,regulates ,GA-Binding Protein Transcription Factor,Cells,2,X,[aapp/bacs],[cell],D12.776.260.615.249;D12.776.930.618.249,A11
486de02e-846e-41a5-814e-95615a85b3d4,C0021966,C0036572,assumed that as ,Iodides,Seizures,1,X,[inch],[sosy],D01.248.497.158.490;D01.475.410,C10.597.742;C23.888.592.742
9354b064-511b-4c2b-b58f-5103095d621b,C0021079,C1520005,contributes to ,Therapeutic immunosuppression,Viral Pathogenesis,4,X,[topp],[patf],E02.095.465.425.450;E05.478.610,
65b2b4f0-58ac-4d90-bfe2-4a263ed61bf8,C0002518,C1175743,is with ,Amino Acid Sequence,SARS coronavirus,2,X,[amas],[virs],G02.111.570.060;L01.453.245.667.060,B04.820.504.540.150.113.937
142959bd-fb10-4a3a-8e10-5f17f5451bcb,orf6,C1512835,demonstrated strongest ,orf6,Interferon Suppression,2,X,????,[phsf],????,
869a6626-2bb7-4378-b38b-430350a3881d,orf6,C0042736,demonstrated Interferon Suppression Among,orf6,Viral Proteins,2,X,????,[aapp/bacs],????,D12.776.964
07a82ea7-5d28-4b81-b4d8-8081a88039fc,C1175743,xenti,may may considered for development of intranasal live but xenti ,SARS coronavirus,xenti,2,X,[virs],????,B04.820.504.540.150.113.937,????
d2bbbe1f-cdce-48fe-bc73-702d82fc58d4,C0230425,C4554533,had descending ,Structure of right thigh,Trend:Type:Point in time:^Patient:Nominal,3,X,[bpoc],[clna],,
d485adc7-2cec-45e0-8f48-e4d7257f4cb5,C3652465,C0017262,turns on ,Interferon,Gene Expression,2,X,[aapp/imft/phsu],[genf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G05.297
102195cb-e6f3-4c8d-a3f0-7d7b6d949c5c,C0206750,C0027270,also induces severe attack on ,Coronavirus Infections,Nicotinamide adenine dinucleotide (NAD),2,X,[dsyn],[bacs/nnon/phsu],C02.782.600.550.200,D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694
e4ada3d0-10e3-42ce-a289-bf4912a3b714,C0020281,C0450442,was minimally effective as viricidal ,Hydrogen Peroxide,Agent,2,X,[inch/irda/phsu],[chvf],D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253,
5281de1e-d64b-4fa7-b68c-b6e4a734cfe3,C1882955,C0020281,is in range of may preferred over ,Rinsing,Hydrogen Peroxide,1,X,[acty],[inch/irda/phsu],,D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253
7e900964-264b-47be-b11d-33d0677ff2fd,C1882955,C0032857,is with diluted ,Rinsing,Povidone-Iodine,1,X,[acty],[orch/phsu],,D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745
6b038c7d-6676-4fb7-ad2e-5ebffc672006,C1305855,C0007222,higher prevalence of ,Body mass index,Cardiovascular Diseases,1,X,[clna],[dsyn],E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,C14
294ee548-9e9c-4959-91e5-c800c6ddd665,C1305855,C0020538,higher prevalence of ,Body mass index,Hypertensive disease,1,X,[clna],[dsyn],E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,C14.907.489
60176863-5320-41fa-bfe8-6a3aa0b0997b,C1175743,N95,has caused severe shortage of N95 ,SARS coronavirus,N95,1,X,[virs],????,B04.820.504.540.150.113.937,????
889d8660-f685-47ff-9cc7-f98808c3a348,C0011121,C0038280,must result in ,Decontamination,Sterilization for infection control,4,X,[topp],[topp],N06.850.780.325,N06.850.780.200.450.850
0cc90fd6-c45b-4ccb-909a-c734229d2063,C0206390,C1175743,surrogate for ,Phage MS2,SARS coronavirus,1,X,[virs],[virs],B04.123.205.600.500;B04.123.691.600.500;B04.820.410.500,B04.820.504.540.150.113.937
731fcf21-d5ed-4577-a3ea-707eb7044c9d,C0543467,C0206058,plummeted due to reduction in ,Operative Surgical Procedures,Elective Surgical Procedures,2,X,[topp],[topp],E04,E04.249
a934d657-2f4a-4357-bd8f-06376886ff1c,C1523935,C1175743,fight ,cellular catabolic process,SARS coronavirus,1,X,[celf],[virs],,B04.820.504.540.150.113.937
395b98f0-70f2-474f-bf4c-5b70a956ad5d,C1523935,C0004391,known as ,cellular catabolic process,Autophagy,2,X,[celf],[celf],,G04.146.399;G04.417.350.091
19c07cf8-75eb-48f7-b289-6701a0a5b1e2,C1523935,C0206419,fight novel ,cellular catabolic process,Genus: Coronavirus,1,X,[celf],[virs],,B04.820.504.540.150
4f4ee2a3-c14b-4fc2-9593-c089ae3c48d3,C0034019,C1947932,would reduce risk of ,public health medicine (field),Smear - instruction imperative,1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
37e89d29-07d2-41fa-85d2-f471c2981541,C0010076,C1706079,had more evidence of physiologic disturbances on ,Coronaviridae,Arrival - action,1,X,[virs],[acty],B04.820.504.540,
90b9ae1e-69fb-4942-96ac-ede288353b59,C0012634,C1706079,had more evidence of physiologic disturbances on ,Disease,Arrival - action,1,X,[dsyn],[acty],C23.550.288,
b14db504-530d-4536-8f31-cad5e56fea68,C0206419,C0439056,was positive for ,Genus: Coronavirus,Throat swab sample,1,X,[virs],[bdsu],B04.820.504.540.150,
2c06c99d-0238-485a-92e9-b142b8091625,=-RRB-,C0032285,presented involvement Among those with ,=-RRB-,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
ff59fb89-5834-4826-8348-c4672aa139b3,=-RRB-,C0206061,had ,=-RRB-,Pneumonia Interstitial,2,X,????,[dsyn],????,C08.381.483
0f1dae24-1acc-4f3e-aaef-51d470199d97,C0599878,C0030755,is in ,disease characteristic,Pediatrics,1,X,[patf],[bmod],,H02.403.670
cc82d786-a94d-40e5-a3cc-ca1618567185,C3826426,C0012634,effective treatment of ,Dynamics,Disease,1,X,[npop],[dsyn],,C23.550.288
a25ba860-6ec4-4c8f-a3b5-a9403ad06833,C1539479,C0013227,is in aquatic compartments of ,FATE1 gene,Pharmaceutical Preparations,1,X,[gngm],[phsu],,D26
51464060-924d-4f7a-ad97-523f6951efe6,C0016510,C0206419,be redefined during ,Foot Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C05.360;C17.800.321,B04.820.504.540.150
eb00e20d-41e4-4a81-849e-8b4da81cbc94,C0206172,C0206419,been how affected by ,Diabetic Foot,Genus: Coronavirus,2,X,[dsyn],[virs],C14.907.320.191;C17.800.893.592.450.200;C19.246.099.500.191;C19.246.099.937.250,B04.820.504.540.150
e1f9d49e-757e-4fbe-b225-9ec4e220bb6a,SEIR,C0948998,is well-known method used in simulations of ,SEIR,Viral Contagious disease,2,X,????,[dsyn],????,
78f960af-5f2e-40c6-a3cc-c586be50e3f3,SEIRS,C0012634,is with additional exit ,SEIRS,Disease,2,X,????,[dsyn],????,C23.550.288
74812d2a-8e3c-44a5-a96d-da211e1cceae,C1175743,C0878544,has shown association with acute myocardial injury ,SARS coronavirus,Cardiomyopathies,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C14.280.238
117bdc49-87d3-471a-8d7d-9697cb160cd5,C0009450,C0878544,has shown association with acute myocardial injury ,Communicable Diseases,Cardiomyopathies,2,X,[dsyn],[dsyn],C01.539.221,C14.280.238
4b35227c-a96f-40b4-9a46-beafc8770825,C1175743,C0027059,has shown association with acute myocardial injury ,SARS coronavirus,Myocarditis,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C14.280.238.625
795ed3e8-93be-49d0-af87-dc28043282cb,C0009450,C0027059,has shown association with acute myocardial injury ,Communicable Diseases,Myocarditis,2,X,[dsyn],[dsyn],C01.539.221,C14.280.238.625
815356ab-55cd-46f1-9bf3-111c4289a2bb,C0161816,C0206419,also occur in ,Cardiac complication,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
ac28f307-3f5c-4296-8115-c8014a7bd2bf,C0161816,C1155266,occur because of high ,Cardiac complication,inflammatory response,4,X,[patf],[patf],,
c37600f7-d3ef-4a10-96d7-72fef2b10f09,C0021822,C3888108,evaluating resources in ,Interview,Import into cell,1,X,[acty],[celf],E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420,
c37600f7-d3ef-4a10-96d7-72fef2b10f09,C0021822,C3888108,evaluating obstacles in ,Interview,Import into cell,1,X,[acty],[celf],E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420,
64d0ddff-e240-4223-8f3f-dc0a49be7762,C0023660,C0003209,is known for its ,Lidocaine,Anti-Inflammatory Agents,1,X,[orch/phsu],[phsu],D02.065.199.092.500;D02.092.146.113.092.500,D27.505.954.158
6c28957b-d051-4fe8-a7e2-5fd8df549849,C0023660,C0010200,reduce ,Lidocaine,Coughing,1,X,[orch/phsu],[sosy],D02.065.199.092.500;D02.092.146.113.092.500,C08.618.248;C23.888.852.293
bea586d4-401b-488f-b93f-80804db9d4ad,C0023660,C0037090,improve ,Lidocaine,Signs and Symptoms Respiratory,1,X,[orch/phsu],[sosy],D02.065.199.092.500;D02.092.146.113.092.500,C23.888.852
9f504d64-37e9-4682-b166-09378a1d4374,C0023660,C0079189,reducing ,Lidocaine,cytokine,1,X,[orch/phsu],[aapp/imft],D02.065.199.092.500;D02.092.146.113.092.500,D12.644.276.374;D12.776.467.374;D23.529.374
cb49ab42-49c2-4434-904b-386c037169db,C0023660,C0024109,protecting patients ,Lidocaine,Lung,1,X,[orch/phsu],[bpoc],D02.065.199.092.500;D02.092.146.113.092.500,A04.411
de774e66-7f6a-4b0b-93f0-84f2631155c0,C0023660,C0206419,is in ,Lidocaine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.065.199.092.500;D02.092.146.113.092.500,B04.820.504.540.150
502d55a0-fb03-42b1-b6db-a118b80263e5,C0035028,C0086418,can can viewed as Global ,Relaxation,Homo sapiens,2,X,[acty],[humn],I03.450.769,B01.050.150.900.649.313.988.400.112.400.400
6f8287d0-394b-4055-9d9e-727bd9c334c4,C1175743,C1522002,of M Protein multiple myeloma is,SARS coronavirus,RNA Recognition Motif,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,G02.111.570.820.709.275.500.869.500
c2d8d449-0fc5-4780-a04f-58cd0428e7ed,C0275522,C0206750,Patients with ,Asymptomatic Infections,Coronavirus Infections,2,X,[dsyn],[dsyn],C23.550.291.187.500,C02.782.600.550.200
c2d8d449-0fc5-4780-a04f-58cd0428e7ed,C0275522,C0206750,constitute substantial component of ,Asymptomatic Infections,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.187.500,C02.782.600.550.200
fb22e7f1-3cee-489e-a470-57fea5f4e33f,C0042762,C0020517,management of patients with ,Science of Virology,Hypersensitivity,2,X,[bmod],[patf],H01.158.273.540.859,C20.543
e25198f4-a956-49e7-a630-857e2f2e0f96,CT/MR,C0265085,showed common pattern ,CT/MR,Cortical hemorrhage,3,X,????,[patf],????,
388cdc32-e39e-49e0-88d6-ffd14884d479,C0304925,C0003402,is Acute-Phase Proteins with,Albumin Human USP,Antioxidants,1,X,[aapp/phsu],[phsu],D12.776.034.841.603;D12.776.124.727.906,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
a897fc81-3f94-4786-aaa8-4a81be4cfd0a,C0001347,C0003402,is with ,Acute-Phase Proteins,Antioxidants,1,X,[aapp/bacs],[phsu],D12.776.124.050,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
64b28693-7258-4fba-bae4-803889f1303a,C0304925,C0001347,is ,Albumin Human USP,Acute-Phase Proteins,1,X,[aapp/phsu],[aapp/bacs],D12.776.034.841.603;D12.776.124.727.906,D12.776.124.050
f752eeb3-864a-47a5-b146-2373304cb09d,C0038952,C0206750,is in ,Continuance of life,Coronavirus Infections,1,X,[acty],[dsyn],I03.784,C02.782.600.550.200
9f419747-6fcf-45e5-a1a8-ed61d5fb0495,C0001924,C1565830,were At ,Albumins,PTGS1 protein human,1,X,[aapp/bacs],[aapp/enzy],D12.776.034,x.x.x.x
7a833c9f-7b78-455d-a29b-0c3c0664249d,C0304925,C0206750,identify patients at risk of death in ,Albumin Human USP,Coronavirus Infections,1,X,[aapp/phsu],[dsyn],D12.776.034.841.603;D12.776.124.727.906,C02.782.600.550.200
1dd77773-d884-4d2a-aa61-a0caf81605fb,C0199848,C0206750,for Coronavirus vaccination is causative agent of,Coronavirus vaccination,Coronavirus Infections,4,X,[topp],[dsyn],,C02.782.600.550.200
070b28b3-9926-491c-a1dd-b6d7a3ba05b5,C0042742,C0086418,have have licensed for use in ,Viral Vaccines,Homo sapiens,2,X,[imft/phsu],[humn],D20.215.894.899,B01.050.150.900.649.313.988.400.112.400.400
c86cf041-dccb-4558-8ce3-600defa17f45,EULAR,C1175743,address several aspects of ,EULAR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
efcf8bbc-6de7-4431-bf5d-34286506ae83,C0022674,C1175743,targeted by ,Renal tubule structure,SARS coronavirus,1,X,[bpoc],[virs],A05.810.453.736.560,B04.820.504.540.150.113.937
efcf8bbc-6de7-4431-bf5d-34286506ae83,C0022674,C1175743,be potential ,Renal tubule structure,SARS coronavirus,1,X,[bpoc],[virs],A05.810.453.736.560,B04.820.504.540.150.113.937
feddc376-89ef-4ec1-a69e-724f3756f4cd,C0022674,C1819995,be potential ,Renal tubule structure,Host Cell,1,X,[bpoc],[celc],A05.810.453.736.560,
888925f7-3751-4d73-8ec3-740ce906636d,C0022709,2DCR,was higher compared to that in 2DCR ,Peptidyl-Dipeptidase A,2DCR,3,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
5b8a3233-48e8-4e9e-b2d1-a916fd1d0ce8,C0022709,C0012634,was higher compared to that in 2DCR ,Peptidyl-Dipeptidase A,Disease,3,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C23.550.288
5b8a3233-48e8-4e9e-b2d1-a916fd1d0ce8,C0022709,C0012634,may may ,Peptidyl-Dipeptidase A,Disease,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C23.550.288
4d15700d-3234-47a3-b9a3-92e85b184469,C0206419,C1167622,using high-throughput ,Genus: Coronavirus,Binding (Molecular Function),2,X,[virs],[moft],B04.820.504.540.150,
4783f93b-8d82-4ada-80f6-b6c32a5ea578,C0206419,C1510827,using high-throughput ,Genus: Coronavirus,Affinity,1,X,[virs],[npop],B04.820.504.540.150,
f7c38711-7fdd-4091-ad7f-46d23c53f726,C0012634,C0599779,was run on ,Disease,Animal Model,1,X,[dsyn],[anim],C23.550.288,E05.598
0174aa11-1527-4832-99c8-44f3d1f7235b,Cov2,C0007634,uses Peptidyl-Dipeptidase A receptor as entry point to,Cov2,Cells,1,X,????,[cell],????,A11
ba351877-2d4c-4723-b4ae-77563bb0a596,Cov2,C0022709,uses ,Cov2,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
637f4026-a189-455b-9dcd-f4dd5aebdafd,Cov2,C0597357,uses ,Cov2,receptor,1,X,????,[aapp/rcpt],????,
654c4667-1034-43ad-a8e8-4b050bc5a3f0,C0815017,C0206419,was associated with higher ,Angiotensin Receptor Antagonists,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.519.162,B04.820.504.540.150
6d221c8c-535e-4dcb-914c-11c1824ffa6d,C2948600,C0683325,investigate ,Aim,clinical aspects,2,X,[inch/phsu],[clna],,
6d221c8c-535e-4dcb-914c-11c1824ffa6d,C2948600,C0683325,describe specific ,Aim,clinical aspects,1,X,[inch/phsu],[clna],,
6d221c8c-535e-4dcb-914c-11c1824ffa6d,C2948600,C0683325,systematically review main ,Aim,clinical aspects,1,X,[inch/phsu],[clna],,
2093bbae-3164-410d-b47c-b11bf804cbe0,C2948600,C1175743,investigate ,Aim,SARS coronavirus,2,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2093bbae-3164-410d-b47c-b11bf804cbe0,C2948600,C1175743,minimize risk of transmission of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2093bbae-3164-410d-b47c-b11bf804cbe0,C2948600,C1175743,summarize data on treatment of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2093bbae-3164-410d-b47c-b11bf804cbe0,C2948600,C1175743,determine prevalence of symptoms among laboratory-confirmed ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2093bbae-3164-410d-b47c-b11bf804cbe0,C2948600,C1175743,evaluate novel immunoassays for detection of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2093bbae-3164-410d-b47c-b11bf804cbe0,C2948600,C1175743,examine seroprevalence of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
8836ebba-50ca-4be4-b030-464545c44193,C0683325,C1175743,is with ,clinical aspects,SARS coronavirus,2,X,[clna],[virs],,B04.820.504.540.150.113.937
9b0c6c3a-9ecb-4d41-935d-4f0684b66160,C0023530,C0004002,were For laboratory result indicators for pediatric inpatients followed by ,Leukopenia,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.546,D08.811.913.477.700.225
9b0c6c3a-9ecb-4d41-935d-4f0684b66160,C0023530,C0004002,were For laboratory result indicators followed by high ,Leukopenia,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.546,D08.811.913.477.700.225
66aa041f-a657-48b2-bc82-a2889a47d95a,C0024282,C0004002,were For laboratory result indicators for inpatients followed by ,Lymphocytosis,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.475.604,D08.811.913.477.700.225
66aa041f-a657-48b2-bc82-a2889a47d95a,C0024282,C0004002,were For laboratory result indicators followed by high ,Lymphocytosis,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.475.604,D08.811.913.477.700.225
675ec9a7-33b5-4016-9dfb-fe0b91bc5b9c,C1135927,C0026769,have developed protocol for management of ,Immunity Herd,Multiple Sclerosis,2,X,[phsf],[dsyn],G12.450.400,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
86a86ac3-08d8-4558-bed4-e34fecfd2249,C0042075,C1704272, includes ,Urologic Diseases,Benign Prostatic Hyperplasia,2,X,[dsyn],[dsyn],C12.777;C13.351.968,C12.294.565.500
c8090085-d67c-45ea-b1e6-6de3db916a93,C0015967,C3714514,can occur along with urological ,Fever,Infection,1,X,[sosy],[patf],C23.888.119.344,C01.539
96c06414-a072-4251-97ad-443d79383a43,C0010076,C1175743,designated SARS coronavirus as,Coronaviridae,SARS coronavirus,2,X,[virs],[virs],B04.820.504.540,B04.820.504.540.150.113.937
96c06414-a072-4251-97ad-443d79383a43,C0010076,C1175743,find ,Coronaviridae,SARS coronavirus,1,X,[virs],[virs],B04.820.504.540,B04.820.504.540.150.113.937
0374a915-d824-4f32-adf9-51e298fe0cba,C0010076,C0206419,designated SARS coronavirus as,Coronaviridae,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540,B04.820.504.540.150
b62ecc60-595b-4e5a-9f94-8f74c3cf1117,C0008139,C4086523,being ,Chiroptera,Intermediate Host,1,X,[mamm],[orgm],B01.050.150.900.649.313.937,
675882f9-2645-431e-8b1b-15b9a19e2d36,COVID-19,C1706374,has led by end of ,COVID-19,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[virs],[aapp/bacs],C000657245,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
675882f9-2645-431e-8b1b-15b9a19e2d36,COVID-19,C1706374,were collected up to ,COVID-19,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[virs],[aapp/bacs],C000657245,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
c613ac38-dba8-43e0-b014-b822f2baf361,C0003451,C3652465,included abidol ,Antiviral Agents,Interferon,2,X,[phsu],[aapp/imft/phsu],D27.505.954.122.388,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
73755f2f-0ad0-45ce-ba58-c14ed6af02d7,C0003451,C0939237,included abidol ,Antiviral Agents,lopinavir / Ritonavir,2,X,[phsu],[phsu],D27.505.954.122.388,
8eff0319-d106-4c36-a9c8-e4943e776a83,C0003451,abidol,included abidol ,Antiviral Agents,abidol,2,X,[phsu],????,D27.505.954.122.388,????
45571929-70db-4300-9eda-a485ff91a69f,C0003451,C0035525,included abidol ,Antiviral Agents,Ribavirin,2,X,[phsu],[nnon/phsu],D27.505.954.122.388,D13.570.800.790
6ed6009f-02c3-4f8b-9141-1c212cbaa91c,C0085278,C0005516,Obtaining serial ,Antiphospholipid Syndrome,Biological Markers,1,X,[dsyn],[clna],C20.111.197,D23.101
9d35dbef-1e0a-4a20-8cd8-82697909490b,C0085278,C0162595,Obtaining Biological Markers in conjunction with,Antiphospholipid Syndrome,Antiphospholipid Antibodies,1,X,[dsyn],[aapp/imft],C20.111.197,D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210
ac5c3dcb-e86a-4bb3-9f54-182ade5ba7f7,C0085278,C1175743,observed in ,Antiphospholipid Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C20.111.197,B04.820.504.540.150.113.937
e335663a-f462-4fcd-bf8e-fcadcc619c19,C0010076,C0056912,find ,Coronaviridae,cytidylyl-3'-5'-guanosine,1,X,[virs],[bacs/nnon],B04.820.504.540,x.x.x.x
0c7d6ecc-10c8-4705-8e56-432ee902f960,C0056912,C0242972,are Diet Protein-Restricted for spike,cytidylyl-3'-5'-guanosine,Diet Protein-Restricted,2,X,[bacs/nnon],[topp],x.x.x.x,E02.642.249.280;G07.203.650.240.280
0fe515b5-da63-49e2-8509-974242e388ce,C0206419,HKU1, includes HKU1,Genus: Coronavirus,HKU1,2,X,[virs],????,B04.820.504.540.150,????
aa8a000d-acaa-4753-9658-30f8131cf5c6,C0206419,3-end,are greater for 3-end ,Genus: Coronavirus,3-end,1,X,[virs],????,B04.820.504.540.150,????
afff6304-cdee-49e1-abb3-1da6624e2c53,C0206419,C0042720,are greater for 3-end ,Genus: Coronavirus,Viral Genome,1,X,[virs],[gngm],B04.820.504.540.150,G05.360.340.358.840
68f8b200-9c6e-47de-bb02-b9db56f4e0c8,HKU1,3-end,are greater for 3-end ,HKU1,3-end,1,X,????,????,????,????
fb98adf0-cd26-4d17-b36c-dfa950514875,HKU1,C0042720,are greater for 3-end ,HKU1,Viral Genome,1,X,????,[gngm],????,G05.360.340.358.840
25239d85-e97c-45dc-bb3f-ccc1a01409da,C1519323,C0056912,seem driven by value of ,Silent Mutation,cytidylyl-3'-5'-guanosine,1,X,[genf],[bacs/nnon],G05.365.590.803,x.x.x.x
25239d85-e97c-45dc-bb3f-ccc1a01409da,C1519323,C0056912,driven by high value of ,Silent Mutation,cytidylyl-3'-5'-guanosine,1,X,[genf],[bacs/nnon],G05.365.590.803,x.x.x.x
b702052a-1631-4cfc-b5e7-e824a7373d0f,C1519323,C0065827,seem driven by value of ,Silent Mutation,Measles Virus Nucleoprotein,1,X,[genf],[aapp/bacs],G05.365.590.803,x.x.x.x
b702052a-1631-4cfc-b5e7-e824a7373d0f,C1519323,C0065827,driven by high value of ,Silent Mutation,Measles Virus Nucleoprotein,1,X,[genf],[aapp/bacs],G05.365.590.803,x.x.x.x
1c025d98-63fa-4ddd-8375-8a45697f6db1,C1519323,C0012476,Using application on ,Silent Mutation,Dinucleoside Phosphates,1,X,[genf],[nnon],G05.365.590.803,D13.695.250
1d0f90d6-ae60-4212-9411-2a21589646d3,C0056912,C0065827,is in ,cytidylyl-3'-5'-guanosine,Measles Virus Nucleoprotein,1,X,[bacs/nnon],[aapp/bacs],x.x.x.x,x.x.x.x
cb2e9588-9ef1-4745-89d8-19c235fdef60,C1519323,C1707391,Using new application of ,Silent Mutation,Choose (action),1,X,[genf],[acty],G05.365.590.803,
38e74099-a724-401e-b879-460a6ae8d196,C1514562,C1167622,match recently identified ,Protein Domain,Binding (Molecular Function),1,X,[amas],[moft],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
9daaf75e-ed95-4940-8e6c-692e75d2cb21,C1514562,C1428222,match recently identified ,Protein Domain,ZC3HAV1 gene,1,X,[amas],[gngm],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
45ed1fe0-45a0-4194-9ece-e475d4267b2c,subtype,C0037090,is with prominent ,subtype,Signs and Symptoms Respiratory,2,X,????,[sosy],????,C23.888.852
221fa9e7-ca95-46a3-a58f-7b3f57e227a0,C0037090,C1327613,is characterized by ,Signs and Symptoms Respiratory,fear response,2,X,[sosy],[phsf],C23.888.852,
4a176e38-a4bd-4f85-b4e7-ccb571e8462e,C0037090,C0036658,is characterized by ,Signs and Symptoms Respiratory,Esthesia,2,X,[sosy],[ortf],C23.888.852,F02.830.816;G11.561.790
69bfab5d-0c56-419e-817e-ba2f02f3e162,C0037090,C0010200, includes ,Signs and Symptoms Respiratory,Coughing,2,X,[sosy],[sosy],C23.888.852,C08.618.248;C23.888.852.293
76a785a9-8134-48aa-a2da-1ed6420c8b1b,C0037090,C0221423,are Indeed associated with poor ,Signs and Symptoms Respiratory,Illness (finding),2,X,[sosy],[sosy],C23.888.852,
ce1fc625-ab14-4b01-a2d2-a8ae668864f7,C0010200,C0221423,are Indeed associated with poor ,Coughing,Illness (finding),2,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
9b2ff178-cefc-46f2-9d7d-da3ed13db1d5,C1099456,C0030319,are First line treatment for,Escitalopram,Panic Disorder,2,X,[orch/phsu],[mobd],D02.092.831.170;D02.626.320;D03.633.100.127.187,F03.080.700
bb98a4b2-61b1-4944-8623-7af681f0a5ce,C1099456,C1708063,are ,Escitalopram,First line treatment,2,X,[orch/phsu],[topp],D02.092.831.170;D02.626.320;D03.633.100.127.187,
711d0daf-329c-4c3c-9f88-b8be93caa55e,C0020404,C0150135,aiming at ,Hydroxyzine,Alleviating anxiety,2,X,[orch/phsu],[topp],D03.383.606.515,
ed6cc6f2-9e4f-44f4-b81e-b4989c95b0a2,C0079460,C0003451,profound effects on ,Granulocyte-Macrophage Colony-Stimulating Factor,Antiviral Agents,8,X,[aapp/imft],[phsu],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,D27.505.954.122.388
a65a5d53-2250-4559-8dd3-e5af11d22389,C0079460,C0020964,profound effects on ,Granulocyte-Macrophage Colony-Stimulating Factor,Immunity,8,X,[aapp/imft],[phsf],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,G12.450
76acd7b8-0a2f-48a6-9410-9858ebdf05fa,C0079460,C0189537,can promote ,Granulocyte-Macrophage Colony-Stimulating Factor,Repair of lung,4,X,[aapp/imft],[topp],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,
942c148e-0131-4f28-90a9-63f901ca8ea2,C0216231,C0038164,is -made form of naturally-occurring,sargramostim,Staphylococcal Protein A,8,X,[aapp/imft/phsu],[aapp/imft/irda],x.x.x.x,D12.776.097.820;D23.050.161.821
896acfa6-3c0e-4717-ab61-1db139facd5d,C0216231,C0079460,is -made form of naturally-occurring,sargramostim,Granulocyte-Macrophage Colony-Stimulating Factor,4,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375
31cb23ef-7b2a-4077-82ef-93ddebf7f406,COVID-19,C1524029,is with ,COVID-19,Mouse MIN NOS,2,X,[virs],[neop],C000657245,
1bb78be1-799c-450c-a9b1-77409471a7ee,C0216231,C0242656,will Upon g/m ,sargramostim,Disease Progression,7,X,[aapp/imft/phsu],[patf],x.x.x.x,C23.550.291.656
ef9b858c-6abb-4580-80c7-b28253c6332e,C0282636,C0184661,primary endpoint of ,Cell Respiration,Interventional procedure,3,X,[celf],[topp],G03.197;G04.270,
036774b6-2cfb-401d-ba54-2e3f924b6412,C2949735,C1856053,started on ,Recruitment,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[acty],[dsyn],,x.x.x.x
a4510dd1-ff12-438c-837a-de68925d7a9d,C0003316,C0022709,blocks ,Epitopes,Peptidyl-Dipeptidase A,2,X,[imft],[aapp/enzy/imft],D23.050.550,D08.811.277.656.350.350.687
35fcd2f5-ee7d-495b-8a11-e2ac6433045d,6LU7,C0039082,identity with ,6LU7,Syndrome,2,X,????,[dsyn],????,C23.550.288.500
01879f7e-8e45-4167-803c-f0976a3c03d2,6LU7,C0030946,identity with ,6LU7,Endopeptidases,4,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
071c95f2-f3fd-4da1-8ad5-353ae190b4f3,C0022709,C0034800,is in conveyor ,Peptidyl-Dipeptidase A,Receptors Cell Surface,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,D12.776.543.750
8a3f605f-3f8a-46e5-ad44-b00f6b8e7fc1,C0242781,C0035253,differ considerably from those in ,disease transmission,Rest,2,X,[patf],[dora],N06.850.310,I03.450.769.647
070dfa98-78d7-49e7-a1a1-caa798a4f67c,C3826426,C0035253,differ considerably from those in ,Dynamics,Rest,2,X,[npop],[dora],,I03.450.769.647
b5e5dbe5-97a0-4735-9b27-4e1cd17e29d8,C0543467,twith,be how deal twith,Operative Surgical Procedures,twith,2,X,[topp],????,E04,????
1d094ac1-bdac-434e-af43-489c55c2a401,C0441655,twith,be how deal twith,Activities,twith,1,X,[acty],????,,????
672b6583-e1dd-4f79-9bca-16248a927b55,nt,C0398623,have COVID ,nt,Thrombophilia,2,X,????,[dsyn],????,C15.378.925
954330db-db51-4a55-8e45-bb0b39fd9965,nt,C0034065,have COVID ,nt,Pulmonary Embolism,2,X,????,[patf],????,C08.381.746;C14.907.355.350.700
f6602f28-9e50-4145-a070-a5a45bb08325,nt,COVID,have COVID ,nt,COVID,2,X,????,????,????,????
ae587e83-35f6-46f0-bbfc-0c6d64cc64a6,nt,C3714514,have COVID ,nt,Infection,1,X,????,[patf],????,C01.539
299a0784-b7aa-4687-9e58-5dec7d4887a7,C0011849,C0008679,is ,Diabetes Mellitus,Chronic disease,1,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C23.550.291.500
a6ecfc14-0224-432d-9e07-78876621e9db,C0011849,C0596620,is ,Diabetes Mellitus,glucose metabolism,2,X,[dsyn],[moft],C18.452.394.750;C19.246,
e1945efa-434b-4047-b07c-3a9cd6f4196b,C0008679,C0012655,is associated with increased ,Chronic disease,Disease susceptibility,1,X,[dsyn],[clna],C23.550.291.500,C23.550.291.687;G07.100.250
0d27f002-4879-493a-84ab-cc087dfa854e,C0008679,C3714514,is associated with increased ,Chronic disease,Infection,1,X,[dsyn],[patf],C23.550.291.500,C01.539
66332984-e9e8-4cf6-85fd-0e52f62c0da5,C0020456,C3714514,worsens course of ,Hyperglycemia,Infection,1,X,[dsyn],[patf],C18.452.394.952,C01.539
c4d5d4df-d17d-40da-aeee-f48c7d7ec465,C1516048,C0086418,is in normal ,Assessed,Homo sapiens,1,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
5ab3c099-2e91-4c58-8e0d-cb8e095e68bd,C1516048,C1292563,is in normal ,Assessed,Myocardial specimen,1,X,[acty],[tisu],,
1e269816-0d47-4f1d-9522-83d077708e07,C0022709,C1292563,is in normal ,Peptidyl-Dipeptidase A,Myocardial specimen,1,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,
d16ad4c7-4ae0-414a-af05-8e11358be204,C1516048,C0012173,is in normal ,Assessed,Dietary Fiber,1,X,[acty],[food],,D09.301.416;G07.203.300.400;J02.500.400
f1149f43-20be-428f-b63a-563b92f7a8bd,C0022709,C0012173,is in normal ,Peptidyl-Dipeptidase A,Dietary Fiber,1,X,[aapp/enzy/imft],[food],D08.811.277.656.350.350.687,D09.301.416;G07.203.300.400;J02.500.400
0f1cd5ad-1d66-4bf6-8e91-a585d538ad73,C0370003,C1999230,across technologies is ,Specimen,Providing (action),3,X,[sbst],[acty],,
53a737a5-469a-4920-b626-56fb5596aa4b,C0683201,C3652465,is in ,specific immunity,Interferon,2,X,[ortf],[aapp/imft/phsu],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
4ef77f41-aaf2-490c-a00a-aa50359cfedc,C0037090,C0206419,were suspected for ,Signs and Symptoms Respiratory,Genus: Coronavirus,1,X,[sosy],[virs],C23.888.852,B04.820.504.540.150
b264678a-0d84-47fc-8ab3-a519a1427b66,C0017337,C0020517,was found most ,Genes,Hypersensitivity,3,X,[gngm],[patf],G05.360.340.024.340,C20.543
3db993b6-5986-47fe-81ea-f9f50040499f,C1706005,C0020517,had ,CD40LG wt Allele,Hypersensitivity,2,X,[gngm],[patf],,C20.543
b6a2ec46-a9ae-48cb-89a5-cd20d11aaa73,LFA,C0020517,had ,LFA,Hypersensitivity,2,X,????,[patf],????,C20.543
b48b1187-2d70-44f6-9664-67994f07e6e8,C0020517,7days,increased in patients with 7days ,Hypersensitivity,7days,4,X,[patf],????,C20.543,????
4d9d9b2d-05ae-43a8-8437-2e8be4d48303,C0543467,C1882509,is considered as ,Operative Surgical Procedures,put - instruction imperative,2,X,[topp],[acty],E04,
da6377d6-0771-4af3-a5dd-7a3e11d9418b,C0543467,C0010356,is considered as ,Operative Surgical Procedures,Cross Infection,2,X,[topp],[patf],E04,C01.539.248;C23.550.291.875.500
8ddf949b-025c-4472-a1cd-8d85715b27ce,C1882509,C0010356,is with high risk of ,put - instruction imperative,Cross Infection,1,X,[acty],[patf],,C01.539.248;C23.550.291.875.500
c1f722be-33b5-486c-9e4b-b3548cc03871,C0206750,C0277548,is in especially early phase of ,Coronavirus Infections,Epidemic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,
c1f722be-33b5-486c-9e4b-b3548cc03871,C0206750,C0277548,is ongoing Epidemic disease of,Coronavirus Infections,Epidemic disease,3,X,[dsyn],[dsyn],C02.782.600.550.200,
f40f67ca-0a36-4c19-97c3-72e4af70604c,C0270724,C0206750,support health during ,Infantile Neuroaxonal Dystrophy,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.744,C02.782.600.550.200
f40f67ca-0a36-4c19-97c3-72e4af70604c,C0270724,C0206750,mitigate effect of ,Infantile Neuroaxonal Dystrophy,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.744,C02.782.600.550.200
f40f67ca-0a36-4c19-97c3-72e4af70604c,C0270724,C0206750,use Extracorporeal Membrane Oxygenation Biological Transport for,Infantile Neuroaxonal Dystrophy,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.228.140.744,C02.782.600.550.200
67665f02-f5ab-47c9-a07b-5108b8f65c8b,C0206750,C0458827,can affect ,Coronavirus Infections,Airway structure,1,X,[dsyn],[bpoc],C02.782.600.550.200,
4fbbc313-e53b-4a7a-be09-7f7a3a869998,C0009450,C0079189,is characterized by overwhelming ,Communicable Diseases,cytokine,1,X,[dsyn],[aapp/imft],C01.539.221,D12.644.276.374;D12.776.467.374;D23.529.374
fe8cd275-5fcb-4e6b-bf18-5a757c7a2bd3,C0086418,C0018823,is with ,Homo sapiens,Heart Transplantation,1,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,E04.100.376.475;E04.928.220.390;E04.936.450.475
93a3ab28-4d6d-4f82-82fc-d118cd1be8a4,C1609165,C1999230,was in low ,tocilizumab,Providing (action),1,X,[aapp/imft/phsu],[acty],x.x.x.x,
c0b6dc41-feb3-4120-86da-5ffa5decb11c,PCR,C4282212,development of positive ,PCR,IgG.serum,2,X,????,[imft],????,
9f3042ef-c747-4623-8a39-4e865890c2dd,C4077748,C2983957,is Monoclonal Antibodies against,clazakizumab,Interleukin-6 human,1,X,[aapp/imft],[aapp/imft/phsu],x.x.x.x,
caec1213-4d40-48aa-85b5-d964d224caf8,C4077748,C0003250,is ,clazakizumab,Monoclonal Antibodies,1,X,[aapp/imft],[aapp/imft],x.x.x.x,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
e678de17-18c4-4876-8b35-b3cb282bb2fb,C2247677,C0206750,is in ,response to cytokine,Coronavirus Infections,1,X,[celf],[dsyn],,C02.782.600.550.200
29723405-323b-473c-8c90-424f2d129217,C0206750,C0023882,know ,Coronavirus Infections,Little's Disease,2,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.140.254
f5c25bfc-26aa-445c-b9e9-fe617ce1de6a,C1457887,C2945704,is with ,Symptoms,Conventional Treatment,1,X,[sosy],[topp],,
abcbc09f-a5cb-47b0-b2eb-84f8adada20f,C0021081,C0242656,have have ceased during ,Immunosuppressive Agents,Disease Progression,1,X,[imft/phsu],[patf],D27.505.696.477.656,C23.550.291.656
3c49ab28-a33c-4da4-bfcd-fe899f3181e1,C0235031,C0085584, includes ,Neurologic Symptoms,Encephalopathies,2,X,[sosy],[dsyn],C10.597;C23.888.592,C10.228.140
a0fc33b2-be66-482c-9ec6-f076cac82d44,C0036572,C3274800,be initial ,Seizures,Disease Presentation,1,X,[sosy],[clna],C10.597.742;C23.888.592.742,
19cdcc4d-8c93-4914-a1a2-56e034db248d,C0235031,C3274800,be initial ,Neurologic Symptoms,Disease Presentation,1,X,[sosy],[clna],C10.597;C23.888.592,
0ee2a0df-0c1e-49cf-8473-9e6fa6c0f67d,C0085584,C3274800,be initial ,Encephalopathies,Disease Presentation,1,X,[dsyn],[clna],C10.228.140,
63322484-3e2a-47ca-bea5-42aa8516bf84,C0036572,C0206750,be initial Disease Presentation of,Seizures,Coronavirus Infections,1,X,[sosy],[dsyn],C10.597.742;C23.888.592.742,C02.782.600.550.200
15e4da19-b548-4c69-9bad-9461d36c3ff4,C0021368,C0027765,may associate with ,Inflammation,nervous system disorder,2,X,[patf],[dsyn],C23.550.470,C10
14f7e041-5159-40c6-87dd-3f7c9994b6ba,C0206750,NYS,is in NYS,Coronavirus Infections,NYS,1,X,[dsyn],????,C02.782.600.550.200,????
a60dfa86-6674-490c-8d9e-a20e7b3f869e,C0042776,C1413336,entered ,Virus,CEL gene,1,X,[virs],[gngm],B04,
a60dfa86-6674-490c-8d9e-a20e7b3f869e,C0042776,C1413336,mediate ,Virus,CEL gene,1,X,[virs],[gngm],B04,
c272f84a-0580-47fd-b7b0-b8e81bb6c0e4,C1175743,C1752727,use ,SARS coronavirus,Proteasome Pathway,2,X,[virs],[moft],B04.820.504.540.150.113.937,
1ef3fbbc-6180-4c13-a1f1-8d02a82d0a74,C1175743,C0599689,use ,SARS coronavirus,Lipoxins,2,X,[virs],[bacs/orch],B04.820.504.540.150.113.937,D10.251.355.255.375
4561aa9e-b4b0-4b60-b5c8-ed41af5da097,C1175743,C0036734,use ,SARS coronavirus,Serine Endopeptidases,2,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.277.656.300.760;D08.811.277.656.959.350
3a5e1ae5-c67d-4f33-83e6-821abe10c2a8,C1175743,C0008905,use ,SARS coronavirus,Clathrin,2,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.776.543.990.200
14b32065-03c2-44e5-baa0-a2baa042f3c7,C1175743,C0033453,use nuclear ,SARS coronavirus,Complement Factor B,2,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D08.622.200;D08.811.277.656.300.760.198;D08.811.277.656.959.350.198;D12.776.124.486.274.900
126bcc03-3c3e-4795-ada1-e364edb94d06,C0013227,C1704259,inhibit ,Pharmaceutical Preparations,Biochemical Pathway,1,X,[phsu],[moft],D26,
199c9e4c-f373-43c3-ac08-2950f9843431,C0206750,C1520005,triggers inflammatory response Along with direct,Coronavirus Infections,Viral Pathogenesis,1,X,[dsyn],[patf],C02.782.600.550.200,
c108a428-89d8-4a5b-bd86-6d82f7d0c2cf,C0206750,C0005525,may represent threat In patients with cancer treated with ,Coronavirus Infections,Biological Response Modifiers,1,X,[dsyn],[imft/phsu],C02.782.600.550.200,D27.505.696.477
a921ca1e-55fd-419d-a13e-5e42ee80532a,C1533734,C0032285,improves clinical outcome of patients with severe ,Administration procedure,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
d89635f9-bba1-4887-b5bd-784d54b0ada6,MSC,C1257975,has emerged despite lack of data of ,MSC,Mesenchymal Stem Cells,1,X,????,[cell],????,A11.329.830.500;A11.872.590.500
35d5008e-c2d4-4f04-8052-539f346c983e,MSCT,C0018133,be reported with first use of MSCT ,MSCT,Graft-vs-Host Disease,2,X,????,[dsyn],????,C20.452
8c1a4aca-baf9-4c15-9e01-f175bc80c313,MSCT,C0024117,is in noninfectious-including ,MSCT,Chronic Obstructive Airway Disease,1,X,????,[dsyn],????,C08.381.495.389
5050b52e-5d22-4f9a-be80-918a87fb931c,MSCT,C0004096,is in noninfectious-including ,MSCT,Asthma,1,X,????,[dsyn],????,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
35dbd68a-4d8f-4a30-a69c-70477c8fb263,MSCT,C1800706,is in noninfectious-including ,MSCT,Idiopathic Pulmonary Fibrosis,1,X,????,[dsyn],????,C08.381.483.487.500;C08.381.765.500
adfa8f0b-675f-4efa-bb09-1c80aa76b49e,C0043481,C0237820,playing role in clinical ,Zinc,Recovery - action,1,X,[bacs/elii/phsu],[acty],D01.268.556.940;D01.268.956.906;D01.552.544.940,
ac00634b-faac-48de-9106-3df14ed4ba4a,C0206750,C0005516,combines multiplex ,Coronavirus Infections,Biological Markers,1,X,[dsyn],[clna],C02.782.600.550.200,D23.101
99d2213b-43c1-4331-8058-dbe893000f7d,C3887461,C0184661,is high risk ,Head and Neck Carcinoma,Interventional procedure,2,X,[neop],[topp],,
426d2859-3dc6-4b93-b02b-08851633f12d,C0003451,C0042210,are needed for ,Antiviral Agents,Vaccines,4,X,[phsu],[aapp/imft/phsu],D27.505.954.122.388,D20.215.894
a430b6bd-ee11-444d-bc02-bf90dc6b7c4a,C0441655,C0042210,are needed for ,Activities,Vaccines,1,X,[acty],[aapp/imft/phsu],,D20.215.894
ba6beb43-56e2-461b-9807-22818f3d28fd,C0700271,C1512488,is Homologous Protein of,M Protein multiple myeloma,Homologous Protein,1,X,[aapp/imft],[aapp],x.x.x.x,
0677b55d-c59e-49de-b7e2-4ea7c4f3d1af,C1175743,C1512488,M Protein multiple myeloma of is,SARS coronavirus,Homologous Protein,1,X,[virs],[aapp],B04.820.504.540.150.113.937,
05ab2219-0634-48ca-8653-32d97fdc6e3b,C0597358,C4049595,can Binding (Molecular Function) to,receptor binding,HLA Complex,1,X,[moft],[aapp/imft],,
61b31d7f-e0b6-4b57-871d-dbf7f8b55ecf,C0597358,C0002085,can Binding (Molecular Function) to,receptor binding,Alleles,1,X,[moft],[gngm],,G05.360.340.024.340.030
f4cd06da-6d2b-4d71-82ed-5e8c92303de9,C0597358,C0003316,serve as effective ,receptor binding,Epitopes,1,X,[moft],[imft],,D23.050.550
6988dc29-5903-467c-8c83-64f3998d89ad,C0597358,C0042210,serve as effective ,receptor binding,Vaccines,1,X,[moft],[aapp/imft/phsu],,D20.215.894
cae14437-3017-4bc5-bb4c-9ebacae32972,C0042776,C0006255,is in lower ,Virus,Bronchi,2,X,[virs],[bpoc],B04,A04.411.125
0393beb3-68e6-455e-9228-de2e6ecd0fdd,C0185112,C1708476,facilitated synchronous ,Therapeutic Mobilization,Implementation,5,X,[topp],[acty],,
f2536fc3-cb24-4cca-964e-e550985b2de3,C0556030,C1718097,deploy existing licensed ,Repositioning (procedure),New medications,6,X,[topp],[phsu],,
a8e21da5-af5d-49b8-9927-eca0bea0bea5,C0556030,C2700061,provides quickest possible ,Repositioning (procedure),Transition (action),3,X,[topp],[acty],,
07c696f8-9d76-41ea-804a-3ae1c4c0be92,C0026187,C0450442,offers advantages compared to ,Minocycline,Agent,2,X,[antb/orch],[chvf],D02.455.426.559.847.562.900.550;D04.615.562.900.550,
1ab5a4ec-81ea-4252-b6d2-48ed1c791218,C0026187,C0035222,offers advantages in terms of potential efficacy in patients with ,Minocycline,Respiratory Distress Syndrome Adult,1,X,[antb/orch],[dsyn],D02.455.426.559.847.562.900.550;D04.615.562.900.550,C08.381.840;C08.618.840
222c1f33-4f0e-4e9d-89d5-67babbb725f5,C0039986,C0206750,is in children with ,Thoracic Surgery Specialty,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.810.803,C02.782.600.550.200
dea45ff1-6608-41bf-b483-4dcbdd439319,C0039986,C0012634,is in children with ,Thoracic Surgery Specialty,Disease,1,X,[bmod],[dsyn],H02.403.810.803,C23.550.288
1b0aff67-801c-4559-ac22-43efb74baac2,C0158644,C1175743,can can worsened by ,Congenital anomaly of lung,SARS coronavirus,1,X,[cgab],[virs],,B04.820.504.540.150.113.937
8d897f64-8ae3-4538-b30a-3ac353cb69f6,C0206750,C0543467,affects indications ,Coronavirus Infections,Operative Surgical Procedures,1,X,[dsyn],[topp],C02.782.600.550.200,E04
fe17d295-c368-4dff-bb3b-fc5af0f02e88,bullae,C0015252,required ,bullae,removal technique,1,X,????,[topp],????,
de1bef8a-585f-41d1-ab9d-d8191a328786,C0002055,C0042720,is in ,Alkalies,Viral Genome,2,X,[inch],[gngm],D01.045,G05.360.340.358.840
4166f123-f3e1-43e7-8b74-95d872c1fa91,C0086418,C1167395,have co-evolved for millennia resulting in complex ,Homo sapiens,Host (organism),1,X,[humn],[orgm],B01.050.150.900.649.313.988.400.112.400.400,
0eae387b-77ef-4ead-a955-006f8423a14d,C0678933,C0003261,associated with viral ,Genetic Loci,Antibody Formation,1,X,[gngm],[biof],G05.360.340.024.380,G12.070
b1ef9c65-2c34-4cde-bcf6-85a14365e431,C0678933,C1414863,associated with viral ,Genetic Loci,FUT2 gene,1,X,[gngm],[gngm],G05.360.340.024.380,
8e4c078b-c66e-4470-ba7e-b1906b377757,C0678933,C0005670,associated with viral ,Genetic Loci,BK Virus,1,X,[gngm],[virs],G05.360.340.024.380,B04.280.210.700.615.100;B04.613.204.670.615.100
f5721d15-511d-4b8a-ae17-9e23fec21674,C2304881,C0796362,for STING1 is ,Merkel cell polyomavirus,chromosome 5q31,1,X,[virs],[celc],B04.280.210.700.615.550;B04.613.204.670.615.550,
20a05b80-10d1-4204-bb38-ae9186e285c5,C0079506,C1520405,for CXCR5 Receptors is,Herpesvirus 7 Human,11q23.3,1,X,[virs],[celc],B04.280.382.150.750.420,
e41dbea6-7c1f-4379-a7f1-577be7067b23,C0005670,C2825753,for FUT2 gene is,BK Virus,19q13.33,1,X,[virs],[celc],B04.280.210.700.615.100;B04.613.204.670.615.100,
a65803f0-4452-4900-9916-cc57fe377bef,C2936489,C0042338,is in ,Pleiotropic Gene,Human herpesvirus 3,1,X,[gngm],[virs],G05.420.556;G05.695.550,B04.280.382.100.900.460
f32d09af-a5f0-4734-b746-fe48c9d7726f,C0017428,EHF,is in EHF,Genome,EHF,1,X,[gngm],????,G05.360.340,????
35079036-766a-4984-86a6-260a5566bc68,C0009450,EHF,is in EHF,Communicable Diseases,EHF,1,X,[dsyn],????,C01.539.221,????
07b71e1c-ddc4-4efc-abbd-940e05e954cb,C0012655,EHF,is in EHF,Disease susceptibility,EHF,1,X,[clna],????,C23.550.291.687;G07.100.250,????
774f04d8-6f9d-4abf-9110-4e1922f1fa0c,EHF,C1336789,in signal is epithelial-specific ,EHF,Transcription Repressor/Corepressor,1,X,????,[aapp/bacs],????,
62ea0a94-977a-4bfd-8e5e-6ae5f8ba3cd4,C2256362,C1602245,allowed for ,system process,Prompt,4,X,[phsf],[phsu],,
16317a66-ffde-418b-baa7-427e77940214,C2256362,C0206750,allowed for ,system process,Coronavirus Infections,4,X,[phsf],[dsyn],,C02.782.600.550.200
55091a51-43cd-40aa-bec4-5ab18086b956,C0007634,C0854532,are understood Despite current knowledge of injury in ,Cells,Myopericarditis,1,X,[cell],[dsyn],A11,
4191150f-a59e-41c0-821d-479131e966cd,C2948600,C0003015,evaluate Clinical Treatment implications with,Aim,Angiotensin-Converting Enzyme Inhibitors,1,X,[inch/phsu],[phsu],,D27.505.519.389.745.085
f490d37f-e177-4028-8a2a-64afc7d2c3dc,C2948600,C0597357,evaluate Clinical Treatment implications with,Aim,receptor,1,X,[inch/phsu],[aapp/rcpt],,
57afafc6-ba25-4eae-8a9d-1fbbc4ec2ae3,C0206750,C0237820,of onset is intensive care unit admission ,Coronavirus Infections,Recovery - action,1,X,[dsyn],[acty],C02.782.600.550.200,
c635a27f-5fa8-4bc4-bfe4-72b9ce00bfdd,C0597404,C3694279, includes ,Respiratory viruses,Middle East Respiratory Syndrome,3,X,[virs],[dsyn],,C02.782.600.550.200
a6baf990-1a1d-4aa5-915f-534beaf25394,C1416797,C0597404,are longer than other ,STMN1 gene,Respiratory viruses,1,X,[gngm],[virs],,
6a2bef82-c291-445d-94ce-5ce312064f4f,C1416797,C3694279,are longer than other ,STMN1 gene,Middle East Respiratory Syndrome,1,X,[gngm],[dsyn],,C02.782.600.550.200
a7148ad5-8a9e-493a-86d2-b5d248f0e884,C0206750,C0679225,is with ,Coronavirus Infections,multiple pathologies,3,X,[dsyn],[dsyn],C02.782.600.550.200,
ac4945fd-5eed-4128-905d-8ea095be9d67,C0012634,C0679225,is multiorgan multiple pathologies with,Disease,multiple pathologies,2,X,[dsyn],[dsyn],C23.550.288,
7027c942-8b52-436a-bae0-05af3afd18a1,C0003250,C1175743,novel specific Viral Vaccines against,Monoclonal Antibodies,SARS coronavirus,1,X,[aapp/imft],[virs],D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224,B04.820.504.540.150.113.937
7027c942-8b52-436a-bae0-05af3afd18a1,C0003250,C1175743,targeting ,Monoclonal Antibodies,SARS coronavirus,1,X,[aapp/imft],[virs],D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224,B04.820.504.540.150.113.937
8310298f-dbef-4dad-aed5-1d7b85ce24f9,C0036734,C0206750,causing ,Serine Endopeptidases,Coronavirus Infections,2,X,[aapp/enzy],[dsyn],D08.811.277.656.300.760;D08.811.277.656.959.350,C02.782.600.550.200
772f9fb7-967c-4897-9db8-589fd64e9a06,C1819995,C0024109,is in ,Host Cell,Lung,2,X,[celc],[bpoc],,A04.411
1eb57379-4c4c-4229-a89d-510a27e16b41,C0017262,C0024109,is in ,Gene Expression,Lung,2,X,[genf],[bpoc],G05.297,A04.411
71cbed14-6c50-450b-af5b-26c7b341ce16,C1819995,C0458827,is in ,Host Cell,Airway structure,2,X,[celc],[bpoc],,
350ffe07-69c9-4a4c-bd38-75303c496017,C0017262,C0458827,is in ,Gene Expression,Airway structure,2,X,[genf],[bpoc],G05.297,
1ceea1d3-8ad7-479d-b45a-daf3eb38dbb1,C0458827,C0017262,used public ,Airway structure,Gene Expression,2,X,[bpoc],[genf],,G05.297
cfa911e3-2e6a-49fc-92ae-20312f92b6dc,C0022709,C0005768,was upregulated in ,Peptidyl-Dipeptidase A,In Blood,2,X,[aapp/enzy/imft],[bdsu],D08.811.277.656.350.350.687,x.x.x.x.x
28bd425b-0568-4cf3-9c6a-be7c0a1b8d23,C0022709,C0004096,was upregulated in ,Peptidyl-Dipeptidase A,Asthma,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
28bd425b-0568-4cf3-9c6a-be7c0a1b8d23,C0022709,C0004096,is in primary ,Peptidyl-Dipeptidase A,Asthma,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
03e516cf-30c7-4075-a3dc-4a4992c5b809,C3263715,C0008058,described ,Pediatric Dermatology Discipline,Chilblains,2,X,[bmod],[dsyn],,C26.212.500.217;C26.417.217
2b4c0ee9-f9cb-4efd-bbb7-200d1a2dbe92,C0206750,C0003467,have increased rates of ,Coronavirus Infections,Anxiety,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.470.132
2b4c0ee9-f9cb-4efd-bbb7-200d1a2dbe92,C0206750,C0003467,major negative psychological outcome of is ,Coronavirus Infections,Anxiety,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.470.132
2b4c0ee9-f9cb-4efd-bbb7-200d1a2dbe92,C0206750,C0003467, includes ,Coronavirus Infections,Anxiety,2,X,[dsyn],[mobd],C02.782.600.550.200,F01.470.132
26c32f21-decc-499d-a1f9-61a2ef1253e5,C2948600,C0014507,present ,Aim,Epidemiology,2,X,[inch/phsu],[bmod],,H02.403.720.500
415a3432-e4bd-4c84-97a5-e2af8c5fc4b4,C0014507,C0599878,include data on sociodemographic ,Epidemiology,disease characteristic,3,X,[bmod],[patf],H02.403.720.500,
f90ee18f-f70e-4ab7-aca8-911091391805,C0035920,C0034386,were among ,Rubella,Quarantine,4,X,[dsyn],[topp],C02.782.930.700.700,N06.850.780.200.450.700
8c888a0b-cf0c-4d09-8463-b2826af71cbc,C0162522,C0149520,treatment for ,Cholecystectomy Laparoscopic,Acute Cholecystitis,2,X,[topp],[dsyn],E04.210.120.172.140;E04.502.250.520.160,C06.130.564.263.500
36401a63-f8b4-4b55-882f-8c2f17829c1d,C0162522,C0206750,remains treatment of choice for ,Cholecystectomy Laparoscopic,Coronavirus Infections,1,X,[topp],[dsyn],E04.210.120.172.140;E04.502.250.520.160,C02.782.600.550.200
36401a63-f8b4-4b55-882f-8c2f17829c1d,C0162522,C0206750,treatment in even ,Cholecystectomy Laparoscopic,Coronavirus Infections,1,X,[topp],[dsyn],E04.210.120.172.140;E04.502.250.520.160,C02.782.600.550.200
a92b9ee0-4926-48d3-93f2-c754f8a26fd9,C0162522,C1521863,remains treatment of choice for ,Cholecystectomy Laparoscopic,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04.210.120.172.140;E04.502.250.520.160,x.x.x.x
a92b9ee0-4926-48d3-93f2-c754f8a26fd9,C0162522,C1521863,treatment in even ,Cholecystectomy Laparoscopic,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04.210.120.172.140;E04.502.250.520.160,x.x.x.x
6bdd5114-868d-4615-8148-7487ca8f1a12,C1175175,C0009566,being most fearsome ,Severe Acute Respiratory Syndrome,Complication,2,X,[dsyn],[patf],C02.782.600.550.200.750;C08.730.730,
ffebd61f-b622-4ca6-8a3e-060f344482c8,C0012634,C0015967,was initially characterized by ,Disease,Fever,3,X,[dsyn],[sosy],C23.550.288,C23.888.119.344
ffebd61f-b622-4ca6-8a3e-060f344482c8,C0012634,C0015967,frequently presents with ,Disease,Fever,2,X,[dsyn],[sosy],C23.550.288,C23.888.119.344
ffebd61f-b622-4ca6-8a3e-060f344482c8,C0012634,C0015967,was After emergence of novel ,Disease,Fever,1,X,[dsyn],[sosy],C23.550.288,C23.888.119.344
44ab80dc-c38b-4ecb-9ffa-f5d3b9f675bb,C0005516,C0206419,have have observed in patients with ,Biological Markers,Genus: Coronavirus,1,X,[clna],[virs],D23.101,B04.820.504.540.150
e74c22d1-aaaf-494c-a133-23ca0d62e92c,C0022709,C0032285,causing ,Peptidyl-Dipeptidase A,Pneumonia,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C08.381.677;C08.730.610
6fcfc3af-7dec-4833-8adf-2d7aac663d71,C0014695,RAS,is negative RAS ,Ergocalciferol,RAS,2,X,[orch/phsu/vita],????,D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,????
49550627-3200-4fb9-93be-cf499d5e1aed,C0014695,C1175175,is in ,Ergocalciferol,Severe Acute Respiratory Syndrome,2,X,[orch/phsu/vita],[dsyn],D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,C02.782.600.550.200.750;C08.730.730
505e2cee-1d10-4ba4-9835-800bb7fd668f,C0206419,C0007222,is with preexisting ,Genus: Coronavirus,Cardiovascular Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C14
505e2cee-1d10-4ba4-9835-800bb7fd668f,C0206419,C0007222,is with concurrent ,Genus: Coronavirus,Cardiovascular Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C14
d936a363-fe42-4dad-8f17-60cc55b6a305,C2348077,C0206419,have have postulated for ,Date Fruit,Genus: Coronavirus,2,X,[food],[virs],B01.650.940.800.575.912.250.093.615,B04.820.504.540.150
f247da48-7217-4048-8e17-a53c9df29e26,C2348077,C0007222,have have postulated for ,Date Fruit,Cardiovascular Diseases,2,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,C14
01d86716-9780-41b2-ab10-440e0e067567,C2348077,C0597357,have have postulated for ,Date Fruit,receptor,2,X,[food],[aapp/rcpt],B01.650.940.800.575.912.250.093.615,
f38b73dc-e1a9-428e-ac99-60cbe565cadb,C2348077,C0022709,have have postulated for ,Date Fruit,Peptidyl-Dipeptidase A,2,X,[food],[aapp/enzy/imft],B01.650.940.800.575.912.250.093.615,D08.811.277.656.350.350.687
2a6cc383-f4ee-4071-8a5f-099d0c2a57fb,C0040861,C0012634,is with suspected ,Triage,Disease,2,X,[topp],[dsyn],N02.421.297.900,C23.550.288
df522334-e521-41c7-9e75-4b2392c22cd9,IRB,C0451610,allow retrospective ,IRB,Patient review,4,X,????,[topp],????,
73202131-64fb-48fe-9041-31adc924e445,C0011849,C0021925,of history is ,Diabetes Mellitus,Intubation,2,X,[dsyn],[topp],C18.452.394.750;C19.246,E02.585;E05.497
482ec504-3008-42b8-95bd-c26f0d0a0a75,MEDLINE,C0206419,Web for literature on use for ,MEDLINE,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
37132795-6b02-47ae-ba81-2c6d922913c8,C1959569,C0206419,spread of ,Volatility,Genus: Coronavirus,1,X,[npop],[virs],G01.645.750;G02.734.933,B04.820.504.540.150
11b51d1c-9e4a-43c8-8cbc-ed1de97684af,C0031336,C1959569,significantly increase equity market ,Pharmacy (field),Volatility,1,X,[bmod],[npop],H02.646,G01.645.750;G02.734.933
e10b47f1-b9db-4f48-b7d1-301c4d1beb2f,C0031740,C0206419,mitigate ,Photochemotherapy,Genus: Coronavirus,1,X,[topp],[virs],E02.186.500;E02.319.685;E02.774.722,B04.820.504.540.150
68a2f86d-c205-4463-a99a-1b6c99aa6938,C0206419,C3714514,either prevent ,Genus: Coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150,C01.539
68a2f86d-c205-4463-a99a-1b6c99aa6938,C0206419,C3714514,is widely defined as proportion among ,Genus: Coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150,C01.539
68a2f86d-c205-4463-a99a-1b6c99aa6938,C0206419,C3714514,causing cluster ,Genus: Coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150,C01.539
6e36edf4-36cb-4349-91e8-efb1afb6bb26,C0221423,C0319157,caused by novel ,Illness (finding),AS virus,1,X,[sosy],[virs],,
1b0fef19-5af8-4fec-b27a-71e63c344f46,C1175743,C1160716,highlighting potential for faecal-oral ,SARS coronavirus,viral transmission,2,X,[virs],[celf],B04.820.504.540.150.113.937,
92b7b3ba-fb90-4eeb-a311-18e014a1e378,C1419818,C2806453,has has related to lineage B ,SARS gene,Betacoronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113
9a34a84f-92be-4ca1-9201-2ee799bda30a,C1419818,C1175743,has has related to lineage B ,SARS gene,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
8a02cffa-d6d9-4baa-b149-a1ae37190170,C1419818,C0008139,has has related to lineage B ,SARS gene,Chiroptera,2,X,[gngm],[mamm],,B01.050.150.900.649.313.937
2357aa74-e65a-47b5-92b6-a56d9712b8b2,C1880022,C0002520,revealed existence of distinct four  S1 S1,Characterization,Amino Acids,1,X,[acty],[aapp/bacs/phsu],,D12.125
2357aa74-e65a-47b5-92b6-a56d9712b8b2,C1880022,C0002520,revealed existence of four  S1 S1,Characterization,Amino Acids,1,X,[acty],[aapp/bacs/phsu],,D12.125
37d77087-3a12-4fe5-aa44-b95c72a9e1db,C1880022,S1,revealed existence of distinct four  S1 S1,Characterization,S1,2,X,[acty],????,,????
37d77087-3a12-4fe5-aa44-b95c72a9e1db,C1880022,S1,revealed existence of four  S1 S1,Characterization,S1,2,X,[acty],????,,????
8c7a3803-b855-4368-befb-8661cf9ebdfa,C1880022,C1419032,revealed existence of distinct four  S1 S1,Characterization,PSMD2 gene,1,X,[acty],[gngm],,
8c7a3803-b855-4368-befb-8661cf9ebdfa,C1880022,C1419032,revealed existence of four  S1 S1,Characterization,PSMD2 gene,1,X,[acty],[gngm],,
b0adfbdc-2ff4-45e6-9593-33e9a85b3928,C1880022,C0597358,revealed existence of distinct four  S1 S1,Characterization,receptor binding,1,X,[acty],[moft],,
b0adfbdc-2ff4-45e6-9593-33e9a85b3928,C1880022,C0597358,revealed existence of four  S1 S1,Characterization,receptor binding,1,X,[acty],[moft],,
63b8f837-d940-4d4b-83df-9cd234e53769,C1880022,C0599220,revealed existence of distinct four  S1 S1,Characterization,Protein Subunits,1,X,[acty],[aapp],,D12.776.813
63b8f837-d940-4d4b-83df-9cd234e53769,C1880022,C0599220,revealed existence of four  S1 S1,Characterization,Protein Subunits,1,X,[acty],[aapp],,D12.776.813
55204f22-d491-486c-9b7e-bafe484ff111,C0012634,C4704836,rapidly evaluate ,Disease,Medical Countermeasures,1,X,[dsyn],[topp],C23.550.288,N06.230.100.195;N06.850.780.588
04e262bf-ceb5-46fc-89c7-a9794b6dbfd6,C0012634,C0026809,was more severe in aged ,Disease,Mus,1,X,[dsyn],[mamm],C23.550.288,B01.050.150.900.649.313.992.635.505.500
c543722b-025c-4e03-a676-95a3971c27e2,C0012634,hACE2,showed more clinically relevant phenotypes than those seen in hACE2 ,Disease,hACE2,1,X,[dsyn],????,C23.550.288,????
93b5fb37-e9f2-42a2-9d9f-d85f6f983fd8,C0012634,C0025936,showed more clinically relevant phenotypes than those seen in hACE2 ,Disease,Mice Transgenic,1,X,[dsyn],[mamm],C23.550.288,B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800
8094da4d-5b11-475f-8bc0-a29d3961085c,C0042210,C0026809,is in immune competent ,Vaccines,Mus,1,X,[aapp/imft/phsu],[mamm],D20.215.894,B01.050.150.900.649.313.992.635.505.500
d533d1c1-6fc0-4bdf-8a5f-82c8677bd1f7,C0042210,mACE2,is with native expression of mACE2,Vaccines,mACE2,1,X,[aapp/imft/phsu],????,D20.215.894,????
ae2112db-7893-400f-990a-ffec9e717fd3,C0598312,C0086418,is in primary ,DNA Replication,Homo sapiens,1,X,[genf],[humn],G02.111.225;G05.226,B01.050.150.900.649.313.988.400.112.400.400
fbe101ed-15c7-4d46-91af-dd7a39fe8c4c,C0598312,C0458827,is in primary ,DNA Replication,Airway structure,1,X,[genf],[bpoc],G02.111.225;G05.226,
8edd2a3c-a816-430c-bdc5-7e2699756766,C0598312,C0014597,is in primary ,DNA Replication,Epithelial Cells,1,X,[genf],[cell],G02.111.225;G05.226,A11.436
d6e8662a-e4c0-4dfd-80aa-8b13834fc60a,C0598312,C0007590,is in primary ,DNA Replication,Cell division,1,X,[genf],[celf],G02.111.225;G05.226,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
6918323e-73b1-48b2-bf93-168b1233641c,C3652465,C0598312,Lastly can Cardiac Arrest 2,Interferon,DNA Replication,1,X,[aapp/imft/phsu],[genf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G02.111.225;G05.226
26d344e4-f1b7-4341-ae95-5b2576ded10e,C3652465,C0086418,Lastly can Cardiac Arrest 2,Interferon,Homo sapiens,1,X,[aapp/imft/phsu],[humn],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B01.050.150.900.649.313.988.400.112.400.400
188103f3-0b36-4a45-9afc-b7600781796a,C3652465,C0458827,Lastly can Cardiac Arrest 2,Interferon,Airway structure,1,X,[aapp/imft/phsu],[bpoc],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
806839aa-e38e-43be-880f-032ca732f764,C3652465,C0014597,Lastly can Cardiac Arrest 2,Interferon,Epithelial Cells,1,X,[aapp/imft/phsu],[cell],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,A11.436
95ff69cd-78b2-4085-a4d1-504b5af21127,C3652465,C0007590,Lastly can Cardiac Arrest 2,Interferon,Cell division,1,X,[aapp/imft/phsu],[celf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
e1436a43-5066-4651-b24c-048b339abee2,C3652465,C0087111,Lastly can potently Cardiac Arrest,Interferon,Therapeutic procedure,1,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,E02
c25b2ef3-204f-427a-83a9-e0a3db303029,C3652465,C1533734,Lastly can potently Cardiac Arrest,Interferon,Administration procedure,1,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
de9e7695-1447-4614-8bae-a8673e5e69de,C3652465,C1175743,can Cardiac Arrest,Interferon,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04.820.504.540.150.113.937
de9e7695-1447-4614-8bae-a8673e5e69de,C3652465,C1175743,was associated For adults with ,Interferon,SARS coronavirus,2,X,[aapp/imft/phsu],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04.820.504.540.150.113.937
14aa31e4-b9ed-42e4-883c-1a8caccc59f2,C0598312,C0026809,is in ,DNA Replication,Mus,1,X,[genf],[mamm],G02.111.225;G05.226,B01.050.150.900.649.313.992.635.505.500
f6bf8070-a956-4c09-bfe6-510bc61d1dc3,C0087111,C0598312,diminished ,Therapeutic procedure,DNA Replication,1,X,[topp],[genf],E02,G02.111.225;G05.226
f6bf8070-a956-4c09-bfe6-510bc61d1dc3,C0087111,C0598312,immune especially anti-influenza Drugs - dental services due to similarities between,Therapeutic procedure,DNA Replication,1,X,[topp],[genf],E02,G02.111.225;G05.226
abb5a4e1-674f-428a-a179-afe87f31aaa7,C1533734,C0598312,diminished ,Administration procedure,DNA Replication,1,X,[topp],[genf],,G02.111.225;G05.226
b0acc736-a7d3-4d73-ae6f-fe1f4a9aa2a4,C0087111,C0026809,diminished In ,Therapeutic procedure,Mus,2,X,[topp],[mamm],E02,B01.050.150.900.649.313.992.635.505.500
5f89d48b-3873-41ee-931e-3c77df645b9b,C1533734,C0026809,diminished In ,Administration procedure,Mus,2,X,[topp],[mamm],,B01.050.150.900.649.313.992.635.505.500
b2e618d0-ee2f-4a63-9195-632da4f879ef,C2986594,C1516635,supports IFN ,Mouse Model,Clinical Treatment,2,X,[emod],[topp],,
910bbb92-ecaa-459d-9171-8bd6c092d397,C2986594,IFN,supports IFN ,Mouse Model,IFN,1,X,[emod],????,,????
bb644338-7707-495c-9156-f342fc35cfd3,C2986594,C0206422,supports IFN ,Mouse Model,Human coronavirus,1,X,[emod],[virs],,
bb644338-7707-495c-9156-f342fc35cfd3,C2986594,C0206422,study ,Mouse Model,Human coronavirus,2,X,[emod],[virs],,
e97770ae-3651-4212-8baa-b56a45bdace2,C2986594,C0012634,supports IFN ,Mouse Model,Disease,1,X,[emod],[dsyn],,C23.550.288
e9c313ac-b30d-48ce-b46c-d137bcb99a86,C1516635,C0206422,is in ,Clinical Treatment,Human coronavirus,1,X,[topp],[virs],,
68bc0e2c-e85b-4199-8b7f-5c34223212ce,C1516635,C0012634,is in ,Clinical Treatment,Disease,1,X,[topp],[dsyn],,C23.550.288
df0231ef-c921-4d81-9cf7-c6f050f2c141,C0206419,C0015607,will probably revolutionize approach to patients in ,Genus: Coronavirus,family medicine (field),1,X,[virs],[bmod],B04.820.504.540.150,H02.403.340.500
ecc6ac1b-0e0d-47a1-937e-640341d59d84,C0005847,C0022709,also express ,Blood Vessel,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.015,D08.811.277.656.350.350.687
3da9bd76-bc22-4357-8b9d-877c2b598cc4,C0027061,C0003130,is with ,Myocardium,Anoxia,4,X,[tisu],[patf],A02.633.580;A07.541.704;A10.690.552.750,C23.888.852.079
3cc18c8c-283d-4985-822f-bdeaadb7a789,C0035243,C0003130,is with ,Respiratory Tract Infections,Anoxia,2,X,[dsyn],[patf],C01.539.739;C08.730,C23.888.852.079
2a93f364-779b-4f6d-951d-46a1056db70c,C0009450,C0003130,is with ,Communicable Diseases,Anoxia,2,X,[dsyn],[patf],C01.539.221,C23.888.852.079
c276dcc1-298b-43c0-9a10-f9e2068b2a42,C0005847,C0206419,are potential targets in ,Blood Vessel,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015,B04.820.504.540.150
c276dcc1-298b-43c0-9a10-f9e2068b2a42,C0005847,C0206419,amount of was In ,Blood Vessel,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015,B04.820.504.540.150
c276dcc1-298b-43c0-9a10-f9e2068b2a42,C0005847,C0206419,distinguished ,Blood Vessel,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015,B04.820.504.540.150
eac1abe3-5d34-4bd2-a0d1-f18bb9aa2982,C0551718,C0206419,clarify potentiality of ,Study report:Finding:Point in time:^Patient:Document:Pathology,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
f83deba7-54b4-4930-91e0-75fd6a56aadf,RAAS,COVID-19,be maintained in ,RAAS,COVID-19,2,X,????,[virs],????,C000657245
8be79a8b-1e10-4141-9130-9ba2ae85cd72,C0079380,COVID-19,combat ,Frameshift Mutation function,COVID-19,1,X,[comd],[virs],G05.365.590.265,C000657245
40f485a6-b435-434a-9c98-38663ee24927,C0243077,COVID-19,combat ,inhibitors,COVID-19,1,X,[chvf],[virs],,C000657245
40f485a6-b435-434a-9c98-38663ee24927,C0243077,COVID-19,also have ,inhibitors,COVID-19,1,X,[chvf],[virs],,C000657245
40f485a6-b435-434a-9c98-38663ee24927,C0243077,COVID-19,Furthermore interact with dyad ,inhibitors,COVID-19,1,X,[chvf],[virs],,C000657245
181f6f2f-c671-4322-b6a9-d84aa6fe5f9b,C0206750,C0370003,were assessed in ,Coronavirus Infections,Specimen,2,X,[dsyn],[sbst],C02.782.600.550.200,
e83e3f00-58ff-4112-bfd7-ce198672139d,C3687742,C1511790,is suitable alternative to NP swabs for ,Oropharyngeal swab,Detection,14,X,[bdsu],[topp],,
84b7f08c-18b8-47a2-aa7c-e568575c0685,nares,C1511790,is suitable alternative to NP swabs for ,nares,Detection,7,X,????,[topp],????,
bcd15a81-ad94-494c-b696-9272684e1328,C3687742,C1175743,is suitable alternative to NP swabs for ,Oropharyngeal swab,SARS coronavirus,10,X,[bdsu],[virs],,B04.820.504.540.150.113.937
bcd15a81-ad94-494c-b696-9272684e1328,C3687742,C1175743,were sufficient for use in tests of ,Oropharyngeal swab,SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
bcd15a81-ad94-494c-b696-9272684e1328,C3687742,C1175743,are suitable for testing for ,Oropharyngeal swab,SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
f274f763-c225-4b1c-a10c-e3e9e794571a,nares,C1175743,is suitable alternative to NP swabs for ,nares,SARS coronavirus,5,X,????,[virs],????,B04.820.504.540.150.113.937
179394da-8eaa-4756-ab55-a6cea045e385,C0012634,C0036974,has produced world-wide ,Disease,Shock,1,X,[dsyn],[patf],C23.550.288,C23.550.835
56b6116d-4cf4-45d3-8db7-1d3a13ed2739,C1515933,C0086418,most distal and vulnerable aspect of ,Alveolus,Homo sapiens,1,X,[bpoc],[humn],,B01.050.150.900.649.313.988.400.112.400.400
ebab8395-6c9d-4f8a-b3a0-933f1ab2d7a2,C1515933,C0040811,most distal and vulnerable aspect of ,Alveolus,Trees (plant),1,X,[bpoc],[plnt],,B01.650.915
66d39a0b-8302-48ed-9926-173693c0a9f9,C1515933,C1708715,are responsible for ,Alveolus,Loading Technique,2,X,[bpoc],[acty],,
3536fd77-af58-42a9-9504-1dd96bc35da4,C1515933,C0014792,are responsible for ,Alveolus,Erythrocytes,2,X,[bpoc],[cell],,A11.118.290;A11.443.240;A15.145.229.334
9a4bca40-d113-472a-9897-a279e0d43fef,C1515933,C0019046,are responsible for ,Alveolus,Hemoglobin,2,X,[bpoc],[aapp/bacs],,D12.776.124.400;D12.776.422.316.762
4a50a322-2c6c-4419-b0f2-197b983aaba5,C0040811,C0021966,is in Part duology ,Trees (plant),Iodides,2,X,[plnt],[inch],B01.650.915,D01.248.497.158.490;D01.475.410
99ad7f1f-c13c-40cc-b6fa-441d723dd2e2,C0040811,duology,is in Part duology ,Trees (plant),duology,2,X,[plnt],????,B01.650.915,????
a9f0a7ed-2e80-4ef3-b760-b916eca3148b,C0040811,C1880022,is in Part duology ,Trees (plant),Characterization,2,X,[plnt],[acty],B01.650.915,
deeb3f61-6cf7-4ef6-aee1-9e9c870c16d5,C0683325,C0012634,is in patients with ,clinical aspects,Disease,1,X,[clna],[dsyn],,C23.550.288
deeb3f61-6cf7-4ef6-aee1-9e9c870c16d5,C0683325,C0012634,might might helpful in ,clinical aspects,Disease,1,X,[clna],[dsyn],,C23.550.288
535104f2-5a02-4b84-9256-e511e47fa8eb,C0683325,C1184743,is in patients with ,clinical aspects,bony process,1,X,[clna],[bpoc],,
02df1b38-8fff-4781-a1cf-f4909604c6d4,COVID-19,C0232462,presented with ,COVID-19,Decrease in appetite,1,X,[virs],[sosy],C000657245,
c624191a-12aa-4952-914c-0e745f87dfe8,C0027950,C0060323,levels of C-reactive protein ,neutrophil,Fibrin fragment D,1,X,[cell],[aapp/bacs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,x.x.x.x
3947b5af-0167-4302-b253-7997d15dd57b,C0027950,C0022917,levels of C-reactive protein ,neutrophil,Lactate Dehydrogenase,1,X,[cell],[aapp/enzy],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,D08.811.682.047.551.400;D08.811.682.047.820.493
612cb3e4-c494-491c-96c0-d6f9c2584e38,C0025124,C0426576,was used in patients with ,Traditional Chinese Medicine,Gastrointestinal symptom,2,X,[bmod],[sosy],E02.190.488.585.520;I01.076.201.450.654.558.520,
92e4ba72-a630-462c-aff7-661c2f8e17db,C0206750,C0302148,include ,Coronavirus Infections,Blood Clot,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.830
92e4ba72-a630-462c-aff7-661c2f8e17db,C0206750,C0302148,discuss recommendations from Society of ,Coronavirus Infections,Blood Clot,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.830
44df0f5d-d14f-4992-88e3-be70098917fd,C0012634,C0302148,include ,Disease,Blood Clot,1,X,[dsyn],[patf],C23.550.288,C14.907.355.830
8589e52c-8797-4b3a-a1a0-4b1ee614f693,C0206750,C0005778,include disseminated ,Coronavirus Infections,Blood coagulation,1,X,[dsyn],[ortf],C02.782.600.550.200,G09.188.390.150
e8f85be9-0756-4e46-9831-bb0ec15cebb0,C0012634,C0005778,include disseminated ,Disease,Blood coagulation,1,X,[dsyn],[ortf],C23.550.288,G09.188.390.150
9d0e9d3e-cdbe-4896-b8b9-52639acb8726,C0151942,C2945695,is in form of acute ,Arterial thrombosis,Limb ischemia,2,X,[patf],[dsyn],,
2abc3bb7-90bf-47f9-a0d3-48f629d06757,C0151942,COVID-19,can occur in ,Arterial thrombosis,COVID-19,1,X,[patf],[virs],,C000657245
721be8f6-fb20-4f8e-b599-128b96830c1c,C2945695,C2745965,is vascular ,Limb ischemia,Emergencies [Disease/Finding],2,X,[dsyn],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
bc5e4eb2-5de0-4d2f-a427-124fb9b84b65,C1175743,C1999230,across technologies is ,SARS coronavirus,Providing (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
adb88fbc-d0e3-48e7-b709-dcd96cabd8f6,C0740766,C0206750,are hallmarks of severe ,acute pneumonia,Coronavirus Infections,2,X,[dsyn],[dsyn],,C02.782.600.550.200
ccf56a65-1b6c-4ea5-a11f-ef4312875117,C0340194,C0206750,are hallmarks of severe ,Respiratory failure without hypercapnia,Coronavirus Infections,2,X,[dsyn],[dsyn],,C02.782.600.550.200
de4d2917-d832-4ea6-a13a-4b76e4e66b27,C1999230,C0013964,is in ,Providing (action),emergency medicine (field),3,X,[acty],[bmod],,H02.403.250
77e032f9-7b78-4c97-a193-bc9822c8c972,C0872147,1st,were searched until May 1st ,DNA Library,1st,1,X,[gngm/nnon],????,G05.360.325,????
77e032f9-7b78-4c97-a193-bc9822c8c972,C0872147,1st,were searched from December 1st 1st ,DNA Library,1st,3,X,[gngm/nnon],????,G05.360.325,????
0b846767-4eed-4a99-a7b1-b6dac42fe96e,C0872147,C0206419,using keywords of ,DNA Library,Genus: Coronavirus,1,X,[gngm/nnon],[virs],G05.360.325,B04.820.504.540.150
803a23cd-babe-4182-8a31-aa1b1bef1be2,C0333557,C0206419,is in patient with ,Watershed infarct,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
19257610-0d63-450f-9288-3d7f9ee2a172,C1856053,C0206419,is in World Health Organization ,Hydranencephaly with Renal Aplasia-Dysplasia,Genus: Coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
e7a91c5a-b10f-4fb2-bafb-176dff4f8c51,C2926735,3days,was varied from 3days 35days ,Duration,3days,1,X,[orch/phsu],????,,????
43076d79-6a14-48f7-b228-910346a40aac,C2926735,35days,was varied from 3days 35days ,Duration,35days,1,X,[orch/phsu],????,,????
5c05e644-f3c9-49b6-8b0b-1cfb85d3042e,C0206419,C0022646,is in ,Genus: Coronavirus,Kidney,4,X,[virs],[bpoc],B04.820.504.540.150,A05.810.453
e62fcd8e-252e-44e3-8409-bb59746f3632,C0206419,C0039597,do effect system from ,Genus: Coronavirus,Testis,1,X,[virs],[bpoc],B04.820.504.540.150,A05.360.444.849;A05.360.576.782;A06.300.312.782
c3add051-67dc-4735-86a1-0743b1660370,C0030755,C0012634,is with confirmed ,Pediatrics,Disease,1,X,[bmod],[dsyn],H02.403.670,C23.550.288
65501fd4-ac6d-48b3-9071-bd008f119004,C0030755,C1856053,is with confirmed ,Pediatrics,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[bmod],[dsyn],H02.403.670,x.x.x.x
fde9badd-5b15-4a01-8e8d-f2be72945d1d,C0030755,C1706374,is with confirmed ,Pediatrics,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[bmod],[aapp/bacs],H02.403.670,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
8c208e22-e913-4f17-b536-4725ead3bc16,C1175743,C0009758,may Despite prevalence of viral presence in ,SARS coronavirus,conjunctiva,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,A09.371.060.200;A09.371.337.168
1c8f8527-3abe-4b6d-84d5-c90a09dbf20e,C0242781,C0009758,may Despite prevalence of viral presence in ,disease transmission,conjunctiva,1,X,[patf],[bpoc],N06.850.310,A09.371.060.200;A09.371.337.168
b3212d02-726a-492f-adf1-8946bd108b13,CRRT,AKI,should should choice for AKI ,CRRT,AKI,1,X,????,????,????,????
87842b83-ed77-46f2-975f-7b5d62d73fa0,CRRT,C0206419,should should choice for AKI ,CRRT,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
d5b49508-b58a-41cf-97a3-8d6d8999932c,C0206419,AKI,is with AKI,Genus: Coronavirus,AKI,2,X,[virs],????,B04.820.504.540.150,????
1c4a9343-e184-4986-a839-240b2113893f,C1533734,C0206419,is in acute phase of AKI,Administration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
1c4a9343-e184-4986-a839-240b2113893f,C1533734,C0206419,improves clinical outcome of patients with severe ,Administration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
1c4a9343-e184-4986-a839-240b2113893f,C1533734,C0206419,are are currently tested in ,Administration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
0061274a-fb32-4670-a2e4-00a7d1f8d014,C1533734,AKI,is in acute phase of AKI,Administration procedure,AKI,1,X,[topp],????,,????
79276c78-29fa-40b1-8c48-7845dcede794,C1290380,C0476236,are most vulnerable for ,Chronic disease of cardiovascular system,Developmental symptoms,8,X,[dsyn],[sosy],,
f2467742-669c-4b8a-8473-06e8fa5135de,C0018801,C1290380,is main ,Heart failure,Chronic disease of cardiovascular system,2,X,[dsyn],[dsyn],C14.280.434,
6e9cefda-dd41-4efa-b5dd-0c7a166487d0,C0021081,C0018129,avoid ,Immunosuppressive Agents,Graft Rejection,2,X,[imft/phsu],[ortf],D27.505.696.477.656,G12.875.545.328
5895eb7f-278d-405c-8e10-097a526da566,C0007189,C0021665,of Society is ,Cardiology discipline,Insulin-Like Growth Factor I,2,X,[bmod],[aapp/bacs],H02.403.429.163,D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400
3011a1f3-a7f7-4a03-906f-fbb0a397a1c2,C0086418,C0003615,was diagnosed with ,Homo sapiens,Appendicitis,4,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
86f9485d-bfeb-4829-91c8-a2b844dd28fa,C0022709,C0020885,was reduced in inflamed ,Peptidyl-Dipeptidase A,ileum,6,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A03.556.124.684.249;A03.556.249.124
6eaa1a41-4e26-48e5-8b8c-18924da19d08,C0035696,C0020885,is in ,RNA Messenger,ileum,2,X,[bacs/nnon],[bpoc],D13.444.735.544,A03.556.124.684.249;A03.556.249.124
77af7169-e372-422d-89c6-27dc2f7f030b,C0022709,C0010346,was restored In active ,Peptidyl-Dipeptidase A,Crohn Disease,12,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C06.405.205.731.500;C06.405.469.432.500
8db3576a-0dc4-4005-9e09-96b00ce4166a,C0022709,C1707455,was downregulated in ,Peptidyl-Dipeptidase A,Comparison,4,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
ed23c166-7554-4402-9b53-efc52db307a9,C0021852,C0010346,was restored In active ,Intestines Small,Crohn Disease,4,X,[bpoc],[dsyn],A03.556.124.684,C06.405.205.731.500;C06.405.469.432.500
b5f33e90-0028-423c-baee-6f587b0e8385,C0021852,C0281481,was In active ,Intestines Small,anti-tumor necrosis factor therapy,2,X,[bpoc],[topp],A03.556.124.684,
b5f33e90-0028-423c-baee-6f587b0e8385,C0021852,C0281481,was restored by ,Intestines Small,anti-tumor necrosis factor therapy,2,X,[bpoc],[topp],A03.556.124.684,
6ce93e26-f13e-421b-8a85-dc76aa9904dd,C0022709,C0281481,was In active ,Peptidyl-Dipeptidase A,anti-tumor necrosis factor therapy,2,X,[aapp/enzy/imft],[topp],D08.811.277.656.350.350.687,
6ce93e26-f13e-421b-8a85-dc76aa9904dd,C0022709,C0281481,was restored by ,Peptidyl-Dipeptidase A,anti-tumor necrosis factor therapy,2,X,[aapp/enzy/imft],[topp],D08.811.277.656.350.350.687,
4a7690d5-4f43-49fc-bbf3-9dd375ea3d60,C0281481,C1448177,is in particularly anti ,anti-tumor necrosis factor therapy,TNF protein human,2,X,[topp],[aapp/bacs],,x.x.x.x
6dbf9753-fa39-4eae-a8d5-1053ae4c48db,C0013081,C0021368,is associated with ,Down-Regulation,Inflammation,2,X,[moft],[patf],G02.111.240;G05.308.200;G07.690.773.937,C23.550.470
b5d80a69-76c1-4f90-97ab-d36d27875345,C0013081,C0010346,is associated with ,Down-Regulation,Crohn Disease,2,X,[moft],[dsyn],G02.111.240;G05.308.200;G07.690.773.937,C06.405.205.731.500;C06.405.469.432.500
aa9288e2-c37b-4118-a3b1-7de0340ef07d,C0021368,C0010346,is in ,Inflammation,Crohn Disease,2,X,[patf],[dsyn],C23.550.470,C06.405.205.731.500;C06.405.469.432.500
aac0ffab-b0e4-4b02-a0fc-ffed4c72c906,C0013227,C0319157,are active against ,Pharmaceutical Preparations,AS virus,2,X,[phsu],[virs],D26,
bdf6df40-6eed-47b6-bb7c-661be7dba1eb,C0243077,C3694279,is in ,inhibitors,Middle East Respiratory Syndrome,3,X,[chvf],[dsyn],,C02.782.600.550.200
65b0449c-1cc9-4666-91ea-1820de713f53,C1510827,C0243077,is in range of known ,Affinity,inhibitors,3,X,[npop],[chvf],,
22d2c04c-0bb1-4466-b248-1b7193daddc5,C0684336,C0178784,is in multiple ,Impaired health,Organ,3,X,[patf],[bpoc],,
6fa575a4-6a77-4829-81e4-62a61a931bf7,C0206419,C0023884, includes ,Genus: Coronavirus,Liver,2,X,[virs],[bpoc],B04.820.504.540.150,A03.620
78f0d86d-e16a-43c0-9012-fa53e478afb3,C0206419,C0006104, includes ,Genus: Coronavirus,Brain,2,X,[virs],[bpoc],B04.820.504.540.150,A08.186.211
48f4b2d1-223d-44da-97bb-d0e7dbfc86eb,C0684336,C0206419,have have reported in ,Impaired health,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
15788d3c-c946-49ce-8838-997722036927,C0684336,C0024109,have have reported in ,Impaired health,Lung,3,X,[patf],[bpoc],,A04.411
b8a88c8b-c3ec-4b02-be39-423ca46d28ff,C0684336,C0018787,have have reported in ,Impaired health,Heart,3,X,[patf],[bpoc],,A07.541
e924eb5d-396e-4345-b182-0008399b21b0,C0684336,C0022646,have have reported in ,Impaired health,Kidney,3,X,[patf],[bpoc],,A05.810.453
1d44092a-9d9d-45f2-b37d-a04ae0cdfdd0,C0684336,C0023884,have have reported in ,Impaired health,Liver,3,X,[patf],[bpoc],,A03.620
ef4adc7d-ee49-47ad-89c4-5d330eb09096,C0684336,C0006104,have have reported in ,Impaired health,Brain,3,X,[patf],[bpoc],,A08.186.211
f42c8024-3477-490d-b568-e8b5383a22bc,C0005779,C0206419,is in ,Blood Coagulation Disorders,Genus: Coronavirus,4,X,[dsyn],[virs],C15.378.100,B04.820.504.540.150
f33653d1-5b23-4e1f-8a66-c638d872da62,C0013806,C1175743,more vulnerable to ,Electroconvulsive Therapy,SARS coronavirus,3,X,[topp],[virs],F04.570.200.583;F04.669.224.300,B04.820.504.540.150.113.937
0e2bd2d9-e3a1-4be1-83ff-920a31b26b68,C0242781,C2698650,using Markov Chain Monte Carlo ,disease transmission,Optimization,2,X,[patf],[acty],N06.850.310,
6d10f044-0703-4942-af05-8ceae83f9370,C0032105,C0005532,are preserved for later genetic ,Plasma,biology (field),1,X,[bdsu],[bmod],A12.207.152.693;A12.207.270.695;A15.145.693,H01.158.273
ba022b92-b623-478b-b00b-e0cca04710e1,C0814435,C0034019,of combination is ,early identification,public health medicine (field),2,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
8a3db9a9-5694-4e49-8ef7-dacb3b0e66b8,C2242456,C0206750,is in patients with ,thyroid function,Coronavirus Infections,2,X,[phsf],[dsyn],,C02.782.600.550.200
a848ba7d-a1b1-48cc-825c-357fdc5e4b12,C2948600,C2242456,evaluate ,Aim,thyroid function,1,X,[inch/phsu],[phsf],,
da3ec5ec-8a0f-4295-8639-88c37e195390,C0451610,C0206750,is with laboratory-confirmed ,Patient review,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
a30f9d28-0d48-4f86-b605-206b702ab311,C0040135,C0206750,Comparison between,Thyroid Hormones,Coronavirus Infections,1,X,[horm],[dsyn],D06.472.931,C02.782.600.550.200
8bceb694-7640-4c4d-ab00-9ad61b0da7e1,C2948600,C0018801,evaluate results of protocol established in advanced ,Aim,Heart failure,1,X,[inch/phsu],[dsyn],,C14.280.434
bc91b948-71ae-4386-a8dc-c0ac1f22df2d,C0242656,C0237820,include in mild cases from onset of symptoms ,Disease Progression,Recovery - action,1,X,[patf],[acty],C23.550.291.656,
0dc0b12a-3012-4ebb-be65-0bfddbc5ebb4,et,C0156149,have treated Coronavirus Infections patients with thromboembolic,et,Gastrointestinal tract vascular insufficiency,1,X,????,[dsyn],????,
35053eec-0f82-47e2-bd47-ad9bcbcdade3,al,C0156149,have treated Coronavirus Infections patients with thromboembolic,al,Gastrointestinal tract vascular insufficiency,1,X,????,[dsyn],????,
42aee4f2-e3c0-4ae5-81fa-dcc77f119629,et,C0206750,is in their ,et,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
5e85d350-f3be-4213-87ff-6e7e05bd0810,al,C0206750,is in their ,al,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
794da422-fd87-4845-b5ff-80f6b50e0bc6,C0014121,C0663332,is In countries still ,Bacterial Endocarditis,Scourge,1,X,[dsyn],[hops/orch],C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407,
84b7bab5-38ac-4a9f-b6d2-db34d0862c90,C0014121,C0035439,is In countries still ,Bacterial Endocarditis,Rheumatic Heart Disease,1,X,[dsyn],[dsyn],C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407,C01.252.410.890.731.649;C14.280.874
84b7bab5-38ac-4a9f-b6d2-db34d0862c90,C0014121,C0035439,is still Scourge in patients with,Bacterial Endocarditis,Rheumatic Heart Disease,1,X,[dsyn],[dsyn],C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407,C01.252.410.890.731.649;C14.280.874
99e3780d-b391-4afb-ba73-5a89ef71fb59,C0663332,C0035439,is in patients with ,Scourge,Rheumatic Heart Disease,1,X,[hops/orch],[dsyn],,C01.252.410.890.731.649;C14.280.874
59be4080-2109-4e83-a41a-b4176c233e07,C0597177,C3146294,are ,Particle,Generation (action),1,X,[chvs],[acty],,
9f7fb10d-9e25-44bd-b695-62ce52ac4574,C0597177,C0010200,are Generation (action) by,Particle,Coughing,1,X,[chvs],[sosy],,C08.618.248;C23.888.852.293
06388d1b-3779-4de7-81a5-3ceee958f311,C0597177,C0242781,facilitate ,Particle,disease transmission,1,X,[chvs],[patf],,N06.850.310
2b45a3d3-525d-435d-afb4-e8714c345a71,C0151946,COVID-19,appears ,Pulmonary thrombosis,COVID-19,1,X,[patf],[virs],,C000657245
a2bd244b-3ac5-46f3-bd9f-7070166448f9,C0151946,C0032285,appears ,Pulmonary thrombosis,Pneumonia,1,X,[patf],[dsyn],,C08.381.677;C08.730.610
d0d0ea32-5f8c-4c74-a06d-2585569d9092,C0151946,C0034065,takes proximal ,Pulmonary thrombosis,Pulmonary Embolism,1,X,[patf],[patf],,C08.381.746;C14.907.355.350.700
38764f1b-5072-474c-b9f4-43fe4e8a0f3c,C1519836,COVID-19,had During COVID19,Urologic Surgeon,COVID-19,1,X,[bmod],[virs],,C000657245
ef584d84-bedb-4973-939d-9d308f0ed9c7,C1519836,COVID19,had During COVID19,Urologic Surgeon,COVID19,1,X,[bmod],????,,????
3a188861-d5e8-4c68-b0e2-1350453accff,C1519836,C0543467,reorganize their daily ,Urologic Surgeon,Operative Surgical Procedures,1,X,[bmod],[topp],,E04
7bdc8429-ca88-426b-9b37-da1cdbdcc3e6,C0242781,C1706214,is with ,disease transmission,Creation,2,X,[patf],[acty],N06.850.310,
c89fc701-aefd-4f31-89dd-6401322320ea,C0242781,C0032320,is with ,disease transmission,Pneumoperitoneum,2,X,[patf],[dsyn],N06.850.310,C06.844.670
faba22f8-f959-4305-af0d-5ac88f53bef9,C0028630,C0079941,is in ,Nucleotides,Open Reading Frames,3,X,[nnon],[gngm],D09.408.620;D13.695,G05.360.335.760.640;G05.360.340.024.340.137.650
12c0bcd0-ac5c-4ba2-8111-99a52f166de0,C1511760,C0079941,is in ,Deletion Mutation,Open Reading Frames,2,X,[comd],[gngm],G05.365.590.762;G05.558.800,G05.360.335.760.640;G05.360.340.024.340.137.650
9102fd0b-37b6-4fa8-a47d-7d8b049a3695,C0017428,clade,were classified into new clade ,Genome,clade,2,X,[gngm],????,G05.360.340,????
c6b1a8c0-b0b8-424b-baa6-b0d419348dab,C0017428,C0026882,were classified into new clade ,Genome,Mutation,2,X,[gngm],[genf],G05.360.340,G05.365.590
1a0db757-1464-4b0e-ac51-3903f70b9f29,clade,C0026882,is with ORF1ab-V378I ,clade,Mutation,2,X,????,[genf],????,G05.365.590
0c4b14fa-7d8d-49b8-b7cc-ac410462dd3c,C0017428,clades,were classified in addition to dominant clades L84S,Genome,clades,2,X,[gngm],????,G05.360.340,????
d156b5a0-67da-4b73-ab0a-af4102d47fcb,C0017428,C0079941,were classified in addition to dominant clades L84S,Genome,Open Reading Frames,2,X,[gngm],[gngm],G05.360.340,G05.360.335.760.640;G05.360.340.024.340.137.650
e84fb5b7-e021-490b-b0b4-5a8c92b408f9,C0017428,L84S,were classified in addition to dominant clades L84S,Genome,L84S,2,X,[gngm],????,G05.360.340,????
87efc8b8-79d8-4558-aea1-03b78134499c,clade,C3714514,may may associated with ,clade,Infection,2,X,????,[patf],????,C01.539
254582b6-94d1-440b-9b95-c42506078697,C0037114,C0325125,compromising masks ,Silicones,Phocidae,1,X,[bodm/orch],[mamm],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,B01.050.150.900.649.313.750.250.700
08ee130f-3f1d-4b1d-b00b-b925b444a47a,C0037114,C0222084,is safe and beneficial option for ,Silicones,Skin structure of face,1,X,[bodm/orch],[bpoc],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,
30589d7c-7c9a-428d-8022-dab3b64d7b7f,C0037114,C0150638,is safe and beneficial option for ,Silicones,Preventing injury,1,X,[bodm/orch],[topp],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,
6ccd480d-73d2-4e52-8452-35ca6315e81a,C3495559,C1819995,is In issue of ,Juvenile arthritis,Host Cell,1,X,[dsyn],[celc],C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198,
4b927b70-c5af-4b78-8632-6c18f28ab83e,etal,C1819995,is In issue of ,etal,Host Cell,1,X,????,[celc],????,
bc4bdd32-105b-458d-b1e4-d32d44651b47,C0004561,C0369497,expressing broadly neutralizing ,B-Lymphocytes,Human immunodeficiency virus type 1 antibody,1,X,[cell],[aapp/imft],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,
47d860b4-f73b-40fc-aec7-6eb0f8af6bfb,C1880022,C1947933,may inform post-hospitalization ,Characterization,care activity,1,X,[acty],[acty],,
c44e4681-1a79-4d5a-97ff-7a010abfc663,C0275524,C4267729,is with other ,Coinfection,Respiratory pathogens,2,X,[dsyn],[orgm],C01.539.218;C02.219;C03.202,
1cf0fa12-7933-4b98-bebc-cb0ee68116cf,C0021760,C0060323,increased significantly at_time ,Interleukin-6,Fibrin fragment D,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,x.x.x.x
1cf0fa12-7933-4b98-bebc-cb0ee68116cf,C0021760,C0060323,Meanwhile increased at_time ,Interleukin-6,Fibrin fragment D,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,x.x.x.x
e0b1444c-4fdd-4b09-8de2-14562ad5f605,C0021760,C0010287,increased significantly at_time ,Interleukin-6,Creatine Kinase,1,X,[aapp/imft],[aapp/enzy],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D08.811.913.696.640.150
e0b1444c-4fdd-4b09-8de2-14562ad5f605,C0021760,C0010287,Meanwhile increased at_time ,Interleukin-6,Creatine Kinase,1,X,[aapp/imft],[aapp/enzy],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D08.811.913.696.640.150
4865ec3e-08d7-4712-a60f-6abe64a167a1,C0085295,C0010287,Meanwhile increased significantly at_time ,Interleukin-10,Creatine Kinase,2,X,[aapp/imft],[aapp/enzy],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D08.811.913.696.640.150
c2fee8c7-c5ed-4071-8299-5cbdcda4590e,C0085295,C0060323,Meanwhile increased significantly at_time ,Interleukin-10,Fibrin fragment D,2,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,x.x.x.x
4cb91982-d478-44e7-8d8a-a7ba0f4c0ed4,C0001899,C0010287,increased significantly at_time ,Alanine Transaminase,Creatine Kinase,1,X,[aapp/enzy],[aapp/enzy],D08.811.913.477.700.100,D08.811.913.696.640.150
4cb91982-d478-44e7-8d8a-a7ba0f4c0ed4,C0001899,C0010287,Meanwhile increased at_time ,Alanine Transaminase,Creatine Kinase,1,X,[aapp/enzy],[aapp/enzy],D08.811.913.477.700.100,D08.811.913.696.640.150
762a4e68-73d3-427b-a46c-e037054b3ef6,C0001899,C0060323,increased significantly at_time ,Alanine Transaminase,Fibrin fragment D,1,X,[aapp/enzy],[aapp/bacs],D08.811.913.477.700.100,x.x.x.x
762a4e68-73d3-427b-a46c-e037054b3ef6,C0001899,C0060323,Meanwhile increased at_time ,Alanine Transaminase,Fibrin fragment D,1,X,[aapp/enzy],[aapp/bacs],D08.811.913.477.700.100,x.x.x.x
84d868a5-a9b2-4be8-9157-d54cada425d7,C0010294,C0060323,increased significantly at_time ,Creatinine,Fibrin fragment D,1,X,[bacs/orch],[aapp/bacs],D03.383.129.308.207,x.x.x.x
84d868a5-a9b2-4be8-9157-d54cada425d7,C0010294,C0060323,Meanwhile increased at_time ,Creatinine,Fibrin fragment D,1,X,[bacs/orch],[aapp/bacs],D03.383.129.308.207,x.x.x.x
2ba3d585-078d-4243-92c7-fbd386484dc0,C0006560,C0010287,Meanwhile increased significantly at_time ,C-reactive protein,Creatine Kinase,2,X,[aapp/imft],[aapp/enzy],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,D08.811.913.696.640.150
6a7d9a1e-2b6a-43e7-981d-4052bc447da4,C0010294,C0010287,Meanwhile increased at_time ,Creatinine,Creatine Kinase,1,X,[bacs/orch],[aapp/enzy],D03.383.129.308.207,D08.811.913.696.640.150
6a7d9a1e-2b6a-43e7-981d-4052bc447da4,C0010294,C0010287,increased significantly at_time ,Creatinine,Creatine Kinase,1,X,[bacs/orch],[aapp/enzy],D03.383.129.308.207,D08.811.913.696.640.150
44d8cbee-1cc2-488c-b8c2-859b2455d6a6,C0006560,C0060323,Meanwhile increased significantly at_time ,C-reactive protein,Fibrin fragment D,2,X,[aapp/imft],[aapp/bacs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,x.x.x.x
769103a6-3ac1-4b9c-a34c-94e888d06339,C0277560,C0206750,is with ,Infantile disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
0420b319-33df-41a0-8ed1-1c04757e4534,C0206750,C1510889,utilizes ,Coronavirus Infections,Angiotensin-converting Enzyme 2 Pathway,2,X,[dsyn],[moft],C02.782.600.550.200,
e531429c-f522-416d-9218-07bc8b5b8829,C0960880,C0009450,may contribute to heterogenous ,angiotensin converting enzyme 2,Communicable Diseases,1,X,[aapp/enzy],[dsyn],x.x.x.x,C01.539.221
bcb93574-c7ea-45ae-b940-463db8edf943,C0684167,C0960880,may alter ,hypertensive medication,angiotensin converting enzyme 2,1,X,[phsu],[aapp/enzy],,x.x.x.x
8d825d6f-c6e4-405c-b764-f01ba52d221b,C0684167,C0103306,may alter ,hypertensive medication,angiotensin I (1-7),1,X,[phsu],[aapp/phsu],,x.x.x.x
a8b7ea33-e86b-4879-b4cb-dd27739528dc,C3826426,C3540027,was modeled via ,Dynamics,Adrenergic and dopaminergic agents combinations,2,X,[npop],[phsu],,
e335c270-928e-4b52-9d92-afed02333e95,C1825598,C0333957,monitoring ,IMPACT gene,Growth acceleration,2,X,[gngm],[patf],,
28d83add-ea3d-4765-9a1c-5c6472fb5c13,C1096155,C1175743,is highly effective measure against dissemination of ,Macrophage Activation Syndrome,SARS coronavirus,2,X,[dsyn],[virs],C20.683.515.800,B04.820.504.540.150.113.937
ad28e02b-1f1a-42bf-8cab-50cb9d95308a,et,C0442893,is in their ,et,Systemic disease,1,X,????,[dsyn],????,
c193c76a-309f-4b77-8f4f-0f522228e08a,al,C0442893,is in their ,al,Systemic disease,1,X,????,[dsyn],????,
99c1cf61-ddb2-4925-9620-1e10f84bac41,C1333684,C0023745,use simple ,GNA12 gene,genetic linkage,2,X,[gngm],[moft],,G05.348
3fdfc241-8056-4882-9d92-298c0b920c5d,C1333684,C4552744,use simple ,GNA12 gene,Daily Living,2,X,[gngm],[dora],,
c8fa5d3d-bf54-45d3-98ac-e025357437dc,C1825598,C0281190,is in ,IMPACT gene,colorectal cancer prevention,2,X,[gngm],[topp],,
686ac6e2-5879-4c34-b902-51faad7cd1b1,C0013404,C3177142,was ,Dyspnea,Main presenting symptom,1,X,[sosy],[sosy],C08.618.326;C23.888.852.371,
764e1ceb-1be7-40b9-bf33-2a637dce6935,C0206750,C0011438,is new challenge in modern ,Coronavirus Infections,Dentistry,1,X,[dsyn],[bmod],C02.782.600.550.200,E06;H02.163
764e1ceb-1be7-40b9-bf33-2a637dce6935,C0206750,C0011438,has brought challenge to world of ,Coronavirus Infections,Dentistry,1,X,[dsyn],[bmod],C02.782.600.550.200,E06;H02.163
9509cf4a-e3d8-45d4-b3d5-671c8402ec66,C0598197,C0010356,caused by ,contagion,Cross Infection,1,X,[npop],[patf],,C01.539.248;C23.550.291.875.500
516fc0e9-b3bd-4c90-b2a4-e571f2b19165,C0012683,C0001962,is with ,Disinfection,Ethanol,1,X,[topp],[orch/phsu],N06.850.780.200.450.850.375,D02.033.375;x.x.x.x
f07f5606-8983-4b2a-82cd-fee720203a38,C0426576,C0206750,are are increasingly recognized in ,Gastrointestinal symptom,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
f07f5606-8983-4b2a-82cd-fee720203a38,C0426576,C0206750,could could used for prognostication in patients with ,Gastrointestinal symptom,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
f07f5606-8983-4b2a-82cd-fee720203a38,C0426576,C0206750,frequently reported in ,Gastrointestinal symptom,Coronavirus Infections,3,X,[sosy],[dsyn],,C02.782.600.550.200
74b13b8d-c7d8-4461-83c1-aa8b9484e7e4,C0206750,C0426576,were compared with ,Coronavirus Infections,Gastrointestinal symptom,4,X,[dsyn],[sosy],C02.782.600.550.200,
3be85799-a106-47fb-bdfc-4fdd0499eb67,C4524574,C0040300,thus poses arisk through ,Ocular Tissue,Body tissue,1,X,[tisu],[tisu],,A10
6ad66d02-8f8e-4e6a-b8d0-d46039ef1680,C4524574,arisk,thus poses arisk ,Ocular Tissue,arisk,1,X,[tisu],????,,????
9f8f74b6-729e-4542-9cd5-df199188239a,C4524574,C0009450,thus poses arisk ,Ocular Tissue,Communicable Diseases,1,X,[tisu],[dsyn],,C01.539.221
97daf9e9-c613-4004-afe1-6b76408a6462,C1175743,C4524574,infect ,SARS coronavirus,Ocular Tissue,1,X,[virs],[tisu],B04.820.504.540.150.113.937,
2cc1f4dd-77a9-4c4d-994a-988251a41af9,CoV2,C4524574,infect ,CoV2,Ocular Tissue,1,X,????,[tisu],????,
a5fd289f-75a2-45c6-8a52-34a2076d97de,C0022709,C0036734,was identified as ,Peptidyl-Dipeptidase A,Serine Endopeptidases,2,X,[aapp/enzy/imft],[aapp/enzy],D08.811.277.656.350.350.687,D08.811.277.656.300.760;D08.811.277.656.959.350
e71b246d-1d07-45af-963d-d76b6b4ac9c3,C0022709,C0030946,was identified as ,Peptidyl-Dipeptidase A,Endopeptidases,2,X,[aapp/enzy/imft],[aapp/enzy/phsu],D08.811.277.656.350.350.687,D08.811.277.656.300
a83accc1-eee3-4819-86b0-d0c152be4b99,C0009450,CoV2,is with CoV2,Communicable Diseases,CoV2,2,X,[dsyn],????,C01.539.221,????
c0cc5500-16b0-4012-af28-b1c6d972dd62,C0022709,C0015392,are In ,Peptidyl-Dipeptidase A,Eye,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A01.456.505.420;A09.371
8735a26f-2d10-49ca-b1a6-b0d36cd5ca9f,C1292533,C0597360,loss of ,Tissue specimen,receptor expression,1,X,[tisu],[genf],,
b9f279fb-e127-42df-b36f-38b9d0bf7649,C0009450,C0010042,must In cases of ,Communicable Diseases,Keratoplasty,1,X,[dsyn],[topp],C01.539.221,E02.095.147.725.225;E04.540.825.374;E04.936.580.225
e6725dc8-5f6f-42db-b2e4-3e6d3d6a6fef,C1692321,C0032285,consistent with ,Cellular infiltrate,Pneumonia,1,X,[patf],[dsyn],,C08.381.677;C08.730.610
3c27df8d-9a28-42e7-ad41-ef5b3b9d1da3,GGO,C0278459,predominantly distributed in peripheral ,GGO,Structure of pulmonic area,1,X,????,[bpoc],????,
00686ae9-0b17-469d-b0ee-c21ff4f183db,C1692321,C0278459,predominantly distributed in peripheral ,Cellular infiltrate,Structure of pulmonic area,1,X,[patf],[bpoc],,
2aa0253b-1168-4ee2-be42-38574b0ff941,GGO,C1692321,was most common ,GGO,Cellular infiltrate,1,X,????,[patf],????,
e83b7c0d-f3f3-4506-a044-664233c5bb19,C0206750,C0005779,is with ,Coronavirus Infections,Blood Coagulation Disorders,1,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.100
ffcf0cdf-9934-48f7-8484-86730faeac94,C0567416,C0009450,prevent ,Molecule,Communicable Diseases,1,X,[sbst],[dsyn],,C01.539.221
ffcf0cdf-9934-48f7-8484-86730faeac94,C0567416,C0009450,control ,Molecule,Communicable Diseases,2,X,[sbst],[dsyn],,C01.539.221
f89a5b52-dd03-452a-b084-c219bab22ce9,C0019134,C1175743,may attenuate course of ,heparin,SARS coronavirus,2,X,[bacs/orch/phsu],[virs],D09.698.373.400,B04.820.504.540.150.113.937
f32fb80e-bd78-4249-9700-fa469e163d84,C0079189,C0024115,appear key drivers ,cytokine,Lung diseases,2,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381
3895aaf6-2b7a-4fab-b401-d530691ace3b,C1879547,C0041904,has has linked to ,Activation action,Up-Regulation (Physiology),2,X,[acty],[moft],,G02.111.905;G05.308.850;G07.690.773.998
f2da0379-4b7a-4eeb-86ee-625435cd8153,C1879547,C0127400,has has linked to ,Activation action,Mediator brand of benfluorex hydrochloride,2,X,[acty],[orch/phsu],,
f2da0379-4b7a-4eeb-86ee-625435cd8153,C1879547,C0127400,protecting system from ,Activation action,Mediator brand of benfluorex hydrochloride,1,X,[acty],[orch/phsu],,
0b5bfdaf-6f96-4e0a-ad0f-ded819dbee1d,C1879547,C0087111,suggest rational ,Activation action,Therapeutic procedure,2,X,[acty],[topp],,E02
5b204107-9b03-4a10-bad1-086638cbda9d,C1879547,C0206750,suggest rational ,Activation action,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
5963ac82-4cfb-45d4-a596-c20864b551cb,C3463820,C0243026,prevent mortality in at least types of experimental ,Inhibition,Sepsis,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.539.757;C23.550.470.790.500
5963ac82-4cfb-45d4-a596-c20864b551cb,C3463820,C0243026,prevent inflammatory response in at least types of experimental,Inhibition,Sepsis,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.539.757;C23.550.470.790.500
5963ac82-4cfb-45d4-a596-c20864b551cb,C3463820,C0243026,prevent Disseminated Intravascular Coagulation in at least types of experimental,Inhibition,Sepsis,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.539.757;C23.550.470.790.500
362a13ab-2115-473e-a356-d5c4813a4f6b,C3463820,C1155266,prevent pathologic systemic ,Inhibition,inflammatory response,2,X,[acty],[patf],F01.145.544;F02.463.425.475;F02.739.794.405,
5439ffd3-5023-4688-80ff-21cd4cdcb960,C3463820,C0012739,prevent ,Inhibition,Disseminated Intravascular Coagulation,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C15.378.100.220;C15.378.463.250;C15.378.925.220
2fb31242-4eac-427a-9930-461565b9f096,C0009835,C0038172,also prevented death from ,Contact Inhibition,Staphylococcus aureus,2,X,[celf],[bact],G04.383,B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100
d8bbab0b-afb1-4f0b-b0d3-910f16514003,C0009835,C0242966,also prevented death from ,Contact Inhibition,Systemic Inflammatory Response Syndrome,2,X,[celf],[dsyn],G04.383,C23.550.470.790;C23.550.835.900
d4d0ced0-6e96-47ae-aab3-3cbefbe26b30,C0009835,C0237798,also prevented death from ,Contact Inhibition,Nonhuman primate,2,X,[celf],[mamm],G04.383,
96c275f6-b773-4d6b-b30c-a7523cbbe88c,C0038172,C0237798,is in ,Staphylococcus aureus,Nonhuman primate,2,X,[bact],[mamm],B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100,
9c726c99-8c21-4616-a098-c6359c4455a2,C0242966,C0237798,is in ,Systemic Inflammatory Response Syndrome,Nonhuman primate,2,X,[dsyn],[mamm],C23.550.470.790;C23.550.835.900,
69b00d6e-0160-4081-a5e9-54012983371a,C0087111,C0597404,immune especially anti-influenza Drugs - dental services due to similarities between,Therapeutic procedure,Respiratory viruses,1,X,[topp],[virs],E02,
0edcf3d7-5d1c-47b4-aa27-351584d805fa,C0087111,C0178784,could Indeed could ,Therapeutic procedure,Organ,1,X,[topp],[bpoc],E02,
a87921b7-3abb-48a2-80dd-6f7c96b32669,C0087111,C0031843,could Indeed could ,Therapeutic procedure,physiological aspects,1,X,[topp],[phsf],E02,x.x.x.x
a87921b7-3abb-48a2-80dd-6f7c96b32669,C0087111,C0031843,can cause severe morbidity ,Therapeutic procedure,physiological aspects,1,X,[topp],[phsf],E02,x.x.x.x
f06ef5d2-bbd4-4538-b700-e61eb533d5a9,C0013404,C0035222,can rapidly progress to ,Dyspnea,Respiratory Distress Syndrome Adult,1,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C08.381.840;C08.618.840
aff44677-8b8c-4c8c-8679-5b643c9ef00e,C2364082,C0206750,occur in in to ,Sense of smell impaired,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
aff44677-8b8c-4c8c-8679-5b643c9ef00e,C2364082,C0206750,are frequent early symptoms of ,Sense of smell impaired,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
aff44677-8b8c-4c8c-8679-5b643c9ef00e,C2364082,C0206750,were prevalent among ,Sense of smell impaired,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
aff44677-8b8c-4c8c-8679-5b643c9ef00e,C2364082,C0206750,were independently highly associated with ,Sense of smell impaired,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
3979395f-b9dd-4957-9310-85f496f0c828,C1175743,C0014442,binds angiotensin-converting ,SARS coronavirus,Enzymes,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811
9570be8d-45d2-422c-be9e-1210c22a0c5e,C0521982,C0032105,analyzing ,Response to treatment,Plasma,1,X,[clna],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
fa09f16e-0020-4ac3-aa4b-397495e86a90,C0521982,C0304475,is with ,Response to treatment,Potassium supplement,1,X,[clna],[inch/phsu],,
fbadfd23-0f6f-4555-8052-9bf0c251fec5,C0920425,C0005525,is with ,cancer therapy,Biological Response Modifiers,1,X,[topp],[imft/phsu],,D27.505.696.477
9aae348b-b82d-4a5b-b813-9acb0bee0e16,PET/CT,C0016327,is with FDG,PET/CT,Fluorides,1,X,????,[inch/phsu],????,D01.248.497.158.380;D01.303.350.300
67889503-6c2e-4195-bc67-7ad9aa331f69,PET/CT,FDG,is with FDG,PET/CT,FDG,1,X,????,????,????,????
ad2c1d32-8aa9-4e7d-89b9-2feb8a6b201e,C1825598,C1516048,should should ,IMPACT gene,Assessed,2,X,[gngm],[acty],,
f2d6fe9e-3c62-41bd-8628-0406b6c06eeb,C0242781,C0206750,control ,disease transmission,Coronavirus Infections,2,X,[patf],[dsyn],N06.850.310,C02.782.600.550.200
f2d6fe9e-3c62-41bd-8628-0406b6c06eeb,C0242781,C0206750,was reconstructed from 9 120 ,disease transmission,Coronavirus Infections,1,X,[patf],[dsyn],N06.850.310,C02.782.600.550.200
507960d9-3e2c-4b4a-84ff-0eb2b7174f1f,C2948600,C1880177,examine ,Aim,Contribution,1,X,[inch/phsu],[acty],,
dc5c2387-a943-4b04-9dd6-1e97f9b2d654,C2948600,C0011570,enhancing ,Aim,Mental Depression,1,X,[inch/phsu],[mobd],,F01.145.126.350
68163677-fd1e-4dfb-a20d-97297f550ced,C0206750,C2259033,is associated with systemic ,Coronavirus Infections,activation of coagulation,1,X,[dsyn],[phsf],C02.782.600.550.200,
68163677-fd1e-4dfb-a20d-97297f550ced,C0206750,C2259033,is associated with high prevalence ,Coronavirus Infections,activation of coagulation,2,X,[dsyn],[phsf],C02.782.600.550.200,
914aa244-e296-4fe6-9b62-fb74791aa86a,C1155266,C2259033,is with ,inflammatory response,activation of coagulation,1,X,[patf],[phsf],,
99dc3618-00c7-44f2-8b14-6542581cebca,C0023756,C0206750,was Due to ,Panthera leo,Coronavirus Infections,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.377.750.600.500,C02.782.600.550.200
744534d6-1021-46f1-835d-b985a7b81e87,C0022671,COVID-19,thought ,Kidney Transplantation,COVID-19,2,X,[topp],[virs],E02.870.500;E04.936.450.485;E04.950.774.400,C000657245
bf9ccc73-1a39-4b4c-967c-daaff8c20859,C0022671,C0012634,thought ,Kidney Transplantation,Disease,2,X,[topp],[dsyn],E02.870.500;E04.936.450.485;E04.950.774.400,C23.550.288
31487039-cda0-42c1-854c-c9bda07773ff,C0004096,COVID-19,may at ,Asthma,COVID-19,3,X,[dsyn],[virs],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C000657245
59e3c81a-9365-4c5d-b147-d35ca614376b,COVID-19,C0598197,is highly ,COVID-19,contagion,2,X,[virs],[npop],C000657245,
cdb258b0-9b24-4cd5-8d23-8053c63331a4,C1880022,C0014442,using ,Characterization,Enzymes,1,X,[acty],[aapp/enzy],,D08.811
6b463f99-eef2-4ef4-891b-39e3b9a612c4,C1880022,C0022702,using ,Characterization,Kinetics,1,X,[acty],[npop],,G01.374.661;G02.111.490
e0831798-42af-474a-b1fc-7c613ddc7720,centre,C1527398,effectively managed urgent dental ,centre,Emergency Care,1,X,????,[topp],????,N02.421.297
3d4b22e1-7108-466e-a25b-352da125859c,DRC,C0206750,is currently experiencing ,DRC,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
d7ac17cc-db9d-45d6-9017-d4711ff09ec6,DRC,C0012634,is currently experiencing ,DRC,Disease,1,X,????,[dsyn],????,C23.550.288
dbb1d1c2-a972-4e9d-b15c-c42fccb1947b,C0086418,C2926735,should ,Homo sapiens,Duration,1,X,[humn],[orch/phsu],B01.050.150.900.649.313.988.400.112.400.400,
77aed41a-a42d-414b-bdb5-4b95c6b40fd6,C3266814,C0270724,establish contingency ,Action,Infantile Neuroaxonal Dystrophy,2,X,[acty],[dsyn],,C10.228.140.744
897ba377-ca47-4aca-a4d6-a836914a586a,C0021400,C0206750,is potentially more lethal than ,Influenza,Coronavirus Infections,2,X,[dsyn],[dsyn],C02.782.620.365;C08.730.310,C02.782.600.550.200
46670263-b5f0-4771-86c1-b5d7b98fd221,C1290857,C0206750,is with ,Disorder of face,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
1f0db1d7-232e-4bf9-862f-ea2c0091e42c,C0037285,C0015230,are are reported including ,Skin Manifestations,Exanthema,2,X,[sosy],[sosy],C23.888.885,C17.800.257
360810b4-c359-40ad-a701-a969f3d89ebd,C0015230,COVID-19,is in covid19 ,Exanthema,COVID-19,2,X,[sosy],[virs],C17.800.257,C000657245
f5c45c72-f783-4b2a-82b3-85775b9aa8d9,C0015230,covid19,is in covid19 ,Exanthema,covid19,2,X,[sosy],????,C17.800.257,????
9a2186be-1543-4fd9-abf0-0fe74081f99a,C0032285,CoV2,positive for CoV2,Pneumonia,CoV2,2,X,[dsyn],????,C08.381.677;C08.730.610,????
e4da76ae-263a-4c18-9799-6c32f634465e,PCR,CoV2,positive for CoV2,PCR,CoV2,2,X,????,????,????,????
3b21e538-794d-4d08-a78c-6e1026a5a8f7,C2350332,C0039194,can inactivate ,Exosomes,T-Lymphocyte,1,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
fc3ac9be-0b33-4f89-b888-7f4e8a62099b,C0035435,C0085253, includes ,Rheumatism,Adult-Onset Still Disease,1,X,[dsyn],[dsyn],C05.799;C17.300.775,C05.550.114.154.870;C05.799.114.870;C17.300.775.099.870;C20.111.199.870
a9ff4113-385d-4077-8cd5-c26654fbd04e,C0035435,C4054044, includes ,Rheumatism,Secondary Hemophagocytic Lymphohistiocytosis,1,X,[dsyn],[dsyn],C05.799;C17.300.775,
fbaf47f7-1440-4718-a8d9-4f9632db1520,C0035435,C0085278, includes ,Rheumatism,Antiphospholipid Syndrome,1,X,[dsyn],[dsyn],C05.799;C17.300.775,C20.111.197
897bd0c8-e927-4a14-89de-c336b1de89bb,C0035435,C0039082,have have included in hyperferritinemic ,Rheumatism,Syndrome,1,X,[dsyn],[dsyn],C05.799;C17.300.775,C23.550.288.500
02915a2b-24a1-4adf-becf-ff67449fd880,C0085253,C0039082,have have included in hyperferritinemic ,Adult-Onset Still Disease,Syndrome,1,X,[dsyn],[dsyn],C05.550.114.154.870;C05.799.114.870;C17.300.775.099.870;C20.111.199.870,C23.550.288.500
9b3a2ac2-6e23-495b-aa64-74c0c9676210,C4054044,C0039082,have have included in hyperferritinemic ,Secondary Hemophagocytic Lymphohistiocytosis,Syndrome,1,X,[dsyn],[dsyn],,C23.550.288.500
7936ef0a-87b2-4e62-83fe-7047edf4f363,C0085278,C0039082,have have included in hyperferritinemic ,Antiphospholipid Syndrome,Syndrome,1,X,[dsyn],[dsyn],C20.111.197,C23.550.288.500
4bd67498-e706-43b3-a62c-3e5b3a83589d,C0206750,C1963758,may benefit from ,Coronavirus Infections,Immunomodulation,1,X,[dsyn],[topp],C02.782.600.550.200,E02.095.465;G12.535
74993939-4ed9-46b3-8e97-574075f03386,C1433062,C0206750,is considered as prime target for anti ,3C-like protease SARS coronavirus,Coronavirus Infections,1,X,[aapp/enzy],[dsyn],x.x.x.x,C02.782.600.550.200
3de011ef-1421-4db7-92a7-f45c120f3e8b,C0071649,C1254351,possess favorable ,polyphenols,Pharmacologic Substance,1,X,[orch/phsu],[phsu],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
cb6dff7e-ffd8-43de-9ac8-c59bc73ae799,C0071649,C0206750,are promising ,polyphenols,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,C02.782.600.550.200
6a3e2de0-483f-4223-a0f6-b7bd89c1c36c,C0206750,C0870392,has triggered massive ,Coronavirus Infections,debate,1,X,[dsyn],[acty],C02.782.600.550.200,
6a3e2de0-483f-4223-a0f6-b7bd89c1c36c,C0206750,C0870392,has generated wide-ranging ,Coronavirus Infections,debate,1,X,[dsyn],[acty],C02.782.600.550.200,
a004fccc-db5e-496f-9db6-9a7fd3de1d6f,C0026636,C4505065,are most prevalent ,Mouth Diseases,Noncommunicable Diseases,1,X,[dsyn],[dsyn],C07.465,C23.550.291.500.750
833eb17a-5f67-4716-9960-b179afb0d369,C0026636,C0035920,being recognized ,Mouth Diseases,Rubella,2,X,[dsyn],[dsyn],C07.465,C02.782.930.700.700
c1ee99c1-8626-47d6-955c-c4010ee0ffc7,C0026636,C0087111,being recognized ,Mouth Diseases,Therapeutic procedure,1,X,[dsyn],[topp],C07.465,E02
645d3f85-81b0-4dfb-a784-a3c7b3744bfd,C0035920,C0087111,most expensive Rubella to,Rubella,Therapeutic procedure,1,X,[dsyn],[topp],C02.782.930.700.700,E02
47accdea-a94e-4260-a273-268f90bc510a,C0242781,C0009450,possible route of be Here may ,disease transmission,Communicable Diseases,2,X,[patf],[dsyn],N06.850.310,C01.539.221
f50ba64f-e405-4409-960e-05978432bd1f,C0012634,C0079189,associated with ,Disease,cytokine,2,X,[dsyn],[aapp/imft],C23.550.288,D12.644.276.374;D12.776.467.374;D23.529.374
f50ba64f-e405-4409-960e-05978432bd1f,C0012634,C0079189,manifest ,Disease,cytokine,1,X,[dsyn],[aapp/imft],C23.550.288,D12.644.276.374;D12.776.467.374;D23.529.374
f50ba64f-e405-4409-960e-05978432bd1f,C0012634,C0079189,known as ,Disease,cytokine,1,X,[dsyn],[aapp/imft],C23.550.288,D12.644.276.374;D12.776.467.374;D23.529.374
3ddbc6f5-9856-4c98-ad31-eaed01ded39b,C1609165,C1335676,are ,tocilizumab,Recombinant Antibody,4,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,
02df12b6-f6a5-4588-bddc-4a27c094e04e,C1609165,C0003250,are ,tocilizumab,Monoclonal Antibodies,2,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
be676af3-f46a-4746-b530-5b213b933740,C4087043,C1335676,are ,Lenzilumab,Recombinant Antibody,4,X,[aapp/imft/phsu],[aapp/imft],,
0da13370-d29b-48e6-8151-d51ade514bab,C4087043,C0003250,are ,Lenzilumab,Monoclonal Antibodies,2,X,[aapp/imft/phsu],[aapp/imft],,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
ed4b844e-9e05-4f18-814a-8349209e464a,C4087043,C0021760,are ,Lenzilumab,Interleukin-6,2,X,[aapp/imft/phsu],[aapp/imft],,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
09ebe754-de16-4795-a640-6f026aec37c3,hypoxic,C0206750,associated with ,hypoxic,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
c835d9e1-d148-4b43-bab2-0a8d7d73f2c3,C1609165,C0264490,have have proposed as potential treatment for ,tocilizumab,Acute respiratory failure,2,X,[aapp/imft/phsu],[dsyn],x.x.x.x,
5f4b94cf-84ca-45a8-9251-ea0a57db5fab,C4087043,C0079189,is in management of ,Lenzilumab,cytokine,2,X,[aapp/imft/phsu],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
d5c19643-6567-414d-9acc-d192ff5e2d0f,C4087043,C0039082,is in management of ,Lenzilumab,Syndrome,2,X,[aapp/imft/phsu],[dsyn],,C23.550.288.500
80bcee8e-1f03-44a9-b486-56dcc864da3e,C1739395,C0206750,has has scarcely reported in patients with ,Takotsubo Cardiomyopathy,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.280.945.900.500,C02.782.600.550.200
c2917f82-178e-4bba-a002-450c8de91845,C0079189,C1739395,trigger ,cytokine,Takotsubo Cardiomyopathy,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C14.280.945.900.500
82c6ecc4-f2ee-4a73-910a-d96a3f498c7d,C0544688,C0206750,rare neurological complication of disease of,complication of disease,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
50f6d9f5-53bb-4410-a086-9d8b4b977289,C1521827,C2349975,is fundamental requirement for ,Preparation,Enhance (action),1,X,[acty],[acty],,
1e95c429-0607-4535-bf88-e16cb23166a1,C1521827,C2917745,is fundamental requirement for ,Preparation,Safe-Guard,1,X,[acty],[orch/phsu],,
b3bbeab7-6374-463c-ba34-b41d8816b5a9,C4267729,C3698360, includes ,Respiratory pathogens,Middle East Respiratory Syndrome Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150.113.750
fc8e011c-30e1-484f-bb6b-820aaaab7fde,C0599878,C0035222,ranging from asymptomatic to ,disease characteristic,Respiratory Distress Syndrome Adult,4,X,[patf],[dsyn],,C08.381.840;C08.618.840
3170c8ee-d1b4-457d-a845-d468feee60a5,C0010357,C0700271,is in antibody binding to ,Cross Reactions,M Protein multiple myeloma,2,X,[moft],[aapp/imft],G12.122.281,x.x.x.x
2820215a-3d9d-4799-bf6a-48436913b1a1,C3265468,C0282682,indicating presence of non ,Virus Neutralization,Antibodies Blocking,2,X,[moft],[aapp/imft/irda],,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
58f50989-5a33-4dc4-82e4-790ba4724ec9,C3265468,C0003316,indicating presence of non ,Virus Neutralization,Epitopes,2,X,[moft],[imft],,D23.050.550
ec24a078-5819-40d8-a293-d29e40e82c07,C0282682,C0282632,will lead to ,Antibodies Blocking,Antibody-Dependent Enhancement,4,X,[aapp/imft/irda],[comd],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,G06.920.095;G12.113
991a2127-e03e-4aca-8112-15eb85b6b5b4,C0282682,C0012634,will lead to ,Antibodies Blocking,Disease,2,X,[aapp/imft/irda],[dsyn],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,C23.550.288
852c12eb-b912-48a9-a3f8-df3096eb3121,C1457887,C0683325,is In terms of ,Symptoms,clinical aspects,1,X,[sosy],[clna],,
e9a10171-6ec2-4342-9186-061d8698cf47,C0683325,C0015219,might might helpful in ,clinical aspects,Biological Evolution,1,X,[clna],[genf],,G05.045;G16.075
dd5b5981-3c5d-42b6-8cb3-903b35d337ef,C0086418,C0018801,is with prior ,Homo sapiens,Heart failure,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C14.280.434
85c6e99a-a9ea-438d-97f1-84fc0de5ecfb,C0061751,C0206750,rapidly evaluated for treatment of patients with ,Glycyrrhizic Acid,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.455.849.919.530.466,C02.782.600.550.200
3bba5930-df18-4fc0-88d6-83000a1328f3,titers,C0206750,Noncommunicable Diseases,titers,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
fe0f8c11-cf73-40bb-8b8f-eae219a51fc9,titers,C4505065,Noncommunicable Diseases,titers,Noncommunicable Diseases,1,X,????,[dsyn],????,C23.550.291.500.750
e9b614ca-dc68-426c-b79e-05ef6322ca60,C4505065,C1167395,may influence ,Noncommunicable Diseases,Host (organism),1,X,[dsyn],[orgm],C23.550.291.500.750,
a8dccd54-3552-4917-b23d-a8de04395544,C4505065,C0021053,may influence ,Noncommunicable Diseases,Immune System Diseases,1,X,[dsyn],[dsyn],C23.550.291.500.750,C20
3a334347-50a5-4353-8cca-4b1933d2760d,C2745965,C0948008, includes ,Emergencies [Disease/Finding],Ischemic stroke,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,
2fc4f80a-5bd3-4a9b-bd9a-88178d8d115c,C0333165,C0040861,require emergent ,Acute obstruction,Triage,1,X,[patf],[topp],,N02.421.297.900
2ec527e7-4d8c-4425-88cd-668390461935,C0948008,C0040861,require emergent ,Ischemic stroke,Triage,1,X,[dsyn],[topp],,N02.421.297.900
e6ac7ed4-71f0-481c-8e35-c47edf6cb0d6,C0333165,C4534538,require emergent ,Acute obstruction,Mechanical thrombectomy,1,X,[patf],[topp],,
4a3ba9f5-54c8-4568-94db-99f3eb855dca,C0948008,C4534538,require emergent ,Ischemic stroke,Mechanical thrombectomy,1,X,[dsyn],[topp],,
43193714-11e8-49b9-8d36-1c9b3d2e7e7f,C0333165,C0225990,is with ,Acute obstruction,Large blood vessel structure,1,X,[patf],[bpoc],,
bfc38b9c-fd74-4656-a7a9-021e63a87a85,C0948008,C0225990,is with ,Ischemic stroke,Large blood vessel structure,1,X,[dsyn],[bpoc],,
092ce24d-186b-4ea8-aa9a-f2bb69594f3b,C0948008,C0333165,is with ,Ischemic stroke,Acute obstruction,1,X,[dsyn],[patf],,
34c7eb98-bc22-40ff-8829-d71dc65f2789,C0023175,C1433062,were studied through docking against ,Lead,3C-like protease SARS coronavirus,4,X,[elii/hops],[aapp/enzy],D01.268.556.435;D01.552.544.435;x.x.x.x,x.x.x.x
eb35c066-f93c-45c9-9b30-bf594ba126c6,C0567416,C1433062,were studied through docking against ,Molecule,3C-like protease SARS coronavirus,4,X,[sbst],[aapp/enzy],,x.x.x.x
7aadce8b-4ff0-4b32-a787-af58a9335f4d,C0206172,C0206750,been how affected by current ,Diabetic Foot,Coronavirus Infections,2,X,[dsyn],[dsyn],C14.907.320.191;C17.800.893.592.450.200;C19.246.099.500.191;C19.246.099.937.250,C02.782.600.550.200
ccfa6372-57de-459c-9f0b-b8db32514fbe,C0071097,C1175743,can reduce ,pioglitazone,SARS coronavirus,2,X,[orch/phsu],[virs],D02.886.675.933.250;D03.383.129.708.933.250,B04.820.504.540.150.113.937
9b577a3a-e24e-40ab-88e4-b30420124f1f,C0071097,C0301872,moderating exaggerated ,pioglitazone,Immune response,4,X,[orch/phsu],[ortf],D02.886.675.933.250;D03.383.129.708.933.250,
f52abab2-cd04-4450-97c7-2b3e7054b4da,C0071097,T2DM,can can continued in people with T2DM,pioglitazone,T2DM,2,X,[orch/phsu],????,D02.886.675.933.250;D03.383.129.708.933.250,????
ae1cf624-df68-4ca4-b9b0-e401a4fa560e,C0008139,C0319157,possess ability on potential go with ,Chiroptera,AS virus,1,X,[mamm],[virs],B01.050.150.900.649.313.937,
96355ad7-82a5-43e2-b090-6e4afd011e1c,C0008139,C0018563,possess ability on other ,Chiroptera,Hand,2,X,[mamm],[bpoc],B01.050.150.900.649.313.937,A01.378.800.667
13430286-1dbf-4943-863f-8a77ad94b904,C1175743,C0035222,include ,SARS coronavirus,Respiratory Distress Syndrome Adult,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.840;C08.618.840
b44e3b08-1b4e-4b7d-8e3c-19080e7e5918,C0013227,C0079189,are studied associated with ,Pharmaceutical Preparations,cytokine,1,X,[phsu],[aapp/imft],D26,D12.644.276.374;D12.776.467.374;D23.529.374
c0384ce9-8893-4152-b73e-68411ad49930,C0032285,C0079189,are associated with ,Pneumonia,cytokine,1,X,[dsyn],[aapp/imft],C08.381.677;C08.730.610,D12.644.276.374;D12.776.467.374;D23.529.374
503fa0ca-04c7-4b4d-bc2f-6a094392f2b9,C0013227,C0021760,belonging as anti ,Pharmaceutical Preparations,Interleukin-6,1,X,[phsu],[aapp/imft],D26,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
3239a5e2-37a9-43ba-9011-65516ef96ce8,C0206750,C0022646,is in ,Coronavirus Infections,Kidney,2,X,[dsyn],[bpoc],C02.782.600.550.200,A05.810.453
13ee6056-b761-41a0-bed6-a56aeb22bbdc,C0012634,C0022646,is in ,Disease,Kidney,2,X,[dsyn],[bpoc],C23.550.288,A05.810.453
5dd19104-62b4-4bd7-8b11-db80dcf75fd1,C0022646,C0206750,in Disease is,Kidney,Coronavirus Infections,1,X,[bpoc],[dsyn],A05.810.453,C02.782.600.550.200
5dd19104-62b4-4bd7-8b11-db80dcf75fd1,C0022646,C0206750,had positive ,Kidney,Coronavirus Infections,1,X,[bpoc],[dsyn],A05.810.453,C02.782.600.550.200
32ecd0da-05f1-4a71-a464-2f6e30dd0b44,C1185740,C0022646,are often initial presentation among ,Tract,Kidney,2,X,[bpoc],[bpoc],,A05.810.453
9eec9ca6-92ce-4abd-9b15-b2f3b6fc7857,C0037090,C0022646,are often initial presentation among ,Signs and Symptoms Respiratory,Kidney,1,X,[sosy],[bpoc],C23.888.852,A05.810.453
b89f3f2a-eb2a-46d9-873c-f56ec034c48f,C0020625,C0021368,may reflect underlying ,Hyponatremia,Inflammation,2,X,[dsyn],[patf],C18.452.950.620,C23.550.470
4cbc6beb-02f2-482c-835f-6c42b97dd8fa,C0020625,C0022671,has has reported in case series ,Hyponatremia,Kidney Transplantation,3,X,[dsyn],[topp],C18.452.950.620,E02.870.500;E04.936.450.485;E04.950.774.400
83cbb885-4874-4b9c-8f2b-0708bad810d0,C0020625,C0206750,is in ,Hyponatremia,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.452.950.620,C02.782.600.550.200
e30b71a2-939e-4bb1-a502-68298b5db504,C0020625,C0021141,secondary to ,Hyponatremia,Inappropriate ADH Syndrome,2,X,[dsyn],[dsyn],C18.452.950.620,C10.228.140.617.738.320;C18.452.950.626;C19.700.490
2033151a-e7ea-432c-a064-d7de19d5dfed,C0020625,C0022646,may occur more frequently in ,Hyponatremia,Kidney,2,X,[dsyn],[bpoc],C18.452.950.620,A05.810.453
c454fd17-2a36-4e5f-b231-7527297a1a2e,C1550100,C0034386,were obtained on 14 day of ,Specimen Type - Serum,Quarantine,1,X,[bdsu],[topp],,N06.850.780.200.450.700
aa65f820-8072-4b09-9fd2-17c0e07d6154,C1707455,C0032042,is with ,Comparison,Placebos,2,X,[acty],[topp],,D26.660;E02.785
68936f58-586c-43f3-85ce-622094278552,C1706778,C0028778,using ,Allocation,Obstruction,1,X,[acty],[patf],,
4e30fee1-cce8-40f0-b338-2524baf434d5,ity118,C0022709,widely expressing ,ity118,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
e8a0d29f-2c19-4ce5-9b80-d13f4eef7308,C0023911,C0206750,is with ,Transplantation of liver,Coronavirus Infections,1,X,[topp],[dsyn],E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490,C02.782.600.550.200
dc6617a2-856b-4d02-bc94-cde5dc91a242,C1175175,C1457887, as clinical,Severe Acute Respiratory Syndrome,Symptoms,2,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,
dc6617a2-856b-4d02-bc94-cde5dc91a242,C1175175,C1457887,COVID-19 as clinical ,Severe Acute Respiratory Syndrome,Symptoms,2,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,
e86c2832-692e-4b47-a9bf-2fe8736ab38f,C1175175,C0024115, as clinical,Severe Acute Respiratory Syndrome,Lung diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381
b9fc2ca8-54d1-4902-aed1-83517592c692,C0683325,C0275522,were compared among patients with disease ,clinical aspects,Asymptomatic Infections,3,X,[clna],[dsyn],,C23.550.291.187.500
9d8ad292-c40d-4c02-9be6-1a17b8e56be2,C0020284,C0030858,were significantly higher in ,Hydrogenase,Pentaerythritol Tetranitrate,2,X,[aapp/enzy],[orch/phsu],D08.811.682.400,D02.033.455.706.690
1cb41992-002b-4436-8477-ce0b358c756f,C0024312,C0242656,might might risk factors for disease ,Lymphopenia,Disease Progression,2,X,[dsyn],[patf],C15.378.553.546.605;C20.673.627,C23.550.291.656
2edb4bee-1828-4d1a-813e-c551f06e6125,C0024312,C0206750,might might risk factors for disease ,Lymphopenia,Coronavirus Infections,1,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C02.782.600.550.200
2edb4bee-1828-4d1a-813e-c551f06e6125,C0024312,C0206750,was associated with severe ,Lymphopenia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C02.782.600.550.200
2edb4bee-1828-4d1a-813e-c551f06e6125,C0024312,C0206750,was common in early stage after onset of ,Lymphopenia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C02.782.600.550.200
79e736be-06b8-4921-a58a-eb511b1936b6,C0019392,C1533719,is classical ,Hesperidin,Discipline of Herbal Medicine,1,X,[orch/phsu/vita],[bmod],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,H01.158.273.118.598.500;H01.158.703.060.500;H02.628.190
b745af2a-7148-46d4-ac01-a1f24232c19d,C0019392,C1360419,is well-known ,Hesperidin,Herbal Drugs,1,X,[orch/phsu/vita],[phsu],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
9f07af0a-e64a-41d8-a2b1-0c9340343a2f,C0019392,C0003402,is well-known ,Hesperidin,Antioxidants,1,X,[orch/phsu/vita],[phsu],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
8b993329-099d-4d28-99da-f1b3108b6833,C0019392,C0022709,entering Host Cell through,Hesperidin,Peptidyl-Dipeptidase A,1,X,[orch/phsu/vita],[aapp/enzy/imft],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,D08.811.277.656.350.350.687
a4f4ced3-7ef0-4cd9-a3e1-17c077aa63a2,C0019392,C0597357,entering Host Cell through,Hesperidin,receptor,1,X,[orch/phsu/vita],[aapp/rcpt],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
98a8180d-7363-4d47-af2c-5923e29e4d68,C0019392,C1819995,entering ,Hesperidin,Host Cell,1,X,[orch/phsu/vita],[celc],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
3497e71f-aef6-4a65-af21-3db8f4a17002,C0019392,C0206750,can block ,Hesperidin,Coronavirus Infections,1,X,[orch/phsu/vita],[dsyn],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,C02.782.600.550.200
efbbd215-0c33-4898-b2c9-63bf6db53439,C0439962,C2929959,is with ,Mixture,Diosmin / Hesperidin,1,X,[sbst],[phsu],,
438f7304-74f3-4968-9502-6679c5d1ddd2,C2929959,C1861172,protect against ,Diosmin / Hesperidin,Venous Thromboembolism,1,X,[phsu],[dsyn],,C14.907.355.590.700
25d6d279-42c4-499e-849a-9155f3d80ed7,C0439962,C1861172,protect against ,Mixture,Venous Thromboembolism,1,X,[sbst],[dsyn],,C14.907.355.590.700
dba864ed-d141-408b-829f-98a1e768869b,C0019392,C0450442,might might used as prophylactic ,Hesperidin,Agent,1,X,[orch/phsu/vita],[chvf],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
22740e79-a5c1-4d05-a65d-1ae565543311,nt,C0009450,have COVID ,nt,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
dc7e8592-2c06-4ef3-8c6f-b18fb40d6140,C0206419,spector,raised spector ,Genus: Coronavirus,spector,1,X,[virs],????,B04.820.504.540.150,????
69687918-1147-45bb-bf2a-b3cd5bb1a3eb,C1880355,C1175175,is with ,Discover,Severe Acute Respiratory Syndrome,1,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
307a616d-dedb-4a85-9d3b-ca91887e3470,C1412002,C0850149,characterized by dyspnea,Atypical pneumonia,Dry cough,1,X,[dsyn],[sosy],,
97c27f26-002e-4197-bb80-7dc34b18da77,C1412002,C0476474,characterized by dyspnea,Atypical pneumonia,persistent fever,1,X,[dsyn],[patf],,
6881bc13-3eb1-4450-b9e4-480ca49785f0,C1412002,dyspnea,characterized by dyspnea,Atypical pneumonia,dyspnea,1,X,[dsyn],????,,????
64db8ae1-6d9b-4a79-8672-4b3a672e5048,C1412002,C0011991,sometimes accompanied by ,Atypical pneumonia,Diarrhea,1,X,[dsyn],[sosy],,C23.888.821.214
7a912912-1fa4-4c43-bd7d-2949ba3362f2,C0012634,C0026766,often followed by ,Disease,Multiple Organ Failure,1,X,[dsyn],[patf],C23.550.288,C23.550.835.525
e2aeb4ca-0612-498b-8547-358ed842cf0f,C2936413,C0035950, includes wild ,Host Range,Ruminants,1,X,[npop],[mamm],G06.462.380;G16.527.200.380,B01.050.150.900.649.313.500.380
511a300f-4107-480d-8cab-93aebb492f65,C0318856,C1328821,has ,Porcine Respiratory Coronavirus,tissue tropism,1,X,[virs],[phsf],B04.820.504.540.150.075.500.500.600,
e9d7876a-81a6-4d6c-a009-a9d87dd462d2,C0318856,C1516375,has ,Porcine Respiratory Coronavirus,Cellular Tropism,2,X,[virs],[celf],B04.820.504.540.150.075.500.500.600,
627bd4f8-4a2c-4b8e-94d6-8031034e5ea6,C0318856,C0024109,has ,Porcine Respiratory Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150.075.500.500.600,A04.411
03796688-3b42-4daf-819f-a1efc90a74ad,C1516375,C0024109,is in ,Cellular Tropism,Lung,1,X,[celf],[bpoc],,A04.411
991da560-f464-4299-9f41-4297daccb2d1,C0872315,C1456573,cause major threat to ,Communicable Diseases Emerging,Global Health,1,X,[dsyn],[bmod],C01.539.221.500,H02.403.371;N01.400.337
1f1c3941-3b02-433d-9279-54260bc11921,C0004933,C0034019,be included in ,Behavior Therapy,public health medicine (field),1,X,[topp],[bmod],F04.754.137,H02.403.720;N01.400.550;N06.850
8004d36d-7469-4434-acbb-380edc4e193a,C2728259,C0547605,assess its efficacy regarding ,Program,prevention of infection,4,X,[orch/phsu],[topp],V02.355.750,
5871612a-612e-48bb-9e1e-aae6d5f95435,C2728259,C0678222,assess its efficacy regarding ,Program,Breast Carcinoma,2,X,[orch/phsu],[neop],V02.355.750,C04.588.180;C17.800.090.500
4d81c2e0-6476-4121-8e93-943d231473e6,C2728259,C0006141,can can transferred to high-volume ,Program,Breast,2,X,[orch/phsu],[bpoc],V02.355.750,A01.236
01ef61bf-ed17-4a00-90a8-e0b1c53b3d4c,C0006145,C0185027,,Breast Diseases,Imbrication (procedure),1,X,[dsyn],[topp],C17.800.090,
01ef61bf-ed17-4a00-90a8-e0b1c53b3d4c,C0006145,C0185027,,Breast Diseases,Imbrication (procedure),1,X,[dsyn],[topp],C17.800.090,
370eb75b-71f8-419c-ad1d-1307b6321084,C0599878,C0011945,is in ,disease characteristic,Physical Dialysis,1,X,[patf],[npop],,E05.196.353;G02.186
47b1bc3b-5168-407b-8a85-013dcdfac17b,C4281807,C1512488,is Homologous Protein of S,Vitronectin human,Homologous Protein,2,X,[aapp/bacs],[aapp],,
6a8e144f-f4d9-4239-af36-7ea2140be8de,C0039336,C0034386,suggesting ,Taste Perception,Quarantine,3,X,[ortf],[topp],F02.830.816.724;G11.561.790.724,N06.850.780.200.450.700
12fa5c21-8578-42cd-a62e-32279254f6f2,C0679381,C0206750,is with ,Pediatric Disorder,Coronavirus Infections,7,X,[dsyn],[dsyn],,C02.782.600.550.200
1b8dea2b-a0cb-4566-9df5-74bc0021bbd4,C0027882,C1175743,are responsible for ,Neurons,SARS coronavirus,6,X,[cell],[virs],A08.675;A11.671,B04.820.504.540.150.113.937
82231061-170c-42d1-80a1-dac3d6c24c70,C0035380,C1175743,is currently standard for ,Reverse Transcription,SARS coronavirus,3,X,[genf],[virs],G02.111.873.500;G05.297.700.500,B04.820.504.540.150.113.937
004027c2-1b42-4255-8a39-2e7dc99df456,C0370003,C0229671,spiking ,Specimen,Serum,3,X,[sbst],[bdsu],,A12.207.152.846;A15.145.846
77f5379a-6bdf-4f22-b850-549d3b8aa6d3,C0370003,C0036087,spiking ,Specimen,saliva,3,X,[sbst],[bdsu],,A12.200.666
77f5379a-6bdf-4f22-b850-549d3b8aa6d3,C0370003,C0036087, includes nasopharyngeal swab ,Specimen,saliva,2,X,[sbst],[bdsu],,A12.200.666
1856ea68-bf0a-4d19-b011-ff6d2a56e75f,C0370003,C3687742,spiking ,Specimen,Oropharyngeal swab,3,X,[sbst],[bdsu],,
1856ea68-bf0a-4d19-b011-ff6d2a56e75f,C0370003,C3687742, includes nasopharyngeal swab ,Specimen,Oropharyngeal swab,2,X,[sbst],[bdsu],,
7545d6b8-e20f-4a09-8e78-2927465887cf,C0370003,C0035380,using conventional ,Specimen,Reverse Transcription,4,X,[sbst],[genf],,G02.111.873.500;G05.297.700.500
c813e780-03c2-43eb-8952-e86eef6dd70d,C0035380,C0370003,is in simulated patient ,Reverse Transcription,Specimen,1,X,[genf],[sbst],G02.111.873.500;G05.297.700.500,
4eda4c7e-9bd3-4b70-84bb-230c25ecfef0,C1563373,C0370003,is in simulated patient ,LAMP2 protein human,Specimen,6,X,[aapp/bacs],[sbst],x.x.x.x,
219e0384-0e55-43ec-a1c8-aefda56e6e0e,C1511790,C0370003,is in simulated patient ,Detection,Specimen,3,X,[topp],[sbst],,
219e0384-0e55-43ec-a1c8-aefda56e6e0e,C1511790,C0370003,is in low viral load ,Detection,Specimen,1,X,[topp],[sbst],,
219e0384-0e55-43ec-a1c8-aefda56e6e0e,C1511790,C0370003,is in 10 of ,Detection,Specimen,1,X,[topp],[sbst],,
f2026ec8-4665-4627-9005-1026814f0efc,C2948600,C1514474,provide insights regarding ,Aim,Prognostic Factors,2,X,[inch/phsu],[clna],,E01.789
c6c3edf7-e377-4920-aba5-c08f656498b2,C0024117,C2074898,is chronic Lung Inflammations in,Chronic Obstructive Airway Disease,chronic Lung Inflammations,4,X,[dsyn],[dsyn],C08.381.495.389,
e2241f62-9cb0-4747-ad47-3690c6d6d687,C2074898,C0001883,causes Airway Obstruction in,chronic Lung Inflammations,Airway Obstruction,4,X,[dsyn],[dsyn],,C08.618.846.185
ed543a04-b7a1-4fa9-99e1-fa29deae12e4,C2074898,C0231999,causes Airway Obstruction in,chronic Lung Inflammations,Airflow,2,X,[dsyn],[phsf],,
62ca720f-ee86-414e-8b7f-c67dd9b6b568,C2074898,C0035245,causes Airway Obstruction in,chronic Lung Inflammations,Respiratory physiology,2,X,[dsyn],[phsf],,G09.772
e61f6297-2529-403b-83ef-6870faa354b4,C1457887,COPD,using COPD ,Symptoms,COPD,2,X,[sosy],????,,????
521e4df6-400e-4602-b70a-cb96c97cbb3d,C0013404,C1540289,using modified ,Dyspnea,CD200 gene,2,X,[sosy],[gngm],C08.618.326;C23.888.852.371,
6e033191-25d7-4ce0-b038-71f7d3e9757c,C0013404,C0018026,using modified ,Dyspnea,Gold,2,X,[sosy],[elii/phsu],C08.618.326;C23.888.852.371,D01.268.556.322;D01.268.956.186;D01.552.544.322;x.x.x.x
57bbf5db-cce8-47e8-9077-b9b199b0f418,C1947933,C2960841,includes smoking cessation ,care activity,Lifestyle change therapy,2,X,[acty],[topp],,
f2d0002a-172c-4768-ad52-018702234cf5,C1947933,C0042196,includes smoking cessation ,care activity,Vaccination,2,X,[acty],[topp],,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
d6231103-d31a-4ef1-a273-c844ec95d561,C1947933,C0006280,includes smoking cessation ,care activity,Bronchodilator Agents,2,X,[acty],[phsu],,D27.505.696.663.050.110;D27.505.954.796.050.100
9db3c540-06c1-4b58-b4e0-8f6c12261197,C0024117,C0206750,worsens risk of ,Chronic Obstructive Airway Disease,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.381.495.389,C02.782.600.550.200
9db3c540-06c1-4b58-b4e0-8f6c12261197,C0024117,C0206750,were most prevalent comorbidities in ,Chronic Obstructive Airway Disease,Coronavirus Infections,1,X,[dsyn],[dsyn],C08.381.495.389,C02.782.600.550.200
f3b61478-7b77-47a8-9f21-0f7b194a390d,C0024117,C0242656,worsens risk of ,Chronic Obstructive Airway Disease,Disease Progression,4,X,[dsyn],[patf],C08.381.495.389,C23.550.291.656
78ecf29e-6985-4a7f-8a8c-8ebc458819b7,C1511790,C1706005,has sensitivity for ,Detection,CD40LG wt Allele,6,X,[topp],[gngm],,
54f74c81-4ae3-46fb-8d15-7f503b9addab,C0009262,C0013227,is well-known ,Colchicine,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],D03.132.225,D26
d1709e52-0b52-412f-bab0-c22febfd9931,C0162529,C0398623,be associated with ,Colitis Ischemic,Thrombophilia,3,X,[dsyn],[dsyn],C06.405.205.265.115;C06.405.469.158.188.115;C14.907.286,C15.378.925
11749be3-d9c2-4de0-8f68-13c149bb6007,C0206750,U.S.,pandemic simultaneously with U.S. ,Coronavirus Infections,U.S.,2,X,[dsyn],????,C02.782.600.550.200,????
8f6b8b06-8353-47f8-aff0-72946cb69657,C0206750,C0242402,pandemic simultaneously with U.S. ,Coronavirus Infections,Opioids,2,X,[dsyn],[hops/orch/phsu],C02.782.600.550.200,D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
43c378a0-28b6-4499-95fb-504ee012f23e,C3825816,C0206750,is with ,Pneumonia in children,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
6906c5e3-8f36-4ab7-8c90-b13b37cf2eb9,C0021054,COVID-19,participate in ,Immunologic Factors,COVID-19,5,X,[imft],[virs],D27.505.696.477,C000657245
9ccd36a1-f34e-40fe-be4c-d7b151972545,C0497552,COVID-19,is in ,Congenital neurologic anomalies,COVID-19,1,X,[cgab],[virs],C10.500;C16.131.666,C000657245
4abd185b-f490-49df-a3fb-222a98f3ea90,C0030567,COVID-19,long-term sequalae of ,Parkinson Disease,COVID-19,1,X,[dsyn],[virs],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,C000657245
0ad62a20-a1a8-4017-a896-5134a1afefce,C0002395,COVID-19,long-term sequalae of ,Alzheimer's Disease,COVID-19,1,X,[dsyn],[virs],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,C000657245
4c522a08-32a2-4fd3-82aa-a80812dab909,C1452534,COVID-19,been ,ACE protein human,COVID-19,1,X,[aapp/bacs],[virs],x.x.x.x,C000657245
7fbca819-04d4-4fb1-8d50-aba215ec937a,C1452534,C2937289,been ,ACE protein human,Adapt (substance),1,X,[aapp/bacs],[orch],x.x.x.x,
a71484e1-7eb7-41ae-9234-da448d1c5b97,C0458827,C0079189,are associated with hyperproduction of ,Airway structure,cytokine,1,X,[bpoc],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
2a5d9e5b-8cc4-4552-8cbe-54dc80746352,C0023516,C0021760,in changes is ,Leukocytes,Interleukin-6,1,X,[cell],[aapp/imft],A11.118.637;A15.145.229.637;A15.382.490,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
6aec012b-f9d6-46b5-a4d0-e34218eb5a27,C0243083,COVID-19,is with ,associated disease,COVID-19,1,X,[patf],[virs],,C000657245
503be9b7-f8e7-4eae-942b-755ba09b8b16,C0023516,C0243083,is with ,Leukocytes,associated disease,1,X,[cell],[patf],A11.118.637;A15.145.229.637;A15.382.490,
7e059959-ccd8-4715-b5ac-6450fce9e402,C0023516,C0024432,is in ,Leukocytes,macrophage,1,X,[cell],[cell],A11.118.637;A15.145.229.637;A15.382.490,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
db7dd511-5ff2-4847-93e4-b45b2566c93f,C0079189,C0012634,lead to ,cytokine,Disease,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.288
e2c8d810-08c5-43aa-89d4-8934cc8d5662,C3463820,C0005456,serving as ,Inhibition,Binding Sites,1,X,[acty],[rcpt],F01.145.544;F02.463.425.475;F02.739.794.405,G02.111.570.120
fa4477e7-2bda-490a-9799-4d4b13c95e7f,C3463820,C0960880,supposedly increases expression of ,Inhibition,angiotensin converting enzyme 2,1,X,[acty],[aapp/enzy],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
fddaffde-1930-457a-aea3-eae1e43fb0bc,RAS,C0007222,remains cornerstone therapy in populations with ,RAS,Cardiovascular Diseases,1,X,????,[dsyn],????,C14
0a73987b-8097-4d00-ad0b-3085c5d84cf4,C3463820,C0007222,remains cornerstone therapy in populations with ,Inhibition,Cardiovascular Diseases,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C14
45b27855-7d04-4814-9726-aeb09081c30d,C0003451,C1335057,with Chemoprevention is,Antiviral Agents,PTPN22 protein human,1,X,[phsu],[aapp/enzy],D27.505.954.122.388,x.x.x.x
e13ccda4-21c1-43ce-8a2c-ade79edad366,C0282515,C0003451,is with ,Chemoprevention,Antiviral Agents,1,X,[topp],[phsu],E02.319.162,D27.505.954.122.388
d1320fcf-5ab5-44f5-884c-2b4aa602cfed,C0003297,COVID-19,are available during ,Antiemetics,COVID-19,1,X,[phsu],[virs],D27.505.696.663.050.030;D27.505.954.427.095;D27.505.954.483.200,C000657245
a30b0562-6e5b-46ab-9200-95ac305de978,C0037090,COVID-19,were suspected for ,Signs and Symptoms Respiratory,COVID-19,1,X,[sosy],[virs],C23.888.852,C000657245
86dd94c7-e89a-4917-9b3f-535e7977a43c,C0597357,C1175175,associated with ,receptor,Severe Acute Respiratory Syndrome,2,X,[aapp/rcpt],[dsyn],,C02.782.600.550.200.750;C08.730.730
380aa3d0-28f0-463c-96fe-2cf3aa565411,C0001617,C0035222,are commonly used as ,Adrenal Cortex Hormones,Respiratory Distress Syndrome Adult,1,X,[horm/orch/phsu],[dsyn],D06.472.040,C08.381.840;C08.618.840
380aa3d0-28f0-463c-96fe-2cf3aa565411,C0001617,C0035222,were associated with higher rate of ,Adrenal Cortex Hormones,Respiratory Distress Syndrome Adult,1,X,[horm/orch/phsu],[dsyn],D06.472.040,C08.381.840;C08.618.840
d23b99c4-cccc-468c-9026-899e3cf16665,ity62,C0036087,is near ubiquitously present in ,ity62,saliva,1,X,????,[bdsu],????,A12.200.666
48cb0388-9dba-491e-babd-018e46691e3f,C0005779,C1514474,currently are considered as ,Blood Coagulation Disorders,Prognostic Factors,1,X,[dsyn],[clna],C15.378.100,E01.789
983e10f8-7513-48bd-835b-df2f8324988a,C1706202,C0012634,was performed on ,Search - action,Disease,3,X,[acty],[dsyn],,C23.550.288
4964067f-857f-46ae-a7af-2104e1ce9e14,C0150457,COV,be associated with better prognosis in patients with severe COV ,Anticoagulant therapy,COV,4,X,[topp],????,,????
73df7da9-ce33-4aa3-a2a2-fe5579b17dea,C0150457,C0009450,be associated with better prognosis in patients with severe COV ,Anticoagulant therapy,Communicable Diseases,4,X,[topp],[dsyn],,C01.539.221
ad047105-e152-40b9-ad23-6fdb4a3541d2,C0005778,C1175743,is in patients with CoV2 ,Blood coagulation,SARS coronavirus,2,X,[ortf],[virs],G09.188.390.150,B04.820.504.540.150.113.937
97a0b36d-7622-46a8-9efb-b99c2f0263b3,C0005778,CoV2,is in patients with CoV2 ,Blood coagulation,CoV2,2,X,[ortf],????,G09.188.390.150,????
bf766cff-9c43-42c9-a6ea-ed889fcfa467,C0031843,CoV2,is in patients with CoV2 ,physiological aspects,CoV2,2,X,[phsf],????,x.x.x.x,????
a829b97e-6e5b-42e2-992e-e29cf0b506de,C0005778,C0009450,is in patients with CoV2 ,Blood coagulation,Communicable Diseases,2,X,[ortf],[dsyn],G09.188.390.150,C01.539.221
7a2cf76b-0b5b-4bf4-a551-4efcb097567b,C0031843,C0009450,is in patients with CoV2 ,physiological aspects,Communicable Diseases,2,X,[phsf],[dsyn],x.x.x.x,C01.539.221
c3bffded-d316-49ea-be68-fc7ff5493ed1,C0015259,C0441655,were ,Exercise,Activities,1,X,[dora],[acty],G11.427.410.698.277;I03.350,
bc1b5191-c911-4afb-8e50-9616cfcbf1ff,C0015259,C0008067,taking ,Exercise,Child Care,2,X,[dora],[dora],G11.427.410.698.277;I03.350,I01.880.787.293.360;N02.421.088
2ab04c0e-1303-425e-aefa-20f91aa70b00,C0033684,C1257954,could suggest six ,Proteins,Cyclooxygenase 2 Inhibitors,1,X,[aapp/bacs],[orch/phsu],D12.776,D27.505.519.389.310.500;D27.505.696.663.850.014.040.500.500.500;D27.505.954.158.030.500.500;D27.505.954.329.030.500.500
3294d183-99aa-4d59-a330-a5d5fdcd1f4f,C0033684,C3469597,could suggest six ,Proteins,Administration of medication,2,X,[aapp/bacs],[topp],D12.776,
de323875-1c77-42b9-8cee-31094e4f00ea,C0033684,C0206419,could suggest six ,Proteins,Genus: Coronavirus,1,X,[aapp/bacs],[virs],D12.776,B04.820.504.540.150
8cbf7ad1-97d6-49bd-9636-e122f5f4e1ff,C0206419,C0301872,has has attributed to ,Genus: Coronavirus,Immune response,1,X,[virs],[ortf],B04.820.504.540.150,
8cbf7ad1-97d6-49bd-9636-e122f5f4e1ff,C0206419,C0301872,manifest ,Genus: Coronavirus,Immune response,1,X,[virs],[ortf],B04.820.504.540.150,
0f37bdff-a0b0-437d-9be8-ceae082b591b,C1999230,C0376358,is in ,Providing (action),Malignant neoplasm of prostate,2,X,[acty],[neop],,
aac415c2-8f53-40f8-9cee-4ae05be30f17,C1825598,C0007134,has affected ,IMPACT gene,Renal Cell Carcinoma,2,X,[gngm],[neop],,C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160
e69885c1-f06e-4c07-890b-1cedc8f0b1b9,C0740457,C0277565,distinguishing mainly between low priority of ,Malignant neoplasm of kidney,Local disease,2,X,[neop],[dsyn],,
2d4d896b-8b74-4730-9f19-2e8e4ecc97e5,ona,C0007134,adaptation in management of ,ona,Renal Cell Carcinoma,2,X,????,[neop],????,C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160
427b0e10-1d98-48a0-9f75-cdeb9c966ba9,ona,C0042077,adaptation among ,ona,Urology,2,X,????,[bmod],????,H02.403.810.860
a74f4285-7d14-459b-baef-09d9888a4851,C0700781,C0032594,is high-molecular-weight fraction of ,Panavir,Polysaccharides,2,X,[orch/phsu],[orch/phsu],D02.455.426.559.389.657.746,D09.698
d74c46ee-7da8-4093-b3d2-11308defb256,C0700781,C3853936,is high-molecular-weight fraction of ,Panavir,Solanum tuberosum extract,4,X,[orch/phsu],[orch/phsu],D02.455.426.559.389.657.746,
e2210d4e-eafc-4e30-b41b-beb861f5853e,C0700781,C1175743,be effective in therapy of ,Panavir,SARS coronavirus,1,X,[orch/phsu],[virs],D02.455.426.559.389.657.746,B04.820.504.540.150.113.937
b4ce7862-754b-4eda-839c-d2af5492b196,C0206419,C0206061,may need care unit admission in in to positive cases for massive ,Genus: Coronavirus,Pneumonia Interstitial,1,X,[virs],[dsyn],B04.820.504.540.150,C08.381.483
82b1b355-6c61-40d7-bbbf-3e28612c3a66,C0012634,C0206061,may need care unit admission in in to positive cases for massive ,Disease,Pneumonia Interstitial,1,X,[dsyn],[dsyn],C23.550.288,C08.381.483
62642b43-5139-4ca9-9277-64fff9873af1,C0040578,ty434,is with ,Trachea,ty434,1,X,[bpoc],????,A04.889,????
85a839a7-0b78-453b-a646-ebf4e3c15df6,C0027540,ty434,is with ,Necrosis,ty434,1,X,[ortf],????,C23.550.717;G04.146.638,????
a199cbfe-807e-45c0-a3ec-c81bb9c90444,C0018681,C0040997,was due to ,Headache,Trigeminal Neuralgia,1,X,[sosy],[dsyn],C23.888.592.612.441,C07.465.299.625.500.700;C10.292.319.625.700.700
d09e8b83-c34b-4498-a176-fca5b99ca20b,C0206419,anosmia,is with sole symptoms of anosmia ,Genus: Coronavirus,anosmia,1,X,[virs],????,B04.820.504.540.150,????
e0f1ca2e-003e-40a6-a8bf-59968872f7b8,C3526617,C0012634,is with ,Outpatient Dialysis,Disease,1,X,[topp],[dsyn],,C23.550.288
b3621628-ffef-4655-82af-6e6c0894ed36,C1285162,C0028754, includes ,Degenerative disorder,Obesity,1,X,[dsyn],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
7270b251-818d-40ed-ad87-44946d32fcc5,C2948600,C3714509,study ,Aim,Nutrition Disorders,1,X,[inch/phsu],[dsyn],,C18.654
5b79ad26-e715-4ce3-a406-9b0f77069234,C0040038,C0206419,have Despite severity of ,Thromboembolism,Genus: Coronavirus,1,X,[patf],[virs],C14.907.355.590,B04.820.504.540.150
1ea4ca26-8bf3-4697-8782-6862507d418c,C0079102,C3274800,may complicate initial ,Cerebral Thrombosis,Disease Presentation,1,X,[dsyn],[clna],C10.228.140.300.525.425;C14.907.253.566.350;C14.907.355.590.213.350,
c5f28734-7295-45b7-9396-525239853f2f,C0079102,C0206419,may complicate initial ,Cerebral Thrombosis,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.300.525.425;C14.907.253.566.350;C14.907.355.590.213.350,B04.820.504.540.150
79274ca6-e684-4d7b-95f5-5d5ed798b355,C0441655,COVID-19,poses dilemma in ,Activities,COVID-19,2,X,[acty],[virs],,C000657245
2495a4b9-9657-4c87-b472-deb0e5d0a788,C0206419,C0556656,be IHR ,Genus: Coronavirus,Meetings,1,X,[virs],[acty],B04.820.504.540.150,
ad0691ff-3f47-409e-bbbb-88c745d3bd53,C0206419,IHR,be IHR ,Genus: Coronavirus,IHR,1,X,[virs],????,B04.820.504.540.150,????
7312e234-ef14-43a9-afe2-9ba6e2c7cf7c,C0206419,C1880022,outbreak of was On ,Genus: Coronavirus,Characterization,1,X,[virs],[acty],B04.820.504.540.150,
ee8bcce8-83cd-4856-93e5-e8e79a6eb391,C3714584,C1705178,is in ,Transformation function,Order (action),1,X,[phsf],[acty],,
48ddfdbf-c5ed-4c22-a180-6497aa5a29da,C1175743,C2926735,environmental surveillance of be should priority part of ,SARS coronavirus,Duration,2,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,
d541187e-d5c2-477d-b25f-627e108c93dc,C0021368,C1175175,is in severe ,Inflammation,Severe Acute Respiratory Syndrome,2,X,[patf],[dsyn],C23.550.470,C02.782.600.550.200.750;C08.730.730
39b92556-6d04-405a-a662-608bd979c4c2,C0206419,CD8,decreased CD8 ,Genus: Coronavirus,CD8,2,X,[virs],????,B04.820.504.540.150,????
9971aa00-72ac-4167-90fb-e434b9570dd7,C2718014,C3711103,is with ,Compassionate Use Trials,CCR5 protein human,4,X,[topp],[aapp/rcpt],E02.931.500;E05.290.250.199;E05.337.300.199,x.x.x.x
5cefdc5c-659e-4884-8529-9006b01ba731,C1947933,C3711103,is with ,care activity,CCR5 protein human,2,X,[acty],[aapp/rcpt],,x.x.x.x
7dac73bb-2854-4bf0-850d-6990210ba8ba,C2718014,C0282682,is with ,Compassionate Use Trials,Antibodies Blocking,4,X,[topp],[aapp/imft/irda],E02.931.500;E05.290.250.199;E05.337.300.199,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
53fa2de3-bb6c-4d91-8b9c-50c1f27bac04,C1947933,C0282682,is with ,care activity,Antibodies Blocking,2,X,[acty],[aapp/imft/irda],,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
7651ac6c-1df0-45b3-a5bb-adedb1b160b7,C2718014,C0032105,is with ,Compassionate Use Trials,Plasma,4,X,[topp],[bdsu],E02.931.500;E05.290.250.199;E05.337.300.199,A12.207.152.693;A12.207.270.695;A15.145.693
a4c7e416-d8f1-4e05-b357-af67adb10d0f,C1947933,C0032105,is with ,care activity,Plasma,2,X,[acty],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
e80d31da-aa37-4008-9e93-186540cdb51f,C2718014,C0021760,is with ,Compassionate Use Trials,Interleukin-6,4,X,[topp],[aapp/imft],E02.931.500;E05.290.250.199;E05.337.300.199,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
de2ed810-d504-4fab-a4c9-abfd9061138b,C1947933,C0021760,is with ,care activity,Interleukin-6,2,X,[acty],[aapp/imft],,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
85b6efb5-f358-4916-be0a-f5149cd24117,C0233514,C0020405,is in ,Abnormal behavior,Hygiene,1,X,[mobd],[bmod],F01.145.126.972;F01.145.179.750,E02.547;N06.850.670
7f295562-d075-4a12-9fb8-bce7763ca1ac,C0041755,C0275518,are considered they occur simultaneously with ,Adverse reaction to drug,Acute infectious disease,1,X,[patf],[dsyn],C25.100,
e6d44668-21a1-45c4-9d6f-061c387cc538,C0020964,C1175743,making more susceptible to ,Immunity,SARS coronavirus,1,X,[phsf],[virs],G12.450,B04.820.504.540.150.113.937
e6d44668-21a1-45c4-9d6f-061c387cc538,C0020964,C1175743,may have ,Immunity,SARS coronavirus,3,X,[phsf],[virs],G12.450,B04.820.504.540.150.113.937
9b09b34f-27b8-427a-a5c1-5ab57b49cce0,C1521863,C0206750,is in development of novel ,estrogen receptor alpha human,Coronavirus Infections,1,X,[aapp/rcpt],[dsyn],x.x.x.x,C02.782.600.550.200
fcd5d3ac-79aa-4111-a45c-957c00554da8,C1521863,C1175743,is in development of novel ,estrogen receptor alpha human,SARS coronavirus,1,X,[aapp/rcpt],[virs],x.x.x.x,B04.820.504.540.150.113.937
1e5b4a37-c80a-4aa8-975c-3cb34a605901,CoV2,C0206750,have reviewed dermatologists tools for their utility in patients affected by ,CoV2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
1e5b4a37-c80a-4aa8-975c-3cb34a605901,CoV2,C0206750,is source of ,CoV2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
e6033edf-1560-4d61-a243-4092636ff53f,C0013227,C0011627,Somewhat widely used in ,Pharmaceutical Preparations,Dermatology field,1,X,[phsu],[bmod],D26,H02.403.225
7a482ab6-bdd2-4d3b-84ad-0e0438b0e430,C0018563,C2359945,also frequently use ,Hand,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[bpoc],[clna],A01.378.800.667,
d6bc9509-f0ea-492f-bfab-645a5492ab80,C0018563,C1979687,also frequently use ,Hand,Dermatologic drugs,1,X,[bpoc],[phsu],A01.378.800.667,
d6bc9509-f0ea-492f-bfab-645a5492ab80,C0018563,C1979687,also use in our,Hand,Dermatologic drugs,1,X,[bpoc],[phsu],A01.378.800.667,
0dbff127-b462-4f1b-a63b-e7d45dcb6171,C0026082,C0206750,had level regarding ,Midwifery,Coronavirus Infections,1,X,[bmod],[dsyn],H02.478.676.416,C02.782.600.550.200
49443dbf-704b-461a-8547-1af28143744e,C0152179,C0206750,elicited Deglutition Disorders following,Vagus Nerve Disorder,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.292.887,C02.782.600.550.200
9c8ae7e3-3737-4ce4-b792-7b8588f2b9be,C0152179,C0011168,elicited ,Vagus Nerve Disorder,Deglutition Disorders,2,X,[dsyn],[dsyn],C10.292.887,C06.405.117.119;C09.775.174
862e3ae9-a657-4e3e-99f3-28aacc004019,C0032290,C0035243,might might overlooked in severe ,Aspiration Pneumonia,Respiratory Tract Infections,2,X,[dsyn],[dsyn],C08.381.677.529;C08.730.610.529,C01.539.739;C08.730
8dcb0b53-7712-4dbc-9c98-0906e2fe5dd3,C0032290,C0206750,might might overlooked in severe ,Aspiration Pneumonia,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.381.677.529;C08.730.610.529,C02.782.600.550.200
ce736e42-79e5-412e-ac45-1dc8e074ff55,C2926735,C0087111,be considered for IFN ,Duration,Therapeutic procedure,1,X,[orch/phsu],[topp],,E02
23e97ab7-0215-4c13-b7dc-9bb311a098fb,C2926735,C0029341,be considered for IFN ,Duration,Orthomyxoviridae,2,X,[orch/phsu],[virs],,B04.820.545
25cafd7f-5984-43a2-b675-c4bdbf98549a,C0441516,C0206750,may increase with increase in ,Demand (clinical),Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
d715cf69-c40f-44b6-9e2e-3806b25d3fe4,C0441516,C0005516,may may ,Demand (clinical),Biological Markers,1,X,[topp],[clna],,D23.101
de1cdff4-9e2d-4ddd-82df-433b89817425,C0441516,C1882509,may may ,Demand (clinical),put - instruction imperative,1,X,[topp],[acty],,
51da7627-b9ad-443b-b932-714417758315,C0012634,C0287990,moving at frantic rumours,Disease,paired basic amino acid cleaving enzyme,1,X,[dsyn],[aapp/enzy],C23.550.288,D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353
9c670976-5ff8-403d-a496-ef13b3a2f763,C0012634,rumours,moving at frantic rumours,Disease,rumours,1,X,[dsyn],????,C23.550.288,????
43b50c57-960b-4ad0-9a7e-94c3635c7f73,C0301872,C0206750,contribute to ,Immune response,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
43b50c57-960b-4ad0-9a7e-94c3635c7f73,C0301872,C0206750,embodies in decrease of ,Immune response,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
5605c11e-fec9-4ff5-8894-de4533ac7e2e,C0301872,C0221423,contribute at second week of ,Immune response,Illness (finding),1,X,[ortf],[sosy],,
cb72a9ac-6054-4a0e-96ce-25459ea0015d,C0032285,C0369768,was defined as ,Pneumonia,Molecular oxygen saturation,1,X,[dsyn],[moft],C08.381.677;C08.730.610,
bc4a1505-2fca-4575-9b99-8a6a9a97bfeb,C0185117,CD4,is in CD4,Expression procedure,CD4,1,X,[topp],????,,????
29466db2-8be9-413e-97b8-c67f3746bfa7,C0206750,C1879547,higher degree of proliferation ,Coronavirus Infections,Activation action,4,X,[dsyn],[acty],C02.782.600.550.200,
e276e3e6-8d88-42e2-8f2d-3ebad596457a,C0206750,C0039195,higher degree of proliferation ,Coronavirus Infections,Cytotoxic T-Lymphocytes,10,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
bbe627fd-a842-4aa3-b787-7f679263ecd5,C0206750,C1140999,had degree without ,Coronavirus Infections,Contraction (finding),2,X,[dsyn],[patf],C02.782.600.550.200,
5bd4b89e-ff84-4838-93b4-cc9f8fb2ac93,C1140999,C0206750,might contribute to development of severe ,Contraction (finding),Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
f0637a06-53e7-4027-a356-372b6acc29d0,C0206750,RGP,were related to socioeconomic RGP ,Coronavirus Infections,RGP,1,X,[dsyn],????,C02.782.600.550.200,????
b2b55e27-4350-45fc-bf3a-86acf6402538,C0025424,C0030054,is with ,Mercury,Oxygen,1,X,[elii/hops],[bacs/elii/phsu],D01.268.556.504;D01.268.956.437;D01.552.544.504;x.x.x.x,D01.268.185.550;D01.362.670;x.x.x.x
386d513e-2f91-4dd2-892e-f9917b67fb30,C2936405,C0037633,seems ,Drug Repositioning,Solutions,2,X,[topp],[sbst],E05.290.875,D26.776
027868bd-b665-4436-abd1-bb079c83689a,C0030576,C0206750,have strong ,Paromomycin,Coronavirus Infections,1,X,[antb/orch],[dsyn],D09.408.051.706,C02.782.600.550.200
161f8bbe-4e90-474e-862c-531df7677c36,C0178849,C0022709,is in their ,species difference,Peptidyl-Dipeptidase A,2,X,[biof],[aapp/enzy/imft],,D08.811.277.656.350.350.687
9120640b-a2bd-4ad4-8543-6823ba8a4e0e,C0178849,C0597357,is in their ,species difference,receptor,2,X,[biof],[aapp/rcpt],,
92c56d5a-6d2d-4558-86b9-7002b25776d9,C0001560,C0819757,is in ,Administration Intranasal,Structure of parenchyma of lung,1,X,[topp],[tisu],E02.319.267.120.655.500,
60f1ac18-688c-4827-b4a9-d24f6ec6241b,C0026809,C1175743,were productively infected with ,Mus,SARS coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.992.635.505.500,B04.820.504.540.150.113.937
b0bfccc8-9be9-4a87-83bb-0105f88aea65,titers,C0024109,is in ,titers,Lung,1,X,????,[bpoc],????,A04.411
4f150edb-8651-486b-a3fc-e8ad7238064d,titers,C0748168,is in ,titers,Pulmonary Pathology,1,X,????,[dsyn],????,
07901663-f1a9-4fb0-8751-8908186f8a1a,C0600250,C0024109,reduced burden in ,Passive Antibody Transfer,Lung,1,X,[topp],[bpoc],E02.095.465.425.400.330;E05.478.550.520,A04.411
89fc0612-19a9-4c00-8891-2e6ed29d598c,C1704241,C0086418,depend on ,complex (molecular entity),Homo sapiens,1,X,[chvs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
de3e9c9b-5ce3-4ed1-adaa-d23e498ecae9,C0043528,C1704241,are ,Zoonoses,complex (molecular entity),1,X,[dsyn],[chvs],C01.908;C02.968;C03.908;C22.969,
e69b32ee-5314-47f7-862c-92af08ed99a1,C1175743,C3698360, includes ,SARS coronavirus,Middle East Respiratory Syndrome Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150.113.750
c3adbbe7-5e6b-45e1-bb83-b912a97c9af6,C1175743,C0021403, includes ,SARS coronavirus,Influenza virus vaccine,1,X,[virs],[imft/phsu],B04.820.504.540.150.113.937,D20.215.894.899.302
c3adbbe7-5e6b-45e1-bb83-b912a97c9af6,C1175743,C0021403,is new ,SARS coronavirus,Influenza virus vaccine,1,X,[virs],[imft/phsu],B04.820.504.540.150.113.937,D20.215.894.899.302
f50968ea-4d1a-4243-9c3f-8614c6538a76,C0270724,C0015357,use ,Infantile Neuroaxonal Dystrophy,Extracorporeal Membrane Oxygenation,3,X,[dsyn],[topp],C10.228.140.744,E02.880.301;E04.292.451
105dd93a-c667-4757-b79e-f8de26df35fc,C0270724,COVID-19,use Extracorporeal Membrane Oxygenation transport for,Infantile Neuroaxonal Dystrophy,COVID-19,1,X,[dsyn],[virs],C10.228.140.744,C000657245
a376b6b7-4350-45c3-8a28-3d97ea5baea5,C0441655,C0949742,regarding spinal ,Activities,Manipulation Therapy,1,X,[acty],[topp],,E02.190.599;E02.779.867;E02.831.535.867
e74274ae-666c-4afa-b664-864b11f35cf7,C0086586,C0885890,is ,Manipulation of spine,Common interventions,1,X,[topp],[topp],E02.779.867.466;E02.831.535.867.466,
e1619dd0-e5ea-458c-b654-9298f70b7bc8,C0086586,C0018722,is ,Manipulation of spine,Health Occupations,1,X,[topp],[bmod],E02.779.867.466;E02.831.535.867.466,H02
df8b35c2-40c2-486e-a28e-01d667a63178,C1706202,C0441655,describe Twitter SMT,Search - action,Activities,1,X,[acty],[acty],,
f05c87e5-7985-46b5-a149-e3bcbd1c7615,C1706202,SMT,describe Twitter SMT,Search - action,SMT,1,X,[acty],????,,????
0ab6e162-6fd8-468e-b680-db285c967904,C1947933,neuro,characterized reality for patients presenting with neuro ,care activity,neuro,2,X,[acty],????,,????
bb96d258-41a5-48f8-94b5-58af499efb7b,C1947933,C2745965,characterized reality for patients presenting with neuro ,care activity,Emergencies [Disease/Finding],2,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
bb96d258-41a5-48f8-94b5-58af499efb7b,C1947933,C2745965,may become first choice in ,care activity,Emergencies [Disease/Finding],4,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
017a4d92-e0b0-40c9-a24c-ac1beeac02d5,C0020336,C0003451,have emerged as potential ,Hydroxychloroquine,Antiviral Agents,1,X,[orch/phsu],[phsu],D03.633.100.810.050.180.350,D27.505.954.122.388
dfc7cae5-8842-4c74-a5a6-fc1c39374ea6,C0008269,C0003451,Recently have emerged as potential ,Chloroquine,Antiviral Agents,1,X,[orch/phsu],[phsu],D03.633.100.810.050.180,D27.505.954.122.388
e1816371-0943-4f1f-8044-24e7e926b2ac,C0013227,C1412268,of events is ,Pharmaceutical Preparations,AES gene,1,X,[phsu],[gngm],D26,
aac55f88-6eef-4909-8a80-577b5b80af49,MEDLINE,C0032042,Comparison Hydroxychloroquine with,MEDLINE,Placebos,1,X,????,[topp],????,D26.660;E02.785
b84ded86-5b7c-47d6-9a24-46d0e5f58e0f,MEDLINE,C0020336,Comparison,MEDLINE,Hydroxychloroquine,1,X,????,[orch/phsu],????,D03.633.100.810.050.180.350
ba56dc29-a09d-40f0-8b07-4dc4041f88b8,C1412268,C1707455,were statistically higher ,AES gene,Comparison,1,X,[gngm],[acty],,
cd7bd0b6-ee18-48b3-b7c6-6bb47b17fc22,C1412268,C0008269,were statistically higher ,AES gene,Chloroquine,1,X,[gngm],[orch/phsu],,D03.633.100.810.050.180
cd7bd0b6-ee18-48b3-b7c6-6bb47b17fc22,C1412268,C0008269,was affected by dosage for ,AES gene,Chloroquine,1,X,[gngm],[orch/phsu],,D03.633.100.810.050.180
45ca1bce-2a50-4e95-93e0-0b662355d282,C1412268,C0032042,were statistically higher ,AES gene,Placebos,1,X,[gngm],[topp],,D26.660;E02.785
db86f263-21b3-4fca-a876-e806be5952f9,C0037285,C0009450,related to ,Skin Manifestations,Communicable Diseases,1,X,[sosy],[dsyn],C23.888.885,C01.539.221
b9279d21-2dce-4ceb-a750-88450ec283b2,C0206750,C0034150,is with retiform ,Coronavirus Infections,Purpura,1,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.100.802;C23.550.414.950;C23.888.885.687
e13755da-c603-4510-9c97-dd9b22da8f81,C0086418,C0597357,has has identified as functional ,Homo sapiens,receptor,5,X,[humn],[aapp/rcpt],B01.050.150.900.649.313.988.400.112.400.400,
e2d11c6c-6860-4ebe-9072-29805687ba9a,C0058362,C0597357,has has identified as functional ,dipeptidyl peptidase II,receptor,2,X,[aapp/enzy],[aapp/rcpt],x.x.x.x,
71abbdba-d105-4337-b462-b45faeed051c,C0058362,C1175743,has has identified as functional ,dipeptidyl peptidase II,SARS coronavirus,2,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
6d34c734-4af1-4c10-945a-c3bc64fcdebd,C0026809,C0024109,sustained high loads in ,Mus,Lung,3,X,[mamm],[bpoc],B01.050.150.900.649.313.992.635.505.500,A04.411
cf879f9e-8e52-434d-b1f9-840ebb8818b4,C0086418,C0040578,sustained high loads in ,Homo sapiens,Trachea,3,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.889
58134921-8264-4942-99a8-9d16f41ca8a2,C0026809,C0040578,sustained high loads in ,Mus,Trachea,3,X,[mamm],[bpoc],B01.050.150.900.649.313.992.635.505.500,A04.889
d8dd0500-335d-4756-ac8c-a3ba44aa6f45,C0086418,C0006104,sustained high loads in ,Homo sapiens,Brain,3,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A08.186.211
9563a243-361f-40b3-b8d9-a9320981b74a,C0026809,C0006104,sustained high loads in ,Mus,Brain,3,X,[mamm],[bpoc],B01.050.150.900.649.313.992.635.505.500,A08.186.211
78579d2e-05ec-4173-ae2b-a5e4f33ac3b7,C0026809,C0009450,sustained loads upon intranasal ,Mus,Communicable Diseases,3,X,[mamm],[dsyn],B01.050.150.900.649.313.992.635.505.500,C01.539.221
2185575b-f70f-46e9-98be-9d0841e89394,C0086418,C1707455,sustained loads In ,Homo sapiens,Comparison,3,X,[humn],[acty],B01.050.150.900.649.313.988.400.112.400.400,
4810e77f-6b50-433d-9e34-d65fad5a71b4,C0026809,C1707455,sustained loads In ,Mus,Comparison,3,X,[mamm],[acty],B01.050.150.900.649.313.992.635.505.500,
ff00b57d-0b8c-447f-8635-87e4e19c453b,C0086418,C1521751,sustained loads In ,Homo sapiens,C57BL/6 Mouse,3,X,[humn],[mamm],B01.050.150.900.649.313.988.400.112.400.400,
56c312ba-9b31-4850-9604-047ff15b1801,C0026809,C1521751,sustained loads In ,Mus,C57BL/6 Mouse,3,X,[mamm],[mamm],B01.050.150.900.649.313.992.635.505.500,
c17fab8e-d5f3-40e1-908d-fe207e13d201,C1707455,C1521751,is with wild-type ,Comparison,C57BL/6 Mouse,3,X,[acty],[mamm],,
199a6469-38b0-454d-b869-41fac4574611,C0206061,C1175743,were seen in ,Pneumonia Interstitial,SARS coronavirus,2,X,[dsyn],[virs],C08.381.483,B04.820.504.540.150.113.937
5e3617cb-6c2e-489b-ae56-ccdde19b5021,C0748168,C0086418,is in ,Pulmonary Pathology,Homo sapiens,2,X,[dsyn],[humn],,B01.050.150.900.649.313.988.400.112.400.400
3bf98318-993d-4a34-8b4e-9dfab7f3d866,C0748168,C0026809,is in ,Pulmonary Pathology,Mus,2,X,[dsyn],[mamm],,B01.050.150.900.649.313.992.635.505.500
23c540d6-14ce-4782-b76f-e210a3895879,C0012644,C0087111,evaluating ,Animal Disease Models,Therapeutic procedure,3,X,[emod],[topp],C22.232;E05.598.500;E05.599.395.080,E02
cb6ba39b-e7e9-4d7b-9f22-5aedd2d9fa75,C0012644,COVID-19,evaluating ,Animal Disease Models,COVID-19,1,X,[emod],[virs],C22.232;E05.598.500;E05.599.395.080,C000657245
ff869046-6c40-4994-b2d8-ee61ba5da295,C0012644,C0042210,evaluating ,Animal Disease Models,Vaccines,1,X,[emod],[aapp/imft/phsu],C22.232;E05.598.500;E05.599.395.080,D20.215.894
f2cffb2b-4ac4-4109-a6ad-5eac4b2eeda9,C1439284,C1883559,is in ,AGTR1 gene,Wild Type,5,X,[gngm],[gngm],,
c74abe26-be2c-45e0-8cce-1ac5b4f569f5,C1167622,C1883559,is in ,Binding (Molecular Function),Wild Type,5,X,[moft],[gngm],,
b8379489-e35f-46f3-89d7-53945196f01c,C1439284,C0026809,is in ,AGTR1 gene,Mus,5,X,[gngm],[mamm],,B01.050.150.900.649.313.992.635.505.500
8e918695-99c9-4860-a8ff-3fdc18cbb822,C1167622,C0026809,is in ,Binding (Molecular Function),Mus,5,X,[moft],[mamm],,B01.050.150.900.649.313.992.635.505.500
608444ee-d9b3-4931-ba1f-aad8c2286300,C0242656,C0242781,origin of ,Disease Progression,disease transmission,1,X,[patf],[patf],C23.550.291.656,N06.850.310
f952b55e-6871-4e62-9a18-fc648b616cea,C0242656,C0206419,origin of ,Disease Progression,Genus: Coronavirus,2,X,[patf],[virs],C23.550.291.656,B04.820.504.540.150
b7ce70ea-a25d-4034-8215-1f84a0346198,C1515933,C0030054,are responsible for ,Alveolus,Oxygen,1,X,[bpoc],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
031728a6-7389-4a7a-a2d6-9101f25e9dba,C0206419,C0003062,is in ,Genus: Coronavirus,Animals,1,X,[virs],[anim],B04.820.504.540.150,B01.050
5b60cb1c-c06d-47e9-a10d-184ee8d50570,C0206419,C1167395,is in ,Genus: Coronavirus,Host (organism),1,X,[virs],[orgm],B04.820.504.540.150,
c75ce40d-7239-4256-8b91-edd6397f0111,C0370003,C1511790,were tested with positives ,Specimen,Detection,2,X,[sbst],[topp],,
aac89086-4f6e-482d-82c2-d6e22cba05a9,C0450254,C0270724,is with ,Pathogenic organism,Infantile Neuroaxonal Dystrophy,2,X,[orgm],[dsyn],,C10.228.140.744
a53e413a-85e5-4182-9aa9-9b531536971d,C0020538,C0012634,is most common comorbidity associated with mortality in current ,Hypertensive disease,Disease,2,X,[dsyn],[dsyn],C14.907.489,C23.550.288
7e48349f-d06d-4f04-88d0-cf8daa9e40f3,ACE2,C0206419,point for ,ACE2,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
8afad276-821c-4178-a599-0bc80f701eb1,C0242821,C0022709,using ,Human body,Peptidyl-Dipeptidase A,2,X,[humn],[aapp/enzy/imft],I01.076.201.450.560;K01.093.378,D08.811.277.656.350.350.687
cb965dd9-c022-4dd1-9630-3b558c44a559,C0242821,C0597357,using Peptidyl-Dipeptidase A as,Human body,receptor,2,X,[humn],[aapp/rcpt],I01.076.201.450.560;K01.093.378,
795bc1ba-d1ea-46b0-9556-3c2e23fd7763,C0242821,C1175175,using Peptidyl-Dipeptidase A as,Human body,Severe Acute Respiratory Syndrome,2,X,[humn],[dsyn],I01.076.201.450.560;K01.093.378,C02.782.600.550.200.750;C08.730.730
f5cec4c1-c54d-4479-8905-465f3d571a97,C0086418,C0087111,develop ,Homo sapiens,Therapeutic procedure,2,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,E02
5b7da5e0-16ab-4465-9e4a-351b7bf0ded8,C0086418,C0199848,develop ,Homo sapiens,Coronavirus vaccination,2,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,
c6d71ed1-147a-4c7d-9440-a425e2a59e74,C0012634,C0199848,develop ,Disease,Coronavirus vaccination,2,X,[dsyn],[topp],C23.550.288,
33e1f590-02d2-4baf-be4a-fa9c2908e54f,C0450254,C0042196,develop Communicable Diseases after intranasal,Pathogenic organism,Vaccination,2,X,[orgm],[topp],,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
48216c35-9944-4cc9-b739-cc4a6622e022,C0450254,C0009450,develop rapidly lethal ,Pathogenic organism,Communicable Diseases,2,X,[orgm],[dsyn],,C01.539.221
8f56e1aa-9546-4fce-bc3f-fdd933c965a5,C0042196,C1175743,is with ,Vaccination,SARS coronavirus,3,X,[topp],[virs],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,B04.820.504.540.150.113.937
b7e71eb1-8642-48e2-8a80-c4fc5bb8ca52,C1515884,C1293116,has officially entered development With ,Acupuncture and Oriental Medicine,Introduction procedure,2,X,[topp],[topp],,
74a0a7d9-3149-4291-bd53-b2ec80cdeec3,C1515884,C0014507,has officially entered development With ,Acupuncture and Oriental Medicine,Epidemiology,1,X,[topp],[bmod],,H02.403.720.500
65b57839-e053-4dfd-a2c7-313697d3f158,C1515884,C0025124,has officially entered development With ,Acupuncture and Oriental Medicine,Traditional Chinese Medicine,2,X,[topp],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
096bf4c0-78b9-4575-bad2-9c192919d7ec,C1515884,C1457887,significantly alleviate ,Acupuncture and Oriental Medicine,Symptoms,2,X,[topp],[sosy],,
3a12fba0-b78f-4a83-bc07-19355b219918,C1515884,C0920467,significantly alleviate ,Acupuncture and Oriental Medicine,disorder control (procedure),2,X,[topp],[topp],,
7c949276-15d2-454b-ab67-5327b408cb54,C1515884,C0010340,reduce occurrence of ,Acupuncture and Oriental Medicine,Critical Illness,2,X,[topp],[dsyn],,C23.550.291.625
01fa05a3-d0cf-442b-a2ac-5eb255be7ee6,C1515884,C0034019,is in new ,Acupuncture and Oriental Medicine,public health medicine (field),2,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
60a1c7bd-80fc-472b-9329-8e3f635d09e4,C1515884,C2745965,is in new ,Acupuncture and Oriental Medicine,Emergencies [Disease/Finding],2,X,[topp],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
888c5dd4-fdca-46cd-93a9-2353da080e7e,C0034019,C0025124,is with ,public health medicine (field),Traditional Chinese Medicine,2,X,[bmod],[bmod],H02.403.720;N01.400.550;N06.850,E02.190.488.585.520;I01.076.201.450.654.558.520
8f0f8bb0-28c1-49c2-8d9b-4c4e87a68ada,C2745965,C0025124,is with ,Emergencies [Disease/Finding],Traditional Chinese Medicine,2,X,[patf],[bmod],C23.550.291.781;N06.230.100.083;N06.850.376,E02.190.488.585.520;I01.076.201.450.654.558.520
dea65122-6a5d-414a-897e-53092dc2b7b1,C0079189,C0243026,lead to ,cytokine,Sepsis,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C01.539.757;C23.550.470.790.500
d08b4f19-8605-4cd1-8d2a-e9214e413d1b,C0026766,C0032113,demonstrated significant improvement after ,Multiple Organ Failure,Plasma Exchange,1,X,[patf],[topp],C23.550.835.525,E02.095.135.750
d08b4f19-8605-4cd1-8d2a-e9214e413d1b,C0026766,C0032113,underwent ,Multiple Organ Failure,Plasma Exchange,1,X,[patf],[topp],C23.550.835.525,E02.095.135.750
735ea329-516c-4e54-836e-eaf89316d4ba,C0036974,C0013778,requiring ,Shock,Electric Countershock,1,X,[patf],[topp],C23.550.835,E02.331.350
ccf89594-19eb-4164-8eb3-5b32a67ee01c,C0036974,C2349751,requiring ,Shock,Invasive positive pressure ventilation,1,X,[patf],[topp],C23.550.835,
9f0c034f-cfc9-4609-b81a-e8053bc68f3f,C0243026,C0026766,is with ,Sepsis,Multiple Organ Failure,1,X,[dsyn],[patf],C01.539.757;C23.550.470.790.500,C23.550.835.525
7d15b16d-86b6-4283-83c2-3f182519ce5f,ORF8,C0003451,were potential inhibitors of key component for,ORF8,Antiviral Agents,1,X,????,[phsu],????,D27.505.954.122.388
f4ee2acd-58cf-4e2a-a8ad-705f528cb941,C0524816,C0003451,were potential inhibitors of key component for,Nucleocapsid Proteins,Antiviral Agents,1,X,[aapp/bacs],[phsu],D12.776.964.970.600,D27.505.954.122.388
52e36344-af21-4e64-9c28-b423563548ee,C2610474,C0003451,component for ,type I interferon signaling pathway,Antiviral Agents,1,X,[celf],[phsu],,D27.505.954.122.388
a46cee5d-56b1-483a-8388-d047ea61b5d3,ORF8,C0015980,inhibit Interferon after treatment with,ORF8,Interferon-beta,1,X,????,[aapp/imft/phsu],????,D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275
131583be-7333-4aa2-8196-985696aa7c64,C0033684,C0015980,inhibit Interferon after treatment with,Proteins,Interferon-beta,1,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275
ae7fd5d9-5517-42ae-9ac1-3e069d036ae9,ORF8,C3652465,inhibit ,ORF8,Interferon,1,X,????,[aapp/imft/phsu],????,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
fa1d35a6-9de8-4f0d-94a1-87c2251cc35d,C1825598,COVID-19,was found ,IMPACT gene,COVID-19,3,X,[gngm],[virs],,C000657245
7a283e09-348b-41b7-8aaa-fd637fcad1cd,C0206419,C1254373,emerged as ,Genus: Coronavirus,etiologic agent,1,X,[virs],[sbst],B04.820.504.540.150,
7a283e09-348b-41b7-8aaa-fd637fcad1cd,C0206419,C1254373,with Severe acute respiratory infection is,Genus: Coronavirus,etiologic agent,1,X,[virs],[sbst],B04.820.504.540.150,
98d876d8-3d0d-4e41-a4ef-ae3f07564a35,C0008269,COVID-19,were ,Chloroquine,COVID-19,3,X,[orch/phsu],[virs],D03.633.100.810.050.180,C000657245
46648978-dfac-4111-9421-ac3e6575a18e,C1521863,C1456573,evoking imminent threat to ,estrogen receptor alpha human,Global Health,1,X,[aapp/rcpt],[bmod],x.x.x.x,H02.403.371;N01.400.337
537fe27b-ebee-4483-a381-71b3f43c7970,C1521863,C0086418,evoking imminent threat to ,estrogen receptor alpha human,Homo sapiens,1,X,[aapp/rcpt],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
a54e00ad-66e6-4735-9426-0a57af10c919,C0319157,C1521863,led ,AS virus,estrogen receptor alpha human,1,X,[virs],[aapp/rcpt],,x.x.x.x
48bd198d-d3bb-4adf-9ff7-a32e7640c722,C1175743,C0037778,has profoundly impacted ,SARS coronavirus,Medical Specialities,4,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403
9894bca3-1198-4248-a735-6c17e925d8ea,C0007222,C1175743,evidence for direct myocardial injury in ,Cardiovascular Diseases,SARS coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150.113.937
a37380aa-d8a4-45ec-8ee5-9e9b5f3d9af7,C0021918,COVID-19,relate to ,Intrinsic factor,COVID-19,1,X,[aapp/bacs/phsu],[virs],D12.776.395.560.494,C000657245
9d91c618-442a-4011-9684-9bc4cf6953c3,C0014467,C0597360,accompanied by increased ,eosinophil,receptor expression,1,X,[cell],[genf],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
d994a150-888a-4e2b-9496-46758aa99b84,C0014467,C1175743,accompanied by increased ,eosinophil,SARS coronavirus,1,X,[cell],[virs],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,B04.820.504.540.150.113.937
4253ba07-e22d-4b52-8bac-2f1caa7d2fcf,C0597360,C0599333,is in ,receptor expression,Epithelium of bronchus,1,X,[genf],[bpoc],,
de759364-4488-452b-88f5-92376cf1c908,C1422064,C0599333,is in ,ACE2 gene,Epithelium of bronchus,1,X,[gngm],[bpoc],,
72c52ea1-0a87-4361-a03b-8e371f3eb739,C0017337,C1422064,highly correlated with ,Genes,ACE2 gene,1,X,[gngm],[gngm],G05.360.340.024.340,
e30304e7-d545-427d-bfc6-4ac4b036920c,C1422064,C0041904,is Linked gene to,ACE2 gene,Up-Regulation (Physiology),2,X,[gngm],[moft],,G02.111.905;G05.308.850;G07.690.773.998
0adb90a2-1aa3-43d4-8a5a-44b652556e18,C1422064,C0314613,is Linked gene to,ACE2 gene,Linked gene,2,X,[gngm],[genf],,
365bb5c2-9147-4926-a820-134d2e9147fc,C0314613,Type-2,is in subset of Type-2 ,Linked gene,Type-2,1,X,[genf],????,,????
b24b9506-805b-46fc-a4d2-06bb64b51ea6,C0314613,C0004096,is in subset of Type-2 ,Linked gene,Asthma,1,X,[genf],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
976a95a0-5cba-4f06-82f4-34e0ff9186c0,C0087111,C1566664,targeting ,Therapeutic procedure,TCF Transcription Factors,1,X,[topp],[aapp/bacs],E02,D12.776.260.730;D12.776.660.235.400.800;D12.776.664.235.400.800;D12.776.930.875
24c94bf1-fc31-4d66-9676-0bc0c2f79a6a,C0087111,C3652465,targeting ,Therapeutic procedure,Interferon,1,X,[topp],[aapp/imft/phsu],E02,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
6559f142-db30-4bcf-beb4-de5dd13f760c,Type-2,COVID-19,may at ,Type-2,COVID-19,1,X,????,[virs],????,C000657245
4a38e740-5d83-49bc-adb1-718ae72108aa,C0004096,C1457887,developing ,Asthma,Symptoms,1,X,[dsyn],[sosy],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,
90cf5975-c0ca-4161-8b44-f45d41f8cd51,C0009450,C0027651,may establish parallelism with challenges faced in road to understanding of ,Communicable Diseases,Neoplasms,1,X,[dsyn],[neop],C01.539.221,C04
1ea9368d-c0c2-49ae-8d13-81bdf32e88dd,C0175754,C1705178,will Creation liaison in,Agenesis of corpus callosum,Order (action),1,X,[cgab],[acty],C10.500.034;C16.131.666.034;C23.300.008,
e2399d16-76e0-421b-8c8f-77d8b92f3351,C1516048,C0441655,changes in blood bank ,Assessed,Activities,1,X,[acty],[acty],,
a1cd8288-8d50-46b0-a589-4cace8afcc7b,C0032113,C1456820,remove ,Plasma Exchange,Tumor Necrosis Factor-alpha,1,X,[topp],[aapp/imft],E02.095.135.750,D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626
7a6c5dfa-d9f9-4f39-a58b-6586ed53bea5,C0032113,C0021745,remove ,Plasma Exchange,Interferon Type II,1,X,[topp],[aapp/imft/phsu],E02.095.135.750,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
c695d4bb-15f3-42d2-bf5e-f2b8369259e2,C0032113,C0021757,remove ,Plasma Exchange,Interleukin-3,1,X,[topp],[aapp/imft],E02.095.135.750,D12.644.276.374.410.240.400;D12.644.276.374.465.032;D12.776.395.240.400;D12.776.467.374.410.240.400;D12.776.467.374.465.032;D23.529.374.410.240.400;D23.529.374.465.169
b89dd91b-144b-434b-823b-0f5dd20d2f29,C0032113,RT-PCR,to Allergic Reaction is two consecutive negative RT-PCR,Plasma Exchange,RT-PCR,1,X,[topp],????,E02.095.135.750,????
87ffd677-bb81-4191-a11f-149858c58687,C0032113,C1175743,to Allergic Reaction is two consecutive negative RT-PCR,Plasma Exchange,SARS coronavirus,1,X,[topp],[virs],E02.095.135.750,B04.820.504.540.150.113.937
74aeef8f-7a43-42d7-ac73-a28657f0661c,C1527304,C1175743,tests for ,Allergic Reaction,SARS coronavirus,1,X,[patf],[virs],C20.543,B04.820.504.540.150.113.937
ac293a16-097e-4e5d-8823-a543753fe235,C0032113,C2744539,using Spectra Optia D2000 ,Plasma Exchange,THBD protein human,1,X,[topp],[aapp/bacs],E02.095.135.750,x.x.x.x
1338a5de-f184-47c5-89c1-c4df7fc5da35,C0032113,D2000,using Spectra Optia D2000 ,Plasma Exchange,D2000,1,X,[topp],????,E02.095.135.750,????
4d65266c-3f90-4744-9723-146b56f52232,C2744539,D2000,equipped with Depuro D2000 ,THBD protein human,D2000,1,X,[aapp/bacs],????,x.x.x.x,????
7b3cbcc0-841a-4f41-9d11-69bbc1b4bb15,C2744539,C0001128,operates with ,THBD protein human,Acids,1,X,[aapp/bacs],[chem],x.x.x.x,D01.029
2a3448f9-49b1-4988-97e4-6b0387276993,C2744539,C0022646,operates as per ,THBD protein human,Kidney,1,X,[aapp/bacs],[bpoc],x.x.x.x,A05.810.453
b5106657-41f3-4ff2-8529-41a64d336751,C0032105,C0001924,is replaced with ,Plasma,Albumins,1,X,[bdsu],[aapp/bacs],A12.207.152.693;A12.207.270.695;A15.145.693,D12.776.034
2592ca5b-4ff7-43d8-aa3b-74c17f98e014,C0032105,C0005779,is replaced with ,Plasma,Blood Coagulation Disorders,1,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C15.378.100
0f62f580-2b11-497d-9532-86ecfb30e729,C0001924,C0005779,is in patients with ,Albumins,Blood Coagulation Disorders,1,X,[aapp/bacs],[dsyn],D12.776.034,C15.378.100
fc2c4d39-1e70-40b9-9a66-a4f137ac476d,C4082587,C0005516,is in inflammatory ,HLA Class II Histocompatibility Antigen Gamma Chain human,Biological Markers,1,X,[aapp/imft],[clna],,D23.101
3cd0369c-1fb7-4241-8a7f-447dbe42155a,C0027627,C0021966,are ,Neoplasm Metastasis,Iodides,1,X,[neop],[inch],C04.697.650;C23.550.727.650,D01.248.497.158.490;D01.475.410
9bf85bae-c5a9-4825-93b0-e853d867fc03,C0031336,C0242781,reduce ,Pharmacy (field),disease transmission,2,X,[bmod],[patf],H02.646,N06.850.310
51917cd3-18b8-4f9c-af14-ddbdb16e58b8,C0031336,C1175743,reduce ,Pharmacy (field),SARS coronavirus,2,X,[bmod],[virs],H02.646,B04.820.504.540.150.113.937
2ac0bad0-3ce6-496c-a7c9-6f1ca3b6b92f,COVID-19,C0161816,been has associated with ,COVID-19,Cardiac complication,1,X,[virs],[patf],C000657245,
2ac0bad0-3ce6-496c-a7c9-6f1ca3b6b92f,COVID-19,C0161816,contributes to ,COVID-19,Cardiac complication,1,X,[virs],[patf],C000657245,
f5be9bb8-8ac3-440b-a754-4c6822bd56cf,COVID-19,C0038454,leading to wide spectrum of vascular damage myocardial injury ,COVID-19,Cerebrovascular accident,1,X,[virs],[dsyn],C000657245,C10.228.140.300.775;C14.907.253.855
e40cde05-ca48-4f36-9a00-2dd8ee6868cd,COVID-19,C0028778,leading to wide spectrum of vascular damage myocardial injury ,COVID-19,Obstruction,1,X,[virs],[patf],C000657245,
78916830-5679-4b72-87c7-a17abd0e7004,C0039082,C0333200,is with characteristics of aortic ,Syndrome,Intramural hematoma,1,X,[dsyn],[patf],C23.550.288.500,
dd0540a1-7e0e-448e-bfa7-3ed60cdab460,C0206277,C0013227,is with ,Fatal Outcome,Pharmaceutical Preparations,1,X,[patf],[phsu],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,D26
c3b8dac8-f355-4a4b-b85c-1553dab5b93a,C1707455,C0020336,is with association ,Comparison,Hydroxychloroquine,2,X,[acty],[orch/phsu],,D03.633.100.810.050.180.350
16a253f3-959d-4194-81f5-0bd2c7fec077,C0020336,C1707455,was In ,Hydroxychloroquine,Comparison,1,X,[orch/phsu],[acty],D03.633.100.810.050.180.350,
60befbe4-3531-4982-b74e-48203382317a,C0020336,C0025598,was In ,Hydroxychloroquine,Metformin,1,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180.350,D02.078.370.141.450
440d8162-d156-4e7f-bacb-0d3fe5fdcc69,C0020336,C3470566,was In ,Hydroxychloroquine,LINC-ROR gene,1,X,[orch/phsu],[gngm],D03.633.100.810.050.180.350,
859121d2-ca4e-4dc1-9da8-d19462a202d4,C1707455,C0025598,is with ,Comparison,Metformin,1,X,[acty],[orch/phsu],,D02.078.370.141.450
17fe077e-38e5-421d-9bce-7fe5f4e4bbe0,C0206277,C0852733,risk by particularly ,Fatal Outcome,Completed Suicide,1,X,[patf],[mobd],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,
277b975a-5a0c-41bc-8ff4-c3e025c2069c,C0020336,C0852733,appears particularly ,Hydroxychloroquine,Completed Suicide,1,X,[orch/phsu],[mobd],D03.633.100.810.050.180.350,
bc44932a-4500-46a0-b0b3-c83ea7a351aa,C0025598,C0852733,appears particularly ,Metformin,Completed Suicide,1,X,[orch/phsu],[mobd],D02.078.370.141.450,
17fdb7f9-420a-4387-850a-5554f81a9aab,C0079941,C0042720,viral 3UTR of ,Open Reading Frames,Viral Genome,1,X,[gngm],[gngm],G05.360.335.760.640;G05.360.340.024.340.137.650,G05.360.340.358.840
7c5f20e4-997f-413e-99b0-fc509bc348e0,C1819995,3UTR,directly target viral 3UTR ,Host Cell,3UTR,1,X,[celc],????,,????
f9059770-fcbe-4cef-9cc9-a6694ab2f416,C1101610,3UTR,directly target viral 3UTR ,MicroRNAs,3UTR,1,X,[bacs/nnon],????,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,????
6238de20-6e67-40c0-b347-f734c6520260,C1819995,C0042720,viral 3UTR of ,Host Cell,Viral Genome,2,X,[celc],[gngm],,G05.360.340.358.840
1be20599-cba3-41c3-acb9-4b9b2593164d,C1101610,C0042720,viral 3UTR of ,MicroRNAs,Viral Genome,2,X,[bacs/nnon],[gngm],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.360.340.358.840
858b9f40-9672-4c88-89ab-5e068d08ec3d,C1819995,C0003451,induce ,Host Cell,Antiviral Agents,1,X,[celc],[phsu],,D27.505.954.122.388
5aac01b5-6c0e-42ab-b21d-4ea77c431668,C1101610,C0003451,induce ,MicroRNAs,Antiviral Agents,1,X,[bacs/nnon],[phsu],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,D27.505.954.122.388
f20ea0fa-8aca-4c16-b473-edb7c7c783e9,C1101610,C1175743,targeting ,MicroRNAs,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150.113.937
f20ea0fa-8aca-4c16-b473-edb7c7c783e9,C1101610,C1175743,are unique for ,MicroRNAs,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150.113.937
f20ea0fa-8aca-4c16-b473-edb7c7c783e9,C1101610,C1175743,can strongly bind to certain key ,MicroRNAs,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150.113.937
0ce0fe6c-bba4-4c0b-b28e-894872ba9165,C1101610,C0017428,targeting ,MicroRNAs,Genome,1,X,[bacs/nnon],[gngm],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.360.340
ccf21685-444a-4bac-afd9-53078d0443c6,C1101610,COVID-19,are unique for ,MicroRNAs,COVID-19,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,C000657245
f21ff2fc-b38b-47cf-b618-2b7af32d1b46,C1101610,C1764827,are unique for ,MicroRNAs,Isolate - microorganism,1,X,[bacs/nnon],[bacs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,
0e27058c-717a-4ec3-b7c3-59f74e5d8d9c,C1764827,COVID-19,have MicroRNAs targets out of,Isolate - microorganism,COVID-19,1,X,[bacs],[virs],,C000657245
68bc2ccd-2cea-4e94-8706-fc69da6a17fb,C1764827,C1101610,have identical ,Isolate - microorganism,MicroRNAs,1,X,[bacs],[bacs/nnon],,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
68bc2ccd-2cea-4e94-8706-fc69da6a17fb,C1764827,C1101610,showed four unique ,Isolate - microorganism,MicroRNAs,1,X,[bacs],[bacs/nnon],,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
a4418404-61a1-4e2f-a5c5-f777a9587ce3,COVID-19,C1101610,showed four unique ,COVID-19,MicroRNAs,1,X,[virs],[bacs/nnon],C000657245,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
3b0ba7e3-dfbe-43da-b6f8-3629a6308371,C0037083,C1101610,be due to low abundance ,Signal Transduction,MicroRNAs,1,X,[celf],[bacs/nnon],G02.111.820;G04.835,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
5853e2e7-e467-40a3-b937-6f3bd869ddb5,C4601203,C3947283,was most recently recognized Bat coronavirus of potential,Porcine enteric Alphacoronavirus,Bat coronavirus,3,X,[virs],[virs],,
c58099b2-6471-43f0-99eb-ae2d3d229579,C4601203,C0206419,was most recently recognized ,Porcine enteric Alphacoronavirus,Genus: Coronavirus,1,X,[virs],[virs],,B04.820.504.540.150
91f287e9-d580-4b92-8d07-4246a53c9a2e,C4601203,C0012634,was most recently recognized ,Porcine enteric Alphacoronavirus,Disease,1,X,[virs],[dsyn],,C23.550.288
81d35a09-2029-4da2-8dbd-f7bf81c50466,C4601203,C0319157,is recognized as regional epizootic ,Porcine enteric Alphacoronavirus,AS virus,2,X,[virs],[virs],,
88ac082f-ef38-4b8c-803e-db4b7e51b61b,C0319157,C1516375,possesses most extensive ,AS virus,Cellular Tropism,4,X,[virs],[celf],,
ab7cc8f2-f3ad-4767-bb02-467c6dcb8b3a,C0022237,C0018563,washing properly ,Isopropyl Alcohol,Hand,4,X,[orch/phsu],[bpoc],D02.033.755.615,A01.378.800.667
7174cddd-c3ba-4207-9f7a-efece8726abc,C0599638,C0239816,may predispose HCWs to ,Drinking Water,Hand eczema,2,X,[sbst],[dsyn],D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418,
ccbe20d1-c244-4090-81be-c2e514f9e67f,C0011740,C0239816,may predispose HCWs to ,Detergents,Hand eczema,2,X,[chvf],[dsyn],D27.720.877.265;J01.516.381,
298ffb0e-ec21-4f4a-a1d5-8a77d1b4b4cb,C0012682,C0239816,may predispose HCWs to ,Disinfectants,Hand eczema,2,X,[sbst],[dsyn],D27.505.954.122.425;D27.720.274,
5eeca59a-0777-46ed-b224-7cd1e0b91b3d,C0042769,C0206419,is caused by novel ,Virus Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C02,B04.820.504.540.150
fc03c423-7057-4bee-86a9-c36f050f9d89,C0040034,COVID-19,were significantly common than ,Thrombocytopenia,COVID-19,4,X,[dsyn],[virs],C15.378.140.855,C000657245
43624d7f-3749-4b41-af79-e40cc0697ef2,C0370003,C0230425,using ,Specimen,Structure of right thigh,2,X,[sbst],[bpoc],,
a49b4206-f720-4e20-9d37-f2dad4c49260,C0230425,C0370003,is in simulated patient ,Structure of right thigh,Specimen,2,X,[bpoc],[sbst],,
739c9331-5000-4af5-9070-e7926dc71dbf,C0039082,C0032285,can manifest as severe ,Syndrome,Pneumonia,2,X,[dsyn],[dsyn],C23.550.288.500,C08.381.677;C08.730.610
3998e580-e4d2-4127-bdb1-ad168c556915,C0016976,C0178784,appear Among adult ,Gallbladder,Organ,1,X,[bpoc],[bpoc],A03.159.439,
4039c2fe-d535-40c2-aed9-3053d8dab126,C0596155,C0178784,appear Among adult ,Basal Cell,Organ,1,X,[cell],[bpoc],,
8fd19464-6dad-47a2-b23c-6c5987b4f91d,C0553257,C1175743,appear permissive to ,Epithelial cell of renal tubule,SARS coronavirus,4,X,[cell],[virs],,B04.820.504.540.150.113.937
b6bfa9c2-70cd-480c-94df-5e42bedcfafc,C0022677,C1175743,appear permissive to ,Kidney Tubules Proximal,SARS coronavirus,2,X,[bpoc],[virs],A05.810.453.736.560.570,B04.820.504.540.150.113.937
0e7a901f-0edb-404c-850a-8501252a5756,C0682610,C1175743,appear permissive to ,Enterocytes,SARS coronavirus,2,X,[cell],[virs],A03.556.124.369.290;A10.615.550.444.290;A11.436.290,B04.820.504.540.150.113.937
39342924-633d-4177-ba28-4dbd337ec676,C1519373,C1175743,appear permissive to ,Goblet cell of small intestine,SARS coronavirus,2,X,[cell],[virs],,B04.820.504.540.150.113.937
fe2eb0b1-7cbe-48ef-bb8a-0607ac1d4e9c,C0682610,C0178784,appear Among adult ,Enterocytes,Organ,1,X,[cell],[bpoc],A03.556.124.369.290;A10.615.550.444.290;A11.436.290,
a17ff5b0-c0d7-4135-a543-e2455539c90e,C1519373,C0178784,appear Among adult ,Goblet cell of small intestine,Organ,1,X,[cell],[bpoc],,
54ddd851-2c37-4683-a507-cd3225bb7492,C0016976,C1175743,appear permissive to ,Gallbladder,SARS coronavirus,3,X,[bpoc],[virs],A03.159.439,B04.820.504.540.150.113.937
4bacb63e-4463-4a99-92bd-c9796992d4a5,C0596155,C1175743,appear permissive to ,Basal Cell,SARS coronavirus,3,X,[cell],[virs],,B04.820.504.540.150.113.937
232c3e43-eaea-4b20-aa7f-e0534293065a,C0553257,C0178784,appear Among adult ,Epithelial cell of renal tubule,Organ,2,X,[cell],[bpoc],,
2292e81b-989c-40a2-99a2-555b6dd8b4f0,C0022677,C0178784,appear Among adult ,Kidney Tubules Proximal,Organ,1,X,[bpoc],[bpoc],A05.810.453.736.560.570,
18a8af75-e3d4-4a52-8cca-022edf620fa4,C0033684,C0597357,may use same ,Proteins,receptor,2,X,[aapp/bacs],[aapp/rcpt],D12.776,
bb3a005a-5785-4171-a0df-f4a9bedcdc1e,C0033684,C0022709,may use ,Proteins,Peptidyl-Dipeptidase A,2,X,[aapp/bacs],[aapp/enzy/imft],D12.776,D08.811.277.656.350.350.687
9f8db2eb-aa60-46f4-aa27-25a6265a9018,C1510827,C0022709,is much higher than that of ,Affinity,Peptidyl-Dipeptidase A,2,X,[npop],[aapp/enzy/imft],,D08.811.277.656.350.350.687
b1a662e4-77fc-4091-8751-106740bbb335,C1510827,C1167622,is much higher than that of ,Affinity,Binding (Molecular Function),2,X,[npop],[moft],,
c32c00a7-1e16-4d73-9327-047680f8942b,C1510827,C3711684,is much higher than that of ,Affinity,S protein severe acute respiratory syndrome coronavirus,2,X,[npop],[aapp/bacs],,x.x.x.x
fa167149-1934-481f-b7fd-41b418f814ca,C0079189,C0021747, includes ,cytokine,Interferons,2,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
e2a61905-d24f-4229-b07a-887c3e542993,C1948023,C0079189,is with inflammatory ,Stimulation (motivation),cytokine,2,X,[npop],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
e2a61905-d24f-4229-b07a-887c3e542993,C1948023,C0079189,limit release of pro-inflammatory ,Stimulation (motivation),cytokine,1,X,[npop],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
67d6634d-56af-4d6b-80b8-3e71cb5d18ed,C1948023,C0021747,is with inflammatory ,Stimulation (motivation),Interferons,2,X,[npop],[aapp/imft],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
b6671d80-0bdd-4348-be27-9aeb5090a275,C0042769,C1175175,may increase risk of ,Virus Diseases,Severe Acute Respiratory Syndrome,2,X,[dsyn],[dsyn],C02,C02.782.600.550.200.750;C08.730.730
bdb38f7f-86dd-4a51-9ad5-8a6d28f8110b,C3687832,C0872315,may Therefore may developed for future ,Drugs - dental services,Communicable Diseases Emerging,1,X,[topp],[dsyn],,C01.539.221.500
037b2c9f-7f5e-4a7c-bef1-cacbe9bac91b,C3687832,C0206419,may Therefore may developed for future ,Drugs - dental services,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
bbfa2cae-d307-4e37-9c11-9e9cf8889c9c,C0582263,C1622204,include ,Structural protein,envelope,1,X,[aapp/bacs],[celc],,
ef519d3a-b8c1-4738-9324-a87610fea187,C0582263,C0599561,include ,Structural protein,e protein,1,X,[aapp/bacs],[aapp/bacs],,
e03545ef-dcb6-4ef4-a556-d3cac74fc2b9,C0582263,C0369637,include ,Structural protein,M NOS ANTIBODY,1,X,[aapp/bacs],[aapp/imft],,
5c0d407e-0732-4331-9695-7d41b662db84,C0582263,C0596901,include ,Structural protein,Membrane,1,X,[aapp/bacs],[celc],,A10.615
d806bd4e-d67e-49ca-919f-08a0ed5e9994,C0582263,C0369718,include ,Structural protein,N not otherwise specified Antibody,1,X,[aapp/bacs],[aapp/imft],,
e47ff038-8a4d-490e-ba0e-06e7127c7063,C0582263,C0178774,include ,Structural protein,Nucleocapsid,1,X,[aapp/bacs],[aapp/bacs/nnon],,A21.249.500;B04.950.500
945135f4-764b-44f1-bec2-623748881d39,C4281807,C1419032,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,PSMD2 gene,1,X,[aapp/bacs],[gngm],,
e4a51d0c-2e25-488a-8b05-29f0b0114484,S1,C1419032,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,PSMD2 gene,1,X,????,[gngm],????,
cae60285-f2ca-4b3b-9528-61c8bd5dcb9b,C0599220,C1419032,facilitates Peptidyl-Dipeptidase A Virus Attachment,Protein Subunits,PSMD2 gene,1,X,[aapp],[gngm],D12.776.813,
856b7595-4ab7-4779-bd05-7bbbba8a48a2,C4281807,C0599220,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,Protein Subunits,1,X,[aapp/bacs],[aapp],,D12.776.813
e3fb028e-47ab-4697-9c4a-7dad0a754688,S1,C0599220,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,Protein Subunits,1,X,????,[aapp],????,D12.776.813
c9febc10-9059-4e17-b52e-b44eccb07596,C4281807,C0033414,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,Promotion (action),1,X,[aapp/bacs],[acty],,
6e5d1874-335d-4ce9-bf6e-0656e7d24e6b,S1,C0033414,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,Promotion (action),1,X,????,[acty],????,
4769abe0-7627-4809-8127-1b3a069dbe85,C0599220,C0033414,facilitates Peptidyl-Dipeptidase A Virus Attachment,Protein Subunits,Promotion (action),1,X,[aapp],[acty],D12.776.813,
de08c485-2460-42de-b8a4-90a49d903734,C4281807,C0025246,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,Membrane Fusion,1,X,[aapp/bacs],[moft],,G04.575
88aa23d2-1dfb-4be1-9c84-1ffbb8723a75,S1,C0025246,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,Membrane Fusion,1,X,????,[moft],????,G04.575
00e86b31-fdc0-47a4-841c-7620d343e0c2,C0599220,C0025246,facilitates Peptidyl-Dipeptidase A Virus Attachment,Protein Subunits,Membrane Fusion,1,X,[aapp],[moft],D12.776.813,G04.575
f3f8fc58-13ff-4db5-b128-58dd67703786,S1,C0022709,facilitates ,S1,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
e9a06c8a-7927-4833-ac77-453afc78a7a5,C0599220,C0022709,facilitates ,Protein Subunits,Peptidyl-Dipeptidase A,1,X,[aapp],[aapp/enzy/imft],D12.776.813,D08.811.277.656.350.350.687
7f8bbf63-f8be-4c34-9a85-af4cb02f8e62,C4281807,C1721019,facilitates ,Vitronectin human,Virus Attachment,1,X,[aapp/bacs],[biof],,G06.920.868
b5f9fd4f-ca3a-4954-8f3b-49c38912c466,S1,C1721019,facilitates ,S1,Virus Attachment,1,X,????,[biof],????,G06.920.868
23630ea9-c414-4f3d-acaa-9a7bbd7ccbc5,C0599220,C1721019,facilitates ,Protein Subunits,Virus Attachment,1,X,[aapp],[biof],D12.776.813,G06.920.868
b8ff5f84-8516-458a-a711-27e11d23544d,C0065827,C0036720,is composed of ,Measles Virus Nucleoprotein,Serine,1,X,[aapp/bacs],[aapp/bacs/phsu],x.x.x.x,D12.125.154.800
45f2f4dd-bd08-400f-a1ed-f958510cd192,C0065827,C4543503,is composed of ,Measles Virus Nucleoprotein,Sandwich,1,X,[aapp/bacs],[food],x.x.x.x,
4b356779-2255-4ceb-b235-d8a9b3eabd9f,NTD,C0427896,forms orthorhombic ,NTD,Crystal - human material,1,X,????,[bdsu],????,
2902e168-42c7-4347-a8ef-21e471571d66,NTD,C1167622,forms ,NTD,Binding (Molecular Function),1,X,????,[moft],????,
f934a0eb-2cfb-4465-b793-21e5195e1732,NTD,C0042720,forms Binding (Molecular Function) to,NTD,Viral Genome,1,X,????,[gngm],????,G05.360.340.358.840
f934a0eb-2cfb-4465-b793-21e5195e1732,NTD,C0042720,forms Crystal - human material to,NTD,Viral Genome,1,X,????,[gngm],????,G05.360.340.358.840
466b5508-1846-4e01-ab46-8930e8ce7ba9,C1519063,C4552744,regulate its ,Phosphorylation Site,Daily Living,1,X,[amas],[dora],,
5539ed0d-f4b4-4ac7-9e8d-a53223a6f22d,C0599561,NTD,contains NTD ,e protein,NTD,1,X,[aapp/bacs],????,,????
96f22cec-1139-4ca8-a110-7ac8c4db46aa,C1442905,C0282629,form viroporins needed for ,CTD gene,Virus Assembly,1,X,[gngm],[biof],,G06.920.925.950
8a6c0e8c-8b0b-4a93-889e-496b4e1b69d3,C0700271,C1707271,possesses hydrophilic ,M Protein multiple myeloma,Carboxy-Terminal Amino Acid,1,X,[aapp/imft],[amas],x.x.x.x,
8a897793-84f6-48a7-83e3-baf6c5f404b7,C0033414,C0042760,facilitates ,Promotion (action),Virion,1,X,[acty],[celc],,A21.249;B04.950
cdec6b1e-8390-46df-a4f6-bbf40402a892,C0033684,C0243052,is essential in ,Proteins,Virus Physiological Phenomena,1,X,[aapp/bacs],[npop],D12.776,G06.920
5b04834e-54d8-464b-83bb-3a7562e39a93,C0582263,C0087111,developing ,Structural protein,Therapeutic procedure,1,X,[aapp/bacs],[topp],,E02
c7fdecb3-f10e-4450-9acb-a38840e568a3,C0206419,C1515090,has drastically reduced ,Genus: Coronavirus,Surgical Oncology specialty,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.429.515.750;H02.403.810.796
0c6a6473-c968-45b3-a032-782c8f90d239,C0030858,C0012634,distinguish Coronavirus Infections from non,Pentaerythritol Tetranitrate,Disease,2,X,[orch/phsu],[dsyn],D02.033.455.706.690,C23.550.288
f34e5984-3821-49d6-ab3f-b53b3389aa36,COVID-19,AUC,is with AUC ,COVID-19,AUC,1,X,[virs],????,C000657245,????
3821d39b-5dc8-4b11-b513-19593d1f5bb4,C0032105,C1711371,allows to FFP2,Plasma,Reprocess,1,X,[bdsu],[acty],A12.207.152.693;A12.207.270.695;A15.145.693,
54202779-17ec-4a74-ac42-bd9add47019c,C0038280,C1711371,allows to FFP2,Sterilization for infection control,Reprocess,1,X,[topp],[acty],N06.850.780.200.450.850,
80c129eb-0d72-436a-bc7b-9e56a2281b07,C0011121,C0032105,is with ,Decontamination,Plasma,3,X,[topp],[bdsu],N06.850.780.325,A12.207.152.693;A12.207.270.695;A15.145.693
4e7166e0-d775-4d49-abe7-64ce4500f338,C0017428,C1175175,is in ,Genome,Severe Acute Respiratory Syndrome,2,X,[gngm],[dsyn],G05.360.340,C02.782.600.550.200.750;C08.730.730
caa9515f-c764-40c2-b1fc-509a2a8e3d6f,C1856053,C1175743,spread of ,Hydranencephaly with Renal Aplasia-Dysplasia,SARS coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150.113.937
9fd5b541-e41b-4a9f-a600-cd50b103cf35,C1947933,C1856053,was suspended beginning on ,care activity,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[acty],[dsyn],,x.x.x.x
548cdbaa-0411-47a7-8ffe-c8e278a5a274,C2986575,hotline,is with hotline ,Connect,hotline,2,X,[acty],????,,????
18867904-844b-4ead-81bb-0f2d9abde81e,C1825598,C0021822,necessitated use of alternative ,IMPACT gene,Interview,2,X,[gngm],[acty],,E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420
e5db1a5b-8a1e-4957-aa1b-8d451adc0365,C0021760,C0309872,provide valuable signals for ,Interleukin-6,PREVENT (product),2,X,[aapp/imft],[phsu],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,
5f8f1968-7c1f-4847-aad3-9d49b1e3fa1f,IFN,C0042542,is in ,IFN,Vero Cells,3,X,????,[cell],????,A11.251.210.955;A11.436.955
a9648597-498f-4ab8-bdec-f2cf1d3d6f53,C1175743,C0318356,is sensitive to many other ,SARS coronavirus,Human virus,6,X,[virs],[virs],B04.820.504.540.150.113.937,
b4fc0bad-1cae-41a1-bee6-5c0fb5bbcde3,C0206419,C0940933,can have serious complications from ,Genus: Coronavirus,infection as a complication,1,X,[virs],[dsyn],B04.820.504.540.150,
23d717bd-bd44-4d10-be91-c5d56dcdcf84,C0206419,C0004093,can have serious complications from ,Genus: Coronavirus,Asthenia,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.089
02b0d724-f318-4c10-843f-9fac20027cc1,C0034991,C1947933, includes interdisciplinary ,Rehabilitation therapy,care activity,4,X,[topp],[acty],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,
701e03e2-9942-4f1f-8a1d-0a1125becdf7,C0206419,C0370003,pandemic calls for expanded opportunities for testing strategies such as home-collected ,Genus: Coronavirus,Specimen,2,X,[virs],[sbst],B04.820.504.540.150,
a39adf84-2301-4179-865c-87987fecdb6d,C2586227,C1175743,were sufficient for use in tests of ,Dried blood spot specimen,SARS coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150.113.937
a39adf84-2301-4179-865c-87987fecdb6d,C2586227,C1175743,are suitable for testing for ,Dried blood spot specimen,SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
95271cef-eed1-4ece-b317-ba5f7a5e87c4,C0146894,C1149341,is with nsp14 ,triphosphate,protein C-terminus binding,1,X,[inch],[moft],,
ba15d9fb-23ba-4531-a68e-ab22372929a6,C0146894,nsp14,is with nsp14 ,triphosphate,nsp14,1,X,[inch],????,,????
676acd90-5162-48d4-bbea-48b5d32fc17b,C1149341,nsp14,is with nsp14 ,protein C-terminus binding,nsp14,1,X,[moft],????,,????
c62e74cc-9c3d-4d3c-9325-e7c4a77ab775,C0146894,C1175743,is with nsp14 ,triphosphate,SARS coronavirus,1,X,[inch],[virs],,B04.820.504.540.150.113.937
0cbca530-efed-428b-bd65-c19ecfea5db6,C1149341,C1175743,is with nsp14 ,protein C-terminus binding,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
41e0cc32-25e4-4b34-bf0b-e9077fd148da,Asn388,C1175743,is highly conserved in present in N7-MTase from ,Asn388,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
38b75fb3-b178-4856-93bf-e62168b655c2,C0031843,C1422268,is in ,physiological aspects,APOM gene,1,X,[phsf],[gngm],x.x.x.x,
d58ecda0-7b8e-4904-a213-a6ec6795b5f1,C0031843,C1167622,is in ,physiological aspects,Binding (Molecular Function),1,X,[phsf],[moft],x.x.x.x,
2f84dfd0-acea-4534-89ff-fc9de44bf1cc,C1450224,C0206750,successfully navigating emerging ,forensic pathology discipline,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.330.300;H02.403.650.249;I01.198.780.937.460,C02.782.600.550.200
7c33a47e-bfd9-416d-af19-c5737c04abc4,C0013227,C0279516,include ,Pharmaceutical Preparations,Anti-Bacterial Agents,2,X,[phsu],[antb],D26,D27.505.954.122.085
c4d75975-ba42-4fb2-bd79-4d6eb842f968,C0013227,C0020974,include ,Pharmaceutical Preparations,passive immunization procedure,2,X,[phsu],[topp],D26,E02.095.465.425.400.330;E05.478.550.520
b3037ee7-1e6f-4fad-ab54-7c42b73882e3,C0184633,C0344211, includes ,Oxygen Therapy Care,Supportive care,1,X,[topp],[topp],E02.880.690,
e2d9c220-ee2c-4195-9ae4-1f01195ff50d,C0184633,C0015357, includes ,Oxygen Therapy Care,Extracorporeal Membrane Oxygenation,1,X,[topp],[topp],E02.880.690,E02.880.301;E04.292.451
4ed0f324-521f-4470-a64f-d8cf5476d010,C0543467,C1515090, includes ,Operative Surgical Procedures,Surgical Oncology specialty,4,X,[topp],[bmod],E04,H02.403.429.515.750;H02.403.810.796
00d9e25d-3e23-410f-8a4a-4499909404ba,C0039082,C0032587,is acute immune-mediated ,Syndrome,Polyradiculoneuropathy,1,X,[dsyn],[dsyn],C23.550.288.500,C10.114.750;C10.314.750;C10.668.829.800.750;C20.111.258.750
af0e4eba-0d5d-4fbb-a9c4-23c4666d1d6c,C0009450,COVID19,causes COVID19,Communicable Diseases,COVID19,1,X,[dsyn],????,C01.539.221,????
46a5b383-b059-49c8-9208-6cb8634e6604,C0035243,C1457887,characterized by main ,Respiratory Tract Infections,Symptoms,1,X,[dsyn],[sosy],C01.539.739;C08.730,
59d23743-fd00-459c-bf01-b25be933d5bf,C0035243,C0032285,characterized by main ,Respiratory Tract Infections,Pneumonia,1,X,[dsyn],[dsyn],C01.539.739;C08.730,C08.381.677;C08.730.610
5492f8d6-99e2-422f-9f71-835bb009a708,C1550661,C0206750,diagnosed with ,Specimen Type - Stool = Fecal,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
0f1c0de9-643f-43b3-9a90-3d433fbee7ce,C0282560,C0370003,were inoculated with ,Caco-2 Cells,Specimen,1,X,[cell],[sbst],A11.251.210.190.160;A11.251.860.180.160;A11.436.140,
1bc86671-5183-493b-bd10-52432d5309c4,C0007590,C1550101,is in ,Cell division,Supernatant,1,X,[celf],[bdsu],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,
7367d9ce-22e2-4ad0-a8bf-4ba5c432d67e,C1511790,C1550661,is in ,Detection,Specimen Type - Stool = Fecal,2,X,[topp],[bdsu],,
8b940624-bbf2-4ae8-bcab-0681e602e3ae,C1511790,C0319157,was intermittent ,Detection,AS virus,1,X,[topp],[virs],,
7d4e3a67-afe4-4de7-ae44-ef78eb48813d,C1511790,C0444279,was intermittent ,Detection,Respiratory sample,1,X,[topp],[bdsu],,
d2988ada-3013-4b3d-99b2-7c9e8800f098,C0319157,C0444279,remained in ,AS virus,Respiratory sample,1,X,[virs],[bdsu],,
a741661f-9e12-460e-b137-68021292fbbc,C0392676,C0015967,is Fever of,Hyperpyrexia,Fever,3,X,[patf],[sosy],,C23.888.119.344
60d190ca-9ad4-41b8-9593-0fea935a4ed3,C0392676,C0206750,is in ,Hyperpyrexia,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
81dfe5e0-09c5-44c6-a7ab-2c6912a91abe,C0034991,C0206750,was During pandemic converted into isolation for ,Rehabilitation therapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200
81dfe5e0-09c5-44c6-a7ab-2c6912a91abe,C0034991,C0206750,was converted into 130-bed ,Rehabilitation therapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200
81dfe5e0-09c5-44c6-a7ab-2c6912a91abe,C0034991,C0206750,should consider effect on ,Rehabilitation therapy,Coronavirus Infections,5,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200
a8cef3f8-0500-4c9a-9cbb-22ca090d102c,C0034991,130-bed,was converted into 130-bed ,Rehabilitation therapy,130-bed,1,X,[topp],????,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,????
b0ba784e-5585-48ba-9a40-a24e4c65025f,C0370003,C0426576,was divided On basis of presence of ,Specimen,Gastrointestinal symptom,1,X,[sbst],[sosy],,
0e85c0dd-de69-492d-b151-e2d191f6498d,C0426576,C0011991,were ,Gastrointestinal symptom,Diarrhea,1,X,[sosy],[sosy],,C23.888.821.214
d826914a-d3cc-4d19-9426-e2d424248bf7,C0426576,C0003123,were ,Gastrointestinal symptom,Anorexia,1,X,[sosy],[dsyn],,C23.888.821.108
f82e5f9c-4eb0-4d27-a38a-b23ad039f371,C0426576,C0027497,were ,Gastrointestinal symptom,Nausea,1,X,[sosy],[sosy],,C23.888.821.712
3b2b2ddc-54d7-4f58-8501-202a18dfed6d,C0016452,C2258685,reduce ,Food,angiotensin converting enzyme activity,1,X,[food],[moft],G07.203.300;J02.500,
5d79f8b7-6ec7-4b17-9c04-b54fb3f7129b,C0016452,C0003402,are ,Food,Antioxidants,1,X,[food],[phsu],G07.203.300;J02.500,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
7dd505c7-29d3-46b2-a1b7-49e61991a2e7,C0012155,C0206750,is in populations with different ,Diet,Coronavirus Infections,1,X,[food],[dsyn],G07.203.650.240,C02.782.600.550.200
45f41f36-0802-4f4d-98a7-d4ea9aa706df,C0206750,C0917801, includes ,Coronavirus Infections,Sleeplessness,2,X,[dsyn],[sosy],C02.782.600.550.200,C10.886.425.800.800;F03.870.400.800.800
71ed7abf-5bc2-4b8b-b0e8-b2e0eb8edb26,C1880177,C0441516,adds new dimension to ,Contribution,Demand (clinical),1,X,[acty],[topp],,
75504945-f674-4e89-9515-8600895e7c62,C1880177,C0221102,adds new dimension to ,Contribution,Excretory function,1,X,[acty],[phsf],,
91f2a3a4-6918-4914-922c-23eb3ede70ff,C1880177,C0324547,adds new dimension to ,Contribution,New Zealand Rabbits,1,X,[acty],[mamm],,B01.050.150.900.649.313.968.700
6057ca7a-8850-4a1d-833f-692f212eae7a,C0009443,C0319157,minimize exposure to ,Common Cold,AS virus,1,X,[dsyn],[virs],C02.782.687.207;C08.730.162,
e8c60483-8cf1-485a-8226-cd15e969714c,C0003280,C0019134, includes ,Anticoagulants,heparin,1,X,[phsu],[bacs/orch/phsu],D27.505.954.502.119,D09.698.373.400
f6382379-7bf4-4c00-868d-202ddc3346b5,C0319157,C0007610,may enter system in nasal cavity in brainstem ,AS virus,Cell Nucleus,1,X,[virs],[celc],,A11.284.430.106;A11.284.430.214.190.875.117
eda09952-bd82-431b-aaee-29e5e3ec9f49,C0319157,C1656385,may enter system in nasal cavity in brainstem ,AS virus,regulation of cellular respiration,1,X,[virs],[celf],,
afad636c-4f8d-4c43-b73b-6193b9d98f5c,C0319157,C0028938,may enter system through ,AS virus,Olfactory Nerve,1,X,[virs],[bpoc],,A08.800.800.120.640
fa038a46-e7d9-42a5-8b4b-ec1bf0f8ade7,C0022709,C0030664,is in various neoplastic ,Peptidyl-Dipeptidase A,Pathology,1,X,[aapp/enzy/imft],[bmod],D08.811.277.656.350.350.687,H02.403.650
fa038a46-e7d9-42a5-8b4b-ec1bf0f8ade7,C0022709,C0030664,exerts Daily Living in various models of,Peptidyl-Dipeptidase A,Pathology,1,X,[aapp/enzy/imft],[bmod],D08.811.277.656.350.350.687,H02.403.650
99f217a5-60e2-4860-8dbc-94bed2bce663,C0008946,C1704241,respond to ,Climate,complex (molecular entity),4,X,[npop],[chvs],G16.500.275.071;N06.230.300.100.250,
6a2814ba-239e-4513-bca5-452630b31bb4,C0206750,C0341439,might negatively affect course of patients with ,Coronavirus Infections,Chronic liver disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,
18f77a31-92be-4c04-bcb4-87ed10d23d75,C0060323,C1707455,were higher in ,Fibrin fragment D,Comparison,1,X,[aapp/bacs],[acty],x.x.x.x,
fd7bf550-b7d7-4601-8f98-db700a02ad11,C0060323,C1947906,were higher in ,Fibrin fragment D,Sorting,1,X,[aapp/bacs],[acty],x.x.x.x,
f064f5b0-e6ea-49b2-9782-60e6dd2c11dd,C1707455,C1947906,is with those from non ,Comparison,Sorting,1,X,[acty],[acty],,
a49519dc-9b1f-4d2f-bbe6-d7efd1d5969b,C0012634,C0024115,might complicate ,Disease,Lung diseases,3,X,[dsyn],[dsyn],C23.550.288,C08.381
37777b57-54d6-44b0-b815-0155d99f3814,C0012634,C0036421,might complicate Lung diseases scenario Lung diseases Lung diseases in,Disease,Systemic Scleroderma,1,X,[dsyn],[dsyn],C23.550.288,C17.300.799;C17.800.784
d4e600f4-53cd-4fdb-99e8-1548b6c9480c,C0206750,C0206062,of outbreak is many patients with underlying ,Coronavirus Infections,Lung Diseases Interstitial,441,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.483
0ead3ddf-b593-4832-9432-cbce3ce9d099,NIOSH,U.S.,recently evaluated quality of FFRs sampled from U.S. ,NIOSH,U.S.,2,X,????,????,????,????
069b3452-f9c0-4f48-a8cf-e27c0479f76f,NIOSH,C0030858,quality of FFRs sampled from U.S. ,NIOSH,Pentaerythritol Tetranitrate,1,X,????,[orch/phsu],????,D02.033.455.706.690
e6fe5d39-c7d2-49a8-9c8a-b4d47407ed9e,C1521827,C0206750,is in hospital due to ,Preparation,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
134c5d84-8e75-4d88-8ce8-96aebdcb374b,C0319157,C0700271,gains entry via ,AS virus,M Protein multiple myeloma,2,X,[virs],[aapp/imft],,x.x.x.x
77f55381-6cfc-46ea-80a7-1057ef0cddd9,C0319157,C1167395,gains entry on ,AS virus,Host (organism),2,X,[virs],[orgm],,
8f235445-0b8f-435d-bd49-1db5b47a40ce,C0319157,C0034800,gains entry on ,AS virus,Receptors Cell Surface,2,X,[virs],[aapp/rcpt],,D12.776.543.750
1bb0fd32-6876-41fd-a9ea-d817b786f440,C0596957,C1704241,further strengthen stability of ,Molecular Dynamics,complex (molecular entity),2,X,[moft],[chvs],E05.599.595.500;G02.111.570.895;L01.224.160.500,
6df501d3-4083-47fa-948c-7061a51d29c3,C1175743,C0426576,causes ,SARS coronavirus,Gastrointestinal symptom,1,X,[virs],[sosy],B04.820.504.540.150.113.937,
7252e0a8-c7d6-48f3-9a19-f6e39bc8478a,C3272275,C0206419,were performed during ,Urgent Procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
855b3dde-04d1-4c6f-ba38-43fb9900e285,C0021368,C0206419,occur with ,Inflammation,Genus: Coronavirus,1,X,[patf],[virs],C23.550.470,B04.820.504.540.150
a56ef8f7-ffa9-41b8-a839-c6a8359fb331,C0003209,C0206419,changes occurs with ,Anti-Inflammatory Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.158,B04.820.504.540.150
d88467cc-c1e6-44de-aacd-0de1566ce5e1,C0242781,C4289682,can can ,disease transmission,Direct Transmission,1,X,[patf],[patf],N06.850.310,
7fc33208-5230-4091-8db9-514772ca1d96,C1175743,C1457887,understanding of ,SARS coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150.113.937,
7fc33208-5230-4091-8db9-514772ca1d96,C1175743,C1457887,is dominated by ,SARS coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150.113.937,
7fc33208-5230-4091-8db9-514772ca1d96,C1175743,C1457887,remains detectable following self-reporting of ,SARS coronavirus,Symptoms,2,X,[virs],[sosy],B04.820.504.540.150.113.937,
ba659793-db06-4f81-b138-d199412ac78d,C0032310,C1457887,is with clinical ,Pneumonia Viral,Symptoms,1,X,[dsyn],[sosy],C02.705;C08.381.677.807;C08.730.610.763,
37ff1fc0-bd07-4c27-82c7-fcdc15c68887,C0032310,C0206419,is with clinical ,Pneumonia Viral,Genus: Coronavirus,1,X,[dsyn],[virs],C02.705;C08.381.677.807;C08.730.610.763,B04.820.504.540.150
7079f1dc-4dc3-4ecf-8f61-bec5a0794954,C0032310,C0012634,is with clinical ,Pneumonia Viral,Disease,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C23.550.288
716479b5-7566-42b7-9b97-887be4184658,C0004096,C0012655,affect ,Asthma,Disease susceptibility,1,X,[dsyn],[clna],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C23.550.291.687;G07.100.250
6acfac1e-23a9-451e-83a2-962dda316cc5,C0004096,C0206419,affect ,Asthma,Genus: Coronavirus,1,X,[dsyn],[virs],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,B04.820.504.540.150
6acfac1e-23a9-451e-83a2-962dda316cc5,C0004096,C0206419,Disease susceptibility of,Asthma,Genus: Coronavirus,2,X,[dsyn],[virs],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,B04.820.504.540.150
843c0af4-5919-41ba-a9d2-27245201277c,C0206419,C0004096,significantly impacted pediatric ,Genus: Coronavirus,Asthma,1,X,[virs],[dsyn],B04.820.504.540.150,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
9264193e-2593-4bfd-bc70-a5983bbf43ab,C0476474,C0206419,is with suspected association to ,persistent fever,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
4d842d9c-74de-455c-b094-6b680345fd30,C4048285,C0199470,was strongly associated with HFNC,C-Reactive Protein human,Mechanical ventilation,1,X,[aapp/imft],[topp],,
5f0ab52c-c6b6-46c9-b69b-31e8cb9e5bcc,C4048285,HFNC,was strongly associated with HFNC,C-Reactive Protein human,HFNC,1,X,[aapp/imft],????,,????
2d4fdab5-6f58-45e1-8c02-ebf95e4edb75,C0022322,C0005532,plays role in several ,Ivermectin,biology (field),1,X,[orch/phsu],[bmod],D02.540.576.500.997;x.x.x.x,H01.158.273
05124a96-dc69-4a45-9eed-750987eb2757,C0206419,C0019682,amplify known ,Genus: Coronavirus,HIV,1,X,[virs],[virs],B04.820.504.540.150,B04.820.650.589.650.350
285b5d86-02e6-4926-a7f0-efd88c5e76cc,C0042776,C0034019,becomes ,Virus,public health medicine (field),1,X,[virs],[bmod],B04,H02.403.720;N01.400.550;N06.850
285b5d86-02e6-4926-a7f0-efd88c5e76cc,C0042776,C0034019,resulting in ,Virus,public health medicine (field),1,X,[virs],[bmod],B04,H02.403.720;N01.400.550;N06.850
d6617bec-5e74-45e1-95ff-b5ccf99b762d,C0206419,C1947933,can address important questions about ,Genus: Coronavirus,care activity,1,X,[virs],[acty],B04.820.504.540.150,
2f2d17c7-a091-4540-8f1a-80585f9edcc2,C2700061,C0020517,are very ,Transition (action),Hypersensitivity,1,X,[acty],[patf],,C20.543
c3c2d166-e8e8-4fb8-9885-99268bfb90fb,C3714552,C0231452,is with cervical ,Weakness,Flexion function,1,X,[sosy],[ortf],,
9c02fe29-6ed8-4b50-8097-e6c627810bce,C3714552,C1540289,is with cervical ,Weakness,CD200 gene,1,X,[sosy],[gngm],,
06aa3795-87bc-4442-b079-ce6089af295c,C2349975,C0039082,is atypical feature in ,Enhance (action),Syndrome,1,X,[acty],[dsyn],,C23.550.288.500
565f970b-9df9-4344-adb6-bbe8ba22c57c,C0683201,C0206419,is in critical patients with ,specific immunity,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
b9157989-3a3d-4a89-938a-4476073cd142,C1512594,C4521448,was investigated in ,IL2 Signaling Pathway,Derived Peripheral Blood Mononuclear Cell,2,X,[celf],[cell],,
1187c1b9-048f-4a5c-b3d1-19f86af3676e,C0169658,C0206419,is in critical patients with ,Janus kinase 1,Genus: Coronavirus,1,X,[aapp/enzy],[virs],D08.811.913.696.620.682.725.124.100;D12.776.476.393.100,B04.820.504.540.150
d6ce8ca1-294e-49f4-9c30-252622640871,C1366394,C0206419,is in critical patients with ,STAT5A protein human,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
56707228-0958-4835-90cb-1b48214635a6,C0206244,C0034386,be unlikely regardless of ,Lifting,Quarantine,1,X,[acty],[topp],G01.374.669,N06.850.780.200.450.700
23719de0-732a-4666-ad48-c4ad69470a62,C0206244,C2926735,be unlikely regardless of ,Lifting,Duration,1,X,[acty],[orch/phsu],G01.374.669,
20c1078e-8839-42e8-b5ce-6e62e18a12b5,C0034386,C2926735,be unlikely regardless of ,Quarantine,Duration,1,X,[topp],[orch/phsu],N06.850.780.200.450.700,
04238ac8-cbe2-4d10-8e5f-0d12cb2043aa,C0005779,C0012739,meets laboratory criteria for ,Blood Coagulation Disorders,Disseminated Intravascular Coagulation,2,X,[dsyn],[dsyn],C15.378.100,C15.378.100.220;C15.378.463.250;C15.378.925.220
76eefb65-5790-4c47-80c2-f66b52751a75,C0630906,C0206419,is in ,vinyltriethoxysilane,Genus: Coronavirus,2,X,[orch],[virs],x.x.x.x,B04.820.504.540.150
85e061b2-4de5-4f0b-a95c-87791a128ee2,C1175743,C0719214,led to most recent pandemic of ,SARS coronavirus,century,1,X,[virs],[phsu/vita],B04.820.504.540.150.113.937,
85e061b2-4de5-4f0b-a95c-87791a128ee2,C1175743,C0719214,outbreak of is worst healthcare ,SARS coronavirus,century,1,X,[virs],[phsu/vita],B04.820.504.540.150.113.937,
e907e7e7-f6ff-45c6-a6aa-21b5827b523b,C1707455,C1536220,is In ,Comparison,ST segment elevation myocardial infarction,1,X,[acty],[dsyn],,C14.280.647.500.875;C14.907.585.500.875
5d0a9deb-260a-4be8-9180-393ed776e105,C0038441,C0012634,create entirely new form of ,Stress Disorders Traumatic,Disease,1,X,[mobd],[dsyn],F03.950.750,C23.550.288
e9d80191-d885-47c9-aca2-caf6432fa71b,C0206750,C0450442,is At state cited as problematic ,Coronavirus Infections,Agent,1,X,[dsyn],[chvf],C02.782.600.550.200,
e9d80191-d885-47c9-aca2-caf6432fa71b,C0206750,C0450442,is cited as most worldwide problematic ,Coronavirus Infections,Agent,1,X,[dsyn],[chvf],C02.782.600.550.200,
3f8cf254-dc9c-4d1f-b9fe-883cd29623c1,C0022709,C0011334,is highest within sinonasal ,Peptidyl-Dipeptidase A,Dental caries,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C07.793.720.210
2936b58c-1190-4d43-b431-0606135de7ee,C0033684,C0011334,is highest within sinonasal ,Proteins,Dental caries,2,X,[aapp/bacs],[dsyn],D12.776,C07.793.720.210
1aad70f0-0b15-4b4f-b0ff-cb44cd8ace86,C0033684,C0819757,was found In ,Proteins,Structure of parenchyma of lung,4,X,[aapp/bacs],[tisu],D12.776,
dbee56fb-af14-4170-a47d-9e23f19e255f,C0022709,C0699040,was found on apical ,Peptidyl-Dipeptidase A,Cell surface,2,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
c62bedf2-43be-41f7-898a-f99ea34e9599,C0033684,C0699040,was found on apical ,Proteins,Cell surface,4,X,[aapp/bacs],[celc],D12.776,
aee99e36-c013-4e48-8e82-f99abf0f94f5,C0033684,C1742865,colocalized with ,Proteins,TMPRSS2 protein human,2,X,[aapp/bacs],[aapp/enzy],D12.776,x.x.x.x
ce0ca42c-679c-468f-953a-1673e6ecc7ca,C1742865,CoV2,chemical cofactor for CoV2,TMPRSS2 protein human,CoV2,2,X,[aapp/enzy],????,x.x.x.x,????
f30dd346-de8b-4804-a558-04d72be9124e,C0033684,C0178555,colocalized with CoV2 ,Proteins,chemical cofactor,2,X,[aapp/bacs],[bacs],D12.776,
fda6070d-c61a-4c74-912a-cb73cd051de5,C0033684,C1175743,colocalized with CoV2 ,Proteins,SARS coronavirus,2,X,[aapp/bacs],[virs],D12.776,B04.820.504.540.150.113.937
fda6070d-c61a-4c74-912a-cb73cd051de5,C0033684,C1175743,could could direct targets for ,Proteins,SARS coronavirus,1,X,[aapp/bacs],[virs],D12.776,B04.820.504.540.150.113.937
04237fc2-a088-4140-a67e-4a16b3230871,C0033684,CoV2,colocalized with CoV2 ,Proteins,CoV2,2,X,[aapp/bacs],????,D12.776,????
3391ccf8-4a12-4252-9510-fc76bb3bed4f,C0033684,C0206750,was increased in demographic with incidence of severe ,Proteins,Coronavirus Infections,2,X,[aapp/bacs],[dsyn],D12.776,C02.782.600.550.200
48dc84da-3352-4e2e-9ea8-0a89904d40fa,C0024264,C1514474,were selected as final ,Lymphocyte,Prognostic Factors,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,E01.789
779c97aa-62d9-4fbe-8412-fd56e673af5f,C2745965,C0034991,consider specific ,Emergencies [Disease/Finding],Rehabilitation therapy,2,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
dddb7375-5232-45c3-b428-43f9095e7829,C0025242,C0022709,may decrease ,Memantine,Peptidyl-Dipeptidase A,1,X,[orch/phsu],[aapp/enzy/imft],D02.455.426.100.050.035.500,D08.811.277.656.350.350.687
b37015f8-1cd4-4da8-a80c-720708ac2154,C0025242,C0021368,reduce ,Memantine,Inflammation,1,X,[orch/phsu],[patf],D02.455.426.100.050.035.500,C23.550.470
2d3e7cd7-b30c-41e2-9854-2620deb024f8,C0025242,C0242606,reduce ,Memantine,Oxidative Stress,1,X,[orch/phsu],[comd],D02.455.426.100.050.035.500,G03.673;G07.775.750
38cddb76-3fdd-41db-950a-6916180c80f2,C1443953,C1175743,caused by ,Acute viral disease,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
4292636f-49c2-442e-b1ee-18c42702785b,C0024109,C1707455,be significantly upregulated in smokers ,Lung,Comparison,2,X,[bpoc],[acty],A04.411,
ab619c72-797c-4952-ae9e-5b7c7cf080cd,C0458827,C1707455,be significantly upregulated in smokers ,Airway structure,Comparison,2,X,[bpoc],[acty],,
26ed87ed-5b5a-477c-8be7-5db8627088a4,C0276653,C0009566,seems increasingly observed ,Invasive Pulmonary Aspergillosis,Complication,2,X,[dsyn],[patf],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,
7a3f85bd-d4d5-4ac8-9b68-34934896815f,C0276653,C0010340,be increasingly observed Complication in,Invasive Pulmonary Aspergillosis,Critical Illness,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C23.550.291.625
7a3f85bd-d4d5-4ac8-9b68-34934896815f,C0276653,C0010340,seems increasingly observed ,Invasive Pulmonary Aspergillosis,Critical Illness,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C23.550.291.625
3482905f-f171-4788-8878-39e546296324,C0276653,C1175175,be increasingly observed Complication in,Invasive Pulmonary Aspergillosis,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C02.782.600.550.200.750;C08.730.730
3482905f-f171-4788-8878-39e546296324,C0276653,C1175175,seems increasingly observed ,Invasive Pulmonary Aspergillosis,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C02.782.600.550.200.750;C08.730.730
82ed95d7-08d8-4c8a-9627-70db545c2be0,C0010340,C1175175,is with ,Critical Illness,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C23.550.291.625,C02.782.600.550.200.750;C08.730.730
e4b21da4-0df1-4584-b33b-ad15745f1beb,C0009566,C0010340,is in ,Complication,Critical Illness,1,X,[patf],[dsyn],,C23.550.291.625
280805f5-960f-4616-9405-e0727c552b62,C0009566,C1175175,is in ,Complication,Severe Acute Respiratory Syndrome,1,X,[patf],[dsyn],,C02.782.600.550.200.750;C08.730.730
a95d1c9f-9e9a-4066-b256-8b37d9349c32,C0206750,C3813209,each with its own ,Coronavirus Infections,PROS1 wt Allele,1,X,[dsyn],[gngm],C02.782.600.550.200,
f0696792-665f-4fc0-bc7f-725431893e11,C0206750,C4552744,has enforced dramatic changes to ,Coronavirus Infections,Daily Living,1,X,[dsyn],[dora],C02.782.600.550.200,
29fac0f9-b630-4fb7-b3a4-7a6dae233eab,C0206750,C1704272,is with ,Coronavirus Infections,Benign Prostatic Hyperplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,C12.294.565.500
26909e5e-4eee-419c-b4e7-2bc21839d951,C0206750,C0040034,may may associated with ,Coronavirus Infections,Thrombocytopenia,1,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.140.855
163c04f9-bd34-49e1-a96d-26d9933c7e59,C0012634,C0040034,may may associated with ,Disease,Thrombocytopenia,1,X,[dsyn],[dsyn],C23.550.288,C15.378.140.855
d11414d4-40cc-40f3-9728-5a097848d3f6,C0079189,C0040034,are leading etiologies of ,cytokine,Thrombocytopenia,2,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C15.378.140.855
3d12edf4-faf3-4785-a4db-8bbe07e0033f,C0009830,C0206750,are leading etiologies of ,Consumption of goods,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
f32e70a5-f4ea-4e4d-b33a-b6049908f774,C0009830,C0040034,are leading etiologies of ,Consumption of goods,Thrombocytopenia,2,X,[acty],[dsyn],,C15.378.140.855
1515ca22-b834-4b56-a7dd-0980443c5f81,C1948029,C0040034,are leading etiologies of ,Destruction (action),Thrombocytopenia,1,X,[acty],[dsyn],,C15.378.140.855
36937c21-cc10-43d5-ac1d-c940aee89302,C1948029,C0206750,are leading etiologies in ,Destruction (action),Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
2b3bc81f-37a8-4c92-8954-782251ae8a7e,C4511035,C1269799,is with other ,Isolated thrombocytopenia,Additional pathologic finding in tumor specimen,1,X,[dsyn],[clna],,
bd11a6f6-0585-41e3-ba89-78f5113462b7,C0020336,C0003811,is known potentially ,Hydroxychloroquine,Cardiac Arrhythmia,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C14.280.067;C23.550.073
0c248e57-383c-4304-905f-0e59b1693758,C0026056,C1956064,was initiated for ,Midazolam,Deep Sedation,2,X,[orch/phsu],[topp],D03.633.100.079.080.575,E03.295
3dea5bb4-0e67-416c-87ae-d2071560206f,C1533734,C1956064,was initiated for ,Administration procedure,Deep Sedation,2,X,[topp],[topp],,E03.295
07050fdc-a484-4636-a9c1-a2bfd4c0c718,C0073393,C0011206,was started for ,Risperidone,Delirium,2,X,[orch/phsu],[mobd],D03.383.742.698.685,C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350
69cb598f-de70-4087-93df-690b071d4040,HCP,C0034019,were notified to Hellenic National ,HCP,public health medicine (field),1,X,????,[bmod],????,H02.403.720;N01.400.550;N06.850
fdddc884-9b5a-42cb-aa70-df2a7a8d5bf9,HCP,C0206750,is with history of occupational exposure to ,HCP,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
99ddd01b-ffca-4f97-81f2-488fcc098597,C3641730,C0005818,demonstrated distinct changes in gene expression profile of ,Cell-Free RNA,Blood Platelet Disorders,1,X,[nnon],[dsyn],D13.444.154,C15.378.140
e8de48ea-720f-49a5-a8b7-dd111f603eac,C3641730,C0206750,demonstrated distinct changes in gene expression profile of ,Cell-Free RNA,Coronavirus Infections,1,X,[nnon],[dsyn],D13.444.154,C02.782.600.550.200
2420f6e0-f74b-42d6-82d7-06c883961cb0,C0005818,C0134835,had increased basally and ,Blood Platelet Disorders,P-Selectin,1,X,[dsyn],[aapp/imft],C15.378.140,D12.776.395.550.200.700.775;D12.776.395.550.625.905;D12.776.503.843.775;D12.776.543.550.200.700.775;D12.776.543.550.625.905;D23.050.301.350.700.775
aed2074a-ef44-4e73-a4be-a130ae505e04,C0039194,C0206750,were significantly elevated in ,T-Lymphocyte,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,C02.782.600.550.200
8196de75-2ea7-4db1-8e92-19bfeb43c295,C0005778,C0302148,is with higher risk of ,Blood coagulation,Blood Clot,2,X,[ortf],[patf],G09.188.390.150,C14.907.355.830
9f5149ae-2406-4f5f-bd0b-1f640cc6f289,C0730585,C0028754,is proposed In ,Low dose heparin prophylaxis,Obesity,2,X,[topp],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
b22df833-c62c-42f4-a1b9-9bf89bf70408,C0730585,LMWH,is with intermediate LMWH,Low dose heparin prophylaxis,LMWH,2,X,[topp],????,,????
992fe8f2-3e1a-4535-8089-a117f8071518,C0028754,C0035222,is with ,Obesity,Respiratory Distress Syndrome Adult,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C08.381.840;C08.618.840
284a7373-d3bf-4be8-a84c-4934c6e8635a,C0035078,C1531698,is with ,Kidney Failure,Active monitoring,4,X,[dsyn],[topp],C12.777.419.780;C13.351.968.419.780,
0d930e1e-464d-4794-9947-0f354e56566f,C0035078,C0019139,is with ,Kidney Failure,Heparin Low-Molecular-Weight,2,X,[dsyn],[orch/phsu],C12.777.419.780;C13.351.968.419.780,D09.698.373.400.300
c7c2d3de-4904-43ea-84d3-c970eeddd51c,C0005847,C0441655,were reduced by fishing ,Blood Vessel,Activities,1,X,[bpoc],[acty],A07.015,
ebbac920-6461-4f22-8ce6-0690999469c2,C1706202,C1004593,focused on ,Search - action,Scopus,1,X,[acty],[bird],,
39540330-d85f-448e-ba1f-55b679063fa5,C0207682,C1175175,blocked 2 ,nafamostat mesilate,Severe Acute Respiratory Syndrome,2,X,[orch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
39540330-d85f-448e-ba1f-55b679063fa5,C0207682,C1175175,also inhibits 2 ,nafamostat mesilate,Severe Acute Respiratory Syndrome,1,X,[orch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
ba8ef801-3c10-45b6-9250-18e5ff2c0efe,C0312860,C1533734,is below its average ,Neutrophil migration function,Administration procedure,3,X,[celf],[topp],,
6d6eaad8-0ef9-44b3-9fbf-a17c4a580c49,C1175175,C0007634,is in ,Severe Acute Respiratory Syndrome,Cells,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11
120d9874-6cc5-49ae-8871-5d78f87ada90,C0009450,C3698360,can cause ,Communicable Diseases,Middle East Respiratory Syndrome Coronavirus,1,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150.113.750
80eebc0e-ab97-4f08-989a-9663d6afdbdd,C0118522,C0038441,making elderly susceptible to ,GA-Binding Protein Transcription Factor,Stress Disorders Traumatic,1,X,[aapp/bacs],[mobd],D12.776.260.615.249;D12.776.930.618.249,F03.950.750
4691f5df-e3db-4256-be62-4119ae601a23,C0118522,C0022709,downregulates ,GA-Binding Protein Transcription Factor,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],D12.776.260.615.249;D12.776.930.618.249,D08.811.277.656.350.350.687
6366d83a-7171-49e2-94a4-15d585dd19ae,C1879547,C0022709,downregulates ,Activation action,Peptidyl-Dipeptidase A,1,X,[acty],[aapp/enzy/imft],,D08.811.277.656.350.350.687
90ac737b-697d-4544-848e-5d9cb5fb18d1,PB125,C0022709,downregulates ,PB125,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
39def167-e67a-47be-9327-941b5959572d,C0162867,C1516048,was ,Tunica Media,Assessed,1,X,[tisu],[acty],A07.015.733,
48ec2d0f-d244-4c62-becf-74bf62f92cc2,C0162867,C0003467,was associated with more negative affect ,Tunica Media,Anxiety,1,X,[tisu],[mobd],A07.015.733,F01.470.132
c374ad0b-7d6a-4166-80c0-49eddea8fad5,C0079613,C0012634,knowledge of ,Adoptive Immunotherapy,Disease,1,X,[topp],[dsyn],E02.095.465.425.400.330.050.400;E05.478.550.520.050.400,C23.550.288
aed29f0e-7441-4b10-85d1-861fb0cc3522,C0162867,C1514593,was associated with positive ,Tunica Media,Psychological Impact,1,X,[tisu],[clna],A07.015.733,
6bd86444-4237-491e-9879-bc7799346a76,C0005768,C0012655,might have role in ,In Blood,Disease susceptibility,1,X,[bdsu],[clna],x.x.x.x.x,C23.550.291.687;G07.100.250
6bd86444-4237-491e-9879-bc7799346a76,C0005768,C0012655,role in increased ,In Blood,Disease susceptibility,1,X,[bdsu],[clna],x.x.x.x.x,C23.550.291.687;G07.100.250
203dde13-ee2e-4acf-b862-d9c1a2f9dbb5,C0005768,C0012634,role to ,In Blood,Disease,2,X,[bdsu],[dsyn],x.x.x.x.x,C23.550.288
203dde13-ee2e-4acf-b862-d9c1a2f9dbb5,C0005768,C0012634,supporting ,In Blood,Disease,1,X,[bdsu],[dsyn],x.x.x.x.x,C23.550.288
56f352ea-4fcd-4203-b3ee-3a8790184e79,C0005516,C0206750,showing correlation to mortality in ,Biological Markers,Coronavirus Infections,1,X,[clna],[dsyn],D23.101,C02.782.600.550.200
56f352ea-4fcd-4203-b3ee-3a8790184e79,C0005516,C0206750,may occur in ,Biological Markers,Coronavirus Infections,1,X,[clna],[dsyn],D23.101,C02.782.600.550.200
f6681681-420d-438d-b3d5-a0283cc87033,C0005516,C0012634,may occur correlating with severity of underlying ,Biological Markers,Disease,2,X,[clna],[dsyn],D23.101,C23.550.288
f6681681-420d-438d-b3d5-a0283cc87033,C0005516,C0012634,related to ,Biological Markers,Disease,1,X,[clna],[dsyn],D23.101,C23.550.288
6b7f5d4e-9b70-4073-9774-f70ef3b199d2,C0021966,C0013227,Speaking remotely with US graduates of Havanas Latin American School of ,Iodides,Pharmaceutical Preparations,1,X,[inch],[phsu],D01.248.497.158.490;D01.475.410,D26
aaab9ceb-7bf7-4b72-af1c-2713397aab5a,C0013227,C2742136,of School is ,Pharmaceutical Preparations,SELE protein human,1,X,[phsu],[aapp/imft],D26,x.x.x.x
d6494f29-0fc7-4797-ab75-14b8e35a99eb,C0021966,C1706374,spoke during break at home in mid ,Iodides,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[inch],[aapp/bacs],D01.248.497.158.490;D01.475.410,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
22ecdc07-a642-45b5-bf70-fd13f8ba12a2,C3146294,C0037633,collectively find ,Generation (action),Solutions,1,X,[acty],[sbst],,D26.776
ac7481ea-05f4-4cfa-9f19-d45200a2f3b0,C3536826,C1707391,were In addition to,antiviral nucleoside analog,Choose (action),6,X,[phsu],[acty],,
b6598bc2-f978-411d-b2ed-8580061f434b,C1667052,C0014442,are more effective drug candidates than ,maraviroc,Enzymes,1,X,[orch/phsu],[aapp/enzy],D02.455.426.392.368.367.726;D03.383.129.799.682,D08.811
fcc36cda-08fd-4f12-92ee-709da496cca6,C1871526,C0014442,are more effective drug candidates than ,raltegravir,Enzymes,1,X,[nnon/phsu],[aapp/enzy],,D08.811
87834ece-0ca3-465e-8b91-78d6c7cd922f,C0520510,C0206750,included patients with diagnosis of ,Materials,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
87834ece-0ca3-465e-8b91-78d6c7cd922f,C0520510,C0206750,maximize utility participating in ,Materials,Coronavirus Infections,2,X,[sbst],[dsyn],,C02.782.600.550.200
5c66bde2-31f0-4b9c-b4a0-e73cb8487884,C1175743,C0230425,for reaction is PCR,SARS coronavirus,Structure of right thigh,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,
e1cc530c-725d-401a-a31f-55e8740ec5a1,C1175743,PCR,for reaction is PCR,SARS coronavirus,PCR,1,X,[virs],????,B04.820.504.540.150.113.937,????
e1cc530c-725d-401a-a31f-55e8740ec5a1,C1175743,PCR,was determined by PCR,SARS coronavirus,PCR,1,X,[virs],????,B04.820.504.540.150.113.937,????
5fad542a-136e-4c86-b685-50f2a9b96506,C0206415,C1175743,is with ,Oligonucleotide Primers,SARS coronavirus,4,X,[nnon],[virs],D13.695.578.424.450.275;D27.720.470.530.600.223.600,B04.820.504.540.150.113.937
6ceb2af1-db46-4c69-88b9-16c58596dcb0,C2347609,C1175743,is with ,Chemical Probe,SARS coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150.113.937
beba4f9e-31d9-4f86-9a22-252aee44ab14,C0009758,C0039409,disease transmission through,conjunctiva,Tears body substance,1,X,[bpoc],[bdsu],A09.371.060.200;A09.371.337.168,A12.200.882
3020d736-28a1-4fd2-b983-057a4fba9110,C3652465,C1422064,highly upregulates ,Interferon,ACE2 gene,1,X,[aapp/imft/phsu],[gngm],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
4890771c-12be-4195-9174-a92975ad2a4b,C1742865,C0026727,is part of T2 ,TMPRSS2 protein human,Mucous body substance,1,X,[aapp/enzy],[bdsu],x.x.x.x,A12.200.503
04b753e2-4cf4-4bf3-bfe9-9626a1f2d099,C1742865,T2,is part of T2 ,TMPRSS2 protein human,T2,1,X,[aapp/enzy],????,x.x.x.x,????
6afb3977-79cc-48c2-8bab-e28c00ab552c,C1742865,C0021368,is part of T2 ,TMPRSS2 protein human,Inflammation,1,X,[aapp/enzy],[patf],x.x.x.x,C23.550.470
4ef0868e-6ce5-4778-a9b1-9279792e9710,C1742865,C3266814,is part of T2 ,TMPRSS2 protein human,Action,1,X,[aapp/enzy],[acty],x.x.x.x,
0afd3b13-123b-4559-95a4-1dc9d1ef8515,C1742865,C0214743,is part of T2 ,TMPRSS2 protein human,Interleukin-13,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
22bfd4cd-ff09-4cd4-bdb3-604ea4c5971a,C3714514,C0301872,also stimulating more pronounced cytotoxic ,Infection,Immune response,2,X,[patf],[ortf],C01.539,
d982c639-3625-4731-a5c4-c59e4790a074,C3714514,C0597404,also stimulating more pronounced cytotoxic ,Infection,Respiratory viruses,2,X,[patf],[virs],C01.539,
d89799e0-8c64-4618-8057-f5736886bb30,C3714514,C0021760,upregulate ,Infection,Interleukin-6,2,X,[patf],[aapp/imft],C01.539,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
43b2f3be-d55d-4444-9560-40cb7a480a00,C1175743,C0450442,is etiological ,SARS coronavirus,Agent,5,X,[virs],[chvf],B04.820.504.540.150.113.937,
4c4e3b44-4e71-4f6d-b56d-44a09b44f46a,C0206750,C0199470,requiring ,Coronavirus Infections,Mechanical ventilation,1,X,[dsyn],[topp],C02.782.600.550.200,
5b8c2745-c464-4c8e-aea2-470770593582,C0032105,PCR,was associated with negative conversion rate of PCR ,Plasma,PCR,1,X,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693,????
50f35b65-92d7-479b-b365-46259431f9df,invivo,C0206750,is in treatment of ,invivo,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
8da9fa75-c553-47c2-a889-70835d0b0884,invivo,C0870392,is currently matter of ,invivo,debate,1,X,????,[acty],????,
334b245e-f435-4474-b664-6502af63d8c3,C0008269,C1167024,accumulates in ,Chloroquine,food vacuole,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,
334b245e-f435-4474-b664-6502af63d8c3,C0008269,C1167024,increasing pH of ,Chloroquine,food vacuole,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,
e328b8cb-0bff-4034-a60b-f5b8703ce405,C0008269,C0024369,accumulates in ,Chloroquine,Lysosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.550
e328b8cb-0bff-4034-a60b-f5b8703ce405,C0008269,C0024369,elevating pH of acidic ,Chloroquine,Lysosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.550
bc93605d-990a-49a1-bb5f-d069e91fc73d,C0003451,C0221106,results from ,Antiviral Agents,Alkalemia,2,X,[phsu],[dsyn],D27.505.954.122.388,
046b26ed-bab1-4540-b675-92974049bff7,C0003451,C0024369,results from ,Antiviral Agents,Lysosomes,1,X,[phsu],[celc],D27.505.954.122.388,A11.284.430.214.190.875.190.550
f25412d2-a746-41ad-9046-f6145a7539a6,C0085078,C0230825,Characterization by accumulation of,Lysosomal Storage Diseases,Multivesicular body,1,X,[dsyn],[celc],C16.320.565.595;C18.452.648.595,A11.284.430.214.190.875.190.880.337.500
3f26fa6a-9923-43dd-a4d8-5acfcaa72644,C0085078,C0007634,Characterization by accumulation of,Lysosomal Storage Diseases,Cells,1,X,[dsyn],[cell],C16.320.565.595;C18.452.648.595,A11
00e756f6-287a-4b9e-a8ae-34f0ba3e1011,C0053738,C1166848,Lipid A of,bis(monoacylglyceryl)phosphate,late endosome,1,X,[bacs/orch],[celc],x.x.x.x,
d99a3c58-fbb6-4843-98b8-f85bc60e6e9e,C3687832,C0053932,induce accumulation of ,Drugs - dental services,Bone Morphogenetic Proteins,2,X,[topp],[aapp/bacs],,D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200
eb453389-442c-404d-8719-5eefdbe40656,C3687832,C1705396,induce accumulation of ,Drugs - dental services,GLI2 wt Allele,2,X,[topp],[gngm],,
b4fda7f0-cd48-4f0a-b6e3-0380acf71d0b,C0053932,C1537068,favour ,Bone Morphogenetic Proteins,Virus Internalization,1,X,[aapp/bacs],[biof],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,G06.920.881
cf896587-ff81-4486-9772-847a2c19e020,C0053932,C1704259,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Biochemical Pathway,1,X,[aapp/bacs],[moft],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,
9f1e2a3a-f23b-49c3-bc08-9d15e06dfc3f,C0053932,C0003451,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Antiviral Agents,1,X,[aapp/bacs],[phsu],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,D27.505.954.122.388
3b8a3f77-03fd-4f1c-aad3-cd28b96bd495,C0053932,C3687832,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Drugs - dental services,1,X,[aapp/bacs],[topp],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,
35e428e6-ba0e-41fd-b9c9-bd419ea838e7,C0053932,C0008269,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Chloroquine,1,X,[aapp/bacs],[orch/phsu],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,D03.633.100.810.050.180
3055eb46-29d2-44f3-8015-1ad87d2fed7f,C0053932,C0042769,play role in ,Bone Morphogenetic Proteins,Virus Diseases,1,X,[aapp/bacs],[dsyn],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,C02
21ecadeb-e358-45f2-9dcc-2af05c85b38a,C0677908,C0005515,is with ,Maintenance therapy,Biological Factors,1,X,[topp],[bacs],,D23
ecc489f5-3cfd-4b74-9e15-bbcfe237e5f1,C0021079,C0042776,have role in treatment of ,Therapeutic immunosuppression,Virus,1,X,[topp],[virs],E02.095.465.425.450;E05.478.610,B04
1ac079d0-0984-4844-b8cc-db4ebd6401b4,C0520997,C1707391,may seem like good ,Thrombolysis function,Choose (action),1,X,[clna],[acty],,
3a6120b6-32e3-481a-8980-ec91474919bf,C2939465,C0206750,is in ,Deficiency of glucose-6-phosphate dehydrogenase,Coronavirus Infections,1,X,[dsyn],[dsyn],C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402,C02.782.600.550.200
82ce9cab-e2ab-4893-924e-d8afde33a311,C0011334,C0009450,may may site of ,Dental caries,Communicable Diseases,1,X,[dsyn],[dsyn],C07.793.720.210,C01.539.221
ed1939a4-b9c4-4057-901a-550e2be449ed,C0011334,C1175743,may may site of ,Dental caries,SARS coronavirus,1,X,[dsyn],[virs],C07.793.720.210,B04.820.504.540.150.113.937
c571cad5-f20c-42a2-923f-bc874a3b631b,C0919453,C0009450,required for ,cancer-predisposing genes,Communicable Diseases,1,X,[gngm],[dsyn],,C01.539.221
ad61b251-fc3b-4870-9c88-61de76e3f4d6,C0162633,C0028429,appears highest from ,Viral Shedding,Nose,1,X,[patf],[bpoc],G07.925,A01.456.505.733;A04.531;A09.531
257179aa-7ac0-4ed5-bcda-f9100f94082c,C1260880,C0678236,be ,Rhinorrhea,Rare Diseases,2,X,[sosy],[dsyn],,C23.550.291.906
02d18d17-dc24-467c-bdd1-2625b10e25f1,C1260880,C1457887,be ,Rhinorrhea,Symptoms,2,X,[sosy],[sosy],,
5a16a8b1-67e9-402f-ad15-7d2ace46e8e7,C1260880,C0206750,be ,Rhinorrhea,Coronavirus Infections,4,X,[sosy],[dsyn],,C02.782.600.550.200
9d512eb5-e81f-408a-b8c0-b14ecd627fba,anosmia,C1260880,is reported sinonasal ,anosmia,Rhinorrhea,1,X,????,[sosy],????,
4e8e88cd-009d-47a4-a679-336b7a1a60de,C0700148,C0678236,appears ,Congestion,Rare Diseases,1,X,[patf],[dsyn],,C23.550.291.906
96f10827-3979-44b5-8bf2-9d3fa77d5bc4,C0700148,C1457887,appears ,Congestion,Symptoms,1,X,[patf],[sosy],,
332d6733-f0f4-41fb-ace5-b2586688e4ed,C0700148,C0206750,appears ,Congestion,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
f8885b89-51ab-41ab-a5f2-8e431837f03a,C0162633,C0242781,may may important ,Viral Shedding,disease transmission,1,X,[patf],[patf],G07.925,N06.850.310
4f3d04ac-cb54-4bce-addb-043eeacccbf2,C0162633,C0010356,may may important ,Viral Shedding,Cross Infection,1,X,[patf],[patf],G07.925,C01.539.248;C23.550.291.875.500
072cf534-eae3-4187-bdc5-a76bfcae13c6,C1711241,C0009450,may may site of ,Sinonasal Tract,Communicable Diseases,1,X,[bpoc],[dsyn],,C01.539.221
03aa6d5e-125e-41d8-9e94-395b82937657,C1704259,C1882509,is in ,Biochemical Pathway,put - instruction imperative,2,X,[moft],[acty],,
b2e013fc-764d-4bbf-9e8b-93e2e8c9154c,C1706202,C0009450,can Providing (action) additional tool for,Search - action,Communicable Diseases,2,X,[acty],[dsyn],,C01.539.221
e5d7ea78-a6ea-4e88-8cf0-d7d5221ba07c,DOH,C0206750,initiated nationwide surveillance program for ,DOH,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
390f9a78-deca-4f2e-ae16-fe757eac779e,C0038280,C0020281,using low temperature process ,Sterilization for infection control,Hydrogen Peroxide,1,X,[topp],[inch/irda/phsu],N06.850.780.200.450.850,D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253
12040020-aaee-43b1-91db-c595c75fc2f0,C2976467,C0024109,improve Respiration at several,EPO protein human,Lung,1,X,[aapp/bacs],[bpoc],x.x.x.x,A04.411
31a0213a-364c-43de-af13-edec737403b2,C2976467,C0035203,improve ,EPO protein human,Respiration,1,X,[aapp/bacs],[phsf],x.x.x.x,G09.772.705
49a08976-e278-4da7-a7dd-a2953029e87c,C1516048,C0011849,is in people with ,Assessed,Diabetes Mellitus,1,X,[acty],[dsyn],,C18.452.394.750;C19.246
76a17e1a-d0f7-4770-9d3f-ef063f744488,C0042487,COVID-19,is in ,Venous Thrombosis,COVID-19,1,X,[patf],[virs],C14.907.355.830.925,C000657245
fdd437d5-f469-493f-b2a9-90785fa4f679,C0042487,C1175743,was markedly higher in patients with CoV2,Venous Thrombosis,SARS coronavirus,1,X,[patf],[virs],C14.907.355.830.925,B04.820.504.540.150.113.937
490bc4f8-c31a-42a6-9927-8cc7bb177e72,C0042487,CoV2,was markedly higher in patients with CoV2,Venous Thrombosis,CoV2,1,X,[patf],????,C14.907.355.830.925,????
3c48eb62-ec2c-464f-8920-b35d40f09d6b,C0149871,COVID-19,is in ,Deep Vein Thrombosis,COVID-19,1,X,[dsyn],[virs],C14.907.355.830.925,C000657245
30f87876-bd73-4b8f-af0d-66facc7622fc,COVID-19,C0199242,should receive ,COVID-19,Anticoagulant prophylaxis,1,X,[virs],[topp],C000657245,
712270a6-27b3-4658-8de7-9417c5c85650,COVID-19,C0019139,should receive Anticoagulant prophylaxis with,COVID-19,Heparin Low-Molecular-Weight,1,X,[virs],[orch/phsu],C000657245,D09.698.373.400.300
26a8fe4c-0ed7-4c31-9f66-b50d9aa401c7,C1511790,CoV2,is in CoV2,Detection,CoV2,1,X,[topp],????,,????
ba5eb17e-87e1-4129-8c9f-cd8dd45a419b,C0042776,C0039409,is in ,Virus,Tears body substance,1,X,[virs],[bdsu],B04,A12.200.882
0dbc1025-db6f-4342-88d1-661b10358297,C0206750,C0018681,are classified into Central Nervous System related ,Coronavirus Infections,Headache,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.592.612.441
0dbc1025-db6f-4342-88d1-661b10358297,C0206750,C0018681,followed by ,Coronavirus Infections,Headache,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.592.612.441
0dbc1025-db6f-4342-88d1-661b10358297,C0206750,C0018681,also reported ,Coronavirus Infections,Headache,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.592.612.441
2805f985-127a-4476-9022-ac77939a292c,C0206750,C0009676,has In regard has associated with neurological anosmia ,Coronavirus Infections,Confusion,1,X,[dsyn],[mobd],C02.782.600.550.200,C10.597.606.337;C23.888.592.604.339;F01.700.250
2b67d83d-0313-4e21-aab8-892af4b59ec7,C0206750,anosmia,has In regard has associated with neurological anosmia ,Coronavirus Infections,anosmia,1,X,[dsyn],????,C02.782.600.550.200,????
41b0f729-1dd9-4f7f-bcaf-8f16f6113256,C0206750,C2364111,has In regard has associated with neurological anosmia ,Coronavirus Infections,Ageusia,1,X,[dsyn],[sosy],C02.782.600.550.200,C10.597.751.861.184;C23.888.592.763.861.184
f55ecd47-d51d-47fa-b9be-e8ba4680dbf1,C0035668,C0444279,was absent in six ,RNA,Respiratory sample,1,X,[nnon],[bdsu],D13.444.735,
e2c60b74-842b-4f62-a591-7314d7d26fe7,C1175743,sera,was absent in acute sera,SARS coronavirus,sera,1,X,[virs],????,B04.820.504.540.150.113.937,????
99deccd1-8cd7-4ce9-a3d9-63477acdf4fe,C0003261,sera,was absent in acute sera,Antibody Formation,sera,1,X,[biof],????,G12.070,????
36272364-7c8e-425c-8772-700aeedad55c,C1175743,C0458578,is in ,SARS coronavirus,Upper respiratory tract,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,
ae5591d0-9c86-4daf-92c9-ec2467866f96,C0023895,C0023884,clinical implications on ,Liver diseases,Liver,1,X,[dsyn],[bpoc],C06.552,A03.620
e4560485-9fdf-4148-bf61-06e6d8711b2a,C0012634,C0027926,is in department of ,Disease,Science of neurosurgery,2,X,[dsyn],[bmod],C23.550.288,H02.403.810.425
35524cd2-32b1-4756-95ef-66ac908b0297,C4042934,C0026882,is in viral ,Mutation Accumulation,Mutation,2,X,[genf],[genf],G05.365.590.594,G05.365.590
20a7d59d-2707-4246-9300-a891875fafa4,C0242781,C0023745,emphasize extent of global epidemiological ,disease transmission,genetic linkage,2,X,[patf],[moft],N06.850.310,G05.348
02726210-6039-4613-a6a1-6e275f7a1c69,C1704259,C0042776,emphasize ,Biochemical Pathway,Virus,1,X,[moft],[virs],,B04
dbab658c-49a5-4761-b6ef-6b5a80320422,C1704259,C1293116,emphasize ,Biochemical Pathway,Introduction procedure,1,X,[moft],[topp],,
c297edbf-b651-4344-9cc1-2be8e0d8c679,C1697446,C3698360,causes severe disease similar to those caused by ,Genital Viral Infections,Middle East Respiratory Syndrome Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.750
1e76402a-aaf1-48d0-92db-c1a1799634ad,C0010356,C0019004,resulted from human-to-human transmission in ,Cross Infection,Hemodialysis,1,X,[patf],[topp],C01.539.248;C23.550.291.875.500,E02.870.300;E02.912.800
3155b323-5b64-471a-b632-4824ca700965,C0019004,HD,is in HD ,Hemodialysis,HD,1,X,[topp],????,E02.870.300;E02.912.800,????
862a1179-9bc7-4776-8939-e96c901e1a1f,C0242781,C0441655,implementing preemptive ,disease transmission,Activities,1,X,[patf],[acty],N06.850.310,
07050cd4-9171-452a-a9f2-6f892de1795a,C0242781,C3841812,can can controlled without closure of ,disease transmission,In center hemodialysis,1,X,[patf],[topp],N06.850.310,
e693ca74-5047-4811-91fe-191b9548df9b,C0206750,C3841812,can can controlled without closure of ,Coronavirus Infections,In center hemodialysis,1,X,[dsyn],[topp],C02.782.600.550.200,
d445571e-a1a2-4eff-b483-8240bbf8bc17,C0010076,C3272452,is family of ,Coronaviridae,Single-Stranded RNA,4,X,[virs],[nnon],B04.820.504.540,
39aa50c4-df0b-4359-97ca-88eb428611fa,C0010076,C0042776,is family of ,Coronaviridae,Virus,2,X,[virs],[virs],B04.820.504.540,B04
fe9a29e4-8817-48f1-8ca4-a3b89b2e3e1d,C3698360,C0221423,causing severe respiratory ,Middle East Respiratory Syndrome Coronavirus,Illness (finding),2,X,[virs],[sosy],B04.820.504.540.150.113.750,
671646d9-1a31-4938-bca6-eddbe6f9be50,C3698360,C4284302,causing epidemics in ,Middle East Respiratory Syndrome Coronavirus,EHD1 wt Allele,2,X,[virs],[gngm],B04.820.504.540.150.113.750,
671646d9-1a31-4938-bca6-eddbe6f9be50,C3698360,C4284302,causing Illness (finding) in,Middle East Respiratory Syndrome Coronavirus,EHD1 wt Allele,2,X,[virs],[gngm],B04.820.504.540.150.113.750,
9e73a337-a46e-4842-9881-4d4c808dcaf2,C0206750,C0815353,is in ,Coronavirus Infections,Male external urethral sphincter,1,X,[dsyn],[bpoc],C02.782.600.550.200,
9a8c3e74-f737-4029-973f-11d60e2ca1e0,C0011206,C0002395,may increase need for treatment of ,Delirium,Alzheimer's Disease,1,X,[mobd],[dsyn],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C10.228.140.380.100;C10.574.945.249;F03.615.400.100
3a873742-cce4-4dc4-ae32-63175eab676d,C0003130,COVID-19,clinical aspects of,Anoxia,COVID-19,1,X,[patf],[virs],C23.888.852.079,C000657245
44cefed5-f41c-450c-bee7-54d87e1584ee,C0011206,C0003130,caused by ,Delirium,Anoxia,1,X,[mobd],[patf],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C23.888.852.079
8755cba4-d433-44ff-8bdb-1457ac73af56,C0011206,COVID-19,is in ,Delirium,COVID-19,2,X,[mobd],[virs],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C000657245
2a5ebf8f-33f3-474f-b0a4-56151c91ca4c,C0011206,C0683325,caused by ,Delirium,clinical aspects,1,X,[mobd],[clna],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,
40e8e457-e110-40f6-9965-da365e827721,C0687133,COVID-19,receiving ,Drug Interactions,COVID-19,2,X,[patf],[virs],G07.690.773.968,C000657245
401cafbc-f23e-42b9-a80e-9154bca99b5f,C0687133,C0002395,should Therefore should considered in ,Drug Interactions,Alzheimer's Disease,1,X,[patf],[dsyn],G07.690.773.968,C10.228.140.380.100;C10.574.945.249;F03.615.400.100
4dad4ed0-d3de-4d14-9b8a-d53c4c7ecd9f,C1514559,C1290886,is responsible In ,Protein Overexpression,Chronic inflammatory disorder,2,X,[genf],[dsyn],,
f11be4a2-cee7-4da8-b45c-3b1b85ebe777,C1514559,C0023516,is in ,Protein Overexpression,Leukocytes,1,X,[genf],[cell],,A11.118.637;A15.145.229.637;A15.382.490
a26f81fb-91d3-488b-8f9d-1185d5923108,C0013227,C0008269, includes ,Pharmaceutical Preparations,Chloroquine,4,X,[phsu],[orch/phsu],D26,D03.633.100.810.050.180
ae87c0d1-f0e1-4a9c-bbec-b9565c0d709d,C0052796,C1153410,strongly suppressed ,Azithromycin,channel activity,1,X,[antb/orch],[moft],D02.540.576.500.992.050,
1d2c045d-ac6e-4b02-a831-9b9c104d0c83,C0052796,C0024264,strongly suppressed ,Azithromycin,Lymphocyte,1,X,[antb/orch],[cell],D02.540.576.500.992.050,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
8638bcec-a275-452c-834b-8433ebcda24f,C0013227,C1153410,strongly suppressed ,Pharmaceutical Preparations,channel activity,1,X,[phsu],[moft],D26,
74b1c90b-82ec-42ee-8958-7212b596b217,C0013227,C0024264,strongly suppressed ,Pharmaceutical Preparations,Lymphocyte,1,X,[phsu],[cell],D26,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
c88a9779-8d59-4a0a-a207-0433859c7798,C0008269,C1153410,strongly suppressed ,Chloroquine,channel activity,1,X,[orch/phsu],[moft],D03.633.100.810.050.180,
403c5b00-4051-4c25-a1b8-846e2b1d02d0,C0008269,C0024264,strongly suppressed ,Chloroquine,Lymphocyte,1,X,[orch/phsu],[cell],D03.633.100.810.050.180,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
9679582f-db03-462f-8473-7939d2ebbaf6,C0079189,C0699748,are responsible for ,cytokine,Pathogenesis,2,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,
2618f166-694b-47fc-ae43-4833a8375a2b,C1175743,C4546913,required ,SARS coronavirus,Oxygen-19,1,X,[virs],[elii],B04.820.504.540.150.113.937,x.x.x.x
b7667808-d69a-4fc1-b770-59bc6f081a02,C1175743,C0242297,required ,SARS coronavirus,Dietary Supplementation,1,X,[virs],[topp],B04.820.504.540.150.113.937,
1b5e9278-d4d7-4c32-9921-8f6e2503fb6b,COVID-19,C0199470,required ,COVID-19,Mechanical ventilation,1,X,[virs],[topp],C000657245,
1100abe8-38bc-4fed-b793-5a26d6ac9595,C1175743,C0199470,required ,SARS coronavirus,Mechanical ventilation,1,X,[virs],[topp],B04.820.504.540.150.113.937,
858e56bb-3a6f-4bf3-9ad1-8dcc83a9f624,C0023530,C1175743,were significantly more common in ,Leukopenia,SARS coronavirus,2,X,[dsyn],[virs],C15.378.553.546,B04.820.504.540.150.113.937
e0081f06-b5be-4f24-a2a7-7cb04dea4983,C0024312,C1175743,were significantly more common in ,Lymphopenia,SARS coronavirus,2,X,[dsyn],[virs],C15.378.553.546.605;C20.673.627,B04.820.504.540.150.113.937
f2ead6a4-da8a-485f-8f77-0e37a8400e1a,C0023530,COVID-19,were significantly common than ,Leukopenia,COVID-19,2,X,[dsyn],[virs],C15.378.553.546,C000657245
29df9147-1c2f-40f7-9402-ff18f6c9aacf,C0596448,C0242656,Characteristically is associated with ,dimer,Disease Progression,1,X,[chvs],[patf],,C23.550.291.656
3ac4d61b-c974-4fe4-b77e-71b6637052c4,C1175175,C0301872,triggers ,Severe Acute Respiratory Syndrome,Immune response,2,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,
e5bda514-f1d5-4e38-8ead-db5fcddd4673,C0398623,C0003280,necessitate ,Thrombophilia,Anticoagulants,1,X,[dsyn],[phsu],C15.378.925,D27.505.954.502.119
5c8cf1f4-a71c-4de9-9037-dbb6a47ccef3,C0398623,C0040018,reduce excessive ,Thrombophilia,Thrombin,1,X,[dsyn],[aapp/enzy/phsu],C15.378.925,D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960
8fa8d16c-2260-4c34-8e87-8d491c492f4a,C0398623,C0019116,preserving adaptive ,Thrombophilia,Hemostatic function,1,X,[dsyn],[ortf],C15.378.925,G09.188.390
2828832e-4e5f-4e0c-91fd-4dd3a2076703,C0398623,COVID-19,bring benefit via ,Thrombophilia,COVID-19,1,X,[dsyn],[virs],C15.378.925,C000657245
beda9834-f4fa-4a5a-8a15-fe55a53e4ec4,C0028754,C0301872,is in ,Obesity,Immune response,1,X,[dsyn],[ortf],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
f39f3a90-83f0-464c-aab4-9c7f82d6fb01,C0034848,C1452534,might might ,Receptors Virus,ACE protein human,1,X,[aapp/rcpt],[aapp/bacs],D12.776.543.750.830,x.x.x.x
5a011634-fe83-45cb-89b9-000535786485,C0103306,C0031843,is with quite balancing barbell ,angiotensin I (1-7),physiological aspects,1,X,[aapp/phsu],[phsf],x.x.x.x,x.x.x.x
069e1b3a-e91e-4f62-ae37-cdda2219c4cd,C0030956,C0003009,converting ,Peptides,angiotensin II,1,X,[aapp/phsu],[aapp/bacs/phsu],D12.644,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
29a50c22-8e28-4c5a-9705-caf979794f42,C0030956,C0103306,converting angiotensin II into,Peptides,angiotensin I (1-7),1,X,[aapp/phsu],[aapp/phsu],D12.644,x.x.x.x
b00bebee-5215-432d-b244-200b41db93e2,C0030956,C0031843,converting angiotensin II into,Peptides,physiological aspects,1,X,[aapp/phsu],[phsf],D12.644,x.x.x.x
2dafb095-f2f8-49a2-8e34-3b75bfe19eb6,C0003009,C0030956,is profoundly active ,angiotensin II,Peptides,1,X,[aapp/bacs/phsu],[aapp/phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D12.644
3b7ced16-b007-4791-9f10-7c091ee8b4f7,C2986569,C1452534,usurp ,Buildup,ACE protein human,1,X,[sbst],[aapp/bacs],,x.x.x.x
1c98d9e5-2b68-4384-a220-916a7957b55e,C0087111,C0914912,blockade of ,Therapeutic procedure,Bradykinin B2 Receptor,1,X,[topp],[aapp/rcpt],E02,D12.776.543.750.695.080.500;D12.776.543.750.720.600.220.500;D12.776.543.750.750.555.220.500
550aff6f-57d7-4537-a847-6c7e41d4c94a,C3463820,C0003641,using ,Inhibition,Aprotinin,1,X,[acty],[aapp/bacs/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,D12.776.083
9ca8a53b-eb59-46bd-89a0-97eb9b353459,C0087111,C0003641,using ,Therapeutic procedure,Aprotinin,1,X,[topp],[aapp/bacs/phsu],E02,D12.776.083
bca10222-53ed-4d8f-99a4-03d5f2b4f80d,C3463820,C1722685,using ,Inhibition,ecallantide,1,X,[acty],[aapp/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
2721ed46-bdad-443e-ae09-fe59900ebed6,C0087111,C1722685,using ,Therapeutic procedure,ecallantide,1,X,[topp],[aapp/phsu],E02,x.x.x.x
5e3e10cf-47e0-4655-ada7-0b4ccfb60f70,C3463820,C0246269,using ,Inhibition,icatibant,1,X,[acty],[aapp/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
b1fd6b91-55cd-4f3e-a5da-2d8a68d12f00,C0087111,C0246269,using ,Therapeutic procedure,icatibant,1,X,[topp],[aapp/phsu],E02,x.x.x.x
f85a6309-1b53-4664-bd17-f9c048e7f8ef,C0087111,C3549397,Inhibition of,Therapeutic procedure,bradykinin biosynthetic process,1,X,[topp],[moft],E02,
565d34bc-788d-42dd-8fd0-6b7c15bca958,C3463820,C0087111,hold ,Inhibition,Therapeutic procedure,1,X,[acty],[topp],F01.145.544;F02.463.425.475;F02.739.794.405,E02
aebfc389-8134-4408-8756-a137d5174607,C1512796,C1175743,carry risk of ,Insertion Mutation,SARS coronavirus,1,X,[genf],[virs],E05.393.420.601.550;G05.365.590.575;G05.558.550,B04.820.504.540.150.113.937
373d3171-848f-4192-83f1-b24b0ec5d802,C0242821,C0024501,worldwide recognized could achieved by ,Human body,Maintenance,4,X,[humn],[acty],I01.076.201.450.560;K01.093.378,N02.628
fff8188e-9667-4894-b944-a73b6ebc825a,C3643615,C0024501,could could only achieved by ,Triumph,Maintenance,2,X,[elii/phsu],[acty],,N02.628
159422c0-cee2-4a06-ad1e-0f65f560b5eb,C0042776,C1825598,has had direct ,Virus,IMPACT gene,1,X,[virs],[gngm],B04,
7a7644c7-78ed-4e83-ba53-ddd8dce66c86,C0016143,C1947933,is essential ,First Aid,care activity,2,X,[topp],[acty],E02.365.305,
01623882-6bc4-49d0-847b-cf706c4b874a,C0010332,C2948600,is needed With ,Crisis Intervention,Aim,2,X,[topp],[inch/phsu],F04.754.252,
a28d244c-0eb7-4ff3-b767-355a91e1e673,C0010332,C0206419,is needed With ,Crisis Intervention,Genus: Coronavirus,1,X,[topp],[virs],F04.754.252,B04.820.504.540.150
846b4621-9e38-4661-8adc-f29ed904fc90,C0087111,C0003204, includes ,Therapeutic procedure,Anti-Infective Agents,3,X,[topp],[phsu],E02,D27.505.954.122
fa2d8af3-38aa-4320-bfb2-f420e332467d,C0543467,C0087111,routinely give symptomatic ,Operative Surgical Procedures,Therapeutic procedure,1,X,[topp],[topp],E04,E02
eef33933-a315-430f-a092-4d25c776ed85,C0543467,C0003204,routinely give symptomatic ,Operative Surgical Procedures,Anti-Infective Agents,1,X,[topp],[phsu],E04,D27.505.954.122
d46b87d0-d0e8-4630-aef7-51fb3a3898db,C0014695,C0339901,decreases ,Ergocalciferol,Acute respiratory infections,1,X,[orch/phsu/vita],[dsyn],D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,
996227ce-556f-456a-b425-91f3959c825f,C0042870,C0339901,is easily modifiable factor of ,Vitamin D Deficiency,Acute respiratory infections,1,X,[dsyn],[dsyn],C18.654.521.500.133.770,
cc5d6310-33ca-461d-8e3f-d372f542c271,C1175743,C1327414,caused hypoxemia of ,SARS coronavirus,cytokine secretion,2,X,[virs],[celf],B04.820.504.540.150.113.937,
a1bda063-ff60-4bce-be2c-2a3a605cf545,C0428692,C0206750,have effect on ,Ambient temperature,Coronavirus Infections,1,X,[npop],[dsyn],,C02.782.600.550.200
0647e8a2-4f5a-405a-b29c-7fb189e752a1,C0023175,C1167395,expand ,Lead,Host (organism),1,X,[elii/hops],[orgm],D01.268.556.435;D01.552.544.435;x.x.x.x,
b9eb1540-f51e-47f2-b52b-64a2b610b06d,studys,C0206750,apply morphoproteomics from forensic autopsy of ,studys,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
821422e7-febd-406f-9ae9-112626540f68,C3812159,C0242629,relative paucity of ,FAM49B wt Allele,CD8-Positive T-Lymphocytes,2,X,[gngm],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
821422e7-febd-406f-9ae9-112626540f68,C3812159,C0242629,rare PD-1 as ,FAM49B wt Allele,CD8-Positive T-Lymphocytes,1,X,[gngm],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
67fe9c63-d74e-4593-8503-1389ad5c8eb7,C0152060,C4322733,absence of ,Transection (procedure),CD56+ NK cell,2,X,[topp],[cell],,
1230e2b5-6c2e-46c5-bae3-8121605c43e4,C0024115,C4322733,absence of ,Lung diseases,CD56+ NK cell,4,X,[dsyn],[cell],C08.381,
c5cacbf9-868d-46d5-a338-333d768c6ecf,C0206750,C4322733,absence of ,Coronavirus Infections,CD56+ NK cell,2,X,[dsyn],[cell],C02.782.600.550.200,
d8233e23-a73f-4188-b512-4a5a90bc6d4a,C0152060,C0253050,nuclear expression of p ,Transection (procedure),Stat3 protein,1,X,[topp],[aapp/bacs],,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
3d773e88-6cb8-4209-95cf-3c31c0bd8874,C0024115,C0253050,nuclear expression of p ,Lung diseases,Stat3 protein,2,X,[dsyn],[aapp/bacs],C08.381,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
ddd47fd1-41a1-43e6-83d9-313b7b23e36a,C0206750,C0253050,nuclear expression of p ,Coronavirus Infections,Stat3 protein,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
db0ce9c5-e2d1-4908-8f49-af2cff5ccf30,C3812159,C4322733,absence of ,FAM49B wt Allele,CD56+ NK cell,2,X,[gngm],[cell],,
6469ccaa-9b4c-4269-95ac-c23df42b2162,C0024115,C0242629,relative paucity of ,Lung diseases,CD8-Positive T-Lymphocytes,4,X,[dsyn],[cell],C08.381,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
6469ccaa-9b4c-4269-95ac-c23df42b2162,C0024115,C0242629,rare PD-1 as ,Lung diseases,CD8-Positive T-Lymphocytes,2,X,[dsyn],[cell],C08.381,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
098fc9df-3215-4be6-a890-50069904346c,C0206750,C0242629,relative paucity of ,Coronavirus Infections,CD8-Positive T-Lymphocytes,2,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
098fc9df-3215-4be6-a890-50069904346c,C0206750,C0242629,rare PD-1 as ,Coronavirus Infections,CD8-Positive T-Lymphocytes,1,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
648ecfe3-c08d-4951-9034-83e4a31c6943,C0152060,C1570089,abundance of intra-alveolar interstitial ,Transection (procedure),CD163 protein human,1,X,[topp],[aapp/imft],,
dc6b7613-4976-4679-b355-a9af77c4b014,C0024115,C1570089,abundance of intra-alveolar interstitial ,Lung diseases,CD163 protein human,2,X,[dsyn],[aapp/imft],C08.381,
6c579adb-328d-49d2-b184-815912b4a4d7,C0206750,C1570089,abundance of intra-alveolar interstitial ,Coronavirus Infections,CD163 protein human,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,
29032d71-b590-4dc3-a3f2-4ddae6b67a7e,C3812159,C1570089,abundance of intra-alveolar interstitial ,FAM49B wt Allele,CD163 protein human,1,X,[gngm],[aapp/imft],,
183e55e4-1fb4-4d14-b453-3d8ef74a33f8,C0152060,C0041484,nuclear expression of ,Transection (procedure),MONOPHENOL MONOOXYGENASE,1,X,[topp],[aapp/enzy],,D08.811.682.690.708.125.500
39d95e15-2d40-4ef0-872e-6c6048eff60a,C0024115,C0041484,nuclear expression of ,Lung diseases,MONOPHENOL MONOOXYGENASE,2,X,[dsyn],[aapp/enzy],C08.381,D08.811.682.690.708.125.500
8a3cc247-a71a-4f83-af39-efd4fbfc5f83,C0206750,C0041484,nuclear expression of ,Coronavirus Infections,MONOPHENOL MONOOXYGENASE,1,X,[dsyn],[aapp/enzy],C02.782.600.550.200,D08.811.682.690.708.125.500
3e76e4c7-4a1c-4cb1-92d4-f4f208184f01,C2985566,C0206750,could address ,Targeted Therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
d39ca941-49a0-4136-b364-5883898a7d6e,C0023779,C0161816,risk of ,Lipids,Cardiac complication,4,X,[orch],[patf],D10,
b0f866a0-6ffb-4cd5-87c4-71495a9c1005,C2003888,C0161816,risk of ,Lower (action),Cardiac complication,4,X,[acty],[patf],,
c88d1db3-b2cb-47dd-aa00-b047b0f4eb17,C0023779,C0206750,risk of ,Lipids,Coronavirus Infections,4,X,[orch],[dsyn],D10,C02.782.600.550.200
1fe18f5e-524c-4e4b-859f-5ca7f31ea426,C2003888,C0206750,risk of ,Lower (action),Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
5704e043-9e93-41d3-a4ed-10c62f1e52d7,C0023779,C0360714,is in particular ,Lipids,Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[orch],[orch/phsu],D10,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
bb4f92de-cd2a-438c-88fc-6d8d1814e5b6,C2003888,C0360714,is in particular ,Lower (action),Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[acty],[orch/phsu],,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
d6ea547f-e4a5-4609-b678-f08395b8cf9b,C1167250,C0007603,subdomains of ,lipid raft,Plasma membrane,2,X,[celc],[celc],,A11.284.149
2a6042e1-6a45-4de1-9e86-cdecb4433ccd,C0020443,C0007603,are associated with subdomains of ,Hypercholesterolemia,Plasma membrane,2,X,[dsyn],[celc],C18.452.584.500.500.396,A11.284.149
6d7904a4-d7f4-4a90-b2bc-cf947253f4f9,C0007603,C0960880,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,angiotensin converting enzyme 2,3,X,[celc],[aapp/enzy],A11.284.149,x.x.x.x
388fa2f2-b839-4542-b5bb-248b28f1080c,C0007603,C0597357,can harbour ,Plasma membrane,receptor,2,X,[celc],[aapp/rcpt],A11.284.149,
c500ad76-cc99-47ce-972d-57815d98a277,C0007603,C4281807,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,Vitronectin human,1,X,[celc],[aapp/bacs],A11.284.149,
b9b21199-b7a8-4e14-90c1-5d122c14cbbb,C0007603,C1175743,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,SARS coronavirus,2,X,[celc],[virs],A11.284.149,B04.820.504.540.150.113.937
cabe0c57-ace4-46e7-a153-ab5a7ae3f773,C0360714,C0023779,possess Activities In addition to their,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lipids,1,X,[orch/phsu],[orch],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,D10
cabe0c57-ace4-46e7-a153-ab5a7ae3f773,C0360714,C0023779,possess effects In addition to their ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lipids,1,X,[orch/phsu],[orch],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,D10
e6dde035-4d6e-4951-9999-39642e50321b,C0360714,C2003888,possess Activities In addition to their,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lower (action),1,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
e6dde035-4d6e-4951-9999-39642e50321b,C0360714,C2003888,possess effects In addition to their ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lower (action),1,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
9b7fb243-698b-4056-8cf7-35c2357382f9,C0360714,C0003209,possess pleiotropic ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Anti-Inflammatory Agents,1,X,[orch/phsu],[phsu],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,D27.505.954.158
8934176d-7767-4b45-9345-2b454f82e588,C0360714,C0441655,possess antithrombotic ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Activities,1,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
3866c560-d85e-4bb9-adce-90ba46a760c4,C1278454,C0021403,is in ,Statin prophylaxis,Influenza virus vaccine,2,X,[topp],[imft/phsu],,D20.215.894.899.302
af852fcb-bfbc-41b1-a556-eca5a5020cec,C1278454,C0009450,is in ,Statin prophylaxis,Communicable Diseases,4,X,[topp],[dsyn],,C01.539.221
7e59da47-048a-4044-8ab7-5247a76027b7,C1278454,C0005768,increase viral clearance from ,Statin prophylaxis,In Blood,2,X,[topp],[bdsu],,x.x.x.x.x
2d061025-afe0-444b-9f9c-62c67bae0724,C1278454,C0019196,increase clearance during chronic ,Statin prophylaxis,Hepatitis C,2,X,[topp],[dsyn],,C02.440.440;C02.782.350.350;C06.552.380.705.440
5b426fba-2367-4512-b349-d8c7c179b539,C0360714,C1433062,may serve as potential ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,3C-like protease SARS coronavirus,2,X,[orch/phsu],[aapp/enzy],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,x.x.x.x
12ba7601-15b1-4e9e-9afa-737960c99606,C0360714,C0243077,may serve as potential ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,inhibitors,1,X,[orch/phsu],[chvf],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
7ada2748-95e8-44c9-9a1e-44d9481bc02a,C0450254,C1819995,use Peptidyl-Dipeptidase A as its,Pathogenic organism,Host Cell,1,X,[orgm],[celc],,
2b27c6cf-a3d3-433b-86d7-d4816c03cb3e,C0450254,C0597357,use Peptidyl-Dipeptidase A as its,Pathogenic organism,receptor,1,X,[orgm],[aapp/rcpt],,
2b27c6cf-a3d3-433b-86d7-d4816c03cb3e,C0450254,C0597357,shares same ,Pathogenic organism,receptor,2,X,[orgm],[aapp/rcpt],,
28331332-194e-4de4-93ba-6d6eb1901d46,C0450254,C0022709,use ,Pathogenic organism,Peptidyl-Dipeptidase A,3,X,[orgm],[aapp/enzy/imft],,D08.811.277.656.350.350.687
28331332-194e-4de4-93ba-6d6eb1901d46,C0450254,C0022709,shares ,Pathogenic organism,Peptidyl-Dipeptidase A,2,X,[orgm],[aapp/enzy/imft],,D08.811.277.656.350.350.687
2c1f6db8-7d17-4101-8d8d-6b499140298a,C1167622,C0034987,locate at ,Binding (Molecular Function),Regulatory Sequences Nucleic Acid,2,X,[moft],[bacs/nnon],,G02.111.570.080.689;G05.360.080.689
ad3f0d91-624a-4b55-8ff6-62ed62d5bcc8,C0086418,C0014939,upregulated by ,Homo sapiens,Estrogens,1,X,[humn],[horm/orch/phsu],B01.050.150.900.649.313.988.400.112.400.400,D27.505.696.399.472.277
e368b9de-4375-44aa-911c-8ba4bc94c741,C0444626,C1175743,is considerably similar to previously reported ,Crystal Structure,SARS coronavirus,1,X,[chvs],[virs],,B04.820.504.540.150.113.937
97449185-13d5-4a33-9f1d-9cd5abb68d9a,C0199470,COVID-19,might reduce Malnutrition due to,Mechanical ventilation,COVID-19,3,X,[topp],[virs],,C000657245
f0b321b8-1751-4522-901b-0ee95a9db4a1,C0199470,C0162429,might reduce ,Mechanical ventilation,Malnutrition,3,X,[topp],[dsyn],,C18.654.521
57fefa35-0089-438e-b445-aa069f819452,C0199470,C0264490,might reduce ,Mechanical ventilation,Acute respiratory failure,3,X,[topp],[dsyn],,
c9d66a80-c185-4b0a-89c6-2c42902bb40b,C0009450,C0086418,be of zoonotic origin to ,Communicable Diseases,Homo sapiens,1,X,[dsyn],[humn],C01.539.221,B01.050.150.900.649.313.988.400.112.400.400
228286cb-61a1-429c-9bda-2f48ecb2b076,C0035204,C0032285,may progress to ,Respiration Disorders,Pneumonia,1,X,[dsyn],[dsyn],C08.618,C08.381.677;C08.730.610
8867c172-b43b-4cf4-b040-8dd8e6350441,C0035204,C0035222,may progress to ,Respiration Disorders,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C08.618,C08.381.840;C08.618.840
3e1a1eb1-290f-4d60-93f0-e9f7837790ea,C0035204,C0026766,may progress to ,Respiration Disorders,Multiple Organ Failure,1,X,[dsyn],[patf],C08.618,C23.550.835.525
edb8d9f6-c95b-498e-86b3-c526209c1198,C4298940,C0014507,were collected In course of ,Environmental specimen,Epidemiology,1,X,[sbst],[bmod],,H02.403.720.500
4b147e91-0a19-4d2b-82f4-46bffd156ec4,C4298940,C0370003,were collected from 68 ,Environmental specimen,Specimen,1,X,[sbst],[sbst],,
9ba441ac-d5ce-4cd1-ad69-dc5cff7b4d47,C0017343,C0206750,identify presence of novel ,Genes env,Coronavirus Infections,1,X,[gngm],[dsyn],G05.360.340.024.340.364.875.172;G05.360.340.358.024.875.172;G05.360.340.358.840.500.172,C02.782.600.550.200
407409f1-bec1-4be0-b697-ca56d4b5790e,C0206750,C1096155,is in ,Coronavirus Infections,Macrophage Activation Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,C20.683.515.800
941b1305-26ab-4d94-9416-083a38737bbd,C0039336,C0206750,is in ,Taste Perception,Coronavirus Infections,3,X,[ortf],[dsyn],F02.830.816.724;G11.561.790.724,C02.782.600.550.200
34980bae-04ca-4371-b74d-53f07d3f0f33,C0039336,C0009450,is in ,Taste Perception,Communicable Diseases,1,X,[ortf],[dsyn],F02.830.816.724;G11.561.790.724,C01.539.221
c715a719-d5d9-4c9e-b25b-31dee423339b,C1254373,C0206750,was identified as novel ,etiologic agent,Coronavirus Infections,2,X,[sbst],[dsyn],,C02.782.600.550.200
4202a1a7-2f21-4fff-ad24-258ee73add16,C1254373,C0039082,was identified as novel ,etiologic agent,Syndrome,1,X,[sbst],[dsyn],,C23.550.288.500
4202a1a7-2f21-4fff-ad24-258ee73add16,C1254373,C0039082,is related to ,etiologic agent,Syndrome,1,X,[sbst],[dsyn],,C23.550.288.500
0d33f858-b94d-4727-b1ad-19515b883f53,C1537068,C0014597,identified on ,Virus Internalization,Epithelial Cells,1,X,[biof],[cell],G06.920.881,A11.436
0d33f858-b94d-4727-b1ad-19515b883f53,C1537068,C0014597,takes ,Virus Internalization,Epithelial Cells,1,X,[biof],[cell],G06.920.881,A11.436
8b1b517c-5ece-4348-8082-91d2b45e69aa,C1537068,C1167395,identified on ,Virus Internalization,Host (organism),1,X,[biof],[orgm],G06.920.881,
8b1b517c-5ece-4348-8082-91d2b45e69aa,C1537068,C1167395,takes ,Virus Internalization,Host (organism),1,X,[biof],[orgm],G06.920.881,
30ed948e-6d2c-4c54-a747-fc93e40b74a6,C1537068,C0022709,takes ,Virus Internalization,Peptidyl-Dipeptidase A,1,X,[biof],[aapp/enzy/imft],G06.920.881,D08.811.277.656.350.350.687
30ed948e-6d2c-4c54-a747-fc93e40b74a6,C1537068,C0022709,Specifically decreased ,Virus Internalization,Peptidyl-Dipeptidase A,1,X,[biof],[aapp/enzy/imft],G06.920.881,D08.811.277.656.350.350.687
6a0e07a9-33a8-47fa-993c-3ed07b04d3db,C1537068,C0042731,takes place upon union of ,Virus Internalization,Viral Matrix Proteins,2,X,[biof],[aapp/bacs],G06.920.881,D12.776.964.970.880.940
95dcad49-04ed-4a37-914f-36009ebd5e72,C1537068,metallo,takes place with type I transmembrane metallo ,Virus Internalization,metallo,1,X,[biof],????,G06.920.881,????
c7d49667-281a-47b1-8fd9-32711758e828,C1537068,C0007075,takes place with type I transmembrane metallo ,Virus Internalization,Carboxypeptidase,1,X,[biof],[aapp/enzy],G06.920.881,D08.811.277.656.350.245
8ce9b9fb-88e7-48f5-925f-1243451ce9c0,C0079189,C0021760, includes IP10 ,cytokine,Interleukin-6,2,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
8c0be1c2-c822-4769-a45d-a05ae785dd35,C0319157,C0220781,triggers ,AS virus,Anabolism,2,X,[virs],[biof],,G03
5d4f4071-c646-428f-a7a0-459a2732522a,C0319157,C0079189,triggers ,AS virus,cytokine,1,X,[virs],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
f7e9d04f-431a-4936-9e3a-e4192b19e5f0,C0319157,C0021760,triggers ,AS virus,Interleukin-6,1,X,[virs],[aapp/imft],,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
699417bf-e20b-4004-bbac-2711531fb2b9,C0319157,C0013081,also promotes ,AS virus,Down-Regulation,1,X,[virs],[moft],,G02.111.240;G05.308.200;G07.690.773.937
dac58e14-ba71-46cd-b74e-0030b582f8e6,C0003009,C1514559,promoting ,angiotensin II,Protein Overexpression,1,X,[aapp/bacs/phsu],[genf],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
a412048b-5cd7-4db6-9c30-f6b4ca88c990,C0003009,C0040048,promoting ,angiotensin II,Thromboplastin,1,X,[aapp/bacs/phsu],[aapp/imft],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D12.776.124.125.900;D23.119.965
812cd2ca-5793-456c-8bd7-1397a11adba5,C0003009,C0005821,promoting ,angiotensin II,Blood Platelets,1,X,[aapp/bacs/phsu],[cell],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,A11.118.188;A15.145.229.188
c877b39c-93ca-4672-be95-c7f302cf35a6,C1514559,C0005821,is in ,Protein Overexpression,Blood Platelets,1,X,[genf],[cell],,A11.118.188;A15.145.229.188
b61e762d-43d4-40f9-94a5-74f077c2432e,C0040048,C1363844,may may critical ,Thromboplastin,Mediator of activation protein,1,X,[aapp/imft],[aapp/bacs],D12.776.124.125.900;D23.119.965,
4cb5052a-38ec-41d9-b403-0821769b3559,C0040048,C0206750,may may critical ,Thromboplastin,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.776.124.125.900;D23.119.965,C02.782.600.550.200
972ad76a-bdd9-42c7-9e27-76d81c9659e1,55-item,C1825598,investigate ,55-item,IMPACT gene,1,X,????,[gngm],????,
bec99d39-0980-4457-9340-d7d3693c447d,55-item,C0206750,investigate ,55-item,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
b642b02b-0b05-44c9-9ae1-bcf400da4289,C0206750,C0423866,had global ,Coronavirus Infections,Lanugo,2,X,[dsyn],[bpoc],C02.782.600.550.200,A17.360
af938c6c-af59-473e-a1d4-a786f37908f4,C0042075,C0442867,were affected than those for ,Urologic Diseases,malignant disease,1,X,[dsyn],[dsyn],C12.777;C13.351.968,
4c3dc4bb-f344-497e-a286-4ebb60853a0e,C3272452,C0598312,is with specific roles in ,Single-Stranded RNA,DNA Replication,2,X,[nnon],[genf],,G02.111.225;G05.226
beb45436-d55b-4989-9a69-78ffc7eb60e4,C0319157,C0598312,is with specific roles in ,AS virus,DNA Replication,2,X,[virs],[genf],,G02.111.225;G05.226
dd78d8cd-058c-4fad-a265-72c22c734669,C3272452,C0206419,is with specific roles in ,Single-Stranded RNA,Genus: Coronavirus,2,X,[nnon],[virs],,B04.820.504.540.150
601c6356-cefa-4759-978a-497673f6beeb,C0442893,C0037284,may may associated with ,Systemic disease,Skin lesion,2,X,[dsyn],[dsyn],,
27d0475d-d84d-48bb-bf1b-4f35346ca6ea,C0037284,C0683325,similar with ,Skin lesion,clinical aspects,2,X,[dsyn],[clna],,
235252d6-9320-4655-b250-8966609f8350,C0037284,C0011609,similar with ,Skin lesion,Drug Eruptions,1,X,[dsyn],[dsyn],,C17.800.174.600;C20.543.206.380;C25.100.468.380
f947ec98-b8b0-44db-879e-a4656e85a454,C0037284,C0008058,similar to ,Skin lesion,Chilblains,2,X,[dsyn],[dsyn],,C26.212.500.217;C26.417.217
a2ed98e2-52c1-4860-a2c5-6daa8f8b9d47,C0037274,C1175743,is with ,Dermatologic disorders,SARS coronavirus,2,X,[dsyn],[virs],C17.800,B04.820.504.540.150.113.937
37a435f7-30e9-4cb1-991f-85908f155150,C0018939,C0024312,exhibits ,Hematological Disease,Lymphopenia,2,X,[dsyn],[dsyn],C15.378,C15.378.553.546.605;C20.673.627
e6a5ef39-68e2-45d2-b180-2ddf8518dd7a,C0018939,C0023530,exhibits ,Hematological Disease,Leukopenia,2,X,[dsyn],[dsyn],C15.378,C15.378.553.546
3bb6dea0-cef9-48ae-97fe-f5b8c35091b4,C0004623,C0021403,have In ,Bacterial Infections,Influenza virus vaccine,2,X,[dsyn],[imft/phsu],C01.252,D20.215.894.899.302
fe695960-77ab-459a-aaa7-7e842b364eaf,=-RRB-,C0206545,is with ,=-RRB-,Human respiratory syncytial virus,1,X,????,[virs],????,B04.820.455.600.670.600.750.730
cc786fcd-f82e-48a2-bdcf-3fde87627da5,C0004623,C0206750,low proportion of ,Bacterial Infections,Coronavirus Infections,2,X,[dsyn],[dsyn],C01.252,C02.782.600.550.200
ac9895c9-9131-4c30-af80-7213150b0715,C0003611,C0003615,is in ,Appendectomy,Appendicitis,2,X,[topp],[dsyn],E04.210.078,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
76f46cea-4934-4a10-9718-77a84e11da2e,C0003611,C0018026,is ,Appendectomy,Gold,1,X,[topp],[elii/phsu],E04.210.078,D01.268.556.322;D01.268.956.186;D01.552.544.322;x.x.x.x
180bdaf3-6142-443f-873c-54502dfb2733,C0459914,C0003237,is with intravenous ,Conservative Treatment,Antibiotics Antitubercular,1,X,[topp],[antb],E02.197,D27.505.954.122.085.255.135
89b6dd92-a4f0-4272-9a2e-420ab345875e,C0003611,C0206750,is in ,Appendectomy,Coronavirus Infections,1,X,[topp],[dsyn],E04.210.078,C02.782.600.550.200
8863a579-204c-4834-bb9f-3c0698899d3a,C0003611,C0012634,is in ,Appendectomy,Disease,1,X,[topp],[dsyn],E04.210.078,C23.550.288
37370ef4-699b-4b47-a128-8312b184dda7,C0003615,C0012634,is with 2019 novel ,Appendicitis,Disease,1,X,[dsyn],[dsyn],C01.539.463.099;C06.405.205.099;C06.405.469.110.207,C23.550.288
b869afa8-1c16-456e-96c1-1505b72d3a05,C3266262,C0206750,was diagnosed with ,Multiple Chronic Conditions,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.500.500,C02.782.600.550.200
0c37b5ff-c0a3-4744-ba68-6eaeb0efb8bb,C0015967,C3854129,was predominant ,Fever,Symptom:Find:Pt:^Patient:Nom,1,X,[sosy],[clna],C23.888.119.344,
5fa6ceb8-3e64-4473-abe0-70dbf9cb0afe,C3854129,C0206750,is in ,Symptom:Find:Pt:^Patient:Nom,Coronavirus Infections,2,X,[clna],[dsyn],,C02.782.600.550.200
3be389a6-ba0b-4402-b32b-b97f286a31fe,C3854129,C0206062,is in ,Symptom:Find:Pt:^Patient:Nom,Lung Diseases Interstitial,2,X,[clna],[dsyn],,C08.381.483
5b1b9ff4-2cc9-4767-a2fc-b9aae1fe7e8e,C0015967,C0206062,was predominant Symptom:Find:Pt:^Patient:Nom in,Fever,Lung Diseases Interstitial,2,X,[sosy],[dsyn],C23.888.119.344,C08.381.483
5b1b9ff4-2cc9-4767-a2fc-b9aae1fe7e8e,C0015967,C0206062,was predominant Symptoms in,Fever,Lung Diseases Interstitial,6,X,[sosy],[dsyn],C23.888.119.344,C08.381.483
33605588-876f-4053-9fc2-267e96e7e958,C0206750,C0038056,have ,Coronavirus Infections,Sputum,4,X,[dsyn],[bdsu],C02.782.600.550.200,A12.200.808
76c23511-71ca-41fd-ae1f-89dfd999b014,C0206750,C0011991,have ,Coronavirus Infections,Diarrhea,4,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.821.214
930d850f-c17e-4afc-865f-7060a1132d7e,C0206062,C1175743,could could vulnerable to ,Lung Diseases Interstitial,SARS coronavirus,4,X,[dsyn],[virs],C08.381.483,B04.820.504.540.150.113.937
930d850f-c17e-4afc-865f-7060a1132d7e,C0206062,C1175743,tend infected with ,Lung Diseases Interstitial,SARS coronavirus,12,X,[dsyn],[virs],C08.381.483,B04.820.504.540.150.113.937
26f2c209-d3cb-4d43-a095-e4dc2695274a,C0036845,C0206750,have potential protect from ,Sesame Oil,Coronavirus Infections,3,X,[food/orch/phsu],[dsyn],D10.212.302.380.775;D10.212.507.775;D10.627.700.865;D20.215.784.750.865;G07.203.300.375.400.725;J02.500.375.400.725,C02.782.600.550.200
d6266f8b-f42e-4691-bfc1-edb7ebe36837,C0015690,C0042776,are active against enveloped ,Fatty Acids Unsaturated,Virus,2,X,[orch],[virs],D10.251.355,B04
d6266f8b-f42e-4691-bfc1-edb7ebe36837,C0015690,C0042776,are in general active against ,Fatty Acids Unsaturated,Virus,2,X,[orch],[virs],D10.251.355,B04
ee42d067-c922-4de9-9842-75588ca14d06,C0015690,C0206750,are in general active against viruses like ,Fatty Acids Unsaturated,Coronavirus Infections,6,X,[orch],[dsyn],D10.251.355,C02.782.600.550.200
a6a617bc-6b9c-45c4-8a08-a94c42b685a3,C2349999,C0015690,incorporate high content of ,Fava Bean (Dietary),Fatty Acids Unsaturated,3,X,[food],[orch],,D10.251.355
207ae0e8-d3fc-4eb5-bf24-189c1f9719ac,C0008269,C0199244,has has used for treatment against ,Chloroquine,Antimalarial prophylaxis,1,X,[orch/phsu],[topp],D03.633.100.810.050.180,
efd99de6-e377-443f-a8ae-92a08bf9b5c8,C0008269,C0003374,has has tolerated as ,Chloroquine,Antimalarials,1,X,[orch/phsu],[phsu],D03.633.100.810.050.180,D27.505.954.122.250.100.085
a18c83ba-abf8-43d5-8656-c9f95841232f,C0852949,C0206750,is in ,Arteriopathic disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
d848cd28-e0c6-4503-a8d1-8d7bb7ea7034,C0302148,C0206750,is in ,Blood Clot,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.830,C02.782.600.550.200
b67b7111-7f08-4224-b772-00bc125a0a88,C1707455,C0920467,timing of ,Comparison,disorder control (procedure),1,X,[acty],[topp],,
1236f406-ee74-47c9-b980-c03d3a7c679a,C0021966,C0034754,have ,Iodides,Reading (activity),1,X,[inch],[dora],D01.248.497.158.490;D01.475.410,L01.559.423.557
e3960f5e-864f-4ebb-98ce-f5ce7e27c406,C0013227,C0035452,have have used in ,Pharmaceutical Preparations,Rheumatology specialty,1,X,[phsu],[bmod],D26,H02.403.429.730
aa871e25-78d5-4a39-9b86-69451076c482,C0012634,C0960756,be ,Disease,factor A,2,X,[dsyn],[orch],C23.550.288,x.x.x.x
1908b8d2-749f-4fcf-bffe-203f00fee5f6,C0012634,C0035436,be ,Disease,Rheumatic Fever,1,X,[dsyn],[dsyn],C23.550.288,C01.252.410.890.731;C05.550.114.843;C05.799.825
2aec0854-0092-4f9d-a0c6-be8d0173f431,C0038454,C0035222,developed more ,Cerebrovascular accident,Respiratory Distress Syndrome Adult,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C08.381.840;C08.618.840
c2b3456b-41c7-48c3-817a-b0f642ed102e,C1707455,C1829939,is with ,Comparison,{Non-patient},2,X,[acty],[clna],,
ca5615d7-3493-487b-9a87-c4180a8f536d,C0012634,C0021400,has emerged Like severe ,Disease,Influenza,1,X,[dsyn],[dsyn],C23.550.288,C02.782.620.365;C08.730.310
6560ec24-bc22-4e76-b21e-1fdfbee915a3,C0033684,C0042769,be altered in response to ,Proteins,Virus Diseases,4,X,[aapp/bacs],[dsyn],D12.776,C02
4cdfd185-291e-48e2-aed1-23b76f32d6ed,C0033684,C0021368,Upregulation of is line with propagation of ,Proteins,Inflammation,2,X,[aapp/bacs],[patf],D12.776,C23.550.470
0e8fbfd0-74bb-4cda-ad25-aa0e10b57b63,C0581528,C0442886,can reduce risk of ,Close observation,Secondary Infections,1,X,[topp],[dsyn],,C01.539.218;C02.219;C03.202
c2e33dd4-8ad0-4ed6-9ebd-a9a5d3bb65d6,C0282636,C1293130,led to ,Cell Respiration,Stabilization,2,X,[celf],[topp],G03.197;G04.270,
41d3a55d-26d9-481d-8c1f-8ba3b26de3e9,C0281169,C0233494, includes acute ,pulmonary complications,Tension,2,X,[patf],[mobd],,
bf953cef-ed14-40eb-bb48-340f6567e7e5,C0206750,C0027627,develop severe ,Coronavirus Infections,Neoplasm Metastasis,2,X,[dsyn],[neop],C02.782.600.550.200,C04.697.650;C23.550.727.650
36210457-c55c-446d-9cef-2c2444f7fd52,C0206750,C0281169,develop severe ,Coronavirus Infections,pulmonary complications,1,X,[dsyn],[patf],C02.782.600.550.200,
663d9dc4-9621-4198-a069-289e8cf27ee9,C0206750,C0264556,develop severe ,Coronavirus Infections,Acute pneumothorax,2,X,[dsyn],[dsyn],C02.782.600.550.200,
a95b9823-ad21-48f3-ad19-2c76986db66b,C0206750,C0233494,develop severe ,Coronavirus Infections,Tension,1,X,[dsyn],[mobd],C02.782.600.550.200,
7e714581-1dc2-41b8-842e-b09601c05186,C1537068,C0004170,datasets from healthy individuals generated by Human Cell ,Virus Internalization,Cervical Atlas,1,X,[biof],[bpoc],G06.920.881,A02.835.232.834.151.500
6b99757d-8575-4a52-99b2-7ea5da541f06,C2717801,C0040649,assessed ,Viral Tropism,Transcription Genetic,1,X,[phsf],[genf],G06.099.925;G06.920.863,G02.111.873;G05.297.700
b6382fc4-4ddf-49d6-8660-21a289ab92b9,C2717801,C0174990,assessed ,Viral Tropism,coronavirus receptor,1,X,[phsf],[aapp/rcpt],G06.099.925;G06.920.863,x.x.x.x
ea6427d1-efef-4146-8fc7-c436ac46462b,C0728888,C0155870,was exposed by national survey of patients with critically ,Enterobacter aerogenes,Pneumonia and influenza,2,X,[bact],[dsyn],B03.440.450.425.275.099;B03.660.250.150.170.049,
1db67bc6-59e6-44f8-b72b-2b29366cfdc0,C0020336,C0035435,are widely used in treatment of ,Hydroxychloroquine,Rheumatism,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C05.799;C17.300.775
118917d9-abde-4d5b-af0a-98dd6313200a,C0014898,C0013227,used other anti ,Esters,Pharmaceutical Preparations,1,X,[orch],[phsu],D02.241.400,D26
8a754960-ca22-48d2-9739-429ecb143233,C0004482,C0013227,used other anti ,Azathioprine,Pharmaceutical Preparations,1,X,[hops/orch/phsu],[phsu],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26
493f8ba1-9f0b-4545-ae6d-e1bea8dc2cf0,C0010583,C0013227,used other anti ,Cyclophosphamide,Pharmaceutical Preparations,1,X,[orch/phsu],[phsu],D02.455.526.728.650.730.243;D02.705.672.500.243,D26
42268caf-a00c-4d2f-8030-abed0853f621,C3652465,C0013227,used other anti ,Interferon,Pharmaceutical Preparations,1,X,[aapp/imft/phsu],[phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D26
594f03d6-f805-4c4d-b5c2-f82047dc7ade,C0025124,C0013227,used other anti ,Traditional Chinese Medicine,Pharmaceutical Preparations,1,X,[bmod],[phsu],E02.190.488.585.520;I01.076.201.450.654.558.520,D26
9ba37c66-3aab-40cd-ab36-7eb47d224de9,C0013227,C0009905,is Anluohuaxian ,Pharmaceutical Preparations,Contraceptives Oral,1,X,[phsu],[phsu],D26,D27.505.696.875.360.276.210;D27.505.954.705.360.276.210
06ecd3c4-8a61-4783-a933-d0d1ffd19ae8,C0013227,C1136140,is Anluohuaxian ,Pharmaceutical Preparations,Long-Term Synaptic Depression,1,X,[phsu],[ortf],D26,G11.561.638.355
13bfb27a-b00b-4dac-a44e-d43ef36d4050,C0009905,C0031336,is provided by Senlong ,Contraceptives Oral,Pharmacy (field),1,X,[phsu],[bmod],D27.505.696.875.360.276.210;D27.505.954.705.360.276.210,H02.646
15f87ad9-72cb-4425-a87c-beba09f8e0c4,C0017428,C0038164,However also allows for ,Genome,Staphylococcal Protein A,1,X,[gngm],[aapp/imft/irda],G05.360.340,D12.776.097.820;D23.050.161.821
c895fed7-a4d9-4fe4-afaa-ca64e49c2606,C0015219,C1880355,opening future ,Biological Evolution,Discover,1,X,[genf],[acty],G05.045;G16.075,
39d9ca37-403c-4f2e-ba60-f4cfde534edb,C0042736,C3826426,have developed quantitative ,Viral Proteins,Dynamics,1,X,[aapp/bacs],[npop],D12.776.964,
87541a74-48f8-4e3a-bbdd-850936a7a42f,C0042736,C4553629,have developed quantitative ,Viral Proteins,MATRix Regimen,1,X,[aapp/bacs],[topp],D12.776.964,
d1b87e3a-ef39-4d00-9f81-1bd06f126436,C0042736,C0022709,have developed quantitative ,Viral Proteins,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],D12.776.964,D08.811.277.656.350.350.687
d1b87e3a-ef39-4d00-9f81-1bd06f126436,C0042736,C0022709,binds ,Viral Proteins,Peptidyl-Dipeptidase A,2,X,[aapp/bacs],[aapp/enzy/imft],D12.776.964,D08.811.277.656.350.350.687
4d32c06f-ee71-4c26-922c-cf6fcc655815,C0042736,C1428660,have developed quantitative ,Viral Proteins,SLC6A19 gene,1,X,[aapp/bacs],[gngm],D12.776.964,
d98acc47-7036-445f-8d5b-b02dac904e2c,C0042736,C0596448,have developed quantitative ,Viral Proteins,dimer,1,X,[aapp/bacs],[chvs],D12.776.964,
19aa8f79-7696-4a35-802c-4bd911b82901,C4553629,C0017428,warranting ,MATRix Regimen,Genome,1,X,[topp],[gngm],,G05.360.340
0f82fb1f-765c-43d3-ab59-f4ce681bc4b4,C4553629,C1175743,warranting ,MATRix Regimen,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
f9efe915-a774-479c-8661-839c18412276,C4553629,C1428660,elucidated potential missense variants from population databases within ,MATRix Regimen,SLC6A19 gene,1,X,[topp],[gngm],,
9cf50eda-c0bd-4b93-89df-3737306ded33,C4553629,C1742865,elucidated potential missense variants from population databases within ,MATRix Regimen,TMPRSS2 protein human,1,X,[topp],[aapp/enzy],,x.x.x.x
de57a870-dd71-48a2-b3e9-fca171b18f76,C0022709,C0043292,falls on ,Peptidyl-Dipeptidase A,X Chromosome,1,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,A11.284.187.865.982;G05.360.162.865.982
c02cb365-54ca-466f-840f-c09635e97d04,C1521827,C1705178,serve in ,Preparation,Order (action),2,X,[acty],[acty],,
e4140764-3be6-418c-afb0-8309cff20837,C0017428,C0086418,is virus core interferes with activities of its counterparts within,Genome,Homo sapiens,1,X,[gngm],[humn],G05.360.340,B01.050.150.900.649.313.988.400.112.400.400
df8c2e25-2e4c-4c0e-bff6-40858be335ee,C0017428,C0598995,is virus core of,Genome,virus core,2,X,[gngm],[aapp/nnon],G05.360.340,
27df33ee-e399-4122-bd9d-498156ca4e23,C1519302,C0017428,are composed of short ,Short Tandem Repeat,Genome,1,X,[bacs/nnon],[gngm],G02.111.570.080.708.800.500;G05.360.080.708.800.500;G05.360.340.024.850.500,G05.360.340
8e637759-5d0c-4486-80d0-55efebac0e65,C1167395,C0012634,diagnose possible ,Host (organism),Disease,1,X,[orgm],[dsyn],,C23.550.288
3bf474c6-a6e7-4938-8f58-e38b58cd9e5d,C0162633,C0920467,may pose threat to ,Viral Shedding,disorder control (procedure),2,X,[patf],[topp],G07.925,
494a0de9-1859-43aa-8fc1-71505b007902,C1175743,C1882509,has ,SARS coronavirus,put - instruction imperative,1,X,[virs],[acty],B04.820.504.540.150.113.937,
14946aa0-0277-4fc2-a174-ad10a2d9a3bb,C0035691,C0010076, includes ,RNA Viruses,Coronaviridae,3,X,[virs],[virs],B04.820,B04.820.504.540
93520614-695f-4df5-aa73-11e527b2ce10,C0035691,C1264606,cause ,RNA Viruses,Persistent infection,1,X,[virs],[dsyn],B04.820,
31c58a62-615f-465f-93df-e42d580b60b0,C0010076,C1264606,cause ,Coronaviridae,Persistent infection,1,X,[virs],[dsyn],B04.820.504.540,
ab13a671-0fdf-49e2-8615-0981949f4954,C0035691,C1167395,cause Persistent infection in,RNA Viruses,Host (organism),1,X,[virs],[orgm],B04.820,
7a41de7a-a91d-409f-964d-b8c952c8b123,C0010076,C1167395,cause Persistent infection in,Coronaviridae,Host (organism),1,X,[virs],[orgm],B04.820.504.540,
33fbff69-d876-4e70-9a31-f32da18b5493,C0162633,C1264606,Empirical evidence of be may indirect proof for ,Viral Shedding,Persistent infection,4,X,[patf],[dsyn],G07.925,
ef75d399-d318-4628-8d02-982999b6909a,C0017428,C1264606,Empirical evidence of be may indirect proof for ,Genome,Persistent infection,2,X,[gngm],[dsyn],G05.360.340,
ac3b9096-8d80-497f-a662-d84ed7787c90,C0520510,C1264606,Empirical evidence of be may indirect proof for ,Materials,Persistent infection,2,X,[sbst],[dsyn],,
d2dee9e1-3ee1-42ba-b1c1-d1da9555bd71,C0242732,C0042776,may facilitate evasion by ,Tropism,Virus,1,X,[phsf],[virs],G07.345.249.845;G15.920,B04
4ee48c6b-1216-4d64-927a-b5184bb1a91c,C0079419,C0079427,are key gatekeepers with ,TP53 gene,Tumor Suppressor Genes,1,X,[gngm],[gngm],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,G05.360.340.024.340.375.249;G05.360.340.024.340.415.400
2e496c5f-096e-41b1-9394-f20dd261c4d1,C0079419,C4552744,are key gatekeepers with ,TP53 gene,Daily Living,1,X,[gngm],[dora],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,
7a573f1c-2506-47c7-9b16-c858d910ae4b,C1155266,C0242606,is with marked ,inflammatory response,Oxidative Stress,1,X,[patf],[comd],,G03.673;G07.775.750
a31c93e5-f4f7-4e07-8544-63ba3d169d0d,C0206750,C0242606,features preeminent ,Coronavirus Infections,Oxidative Stress,2,X,[dsyn],[comd],C02.782.600.550.200,G03.673;G07.775.750
16f6cd9d-7249-4342-9809-d2885316b98f,C0242606,C0596263,acts as as initiator of ,Oxidative Stress,Carcinogenesis,1,X,[comd],[neop],G03.673;G07.775.750,C04.697.098;C23.550.727.098
f3fff33d-9f9b-4d78-907e-a8dfe1dca6f7,C0596263,C1175743,associated with ,Carcinogenesis,SARS coronavirus,1,X,[neop],[virs],C04.697.098;C23.550.727.098,B04.820.504.540.150.113.937
e43637a7-205e-490c-a450-a188e155c279,C0266257,C0085845,include elevation of ,Congenital anomaly of liver,Aspartate,1,X,[cgab],[aapp/bacs],,D12.125.067.500;D12.125.119.170;D12.125.427.040
3209d935-6762-408d-acda-1cd9c7050fcf,C0266257,C0040676,include elevation of ,Congenital anomaly of liver,Transferase,1,X,[cgab],[aapp/enzy],,D08.811.913
cfd9c48d-5902-4e04-b26d-cc4470c8ca67,C0266257,C0376147,include elevation of ,Congenital anomaly of liver,SGPT - Glutamate pyruvate transaminase,1,X,[cgab],[aapp/enzy],,
bfe6f497-fcb9-41dd-b4a7-c842ff6de9c7,C0266257,C0005437,include elevation of ,Congenital anomaly of liver,Bilirubin,1,X,[cgab],[bacs/orch],,D03.383.129.578.840.249.184;D03.633.400.909.249.184;D04.345.783.249.184;D23.767.193.184
cdba877e-aef5-448e-b46d-b5388733cb12,C0058362,C0682610,is expressed on ,dipeptidyl peptidase II,Enterocytes,1,X,[aapp/enzy],[cell],x.x.x.x,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
2f531b33-0510-492b-acd4-fb7d968767a5,C0058362,C0020885,is expressed on ,dipeptidyl peptidase II,ileum,1,X,[aapp/enzy],[bpoc],x.x.x.x,A03.556.124.684.249;A03.556.249.124
e19b28a6-59ac-46e6-a8bb-72d24313f464,C1292459,C4287874,raised concern in addition to ,Specimen from patient,Droplet Transmission,1,X,[bdsu],[patf],,
82a63517-2f19-40c2-b7bd-80acba25776c,C1947933,C3812666,usually take place in ,care activity,Personal Contact,1,X,[acty],[acty],,
bbcb0b8f-cc95-4a68-a079-a9dff187d538,C1947933,C0087111,usually take place to remote ,care activity,Therapeutic procedure,1,X,[acty],[topp],,E02
4f905024-8fd6-46ee-ae85-c17e4158a81e,C1145670,C0162434,progressing into ,Respiratory Failure,Olfactory Cortex,2,X,[dsyn],[bpoc],C08.618.846,A08.186.211.200.885.287.500.620;A08.186.211.200.885.287.500.814.695;A08.186.211.200.885.287.750
9aff190b-4c01-4ac4-b867-d3c0ddae2339,C1145670,C2699153,may result from viral ,Respiratory Failure,Cell Invasion,1,X,[dsyn],[patf],C08.618.846,
abdaab0f-bade-4758-b400-b59f78e99a16,C1145670,C0028938,may result from viral ,Respiratory Failure,Olfactory Nerve,1,X,[dsyn],[bpoc],C08.618.846,A08.800.800.120.640
4e533b36-41c7-46f4-bda3-b94e1f57f932,C0007820,C0225990,is in particular ,Cerebrovascular Disorders,Large blood vessel structure,1,X,[dsyn],[bpoc],C10.228.140.300;C14.907.253,
021d45e9-154a-4be2-b1ed-98fb3bce6977,C0007820,C0948008,is in particular ,Cerebrovascular Disorders,Ischemic stroke,1,X,[dsyn],[dsyn],C10.228.140.300;C14.907.253,
3e9dc3d8-26a5-4189-8c51-2b302be0c2e5,C1855020,C0079189,is associated to ,Acute necrotizing encephalopathy,cytokine,2,X,[dsyn],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
5809d090-afc0-40ec-943e-0e6f897959bd,PNS,C0206750,is in ,PNS,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
4b3ee93a-8f88-49ad-a22f-495c5e0ad705,C0027765,C0035410,include rare instances with ,nervous system disorder,Rhabdomyolysis,1,X,[dsyn],[patf],C10,C05.651.807
22c3db35-ddff-4139-b57f-469814c47604,C0027765,C0393799,include ,nervous system disorder,Miller Fisher Syndrome,1,X,[dsyn],[dsyn],C10,C10.114.750.100.500;C10.228.140.252.500;C10.292.562.350;C10.314.750.450.500;C10.668.829.350.500;C10.668.829.800.750.300.500;C11.590.312;C20.111.258.750.400.500
3a0fcea2-2bc8-41fd-a0e3-17d8c3952bd9,C0027765,C0032541,include ,nervous system disorder,Polyneuritis,1,X,[dsyn],[dsyn],C10,C10.668.829.650
e19d2e04-7d36-4092-ab27-a53f92bdc551,C0027765,C0039082,include Guillain-Barr ,nervous system disorder,Syndrome,1,X,[dsyn],[dsyn],C10,C23.550.288.500
04a8f987-a3fe-4081-a9ee-1ba40d920934,C0035222,C0206419,is in ,Respiratory Distress Syndrome Adult,Genus: Coronavirus,3,X,[dsyn],[virs],C08.381.840;C08.618.840,B04.820.504.540.150
aee93d22-dead-489d-918d-b20301f0932b,C0079189,C0042769,is in response to ,cytokine,Virus Diseases,4,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C02
7013eb8f-3886-40a7-8f08-d9f4dbcea939,C0242656,C1290884,is in ,Disease Progression,Inflammatory disorder,1,X,[patf],[dsyn],C23.550.291.656,
0b0fd4a4-2d18-4285-992d-0e8303cf1e4a,C0242656,C0079189,is in ,Disease Progression,cytokine,1,X,[patf],[aapp/imft],C23.550.291.656,D12.644.276.374;D12.776.467.374;D23.529.374
2aa5d502-83eb-4f90-944a-3f0f2df5c0dd,C0376520,C0162772,induces ,Dietary Iron,Reactive Oxygen Species,1,X,[inch],[bacs/elii],D01.490.600;D02.691.550.600,D01.339.431;D01.650.775
bdd90804-f74a-4c3e-a59d-e4ed09b8202e,C0026237,C2244223,are huperzine B of,Mitochondria,cellular homeostasis,2,X,[celc],[celf],A11.284.430.214.190.875.564;A11.284.835.626,
cb432a2c-4759-4aed-ab7a-97cca752b1db,C0026237,C0063034,are ,Mitochondria,huperzine B,1,X,[celc],[orch/phsu],A11.284.430.214.190.875.564;A11.284.835.626,x.x.x.x
49f9b85b-5cf5-4629-bf00-ed4cc2ec4acf,C0026237,C0005821,may circulate cell-free in non-nucleated ,Mitochondria,Blood Platelets,1,X,[celc],[cell],A11.284.430.214.190.875.564;A11.284.835.626,A11.118.188;A15.145.229.188
2329a88b-ac20-4d9e-87a3-0711f22d3767,C0026237,C3894683,may circulate in ,Mitochondria,Extracellular Vesicles,1,X,[celc],[celc],A11.284.430.214.190.875.564;A11.284.835.626,A11.284.295.588
b393b254-42bc-4f01-890c-ea39d6934426,C0025123,C0087111,has In China has widely used to ,chinese medicine,Therapeutic procedure,1,X,[bmod],[topp],,E02
e15a0978-b7e1-445e-899e-2e85b48b2ee6,C0025123,C0012634,has In China has widely used to ,chinese medicine,Disease,1,X,[bmod],[dsyn],,C23.550.288
ac5ad5af-7de4-4580-9474-e73d1bcd8940,C0025123,C0035204,plays role in treatment of ,chinese medicine,Respiration Disorders,1,X,[bmod],[dsyn],,C08.618
c24eb56a-392c-46e9-a111-84eca9a1b4f9,C0035691,C0312860,containing ,RNA Viruses,Neutrophil migration function,1,X,[virs],[celf],B04.820,
008b93ee-4e6d-42c3-8d25-605cd9bdd7e6,C0319157,C1628327,is ,AS virus,Zoonotic pathogen,1,X,[virs],[orgm],,
75d13850-8922-4c6d-a9ff-67b2251bc61e,C0319157,C0683325,is ,AS virus,clinical aspects,1,X,[virs],[clna],,
7252a92c-114f-41ab-8a95-60f96aa3db33,C0319157,C2936329,is ,AS virus,Asymptomatic Diseases,1,X,[virs],[dsyn],,C23.550.291.187
5a1fadd7-07ab-428b-a684-c8b9b951c62b,C2936329,C0086418,is in ,Asymptomatic Diseases,Homo sapiens,1,X,[dsyn],[humn],C23.550.291.187,B01.050.150.900.649.313.988.400.112.400.400
9dcfd4ba-17cd-4831-91f4-9408ae62df76,C1112565,C0949920,has has described in association with ,pneumatosis intestinalis,Norovirus,1,X,[dsyn],[virs],,B04.820.095.550
a83b00cc-78da-4c5d-94a4-68f1bfa4b6f1,C0015929,C0206419,is in ,Fetal Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C13.703.277;C16.300,B04.820.504.540.150
975145d3-1109-464d-a82e-088e301a89c9,C0042210,C0319157,curb pandemic spread of zoonotic ,Vaccines,AS virus,1,X,[aapp/imft/phsu],[virs],D20.215.894,
8e3501a2-6554-41fc-9d98-3040ce8676a8,C1880355,C0319157,curb pandemic spread of zoonotic ,Discover,AS virus,1,X,[acty],[virs],,
a2ef5b1d-b582-4647-a677-745252d77056,C0017968,C0475463,is main target of ,Glycoproteins,Antibodies Neutralizing,1,X,[aapp/bacs],[aapp/imft],D09.400.430;D12.776.395,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
62cc4210-3559-44e9-93d4-211abf4e7eef,S309,C0032594,recognizes ,S309,Polysaccharides,1,X,????,[orch/phsu],????,D09.698
4765923c-f32c-4ff9-8a25-087211825186,S309,C0003316,recognizes ,S309,Epitopes,1,X,????,[imft],????,D23.050.550
fa5130b0-5dc7-4b6b-b16d-2152167fb87c,C0003316,C0597357,is conserved competing with ,Epitopes,receptor,2,X,[imft],[aapp/rcpt],D23.050.550,
ad6a61fd-d8a1-457c-8177-29d1f13efe69,C0003316,C1947904,is conserved competing with ,Epitopes,Attachment (action),2,X,[imft],[acty],D23.050.550,
f6c5ef71-a36a-4d7c-acbd-cb5ff1b622e6,C0678420,S309, includes S309,Cocktail,S309,1,X,[food],????,,????
e4c4559c-0389-4b2c-851f-fe8b277944fb,C0678420,C0596988,may limit emergence of neutralization-escape ,Cocktail,mutant,1,X,[food],[comd],,
08d60564-0174-48a5-8fb9-ca10808c7a5f,S309,C0596988,may limit emergence of neutralization-escape ,S309,mutant,1,X,????,[comd],????,
81550874-db56-4fe8-960b-0b1dff342eac,COPC,C2728259,were applied in CST ,COPC,Program,2,X,????,[orch/phsu],????,V02.355.750
eba87ee7-e4ed-4bd6-a40f-568bdfd5ebbe,C2948600,C0423866,slow ,Aim,Lanugo,2,X,[inch/phsu],[bpoc],,A17.360
9577d9cb-f072-4685-896e-8d51ecbcbe04,C2948600,C0814435,slow Lanugo disease transmission through,Aim,early identification,2,X,[inch/phsu],[topp],,
83d40d60-7ec4-4414-9f9a-684e3016a5bd,C0003507,COVID,is in COVID ,Aortic Valve Stenosis,COVID,1,X,[dsyn],????,C14.280.484.150;C14.280.955.249,????
49d179e5-031c-4e0c-a5ef-9e998752b3d0,C0003507,C1521863,is in COVID ,Aortic Valve Stenosis,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C14.280.484.150;C14.280.955.249,x.x.x.x
4fa6dd91-82da-4aa5-8b15-d78904f8dbf8,C0225706,C0225730,was more extensively involved than ,Right lung,Left lung,1,X,[bpoc],[bpoc],,
19a76b08-32b8-483c-9496-274da91b17f0,C0225758,C0225756,was extensively involved than ,Structure of lower lobe of lung,Structure of upper lobe of lung,1,X,[bpoc],[bpoc],,
73a70b0a-dd8c-4953-82ed-ddf38f6f6ecd,C0444279,C0035380,tested by ,Respiratory sample,Reverse Transcription,1,X,[bdsu],[genf],,G02.111.873.500;G05.297.700.500
d99db2ba-f85e-4bca-99f9-6cb4f1244e7b,C0012739,C0206419,are life-threatening for patients with ,Disseminated Intravascular Coagulation,Genus: Coronavirus,1,X,[dsyn],[virs],C15.378.100.220;C15.378.463.250;C15.378.925.220,B04.820.504.540.150
e980e815-77cd-4357-bff8-94bf1b230a76,C0034848,C0042774,significantly decreasing ,Receptors Virus,Virus Replication,1,X,[aapp/rcpt],[celf],D12.776.543.750.830,G06.920.925
57143649-7157-492e-8252-8c82b524db36,C0034848,C0015219,significantly decreasing risk of ,Receptors Virus,Biological Evolution,1,X,[aapp/rcpt],[genf],D12.776.543.750.830,G05.045;G16.075
d58dcd2b-6cb2-4909-a3fa-938f2fd56fe4,C0028429,C0039336,identified patients with reduction of ,Nose,Taste Perception,4,X,[bpoc],[ortf],A01.456.505.733;A04.531;A09.531,F02.830.816.724;G11.561.790.724
2fa4f74c-7c09-426b-a154-9766db504ddb,C0003018,C0030664,is in various neoplastic ,Angiotensins,Pathology,1,X,[aapp/bacs/phsu],[bmod],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,H02.403.650
3509c899-a0dc-45f4-9422-baf0a7cc3bf1,C0206419,C0017181,is with ,Genus: Coronavirus,Gastrointestinal Hemorrhage,1,X,[virs],[patf],B04.820.504.540.150,C06.405.227;C23.550.414.788
2c926463-9f66-4517-ae4a-edd25f3daae5,C0849867,C0035222,is with large number of ,Widespread Disease,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],,C08.381.840;C08.618.840
41c86cf7-9e3c-4775-94ce-f3f7543fd495,PCR,C0014507,is in symptomatic patient at high ,PCR,Epidemiology,1,X,????,[bmod],????,H02.403.720.500
05f7bdd2-f72c-414b-90c6-8b9c96cbc634,C0009450,C2348077,missed by limited testing performed to ,Communicable Diseases,Date Fruit,1,X,[dsyn],[food],C01.539.221,B01.650.940.800.575.912.250.093.615
9f25f4df-5a87-4525-b85a-874dff957e01,C0206419,C0559758,can induce ,Genus: Coronavirus,MULTISYSTEM DISORDER,1,X,[virs],[dsyn],B04.820.504.540.150,
c997e937-ca94-4b21-b58e-3750f57dfa66,C0021368,C0005778,participate in dysfunctional ,Inflammation,Blood coagulation,2,X,[patf],[ortf],C23.550.470,G09.188.390.150
2dff1deb-46fc-40f7-8dbd-fa0ed7c38124,C3241922,C0042776,was how affected by ,Operation Activity,Virus,4,X,[acty],[virs],,B04
f94c9663-48df-4d43-9d5c-d6eb51c10024,C0543467,C0019144,were performed including major ,Operative Surgical Procedures,Hepatectomy,2,X,[topp],[topp],E04,E04.210.556
1f5aa195-e90e-4397-b7c5-e373d98ed366,C2948600,C0846672,introduce our experience based remote patient LTSC,Aim,systems therapy,2,X,[inch/phsu],[topp],,
5cb8974d-bd18-4025-b138-43e7144d40c6,C2948600,LTSC,introduce our experience based remote patient LTSC,Aim,LTSC,2,X,[inch/phsu],????,,????
9d6259fa-9601-48c3-ae64-24d3c5d081ed,C0423866,C1175743,spread of ,Lanugo,SARS coronavirus,2,X,[bpoc],[virs],A17.360,B04.820.504.540.150.113.937
5d332967-2305-46ec-b506-8d8dce996984,C0206422,C1550661,can can variably found in ,Human coronavirus,Specimen Type - Stool = Fecal,2,X,[virs],[bdsu],,
4846a93b-a860-4207-98d4-0ddb851e61f9,C0206422,C1457887,have have variably associated with ,Human coronavirus,Symptoms,2,X,[virs],[sosy],,
1d5f643c-c33f-44c7-be7c-f576d3f94b3b,C0206422,C0017160,have have variably associated with ,Human coronavirus,Gastroenteritis,2,X,[virs],[dsyn],,C06.405.205
cca2d1aa-949d-4311-9c6e-17474a84d061,C0221102,C0015733,is in ,Excretory function,Feces,2,X,[phsf],[bdsu],,A12.459
e7adcc69-ce1c-45c3-ac2b-9cf113375da4,C0370003,C0206419,exceed fourteen day period after onset for ,Specimen,Genus: Coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150
5a377225-142b-46b1-95c9-dddfb1f9502c,C0305052,COVID-19,can ,Gamma globulin serum,COVID-19,1,X,[aapp/imft/phsu],[virs],,C000657245
cf362846-9343-4f81-be6d-c73da2a2ec35,TLR3,COVID-19,be considered as ,TLR3,COVID-19,1,X,????,[virs],????,C000657245
363350b4-7f40-4c72-9386-1e16d2cbd1e5,C0243192,COVID-19,be considered as ,agonists,COVID-19,1,X,[phsu],[virs],x.x.x,C000657245
547f6f02-01e6-417d-ba45-cd978ec470e2,C2936405,COVID-19,is in ,Drug Repositioning,COVID-19,1,X,[topp],[virs],E05.290.875,C000657245
a8ce8e51-feef-4a21-a3bd-9d1e1000e483,C0206419,C0011438,has had significant ,Genus: Coronavirus,Dentistry,1,X,[virs],[bmod],B04.820.504.540.150,E06;H02.163
f2b1bded-9bda-495f-b711-6ad5853c693d,C0012634,C0011438,has had significant ,Disease,Dentistry,1,X,[dsyn],[bmod],C23.550.288,E06;H02.163
b084e1a6-0b85-4619-87ad-0969ba3c7f17,6LU7,C1175743,identity with ,6LU7,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
de848112-fc5d-4e6c-8734-082cb8e9ab2c,C0023911,COVID-19,is with ,Transplantation of liver,COVID-19,1,X,[topp],[virs],E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490,C000657245
fcbcd30a-c9a7-4c26-9649-4be69ac84c01,C0206419,C0011311,is with false-positive ,Genus: Coronavirus,Dengue Fever,1,X,[virs],[dsyn],B04.820.504.540.150,C02.081.270;C02.782.350.250.214;C02.782.417.214
29834ad3-4dcc-43bc-8b09-288c5d9c5aca,C0206419,C0036745,is with false-positive ,Genus: Coronavirus,Study of serum,1,X,[virs],[bmod],B04.820.504.540.150,H02.781
11129669-44ae-4963-8351-7f63f8d1cb84,C0013227,C3714514,are approved for other ,Pharmaceutical Preparations,Infection,2,X,[phsu],[patf],D26,C01.539
59b10306-c13c-4ea4-bce0-77511cde11de,C0013227,C0683949,have performed well in ,Pharmaceutical Preparations,animal study,2,X,[phsu],[anim],D26,
556c8a78-1f27-427b-a8fd-63e633c4cba3,C0207682,C0312860,Furthermore blocked SARS coronavirus with effective concentration around 10,nafamostat mesilate,Neutrophil migration function,1,X,[orch/phsu],[celf],,
a1a76de7-4cc4-48dd-aa9f-06c24bd746af,C0207682,C0007634,also inhibits SARS coronavirus in,nafamostat mesilate,Cells,1,X,[orch/phsu],[cell],,A11
0855e45f-ff0b-480c-a50f-056c97653def,C2948600,C0544357,evaluate immunoassays in ,Aim,human plasma,1,X,[inch/phsu],[phsu],,
2d77306b-93da-4738-aeb1-c2c77cc61712,C1627946,COVID-19,confirmed ,SARS coronavirus IgM,COVID-19,1,X,[aapp/imft],[virs],,C000657245
7b0b8bb6-bcaf-4347-9325-10f1446da766,C1718953,COVID-19,confirmed ,Severe acute respiratory syndrome coronavirus Ab,COVID-19,1,X,[aapp/imft],[virs],,C000657245
e8c039f8-dba9-4f66-8240-441e051c81ff,C1627946,C0178913,confirmed ,SARS coronavirus IgM,Blood specimen,1,X,[aapp/imft],[bdsu],,
3051b1cd-a5a4-4135-ac58-180ca7b767d3,C1718953,C0178913,confirmed ,Severe acute respiratory syndrome coronavirus Ab,Blood specimen,1,X,[aapp/imft],[bdsu],,
2baeafe6-7efc-4aad-86dc-68ebf4a300fe,C1627946,C1718953,is in RT-PCR,SARS coronavirus IgM,Severe acute respiratory syndrome coronavirus Ab,1,X,[aapp/imft],[aapp/imft],,
9628fa6c-5df9-4433-95c6-bbf3bbc3bff5,C1627946,RT-PCR,is in RT-PCR,SARS coronavirus IgM,RT-PCR,1,X,[aapp/imft],????,,????
6846b167-843a-4196-9642-4b043566f257,C1718953,RT-PCR,is in RT-PCR,Severe acute respiratory syndrome coronavirus Ab,RT-PCR,1,X,[aapp/imft],????,,????
c596d92b-af80-49de-95ce-c6bf5ddf756e,COVID-19,C0178913,is with serial ,COVID-19,Blood specimen,1,X,[virs],[bdsu],C000657245,
e7e4a865-a2da-4cf2-8820-88a169317155,C0206419,C0719214,has emerged as once in a ,Genus: Coronavirus,century,1,X,[virs],[phsu/vita],B04.820.504.540.150,
b0b4bed0-9eaf-454e-872c-65bfa1b03311,C0206419,C1947951,supporting ,Genus: Coronavirus,Anatomical Apparatus,1,X,[virs],[anst],B04.820.504.540.150,
41d8a652-880c-448f-9bdf-1e85d3d11c29,C0678591,kcal,was calculated -2.80 0.84 kcal ,free energy,kcal,4,X,[npop],????,,????
13b665bc-cce1-470b-8396-d3c18aa16f7e,C0678591,C0324740,was calculated -2.80 0.84 kcal ,free energy,Talpidae,4,X,[npop],[mamm],,B01.050.150.900.649.473.450
b9ebded0-b39a-4320-8e65-d102c6caa4b8,C0035139,C1152412,is in blocking of ,Surgical Replantation,RNA-directed RNA polymerase activity,2,X,[topp],[genf],E04.936.494,
d04cbfc0-7858-457c-8f9e-40c0f1f49a09,D618,remdesivir,be contributors to ,D618,remdesivir,2,X,????,[clnd],????,
d04cbfc0-7858-457c-8f9e-40c0f1f49a09,D618,remdesivir,are found ,D618,remdesivir,2,X,????,[clnd],????,
dec924b2-9475-4498-9f10-4eae30122481,S549,remdesivir,be contributors to ,S549,remdesivir,2,X,????,[clnd],????,
dec924b2-9475-4498-9f10-4eae30122481,S549,remdesivir,are found ,S549,remdesivir,2,X,????,[clnd],????,
659906eb-13df-4dd8-aed9-cc302d9a2746,R555,remdesivir,be contributors to ,R555,remdesivir,2,X,????,[clnd],????,
659906eb-13df-4dd8-aed9-cc302d9a2746,R555,remdesivir,are found ,R555,remdesivir,2,X,????,[clnd],????,
d67ecf44-6451-4a8c-a952-72ebcdb9d330,D618,C1167622,be contributors to ,D618,Binding (Molecular Function),2,X,????,[moft],????,
d67ecf44-6451-4a8c-a952-72ebcdb9d330,D618,C1167622,are found ,D618,Binding (Molecular Function),2,X,????,[moft],????,
038722b6-93b0-4120-b3c1-8fd71275c17f,S549,C1167622,be contributors to ,S549,Binding (Molecular Function),2,X,????,[moft],????,
038722b6-93b0-4120-b3c1-8fd71275c17f,S549,C1167622,are found ,S549,Binding (Molecular Function),2,X,????,[moft],????,
50a40cad-b019-47e4-bec5-4d02c8550a22,R555,C1167622,be contributors to ,R555,Binding (Molecular Function),2,X,????,[moft],????,
50a40cad-b019-47e4-bec5-4d02c8550a22,R555,C1167622,are found ,R555,Binding (Molecular Function),2,X,????,[moft],????,
7fc67ee9-4112-4574-b019-493c17a349f0,D618,C1510827,be contributors to ,D618,Affinity,2,X,????,[npop],????,
7fc67ee9-4112-4574-b019-493c17a349f0,D618,C1510827,are found ,D618,Affinity,2,X,????,[npop],????,
e4460a85-e69e-4621-81e7-c52d0f267c1e,S549,C1510827,be contributors to ,S549,Affinity,2,X,????,[npop],????,
e4460a85-e69e-4621-81e7-c52d0f267c1e,S549,C1510827,are found ,S549,Affinity,2,X,????,[npop],????,
653119ba-991d-4120-b1e3-c72e49572d62,R555,C1510827,be contributors to ,R555,Affinity,2,X,????,[npop],????,
653119ba-991d-4120-b1e3-c72e49572d62,R555,C1510827,are found ,R555,Affinity,2,X,????,[npop],????,
3ec309e2-d649-4ded-92eb-3a93d9f46c29,remdesivir,C1628999,potentially act as ,remdesivir,SARS coronavirus RNA,1,X,[clnd],[nnon],,
05efcee9-50ab-4eb6-8b44-70de44a618ae,remdesivir,C0851166,potentially act as ,remdesivir,TERMINATOR Veterinary Product,1,X,[clnd],[phsu],,
49248f36-8869-48c4-8fa3-9f022f36838e,remdesivir,C1328949,effectively stopping its ,remdesivir,RNA replication,1,X,[clnd],[genf],,
b4325266-be7f-4b8e-93a1-90ec4e2b7798,remdesivir,C2698650,potentially act with key residues also identified for future lead ,remdesivir,Optimization,2,X,[clnd],[acty],,
daefc912-ac0f-4211-8346-2a765a948477,27th,C0077401,between one is 2020 with ,27th,Troponin I,1,X,????,[aapp/bacs],????,D05.500.945.925;D05.750.078.730.825.925;D12.776.210.500.910.925;D12.776.220.525.825.925
8f1b74f8-b587-4d07-b201-3b0f8fe92325,C0007222,C0041199,was more prevalent in patients with ,Cardiovascular Diseases,Troponin,1,X,[dsyn],[aapp/bacs],C14,D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825
af4756df-2a5e-4a5c-8cc5-7196e37e888b,C1457887,C0022646,are often initial presentation among ,Symptoms,Kidney,1,X,[sosy],[bpoc],,A05.810.453
ffd857d8-034c-4239-a63b-592d3a9eb2c4,C0020625,COVID-19,is in ,Hyponatremia,COVID-19,1,X,[dsyn],[virs],C18.452.950.620,C000657245
df87bd81-c7de-4dd8-98ba-3870ca7c35c3,C0281182,C0441655,scaled down significantly their ,Screening for malignant neoplasm of breast,Activities,2,X,[topp],[acty],,
355dfb20-bc99-4dfa-9506-3a8ec36acccb,C1175743,C0597404,may enter system Like other ,SARS coronavirus,Respiratory viruses,2,X,[virs],[virs],B04.820.504.540.150.113.937,
120efbe4-a536-4fb1-9a62-e770ea45363d,C0085584,COVID-19,has ,Encephalopathies,COVID-19,2,X,[dsyn],[virs],C10.228.140,C000657245
0d7224e9-2209-4d47-8a46-761138c2ed15,C0085584,C1457887,has has described as presenting ,Encephalopathies,Symptoms,2,X,[dsyn],[sosy],C10.228.140,
fe39cb8f-b512-47b3-9aed-ea38fa5e4467,C0872315,C0450254,were characterized by their novel ,Communicable Diseases Emerging,Pathogenic organism,4,X,[dsyn],[orgm],C01.539.221.500,
fd41bff3-0abe-4262-9985-e2bb39e851af,C1275666,C0003241, includes ,Fusion inhibitor,Antibodies,2,X,[phsu],[aapp/imft/phsu],,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
4fa04810-42cf-4e45-be76-94c310ae446a,C1275666,C0033607, includes ,Fusion inhibitor,Protease Inhibitors,2,X,[phsu],[phsu],,D27.505.519.389.745
edb579be-67cd-48df-afa9-943decaeb683,C1275666,C0030956, includes ,Fusion inhibitor,Peptides,2,X,[phsu],[aapp/phsu],,D12.644
3d89302a-f030-494c-96ee-4d04460a6bd1,WBE,C0005516,Protein Domain in sewage ,WBE,Biological Markers,1,X,????,[clna],????,D23.101
3d89302a-f030-494c-96ee-4d04460a6bd1,WBE,C0005516,Protein Domain in fragment,WBE,Biological Markers,1,X,????,[clna],????,D23.101
aa0e3719-491b-422b-9dc6-a87a57845a88,C1514562,C0005516,is in sewage ,Protein Domain,Biological Markers,1,X,[amas],[clna],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,D23.101
aa0e3719-491b-422b-9dc6-a87a57845a88,C1514562,C0005516,is in fragment ,Protein Domain,Biological Markers,1,X,[amas],[clna],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,D23.101
1b53b800-43c4-495e-95a0-809bedc6f378,C0005532,C0206419,is partially known with aspects in common with other ,biology (field),Genus: Coronavirus,3,X,[bmod],[virs],H01.158.273,B04.820.504.540.150
3c394ac6-962b-4cf3-aadb-05ca22820f14,C0005525,C0441655,restores immunological ,Biological Response Modifiers,Activities,1,X,[imft/phsu],[acty],D27.505.696.477,
b331f872-a773-45be-88e7-a88400219204,C0005525,C0334227,restores immunological activity against ,Biological Response Modifiers,Tumor cells malignant,3,X,[imft/phsu],[cell],D27.505.696.477,
fe99a48e-3762-47c9-9298-a920ddc60f7e,C0018563,C0441516,be in hence ,Hand,Demand (clinical),2,X,[bpoc],[topp],A01.378.800.667,
076b9e64-f834-471f-a38e-f67da080d6d4,1st,C0206750,until Search - action is 2019 novel,1st,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
b0d2317d-338d-4784-9dc5-29074ee71e18,C0013227,C0341439,is with ,Pharmaceutical Preparations,Chronic liver disease,1,X,[phsu],[dsyn],D26,
fa3d31eb-cdf3-4ac9-b94f-e2243128bd96,C0243077,C1738934, includes ,inhibitors,boceprevir,1,X,[chvf],[aapp/phsu],,x.x.x.x
902a8ff0-0409-4c4f-8563-3f8403d0c852,C0444626,C1167622,revealed two ,Crystal Structure,Binding (Molecular Function),2,X,[chvs],[moft],,
902a8ff0-0409-4c4f-8563-3f8403d0c852,C0444626,C1167622,has revealed molecular determinants responsible for ,Crystal Structure,Binding (Molecular Function),2,X,[chvs],[moft],,
902a8ff0-0409-4c4f-8563-3f8403d0c852,C0444626,C1167622,has revealed potential inhibitor ,Crystal Structure,Binding (Molecular Function),2,X,[chvs],[moft],,
fe3ecee0-88ba-495f-bb97-31db73ce001e,C0444626,C3537453,is with ,Crystal Structure,GBA wt Allele,1,X,[chvs],[gngm],,
48855602-e36c-4174-aee7-1da3b31ff1fb,C0216231,C0086418,is ,sargramostim,Homo sapiens,2,X,[aapp/imft/phsu],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
a1770aa7-dfd4-4b57-8dd2-37a32627081c,C0216231,g/m,will Upon g/m ,sargramostim,g/m,3,X,[aapp/imft/phsu],????,x.x.x.x,????
f6644323-94df-49d1-bea8-40eea656068b,C0683325,C0035222,include ,clinical aspects,Respiratory Distress Syndrome Adult,2,X,[clna],[dsyn],,C08.381.840;C08.618.840
255596a7-6320-45b5-8ca3-d487fb387c3e,C0683325,C3665444,include ,clinical aspects,Neutrophilia (disorder),2,X,[clna],[dsyn],,
fe677dd0-a67a-4804-bbde-e2c75d5daa4a,C0683325,C0079189,include ,clinical aspects,cytokine,2,X,[clna],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
ba47b321-b501-4c54-a916-52b308534f7d,C0746885,COVID-19,contributes to ,neutrophilic,COVID-19,2,X,[celf],[virs],,C000657245
82531b0f-7b4a-405b-87f2-6607012889f1,C0746885,C0011849,contributes to higher mortality of ,neutrophilic,Diabetes Mellitus,2,X,[celf],[dsyn],,C18.452.394.750;C19.246
61519d46-a6e7-427d-9344-ae9c169d050a,C0021368,C0011849,contributes to higher mortality of ,Inflammation,Diabetes Mellitus,2,X,[patf],[dsyn],C23.550.470,C18.452.394.750;C19.246
95ea0993-e487-422c-a1d3-9fac2c8d5e15,C0543829,C0683465,is in ,pneumonia clinical,novel AODU treatment method,4,X,[dsyn],[topp],,
626d0be7-d3b6-4f07-9c7e-6e625409ce6e,C0543829,C0206750,is in ,pneumonia clinical,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
42a142c4-c8b5-471b-bd48-c8feb74524ef,C2986594,C0032285,study ,Mouse Model,Pneumonia,2,X,[emod],[dsyn],,C08.381.677;C08.730.610
db7c1b8e-941a-41ba-891b-e27a5da22b35,C0025124,C0206750,is in Novel ,Traditional Chinese Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],E02.190.488.585.520;I01.076.201.450.654.558.520,C02.782.600.550.200
db7c1b8e-941a-41ba-891b-e27a5da22b35,C0025124,C0206750,have shown ,Traditional Chinese Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],E02.190.488.585.520;I01.076.201.450.654.558.520,C02.782.600.550.200
5de118c6-3028-4bfa-af66-8ea1133cc83b,C0025124,C0032285,is in Novel ,Traditional Chinese Medicine,Pneumonia,2,X,[bmod],[dsyn],E02.190.488.585.520;I01.076.201.450.654.558.520,C08.381.677;C08.730.610
15d70752-d6aa-4978-baf6-000386e42aa6,C0025919,C0042776,is infected with HCoV-229 E ,Mice Inbred BALB C,Virus,2,X,[mamm],[virs],B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338,B04
25c03740-2128-4b3e-b52d-58011a37b166,C0039215,C0032285,reduced ,CD4 Positive T Lymphocytes,Pneumonia,2,X,[cell],[dsyn],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,C08.381.677;C08.730.610
4cf0fcc7-973c-4e64-9f57-3dace8369fea,C0039215,C0040300,reduced ,CD4 Positive T Lymphocytes,Body tissue,1,X,[cell],[tisu],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,A10
c5758ad5-64ca-40d7-8d9f-1b4d791c4b8b,C0039082,C0042776,may attribute to its function of in ,Syndrome,Virus,2,X,[dsyn],[virs],C23.550.288.500,B04
0276d38e-257c-4fa6-9dd5-9a4c3a08d223,C0039082,C1511692,may attribute to its function of in ,Syndrome,DNA Replication Inhibition,2,X,[dsyn],[genf],C23.550.288.500,
2b4cece3-60d2-479c-aad0-357d86dea730,C0039082,C3463820,may attribute to its function of in ,Syndrome,Inhibition,2,X,[dsyn],[acty],C23.550.288.500,F01.145.544;F02.463.425.475;F02.739.794.405
5b824150-afb5-4888-bf47-42f0040eb043,C0042776,C0037088,plays role in ,Virus,Signs and Symptoms,1,X,[virs],[sosy],B04,C23.888
51111370-b237-4dbb-90a3-3d9bc877a792,MT-PCR,C1511790,is reliable assay for ,MT-PCR,Detection,1,X,????,[topp],????,
b89fb242-1c7a-4d3c-8e86-68f9e65c8a30,MT-PCR,C1175743,is reliable assay for ,MT-PCR,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
d2155c8a-4c28-4727-8d1b-034507ff42da,C0265267,C0206750,is associated with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
3f4a6d29-c606-4373-860c-b2175e9c879c,C3864824,C0263940,help ,paritaprevir,Curb,1,X,[orch/phsu],[dsyn],,
a66892ff-c47c-4f5b-828d-932933e25f8d,C3864824,C0206750,help ,paritaprevir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],,C02.782.600.550.200
35d99571-720f-4c20-952a-0492ed8eb4fc,C0030106,C0011334,could of could help in control of ,Ozone,Dental caries,2,X,[chem],[dsyn],D01.362.670.600;x.x.x.x,C07.793.720.210
4ed8b50f-0c43-4671-a199-1e5a8129189e,C0012634,C0011945,occur among patients on in-center ,Disease,Physical Dialysis,2,X,[dsyn],[npop],C23.550.288,E05.196.353;G02.186
d17357db-52d3-48ff-a151-aae9f6b3b8e3,C0015967,C0015672,42-year-old patient ,Fever,Fatigue,1,X,[sosy],[sosy],C23.888.119.344,C23.888.369
c6ed0f88-c77a-44b8-8364-40ff62c25ecc,C0206750,C1704532,can can treated with ,Coronavirus Infections,Active Method,1,X,[dsyn],[topp],C02.782.600.550.200,
1cc8b35f-defb-4635-9f60-d5db4c89701a,C0021760,C0948245,plays role in ,Interleukin-6,Cytokine Release Syndrome,1,X,[aapp/imft],[dsyn],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,
f6ed35d6-9850-467b-92d0-4bb311f345eb,C1706202,C0872147,using Cochrane ,Search - action,DNA Library,2,X,[acty],[gngm/nnon],,G05.360.325
7138b010-68e8-4a72-af94-9dd8a1fd6846,C0069590,C0206750,compared between severe ,ORALIT,Coronavirus Infections,1,X,[inch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
fd4eb5a8-69ce-4568-bedc-c594c7131572,C0069590,C1829939,compared between severe ,ORALIT,{Non-patient},1,X,[inch/phsu],[clna],x.x.x.x,
138d053c-d293-4be6-af33-23a70035f7f6,C0034019,citys,was key to citys ,public health medicine (field),citys,1,X,[bmod],????,H02.403.720;N01.400.550;N06.850,????
be1ab255-de61-4781-943c-bc908ef2877c,C4534538,C0801658,increased including only hospitalizations with discharge ,Mechanical thrombectomy,Diagnosis.primary:Impression/interpretation of study:Point in time:^Patient:Nominal,2,X,[topp],[clna],,
85db898c-7a21-48dd-b731-7fa318c8430e,C4534538,C1856053,increased including only hospitalizations with discharge ,Mechanical thrombectomy,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[topp],[dsyn],,x.x.x.x
3d23566a-3c7c-4c21-9deb-d0ec1a254209,C0206750,COV2,is caused by COV2,Coronavirus Infections,COV2,3,X,[dsyn],????,C02.782.600.550.200,????
380a7cda-2a47-43ba-b532-956b0f91966f,C0012634,COV2,is caused by COV2,Disease,COV2,3,X,[dsyn],????,C23.550.288,????
8ad4c50e-f160-4e80-bc37-6eb2a49bea6f,C0310255,C0745283,must Normally must employed for completion of ,survive,INFECTIOUS PROCESS,1,X,[phsu],[patf],,
fb3513b2-9976-400f-8a80-05080e1c3c9b,C1157569,C0035696,involves interaction of RPs with ,viral translation,RNA Messenger,2,X,[celf],[bacs/nnon],,D13.444.735.544
fb3513b2-9976-400f-8a80-05080e1c3c9b,C1157569,C0035696,involves interaction with viral ,viral translation,RNA Messenger,1,X,[celf],[bacs/nnon],,D13.444.735.544
78a70e43-6ba7-46ef-93e5-5c1d0a581937,C0020538,C0242656,are Additionally risk factors for ,Hypertensive disease,Disease Progression,1,X,[dsyn],[patf],C14.907.489,C23.550.291.656
ccb4f22c-6ceb-4dca-b9c6-ef1523e2d434,C0011849,C0242656,is ,Diabetes Mellitus,Disease Progression,2,X,[dsyn],[patf],C18.452.394.750;C19.246,C23.550.291.656
61ad0b7e-15f9-4b85-8361-4012aacdae80,C3489532,C0220806,extract co-occurrences among ,Cone-Rod Dystrophy 2,Chemicals,1,X,[dsyn],[chem],C11.270.152;C11.768.585.658.250;C16.320.290.152,
d4e79e2e-1ec0-4571-85c6-abc233c6c58b,C3489532,C0012634,extract co-occurrences among ,Cone-Rod Dystrophy 2,Disease,1,X,[dsyn],[dsyn],C11.270.152;C11.768.585.658.250;C16.320.290.152,C23.550.288
bedac6d5-d604-4e7c-bc5e-e226109b1e19,C3489532,C0017337,extract co-occurrences among ,Cone-Rod Dystrophy 2,Genes,1,X,[dsyn],[gngm],C11.270.152;C11.768.585.658.250;C16.320.290.152,G05.360.340.024.340
c647533a-9940-4a39-add2-d09dcacf13bc,C3489532,C0026882,extract co-occurrences among ,Cone-Rod Dystrophy 2,Mutation,1,X,[dsyn],[genf],C11.270.152;C11.768.585.658.250;C16.320.290.152,G05.365.590
2a90dcc6-7183-4e7b-a296-e03597f56722,C3489532,SPARQL,first utilized SPARQL,Cone-Rod Dystrophy 2,SPARQL,1,X,[dsyn],????,C11.270.152;C11.768.585.658.250;C16.320.290.152,????
d1792f97-3d0d-40f2-8fde-c208771f2322,C3146294,C3241922,using Average ,Generation (action),Operation Activity,1,X,[acty],[acty],,
e36d8802-8536-4daa-8604-92d6eb5c5069,C0086312,C3146294,achieved precision For edge embeddings ,Forests,Generation (action),1,X,[npop],[acty],G16.500.275.157.437;N06.230.124.343,
98496a8b-46b1-4c16-815a-02f927c8698e,C1511790,C1079230,is in their corresponding ,Detection,Subgroup A Nepoviruses,1,X,[topp],[virs],,
95528b14-b741-49d0-897b-1ef05a584b38,C3146294,C0206750,extract significant associations for ,Generation (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
9a636123-fd33-4b43-a7d2-628bafa466a8,C0042765,C0319157,AS virus as well by lower inocula,Virulence,AS virus,1,X,[biof],[virs],G06.930,
34512a5f-d9ea-4eaf-ab84-29715b8ce6a2,C0042765,inocula,AS virus as well by lower inocula,Virulence,inocula,1,X,[biof],????,G06.930,????
5ab1b8e5-1447-44e4-9bea-e38591b7da8a,C0022942,C0206419,may of may value during ,Lactoferrin,Genus: Coronavirus,1,X,[aapp/bacs],[virs],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,B04.820.504.540.150
29f519aa-d7c3-445b-a59a-6ab02fcf1264,C1566558,C1706202,are of relevant interest in ,Natural Products,Search - action,2,X,[bacs],[acty],D20.215,
9e98a0ce-7447-481c-9920-d4f1c5dcbfef,C1566558,C1718097,are of relevant interest in ,Natural Products,New medications,2,X,[bacs],[phsu],D20.215,
47f17a66-643d-4034-be22-23f6e29f3b6b,C2933176,C0325969,is common in legal ,buriti oil,Amazona,1,X,[orch/phsu],[bird],x.x.x.x,B01.050.150.900.248.710.672.050
36d90c32-b525-4552-b2f5-2a81b2522e80,COVID-19,silico,was investigated using in silico ,COVID-19,silico,4,X,[virs],????,C000657245,????
f1d3e939-81aa-4c20-8fb3-abef76bc28c8,C0005532,silico,was investigated using in silico ,biology (field),silico,4,X,[bmod],????,H01.158.273,????
fecc59d2-987d-43b1-9f5b-ea8cec54c01a,C0441655,silico,was investigated using in silico ,Activities,silico,4,X,[acty],????,,????
8a3670aa-f254-4357-af55-eeedfcc2beb6,C0542479,C0220781,is in 2GTB ,Energy Physics,Anabolism,1,X,[npop],[biof],,G03
99a7d35c-c6d0-4455-ab0d-38e5903c2009,C0542479,2GTB,is in formation of 2GTB ,Energy Physics,2GTB,2,X,[npop],????,,????
bfe317ee-ab98-44ec-9538-c5fb8db33267,C0542479,C4327142,is in formation of 2GTB ,Energy Physics,peptidase complex,2,X,[npop],[celc],,
ed1e1e99-730b-4bf0-a9d8-d9c38c90420a,C0542479,C1742862,is with 13 ,Energy Physics,CISH protein human,2,X,[npop],[aapp/bacs],,
36e8cbfc-57e5-46e3-b864-959d039b19c3,C0872152,COVID-19,is with ,Drug Development,COVID-19,2,X,[bmod],[virs],E05.290;H01.158.703.007.338;H01.181.466.338,C000657245
f5aed59c-b2a1-4599-9200-19b05a3ca2e8,C0949266,remdesivir, includes ,Therapies Investigational,remdesivir,1,X,[topp],[clnd],E02.931,
f9cb2258-aa78-4d04-9ed4-57264f3f983e,C0683465,remdesivir, includes ,novel AODU treatment method,remdesivir,1,X,[topp],[clnd],,
737173f0-da64-4e2f-b9b4-cea70030a5bf,C0206419,C0020538,is with ,Genus: Coronavirus,Hypertensive disease,1,X,[virs],[dsyn],B04.820.504.540.150,C14.907.489
36401637-c9a6-41ac-a1c4-1b7db7649cbe,C0024109,C0009450,are main ,Lung,Communicable Diseases,1,X,[bpoc],[dsyn],A04.411,C01.539.221
36401637-c9a6-41ac-a1c4-1b7db7649cbe,C0024109,C0009450,involved in ,Lung,Communicable Diseases,1,X,[bpoc],[dsyn],A04.411,C01.539.221
75c17c7b-5865-42f0-9da8-414760951093,C0206419,C0178784,triggers mechanisms main ,Genus: Coronavirus,Organ,1,X,[virs],[bpoc],B04.820.504.540.150,
75c17c7b-5865-42f0-9da8-414760951093,C0206419,C0178784,affecting most ,Genus: Coronavirus,Organ,1,X,[virs],[bpoc],B04.820.504.540.150,
168d0541-6310-4e3c-875f-f4816b49f9c1,C0939237,C3652465,combined with ,lopinavir / Ritonavir,Interferon,1,X,[phsu],[aapp/imft/phsu],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
a5ab9f8e-4338-456d-b30d-16647bd069c9,C0013227,C3652465,include ,Pharmaceutical Preparations,Interferon,1,X,[phsu],[aapp/imft/phsu],D26,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
e084794b-67cc-4df5-9209-acd034311efa,C0199176,C0206419,are critical need With rise of ,Prophylactic treatment,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
e084794b-67cc-4df5-9209-acd034311efa,C0199176,C0206419,is in moderate-to-severe onco ,Prophylactic treatment,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
6a41749d-1581-42d9-8fbc-d268cec39168,C0206419,C0751956,may may also complicated with ,Genus: Coronavirus,Acute Cerebrovascular Accidents,1,X,[virs],[dsyn],B04.820.504.540.150,C10.228.140.300.775;C14.907.253.855
c71eae18-0f11-4faa-9f48-fd905abdf98a,C0005532,C1705178,associated with comorbidities ,biology (field),Order (action),1,X,[bmod],[acty],H01.158.273,
66851c0d-d1eb-41e0-b003-e41d8261b90f,C0009450,C0029341, includes ,Communicable Diseases,Orthomyxoviridae,1,X,[dsyn],[virs],C01.539.221,B04.820.545
996484a7-87ea-42cb-93c0-7007fc0393bf,C0024264,C2062441,were higher compared with ,Lymphocyte,Influenza A,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
2d3f84ce-5c15-47a8-818d-92e1c64763ad,C0206419,C0023516,showed significantly lower levels of ,Genus: Coronavirus,Leukocytes,1,X,[virs],[cell],B04.820.504.540.150,A11.118.637;A15.145.229.637;A15.382.490
2d3f84ce-5c15-47a8-818d-92e1c64763ad,C0206419,C0023516,Show levels of,Genus: Coronavirus,Leukocytes,1,X,[virs],[cell],B04.820.504.540.150,A11.118.637;A15.145.229.637;A15.382.490
51f3c506-56fc-4131-8628-be2116087e0c,C0275522,C0012634,ratio of is In fact useful indicator of burden of ,Asymptomatic Infections,Disease,1,X,[dsyn],[dsyn],C23.550.291.187.500,C23.550.288
6532b5a9-947a-45dd-a729-4b9d15ab2235,C1948023,C0520510,design ,Stimulation (motivation),Materials,1,X,[npop],[sbst],,
e8fc808d-9bbd-43c3-8960-534cdde6f7d6,C0301872,C1175743,would find applications in context of vaccine development for ,Immune response,SARS coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150.113.937
e8fc808d-9bbd-43c3-8960-534cdde6f7d6,C0301872,C1175743,Pathogenesis against,Immune response,SARS coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150.113.937
2c6d9535-d7f2-409d-aba0-99e98ee17185,C0032285,C0026766,is with ,Pneumonia,Multiple Organ Failure,1,X,[dsyn],[patf],C08.381.677;C08.730.610,C23.550.835.525
de5bb9a4-b59f-4f4b-9b9a-cc14ef94fad7,C1457887,C4521554,comorbidities on ,Symptoms,Time of intubation:TmStp:Pt:^Patient:Qn,2,X,[sosy],[clna],,
0c3ab21f-f437-4a4d-8a24-41fdf862b242,C1265799,C1175743,is in patient with presumed ,Massive embolus,SARS coronavirus,2,X,[patf],[virs],,B04.820.504.540.150.113.937
f5106834-a123-4f39-ba88-cad406da3d9c,C0021403,C0719214,have occurred for many ,Influenza virus vaccine,century,1,X,[imft/phsu],[phsu/vita],D20.215.894.899.302,
b8e92c17-8820-46dc-a3fa-6b631984927a,C0037356,C0719214,have occurred for many ,Smallpox Viruses,century,1,X,[virs],[phsu/vita],B04.280.650.160.650.930,
88f37d66-ec01-476e-9c9a-7199bdf941ca,C0032064,C0719214,have occurred for many ,Plague,century,1,X,[dsyn],[phsu/vita],C01.252.400.310.980.745,
8485df1d-59fa-4898-a0b7-39c6c0981a7b,C1175175,C0042776,counter ,Severe Acute Respiratory Syndrome,Virus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04
8485df1d-59fa-4898-a0b7-39c6c0981a7b,C1175175,C0042776,is with authentic patient-derived ,Severe Acute Respiratory Syndrome,Virus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04
412fe3d3-8614-4400-b76e-00ad47464dd4,C0028429,C0013404,is complicated by ,Nose,Dyspnea,1,X,[bpoc],[sosy],A01.456.505.733;A04.531;A09.531,C08.618.326;C23.888.852.371
7d42c575-28fc-4c4c-9b63-8267c0504c7d,C0040732,C0206419,is in ,Transplantation,Genus: Coronavirus,1,X,[topp],[virs],E04.936,B04.820.504.540.150
c605132a-a73e-44ad-a9d6-f6439d48d42a,C0020119,C1415647,is in ,Human Development,HNRNPM gene,1,X,[phsf],[gngm],F01.525;G07.345.374,
0029ae04-30e8-4021-b05c-6dc69b2fb760,C1457887,C0037090,are mainly ,Symptoms,Signs and Symptoms Respiratory,1,X,[sosy],[sosy],,C23.888.852
20667f2e-0914-4a3c-9a26-90670fb49110,C0231528,C0027765,was most common ,Myalgia,nervous system disorder,2,X,[sosy],[dsyn],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C10
7a93bf10-64fd-4a82-9dba-0b9589fbae03,C0231528,C0018681,was most common ,Myalgia,Headache,1,X,[sosy],[sosy],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C23.888.592.612.441
57bfa9c9-5d23-49b2-a0be-5ac896312fb0,C0027765,C0018681,followed by ,nervous system disorder,Headache,2,X,[dsyn],[sosy],C10,C23.888.592.612.441
f0240349-8fa8-480f-8eed-af6e034b7d38,C0242781,C0439962,was Besides imported cases ,disease transmission,Mixture,3,X,[patf],[sbst],N06.850.310,
4551af7a-5362-453f-9300-91ce6464ecee,C0013604,C0302158,Leucocytic infiltrate of,Edema,Leucocytic infiltrate,1,X,[sosy],[patf],C23.888.277,
12079b9c-f848-4040-9594-63c90ac6fdce,C1515933,C0302158,of Edema is,Alveolus,Leucocytic infiltrate,1,X,[bpoc],[patf],,
483c2403-d886-4301-908c-31bc63614143,C0302158,C0439861,mainly consisted in interstitial ,Leucocytic infiltrate,Substance,1,X,[patf],[sbst],,
88d7080e-0e28-4ee3-97ad-379217086363,C0302158,C0024432,mainly consisted of ,Leucocytic infiltrate,macrophage,1,X,[patf],[cell],,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
f71ead03-288d-4d60-aa36-9b258720d207,C0042769,C0018787,often affected ,Virus Diseases,Heart,1,X,[dsyn],[bpoc],C02,A07.541
0385becc-4af9-4ca3-9082-9ae95edde6b7,LTCF,C1705178,is in ,LTCF,Order (action),1,X,????,[acty],????,
71111e2b-b1b5-4dcd-81b5-92beb88503aa,C0040300,C0206750,known comorbidities of ,Body tissue,Coronavirus Infections,1,X,[tisu],[dsyn],A10,C02.782.600.550.200
1c770c34-98b8-4004-bd17-84ba201934d3,C0567416,C0014609,were expressed in ,Molecule,Epithelium,1,X,[sbst],[tisu],,A10.272
811d4450-e138-4310-8789-9e7e05726126,C0567416,C4330475,were expressed in ,Molecule,Immune Cell,1,X,[sbst],[cell],,
1c8a3173-17da-4c1e-807a-4d4c4c0ea18b,C0004096,C0022709,generally led to higher expression of ,Asthma,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,D08.811.277.656.350.350.687
8622969e-3d31-4691-99bf-13b54afe60f5,C0024117,C0022709,generally led to higher expression of ,Chronic Obstructive Airway Disease,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C08.381.495.389,D08.811.277.656.350.350.687
9f78a664-2b5a-40af-844c-d66a58fdb945,C0020538,C0022709,generally led to higher expression of ,Hypertensive disease,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C14.907.489,D08.811.277.656.350.350.687
4d2fe9e9-b3a6-4a2a-b952-0b89b7773d84,C1175175,C4330475,is in ,Severe Acute Respiratory Syndrome,Immune Cell,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,
0b97a99d-6cca-483a-acd0-39a173502d38,C3176928,C0206750,might contribute to ,Condition status,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
6a8bab88-948f-4bc5-ba96-4e522a49481f,C0597360,C0206750,might contribute to ,receptor expression,Coronavirus Infections,1,X,[genf],[dsyn],,C02.782.600.550.200
a12ddd80-bb7e-4c74-a7c2-7cf6b7a802aa,C0079189,C0014038,contributes to ,cytokine,Encephalitis,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C10.228.140.430
6c90d669-8d10-47a4-94d8-cfc6bc1eeb1c,C0014038,C0679861,may Providing (action) clues to,Encephalitis,Complications of treatment,2,X,[dsyn],[patf],C10.228.140.430,
6c90d669-8d10-47a4-94d8-cfc6bc1eeb1c,C0014038,C0679861,may provide significant clues to ,Encephalitis,Complications of treatment,2,X,[dsyn],[patf],C10.228.140.430,
0b5bff6c-1077-4360-b30f-015ba433cf6c,C0014038,C1175743,may Providing (action) clues to,Encephalitis,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.430,B04.820.504.540.150.113.937
0b5bff6c-1077-4360-b30f-015ba433cf6c,C0014038,C1175743,may provide significant clues to ,Encephalitis,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.430,B04.820.504.540.150.113.937
223952b5-33aa-4f73-a304-fbe9721f2c7a,C0679861,C1175743,caused by ,Complications of treatment,SARS coronavirus,2,X,[patf],[virs],,B04.820.504.540.150.113.937
ed72818b-4fb4-47c5-8e9a-66fd3899d18f,C0078057,C0014038,probably plays role in ,vascular factor,Encephalitis,8,X,[aapp],[dsyn],x.x.x.x,C10.228.140.430
002e8c18-a521-4174-af5e-bc074303d797,C0078057,C2949735,facilitating ,vascular factor,Recruitment,4,X,[aapp],[acty],x.x.x.x,
bfb5068c-e7ab-43cc-ac42-793c681dd5ab,C0078057,C0440752,facilitating ,vascular factor,Inflammatory cell,4,X,[aapp],[cell],x.x.x.x,
8b42afd7-e716-4128-a3e2-51aee98eb11e,C0078057,C1113649,regulating level of ,vascular factor,Angiopoietins,2,X,[aapp],[aapp/bacs],x.x.x.x,D12.644.276.100.100;D12.776.467.100.100;D23.529.100.100
6ac92197-7228-470e-a492-4762b1061444,C0078057,C0006104,is distributed in ,vascular factor,Brain,2,X,[aapp],[bpoc],x.x.x.x,A08.186.211
2c28e987-df98-4158-b3a2-0c73263b7346,C1113649,C1175743,Also is considered as products of ,Angiopoietins,SARS coronavirus,2,X,[aapp/bacs],[virs],D12.644.276.100.100;D12.776.467.100.100;D23.529.100.100,B04.820.504.540.150.113.937
5c6b3b27-6b37-4243-ab96-3c1bd92b79d9,C1175175,C0235031,is with ,Severe Acute Respiratory Syndrome,Neurologic Symptoms,2,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,C10.597;C23.888.592
0c622634-c78f-40f2-b531-b92740ce3198,C1705178,C1175743,support Organ Transplantation in even,Order (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
8a83edc9-da7a-4f3f-ba3e-d796f3a024bd,C1705178,C0029216,support continued ,Order (action),Organ Transplantation,1,X,[acty],[topp],,E04.936.450
787bd2f5-26a7-4e86-b000-cd4147423eff,C1704259,C0029216,support continued ,Biochemical Pathway,Organ Transplantation,1,X,[moft],[topp],,E04.936.450
157bd023-b0e4-47ce-aa9c-7ab5948bb2ec,C1290857,C0012634,is with ,Disorder of face,Disease,1,X,[dsyn],[dsyn],,C23.550.288
906a5749-eb05-4736-bd84-87dd36db7d0f,C0221423,C0012634,is with ,Illness (finding),Disease,1,X,[sosy],[dsyn],,C23.550.288
1f65d36f-b732-4bd1-a6a0-ab833076f746,C0086982,C0007595,implicated in aberrant ,Signal Transduction Pathways,cell growth,2,X,[moft],[celf],G02.111.820;G04.835,
80acef09-a5ae-4e2f-8453-06e50db755e8,C0079189,C0301872,weakens ,cytokine,Immune response,1,X,[aapp/imft],[ortf],D12.644.276.374;D12.776.467.374;D23.529.374,
6288c7d5-cee4-4f47-8990-fda30382959c,C0079189,C0027651,weakens ,cytokine,Neoplasms,1,X,[aapp/imft],[neop],D12.644.276.374;D12.776.467.374;D23.529.374,C04
16436b30-f4d1-4102-86de-045793a0bf7c,C0206750,C3714514,may need monitored post ,Coronavirus Infections,Infection,2,X,[dsyn],[patf],C02.782.600.550.200,C01.539
16436b30-f4d1-4102-86de-045793a0bf7c,C0206750,C3714514,causing cluster ,Coronavirus Infections,Infection,1,X,[dsyn],[patf],C02.782.600.550.200,C01.539
9a417d1f-48ae-48a9-aa48-c227d548be2f,C0319157,C0032285,was identified in outbreak of ,AS virus,Pneumonia,2,X,[virs],[dsyn],,C08.381.677;C08.730.610
ea285956-4d08-4e95-afee-0ac25cf1eaa8,C0011682,wetted,using sessile wetted ,Desiccation,wetted,1,X,[npop],????,E05.196.335;G02.176,????
8363f596-7a42-40fe-9d30-c6c18a825ebb,C0006145,GGO,are areas of GGO,Breast Diseases,GGO,1,X,[dsyn],????,C17.800.090,????
ccc797b9-903d-4bfe-9d1c-dabd1fefd081,C0206419,C0857828,is in ,Genus: Coronavirus,infection in the elderly,1,X,[virs],[dsyn],B04.820.504.540.150,
96ae5af4-f575-47c5-bbc2-a87bda9c3489,C0206419,C0277562,is in ,Genus: Coronavirus,Adult disease,1,X,[virs],[dsyn],B04.820.504.540.150,
e196d1a5-c428-4970-9530-dcc19ca4e4b7,C4050231,C0206419,is in ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
22c66b78-2467-4b47-9e77-f8152ad6f1fc,C0014507,C0012655,is mathematical model based on ,Epidemiology,Disease susceptibility,2,X,[bmod],[clna],H02.403.720.500,C23.550.291.687;G07.100.250
385bed8d-4aa0-4840-987f-be3353896423,C3826426,C0012655,is mathematical model based on ,Dynamics,Disease susceptibility,2,X,[npop],[clna],,C23.550.291.687;G07.100.250
7e5e227c-cbd4-4d24-ade0-5c5f2e1ac939,C0014507,C0009450,is mathematical model based on ,Epidemiology,Communicable Diseases,2,X,[bmod],[dsyn],H02.403.720.500,C01.539.221
7d914486-b01d-4cde-a747-908ac5fec772,C3826426,C0009450,is mathematical model based on ,Dynamics,Communicable Diseases,2,X,[npop],[dsyn],,C01.539.221
4b4235df-4112-422f-812a-63ca5328974f,C0014507,C0237820,is mathematical model based on ,Epidemiology,Recovery - action,2,X,[bmod],[acty],H02.403.720.500,
5d9b2330-e788-4ac2-93b7-2d700371c101,C3826426,C0237820,is mathematical model based on ,Dynamics,Recovery - action,2,X,[npop],[acty],,
d1a8154c-1afe-4561-abce-8d2ca17c7b21,C1515884,C0206419,can cure ,Acupuncture and Oriental Medicine,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
a48f2d50-495a-43c1-ba44-6e217b9bc924,C1175743,C0075804,encode ,SARS coronavirus,TANDEM,2,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,
6b10b717-9d39-4a15-8c8b-1d5edc9a14a5,C1175743,C0582263,encode TANDEM macrodomains within non,SARS coronavirus,Structural protein,2,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,
879f9314-c42a-4faa-9365-574f801c591a,Mac1,C0960756,implicating domain as ,Mac1,factor A,2,X,????,[orch],????,x.x.x.x
9ce0543e-fd8c-438f-85ba-d557f5ab99d7,Mac1,C0042765,implicating domain as ,Mac1,Virulence,1,X,????,[biof],????,G06.930
dc37a99c-8e12-41ce-ad9f-105703beb596,Mac1,C0699748,is essential for ,Mac1,Pathogenesis,1,X,????,[patf],????,
4e5cc71e-9021-41d8-8d03-8940a1f15a97,Mac1,C0599779,is essential for ,Mac1,Animal Model,1,X,????,[anim],????,E05.598
b12e3afc-4a4b-4dc4-930c-5f88f8108f31,Mac1,C0009450,is essential for ,Mac1,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
ef0a5224-ff21-4f85-826a-7c809567bdbf,C0699748,C0599779,is in multiple ,Pathogenesis,Animal Model,1,X,[patf],[anim],,E05.598
32a9d1a1-af93-4999-99e6-d9fee03ce8b2,C0699748,C0009450,is in multiple ,Pathogenesis,Communicable Diseases,1,X,[patf],[dsyn],,C01.539.221
f1b87562-4b4e-4c41-84e8-fc1568cfa8e3,C0033666,C0301872,is part of ,Post-Translational Protein Processing,Immune response,1,X,[moft],[ortf],G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600,
0a9751e6-6c7f-4b46-8376-c46bfc4caef5,C0033666,C0042769,is part of ,Post-Translational Protein Processing,Virus Diseases,1,X,[moft],[dsyn],G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600,C02
b0b31fb5-c028-4eeb-99a7-58dd8dd1ac54,C1704241,C0001461,is with ,complex (molecular entity),Adenosine Diphosphate Ribose,2,X,[chvs],[bacs/nnon],,D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125
3328fe2d-4de1-4f89-a4b4-397b3d485aa0,Mac1,C1704241,is in ,Mac1,complex (molecular entity),2,X,????,[chvs],????,
64f44ef3-d6c7-4d55-b7fa-702a6d7667c3,Mac1,C0001461,is in ,Mac1,Adenosine Diphosphate Ribose,2,X,????,[bacs/nnon],????,D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125
6452bd95-4e3a-48d5-89a0-bfa313f55a59,C3694279,C1707455,shown by structural ,Middle East Respiratory Syndrome,Comparison,1,X,[dsyn],[acty],C02.782.600.550.200,
336ed183-0340-4e45-9078-5b2a09b51031,C0206419,C0033666,removes ,Genus: Coronavirus,Post-Translational Protein Processing,1,X,[virs],[moft],B04.820.504.540.150,G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
9c9b5c85-34c7-4a04-82c3-6f9aa29fccaf,C0206419,C0001461,removes ,Genus: Coronavirus,Adenosine Diphosphate Ribose,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125
2310c9a2-25e9-415c-ae06-d5a3a06f55b6,C0206419,C0033684,removes Adenosine Diphosphate Ribose from,Genus: Coronavirus,Proteins,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D12.776
f9cbecd2-3ee2-47a1-85be-1eba6258f0d7,C1514562,C0699748,is essential for CoV ,Protein Domain,Pathogenesis,1,X,[amas],[patf],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
f0236656-fe41-40f8-9ab8-d16a3bbe3d4e,C1514562,C0087111,may may novel ,Protein Domain,Therapeutic procedure,1,X,[amas],[topp],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,E02
30415fff-aae0-462a-8f54-e6da045d8634,C0020964,C0003320,exposure sunlight exposure to various ,Immunity,Antigens,3,X,[phsf],[imft],G12.450,D23.050
e84f0fa1-09fc-466a-8f19-ce4ef1ee8177,C0025594,C1825598,may have ,Meteorological Factors,IMPACT gene,3,X,[npop],[gngm],G16.500.750;N06.230.300,
f86cd0d5-3dfe-4604-bc12-eb18b61cf543,C0025594,C1175743,may have ,Meteorological Factors,SARS coronavirus,3,X,[npop],[virs],G16.500.750;N06.230.300,B04.820.504.540.150.113.937
14c8fdc5-4855-4b98-afe4-e6ebe5578d28,C0020964,C1825598,may have ,Immunity,IMPACT gene,3,X,[phsf],[gngm],G12.450,
ea35e421-653f-43bc-b9b6-171cf4162cef,C0391001,C0237820,is with satisfactory ,peginterferon alfa-2a,Recovery - action,1,X,[aapp/imft/phsu],[acty],x.x.x.x,
2b4a255a-52f0-4406-936b-61fd1eb22c8f,C0700271,C0525033,receptor by,M Protein multiple myeloma,Probiotics,1,X,[aapp/imft],[bact],x.x.x.x,G07.203.300.456.500;J02.500.456.500
d01bb641-8d08-41d4-8211-82ee9259c8c7,C1522002,C0567416,counter effect of ,RNA Recognition Motif,Molecule,1,X,[aapp/bacs],[sbst],G02.111.570.820.709.275.500.869.500,
f3370d89-cbc4-440a-a511-886c08807121,C1522002,C4281807,Vitronectin human of S,RNA Recognition Motif,Vitronectin human,1,X,[aapp/bacs],[aapp/bacs],G02.111.570.820.709.275.500.869.500,
a83a2d58-34de-4b4f-a82d-c4f16c769007,C1522002,C0022709,Vitronectin human with,RNA Recognition Motif,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],G02.111.570.820.709.275.500.869.500,D08.811.277.656.350.350.687
f8e4c01f-28f5-408a-bd12-0f8f734a6e52,C1522002,C0597357,Vitronectin human with,RNA Recognition Motif,receptor,1,X,[aapp/bacs],[aapp/rcpt],G02.111.570.820.709.275.500.869.500,
83633a5a-ad38-4d8a-93db-5ec83fe36f21,C4281807,C0597357,is with ,Vitronectin human,receptor,3,X,[aapp/bacs],[aapp/rcpt],,
99ae0fcc-62eb-49ef-9bb5-21744172e6c0,C0206419,C0815353,is in ,Genus: Coronavirus,Male external urethral sphincter,1,X,[virs],[bpoc],B04.820.504.540.150,
7a756d25-cc46-4e7f-8c6c-59095b617331,C0042769,C0150755,calls for extended ,Virus Diseases,Safety precautions,1,X,[dsyn],[topp],C02,
b71b7325-ab04-4ab4-b0bf-309464386f7a,C0083528,C0935989,managed with ,N(6)-carboxymethyllysine,imatinib,1,X,[aapp/bacs],[orch/phsu],x.x.x.x,
8431448a-160a-45e7-9370-396926ea60bd,bullous,C0041834,is with ,bullous,Erythema,1,X,????,[dsyn],????,C17.800.229;C23.888.885.328
d67ed25b-4b90-4d31-a9a4-3414673b3203,C0041755,C0041834,is with ,Adverse reaction to drug,Erythema,1,X,[patf],[dsyn],C25.100,C17.800.229;C23.888.885.328
15304c7b-0682-4c17-8699-eb9efb3b6596,C0206419,C0042077,is in also ,Genus: Coronavirus,Urology,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.810.860
d1d27cfc-45ae-4cb4-8866-2243c9530537,C0001443,C0001471,counteracts effects by ,Adenosine,Receptors Purinergic P1,1,X,[bacs/nnon/phsu],[aapp/rcpt],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,D12.776.543.750.695.700.700;D12.776.543.750.720.700.700
6462c0aa-d76c-4334-9103-b417bc82e9a1,C0001443,C1948023,counteracts effects by ,Adenosine,Stimulation (motivation),1,X,[bacs/nnon/phsu],[npop],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,
fe1262b3-fb95-46bf-b5ba-6de1576aea60,C0001443,C0004482,counteracts ,Adenosine,Azathioprine,1,X,[bacs/nnon/phsu],[hops/orch/phsu],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111
ec6f5840-494c-43ea-832e-6a6de9d3b9d2,C1325584,C0006826,are critical ,lateral element,Malignant Neoplasms,1,X,[celc],[neop],,C04
f13e41f9-7fec-469a-ad0e-abb8fb288a93,C0015967,C0850149,is with ,Fever,Dry cough,1,X,[sosy],[sosy],C23.888.119.344,
b5fa5f0d-46a9-4dc4-9571-f6cceb0c6bf4,C0242184,C0850149,is with ,Hypoxia,Dry cough,1,X,[patf],[sosy],C23.888.852.079,
1da1e733-9518-4781-ac00-a81a71e7dd63,C3274800,C0206419,prevalence of ,Disease Presentation,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
2e59a382-0feb-45d1-a55f-90b8950e05ff,C0206419,C0010340,developed ,Genus: Coronavirus,Critical Illness,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.625
1aa07f94-0ccb-4b49-9343-70ff9197fc92,C1000689,C0206419,M of ,Clerodendrum,Genus: Coronavirus,1,X,[plnt],[virs],B01.650.940.800.575.912.250.583.520.121,B04.820.504.540.150
581a8c6b-e75e-420d-8e63-76aafaeed20f,C0075816,C0597400,displaying efficacy with concerned,taraxerol,respiratory protein,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,
bc801f12-3ba9-44d7-a712-d7c14350ca60,C0075816,C4050231,exhibited better ,taraxerol,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[orch/phsu],[clna],x.x.x.x,
3a6fdf78-4360-41c4-a676-102ea440607a,C0206419,C0850624,is emergent ,Genus: Coronavirus,cardiovascular risk factor,1,X,[virs],[dsyn],B04.820.504.540.150,
771a6e75-327f-4e86-ba43-43e816863b78,C0206419,C1412002,was reported responsible for cluster of ,Genus: Coronavirus,Atypical pneumonia,2,X,[virs],[dsyn],B04.820.504.540.150,
45e1b95e-9aa0-42fe-93e5-fb5b1d42bfb7,C0206419,C0314732,is novel ,Genus: Coronavirus,Infectious agent,1,X,[virs],[orgm],B04.820.504.540.150,
f5850031-6d2a-4b89-a9d9-364b61a46931,C0206419,C0225336,affecting ,Genus: Coronavirus,Endothelial Cells,1,X,[virs],[cell],B04.820.504.540.150,A11.436.275
df1ec681-8b4a-417e-8fb7-cd13f2feea21,C0206419,C0598197,is novel pandemic ,Genus: Coronavirus,contagion,1,X,[virs],[npop],B04.820.504.540.150,
df1ec681-8b4a-417e-8fb7-cd13f2feea21,C0206419,C0598197,is highly ,Genus: Coronavirus,contagion,1,X,[virs],[npop],B04.820.504.540.150,
1dcdd1bd-b3c0-4d0b-bc0d-95709013dbe4,C0012634,C0598197,is novel pandemic ,Disease,contagion,1,X,[dsyn],[npop],C23.550.288,
1dcdd1bd-b3c0-4d0b-bc0d-95709013dbe4,C0012634,C0598197,is highly ,Disease,contagion,1,X,[dsyn],[npop],C23.550.288,
c4667b17-4c88-4e21-91fb-78829d87d8cd,C0598197,C0015967,frequently presents with ,contagion,Fever,1,X,[npop],[sosy],,C23.888.119.344
ffbe3478-d5bf-4ec1-b256-45a76ed9d054,C0035668,C0026809,is in ,RNA,Mus,1,X,[nnon],[mamm],D13.444.735,B01.050.150.900.649.313.992.635.505.500
19d329a2-519f-41bf-96c3-da93791a715c,situ,C0026809,is in ,situ,Mus,1,X,????,[mamm],????,B01.050.150.900.649.313.992.635.505.500
f173abea-ae1d-4313-a191-ef49280b3a98,C0206419,C1742865,colocalized with ,Genus: Coronavirus,TMPRSS2 protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150,x.x.x.x
3dd77a46-193d-490d-88ee-faf6aaca6560,C0035668,C1742865,colocalized with ,RNA,TMPRSS2 protein human,1,X,[nnon],[aapp/enzy],D13.444.735,x.x.x.x
27c0c450-b3d3-488a-a6e9-566166214b91,C0206419,C0035696,colocalized with ,Genus: Coronavirus,RNA Messenger,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D13.444.735.544
3208b463-68c7-47bd-baac-9d962ffee9ce,C0035668,C0035696,colocalized with ,RNA,RNA Messenger,1,X,[nnon],[bacs/nnon],D13.444.735,D13.444.735.544
9db14a0d-b7f2-4644-82ec-515899f3081b,C0035668,C0024109,colocalized in ,RNA,Lung,1,X,[nnon],[bpoc],D13.444.735,A04.411
d05fd223-d462-4bd5-99b6-03f0781ccd53,C0206419,C4289682,may involve ,Genus: Coronavirus,Direct Transmission,2,X,[virs],[patf],B04.820.504.540.150,
4b8dbfab-33e0-4113-9867-630977d90d56,C0206419,C0024141,is in patients with ,Genus: Coronavirus,Lupus Erythematosus Systemic,4,X,[virs],[dsyn],B04.820.504.540.150,C17.300.480;C20.111.590
fbfd5a29-ccd2-440d-bf44-9377a6ab002e,C0206419,C0684249,is in patients with ,Genus: Coronavirus,Carcinoma of lung,2,X,[virs],[neop],B04.820.504.540.150,
53f64561-98c7-4ee3-aff3-262dccce3723,C0684249,C0015967,is with ,Carcinoma of lung,Fever,2,X,[neop],[sosy],,C23.888.119.344
a326641a-032c-420c-a44d-bfe493e037f5,C0206419,C0012655,raised many questions about higher ,Genus: Coronavirus,Disease susceptibility,1,X,[virs],[clna],B04.820.504.540.150,C23.550.291.687;G07.100.250
e8b1d430-07a9-42c6-a170-242b7eff4058,C1565489,C0206750,could potentially induce more complications in patients with ,Renal Insufficiency,Coronavirus Infections,4,X,[dsyn],[dsyn],C12.777.419.780;C13.351.968.419.780,C02.782.600.550.200
90434efb-66ee-4b08-8b12-de7716ac806a,C2948600,C0020538,summarize prevalence of ,Aim,Hypertensive disease,1,X,[inch/phsu],[dsyn],,C14.907.489
6697604a-1a76-4ddd-80ec-91e6bdb80f46,C0302106,C0040034,account for delayed-phase ,Platelet destruction,Thrombocytopenia,2,X,[comd],[dsyn],,C15.378.140.855
41572981-5849-429e-a21d-842b0e8ef7bb,C0026187,C1254351,offers advantages compared to ,Minocycline,Pharmacologic Substance,2,X,[antb/orch],[phsu],D02.455.426.559.847.562.900.550;D04.615.562.900.550,
887f0227-9f79-4a67-b983-2568972053b4,C0206061,C0016059, includes ,Pneumonia Interstitial,Fibrosis,1,X,[dsyn],[patf],C08.381.483,C23.550.355
dc6a4b27-d61f-4b1b-adad-6e034ffbe2e8,C1457887,C0206062,is in ,Symptoms,Lung Diseases Interstitial,6,X,[sosy],[dsyn],,C08.381.483
d68ae0bb-72c9-4c21-a298-3bb8b75caad4,C0012655,C0010076,is in ,Disease susceptibility,Coronaviridae,1,X,[clna],[virs],C23.550.291.687;G07.100.250,B04.820.504.540
ec41a2df-5c5c-48c6-9ddb-823ae304bf48,C3652465,C0022709,highly upregulates ,Interferon,Peptidyl-Dipeptidase A,1,X,[aapp/imft/phsu],[aapp/enzy/imft],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D08.811.277.656.350.350.687
b65512aa-8f1f-41f6-81f6-262374d086b9,C0030946,C0026727,is part of T2 ,Endopeptidases,Mucous body substance,1,X,[aapp/enzy/phsu],[bdsu],D08.811.277.656.300,A12.200.503
2cf98e8a-4436-42b1-8fe8-784c511fcdbd,C0030946,T2,is part of T2 ,Endopeptidases,T2,1,X,[aapp/enzy/phsu],????,D08.811.277.656.300,????
95e0e293-8064-492f-a723-4d58342c82cf,C0030946,C0021368,is part of T2 ,Endopeptidases,Inflammation,1,X,[aapp/enzy/phsu],[patf],D08.811.277.656.300,C23.550.470
ca906a95-227e-41a2-8e43-8339a56bf86a,C0030946,C3266814,is part of T2 ,Endopeptidases,Action,1,X,[aapp/enzy/phsu],[acty],D08.811.277.656.300,
f6ff7581-7420-4ae1-9983-03b824472255,C0030946,C0214743,is part of T2 ,Endopeptidases,Interleukin-13,1,X,[aapp/enzy/phsu],[aapp/imft],D08.811.277.656.300,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
92ba28e6-90fc-4bd0-bbcb-999b01f3c4cf,C0206750,C0559758,can induce ,Coronavirus Infections,MULTISYSTEM DISORDER,1,X,[dsyn],[dsyn],C02.782.600.550.200,
def7af9a-e3a7-4c3c-a900-aefd49703a12,C0206750,C0005854,cross ,Coronavirus Infections,Blood - brain barrier anatomy,1,X,[dsyn],[bpoc],C02.782.600.550.200,A07.035;A08.186.211.035
8284c9bd-1975-421b-8462-424078e0b92b,C1299575,C0206750,recommended for ,Treatment modification,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
8e3316b4-a4e1-40a3-bd26-a6bc151911a4,C1299575,C0021390,is in ,Treatment modification,Inflammatory Bowel Diseases,5,X,[topp],[dsyn],,C06.405.205.731;C06.405.469.432
05c487b4-ef07-4a25-93ec-52a452774532,C0394664,C0184661,is effective ,Acupuncture procedure,Interventional procedure,1,X,[topp],[topp],E02.190.044,
1e9d8431-d429-4dc8-a21d-85c723b5b1ed,C0394664,C0012634,is effective and safe Interventional procedure for,Acupuncture procedure,Disease,1,X,[topp],[dsyn],E02.190.044,C23.550.288
18c188c0-221a-4483-8aa7-d50b1dccfbac,C0020852,C0206750,is in ,Immunoglobulin G,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,C02.782.600.550.200
34c6fd14-17a3-4666-b2f0-0db91ebdc710,C0012634,COVID19,significantly increase COVID19,Disease,COVID19,1,X,[dsyn],????,C23.550.288,????
cd7ceb70-7515-404d-b38f-19951493fb8e,C0006826,COVID-19,significantly increase COVID19,Malignant Neoplasms,COVID-19,1,X,[neop],[virs],C04,C000657245
0d032ad1-16e2-4e6f-b00e-6f665b395f16,C0006826,COVID19,significantly increase COVID19,Malignant Neoplasms,COVID19,1,X,[neop],????,C04,????
c7c4c5ba-a7b7-4494-a484-62a3f316747c,C0009450,enzyme2,is facilitated by angiotensinconverting enzyme2,Communicable Diseases,enzyme2,1,X,[dsyn],????,C01.539.221,????
6ca2bf52-990c-42de-a1e5-580b4c518785,C0009450,C0022709,is facilitated by ,Communicable Diseases,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C01.539.221,D08.811.277.656.350.350.687
c63f08c5-ec0d-4374-a1ea-768747355b0d,C0009450,C0006826,is in ,Communicable Diseases,Malignant Neoplasms,1,X,[dsyn],[neop],C01.539.221,C04
fa6f46bb-0916-4dc4-a4c9-dae85e406f3d,C0127400,C0006826,is in ,Mediator brand of benfluorex hydrochloride,Malignant Neoplasms,1,X,[orch/phsu],[neop],,C04
074a099b-590a-4425-9dcb-2459ae91777f,C0030946,C0279671,was overexpressed in ,Endopeptidases,Cervical Squamous Cell Carcinoma,2,X,[aapp/enzy/phsu],[neop],D08.811.277.656.300,
b4d70321-6f23-43ba-8666-d5f3f1b1005b,C0030946,C0007112,was overexpressed with ,Endopeptidases,Adenocarcinoma of prostate,2,X,[aapp/enzy/phsu],[neop],D08.811.277.656.300,
4b2d9dc4-aa1f-490b-abad-eb29ede3c2ea,CTSL,C0598798,was upregulated in ,CTSL,Lymphoid neoplasm,1,X,????,[neop],????,
bf27bd74-048f-4159-9f51-8cfbf2db2e7d,CTSL,C0024299,was upregulated in ,CTSL,Lymphoma,1,X,????,[neop],????,C04.557.386;C15.604.515.569;C20.683.515.761
4fd040d8-904c-4f7c-8936-2a5c55679e21,C0024880,C4330475,are ,mast cell,Immune Cell,1,X,[cell],[cell],A11.329.427;A15.382.652,
d35d1de8-3710-43e4-af98-f1fdba6d6516,C0024880,C0920672,are ,mast cell,virus pathogenesis,2,X,[cell],[comd],A11.329.427;A15.382.652,
03248624-1ef4-4583-b1d6-bcbaca3b7a16,C0037473,C0024109,improve Mus Continuance of life in,Sodium,Lung,1,X,[bacs/elii],[bpoc],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,A04.411
03248624-1ef4-4583-b1d6-bcbaca3b7a16,C0037473,C0024109,improve Viral respiratory infection changes in,Sodium,Lung,1,X,[bacs/elii],[bpoc],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,A04.411
98028cf9-2949-4b47-befb-42c94117e04d,C0037473,C0729531,improve Viral respiratory infection changes in,Sodium,Viral respiratory infection,3,X,[bacs/elii],[dsyn],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
8fd9277e-4cb3-49e1-b186-bdb362b8692d,C0037473,C0220806,PREVENT (product) release of inflammatory,Sodium,Chemicals,1,X,[bacs/elii],[chem],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
a0003e62-4537-48cc-9e65-5baebaac3deb,C0037473,C0920880,described as MC ,Sodium,Stabilizer - function,1,X,[bacs/elii],[ortf],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
06958f7a-597e-47bb-8f03-234ebbca1c89,C0037473,C0026809,improve ,Sodium,Mus,1,X,[bacs/elii],[mamm],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,B01.050.150.900.649.313.992.635.505.500
3d1d4b24-57e0-4fbd-84b2-a753069ad966,C0037473,C0038952,improve ,Sodium,Continuance of life,1,X,[bacs/elii],[acty],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,I03.784
88e74dc3-fbaa-45cd-8ef8-99340899f7e9,C0069964,C0019868,is involved also in MCs ,palmidrol,Homeostasis,1,X,[orch],[biof],x.x.x.x,G07.410
2b10494f-536e-46d1-ae25-2731d4ae2423,C0019868,C0042769,is with inhibitory effect on respiratory tract during ,Homeostasis,Virus Diseases,1,X,[biof],[dsyn],G07.410,C02
d5dc2a24-ea35-44fc-9416-297a55654334,C0030738,C0024109,playing role in inflamed ,Peas - dietary,Lung,1,X,[food],[bpoc],B01.650.940.800.575.912.250.401.630,A04.411
4ec0d197-6b51-46c3-abe4-564b0ea92120,C0030738,C0206750,playing role in inflamed ,Peas - dietary,Coronavirus Infections,1,X,[food],[dsyn],B01.650.940.800.575.912.250.401.630,C02.782.600.550.200
61e3a4fb-01d3-44c7-8b41-56717bfd1c40,C0037473,C0127400,suppress pro-inflammatory ,Sodium,Mediator brand of benfluorex hydrochloride,1,X,[bacs/elii],[orch/phsu],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
c9606cf8-c21d-4ef5-9dc8-13b3f7eacd22,C0037473,C1879547,suppress MC ,Sodium,Activation action,1,X,[bacs/elii],[acty],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
f8b878b3-c8a1-42bb-b6bf-f7e621475bd7,C0030738,C0127400,suppress pro-inflammatory ,Peas - dietary,Mediator brand of benfluorex hydrochloride,1,X,[food],[orch/phsu],B01.650.940.800.575.912.250.401.630,
cab7a498-11d1-4f6c-827b-ba6c734094e3,C0030738,C1879547,suppress MC ,Peas - dietary,Activation action,1,X,[food],[acty],B01.650.940.800.575.912.250.401.630,
40a18e5f-8db8-4e44-a43d-07ca07f4316d,C1175743,C0022742,has brought world to its ,SARS coronavirus,Knee,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,A01.378.610.450
9846facb-2be0-4efe-8f4c-a8072122037c,C0012634,C0022742,has brought world to its ,Disease,Knee,1,X,[dsyn],[bpoc],C23.550.288,A01.378.610.450
ce993252-0ec8-4b41-8dec-7ffd6b71d92b,C0242821,C0206750,indicates sex differences in clinical outcomes of ,Human body,Coronavirus Infections,1,X,[humn],[dsyn],I01.076.201.450.560;K01.093.378,C02.782.600.550.200
98f220d8-e4b5-4874-ac4e-c35f7e7a9cee,C2745965,C0206750,caused by ,Emergencies [Disease/Finding],Coronavirus Infections,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.600.550.200
98f220d8-e4b5-4874-ac4e-c35f7e7a9cee,C2745965,C0206750,is in patients with ,Emergencies [Disease/Finding],Coronavirus Infections,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.600.550.200
98f220d8-e4b5-4874-ac4e-c35f7e7a9cee,C2745965,C0206750,should During pandemic should acquainted with ,Emergencies [Disease/Finding],Coronavirus Infections,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.600.550.200
1d674e11-8622-47c4-927f-458f45cfbc28,C0021966,durante,is in completo isolamento durante da ,Iodides,durante,1,X,[inch],????,D01.248.497.158.490;D01.475.410,????
5382a9f7-cf52-4a13-9a73-0e74a25e24df,C0021966,C0023749,is in completo isolamento durante da ,Iodides,Linoleic Acid,1,X,[inch],[bacs/orch/phsu],D01.248.497.158.490;D01.475.410,D10.251.355.310.515.500;D10.251.355.343.500.500
bf6b304e-0ae1-4cbe-aaf5-cbf48b1fdb62,C0021966,da,is in completo isolamento durante da ,Iodides,da,1,X,[inch],????,D01.248.497.158.490;D01.475.410,????
1d128ed7-5d21-43f4-9912-1e45c917bc01,TT,C0021966,Come comunicare con durante da ,TT,Iodides,1,X,????,[inch],????,D01.248.497.158.490;D01.475.410
dc93d6ca-bc59-4dbe-bd23-a4f1719c5bb1,TT,durante,Come comunicare con durante da ,TT,durante,1,X,????,????,????,????
93f7627a-401a-4f82-8558-d350eca4c25a,TT,C0023749,Come comunicare con durante da ,TT,Linoleic Acid,1,X,????,[bacs/orch/phsu],????,D10.251.355.310.515.500;D10.251.355.343.500.500
8c671b85-88f7-4e06-83b1-fe5d474e4dbe,TT,da,Come comunicare con durante da ,TT,da,1,X,????,????,????,????
91403bed-da15-41a2-8e82-8ea48de636f4,TT,C0206750,Come comunicare con durante da ,TT,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
f079381a-634c-4c4e-aacd-6467ba57b54a,C0039082,C1706374,is in ,Syndrome,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C23.550.288.500,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
d2cd1e34-cee1-4291-9138-e28c6df6ec6e,C0547605,C0309872,help ,prevention of infection,PREVENT (product),2,X,[topp],[phsu],,
ff256a69-4e84-49b4-8a44-8d0a05e34cd1,C0547605,C0063034,becoming independent ,prevention of infection,huperzine B,2,X,[topp],[orch/phsu],,x.x.x.x
eb6f0a60-d625-4dfc-819e-d871518c0042,C0547605,C0242781,becoming independent ,prevention of infection,disease transmission,2,X,[topp],[patf],,N06.850.310
dd7ef644-e245-4ef2-9d7b-85a666dc8834,C0199176,LGBTQ,mitigate Psychological Trauma ramifications among LGBTQ,Prophylactic treatment,LGBTQ,2,X,[topp],????,,????
dfc63033-651d-4828-8838-e69c69bf6e97,C0199176,C3203533,mitigate ,Prophylactic treatment,Psychological Trauma,4,X,[topp],[mobd],,F03.950.750.375
c9d71755-43df-4923-a688-529ae93ae14e,C0574785,C0009830,is related to high ,Lower Urinary Tract Symptoms,Consumption of goods,1,X,[sosy],[acty],C23.888.942.343,
0eac30de-d107-4cbf-9d46-eeae89449fb5,C0206058,C0543467,individualizing ,Elective Surgical Procedures,Operative Surgical Procedures,1,X,[topp],[topp],E04.249,E04
cab2d82a-dde0-4953-8202-74041eae75c9,C0206058,C1707391,individualizing ,Elective Surgical Procedures,Choose (action),1,X,[topp],[acty],E04.249,
91892864-865d-464f-a2e3-14ba42159f52,C0270724,C0005528,use ,Infantile Neuroaxonal Dystrophy,Biological Transport,2,X,[dsyn],[celf],C10.228.140.744,G03.143
29e4c86b-ca25-4c40-b6a5-49416b1187cc,C1880355,C0206750,is in patients with ,Discover,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
29e4c86b-ca25-4c40-b6a5-49416b1187cc,C1880355,C0206750,improving diagnosis in ,Discover,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
965fb895-338f-4ac7-b50d-9a9b4c799e32,physico,C1179907,enable diffuse passively through ,physico,Wall of endosome,1,X,????,[celc],????,
d0597152-fcde-4604-b537-a3d055e2eccd,C0243178,C1179907,enable diffuse passively through ,chemical properties,Wall of endosome,1,X,[npop],[celc],,
fba73e97-3313-42c5-a019-f49f301b14e0,physico,C1659610,undergo trapping in ,physico,vesicle lumen,2,X,????,[celc],????,
792378aa-2e10-4196-8b73-9a3219178924,C0243178,C1659610,undergo trapping in ,chemical properties,vesicle lumen,2,X,[npop],[celc],,
93365d57-654e-4c61-a5df-9f44e0d78ad8,C1947930,C0309872,Aim to,Cleaning (activity),PREVENT (product),2,X,[acty],[phsu],,
f769cac0-3241-49d7-a3e5-ee03e303a755,C0184661,C0309872,Aim to,Interventional procedure,PREVENT (product),2,X,[topp],[phsu],,
640685c3-464f-46ff-bb57-2cfeba55edcb,C1947930,C0445623,Aim regardless of,Cleaning (activity),Microorganism,2,X,[acty],[orgm],,
2a95a618-dcc4-43fb-8532-8432651cf2cf,C0184661,C0445623,Aim regardless of,Interventional procedure,Microorganism,2,X,[topp],[orgm],,
c16164a6-af10-4784-8695-0f5d5a4c8a1c,C1175175,C0719214,is third zoonotic ,Severe Acute Respiratory Syndrome,century,1,X,[dsyn],[phsu/vita],C02.782.600.550.200.750;C08.730.730,
c16164a6-af10-4784-8695-0f5d5a4c8a1c,C1175175,C0719214,is third Coronavirus Infections identified during twentyfirst,Severe Acute Respiratory Syndrome,century,3,X,[dsyn],[phsu/vita],C02.782.600.550.200.750;C08.730.730,
1e98a56e-dfd0-4e8a-a785-73c4a95c3d1b,C0041621,C0204727,managing critically ill patients on ,Ultrasonic Shockwave,Isolation procedure,1,X,[npop],[topp],G01.750.770.776.891.500,
6b62c2a0-e1e5-46c4-a8fa-c72161657329,C1175175,C0012634,is major cause of mortality after ,Severe Acute Respiratory Syndrome,Disease,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C23.550.288
8aca8f36-4676-47a8-b7e2-77b80ae7c0a2,C0520817,C1457887,may may ,Physical disability,Symptoms,1,X,[patf],[sosy],,
c9875dfb-e17c-439b-a03c-13ab34a64a81,C0520817,C0730321,may may ,Physical disability,Punctate inner choroidopathy,1,X,[patf],[dsyn],,
dfa0275a-96df-451c-a886-806b28ddc76c,C0338656,C1457887,may may ,Impaired cognition,Symptoms,1,X,[mobd],[sosy],F03.615.250.700,
52f4b633-3206-4af6-bae6-0356ebb7cd0b,C0338656,C0730321,may may ,Impaired cognition,Punctate inner choroidopathy,1,X,[mobd],[dsyn],F03.615.250.700,
96e9c9bc-076f-4a84-8a45-dc683e300e5d,C1815399,C0730321,minimize ,Special Care (pharmacologic substance),Punctate inner choroidopathy,1,X,[phsu],[dsyn],,
c7071bad-c515-404e-b4ec-d19309f8d6b5,C3536912,C3830624,of darunavir 800 MG is,Human Immunodeficiency Virus Protease Inhibitor [EPC],Cytochrome P450 3A4 Inhibitor,1,X,[phsu],[chvf],,
9f12158c-2400-407e-806d-652a08e91757,C3505765,C3830624,of darunavir 800 MG is,darunavir 800 MG,Cytochrome P450 3A4 Inhibitor,1,X,[clnd],[chvf],,
14e38f78-d278-4036-8592-c5c577805fc3,C3830624,C0599685,is indicated in combination with ,Cytochrome P450 3A4 Inhibitor,Anti-Retroviral Agents,1,X,[chvf],[phsu],,D27.505.954.122.388.077
40edbc2b-64e7-4771-bf1f-5ff9ce22e90c,C3830624,C0019693,is indicated in combination with ,Cytochrome P450 3A4 Inhibitor,HIV Infections,1,X,[chvf],[dsyn],,C02.782.815.616.400;C02.800.801.400;C20.673.480
2bbe17cb-e373-4438-a539-f01414b49de8,C1435444,C1516048,Activities of was,darunavir,Assessed,1,X,[orch/phsu],[acty],D02.065.884.438;D02.241.081.251.222;D02.886.590.700.400;D03.383.312.303,
7a3cecc4-8006-456f-8a36-659f4c46cc10,C0003451,C1516048,were To end ,Antiviral Agents,Assessed,2,X,[phsu],[acty],D27.505.954.122.388,
75b51e18-229f-4ced-a200-11cf8750a8af,C0441655,C1516048,was ,Activities,Assessed,1,X,[acty],[acty],,
ea118c29-50ad-47eb-89ac-05568c3a5e31,C0013936,C0319157,could could affected by ,Embryonic Development,AS virus,1,X,[ortf],[virs],G07.345.500.325.180;G08.686.784.170.104,
22206eb8-4e2d-4353-bc3b-e9e3280462d1,C0543467,C0278996,is in ,Operative Surgical Procedures,Malignant Head and Neck Neoplasm,2,X,[topp],[neop],E04,
3a827b97-cf65-44e5-b80f-a3967c333470,C1457887,C0007222,were more common in patients with ,Symptoms,Cardiovascular Diseases,1,X,[sosy],[dsyn],,C14
9ae0435f-8928-4c79-8123-fe0d162f6809,C0019046,C0849867,were ,Hemoglobin,Widespread Disease,1,X,[aapp/bacs],[dsyn],D12.776.124.400;D12.776.422.316.762,
f022754e-b109-4c99-b44a-c3d793609f31,C0007222,C0012634,was associated with critical ,Cardiovascular Diseases,Disease,1,X,[dsyn],[dsyn],C14,C23.550.288
f022754e-b109-4c99-b44a-c3d793609f31,C0007222,C0012634,increase chances of fatal ,Cardiovascular Diseases,Disease,1,X,[dsyn],[dsyn],C14,C23.550.288
8e41a061-fa33-4a3d-9850-d0ee83caaeec,CVD,C0206750,are recommended in ,CVD,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
c97a5b43-9814-4e61-a896-d9b99859ba25,C1516048,C0206750,are recommended in ,Assessed,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
c97a5b43-9814-4e61-a896-d9b99859ba25,C1516048,C0206750,governing medical recommendations regarding UME during ,Assessed,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
c97a5b43-9814-4e61-a896-d9b99859ba25,C1516048,C0206750,is in responses to ,Assessed,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
c97a5b43-9814-4e61-a896-d9b99859ba25,C1516048,C0206750,provide answers in patients with ,Assessed,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
6f4cd763-4b93-45b6-9339-2101d432f2d9,CVD,C0007222,are recommended in ,CVD,Cardiovascular Diseases,1,X,????,[dsyn],????,C14
34db1170-7cdf-4543-bd5c-ca955e634dd5,C1516048,C0007222,are recommended in ,Assessed,Cardiovascular Diseases,1,X,[acty],[dsyn],,C14
e0ec28ec-048d-4b7a-b6e9-00e4ba3aa448,C0016143,C0206750,Facing shortage during ,First Aid,Coronavirus Infections,1,X,[topp],[dsyn],E02.365.305,C02.782.600.550.200
b948cee9-5fb3-4b7d-bd6b-6cddde20e190,C1999230,C0012634,Facing shortage during ,Providing (action),Disease,1,X,[acty],[dsyn],,C23.550.288
f1ff425b-d54f-4e0f-a8a2-46043ecec296,C0016143,C0012634,Facing shortage during ,First Aid,Disease,1,X,[topp],[dsyn],E02.365.305,C23.550.288
72b3042c-1682-4588-82e8-afb0364ca4b4,C1999230,C0034991,is essential for their ,Providing (action),Rehabilitation therapy,1,X,[acty],[topp],,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
620ee128-4a8c-46e0-8591-c5df3f5c3dfe,C0016143,C0034991,is essential for their ,First Aid,Rehabilitation therapy,1,X,[topp],[topp],E02.365.305,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
97f34c61-d2e8-405b-ad4f-5126bed0b3f3,C1947933,C2359945,stopping ,care activity,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[acty],[clna],,
8a0670eb-682d-4175-8bb9-928bd71640f3,C1300200,C0009450,also is challenge ,Anesthesia management,Communicable Diseases,1,X,[topp],[dsyn],,C01.539.221
97702310-2ddf-42a9-9069-b28f345be827,C0035204,COVID-19,caused by ,Respiration Disorders,COVID-19,1,X,[dsyn],[virs],C08.618,C000657245
80ad9eb5-629f-49e5-9149-0b8ae8af1746,C0035204,C0206750,is in ,Respiration Disorders,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.618,C02.782.600.550.200
6c84470d-793f-4f7b-982a-a7ec28c6f69b,C0042210,COVID-19,getting ,Vaccines,COVID-19,1,X,[aapp/imft/phsu],[virs],D20.215.894,C000657245
a202cb91-7b6b-416b-9801-58b84577fda7,C4048299,C0003451,have ,Tissue Factor,Antiviral Agents,1,X,[aapp/imft],[phsu],D12.776.124.125.900;D23.119.965,D27.505.954.122.388
1a603866-2f06-4e44-9fbb-108925a144ec,C4048299,C1175743,shown in case of ,Tissue Factor,SARS coronavirus,2,X,[aapp/imft],[virs],D12.776.124.125.900;D23.119.965,B04.820.504.540.150.113.937
43dd645f-8745-43f4-8c29-1398a11fc572,dyad,COVID-19,is in ,dyad,COVID-19,1,X,????,[virs],????,C000657245
e738b289-7bbe-422a-8623-3ff67b366312,C0012634,C1511790,was first ,Disease,Detection,1,X,[dsyn],[topp],C23.550.288,
d57ef8f9-12c2-4802-9d56-485109a44df3,C0567416,C0034850,are known regulators of ,Molecule,Endosomes,1,X,[sbst],[celc],,A11.284.430.214.190.875.190.880.337
b67e2907-3637-42ba-9f7d-d895eea4bf6c,C0567416,C0024369,are known regulators of ,Molecule,Lysosomes,1,X,[sbst],[celc],,A11.284.430.214.190.875.190.550
83c4e252-7bf5-42bc-9e95-36111b5a8c6d,C0034850,C0029219,are subcellular ,Endosomes,Organelles,1,X,[celc],[celc],A11.284.430.214.190.875.190.880.337,A11.284.430.214.190.875
5636be68-5f84-40ab-ac58-e7ffdd554e0f,C0024369,C0029219,are subcellular ,Lysosomes,Organelles,1,X,[celc],[celc],A11.284.430.214.190.875.190.550,A11.284.430.214.190.875
ba804f2f-af60-4ed9-b5d9-cce6708056e5,C0034850,C0004391,are subcellular ,Endosomes,Autophagy,1,X,[celc],[celf],A11.284.430.214.190.875.190.880.337,G04.146.399;G04.417.350.091
513ef665-4e32-4a22-a2c2-7ce4efa12ec5,C0024369,C0004391,are subcellular ,Lysosomes,Autophagy,1,X,[celc],[celf],A11.284.430.214.190.875.190.550,G04.146.399;G04.417.350.091
e831927e-94a8-4136-ad4b-5164099875bc,C0008269,C0004391,inhibit ,Chloroquine,Autophagy,1,X,[orch/phsu],[celf],D03.633.100.810.050.180,G04.146.399;G04.417.350.091
9b99916d-eb21-432f-a14d-d8d3cf478e4a,C0020336,C0004391,inhibit ,Hydroxychloroquine,Autophagy,1,X,[orch/phsu],[celf],D03.633.100.810.050.180.350,G04.146.399;G04.417.350.091
872b63f1-0b7d-4f6c-8d91-872a76df20a2,C0008269,C0034850,elevating pH of acidic ,Chloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.880.337
872b63f1-0b7d-4f6c-8d91-872a76df20a2,C0008269,C0034850,prevent coronavirus receptor recognition by,Chloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.880.337
f785526f-3a92-48cf-b6d2-f71e99bf2147,C0020336,C0034850,elevating pH of acidic ,Hydroxychloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,A11.284.430.214.190.875.190.880.337
f785526f-3a92-48cf-b6d2-f71e99bf2147,C0020336,C0034850,prevent coronavirus receptor recognition by,Hydroxychloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,A11.284.430.214.190.875.190.880.337
896555d0-53e2-45d6-b81a-019520242aa0,C0020336,C0024369,elevating pH of acidic ,Hydroxychloroquine,Lysosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,A11.284.430.214.190.875.190.550
735d493d-e1d0-4961-b70b-38b1562f933f,C0060323,ug/ml,was 2.4 ug/ml,Fibrin fragment D,ug/ml,2,X,[aapp/bacs],????,x.x.x.x,????
735d493d-e1d0-4961-b70b-38b1562f933f,C0060323,ug/ml,was 0.93 ug/ml,Fibrin fragment D,ug/ml,2,X,[aapp/bacs],????,x.x.x.x,????
dfc292dd-4a3c-45f5-98d4-310e58fc5760,C1706853,C1511790,can can ,Assembly (construction),Detection,1,X,[acty],[topp],,
3ad6fbba-67cd-4472-99df-f87dff500636,C1155266,C1825598,has direct ,inflammatory response,IMPACT gene,1,X,[patf],[gngm],,
f69cb16c-aadf-402f-aded-1ad9ecd51547,C0021822,SME,is with UK biomedical SME ,Interview,SME,1,X,[acty],????,E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420,????
2fc21e0b-61ec-4b40-91f8-66851870dc6e,C0069590,C2699239,are reported for ,ORALIT,SD Rat Strain,1,X,[inch/phsu],[mamm],x.x.x.x,
502e6bd2-d702-4118-ac36-9e7e3aef2073,C0206750,cueing,contribute toward deleterious partisan cueing,Coronavirus Infections,cueing,1,X,[dsyn],????,C02.782.600.550.200,????
c9d7ef70-066f-4d99-9d39-9b47b309f28e,4th,C1706374,were transported On ,4th,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
7ed78216-f862-47c4-81b9-6cba66ea0df8,4th,C1709694,were transported to Lahore for ,4th,Processing (action),1,X,????,[acty],????,
beaf166d-133a-4f80-aab0-bde4361c27ad,C0035668,PCR,using real-time PCR,RNA,PCR,1,X,[nnon],????,D13.444.735,????
587cbf5a-5ce1-4020-be98-3a4cf832bbc3,C0035668,C1414174,using QIAsymphony ,RNA,DSPP gene,1,X,[nnon],[gngm],D13.444.735,
d8dddd70-a5ee-4d67-ba8b-87b2d47d6e18,C0035668,C0920672,using QIAsymphony ,RNA,virus pathogenesis,1,X,[nnon],[comd],D13.444.735,
9f46723b-8cbe-48c6-be0f-57440a50cf01,C1175743,C0225828,affects specific ,SARS coronavirus,Myocytes Cardiac,1,X,[virs],[cell],B04.820.504.540.150.113.937,A07.541.704.570;A10.690.552.750.570;A11.620.500
9f46723b-8cbe-48c6-be0f-57440a50cf01,C1175743,C0225828,might attack ,SARS coronavirus,Myocytes Cardiac,1,X,[virs],[cell],B04.820.504.540.150.113.937,A07.541.704.570;A10.690.552.750.570;A11.620.500
d20e21c4-4a09-4b8e-bf2f-2bed527a440f,C1175743,C1707758,affects patients in aspects of ,SARS coronavirus,Direct Contact Transmission Infection,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
e75e940f-cdda-49fe-8d22-4ef0802694b1,C0087111,C4522152, includes catheter ,Therapeutic procedure,Directed Blood Product Donation,2,X,[topp],[phsu],E02,
85a165f4-b8ac-42ee-a895-4e4667184b6b,C0087111,C0520997, includes catheter ,Therapeutic procedure,Thrombolysis function,2,X,[topp],[clna],E02,
a41adab0-a919-4403-965f-5f8f0e9091b6,SGP,C0017973,Binding (Molecular Function),SGP,Glycosaminoglycans,1,X,????,[bacs/orch/phsu],????,D09.698.373
baf7ce76-4c3e-4cdc-b9d6-0bfb38d7d663,SGP,C0019143,Binding (Molecular Function),SGP,Heparitin Sulfate,1,X,????,[bacs/orch],????,D09.698.373.425
399833b1-4abd-46ba-9512-9ed48ed3e350,C0019143,C1512977,is found on surface of virtually all ,Heparitin Sulfate,Mammalian Cell,1,X,[bacs/orch],[cell],D09.698.373.425,
341337e6-397b-4626-b530-5ee76f861018,C0032594,C2717802,potently neutralized pLV-S Viral Structures with clear SGP,Polysaccharides,Viral Structures,2,X,[orch/phsu],[anst],D09.698,A21
911c4122-1f60-4da9-a756-055803e2c2e2,C0032594,SGP,potently neutralized pLV-S Viral Structures with clear SGP,Polysaccharides,SGP,1,X,[orch/phsu],????,D09.698,????
98b79a0d-6bd9-46bf-ad99-16f06b60b706,C2717802,C0243052,is in anti ,Viral Structures,Virus Physiological Phenomena,1,X,[anst],[npop],A21,G06.920
54ffad22-34a3-467e-bd85-b6726c4069a4,C0599331,C1112211,is Hepatic Infection for initial,Nasal Epithelium,Hepatic Infection,2,X,[tisu],[dsyn],A04.531.520;A04.760.600;A10.615.550.760.600,
d1536a7e-fb12-4ddb-8d48-b4cd9e00e63d,C0019134,C0199176,Administration Intranasal of be effective,heparin,Prophylactic treatment,1,X,[bacs/orch/phsu],[topp],D09.698.373.400,
b48eb522-5352-425d-803d-56f8651a5aef,C0001560,C0199176,be effective ,Administration Intranasal,Prophylactic treatment,1,X,[topp],[topp],E02.319.267.120.655.500,
a77acf68-a65c-4477-b0e2-abffe0f97aea,C0013227,C3463820,can have proarrhythmic actions resulting from their ,Pharmaceutical Preparations,Inhibition,2,X,[phsu],[acty],D26,F01.145.544;F02.463.425.475;F02.739.794.405
66b0147f-8419-40d2-8691-6f398246add1,C0013227,C0022009,can have proarrhythmic actions resulting from their ,Pharmaceutical Preparations,Ion Channel,1,X,[phsu],[aapp/bacs],D26,D12.776.157.530.400;D12.776.543.550.450;D12.776.543.585.400
52dd3fbc-00f8-4138-ae4b-352c882a9ce1,C0206750,C0349410,clinical presentation of is ,Coronavirus Infections,Single organ dysfunction,1,X,[dsyn],[sosy],C02.782.600.550.200,
2736d230-44e4-411c-8409-5674c49beee0,C0005779,C0349410,clinical presentation of is ,Blood Coagulation Disorders,Single organ dysfunction,1,X,[dsyn],[sosy],C15.378.100,
473d0ae3-7dbc-4686-a3d0-706027f8d16d,C0028910,C0015982,is massive ,Oils Volatile,Fibrin,1,X,[orch],[aapp/bacs/phsu],D10.627.675,D12.776.124.270
9ccfa9f1-5c39-4c59-9daf-5e581c5b96cd,C0005779,C0015982,Oils Volatile of is massive,Blood Coagulation Disorders,Fibrin,1,X,[dsyn],[aapp/bacs/phsu],C15.378.100,D12.776.124.270
22d6de47-0249-4afb-8de2-888b9d9843cb,C1707455,C0684256,is with ,Comparison,Bacterial sepsis,1,X,[acty],[dsyn],,
e3412db0-5632-4419-8a7c-cd49a26a793b,C1707455,C0005779,is with ,Comparison,Blood Coagulation Disorders,1,X,[acty],[dsyn],,C15.378.100
9baf5efe-8379-4733-ae32-58345a6eabaa,C1707455,C0012739,is with ,Comparison,Disseminated Intravascular Coagulation,1,X,[acty],[dsyn],,C15.378.100.220;C15.378.463.250;C15.378.925.220
9248388d-c1a1-4dae-b893-e9fde7347e97,C0301872,C0024264,orchestrated by inflammatory ,Immune response,Lymphocyte,1,X,[ortf],[cell],,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
9248388d-c1a1-4dae-b893-e9fde7347e97,C0301872,C0024264,embodies in decrease of ,Immune response,Lymphocyte,1,X,[ortf],[cell],,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
43cd69d6-728b-4c3c-9e20-f3bbdffc420a,C0301872,C0007587,orchestrated by inflammatory ,Immune response,Cell Death,1,X,[ortf],[celf],,G04.146
70ed6a07-b6a6-437f-911d-70208b2cb329,C0301872,C0003130,orchestrated by inflammatory ,Immune response,Anoxia,1,X,[ortf],[patf],,C23.888.852.079
96e45784-2a06-434c-bef4-dcad36da0b0a,C0012634,C3850088,are analogous with various ,Disease,Neutrophil Extracellular Traps,2,X,[dsyn],[celc],C23.550.288,A11.284.295.495
6122a7ce-0f4d-49a8-a9cf-026907b6ff7f,C3714552,C0206750,dealing with spread of ,Weakness,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
3034246a-6eab-4bbf-959d-e6959a63268d,C0206750,C1947951,supporting ,Coronavirus Infections,Anatomical Apparatus,1,X,[dsyn],[anst],C02.782.600.550.200,
a9370b94-efc8-4d71-813f-6664eafcde64,remdesivir,C0023175,potentially act as ,remdesivir,Lead,1,X,[clnd],[elii/hops],,D01.268.556.435;D01.552.544.435;x.x.x.x
f17f3893-5310-468a-b9c6-625d11211738,C1175743,C0023175,is with key residues also identified for future ,SARS coronavirus,Lead,1,X,[virs],[elii/hops],B04.820.504.540.150.113.937,D01.268.556.435;D01.552.544.435;x.x.x.x
c1a333a2-2607-4de0-af1c-8efd860fbe8b,C1175743,C2698650,is with key residues also identified for future ,SARS coronavirus,Optimization,1,X,[virs],[acty],B04.820.504.540.150.113.937,
8913adeb-d41d-4c6d-9cab-6700a61ae523,C0520510,U.S.,cost of is 50 U.S. ,Materials,U.S.,1,X,[sbst],????,,????
0c93e5b6-376b-49be-a9a8-e9e12cb75b88,C1175743,C0039082,causes multisystem ,SARS coronavirus,Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C23.550.288.500
c9a92916-8bee-4062-b072-b85c7ce8687e,C0086418,C1145670,was admitted with ,Homo sapiens,Respiratory Failure,2,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C08.618.846
63a771e0-b9b6-45d4-b617-92e1a894af03,C0086418,C0948245,was admitted with ,Homo sapiens,Cytokine Release Syndrome,2,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
7d67ce62-c383-490a-a85d-c06139035e7f,C0086418,C0022116,was admitted with ,Homo sapiens,Ischemia,2,X,[humn],[patf],B01.050.150.900.649.313.988.400.112.400.400,C23.550.513
1e9cff4f-4781-4dd7-863b-7d56b3cf9841,C0005778,C0032143,triggered trial of ,Blood coagulation,alteplase,1,X,[ortf],[aapp/enzy/phsu],G09.188.390.150,D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970
5d985104-ab50-4323-b737-fc6a68277056,C0005516,C0032143,triggered trial of ,Biological Markers,alteplase,1,X,[clna],[aapp/enzy/phsu],D23.101,D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970
0b236500-faa7-4431-b337-4440b575e2ec,C0032143,C0087111,combination of be could ,alteplase,Therapeutic procedure,1,X,[aapp/enzy/phsu],[topp],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,E02
7254fbef-a64c-4284-a464-3448344c12e4,C0032143,C0206750,combination of be could ,alteplase,Coronavirus Infections,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,C02.782.600.550.200
31e4b7ee-4f37-44da-a8ad-8609cd732579,C0032143,C0035222,combination of be could ,alteplase,Respiratory Distress Syndrome Adult,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,C08.381.840;C08.618.840
034bd578-07ab-48a1-afd3-d505660c8af9,C0032143,C2917274,combination of be could ,alteplase,Increased Blood Viscosity [PE],1,X,[aapp/enzy/phsu],[ortf],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,
d83744d3-8014-40f1-a601-b3b81099d29c,C0041621,C0206750,infected with 2019 ,Ultrasonic Shockwave,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776.891.500,C02.782.600.550.200
d83744d3-8014-40f1-a601-b3b81099d29c,C0041621,C0206750,valid aid in patients with suspect ,Ultrasonic Shockwave,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776.891.500,C02.782.600.550.200
d83744d3-8014-40f1-a601-b3b81099d29c,C0041621,C0206750,could represent valid diagnostic aid in patients with ,Ultrasonic Shockwave,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776.891.500,C02.782.600.550.200
b024902a-44b1-4c9c-8e2d-4ae4494a2f09,C0041621,C0012634,infected with 2019 ,Ultrasonic Shockwave,Disease,1,X,[npop],[dsyn],G01.750.770.776.891.500,C23.550.288
708aa373-c187-49a3-8127-cb82ee9edac3,C0041621,C4554533,use of is emerging ,Ultrasonic Shockwave,Trend:Type:Point in time:^Patient:Nominal,1,X,[npop],[clna],G01.750.770.776.891.500,
d3ae661c-e2d5-466c-8661-0c2eefe88e62,C0024109,C0748159,revealed serious ,Lung,pulmonary involvement,1,X,[bpoc],[dsyn],A04.411,
80e0227f-859b-472a-baad-00ff7e062347,RAS,C0682972,is complicated network of ,RAS,G-Protein-Coupled Receptors,1,X,????,[aapp/rcpt],????,D12.776.543.750.695
e2007ea8-9621-4a9e-9857-a2aff9101776,RAS,C0030946,produced by ,RAS,Endopeptidases,1,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
24ba2304-bbaa-469b-8df0-cdb2b2ea19a5,C3657282,C0030946,produced by ,alamandine,Endopeptidases,1,X,[aapp],[aapp/enzy/phsu],x.x.x.x,D08.811.277.656.300
69869bb9-b860-4928-8849-8f7860ca51c1,RAS,C0597357,produced by ,RAS,receptor,1,X,????,[aapp/rcpt],????,
9726d50e-a9ed-40fb-9e91-1e298e43699a,C3657282,C0597357,produced by ,alamandine,receptor,1,X,[aapp],[aapp/rcpt],x.x.x.x,
8cf4eff7-cf17-4de8-8dbc-2d796949cb4c,C0004457,RAS,have have identified in RAS ,Axis vertebra,RAS,1,X,[bpoc],????,A02.835.232.834.151.383,????
632692f6-08a5-4403-8bb9-15cfb9705b5d,C0021966,C0004457,reviewed possible roles of RAS ,Iodides,Axis vertebra,2,X,[inch],[bpoc],D01.248.497.158.490;D01.475.410,A02.835.232.834.151.383
53c2af71-9674-4b37-83be-d0d53dfa5a6b,C0021966,RAS,reviewed possible roles of RAS ,Iodides,RAS,2,X,[inch],????,D01.248.497.158.490;D01.475.410,????
440848c2-13a4-4292-a435-bd56091acf18,C3463820,C0678222,could could useful in ,Inhibition,Breast Carcinoma,2,X,[acty],[neop],F01.145.544;F02.463.425.475;F02.739.794.405,C04.588.180;C17.800.090.500
99107e17-46da-4398-ba0d-0cee4f83983f,RAS,C0678222,offers multifaceted opportunities for development of compounds for ,RAS,Breast Carcinoma,4,X,????,[neop],????,C04.588.180;C17.800.090.500
07df1da3-7231-439d-8441-08baeea0cec8,C0018801,C0206750,structured approach to care of patients with ,Heart failure,Coronavirus Infections,5,X,[dsyn],[dsyn],C14.280.434,C02.782.600.550.200
f042b2ee-b7fb-4ce5-91c1-4a98b1fe7338,C0018801,C1882932,is with comorbid ,Heart failure,Representation (action),1,X,[dsyn],[acty],C14.280.434,
a36712b4-a401-4969-8f06-c87c0924a62b,C0018801,C1457887,formidable challenge as ,Heart failure,Symptoms,1,X,[dsyn],[sosy],C14.280.434,
88bd13cb-4cad-4a0e-b9c4-1463e3102d62,C0018801,C0012634,formidable challenge as ,Heart failure,Disease,1,X,[dsyn],[dsyn],C14.280.434,C23.550.288
2daeb488-2f65-42bd-8598-dba888170811,C0018801,C0243087,is with ,Heart failure,concomitant disease,2,X,[dsyn],[patf],C14.280.434,
be562b77-679b-4103-94ac-f01f73b69341,C0018801,C0556656,conducted web-based ,Heart failure,Meetings,2,X,[dsyn],[acty],C14.280.434,
01318b12-ceef-4c38-941e-bbc8f29954b1,C0206750,C0178784,is with ,Coronavirus Infections,Organ,1,X,[dsyn],[bpoc],C02.782.600.550.200,
64ef94c3-53c0-4e44-8f86-bd8be0168fbe,C0751956,C0012634,may have undiagnosed ,Acute Cerebrovascular Accidents,Disease,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C23.550.288
997be1b4-cf77-469c-a789-5a987addf9ee,C0040802,C0206750,compared between ,travel,Coronavirus Infections,1,X,[dora],[dsyn],I03.883,C02.782.600.550.200
9cd56325-3d2a-4098-8d9a-8199871d7ffa,C0079380,C0206750,combat current ,Frameshift Mutation function,Coronavirus Infections,1,X,[comd],[dsyn],G05.365.590.265,C02.782.600.550.200
bc02171d-5557-43c2-9940-85230422d084,C0596448,C1184743,being consumed in ,dimer,bony process,1,X,[chvs],[bpoc],,
bd653283-e981-40b5-b6b9-d6ba017c8f2b,C0001617,C1861452,is In other very similar ,Adrenal Cortex Hormones,Storm Syndrome,2,X,[horm/orch/phsu],[dsyn],D06.472.040,x.x.x.x
d069c51a-f01e-4d69-bf85-b544ed545fc8,C0309847,C0042077,is in functional ,premier,Urology,3,X,[aapp/imft/phsu],[bmod],,H02.403.810.860
b7674ac1-e73e-42e7-b1e2-c820a8505d3d,C0032143,C1856053,decreased In ,alteplase,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,x.x.x.x
6dd47f7d-31ad-44a3-b9d7-b9e56fcb9ddf,C0678812,C0017710,is with ,systemic administration,Glucocorticoids,2,X,[topp],[horm/orch],,D06.472.040.543;D27.505.696.399.472.488
9614b5fa-5c13-4a98-b39d-85d8d7cb2681,C0678812,C0032285,alleviate ,systemic administration,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
43fd804a-872d-499f-b7d7-43fe7c2fa730,C0678812,C0013604,alleviate ,systemic administration,Edema,2,X,[topp],[sosy],,C23.888.277
065839d3-b2b4-4ae3-a131-fc18f5618fe7,C0013604,C0035222,may decrease development of ,Edema,Respiratory Distress Syndrome Adult,2,X,[sosy],[dsyn],C23.888.277,C08.381.840;C08.618.840
2b7186d3-dcb6-44f5-9c33-a13669694f49,C0024109,C0225704,is in imaged ,Lung,Basal segment of lung,3,X,[bpoc],[bpoc],A04.411,
763263b0-0d9f-4987-bb0e-f2fa467cd089,C0933845,C0225704,is in imaged ,Parenchyma,Basal segment of lung,1,X,[bpoc],[bpoc],,
c30f979a-5ac6-4f8d-8b19-00b9bf99ba53,C0009450,C0199470,may lead to requirement of ,Communicable Diseases,Mechanical ventilation,1,X,[dsyn],[topp],C01.539.221,
f597bd98-4aa5-4ec7-9cf8-a2075880c732,C0206750,C0184893,practice of ,Coronavirus Infections,Emergency operation,1,X,[dsyn],[topp],C02.782.600.550.200,
0221bfb4-1df7-476c-848f-0da7955512d1,C0020598,C0014695,may may associated with ,Hypocalcemia,Ergocalciferol,1,X,[dsyn],[orch/phsu/vita],C18.452.174.509;C18.452.950.509,D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439
308e1658-1cb8-4483-8eb4-158d7a1648fe,C0030946,C1537068,required for ,Endopeptidases,Virus Internalization,1,X,[aapp/enzy/phsu],[biof],D08.811.277.656.300,G06.920.881
e544c436-a178-45f6-ba4a-51803d77d279,C1257974,C0007634,offers various ,Regenerative Medicine,Cells,1,X,[bmod],[cell],H02.403.750,A11
d806aa82-286f-48cf-8a5c-d5f0cfe483ee,C1257974,C0040300,offers various ,Regenerative Medicine,Body tissue,2,X,[bmod],[tisu],H02.403.750,A10
07aa5161-9990-4a05-83fb-383f140cc3d5,C1257974,C0087111,offers various ,Regenerative Medicine,Therapeutic procedure,1,X,[bmod],[topp],H02.403.750,E02
ab30858f-0140-479c-b847-3c096a72a469,C1257974,C0872278,offers related ,Regenerative Medicine,stem cell therapy,1,X,[bmod],[topp],H02.403.750,
240a7595-b08a-4908-bd45-aa99f40cd3f4,C1257974,C4289797,offers ,Regenerative Medicine,Chimeric Antigen Receptor T-Cell Therapy,2,X,[bmod],[topp],H02.403.750,
d4f78c6f-6bf3-42e2-93d7-6896b80b0a04,C1257974,C2350332,offers ,Regenerative Medicine,Exosomes,1,X,[bmod],[celc],H02.403.750,A11.284.295.588.750;A11.284.430.214.190.875.190.880.495
619ad668-e725-4faa-87f9-a90e457bde43,C1257974,C1831784,offers ,Regenerative Medicine,natural killer cell therapy,2,X,[bmod],[topp],H02.403.750,
025d6df6-0ab3-4f91-904c-7149810637e1,C1257975,C1457887,can reduce inflammatory ,Mesenchymal Stem Cells,Symptoms,1,X,[cell],[sosy],A11.329.830.500;A11.872.590.500,
c01d0796-ca68-4218-94b3-61ea4135f933,C1257975,C0079189,protect against ,Mesenchymal Stem Cells,cytokine,1,X,[cell],[aapp/imft],A11.329.830.500;A11.872.590.500,D12.644.276.374;D12.776.467.374;D23.529.374
cc7fd969-739c-43a0-a528-23e3c1c1d59d,C0022688,C0206750,candidate for ,Natural Killer Cells,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537,C02.782.600.550.200
7405caeb-47ab-4023-a7e5-ddce4b8957ac,C0022688,C0302189,candidate for ,Natural Killer Cells,Cell Therapy,1,X,[cell],[topp],A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537,E02.095.147
4ee27c2a-220c-40fc-9ba9-bbec82ec28a0,C0004936,C0206750,caused by ,Mental disorders,Coronavirus Infections,1,X,[mobd],[dsyn],F03,C02.782.600.550.200
8ba2bd9b-b1db-4f01-b47a-8c03a3c51b40,C1707455,C0039215,is with low ,Comparison,CD4 Positive T Lymphocytes,1,X,[acty],[cell],,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200
81cf6f0a-494a-45a0-92b9-ffae727bf48d,C0039215,C0319157,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,AS virus,1,X,[cell],[virs],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,
090b8363-d495-4d1b-b576-a592fca584d9,C0039215,2weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,2weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
97c05311-6470-4570-b398-38b1015e266c,C0039215,3weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,3weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
229a9bda-06c5-4ebb-bbf1-a265ede55c1d,C0039215,4weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,4weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
5f4e7be1-53cd-4537-9d6b-734eb9ab70fc,C0039215,5weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,5weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
c5a122dc-0a6f-429e-8b99-f820b526a39f,C0039215,C0042769,predicting ,CD4 Positive T Lymphocytes,Virus Diseases,1,X,[cell],[dsyn],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,C02
0f48f199-964d-4dac-b90c-1ea99ae0168a,C0039215,C0206750,predicting ,CD4 Positive T Lymphocytes,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,C02.782.600.550.200
c5c7a124-5a1f-4450-bbbc-fab035df3ab3,C1707455,C0012634,is with volume of data on ,Comparison,Disease,1,X,[acty],[dsyn],,C23.550.288
77a484a0-4c25-43f6-a27b-9963deba80f1,C1268935,C1856053,arrived In late ,Congenital Thrombotic Thrombocytopenic Purpura,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C15.378.100.802.687.680;C15.378.140.855.925.750.680;C15.378.925.850;C23.550.414.950.687.680;C23.888.885.687.687.680,x.x.x.x
6c31cb84-8bd8-4110-9028-308c82114124,C1268935,C0543859,arrived in ,Congenital Thrombotic Thrombocytopenic Purpura,Amyotrophic Lateral Sclerosis Guam Form,1,X,[dsyn],[dsyn],C15.378.100.802.687.680;C15.378.140.855.925.750.680;C15.378.925.850;C23.550.414.950.687.680;C23.888.885.687.687.680,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050
65304e00-109a-45d2-8f19-9becaff5ad0b,C0475463,C0020964,presence of is promising indicator of short-term ,Antibodies Neutralizing,Immunity,1,X,[aapp/imft],[phsf],D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244,G12.450
b4721913-a09d-4212-957e-0aa9ec052bf4,C0475463,C0003241,represent ,Antibodies Neutralizing,Antibodies,1,X,[aapp/imft],[aapp/imft/phsu],D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
c0c04c2a-8320-4fda-94a6-2db1b86a0d52,C0009566,C0630906,as Thromboembolism of vein is,Complication,vinyltriethoxysilane,1,X,[patf],[orch],,x.x.x.x
0d6c1f1c-de7b-4a94-8afd-4180f41541bf,C0871208,C0009450,reducing ,Rating (action),Communicable Diseases,1,X,[acty],[dsyn],,C01.539.221
0492e3b8-b38e-4e90-8bcb-c086f571d28f,C0232024,C2745965,significantly decreased after declaration of ,Total airway resistance,Emergencies [Disease/Finding],2,X,[clna],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
4177d82d-f090-4f6a-9897-c4e9526db4c7,C0232024,2-week,significantly decreased during 2-week ,Total airway resistance,2-week,2,X,[clna],????,,????
d08b76c4-e0de-4b8d-80a5-7d8f11a00016,C0035668,C1546536,is in ,RNA,Air sample,2,X,[nnon],[sbst],D13.444.735,
a549511f-ddff-45ca-bad9-8fa9f424d3d0,C1546536,C1175743,were negative for ,Air sample,SARS coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150.113.937
31485ddb-28fc-4aae-b43c-3e23d82c8be9,C0035668,C0009450,is in patients singly isolated inside airborne ,RNA,Communicable Diseases,2,X,[nnon],[dsyn],D13.444.735,C01.539.221
6920265c-a124-4d63-95ff-e12e75f48741,C0035668,C3536832,is in patients singly isolated inside airborne ,RNA,Air,2,X,[nnon],[inch/phsu],D13.444.735,G16.500.275.063.150;N06.230.300.100.150
8d1b7ca8-ea79-4aef-be2d-3f4262d63814,C2948600,C0021932,Comparison effectiveness during,Aim,Intubation Intratracheal,1,X,[inch/phsu],[topp],,E02.041.500;E02.585.578;E05.497.578
ece64875-73d7-4fb7-b50f-750c4bb43fc4,C2948600,C0004764,Comparison effectiveness of different,Aim,Contraception Barrier,2,X,[inch/phsu],[topp],,E02.875.194.285
c2e18e1c-d940-424f-89b1-b1dc5c425a32,C2948600,C0508431,Providing (action) practical,Aim,answer questions,1,X,[inch/phsu],[topp],,
a7d3fbd2-8310-4995-986f-e7c7805d36a4,C0508431,C0015259,promote participation in ,answer questions,Exercise,1,X,[topp],[dora],,G11.427.410.698.277;I03.350
18f5eea1-446d-4d2d-96d3-6816386a96c9,C0015259,C1516048,were ,Exercise,Assessed,1,X,[dora],[acty],G11.427.410.698.277;I03.350,
4c9ce4d8-c99b-40e3-a251-6c19bb6972ac,C0751956,C0037088,was most common ,Acute Cerebrovascular Accidents,Signs and Symptoms,1,X,[dsyn],[sosy],C10.228.140.300.775;C14.907.253.855,C23.888
0167aa6b-a25e-4de1-b518-aecef9237f3f,C0751956,C0027855,was most common Signs and Symptoms on,Acute Cerebrovascular Accidents,Neurology speciality,2,X,[dsyn],[bmod],C10.228.140.300.775;C14.907.253.855,H02.403.600
32ed253f-ac95-4f5e-aee1-17adefcd41ea,C3266262,C1856053,launched Trainee Pandemic Role Allocation Tool In,Multiple Chronic Conditions,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C23.550.291.500.500,x.x.x.x
6547f276-aa87-423c-aff2-92b8ea3dd927,C3266262,C1706778,launched Trainee Pandemic Role ,Multiple Chronic Conditions,Allocation,1,X,[dsyn],[acty],C23.550.291.500.500,
270c1b14-cf04-4f40-b01d-11f10f7d9b7e,COVID-19,C0851312,may exacerbate delays in time to ,COVID-19,Breast surgery specialty,2,X,[virs],[bmod],C000657245,
57289a1c-1425-4862-ad27-642bd3aa5704,COVID-19,C0011311,is with false-positive ,COVID-19,Dengue Fever,1,X,[virs],[dsyn],C000657245,C02.081.270;C02.782.350.250.214;C02.782.417.214
1642bd84-da80-4e4c-85a4-bb94d56a5839,COVID-19,C0036745,is with false-positive ,COVID-19,Study of serum,1,X,[virs],[bmod],C000657245,H02.781
2145e797-95ff-49ff-836c-8ca609e3217f,C1512523,C0206419,has great potential for treatment of patients with ,hydrochloride,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
75749c10-9824-4be7-91b9-1c51f88706ec,C0035222,C0023516,persistently elevated values for ,Respiratory Distress Syndrome Adult,Leukocytes,2,X,[dsyn],[cell],C08.381.840;C08.618.840,A11.118.637;A15.145.229.637;A15.382.490
01781df8-05f1-424b-aed6-35f99a95d1f5,C0035222,C0021760,persistently elevated values for ,Respiratory Distress Syndrome Adult,Interleukin-6,2,X,[dsyn],[aapp/imft],C08.381.840;C08.618.840,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
489fb71a-10e7-4813-b23d-1c806940ed98,C0035222,C0022917,persistently elevated values for ,Respiratory Distress Syndrome Adult,Lactate Dehydrogenase,2,X,[dsyn],[aapp/enzy],C08.381.840;C08.618.840,D08.811.682.047.551.400;D08.811.682.047.820.493
4e857613-1890-4578-b14c-fcce2255f48c,C0035222,C0010287,persistently elevated values for ,Respiratory Distress Syndrome Adult,Creatine Kinase,2,X,[dsyn],[aapp/enzy],C08.381.840;C08.618.840,D08.811.913.696.640.150
f0522997-a7a8-4e5e-a164-48a0c80156ff,C0035222,C0060323,persistently elevated values for ,Respiratory Distress Syndrome Adult,Fibrin fragment D,2,X,[dsyn],[aapp/bacs],C08.381.840;C08.618.840,x.x.x.x
b22f1525-43a3-4e0b-a619-d13efb830794,C3826426,C0242781,importance of route of ,Dynamics,disease transmission,1,X,[npop],[patf],,N06.850.310
b22f1525-43a3-4e0b-a619-d13efb830794,C3826426,C0242781,understanding temporal course of ,Dynamics,disease transmission,1,X,[npop],[patf],,N06.850.310
2faccd24-bb36-46f1-aaf3-8388cf54b644,C2926735,C0242781,importance of asymptomatic ,Duration,disease transmission,1,X,[orch/phsu],[patf],,N06.850.310
10ac4510-2e4a-4160-b6db-66ee137348a2,C1457887,C2364082, includes ,Symptoms,Sense of smell impaired,2,X,[sosy],[sosy],,
745bae6e-51b2-4ffa-a573-e7f14f0cb221,C1707391,C1457887,ranging from common ,Choose (action),Symptoms,2,X,[acty],[sosy],,
23a0e3dd-659e-44f8-8649-919e5b79e715,C1707391,C2364082,ranging from common ,Choose (action),Sense of smell impaired,2,X,[acty],[sosy],,
4fce4a2f-d1db-4f48-9c07-41b08ec8915b,CXR,C1175175,is with ,CXR,Severe Acute Respiratory Syndrome,1,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
544df6f7-ca15-4de8-bcbd-d15bc43cbc88,C0011945,C0206419,are more vulnerable to severe ,Physical Dialysis,Genus: Coronavirus,1,X,[npop],[virs],E05.196.353;G02.186,B04.820.504.540.150
ccaa1341-2a49-4a55-87da-09baa2f01d9d,HVA,C0019004,has IMPACT gene As life-line of,HVA,Hemodialysis,1,X,????,[topp],????,E02.870.300;E02.912.800
4993d79f-eb59-4abd-83e2-219b101e274a,HVA,C1825598,has profound ,HVA,IMPACT gene,1,X,????,[gngm],????,
6e23acbb-c6c2-459c-b229-1471e6934c5c,HVA,C0011945,has profound ,HVA,Physical Dialysis,1,X,????,[npop],????,E05.196.353;G02.186
493e677a-1046-4211-a995-5d78164b277c,C0028040,CRS,constitute novel potential CRS ,Nicotine,CRS,1,X,[hops/orch],????,D03.132.760.570;D03.383.725.518,????
c0431b11-0ae3-443c-a6d6-8f26d88cec7d,CRS,C1175743,is in severe ,CRS,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
dc2e82ff-4a00-4bf9-9c7e-bbea647c915a,C0206750,C0010076,is ,Coronavirus Infections,Coronaviridae,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540
4204f222-6737-44c1-b598-5c477647f503,C0009450,C0010076,caused by new variable ,Communicable Diseases,Coronaviridae,1,X,[dsyn],[virs],C01.539.221,B04.820.504.540
873e40f7-6174-4506-965d-bc6ed2cc3534,C1511790,C0034019,informs ,Detection,public health medicine (field),1,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
6be6ce37-eaa4-4d27-bf23-083cfefa2a69,C1511790,C3163724,is in respiratory tract ,Detection,Nucleic acid specimen,1,X,[topp],[celc],,
0af45c00-5881-4ab3-81af-ca3198d0e77c,COVID19,C1175743,is ,COVID19,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
c6583caa-21b8-4c0c-b4e9-2a991f26150e,C0009450,C1456573,is In exceptional situation of ,Communicable Diseases,Global Health,1,X,[dsyn],[bmod],C01.539.221,H02.403.371;N01.400.337
c6583caa-21b8-4c0c-b4e9-2a991f26150e,C0009450,C1456573,has led to ,Communicable Diseases,Global Health,1,X,[dsyn],[bmod],C01.539.221,H02.403.371;N01.400.337
884ba71a-911e-4909-bb2d-22ad6840c8ba,C0011127,C0040300,underlying ,Pressure Ulcer,Body tissue,1,X,[dsyn],[tisu],C17.800.893.665,A10
f2c009d8-f436-4df8-b896-f6ac44686aed,C0041582,C0030193,are ,Ulcer,Pain,1,X,[patf],[sosy],C23.550.891,C23.888.592.612;F02.830.816.444;G11.561.790.444
6646a6b1-86c3-4d21-9d66-a975ad3f1755,C0035203,C0035222,is indicated for patients with severe ,Respiration,Respiratory Distress Syndrome Adult,2,X,[phsf],[dsyn],G09.772.705,C08.381.840;C08.618.840
9b86779d-86dc-44f1-8258-9b1a1365589a,C0035203,C1175175,is indicated for patients with severe ,Respiration,Severe Acute Respiratory Syndrome,2,X,[phsf],[dsyn],G09.772.705,C02.782.600.550.200.750;C08.730.730
04d60aa6-97ba-48cc-ad52-f76efd87e5ad,C2948600,C0036576,facilitate ,Aim,Genetic Selection,1,X,[inch/phsu],[genf],,G05.783
280cee9c-0a73-4ca3-b5d5-abd2575495df,C2948600,C0199176,facilitate ,Aim,Prophylactic treatment,1,X,[inch/phsu],[topp],,
314542ab-fc53-4e45-8476-75a5731d5651,C1947933,C0009450,are of Up of patients admitted to ICU with confirmed ,care activity,Communicable Diseases,1,X,[acty],[dsyn],,C01.539.221
eb725fcc-b11a-4142-a89c-f964ede46beb,C0302908,C0206750,nature of ,Liquid substance,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
32514dff-08a2-4cd3-ba68-a8b1b925eb1e,C1999230,C1521827,is in ,Providing (action),Preparation,1,X,[acty],[acty],,
1e01c955-6f24-4773-97da-0485aee6bb14,JID,C0042742,of Bulletin is ,JID,Viral Vaccines,1,X,????,[imft/phsu],????,D20.215.894.899
18b207cf-17a2-4b4e-b319-de503a86158c,C0557989,C0242781,contribute to interruption ,Restriction of movement,disease transmission,1,X,[topp],[patf],,N06.850.310
b1c94cd2-0669-4aba-9fde-8bbefc4b9ace,C0557989,C0206750,contribute to interruption ,Restriction of movement,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
5a2868d0-b7e5-4132-8482-963f9a58230d,KRT,C3649547,moderating ,KRT,Continuous renal replacement therapy,1,X,????,[topp],????,
d714887f-5696-4871-af50-26b23c91d0ea,C0031139,C1707391,is in ,Peritoneal Dialysis,Choose (action),1,X,[topp],[acty],E02.870.300.650;E02.912.800.650,
8632cd36-5ab5-4d99-9227-5f638202bdfd,C3714514,C0010200,may result from patient due to ,Infection,Coughing,1,X,[patf],[sosy],C01.539,C08.618.248;C23.888.852.293
2d4cd213-ffd5-4737-a061-00cf099a1662,C1947933,C1999230,are reorganizing resources to ,care activity,Providing (action),1,X,[acty],[acty],,
95ebfdce-a7e5-49d6-9b33-418535db8ec4,C0087111,C0596756,addressing ,Therapeutic procedure,immunopathology specialty,1,X,[topp],[bmod],E02,
3f802e46-efa4-4510-affa-8c396e19fc78,C0301872,C0042769,represents line of defense against ,Immune response,Virus Diseases,3,X,[ortf],[dsyn],,C02
a27f6e0c-83ed-46ca-ad25-abad563f71ad,C0282554,C1167395,clearly reflects widespread dysregulation of ,chemokine,Host (organism),1,X,[aapp/imft],[orgm],D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200,
5527e2aa-dc7b-40eb-a67b-0a03836d4226,C0079189,C1167395,clearly reflects widespread dysregulation of ,cytokine,Host (organism),1,X,[aapp/imft],[orgm],D12.644.276.374;D12.776.467.374;D23.529.374,
dbde22b8-1457-4d61-8c31-31b00210f138,C0040408,C0025124,is important component of ,Tongue,Traditional Chinese Medicine,2,X,[bpoc],[bmod],A03.556.500.885;A14.549.885,E02.190.488.585.520;I01.076.201.450.654.558.520
9ea32c79-b36e-4317-bd6f-370fcc62bf3f,C0040408,C2646699,First were analyzed by groups of ,Tongue,Assessor (genus),2,X,[bpoc],[fish],A03.556.500.885;A14.549.885,
44f73bec-7154-419d-b261-7bd6b03f4965,C2948600,C1285375,evaluate ,Aim,Neoplasm of musculoskeletal system,1,X,[inch/phsu],[neop],,
32bfe5a4-3c04-4ac2-b91f-c21be59d08d8,C0006826,C1692321,involve ,Malignant Neoplasms,Cellular infiltrate,1,X,[neop],[patf],C04,
a984be20-c8d2-45b9-9b47-d71ee2179735,C0006826,C0824497,involve ,Malignant Neoplasms,Neurovascular bundle,1,X,[neop],[bpoc],C04,
44d73515-8673-4e2d-8768-81d3eb99e989,C0087111,C0030193,can cause severe morbidity ,Therapeutic procedure,Pain,1,X,[topp],[sosy],E02,C23.888.592.612;F02.830.816.444;G11.561.790.444
2f6694c1-e7ef-4ed6-9f94-d3af0001c1d9,C0520510,C1167395,maximize utility participating in ,Materials,Host (organism),2,X,[sbst],[orgm],,
bcf0dfd9-db54-402f-b28e-a8619a591549,C0520510,C0017398,maximize utility participating in ,Materials,Science of genetics,2,X,[sbst],[bmod],,H01.158.273.343
4d795e21-7714-4065-81fb-5d1d073a90b2,C0242656,C0282632,due to ,Disease Progression,Antibody-Dependent Enhancement,1,X,[patf],[comd],C23.550.291.656,G06.920.095;G12.113
8faf5651-9d53-4e8c-ad00-a5f0c29ba8ae,C2948600,C1883254,provide rapid ,Aim,Synthesis,1,X,[inch/phsu],[acty],,
6ba93437-cb64-4ed0-aae2-987ef208372e,C1175743,C0027765,causes ,SARS coronavirus,nervous system disorder,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C10
084885ba-f04c-4eb6-861c-69f1dc74ec2c,C0235031,C0018681,can can divided into system ,Neurologic Symptoms,Headache,2,X,[sosy],[sosy],C10.597;C23.888.592,C23.888.592.612.441
b69fa297-0b52-4529-9547-09bb317128d5,C0243072,C1883254,were ,derivatives,Synthesis,1,X,[chvs],[acty],,
cf384486-6321-40ba-be75-52602146f810,C0567416,C0013227,be considered as orally active ,Molecule,Pharmaceutical Preparations,1,X,[sbst],[phsu],,D26
f0155881-4c63-49c8-8fa8-738a1e5c9bf1,C0243072,C1510827,exhibit good theoretical ,derivatives,Affinity,1,X,[chvs],[npop],,
860fcabe-321d-4c79-83b5-7d907986e3d6,C1457887,C0007450,using ,Symptoms,Felis catus,1,X,[sosy],[mamm],,B01.050.150.900.649.313.750.377.750.250.125
63b40e44-c1fd-424b-ae1e-d820e000e5fd,C0024117,COVID-19,risk of ,Chronic Obstructive Airway Disease,COVID-19,1,X,[dsyn],[virs],C08.381.495.389,C000657245
63b40e44-c1fd-424b-ae1e-d820e000e5fd,C0024117,COVID-19,worsens ,Chronic Obstructive Airway Disease,COVID-19,1,X,[dsyn],[virs],C08.381.495.389,C000657245
ec27b37f-aa3d-466d-825c-e7d59edc8069,C1299575,COVID-19,recommended for ,Treatment modification,COVID-19,1,X,[topp],[virs],,C000657245
bf192397-b1da-4679-aa70-5bb9b2b65f86,C0206750,C0053260,disproportionally affects ,Coronavirus Infections,benzoyl L-arginine methyl ester,2,X,[dsyn],[aapp/bacs],C02.782.600.550.200,x.x.x.x
f0a78c77-8bc7-45ac-b5b5-516cec81a006,C0034019,C0009450,started following ,public health medicine (field),Communicable Diseases,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C01.539.221
a30e7ac6-46f9-447f-b5ec-245b7b5214bc,C0206750,C1708476,has moved despite ,Coronavirus Infections,Implementation,3,X,[dsyn],[acty],C02.782.600.550.200,
a30e7ac6-46f9-447f-b5ec-245b7b5214bc,C0206750,C1708476,has required worldwide ,Coronavirus Infections,Implementation,1,X,[dsyn],[acty],C02.782.600.550.200,
a30e7ac6-46f9-447f-b5ec-245b7b5214bc,C0206750,C1708476,has resulted in widespread ,Coronavirus Infections,Implementation,1,X,[dsyn],[acty],C02.782.600.550.200,
d0a1eb09-e153-4725-9014-94112cd6ffe2,C0206750,C2923471,has moved at different ,Coronavirus Infections,Time to peak,2,X,[dsyn],[clna],C02.782.600.550.200,
d0a1eb09-e153-4725-9014-94112cd6ffe2,C0206750,C2923471,has moved from country ,Coronavirus Infections,Time to peak,4,X,[dsyn],[clna],C02.782.600.550.200,
a68f514a-d102-4e48-8a7b-cec59f93ed07,C0011382,COVID-19,is in ,Dental Occlusion,COVID-19,1,X,[ortf],[virs],E06.276;G10.549.208,C000657245
ef1b20cc-c221-49db-8d8e-60ef21e9fb5f,C0520997,COVID-19,resulted in ,Thrombolysis function,COVID-19,1,X,[clna],[virs],,C000657245
bffb1e81-d189-4347-b8a4-e4ea52b133f7,C0034771,COVID-19,resulted in ,Recanalization,COVID-19,1,X,[topp],[virs],,C000657245
a9cf6d61-be56-4650-a50e-9ebac4aa19f5,C0034771,C4534538,achieved with ,Recanalization,Mechanical thrombectomy,1,X,[topp],[topp],,
4dedd144-39b1-48fe-92b8-bda02416811c,C1293116,C0042769,is earlier than first case of ,Introduction procedure,Virus Diseases,1,X,[topp],[dsyn],,C02
618a6c11-212a-455b-8ef1-0eafff522722,C0042769,C0040811,are dispersed among most types in phylogenetic ,Virus Diseases,Trees (plant),1,X,[dsyn],[plnt],C02,B01.650.915
677bf1f7-7ea7-4466-9d80-a0d0d7709946,C0017428,C0040811,are dispersed among most types in phylogenetic ,Genome,Trees (plant),1,X,[gngm],[plnt],G05.360.340,B01.650.915
fc375f7d-4663-4463-a14b-d20abe6244dc,C0087111,C3463820,aimed at ,Therapeutic procedure,Inhibition,1,X,[topp],[acty],E02,F01.145.544;F02.463.425.475;F02.739.794.405
e65daa14-3fcf-4c7e-b954-09b1d665e0e3,C0087111,C0751982,aimed at ,Therapeutic procedure,Neutrophil Infiltration,1,X,[topp],[phsf],E02,G12.632
df090a5c-babf-4ea4-bab4-b8b668beb562,C0087111,C1879547,aimed at ,Therapeutic procedure,Activation action,1,X,[topp],[acty],E02,
e95cf5c9-12c3-4a04-83f3-810199acfd9b,C0087111,C1622891,aimed at ,Therapeutic procedure,Mast cell degranulation,1,X,[topp],[celf],E02,
094ddfa2-f222-4d8f-aae6-4eb322859016,C0087111,C3850088,aimed at ,Therapeutic procedure,Neutrophil Extracellular Traps,1,X,[topp],[celc],E02,A11.284.295.495
d10a65ec-1639-4257-ad5e-1f766338e265,C1825598,C1856053,is in mid ,IMPACT gene,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[gngm],[dsyn],,x.x.x.x
eb0df1e1-bea6-491f-b39c-64f309e5e90e,C0028630,C0220781,encode putative ,Nucleotides,Anabolism,1,X,[nnon],[biof],D09.408.620;D13.695,G03
abd1bca6-9f06-43ac-9c8b-104f90e3537f,C0028630,C0033684,encode putative ,Nucleotides,Proteins,1,X,[nnon],[aapp/bacs],D09.408.620;D13.695,D12.776
f24b6787-ebe4-4db5-9cf5-d173ca45f1db,C0079941,C0220781,responsible for ,Open Reading Frames,Anabolism,1,X,[gngm],[biof],G05.360.335.760.640;G05.360.340.024.340.137.650,G03
c5f1af76-707c-4636-84f7-a35fbf666b5c,C0079941,C0033684,responsible for ,Open Reading Frames,Proteins,1,X,[gngm],[aapp/bacs],G05.360.335.760.640;G05.360.340.024.340.137.650,D12.776
21f1a6b0-1f59-4228-a3af-c65314dd5595,C0012634,C0040802,may may contained through hand hygiene physical distancing ,Disease,travel,4,X,[dsyn],[dora],C23.550.288,I03.883
5ad3f386-78fc-442e-a9e4-8b1207d809c3,dataset,COVID-19,is with ,dataset,COVID-19,2,X,????,[virs],????,C000657245
404900a4-0e09-45ab-81eb-6481932df391,dataset,C0012634,is with ,dataset,Disease,2,X,????,[dsyn],????,C23.550.288
e598c3ca-8ae7-4df9-bb86-7ae5c5395a3b,C0005516,COVID-19,related to ,Biological Markers,COVID-19,1,X,[clna],[virs],D23.101,C000657245
1332c3c6-c807-4d85-915d-ee111623e965,2B,C1175743,share genetically distinct from original ,2B,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
62662dd4-a0e2-4a86-a1c8-466d00a693f4,C0017428,C0008139,harbored in ,Genome,Chiroptera,1,X,[gngm],[mamm],G05.360.340,B01.050.150.900.649.313.937
907d5753-947c-4ab6-9459-4743e87f2d45,C1175743,C0042774,maintains similar ,SARS coronavirus,Virus Replication,1,X,[virs],[celf],B04.820.504.540.150.113.937,G06.920.925
be6e4980-90dc-4fb5-aa60-a045e5c0e81a,C1175743,C0022702,maintains similar ,SARS coronavirus,Kinetics,1,X,[virs],[npop],B04.820.504.540.150.113.937,G01.374.661;G02.111.490
f6d2b5ec-03b6-4fe0-b889-1d2885a9233a,C1175743,C0042542,maintains Virus Replication Kinetics to,SARS coronavirus,Vero Cells,2,X,[virs],[cell],B04.820.504.540.150.113.937,A11.251.210.955;A11.436.955
640438bb-10a0-400e-80dc-af086162a51c,C0206750,C3539076,Interferon,Coronavirus Infections,Pretreatment,1,X,[dsyn],[acty],C02.782.600.550.200,
1db955c6-d60f-41b7-a5e8-36bb3779abee,C1175743,C0021966,is in context of type IFN,SARS coronavirus,Iodides,1,X,[virs],[inch],B04.820.504.540.150.113.937,D01.248.497.158.490;D01.475.410
9c2af716-b406-401f-b4d5-0a6473b91c99,C1175743,IFN,is in context of type IFN,SARS coronavirus,IFN,1,X,[virs],????,B04.820.504.540.150.113.937,????
87dcef57-53e4-49a5-8e79-2904567e8a28,C0031715,C1175743,Examining IFN,Phosphorylation,SARS coronavirus,1,X,[moft],[virs],G02.111.665;G02.607.780;G03.796,B04.820.504.540.150.113.937
106fcac8-5e06-43f6-b324-c1d81b0f6869,C0031715,C0021966,Examining IFN,Phosphorylation,Iodides,1,X,[moft],[inch],G02.111.665;G02.607.780;G03.796,D01.248.497.158.490;D01.475.410
a142a8ae-66b7-41a7-98a4-d95eb00c3da1,C0031715,IFN,Examining IFN,Phosphorylation,IFN,1,X,[moft],????,G02.111.665;G02.607.780;G03.796,????
43a8a80d-90bb-434e-a27c-5af03e46bb1d,C0031715,C3652465,Examining ,Phosphorylation,Interferon,1,X,[moft],[aapp/imft/phsu],G02.111.665;G02.607.780;G03.796,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
fe0b8304-7b63-41d6-837d-52cdfa5ba1e4,C0031715,C1948023,Examining ,Phosphorylation,Stimulation (motivation),1,X,[moft],[npop],G02.111.665;G02.607.780;G03.796,
d431033d-40ea-47ca-bfe7-ade40a36b6d9,C0031715,C0920532,Examining ,Phosphorylation,gene induction,2,X,[moft],[genf],G02.111.665;G02.607.780;G03.796,
5954a12c-b8d1-4b4d-8248-1c2376ccaa29,C0031715,C0162493,Examining ,Phosphorylation,Transcriptional Activation,2,X,[moft],[genf],G02.111.665;G02.607.780;G03.796,G05.308.800
4490498d-0c6c-4be1-80d7-2695a4e4af34,IFN,C1175743,finding ,IFN,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
6c5680c1-f3f2-48a3-a3c3-2b3b89c361af,Calu3,C1175743,finding ,Calu3,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
7e9736d7-a7fb-40a9-8463-2af9321656ad,C1425360,C1175743,finding ,CD244 gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
f83ca31b-4f24-4dc1-941f-d3fc979439c4,C0042774,C1175743,relative to ,Virus Replication,SARS coronavirus,1,X,[celf],[virs],G06.920.925,B04.820.504.540.150.113.937
f83ca31b-4f24-4dc1-941f-d3fc979439c4,C0042774,C1175743,targeting ,Virus Replication,SARS coronavirus,1,X,[celf],[virs],G06.920.925,B04.820.504.540.150.113.937
8c25b9b6-e1af-498a-8830-25b2c5586f14,C1175743,C0042736,is in ,SARS coronavirus,Viral Proteins,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.776.964
3057470f-5ddc-4775-8c64-d803face4dd1,C0005847,C1422064,also express ,Blood Vessel,ACE2 gene,1,X,[bpoc],[gngm],A07.015,
0026cadf-cff6-490d-a653-9f1881655a79,C0005847,COVID-19,are potential targets in ,Blood Vessel,COVID-19,1,X,[bpoc],[virs],A07.015,C000657245
33a4c2c9-c541-471e-b4f4-e6f5e1c5a49c,C0018787,COVID-19,are potential targets in ,Heart,COVID-19,2,X,[bpoc],[virs],A07.541,C000657245
4e6e9f88-b39c-43be-b54b-47ede66386d2,C0027061,C0027059,cause ,Myocardium,Myocarditis,1,X,[tisu],[dsyn],A02.633.580;A07.541.704;A10.690.552.750,C14.280.238.625
cd987efa-1c25-44bd-9a6e-50d525f14ec2,C1515090,C1521827,can However under unique circumstances with ,Surgical Oncology specialty,Preparation,1,X,[bmod],[acty],H02.403.429.515.750;H02.403.810.796,
78a1d306-273b-4334-bda2-d4cebaf97eb1,C0206750,C1515090,has reduced ,Coronavirus Infections,Surgical Oncology specialty,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.429.515.750;H02.403.810.796
fed1552a-4c59-444a-aa88-0b8afe6dfe74,C1175743,C3542961,affect ,SARS coronavirus,NERVOUS SYSTEM DRUGS,2,X,[virs],[phsu],B04.820.504.540.150.113.937,
a32f8e6d-068c-44e5-9adc-367d1928d4c6,C0596773,C0015219,is with clinical findings during ,Infectious Encephalitis,Biological Evolution,2,X,[dsyn],[genf],C10.228.140.430.520;C10.228.228.399,G05.045;G16.075
88038b63-5bed-4df8-9c8a-0b91dc34dd87,C0596773,C0206750,is with clinical findings during ,Infectious Encephalitis,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.228.140.430.520;C10.228.228.399,C02.782.600.550.200
636328be-760c-4220-b82b-679803f6d119,C0015392,C1825598,has more devastating ,Eye,IMPACT gene,2,X,[bpoc],[gngm],A01.456.505.420;A09.371,
0e8daef5-d09f-4505-a1da-5df44214adfe,C4554533,C0206419,is in ,Trend:Type:Point in time:^Patient:Nominal,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
5a44f51b-8c67-4d5a-b85b-344c857a649a,C0521982,C0034538,is with ,Response to treatment,Ionizing radiation,1,X,[clna],[npop],,G01.750.750
21221291-2fe5-4eab-ba43-e2c6ff14ecee,C1280903,C0206419,is in severe ,Exploration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
0426c421-a80d-4abc-becb-3e7e040fb26a,C0206419,C1706214,is ,Genus: Coronavirus,Creation,1,X,[virs],[acty],B04.820.504.540.150,
949b67fa-f62c-43e3-bd76-41036b3e10bf,C0877629,C0184661,handling ,infection prophylaxis,Interventional procedure,1,X,[topp],[topp],,
a9f94bfe-b643-4b8a-9d12-29795f32c57d,EISS,C0009450,specifically tracking confirmed cases of ,EISS,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
3c66033c-2272-47ed-b480-6f526432ca31,C1516048,C0012155,using Household ,Assessed,Diet,1,X,[acty],[food],,G07.203.650.240
610c8826-3795-4d69-b867-b96bb136419b,C0206419,C0003968,included ,Genus: Coronavirus,Ascorbic Acid,1,X,[virs],[orch/phsu/vita],B04.820.504.540.150,D02.241.081.844.107;D02.241.511.902.107;D09.811.100
c7232222-6f71-42c9-a07c-e9bdb62e887c,C0206419,C0525033,included ,Genus: Coronavirus,Probiotics,1,X,[virs],[bact],B04.820.504.540.150,G07.203.300.456.500;J02.500.456.500
a7df5199-23ba-4bee-b9e4-7dc844280981,C0206419,C0242295,included ,Genus: Coronavirus,Dietary Supplements,1,X,[virs],[food],B04.820.504.540.150,G07.203.300.456;J02.500.456
87e68fce-0c21-4c89-9c46-25b5e71d3348,C0206419,C0001962,included ,Genus: Coronavirus,Ethanol,1,X,[virs],[orch/phsu],B04.820.504.540.150,D02.033.375;x.x.x.x
39b71abe-a56a-4a75-84f1-0495253b0ee9,C0206419,C0148405,included ,Genus: Coronavirus,Vinegar,1,X,[virs],[irda/orch/phsu],B04.820.504.540.150,D02.241.081.018.165;D10.251.400.045.500
7ef7f956-e897-4e14-8688-6679305f19b1,C0008067,C0014544,is with ,Child Care,Epilepsy,2,X,[dora],[dsyn],I01.880.787.293.360;N02.421.088,C10.228.140.490
514e7041-3cd4-4cea-993c-c6ce614b1985,C1328819,C0042769,effective against other ,Small Molecule,Virus Diseases,1,X,[orch],[dsyn],,C02
19e52d36-04e3-4bce-a8f5-3c7f727826a5,C1175743,C1152412,of RNA-Directed RNA Polymerase is,SARS coronavirus,RNA-directed RNA polymerase activity,1,X,[virs],[genf],B04.820.504.540.150.113.937,
19e52d36-04e3-4bce-a8f5-3c7f727826a5,C1175743,C1152412,is 10-fold more active than other viral ,SARS coronavirus,RNA-directed RNA polymerase activity,1,X,[virs],[genf],B04.820.504.540.150.113.937,
ed77f8f7-a3b7-4106-8930-6ab89862fbc9,C0598312,C0033684,depends on three encoded ,DNA Replication,Proteins,1,X,[genf],[aapp/bacs],G02.111.225;G05.226,D12.776
69bd475c-b1f4-4540-9b9e-1daa08d8c278,C0920283,C1167622,screened Antiviral Agents for,DNA Helicases,Binding (Molecular Function),1,X,[aapp/enzy],[moft],D08.811.277.040.025.159;D08.811.399.340,
bcf1e189-eaff-44ce-b88b-f8694614fd11,C0920283,C0033684,screened Antiviral Agents for,DNA Helicases,Proteins,1,X,[aapp/enzy],[aapp/bacs],D08.811.277.040.025.159;D08.811.399.340,D12.776
f15a93c9-be5c-458e-9c2a-390b7596554c,C0920283,C0003451,screened FDA-approved ,DNA Helicases,Antiviral Agents,1,X,[aapp/enzy],[phsu],D08.811.277.040.025.159;D08.811.399.340,D27.505.954.122.388
6033b389-baa5-47a8-bfdd-f59ef8b41f46,C0920283,C0013230,screened ~ 3300 ,DNA Helicases,Investigational New Drugs,1,X,[aapp/enzy],[phsu],D08.811.277.040.025.159;D08.811.399.340,D26.371
d57c70c8-5db5-4931-b7a5-b4c0cdb38b91,C0920283,C0678749,screened ~ 3300 ,DNA Helicases,drug binding,1,X,[aapp/enzy],[phsf],D08.811.277.040.025.159;D08.811.399.340,
78ac1e66-c93d-4eae-a965-9065905b750b,C1167622,C1880157,using ,Binding (Molecular Function),Computation (action),1,X,[moft],[acty],,
0625f0fe-d5d2-4d37-a273-a22963ccc949,C4080052,C0687133,has well-characterized ,elbasvir,Drug Interactions,1,X,[orch/phsu],[patf],,G07.690.773.968
79562cdb-1d5f-4fc7-9d2a-bf842df900dd,C4080052,C0087111,has toxicity At ,elbasvir,Therapeutic procedure,1,X,[orch/phsu],[topp],,E02
c8065540-ccc0-4d25-b115-607403278b5c,C1175743,C4080052,treatment with ,SARS coronavirus,elbasvir,1,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,
5c1a2a4a-31a1-43e4-8f46-8fd3d816ecc1,C0013227,C4080053, includes ,Pharmaceutical Preparations,grazoprevir,1,X,[phsu],[orch/phsu],D26,
5199447f-4630-4519-8cda-5e0179f28432,C3266814,C0013227,renders Mutation to,Action,Pharmaceutical Preparations,1,X,[acty],[phsu],,D26
57baaa29-3023-4965-a43e-a3e717e973f6,C3266814,C0026882,renders viral ,Action,Mutation,1,X,[acty],[genf],,G05.365.590
2c0df4c3-6bdc-4a04-9728-bc2bc4b75511,C3178870,C0008073,plays role in ,Endoplasmic Reticulum Stress,Developmental Disabilities,4,X,[comd],[mobd],G04.434,F03.625.421
c5e72da3-b5f6-42e3-8d54-81dc3d95f6e4,C3178870,C1175743,is in patients infected with ,Endoplasmic Reticulum Stress,SARS coronavirus,1,X,[comd],[virs],G04.434,B04.820.504.540.150.113.937
729243db-496d-47e9-b7d3-1b367c33d076,C0005516,C1175743,is in patients infected with ,Biological Markers,SARS coronavirus,1,X,[clna],[virs],D23.101,B04.820.504.540.150.113.937
4841db91-4053-4646-b474-5563c674bdc2,C1415761,C1707455,were found 2 positive cases ,HSPA5 gene,Comparison,1,X,[gngm],[acty],,
3d9b916f-f4c1-4f50-8b61-91b676036d50,C1415761,C1175743,was significantly higher in ,HSPA5 gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
06a76fb2-8310-4514-8cf8-77090408a304,C0600388,C1175743,was significantly higher in ,Extracellular Signal Regulated Kinases,SARS coronavirus,1,X,[aapp/enzy],[virs],D08.811.913.696.620.682.700.567.249;D12.644.360.450.169;D12.776.476.450.169,B04.820.504.540.150.113.937
5689df31-511e-4e0a-a51e-8e0260ebb1e1,C1457887,pyrexia,vary from asymptomatic grade pyrexia,Symptoms,pyrexia,2,X,[sosy],????,,????
37f00fe4-c741-4857-b8db-ac898c3d83fb,C0007806,C0021760,also showed markedly increased levels of ,Cerebrospinal Fluid,Interleukin-6,1,X,[bdsu],[aapp/imft],A12.207.270.210,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
0dac0541-0f5d-4cf6-8068-2eddce2c44e9,C0206419,C0027765,is with ,Genus: Coronavirus,nervous system disorder,1,X,[virs],[dsyn],B04.820.504.540.150,C10
d4015ef3-9a8d-47b6-925e-e40016cf2e0c,C0544688,C0027765,is with ,complication of disease,nervous system disorder,1,X,[patf],[dsyn],,C10
e8ba7747-c0a9-45b3-b50a-0a43fa5caee7,C1175743,C0151946,often developing into ,SARS coronavirus,Pulmonary thrombosis,3,X,[virs],[patf],B04.820.504.540.150.113.937,
7ff27d4f-bc60-4add-8b74-27b8553bbabd,C1175743,C0034069,often developing into ,SARS coronavirus,Pulmonary Fibrosis,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.765
fd243322-959e-415d-a4bb-b3c1e436f845,C0034069,C0151946,is with ,Pulmonary Fibrosis,Pulmonary thrombosis,1,X,[dsyn],[patf],C08.381.765,
2a7e3e09-ed56-4743-9476-44b22c91cbc1,C0206419,M1,manifest prevalence of M1 ,Genus: Coronavirus,M1,1,X,[virs],????,B04.820.504.540.150,????
12dafd5a-1aed-4ae8-8c4e-980af546db17,C0012634,M1,manifest prevalence of M1 ,Disease,M1,1,X,[dsyn],????,C23.550.288,????
0ced4f7d-a789-4c1a-983c-0872ef09abb0,C0206419,C0024432,manifest prevalence of M1 ,Genus: Coronavirus,macrophage,1,X,[virs],[cell],B04.820.504.540.150,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
0a3f5b63-b775-4962-aa23-cf622aee34ed,C0012634,C0024432,manifest prevalence of M1 ,Disease,macrophage,1,X,[dsyn],[cell],C23.550.288,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
96a29353-bd14-47a4-b2d1-b543eda9e9f1,C0012634,C0301872,manifest ,Disease,Immune response,1,X,[dsyn],[ortf],C23.550.288,
96a29353-bd14-47a4-b2d1-b543eda9e9f1,C0012634,C0301872,impair ,Disease,Immune response,1,X,[dsyn],[ortf],C23.550.288,
1cdc6256-4fb2-4f18-8b5b-a08e35999912,C1948023,C3178844,enhance immune-modulating properties of ,Stimulation (motivation),Mesenchymal Stromal Cells,1,X,[npop],[cell],,A11.329.830.500;A11.872.590.500
eb925a97-d90a-4369-bc81-1d76f32ed564,C0087111,C2745965,is in ,Therapeutic procedure,Emergencies [Disease/Finding],1,X,[topp],[patf],E02,C23.550.291.781;N06.230.100.083;N06.850.376
d41e08c1-9dfc-4c50-a71a-41a608003c08,C0208757,C0087111,be ,Receptor Cannabinoid CB2,Therapeutic procedure,1,X,[aapp/rcpt],[topp],D12.776.543.750.695.125.200,E02
4450ecb3-badb-431f-838c-0b68a09c38e2,C0208757,C0206419,be ,Receptor Cannabinoid CB2,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],D12.776.543.750.695.125.200,B04.820.504.540.150
43e45b8f-1252-4c24-8396-5c0c260f7c67,C0208757,C2745965,be ,Receptor Cannabinoid CB2,Emergencies [Disease/Finding],1,X,[aapp/rcpt],[patf],D12.776.543.750.695.125.200,C23.550.291.781;N06.230.100.083;N06.850.376
61d62be0-7cc5-4d22-b771-9fa47fbfad4c,C1706214,C1175743,are faced with decisions regarding treatment of ,Creation,SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
e46bc5bf-3185-4136-97de-6fa5f9a15d7b,C0206419,C1096155,caused worldwide rapid ,Genus: Coronavirus,Macrophage Activation Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C20.683.515.800
3119d126-f8f2-4087-8a6a-d81c8c1ab16b,C1704259,C0022709,activated by ,Biochemical Pathway,Peptidyl-Dipeptidase A,1,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
daecc8d5-c064-4ed8-bbf2-461b00052f7f,C0301872,C0024109,severely damages healthy ,Immune response,Lung,1,X,[ortf],[bpoc],,A04.411
725cd02e-da83-4108-a168-7f68b61c1fc5,C0741933,C0027059, includes fulminant ,cardiac symptom,Myocarditis,6,X,[sosy],[dsyn],,C14.280.238.625
312a0928-49d8-43b9-9979-180d43a70f24,C0741933,C0221423,are frequent in patients in state of ,cardiac symptom,Illness (finding),4,X,[sosy],[sosy],,
621cd354-5789-4377-8fe0-1ab868ab35d2,C0027059,C0221423,are frequent in patients in state of ,Myocarditis,Illness (finding),4,X,[dsyn],[sosy],C14.280.238.625,
8887bb7e-774d-4499-bfa5-f7439d9a4503,C0057678,C0003174,is ,diacetylrhein,Anthraquinones,2,X,[orch/phsu],[orch/phsu],x.x.x.x,D02.455.426.559.847.117.159;D02.806.100;D04.615.117.159
45bc220d-780e-4dae-89c6-6621e5534db0,C0057678,C0013227,is ,diacetylrhein,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],x.x.x.x,D26
93346298-24af-4010-bcb6-7d1d38c36b11,C0870883,C0073177,is ,Metabolite,rhein,2,X,[bacs],[orch/phsu],,x.x.x.x
d036ba4a-02e9-4328-ac31-b1950dd74a32,C0073177,C1175175,suggesting rhein as potential therapeutic agent for treatment of,rhein,Severe Acute Respiratory Syndrome,1,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200.750;C08.730.730
4988f418-4871-4d62-9502-23047ccec92d,C0073177,C3711684,inhibits ,rhein,S protein severe acute respiratory syndrome coronavirus,6,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
43a5acfa-7545-4ed3-b2c3-c8b58fdb9b82,C0057678,C0206750,is multi-target drug useful for ,diacetylrhein,Coronavirus Infections,2,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
4ea252b2-e05a-49e4-b5c0-dd42167346ca,C0003174,C0079189,may control conditions by multi-faceted ,Anthraquinones,cytokine,2,X,[orch/phsu],[aapp/imft],D02.455.426.559.847.117.159;D02.806.100;D04.615.117.159,D12.644.276.374;D12.776.467.374;D23.529.374
509a7fef-7302-4a0a-846e-bed34294b12b,C0003174,C3463820,may control conditions by multi-faceted ,Anthraquinones,Inhibition,2,X,[orch/phsu],[acty],D02.455.426.559.847.117.159;D02.806.100;D04.615.117.159,F01.145.544;F02.463.425.475;F02.739.794.405
f8894431-994f-4a1f-9420-8a613f1749ed,C0042210,C0012634,contain spread of ,Vaccines,Disease,1,X,[aapp/imft/phsu],[dsyn],D20.215.894,C23.550.288
f8894431-994f-4a1f-9420-8a613f1749ed,C0042210,C0012634,Pharmaceutical Preparations against,Vaccines,Disease,1,X,[aapp/imft/phsu],[dsyn],D20.215.894,C23.550.288
0115389a-23dd-4311-a971-37e12c979ba8,C0748355,C0206750,pathophysiology of ,Acute respiratory distress,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
d1a97f65-6a5b-444d-826b-bd0a37a91ed9,C0450254,C0007634,shares same ,Pathogenic organism,Cells,2,X,[orgm],[cell],,A11
66610b9a-8484-4da6-909e-6c90bd6c9b20,C0450254,C0058362,shares same ,Pathogenic organism,dipeptidyl peptidase II,2,X,[orgm],[aapp/enzy],,x.x.x.x
560b97e9-b708-4fab-b2c3-a78171e84cfa,C0024109,C0034069,had characteristics of ,Lung,Pulmonary Fibrosis,4,X,[bpoc],[dsyn],A04.411,C08.381.765
1aa6b121-1c5a-418e-8168-3149c3f7def1,C0022709,C0003842,mainly locates in ,Peptidyl-Dipeptidase A,Arteries,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A07.015.114
f4b9f783-1463-47b7-82aa-f4c7f4aa5a61,C0086418,C0225828,Failed have higher percentage of ,Homo sapiens,Myocytes Cardiac,2,X,[humn],[cell],B01.050.150.900.649.313.988.400.112.400.400,A07.541.704.570;A10.690.552.750.570;A11.620.500
452900f3-3a88-4f53-8fdf-af26067f6eff,C0018787,C0225828,Failed have higher percentage of ,Heart,Myocytes Cardiac,2,X,[bpoc],[cell],A07.541,A07.541.704.570;A10.690.552.750.570;A11.620.500
649a5ac9-4b8c-4a44-9734-f4a7d15901c4,C0022709,C0206545,was expressed in ,Peptidyl-Dipeptidase A,Human respiratory syncytial virus,3,X,[aapp/enzy/imft],[virs],D08.811.277.656.350.350.687,B04.820.455.600.670.600.750.730
e5b7b6f8-8a58-45f4-91fe-d7d25b01462f,C0022709,C0026809,was expressed in ,Peptidyl-Dipeptidase A,Mus,3,X,[aapp/enzy/imft],[mamm],D08.811.277.656.350.350.687,B01.050.150.900.649.313.992.635.505.500
d2925bf1-3738-4490-b264-f9b65b11fbe5,C0022709,C0023810,was expressed in ,Peptidyl-Dipeptidase A,Lipopolysaccharides,3,X,[aapp/enzy/imft],[orch],D08.811.277.656.350.350.687,D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500
82049f97-44f8-46f2-aebd-99ca98539211,C0206750,C1524029,is with recent confirmed ,Coronavirus Infections,Mouse MIN NOS,2,X,[dsyn],[neop],C02.782.600.550.200,
f82777eb-13e3-496a-a783-e6b5e71f7c4e,C0557061,C0018801,may apply focused on ,Discussion (procedure),Heart failure,2,X,[topp],[dsyn],,C14.280.434
42a925db-a94c-48b5-943a-b9b33ed52d41,C0206750,C0232024,of number is ,Coronavirus Infections,Total airway resistance,2,X,[dsyn],[clna],C02.782.600.550.200,
c8121cea-9544-4d87-91c9-5ec21cbac4c8,C1175743,C0450254,is highly ,SARS coronavirus,Pathogenic organism,3,X,[virs],[orgm],B04.820.504.540.150.113.937,
0ea95dbe-9088-4467-b8b1-86ede62275b3,C0544688,C1175743,have have seen following ,complication of disease,SARS coronavirus,4,X,[patf],[virs],,B04.820.504.540.150.113.937
9e05d863-9d5a-4316-afb8-7ce35d77df71,C0543467,C0206750,provide Hospital beds attachment:Finding:Point in time:^Patient:Document for,Operative Surgical Procedures,Coronavirus Infections,1,X,[topp],[dsyn],E04,C02.782.600.550.200
9e05d863-9d5a-4316-afb8-7ce35d77df71,C0543467,C0206750,provide resources for ,Operative Surgical Procedures,Coronavirus Infections,1,X,[topp],[dsyn],E04,C02.782.600.550.200
9e05d863-9d5a-4316-afb8-7ce35d77df71,C0543467,C0206750,is in patients with ,Operative Surgical Procedures,Coronavirus Infections,2,X,[topp],[dsyn],E04,C02.782.600.550.200
6ce92ae7-352f-43c5-be44-f3d244523e6e,C0543467,C1705178,have As result have suspended in ,Operative Surgical Procedures,Order (action),1,X,[topp],[acty],E04,
6ce92ae7-352f-43c5-be44-f3d244523e6e,C0543467,C1705178,is mandatory in ,Operative Surgical Procedures,Order (action),1,X,[topp],[acty],E04,
c3197e7f-5806-49c7-abc2-22c4f5b7d743,C0543467,C2359943,provide ,Operative Surgical Procedures,Hospital beds attachment:Finding:Point in time:^Patient:Document,1,X,[topp],[clna],E04,
942c4459-be35-4915-a8bc-443204fee51c,C1175743,C0243083,been associated disease with,SARS coronavirus,associated disease,2,X,[virs],[patf],B04.820.504.540.150.113.937,
83ca7154-81cc-4588-ae78-d570995bde36,C1175743,C0011991,been associated disease with,SARS coronavirus,Diarrhea,1,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.821.214
8eed30a8-fadb-4c84-b44e-6489e4394108,C0012634,C0035204,is viral ,Disease,Respiration Disorders,1,X,[dsyn],[dsyn],C23.550.288,C08.618
8eed30a8-fadb-4c84-b44e-6489e4394108,C0012634,C0035204,can result in severe ,Disease,Respiration Disorders,1,X,[dsyn],[dsyn],C23.550.288,C08.618
8eed30a8-fadb-4c84-b44e-6489e4394108,C0012634,C0035204,causes ,Disease,Respiration Disorders,1,X,[dsyn],[dsyn],C23.550.288,C08.618
6c9f2c90-7bba-4630-9e92-8efad8d5c6fa,C1433062,COVID-19,is considered as ,3C-like protease SARS coronavirus,COVID-19,1,X,[aapp/enzy],[virs],x.x.x.x,C000657245
accb0434-a29b-4c36-a9c0-4e8837b2d911,COVID-19,C0033727,Communicated by Ramaswamy,COVID-19,Protons,1,X,[virs],[elii],C000657245,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
c6faa97f-f335-429c-9ed8-1acd1f5ab0e9,C0071649,COVID-19,are ,polyphenols,COVID-19,1,X,[orch/phsu],[virs],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,C000657245
80bb3c1f-b388-4557-b1ee-0528bd3f911a,C0071649,C0033727,are ,polyphenols,Protons,1,X,[orch/phsu],[elii],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
28bb1dad-5831-4878-a50b-9759fcbe58c9,C1175743,C0458827,is in ,SARS coronavirus,Airway structure,2,X,[virs],[bpoc],B04.820.504.540.150.113.937,
e43c381b-cda9-4f8c-b0a5-c4b39fcbd754,C2948600,C1456573,SARS coronavirus as,Aim,Global Health,1,X,[inch/phsu],[bmod],,H02.403.371;N01.400.337
c3b4562b-3760-4fb5-9a14-480f0e58f8d6,C1175743,C1546536,was present in ,SARS coronavirus,Air sample,1,X,[virs],[sbst],B04.820.504.540.150.113.937,
2b0ec20d-076b-4937-b91e-a26f1de86aba,C0337000,PCR,showed suitable performance followed by PCR ,Cyclonic Storms,PCR,2,X,[npop],????,G16.500.175.500;N06.230.100.230.100,????
d75ded35-9f89-4018-8bff-6bbf049d262e,C0017237,C1175743,showed suitable performance for trapping PCR ,Gelatin,SARS coronavirus,2,X,[aapp/phsu],[virs],D12.776.860.476,B04.820.504.540.150.113.937
6e2ab9f2-46e3-413d-85af-cb66dfe8b010,C0017237,PCR,showed suitable performance for trapping PCR ,Gelatin,PCR,2,X,[aapp/phsu],????,D12.776.860.476,????
28012efe-d60e-4ce6-a440-b8837cc97077,hypoxic,COVID-19,associated with ,hypoxic,COVID-19,1,X,????,[virs],????,C000657245
448b6c74-137f-4965-a568-535cf5b83460,C0264490,COVID-19,associated with ,Acute respiratory failure,COVID-19,1,X,[dsyn],[virs],,C000657245
42f23580-dcfb-48a4-8c64-60fa2e815012,C4284302,C0193062,includes ,EHD1 wt Allele,Rectum excision (procedure),1,X,[gngm],[topp],,E04.210.895
792f0528-a7e9-4d84-bc47-a16c945afbfb,C4284302,C2887352,includes ,EHD1 wt Allele,Intraoperative cardiac arrest,1,X,[gngm],[patf],,
5956d730-f11a-4cdd-8398-38d2e9efacf4,C0193062,C2887352,is with ,Rectum excision (procedure),Intraoperative cardiac arrest,1,X,[topp],[patf],E04.210.895,
8fc3054c-20f4-4b78-af5d-898cfde110d7,C0338106,C0034065,ascending ,Adenocarcinoma of colon,Pulmonary Embolism,1,X,[neop],[patf],,C08.381.746;C14.907.355.350.700
d198916d-fe54-44de-a6a4-5689ebe0b339,C0019080,C0192861,necessitated acute ,Hemorrhage,Right colectomy,1,X,[patf],[topp],C23.550.414,
0136f101-7f44-4acc-8ee7-fa53ae67903f,C0021081,C0009429,multiply chances of opportunistic in ,Immunosuppressive Agents,Combined Modality Therapy,1,X,[imft/phsu],[topp],D27.505.696.477.656,E02.186
12cc777e-5dfd-4947-8c65-c197c3e76599,C0021081,C0206750,multiply chances of opportunistic in ,Immunosuppressive Agents,Coronavirus Infections,1,X,[imft/phsu],[dsyn],D27.505.696.477.656,C02.782.600.550.200
ba5f657f-76ce-4792-9bf5-8b4111c4c10d,C1531518,C0206750,multiply chances of opportunistic so due to ,Biological treatment,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
e93427bb-242a-41b4-b7ad-f23df7a49213,C1175743,C0035204,primarily causes ,SARS coronavirus,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.618
835bd824-5a0f-4bde-84a1-bb21ba042b5f,C0021390,C0960756,can due to can ,Inflammatory Bowel Diseases,factor A,2,X,[dsyn],[orch],C06.405.205.731;C06.405.469.432,x.x.x.x
2d606b55-b384-4740-9faa-e5c15c6dca5e,COVID,C0009450,is much more than ,COVID,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
35d30567-7b8b-4a7e-9a37-40c279ae6a48,C0060323,C0302148,OR for ,Fibrin fragment D,Blood Clot,1,X,[aapp/bacs],[patf],x.x.x.x,C14.907.355.830
3c04a9dc-60b3-4346-aab8-7b8b28feeaba,C0302148,C0019080,OR for ,Blood Clot,Hemorrhage,1,X,[patf],[patf],C14.907.355.830,C23.550.414
613f5956-ba5a-4b86-865a-ce2a85ad7a74,C0005516,C0006560,included ,Biological Markers,C-reactive protein,1,X,[clna],[aapp/imft],D23.101,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
a8d1fc4b-1574-4fda-9bfd-2b94d353acd3,C0012739,C0019080,were associated with significant ,Disseminated Intravascular Coagulation,Hemorrhage,1,X,[dsyn],[patf],C15.378.100.220;C15.378.463.250;C15.378.925.220,C23.550.414
923ad381-a617-4f65-b4b9-8d50187e9d6a,C0040034,C0019080,were associated with significant ,Thrombocytopenia,Hemorrhage,1,X,[dsyn],[patf],C15.378.140.855,C23.550.414
c0de31c6-5606-43f1-bff8-5fd329bce7a7,C0020517,EMBASE,is in EMBASE,Hypersensitivity,EMBASE,1,X,[patf],????,C20.543,????
be6f3177-2902-45b9-a346-9f50ee83fa2b,C1706202,EMBASE,is in EMBASE,Search - action,EMBASE,1,X,[acty],????,,????
d2fc9bf7-456f-48d7-b6dc-0184650756fe,C0009450,C0242295,can can used as ,Communicable Diseases,Dietary Supplements,2,X,[dsyn],[food],C01.539.221,G07.203.300.456;J02.500.456
01811038-9e2c-466b-a0f0-5b0c42c482a4,C0009450,C0028606,can can used as ,Communicable Diseases,Nucleic Acids,2,X,[dsyn],[bacs/nnon],C01.539.221,D13.444
46b5578b-9b79-4638-b171-9ece28521dbd,C3540676,COVID-19,be maintained in ,Blockade,COVID-19,1,X,[elii/phsu],[virs],,C000657245
06c714ba-ec2e-47f7-8787-21f6e5791b38,C1708476,COVID-19,will reduce ,Implementation,COVID-19,1,X,[acty],[virs],,C000657245
ad8c9406-8813-44ac-b7ef-72906268b389,COVID-19,C0795934,has opened new ,COVID-19,Digitorenocerebral Syndrome,1,X,[virs],[dsyn],C000657245,x.x.x.x
93b1ed97-2e07-455a-97c3-aa89b7b903dd,COVID-19,C0003504,has opened new ,COVID-19,Aortic Valve Insufficiency,1,X,[virs],[dsyn],C000657245,C14.280.484.095
6e259e90-b7f6-43e7-8a14-1bd3eb79e2ef,C2948600,C0031336,offer ,Aim,Pharmacy (field),1,X,[inch/phsu],[bmod],,H02.646
d14aee93-c120-4b4c-8c2d-0020e031d693,C0242781,C0887950,is scale-free with few ,disease transmission,Genomics,1,X,[patf],[bmod],N06.850.310,H01.158.273.180.350;H01.158.273.343.350
1b7de797-911e-44a2-b06f-7edcf961fc1e,C1704259,C0023745,emphasize extent of epidemiological ,Biochemical Pathway,genetic linkage,1,X,[moft],[moft],,G05.348
642a8821-4f07-47e5-a2c7-e24c77fa2113,C1293116,C0023745,emphasize extent of epidemiological ,Introduction procedure,genetic linkage,1,X,[topp],[moft],,G05.348
4f83583a-6cf6-4648-b85e-7e8a3fd4f741,COVID-19,C0206061,is new clinical syndrome from upper respiratory ,COVID-19,Pneumonia Interstitial,1,X,[virs],[dsyn],C000657245,C08.381.483
4f83583a-6cf6-4648-b85e-7e8a3fd4f741,COVID-19,C0206061,is new syndrome from mild upper respiratory ,COVID-19,Pneumonia Interstitial,1,X,[virs],[dsyn],C000657245,C08.381.483
9e9aca3e-d771-43e4-863a-32722d7a7559,COVID-19,C0025962,is new clinical syndrome from upper respiratory ,COVID-19,Microcirculation,1,X,[virs],[ortf],C000657245,G09.330.100.645
9e9aca3e-d771-43e4-863a-32722d7a7559,COVID-19,C0025962,aggravated in ,COVID-19,Microcirculation,1,X,[virs],[ortf],C000657245,G09.330.100.645
aad41898-ad13-4bb9-b7c7-151510ee8a6e,COVID-19,C0302148,aggravated by ,COVID-19,Blood Clot,1,X,[virs],[patf],C000657245,C14.907.355.830
6ce5fa3b-b348-4492-9ae5-cba1da30dba8,C0221423,C1880022,from syndrome is ,Illness (finding),Characterization,1,X,[sosy],[acty],,
1c09c551-6bfa-41fd-bccc-03bb38e60df0,C0013227,C0242656,be evaluated in relation to pathophysiology of ,Pharmaceutical Preparations,Disease Progression,1,X,[phsu],[patf],D26,C23.550.291.656
cfef79f2-a5ad-487b-980a-a5e3298ff487,C0024348,C0206419,was optimized with endemic ,Lysis,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
f9c9842a-46d2-48aa-a915-5cd81042eb15,C0887950,C0520510,were used as control ,Genomics,Materials,1,X,[bmod],[sbst],H01.158.273.180.350;H01.158.273.343.350,
298a5fea-39c6-4702-b5fc-c596cffb26c3,C0035668,C0520510,were used as control ,RNA,Materials,1,X,[nnon],[sbst],D13.444.735,
1b88dfcb-923b-4786-a6d3-5f3d724b4c36,C0035668,C0038164,is in ,RNA,Staphylococcal Protein A,4,X,[nnon],[aapp/imft/irda],D13.444.735,D12.776.097.820;D23.050.161.821
1e20e891-20a9-47d5-ae19-010635fc9068,C0035668,C2987482,is in ,RNA,Animal Coat,2,X,[nnon],[bpoc],D13.444.735,
4e2a05e4-3b84-42f2-87ff-37cb263e0d1f,C0185115,C0206750,decreased Recovery - action of endemic,Extraction,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
90dfd4ec-6c3f-487a-be45-f7225343582d,C0028606,C0035668,transcribed ,Nucleic Acids,RNA,1,X,[bacs/nnon],[nnon],D13.444,D13.444.735
30a6dac9-acb1-4995-aa44-1014b2b62989,C0185115,C0035668,transcribed ,Extraction,RNA,1,X,[topp],[nnon],,D13.444.735
8b199d41-9d49-455c-8699-ebc9585a8351,C0028606,C4698072,transcribed ,Nucleic Acids,NL63,1,X,[bacs/nnon],[virs],D13.444,
46ccf870-d6dc-472f-9b9a-8a7c91a3dc42,C0185115,C4698072,transcribed ,Extraction,NL63,1,X,[topp],[virs],,
a3d216c3-fb76-4e62-9194-64370cfb84c3,C0237820,C4698072,transcribed ,Recovery - action,NL63,1,X,[acty],[virs],,
03f1733b-f50c-4206-8437-f4bf37e66d97,C0237820,C0035668,transcribed ,Recovery - action,RNA,1,X,[acty],[nnon],,D13.444.735
bcc68952-a492-40d7-a847-41900d2fd376,C0042776,C4698072,compared to RNA is,Virus,NL63,1,X,[virs],[virs],B04,
a3677eab-b550-421e-ba3b-34fedc0c5730,C1628999,C0035668,had Recovery - action through amplification compared to,SARS coronavirus RNA,RNA,1,X,[nnon],[nnon],,D13.444.735
ba944744-8d6a-495e-a1cd-9154454971a4,C1628999,C0237820,had more reliable ,SARS coronavirus RNA,Recovery - action,1,X,[nnon],[acty],,
c19ad6d8-b707-4534-8106-a47e9883443d,C1628999,C0185115,had more reliable ,SARS coronavirus RNA,Extraction,1,X,[nnon],[topp],,
bffe32cc-c7b3-4c9a-9882-629ff964697e,C0237820,C0024348,combining ,Recovery - action,Lysis,2,X,[acty],[patf],,
d278ab9d-7065-4604-9638-14043c35a960,C0237820,C0006353,combining ,Recovery - action,Buffers,2,X,[acty],[irda/phsu],,D27.720.470.280
c279a893-c6ee-4987-8823-de4ba70a9ed2,C0237820,C4553629,combining Lysis Buffers with clinical,Recovery - action,MATRix Regimen,2,X,[acty],[topp],,
73ce0d2e-cec9-40f6-9aab-8daa310c82b3,C0206750,C0185115,optimizing ,Coronavirus Infections,Extraction,1,X,[dsyn],[topp],C02.782.600.550.200,
811814ac-73c4-413d-821d-38e560fc850a,C0597363,C0042776,is In absence of live attenuated ,recombinant virus,Virus,2,X,[virs],[virs],,B04
d7ac8ee0-d5e0-457e-9583-bed0c004967e,C0597363,C0038164,is in ,recombinant virus,Staphylococcal Protein A,2,X,[virs],[aapp/imft/irda],,D12.776.097.820;D23.050.161.821
2a0ea776-e971-488a-be53-e1ae48ead05d,C0597363,C2987482,is in ,recombinant virus,Animal Coat,2,X,[virs],[bpoc],,
437c0a2f-64c5-4a37-afbe-99bec1b05b3b,COVID-19,C0684249,is in patients with ,COVID-19,Carcinoma of lung,2,X,[virs],[neop],C000657245,
1015de00-2e7d-4e29-b3cd-b90f77bacca2,C0242943,C0015219,is ,Molecular Mimicry,Biological Evolution,1,X,[moft],[genf],G02.111.560;G05.545;G16.012.750.500,G05.045;G16.075
fa560bd7-5daf-41ea-8753-1b00c1ec367e,C0242943,C0042776,is ,Molecular Mimicry,Virus,1,X,[moft],[virs],G02.111.560;G05.545;G16.012.750.500,B04
2fb81474-7993-4f37-b6d5-c1bd55910d90,C0287990,C1879547,is critical for ,paired basic amino acid cleaving enzyme,Activation action,1,X,[aapp/enzy],[acty],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
affac436-fffd-41a5-83a0-7e7dfeaea11a,C0026882,C0002006,causes ,Mutation,Aldosterone,1,X,[genf],[horm/orch/phsu],G05.365.590,D04.210.500.745.745.654.062;D06.472.040.585.353.118
9230dfab-1af5-47dc-a60c-62a8452cb5d3,C0034848,COVID-19,is in ,Receptors Virus,COVID-19,1,X,[aapp/rcpt],[virs],D12.776.543.750.830,C000657245
b25adf7e-328e-4174-a060-22cfeaea9c26,C0022709,COVID-19,is in ,Peptidyl-Dipeptidase A,COVID-19,1,X,[aapp/enzy/imft],[virs],D08.811.277.656.350.350.687,C000657245
2a310348-533e-45c9-9ff2-4d87786d2f2f,C0034848,C0007634,is in ,Receptors Virus,Cells,1,X,[aapp/rcpt],[cell],D12.776.543.750.830,A11
bb2a0b09-76d0-451b-83a6-fb4e0c887448,C0034848,C0024109,is in ,Receptors Virus,Lung,1,X,[aapp/rcpt],[bpoc],D12.776.543.750.830,A04.411
9b3284ac-31d0-4bb2-84a6-f894162f804a,C0007634,C0185027,shows significant ,Cells,Imbrication (procedure),1,X,[cell],[topp],A11,
e95d0c6a-e542-4268-a7dc-5a2d56cd4db9,C0035668,C0185027,shows significant ,RNA,Imbrication (procedure),1,X,[nnon],[topp],D13.444.735,
436f464f-51c8-4478-9240-6ab1a4f3cd02,C0011164,C1175743,wired into ,Abnormal degeneration,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
1f09db47-0356-459c-afc0-8eaf348e81bb,C0015219,C0233577,may may driven by its ,Biological Evolution,Mimicry,1,X,[genf],[mobd],G05.045;G16.075,
9b15a8dd-5f0b-43f3-922c-3d7dce9ef168,C0038164,C0019868,critical for ,Staphylococcal Protein A,Homeostasis,1,X,[aapp/imft/irda],[biof],D12.776.097.820;D23.050.161.821,G07.410
0b363875-e1e0-4967-a6b6-99c6e0f6a0fe,C0038164,C0458827,critical for ,Staphylococcal Protein A,Airway structure,1,X,[aapp/imft/irda],[bpoc],D12.776.097.820;D23.050.161.821,
521f197b-57c9-4155-a85e-111fd0f96540,C0038164,C0302908,critical for ,Staphylococcal Protein A,Liquid substance,1,X,[aapp/imft/irda],[sbst],D12.776.097.820;D23.050.161.821,
0fb1bcc9-36cd-452f-971a-ed680cbd3f4b,C0005768,C1856053,were in ,In Blood,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[bdsu],[dsyn],x.x.x.x.x,x.x.x.x
4e8df8e9-c235-4d0f-bd25-bb09cab11e07,C1273858,C0005768,conserve ,Transfusion Medicine,In Blood,1,X,[bmod],[bdsu],H02.403.429.445.500,x.x.x.x.x
3f8e6a18-581d-47dc-accf-3dbba7d774f8,C3658340,C0005768,conserve ,Hospital Medicine,In Blood,1,X,[bmod],[bdsu],H02.403.377,x.x.x.x.x
8c916af7-aeab-4591-b97e-6ae24b10fc33,C0013227,C0429028,prolong ,Pharmaceutical Preparations,QT interval feature (observable entity),2,X,[phsu],[clna],D26,
7816a209-04f5-42e6-93e4-81d089edcae4,C0013227,C0040479,accordingly put - instruction imperative patients at increased risk for,Pharmaceutical Preparations,Torsades de Pointes,1,X,[phsu],[dsyn],D26,C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700
7816a209-04f5-42e6-93e4-81d089edcae4,C0013227,C0040479,accordingly may put patients at increased risk for ,Pharmaceutical Preparations,Torsades de Pointes,1,X,[phsu],[dsyn],D26,C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700
7740cc6a-d759-44ef-b322-fc5ca703d474,MEDLINE,C0011071,artesunate for risk of QT prolongation torsades ventricular arrhythmia and,MEDLINE,Sudden death,1,X,????,[patf],????,C23.550.260.322
ec121dde-4cfa-4783-b470-aa55d2ff5abc,MEDLINE,C0008269,artesunate for risk of QT prolongation torsades ventricular arrhythmia and,MEDLINE,Chloroquine,1,X,????,[orch/phsu],????,D03.633.100.810.050.180
978142f0-7886-4380-a167-e3f62dbdabb8,C0008269,C0003811,potentially increase risk of ,Chloroquine,Cardiac Arrhythmia,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C14.280.067;C23.550.073
2be91a3f-1d6b-4324-bfc1-68d74bd5c729,C4553629,genomic,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,genomic,1,X,[topp],????,,????
a294203c-312d-4bd6-ba09-589514fa62cb,C4553629,y43,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,y43,1,X,[topp],????,,????
71a7b969-1852-48fa-8558-ed6f17b3285f,C0013227,C0012854,reduce extracellular ,Pharmaceutical Preparations,DNA,1,X,[phsu],[bacs/nnon],D26,D13.444.308
3de3a0bd-411c-4d6c-bfc0-805abd07ae83,C0013227,C1515933,reduce extracellular ,Pharmaceutical Preparations,Alveolus,1,X,[phsu],[bpoc],D26,
b969d237-1ae8-411c-b145-18722e2f4ca3,PPE,C0206750,becomes at ,PPE,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
4963c821-fd9d-4c59-bad4-53cc98d1a856,C0282624,C0206750,reconverted during ,Minimally Invasive Surgical Procedures,Coronavirus Infections,1,X,[topp],[dsyn],E04.502,C02.782.600.550.200
d97b4442-e7ab-4afd-8696-7ee6f579fb09,C1415347,RCT,is pragmatic RCT,GTF2I gene,RCT,1,X,[gngm],????,,????
d9db47c4-1753-4525-96f3-b977c4cd40eb,C4082365,RCT,is pragmatic RCT,Choline O-Acetyltransferase human,RCT,1,X,[aapp/enzy],????,,????
6ac57c1e-9e3d-4d02-8456-9ada7f9e07ae,RCT,C1415347,using sub-cohort of ,RCT,GTF2I gene,2,X,????,[gngm],????,
bb3ad379-0bf0-4603-a509-729b6104fd9e,RCT,C0206750,using ,RCT,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
9ae039b0-6a36-4ef5-8864-ab7c7fff5996,C0206750,C1415347,sub-cohort of ,Coronavirus Infections,GTF2I gene,1,X,[dsyn],[gngm],C02.782.600.550.200,
8ef39bfe-ecc2-4c70-9fa7-a9855e4c827f,C1415347,C0441655,includes ,GTF2I gene,Activities,1,X,[gngm],[acty],,
bfe1f94f-505d-41e5-ad79-06fe0d8d817f,C4082365,C0441655,includes ,Choline O-Acetyltransferase human,Activities,1,X,[aapp/enzy],[acty],,
8a118932-a17f-4ee6-a7b8-36f5f4e66e6f,C2728259,C0441655,includes ,Program,Activities,1,X,[orch/phsu],[acty],V02.355.750,
d739465a-7c35-48a7-bd6d-d3d84204003a,C0184661,4-week,will receive 4-week ,Interventional procedure,4-week,1,X,[topp],????,,????
3c0071d6-8a56-4611-bf25-e0b8c14d9480,C0184661,C1415347,will receive 4-week ,Interventional procedure,GTF2I gene,1,X,[topp],[gngm],,
afafc393-c9f2-4f05-9fd0-c0ac93888620,C0184661,C4082365,will receive 4-week ,Interventional procedure,Choline O-Acetyltransferase human,1,X,[topp],[aapp/enzy],,
665c2904-79e9-41f4-ae81-d2fd82c9cf6d,C0184661,C2728259,will receive 4-week ,Interventional procedure,Program,1,X,[topp],[orch/phsu],,V02.355.750
662c9925-d63b-4c9e-8127-326b3c654e6a,C0918259,C1167518,is among thus mainstay of ,medical nutritional therapy,viral nucleocapsid location,1,X,[topp],[celc],,
91fec34a-d349-4650-8e12-6e1dc2528468,C0918259,C0206750,is among thus mainstay of ,medical nutritional therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
d1e43f71-b481-46c6-bb2c-c8c523c54d7c,C4534538,C0038454,increased including only hospitalizations with discharge ,Mechanical thrombectomy,Cerebrovascular accident,1,X,[topp],[dsyn],,C10.228.140.300.775;C14.907.253.855
eb7c1178-bf9e-4922-8b9c-35ecb12a8619,C0206750,C0037633,has demonstrated strong potential of various health ,Coronavirus Infections,Solutions,2,X,[dsyn],[sbst],C02.782.600.550.200,D26.776
9e4932ec-8cfe-4983-b16d-afcc594cfd2c,C0231528,C0009450,were present mostly in early stages of ,Myalgia,Communicable Diseases,3,X,[sosy],[dsyn],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C01.539.221
4eea104b-6cf4-4e93-9b56-a379f5b5807a,C0018681,C0009450,were present in mostly stages of ,Headache,Communicable Diseases,2,X,[sosy],[dsyn],C23.888.592.612.441,C01.539.221
5e95bb6d-2d0f-45ed-bf2f-550d5f9c376d,C0012833,C0009450,were present mostly in early stages of ,Dizziness,Communicable Diseases,3,X,[sosy],[dsyn],C23.888.592.763.237,C01.539.221
930c54b1-fea5-4fd6-ac2c-af2bed310cb0,C0009792,C0206750,occurred commonly in severe ,Consciousness Disorders,Coronavirus Infections,2,X,[mobd],[dsyn],C10.597.606.358;C23.888.592.604.359;F01.700.315;F03.615.300,C02.782.600.550.200
546fe8f7-0ed0-42a6-a22d-e8d2904a3479,C2745965,C0719214,is in ,Emergencies [Disease/Finding],century,1,X,[patf],[phsu/vita],C23.550.291.781;N06.230.100.083;N06.850.376,
bde904d6-2abd-4156-92cb-53067d54731d,C1181031,L3606F,is with ORF1a L3606F ,Apical ramus of posterior segmental artery,L3606F,2,X,[bpoc],????,,????
3d3158d2-ee4a-4e2f-b05d-2c06bf96e7e7,C1181031,C0026882,is with ORF1a L3606F ,Apical ramus of posterior segmental artery,Mutation,2,X,[bpoc],[genf],,G05.365.590
9f646ed1-d194-42dc-894f-00bd888dad4b,C0026882,C1181031,most consistent with Western European Clade L3606F ,Mutation,Apical ramus of posterior segmental artery,1,X,[genf],[bpoc],G05.365.590,
40d618d1-f11f-4360-a1e0-c8885947ccdb,C0026882,L3606F,most consistent with Western European Clade L3606F ,Mutation,L3606F,1,X,[genf],????,G05.365.590,????
e4ac9c82-8908-40d9-a79e-5f4b6fa52759,C0003062,C0003451,identify potential ,Animals,Antiviral Agents,3,X,[anim],[phsu],B01.050,D27.505.954.122.388
49f269ed-6da0-4c2a-887f-a5270cf5fcd9,C0003062,C0086418,identify potential ,Animals,Homo sapiens,1,X,[anim],[humn],B01.050,B01.050.150.900.649.313.988.400.112.400.400
49f269ed-6da0-4c2a-887f-a5270cf5fcd9,C0003062,C0086418,identify Therapeutic procedure Antiviral Agents candidates with strong,Animals,Homo sapiens,1,X,[anim],[humn],B01.050,B01.050.150.900.649.313.988.400.112.400.400
fe640b1b-dfaf-4984-b656-2cab70314831,C1516048,C0015859,is in ,Assessed,Ferrets,1,X,[acty],[mamm],,B01.050.150.900.649.313.750.250.575.350
0948e0d1-886c-4e08-a063-b81840b54d49,C0003451,C0015859,were Assessed in,Antiviral Agents,Ferrets,1,X,[phsu],[mamm],D27.505.954.122.388,B01.050.150.900.649.313.750.250.575.350
0948e0d1-886c-4e08-a063-b81840b54d49,C0003451,C0015859,were To end ,Antiviral Agents,Ferrets,1,X,[phsu],[mamm],D27.505.954.122.388,B01.050.150.900.649.313.750.250.575.350
ad38f068-f557-4a88-b5af-27aaef93c1d5,C0003451,C0009450,were Assessed in,Antiviral Agents,Communicable Diseases,1,X,[phsu],[dsyn],D27.505.954.122.388,C01.539.221
ad38f068-f557-4a88-b5af-27aaef93c1d5,C0003451,C0009450,were To end ,Antiviral Agents,Communicable Diseases,1,X,[phsu],[dsyn],D27.505.954.122.388,C01.539.221
7790a922-f7a0-4c63-9e59-e39425f15eea,C0939237,C1516048,efficacies of were To end ,lopinavir / Ritonavir,Assessed,1,X,[phsu],[acty],,
678b87b7-7397-4cd4-8056-58f1f4744d48,C0596007,C1516048,efficacies of were To end ,Hydroxychloroquine Sulfate,Assessed,1,X,[orch/phsu],[acty],D03.633.100.810.050.180.350,
e718a509-6fd4-40ab-9c4c-87bdfe623723,C1532298,C1516048,efficacies of were To end ,Emtricitabine and tenofovir product,Assessed,1,X,[orch/phsu],[acty],,
d4ae4679-362e-40de-94c0-56862eb804f9,C0939237,C0015859,efficacies of were To end ,lopinavir / Ritonavir,Ferrets,1,X,[phsu],[mamm],,B01.050.150.900.649.313.750.250.575.350
a1bc8d46-4816-4e11-a305-e61eca566211,C0596007,C0015859,efficacies of were To end ,Hydroxychloroquine Sulfate,Ferrets,1,X,[orch/phsu],[mamm],D03.633.100.810.050.180.350,B01.050.150.900.649.313.750.250.575.350
9e257129-c13c-4e56-ada9-a7c24cac0a3a,C1532298,C0015859,efficacies of were To end ,Emtricitabine and tenofovir product,Ferrets,1,X,[orch/phsu],[mamm],,B01.050.150.900.649.313.750.250.575.350
87d432d7-5d39-4049-a0a3-af30772319e8,C0939237,C0009450,efficacies of were To end ,lopinavir / Ritonavir,Communicable Diseases,1,X,[phsu],[dsyn],,C01.539.221
5e18d53e-cca3-4808-8b4c-89bf984b4929,C0596007,C0009450,efficacies of were To end ,Hydroxychloroquine Sulfate,Communicable Diseases,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.539.221
394ecd6f-85e9-436f-9328-a0d88f981e3e,C1532298,C0009450,efficacies of were To end ,Emtricitabine and tenofovir product,Communicable Diseases,1,X,[orch/phsu],[dsyn],,C01.539.221
4c987b38-ffed-4eff-aefa-b5953189a208,titers,C1550661,is in nasal washes ,titers,Specimen Type - Stool = Fecal,1,X,????,[bdsu],????,
291dc98c-bf3f-4caf-8f11-231bd2d5d9b6,titers,C0040300,is in nasal washes ,titers,Body tissue,1,X,????,[tisu],????,A10
8473d448-995a-45e1-a2df-da1af37dbad2,C1532298,C0036082,showed virus titers than ,Emtricitabine and tenofovir product,Saline Solution,1,X,[orch/phsu],[sbst],,D26.776.498.500.750
843f9a9f-aef1-4d1d-88b6-5b70088004ad,C1532298,titers,showed lower virus titers ,Emtricitabine and tenofovir product,titers,1,X,[orch/phsu],????,,????
f7c1757f-60ef-49d9-8b9a-3d60b5425bf0,C1532298,8days,showed virus titers at 8days ,Emtricitabine and tenofovir product,8days,1,X,[orch/phsu],????,,????
e91034d7-0078-439a-9985-bf9c3ff3c32c,C0015859,C0004482,were treated with ,Ferrets,Azathioprine,1,X,[mamm],[hops/orch/phsu],B01.050.150.900.649.313.750.250.575.350,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111
b2d9b26e-430d-4f25-aa77-14e5122a508e,C0015859,C0042769,further explore effect on ,Ferrets,Virus Diseases,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.250.575.350,C02
28a481cb-179c-49d0-8bad-0ea1fe64dc8c,C0015859,C2359945,were treated with ,Ferrets,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[mamm],[clna],B01.050.150.900.649.313.750.250.575.350,
d197a796-4d8e-4ae1-bb0e-f4c5d4422706,C0004482,C0221423,exhibited longer period of ,Azathioprine,Illness (finding),1,X,[hops/orch/phsu],[sosy],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,
075804fd-52f0-4bb6-93ba-0b64fa9e3e75,C0015859,C0221423,exhibited longer period of ,Ferrets,Illness (finding),1,X,[mamm],[sosy],B01.050.150.900.649.313.750.250.575.350,
a0141b89-0457-46b1-a478-e58e005a38a4,C0004482,C0319157,showed delayed ,Azathioprine,AS virus,3,X,[hops/orch/phsu],[virs],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,
aa992ab7-2b30-4162-86e6-8e44c78ea5bf,C0015859,C0319157,showed delayed ,Ferrets,AS virus,3,X,[mamm],[virs],B01.050.150.900.649.313.750.250.575.350,
27ee04f2-4b76-483b-85d3-15e7c7fdfba3,C0004482,titers,exhibited virus titers,Azathioprine,titers,1,X,[hops/orch/phsu],????,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,????
27ee04f2-4b76-483b-85d3-15e7c7fdfba3,C0004482,titers,exhibited significantly lower serum neutralization antibody titers,Azathioprine,titers,1,X,[hops/orch/phsu],????,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,????
27ee04f2-4b76-483b-85d3-15e7c7fdfba3,C0004482,titers,showed low SN titers,Azathioprine,titers,2,X,[hops/orch/phsu],????,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,????
fcd28afd-b70b-483b-af25-67cc2dd12b05,C0015859,titers,exhibited virus titers,Ferrets,titers,1,X,[mamm],????,B01.050.150.900.649.313.750.250.575.350,????
fcd28afd-b70b-483b-af25-67cc2dd12b05,C0015859,titers,exhibited significantly lower serum neutralization antibody titers,Ferrets,titers,1,X,[mamm],????,B01.050.150.900.649.313.750.250.575.350,????
fcd28afd-b70b-483b-af25-67cc2dd12b05,C0015859,titers,showed low SN titers,Ferrets,titers,2,X,[mamm],????,B01.050.150.900.649.313.750.250.575.350,????
c768cdf1-d53d-42f1-87c2-d5e7a0cfa6f6,C0004482,C0036082,exhibited period Compared to ,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
c768cdf1-d53d-42f1-87c2-d5e7a0cfa6f6,C0004482,C0036082,exhibited virus titers Compared to ,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
c768cdf1-d53d-42f1-87c2-d5e7a0cfa6f6,C0004482,C0036082,exhibited AS virus clearance Compared to,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
c768cdf1-d53d-42f1-87c2-d5e7a0cfa6f6,C0004482,C0036082,exhibited serum neutralization antibody titers Compared to ,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
ffa47bf9-c001-4ab1-a3a1-4f93bce8d773,C0015859,C0036082,exhibited period Compared to ,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
ffa47bf9-c001-4ab1-a3a1-4f93bce8d773,C0015859,C0036082,exhibited virus titers Compared to ,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
ffa47bf9-c001-4ab1-a3a1-4f93bce8d773,C0015859,C0036082,exhibited AS virus clearance Compared to,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
ffa47bf9-c001-4ab1-a3a1-4f93bce8d773,C0015859,C0036082,exhibited serum neutralization antibody titers Compared to ,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
ea67aac8-1eea-40cd-b1bd-1de855636c64,titers,C1266928,is in ,titers,Nasal turbinate bone structure,1,X,????,[bpoc],????,A02.835.232.781.324.948;A04.531.898
1b6e13a5-8d50-415d-9930-2078a7faa188,C0015859,C0003062,should Despite potential discrepancy between ,Ferrets,Animals,1,X,[mamm],[anim],B01.050.150.900.649.313.750.250.575.350,B01.050
87adf4d2-08d5-43de-b7c2-1053620244a2,C0015859,C0087111,should Despite potential discrepancy between ,Ferrets,Therapeutic procedure,1,X,[mamm],[topp],B01.050.150.900.649.313.750.250.575.350,E02
de9ba597-abde-4114-94eb-edd5031dc57f,C0015859,C0206750,should Despite potential discrepancy between ,Ferrets,Coronavirus Infections,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.250.575.350,C02.782.600.550.200
6cd158ff-a542-4b1a-9f55-48095914d405,C0004482,C0009450,resulting in prolonged ,Azathioprine,Communicable Diseases,1,X,[hops/orch/phsu],[dsyn],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,C01.539.221
c32c5d4f-7073-48a9-bc30-64d5ca41475c,C0015859,C0009450,resulting in prolonged ,Ferrets,Communicable Diseases,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.250.575.350,C01.539.221
6295880c-3016-4f2f-a4d5-2481aa1193cd,C0003062,C0087111,identify ,Animals,Therapeutic procedure,1,X,[anim],[topp],B01.050,E02
f3f37d9b-ddfc-4c1d-b916-24125a5705f1,C0027651,C0441655,maintaining ,Neoplasms,Activities,1,X,[neop],[acty],C04,
f0f3e549-dd94-4a3a-ab2a-c3583ef80c13,C0027651,C1856053,was converted On 13th,Neoplasms,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[neop],[dsyn],C04,x.x.x.x
9330662e-41be-4bad-b850-c1dea6a06d02,C0027651,13th,was converted On 13th,Neoplasms,13th,2,X,[neop],????,C04,????
662ff66f-cbdd-41ed-a297-536cc7e38260,PET/CT,C1175743,hypothesize ,PET/CT,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
9ba444f7-f546-4c4b-84b1-dc367cc6391a,PET/CT,C0032285,hypothesize ,PET/CT,Pneumonia,1,X,????,[dsyn],????,C08.381.677;C08.730.610
d1d290a5-da9d-4e46-ae5e-e719d19a725f,PET/CT,C0020517,is ,PET/CT,Hypersensitivity,1,X,????,[patf],????,C20.543
1d3414e3-d83e-4ba5-8b43-3f3e05cd4f55,C2926735,ona,force ona ,Duration,ona,2,X,[orch/phsu],????,,????
b0cd7636-0a2e-4aed-86e5-c0dc6f43a226,C2926735,C0042077,force adaptation in management among ,Duration,Urology,1,X,[orch/phsu],[bmod],,H02.403.810.860
131843e4-df60-4f66-8a46-9ad8b4a49e18,C0032857,C3694279,rapidly inactivates ,Povidone-Iodine,Middle East Respiratory Syndrome,2,X,[orch/phsu],[dsyn],D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745,C02.782.600.550.200
9dba6c49-49f8-4a83-b72f-2435b7b6384a,C0032857,C0206419,rapidly inactivates ,Povidone-Iodine,Genus: Coronavirus,2,X,[orch/phsu],[virs],D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745,B04.820.504.540.150
3ac7b879-664a-4012-b373-43262b67f6f3,C0032857,C1175743,rapidly inactivates ,Povidone-Iodine,SARS coronavirus,3,X,[orch/phsu],[virs],D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745,B04.820.504.540.150.113.937
8f3ed7fd-4e20-4709-b954-df3f0221b330,C0206419,C0679637,has brought ,Genus: Coronavirus,major surgery,2,X,[virs],[topp],B04.820.504.540.150,
9fe64140-0c00-465c-8e40-064d2211230c,C0012634,C0679637,has brought ,Disease,major surgery,2,X,[dsyn],[topp],C23.550.288,
fdea7c2a-03cb-4c18-87a5-38f8d2508bde,C1135662,C0012854,digests ,Dornase Alfa,DNA,1,X,[aapp/enzy/phsu],[bacs/nnon],x.x.x.x,D13.444.308
bb6ef0a7-0e11-43cc-acf7-6912361e5574,C1135662,C0577978,digests DNA in,Dornase Alfa,Mucoid sputum,1,X,[aapp/enzy/phsu],[sosy],x.x.x.x,
51603113-35c2-49ea-9e3b-7172883423df,C3850088,C0042784,contributes to ,Neutrophil Extracellular Traps,Viscosity,1,X,[celc],[npop],A11.284.295.495,G02.930
ac087bf3-65ca-48ec-a69c-1a2f52e8010b,C3850088,C0036537,contributes to ,Neutrophil Extracellular Traps,Bodily secretions,1,X,[celc],[bdsu],A11.284.295.495,A12.200
91dee02d-f2f8-4205-ad4f-3b58c35be816,C3850088,COVID-19,are found in ,Neutrophil Extracellular Traps,COVID-19,1,X,[celc],[virs],A11.284.295.495,C000657245
e234639f-7878-40d2-a13a-9f21cdf6055f,C3850088,C0229671,are found in ,Neutrophil Extracellular Traps,Serum,1,X,[celc],[bdsu],A11.284.295.495,A12.207.152.846;A15.145.846
8f760d3a-16f1-45e1-a4dd-7cb9daf63333,C1135662,COVID-19,may ,Dornase Alfa,COVID-19,1,X,[aapp/enzy/phsu],[virs],x.x.x.x,C000657245
920d3972-d078-4d29-bc8f-9b22009e470a,C1135662,C0042776,minimize risk of ,Dornase Alfa,Virus,1,X,[aapp/enzy/phsu],[virs],x.x.x.x,B04
aa6ddbfb-7ec3-4cc3-ae5d-6f5075042ba3,C1135662,in-line,was administered through in-line ,Dornase Alfa,in-line,1,X,[aapp/enzy/phsu],????,x.x.x.x,????
6661e4b3-b72c-431c-8e40-90e94a53b0c7,in-line,C0001927,is with ,in-line,Albuterol,1,X,????,[orch/phsu],????,D02.033.100.291.057;D02.092.063.291.057;D02.092.471.683.061
8cff7c83-1736-48ec-a290-f54b0cfc0136,C3853628,C2926735,can effectively shorten ,Granule,Duration,2,X,[sbst],[orch/phsu],,
21308e69-f7c4-468f-bf72-21772d1cf5f9,C3853628,COVID-19,can effectively shorten Duration In,Granule,COVID-19,1,X,[sbst],[virs],,C000657245
5d0b66ea-ea07-436c-916f-df46cdd53077,C3853628,C3852990,promote ,Granule,Pulmonary Absorption,4,X,[sbst],[ortf],,G03.015.500.703;G03.787.024.500.703;G07.690.725.015.500.703;G09.772.813
8b5a967f-1e4a-4a67-beba-8ff81681ac62,C3853628,C0302306,promote ,Granule,Inflammatory exudate,2,X,[sbst],[bdsu],,
d3293b98-b124-4e20-b04e-5a31d20d08be,C3853628,C0559546,promote Pulmonary Absorption without obvious,Granule,Adverse reactions,2,X,[sbst],[patf],,
0e436efe-9f3e-4dad-8405-4b4e52509a0f,C1628999,PCR,Currently takes put - instruction imperative by real-time PCR,SARS coronavirus RNA,PCR,1,X,[nnon],????,,????
3c0b5864-e735-43e5-b6a2-e00b430072f5,C1511790,PCR,Currently takes put - instruction imperative by real-time PCR,Detection,PCR,1,X,[topp],????,,????
e5003b7b-336a-4e90-9ea0-5f3fd6009d9a,C1628999,C1882509,takes ,SARS coronavirus RNA,put - instruction imperative,2,X,[nnon],[acty],,
4ce470d1-b977-4624-9e10-97024e849223,C1511790,C1882509,takes ,Detection,put - instruction imperative,2,X,[topp],[acty],,
aeec4e84-d964-44b3-be0a-01da3a460bf0,GGO,C1265876,combined with focal consolidation ,GGO,Abnormally opaque structure (morphologic abnormality),1,X,????,[patf],????,
999246f6-3d64-4b0f-ba5a-db266f562d8f,COVID-19,C1516048,possible IMPACT gene of is,COVID-19,Assessed,1,X,[virs],[acty],C000657245,
78d0c3b0-38e6-426b-8edc-4e58d019cfde,C1321164,C0087111,re-design our ,Gynecologic Oncology,Therapeutic procedure,1,X,[bmod],[topp],,E02
0a24de08-c689-4750-bd4e-25a8ffa7649e,C0856169,C0087086,leads to formation of ,endothelial dysfunction,Thrombus,1,X,[dsyn],[patf],,C14.907.355.830
93740c41-e039-4cb3-bde4-8f22462e54dc,C0856169,C0507816,leads to formation of ,endothelial dysfunction,Pulmonary capillary,1,X,[dsyn],[bpoc],,
e09efa29-78fe-42cf-84d2-e903b3516194,C0282636,C0206419,is in patients with severe ,Cell Respiration,Genus: Coronavirus,1,X,[celf],[virs],G03.197;G04.270,B04.820.504.540.150
18a96490-c05e-4a43-a109-8f342244412f,C0282636,C0398623,is in patients with severe ,Cell Respiration,Thrombophilia,1,X,[celf],[dsyn],G03.197;G04.270,C15.378.925
d86fad93-7903-4d52-b4ca-13ebc529e9ca,C1145670,C0199451,requiring helmet ,Respiratory Failure,Continuous Positive Airway Pressure,1,X,[dsyn],[topp],C08.618.846,E02.041.625.790.259;E02.880.820.790.259
d2f0fe2a-4653-41cf-95aa-3292fe7c9b90,C1145670,C0087086,requiring pro ,Respiratory Failure,Thrombus,1,X,[dsyn],[patf],C08.618.846,C14.907.355.830
a12c642e-b318-4e38-ad2a-031950271e76,C1096021,C0042495,improving ,antiplatelet therapy,Ventilation-Perfusion Ratio,1,X,[topp],[ortf],,E01.370.386.700.650.900;G09.772.920
e573112b-035d-4809-a8a9-0965fbca28c8,C1096021,C0206419,improving Ventilation-Perfusion Ratio in,antiplatelet therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
80200034-836b-4ed0-a2da-71d4a3d3f4fa,C1096021,C1145670,improving Ventilation-Perfusion Ratio in,antiplatelet therapy,Respiratory Failure,1,X,[topp],[dsyn],,C08.618.846
41e8411b-44a3-42ce-a687-a6792956ed74,C1825598,C0007222,will translate given high prevalence of ,IMPACT gene,Cardiovascular Diseases,1,X,[gngm],[dsyn],,C14
44179b99-5f53-4f05-87ef-6ceca4af12ec,C0005821,COVID-19,can Assessed,Blood Platelets,COVID-19,1,X,[cell],[virs],A11.118.188;A15.145.229.188,C000657245
ac4e0c9c-6556-4de2-a617-8ea28e5f4a8d,C0231832,C0206750,is with ,Respiratory rate,Coronavirus Infections,1,X,[clna],[dsyn],E01.370.600.875.875;G09.772.705.730,C02.782.600.550.200
126c3052-9560-4ae4-aa89-54568286c443,C0004238,C0206750,is common clinical manifestation in hospitalized patients with ,Atrial Fibrillation,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.280.067.198;C23.550.073.198,C02.782.600.550.200
6d3d11f4-55fc-447d-9c38-e48da38c64d0,C0004238,C0012634,is common manifestation in hospitalized patients with ,Atrial Fibrillation,Disease,2,X,[dsyn],[dsyn],C14.280.067.198;C23.550.073.198,C23.550.288
5c0644e6-6732-4ceb-8fa9-8bf897243a64,C0003280,C0019080,may lead to significant bradycardia ventricular arrhythmias or severe ,Anticoagulants,Hemorrhage,2,X,[phsu],[patf],D27.505.954.502.119,C23.550.414
b64ef41b-494d-4d29-bb6f-f63d54912ff3,C0687133,C0019080,may lead to significant bradycardia ventricular arrhythmias or severe ,Drug Interactions,Hemorrhage,2,X,[patf],[patf],G07.690.773.968,C23.550.414
b87fa35d-ee38-4f6f-adea-649afcc1a8d6,C0003195,C0019080,may lead to significant bradycardia ventricular arrhythmias or severe ,Anti-Arrhythmia Agents,Hemorrhage,2,X,[phsu],[patf],D27.505.954.411.097,C23.550.414
0e1e4857-6d09-4ca6-b9fd-88378bae8f7f,C0206750,C0004238,is with ,Coronavirus Infections,Atrial Fibrillation,2,X,[dsyn],[dsyn],C02.782.600.550.200,C14.280.067.198;C23.550.073.198
cd0063e5-19f6-4767-90f2-864c369168c1,C0206750,C0243087,is with ,Coronavirus Infections,concomitant disease,1,X,[dsyn],[patf],C02.782.600.550.200,
8b1bc330-8132-4f69-965e-83ff077611af,C0086418,C0003241,clarify role of ,Homo sapiens,Antibodies,1,X,[humn],[aapp/imft/phsu],B01.050.150.900.649.313.988.400.112.400.400,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
9bfae80d-6ff1-4b18-8fc4-bdd285b342b1,C0086418,C0699748,clarify role of ,Homo sapiens,Pathogenesis,1,X,[humn],[patf],B01.050.150.900.649.313.988.400.112.400.400,
fceb2fa0-8c64-4c72-a74f-2b22f10fe027,C0012634,C0019682, includes ,Disease,HIV,2,X,[dsyn],[virs],C23.550.288,B04.820.650.589.650.350
520e4e94-cbd1-4731-bc97-3df7a653bca8,C4086266,C0206750,takes place in ,Escalation,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
58f3b7c0-0c42-43e1-887c-9f9bfb0f4c2b,C4086266,C0042384,takes place in ,Escalation,Vasculitis,1,X,[acty],[dsyn],,C14.907.940
a6721814-e4ff-4c26-b64e-e2b32d1eaccf,C0021760,myokine,is key myokine,Interleukin-6,myokine,1,X,[aapp/imft],????,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,????
4288d6f7-c2c6-4635-9798-852369221b1c,C1707455,C0815172,was performed between clinicopathological ,Comparison,patient characteristics,6,X,[acty],[clna],,
f03798b5-77ee-4db7-8476-bb7fbffc5d1b,C1707455,C0003615,was performed between clinicopathological ,Comparison,Appendicitis,2,X,[acty],[dsyn],,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
9676a555-7886-441d-a561-d632b4d601c2,C2949735,20th,began 20th,Recruitment,20th,1,X,[acty],????,,????
c1a039c0-6649-42a6-bcbb-de153c515d32,C2949735,31st,is expected complete 31st ,Recruitment,31st,1,X,[acty],????,,????
69109f02-450c-4310-90ba-00bc754418ea,C0206750,C0254211,was cured With treatment with ,Coronavirus Infections,arbidol,1,X,[dsyn],[orch/phsu],C02.782.600.550.200,x.x.x.x
3fcabb47-f1be-42bc-8277-9f8fe6e0dda7,C0206750,C1512523,was cured With treatment with ,Coronavirus Infections,hydrochloride,1,X,[dsyn],[inch/phsu],C02.782.600.550.200,
d2ed16fe-03eb-4c00-acfe-4f6a8e68ac74,C0000936,C0024299,is in ,Visual Accommodation,Lymphoma,1,X,[ortf],[neop],G14.010,C04.557.386;C15.604.515.569;C20.683.515.761
28c7426e-4824-4073-9490-e65991e52695,C0024299,C0278348,undergoing intensive ,Lymphoma,Immunotherapy for cancer,1,X,[neop],[topp],C04.557.386;C15.604.515.569;C20.683.515.761,
9747023c-574c-45fa-9e88-08690b3148cd,C1707814,C0278348,should For patients treated with ,Dose Reduced,Immunotherapy for cancer,1,X,[topp],[topp],,
9a9e0ba0-e83c-4a58-9092-d56be978d7c3,C0012634,C0024117, includes ,Disease,Chronic Obstructive Airway Disease,1,X,[dsyn],[dsyn],C23.550.288,C08.381.495.389
f6bd0b90-aff7-430d-8924-0df63f87f1fb,C0206750,6th,will will enrolled in trial from 6th 31st ,Coronavirus Infections,6th,1,X,[dsyn],????,C02.782.600.550.200,????
5a4b6980-5c57-48d2-8e8e-cd2ed9d3ddda,C0206750,31st,will will enrolled in trial from 6th 31st ,Coronavirus Infections,31st,1,X,[dsyn],????,C02.782.600.550.200,????
d9d87b40-af90-4914-8557-13ded55878d6,C0229664,C0039194,detect phenotype of ,peripheral blood,T-Lymphocyte,1,X,[bdsu],[cell],,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
eb040b0d-5073-4bb2-bc82-9a6a89fa2ca2,C0229664,C0806987,detect gene profile of ,peripheral blood,mononuclear cells,1,X,[bdsu],[cell],,
a8d43e4a-12a2-4311-88b1-45f28bb5bfe9,C0005768,C0025320,subjects before ,In Blood,Menopause,1,X,[bdsu],[phsf],x.x.x.x.x,G08.686.157.500;G08.686.841.249.500
7b4067e7-c6b1-432a-86bf-fdb79cbcb405,C4321295,C0025320,subjects before ,CGA wt Allele,Menopause,1,X,[gngm],[phsf],,G08.686.157.500;G08.686.841.249.500
8bc3bb15-914e-43d5-9fcd-bad06ef111b6,C0681562,C0012682,applying ,food product,Disinfectants,1,X,[food],[sbst],,D27.505.954.122.425;D27.720.274
f581819f-ca81-4e45-bb27-a2bf7befac83,C0681562,C1947930,applying household ,food product,Cleaning (activity),1,X,[food],[acty],,
fdc2f4e5-7ee1-4062-8815-7af0cdece5a0,C0035372,C0206750,should In context of current ,Rett Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.597.606.360.455.937;C16.320.322.500.937;C16.320.400.525.937,C02.782.600.550.200
466e7629-708c-4435-be47-88f08bb33125,C1882932,C0012634,great challenge for time-sensitive ,Representation (action),Disease,1,X,[acty],[dsyn],,C23.550.288
4ecc0cf2-88e9-4986-8ff6-9c70d9b91476,C0206750,C0872079,was constructed by ,Coronavirus Infections,protein protein interaction,2,X,[dsyn],[moft],C02.782.600.550.200,
e6c09c8a-d7c2-4adb-8c55-7c6ed15a9472,C0684309,C0872079,was constructed by ,Disease model,protein protein interaction,2,X,[emod],[moft],,
1383d066-8746-42c0-979b-c86938f50227,C0206750,C0017337,was constructed by ,Coronavirus Infections,Genes,2,X,[dsyn],[gngm],C02.782.600.550.200,G05.360.340.024.340
8b7fcf7c-90f2-405c-9061-04207098f88c,C0684309,C0017337,was constructed by ,Disease model,Genes,2,X,[emod],[gngm],,G05.360.340.024.340
a441bd62-9b00-4bec-8add-e799d306e2a9,C0206750,C1518039,was constructed in ,Coronavirus Infections,Mouse Lung,2,X,[dsyn],[tisu],C02.782.600.550.200,
4fa3c974-7ef2-44aa-a448-012e922496fc,C0684309,C1518039,was constructed in ,Disease model,Mouse Lung,2,X,[emod],[tisu],,
7f7d15bc-eb67-40b7-9063-eed8eef0daf6,C0684309,C1175743,was constructed in ,Disease model,SARS coronavirus,2,X,[emod],[virs],,B04.820.504.540.150.113.937
c01978fa-dfdd-430d-8e59-db415bfab442,C1515884,C4050231,is with high disturbance ,Acupuncture and Oriental Medicine,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,2,X,[topp],[clna],,
4d5a07e5-a4b6-41f3-bd7b-5b41b28c1706,C1515884,C2741673,is with high disturbance ,Acupuncture and Oriental Medicine,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[topp],[clna],,
a446e6b9-a34e-4450-95bc-a9b57b4b75c3,C1515884,C0206750,is with high disturbance ,Acupuncture and Oriental Medicine,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
298fb0ce-9551-4c1c-8c00-2712b00cd39c,C0682897,C4050231,is with disturbance ,flavor enhancers,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[sbst],[clna],D26.650.294;D27.720.372.300.353;D27.720.744.294;G07.203.300.514.500.400;J02.500.514.500.400,
f1e4fbd5-9058-4903-899a-32f64cce1021,C1515884,C0024109,main meridian of is ,Acupuncture and Oriental Medicine,Lung,1,X,[topp],[bpoc],,A04.411
522d813f-ff07-4bb9-91f2-b5578aaae96b,C1515884,C0018787,main meridian of is ,Acupuncture and Oriental Medicine,Heart,1,X,[topp],[bpoc],,A07.541
10e64ee8-298c-4515-8d87-2de32fd585aa,C1515884,C0037993,main meridian of is ,Acupuncture and Oriental Medicine,Spleen,1,X,[topp],[bpoc],,A10.549.700;A15.382.520.604.700
1404faeb-23ba-4347-b2e0-f6685daf9e72,C1515884,C0023884,main meridian of is ,Acupuncture and Oriental Medicine,Liver,1,X,[topp],[bpoc],,A03.620
010da428-7876-4c08-8c36-f29f19b3351e,C1515884,C0038351,main meridian of is ,Acupuncture and Oriental Medicine,Stomach,1,X,[topp],[bpoc],,A03.556.875.875
084afeb7-4f77-496e-a019-4e27e682648a,C3687832,C1511539,form significant number of non ,Drugs - dental services,Covalent Interaction,1,X,[topp],[moft],,
fe452fa8-083a-4570-ba7e-f392d501af35,COVID,C1825598,perceived ,COVID,IMPACT gene,1,X,????,[gngm],????,
602d030d-b29c-4971-9ca9-a75d957a4717,C1552133,C1825598,perceived ,19s,IMPACT gene,1,X,[bpoc],[gngm],,
7ef134ad-2316-4031-b61a-c8ceeef6b821,C0243026,COVID-19,are among ,Sepsis,COVID-19,1,X,[dsyn],[virs],C01.539.757;C23.550.470.790.500,C000657245
fad81ac7-1bff-4fbe-82d5-29f84ce9119f,C0302148,COVID-19,is in ,Blood Clot,COVID-19,1,X,[patf],[virs],C14.907.355.830,C000657245
3ccf3370-02b7-43d7-a50c-0686c105a11f,MSC,COVID-19,is in ,MSC,COVID-19,1,X,????,[virs],????,C000657245
46aaaf48-f15b-4822-83bc-6de31872194f,C2936490,10-fold,peaked at nearly 10-fold ,Out-of-Hospital Cardiac Arrest,10-fold,1,X,[patf],????,C14.280.383.610,????
95018d4a-bec8-4466-9d49-8ca12a2e8044,C2936490,C1706374,peaked On ,Out-of-Hospital Cardiac Arrest,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[patf],[aapp/bacs],C14.280.383.610,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
be3176b2-0607-4774-8fe3-bb5e4b4fbb9f,C1707455,C1856053,is with ,Comparison,Hydranencephaly with Renal Aplasia-Dysplasia,5,X,[acty],[dsyn],,x.x.x.x
0043ce8b-4058-44a0-8ddd-21f5083628cf,C1707455,C2936490,is with ,Comparison,Out-of-Hospital Cardiac Arrest,2,X,[acty],[patf],,C14.280.383.610
1057ce4b-f4b7-4a88-aa16-b16fe003fce5,C1707455,C1706374,is with ,Comparison,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
7982a2bf-16b8-4c48-9a02-f3a64ee0d8e1,C1707455,C0018790,odds of ,Comparison,Cardiac Arrest,1,X,[acty],[dsyn],,C14.280.383
cb0754b6-155e-4d64-9d35-3335a5ebfc63,COVID-19,C0301630,had substantial ,COVID-19,Reduction (chemical),1,X,[virs],[npop],C000657245,
c26ccedd-cac1-4ffe-b0a9-0e60ba3d3f77,C0001617,COVID-19,mortality of ,Adrenal Cortex Hormones,COVID-19,1,X,[horm/orch/phsu],[virs],D06.472.040,C000657245
c26ccedd-cac1-4ffe-b0a9-0e60ba3d3f77,C0001617,COVID-19,reduce only ,Adrenal Cortex Hormones,COVID-19,1,X,[horm/orch/phsu],[virs],D06.472.040,C000657245
1b5499a0-1bc4-4f95-a052-add796898ae7,C0011777,COVID-19,mortality of ,Dexamethasone,COVID-19,1,X,[orch/phsu],[virs],D04.210.500.745.432.769.344;D04.210.500.908.238,C000657245
1b5499a0-1bc4-4f95-a052-add796898ae7,C0011777,COVID-19,reduce only ,Dexamethasone,COVID-19,1,X,[orch/phsu],[virs],D04.210.500.745.432.769.344;D04.210.500.908.238,C000657245
f36539a7-c24f-4e3b-a510-df5ece3e94cf,C0079189,C0543419,Instead are responsible for ,cytokine,Sequela of disorder,1,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,
e8435fba-0f08-409a-ad15-f2641389566f,C0011777,C0001617,is synthetic ,Dexamethasone,Adrenal Cortex Hormones,1,X,[orch/phsu],[horm/orch/phsu],D04.210.500.745.432.769.344;D04.210.500.908.238,D06.472.040
903569f9-79d0-4ca9-8b35-c7be38f41619,C0011777,C0079189,would limit production of effect of ,Dexamethasone,cytokine,1,X,[orch/phsu],[aapp/imft],D04.210.500.745.432.769.344;D04.210.500.908.238,D12.644.276.374;D12.776.467.374;D23.529.374
d3e8dd5f-e3df-4483-a3c4-8fe92763e66a,C0011777,C0024432,Moreover would block ,Dexamethasone,macrophage,1,X,[orch/phsu],[cell],D04.210.500.745.432.769.344;D04.210.500.908.238,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
982245f2-b5d9-43cf-a712-7fe832cca24c,C0242821,C0003241,generating protective ,Human body,Antibodies,1,X,[humn],[aapp/imft/phsu],I01.076.201.450.560;K01.093.378,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
724c1866-9d6a-4cc7-9a76-6a95904d5e04,C0232117,C1533734,may Instead may followed by ,Pulse Rate,Administration procedure,1,X,[clna],[topp],E01.370.600.875.500;G09.330.380.500,
bde0e2d9-d1ce-40a9-b4d5-6562a31f1980,C0232117,C0040864,may Instead may followed by ,Pulse Rate,Triamcinolone,1,X,[clna],[orch/phsu],E01.370.600.875.500;G09.330.380.500,D04.210.500.745.432.915;D04.210.500.908.891
d31898e4-0602-48b0-8e2e-66b78b3afe0c,C0232117,C0024109,concentrate in ,Pulse Rate,Lung,1,X,[clna],[bpoc],E01.370.600.875.500;G09.330.380.500,A04.411
fdcc3204-145a-4822-95c1-3df5829b20a1,C0003451,C0018790,ability to ,Antiviral Agents,Cardiac Arrest,1,X,[phsu],[dsyn],D27.505.954.122.388,C14.280.383
2e25261f-c46d-4e74-affc-7011788954fb,C0003451,C0024880,ability to ,Antiviral Agents,mast cell,1,X,[phsu],[cell],D27.505.954.122.388,A11.329.427;A15.382.652
166ce921-84ba-4e18-8f6d-dd980fa9521a,C0024880,C0079189,are main source of ,mast cell,cytokine,2,X,[cell],[aapp/imft],A11.329.427;A15.382.652,D12.644.276.374;D12.776.467.374;D23.529.374
e25fc18a-7267-4ad0-b222-96f561b27e65,C0024880,C0024109,are main source of ,mast cell,Lung,2,X,[cell],[bpoc],A11.329.427;A15.382.652,A04.411
82f6dcd3-68aa-4d93-90ef-401f30af4dc4,C0451610,COVID-19,is with ,Patient review,COVID-19,1,X,[topp],[virs],,C000657245
d38626cb-5016-4a64-9b63-4b696ad2a44b,C0037088,C1533734,will help local ,Signs and Symptoms,Administration procedure,1,X,[sosy],[topp],C23.888,
8e51f90a-0ca9-471b-b213-16d2dcae2897,C0006863,C1175743,downregulate receptor expression for CoV2,Cannabidiol,SARS coronavirus,1,X,[orch/phsu],[virs],D02.455.849.090.100,B04.820.504.540.150.113.937
51dd3723-59d3-4675-b0e4-4fdc4f8f2dc1,C0700268,C1175743,downregulate receptor expression for CoV2,Cannabis sativa plant,SARS coronavirus,1,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
a16b0a61-fc93-4bc5-9769-784e82927227,C2828366,C1175743,downregulate receptor expression for CoV2,Extract (substance),SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
6e12c831-c821-434b-9b0c-6ccf16e3499b,C0006863,CoV2,downregulate receptor expression for CoV2,Cannabidiol,CoV2,1,X,[orch/phsu],????,D02.455.849.090.100,????
48cfe900-8645-4634-9d97-9d7a0a603b9a,C0700268,CoV2,downregulate receptor expression for CoV2,Cannabis sativa plant,CoV2,1,X,[orch/phsu],????,,????
727aa604-30f3-4b73-a56d-afb3ad5416e6,C2828366,CoV2,downregulate receptor expression for CoV2,Extract (substance),CoV2,1,X,[sbst],????,,????
e7f459db-5855-4399-b32f-61a08af7e1ec,C0006863,C0086418,downregulate receptor expression for CoV2,Cannabidiol,Homo sapiens,1,X,[orch/phsu],[humn],D02.455.849.090.100,B01.050.150.900.649.313.988.400.112.400.400
e323364a-f026-4661-a9a2-589d8a6b60c3,C0700268,C0086418,downregulate receptor expression for CoV2,Cannabis sativa plant,Homo sapiens,1,X,[orch/phsu],[humn],,B01.050.150.900.649.313.988.400.112.400.400
a1a7cc80-18ab-4370-a588-082a56d779c7,C2828366,C0086418,downregulate receptor expression for CoV2,Extract (substance),Homo sapiens,1,X,[sbst],[humn],,B01.050.150.900.649.313.988.400.112.400.400
f30b7de5-f2c6-4461-afa1-61867ac29f90,C0006863,C0014609,downregulate receptor expression for CoV2,Cannabidiol,Epithelium,1,X,[orch/phsu],[tisu],D02.455.849.090.100,A10.272
519827d0-fd74-4f20-83a0-ba5980d7466b,C0700268,C0014609,downregulate receptor expression for CoV2,Cannabis sativa plant,Epithelium,1,X,[orch/phsu],[tisu],,A10.272
1c47037f-4a49-4965-aea3-4fce7e99fdff,C2828366,C0014609,downregulate receptor expression for CoV2,Extract (substance),Epithelium,1,X,[sbst],[tisu],,A10.272
26fc54ed-311e-4a03-9dfe-5d2ad27aac46,C0006863,C0597360,downregulate ,Cannabidiol,receptor expression,2,X,[orch/phsu],[genf],D02.455.849.090.100,
8cb8a5b8-f494-4403-9b46-0be742bbf386,C0700268,C0597360,downregulate ,Cannabis sativa plant,receptor expression,2,X,[orch/phsu],[genf],,
8ab524cc-3650-4273-af3b-c6c7ae9bdda9,C2828366,C0597360,downregulate ,Extract (substance),receptor expression,2,X,[sbst],[genf],,
8dbbb268-49b6-4c34-ab5a-df2ae50b66d4,CoV2,C0086418,is in several models of ,CoV2,Homo sapiens,1,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
73d36aef-7694-495c-bc1b-da88614230ed,C1175743,C0014609,is in several models of ,SARS coronavirus,Epithelium,1,X,[virs],[tisu],B04.820.504.540.150.113.937,A10.272
cfdc75c3-de60-4dfa-8137-3a6807f6f0ae,CoV2,C0014609,is in several models of ,CoV2,Epithelium,1,X,????,[tisu],????,A10.272
5a6c4738-aee1-4fb6-afa6-9a413015be1d,C2987634,C0003451,can display direct ,Agonist,Antiviral Agents,1,X,[phsu],[phsu],,D27.505.954.122.388
ae545bff-2242-4f1a-af2f-0c023c400244,C0166418,C3156591,are regulators of ,Peroxisome Proliferator-Activated Receptors,fibroblast activation,2,X,[aapp/rcpt],[celf],D12.776.826.239;D12.776.930.705,
149746e7-e20d-48d5-b1d5-96bef8ec3724,C0243192,C3156591,are regulators of ,agonists,fibroblast activation,2,X,[phsu],[celf],x.x.x,
90c0910b-44db-4c0b-ab64-6b576141ed7e,C0166418,C0225360,are regulators of ,Peroxisome Proliferator-Activated Receptors,Myofibroblasts,1,X,[aapp/rcpt],[cell],D12.776.826.239;D12.776.930.705,A11.329.228.975;A11.620.520.500
98429d6d-d58b-442b-b172-7509363d9d0b,C0243192,C0225360,are regulators of ,agonists,Myofibroblasts,1,X,[phsu],[cell],x.x.x,A11.329.228.975;A11.620.520.500
b8feeed9-0b30-44ff-8782-286367890c78,C0243192,C0034069,can Cardiac Arrest development of,agonists,Pulmonary Fibrosis,1,X,[phsu],[dsyn],x.x.x,C08.381.765
c6d4b87f-a3d1-4d65-8afd-a5a223a1ff3e,C0683201,COVID-19,is in ,specific immunity,COVID-19,1,X,[ortf],[virs],,C000657245
fd39419c-5229-42f4-bb2d-47448c4ea2a8,C0169658,COVID-19,is in ,Janus kinase 1,COVID-19,1,X,[aapp/enzy],[virs],D08.811.913.696.620.682.725.124.100;D12.776.476.393.100,C000657245
d966dd8c-6191-4d04-b3c7-2fb8937eb991,C1366394,COVID-19,is in ,STAT5A protein human,COVID-19,1,X,[aapp/bacs],[virs],x.x.x.x,C000657245
73a490a4-ae3e-46e5-a48e-cc9bffc704db,C0169658,C0032285,is in ,Janus kinase 1,Pneumonia,1,X,[aapp/enzy],[dsyn],D08.811.913.696.620.682.725.124.100;D12.776.476.393.100,C08.381.677;C08.730.610
05bf164d-5c79-4c9a-abca-3f955cdf113b,C1366394,C0032285,is in ,STAT5A protein human,Pneumonia,1,X,[aapp/bacs],[dsyn],x.x.x.x,C08.381.677;C08.730.610
0758d24a-fb29-4193-84e2-c1a0a0cbf356,C0035685,C1335439,is promising target with ,RNA-Directed RNA Polymerase,Polymerase,1,X,[aapp/enzy],[aapp/enzy],D08.811.913.696.445.735.780,
03d96835-2e8f-4399-b046-9b2b5e17010e,C0035685,C0243077,is promising target with ,RNA-Directed RNA Polymerase,inhibitors,1,X,[aapp/enzy],[chvf],D08.811.913.696.445.735.780,
ba2a9274-563e-44b8-9c1e-3c2efeb3bba8,C0035685,C0042769,is promising target with ,RNA-Directed RNA Polymerase,Virus Diseases,1,X,[aapp/enzy],[dsyn],D08.811.913.696.445.735.780,C02
dfed10cc-fa2a-4233-9a83-41812d4a3b17,C1152412,COVID-19,supporting Nucleoside Analogs as,RNA-directed RNA polymerase activity,COVID-19,1,X,[genf],[virs],,C000657245
55c1004f-96b0-417e-96c4-986305b32ffe,C0206419,C0001074,represents ,Genus: Coronavirus,Structure of achilles tendon,1,X,[virs],[bpoc],B04.820.504.540.150,A02.880.176
5db9f733-fb74-4332-be4a-3cae6e894d33,C1152412,C0001074,represents ,RNA-directed RNA polymerase activity,Structure of achilles tendon,1,X,[genf],[bpoc],,A02.880.176
c3b3bdf5-023f-4007-b239-2acd0b4a97f4,C0206419,C0018870,represents ,Genus: Coronavirus,Heel,1,X,[virs],[bpoc],B04.820.504.540.150,A01.378.610.250.510
499d6ae1-4b1b-4439-a030-e39119b711db,C1152412,C0018870,represents ,RNA-directed RNA polymerase activity,Heel,1,X,[genf],[bpoc],,A01.378.610.250.510
e3a306e8-5774-44e5-a9c2-16a018195dc2,C1152412,C1175743,represents ,RNA-directed RNA polymerase activity,SARS coronavirus,1,X,[genf],[virs],,B04.820.504.540.150.113.937
85b31c3d-7e0f-468d-8370-9c85670f9cb1,C0206419,C1579410,supporting ,Genus: Coronavirus,Nucleoside Analogs,1,X,[virs],[nnon/phsu],B04.820.504.540.150,D09.408.595;D13.570
e2bf5dbb-fb8f-46e7-865a-0e1f30253d92,C1152412,C1579410,supporting ,RNA-directed RNA polymerase activity,Nucleoside Analogs,1,X,[genf],[nnon/phsu],,D09.408.595;D13.570
67d83349-a462-4c01-9b09-2f8f9762db4d,C0010357,C0597404,testing clinical samples positive for various ,Cross Reactions,Respiratory viruses,1,X,[moft],[virs],G12.122.281,
44366614-d137-49fe-aef4-9ae08e81251e,C0206419,C0815107,has daunted world with its ,Genus: Coronavirus,psychological distress,1,X,[virs],[mobd],B04.820.504.540.150,
855f20e0-5a24-4090-bcce-b0b56fe91a39,C3714634,C1175743,make such individuals more sensitive to environmental stress factors ,Biological Processes,SARS coronavirus,2,X,[biof],[virs],G16,B04.820.504.540.150.113.937
c460f711-baca-4912-b6af-3533907e5ae6,C3714634,C0314732,make such individuals more sensitive to environmental stress ,Biological Processes,Infectious agent,1,X,[biof],[orgm],G16,
ee368cba-ecf2-45a6-80fc-17cb66f10ed7,C0030012,C3714634,appear important ,Oxidation-Reduction,Biological Processes,2,X,[moft],[biof],G02.700;G03.295.531,G16
1ec90df4-9570-4b07-ae2f-064cee5e56bb,C0019868,C3714634,appear important ,Homeostasis,Biological Processes,2,X,[biof],[biof],G07.410,G16
6a015cd4-cff2-4fcf-bb98-1bf2fc3b48d3,C3714634,C0012655,may account for increased ,Biological Processes,Disease susceptibility,1,X,[biof],[clna],G16,C23.550.291.687;G07.100.250
84b52654-2220-47c5-87b4-5618ede4fb2b,C0162578,C1825598,is highly ,Thrombectomy,IMPACT gene,1,X,[topp],[gngm],E04.100.814.842,
1c704304-3826-44dc-aa92-79bc1de67432,C0024115,C0039082,is related to ,Lung diseases,Syndrome,2,X,[dsyn],[dsyn],C08.381,C23.550.288.500
459f8e2d-9d76-42d3-931d-18e1ffe4159c,C0024115,C0206422,are three ,Lung diseases,Human coronavirus,2,X,[dsyn],[virs],C08.381,
6a4d64d3-4b63-4d62-a7f2-5bfb6f306699,C1254373,C0206422,are three ,etiologic agent,Human coronavirus,1,X,[sbst],[virs],,
6eeaab80-2550-4947-83e0-391296398333,C0018787,C1882509,is taking ,Heart,put - instruction imperative,2,X,[bpoc],[acty],A07.541,
38d4a6b8-942d-4e15-99d6-c4a7aab56e14,C0184893,C1882509,is taking ,Emergency operation,put - instruction imperative,2,X,[topp],[acty],,
11117d88-75f1-4742-a7f3-d5ef6e008e46,C2948600,C0038952,model ,Aim,Continuance of life,1,X,[inch/phsu],[acty],,I03.784
2de56eb1-475f-4d78-a7ba-fa20a7b71e8e,C2948600,C0598934,model ,Aim,tumor growth,1,X,[inch/phsu],[neop],,
d51e8e07-3004-4dea-b6c4-1517461fd6aa,C2948600,C0007137,model ,Aim,Squamous cell carcinoma,1,X,[inch/phsu],[neop],,C04.557.470.200.400;C04.557.470.700.400
15cf2a7a-3b17-4b1c-8b5b-9233183c758d,C0009450,C0062549,measured by levels immunoglobulins M ,Communicable Diseases,gastrin 17,1,X,[dsyn],[aapp/horm],C01.539.221,x.x.x.x
2d265f6f-3ecc-42ed-a98d-d62f8dc9b092,C1306587,C0036572,is with clinical ,Acute encephalopathy,Seizures,1,X,[dsyn],[sosy],,C10.597.742;C23.888.592.742
7163b600-0aa4-4799-b380-086da20831c7,C0231217,C0206750,Previously were seen in patients with advanced ,Multiple symptoms,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
b9a8e12a-8c1a-424b-8e4e-645ba262b9b6,C4023516,C0206750,are possible in patients with ,Symptomatic seizures,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
40ce34d0-1846-4da9-a8ef-f80bc32aa5e2,C0036572,C0079189,precipitated by ,Seizures,cytokine,1,X,[sosy],[aapp/imft],C10.597.742;C23.888.592.742,D12.644.276.374;D12.776.467.374;D23.529.374
ae914fdc-5c1e-4ad2-a370-7232b8951d45,C0036572,C0042769,precipitated as part of ,Seizures,Virus Diseases,1,X,[sosy],[dsyn],C10.597.742;C23.888.592.742,C02
9aad87bd-3df1-4222-9347-338ffe3aee20,C0920672,C0301872,involves ,virus pathogenesis,Immune response,1,X,[comd],[ortf],,
d01e980f-31b8-4f94-b242-21c7059683c6,C0920672,C0079189,involves ,virus pathogenesis,cytokine,1,X,[comd],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
77026ecf-70d3-4728-b4a8-25a52ffc3df9,C0920672,C0040300,causing effect in addition to ,virus pathogenesis,Body tissue,1,X,[comd],[tisu],,A10
2d005358-dec2-47f8-b1f9-9992ddf61ab5,C0920672,C1948029,causing effect in addition to ,virus pathogenesis,Destruction (action),1,X,[comd],[acty],,
805bc3a1-b30d-467a-b859-0ad9109a2c71,C0920672,C0178784,causing deleterious effect on ,virus pathogenesis,Organ,1,X,[comd],[bpoc],,
2e8377f2-8fbb-4f4d-9b34-ffb542ef2961,C0920672,C0031843,causing deleterious effect on ,virus pathogenesis,physiological aspects,1,X,[comd],[phsf],,x.x.x.x
8cff958c-cb41-4f56-b46d-7b39a9a93cf4,C0019185,C0242781,be ,Murine hepatitis virus,disease transmission,1,X,[virs],[patf],B04.450.580;B04.820.504.540.150.113.875,N06.850.310
a6492ffb-6df2-4685-bc95-17f6ba69bc77,C0019185,C0006104,be disease transmission into,Murine hepatitis virus,Brain,2,X,[virs],[bpoc],B04.450.580;B04.820.504.540.150.113.875,A08.186.211
85a6dd32-a854-4ddd-afad-35b845478af7,C1327414,C0281178,indicates rationale for ,cytokine secretion,anti-cytokine therapy,1,X,[celf],[topp],,
93283843-5ad0-4b58-b73f-25b865ae50a9,C1327414,C0206750,indicates rationale for ,cytokine secretion,Coronavirus Infections,1,X,[celf],[dsyn],,C02.782.600.550.200
de6879e2-5b81-4ba8-a0f8-58c505f74a67,C2985566,C1707391,may become For ,Targeted Therapy,Choose (action),2,X,[topp],[acty],,
b650ada3-24cc-47b8-bd75-246566e3ffcd,C0005525,C1707391,may become For ,Biological Response Modifiers,Choose (action),2,X,[imft/phsu],[acty],D27.505.696.477,
94084c82-d0c5-474d-8bd8-2e01e3a134e0,C0746102,C0004096, includes ,Chronic lung disease,Asthma,1,X,[dsyn],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
cbb9b77c-4e24-4358-b979-703a493529e3,C0746102,C0008679,children with data on ,Chronic lung disease,Chronic disease,1,X,[dsyn],[dsyn],,C23.550.291.500
cebb3b05-9ea8-436a-b599-f61ddfc147e7,C0004096,C0008679,children with data on ,Asthma,Chronic disease,1,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C23.550.291.500
cebb3b05-9ea8-436a-b599-f61ddfc147e7,C0004096,C0008679,is common ,Asthma,Chronic disease,2,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C23.550.291.500
833aff99-c82f-4d59-87a5-da7251e07aea,C0011849,C0856169,are linked to ,Diabetes Mellitus,endothelial dysfunction,1,X,[dsyn],[dsyn],C18.452.394.750;C19.246,
752fea43-aa91-4ef5-aea2-decb6bdad0d0,C1879547,C0003009,protecting system from ,Activation action,angiotensin II,1,X,[acty],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
9ff28437-4be5-4676-b74d-d57a5fcd06cf,C1879547,C0042396,protecting system from ,Activation action,Vascular constriction (function),1,X,[acty],[ortf],,G09.330.380.925
1f53441b-c27e-47e9-9434-d34e3d230cb6,C1879547,C0073591,protecting system from ,Activation action,rosoxacin,1,X,[acty],[antb/orch],,x.x.x.x
6627a521-e4ed-4a66-8d94-8797c83f6c70,C0021966,C0009450,summarize clinical data on risk for ,Iodides,Communicable Diseases,2,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C01.539.221
989fbfc6-faf7-49d3-93bd-d77f021248ce,C0021966,C0011849,summarize clinical data on risk for ,Iodides,Diabetes Mellitus,2,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C18.452.394.750;C19.246
682ebf6f-551e-4cb7-9396-443a833d529b,C0398623,C0011849,may render individuals with ,Thrombophilia,Diabetes Mellitus,1,X,[dsyn],[dsyn],C15.378.925,C18.452.394.750;C19.246
45739ad2-665e-48dc-ba6d-e5ca95459803,C0398623,C0012655,may render individuals with ,Thrombophilia,Disease susceptibility,1,X,[dsyn],[clna],C15.378.925,C23.550.291.687;G07.100.250
38e3a2f9-f115-4cf1-97a7-cd67b6693273,C0398623,C0206750,play role in overall ,Thrombophilia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.925,C02.782.600.550.200
11a9eead-e362-4386-9b70-aa7b472dee91,C0019134,C0206750,may Given complications specific to ,heparin,Coronavirus Infections,1,X,[bacs/orch/phsu],[dsyn],D09.698.373.400,C02.782.600.550.200
7282212c-8423-46fe-84cd-a8e4659ed960,30-day,C0206750,was significantly higher compared with control patients without ,30-day,Coronavirus Infections,6,X,????,[dsyn],????,C02.782.600.550.200
9735f7a2-24d5-4ad5-b5c9-efabf6126e84,C0037285,C0206750,are becoming in adults with ,Skin Manifestations,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.885,C02.782.600.550.200
46b94d40-6a5a-42df-8b4e-c6a565e41a81,C0011849,C0684336,is with ,Diabetes Mellitus,Impaired health,1,X,[dsyn],[patf],C18.452.394.750;C19.246,
5849e937-a11b-481b-ac1a-5ce6a5ab993b,C1175743,C0013969,reduction in non ,SARS coronavirus,Emergency treatment,1,X,[virs],[topp],B04.820.504.540.150.113.937,E02.365
06901b97-31eb-495c-a555-70b5acb7d965,C0039984,C0012634,with patients is group of ,Thoracic Outlet Syndrome,Disease,1,X,[dsyn],[dsyn],C10.668.829.550.850;C14.907.863,C23.550.288
a6f2ff25-e813-46ce-ae92-56e609cd6d06,C0039984,C1880022,with patients is group of ,Thoracic Outlet Syndrome,Characterization,1,X,[dsyn],[acty],C10.668.829.550.850;C14.907.863,
dd761ad9-77e1-4669-a909-76c7310db2d3,C1956396,C2717899,presenting with acute ,Venous Thoracic Outlet Syndrome,Upper Extremity Deep Vein Thrombosis,1,X,[dsyn],[patf],C10.668.829.550.850;C14.907.863,C14.907.355.830.925.885
0df15773-29a8-4c22-9138-84a2bd45977b,C1956396,C0919631,presenting with ,Venous Thoracic Outlet Syndrome,Upper Extremity Deep Vein Thrombosis Primary,1,X,[dsyn],[dsyn],C10.668.829.550.850;C14.907.863,C14.907.355.830.925.885
85ffe318-2d1e-4459-959d-525aa3784232,C0455760,C1707391,may may considered for ,Catheter procedure,Choose (action),2,X,[topp],[acty],,
24f4347f-33e8-4f78-9d75-fb8651da88f2,C0455760,C0038532,may may considered for ,Catheter procedure,Structure of subclavian vein,2,X,[topp],[bpoc],,A07.015.908.877
d12e0e4f-69ad-4485-98d1-454a735ae905,C0455760,C1116449,may may considered for ,Catheter procedure,central vein,2,X,[topp],[bpoc],,
f891a223-95ac-40b8-8a3b-69ea2f730dc0,C0455760,C0028778,may may considered for ,Catheter procedure,Obstruction,2,X,[topp],[patf],,
76f448d7-6532-4f15-bfcc-edb231a5fac7,C1707391,C0038532,is with central ,Choose (action),Structure of subclavian vein,1,X,[acty],[bpoc],,A07.015.908.877
9b483640-8fb6-455d-a29f-76ca7a3a070d,C1707391,C1116449,is with central ,Choose (action),central vein,1,X,[acty],[bpoc],,
5ee921b4-a7ce-4a9a-a0bd-592aed72828c,C1707391,C0028778,is with central ,Choose (action),Obstruction,1,X,[acty],[patf],,
c218d7eb-ed67-4ee8-99fc-1a0a46f0362e,C0455760,C0019004,threatened ,Catheter procedure,Hemodialysis,1,X,[topp],[topp],,E02.870.300;E02.912.800
1d6ac0aa-88b6-4916-ae11-7083aa250145,C1880177,C0206750,is in ,Contribution,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
c68431ad-da95-4e29-8911-8d0c3386e38c,C0037274,C0206750,have have reported in patients with ,Dermatologic disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],C17.800,C02.782.600.550.200
5e6d37ff-e606-4f7d-a6eb-8cd7f7293dd9,C0206750,C2936405,has highlighted important role for ,Coronavirus Infections,Drug Repositioning,1,X,[dsyn],[topp],C02.782.600.550.200,E05.290.875
e57ddf20-f155-475c-9ec4-5cb2b4e3ca64,C0567416,C0441655,is with well-known broad-spectrum ,Molecule,Activities,1,X,[sbst],[acty],,
c96911f1-2c4c-427b-ae27-a74626a85418,C0007906,C0567416,represent widely accessible ,Cetylpyridinium,Molecule,1,X,[orch/phsu],[sbst],D03.383.725.762.232,
57a7e70d-99f3-437c-b49f-65d428139097,C0007906,C0003451,represent widely accessible ,Cetylpyridinium,Antiviral Agents,1,X,[orch/phsu],[phsu],D03.383.725.762.232,D27.505.954.122.388
bf14d9bc-494c-40dd-8c46-41840bdc64c3,C0007906,C0441655,represent widely accessible ,Cetylpyridinium,Activities,1,X,[orch/phsu],[acty],D03.383.725.762.232,
b1354b5e-e295-4ac6-9ec5-faefdb7e7436,C0066586,C0567416,represent widely accessible antiseptic ,miramistin,Molecule,1,X,[orch/phsu],[sbst],x.x.x.x,
543a4608-4c05-4aa1-83c3-a3f1ffd5c81e,C0066586,C0003451,represent widely accessible antiseptic ,miramistin,Antiviral Agents,1,X,[orch/phsu],[phsu],x.x.x.x,D27.505.954.122.388
6f60e204-fd31-4b11-a3ff-2cbe2f3dfdc6,C0066586,C0441655,represent widely accessible antiseptic ,miramistin,Activities,1,X,[orch/phsu],[acty],x.x.x.x,
b00f73e7-e9e4-436c-b83d-4c4f77f31a66,C0578399,C0567416,represent widely accessible antiseptic ,Quaternary Ammonium Compounds,Molecule,1,X,[orch],[sbst],D01.625.062.500;D02.092.877;D02.675.276,
a95696f5-0313-4af6-98e9-163325026a0e,C0008203,C0567416,represent widely accessible antiseptic ,Chlorides,Molecule,2,X,[inch],[sbst],D01.210.450.150;D01.248.497.158.215,
6c72a3d1-6035-4d21-854d-bfa39e18dc3a,C0578399,C0003451,represent widely accessible antiseptic ,Quaternary Ammonium Compounds,Antiviral Agents,1,X,[orch],[phsu],D01.625.062.500;D02.092.877;D02.675.276,D27.505.954.122.388
16cc78c6-ad89-4a59-af9c-d766c5817309,C0008203,C0003451,represent widely accessible antiseptic ,Chlorides,Antiviral Agents,2,X,[inch],[phsu],D01.210.450.150;D01.248.497.158.215,D27.505.954.122.388
b138ee2a-1edc-434b-bedc-5c3021d9a721,C0578399,C0441655,represent widely accessible antiseptic ,Quaternary Ammonium Compounds,Activities,1,X,[orch],[acty],D01.625.062.500;D02.092.877;D02.675.276,
22724cdc-f888-4435-9c7f-755c92baa481,C0008203,C0441655,represent widely accessible antiseptic ,Chlorides,Activities,2,X,[inch],[acty],D01.210.450.150;D01.248.497.158.215,
dba88de1-29ad-446f-a987-60f518bc153c,C0008203,C0087111,represent repurposing opportunity as ,Chlorides,Therapeutic procedure,1,X,[inch],[topp],D01.210.450.150;D01.248.497.158.215,E02
5b49b59c-675a-403b-9492-acd7e9e5a08b,C0008203,C1175743,represent repurposing opportunity as ,Chlorides,SARS coronavirus,1,X,[inch],[virs],D01.210.450.150;D01.248.497.158.215,B04.820.504.540.150.113.937
34196991-3477-44d5-aa72-cfadc7da74e3,C0019004,C0015672,on patients is ,Hemodialysis,Fatigue,1,X,[topp],[sosy],E02.870.300;E02.912.800,C23.888.369
de89b286-6da5-4283-9100-8972b156a6d2,C0036974,C0019004,is in patients on ,Shock,Hemodialysis,1,X,[patf],[topp],C23.550.835,E02.870.300;E02.912.800
e4a326fa-00ed-4f31-8d78-1e0a999227a5,C0024115,C0015967, includes ,Lung diseases,Fever,2,X,[dsyn],[sosy],C08.381,C23.888.119.344
424d5367-8361-4aa0-a20c-63833d53b34b,C0024115,C0019004,were less common in patients on ,Lung diseases,Hemodialysis,14,X,[dsyn],[topp],C08.381,E02.870.300;E02.912.800
37a1ef55-ae9e-4345-9d87-31787d90d8c8,C0015967,C0019004,were less common in patients on ,Fever,Hemodialysis,2,X,[sosy],[topp],C23.888.119.344,E02.870.300;E02.912.800
36ba9345-11f8-49fb-a22d-271444926789,C0010200,C0019004,were common in patients on ,Coughing,Hemodialysis,1,X,[sosy],[topp],C08.618.248;C23.888.852.293,E02.870.300;E02.912.800
0332a9ac-c3f2-4255-b2cb-97e2939d3aac,C0019004,C0206750,is with ,Hemodialysis,Coronavirus Infections,1,X,[topp],[dsyn],E02.870.300;E02.912.800,C02.782.600.550.200
1a4ee30a-d593-44c4-8f58-f8fd384a8715,C0019004,C0012634,is with ,Hemodialysis,Disease,1,X,[topp],[dsyn],E02.870.300;E02.912.800,C23.550.288
c45e18aa-fb98-4ba1-848c-5af561f7d5d2,C1825598,C1306597,check ,IMPACT gene,Psychiatric problem,1,X,[gngm],[mobd],,
1feeddd9-f9fa-4c76-92b5-a7b97625bba1,C1621287,C1175743,are needed for ,antibody activity,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
97361b34-bc11-4dee-8c67-818ada40c4a3,C1621287,C0042210,are needed for ,antibody activity,Vaccines,1,X,[moft],[aapp/imft/phsu],,D20.215.894
b01ff1c8-41ab-4a24-b1b7-25b81130a07d,C0302148,C0242656,emerged as possible explanation ,Blood Clot,Disease Progression,2,X,[patf],[patf],C14.907.355.830,C23.550.291.656
0f947f17-4e73-4bda-b05b-b7f476a65658,C3277428,C0948245,is with ,Severe viral infections,Cytokine Release Syndrome,1,X,[dsyn],[dsyn],,
18301c92-3da1-4ca4-9421-c732d7711825,C3277428,C0206750,is with ,Severe viral infections,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
f7c4e999-83f4-40db-813a-493223d0d440,C3277428,C1706202,is with ,Severe viral infections,Search - action,1,X,[dsyn],[acty],,
9f23ea3a-09df-49df-8ecd-ab487cf3bf17,C1167395,C0745283,must Normally must employed for completion of ,Host (organism),INFECTIOUS PROCESS,2,X,[orgm],[patf],,
afdf9886-ea44-4b80-8454-44ce9fe846ac,C0024312,C3277428,was associated with ,Lymphopenia,Severe viral infections,1,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,
edcb235a-1afd-47c0-82bf-2b85ba631352,C0034019,C0031843,classify app ,public health medicine (field),physiological aspects,2,X,[bmod],[phsf],H02.403.720;N01.400.550;N06.850,x.x.x.x
cafb6369-dd33-4970-9100-7f5d2c5752f0,PIBD,ESPGHAN,affiliated with Porto ESPGHAN,PIBD,ESPGHAN,1,X,????,????,????,????
cf84b2b1-37d4-4129-8bed-15dff1647f10,centres,ESPGHAN,affiliated with Porto ESPGHAN,centres,ESPGHAN,1,X,????,????,????,????
a8533892-bf8b-4d03-9d72-ccdb2da31297,C0206750,C2828389,created by ,Coronavirus Infections,Exclusion,1,X,[dsyn],[acty],C02.782.600.550.200,
109a96e6-3f6d-43b9-a6a7-5a0b26cce7e0,C0319157,U.S.,reduce burden on U.S. ,AS virus,U.S.,1,X,[virs],????,,????
4807d44f-780d-4b84-ae58-b3c97966b84a,C1882932,C0034019,always necessitate Emergency Care during even,Representation (action),public health medicine (field),1,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
85fd8d11-2e65-499d-ab4c-0dfe4e0ad5ab,C1882932,C2745965,always necessitate Emergency Care during even,Representation (action),Emergencies [Disease/Finding],1,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
e0a52c2d-b5de-4df8-9fd5-42ed91e10628,C1882932,C1527398,always necessitate immediate ,Representation (action),Emergency Care,1,X,[acty],[topp],,N02.421.297
422e493f-f0d1-4eb0-a91e-3014212cf5eb,C1457887,C0221423,signs of serious ,Symptoms,Illness (finding),1,X,[sosy],[sosy],,
4b50a44a-c475-45b7-8d1e-718f2ffaedd2,C1175175,C0441516,resulting in higher ,Severe Acute Respiratory Syndrome,Demand (clinical),1,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,
208cd1f3-40d8-420c-945d-efdebc7af078,C1175175,C0040590,resulting in higher ,Severe Acute Respiratory Syndrome,Tracheostomy procedure,1,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,E02.041.750;E04.579.935;E04.580.900;E04.928.780
5d5436a6-fca2-4429-a9ce-e9ef37738793,C0027485,C0012634,like incident is only ,Natural Disasters,Disease,1,X,[npop],[dsyn],N06.230.100.230,C23.550.288
2a141eaf-d222-4066-8ab9-10785b37ff2a,C0872152,C0206750,combat ,Drug Development,Coronavirus Infections,1,X,[bmod],[dsyn],E05.290;H01.158.703.007.338;H01.181.466.338,C02.782.600.550.200
f33f8663-479b-458c-909b-5d5143d1d58b,C1175743,C0010827,was characterized by severe lung injury due to ,SARS coronavirus,Cytopathogenic Effect Viral,1,X,[virs],[comd],B04.820.504.540.150.113.937,E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190
5766c07c-8915-463f-b35a-8cffdfc13545,C0441636,C0018810,is with increasing ,Surgical shortening - action,heart rate,1,X,[topp],[clna],,E01.370.600.875.500;G09.330.380.500
cec54158-de2c-4118-a748-c03d3dc65385,C2347784,C0021932,need for ,Clinical Endpoint,Intubation Intratracheal,1,X,[clna],[topp],,E02.041.500;E02.585.578;E05.497.578
072201aa-e5cf-4564-b0ff-1db447b02a6d,C0021932,C0441636,compared to patients with PR interval ,Intubation Intratracheal,Surgical shortening - action,1,X,[topp],[topp],E02.041.500;E02.585.578;E05.497.578,
497419d8-2fec-49db-ab53-5e363db7065c,C0037088,C0021932,need for ,Signs and Symptoms,Intubation Intratracheal,1,X,[sosy],[topp],C23.888,E02.041.500;E02.585.578;E05.497.578
2dcbf25c-9e9b-4881-ab27-d96de1497898,C2948600,C0678222,advocating delay ,Aim,Breast Carcinoma,2,X,[inch/phsu],[neop],,C04.588.180;C17.800.090.500
dfd87b50-54ee-4988-81cf-4b2c189b5d25,C0010408,C0678222,also reducing ,Cryosurgery,Breast Carcinoma,2,X,[topp],[neop],E04.014.180,C04.588.180;C17.800.090.500
a01aa803-7d95-4969-aac6-b06e7931d5d3,C0010408,C1825598,also reducing ,Cryosurgery,IMPACT gene,1,X,[topp],[gngm],E04.014.180,
cce85637-6930-4953-8798-62991b532e35,C0034754,C0450030,were Ease Gunning ,Reading (activity),Fog,1,X,[dora],[npop],L01.559.423.557,G16.500.275.063.725;G16.500.750.775;N06.230.300.100.725
971c8537-3270-473b-a887-f663c6c543a6,C0034754,C0037365,were Ease Simple Measure of Gobbledygook ,Reading (activity),Smog,1,X,[dora],[npop],L01.559.423.557,D20.633.875
9bcabe68-83e1-445a-b458-046c59bea5d9,C2949735,C1882932,yielded ,Recruitment,Representation (action),1,X,[acty],[acty],,
27412630-f948-4edf-b3c6-910ab41eed0b,C2949735,C0037778,yielded ,Recruitment,Medical Specialities,1,X,[acty],[bmod],,H02.403
4f508380-4b8a-47b8-8e09-201de5e39862,C4083212,NEI,are supported by NEI ,Alopecia Male Pattern,NEI,1,X,[dsyn],????,C17.800.329.937.122;C23.300.035,????
550558f2-8982-40b7-b0f4-c92eafc9bf9b,C0050451,RPB,unrestricted grant from RPB,acetohydroxamic acid,RPB,1,X,[orch/phsu],????,x.x.x.x,????
fb3f867a-6128-498b-bd78-7d5b619f716a,ACP,C0150232,are Family support by Parker,ACP,Family support,3,X,????,[topp],????,
cc5ea181-c370-4a07-911c-6a648847fa6b,C1552154,C0150232,are Family support by Parker,Js,Family support,2,X,[bpoc],[topp],,
8b4ea3bf-6751-4437-9814-956eee4bd3e0,C1148382,C3714514,key Immune Cell in,Monocytes+Macrophages,Infection,2,X,[cell],[patf],,C01.539
8b4ea3bf-6751-4437-9814-956eee4bd3e0,C1148382,C3714514,are considered key ,Monocytes+Macrophages,Infection,2,X,[cell],[patf],,C01.539
9b547ae0-1e9a-4434-80af-cba2b098d8e7,C1148382,C0019630,key Immune Cell in,Monocytes+Macrophages,Histocompatibility Antigens Class II,2,X,[cell],[aapp/imft],,D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410
9b547ae0-1e9a-4434-80af-cba2b098d8e7,C1148382,C0019630,are considered key ,Monocytes+Macrophages,Histocompatibility Antigens Class II,2,X,[cell],[aapp/imft],,D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410
3f377984-6bde-4def-80b5-c9a62f27765c,C1148382,C4330475,are considered key ,Monocytes+Macrophages,Immune Cell,2,X,[cell],[cell],,
6e1f007d-2f23-4e0b-a5c9-4c44fca4fca5,C4330475,C3714514,is in ,Immune Cell,Infection,1,X,[cell],[patf],,C01.539
3e775076-441a-4e80-8918-7fa70e3817fb,C4330475,C0026473,is in ,Immune Cell,Monocytes,1,X,[cell],[cell],,A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547
dbda5012-5677-4821-83d8-4a8cb82cf60c,C4330475,C0019764,is in ,Immune Cell,HLA-DR Antigens,1,X,[cell],[aapp/imft],,D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440
f30e08b3-9789-4940-99d2-2a4eff7a599d,C4330475,C0019630,is in ,Immune Cell,Histocompatibility Antigens Class II,1,X,[cell],[aapp/imft],,D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410
82f2b41d-84df-4b5e-9112-4ff9afcceb4e,C0010340,COVID-19,is with ,Critical Illness,COVID-19,1,X,[dsyn],[virs],C23.550.291.625,C000657245
139e55ad-c629-4361-9ece-2beec61db3c6,C0026473,C0010340,was significantly lower in ,Monocytes,Critical Illness,4,X,[cell],[dsyn],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,C23.550.291.625
9df81545-85f5-4144-96ea-e81fa10c14fb,C0019764,C0010340,was significantly lower in ,HLA-DR Antigens,Critical Illness,4,X,[aapp/imft],[dsyn],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,C23.550.291.625
1d803049-25c4-4195-9e06-345d06a0df05,C0026473,C0003241,was significantly lower in ,Monocytes,Antibodies,1,X,[cell],[aapp/imft/phsu],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
1d803049-25c4-4195-9e06-345d06a0df05,C0026473,C0003241,was lower with median difference of 21508 ,Monocytes,Antibodies,1,X,[cell],[aapp/imft/phsu],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
e6f81e72-0c93-41cc-b29d-6ff4fd92219b,C0019764,C0003241,was significantly lower in ,HLA-DR Antigens,Antibodies,1,X,[aapp/imft],[aapp/imft/phsu],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
e6f81e72-0c93-41cc-b29d-6ff4fd92219b,C0019764,C0003241,was lower with median difference of 21508 ,HLA-DR Antigens,Antibodies,1,X,[aapp/imft],[aapp/imft/phsu],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
470cf5db-e791-4cf3-aaf0-45c7c0157766,C0026473,C0007634,was significantly lower in ,Monocytes,Cells,1,X,[cell],[cell],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,A11
470cf5db-e791-4cf3-aaf0-45c7c0157766,C0026473,C0007634,was lower with median difference of 21508 ,Monocytes,Cells,1,X,[cell],[cell],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,A11
5a40d755-1917-43fc-81f7-9750b8655624,C0019764,C0007634,was significantly lower in ,HLA-DR Antigens,Cells,1,X,[aapp/imft],[cell],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,A11
5a40d755-1917-43fc-81f7-9750b8655624,C0019764,C0007634,was lower with median difference of 21508 ,HLA-DR Antigens,Cells,1,X,[aapp/imft],[cell],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,A11
27b86078-b5e4-4c21-ae19-2f4ed8008d31,C0026473,C1829939,was lower compared to ,Monocytes,{Non-patient},4,X,[cell],[clna],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,
56f4607a-7bba-471e-8365-b3d9ae00f36a,C0019764,C1829939,was lower compared to ,HLA-DR Antigens,{Non-patient},4,X,[aapp/imft],[clna],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,
7971c43f-07e8-4c9d-bca6-0244fe660dbb,C0019764,C0301872,indicating dysfunctional ,HLA-DR Antigens,Immune response,1,X,[aapp/imft],[ortf],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,
917f619a-1965-4ae9-b6ce-86a1e3657a4e,C2948600,C0010340,is in population of ,Aim,Critical Illness,1,X,[inch/phsu],[dsyn],,C23.550.291.625
6798dd3e-c83d-4fe6-8f2c-ad759280a2b6,C1293132,C1705178,is in ,Anchoring procedure,Order (action),1,X,[topp],[acty],,
c23fa963-3de3-4677-97d5-cd701b1e4a14,C0206750,COVID-19,causes ,Coronavirus Infections,COVID-19,1,X,[dsyn],[virs],C02.782.600.550.200,C000657245
6a172741-cc15-4ae8-bc32-420045dacaa3,C4601203,C0086418,was most recently recognized CoV prior to ,Porcine enteric Alphacoronavirus,Homo sapiens,1,X,[virs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
3d8887ff-aae8-4aff-85fd-f5c76b1ed17e,C4601203,C1175175,was most recently recognized CoV prior to ,Porcine enteric Alphacoronavirus,Severe Acute Respiratory Syndrome,1,X,[virs],[dsyn],,C02.782.600.550.200.750;C08.730.730
223e8d96-f72e-41b3-ad2f-f96cbf1fd04e,C0008139,C0243083,of CoV is ,Chiroptera,associated disease,2,X,[mamm],[patf],B01.050.150.900.649.313.937,
616c7fc7-6296-484d-a24e-b7b61fe0ca27,C4601203,C0008139,was most recently recognized CoV of potential ,Porcine enteric Alphacoronavirus,Chiroptera,1,X,[virs],[mamm],,B01.050.150.900.649.313.937
624ad062-f887-46de-a3cc-04d989cc17f4,C2921039,C0747973,is largely ,Transcatheter mitral valve repair,Elective procedure,1,X,[topp],[topp],,
e511a571-36fa-4eb8-a021-002b31505da1,C0036980,COVID-19,were treated with amidst ,Shock Cardiogenic,COVID-19,1,X,[patf],[virs],C14.280.647.500.750;C14.907.585.500.750;C23.550.835.550,C000657245
770c6467-d5bc-4f67-beed-07d09b9e48d7,C0036980,amidst,were treated with amidst ,Shock Cardiogenic,amidst,1,X,[patf],????,C14.280.647.500.750;C14.907.585.500.750;C23.550.835.550,????
0b304bc9-1fba-4404-8d1f-8d35c09841f1,C4048329,C0393022,is with ,Immunosuppression,rituximab,1,X,[dsyn],[aapp/imft/phsu],E02.095.465.425.450;E05.478.610,D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
264bfe63-4d13-4f35-9de9-d3439b285749,C0199470,C0206750,treat Respiratory Failure in,Mechanical ventilation,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
32c54ca2-97eb-482d-9b36-0dd1125a4fd9,C0199470,C0012634,treat Respiratory Failure in,Mechanical ventilation,Disease,1,X,[topp],[dsyn],,C23.550.288
65d5c389-85e6-445e-b19d-c3e389802d9b,C0199470,C1145670,treat ,Mechanical ventilation,Respiratory Failure,1,X,[topp],[dsyn],,C08.618.846
4e5ef495-1630-485f-840b-47306b692fa1,C0027059,C0018801,is with ,Myocarditis,Heart failure,1,X,[dsyn],[dsyn],C14.280.238.625,C14.280.434
68637ad1-4cde-490a-b1c2-7330fe917bd2,C3655548,C1707455,is in ,Height Kidney,Comparison,1,X,[clna],[acty],,
e1c8ba48-c7a9-4bcb-8c03-4150723ec737,C3655548,C0026809,is with female ,Height Kidney,Mus,1,X,[clna],[mamm],,B01.050.150.900.649.313.992.635.505.500
cf7a2041-00b8-4d70-ab65-b2522a9915d6,C0020538,C0960756,is ,Hypertensive disease,factor A,2,X,[dsyn],[orch],C14.907.489,x.x.x.x
d863c52c-bd51-49a3-936e-7aef0988913a,C0206750,C0700431,is having significant ,Coronavirus Infections,Cardiac rehabilitation,2,X,[dsyn],[topp],C02.782.600.550.200,E02.760.169.063.500.185;E02.831.185;H02.403.680.600.250;N02.421.784.244
dee0d43b-e180-4e80-a681-0225ab6facc1,C0021852,C1448177,was In active ,Intestines Small,TNF protein human,1,X,[bpoc],[aapp/bacs],A03.556.124.684,x.x.x.x
dee0d43b-e180-4e80-a681-0225ab6facc1,C0021852,C1448177,was restored by ,Intestines Small,TNF protein human,1,X,[bpoc],[aapp/bacs],A03.556.124.684,x.x.x.x
7bd631f4-16f1-4a2e-8a5d-dc96552512d4,C0022709,C1448177,was In active ,Peptidyl-Dipeptidase A,TNF protein human,1,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,x.x.x.x
7bd631f4-16f1-4a2e-8a5d-dc96552512d4,C0022709,C1448177,was restored by ,Peptidyl-Dipeptidase A,TNF protein human,1,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,x.x.x.x
7e0fd71f-d4ef-418b-99a3-44e99caf13ce,C2348077,C0206750,Biological Evolution of,Date Fruit,Coronavirus Infections,1,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,C02.782.600.550.200
b11e712b-b84d-49f4-9b30-3d1dabd8b00f,C3241922,C0087111,routinely give symptomatic ,Operation Activity,Therapeutic procedure,2,X,[acty],[topp],,E02
bb36997c-a7cc-485c-a9f3-288c41bfa85b,C3241922,C0003204,routinely give symptomatic ,Operation Activity,Anti-Infective Agents,2,X,[acty],[phsu],,D27.505.954.122
a4d0bcf6-47b0-42a9-95d1-2487acecb5a4,C0206750,GIE,is in GIE ,Coronavirus Infections,GIE,2,X,[dsyn],????,C02.782.600.550.200,????
b6c7916e-b470-4afc-85cc-8f38e4fb4148,C0009326,C0206750,is with ,Collagen Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C17.300.200,C02.782.600.550.200
19b16b00-892d-4159-b053-bb8cefa9238e,C0000983,C1457887,improvement in individual ,Acetic Acid,Symptoms,2,X,[irda/orch],[sosy],D02.241.081.018.165;D10.251.400.045.500,
268ae2a5-5730-4ac2-90d1-0fc08c5275d3,C0000983,C0206750,be promising adjuvant therapy in cases of,Acetic Acid,Coronavirus Infections,2,X,[irda/orch],[dsyn],D02.241.081.018.165;D10.251.400.045.500,C02.782.600.550.200
2e5fbeb8-8d8f-4c32-9923-049cec61d786,C0012683,C0206750,be promising adjuvant therapy in cases of,Disinfection,Coronavirus Infections,2,X,[topp],[dsyn],N06.850.780.200.450.850.375,C02.782.600.550.200
40861ae2-a09e-4954-a4e5-4d7d0a17d0a2,C0677850,C0206750,is in cases of non-severe ,adjuvant therapy,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
27889f88-1c03-4eb2-b8a3-49363f4048ae,C0000983,C0677850,be promising ,Acetic Acid,adjuvant therapy,2,X,[irda/orch],[topp],D02.241.081.018.165;D10.251.400.045.500,
143f8200-f201-4768-8d2e-d7a91e9ce190,C0012683,C0677850,be promising ,Disinfection,adjuvant therapy,2,X,[topp],[topp],N06.850.780.200.450.850.375,
6680800d-832f-4808-b9c1-4d3344d58e42,C0013227,C1707391,could could then ,Pharmaceutical Preparations,Choose (action),1,X,[phsu],[acty],D26,
ab8c41cc-3618-4756-880d-60bc43595211,C0014695,C0035100,inhibits ,Ergocalciferol,Chymosin,1,X,[orch/phsu/vita],[aapp/enzy],D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,D08.811.277.656.074.500.200;D08.811.277.656.300.048.200
668174f1-d98a-4ca8-bfee-c3b5a3fe7eb1,C3146294,C2359945,is in certain ,Generation (action),Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[acty],[clna],,
b1b522dd-ad23-41c3-ae3d-051355fbb7a0,C0026769,C0007634,for treatment is CD20 ,Multiple Sclerosis,Cells,1,X,[dsyn],[cell],C10.114.375.500;C10.314.350.500;C20.111.258.250.500,A11
fe68ca05-ff22-4762-90c0-ab8857f799a9,C0393022,C0007634,with treatment is CD20 ,rituximab,Cells,1,X,[aapp/imft/phsu],[cell],D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,A11
b63a2147-cc45-4d4b-812d-ba5ee7c4f386,C0432618,C0450442,depleting ,Blood group antibody B,Agent,2,X,[aapp/imft],[chvf],,
6e27cce5-d05f-441a-9189-5ddce9d63d5a,CD20,C0450442,depleting ,CD20,Agent,1,X,????,[chvf],????,
f321d6ac-cf18-41f8-b562-6f0a23e490e5,C0007634,C0450442,depleting ,Cells,Agent,1,X,[cell],[chvf],A11,
116cea97-520e-4dcb-89f1-570cc6cd5587,C1999230,CoV2,example for control of CoV2,Providing (action),CoV2,1,X,[acty],????,,????
f1d612bd-7425-4708-9f20-cebe727340d0,C0683465,C1825598,adapt for ,novel AODU treatment method,IMPACT gene,1,X,[topp],[gngm],,
2ebb2b45-30cc-4486-861e-749b6d4ef4ef,C0027059,C0369718,is in ,Myocarditis,N not otherwise specified Antibody,1,X,[dsyn],[aapp/imft],C14.280.238.625,
99c818f3-fb83-40b5-b90e-4068b3103d1f,C2003888,C0027059,rate of ,Lower (action),Myocarditis,1,X,[acty],[dsyn],,C14.280.238.625
51b8c999-e7c6-4dbb-a2b7-8b6981d492b8,C0521083,C0026691,differed from comparator group of classical ,Kava,Mucocutaneous Lymph Node Syndrome,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.812.666.249,C14.907.940.560;C15.604.560;C17.800.862.560
b709a50a-5304-4f52-9085-41f9d49d14b7,C0206750,C0026691,differed from comparator group of classical ,Coronavirus Infections,Mucocutaneous Lymph Node Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.940.560;C15.604.560;C17.800.862.560
46a2cfa3-dfa2-42bf-8815-c8094b7dce22,C0521083,C0039082,likely represents new inflammatory ,Kava,Syndrome,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.812.666.249,C23.550.288.500
a9f2624e-6703-4ad1-9338-f2055ba6c9d0,C0521083,C1175175,likely represents new inflammatory ,Kava,Severe Acute Respiratory Syndrome,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.812.666.249,C02.782.600.550.200.750;C08.730.730
0035f5c8-8424-49e7-840d-d6f0d6372b0c,C0042720,C0012634,were sampled from patients diagnosed with 3rd 15th,Viral Genome,Disease,1,X,[gngm],[dsyn],G05.360.340.358.840,C23.550.288
fabef67a-ce5f-4724-b665-b910c08d9923,C0042720,3rd,were sampled from patients diagnosed with 3rd 15th,Viral Genome,3rd,1,X,[gngm],????,G05.360.340.358.840,????
35d8e0ab-ee5f-4c7f-a541-e21a891bb66f,C0042720,15th,were sampled from patients diagnosed with 3rd 15th,Viral Genome,15th,1,X,[gngm],????,G05.360.340.358.840,????
3abe480e-56ec-4a90-8613-7bd695b128ff,C0032105,C3714514,has has used with degrees of success to ,Plasma,Infection,1,X,[bdsu],[patf],A12.207.152.693;A12.207.270.695;A15.145.693,C01.539
f6acf075-d4f0-4655-b0b3-13248bb4a2e1,C0278347,C0032105,is with convalescent ,Transfusion of plasma,Plasma,1,X,[topp],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
5a8e1713-0dba-4c6b-a941-c74ca7b9c71c,C2364111,C0206750,were more prevalent among ,Ageusia,Coronavirus Infections,1,X,[sosy],[dsyn],C10.597.751.861.184;C23.888.592.763.861.184,C02.782.600.550.200
38ca1c37-00b5-4d0b-8396-d3c2c79d79ff,C0519551,C1175743,is in patients with ,Skull Base Operation,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
be21dbb1-a005-405a-9625-09c5bf25c07d,C4075512,C0206750,associated with ,Flap necrosis,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
be21dbb1-a005-405a-9625-09c5bf25c07d,C4075512,C0206750,is in patient with ,Flap necrosis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
f4cc9bbd-d6ad-4e24-b1ff-b5be87b6cf19,C0002055,C0038925,using ,Alkalies,Surgical Flaps,1,X,[inch],[bpoc],D01.045,A10.850.710;E07.862.710
78b77a95-6227-4067-98c3-e4f9b93885b7,C0002055,C2930680,using ,Alkalies,Pedicled Flap,2,X,[inch],[bpoc],D01.045,A10.850.710;E07.862.710
5d75a07d-c06d-420c-8954-26fe8dd3cf00,C0035222,C0242184,complicated by ,Respiratory Distress Syndrome Adult,Hypoxia,1,X,[dsyn],[patf],C08.381.840;C08.618.840,C23.888.852.079
8adbfcaf-0e4b-4def-9ae4-78e022f11403,C0035222,C1145670,complicated by ,Respiratory Distress Syndrome Adult,Respiratory Failure,1,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C08.618.846
88fb1af0-ef4b-4496-8e07-65e9043be248,C0544688,C2586211,contributed to ,complication of disease,Thrombosis of blood vessel,2,X,[patf],[patf],,
fc23fba1-d7bb-4cbd-bf36-4aec28954f0f,C0206750,C2586211,contributed to ,Coronavirus Infections,Thrombosis of blood vessel,2,X,[dsyn],[patf],C02.782.600.550.200,
50f6e9c0-fa08-46df-a4a6-8aa23a04086f,C0544688,C0456605,contributed to ,complication of disease,Pedicle,1,X,[patf],[bpoc],,
cdc1a457-7a46-4e6a-a0f0-5fc61ceb3552,C0206750,C0456605,contributed to ,Coronavirus Infections,Pedicle,1,X,[dsyn],[bpoc],C02.782.600.550.200,
a8545121-dc18-4736-b9b4-8b008b4b9159,C0034386,C0815107,experienced greater ,Quarantine,psychological distress,1,X,[topp],[mobd],N06.850.780.200.450.700,
1f27f30d-159c-464b-99d4-a424cd318b81,C3273807,C0206750,may increase likelihood of ,Sodium-Glucose Transporter 2 Inhibitors,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D27.505.519.936;D27.505.696.422.750,C02.782.600.550.200
e3f1194f-ba91-4203-82cc-cdf34794d65e,C3273807,C0220982,may increase likelihood of ,Sodium-Glucose Transporter 2 Inhibitors,Ketoacidosis,1,X,[orch/phsu],[patf],D27.505.519.936;D27.505.696.422.750,C18.452.076.176.652
61d6d018-3094-4022-9294-964f224b6b3f,C3273807,C0311276,may increase likelihood among patients with ,Sodium-Glucose Transporter 2 Inhibitors,Severe malnutrition,2,X,[orch/phsu],[dsyn],D27.505.519.936;D27.505.696.422.750,
8eb8cc82-5946-4b8f-bc0f-255c055bb84c,C3273807,C0021641,may increase likelihood among patients with ,Sodium-Glucose Transporter 2 Inhibitors,Insulin,1,X,[orch/phsu],[aapp/horm/phsu],D27.505.519.936;D27.505.696.422.750,D06.472.699.587.200.500.625;D12.644.548.586.200.500.625
6437faca-37cb-4cf8-8b24-342811908256,C0206415,C0370003,is with same clinical ,Oligonucleotide Primers,Specimen,1,X,[nnon],[sbst],D13.695.578.424.450.275;D27.720.470.530.600.223.600,
2547149b-8992-433b-9451-a64986de8862,C0206750,C0027855,is in ,Coronavirus Infections,Neurology speciality,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.600
b0335c98-7cca-437a-b50e-1a0a5d6bc7df,C0020964,C0022661,is in patients with ,Immunity,Kidney Failure Chronic,1,X,[phsf],[dsyn],G12.450,C12.777.419.780.750.500;C13.351.968.419.780.750.500
1103ac41-5de2-449d-b686-1d4172cd2573,G1P0,C0015915,had conceived twins via ,G1P0,Fertilization in Vitro,1,X,????,[topp],????,E02.875.800.750;E05.820.800.750
04677230-4811-4dc5-9d8b-07e3e9e338ad,COVID-19,C0035243,poses threat to its high rate of spread of ,COVID-19,Respiratory Tract Infections,1,X,[virs],[dsyn],C000657245,C01.539.739;C08.730
04677230-4811-4dc5-9d8b-07e3e9e338ad,COVID-19,C0035243,is highly ,COVID-19,Respiratory Tract Infections,1,X,[virs],[dsyn],C000657245,C01.539.739;C08.730
f7a6a6a3-2288-4fce-ba71-3ddd75a1c26d,C1706202,C2745965,is urgent at time of ,Search - action,Emergencies [Disease/Finding],1,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
5fbd31a2-b420-4a6e-8582-588c378522ed,C0072027,C0237820,decreased during ,procalcitonin,Recovery - action,1,X,[aapp/bacs],[acty],D06.472.699.666;D12.644.548.744;D12.776.811.555,
c145a63f-a710-4a12-b9b4-90fe6bec876a,C1999230,C0034072,detects ,Providing (action),Cor pulmonale,1,X,[acty],[dsyn],,C14.280.832
474e3063-ed48-4d65-9cb2-a80eab96ac8b,C0027442,C1175743,in SARS coronavirus is,Nasopharynx,SARS coronavirus,1,X,[bpoc],[virs],A04.623.557;A14.724.557,B04.820.504.540.150.113.937
fa42e47a-7c9d-4eab-9476-ea9a144eff40,C0040053,C0206750,is in ,Thrombosis,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.830,C02.782.600.550.200
3af92f75-ed00-4ada-b7a1-f55e1beb133a,COVID-19,C0029166,is with ,COVID-19,Oral Manifestations,1,X,[virs],[sosy],C000657245,C07.465.634;C23.888.619
b204f4b1-dd2e-4019-9018-6b7f2bbf60f6,intra,C0041582,vary from ,intra,Ulcer,1,X,????,[patf],????,C23.550.891
6752d395-a39e-4ce8-9443-782ee5c88531,C0029166,C0041582,vary from ,Oral Manifestations,Ulcer,1,X,[sosy],[patf],C07.465.634;C23.888.619,C23.550.891
03e93224-17aa-4afc-ae51-89dc67cf927c,intra,C0026724,vary in palatal ,intra,Mucous Membrane,1,X,????,[tisu],????,A10.615.550
4b2956dd-a5b0-4769-8bfb-6849400f570a,C0029166,C0026724,vary in palatal ,Oral Manifestations,Mucous Membrane,1,X,[sosy],[tisu],C07.465.634;C23.888.619,A10.615.550
2d7c4863-e75a-491a-b144-043d7c92a0dd,C0042196,C0199810,is with ,Vaccination,Measles-mumps-rubella vaccination,1,X,[topp],[topp],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,
0145949d-1a89-40ed-b09d-ae6a0fadde60,C0042196,C0042210,is with ,Vaccination,Vaccines,1,X,[topp],[aapp/imft/phsu],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,D20.215.894
a0b50162-b6bb-4b4a-a569-66e901cee134,C0178575,C0199810,offered by ,cross immunity,Measles-mumps-rubella vaccination,1,X,[moft],[topp],,
89f10173-c48a-41bd-a0e8-77fe10911004,COVID-19,C0080078,further disease transmission of was,COVID-19,Range of Motion Articular,1,X,[virs],[clna],C000657245,E01.370.600.700;G11.427.760
53f7de68-433c-4c9d-b801-400afb75d55b,C0242781,C0086418,was because of ,disease transmission,Homo sapiens,1,X,[patf],[humn],N06.850.310,B01.050.150.900.649.313.988.400.112.400.400
fc90b3c8-2914-4d83-aa41-97a7df7212cc,C0242781,C0080078,was because of ,disease transmission,Range of Motion Articular,1,X,[patf],[clna],N06.850.310,E01.370.600.700;G11.427.760
fd4ff62c-6997-41d7-b47f-4d2042205be4,C0034386,C0038436,give rise to ,Quarantine,Post-Traumatic Stress Disorder,1,X,[topp],[mobd],N06.850.780.200.450.700,F03.950.750.500
be68bc0d-1cc9-4203-b371-d5363caa1ba7,COVID-19,C0033909,has influenced ,COVID-19,Psychology,1,X,[virs],[bmod],C000657245,F04.096.628
305b49d3-402c-4e32-90b8-03ec310584d9,C0034386,C0033909,has influenced ,Quarantine,Psychology,1,X,[topp],[bmod],N06.850.780.200.450.700,F04.096.628
81b58302-8d40-4a43-9d47-dad534e29c39,C1522455,C0011127,cure ,Recombinant Fibroblast Growth Factor 1,Pressure Ulcer,2,X,[aapp/phsu],[dsyn],,C17.800.893.665
d5b3d062-bcdc-474c-b4f4-6df77e93ad91,C0086418,C0011127,cure ,Homo sapiens,Pressure Ulcer,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C17.800.893.665
d5b3d062-bcdc-474c-b4f4-6df77e93ad91,C0086418,C0011127,is effective agent for facemask wearing-induced ,Homo sapiens,Pressure Ulcer,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C17.800.893.665
c869961c-d7c6-4dce-a90f-555819695eb7,C0242656,C0001566,Administration Topical with,Disease Progression,Administration Topical,1,X,[patf],[topp],C23.550.291.656,E02.319.267.120
cfc343f2-def4-4b70-a50f-400737609c24,C0242656,C0086418,Administration Topical with,Disease Progression,Homo sapiens,1,X,[patf],[humn],C23.550.291.656,B01.050.150.900.649.313.988.400.112.400.400
4d545b48-d526-465f-97a8-dfc7a5205d65,C0001566,C0242656,significantly inhibit ,Administration Topical,Disease Progression,1,X,[topp],[patf],E02.319.267.120,C23.550.291.656
b7922aea-19bc-4c05-9421-e612f68e0c0c,C0001566,C0011127,significantly inhibit ,Administration Topical,Pressure Ulcer,1,X,[topp],[dsyn],E02.319.267.120,C17.800.893.665
0e017b49-7ff1-446e-924d-cf6b3fe49aba,C0001566,C0086418,is with ,Administration Topical,Homo sapiens,1,X,[topp],[humn],E02.319.267.120,B01.050.150.900.649.313.988.400.112.400.400
3c82e8fa-46a1-4a30-8fc4-2b2ffa9a08be,C0450254,C1705178,is in ,Pathogenic organism,Order (action),1,X,[orgm],[acty],,
0bf6d4b4-79a9-4462-a042-aa1315963bce,C1175175,C1510837,positively correlates with ,Severe Acute Respiratory Syndrome,Airborne Particulate Matter,1,X,[dsyn],[hops],C02.782.600.550.200.750;C08.730.730,D20.633
a5a68963-59ed-4083-ab54-7c672565c52f,C0001869,C0086589,thus serve as ,Air Pollutants,Surrogate Markers,1,X,[hops],[clna],D27.888.284.101,D23.101
4323d869-d52c-43f7-b6a9-9a2d724972a6,C0001869,C0009450,complement ,Air Pollutants,Communicable Diseases,1,X,[hops],[dsyn],D27.888.284.101,C01.539.221
13ac5560-313b-476c-90dd-6b6933c9a01a,C0206750,C0004096,is causing shortage of critical inhalers needed by patients with ,Coronavirus Infections,Asthma,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
fadbfacc-36bf-48b9-be31-8d3adfb538bb,C1967692,defence,line of defence,Albuterol Metered Dose Inhaler,defence,3,X,[clnd],????,,????
f9b75344-e93a-42b7-a343-3296da9cc9db,C1967692,C0476273,have ,Albuterol Metered Dose Inhaler,Respiratory distress,2,X,[clnd],[sosy],,
568aa840-e634-4812-a8c6-ea500935d55a,C1967692,C1999230,is on now ,Albuterol Metered Dose Inhaler,Providing (action),1,X,[clnd],[acty],,
d1f803be-3a4d-4cc7-bc0e-c3a3e8a484b8,C3534575,COVID-19,likely be impacted by ,Animal Health,COVID-19,2,X,[dsyn],[virs],,C000657245
dbfe059e-68fd-4e5c-bd52-ca633a006a3b,C0206750,C0003062,is in ,Coronavirus Infections,Animals,1,X,[dsyn],[anim],C02.782.600.550.200,B01.050
e26fc89b-77b1-4ddd-bd90-3fd68c6954ae,C3266814,C3534575,adapting ,Action,Animal Health,1,X,[acty],[dsyn],,
009b4fbb-17f0-4b7e-ad24-82037daf7b35,C0079189,C1184743,may complicate ,cytokine,bony process,1,X,[aapp/imft],[bpoc],D12.644.276.374;D12.776.467.374;D23.529.374,
d2235023-176d-42a8-967c-6ca4c972a3ed,C1861452,C1184743,may complicate ,Storm Syndrome,bony process,1,X,[dsyn],[bpoc],x.x.x.x,
4ef92584-5f27-468c-9bd7-2ad3a7bdc703,C0243026,AKI,is with AKI,Sepsis,AKI,1,X,[dsyn],????,C01.539.757;C23.550.470.790.500,????
4290dae1-e11d-4311-863e-71790714a458,C3649547,C0243026,has has practiced in AKI,Continuous renal replacement therapy,Sepsis,1,X,[topp],[dsyn],,C01.539.757;C23.550.470.790.500
460b0708-9f68-4520-be0e-910b024de46f,C3649547,AKI,has has practiced in AKI,Continuous renal replacement therapy,AKI,1,X,[topp],????,,????
d2c7d988-1e87-4081-b2c9-7d66d66d447d,C0682568,C1882932,are two ,membrane by function,Representation (action),1,X,[bpoc],[acty],,
0daedb12-9b0b-4ead-8a14-062bd63125a9,C0682568,C0596901,are two ,membrane by function,Membrane,1,X,[bpoc],[celc],,A10.615
23c357a2-9636-446e-8afb-ff731a395cf5,C0441516,C1999230,has rapidly exceeded its ,Demand (clinical),Providing (action),2,X,[topp],[acty],,
40633a94-b55c-4ea1-8034-77363306b110,C0206058,C1548354,allocating ,Elective Surgical Procedures,Specialty Type - Intensive care,1,X,[topp],[bmod],E04.249,
8a228fdf-92a7-4ad2-b33f-f85e71a50c1b,C0206058,C2745965,allocating Specialty Type - Intensive care beds to,Elective Surgical Procedures,Emergencies [Disease/Finding],1,X,[topp],[patf],E04.249,C23.550.291.781;N06.230.100.083;N06.850.376
6ea20e6c-503b-4d71-a477-3081601f2269,C0184893,C4283938,underwent awake ,Emergency operation,Open Surgical Procedure,2,X,[topp],[topp],,
f1e7e31f-ef0f-48e4-9846-49320b9444d0,C0026764,C0206750,diagnosed with ,Multiple Myeloma,Coronavirus Infections,1,X,[neop],[dsyn],C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650,C02.782.600.550.200
d440fc07-d5d7-4785-b145-6b216fe3ff24,C0206750,C3463820,screened compounds for their ,Coronavirus Infections,Inhibition,1,X,[dsyn],[acty],C02.782.600.550.200,F01.145.544;F02.463.425.475;F02.739.794.405
2cd308b7-cb83-47d5-84ca-f15b0d68c831,C0006145,C0206750,thin-section CT of ,Breast Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C17.800.090,C02.782.600.550.200
cfc71934-0c88-42f8-be2f-428e17adda6a,C1422064,C0206750,point for ,ACE2 gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
cfc71934-0c88-42f8-be2f-428e17adda6a,C1422064,C0206750,was increased in demographic with incidence of ,ACE2 gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
b9acdde3-2ecc-460b-bd5b-b47abe4e9293,C1155266,C0079189,are counteracted by anti-inflammatory ,inflammatory response,cytokine,1,X,[patf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
01ee851a-d3df-4aa0-a740-92cfc82837aa,C0004096,C0027430,Chronic sinusitis with,Asthma,Nasal Polyps,1,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C08.460.572;C09.603.557;C23.300.825.557
0cebd0a7-b992-48c6-91af-6d7da31c6d7d,C0149516,C0027430,is with ,Chronic sinusitis,Nasal Polyps,1,X,[dsyn],[dsyn],,C08.460.572;C09.603.557;C23.300.825.557
b637ed7b-60e7-4948-bc2d-dd5b9c54f20e,C1531518,C0237820,be stopped until clinical ,Biological treatment,Recovery - action,1,X,[topp],[acty],,
9b7f449f-70a8-4096-829f-47af934fe106,C0206750,C0020115,has changed worldwide ,Coronavirus Infections,Human Activities,1,X,[dsyn],[acty],C02.782.600.550.200,I03
6da33c90-1285-45cb-866d-5a8d851f9b76,C0012634,C0020115,has changed worldwide ,Disease,Human Activities,1,X,[dsyn],[acty],C23.550.288,I03
7509c89c-f83e-4966-8970-0bdad6a1d234,C0237798,C1457887,develop ,Nonhuman primate,Symptoms,1,X,[mamm],[sosy],,
24ea5582-c227-492b-a55a-fcd343ddb2a0,C0237798,C0086418,develop ,Nonhuman primate,Homo sapiens,1,X,[mamm],[humn],,B01.050.150.900.649.313.988.400.112.400.400
cb91d2b6-9284-410b-830c-5ef380183cd9,C1457887,C0086418,similar to those in ,Symptoms,Homo sapiens,1,X,[sosy],[humn],,B01.050.150.900.649.313.988.400.112.400.400
e5c8c1ed-39fd-4176-8af8-c19b5bdc9f96,C1175743,C0598312,is ,SARS coronavirus,DNA Replication,1,X,[virs],[genf],B04.820.504.540.150.113.937,G02.111.225;G05.226
6da489f4-4687-4265-98bc-0c4913a95a28,C0037274,C1175175,associated with ,Dermatologic disorders,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C17.800,C02.782.600.550.200.750;C08.730.730
fbe018b4-544f-43da-9558-734f9aa18e2d,C0206750,CoV2,is caused by CoV2,Coronavirus Infections,CoV2,1,X,[dsyn],????,C02.782.600.550.200,????
4bbb01ea-fa47-4985-9d47-c1562153e3b4,C0008269,C0206750,are are now used for treatment of ,Chloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C02.782.600.550.200
4bbb01ea-fa47-4985-9d47-c1562153e3b4,C0008269,C0206750,clinical symptoms of ,Chloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C02.782.600.550.200
e41591ac-4b8d-43d5-9030-9cd4499c6c1c,C0079189,C4054044, includes ,cytokine,Secondary Hemophagocytic Lymphohistiocytosis,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,
1fc6477a-0d36-4fe2-bff4-032d35c16cdb,C0079189,C1334815, includes ,cytokine,Multi-centric Castleman's Disease,1,X,[aapp/imft],[neop],D12.644.276.374;D12.776.467.374;D23.529.374,x.x.x.x
eefc0963-3644-42fc-8a45-b8633f589e03,C0079189,C4289797, includes ,cytokine,Chimeric Antigen Receptor T-Cell Therapy,1,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,
a1f34a8e-c093-447b-9028-ceb4e1b5dee5,C0079189,C0948245, includes ,cytokine,Cytokine Release Syndrome,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,
d7e5a84e-afb5-49b1-89c0-b4c25b390bdf,C0087111,C0079189,mainstay of treatment in ,Therapeutic procedure,cytokine,2,X,[topp],[aapp/imft],E02,D12.644.276.374;D12.776.467.374;D23.529.374
d7e5a84e-afb5-49b1-89c0-b4c25b390bdf,C0087111,C0079189,targeting ,Therapeutic procedure,cytokine,1,X,[topp],[aapp/imft],E02,D12.644.276.374;D12.776.467.374;D23.529.374
47e9419b-47e5-479e-9acd-4b0efee72bee,C0087111,C0086982,targeting ,Therapeutic procedure,Signal Transduction Pathways,1,X,[topp],[moft],E02,G02.111.820;G04.835
e74568e0-a562-428c-bb19-a543aaf10bc0,C3540676,C0079189,is in known ,Blockade,cytokine,1,X,[elii/phsu],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
dbe5bb1d-1bb1-4ca7-b183-57649ed3972c,C0005516,COVID,establish foundation for future diagnostic criteria of COVID ,Biological Markers,COVID,1,X,[clna],????,D23.101,????
d71c21ef-2356-43e3-93f3-3ed1d2b86320,C0005516,C0079189,establish foundation for future diagnostic criteria of COVID ,Biological Markers,cytokine,1,X,[clna],[aapp/imft],D23.101,D12.644.276.374;D12.776.467.374;D23.529.374
71f6c318-7fe2-40ed-98a1-98e3d5736ae7,C0005516,C1705178,contrasted in ,Biological Markers,Order (action),1,X,[clna],[acty],D23.101,
0ab31a80-2ff7-4959-a637-63aa46f5c6eb,C0026809,COVID-19,exhibit ,Mus,COVID-19,1,X,[mamm],[virs],B01.050.150.900.649.313.992.635.505.500,C000657245
bec5cf52-629a-4a62-bf72-def60016825a,C0004238,C0206419,is common manifestation in hospitalized patients with ,Atrial Fibrillation,Genus: Coronavirus,1,X,[dsyn],[virs],C14.280.067.198;C23.550.073.198,B04.820.504.540.150
9886d63f-6b99-4782-97f4-9205e62a3dac,C0004238,C0003195, includes ,Atrial Fibrillation,Anti-Arrhythmia Agents,1,X,[dsyn],[phsu],C14.280.067.198;C23.550.073.198,D27.505.954.411.097
34d53b79-c5a2-4220-8e2d-4bde1041e7d9,C0013227,C0004238,used to ,Pharmaceutical Preparations,Atrial Fibrillation,1,X,[phsu],[dsyn],D26,C14.280.067.198;C23.550.073.198
c9220795-dfb6-41fc-8a60-73a682bb27a6,C0013227,C0003195,used to ,Pharmaceutical Preparations,Anti-Arrhythmia Agents,1,X,[phsu],[phsu],D26,D27.505.954.411.097
18056c84-4738-4963-a130-285954ed2eee,COVID-19,C0004238,is with concomitant ,COVID-19,Atrial Fibrillation,2,X,[virs],[dsyn],C000657245,C14.280.067.198;C23.550.073.198
c4b7888b-f6de-421e-91be-eb4fb0d19834,C0034386,C0242781,significantly reduced ,Quarantine,disease transmission,1,X,[topp],[patf],N06.850.780.200.450.700,N06.850.310
d0896174-2da3-4c0a-b3a5-8bd589fe5a72,C0849867,C0038443,has led to unprecedented ,Widespread Disease,Stress Psychological,2,X,[dsyn],[mobd],,F01.145.126.990;F02.830.900
e57a757e-c791-4e0f-b181-2f508a4be7a7,C0042776,U.S,is in U.S ,Virus,U.S,1,X,[virs],????,B04,????
ff7e6511-7fbe-4c22-ab40-d7266e6b8c17,COVID-19,C0032285,leading to ,COVID-19,Pneumonia,2,X,[virs],[dsyn],C000657245,C08.381.677;C08.730.610
a40ae49a-57f0-4a10-9294-6034776b642a,COVID-19,C1457887,leading to ,COVID-19,Symptoms,1,X,[virs],[sosy],C000657245,
4381568a-4acc-4669-936c-e9466b3686ac,C0042776,C1457887,leading to ,Virus,Symptoms,3,X,[virs],[sosy],B04,
afbb7c0a-04c0-4e36-9994-f0be33fe8907,C0042776,C0024109,directly targets ,Virus,Lung,3,X,[virs],[bpoc],B04,A04.411
413866ec-7b66-4bf2-afcd-5b4380f45dfd,CoV2,COVID-19,agent of ,CoV2,COVID-19,1,X,????,[virs],????,C000657245
c6ea5387-557b-4a29-95b0-e9bb50e1c3e0,CoV2,C0012634,agent of ,CoV2,Disease,1,X,????,[dsyn],????,C23.550.288
a2e23537-f216-4013-bb98-08976033c29b,C2605770,C0005854,was predicted poor ,quinadoline B,Blood - brain barrier anatomy,1,X,[orch],[bpoc],x.x.x.x,A07.035;A08.186.211.035
28a50791-e9c4-4a8f-bad7-46d892b10e98,C2605770,C0870883,was predicted Blood - brain barrier anatomy capacities Of five,quinadoline B,Metabolite,1,X,[orch],[bacs],x.x.x.x,
28a50791-e9c4-4a8f-bad7-46d892b10e98,C2605770,C0870883,was predicted probability Of five ,quinadoline B,Metabolite,1,X,[orch],[bacs],x.x.x.x,
337eeda4-06d6-48ee-99ed-2edc0c694858,C0005854,ADMET,confer favorable ADMET ,Blood - brain barrier anatomy,ADMET,1,X,[bpoc],????,A07.035;A08.186.211.035,????
2a25a177-b338-4efe-b0ba-519ccac95159,C0010827,C0024109,mediate ,Cytopathogenic Effect Viral,Lung,1,X,[comd],[bpoc],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,A04.411
c6b85872-95de-4b99-8649-1643ed0d53d2,C1366480,C0229671,is in ,KITLG gene,Serum,1,X,[gngm],[bdsu],,A12.207.152.846;A15.145.846
34cf47d9-b1b1-4dd6-97e0-d2af022a7f80,C0547605,C0018581,were suboptimal with facilities for ,prevention of infection,Handwashing,1,X,[topp],[acty],,N06.850.670.150.500
68ad1ce4-8f7c-4ea4-b1f5-186a3b0c3fff,C0547605,C0369718,were suboptimal with facilities for ,prevention of infection,N not otherwise specified Antibody,1,X,[topp],[aapp/imft],,
08e3b18f-80ed-4ed6-a450-c4ae27ff96ee,C4050366,COVID-19,are constrained during ,Petroleum Hydrocarbon Compound,COVID-19,2,X,[hops],[virs],,C000657245
5bef6aa8-b755-4db9-97c6-78828452a73b,C4050366,C4552744,are constrained in their ,Petroleum Hydrocarbon Compound,Daily Living,2,X,[hops],[dora],,
5b7ff226-92f2-4266-8a44-1027cac5b19f,C4050366,C1999230,is in India ,Petroleum Hydrocarbon Compound,Providing (action),1,X,[hops],[acty],,
c30d4825-a25c-49f3-bfd7-d9674032087d,C3537403,C0206419,is in ,Cause of death.primary:Finding:Point in time:^Patient:Nominal,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
b9fdb382-166e-4c06-91fd-fe87099750af,C3537403,C0012634,is in ,Cause of death.primary:Finding:Point in time:^Patient:Nominal,Disease,1,X,[clna],[dsyn],,C23.550.288
dde1df5b-cc27-47e5-8303-495a437dfdd8,C0035229,C0206419,is Cause of death.primary:Finding:Point in time:^Patient:Nominal in,Respiratory Insufficiency,Genus: Coronavirus,1,X,[patf],[virs],C08.618.846,B04.820.504.540.150
6095a88c-010d-4027-aecf-bf10ea189fec,C0035229,C0012634,is Cause of death.primary:Finding:Point in time:^Patient:Nominal in,Respiratory Insufficiency,Disease,1,X,[patf],[dsyn],C08.618.846,C23.550.288
052c7df8-6aa9-475b-9510-2d0fc0c29134,C0035229,C3537403,is ,Respiratory Insufficiency,Cause of death.primary:Finding:Point in time:^Patient:Nominal,1,X,[patf],[clna],C08.618.846,
ee01ad56-73d9-4b62-8e55-9afcc96359f2,C0024109,C1285830,also showed distinctive ,Lung,Blood vessel feature,1,X,[bpoc],[clna],A04.411,
3cfb7565-f3e4-4c2f-8432-c16419fdc282,C0024109,C0007603,disrupted ,Lung,Plasma membrane,1,X,[bpoc],[celc],A04.411,A11.284.149
042105a9-f01b-4794-9b05-a9e60c10cfc9,C1508661,C0206419,is in patients with ,Pulmonary vessels,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
bd13d652-5ec4-4889-bd92-1565d0d75dfe,C1440080,C0021403,were times as prevalent in patients as in patients with ,Alveolar,Influenza virus vaccine,2,X,[bpoc],[imft/phsu],,D20.215.894.899.302
57171e90-d17c-4171-882a-d9ef9939804c,C0006901,C0021403,were times as prevalent in patients as in patients with ,Blood capillaries,Influenza virus vaccine,2,X,[bpoc],[imft/phsu],A07.015.461.165,D20.215.894.899.302
8249c2e5-e6ac-4e04-8a38-b56a41d29465,C1440080,C0206419,were times as prevalent in patients with ,Alveolar,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
d6ebe74d-114e-4591-945f-a2e92546a010,C0006901,C0206419,were times as prevalent in patients with ,Blood capillaries,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015.461.165,B04.820.504.540.150
e2ff1a94-34ae-40a4-8c1b-bc9bf2c89440,C0027651,C0024109,amount of was In ,Neoplasms,Lung,4,X,[neop],[bpoc],C04,A04.411
7d46e9b3-6c43-4f15-8795-ba0cc7943b82,C0027651,C0021403,amount of was In ,Neoplasms,Influenza virus vaccine,2,X,[neop],[imft/phsu],C04,D20.215.894.899.302
9f45e7dd-69ae-4c91-9e4f-f7d96ea8a775,C0005847,C0021403,amount of was In ,Blood Vessel,Influenza virus vaccine,1,X,[bpoc],[imft/phsu],A07.015,D20.215.894.899.302
2261f9cd-75f1-4826-a729-a9cc254fe34f,C0005847,C0024115,distinguished ,Blood Vessel,Lung diseases,1,X,[bpoc],[dsyn],A07.015,C08.381
94b4c382-c9ad-4e81-a575-2349fde00fa4,C0302600,C0024115,distinguished ,Angiogenic Process,Lung diseases,1,X,[ortf],[dsyn],,C08.381
e40f5535-a824-422f-80f3-5c7bb53192b9,C0302600,C0206419,distinguished ,Angiogenic Process,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
0a0ef2d9-e9d7-4d36-bf4a-8d6871b53513,C0087111,C0003467,increased ,Therapeutic procedure,Anxiety,1,X,[topp],[mobd],E02,F01.470.132
34475ba6-00d3-4d8c-b475-e6e3f4f3f72f,COVID-19,C0282686,causes most damage to ,COVID-19,Respiratory System Agents,1,X,[virs],[phsu],C000657245,D27.505.954.796
68d05acb-1759-453e-a134-63861ae7d28d,COVID-19,C0815107,also induces ,COVID-19,psychological distress,1,X,[virs],[mobd],C000657245,
b5b69065-c667-46df-8c45-87135ce8c23e,C0011570,C0034386,affecting ,Mental Depression,Quarantine,1,X,[mobd],[topp],F01.145.126.350,N06.850.780.200.450.700
b4a1e2c6-e71a-4b7f-a47e-ee0cb169ae2d,C0003467,C0034386,affecting ,Anxiety,Quarantine,1,X,[mobd],[topp],F01.470.132,N06.850.780.200.450.700
a3de8c58-e0bb-4f5e-941c-8851e0b77c79,COVID-19,C0030193,also induces psychological distress Besides physical,COVID-19,Pain,1,X,[virs],[sosy],C000657245,C23.888.592.612;F02.830.816.444;G11.561.790.444
d6c7e71a-ae75-462a-b227-01253d97f626,C0007603,C3711684,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,S protein severe acute respiratory syndrome coronavirus,2,X,[celc],[aapp/bacs],A11.284.149,x.x.x.x
66976567-ba56-4fe5-a6a0-b2e4844a4ed9,C0599946,C0007634,is in ,Attenuation,Cells,1,X,[acty],[cell],,A11
3b4f6779-02de-4a9b-8c0b-8eb3330237e5,C0206750,C1947932,has quickly ,Coronavirus Infections,Smear - instruction imperative,1,X,[dsyn],[acty],C02.782.600.550.200,
80f9692d-2373-4fcd-8dfa-f3fb1ea1d245,C0206750,C0040590,may require ,Coronavirus Infections,Tracheostomy procedure,1,X,[dsyn],[topp],C02.782.600.550.200,E02.041.750;E04.579.935;E04.580.900;E04.928.780
9866a1b2-b7a8-4a78-ba03-c67249be5071,C2945733,C0206750,is in ,change of tube,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
08dee9d9-6317-4b8c-9237-8db9045d8f9d,C2945733,C0220781,cause significant droplet ,change of tube,Anabolism,1,X,[topp],[biof],,G03
dd050439-69f3-4fe2-9036-a32d6f2d0942,C2945733,C0883304,is in particular ,change of tube,placement of tube,2,X,[topp],[topp],,
ad0f050b-5d31-42bf-a32a-43ce9215e37e,C0161816,C0018801, includes ,Cardiac complication,Heart failure,1,X,[patf],[dsyn],,C14.280.434
a60817c2-f164-4f29-b20a-a08477befb85,C1175743,C0010834,localizing at perinuclear locations within ,SARS coronavirus,Cytoplasm,1,X,[virs],[celc],B04.820.504.540.150.113.937,A11.284.430.214
edec3d64-a4a2-463b-a502-8865cbff3e59,C0010827,C3658289,induced ,Cytopathogenic Effect Viral,Human Induced Pluripotent Stem Cells,1,X,[comd],[cell],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,A11.872.040.500;A11.872.700.500
acde777e-fabf-44c5-bd58-39f543fc682e,C0010827,C0162638,induced ,Cytopathogenic Effect Viral,Apoptosis,1,X,[comd],[celf],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,G04.146.160
43bb04ee-9862-485b-80ce-aff397169a23,C0010827,C0009450,induced ,Cytopathogenic Effect Viral,Communicable Diseases,1,X,[comd],[dsyn],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,C01.539.221
5a6e7f01-f372-47ec-b69c-a3bbbb71e0d8,C0028938,C0348165,is important route of entry to ,Olfactory Nerve,Central Nervous System Viral Diseases,3,X,[bpoc],[dsyn],A08.800.800.120.640,C02.182;C10.228.228.245
e274bb7c-f652-47af-97b6-f4cbfcb40815,C0597357,C0458827,are found throughout ,receptor,Airway structure,2,X,[aapp/rcpt],[bpoc],,
ce7f3a23-ee0c-42b5-b072-4c41a9ae8df4,C0007447,C0458827,are found throughout ,Cations,Airway structure,2,X,[chvs],[bpoc],D01.248.497.300,
51df4d40-defa-443d-befd-8ab7c3920cd0,C0369637,C0458827,are found throughout ,M NOS ANTIBODY,Airway structure,2,X,[aapp/imft],[bpoc],,
ff73c399-b61d-47c3-98b7-70900615d53d,C1519442,C0042769,are involved in responses to ,Specialized epithelial cell,Virus Diseases,2,X,[cell],[dsyn],,C02
def46b18-e40b-4ea5-9c61-cf7ed66c234a,C0021368,C1334521,is in ,Inflammation,TRPM5 protein human,2,X,[patf],[aapp/bacs],C23.550.470,x.x.x.x
7f8a9096-08d6-4d45-8284-782d0e7d387c,C1519595,C0036734,encodes for ,Transcript,Serine Endopeptidases,2,X,[nnon],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
4310f901-bd39-40c0-af7b-6557ee92b2f5,C0036734,C1175743,primes ,Serine Endopeptidases,SARS coronavirus,2,X,[aapp/enzy],[virs],D08.811.277.656.300.760;D08.811.277.656.959.350,B04.820.504.540.150.113.937
a8c5c6a1-df88-4c73-aecd-fbf7fd1d97a3,C1452534,C0597357,is essential ,ACE protein human,receptor,1,X,[aapp/bacs],[aapp/rcpt],x.x.x.x,
e65a9159-17ac-4236-beb9-092ce980c697,C0022709,C1514760,is essential receptor for,Peptidyl-Dipeptidase A,Receptor Cell,2,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,
b898a4bd-8ef7-4675-a281-4189b1543f0d,C1452534,C1514760,is essential receptor for,ACE protein human,Receptor Cell,1,X,[aapp/bacs],[cell],x.x.x.x,
4eb819e3-f96f-49ec-bd00-02d9a2c4fd80,C0022709,C4552744,exerts protective ,Peptidyl-Dipeptidase A,Daily Living,2,X,[aapp/enzy/imft],[dora],D08.811.277.656.350.350.687,
99e0ef96-a025-48cc-9a82-735f84033701,C0960880,C0003009,leads to overactivation of ,angiotensin converting enzyme 2,angiotensin II,2,X,[aapp/enzy],[aapp/bacs/phsu],x.x.x.x,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
8ff30db4-c470-464a-beab-719b590613a7,C0013081,C0003009,leads to overactivation of ,Down-Regulation,angiotensin II,2,X,[moft],[aapp/bacs/phsu],G02.111.240;G05.308.200;G07.690.773.937,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
5a4085de-c519-456f-93d5-aaf47874e798,C0960880,C1439284,leads to overactivation of ,angiotensin converting enzyme 2,AGTR1 gene,1,X,[aapp/enzy],[gngm],x.x.x.x,
57974578-3995-4fbb-99f8-7638ba8a8d53,C0013081,C1439284,leads to overactivation of ,Down-Regulation,AGTR1 gene,1,X,[moft],[gngm],G02.111.240;G05.308.200;G07.690.773.937,
fcb79baa-dec1-4511-b474-c4df748572d4,C0960880,C0004457,leads to overactivation of ,angiotensin converting enzyme 2,Axis vertebra,1,X,[aapp/enzy],[bpoc],x.x.x.x,A02.835.232.834.151.383
9536d362-1b3f-4e04-ab10-fe144d683cd5,C0013081,C0004457,leads to overactivation of ,Down-Regulation,Axis vertebra,1,X,[moft],[bpoc],G02.111.240;G05.308.200;G07.690.773.937,A02.835.232.834.151.383
989cff5e-e4e7-41a9-8f5c-7245d464fe66,C0087111,C0003009,reducing ,Therapeutic procedure,angiotensin II,1,X,[topp],[aapp/bacs/phsu],E02,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
f31e63e5-1ee4-41b8-a954-678d6469d74d,C0087111,C0599946,reducing effects rather than ,Therapeutic procedure,Attenuation,1,X,[topp],[acty],E02,
ae4f4ddf-c02e-4834-b596-7a841631fcc3,C0026639,C0206750,has Furthermore has accepted as high-risk route for ,Oral mucous membrane structure,Coronavirus Infections,1,X,[bpoc],[dsyn],A10.615.550.599;A14.549.512,C02.782.600.550.200
8693a685-c6e9-49f6-969d-24c298d3f861,C1825598,C0424166,have produced ,IMPACT gene,Social Anxiety,1,X,[gngm],[mobd],,F01.470.132
e914c13a-415c-419c-8619-0a4969cab89b,C1825598,C0011570,have produced ,IMPACT gene,Mental Depression,1,X,[gngm],[mobd],,F01.145.126.350
d1f87268-d8ea-4689-bc81-051a4e234e4f,C0441516,C0033174,were observed in ,Demand (clinical),Private Practice,1,X,[topp],[bmod],,N04.452.758.745
660301a4-cc04-4936-b35e-33c6e618ef81,C0870196,C0003467,suffer including ,Behavioral health,Anxiety,1,X,[bmod],[mobd],,F01.470.132
dbc62fd3-dfca-4701-bebb-f8c78a6b7768,C0870196,C0011570,suffer including ,Behavioral health,Mental Depression,1,X,[bmod],[mobd],,F01.145.126.350
f9bf9ccf-57b0-4893-ab03-dfc76b7894d9,C0870196,C0521991,suffer including ,Behavioral health,Symptoms of stress,1,X,[bmod],[sosy],,
0f299c20-644a-4029-b6af-543551403914,C1457887,C0001962,exacerbate ,Symptoms,Ethanol,1,X,[sosy],[orch/phsu],,D02.033.375;x.x.x.x
dcc5e707-bbba-42e6-9dfe-c2fcb0bbdb26,C1457887,C2961731,remit ,Symptoms,Overtime,1,X,[sosy],[orch/phsu],,
30e3c2a4-0c4a-4485-946e-94c863d9223b,C1829939,C0035222,those with ,{Non-patient},Respiratory Distress Syndrome Adult,1,X,[clna],[dsyn],,C08.381.840;C08.618.840
3c4dc123-4d71-4a1a-be6c-0e9c4b3c9c99,C0553741,C0035222,those with ,Fluid Management,Respiratory Distress Syndrome Adult,1,X,[topp],[dsyn],,C08.381.840;C08.618.840
fb99c75c-e9f2-4507-afa8-3129efddbcea,C0553741,C1829939,is in critically ill ,Fluid Management,{Non-patient},2,X,[topp],[clna],,
80950b53-2d84-4cc6-b7ec-3184d9b753dc,C0009450,C0041621,contamination of ,Communicable Diseases,Ultrasonic Shockwave,2,X,[dsyn],[npop],C01.539.221,G01.750.770.776.891.500
fd06bf12-724a-44e1-b618-aab2b0982a75,C1140621,C0005889,is better than mini ,Leg,Body Fluids,2,X,[bpoc],[bdsu],A01.378.610.500,A12.207
8df1855f-8728-409e-9501-f0a8095994ef,C0008971,C0206750,have During ,Clinical Protocols,Coronavirus Infections,2,X,[topp],[dsyn],E02.183;N05.715.360.330.125,C02.782.600.550.200
4c8f11df-673b-4d29-84a5-560be4bb3358,C0008971,C2745965,have During ,Clinical Protocols,Emergencies [Disease/Finding],2,X,[topp],[patf],E02.183;N05.715.360.330.125,C23.550.291.781;N06.230.100.083;N06.850.376
2e52e1cc-be3e-42c5-b42e-467f8cf858c2,C0027059,C1536220,masquerading as ,Myocarditis,ST segment elevation myocardial infarction,1,X,[dsyn],[dsyn],C14.280.238.625,C14.280.647.500.875;C14.907.585.500.875
bef704f7-12dd-497a-950e-67a1b6514996,C0206419,C0022658,poses significant challenges in area ,Genus: Coronavirus,Kidney Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C12.777.419;C13.351.968.419
9eaf8d7c-eaa8-4206-bbb9-baebb11c8f8d,C0543467,C0206419,should should based on recommendations in ,Operative Surgical Procedures,Genus: Coronavirus,1,X,[topp],[virs],E04,B04.820.504.540.150
bb4b41b8-96fc-411a-a1c9-1af34a7a9955,C0543467,C1521863,should should based on recommendations in ,Operative Surgical Procedures,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04,x.x.x.x
6caa9520-f953-4bc4-9fac-7e96d7f0ab51,C0598294,silico,were subjected to to silico ,Fish Proteins,silico,2,X,[aapp/bacs],????,D12.776.325,????
2a5559f5-178f-4bea-8aa3-27871f8e4569,C0598294,C0020291,were subjected to to silico ,Fish Proteins,Hydrolysis,2,X,[aapp/bacs],[npop],D12.776.325,G02.380
f84ee9cb-e64b-4a09-a50e-5f5c3a882ee5,C0027293,C0010744,followed by ,Cytochrome c Reductase,Cytochromes b,1,X,[aapp/enzy],[aapp/enzy],D08.811.682.608.504.500;D12.776.157.427.374.375.863.500;D12.776.331.887;D12.776.556.579.374.375.140.500,D08.244.187.249;D12.776.422.220.187.249
101822ee-604b-4ea5-be0b-5b9fefa40ed1,C0027293,C0038164,be ,Cytochrome c Reductase,Staphylococcal Protein A,2,X,[aapp/enzy],[aapp/imft/irda],D08.811.682.608.504.500;D12.776.157.427.374.375.863.500;D12.776.331.887;D12.776.556.579.374.375.140.500,D12.776.097.820;D23.050.161.821
2c6b6d0a-36e4-49ac-b8fa-7fc9eca23f02,C0028954,C0303231,can can used as ,Oligopeptides,Lead compound,1,X,[aapp],[chvs],D12.644.456,
38a5c022-4402-47a2-8c20-e43000435c1c,C0028954,C0243077,design potential ,Oligopeptides,inhibitors,1,X,[aapp],[chvf],D12.644.456,
55fe8e0b-9854-481e-8134-1836ee43cf07,C0028954,C0206419,design potential ,Oligopeptides,Genus: Coronavirus,1,X,[aapp],[virs],D12.644.456,B04.820.504.540.150
f2d1c98a-a9e0-40dd-9133-cd4dc50bd229,C0242297,C0206419,can In summary can helpful for ,Dietary Supplementation,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
a1f7f958-631e-4824-a145-b6fe98487cd4,C0079189,C0026473,may may produced by subset of ,cytokine,Monocytes,1,X,[aapp/imft],[cell],D12.644.276.374;D12.776.467.374;D23.529.374,A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547
ffdb0c7d-e24e-4af1-9986-523749a5f2e5,C1704259,C4330475,is in peripheral ,Biochemical Pathway,Immune Cell,1,X,[moft],[cell],,
5243b065-053c-4d14-a649-c40786a0cc43,C0596756,C0206419,is in severe ,immunopathology specialty,Genus: Coronavirus,1,X,[bmod],[virs],,B04.820.504.540.150
7547b66b-d1e8-43c4-96f9-63b4d150a175,C4330475,C0596756,might lead to ,Immune Cell,immunopathology specialty,1,X,[cell],[bmod],,
713b1018-4253-4f8f-9537-8eefee2594f6,C4330475,C0206419,might lead to ,Immune Cell,Genus: Coronavirus,1,X,[cell],[virs],,B04.820.504.540.150
1ac26a01-eea9-435a-bbed-89297b6a5124,C0206419,C1413336,applied single ,Genus: Coronavirus,CEL gene,1,X,[virs],[gngm],B04.820.504.540.150,
df2bcc36-f52b-4778-a976-3f24fc6274ea,C0206419,C1321301,profile ,Genus: Coronavirus,Peripheral blood mononuclear cell (cell),1,X,[virs],[cell],B04.820.504.540.150,
9fb2b42e-d174-45a5-9b9e-1e5ea55726a8,C0206419,C0284778,applied ,Genus: Coronavirus,RNA Small Cytoplasmic,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D13.444.735.790.552.750
c86b3540-00a9-4a13-938c-746d949b2835,C1828381,C1160716,enforcing best practices for ,Advising (action),viral transmission,3,X,[acty],[celf],,
3359d7c9-5ba2-4881-a2c3-e90e0028468b,C0021966,C0012682,offers safe alternative to ,Iodides,Disinfectants,1,X,[inch],[sbst],D01.248.497.158.490;D01.475.410,D27.505.954.122.425;D27.720.274
5c39eda8-cfd8-4dca-8fa0-c2ce727f060e,C1175743,C0700271,occurs through ,SARS coronavirus,M Protein multiple myeloma,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,x.x.x.x
5c39eda8-cfd8-4dca-8fa0-c2ce727f060e,C1175743,C0700271,binding ,SARS coronavirus,M Protein multiple myeloma,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,x.x.x.x
8cf9d172-0749-4075-a4e6-4e1b0302f312,C1175743,C2247081,occurs to ,SARS coronavirus,host cell membrane,1,X,[virs],[celc],B04.820.504.540.150.113.937,
1ccad9d6-f390-418c-a5ae-0871752327e0,ACE2,C1171346,is in ,ACE2,Human Embryonic Stem Cells,1,X,????,[cell],????,A11.872.700.250.750
46134ed0-2051-43fb-b90a-b8fac86308fa,ACE2,C0920751,is in ,ACE2,Heart cell,1,X,????,[cell],????,
4bc73352-26ca-450c-98da-d476436ee74a,C0012655,C0206419,is in male ,Disease susceptibility,Genus: Coronavirus,1,X,[clna],[virs],C23.550.291.687;G07.100.250,B04.820.504.540.150
777827dd-3198-4c04-b45a-7973b0003825,C0018581,C0599638,is with ,Handwashing,Drinking Water,1,X,[acty],[sbst],N06.850.670.150.500,D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418
c3192e28-4c4f-487e-a328-8e299dc79a35,C0599685,C0206419,has has experimentally used for ,Anti-Retroviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388.077,B04.820.504.540.150
4cc9244b-af03-4c05-b962-46320a0da9fb,C0599685,C1856053,has has experimentally used for ,Anti-Retroviral Agents,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[phsu],[dsyn],D27.505.954.122.388.077,x.x.x.x
82d19966-7c4c-4a24-a3ea-94575012556b,C0013227,C1856053,has has experimentally used for ,Pharmaceutical Preparations,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[phsu],[dsyn],D26,x.x.x.x
84768ef9-9df9-41c2-a056-97294f930652,C1138226,C1856053,has has experimentally used for ,favipiravir,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[orch/phsu],[dsyn],x.x.x.x,x.x.x.x
07d784f8-d3b7-4b05-aa3b-0791dc9fc110,C0206419,C0020336, includes ,Genus: Coronavirus,Hydroxychloroquine,1,X,[virs],[orch/phsu],B04.820.504.540.150,D03.633.100.810.050.180.350
65ac054c-b61e-47df-9463-2b4e2f2b133e,ICTRP,C1706202,were ,ICTRP,Search - action,1,X,????,[acty],????,
98d504c0-6413-4921-8933-c2b03e209029,C1145670,C0221423,is associated with high mortality ,Respiratory Failure,Illness (finding),1,X,[dsyn],[sosy],C08.618.846,
318d9189-1b0a-4014-9f18-86124de907fb,C1145670,C0021925,requiring ,Respiratory Failure,Intubation,1,X,[dsyn],[topp],C08.618.846,E02.585;E05.497
4f7854c2-a735-4486-93a2-5a5cec0cf6c8,C0013227,C0700271,measured ,Pharmaceutical Preparations,M Protein multiple myeloma,1,X,[phsu],[aapp/imft],D26,x.x.x.x
8abe9fff-89c3-4422-b299-e7c9b6affd0a,C0013227,C0042720,measured ,Pharmaceutical Preparations,Viral Genome,1,X,[phsu],[gngm],D26,G05.360.340.358.840
37696409-996d-4e2a-8dbb-2ec7faa31e52,C0231239,C0596957,is in ,Fluctuation,Molecular Dynamics,1,X,[sosy],[moft],,E05.599.595.500;G02.111.570.895;L01.224.160.500
384c388f-6b99-4ffc-aae1-406bd3022390,C0596973,C0026597,is in constant ,monomer,Motion,1,X,[chvs],[npop],,G01.482
61458fc4-ce34-45a7-9e21-038b770fb4d3,C0596973,C1547282,is in constant ,monomer,Show,1,X,[chvs],[anim],,
ad0d49fb-f378-4e32-a415-821016ba35ce,C0700271,C0026597,form of is constant ,M Protein multiple myeloma,Motion,1,X,[aapp/imft],[npop],x.x.x.x,G01.482
0043a5ff-59cf-411b-8dbe-82ab5b4b2de6,C0700271,C1547282,form of is constant ,M Protein multiple myeloma,Show,1,X,[aapp/imft],[anim],x.x.x.x,
ff6e94fd-40af-4c0c-9443-66220d17f56f,C1175743,C1413336,is in published ,SARS coronavirus,CEL gene,1,X,[virs],[gngm],B04.820.504.540.150.113.937,
22f7c97d-5d27-4cd7-a5e8-4c759185ba6f,C0567416,C0162969, includes ,Molecule,Chitosan,1,X,[sbst],[orch/phsu],,D05.750.078.139.500;D09.698.211.500
cb22d37f-74fe-437a-ac7c-9252c22ff4d9,C0278996,C1882509,is in ,Malignant Head and Neck Neoplasm,put - instruction imperative,1,X,[neop],[acty],,
f886a959-1a98-4ec2-b555-db38da4187a9,C1947933,C1882509,is in ,care activity,put - instruction imperative,1,X,[acty],[acty],,
a0964a30-794f-4aca-b2d3-898b4715f45a,C1552133,C0206419,screening for fear of ,19s,Genus: Coronavirus,2,X,[bpoc],[virs],,B04.820.504.540.150
f0a9ff40-146f-4b56-a321-430706e1fd14,C1257792,C1422064,express ,Vascular Endothelial Cells,ACE2 gene,1,X,[cell],[gngm],A11.436.275,
1b13c2a5-65ef-4c87-9313-191c9cd3e66c,C1257792,C0033684,express ,Vascular Endothelial Cells,Proteins,1,X,[cell],[aapp/bacs],A11.436.275,D12.776
5b18ba17-cbca-435d-831d-994dc3506012,C0040048,C1879547,entails ,Thromboplastin,Activation action,1,X,[aapp/imft],[acty],D12.776.124.125.900;D23.119.965,
bf4d1f47-73d0-43de-93e7-17d7b2b08509,C0040048,C0068355,entails ,Thromboplastin,NADPH Oxidase,1,X,[aapp/imft],[aapp/enzy],D12.776.124.125.900;D23.119.965,D08.811.682.608.575;D12.776.331.894;D12.776.543.653
8eb04fed-29ec-4e69-b0a5-d485de4ee6d7,C1523116,C0040649,drives induced ,positive regulation of NF-kappaB transcription factor activity,Transcription Genetic,1,X,[celf],[genf],,G02.111.873;G05.297.700
43f05290-a008-47e2-9fbb-6027cff9b523,C1523116,C0812327,drives induced ,positive regulation of NF-kappaB transcription factor activity,Transcription factor genes,1,X,[celf],[gngm],,
0e62acea-e86e-4bca-b939-1dcc6b0ff17d,C3272452,C0007634,are taken up into ,Single-Stranded RNA,Cells,1,X,[nnon],[cell],,A11
0a74d893-ebaf-4a6c-88e0-f634f4b86bb5,C3272452,C0034850,are taken up into ,Single-Stranded RNA,Endosomes,1,X,[nnon],[celc],,A11.284.430.214.190.875.190.880.337
947e1159-064f-403a-be77-987e0b295e91,C0042776,C0034850,are taken up into ,Virus,Endosomes,1,X,[virs],[celc],B04,A11.284.430.214.190.875.190.880.337
d5cb862f-fcd6-4d42-a06a-614285657a7c,C0034850,C0035668,stimulate Endosomes Anabolism via,Endosomes,RNA,1,X,[celc],[nnon],A11.284.430.214.190.875.190.880.337,D13.444.735
f79ddb00-f6bb-4a74-bc85-b6e216f7fe75,C0034850,C1579758,stimulate Endosomes Anabolism via,Endosomes,Toll-Like Receptor 7,1,X,[celc],[aapp/imft/rcpt],A11.284.430.214.190.875.190.880.337,D12.776.543.750.705.910.500.700
28e7734d-2d6a-46c7-8dfd-80dd272efba1,C0034850,C0220781,stimulate ,Endosomes,Anabolism,1,X,[celc],[biof],A11.284.430.214.190.875.190.880.337,G03
9162bc03-d234-45da-a116-b8a3f09c790a,C0034850,C1325739,stimulate ,Endosomes,NADPH oxidase complex location,1,X,[celc],[celc],A11.284.430.214.190.875.190.880.337,
9844cffe-114b-4c22-b8ae-4108664d03ad,C1175175,C0230425,using real-time PCR,Severe Acute Respiratory Syndrome,Structure of right thigh,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,
b9c3b89e-384f-48e8-a510-f99d78a96224,C1175175,PCR,using real-time PCR,Severe Acute Respiratory Syndrome,PCR,1,X,[dsyn],????,C02.782.600.550.200.750;C08.730.730,????
ed8695a8-8c28-4749-bf4c-112dcf6b59e6,C0184661,C0003451,is In absence of specific ,Interventional procedure,Antiviral Agents,1,X,[topp],[phsu],,D27.505.954.122.388
a443b789-4c32-4221-848b-adebb01feed0,C0960756,C0206419,contributing factor A to,factor A,Genus: Coronavirus,2,X,[orch],[virs],x.x.x.x,B04.820.504.540.150
ac17a602-0892-4a1b-8413-faf39b26e845,C1697446,C3694279,causes severe disease similar to those caused by ,Genital Viral Infections,Middle East Respiratory Syndrome,1,X,[dsyn],[dsyn],,C02.782.600.550.200
677d4312-c047-496b-b755-d0b0dedb1ff9,C0275522,C0206419,substantial component of ,Asymptomatic Infections,Genus: Coronavirus,2,X,[dsyn],[virs],C23.550.291.187.500,B04.820.504.540.150
08691831-e982-4c1f-9450-25dc5ca5c8ba,C0035668,C0206419,decreased Recovery - action of endemic,RNA,Genus: Coronavirus,1,X,[nnon],[virs],D13.444.735,B04.820.504.540.150
0a233093-2f1c-4041-b8f1-02714c66696d,C0185115,C0206419,decreased Recovery - action of endemic,Extraction,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
4c024d69-f382-494f-bd70-784ff2bf00e0,C0206419,C0185115,optimizing ,Genus: Coronavirus,Extraction,1,X,[virs],[topp],B04.820.504.540.150,
d0ca30f2-fab4-43ae-a6c2-bbc11c7bbed6,C1095830,C1706202,were ,Apple,Search - action,1,X,[food],[acty],B01.650.940.800.575.912.250.859.937.500.444,
328cb8f3-96a4-4350-ae03-a69e1283aa42,C0001617,bodys,delayed bodys ,Adrenal Cortex Hormones,bodys,1,X,[horm/orch/phsu],????,D06.472.040,????
1cc62252-0296-4f86-a4eb-89bdc2667ac9,C0001617,C0042776,delayed bodys ,Adrenal Cortex Hormones,Virus,1,X,[horm/orch/phsu],[virs],D06.472.040,B04
3376b4a5-7240-4e91-b459-8782b33b0ca2,C3714514,C0241144,include ,Infection,Petechiae of skin,1,X,[patf],[sosy],C01.539,
e09616ca-5461-43a2-9538-c18394fa11a3,C1416797,C0206750,feel In ,STMN1 gene,Coronavirus Infections,2,X,[gngm],[dsyn],,C02.782.600.550.200
a67ad9f6-82d5-4f70-aa6f-cddcb955c95b,C1416797,C0012634,feel In ,STMN1 gene,Disease,1,X,[gngm],[dsyn],,C23.550.288
ea99b3db-98ad-4f3e-b335-87f51f9e3a64,C0037090,C0242656,are typically found during ,Signs and Symptoms Respiratory,Disease Progression,2,X,[sosy],[patf],C23.888.852,C23.550.291.656
df6933e8-3a2e-4bcf-a55d-6068166c1a2f,C4554533,C0597404,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Respiratory viruses,1,X,[clna],[virs],,
f9f4ba67-cb3c-493c-9644-235324e30f59,C4554533,C0035243,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Respiratory Tract Infections,1,X,[clna],[dsyn],,C01.539.739;C08.730
46cb73e8-9580-4a12-9c9b-cb7f62c1b4a0,C4554533,C0022882,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Laboratory Infection,1,X,[clna],[dsyn],,C01.539.503;C24.506
495079cd-7a33-4dec-bc51-2ae93df665ad,C4554533,C0521839,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Influenza-like illness,1,X,[clna],[dsyn],,
bc7edaf1-980c-43e5-b2fc-685cf3af56f9,C4554533,favour,is in favour N95 ,Trend:Type:Point in time:^Patient:Nominal,favour,1,X,[clna],????,,????
894efcbf-9b04-4727-acb8-bbad5a410747,C4554533,N95,is in favour N95 ,Trend:Type:Point in time:^Patient:Nominal,N95,1,X,[clna],????,,????
7367677b-f899-4a50-ad95-a09aa82f6bc2,N95,C0035243,protect HCWs from clinical ,N95,Respiratory Tract Infections,1,X,????,[dsyn],????,C01.539.739;C08.730
a33f3795-f03d-4c36-aded-f6fd38bbd40c,N95,C0275521,protect HCWs from clinical ,N95,Clinical infection,1,X,????,[dsyn],????,
c9665779-6ccc-4925-8d87-2e6648fca9d9,C2948600,C0038454,describe specific ,Aim,Cerebrovascular accident,1,X,[inch/phsu],[dsyn],,C10.228.140.300.775;C14.907.253.855
9808bd26-21e7-4afb-af77-5cebc8b193f7,C2948600,C0000983,evaluate effect of ,Aim,Acetic Acid,1,X,[inch/phsu],[irda/orch],,D02.241.081.018.165;D10.251.400.045.500
2e84a8e0-05c2-4e50-b178-f5f5732c427e,C0206750,21st,is in 21st ,Coronavirus Infections,21st,3,X,[dsyn],????,C02.782.600.550.200,????
43619215-06f5-4dcc-ae85-3019c3981c64,C1456573,21st,is in 21st ,Global Health,21st,2,X,[bmod],????,H02.403.371;N01.400.337,????
9b07db43-f2c3-426f-b3c7-78b84ffc999c,C0012634,C0878751,is in ,Disease,late pregnancy,1,X,[dsyn],[patf],C23.550.288,
49727d9a-765a-44ff-a1e7-ebb2a04dde27,C0025011,C0048243,of Glycoproteins is 6VSB,Measles virus,4-dichlorobenzene,1,X,[virs],[hops/orch],B04.820.455.600.650.500.500,x.x.x.x
b0a6e2ab-d1dc-42c0-9138-39889123671b,C0017968,C0048243,of Glycoproteins is 6VSB,Glycoproteins,4-dichlorobenzene,1,X,[aapp/bacs],[hops/orch],D09.400.430;D12.776.395,x.x.x.x
3ab0ff17-02e5-452f-883c-0928cea65c56,C0025011,6VSB,of Glycoproteins is 6VSB,Measles virus,6VSB,1,X,[virs],????,B04.820.455.600.650.500.500,????
8f906da1-73bb-4a8e-a927-870bede32ee0,C0017968,6VSB,of Glycoproteins is 6VSB,Glycoproteins,6VSB,1,X,[aapp/bacs],????,D09.400.430;D12.776.395,????
c4628356-607f-49db-9178-2eec11271d4a,C0849867,C1175743,has has associated with high rates of ,Widespread Disease,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
f3ca1ba5-56c8-4ecd-9c4d-2a1a80ed9e2a,C0026652,C0206750,improve Symptoms with,Moxibustion,Coronavirus Infections,1,X,[topp],[dsyn],E02.190.044.588,C02.782.600.550.200
8a484de3-0785-4a98-8874-fc264c486cb9,C0030755,C0010200,is with ,Pediatrics,Coughing,1,X,[bmod],[sosy],H02.403.670,C08.618.248;C23.888.852.293
ccc7cccf-d206-4427-8b67-d25065e573a0,C0598197,C3714514,had on growth rate of ,contagion,Infection,1,X,[npop],[patf],,C01.539
31ffd3ce-711d-4bfd-96f8-04bda6284a5e,C1175743,C0005775,might attack Myocytes Cardiac through,SARS coronavirus,Blood Circulation,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G09.330.100
31ffd3ce-711d-4bfd-96f8-04bda6284a5e,C1175743,C0005775,might attack Organ into,SARS coronavirus,Blood Circulation,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G09.330.100
31ffd3ce-711d-4bfd-96f8-04bda6284a5e,C1175743,C0005775,can reach system from ,SARS coronavirus,Blood Circulation,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G09.330.100
9cb313d5-8ab0-4e50-9b23-9a7fb50c5c85,C0026809,C0023810,treated by ,Mus,Lipopolysaccharides,1,X,[mamm],[orch],B01.050.150.900.649.313.992.635.505.500,D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500
64ac081a-1df2-4f3f-87b8-0b6d0443741d,C1175743,C0178784,might attack other ,SARS coronavirus,Organ,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,
311cf70d-a35e-41c2-aef3-99115c7967b9,C1175743,C1824356,might attack Organ by,SARS coronavirus,KIAA1551 gene,1,X,[virs],[gngm],B04.820.504.540.150.113.937,
ae8fcb2b-0412-4150-badb-399737b9d35f,C0206750,C0796085,has placed strain on many aspects of ,Coronavirus Infections,Nance-Horan syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d67d8fe7-990d-4576-87ca-e5feef603e20,C0029892,C0206750,are needed for preoperative ,Otolaryngology specialty,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.810.526,C02.782.600.550.200
8bc31701-1e94-4078-8626-0f195b27805a,C0007634,C0022709,targeting ,Cells,Peptidyl-Dipeptidase A,2,X,[cell],[aapp/enzy/imft],A11,D08.811.277.656.350.350.687
9a90850a-0b0d-48a4-adae-cf9e1fedee87,C1167622,C0309872,seems to ,Binding (Molecular Function),PREVENT (product),2,X,[moft],[phsu],,
3dbc3fc9-3543-4df1-9414-d2f77b286750,C0022709,C0390423,enter Cells by only,Peptidyl-Dipeptidase A,Angiotensin II Receptor Type 2,2,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,D12.776.543.750.695.047.687;D12.776.543.750.750.130.875
dc58a247-b7f9-459f-a457-93d737c46b1b,C0022709,C0014139,enter induced ,Peptidyl-Dipeptidase A,Endocytosis,2,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,G04.417
d2c70b09-0233-4b29-b065-941d3fc9222b,C0022709,C1439284,enter Cells by,Peptidyl-Dipeptidase A,AGTR1 gene,2,X,[aapp/enzy/imft],[gngm],D08.811.277.656.350.350.687,
4ffc0d25-27c1-4b27-a44e-df909f6fb6e1,C1439284,C1175743,be ideal candidate for treatment of ,AGTR1 gene,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
533ef6a7-2625-47be-b650-757fd1663f23,C0243076,C1175743,be ideal candidate for treatment of ,antagonists,SARS coronavirus,2,X,[chvf],[virs],,B04.820.504.540.150.113.937
edd575d7-f36c-439b-bda4-d5aa7b4ed9da,C4281807,C2700061,being observed ,Vitronectin human,Transition (action),2,X,[aapp/bacs],[acty],,
77f95a3e-7de7-4183-8f77-1cfa044398e6,C4281807,C1514535,being observed ,Vitronectin human,Protein Binding Motif,2,X,[aapp/bacs],[amas],,
2eed007b-66dc-40e2-8f04-6db0657d2533,C4281807,C0597358,being observed ,Vitronectin human,receptor binding,2,X,[aapp/bacs],[moft],,
ad7f2c74-5502-4c39-9c32-3b3ba32fb559,C4281807,C0599638,is in ,Vitronectin human,Drinking Water,2,X,[aapp/bacs],[sbst],,D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418
7b732a75-507e-4095-8ddc-9f20b74f87f4,C0597358,C0013227,was more exposed to solvent to possible ,receptor binding,Pharmaceutical Preparations,2,X,[moft],[phsu],,D26
4759ea50-0e0f-4098-808f-ff71aef1d0cd,C0023688,C1167622,is with kcal ,Ligands,Binding (Molecular Function),1,X,[chem],[moft],D27.720.470.480,
4759ea50-0e0f-4098-808f-ff71aef1d0cd,C0023688,C1167622,has revealed molecular determinants responsible for ,Ligands,Binding (Molecular Function),2,X,[chem],[moft],D27.720.470.480,
4759ea50-0e0f-4098-808f-ff71aef1d0cd,C0023688,C1167622,has revealed potential inhibitor ,Ligands,Binding (Molecular Function),2,X,[chem],[moft],D27.720.470.480,
d0af4c64-35e8-44b2-b0d1-7ad565ca5c59,C0023688,C0542479,is with kcal ,Ligands,Energy Physics,1,X,[chem],[npop],D27.720.470.480,
2b520343-3fb6-456b-8d41-428dcf6a5fcd,C0023688,kcal,is with kcal ,Ligands,kcal,1,X,[chem],????,D27.720.470.480,????
f46ae926-21fd-461b-bae6-1afc07c0166e,C0023688,C0324740,is with kcal ,Ligands,Talpidae,1,X,[chem],[mamm],D27.720.470.480,B01.050.150.900.649.473.450
9f37b0a4-d884-4a36-8832-4fb903b8ab3e,C1441506,C1098032,using MM ,Calculation,poly(tetramethylene succinate-co-tetramethylene adipate),1,X,[acty],[orch],,x.x.x.x
9d90f183-382e-4e70-bc9a-83ae932dda62,C1321919,C0751408,indeed may rival ,TLR4 protein human,Suffering Physical,1,X,[aapp/rcpt],[sosy],x.x.x.x,C23.888.592.612;F02.830.816.444;G11.561.790.444
215d9294-662b-4b42-8ba1-8de750035698,C1321919,C0221423,indeed may rival ,TLR4 protein human,Illness (finding),1,X,[aapp/rcpt],[sosy],x.x.x.x,
92d7d6f3-315d-4156-9366-629249763d42,C4300185,C1947933,incorporate practices into routine ,Palliative care.team,care activity,1,X,[bmod],[acty],,
5a82fc58-1963-4386-ad0a-3850e7763c5c,C4300185,C0185027,are well poised Given significant ,Palliative care.team,Imbrication (procedure),1,X,[bmod],[topp],,
662a281f-f9ce-439d-8302-9c703ccdc106,C4300185,C0886052,are well poised Given significant ,Palliative care.team,wound care,1,X,[bmod],[topp],,
0e02d422-106c-429b-a857-ceaa623d2472,PHQ-9,C0206750,visited more ,PHQ-9,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
c31ceec1-dc94-40ad-ba06-d0346613ab92,C0032227,C0225756,lesions in ,Pleural effusion disorder,Structure of upper lobe of lung,1,X,[dsyn],[bpoc],C08.528.652,
f84e33b2-a220-4dbf-9192-05819cb37db8,C2948600,C2700061,compare appointment data in weeks after ,Aim,Transition (action),1,X,[inch/phsu],[acty],,
f84e33b2-a220-4dbf-9192-05819cb37db8,C2948600,C2700061,compare patient demographics in weeks after ,Aim,Transition (action),1,X,[inch/phsu],[acty],,
a349c363-bc4b-434d-8c37-1e2d2aee547f,C0206750,C1882509,has ,Coronavirus Infections,put - instruction imperative,1,X,[dsyn],[acty],C02.782.600.550.200,
a630abb9-e1fb-45a5-abb5-cc3f616e4352,C0012634,C1882509,has ,Disease,put - instruction imperative,1,X,[dsyn],[acty],C23.550.288,
eb4fede1-6e26-4895-a827-1c3de4a760c6,C2348077,COVID-19,Biological Evolution of,Date Fruit,COVID-19,1,X,[food],[virs],B01.650.940.800.575.912.250.093.615,C000657245
7a6f2c2d-e13b-4747-93fb-2a03ceca2519,C1457887,C0079189,suggest ,Symptoms,cytokine,3,X,[sosy],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
005b02af-c73b-43c9-b519-506dc2d11486,C1457887,C1861452,suggest ,Symptoms,Storm Syndrome,3,X,[sosy],[dsyn],,x.x.x.x
8c643d1c-7c98-4e45-a5f0-22663fec19f7,C1457887,C0042769,suggest ,Symptoms,Virus Diseases,3,X,[sosy],[dsyn],,C02
3e68d448-347a-49cd-b35e-7c72a328d4e3,C1861452,C0042769,is in response to ,Storm Syndrome,Virus Diseases,3,X,[dsyn],[dsyn],x.x.x.x,C02
13d6e02b-e6b3-4fd3-b631-133a757321ea,C0003280,C3687832,are among ,Anticoagulants,Drugs - dental services,1,X,[phsu],[topp],D27.505.954.502.119,
4a5a9835-c3a2-4d8d-ab20-bbdb77cda9a8,C0032105,C3687832,are among ,Plasma,Drugs - dental services,1,X,[bdsu],[topp],A12.207.152.693;A12.207.270.695;A15.145.693,
afdaac1a-7258-4acb-90b1-00a1c2ade5e4,C0003451,C3687832,are among ,Antiviral Agents,Drugs - dental services,1,X,[phsu],[topp],D27.505.954.122.388,
7cc662e7-89f3-4319-be7f-f6f84ba9d022,C0001617,C3687832,are among ,Adrenal Cortex Hormones,Drugs - dental services,1,X,[horm/orch/phsu],[topp],D06.472.040,
f14f47d5-e615-4c81-96d6-2c8df649245e,C0003374,C3687832,are among ,Antimalarials,Drugs - dental services,1,X,[phsu],[topp],D27.505.954.122.250.100.085,
a1c7e9a0-e57b-4354-ad48-0f8b822bc9fd,C1328819,C3687832,are among ,Small Molecule,Drugs - dental services,1,X,[orch],[topp],,
37af914d-c61d-4067-b651-45e51f73cd1a,C0008679,C0221423,associated with development of ,Chronic disease,Illness (finding),1,X,[dsyn],[sosy],C23.550.291.500,
130a6dc5-5fe6-492c-933c-7e2726576d44,C0009450,C0450254,is with suspected ,Communicable Diseases,Pathogenic organism,1,X,[dsyn],[orgm],C01.539.221,
7405c8e5-09db-4d5a-9ff2-6732be7c6ba5,COVID-19,C0003811,contributes to ,COVID-19,Cardiac Arrhythmia,1,X,[virs],[dsyn],C000657245,C14.280.067;C23.550.073
951336d9-74ec-40be-a6bb-27e04211e442,C3260929,COVID-19,is in ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,COVID-19,2,X,[clna],[virs],,C000657245
4ee9d60d-0729-4576-94de-ab48bf386377,C0221423,C1456573,pandemic of is ,Illness (finding),Global Health,1,X,[sosy],[bmod],,H02.403.371;N01.400.337
3bd1a4f1-885d-4fbc-a65b-16dad0ce6983,C0023870,C3463820,has shown at ,Lithium,Inhibition,1,X,[elii/phsu],[acty],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,F01.145.544;F02.463.425.475;F02.739.794.405
d69438f8-cb29-4645-bb2f-56341cfc3221,C0023870,C0598312,has shown at ,Lithium,DNA Replication,1,X,[elii/phsu],[genf],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,G02.111.225;G05.226
20761a60-9841-4fa2-a5b0-2a166d57ddbc,C0023870,C0206419,has shown at ,Lithium,Genus: Coronavirus,1,X,[elii/phsu],[virs],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,B04.820.504.540.150
2f7054d3-2e5f-43e2-95a3-42787131169d,C0023870,C0003062,has shown at ,Lithium,Animals,1,X,[elii/phsu],[anim],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,B01.050
5939a855-0244-4748-a5c1-c2831cf13b58,C0023870,C3266814,exert protective ,Lithium,Action,1,X,[elii/phsu],[acty],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,
12daacad-c674-44d3-a619-9fdfbe4a9027,C0023870,C0041912,exert Action against,Lithium,Upper Respiratory Infections,1,X,[elii/phsu],[dsyn],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,C01.539.739;C08.730
461817a1-1321-405e-823e-2a37aa280d95,C2948600,C0030106,explore associations among ,Aim,Ozone,1,X,[inch/phsu],[chem],,D01.362.670.600;x.x.x.x
7f2aaec8-a1de-4876-9c0c-4b546f4b7c8b,C0034602,C0012634,play role in diagnosis of various ,Interventional radiology,Disease,1,X,[bmod],[dsyn],H02.403.740.675,C23.550.288
2203dbd2-6776-453f-bcde-c82457ebd011,C0032285,C1861172,increased risk of ,Pneumonia,Venous Thromboembolism,1,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C14.907.355.590.700
bee09281-2c69-40c7-b56c-385cbede338f,C0520997,C0940931,death from ,Thrombolysis function,hemorrhage as a complication,1,X,[clna],[dsyn],,
0f9d5f9c-b264-4f6d-b366-06b5616a0eea,C0184661,COVID-19,is with ,Interventional procedure,COVID-19,1,X,[topp],[virs],,C000657245
d34cc272-11e7-431f-a9a5-defbce381286,C0087111,C0025124,is with ,Therapeutic procedure,Traditional Chinese Medicine,1,X,[topp],[bmod],E02,E02.190.488.585.520;I01.076.201.450.654.558.520
eb354d48-650a-4cb9-bfc0-c90ad797b5a5,C0178784,COVID-19,is in ,Organ,COVID-19,1,X,[bpoc],[virs],,C000657245
04605aa5-4099-43fc-b18c-5e70fcc50a90,AEC2,C3463820,could could direct targets for ,AEC2,Inhibition,1,X,????,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405
ea96097e-ee22-4bb6-87b3-764be2460cca,AEC2,C1175743,could could direct targets for ,AEC2,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
b5e44ee4-68b3-4b2e-ac2d-8cbb14f9090b,C0034392,COVID-19,could ,Quercetin,COVID-19,1,X,[orch/phsu/vita],[virs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,C000657245
7e21478b-7847-4436-a194-46d7038066bf,C0064280,COVID-19,could ,kaempferol,COVID-19,1,X,[orch],[virs],x.x.x.x,C000657245
4d375dbc-30b1-4fed-a7c6-3409422a8696,C0065264,COVID-19,could ,Luteolin,COVID-19,1,X,[orch/phsu],[virs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,C000657245
cd581f56-ea3a-4bd9-96da-59b8740bcb99,C0047611,COVID-19,could ,3-methylquercetin,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
85d95a68-1055-4b08-8582-28c406506080,C0052927,COVID-19,could ,baicalein,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
952b5f04-6a03-4e08-9a67-494ccc92931c,C0251223,COVID-19,could ,wogonin,COVID-19,1,X,[orch],[virs],x.x.x.x,C000657245
5b89085c-2b32-43ab-be00-5852b0e716fa,C0034392,AEC2,targeting on AEC2,Quercetin,AEC2,1,X,[orch/phsu/vita],????,D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,????
6909dbb1-d13f-49b1-b83e-2ab6b056a0e4,C0064280,AEC2,targeting on AEC2,kaempferol,AEC2,1,X,[orch],????,x.x.x.x,????
736ff804-cedb-493d-821b-7af08457a92b,C0065264,AEC2,targeting on AEC2,Luteolin,AEC2,1,X,[orch/phsu],????,D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,????
b8cc69e5-fcde-4e98-a81c-cad88c90fc84,C0047611,AEC2,targeting on AEC2,3-methylquercetin,AEC2,1,X,[orch/phsu],????,x.x.x.x,????
6ff6bd07-c843-4919-8f06-e2960136394b,C0052927,AEC2,targeting on AEC2,baicalein,AEC2,1,X,[orch/phsu],????,x.x.x.x,????
92dd4cd8-bb6e-4fa8-8d8f-7f27b7f1b3c3,C0068450,AEC2,targeting on AEC2,naringenin,AEC2,1,X,[orch/phsu],????,x.x.x.x,????
31155c38-0c60-444e-9d52-bfd7fcee02fc,C0251223,AEC2,targeting on AEC2,wogonin,AEC2,1,X,[orch],????,x.x.x.x,????
ddb6c79a-c5fd-457d-9a9e-9c5cff1e9af3,C0034392,C0016693,eliminating ,Quercetin,Free Radicals,1,X,[orch/phsu/vita],[bacs/chvs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D01.339;D02.389
77903604-2835-462d-b460-f8607143228c,C0064280,C0016693,eliminating ,kaempferol,Free Radicals,1,X,[orch],[bacs/chvs],x.x.x.x,D01.339;D02.389
45615fda-1376-40b8-ae5c-0392b3d05003,C0065264,C0016693,eliminating ,Luteolin,Free Radicals,1,X,[orch/phsu],[bacs/chvs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,D01.339;D02.389
9282ebfe-648f-47b6-a10b-7b44bdb2706e,C0047611,C0016693,eliminating ,3-methylquercetin,Free Radicals,1,X,[orch/phsu],[bacs/chvs],x.x.x.x,D01.339;D02.389
3c884aea-138f-47ae-9b56-82443bcaa000,C0052927,C0016693,eliminating ,baicalein,Free Radicals,1,X,[orch/phsu],[bacs/chvs],x.x.x.x,D01.339;D02.389
44a9ec02-7900-4953-acbb-b56face18689,C0068450,C0016693,eliminating ,naringenin,Free Radicals,1,X,[orch/phsu],[bacs/chvs],x.x.x.x,D01.339;D02.389
1c11817d-37b7-42a1-9d1a-c96af93eb8f6,C0251223,C0016693,eliminating ,wogonin,Free Radicals,1,X,[orch],[bacs/chvs],x.x.x.x,D01.339;D02.389
cf529abf-eca7-4bfa-9edc-b393c83ba9cd,C1565860,C1512589,is in NF-B ,PTGS2 protein human,IL17 Signaling Pathway,2,X,[aapp/enzy],[celf],x.x.x.x,
8c5f7df2-f1ac-427d-a3dd-b0619cd9b230,C1565860,C0003695,is in NF-B ,PTGS2 protein human,Arachidonic Acid,1,X,[aapp/enzy],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
0b337827-0f39-403c-aa25-ca723dbf98bc,C1565860,C0215848,is in NF-B ,PTGS2 protein human,Hypoxia-Inducible Factor 1,1,X,[aapp/enzy],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
0747decd-33f3-4def-96fd-fe044b9cb6e7,C1565860,NF-B,is in NF-B ,PTGS2 protein human,NF-B,1,X,[aapp/enzy],????,x.x.x.x,????
c201c2ba-867d-457b-ae4d-29b55fefa143,C1565860,C0034678,is in NF-B ,PTGS2 protein human,ras Oncogene,1,X,[aapp/enzy],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
2a41a6eb-952f-4cfc-82ef-e2d89332a799,C1565860,C1448177,is in NF-B ,PTGS2 protein human,TNF protein human,1,X,[aapp/enzy],[aapp/bacs],x.x.x.x,x.x.x.x
3728aa20-b3b6-4fb0-aa55-0f02288f3276,C0034392,C1565860,eliminating Free Radicals through NF-B,Quercetin,PTGS2 protein human,1,X,[orch/phsu/vita],[aapp/enzy],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,x.x.x.x
e7aadf9f-0986-434d-bd0d-628b51fe54d4,C0064280,C1565860,eliminating Free Radicals through NF-B,kaempferol,PTGS2 protein human,1,X,[orch],[aapp/enzy],x.x.x.x,x.x.x.x
68525450-45e8-425f-b1fd-c27c5aa3b148,C0065264,C1565860,eliminating Free Radicals through NF-B,Luteolin,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,x.x.x.x
c4988adf-db2e-4fd9-a364-d97a4a09698a,C0047611,C1565860,eliminating Free Radicals through NF-B,3-methylquercetin,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
b46f45d3-2e04-49e3-bc47-d2aca0584f9c,C0052927,C1565860,eliminating Free Radicals through NF-B,baicalein,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
1f286f25-3f32-4930-a20e-120bdfd32d55,C0068450,C1565860,eliminating Free Radicals through NF-B,naringenin,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
92cb2072-afb6-47f0-bfef-c6ef60624b24,C0251223,C1565860,eliminating Free Radicals through NF-B,wogonin,PTGS2 protein human,1,X,[orch],[aapp/enzy],x.x.x.x,x.x.x.x
9bca8355-7554-4968-b084-4f1fd2efce61,C0034392,C1512589,eliminating Free Radicals through NF-B,Quercetin,IL17 Signaling Pathway,2,X,[orch/phsu/vita],[celf],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,
438bee8b-dea5-4160-984c-8e04d5e5fc9f,C0064280,C1512589,eliminating Free Radicals through NF-B,kaempferol,IL17 Signaling Pathway,2,X,[orch],[celf],x.x.x.x,
b5f6da93-b808-4ec3-8999-332c64ed540c,C0065264,C1512589,eliminating Free Radicals through NF-B,Luteolin,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,
21825bde-7b9a-41bc-b10b-7843ebcd737a,C0047611,C1512589,eliminating Free Radicals through NF-B,3-methylquercetin,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],x.x.x.x,
e4a30d37-1775-43b2-ac7c-c00c868be604,C0052927,C1512589,eliminating Free Radicals through NF-B,baicalein,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],x.x.x.x,
786009ef-f941-4170-84d6-5dda423ccbe6,C0068450,C1512589,eliminating Free Radicals through NF-B,naringenin,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],x.x.x.x,
0aa586f9-e0f4-4ae6-a907-8a63c1d174ae,C0251223,C1512589,eliminating Free Radicals through NF-B,wogonin,IL17 Signaling Pathway,2,X,[orch],[celf],x.x.x.x,
fff5ec20-154b-4f12-9e62-dfd4d4e5438b,C0034392,C0003695,eliminating Free Radicals through NF-B,Quercetin,Arachidonic Acid,1,X,[orch/phsu/vita],[orch],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D10.251.355.255.100.100;D10.251.355.310.166.100
992c25e0-a5a3-4a21-8db6-e44585e499b6,C0064280,C0003695,eliminating Free Radicals through NF-B,kaempferol,Arachidonic Acid,1,X,[orch],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
7c4399f7-8ee7-43a6-a556-15049e83d9e5,C0065264,C0003695,eliminating Free Radicals through NF-B,Luteolin,Arachidonic Acid,1,X,[orch/phsu],[orch],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,D10.251.355.255.100.100;D10.251.355.310.166.100
12393c72-d065-4d39-a13d-16d4ab47b77e,C0047611,C0003695,eliminating Free Radicals through NF-B,3-methylquercetin,Arachidonic Acid,1,X,[orch/phsu],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
2fb67f50-dda9-467b-88cc-445d3ce2409b,C0052927,C0003695,eliminating Free Radicals through NF-B,baicalein,Arachidonic Acid,1,X,[orch/phsu],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
9a6cabc9-9589-4139-a5f7-b654157bde8f,C0068450,C0003695,eliminating Free Radicals through NF-B,naringenin,Arachidonic Acid,1,X,[orch/phsu],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
32686289-80e1-4712-aa42-377c540c3eb2,C0251223,C0003695,eliminating Free Radicals through NF-B,wogonin,Arachidonic Acid,1,X,[orch],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
16454e11-cc04-49b4-ba52-5a9b11c40ffa,C0034392,C0215848,eliminating Free Radicals through NF-B,Quercetin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu/vita],[aapp/bacs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D12.776.260.103.625;D12.776.930.125.625
31f32319-8a11-4226-9f1a-746ab5dc472a,C0064280,C0215848,eliminating Free Radicals through NF-B,kaempferol,Hypoxia-Inducible Factor 1,1,X,[orch],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
ceb8a122-b84f-4ce6-a037-199560d91e4f,C0065264,C0215848,eliminating Free Radicals through NF-B,Luteolin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,D12.776.260.103.625;D12.776.930.125.625
ccf772ab-b161-4e54-9749-d5d6d325f0c7,C0047611,C0215848,eliminating Free Radicals through NF-B,3-methylquercetin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
531c455e-8ab7-4194-86c1-210d39ae3901,C0052927,C0215848,eliminating Free Radicals through NF-B,baicalein,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
117cf0b4-e56d-4b6b-ba8f-6d81369ee147,C0068450,C0215848,eliminating Free Radicals through NF-B,naringenin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
8a993868-8d1d-4c8e-80ca-2401a379c152,C0251223,C0215848,eliminating Free Radicals through NF-B,wogonin,Hypoxia-Inducible Factor 1,1,X,[orch],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
224b72ad-ef12-4625-b103-3135b4819fa3,C0034392,NF-B,eliminating Free Radicals through NF-B,Quercetin,NF-B,1,X,[orch/phsu/vita],????,D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,????
e12114d1-e0f3-4b20-989f-afcc911540a2,C0064280,NF-B,eliminating Free Radicals through NF-B,kaempferol,NF-B,1,X,[orch],????,x.x.x.x,????
8e893e60-7935-4253-987e-690cc25fb49a,C0065264,NF-B,eliminating Free Radicals through NF-B,Luteolin,NF-B,1,X,[orch/phsu],????,D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,????
4410d664-069f-41ff-a0f8-62e70688224f,C0047611,NF-B,eliminating Free Radicals through NF-B,3-methylquercetin,NF-B,1,X,[orch/phsu],????,x.x.x.x,????
c3660a1e-e2e3-46a8-85b8-0237a78261f7,C0052927,NF-B,eliminating Free Radicals through NF-B,baicalein,NF-B,1,X,[orch/phsu],????,x.x.x.x,????
3406881a-a14e-4c69-83cf-ef47a71583dd,C0068450,NF-B,eliminating Free Radicals through NF-B,naringenin,NF-B,1,X,[orch/phsu],????,x.x.x.x,????
bb83092c-90a4-44f8-969d-ace4d6fcc11a,C0251223,NF-B,eliminating Free Radicals through NF-B,wogonin,NF-B,1,X,[orch],????,x.x.x.x,????
488aaae4-ef10-422e-b3f5-4ded389ed1ad,C0034392,C0034678,eliminating Free Radicals through NF-B,Quercetin,ras Oncogene,1,X,[orch/phsu/vita],[gngm],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,G05.360.340.024.340.375.500.791.550
e106cfde-6f62-4f4f-9958-d35079ef4ae9,C0064280,C0034678,eliminating Free Radicals through NF-B,kaempferol,ras Oncogene,1,X,[orch],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
d974922d-2bca-4ebe-949b-73454c79a47b,C0065264,C0034678,eliminating Free Radicals through NF-B,Luteolin,ras Oncogene,1,X,[orch/phsu],[gngm],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,G05.360.340.024.340.375.500.791.550
071f23e1-d8f4-48b2-9e89-e9b114915cd4,C0047611,C0034678,eliminating Free Radicals through NF-B,3-methylquercetin,ras Oncogene,1,X,[orch/phsu],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
5bd048e6-f40e-47ab-ba8e-c69db8d66ef3,C0052927,C0034678,eliminating Free Radicals through NF-B,baicalein,ras Oncogene,1,X,[orch/phsu],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
ebccfa2d-5704-4685-9191-731d916f23a4,C0068450,C0034678,eliminating Free Radicals through NF-B,naringenin,ras Oncogene,1,X,[orch/phsu],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
5c92cc89-db2c-4d60-a9d9-f47ece7bb3ca,C0251223,C0034678,eliminating Free Radicals through NF-B,wogonin,ras Oncogene,1,X,[orch],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
9843ae96-4c97-4666-88f7-2cee98f47443,C0034392,C1448177,eliminating Free Radicals through NF-B,Quercetin,TNF protein human,1,X,[orch/phsu/vita],[aapp/bacs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,x.x.x.x
6fa14216-a162-4d8d-ba13-25b3673b8b8d,C0064280,C1448177,eliminating Free Radicals through NF-B,kaempferol,TNF protein human,1,X,[orch],[aapp/bacs],x.x.x.x,x.x.x.x
3eb16cba-1531-47f7-bbd0-d24f31d47b83,C0065264,C1448177,eliminating Free Radicals through NF-B,Luteolin,TNF protein human,1,X,[orch/phsu],[aapp/bacs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,x.x.x.x
0148b142-92ef-4ed6-8449-a44e4c72ad0a,C0047611,C1448177,eliminating Free Radicals through NF-B,3-methylquercetin,TNF protein human,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
9ca2fce9-fb27-47d3-a361-783745f1bbe1,C0052927,C1448177,eliminating Free Radicals through NF-B,baicalein,TNF protein human,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
3568e110-fef9-4d69-bb4f-54bbcd4e2155,C0068450,C1448177,eliminating Free Radicals through NF-B,naringenin,TNF protein human,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
1afc668a-248b-4dc0-a489-62f4725e7971,C0251223,C1448177,eliminating Free Radicals through NF-B,wogonin,TNF protein human,1,X,[orch],[aapp/bacs],x.x.x.x,x.x.x.x
0504aa34-c15f-44ff-a141-2ec81cb9ba19,C1527398,C0872315,is diagnosed with ,Emergency Care,Communicable Diseases Emerging,2,X,[topp],[dsyn],N02.421.297,C01.539.221.500
8aa19d26-a4e3-4844-ac10-572f485ff40f,C0185003,C0206419,have occurred due to ,Reparative closure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
1125be03-ac26-4bbc-872f-92963eeccb6e,C0185003,C0012634,have occurred due to ,Reparative closure,Disease,1,X,[topp],[dsyn],,C23.550.288
8f5de3c7-b2ae-42af-bf4e-4eac579f3ee2,C0185003,C2745965,are in However contravention of laws for provision of ,Reparative closure,Emergencies [Disease/Finding],1,X,[topp],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
7855b6b9-8953-4a27-a0f6-7494a0816a63,C0185003,C1947933,are in However contravention of laws for provision of ,Reparative closure,care activity,1,X,[topp],[acty],,
e5778bd5-44bf-494b-90a8-523ce8d690a5,C1947933,C1602245,enable to avail ,care activity,Prompt,1,X,[acty],[phsu],,
7843713d-f8a0-4c1e-8ec6-1b17f36e87e0,C0185003,C1856053,occurred to ,Reparative closure,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[topp],[dsyn],,x.x.x.x
90bc6166-25bd-4e2e-9f72-f0e92ec36e3e,C0185003,C1516048,present status of were ,Reparative closure,Assessed,1,X,[topp],[acty],,
c9cc02a9-3273-4caf-924e-59ee79f8a951,C0040861,COVID-19,were effective in ,Triage,COVID-19,1,X,[topp],[virs],N02.421.297.900,C000657245
808fc006-9580-46be-880a-0cd5f48e457a,C0040861,C0030693,were effective in ,Triage,Patient Isolation,2,X,[topp],[topp],N02.421.297.900,E02.770;N06.850.780.200.450.650
65095cf4-7d68-4568-a85f-372db18b089a,C1707455,C1628999,is with PCR ,Comparison,SARS coronavirus RNA,1,X,[acty],[nnon],,
34d9f6fe-7fb0-4f2b-bec0-85324f298759,C1707455,PCR,is with PCR ,Comparison,PCR,1,X,[acty],????,,????
2e46bd63-999d-4639-8b13-2a5b7c342125,C0036745,C1175743,be useful test for diagnosis of active ,Study of serum,SARS coronavirus,1,X,[bmod],[virs],H02.781,B04.820.504.540.150.113.937
9f197fa6-27c0-4a31-9a33-f29dde02627b,C0042776,C0003451,propose several possible targets for ,Virus,Antiviral Agents,1,X,[virs],[phsu],B04,D27.505.954.122.388
c4026002-deb7-402a-816f-06690eaaa570,C0017337,C0543467,could With advantage of CoV2 ,Genes,Operative Surgical Procedures,1,X,[gngm],[topp],G05.360.340.024.340,E04
fc7d11a8-2f2e-443d-bfe8-2b33d87cc3a5,C0748355,COVID-19,pathophysiology of ,Acute respiratory distress,COVID-19,1,X,[dsyn],[virs],,C000657245
b044050e-e0c3-4a5e-bd7e-1aebbfca4b47,C0009450,C3714514,evaluated patients with suspected ,Communicable Diseases,Infection,1,X,[dsyn],[patf],C01.539.221,C01.539
318d60eb-1e5a-4877-a6ab-9c9107d7641f,C1158478,COVID-19,have role In ,DNA Integration,COVID-19,1,X,[genf],[virs],,C000657245
5e2a13de-cff8-418d-9cc2-068d350e74d8,C1158478,C2745965,have role In ,DNA Integration,Emergencies [Disease/Finding],1,X,[genf],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
633450f4-9456-4525-a03b-f7972bc4cf11,C0174990,C1397014,hypothesized immune-hematological mechanism based on renin-angiotensin system ,coronavirus receptor,Imbalance,1,X,[aapp/rcpt],[sosy],x.x.x.x,
0426e91f-b42c-4cbc-9821-c198d6961e62,C0597357,C1397014,hypothesized immune-hematological mechanism based on renin-angiotensin system ,receptor,Imbalance,1,X,[aapp/rcpt],[sosy],,
8210ff53-33e2-4fd1-b337-099a4fd375e8,C0597357,C1413811,is with reduction of ,receptor,CTSC gene,1,X,[aapp/rcpt],[gngm],,
aa718f4f-3bbf-4787-9ed9-d6d16c68fb4f,RAS,C1413811,is with reduction of ,RAS,CTSC gene,1,X,????,[gngm],????,
cf481335-72db-4533-913a-c6593d821be1,C0004457,C1413811,is with reduction of ,Axis vertebra,CTSC gene,1,X,[bpoc],[gngm],A02.835.232.834.151.383,
97f3a9c4-9342-400b-9244-5d363272d168,C0301630,C0038941,is in perioperative ,Reduction (chemical),Surgical Wound Infection,1,X,[npop],[patf],,C01.539.947.692;C23.550.767.925
d0e9d1fb-5505-49de-8352-b883e500355c,C0301630,C4520447,are obtained by multifaceted approach ,Reduction (chemical),Decolonization,1,X,[npop],[topp],,
d0e9d1fb-5505-49de-8352-b883e500355c,C0301630,C4520447,are obtained by multifaceted patient ,Reduction (chemical),Decolonization,1,X,[npop],[topp],,
70b045c9-eb5b-4e08-9b40-60661a28f501,C3540027,C3714514,had expected incidence 0.20 ,Adrenergic and dopaminergic agents combinations,Infection,1,X,[phsu],[patf],,C01.539
629dc3b8-65a9-4fb2-8d01-aaffc00248db,C0009324,C1705178,is in ,Ulcerative Colitis,Order (action),2,X,[dsyn],[acty],C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249,
cff90b7b-2e27-4731-9ca3-7096693282ba,C0042776,C0422879,causes ,Virus,CNS symptom,2,X,[virs],[sosy],B04,
3dd9e87b-f5d8-40e5-b141-72ba58217e53,C0011206,C3714514,be should recognized as potential feature of ,Delirium,Infection,1,X,[mobd],[patf],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C01.539
ea92fc90-9f8a-4177-a157-80ba085ae8c2,C0011206,C1175743,be should recognized as potential feature of ,Delirium,SARS coronavirus,1,X,[mobd],[virs],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,B04.820.504.540.150.113.937
b39077fb-37fc-4d9b-8f6e-95ff232bf810,C0011206,C1457887,may may presenting ,Delirium,Symptoms,1,X,[mobd],[sosy],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,
f859cc46-75d4-4ded-b701-4c50f16464dc,C0011206,C0085584,represents ,Delirium,Encephalopathies,1,X,[mobd],[dsyn],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C10.228.140
96b5041d-ffaf-4b9b-a216-56a8baaa646c,C0206750,C0002736,has created unprecedented challenges for ,Coronavirus Infections,Amyotrophic Lateral Sclerosis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050
8aeaa26b-45d1-42bd-8d92-62b5533c99fa,C0012634,C0002736,has created unprecedented challenges for ,Disease,Amyotrophic Lateral Sclerosis,1,X,[dsyn],[dsyn],C23.550.288,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050
d1589712-1e9f-4877-9345-aa3d14417ed2,C0012634,C1947933,has created unprecedented challenges for ,Disease,care activity,1,X,[dsyn],[acty],C23.550.288,
8639f5b7-e8bc-412b-baf1-828a1a897a71,C0042776,C1511790,was also ,Virus,Detection,1,X,[virs],[topp],B04,
1e0e9470-e918-4000-b497-6dcc913aef21,C1707455,C0021189,may reduce spread in assisted ,Comparison,Independent Living,1,X,[acty],[dora],,I03.050.500;N01.224.791.550;N06.850.505.400.800.550
ee30ab14-5061-4348-9d83-06d7e0fc3077,C1096155,3-D,Fortunately distributed manufacturing with recent development of manufacturing technologies like 3-D ,Macrophage Activation Syndrome,3-D,1,X,[dsyn],????,C20.683.515.800,????
4ceea71d-85e8-4356-8243-8d029c267c2e,C1825598,C0849867,be felt by ,IMPACT gene,Widespread Disease,1,X,[gngm],[dsyn],,
24d0e526-9cfb-4680-9fa9-d2f93614913b,C1520005,C0221423,ultimately named with clinical ,Viral Pathogenesis,Illness (finding),2,X,[patf],[sosy],,
2b7672c8-106b-4ddd-b762-20fa91c9e14a,C0017181,C1145670,Nevertheless poses challenges to patients due to high-risk of concomitant ,Gastrointestinal Hemorrhage,Respiratory Failure,1,X,[patf],[dsyn],C06.405.227;C23.550.414.788,C08.618.846
8e04c827-8457-44ba-a03e-a0692a1080e0,C0017181,C0206750,is in ,Gastrointestinal Hemorrhage,Coronavirus Infections,1,X,[patf],[dsyn],C06.405.227;C23.550.414.788,C02.782.600.550.200
e1d2f8e0-910a-4e4f-834d-6c2c0531b40b,C0035668,C3687742,is in ,RNA,Oropharyngeal swab,1,X,[nnon],[bdsu],D13.444.735,
a0f51127-9b86-4eea-aa9d-abdfe52f373c,C0597404,C0206750, includes ,Respiratory viruses,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
877b0f91-8695-4eb6-a8ec-9d86742b18f5,C1441506,C0034700,introduced novel Au-decorated ,Calculation,Rats Inbred BN,1,X,[acty],[mamm],,B01.050.050.199.520.760.110;B01.050.150.900.649.313.992.635.505.700.400.110
80428e01-5289-4e5d-88db-3c5184c16375,C0005775,C0302908,is with ,Blood Circulation,Liquid substance,1,X,[phsf],[sbst],G09.330.100,
2891bbf9-8d90-47e2-9b6e-3b739c7d7d6d,C0012634,C0028429,Cyanosis of,Disease,Nose,2,X,[dsyn],[bpoc],C23.550.288,A01.456.505.733;A04.531;A09.531
d09f0c88-383f-42f0-979f-7810d7fcd33d,C0012634,C0016129,Cyanosis of,Disease,Fingers,2,X,[dsyn],[bpoc],C23.550.288,A01.378.800.667.430
9ce4da1a-d87e-4b5f-82c5-b642b920a729,C0010520,C0017086,became dried ,Cyanosis,Gangrene,2,X,[sosy],[dsyn],C23.888.248,C23.550.717.427
9993018c-4bcf-499a-89ab-de349746d6a6,C0206750,C0036983,could In cases could complicated by ,Coronavirus Infections,Septic Shock,2,X,[dsyn],[patf],C02.782.600.550.200,C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712
beb865e8-5b24-43f9-b640-7d4e9109640a,C0206750,C0026766,could In cases could complicated by ,Coronavirus Infections,Multiple Organ Failure,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835.525
ead3abdc-3db0-46b9-bcff-17c72be78e8a,C2745965,C1707455,is in ,Emergencies [Disease/Finding],Comparison,1,X,[patf],[acty],C23.550.291.781;N06.230.100.083;N06.850.376,
e6562659-dfbf-4223-a594-dbd9d183fd16,C2745965,C0018563,is in ,Emergencies [Disease/Finding],Hand,1,X,[patf],[bpoc],C23.550.291.781;N06.230.100.083;N06.850.376,A01.378.800.667
fabb7ee5-500b-4a6a-9a1c-cbec90bb44ef,C0021760,C0079189,plays role in ,Interleukin-6,cytokine,3,X,[aapp/imft],[aapp/imft],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D12.644.276.374;D12.776.467.374;D23.529.374
ec8634db-978c-4ee9-abe2-a7f34281bae6,C1609165,C0087111,has has proposed to ,tocilizumab,Therapeutic procedure,1,X,[aapp/imft/phsu],[topp],x.x.x.x,E02
6949adcd-a1d9-4dec-be73-c7574588386e,C0023884,TCZ,caused by TCZ,Liver,TCZ,1,X,[bpoc],????,A03.620,????
77434a52-3023-45e9-8edf-9ef8b9eb5be8,C0860207,TCZ,associated with use of TCZ,Drug-Induced Liver Disease,TCZ,1,X,[dsyn],????,C06.552.100;C25.100.562;C25.723.260,????
ffe2c76c-382c-4a2b-9866-ad8af59b81d5,TCZ,C0002594,had effect ,TCZ,Transaminases,2,X,????,[aapp/enzy],????,D08.811.913.477.700
0a1911ec-57cf-4ae1-a04c-ad9bb72e7242,TCZ,C0079189,Nevertheless had effect on clinical parameters in ,TCZ,cytokine,1,X,????,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374
d83ccb68-eaf5-4b48-b098-bbd925bbc169,C0232741,C2922974,is imperative because of frequent ,Liver function,Polypharmacy,1,X,[ortf],[topp],,E02.319.698
99c28140-d56f-4ad7-8e12-41e8cfc9a064,C4547399,C0275522,with 3.15 is ,CI-2,Asymptomatic Infections,1,X,[aapp/phsu],[dsyn],,C23.550.291.187.500
af00da42-43c0-42d4-ab9d-fb71534eefcb,C1963724,C0206750,on female is causative agent for ,Antiretroviral therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
2fec634a-bf80-4041-b446-1eb00cbf1965,C1963724,C0012634,on female is causative agent for ,Antiretroviral therapy,Disease,1,X,[topp],[dsyn],,C23.550.288
27066889-1f88-43a9-9198-aed6f37a0871,C0319157,C0086022,acting as inanimate ,AS virus,Cloning Vectors,1,X,[virs],[nnon],,G05.360.337
56f84d2c-9c8c-47c2-9504-9bd80dadcc26,C0319157,C1533724,acting as ,AS virus,Fomes,1,X,[virs],[fngs],,B01.300.179.120.174
ab45b6c6-9925-4732-b2b4-eb115a389b0e,C0042760,C0036087,are present in ,Virion,saliva,2,X,[celc],[bdsu],A21.249;B04.950,A12.200.666
8aada390-b9cf-47b9-9351-77b12e647ee7,C3826466,C0206750,may how may impacted by ,Dentistry--Practice,Coronavirus Infections,1,X,[bmod],[dsyn],,C02.782.600.550.200
2c6b8792-b4aa-45e6-bc1d-cd0e20b6294b,C0042769,C3272275,has stimulated ,Virus Diseases,Urgent Procedure,1,X,[dsyn],[topp],C02,
b1505c2c-24da-40b8-92da-2eb37da142d8,C0042769,C0015392,has stimulated ,Virus Diseases,Eye,1,X,[dsyn],[bpoc],C02,A01.456.505.420;A09.371
8cac3ad9-27d6-4360-bcae-068cad5ad46f,C0042210,C0057256,is adjuvanted with -3 ,Vaccines,Defensins,1,X,[aapp/imft/phsu],[aapp/imft/phsu],D20.215.894,D12.644.050.200;D12.776.543.695.054.200
e2fcc246-8e83-4d93-9149-2aa8b8e5f026,C0042210,C0301872,elicit strong ,Vaccines,Immune response,1,X,[aapp/imft/phsu],[ortf],D20.215.894,
77182f0f-3e18-4b10-9d9a-3efe13c6aff5,C1457887,C0042776,probably linked to ,Symptoms,Virus,1,X,[sosy],[virs],,B04
b35065cb-aa41-45fa-bd9e-a0ef889212c9,C1257753,C0006625,been focus on rising rates of childhood ,Child Malnutrition,Cachexia,1,X,[dsyn],[sosy],C18.654.180,C23.888.144.243.963.500.500
03b33a70-b4f6-4414-8196-64f87b879f6c,C1456573,C0162429,is in ,Global Health,Malnutrition,1,X,[bmod],[dsyn],H02.403.371;N01.400.337,C18.654.521
f73527e7-26c0-4dc2-96bc-e44e6b622da6,C0879626,C0206750,Acute disease of cardiovascular system effects of,Adverse effects,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
5177bdda-f31b-4be9-ac27-0510211e962e,C0007222,C1175175,evidence for direct myocardial injury in ,Cardiovascular Diseases,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200.750;C08.730.730
10faccf7-3c52-44fb-ac15-b61d2baca07d,C0567416,C0036658,have In ,Molecule,Esthesia,1,X,[sbst],[ortf],,F02.830.816;G11.561.790
ed0aa608-0451-4064-9c79-44b577fb7005,C0032100,C0003451,exhibit significant inhibitory ,Plants Medicinal,Antiviral Agents,1,X,[plnt],[phsu],B01.650.560,D27.505.954.122.388
9e76fcd4-c914-465b-8380-693ff560b643,C0032100,C1175743,exhibit significant inhibitory ,Plants Medicinal,SARS coronavirus,1,X,[plnt],[virs],B01.650.560,B04.820.504.540.150.113.937
733fac09-9283-4364-b33f-b615cf6f49e2,C0032081,C1705178,are In review discussed in ,Plant Extracts,Order (action),1,X,[bacs/phsu],[acty],D20.215.784.500;D26.667,
32a72de6-1568-4dc7-8c65-ebe824b9365a,C0036572,C0009450,determinants for number of ,Seizures,Communicable Diseases,1,X,[sosy],[dsyn],C10.597.742;C23.888.592.742,C01.539.221
50916ed6-4814-46ff-958a-ab33c3cc2ca1,C0206750,C0005717,is in ,Coronavirus Infections,Gilchrist Disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.800.200.055;C01.703.295.055;C01.703.534.395;C08.381.472.350;C08.730.435.395;C17.800.838.208.055
42aa56fd-9dc9-4681-b042-9990bfe4e65e,C0028606,4days,was 4days,Nucleic Acids,4days,1,X,[bacs/nnon],????,D13.444,????
9c1692c4-4b6f-484c-81ee-3bd7b617cde6,C0042769,C1457887,may reveal light ,Virus Diseases,Symptoms,2,X,[dsyn],[sosy],C02,
96b4b8c4-82a6-47a9-8f58-3e3e8a93d5b9,C0206750,C0282632,could promote ,Coronavirus Infections,Antibody-Dependent Enhancement,1,X,[dsyn],[comd],C02.782.600.550.200,G06.920.095;G12.113
140311ac-29cc-4485-89d5-bab72f7be3ee,C1175175,C0003241,experimentally shown for ,Severe Acute Respiratory Syndrome,Antibodies,2,X,[dsyn],[aapp/imft/phsu],C02.782.600.550.200.750;C08.730.730,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
29c94fb6-5b6c-4691-8f34-66a70626338b,C1175175,C3694279,experimentally shown for ,Severe Acute Respiratory Syndrome,Middle East Respiratory Syndrome,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C02.782.600.550.200
7b662880-83fe-44db-b94b-1a15a1b57511,C0206750,C0003241,could promote Antibody-Dependent Enhancement experimentally shown for,Coronavirus Infections,Antibodies,1,X,[dsyn],[aapp/imft/phsu],C02.782.600.550.200,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
e414db85-213a-4e98-83b1-258f5de179a8,C0206750,C3694279,could promote Antibody-Dependent Enhancement experimentally shown for,Coronavirus Infections,Middle East Respiratory Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.600.550.200
ef2793ec-f8e7-47fa-984e-7d256c4f2c07,C1175175,C0282632,could promote ,Severe Acute Respiratory Syndrome,Antibody-Dependent Enhancement,1,X,[dsyn],[comd],C02.782.600.550.200.750;C08.730.730,G06.920.095;G12.113
7c663414-1564-4da0-8151-018d5b9c131f,C0206750,C0521839,can manifest with ,Coronavirus Infections,Influenza-like illness,1,X,[dsyn],[dsyn],C02.782.600.550.200,
f8248e28-662b-4aa1-81e2-381a53fd1102,C1705178,C0015219,postpone opening in response to ,Order (action),Biological Evolution,1,X,[acty],[genf],,G05.045;G16.075
389e3673-be85-4976-8b31-d348444c6a48,C1705178,C0206750,postpone opening in response to ,Order (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
14f1e6a7-9f3f-4b80-9ac6-fd1efd56e638,C0011139,C0086418,is difficult ,Defective Viruses,Homo sapiens,1,X,[virs],[humn],B04.265,B01.050.150.900.649.313.988.400.112.400.400
18b6c8d1-3c6a-4d05-8c29-52fcc2e783c1,C0011139,C0042776,is difficult ,Defective Viruses,Virus,1,X,[virs],[virs],B04.265,B04
90d0bf25-7a9e-4312-9973-2f48e80526f6,C0086418,C0042776,fight against ,Homo sapiens,Virus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04
f25cfb90-01ff-4bcd-908e-45abc78103b6,C0009443,C0042776,minimize exposure of cells to ,Common Cold,Virus,1,X,[dsyn],[virs],C02.782.687.207;C08.730.162,B04
6904aa4b-8090-4f99-9669-a7138c7322ff,C0333514,C0006104,is in ,Zonal necrosis,Brain,1,X,[patf],[bpoc],,A08.186.211
bed4161e-df28-4223-a985-3918f0f3b6ab,C0264490,C1175743,could due to could effects of ,Acute respiratory failure,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
bf18ed15-a83f-4d7f-aa5a-ccb144d7b146,C0264490,C0035216,could due to could effects of ,Acute respiratory failure,Respiratory Center,2,X,[dsyn],[bpoc],,A08.186.211.132.772.646
70478789-c288-4ac6-9821-367faab013f7,C0264490,C0006121,could due to could effects of ,Acute respiratory failure,Brain Stem,1,X,[dsyn],[bpoc],,A08.186.211.132
80f85033-8d6a-4f56-a7e4-00db53770ca8,C0035216,C0006121,is in ,Respiratory Center,Brain Stem,2,X,[bpoc],[bpoc],A08.186.211.132.772.646,A08.186.211.132
c1aa7ff9-e513-4610-ae13-fb48a380892f,C0035204,C0598197,caused by highly ,Respiration Disorders,contagion,1,X,[dsyn],[npop],C08.618,
76461757-c890-42c1-8a56-8e1c7f1e0627,C0024264,CD4, includes CD4,Lymphocyte,CD4,1,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
ae4ba2fc-61c9-48f4-a10f-8216bd05d0ac,C0085295,C0206750,were remarkably up-regulated in patients with severe ,Interleukin-10,Coronavirus Infections,3,X,[aapp/imft],[dsyn],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,C02.782.600.550.200
e3950bd4-bb67-4815-9c56-9c3d9fc3930f,C1704259,C0003451,involved in such ,Biochemical Pathway,Antiviral Agents,1,X,[moft],[phsu],,D27.505.954.122.388
270f4598-2644-40c9-9b77-77c60a94cb49,C2948600,C0032285,discuss emergent repair in patients affected by ,Aim,Pneumonia,1,X,[inch/phsu],[dsyn],,C08.381.677;C08.730.610
270f4598-2644-40c9-9b77-77c60a94cb49,C2948600,C0032285,investigate ,Aim,Pneumonia,1,X,[inch/phsu],[dsyn],,C08.381.677;C08.730.610
2a0892bd-e4ff-4bf4-b6ad-e5ad407ffde3,C0086418,C0741160,was admitted for ,Homo sapiens,Aortic Aneurysm Ruptured,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C14.907.055.185.125;C14.907.055.239.175;C14.907.109.139.175;C26.761.125
10958cb2-b304-42fb-90ca-a682e5d6fbbc,C0034065,C0206750,may play role in severe ,Pulmonary Embolism,Coronavirus Infections,1,X,[patf],[dsyn],C08.381.746;C14.907.355.350.700,C02.782.600.550.200
3fbacbb8-8204-4e0b-b192-14f8f5dc2322,C0772257,C0325969,is common in legal ,fruit extracts,Amazona,1,X,[orch/phsu],[bird],,B01.050.150.900.248.710.672.050
1ae12628-9cc3-4cd4-9cc9-8f34e5a175b4,C0872152,C3266814,is with ,Drug Development,Action,1,X,[bmod],[acty],E05.290;H01.158.703.007.338;H01.181.466.338,
52fa5aa2-6972-48ea-bf23-74b397979c62,on-site,C1706005,rapid diagnosis of ,on-site,CD40LG wt Allele,1,X,????,[gngm],????,
2f48724e-0444-45b4-8534-e9350e8eb7eb,on-site,C1175743,rapid diagnosis of ,on-site,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
c8598776-4bb7-4639-96a8-0a881d8f9648,on-site,C0206419,rapid diagnosis of ,on-site,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
26dc142c-07b2-4b48-ab4b-bb10a47d4226,C0009359,C1706005,achieve rapid diagnosis of ,Gold Colloid,CD40LG wt Allele,1,X,[inch/phsu],[gngm],D01.379.400,
1661a9b4-57fc-4f2a-96db-a96bce708fc7,C0806140,C1706005,achieve rapid diagnosis of ,Flow,CD40LG wt Allele,1,X,[npop],[gngm],,
e6994061-bb38-4e9b-b432-d56841b1129f,C0009359,C1175743,achieve rapid diagnosis of ,Gold Colloid,SARS coronavirus,1,X,[inch/phsu],[virs],D01.379.400,B04.820.504.540.150.113.937
a7c56203-0799-4d84-906b-e7953467267c,C0806140,C1175743,achieve rapid diagnosis of ,Flow,SARS coronavirus,1,X,[npop],[virs],,B04.820.504.540.150.113.937
9a12d807-4538-4e22-9734-525b99f5adde,C0009359,C0206419,achieve rapid diagnosis of ,Gold Colloid,Genus: Coronavirus,1,X,[inch/phsu],[virs],D01.379.400,B04.820.504.540.150
d8aec480-6f09-4015-9790-60734f185a22,C0806140,C0206419,achieve rapid diagnosis of ,Flow,Genus: Coronavirus,1,X,[npop],[virs],,B04.820.504.540.150
1a081fa1-6948-4dbf-9a4f-c7b5da7c3b26,C2698650,C1706005,altering amount of ,Optimization,CD40LG wt Allele,1,X,[acty],[gngm],,
eb73799a-c916-4e16-8639-9a248a6dfad7,C1707391,C1511790,is in ,Choose (action),Detection,1,X,[acty],[topp],,
0014eb87-dd92-48b9-a0bf-79f700210169,C1707391,C1706005,is in ,Choose (action),CD40LG wt Allele,1,X,[acty],[gngm],,
3220cfec-99d7-4891-91df-960b23a4bb65,C0042730,C4284413,is with ,Viral Interference,Severe Fever with Thrombocytopenia Syndrome,1,X,[npop],[dsyn],G06.920.800,
8658261f-3b8d-479f-a06a-240423f55a92,C3241922,C0023693,is in ,Operation Activity,Light,2,X,[acty],[npop],,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
a4ebd907-d5b5-401c-a466-3ce2a052159d,C1175743,C1547282,has ,SARS coronavirus,Show,1,X,[virs],[anim],B04.820.504.540.150.113.937,
583e3fc1-af5e-4236-bd5a-154b1511eb7b,C0009450,C1547282,has ,Communicable Diseases,Show,1,X,[dsyn],[anim],C01.539.221,
41fa2529-b762-4f6e-b864-ee9023833ae1,C1547282,C0878544,is with acute myocardial injury ,Show,Cardiomyopathies,1,X,[anim],[dsyn],,C14.280.238
9d8c92e6-7461-49d7-a0b9-6385a0ae2349,C1547282,C0027059,is with acute myocardial injury ,Show,Myocarditis,1,X,[anim],[dsyn],,C14.280.238.625
d343fda4-96c4-4d05-a5af-ee850ebdf80c,C0242781,C0034991,is in ,disease transmission,Rehabilitation therapy,1,X,[patf],[topp],N06.850.310,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
52ea4572-98dc-4f27-8644-c3d35e6f8457,C0237820,C1175743,assessed risk of ,Recovery - action,SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
ac7b910c-448c-4d54-ae33-ff9684121801,C0206419,C0011535,were reported in our ,Genus: Coronavirus,Deoxyuridine,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D03.383.742.680.852.300;D13.570.230.430;D13.570.685.852.300
b2fa77cc-6a62-4d46-9ed2-7c1a963d35b7,C0184661,C1175743,spread of ,Interventional procedure,SARS coronavirus,2,X,[topp],[virs],,B04.820.504.540.150.113.937
081c6f79-49f7-438e-8f16-b54e4c90ec88,C0184661,C0206419,spread of ,Interventional procedure,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
a7e44b63-92d5-4b1d-a280-28afe6c06848,C0206419,C0948245,is associated with development with worst outcome resulting in ,Genus: Coronavirus,Cytokine Release Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,
29d3b158-879a-49ae-a4a0-be3f0e9b3ab8,COV,C2745965,was declared pandemic health ,COV,Emergencies [Disease/Finding],1,X,????,[patf],????,C23.550.291.781;N06.230.100.083;N06.850.376
8ad61deb-a72e-43bf-865e-43db92f643b0,COV,C0206419,causing ,COV,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
00d4e356-c2cc-4ce1-8661-f33bbe5e31f7,C1175743,C0301872,inducing disrupted ,SARS coronavirus,Immune response,1,X,[virs],[ortf],B04.820.504.540.150.113.937,
00d4e356-c2cc-4ce1-8661-f33bbe5e31f7,C1175743,C0301872,can stimulate pronounced ,SARS coronavirus,Immune response,2,X,[virs],[ortf],B04.820.504.540.150.113.937,
144cbd9e-d476-4e2c-9d2a-9ed7ef245091,C1175743,C0024312,inducing ,SARS coronavirus,Lymphopenia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C15.378.553.546.605;C20.673.627
686ba45b-49eb-43b7-a57a-c98fd8da4125,C0028754,C0021376,is associated with ,Obesity,Chronic inflammation,2,X,[dsyn],[patf],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
886cd468-9ed1-40fd-ae30-1fdf4f00fa5a,C0599949,C0009450,could favor ,Arterial Stiffness,Communicable Diseases,1,X,[phsf],[dsyn],G09.330.940,C01.539.221
831bba1b-afc7-4ef3-bf1e-8fde6fbe7cec,C0856169,C0009450,could favor ,endothelial dysfunction,Communicable Diseases,1,X,[dsyn],[dsyn],,C01.539.221
27ed0ac5-22f2-4e2c-8037-dcd08c7f3fc2,C0856169,C1175743,could favor Communicable Diseases by,endothelial dysfunction,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
9492388c-e587-4239-a5c1-64b3dd19c7fc,C0599949,C1175743,could favor Communicable Diseases by,Arterial Stiffness,SARS coronavirus,1,X,[phsf],[virs],G09.330.940,B04.820.504.540.150.113.937
526b6667-f330-44a6-96a2-e1fb3da4ab93,C0450442,C1707391,could could administrated in ,Agent,Choose (action),1,X,[chvf],[acty],,
851baffd-ced2-4375-988b-adfdf682db78,C0450442,C0206419,could could administrated in ,Agent,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
c9ce5218-5190-465e-a3bb-bab0196b6bfa,C1707391,C0206419,is with ,Choose (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
ef89f7d5-2902-4deb-be83-e2da5f87cc2f,C0003467,C0206419,caused by ,Anxiety,Genus: Coronavirus,2,X,[mobd],[virs],F01.470.132,B04.820.504.540.150
85b3d5f3-f044-4727-beb2-0eba90efc453,C2699153,C0006121,alter ,Cell Invasion,Brain Stem,1,X,[patf],[bpoc],,A08.186.211.132
3f95bfaf-fcef-450a-afe1-eb6ff7503360,C1175743,C0034386,is in rooms of ,SARS coronavirus,Quarantine,1,X,[virs],[topp],B04.820.504.540.150.113.937,N06.850.780.200.450.700
74a25664-abab-4bde-a5f3-c5193e1087c1,C0042776,C0598197,is highly ,Virus,contagion,2,X,[virs],[npop],B04,
fc5fd343-eaa8-41cf-bf2e-7d4482c9fd1f,C0199176,C0242781,reducing ,Prophylactic treatment,disease transmission,1,X,[topp],[patf],,N06.850.310
a3389a30-4fb5-4a81-801f-a4e98c015a0a,C0030975,C0001546,perspective as ,Perceptual Disorders,Adjustment Disorders,1,X,[mobd],[mobd],C10.597.606.762;C23.888.592.604.764;F01.700.750,F03.950.500
49991bdf-1789-43f4-8a87-38bbc97d904f,C0030975,C0206750,perspective as ,Perceptual Disorders,Coronavirus Infections,1,X,[mobd],[dsyn],C10.597.606.762;C23.888.592.604.764;F01.700.750,C02.782.600.550.200
134b2f8b-6b4d-443f-be0d-3c0025a5a2d7,C1514593,C1707455,is in ,Psychological Impact,Comparison,1,X,[clna],[acty],,
66f3af99-c602-45b8-889b-66bb04863ef0,C1514593,C3698360,is in ,Psychological Impact,Middle East Respiratory Syndrome Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150.113.750
cf1fd22c-7d89-41b2-b8ed-2b3fc992f80c,C2948600,C2922974,reduce ,Aim,Polypharmacy,1,X,[inch/phsu],[topp],,E02.319.698
a3968900-cea7-4fda-b234-453f28ff54ec,C0003615,C2745965,is most common abdominal surgical ,Appendicitis,Emergencies [Disease/Finding],2,X,[dsyn],[patf],C01.539.463.099;C06.405.205.099;C06.405.469.110.207,C23.550.291.781;N06.230.100.083;N06.850.376
6bff1d6f-f8df-4aaf-9e68-1711f96092a8,C0012644,C0012634,evaluating ,Animal Disease Models,Disease,2,X,[emod],[dsyn],C22.232;E05.598.500;E05.599.395.080,C23.550.288
b32dbbda-20c5-4df0-8377-cf0388d1f12b,C0087111,C0242781,can suppress ,Therapeutic procedure,disease transmission,1,X,[topp],[patf],E02,N06.850.310
89d0dd88-4302-4ed9-9a7c-febd79a04e90,C0087111,C0012634,ameliorate ,Therapeutic procedure,Disease,1,X,[topp],[dsyn],E02,C23.550.288
ab9a1724-230e-4812-a9da-31c60e3f879b,C0016452,C2741673,taking equity principles into ,Food,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[food],[clna],G07.203.300;J02.500,
a08f1577-a798-43a0-91f0-9d09b2129bd6,C0428719,C0038638,using hospital wall ,Airway pressure,Suction drainage,1,X,[clna],[topp],,E04.237.890
315fd4b9-c1d1-41ba-9fb5-dcafb770ce45,C0030693,C0038638,using hospital wall ,Patient Isolation,Suction drainage,1,X,[topp],[topp],E02.770;N06.850.780.200.450.650,E04.237.890
30bb351e-6415-4954-82d4-f47fc5eeb91c,C0035691,C0028630,containing ,RNA Viruses,Nucleotides,2,X,[virs],[nnon],B04.820,D09.408.620;D13.695
20a4763c-b8d1-4abd-bd4a-5cd8f4ecc892,C0028630,C0002520,encoding ,Nucleotides,Amino Acids,2,X,[nnon],[aapp/bacs/phsu],D09.408.620;D13.695,D12.125
f6fbe106-4956-4257-a184-12a9eb2a20b3,C0017428,C1427622,is arranged as ,Genome,AHI1 gene,2,X,[gngm],[gngm],G05.360.340,
e5d7ba1b-59db-4e81-988e-51064094cc88,C0017428,5p,is arranged as 5p ,Genome,5p,2,X,[gngm],????,G05.360.340,????
adc9973a-bffd-44ff-8d4f-7ff6cd3504fa,C0017428,C0178827,is arranged as 5p ,Genome,replicase,2,X,[gngm],[aapp/enzy],G05.360.340,
2fbbc446-5787-40bf-b76d-18b0ea78e0a5,C0042776,C0314732,are obligate intracellular ,Virus,Infectious agent,2,X,[virs],[orgm],B04,
04077b5e-ad01-4761-965c-0aa97acf4d26,C0042776,C1456706,ensure their ,Virus,Fitness,2,X,[virs],[dora],B04,
9ce219d9-6789-4368-851b-ad961da6a712,C0042776,C0038952,ensure ,Virus,Continuance of life,2,X,[virs],[acty],B04,I03.784
70db481e-4c3f-43f4-8ad5-3743d1b052fc,C1101610,C0017262,are potent ,MicroRNAs,Gene Expression,2,X,[bacs/nnon],[genf],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.297
3b46696a-45bb-432a-a1ed-d0309738854c,C0017262,C0042769,are modulators of ,Gene Expression,Virus Diseases,2,X,[genf],[dsyn],G05.297,C02
3b46696a-45bb-432a-a1ed-d0309738854c,C0017262,C0042769,could play role in treatment of ,Gene Expression,Virus Diseases,2,X,[genf],[dsyn],G05.297,C02
e5be88fd-f3a8-4d75-b400-3a3b399f6bec,C1171366,C1101610,effects of ,Structural Genomics,MicroRNAs,2,X,[bmod],[bacs/nnon],,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
f85c13bf-7415-44f8-976a-15ef39a6c265,C1171366,C0042774,effects on ,Structural Genomics,Virus Replication,2,X,[bmod],[celf],,G06.920.925
4240fed9-0e52-470c-85e8-baf766c0f783,C0206419,C0042774,of Structural Genomics is effects on,Genus: Coronavirus,Virus Replication,2,X,[virs],[celf],B04.820.504.540.150,G06.920.925
3c7ecdb0-9ca5-4291-8a22-36f6e2711627,C0547605,C0886052,providing practical algorithm for ,prevention of infection,wound care,2,X,[topp],[topp],,
d1992737-2f3f-40fc-8884-5a3dbdb53e2e,C0021966,C1880177,deepen ,Iodides,Contribution,1,X,[inch],[acty],D01.248.497.158.490;D01.475.410,
7f41363d-b3e8-4305-9f8d-e18f63eaa127,et,C0026837,criticize lack of ,et,Muscle Rigidity,1,X,????,[sosy],????,C05.651.504;C10.597.613.550.500;C23.888.592.608.550.500
ee172477-9025-48fe-83c9-ac74e0ecc6ea,al,C0026837,criticize lack of ,al,Muscle Rigidity,1,X,????,[sosy],????,C05.651.504;C10.597.613.550.500;C23.888.592.608.550.500
d8427719-9b5a-4a88-9e34-b775b64bab54,et,C0752252,criticize lack in reports on ,et,Neuromuscular Manifestations,1,X,????,[sosy],????,C10.597.613;C23.888.592.608
7524c9be-da3d-491e-a02c-b5ccd7ad6c00,al,C0752252,criticize lack in reports on ,al,Neuromuscular Manifestations,1,X,????,[sosy],????,C10.597.613;C23.888.592.608
6edb23c8-7b7f-45a0-957e-727bedf9a51a,C3853628,C0206750,treating ,Granule,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
6edb23c8-7b7f-45a0-957e-727bedf9a51a,C3853628,C0206750,is effective treatment for ,Granule,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
6edb23c8-7b7f-45a0-957e-727bedf9a51a,C3853628,C0206750,can effectively shorten Duration In patients with,Granule,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
fe658016-1621-4b78-bc3c-5762ac908b55,C0042776,C0042736,produce ,Virus,Viral Proteins,1,X,[virs],[aapp/bacs],B04,D12.776.964
f0d62f78-a683-463f-b006-424da9a1ba8d,C0030012,C0012634,is maintained In physiological ,Oxidation-Reduction,Disease,2,X,[moft],[dsyn],G02.700;G03.295.531,C23.550.288
0335ce6d-78cf-4afb-b694-f03904ceb854,C0030012,C0014442,is In physiological ,Oxidation-Reduction,Enzymes,1,X,[moft],[aapp/enzy],G02.700;G03.295.531,D08.811
0335ce6d-78cf-4afb-b694-f03904ceb854,C0030012,C0014442,is maintained by ,Oxidation-Reduction,Enzymes,1,X,[moft],[aapp/enzy],G02.700;G03.295.531,D08.811
65725c6e-ada3-4b63-a7b4-7158d1094811,C0042776,C0242606,induce ,Virus,Oxidative Stress,1,X,[virs],[comd],B04,G03.673;G07.775.750
7bf259ca-03bd-4977-9d80-76734dc1c307,C0242606,C0343537,facilitates specific steps of ,Oxidative Stress,Specific viral infections,1,X,[comd],[dsyn],G03.673;G07.775.750,
7fdc8f99-ecf5-422c-8a16-c351f9809178,C0242606,C1155266,activates ,Oxidative Stress,inflammatory response,1,X,[comd],[patf],G03.673;G07.775.750,
ba056b85-93bf-4bcb-957e-9fe451ae3ed7,C0206750,C2963164,has spread like ,Coronavirus Infections,Wildfires,1,X,[dsyn],[npop],C02.782.600.550.200,G01.311.988;N06.230.100.230.925;N06.230.216.875
cb4d00a2-0ff3-4ab7-904e-ddd90cbba335,C0012634,C2963164,has spread like ,Disease,Wildfires,1,X,[dsyn],[npop],C23.550.288,G01.311.988;N06.230.100.230.925;N06.230.216.875
283a6e44-304e-4a34-8f65-d9264d11d388,C0021755,C1175743,have have associated with ,Interleukin-1,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.010;D12.644.276.374.500.400;D12.776.467.374.465.010;D12.776.467.374.500.400;D23.529.374.465.131;D23.529.374.500.400,B04.820.504.540.150.113.937
7c7c43c5-fef3-4434-af25-5df3e26a9e62,C0079189,humoral,are responsible for poor humoral ,cytokine,humoral,1,X,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374,????
c107a582-e152-4093-a574-69a1e21399fd,vitro,C0242606,have demonstrated Acetylcysteine under especially when,vitro,Oxidative Stress,1,X,????,[comd],????,G03.673;G07.775.750
e5169c43-32b5-4d7a-a363-820525de96a3,vitro,C0001047,have demonstrated ,vitro,Acetylcysteine,1,X,????,[aapp/phsu],????,D02.886.030.230.259;D12.125.166.230.259
eff645bb-1e5d-4aad-ac45-47516d2ad3ac,C0001047,C0017817,replenish ,Acetylcysteine,Glutathione,1,X,[aapp/phsu],[aapp/bacs],D02.886.030.230.259;D12.125.166.230.259,D12.644.456.448
bbfbef65-afae-4320-80a0-252c86c9eee0,C0001047,C0086418,is in ,Acetylcysteine,Homo sapiens,2,X,[aapp/phsu],[humn],D02.886.030.230.259;D12.125.166.230.259,B01.050.150.900.649.313.988.400.112.400.400
c9cba454-e91e-459c-9a7f-92c84a7168cb,C0001047,C1155046,increase ,Acetylcysteine,T-Cell Proliferation,2,X,[aapp/phsu],[celf],D02.886.030.230.259;D12.125.166.230.259,
d0af0182-88dd-44be-8fc0-f6e8f9f38ebf,C0001047,C1424250,Cardiac Arrest,Acetylcysteine,NLRP3 gene,1,X,[aapp/phsu],[gngm],D02.886.030.230.259;D12.125.166.230.259,
cbc695df-f39c-4f1f-a7c7-92ca3b2d990f,C0001047,C2936529,Cardiac Arrest,Acetylcysteine,Inflammasomes,1,X,[aapp/phsu],[aapp/bacs],D02.886.030.230.259;D12.125.166.230.259,D05.500.224
b57637d7-043f-4b6a-9166-c3093749232b,C0001047,C1704259,Cardiac Arrest,Acetylcysteine,Biochemical Pathway,1,X,[aapp/phsu],[moft],D02.886.030.230.259;D12.125.166.230.259,
e06ca246-f668-4e70-9759-acb70df88c68,C0032105,C0086418,is in ,Plasma,Homo sapiens,1,X,[bdsu],[humn],A12.207.152.693;A12.207.270.695;A15.145.693,B01.050.150.900.649.313.988.400.112.400.400
1d3031b3-eeb8-497d-8e94-fb9ef69a5ec0,C1448177,C0086418,is in ,TNF protein human,Homo sapiens,1,X,[aapp/bacs],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
5a0d6531-060f-4407-bde0-c6cac8cb3d0e,C0001047,C0206750,act as potential agent in treatment of ,Acetylcysteine,Coronavirus Infections,1,X,[aapp/phsu],[dsyn],D02.886.030.230.259;D12.125.166.230.259,C02.782.600.550.200
49bee28d-799b-4d2b-82c5-31520c3e9e05,C0001047,C0039194,improving ,Acetylcysteine,T-Lymphocyte,1,X,[aapp/phsu],[cell],D02.886.030.230.259;D12.125.166.230.259,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
dac3b727-122e-4caf-8257-33113b5e052f,C0001047,C0021368,modulating ,Acetylcysteine,Inflammation,1,X,[aapp/phsu],[patf],D02.886.030.230.259;D12.125.166.230.259,C23.550.470
4ae1ea94-3bd5-4b7c-9b06-d81d1403fd18,C0304229,C0003451,is with ,Experimental drug,Antiviral Agents,1,X,[phsu],[phsu],,D27.505.954.122.388
8947c5ea-fb3f-499b-8e31-82c4c4c2e379,C0723285,C0013604,appear depending ,Septa,Edema,1,X,[antb/orch],[sosy],,C23.888.277
268ad7fe-9c6e-4852-b307-d78b4ea6277c,C0723285,C0333563,appear depending ,Septa,Hyaline membrane,1,X,[antb/orch],[patf],,
c58ee405-8434-4373-a62d-3f2678fffa40,C0723285,C0014609,appear depending ,Septa,Epithelium,1,X,[antb/orch],[tisu],,A10.272
4212586c-6ae9-494e-ba03-3e2e78a76bb1,C0723285,C0021368,appear depending ,Septa,Inflammation,1,X,[antb/orch],[patf],,C23.550.470
fbf6b5e0-30e7-4470-ba0e-2f57815787eb,C0723285,C0016059,appear depending ,Septa,Fibrosis,1,X,[antb/orch],[patf],,C23.550.355
b781badf-3dd7-46e2-bca7-5da28fb11f60,C1457887,C0282686,are primarily generated from ,Symptoms,Respiratory System Agents,1,X,[sosy],[phsu],,D27.505.954.796
ca474d8d-3dd3-4941-a2ce-801629e0dbb3,C0235031,C2699153,raising concerns of its potential for ,Neurologic Symptoms,Cell Invasion,1,X,[sosy],[patf],C10.597;C23.888.592,
891feaa5-26f3-4892-8986-16eaf0c5fe1d,C2948600,C0003615,Comparison incidence of,Aim,Appendicitis,1,X,[inch/phsu],[dsyn],,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
dcde036d-c499-425d-ad2a-bf34e281e564,C0065827,C0009450,were tested by ,Measles Virus Nucleoprotein,Communicable Diseases,1,X,[aapp/bacs],[dsyn],x.x.x.x,C01.539.221
69bf6788-73bf-4a44-9e06-daf3c5eda4cb,C1175743,C0442886,can ,SARS coronavirus,Secondary Infections,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.218;C02.219;C03.202
56ddf6d8-5747-4b79-b663-120bf8712b36,CoV2,C0442886,can ,CoV2,Secondary Infections,1,X,????,[dsyn],????,C01.539.218;C02.219;C03.202
d89517b3-73f1-4bac-a6da-d7272ebff4ad,C1175743,C1290379,can ,SARS coronavirus,Acute disease of cardiovascular system,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
7a76977c-c10d-4ccb-9557-3d33c39bd79a,CoV2,C1290379,can ,CoV2,Acute disease of cardiovascular system,1,X,????,[dsyn],????,
35e1615b-b253-49df-8f47-c0a9e5d80aa9,C0442886,C1290379,can ,Secondary Infections,Acute disease of cardiovascular system,1,X,[dsyn],[dsyn],C01.539.218;C02.219;C03.202,
270062ba-579b-475c-80a4-995b572e61e9,C0278347,C0003451,repurposing of ,Transfusion of plasma,Antiviral Agents,1,X,[topp],[phsu],,D27.505.954.122.388
41adac84-a5e8-4abc-86a8-83374d4f2ff1,C0002520,C0319157,is with adaptive value for ,Amino Acids,AS virus,1,X,[aapp/bacs/phsu],[virs],D12.125,
02279f76-e84d-4867-a658-9956ade78fea,C1175743,C0042769,emerged as ,SARS coronavirus,Virus Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02
2b19ca6c-3783-4cfd-a5f9-6cef704d777c,C0007590,C0086418,is in ,Cell division,Homo sapiens,1,X,[celf],[humn],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,B01.050.150.900.649.313.988.400.112.400.400
6de28ece-ce7a-4514-9d65-aa6445e39beb,C0007590,C0024109,is in ,Cell division,Lung,1,X,[celf],[bpoc],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,A04.411
20fde03a-4729-47e7-9dda-bb745ae2658a,remdesivir,C0001443,Prodrugs of,remdesivir,Adenosine,1,X,[clnd],[bacs/nnon/phsu],,D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x
f4106a5f-2637-4f98-837c-0254ef0d9936,remdesivir,C0243071,Prodrugs of,remdesivir,Analog,1,X,[clnd],[chvs],,
54291a6c-89f2-4d70-a4f3-58c036538329,C0030016,C0369637,= ,Oxidoreductase,M NOS ANTIBODY,1,X,[aapp/enzy],[aapp/imft],D08.811.682,
7c4a44b5-b0ef-4c2d-af5c-e64d7f4e9e90,RDV,C0026809,diminished In ,RDV,Mus,1,X,????,[mamm],????,B01.050.150.900.649.313.992.635.505.500
0fe7379b-9c18-47fc-b1ff-74bf83b52e83,C0087111,C0319157,diminished In ,Therapeutic procedure,AS virus,1,X,[topp],[virs],E02,
c67b8b8c-2d5b-4047-8b67-00672b5c6b8a,RDV,C0319157,diminished In ,RDV,AS virus,1,X,????,[virs],????,
eff73877-4154-4b64-accf-0b46a2c787fd,C1533734,C0319157,diminished In ,Administration procedure,AS virus,1,X,[topp],[virs],,
9b1f06ad-e9de-459e-a59f-9094055342f0,RDV,C0024109,diminished ,RDV,Lung,1,X,????,[bpoc],????,A04.411
507b2182-1a0e-41c4-b268-f9f4d009c629,C1533734,C0024109,diminished ,Administration procedure,Lung,1,X,[topp],[bpoc],,A04.411
9dc55425-205c-48ff-85af-05cd51dd661b,C0087111,C1707455,improved function as ,Therapeutic procedure,Comparison,1,X,[topp],[acty],E02,
b635cd26-405c-4aa0-9c3d-3295cfb257e9,RDV,C1707455,improved function as ,RDV,Comparison,1,X,????,[acty],????,
f41cdc8b-5315-4c13-8467-c38aeb921a84,C1533734,C1707455,improved function as ,Administration procedure,Comparison,1,X,[topp],[acty],,
484e3cc1-3549-4647-a6e0-709d54964b27,C0087111,C0003062,improved function as ,Therapeutic procedure,Animals,1,X,[topp],[anim],E02,B01.050
5ccee43c-211d-4e67-a427-c9ea43d4ab86,RDV,C0003062,improved function as ,RDV,Animals,1,X,????,[anim],????,B01.050
8e07959d-2da2-427d-a372-1fb2be7146f3,C1533734,C0003062,improved function as ,Administration procedure,Animals,1,X,[topp],[anim],,B01.050
26a03d68-021f-4076-be9a-a7bf9017ca33,RDV,C1175743,is potently active against ,RDV,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
97de9b29-0ced-45c5-a799-8f15d44c0d56,C1511790,COVID-19,understanding ,Detection,COVID-19,1,X,[topp],[virs],,C000657245
31f5c4eb-14e3-4dee-92b1-0d6f355fc0c7,C1175175,C0062549,measured by levels immunoglobulins M ,Severe Acute Respiratory Syndrome,gastrin 17,1,X,[dsyn],[aapp/horm],C02.782.600.550.200.750;C08.730.730,x.x.x.x
9ee67f2e-c664-4860-bae1-1e13f16bf6f5,C0596957,C0872079,elucidate structural origin of differential ,Molecular Dynamics,protein protein interaction,1,X,[moft],[moft],E05.599.595.500;G02.111.570.895;L01.224.160.500,
292dc283-f320-4b9b-bf2d-2ae3e791ae1d,C0596957,C0597357,elucidate structural origin of differential ,Molecular Dynamics,receptor,1,X,[moft],[aapp/rcpt],E05.599.595.500;G02.111.570.895;L01.224.160.500,
64458d1d-3adf-4792-bfff-b4a3dfc0c95d,C0596957,C0022709,elucidate structural origin of differential ,Molecular Dynamics,Peptidyl-Dipeptidase A,1,X,[moft],[aapp/enzy/imft],E05.599.595.500;G02.111.570.895;L01.224.160.500,D08.811.277.656.350.350.687
11d2f678-ddc5-427f-9f1e-36766619aea2,C0020276,C0206419,is in 2019 novel ,Hydrogen Bonding,Genus: Coronavirus,1,X,[npop],[virs],G02.282,B04.820.504.540.150
3e6cc78b-6704-4b03-9493-a5a8df9f554b,C0033382,C1175743,is in short 12-residue loop lead to conformation shift toward more tilted binding groove with ,Proline,SARS coronavirus,1,X,[aapp/bacs],[virs],D12.125.072.401.623,B04.820.504.540.150.113.937
64b4dc18-588e-49cb-b10e-36a4f98e9c46,COVID-19,C0309872,could increase public concern to ,COVID-19,PREVENT (product),1,X,[virs],[phsu],C000657245,
eb2c4e63-e855-4785-ad57-5f7c199a5f55,C0065827,C0678815,overcome challenges associated with ,Measles Virus Nucleoprotein,Administration Mucosal,1,X,[aapp/bacs],[topp],x.x.x.x,E02.319.267.120.655
928df832-37c9-4aa2-91bd-9f90f5e0419c,C0065827,C0024109,offer benefits proposed as administration route for agents against viral ,Measles Virus Nucleoprotein,Lung,1,X,[aapp/bacs],[bpoc],x.x.x.x,A04.411
cbd7c943-f0a6-4020-9aae-5d618712e299,C0065827,C0042769,offer benefits proposed as administration route for agents against viral ,Measles Virus Nucleoprotein,Virus Diseases,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02
19a40f1a-3f4a-43c2-9ca4-8a6b753d58c8,COVID-19,C0008073,present greater risk to people with ,COVID-19,Developmental Disabilities,1,X,[virs],[mobd],C000657245,F03.625.421
902f1e0e-0b86-4f16-95b2-e9a55425b925,COVID-19,C0162574,present risk at especially younger ,COVID-19,Glycation End Products Advanced,1,X,[virs],[bacs/orch],C000657245,D12.776.643.500
c9141361-752a-4e2f-b1af-438adc7007e1,C0162358,C2745965,respond to future ,Ecosystem,Emergencies [Disease/Finding],1,X,[npop],[patf],G16.500.275.157;N06.230.124,C23.550.291.781;N06.230.100.083;N06.850.376
36a856b1-c32c-449b-bc25-e324b7e7b4b5,C3534339,C0243005,avoid disruption in context of small ,alternate pathway,Radiation Oncology specialty,1,X,[moft],[bmod],,H02.403.429.515.500;H02.403.740.650
1d035a28-f479-439d-ae1b-2ba69686e906,C0020517,C0087111,dose per fraction ,Hypersensitivity,Therapeutic procedure,1,X,[patf],[topp],C20.543,E02
68ce102f-5a3d-439b-a49c-5da66e99da3d,C0034519,C0087111,dose per fraction ,Electromagnetic Radiation,Therapeutic procedure,1,X,[npop],[topp],G01.358.500.505;G01.750.250,E02
ce3ff610-5ac2-4ef8-8869-f19a7c7b720e,C0034991,C1825598,merits particular consideration given potential ,Rehabilitation therapy,IMPACT gene,1,X,[topp],[gngm],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,
51a56edc-833f-4b5d-92d5-9d621230ce9b,C0005778,C1514474,currently are considered as ,Blood coagulation,Prognostic Factors,1,X,[ortf],[clna],G09.188.390.150,E01.789
14cb3282-c218-4f8f-b32f-6367a38f93ba,DIC,C0243026,is known associated with DIC,DIC,Sepsis,2,X,????,[dsyn],????,C01.539.757;C23.550.470.790.500
153f3770-4238-4415-940a-3357c172cbeb,C0221423,C0009443,ranging from ,Illness (finding),Common Cold,1,X,[sosy],[dsyn],,C02.782.687.207;C08.730.162
4681ce8e-0053-44d9-a9e1-6eab882d6db9,C0221423,C1442786,ranging from ,Illness (finding),Acute respiratory tract infection,1,X,[sosy],[dsyn],,
7fb948a4-2934-4560-9a99-afdc6c17d34d,C3463820,C1257954,could suggest ,Inhibition,Cyclooxygenase 2 Inhibitors,1,X,[acty],[orch/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,D27.505.519.389.310.500;D27.505.696.663.850.014.040.500.500.500;D27.505.954.158.030.500.500;D27.505.954.329.030.500.500
c897f954-7056-466b-b510-86af440f3c19,C3463820,C3469597,could suggest ,Inhibition,Administration of medication,2,X,[acty],[topp],F01.145.544;F02.463.425.475;F02.739.794.405,
289252b4-03ae-4a7f-9f50-c3ddc8ed8390,C0277554,C0206750,is in ,primary disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
07fe6be3-cf0a-4db4-98ea-90f44b2fcc70,C0029235,C0277554,is in ,Organism,primary disorders,1,X,[orgm],[dsyn],,
c1131c46-78ad-46fc-a04c-6d5b06e32d6e,C1704259,C0009450,is in ,Biochemical Pathway,Communicable Diseases,1,X,[moft],[dsyn],,C01.539.221
a79ad2e6-3e1b-44c5-9dc8-6a5a3eb30621,C1704259,C0019879,importance of ,Biochemical Pathway,Homocystine,1,X,[moft],[aapp/bacs],,D02.886.030.554;D12.125.095.533;D12.125.119.658;D12.125.166.554
4351ed4b-92c4-4967-a6e8-0aba1706a9f7,C0087162,C1175743,should Hence should incorporated in ,Vitamin B6,SARS coronavirus,1,X,[orch/phsu/vita],[virs],D03.383.725.676.925,B04.820.504.540.150.113.937
666f066b-9e84-4dd2-a455-9a1cebb0ee67,C0016410,C1175743,should Hence should incorporated in ,Folic Acid,SARS coronavirus,1,X,[orch/phsu/vita],[virs],D03.633.100.733.631.400,B04.820.504.540.150.113.937
0ca96cf6-b8a4-4026-8a29-613f0aba5806,C0042845,C1175743,should Hence should incorporated in ,Vitamin B 12,SARS coronavirus,1,X,[orch/phsu/vita],[virs],D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777,B04.820.504.540.150.113.937
6d6903ae-a317-4b1c-800d-794158d4cc3d,C0014467,C4330475,have Classically have considered as ,eosinophil,Immune Cell,1,X,[cell],[cell],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
91bd4fbd-7161-462d-8edb-af5097caac86,C0014467,C0699748,have Classically have considered as ,eosinophil,Pathogenesis,1,X,[cell],[patf],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
f79633fc-16bd-4043-953a-10908f1d4d67,C0014467,C0301872,being always associated to type ,eosinophil,Immune response,1,X,[cell],[ortf],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
98eaf7ce-477e-4d5f-b167-c0a9885f52cd,C0567416,C0670896, includes ,Molecule,Toll-like receptors,1,X,[sbst],[aapp/rcpt],,D12.776.543.750.705.910.500
7597b05d-2ce1-49fd-88e6-ab846b531972,C0597357,C0567416,is in last years recognizing through several ,receptor,Molecule,1,X,[aapp/rcpt],[sbst],,
c40c5835-c901-45cb-aa9b-352932f567b3,C0597357,C0670896,is in last years recognizing through several ,receptor,Toll-like receptors,1,X,[aapp/rcpt],[aapp/rcpt],,D12.776.543.750.705.910.500
4b851f1c-5c67-4d6e-bd73-f4c2170df14c,C4330475,C0699748,is in ,Immune Cell,Pathogenesis,1,X,[cell],[patf],,
3d989bb0-fb43-40d1-bec5-2df8c7aa371b,C0596448,C1175743,very similar to that of ,dimer,SARS coronavirus,1,X,[chvs],[virs],,B04.820.504.540.150.113.937
d711ba55-5b12-4309-815a-e612a0c4cd08,C0065827,C0003241,is common target of patient ,Measles Virus Nucleoprotein,Antibodies,1,X,[aapp/bacs],[aapp/imft/phsu],x.x.x.x,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
d6da06a3-9178-44c1-904a-cf19e8503e9c,C0243071,COVID-19,might ,Analog,COVID-19,1,X,[chvs],[virs],,C000657245
7d764574-1cad-4cce-93d8-b246394a5399,C0042776,C0231528,causes ,Virus,Myalgia,1,X,[virs],[sosy],B04,C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500
6b7c177e-a428-474b-b644-0304637bd0d3,C0042776,C0009566,causes Coughing most fearsome,Virus,Complication,1,X,[virs],[patf],B04,
6e0a998e-fb2b-4a9c-97f8-e756efd94c46,C0015392,C0009450,related to ,Eye,Communicable Diseases,1,X,[bpoc],[dsyn],A01.456.505.420;A09.371,C01.539.221
3a148ba5-0dff-42f4-94cc-9ac2c895b37c,COVID-19,C0277562,is with underlying chronic ,COVID-19,Adult disease,1,X,[virs],[dsyn],C000657245,
a6ec9a1f-40fb-4a5a-be44-69a758afcd4c,C0011570,C0012634,has has observed in ,Mental Depression,Disease,1,X,[mobd],[dsyn],F01.145.126.350,C23.550.288
27a9c874-990d-4e05-bb66-379d122b407f,C0301872,C0011570,patients with self-reported ,Immune response,Mental Depression,1,X,[ortf],[mobd],,F01.145.126.350
04891729-0ff5-4afb-a4e7-e035d1407917,C0011570,COVID-19,occurred at ,Mental Depression,COVID-19,1,X,[mobd],[virs],F01.145.126.350,C000657245
1582ace7-9aa5-4e12-b171-2f1a457726c0,C0026727,C0006255,is in ,Mucous body substance,Bronchi,1,X,[bdsu],[bpoc],A12.200.503,A04.411.125
8d242e50-0cb4-4b7b-87ab-7c6b32856ba3,C0027540,C0013608,disease with ,Necrosis,Edema Cardiac,1,X,[ortf],[dsyn],C23.550.717;G04.146.638,C14.280.434.482;C23.888.277.197
aa280ab3-2c6a-4c97-81de-9969646914d5,C0021368,C0242656,are suggestive of irreversible ,Inflammation,Disease Progression,1,X,[patf],[patf],C23.550.470,C23.550.291.656
6fb4e507-196f-4795-94b4-2e49bdb67553,C0040156,C1175743,may result in more severe complications from ,Thyrotoxicosis,SARS coronavirus,2,X,[dsyn],[virs],C19.874.397.685,B04.820.504.540.150.113.937
15cdeedb-8145-4237-861e-8e42bd9d2203,C0272178,COVID-19,may favour ,Drug-induced neutropenia,COVID-19,1,X,[dsyn],[virs],,C000657245
fc3c992e-4960-4960-b044-cede87388ced,C0272178,C0242656,may favour ,Drug-induced neutropenia,Disease Progression,2,X,[dsyn],[patf],,C23.550.291.656
9ed7fac3-5575-4183-80b8-8581d43a9ef0,C0272178,C0009450,may favour ,Drug-induced neutropenia,Communicable Diseases,2,X,[dsyn],[dsyn],,C01.539.221
4642a5cd-446a-4650-9be1-da7f5840cbce,C0272178,C1175743,be confused with ,Drug-induced neutropenia,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
62bb3037-cbe8-4c53-bd81-3cca7228d909,C2188405,C0040156,may may undertaken in cases of ,urgent Operation,Thyrotoxicosis,2,X,[topp],[dsyn],,C19.874.397.685
4a4ad437-6727-4fdf-9739-457beda8b583,C0035139,C0040135,is with ,Surgical Replantation,Thyroid Hormones,2,X,[topp],[horm],E04.936.494,D06.472.931
ee0eba0e-b01b-4e81-9ae6-2c441a59e18d,C1412208,C0035028,is with intervals of ,ADAMTS2 gene,Relaxation,1,X,[gngm],[acty],,I03.450.769
9e6f95f6-8b95-4a35-b146-bb8032669d76,C0301630,COVID-19,be effective strategy for ,Reduction (chemical),COVID-19,1,X,[npop],[virs],,C000657245
d77618a6-6907-41af-a64f-3ef818a242d2,COVID-19,RT-PCR,is with twice negative RT-PCR,COVID-19,RT-PCR,1,X,[virs],????,C000657245,????
f93e1b15-16a6-4ccf-960d-1795fbc51b4a,C0042210,C0920467,importance in ,Vaccines,disorder control (procedure),2,X,[aapp/imft/phsu],[topp],D20.215.894,
f2cf71c1-2eed-42fe-91c6-a67cde40360e,C0206750,C1706202,is current threat is urgent need ,Coronavirus Infections,Search - action,2,X,[dsyn],[acty],C02.782.600.550.200,
f2cf71c1-2eed-42fe-91c6-a67cde40360e,C0206750,C1706202,induced cardiac muscle cell apoptotic process In our literature,Coronavirus Infections,Search - action,1,X,[dsyn],[acty],C02.782.600.550.200,
01daf006-42cc-433c-b4b3-924cbef65e37,C1415188,C1167395,directly Binding (Molecular Function) to,GP2 gene,Host (organism),2,X,[gngm],[orgm],,
179ce1a7-6494-48aa-9d1e-c15bc3748d88,C1415188,C0022709,directly Binding (Molecular Function) to,GP2 gene,Peptidyl-Dipeptidase A,2,X,[gngm],[aapp/enzy/imft],,D08.811.277.656.350.350.687
4f94f0e0-f581-4edc-99ab-3cb46cc85d1c,C2936405,C0009450,may facilitate rapid drug ,Drug Repositioning,Communicable Diseases,2,X,[topp],[dsyn],E05.290.875,C01.539.221
9473a006-3ddf-4b05-ba32-0f4402e342d2,C1831905,C1167622,was verified Through in ,eltrombopag,Binding (Molecular Function),2,X,[aapp/phsu],[moft],x.x.x.x,
9473a006-3ddf-4b05-ba32-0f4402e342d2,C1831905,C1167622,possess ,eltrombopag,Binding (Molecular Function),2,X,[aapp/phsu],[moft],x.x.x.x,
f969d0af-36d2-4eab-9c46-7bf4a12ec3e0,C1831905,C4281807,possess ,eltrombopag,Vitronectin human,2,X,[aapp/phsu],[aapp/bacs],x.x.x.x,
f969d0af-36d2-4eab-9c46-7bf4a12ec3e0,C1831905,C4281807,could potentially affect ,eltrombopag,Vitronectin human,4,X,[aapp/phsu],[aapp/bacs],x.x.x.x,
b6479893-04fa-4e2f-b195-61a250dbc05a,C1831905,C1510827,possess ,eltrombopag,Affinity,2,X,[aapp/phsu],[npop],x.x.x.x,
7d333adc-b427-48aa-a4d5-6a0ae459d81d,C1831905,C0022709,could potentially affect ,eltrombopag,Peptidyl-Dipeptidase A,2,X,[aapp/phsu],[aapp/enzy/imft],x.x.x.x,D08.811.277.656.350.350.687
07c0c01c-aa42-4533-9618-c3755f988c32,C0032105,C0013227,are among ,Plasma,Pharmaceutical Preparations,2,X,[bdsu],[phsu],A12.207.152.693;A12.207.270.695;A15.145.693,D26
0a2d689c-51e5-40c5-9a5d-84b8b6e0977e,C0003280,C0013227,are among ,Anticoagulants,Pharmaceutical Preparations,2,X,[phsu],[phsu],D27.505.954.502.119,D26
86cc840e-c15a-4728-a419-f001ab1ceb30,C0003374,C0013227,are among ,Antimalarials,Pharmaceutical Preparations,2,X,[phsu],[phsu],D27.505.954.122.250.100.085,D26
0e6048f3-457e-409a-a9f2-7014cde38c2d,C1328819,C0013227,are among ,Small Molecule,Pharmaceutical Preparations,2,X,[orch],[phsu],,D26
d8460fd9-b323-41fe-91a6-76709255047a,C1514562,C1167395,built ,Protein Domain,Host (organism),2,X,[amas],[orgm],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
bd9bbe2e-4ff9-4d6f-86d4-fb5b159a0de7,C1514562,C0017337,built ,Protein Domain,Genes,2,X,[amas],[gngm],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,G05.360.340.024.340
237b0002-8f29-4542-8bfc-cd27e819626c,C0458827,C0206750,is in ,Airway structure,Coronavirus Infections,1,X,[bpoc],[dsyn],,C02.782.600.550.200
b0aa00a1-26da-404c-986c-6d6d330bfde9,C1956108,C0206750,is in ,Microbiome,Coronavirus Infections,2,X,[orgm],[dsyn],G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500,C02.782.600.550.200
cafd0f9e-8103-4bb1-9b82-2c90a424c071,C0445623,C0206750,were also Detection in in,Microorganism,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
cafd0f9e-8103-4bb1-9b82-2c90a424c071,C0445623,C0206750,were also detected in in ,Microorganism,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
d0415fb9-770d-406c-bd54-596e2ec2b9e5,C0445623,C1511790,were also ,Microorganism,Detection,1,X,[orgm],[topp],,
f8cf4c8a-ac11-4d7e-86df-0d26ab8b83a8,C1704259,C1511617, includes ,Biochemical Pathway,Cytokine Signaling,2,X,[moft],[moft],,
c2231417-3efe-4c41-a222-587471c962df,C1167395,C1704259,revealed transcriptional signature of genes significantly associated with immune ,Host (organism),Biochemical Pathway,2,X,[orgm],[moft],,
c2231417-3efe-4c41-a222-587471c962df,C1167395,C1704259,is in certain ,Host (organism),Biochemical Pathway,2,X,[orgm],[moft],,
41d4e6c4-c583-43bd-9ade-56e54bd735d8,C1167395,C1511617,revealed transcriptional signature of genes significantly associated with immune ,Host (organism),Cytokine Signaling,2,X,[orgm],[moft],,
fe3a0f26-82fb-4dc3-9a15-6350a73ef049,C0206750,C1956108,have more disrupted airway ,Coronavirus Infections,Microbiome,2,X,[dsyn],[orgm],C02.782.600.550.200,G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
70c1b61d-6540-4d3a-bf93-bd23ce996c14,C1704259,C0021745, includes ,Biochemical Pathway,Interferon Type II,1,X,[moft],[aapp/imft/phsu],,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
92395470-0f6e-49cb-acb9-0fb4a97bc4de,C1704259,C0017011, includes ,Biochemical Pathway,Gamma Rays,1,X,[moft],[npop],,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
3795f797-b8bd-49d2-81b6-441f2ed9ff4f,C0032930,C1704259,is in certain ,Precipitating Factors,Biochemical Pathway,2,X,[clna],[moft],N05.715.350.200.650;N06.850.490.625.500,
be026737-8199-4d75-9d1a-377ec5d1dcf4,C0301872,C1704259,is in certain ,Immune response,Biochemical Pathway,2,X,[ortf],[moft],,
088ad4de-eb1d-4f54-bcfc-39579bdf2c30,C0032930,C0037083,is in certain ,Precipitating Factors,Signal Transduction,3,X,[clna],[celf],N05.715.350.200.650;N06.850.490.625.500,G02.111.820;G04.835
913ef69f-476c-49bb-82a1-39be90d82069,C1167395,C0037083,is in certain ,Host (organism),Signal Transduction,3,X,[orgm],[celf],,G02.111.820;G04.835
d48b0945-30d8-4ce7-9081-f1f621880e47,C0301872,C0037083,is in certain ,Immune response,Signal Transduction,3,X,[ortf],[celf],,G02.111.820;G04.835
ea1bdebb-0a19-49e8-92ab-365a78eb0166,C0032930,C0021745,is in certain ,Precipitating Factors,Interferon Type II,2,X,[clna],[aapp/imft/phsu],N05.715.350.200.650;N06.850.490.625.500,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
856cb01d-60ab-4252-90d5-05fb988b34ca,C1167395,C0021745,is in certain ,Host (organism),Interferon Type II,2,X,[orgm],[aapp/imft/phsu],,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
ec6c9eb6-751e-45e3-ad24-264f0990867d,C0301872,C0021745,is in certain ,Immune response,Interferon Type II,2,X,[ortf],[aapp/imft/phsu],,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
32b23fa4-a700-4786-a0e8-ce7dfea44d5e,C0032930,C0017011,is in certain ,Precipitating Factors,Gamma Rays,2,X,[clna],[npop],N05.715.350.200.650;N06.850.490.625.500,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
067ea48b-0a6d-49f5-819c-1ffbf8fc73f2,C1167395,C0017011,is in certain ,Host (organism),Gamma Rays,2,X,[orgm],[npop],,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
81bb8a77-6b2e-49ef-80e7-de06c448058e,C0301872,C0017011,is in certain ,Immune response,Gamma Rays,2,X,[ortf],[npop],,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
f8821d0a-8259-4cee-8a07-4de5c267e36d,C0242184,C0184633,is with ,Hypoxia,Oxygen Therapy Care,1,X,[patf],[topp],C23.888.852.079,E02.880.690
2a863692-a845-4512-95e3-d74f7c0456b0,C0242184,C1524029,is with ,Hypoxia,Mouse MIN NOS,1,X,[patf],[neop],C23.888.852.079,
5eb94f0d-5d38-48f2-96b6-86f0519c2d8d,C0806140,C0206750,regarding ,Flow,Coronavirus Infections,1,X,[npop],[dsyn],,C02.782.600.550.200
e07f7fa1-7197-4f26-9f30-b35ccad33812,C0404844,C0206750,have positive attitude toward ,Non-viable pregnancy,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
aab0627a-d08c-4275-b884-217e53744e7e,C0086418,3-week,was brought with 3-week ,Homo sapiens,3-week,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
7653b8dd-b8c8-48e8-8e2a-fc11a6cf7ddf,C0086418,4hours,worsening suddenly in preceding 4hours,Homo sapiens,4hours,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
fbe6b310-4bb8-436f-b09c-2a7e38eae7f4,C0079189,C0020336,were compared between ,cytokine,Hydroxychloroquine,1,X,[aapp/imft],[orch/phsu],D12.644.276.374;D12.776.467.374;D23.529.374,D03.633.100.810.050.180.350
d39e43c2-9799-4216-8906-df72b356cb0f,C0028754,C0010200,have ,Obesity,Coughing,2,X,[dsyn],[sosy],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C08.618.248;C23.888.852.293
05294c27-848c-43b7-b83f-7511480a695c,C0042776,C3272452,is with positive-polarity ,Virus,Single-Stranded RNA,1,X,[virs],[nnon],B04,
8f18ec84-ee93-4788-aaab-44aa8cdd6b6d,C0041199,C0206750,were frequently observed in ,Troponin,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825,C02.782.600.550.200
13e681c9-71c5-4c2a-91ce-289c48fd0254,C0206750,C0683585,resulted ,Coronavirus Infections,free time,1,X,[dsyn],[dora],C02.782.600.550.200,
68852121-cc6d-4375-98fb-6a7a7247204d,C2745965,C0683585,resulted ,Emergencies [Disease/Finding],free time,1,X,[patf],[dora],C23.550.291.781;N06.230.100.083;N06.850.376,
060ecced-da49-47db-9efe-36d2c771cada,C0233514,C0206750,predating ,Abnormal behavior,Coronavirus Infections,1,X,[mobd],[dsyn],F01.145.126.972;F01.145.179.750,C02.782.600.550.200
84deeb6f-5b7f-4a81-b6d6-63054c821e56,C0441516,C0087111,would improve our ability to ,Demand (clinical),Therapeutic procedure,1,X,[topp],[topp],,E02
5cf9ff48-5bc4-4b1f-93e0-2f72d92fecd4,C0543467,C0218063,is critical in ,Operative Surgical Procedures,Ensure (product),1,X,[topp],[food],E04,
d6fb7115-947c-4686-acbb-cc4e1ccc242f,dataset,C1280903,presents dataset ,dataset,Exploration procedure,1,X,????,[topp],????,
5491e42c-1e65-4f1e-98a1-020f6b79bda7,dataset,C0872252,presents dataset ,dataset,Proteomics,1,X,????,[bmod],????,H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
88b28c84-d624-47d7-ab82-5d65b7472471,C0042736,C0041236,digested with ,Viral Proteins,TRYPSIN,1,X,[aapp/bacs],[aapp/enzy/phsu],D12.776.964,D08.811.277.656.300.760.895;D08.811.277.656.959.350.895
dbd98633-d0ac-4562-a681-9c7f9a7df1d9,C2718059,C0005532,requires translation of basic ,Precision Medicine,biology (field),1,X,[topp],[bmod],E02.574;H02.403.200.700,H01.158.273
1af64889-8b03-4b9e-a827-527f1e69855a,C1158478,C0017398,yielded unexpected insights highlighted by unique case of ,DNA Integration,Science of genetics,1,X,[genf],[bmod],,H01.158.273.343
d05e3853-55cf-4f46-9ebe-eb3335aae278,C0035668,C2718059,power of be can critical tool moving for sciences applied to ,RNA,Precision Medicine,1,X,[nnon],[topp],D13.444.735,E02.574;H02.403.200.700
93ee429a-91b5-48fe-802a-a040fdf0d0d4,C0337279,C0330093,is with cutting ,Drilling - action,Burr - plant,1,X,[topp],[plnt],,
e2829890-f89e-4946-82f0-f61d20a04709,C0178774,C0003320,is important ,Nucleocapsid,Antigens,2,X,[aapp/bacs/nnon],[imft],A21.249.500;B04.950.500,D23.050
0ef26594-bb16-4b13-85f8-690f833445e9,C0065827,C0003320,is important ,Measles Virus Nucleoprotein,Antigens,2,X,[aapp/bacs],[imft],x.x.x.x,D23.050
98b17983-3d5c-435e-ac6c-b51e9b5b53d9,C0178774,C0206750,is important Antigens for,Nucleocapsid,Coronavirus Infections,2,X,[aapp/bacs/nnon],[dsyn],A21.249.500;B04.950.500,C02.782.600.550.200
09fc4391-7ac0-4ee7-8529-3d5737686718,C0206750,C0035668,participate in ,Coronavirus Infections,RNA,2,X,[dsyn],[nnon],C02.782.600.550.200,D13.444.735
6e73d84b-2e39-4110-9207-8b41295f003c,C0065827,C0596448,is largely ,Measles Virus Nucleoprotein,dimer,2,X,[aapp/bacs],[chvs],x.x.x.x,
dee6c29b-e820-4fea-b94e-6580f52c29e0,C0028910,C0003451,have shown as ,Oils Volatile,Antiviral Agents,1,X,[orch],[phsu],D10.627.675,D27.505.954.122.388
dee6c29b-e820-4fea-b94e-6580f52c29e0,C0028910,C0003451,may potentiate other ,Oils Volatile,Antiviral Agents,1,X,[orch],[phsu],D10.627.675,D27.505.954.122.388
e027d693-8267-4ede-9220-ea49190ca96d,C0028910,C0042776,have shown as ,Oils Volatile,Virus,1,X,[orch],[virs],D10.627.675,B04
cdddff46-9fde-481d-9268-5d72d8de920c,C0028910,C0033684,interact with key ,Oils Volatile,Proteins,1,X,[orch],[aapp/bacs],D10.627.675,D12.776
cc1311ff-e1e4-4e7a-b86e-79ec21d25836,C0028910,C1175743,interact with key ,Oils Volatile,SARS coronavirus,1,X,[orch],[virs],D10.627.675,B04.820.504.540.150.113.937
707f66fd-0f71-4b9a-9b69-caf2f46c3438,C0015637,C1175743,showed most exothermic docking to ,Farnesol,SARS coronavirus,2,X,[orch/phsu],[virs],D02.033.415.400;D02.455.849.765.424;D10.289.400,B04.820.504.540.150.113.937
f8e23a83-265e-4698-aeb4-64b8dc21b4b0,C0542479,C0033684,is with other ,Energy Physics,Proteins,2,X,[npop],[aapp/bacs],,D12.776
0400b26d-49a4-4815-87c7-3cec36ca6b02,C0015637,C1817569,is with ,Farnesol,acireductone dioxygenase [iron(II)-requiring] activity,1,X,[orch/phsu],[moft],D02.033.415.400;D02.455.849.765.424;D10.289.400,
f89da579-d4e2-4fc9-94ae-95a2023d93af,C0542479,C0042776,interact with ,Energy Physics,Virus,1,X,[npop],[virs],,B04
a148174b-54bc-4bbb-982d-81d71b914673,C1184743,C0040452,are at ,bony process,Tooth root structure,1,X,[bpoc],[bpoc],,A14.549.167.900.750
d1add88b-2b81-4210-90c4-ef5c68c4fc40,C1184743,C0679225,are at ,bony process,multiple pathologies,1,X,[bpoc],[dsyn],,
e478e82b-efa1-45d8-b573-933629e9a72d,C0030054,C0013404,incompatible without ,Oxygen,Dyspnea,1,X,[bacs/elii/phsu],[sosy],D01.268.185.550;D01.362.670;x.x.x.x,C08.618.326;C23.888.852.371
4203a636-1c7c-4e43-a176-6e57cbd66c1f,C0206750,C1152633,idiosyncratic receptor activity on,Coronavirus Infections,receptor activity,3,X,[dsyn],[moft],C02.782.600.550.200,
c32cd8a1-2233-464a-9bca-92e0d15c989a,C0206750,C0030054,idiosyncratic receptor activity on,Coronavirus Infections,Oxygen,2,X,[dsyn],[bacs/elii/phsu],C02.782.600.550.200,D01.268.185.550;D01.362.670;x.x.x.x
b567bcfc-9e25-442a-9482-0e2fbdcdd100,C0013404,C0030054,is in ,Dyspnea,Oxygen,1,X,[sosy],[bacs/elii/phsu],C08.618.326;C23.888.852.371,D01.268.185.550;D01.362.670;x.x.x.x
a0db2365-57f3-43a6-84b3-f41134979828,C0013404,C0086168,is in ,Dyspnea,Dissociation,1,X,[sosy],[mobd],C08.618.326;C23.888.852.371,F03.300
f5ef0adb-81c8-48e7-a7d2-a7b1e737c41a,C0035452,C0009326,received national ,Rheumatology specialty,Collagen Diseases,1,X,[bmod],[dsyn],H02.403.429.730,C17.300.200
b28a8c14-ef46-4dbe-85ce-b9981788ac25,C0730400,C0206750,have higher risk for ,Solid organ transplant,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
0b8b7908-e898-4777-b3a3-d0f575aa1259,C0039336,C0012634,is in ,Taste Perception,Disease,1,X,[ortf],[dsyn],F02.830.816.724;G11.561.790.724,C23.550.288
1d39afae-5d4b-4430-accb-6b4acb37fe35,C1260880,C0012634,was high in ,Rhinorrhea,Disease,2,X,[sosy],[dsyn],,C23.550.288
ea638463-6918-447e-b86e-aaa2a2f8b7f3,C1260880,C0010076,was high in ,Rhinorrhea,Coronaviridae,2,X,[sosy],[virs],,B04.820.504.540
b54d0c35-7c57-428d-8163-48a4bb69166f,C0206750,C0039336,are associated with smell ,Coronavirus Infections,Taste Perception,1,X,[dsyn],[ortf],C02.782.600.550.200,F02.830.816.724;G11.561.790.724
689982d3-6669-4eff-9a21-9cd960a6db2a,C1327414,C0012634,creates critical ,cytokine secretion,Disease,1,X,[celf],[dsyn],,C23.550.288
c9c2e186-2f29-42a7-b7f0-ae2e91712059,C1327414,C0018563,creates Disease On other,cytokine secretion,Hand,1,X,[celf],[bpoc],,A01.378.800.667
fc3d6f42-aa59-4847-9b4b-cf895a1c4c28,C0206422,C1456573,recently appeared as ,Human coronavirus,Global Health,1,X,[virs],[bmod],,H02.403.371;N01.400.337
52f815e8-873a-4510-9a96-73fb9a83852d,C0206750,UME,IMPACT gene UME,Coronavirus Infections,UME,1,X,[dsyn],????,C02.782.600.550.200,????
7802560d-1d6e-4fe7-a10d-e4de91c2d411,C1516048,C0242821,governing medical UME,Assessed,Human body,1,X,[acty],[humn],,I01.076.201.450.560;K01.093.378
5a62bfdf-6398-4a27-a87b-3fe1000447aa,C1516048,UME,governing medical UME,Assessed,UME,1,X,[acty],????,,????
7040c1cb-926d-4723-818a-a30a25a2fd51,C1562764,C0237820,alleviate aid in quicker ,Osteopathic Manipulative Medicine,Recovery - action,1,X,[bmod],[acty],H02.403.640,
7040c1cb-926d-4723-818a-a30a25a2fd51,C1562764,C0237820,alleviate Lung Symptoms in quicker,Osteopathic Manipulative Medicine,Recovery - action,1,X,[bmod],[acty],H02.403.640,
7c4cafb1-0c7a-4bcd-a55f-3801503ae870,C1562764,C0221423,alleviate aid in quicker ,Osteopathic Manipulative Medicine,Illness (finding),1,X,[bmod],[sosy],H02.403.640,
7c4cafb1-0c7a-4bcd-a55f-3801503ae870,C1562764,C0221423,alleviate Lung Symptoms in quicker,Osteopathic Manipulative Medicine,Illness (finding),1,X,[bmod],[sosy],H02.403.640,
deffb8c4-8542-4e58-9828-973dd4fdc4a5,C1562764,C0024109,alleviate ,Osteopathic Manipulative Medicine,Lung,1,X,[bmod],[bpoc],H02.403.640,A04.411
041269dc-58ca-498a-9d20-b5194a30b0b5,C1562764,C1457887,alleviate ,Osteopathic Manipulative Medicine,Symptoms,1,X,[bmod],[sosy],H02.403.640,
f8d0c83a-7aed-4b75-b36b-c4ee3cca28b2,C0206750,C0161816,has many ,Coronavirus Infections,Cardiac complication,1,X,[dsyn],[patf],C02.782.600.550.200,
5c82f36a-0bb9-453b-ac31-b6fdf864e692,C0034848,C0206750,underlying risk factors for ,Receptors Virus,Coronavirus Infections,1,X,[aapp/rcpt],[dsyn],D12.776.543.750.830,C02.782.600.550.200
258e554f-1b05-46da-8585-f8a573ff8810,C0023688,C0206750,underlying risk factors for ,Ligands,Coronavirus Infections,1,X,[chem],[dsyn],D27.720.470.480,C02.782.600.550.200
9d6dee8d-ffa8-4f08-8f6b-4dfe85f81775,C2948600,C1621296,emphasize mechanism of ,Aim,receptor ligand,1,X,[inch/phsu],[moft],,
c35973f8-3e29-47ca-b795-581dc090c005,C0011849,C0960756,is ,Diabetes Mellitus,factor A,2,X,[dsyn],[orch],C18.452.394.750;C19.246,x.x.x.x
52b7f565-49fc-4785-af01-024fd7acc68e,C1862322,C0206750,is in ,Ovalocytosis Malaysian-Melanesian-Filipino Type,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
a1bbf931-8a38-4b2c-b3d6-a9ec11f2f00c,C0087111,C0008679,optimize therapy delivery to patients with ,Therapeutic procedure,Chronic disease,1,X,[topp],[dsyn],E02,C23.550.291.500
c560dcb7-c81c-4a32-ac4b-de8193646f3a,COVID-19,C3542961,attack ,COVID-19,NERVOUS SYSTEM DRUGS,1,X,[virs],[phsu],C000657245,
2ef63793-cf50-410a-99c6-7f7a404b162c,C0242781,C0040802,is in various person-to-person crowd funerals ,disease transmission,travel,1,X,[patf],[dora],N06.850.310,I03.883
778122ec-ede0-4af5-9acb-e2f8cd107a6d,C1175743,C2806453,is ,SARS coronavirus,Betacoronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150.113
db83aa5b-8b03-4aa1-915e-24cc3a4aa537,C0003451,C0949892,was initially developed for treatment of ,Antiviral Agents,Ebolavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.455.300.200
09d88143-0988-4300-abee-7211c20365b5,N95,C0036082,using aerosolized ,N95,Saline Solution,1,X,????,[sbst],????,D26.776.498.500.750
1903d380-c45d-4e82-b699-88d3fb97e559,C0036572,C0036082,using aerosolized ,Seizures,Saline Solution,1,X,[sosy],[sbst],C10.597.742;C23.888.592.742,D26.776.498.500.750
9aa86016-79ca-4bcf-a757-afaf094f9362,C0020852,C0806140,demonstrate performance of two enzyme-linked assay assays in comparison to one ,Immunoglobulin G,Flow,1,X,[aapp/imft/phsu],[npop],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,
eb9ece9e-8be5-49f1-a6a3-24b53074437a,C0024875,C0002346,is used as ,Massage,Alternative Medicine,1,X,[topp],[bmod],E02.190.599.750.750;E02.779.867.880.750;E02.831.535.867.880.750,E02.190
f6d40bbe-b13c-46f0-b870-7bdf93b3b4fa,C0024875,C0184661,is effective ,Massage,Interventional procedure,1,X,[topp],[topp],E02.190.599.750.750;E02.779.867.880.750;E02.831.535.867.880.750,
a7dfe012-a450-44bb-ade7-3d18005d3a76,C0330941,COVID-19,treating ,Melia azedarach,COVID-19,1,X,[plnt],[virs],B01.650.940.800.575.912.250.715.500.500,C000657245
e6c972be-688f-4076-aebb-4ebed03d5973,C1414371,COVID-19,treating ,ELAVL1 gene,COVID-19,1,X,[gngm],[virs],,C000657245
656d014f-c2d7-44bd-a074-ec05991b21f5,C0010837,COVID-19,treating ,Cytoplasmic Granules,COVID-19,1,X,[celc],[virs],A11.284.430.214.190.500;A11.284.430.214.190.875.190.190,C000657245
c156ced2-a441-4996-b031-2ae8d45c2aac,C0319157,C1825598,has had direct ,AS virus,IMPACT gene,1,X,[virs],[gngm],,
8991d6ac-f082-4396-8ff7-4a050cece05d,C0010332,C0206750,is needed With ,Crisis Intervention,Coronavirus Infections,1,X,[topp],[dsyn],F04.754.252,C02.782.600.550.200
a408b247-0141-49ee-8674-8a20644d5ecc,C0009450,C1697446,is with zoonotic ,Communicable Diseases,Genital Viral Infections,2,X,[dsyn],[dsyn],C01.539.221,
1cd01dbb-1874-4365-8ec4-6d450b380524,COVID-19,C1697446,is caused by ,COVID-19,Genital Viral Infections,2,X,[virs],[dsyn],C000657245,
570e401e-eb9d-4347-b61a-81fd3b48f5d9,C1175743,C1668248,is close to genetically two lated ,SARS coronavirus,Iso,1,X,[virs],[fish],B04.820.504.540.150.113.937,
c29c6b9f-0ea2-484d-8c46-bebc9e42a2cf,C1175743,lated,is close to genetically two lated ,SARS coronavirus,lated,1,X,[virs],????,B04.820.504.540.150.113.937,????
e8013690-dec2-4057-962c-83df7e909e2e,C1175743,C0008139,is close to genetically two lated ,SARS coronavirus,Chiroptera,1,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.937
cc9a560d-1930-4590-88c9-f918c4c843f5,C0162358,C0009450,facilitating emergence of new ,Ecosystem,Communicable Diseases,1,X,[npop],[dsyn],G16.500.275.157;N06.230.124,C01.539.221
c0f37360-0b4b-45b6-95f4-4ba5183642af,C0021368,C0699748,play role in ,Inflammation,Pathogenesis,1,X,[patf],[patf],C23.550.470,
0ec6bc04-44ab-4b0d-abc0-992f71989a78,C1257975,C0031843,possess comprehensive powerful ,Mesenchymal Stem Cells,physiological aspects,1,X,[cell],[phsf],A11.329.830.500;A11.872.590.500,x.x.x.x
f05f22bd-62f9-46b9-9b15-2b6c4b07f395,C0021440,COVID-19,has shown ,Intravenous infusion procedures,COVID-19,1,X,[topp],[virs],E02.319.267.082.500;E02.319.267.510.590,C000657245
6bf93d31-42cc-4864-bf50-3afae6762bc5,C0040732,C0032285,was ,Transplantation,Pneumonia,2,X,[topp],[dsyn],E04.936,C08.381.677;C08.730.610
9f24825c-db6c-4028-bdbc-4b86dfefd55b,C0042720,FFPE,was sequenced by next-generation sequencing from FFPE ,Viral Genome,FFPE,1,X,[gngm],????,G05.360.340.358.840,????
cbaa9586-d17a-4cef-a06f-876eae96804a,C0042720,C0819757,was sequenced by next-generation sequencing from FFPE ,Viral Genome,Structure of parenchyma of lung,1,X,[gngm],[tisu],G05.360.340.358.840,
d27583ff-7fe0-471e-a330-e1606f8ad818,C0042720,C1533157,was sequenced by next-generation sequencing from FFPE ,Viral Genome,Block Specimens,1,X,[gngm],[bdsu],G05.360.340.358.840,
4ca7745a-b853-4669-95c7-60b04a49aa9e,C0035736,C1511790,was ,RNA Viral,Detection,1,X,[nnon],[topp],D13.444.735.828,
7b1e00d5-c3f8-41f8-a8f8-6fc2d0e2a194,C0035736,C0006255,was ,RNA Viral,Bronchi,1,X,[nnon],[bpoc],D13.444.735.828,A04.411.125
a5e070e4-a0a9-4f01-9eca-5a5845009799,C0035736,C0024204,was ,RNA Viral,lymph nodes,1,X,[nnon],[bpoc],D13.444.735.828,A10.549.400;A15.382.520.604.412
becc47db-5b9a-4225-872a-b07801665af0,C0035736,C0037993,was ,RNA Viral,Spleen,1,X,[nnon],[bpoc],D13.444.735.828,A10.549.700;A15.382.520.604.700
4a0542bc-9a55-4a42-be02-107a3b225fbb,C1511790,C0024109,is in ,Detection,Lung,1,X,[topp],[bpoc],,A04.411
7393ec40-5d08-4aac-8859-85844c3499c9,C1511790,C0006255,is in ,Detection,Bronchi,1,X,[topp],[bpoc],,A04.411.125
8da8c0c2-468d-4fca-a080-66704448b490,C1511790,C0024204,is in ,Detection,lymph nodes,1,X,[topp],[bpoc],,A10.549.400;A15.382.520.604.412
7af43ff8-c9ad-4a83-8af8-527335f6d3ac,C1511790,C0037993,is in ,Detection,Spleen,1,X,[topp],[bpoc],,A10.549.700;A15.382.520.604.700
e0e6f057-7e33-4556-9c43-88402989967f,manythe,C0012222,could have role in rapid ,manythe,Diffusion,1,X,????,[npop],????,G01.202;G02.196
b0ff308a-f2cf-4e38-a291-d5036aecb0b1,manythe,C0012634,could have role in rapid ,manythe,Disease,1,X,????,[dsyn],????,C23.550.288
d92982ae-e825-4452-a9b9-64a0680c8a03,C0282624,C0184661,be ,Minimally Invasive Surgical Procedures,Interventional procedure,1,X,[topp],[topp],E04.502,
b9aa8727-7af0-4e89-adba-fa0a0b14a61d,C0806140,C0030054,is preferred for patients with higher ,Flow,Oxygen,1,X,[npop],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
8df6f8ed-a31c-49e0-97bc-03aaa3c3afb3,C0206419,C1704532,is ,Genus: Coronavirus,Active Method,1,X,[virs],[topp],B04.820.504.540.150,
65637d09-1a5d-4f8b-93f6-ffeaa9aad792,C2827774,C0206419,are are evaluated for treatment of ,Current Therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
d9ed7127-1b58-474d-9c46-68e1f73cea75,C0206419,C0004936,possesses challenges for individuals with ,Genus: Coronavirus,Mental disorders,1,X,[virs],[mobd],B04.820.504.540.150,F03
c8053cf9-d749-4d22-a7b7-89ad76e85ded,C0012634,C0026769, includes ,Disease,Multiple Sclerosis,1,X,[dsyn],[dsyn],C23.550.288,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
d86e0a60-b2d7-4e11-ac25-11d046405823,C0021079,C1825598,have major ,Therapeutic immunosuppression,IMPACT gene,1,X,[topp],[gngm],E02.095.465.425.450;E05.478.610,
87f47a90-8a33-4528-aa33-44c16c6de244,C0021079,C0009450,have major ,Therapeutic immunosuppression,Communicable Diseases,1,X,[topp],[dsyn],E02.095.465.425.450;E05.478.610,C01.539.221
78ca826a-1a02-4134-830f-b86296471df9,C0021079,C1175743,have major ,Therapeutic immunosuppression,SARS coronavirus,1,X,[topp],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150.113.937
210f381d-7d96-4392-b444-7566059ce87f,C0206422,C0021747,is in ,Human coronavirus,Interferons,1,X,[virs],[aapp/imft],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
f319c940-3e5d-4c5b-9a7f-0311d5c0fc49,C0206422,C0289884,is in ,Human coronavirus,glatiramer acetate,1,X,[virs],[aapp/phsu],,D12.644.219
00aa14cf-65f2-42e3-9051-cceceac4b0ab,C0206422,C1718383,is in ,Human coronavirus,teriflunomide,1,X,[virs],[orch/phsu],,x.x.x.x
19afc605-c42b-4a74-aeff-7280119c59bb,C0024312,C0092801, includes ,Lymphopenia,Cladribine,1,X,[dsyn],[nnon/phsu],C15.378.553.546.605;C20.673.627,D03.633.100.759.590.138.300.200;D03.633.100.759.590.138.325.075;D13.570.230.229.075;D13.570.583.138.300.200;D13.570.583.138.325.075;D13.570.800.096.300.200
bc188900-57de-422d-911c-5fcb7b28dc13,C0024312,C0383429, includes ,Lymphopenia,alemtuzumab,1,X,[dsyn],[aapp/imft/phsu],C15.378.553.546.605;C20.673.627,D12.776.124.486.485.114.224.060.313;D12.776.124.790.651.114.224.060.375;D12.776.377.715.548.114.224.200.375
7310cfc4-591d-4ac0-bf92-bf38f9652256,C0024312,C0058218, includes ,Lymphopenia,dimethyl fumarate,1,X,[dsyn],[imft/orch/phsu],C15.378.553.546.605;C20.673.627,D02.241.081.337.302.500
d0fe2e57-de65-4052-b393-23e48dfd04dd,C0012634,C0024312,causing ,Disease,Lymphopenia,1,X,[dsyn],[dsyn],C23.550.288,C15.378.553.546.605;C20.673.627
0cac0e21-2cb9-4ff9-bfb7-593592e111c7,C0012634,C0092801,causing ,Disease,Cladribine,1,X,[dsyn],[nnon/phsu],C23.550.288,D03.633.100.759.590.138.300.200;D03.633.100.759.590.138.325.075;D13.570.230.229.075;D13.570.583.138.300.200;D13.570.583.138.325.075;D13.570.800.096.300.200
8f59de17-b5dc-4472-a034-ed737ab783cd,C0012634,C0383429,causing ,Disease,alemtuzumab,1,X,[dsyn],[aapp/imft/phsu],C23.550.288,D12.776.124.486.485.114.224.060.313;D12.776.124.790.651.114.224.060.375;D12.776.377.715.548.114.224.200.375
25548dbd-4eca-443b-850f-b19ff3a22eda,C0012634,C0058218,causing ,Disease,dimethyl fumarate,1,X,[dsyn],[imft/orch/phsu],C23.550.288,D02.241.081.337.302.500
4c6839a3-29c4-41d0-bf2b-e828cbc477b4,C0206419,C0001288,also demonstrated solid discrimination ,Genus: Coronavirus,Activities of Daily Living (activity),2,X,[virs],[dora],B04.820.504.540.150,E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110
d925308f-fd60-453e-b847-3167cd67949c,C0206419,C0684336,also demonstrated solid discrimination ,Genus: Coronavirus,Impaired health,1,X,[virs],[patf],B04.820.504.540.150,
37b0e621-192c-4361-a131-9365d82d4287,C1705285,C1825598,may have ,Mutation Abnormality,IMPACT gene,1,X,[comd],[gngm],,
c61956f2-292f-4967-875d-7e85264e261d,C2948600,C1624602,examine seroprevalence of ,Aim,Anti-Antibodies,1,X,[inch/phsu],[aapp/imft],,D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071
18cb5f99-f223-4797-a78a-c9a7d1093119,C1510586,C0012634,is ,Autism Spectrum Disorders,Disease,1,X,[mobd],[dsyn],F03.625.164.113,C23.550.288
e0024cc0-4b12-4c78-ba98-01d28a8f4052,C1707455,C0041671,draw Attention Deficit Disorder to,Comparison,Attention Deficit Disorder,2,X,[acty],[mobd],,F03.625.094.150
a2710f04-11c6-4c09-8586-d35ce0fb6f80,C0012634,C2741673,is well taken into ,Disease,Account number:Identifier:Point in time:^Patient:Nominal,2,X,[dsyn],[clna],C23.550.288,
e4614986-332e-44dc-aca2-5064bf065beb,C0025124,C0034019,better serve ethical review in ,Traditional Chinese Medicine,public health medicine (field),1,X,[bmod],[bmod],E02.190.488.585.520;I01.076.201.450.654.558.520,H02.403.720;N01.400.550;N06.850
1b8fb17f-b108-45ec-9d72-95fbac1cb454,C0025124,C2745965,better serve ethical review in ,Traditional Chinese Medicine,Emergencies [Disease/Finding],1,X,[bmod],[patf],E02.190.488.585.520;I01.076.201.450.654.558.520,C23.550.291.781;N06.230.100.083;N06.850.376
d0cc1ffa-1cae-44f7-add7-7c63dd473a8b,C0206750,C0441516,potentially placing additional ,Coronavirus Infections,Demand (clinical),1,X,[dsyn],[topp],C02.782.600.550.200,
d0cc1ffa-1cae-44f7-add7-7c63dd473a8b,C0206750,C0441516,situation ,Coronavirus Infections,Demand (clinical),1,X,[dsyn],[topp],C02.782.600.550.200,
4874d211-c00c-4619-9d3f-1f82b4c28b9e,C0206750,3D,= 3D ,Coronavirus Infections,3D,1,X,[dsyn],????,C02.782.600.550.200,????
ae8b3f09-2180-4eb9-89dc-a7eb88df70c9,C2348077,C0012634,develop practical recommendations on use in ,Date Fruit,Disease,1,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,C23.550.288
1818e13d-9c55-4296-ab5d-368b313ef544,C2745965,C0006405,allow ,Emergencies [Disease/Finding],Buprenorphine,1,X,[patf],[orch/phsu],C23.550.291.781;N06.230.100.083;N06.850.376,D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150
5c4ec9ae-1e77-47c2-971d-671688a2eba3,C0086418,C4237239,is with ,Homo sapiens,Opioid use disorder severe,2,X,[humn],[mobd],B01.050.150.900.649.313.988.400.112.400.400,
39ca5349-ee22-4bba-88db-e37ae8f99278,C0679771,C0012634,facilitated videoconference at ,Harm Reduction,Disease,1,X,[topp],[dsyn],F01.145.477,C23.550.288
21fc5997-73b9-484c-8874-a90aafec1f12,C0679771,C0085281,facilitated videoconference with ,Harm Reduction,Addictive Behavior,1,X,[topp],[mobd],F01.145.477,F01.145.527.100.120
bd812835-8e32-4943-b84d-3a1c5651e3ba,C0206750,C0006405,allow ,Coronavirus Infections,Buprenorphine,1,X,[dsyn],[orch/phsu],C02.782.600.550.200,D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150
6ef8da4b-b57e-422e-be7f-a3326b605fcf,AKI,C0319157,could from could synergistic effect of ,AKI,AS virus,1,X,????,[virs],????,
e696da5d-400f-4c56-9a82-96bb277fbaf1,C4048329,C0870392,is under In addition ,Immunosuppression,debate,1,X,[dsyn],[acty],E02.095.465.425.450;E05.478.610,
80797cd9-12e9-4216-b0cd-4beaac50194a,C0441516,COVID-19,were balanced during ,Demand (clinical),COVID-19,2,X,[topp],[virs],,C000657245
1dc1592f-6dda-4522-9125-e23496eafdb8,C0441516,C0034019,were balanced during ,Demand (clinical),public health medicine (field),2,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
434295a6-ae71-47f7-9a81-ed7b2e705eab,C0441516,C2745965,were balanced during ,Demand (clinical),Emergencies [Disease/Finding],2,X,[topp],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
785f02ef-84a4-4865-b510-9e1e83903428,C0032583,C0035736,are translated from ,Polyproteins,RNA Viral,1,X,[aapp/bacs],[nnon],D12.776.775,D13.444.735.828
a246cd81-44ee-46fe-9a6d-8c08865eed6b,C1441506,C1513397,estimate thermal parameters dipole moment polarizability and ,Calculation,Molecular Medicine,2,X,[acty],[bmod],,H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530
41f7c52c-c2c2-4305-be19-3489e837c2a0,C1441506,C0376534,estimate thermal parameters dipole moment polarizability and ,Calculation,Electrostatics,1,X,[acty],[npop],,G01.358.500.249.820
4501ee37-943a-424b-a7ad-8860ee169ea5,C0013227,C0678749,evaluate ,Pharmaceutical Preparations,drug binding,2,X,[phsu],[phsf],D26,
15c2dafe-a9ec-4727-af5b-0321faa7b2a7,C0013227,C1433062,were docked on ,Pharmaceutical Preparations,3C-like protease SARS coronavirus,1,X,[phsu],[aapp/enzy],D26,x.x.x.x
42facf92-0e36-4aca-83f7-6775fe4dc68f,C0002641,C1175743,might serve as good inhibitor to ,Amodiaquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.060,B04.820.504.540.150.113.937
0c1d3d9c-8821-4ba0-8190-7be64550277b,C0020336,C0024141,is standard of care in treatment of ,Hydroxychloroquine,Lupus Erythematosus Systemic,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C17.300.480;C20.111.590
b30d040f-decb-414d-9c9d-222d5871a674,C0020336,C0003873,is standard of care in treatment of ,Hydroxychloroquine,Rheumatoid Arthritis,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199
38fb6518-c6e4-4429-b47b-44b7fa99db11,C0020336,C0035436,is standard of care in treatment of ,Hydroxychloroquine,Rheumatic Fever,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.252.410.890.731;C05.550.114.843;C05.799.825
5ed6ed67-5556-45c6-bc95-8097903180a9,HCQ,C0229671,is in ,HCQ,Serum,1,X,????,[bdsu],????,A12.207.152.846;A15.145.846
f4e68f86-f75e-4bba-9aef-e043efe2b620,C0229664,C4553629,was found superior sample ,peripheral blood,MATRix Regimen,2,X,[bdsu],[topp],,
3055734d-6841-44c9-a0de-13e1b4b977dd,C1608383,C0020336,should Thus should used for ,whole blood specimen,Hydroxychloroquine,1,X,[bdsu],[orch/phsu],,D03.633.100.810.050.180.350
5b81e560-96dc-4447-9b29-da7ccd9547c1,C0035668,C1550661,was However since ,RNA,Specimen Type - Stool = Fecal,2,X,[nnon],[bdsu],D13.444.735,
d8aac2cd-7a71-4f8b-8f4e-912f445f6a22,C0178784,C1175175,also be considered as potential high risk for ,Organ,Severe Acute Respiratory Syndrome,1,X,[bpoc],[dsyn],,C02.782.600.550.200.750;C08.730.730
2783d192-39b4-435f-917c-6aefc35fd217,C0597360,C0682610,is in absorptive ,receptor expression,Enterocytes,1,X,[genf],[cell],,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
fe6c3aea-4589-42df-a643-e0ee22e4950f,C0549622,C0206750,is in current ,Sexual Dysfunction,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
fc01fb47-d759-49a1-9de3-7739458f1a73,C0598095,C0206750,is in current ,sexual dimorphism (cellular),Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
14091c3c-8033-496e-a968-009360a17007,C0549622,C0012634,is in current ,Sexual Dysfunction,Disease,1,X,[mobd],[dsyn],,C23.550.288
3a4b0e57-e567-49aa-ba25-195beb0c4951,C0598095,C0012634,is in current ,sexual dimorphism (cellular),Disease,1,X,[ortf],[dsyn],,C23.550.288
b027ab1f-e035-47ed-843d-6c6939aafe33,C0036884,C1175175,regulate ,Gonadal Steroid Hormones,Severe Acute Respiratory Syndrome,1,X,[horm/phsu],[dsyn],D06.472.334.851,C02.782.600.550.200.750;C08.730.730
b01769a8-f8c4-465a-8144-cbcd469c0800,C0206750,C0029355,has refocussed ,Coronavirus Infections,Orthopedics,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.810.494
03acfa09-2fc0-4306-896a-575587034a12,C0032930,C0543467,are in Paradoxically ,Precipitating Factors,Operative Surgical Procedures,1,X,[clna],[topp],N05.715.350.200.650;N06.850.490.625.500,E04
b4cbedbc-6360-4c99-ad2f-de6a283bd3a4,C0004093,C0013404,followed by ,Asthenia,Dyspnea,1,X,[sosy],[sosy],C23.888.089,C08.618.326;C23.888.852.371
f10c131b-5392-4b93-8c0e-e952c1c808b4,C0004093,C0010200,followed by ,Asthenia,Coughing,1,X,[sosy],[sosy],C23.888.089,C08.618.248;C23.888.852.293
240b6395-8bc4-4b79-b1a1-97d7b2567b36,C0004093,C0038056,followed by ,Asthenia,Sputum,1,X,[sosy],[bdsu],C23.888.089,A12.200.808
9b024e9f-2c77-49ae-a163-819f43ffcf48,C1457887,C0004093,was ,Symptoms,Asthenia,1,X,[sosy],[sosy],,C23.888.089
24ca86a0-f6de-48f6-b21f-7644d0be2d24,C0771571,17th,was From middle of 17th ,Cinchona bark extract,17th,2,X,[orch/phsu],????,,????
076b1365-b1b8-4190-803a-518f2f691c1f,C0040811,17th,was From middle of 17th ,Trees (plant),17th,1,X,[plnt],????,B01.650.915,????
4948668c-1f1f-470d-aae4-2bc80ab87d15,C0771571,C0003374,was From middle of 17th ,Cinchona bark extract,Antimalarials,2,X,[orch/phsu],[phsu],,D27.505.954.122.250.100.085
4948668c-1f1f-470d-aae4-2bc80ab87d15,C0771571,C0003374,was used as ,Cinchona bark extract,Antimalarials,2,X,[orch/phsu],[phsu],,D27.505.954.122.250.100.085
ce52b8be-3166-4123-b8f3-980680aa9a9a,C0040811,C0003374,was From middle of 17th ,Trees (plant),Antimalarials,1,X,[plnt],[phsu],B01.650.915,D27.505.954.122.250.100.085
ce52b8be-3166-4123-b8f3-980680aa9a9a,C0040811,C0003374,was used as ,Trees (plant),Antimalarials,1,X,[plnt],[phsu],B01.650.915,D27.505.954.122.250.100.085
62ba2d5c-73b7-4e9a-8a4f-dfb5b4e9535c,C0771571,C1015216,contains ,Cinchona bark extract,Cinchona pubescens,1,X,[orch/phsu],[plnt],,B01.650.940.800.575.912.250.456.937.250
94a05ea6-c515-4298-8352-8ccc426c4ac4,C0008269,C0018966,leading to increase in ,Chloroquine,Heme,1,X,[orch/phsu],[bacs/orch],D03.633.100.810.050.180,D03.383.129.578.840.500.640.587;D03.633.400.909.500.640.587;D04.345.783.500.640.587;D23.767.727.640.587
e3f2273a-c06b-4852-8ee3-a9c4d748bc0d,C0008269,C1335439,inhibits protozoan ,Chloroquine,Polymerase,1,X,[orch/phsu],[aapp/enzy],D03.633.100.810.050.180,
988e7ef2-3bdf-4a93-954b-177d5aee141d,C0013227,C0221106,inhibits infectivity by ,Pharmaceutical Preparations,Alkalemia,2,X,[phsu],[dsyn],D26,
4f561a9b-ac7f-4696-94ad-9e0eedb83484,C0013227,C0034848,blocking ,Pharmaceutical Preparations,Receptors Virus,1,X,[phsu],[aapp/rcpt],D26,D12.776.543.750.830
9a70069a-5fef-4584-bf1f-e41d1b727c7a,C0013227,C0034800,blocking ,Pharmaceutical Preparations,Receptors Cell Surface,1,X,[phsu],[aapp/rcpt],D26,D12.776.543.750
ba83873f-c3b7-4e84-b280-afe21f3633af,C0319157,C0017082,is with ,AS virus,Gangliosides,1,X,[virs],[orch/phsu],,D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475
aece9051-23c5-482d-bd62-3080dab4fb55,C4281807,C0017082,is with ,Vitronectin human,Gangliosides,1,X,[aapp/bacs],[orch/phsu],,D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475
5bea8332-e499-4a50-bf44-1e19b8521fff,C0872152,C3272275,is Currently ,Drug Development,Urgent Procedure,1,X,[bmod],[topp],E05.290;H01.158.703.007.338;H01.181.466.338,
ecc5d950-623d-47c1-a756-c3499f4e454e,C0013227,C1947933,adoption of be must ,Pharmaceutical Preparations,care activity,1,X,[phsu],[acty],D26,
b2276491-0100-4761-a8bc-337ee1b9b9c0,C1175743,C0012655,thus highlighting concerns about gender ,SARS coronavirus,Disease susceptibility,1,X,[virs],[clna],B04.820.504.540.150.113.937,C23.550.291.687;G07.100.250
7d239e75-e1f2-4862-ab49-cd3143785364,C0229671,C0242656,could affect ,Serum,Disease Progression,1,X,[bdsu],[patf],A12.207.152.846;A15.145.846,C23.550.291.656
f27bacae-bebe-4636-85d9-5189bb27baf1,C2603360,C0022709,co-regulating expression of ,T prime,Peptidyl-Dipeptidase A,1,X,[clna],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6c0ffbd9-b9e4-4345-8537-c9d9edfe3da7,C2603360,C1819995,co-regulating expression of ,T prime,Host Cell,1,X,[clna],[celc],,
1d1ef72e-3bb7-4719-a0cc-e8c64c9fd82c,C2603360,C1175743,may facilitate ,T prime,SARS coronavirus,1,X,[clna],[virs],,B04.820.504.540.150.113.937
66fa9d13-02b3-4c5a-8bc7-fab8747196d7,C0229671,C0856169,may predispose to ,Serum,endothelial dysfunction,1,X,[bdsu],[dsyn],A12.207.152.846;A15.145.846,
1b2f3ffa-4d62-4e42-9a9d-4ed5b00aaef8,C0028754,C0020619,is associated with functional ,Obesity,Hypogonadism,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C19.391.482
8949c6d5-49b3-4f36-833a-1d1f887fb0df,C2603360,C0849867,may predispose men to ,T prime,Widespread Disease,1,X,[clna],[dsyn],,
bc27dfbe-0d08-4a02-8e8e-20c297078d14,C2603360,C0206750,may predispose men to ,T prime,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
f755b1a3-35e2-4b0f-8694-8f2ff08abcc5,C2603360,C0009450,may predispose men to ,T prime,Communicable Diseases,1,X,[clna],[dsyn],,C01.539.221
efaf46c5-105a-4ca2-b3d6-0a323d254edf,C2603360,C1707455,is in ,T prime,Comparison,1,X,[clna],[acty],,
4ed6f0a6-8190-4b55-b3a2-e9489d15e981,C0012634,C0441516,situation ,Disease,Demand (clinical),1,X,[dsyn],[topp],C23.550.288,
a9f55342-8ae3-4f94-a142-e670fd29425c,onwards,C1706374,offered Coronavirus Infections education self-assessment and  tracking diary From,onwards,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
1057fbd4-b547-41a6-8061-f00dc8c99faf,ETZ,C1706374,offered Coronavirus Infections education self-assessment and tracking diary From,ETZ,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
eb140406-98c5-4664-bbb3-d40855a68889,onwards,C0206750,offered ,onwards,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
92baf04a-226e-4961-a7e1-7cb7344db1d3,ETZ,C0206750,offered ,ETZ,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
11e83981-eb77-4155-b3e6-99a5d75835d0,onwards,C1457887,offered ,onwards,Symptoms,1,X,????,[sosy],????,
f7f60de3-fcc9-4baa-a6e0-34aa64eb20da,ETZ,C1457887,offered ,ETZ,Symptoms,1,X,????,[sosy],????,
19d18f30-f1e4-4367-a5c5-26bed1217efb,C1533734,C1704259,optimize diagnostic ,Administration procedure,Biochemical Pathway,1,X,[topp],[moft],,
96499a9d-483a-42ee-becf-63a7eb339082,C0309872,C0521982,can increase chances of ,PREVENT (product),Response to treatment,1,X,[phsu],[clna],,
66c27783-2c7d-4878-83af-cf74f46feaaf,C0309872,C0206750,can increase chances of ,PREVENT (product),Coronavirus Infections,1,X,[phsu],[dsyn],,C02.782.600.550.200
34aeb622-f0a1-4dce-a663-5cc45c43c2c5,C0309872,C1701940,treating early ,PREVENT (product),Pneumonia Ventilator-Associated,1,X,[phsu],[dsyn],,C01.539.248.500;C08.381.677.800;C08.730.610.750
c5672dd1-1d7e-4e6e-8cc5-3160532e145d,C3260929,C0021368,still remains Due to lack of clinical studies on ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Inflammation,4,X,[clna],[patf],,C23.550.470
298cbd93-5da6-434d-a627-4e055ebcdda2,C0206750,C0034848,Affinity to,Coronavirus Infections,Receptors Virus,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,D12.776.543.750.830
d9aacd75-2f5b-4022-accd-209b04ad4747,C0155686,C0034848,Affinity to,Acute myocarditis,Receptors Virus,1,X,[dsyn],[aapp/rcpt],,D12.776.543.750.830
d3161380-df69-446e-bc5a-815a790b73a7,C0206750,C0700271,Affinity to,Coronavirus Infections,M Protein multiple myeloma,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,x.x.x.x
44226f30-2b81-4837-be7f-1d85584958a1,C0155686,C0700271,Affinity to,Acute myocarditis,M Protein multiple myeloma,1,X,[dsyn],[aapp/imft],,x.x.x.x
10315c8b-e67f-415e-822a-e52c8df7887f,C0206750,C1327414,Affinity to,Coronavirus Infections,cytokine secretion,1,X,[dsyn],[celf],C02.782.600.550.200,
cd5293e0-0be6-4127-9697-91c20564fc33,C0155686,C1327414,Affinity to,Acute myocarditis,cytokine secretion,1,X,[dsyn],[celf],,
f0e8cdbb-dc03-4a60-aaa8-e32a470fe662,C0155686,C0003130,Affinity to,Acute myocarditis,Anoxia,1,X,[dsyn],[patf],,C23.888.852.079
a0dee6fb-7a87-4066-9fac-d9a5cb180b75,C0155686,C1706202,induced cardiac muscle cell apoptotic process In our literature,Acute myocarditis,Search - action,1,X,[dsyn],[acty],,
ef7a0713-be68-4d16-a80b-b613d75d7d46,C0206750,C2611954,induced ,Coronavirus Infections,cardiac muscle cell apoptotic process,1,X,[dsyn],[celf],C02.782.600.550.200,
77872e23-b17d-4293-9af0-5a4eb4df89c6,C0155686,C2611954,induced ,Acute myocarditis,cardiac muscle cell apoptotic process,1,X,[dsyn],[celf],,
ba19a7bf-a3e1-4639-94a2-3f2177e17604,C1706202,C0027061,identified several potential mechanisms of ,Search - action,Myocardium,1,X,[acty],[tisu],,A02.633.580;A07.541.704;A10.690.552.750
26d21eb6-d0bd-46e0-9507-d52f1861560d,C0206750,C0034865,may become because of ,Coronavirus Infections,Recombination Genetic,1,X,[dsyn],[genf],C02.782.600.550.200,G05.728
e1f264d0-0cdf-47d5-af35-b03f9c57d0e6,C0199176,C0309872,are mandatory to ,Prophylactic treatment,PREVENT (product),2,X,[topp],[phsu],,
75ecf233-848d-4403-892e-15c7bc980482,C0199176,C1175175,are mandatory to ,Prophylactic treatment,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],,C02.782.600.550.200.750;C08.730.730
57058d09-5045-4ddd-8cd3-af4fd4b0acc5,C0039986,C1298802,are frequent Among ,Thoracic Surgery Specialty,Emergency procedure,1,X,[bmod],[topp],H02.403.810.803,
11b08ab9-4f21-4b49-b403-f140d3979976,C0543467,C1298802,are frequent Among ,Operative Surgical Procedures,Emergency procedure,1,X,[topp],[topp],E04,
c148618a-fc59-491e-a3d3-afb50eab4cb7,C1704259,C1705178,is mandatory in ,Biochemical Pathway,Order (action),1,X,[moft],[acty],,
7fe6fec2-7ec4-46c4-8763-53007a2be943,C1707455,C0016059,is with non ,Comparison,Fibrosis,1,X,[acty],[patf],,C23.550.355
f8e64b36-9398-4b82-b9ff-3f795d8d139d,C0016059,C0149783,had longer-term of hospitalization pulsed ,Fibrosis,Steroid therapy,1,X,[patf],[topp],C23.550.355,
f85516cb-c3bd-436d-86ca-9084ba7f6bd9,C0016059,C0280274,had longer-term of hospitalization pulsed ,Fibrosis,Antiviral Therapy,1,X,[patf],[topp],C23.550.355,
1364b166-0eaf-443e-9c58-a2beada630dd,C4553629,y31,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,y31,1,X,[topp],????,,????
88634e20-1cf8-48b9-8002-55a9cc79000c,C0026652,COVID-19,improve Symptoms with,Moxibustion,COVID-19,1,X,[topp],[virs],E02.190.044.588,C000657245
0bcce161-e10f-4fa5-a998-e701c2b29893,C1265876,C1707455,increase beyond ,Abnormally opaque structure (morphologic abnormality),Comparison,1,X,[patf],[acty],,
0db3ca39-6a4c-4fda-8136-ed46e0bdc339,C1447020,C0014609,is variously expressed on ,DPP4 protein human,Epithelium,2,X,[aapp/enzy],[tisu],x.x.x.x,A10.272
761c3238-2466-42d4-9554-538f9bd13558,C1447020,C0031845,was implicated in various ,DPP4 protein human,Physiological Processes,1,X,[aapp/enzy],[phsf],x.x.x.x,G07
08db82a3-97d2-46ab-8036-c2714c87b094,C1447020,C0086418,is in ,DPP4 protein human,Homo sapiens,1,X,[aapp/enzy],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
f4125a24-d4b3-4b3f-8c6d-0c91ceb2f9f4,C2728259,C1856053,was held from ,Program,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[orch/phsu],[dsyn],V02.355.750,x.x.x.x
d585b175-5df6-4405-bb7d-8bc9d880dc96,C0319157,U.S,is in U.S ,AS virus,U.S,1,X,[virs],????,,????
ae918bd4-b27b-4974-b0c9-8881ba7e465c,C2936695,C1511790,were proposed for ,Graphene,Detection,2,X,[elii],[topp],D01.268.150.300;D01.578.300;x.x.x.x,
d60738f9-b741-43a9-a3a4-c5a782d41ee6,C2936695,C0005516,were proposed for ,Graphene,Biological Markers,2,X,[elii],[clna],D01.268.150.300;D01.578.300;x.x.x.x,D23.101
ae236c2c-ef74-43f1-8b31-e69651fdb35d,C2936695,C1720804,numerous methods including optical ,Graphene,Raman Scattering,2,X,[elii],[npop],D01.268.150.300;D01.578.300;x.x.x.x,E05.196.822.860;E05.196.867.890
98970261-227c-4f57-9ca0-156c8a6911c0,C0038454,COVID-19,should closely Assessed lung apices during,Cerebrovascular accident,COVID-19,3,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,C000657245
7df3ecd3-faaf-4b2e-8cd7-ae1e032439ed,C0038454,apices,should Assessed lung apices,Cerebrovascular accident,apices,1,X,[dsyn],????,C10.228.140.300.775;C14.907.253.855,????
3c0692d8-0fd3-4925-b484-b6241ecb4328,C4554671,COVID-19,may ,CERNA3 gene,COVID-19,1,X,[gngm],[virs],,C000657245
2cbe3f59-4fae-4d33-ac13-28cbdae92a71,C4554671,C0009450,may ,CERNA3 gene,Communicable Diseases,1,X,[gngm],[dsyn],,C01.539.221
2ad677ae-8c1f-4949-b090-e69004c268fc,C0038952,C0374505,was in ,Continuance of life,Group Therapies,1,X,[acty],[topp],I03.784,
0d0c573b-cddd-4ae1-90c5-a5908225a9f7,C0038952,C1707455,was in ,Continuance of life,Comparison,1,X,[acty],[acty],I03.784,
230ea999-86c3-4a57-bf71-f4821be1f053,C0231832,C1947933,were associated with need for ICU ,Respiratory rate,care activity,1,X,[clna],[acty],E01.370.600.875.875;G09.772.705.730,
a0ee3681-b0c7-4645-997d-9bee85eb1fb5,C0960756,C0543467,is in ,factor A,Operative Surgical Procedures,2,X,[orch],[topp],x.x.x.x,E04
9d0d290c-3836-4b6a-8c28-c63d988996c4,C1706202,C0014507,summarize latest publishedinformation about ,Search - action,Epidemiology,1,X,[acty],[bmod],,H02.403.720.500
39b238aa-0642-441d-98f8-45ba37f1dfc8,C0013404,C0015967,are ,Dyspnea,Fever,1,X,[sosy],[sosy],C08.618.326;C23.888.852.371,C23.888.119.344
a1bd612d-afa9-421d-9d06-96abc25ba2b4,C0015967,C0014507,is based on ,Fever,Epidemiology,1,X,[sosy],[bmod],C23.888.119.344,H02.403.720.500
c3494809-46d1-454c-b4ef-5e360e4cf62a,C2933547,C1707391,is in 2016 ,Nominee,Choose (action),1,X,[hops/orch],[acty],,
b8c1db9d-83e0-4674-941e-234ebb514579,C0679699,C0004153,is in patients with established ,Secondary Prevention,Atherosclerosis,1,X,[topp],[dsyn],E02.897;N02.421.726.825;N06.850.780.750,C14.907.137.126.307
0f721dd2-00a7-49a4-9016-7ed3f23b52ff,C0034019,C1707455,were Choose (action) for systematic,public health medicine (field),Comparison,1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
c8b22eed-044c-4eb3-b3b1-28bab2e84967,C0034019,C0270724,were Choose (action) for systematic,public health medicine (field),Infantile Neuroaxonal Dystrophy,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C10.228.140.744
00093ee8-11e4-4084-a81f-db8539cd0905,C1707455,C0270724,is with COVID19 ,Comparison,Infantile Neuroaxonal Dystrophy,1,X,[acty],[dsyn],,C10.228.140.744
00f7cc67-6adc-4339-bc86-7f04cc58fe22,C1707455,COVID19,is with COVID19 ,Comparison,COVID19,1,X,[acty],????,,????
be374a5e-304c-46c3-a118-232ecd525931,C0034019,C1707391,were ,public health medicine (field),Choose (action),1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
e2975a06-c771-413b-9ce2-be289bda4080,C0013879,COVID-19,basically meet ,Elements,COVID-19,1,X,[elii],[virs],D01.268,C000657245
1bf1e0c4-292f-47ea-b63c-7df430c844b5,C0034019,C1527075,need ,public health medicine (field),Revision procedure,2,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,
1591fab5-d7cb-4557-b3e1-ac0b07291aaa,C3463820,C0319157,blocks ,Inhibition,AS virus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,
d4047225-b568-4093-aaad-e0a618d6a19a,C3463820,C0022709,blocks AS virus fusion with,Inhibition,Peptidyl-Dipeptidase A,1,X,[acty],[aapp/enzy/imft],F01.145.544;F02.463.425.475;F02.739.794.405,D08.811.277.656.350.350.687
49fc7521-68e1-4b77-9d5c-8f498f82381e,C0014442,C1656555,facilitates ,Enzymes,viral entry into host cell,2,X,[aapp/enzy],[celf],D08.811,
cecfe25a-1916-449d-a5be-90f5fe721b3d,C0014442,C4085054,facilitates ,Enzymes,PARTICL gene,1,X,[aapp/enzy],[gngm],D08.811,
7a397a21-9e39-4c22-9935-663138be35de,C0702166,C0012634,were most common ,Acne,Disease,1,X,[dsyn],[dsyn],C17.800.030.150;C17.800.794.111,C23.550.288
2be40acf-732f-4580-a0d6-3a31c85760d0,C3665596,C0012634,were most common ,Warts,Disease,1,X,[neop],[dsyn],C02.256.650.810;C02.825.810;C02.928.914;C17.800.838.790.810,C23.550.288
be0e815a-f333-4104-aea4-d766ed2bcbda,C0036508,C0012634,were most common ,Seborrheic dermatitis,Disease,1,X,[dsyn],[dsyn],C17.800.174.580;C17.800.794.230;C17.800.815.580;C17.800.859.350,C23.550.288
fa3b4ca9-564d-4fda-bf43-602d669506b4,C0042109,C0012634,were most common ,Urticaria,Disease,1,X,[dsyn],[dsyn],C17.800.862.945;C20.543.480.904,C23.550.288
abd485c3-0630-48d6-881f-5c1e219fecdd,C0033860,C0012634,were most common ,Psoriasis,Disease,1,X,[dsyn],[dsyn],C17.800.859.675,C23.550.288
b48da9c6-e123-43c9-8988-32ce6ea3ddc0,C1825598,C0037274,trends of ,IMPACT gene,Dermatologic disorders,1,X,[gngm],[dsyn],,C17.800
4f4dc0e4-25c6-4323-8e2f-9a61e35655b5,C0206750,DMHS,has resulted in significant increase in contact with DMHS,Coronavirus Infections,DMHS,1,X,[dsyn],????,C02.782.600.550.200,????
49469ddf-bbf7-4cb5-b188-173d8bf053d2,DMHS,C1999230,could play role in ,DMHS,Providing (action),2,X,????,[acty],????,
3d72ea04-e639-448e-9239-de6ab1963a9f,C0018801,C0010340,is in especially ,Heart failure,Critical Illness,1,X,[dsyn],[dsyn],C14.280.434,C23.550.291.625
6f054f4f-f932-41b9-a251-2a567035700a,C0597404,C1999230,have ,Respiratory viruses,Providing (action),8,X,[virs],[acty],,
1146604e-e9e9-4cc5-8a53-cfc46be67604,C0597404,C1521827,have ,Respiratory viruses,Preparation,8,X,[virs],[acty],,
93007f84-536a-42b7-82f6-a9dd9a05eec2,C0597404,C0015357,have ,Respiratory viruses,Extracorporeal Membrane Oxygenation,4,X,[virs],[topp],,E02.880.301;E04.292.451
885228a8-3106-49ee-9f81-8ec308d5fa19,C1175175,C1999230,have ,Severe Acute Respiratory Syndrome,Providing (action),4,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
544ec5e4-86c5-4ef8-b73e-7c7343e8799c,C1175175,C1521827,have ,Severe Acute Respiratory Syndrome,Preparation,4,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
57aa0c22-8267-40d7-bfc9-9c9394adc6a8,C1175175,C0015357,have ,Severe Acute Respiratory Syndrome,Extracorporeal Membrane Oxygenation,2,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,E02.880.301;E04.292.451
8bdc848b-7ccb-41be-84f3-d8aadd3607f6,C0746885,C0206750,contributes to higher mortality of ,neutrophilic,Coronavirus Infections,2,X,[celf],[dsyn],,C02.782.600.550.200
7eedbedc-33ff-4d3b-bef9-7a215be926dd,C0007430,C0547605,are usually built Per ,Catheterization,prevention of infection,2,X,[topp],[topp],E02.148;E05.157,
3e17bfe2-757c-4fb9-8113-c10b75406481,C0007430,C0021778,are usually built as ,Catheterization,Intermittent Positive-Pressure Ventilation,2,X,[topp],[topp],E02.148;E05.157,E02.041.625.790.550;E02.880.820.790.550
2844bc26-6a16-4a5a-9e59-3d000e74b5cd,C0042776,C0014139,use ,Virus,Endocytosis,1,X,[virs],[celf],B04,G04.417
f40948e1-8ee0-4834-aadd-2f60e5e0cde0,C0085155,C1175743,Furthermore are identified as potential candidates repurposing as blockers of potential routes for ,Generic Drugs,SARS coronavirus,1,X,[phsu],[virs],D26.360,B04.820.504.540.150.113.937
c2b03033-2bae-4a84-b979-40d62a392414,C1334043,C0206422,is with other ,Homologous Gene,Human coronavirus,1,X,[gngm],[virs],,
542109e6-afb0-48e9-af69-6d1c39466c1a,C0206422,C3542961,have had ,Human coronavirus,NERVOUS SYSTEM DRUGS,1,X,[virs],[phsu],,
9a6a8ca2-3777-47b2-9ab4-754a10b1eb80,C0014038,C0206750,have have associated with ,Encephalitis,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.430,C02.782.600.550.200
a5726224-4cda-40d9-beec-7403794c2896,C0011304,C0206750,have have associated with ,Demyelination,Coronavirus Infections,1,X,[patf],[dsyn],C10.314,C02.782.600.550.200
8d628826-0310-46fd-8fc5-8cb41ad873e9,C0442874,C0206750,have have associated with ,Neuropathy,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
9c856b37-1c7a-4981-820c-358bc7cd49a2,C0038454,C0206750,have have associated with ,Cerebrovascular accident,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C02.782.600.550.200
1fb19c52-aac0-42a7-9f74-a8e475aa9eb4,C0206750,C0027765,is with ,Coronavirus Infections,nervous system disorder,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10
53ad8f72-3be9-47e8-92c0-886294346612,C0042776,C2806453,are related ,Virus,Betacoronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113
0dda1718-262f-44e4-b0b1-7378d649c57c,ageing,C0243107,Developmental delay (disorder) on,ageing,development aspects,1,X,????,[phsf],????,
750e9438-49cf-45c1-925d-4aaac3e93d3b,C0035204,C0319157,is in ,Respiration Disorders,AS virus,1,X,[dsyn],[virs],C08.618,
e718818d-51e2-4dd3-8778-2f16175eed44,C0035204,C0032310,is in ,Respiration Disorders,Pneumonia Viral,1,X,[dsyn],[dsyn],C08.618,C02.705;C08.381.677.807;C08.730.610.763
2d3b2589-aca7-4e99-9abd-a4f220c05906,C0012634,C0032310,is in ,Disease,Pneumonia Viral,1,X,[dsyn],[dsyn],C23.550.288,C02.705;C08.381.677.807;C08.730.610.763
3b8fcf40-04fc-4c27-8038-26f4ff59ce10,C0035204,C1265876,is in ,Respiration Disorders,Abnormally opaque structure (morphologic abnormality),1,X,[dsyn],[patf],C08.618,
185e918d-6922-4c60-a8ee-c8589c2c4913,C0012634,C1265876,is in ,Disease,Abnormally opaque structure (morphologic abnormality),1,X,[dsyn],[patf],C23.550.288,
7cf1fd1d-e7f8-463c-8b26-e8c403ec2ebf,C1293122,C0206750,is with ,Augmentation procedure,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
fa3e67b5-0f3a-477b-a99e-3336d056c702,C1997614,C1175743,is in patients hospitalised for ,Thromboembolism of vein,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
e5b3ca75-cb0d-4fc0-8cd4-1fcb75325077,C0024109,C0398623,may contribute to transient ,Lung,Thrombophilia,1,X,[bpoc],[dsyn],A04.411,C15.378.925
fd282f79-e6c0-43d8-889b-05e8ff5aa13e,C1155266,C0398623,may contribute to transient ,inflammatory response,Thrombophilia,1,X,[patf],[dsyn],,C15.378.925
a265bed8-2dae-4675-a1ad-205f0c82edb7,C0034065,C0476273,may cause further ,Pulmonary Embolism,Respiratory distress,1,X,[patf],[sosy],C08.381.746;C14.907.355.350.700,
a0546f9b-377f-44f5-9c8f-010f565bb7e7,C0034065,C0242656,was in one case diagnosed during phase ,Pulmonary Embolism,Disease Progression,1,X,[patf],[patf],C08.381.746;C14.907.355.350.700,C23.550.291.656
a0546f9b-377f-44f5-9c8f-010f565bb7e7,C0034065,C0242656,was diagnosed during convalescent phase ,Pulmonary Embolism,Disease Progression,1,X,[patf],[patf],C08.381.746;C14.907.355.350.700,C23.550.291.656
2e12ba13-501a-4f44-a748-c4fb5de78591,C3272452,RT-PCR,can can detected by RT-PCR ,Single-Stranded RNA,RT-PCR,2,X,[nnon],????,,????
1aeb6c15-74c7-45b4-94a1-a25b1eb8f48f,C1262020,C0013604, includes ,diffuse alveolar damage,Edema,1,X,[dsyn],[sosy],,C23.888.277
a07324bb-6a79-424a-a75a-b9be76e709f0,C1262020,C0333563, includes ,diffuse alveolar damage,Hyaline membrane,1,X,[dsyn],[patf],,
63e2b8a3-71cc-4c8f-ae70-86221201108c,C0024109,C1262020,showed various stages of ,Lung,diffuse alveolar damage,1,X,[bpoc],[dsyn],A04.411,
4e771c20-5a94-45f0-85a9-94e4148883a7,C0024109,C0225698,showed various stages of ,Lung,Alveolar Epithelial Cells,2,X,[bpoc],[cell],A04.411,A04.411.715.100;A11.436.081
e484b9dd-07b8-4b72-ba4b-55c69437e716,C0024109,C0013604,showed various stages of ,Lung,Edema,1,X,[bpoc],[sosy],A04.411,C23.888.277
2f9f1404-5f67-4bc5-ac15-a6888bf0a909,C0024109,C0333563,showed various stages of ,Lung,Hyaline membrane,1,X,[bpoc],[patf],A04.411,
a2eecd0d-804c-45cc-ab7a-43fc9ef9ae6c,C0302148,C0021308,was associated with ,Blood Clot,Infarction,1,X,[patf],[patf],C14.907.355.830,C23.550.513.355;C23.550.717.489
d9d1b8ee-2a1d-414a-9f82-4fcb1a076fe6,C0206750,C0865850,leading to ,Coronavirus Infections,Acute respiratory insufficiency,1,X,[dsyn],[dsyn],C02.782.600.550.200,
99a37d99-304d-40f0-92fd-8629b0fd63be,C0206750,C0376545,poses unique challenge to care of patients with ,Coronavirus Infections,Hematologic Neoplasms,1,X,[dsyn],[neop],C02.782.600.550.200,C04.588.448;C15.378.400
1d7f8bea-2a6e-441b-aefe-4a013f0ce2b1,C0032310,C0006826,cause disproportionately severe disease in patients with ,Pneumonia Viral,Malignant Neoplasms,1,X,[dsyn],[neop],C02.705;C08.381.677.807;C08.730.610.763,C04
37ff4a72-752d-407e-87cb-104bdff5c390,C0678236,C0206750,is in current pandemic ,Rare Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.906,C02.782.600.550.200
e8ec72c2-3ffd-4005-9eb5-cc73a3673c58,COVID-19,C1155266,triggering ,COVID-19,inflammatory response,1,X,[virs],[patf],C000657245,
f3666f25-2969-4f2f-9080-0824b430b5c3,COVID-19,C0024291,simulate ,COVID-19,Lymphohistiocytosis Hemophagocytic,1,X,[virs],[dsyn],C000657245,C15.604.250.410.575
2b4e5f8c-7dbd-43ce-a1d4-6e6f668021b7,C0020517,C0072027,suggesting ,Hypersensitivity,procalcitonin,1,X,[patf],[aapp/bacs],C20.543,D06.472.699.666;D12.644.548.744;D12.776.811.555
524b1e2d-1dcf-4e28-b91c-3f4634acac36,COVID-19,C0857828,is in ,COVID-19,infection in the elderly,1,X,[virs],[dsyn],C000657245,
a4453644-b5b7-4f5e-82d8-de0e3dc45330,C0857828,COVID-19,is with ,infection in the elderly,COVID-19,1,X,[dsyn],[virs],,C000657245
f678b085-60a3-4832-a5c0-eafbc685394e,C0857828,C0009450,is with ,infection in the elderly,Communicable Diseases,1,X,[dsyn],[dsyn],,C01.539.221
0d3bb84b-a49b-4ff8-85f3-42041c2b2674,C0242781,COVID-19,was fitted to ,disease transmission,COVID-19,1,X,[patf],[virs],N06.850.310,C000657245
b75e19be-e66e-497d-ba19-aa5d2923b14b,C0031640,C1448177,of role is particularly ,phosphoric diester hydrolase,TNF protein human,1,X,[aapp/enzy],[aapp/bacs],D08.811.277.352.640,x.x.x.x
aa5c9666-aed1-447a-a036-718a5eb58f00,C3463820,C1448177,through role is particularly ,Inhibition,TNF protein human,1,X,[acty],[aapp/bacs],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
b0b2edec-4e29-409f-9ada-36864291f059,C1155266,C1448177,in role is particularly ,inflammatory response,TNF protein human,1,X,[patf],[aapp/bacs],,x.x.x.x
aaca11d8-10cc-4339-aeb0-d6c4d37f122e,C2936609,COVID-19,attenuate cytokine storm in,Phosphodiesterase 4 Inhibitors,COVID-19,1,X,[phsu],[virs],D27.505.519.389.735.374,C000657245
7eaab47a-1d96-41cd-b638-0ebd27b27d89,C2936609,C0079189,attenuate ,Phosphodiesterase 4 Inhibitors,cytokine,1,X,[phsu],[aapp/imft],D27.505.519.389.735.374,D12.644.276.374;D12.776.467.374;D23.529.374
350ec1af-e145-41f7-9e0c-269115c88041,C3463820,C0079189,attenuate ,Inhibition,cytokine,1,X,[acty],[aapp/imft],F01.145.544;F02.463.425.475;F02.739.794.405,D12.644.276.374;D12.776.467.374;D23.529.374
4ee6adb2-3b1a-49cc-af64-e5764c336dde,C0678236,C0023884,affecting ,Rare Diseases,Liver,2,X,[dsyn],[bpoc],C23.550.291.906,A03.620
c73044ee-33fc-4d7a-938c-d8d057d113e7,C0678236,C3542961,affecting ,Rare Diseases,NERVOUS SYSTEM DRUGS,2,X,[dsyn],[phsu],C23.550.291.906,
44a923fd-9862-4f0a-83b3-24c615968ff0,C0678236,C0018787,affecting ,Rare Diseases,Heart,2,X,[dsyn],[bpoc],C23.550.291.906,A07.541
67c9797d-ae34-4b70-b2fb-0ae29d995587,C0678236,C0022646,affecting ,Rare Diseases,Kidney,2,X,[dsyn],[bpoc],C23.550.291.906,A05.810.453
abda0c04-ca4e-4232-af28-75b7a58db5ce,C0268381,C0018787,often present with ,Primary amyloidosis,Heart,1,X,[dsyn],[bpoc],C04.557.595.250;C18.452.845.500.550;C20.683.515.507;C20.683.780.565,A07.541
c6bbd404-0c41-41a6-b639-98f2e639353c,C0268381,C0277543,often present with ,Primary amyloidosis,Functional disease present,1,X,[dsyn],[dsyn],C04.557.595.250;C18.452.845.500.550;C20.683.515.507;C20.683.780.565,
6d66fe5c-85e0-453c-a24d-3c5170536c05,C1457887,C0032310,is in groups with ,Symptoms,Pneumonia Viral,1,X,[sosy],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
b6e90436-2b23-4bf0-afdd-a164dbe2b96f,C0015967,C0032310,were main Symptoms in groups with,Fever,Pneumonia Viral,1,X,[sosy],[dsyn],C23.888.119.344,C02.705;C08.381.677.807;C08.730.610.763
7570eb2a-3ee8-4810-9eaa-fa71edf24a03,C0010200,C0032310,were main Symptoms in groups with,Coughing,Pneumonia Viral,1,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.705;C08.381.677.807;C08.730.610.763
63534350-88c2-47d7-b713-7ee7d7610713,C0038056,C0032310,were main Symptoms in groups with,Sputum,Pneumonia Viral,1,X,[bdsu],[dsyn],A12.200.808,C02.705;C08.381.677.807;C08.730.610.763
fa9a7835-bf3d-4881-acbe-5f7b1d88de62,C0032227,C2062441,were more common in patients with ,Pleural effusion disorder,Influenza A,1,X,[dsyn],[dsyn],C08.528.652,
a282c7fd-0bf6-4850-896c-d90c36080a9c,C0032227,C0032285,were more common in patients with ,Pleural effusion disorder,Pneumonia,2,X,[dsyn],[dsyn],C08.528.652,C08.381.677;C08.730.610
399a2377-eeae-40cd-8aeb-a070e19982f5,C0020564,COVID-19,were common in ,Hypertrophy,COVID-19,1,X,[patf],[virs],C23.300.775,C000657245
4cf08a65-bd15-497b-a295-ea88e4c531db,C0032227,COVID-19,were common in ,Pleural effusion disorder,COVID-19,1,X,[dsyn],[virs],C08.528.652,C000657245
fdc9b2ad-9aed-4d32-a399-07cfa352aa6f,C0020564,C0032285,were common in ,Hypertrophy,Pneumonia,1,X,[patf],[dsyn],C23.300.775,C08.381.677;C08.730.610
5bfcadab-acef-4ceb-8b8c-27c3ebc7e267,C0264545,C0032285,were common in ,Thickening of pleura,Pneumonia,1,X,[dsyn],[dsyn],,C08.381.677;C08.730.610
3f605b09-9430-4bb9-a820-285f6564506b,C0086312,C1828170,showed mean standard ,Forests,Mean deviation,1,X,[npop],[clna],G16.500.275.157.437;N06.230.124.343,
75350433-777c-4b4c-83a2-f9a15f8d7e57,C0086312,C0020517,showed mean standard ,Forests,Hypersensitivity,1,X,[npop],[patf],G16.500.275.157.437;N06.230.124.343,C20.543
8c279c23-2300-4915-b6c7-957688d7625b,COVID-19,C0878751,is in ,COVID-19,late pregnancy,1,X,[virs],[patf],C000657245,
06a442c3-23ef-450a-a8f3-a390ed079526,C0009450,C0878751,is in ,Communicable Diseases,late pregnancy,1,X,[dsyn],[patf],C01.539.221,
eefefd73-41fb-45d7-b59b-920d8e1d9af8,C0162633,19days,was 19days,Viral Shedding,19days,2,X,[patf],????,G07.925,????
f5049671-87bc-43c6-af1f-ec7ec73a82b4,C0035668,19days,was 19days,RNA,19days,1,X,[nnon],????,D13.444.735,????
dc32b4f3-62ea-48dc-bffc-83a1f422bdf8,C0018581,C0206750,have have advocated as proactive measures against spread of ,Handwashing,Coronavirus Infections,1,X,[acty],[dsyn],N06.850.670.150.500,C02.782.600.550.200
dc32b4f3-62ea-48dc-bffc-83a1f422bdf8,C0018581,C0206750,was most common practice in response to ,Handwashing,Coronavirus Infections,1,X,[acty],[dsyn],N06.850.670.150.500,C02.782.600.550.200
4d97f678-4358-4f79-a87a-4ecb2c933c7e,C0019247,C0018799,represent heterogenous group of ,Hereditary Diseases,Heart Diseases,2,X,[dsyn],[dsyn],C16.320,C14.280
ff1397bd-53e1-4075-a6f0-3f279a3ffbc1,C0018787,C0018799,represent heterogenous group of ,Heart,Heart Diseases,1,X,[bpoc],[dsyn],A07.541,C14.280
53a97978-9880-4c25-91cf-e4c4ea64b45f,C2316160,C0206750,is in critically ill patients with ,Infection of bloodstream,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
c3c5b596-3b88-4dd4-870d-dc7d2fc11d6e,C0018799,C0009450,seems result of inflammatory storm in response to ,Heart Diseases,Communicable Diseases,2,X,[dsyn],[dsyn],C14.280,C01.539.221
c4eecd16-0735-47b4-818b-62658bedc9d2,C2948600,C0042776,suppress spread of ,Aim,Virus,1,X,[inch/phsu],[virs],,B04
c4eecd16-0735-47b4-818b-62658bedc9d2,C2948600,C0042776,investigate ,Aim,Virus,1,X,[inch/phsu],[virs],,B04
68736538-9e1a-4ef2-b5c0-abcad90f0523,C1825598,C3825997,at look is changes to ,IMPACT gene,Medicine--Practice,2,X,[gngm],[bmod],,
74a2fe37-518a-419d-9be7-2455c0ec791a,C0021966,C3825997,changes to ,Iodides,Medicine--Practice,2,X,[inch],[bmod],D01.248.497.158.490;D01.475.410,
8d6721fb-52d6-40dd-acac-4a001ba51566,COVID-19,C0032064,comparable to past epidemics like ,COVID-19,Plague,1,X,[virs],[dsyn],C000657245,C01.252.400.310.980.745
b0095338-8f63-4af7-bd43-6fa8596df4fe,COVID-19,C0021400,comparable to past epidemics like ,COVID-19,Influenza,1,X,[virs],[dsyn],C000657245,C02.782.620.365;C08.730.310
89573f45-1971-4374-8208-c8d5ceba8b5a,C0599779,C0699748,study ,Animal Model,Pathogenesis,1,X,[anim],[patf],E05.598,
17a0ee5a-1c23-4e70-916f-2d57d3bdb064,C0599779,C0206750,study ,Animal Model,Coronavirus Infections,1,X,[anim],[dsyn],E05.598,C02.782.600.550.200
c5d68bf6-bf8f-43cc-af86-c2d590c5153a,C0237798,C0009450,are considered gold model for many ,Nonhuman primate,Communicable Diseases,1,X,[mamm],[dsyn],,C01.539.221
c5d68bf6-bf8f-43cc-af86-c2d590c5153a,C0237798,C0009450,gold standard model for many ,Nonhuman primate,Communicable Diseases,1,X,[mamm],[dsyn],,C01.539.221
6968548f-b2db-45ba-9a1b-9979c60acf9a,C0237798,C0450254,are considered gold model for many ,Nonhuman primate,Pathogenic organism,1,X,[mamm],[orgm],,
6968548f-b2db-45ba-9a1b-9979c60acf9a,C0237798,C0450254,gold standard model for many ,Nonhuman primate,Pathogenic organism,1,X,[mamm],[orgm],,
2179f919-d69f-4377-9bf6-c443231187d6,C0026438,C1175743,support high level of ,Cercopithecus aethiops,SARS coronavirus,2,X,[mamm],[virs],B01.050.150.900.649.313.988.400.112.199.120.126.110,B04.820.504.540.150.113.937
04a465bc-df4f-4fdb-a406-200a9f628aee,C0026438,C0035204,develop pronounced ,Cercopithecus aethiops,Respiration Disorders,1,X,[mamm],[dsyn],B01.050.150.900.649.313.988.400.112.199.120.126.110,C08.618
424dcf0c-bd9d-421f-a397-ee965c909e7a,C0035204,C0237798,reported for other ,Respiration Disorders,Nonhuman primate,1,X,[dsyn],[mamm],C08.618,
c69f3cde-b2fe-4e84-9d51-17eb67e237ff,C0042774,C0026438,can Importantly can produced in ,Virus Replication,Cercopithecus aethiops,1,X,[celf],[mamm],G06.920.925,B01.050.150.900.649.313.988.400.112.199.120.126.110
b4d6ca95-74a0-40ca-963a-24572b88f5c9,COVID-19,C0010332,is world-wide Crisis Intervention without effective,COVID-19,Crisis Intervention,2,X,[virs],[topp],C000657245,F04.754.252
82ba89c5-7772-4edd-8425-7e6c5c598eff,C3687832,C0012634,were developed for other ,Drugs - dental services,Disease,1,X,[topp],[dsyn],,C23.550.288
3893ceb8-0985-4424-baf9-80066f17bdf2,C0206750,C0025831,is methylated by two ,Coronavirus Infections,Methyltransferase,1,X,[dsyn],[aapp/enzy],C02.782.600.550.200,D08.811.913.555.500
ade10df6-7f8a-4ee4-bfce-7508e45a8788,C0035670,C0025831,is methylated by two ,RNA Caps,Methyltransferase,1,X,[bacs/nnon],[aapp/enzy],D03.633.100.759.646.454.700;D13.444.735.544.500;D13.695.667.454.700;D13.695.827.426.700,D08.811.913.555.500
6e7524b7-d5ae-4afe-a17b-561389216729,C0025723,C0036002,form ,Methylation,S-Adenosylmethionine,1,X,[moft],[aapp/bacs/phsu],G02.111.035.538;G02.607.094.538;G03.059.538,D02.886.030.676.180;D03.633.100.759.590.138.264;D12.125.166.676.180;D13.570.583.138.264;D13.570.800.096.264
1b641f63-e026-4510-804c-783cf6f36c9d,C0025723,C1167395,depends on level in ,Methylation,Host (organism),1,X,[moft],[orgm],G02.111.035.538;G02.607.094.538;G03.059.538,
ac559236-8493-4d59-9ef2-ec7ea256bbfd,C1514798,COVID-19,Aim to,Recombinants,COVID-19,1,X,[orgm],[virs],,C000657245
e24a1ce6-2eb5-42ce-8d05-f78fe5ac08a6,C0064548,COVID-19,Aim to,Methionine gamma-lyase,COVID-19,1,X,[aapp/enzy],[virs],x.x.x.x,C000657245
091b020e-f241-45ae-adbe-2fa8f703ddc3,C1514798,C0087111,Aim to,Recombinants,Therapeutic procedure,1,X,[orgm],[topp],,E02
0c51a994-1b0f-4b23-a60e-c641677becce,C0064548,C0087111,Aim to,Methionine gamma-lyase,Therapeutic procedure,1,X,[aapp/enzy],[topp],x.x.x.x,E02
c3d5859d-69de-49fd-8951-3cf9c538cf02,C0596290,C0520917,have ,Cell Proliferation,Increased metabolic requirement,1,X,[celf],[patf],G04.161.750;G07.345.249.410.750,
54171ed4-d227-46b3-874a-0b596b195447,C0596290,C0025646,have ,Cell Proliferation,Methionine,1,X,[celf],[aapp/bacs/phsu],G04.161.750;G07.345.249.410.750,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
ab6920fa-a427-451b-b921-4127f4274138,C0039194,C0025646,greatly increases ,T-Lymphocyte,Methionine,1,X,[cell],[aapp/bacs/phsu],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
6762f3a8-bc1a-4702-a3c0-d1a9665d1cab,C1879547,C0025646,greatly increases ,Activation action,Methionine,1,X,[acty],[aapp/bacs/phsu],,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
c0043ca8-170a-4081-815a-669d0b160fad,C0024432,C0025646,restricting ,macrophage,Methionine,1,X,[cell],[aapp/bacs/phsu],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
c3686046-d347-49fe-82bf-a15a07f80183,C0079189,C0025646,restricting ,cytokine,Methionine,1,X,[aapp/imft],[aapp/bacs/phsu],D12.644.276.374;D12.776.467.374;D23.529.374,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
8a6d24ef-a367-4443-87a5-1e2e08b51609,C1514798,C0206750,be promising treatment for ,Recombinants,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
8a6d24ef-a367-4443-87a5-1e2e08b51609,C1514798,C0206750,spread of ,Recombinants,Coronavirus Infections,2,X,[orgm],[dsyn],,C02.782.600.550.200
44ee3aac-c535-4a66-a9fd-a6bb446469b5,C0064548,C0206750,be promising treatment for ,Methionine gamma-lyase,Coronavirus Infections,1,X,[aapp/enzy],[dsyn],x.x.x.x,C02.782.600.550.200
9a53c503-7128-47f2-8f24-7cb51fd7994f,C1708476,C1856053,of weeks is ,Implementation,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[acty],[dsyn],,x.x.x.x
c6394dba-bbb2-4343-b181-dca54fc0b477,C0242781,C0034386,using strategies of ,disease transmission,Quarantine,1,X,[patf],[topp],N06.850.310,N06.850.780.200.450.700
b0bc9668-2b54-425b-9ef1-83072441fe06,C0079189,C1175175,associated to ,cytokine,Severe Acute Respiratory Syndrome,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C02.782.600.550.200.750;C08.730.730
69cbc9b9-745b-4800-ad53-393188002492,C1861452,C1175175,associated to ,Storm Syndrome,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200.750;C08.730.730
7d1ab1d9-9e1a-4e07-80e3-b6281ae1d260,C0079189,C0021368,associated with ,cytokine,Inflammation,1,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.470
aa68d656-fb7e-49ce-98b0-dcc4e44e390d,C1861452,C0021368,associated with ,Storm Syndrome,Inflammation,1,X,[dsyn],[patf],x.x.x.x,C23.550.470
73f26475-1245-4d5b-ba3e-65d9eaa4d339,C1720208,C0184893,encompass ,Ophthalmic plastic surgery,Emergency operation,1,X,[bmod],[topp],,
0bac17e1-24e9-4413-95e8-8d885269fe3f,C0206750,C2364082,lead to ,Coronavirus Infections,Sense of smell impaired,2,X,[dsyn],[sosy],C02.782.600.550.200,
e25b2138-6497-43e5-97c0-41d8ef0474f8,C0018681,C0206750,related to ,Headache,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.592.612.441,C02.782.600.550.200
e25b2138-6497-43e5-97c0-41d8ef0474f8,C0018681,C0206750,was reported in in ,Headache,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.592.612.441,C02.782.600.550.200
e25b2138-6497-43e5-97c0-41d8ef0474f8,C0018681,C0206750,is in symptomatic ,Headache,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.592.612.441,C02.782.600.550.200
7ff28511-22cf-44dd-ae89-fff527c3fbf5,C0021966,C0393735,discuss my ,Iodides,Headache Disorders,1,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C10.228.140.546
16637cb3-a532-46de-8d56-2ec5c8d479b2,C0021966,MEDLINE,review MEDLINE ,Iodides,MEDLINE,2,X,[inch],????,D01.248.497.158.490;D01.475.410,????
18428e01-4757-4765-9043-0015dceb5738,C0021966,C0018681,review MEDLINE ,Iodides,Headache,2,X,[inch],[sosy],D01.248.497.158.490;D01.475.410,C23.888.592.612.441
846ab0e3-dbc1-4552-9929-7170246c69c8,C0018681,C0003130,attributed to ,Headache,Anoxia,1,X,[sosy],[patf],C23.888.592.612.441,C23.888.852.079
61b3664e-4416-4632-b66f-48e5f28ce4a2,C0744633,C0042749,attributed to ,Acute headache,Viremia,1,X,[sosy],[dsyn],,C02.937;C23.550.470.790.500.900
8d8c563a-6ed9-4871-81ff-9c18c7378edc,C0018681,C0079189,is probably related to ,Headache,cytokine,1,X,[sosy],[aapp/imft],C23.888.592.612.441,D12.644.276.374;D12.776.467.374;D23.529.374
62108199-2fc8-4dbb-ab42-dcf2abee4e4f,C1175743,C0242732,has wide ,SARS coronavirus,Tropism,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G07.345.249.845;G15.920
63731f78-4e59-4bfc-b3ab-2b1cbfdabfb3,N2,C0020517,was found most ,N2,Hypersensitivity,1,X,????,[patf],????,C20.543
17058191-9efc-472f-aef8-91a1bca3f9ff,N2,C0007806,was found most ,N2,Cerebrospinal Fluid,1,X,????,[bdsu],????,A12.207.270.210
17b3d41d-6b3e-4066-a78a-176836432791,C0017337,C0007806,was found most ,Genes,Cerebrospinal Fluid,1,X,[gngm],[bdsu],G05.360.340.024.340,A12.207.270.210
dfecc690-534d-40e2-9972-17b9280e2db2,C0220853,C1175743,were found in PCR-positive for ,Hydroxide Ion,SARS coronavirus,2,X,[elii],[virs],x.x.x.x,B04.820.504.540.150.113.937
1fa69bf8-b450-448c-a899-161f404ff3ac,C0849867,C3272275,requires ,Widespread Disease,Urgent Procedure,1,X,[dsyn],[topp],,
a169c201-818e-4bcd-aa14-6cc73727a925,C0849867,C2825812,requires ,Widespread Disease,Deploy,1,X,[dsyn],[acty],,
89ee7024-9f04-4475-ae58-87595a688194,C0849867,C0087111,requires ,Widespread Disease,Therapeutic procedure,1,X,[dsyn],[topp],,E02
bb34d7d7-f008-4226-adf7-aa9ca7b467d3,C0003451,COVID-19,are main class of ,Antiviral Agents,COVID-19,1,X,[phsu],[virs],D27.505.954.122.388,C000657245
5c0eef23-b3c7-44b1-959c-0025dd5922cb,COVID-19,C0004093,can have serious complications respiratory with severe ,COVID-19,Asthenia,1,X,[virs],[sosy],C000657245,C23.888.089
6bcd0c4d-ec35-4154-bccf-3633567bdacf,C0035222,C1879547,sustained by uncontrolled inflammatory ,Respiratory Distress Syndrome Adult,Activation action,1,X,[dsyn],[acty],C08.381.840;C08.618.840,
1b6ba706-1943-4f55-aac5-9fa0c596e48f,C0024432,C0039082,plays role in ,macrophage,Syndrome,1,X,[cell],[dsyn],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,C23.550.288.500
68e5e0b4-99a1-44bc-8d35-54bc3af1dbe5,C0597357,C0032285,target in ,receptor,Pneumonia,2,X,[aapp/rcpt],[dsyn],,C08.381.677;C08.730.610
2626c37c-4d69-4ab0-be29-1004b67decc9,C0370003,and2019,Comparison volumes in 2020 and2019,Specimen,and2019,1,X,[sbst],????,,????
f450e8d8-8926-40ce-b139-e9cad44a6e21,C1262020,C0206750,is ubiquitous finding in inpatient ,diffuse alveolar damage,Coronavirus Infections,2,X,[dsyn],[dsyn],,C02.782.600.550.200
67ab8d8f-a30b-4265-b140-5f4d51c30957,C1262020,C0012634,is ubiquitous finding in inpatient ,diffuse alveolar damage,Disease,1,X,[dsyn],[dsyn],,C23.550.288
18169413-41aa-4518-b9c3-47fec20da313,C0020336,C1706202,conduct literature ,Hydroxychloroquine,Search - action,1,X,[orch/phsu],[acty],D03.633.100.810.050.180.350,
c921b62c-d877-4d7b-8193-94f4e92d3b97,C0206750,C0520679,is with ,Coronavirus Infections,Sleep Apnea Obstructive,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.618.085.852.850;C10.886.425.800.750.850
9f283eba-98e9-4235-a5ef-6f9e81abcbc6,C0206750,C3714552,has illuminated ,Coronavirus Infections,Weakness,1,X,[dsyn],[sosy],C02.782.600.550.200,
13820835-85a3-48cb-95a9-6c93d3d18eed,C0206750,C0014507,has generated wide-ranging ,Coronavirus Infections,Epidemiology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.720.500
d96bd685-bd14-4f4c-8d55-1196caf628c3,C0040038,C0940933,are recognised complications of viral ,Thromboembolism,infection as a complication,1,X,[patf],[dsyn],C14.907.355.590,
9d692f60-9643-4106-9143-e223d73cb366,C0281169,C0206750,is in context of ,pulmonary complications,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
696cef23-bfe2-4039-aa06-5d4fadfdf540,C0281169,C0012634,is in context of ,pulmonary complications,Disease,2,X,[patf],[dsyn],,C23.550.288
7527eef2-67c4-486a-9828-b233676e955c,C0042971,C0206750,of levels is point towards relevant involvement in patients with severe ,von Willebrand factor,Coronavirus Infections,1,X,[aapp/bacs/phsu],[dsyn],D12.776.124.125.920;D23.119.985,C02.782.600.550.200
2b36446b-0dba-4f92-a82d-fff9aba5919e,C0026941,C0450254,is atypical bacterial ,Mycoplasma pneumoniae,Pathogenic organism,1,X,[bact],[orgm],B03.440.860.580.553.553.650,
7083f794-4252-4b70-ba7e-fb7ee74968f3,C1457887,C0278061,were ,Symptoms,Abnormal mental state,1,X,[sosy],[mobd],,
9483a163-19c1-4cbf-948a-8f733eebaf6d,C0003316,silico,using in silico ,Epitopes,silico,2,X,[imft],????,D23.050.550,????
ff29d3bf-d21b-4597-bf32-b296ec747ab5,C0042210,silico,using in silico ,Vaccines,silico,2,X,[aapp/imft/phsu],????,D20.215.894,????
558b19b5-f271-4fa3-adaa-7b3965580397,C0042210,C0282580,using ,Vaccines,Epitopes T-Lymphocyte,1,X,[aapp/imft/phsu],[imft],D20.215.894,D23.050.550.402
9793f8da-706c-4558-ac51-790562076adc,C0282580,C0003320,can act as ,Epitopes T-Lymphocyte,Antigens,1,X,[imft],[imft],D23.050.550.402,D23.050
c51b9068-9f38-4225-9207-79bb7670d07b,C0282580,C0301872,elicits immune ,Epitopes T-Lymphocyte,Immune response,2,X,[imft],[ortf],D23.050.550.402,
395f8da4-f510-48a5-96cb-cae600bcd2db,NCBI,C3658243,was used for retrieval of surface ,NCBI,Spike Glycoprotein Coronavirus,2,X,????,[aapp/bacs],????,D12.776.543.512.500.665;D12.776.964.970.880.910.665
3726923b-58c5-41c2-8868-5836f7f98383,silico,C0002520,composed of 50S ,silico,Amino Acids,1,X,????,[aapp/bacs/phsu],????,D12.125
9f9fce80-497b-4121-8b08-fe0062868de5,silico,50S,composed of 50S ,silico,50S,1,X,????,????,????,????
fff232f9-0add-4d4e-b74d-1c26431fa115,silico,C0035552,composed of 50S ,silico,Ribosomal Proteins,1,X,????,[aapp/bacs],????,D12.776.835
a295ffd2-6b5c-4926-891b-1efd70fd9567,silico,C0001551,composed of 50S ,silico,Immunologic Adjuvants,1,X,????,[imft/phsu],????,D27.505.696.477.067
5a1a8a58-8fb6-4635-9089-d95d5bd71d08,C0599934,C0301872,enhance nCoV-19,Vaccines Peptide,Immune response,1,X,[imft/phsu],[ortf],D20.215.894.860,
acad7c09-9dbc-4f55-8303-a037f154a3fe,C0599934,nCoV-19,enhance nCoV-19,Vaccines Peptide,nCoV-19,1,X,[imft/phsu],????,D20.215.894.860,????
c0a1f3d7-ca94-46e1-8cae-b2ffafae1fe9,C0871208,C1175175,is in patients with ,Rating (action),Severe Acute Respiratory Syndrome,1,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
2c1b82fa-3e6b-429e-9565-7b681b7a1d22,TOCI,C4048285,had higher baseline ,TOCI,C-Reactive Protein human,1,X,????,[aapp/imft],????,
ac46e0fd-d96a-4f03-97da-d062b9194277,C0023688,C3891814,has revealed molecular determinants responsible for ,Ligands,Substrate,1,X,[chem],[sbst],D27.720.470.480,
b0187259-743c-40c5-8257-47741c027257,C1167622,C3891814,has revealed molecular determinants responsible for ,Binding (Molecular Function),Substrate,1,X,[moft],[sbst],,
ea99fe7c-580c-4b27-8169-63e782e890ed,C0043309,C3891814,has revealed molecular determinants responsible for ,Roentgen Rays,Substrate,1,X,[npop],[sbst],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,
7846ff28-8b17-4371-ab72-127f0b9b407b,C0444626,C3891814,has revealed molecular determinants responsible for ,Crystal Structure,Substrate,1,X,[chvs],[sbst],,
58b0a426-6b27-41db-aefd-958a50dcfd5c,C0043309,C1167622,has revealed molecular determinants responsible for ,Roentgen Rays,Binding (Molecular Function),2,X,[npop],[moft],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,
58b0a426-6b27-41db-aefd-958a50dcfd5c,C0043309,C1167622,has revealed potential inhibitor ,Roentgen Rays,Binding (Molecular Function),2,X,[npop],[moft],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,
dc6b52f0-ecfa-4316-acfd-658093dca3ac,C0042776,C3947283,is closely related to ,Virus,Bat coronavirus,2,X,[virs],[virs],B04,
32c06472-fb2e-42da-b10c-052530ef7c81,C0939237,C1167622,show best ,lopinavir / Ritonavir,Binding (Molecular Function),1,X,[phsu],[moft],,
a1d4923f-49cd-49a2-a689-2959bb470a5a,C0663733,C1167622,show best ,tipranavir,Binding (Molecular Function),1,X,[orch/phsu],[moft],x.x.x.x,
0149ae03-6d80-4011-9980-12de5892e2f2,C1871526,C1167622,show best ,raltegravir,Binding (Molecular Function),1,X,[nnon/phsu],[moft],,
5c4fc43b-939d-4771-8453-6c427ab72bc6,C0939237,C1433062,show best ,lopinavir / Ritonavir,3C-like protease SARS coronavirus,2,X,[phsu],[aapp/enzy],,x.x.x.x
5c4fc43b-939d-4771-8453-6c427ab72bc6,C0939237,C1433062,best Binding (Molecular Function) with,lopinavir / Ritonavir,3C-like protease SARS coronavirus,2,X,[phsu],[aapp/enzy],,x.x.x.x
a44ee8b8-6150-4855-8c3a-f48ba42c6721,C0663733,C1433062,show best ,tipranavir,3C-like protease SARS coronavirus,2,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
a44ee8b8-6150-4855-8c3a-f48ba42c6721,C0663733,C1433062,best Binding (Molecular Function) with,tipranavir,3C-like protease SARS coronavirus,2,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
59ca3ef9-f7f9-49e8-af3f-61151cded344,C1871526,C1433062,show best ,raltegravir,3C-like protease SARS coronavirus,2,X,[nnon/phsu],[aapp/enzy],,x.x.x.x
59ca3ef9-f7f9-49e8-af3f-61151cded344,C1871526,C1433062,best Binding (Molecular Function) with,raltegravir,3C-like protease SARS coronavirus,2,X,[nnon/phsu],[aapp/enzy],,x.x.x.x
43b000db-dbb1-425a-9992-09c763d97cae,C0184661,at-risk,reaches highly at-risk ,Interventional procedure,at-risk,1,X,[topp],????,,????
a0fd656c-b5df-4f4c-9042-ef1f1c46a557,C0033414,C0022709,is ,Promotion (action),Peptidyl-Dipeptidase A,1,X,[acty],[aapp/enzy/imft],,D08.811.277.656.350.350.687
ec7852b9-99ef-49f9-ba13-56fd3d9c5a0a,C3888108,C0022709,is ,Import into cell,Peptidyl-Dipeptidase A,1,X,[celf],[aapp/enzy/imft],,D08.811.277.656.350.350.687
de6a1e08-3763-427a-9416-980317e6391d,C0301626,C3894683,using ,Competitive inhibition,Extracellular Vesicles,1,X,[moft],[celc],,A11.284.295.588
053c48d7-cb55-44c7-8eb7-b36552c76b83,C0301626,C3178844,using ,Competitive inhibition,Mesenchymal Stromal Cells,2,X,[moft],[cell],,A11.329.830.500;A11.872.590.500
125615ec-5841-4a83-9086-4a083a7ec8f6,C0301626,C1184743,using ,Competitive inhibition,bony process,1,X,[moft],[bpoc],,
ea754207-6d33-474f-a590-6faabe2d35ed,C0301626,C0022709,overexpressing ,Competitive inhibition,Peptidyl-Dipeptidase A,1,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
3b2eddbc-fcbb-46e0-834f-43c2ce53cf51,C0009450,C1515119,is associated with higher mortality in those on ,Communicable Diseases,systemic therapy,1,X,[dsyn],[topp],C01.539.221,
3b2eddbc-fcbb-46e0-834f-43c2ce53cf51,C0009450,C1515119,is associated in particularly those on ,Communicable Diseases,systemic therapy,1,X,[dsyn],[topp],C01.539.221,
fe4ae409-db10-455f-a371-60c80bb5fa38,C0919976,C1367202,treated with ,renal cancer metastatic,ipilimumab,1,X,[neop],[aapp/imft/phsu],,D12.776.124.486.485.114.224.060.798;D12.776.124.790.651.114.224.060.798;D12.776.377.715.548.114.224.200.798
32f9e67d-d2d1-43b5-b7f2-25965a4772ae,C4288754,C4055433,treated with ,Metastatic urothelial carcinoma,atezolizumab,1,X,[neop],[orch/phsu],,x.x.x.x
7b0ae338-8122-457c-bec9-decd8df8b879,C0005522,C1879547,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,Activation action,2,X,[bacs/phsu],[acty],D20.215,
c3922184-1081-4a22-9bbf-999120da2870,C0043528,C0034019,cause grave ,Zoonoses,public health medicine (field),1,X,[dsyn],[bmod],C01.908;C02.968;C03.908;C22.969,H02.403.720;N01.400.550;N06.850
78d51852-6349-4682-b2ec-9cbdef97ac7c,C0206750,C0230770,is with modified ,Coronavirus Infections,Endoplasmic reticulum membrane,1,X,[dsyn],[celc],C02.782.600.550.200,
5c7bec4d-7083-4fb9-aaae-5b9d15d92bf2,C0035668,C0230770,is with modified ,RNA,Endoplasmic reticulum membrane,1,X,[nnon],[celc],D13.444.735,
743f526f-33ba-4992-ae58-61c329d4efa4,C0230770,C0598312,are transformed into viral ,Endoplasmic reticulum membrane,DNA Replication,1,X,[celc],[genf],,G02.111.225;G05.226
627a6d36-3d32-48c9-a46e-2d7123592ce5,C0230770,C0029219,are transformed into viral ,Endoplasmic reticulum membrane,Organelles,1,X,[celc],[celc],,A11.284.430.214.190.875
1cfd4c2c-ab23-47dc-aee5-ff70098f52d1,C0596901,C3887654,be ,Membrane,POLYARTERITIS NODOSA CHILDHOOD-ONSET,2,X,[celc],[dsyn],A10.615,
52068503-54a7-4bd2-bc42-7bb815dae3d5,C0596901,C0206750,be ,Membrane,Coronavirus Infections,2,X,[celc],[dsyn],A10.615,C02.782.600.550.200
7338b38c-7c2d-4a18-b172-021a0ae091cf,C0596901,C0029219,be ,Membrane,Organelles,2,X,[celc],[celc],A10.615,A11.284.430.214.190.875
081aac9e-4619-453f-ab57-41e37e75e06b,C0596901,C0013879,be ,Membrane,Elements,2,X,[celc],[elii],A10.615,D01.268
91d9abbe-9a16-4c10-b594-4997bd04288d,C0596901,C0017011,previously thought restricted to ,Membrane,Gamma Rays,1,X,[celc],[npop],A10.615,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
582835b2-b0c6-41eb-a471-66d0784da0be,C0020336,C0012634,has has proposed as possible treatment for ,Hydroxychloroquine,Disease,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C23.550.288
2c28e9b9-f4b4-488d-a0e3-90ed479fe263,C0060369,C0086982,regulating ,Fibroblast Growth Factor Receptors,Signal Transduction Pathways,1,X,[aapp/rcpt],[moft],D12.776.543.750.750.400.370,G02.111.820;G04.835
64df4378-2687-452f-be9a-2f01e0eef6f9,C0060369,C1184743,regulating ,Fibroblast Growth Factor Receptors,bony process,1,X,[aapp/rcpt],[bpoc],D12.776.543.750.750.400.370,
5128e484-0166-484a-b1ee-830c3e626792,C0060369,C0034069,regulating ,Fibroblast Growth Factor Receptors,Pulmonary Fibrosis,1,X,[aapp/rcpt],[dsyn],D12.776.543.750.750.400.370,C08.381.765
ff0eab1f-866e-47bf-8821-23d305930c6c,C1568520,C2612061,can inhibit proliferation of ,FLT1 protein human,fibroblast migration,1,X,[aapp/enzy/rcpt],[celf],x.x.x.x,
6c65658b-1af7-4647-af45-74c8ecf48f27,C0060369,C2612061,can inhibit proliferation of ,Fibroblast Growth Factor Receptors,fibroblast migration,1,X,[aapp/rcpt],[celf],D12.776.543.750.750.400.370,
c4b2d7d9-e76d-4f32-a3de-a1ce77ac7ce8,C0206750,C0025124,is in ,Coronavirus Infections,Traditional Chinese Medicine,1,X,[dsyn],[bmod],C02.782.600.550.200,E02.190.488.585.520;I01.076.201.450.654.558.520
3a03f62a-eb47-48cc-9f2b-e9a29d2b5d86,C0012634,C0025124,is in ,Disease,Traditional Chinese Medicine,1,X,[dsyn],[bmod],C23.550.288,E02.190.488.585.520;I01.076.201.450.654.558.520
a91b3d87-03aa-4536-b2de-7dd194a54889,2019and,C0025124,is in ,2019and,Traditional Chinese Medicine,1,X,????,[bmod],????,E02.190.488.585.520;I01.076.201.450.654.558.520
8fec513f-9676-4e0a-9046-a7a476f14421,C0019240,C0272285,were then filtered with ,Herb,Heparin-induced thrombocytopenia,2,X,[plnt],[dsyn],,
3a3ac0b4-f410-4b01-9d48-fe5350098473,C0019240,C0871208,were then filtered with ,Herb,Rating (action),2,X,[plnt],[acty],,
565f67b9-4769-4b3c-ad87-6c9e7497295a,C0034069,C0024109,mostly belong to ,Pulmonary Fibrosis,Lung,1,X,[dsyn],[bpoc],C08.381.765,A04.411
b3c549e3-5dee-4179-8556-f4125c2f9d3a,C1457887,C3891560,is ,Symptoms,Alarmins,1,X,[sosy],[aapp/bacs],,D23.035
0e88d7c4-32b8-4d9c-a210-0d4034c41af3,C1457887,C0018837,is ,Symptoms,Heat (physical force),1,X,[sosy],[npop],,
0e096ec3-7b36-4f5c-9c0a-f3fcf66a2a7c,C0024109,C0005889,always causes impairment of ,Lung,Body Fluids,1,X,[bpoc],[bdsu],A04.411,A12.207
859f6cfd-7e07-40f2-b5fc-bd4d49f460bb,C0034069,C0206750,caused by ,Pulmonary Fibrosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C08.381.765,C02.782.600.550.200
c0567316-768a-41e2-be16-e7f796436c53,C0033308,C0021079,give ,Progesterone,Therapeutic immunosuppression,1,X,[horm/orch/phsu],[topp],D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750,E02.095.465.425.450;E05.478.610
fb26160a-2647-4dcb-9878-2888d57292b9,C0014939,C3714514,humoral response to viral ,Estrogens,Infection,1,X,[horm/orch/phsu],[patf],D27.505.696.399.472.277,C01.539
fb26160a-2647-4dcb-9878-2888d57292b9,C0014939,C3714514,stimulate humoral ,Estrogens,Infection,1,X,[horm/orch/phsu],[patf],D27.505.696.399.472.277,C01.539
a75ac654-dc31-4017-9cc0-fd4ed7576584,C0014939,humoral,stimulate humoral ,Estrogens,humoral,1,X,[horm/orch/phsu],????,D27.505.696.399.472.277,????
bb356ab6-400b-41c1-903f-da329ec14291,C0039601,C0021079,give ,Testosterone,Therapeutic immunosuppression,1,X,[horm/orch/phsu],[topp],D04.210.500.054.079.429.824;D06.472.334.851.968.984,E02.095.465.425.450;E05.478.610
338bdd95-fe3c-4a12-a9a1-fb62bff4cf7e,C0014939,C0014912,is in particular ,Estrogens,Estradiol,1,X,[horm/orch/phsu],[horm/orch/phsu],D27.505.696.399.472.277,D04.210.500.365.415.248;D06.472.334.851.437.500
3674a9ba-8d3b-45ee-bea9-44e4b81f8228,C0014939,C0544688,protect women from most serious ,Estrogens,complication of disease,1,X,[horm/orch/phsu],[patf],D27.505.696.399.472.277,
3f0c4ee1-6f34-4d55-9a72-f5d4e31a240a,C0014939,C0206750,protect women from most serious ,Estrogens,Coronavirus Infections,1,X,[horm/orch/phsu],[dsyn],D27.505.696.399.472.277,C02.782.600.550.200
1fca966f-8e49-402d-861d-506c8863b8a0,C0013227,C0009871,keep such as combined ,Pharmaceutical Preparations,Contraceptive Agents,1,X,[phsu],[phsu],D26,D27.505.696.875.360;D27.505.954.705.360
61ae982f-bd50-41e7-9625-61edec5f28a7,C0630906,C0221423,of incidence is particularly those with severe ,vinyltriethoxysilane,Illness (finding),1,X,[orch],[sosy],x.x.x.x,
e43495aa-eb56-4b09-ba35-6a59df8e2a41,C0032310,C1175175, includes ,Pneumonia Viral,Severe Acute Respiratory Syndrome,2,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C02.782.600.550.200.750;C08.730.730
7a3e4bd7-8e52-427e-9850-effd1ab81e43,C0221423,C0630906,is similar to high ,Illness (finding),vinyltriethoxysilane,2,X,[sosy],[orch],,x.x.x.x
e51e8f0f-67f5-4d72-8430-3bb6f8ce1140,C0221423,C0871208,is similar to high ,Illness (finding),Rating (action),2,X,[sosy],[acty],,
7daa071d-57be-4d64-bb68-f29b89931fc9,C0221423,C0032310,is similar to high ,Illness (finding),Pneumonia Viral,1,X,[sosy],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
b0d2216b-67d9-4371-8ed6-6550bb1ac5e8,C0473485,C1825598,has negative ,Maternal distress,IMPACT gene,1,X,[patf],[gngm],,
14e696f3-b055-4ee3-b1dc-15311a5ccf41,C0206750,pre,reported less positive affectivity than pre ,Coronavirus Infections,pre,1,X,[dsyn],????,C02.782.600.550.200,????
c7d41c55-63a5-4f19-b78d-e8dd33ccb4e7,C0040861,C0309872,will assist in ,Triage,PREVENT (product),1,X,[topp],[phsu],N02.421.297.900,
6f99c6d4-ba80-47d5-bcbc-d438dbf88946,C0013227,C0009450,are used in patients with risk factors caused by ,Pharmaceutical Preparations,Communicable Diseases,1,X,[phsu],[dsyn],D26,C01.539.221
40e5996e-0cc9-479a-b191-84cd0133ea6f,C0022709,C0031843,has central ,Peptidyl-Dipeptidase A,physiological aspects,1,X,[aapp/enzy/imft],[phsf],D08.811.277.656.350.350.687,x.x.x.x
305cc749-993b-4365-9f10-5e158ebc317c,C0597357,C0031843,has central ,receptor,physiological aspects,1,X,[aapp/rcpt],[phsf],,x.x.x.x
e7e4fad3-ce3f-4503-96d3-ed71eb347393,C0022709,C0876973,has physiological aspects During,Peptidyl-Dipeptidase A,Infectious Lung Disorder,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,
c8bda4bf-5e28-45a0-8f2f-373ca7370b3a,C0597357,C0876973,has physiological aspects During,receptor,Infectious Lung Disorder,2,X,[aapp/rcpt],[dsyn],,
b2f73818-111b-4035-a32c-cbe155a46c9c,C0597357,C0225698,has physiological aspects During,receptor,Alveolar Epithelial Cells,1,X,[aapp/rcpt],[cell],,A04.411.715.100;A11.436.081
1b536e08-bdae-4cd0-b37e-ca356af58377,C0003374,C3158557,impair ,Antimalarials,terminal glycosylation,1,X,[phsu],[moft],D27.505.954.122.250.100.085,
2a0ca31e-4a24-4719-8037-b8222edf13c7,C0055447,C3158557,impair ,chloroquine phosphate,terminal glycosylation,1,X,[orch/phsu],[moft],x.x.x.x,
bb34692e-0294-4e29-9f3f-16370eabf07e,C0003374,C0022709,impair terminal glycosylation without significant change,Antimalarials,Peptidyl-Dipeptidase A,2,X,[phsu],[aapp/enzy/imft],D27.505.954.122.250.100.085,D08.811.277.656.350.350.687
090c074f-3d46-488c-857e-597652999fce,C0055447,C0022709,impair terminal glycosylation without significant change,chloroquine phosphate,Peptidyl-Dipeptidase A,2,X,[orch/phsu],[aapp/enzy/imft],x.x.x.x,D08.811.277.656.350.350.687
e88fcc1a-e019-4b8d-b0f2-420cc3a9df81,C0003374,C0699040,impair terminal glycosylation without significant change,Antimalarials,Cell surface,1,X,[phsu],[celc],D27.505.954.122.250.100.085,
229d1316-1cbb-4163-817d-c6a4b4c18590,C0055447,C0699040,impair terminal glycosylation without significant change,chloroquine phosphate,Cell surface,1,X,[orch/phsu],[celc],x.x.x.x,
198c8289-f152-458e-a80d-9c8999c67fb1,C0020336,C3158557,impair ,Hydroxychloroquine,terminal glycosylation,1,X,[orch/phsu],[moft],D03.633.100.810.050.180.350,
2ee3c1ec-02e2-4ea3-b03d-60771052fb23,C0020336,C0022709,impair terminal glycosylation without significant change,Hydroxychloroquine,Peptidyl-Dipeptidase A,2,X,[orch/phsu],[aapp/enzy/imft],D03.633.100.810.050.180.350,D08.811.277.656.350.350.687
f7bd73a4-d5ec-4352-b39f-aa86596cc737,C0020336,C0699040,impair terminal glycosylation without significant change,Hydroxychloroquine,Cell surface,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,
a0c5ee78-bcb8-48fa-904a-8a30665a91ae,C0003374,C0243077,might therefore might potent ,Antimalarials,inhibitors,1,X,[phsu],[chvf],D27.505.954.122.250.100.085,
c4d8a445-7c94-4e2a-8285-6f812c9a7f79,C0003374,C1175743,might therefore might potent ,Antimalarials,SARS coronavirus,1,X,[phsu],[virs],D27.505.954.122.250.100.085,B04.820.504.540.150.113.937
7c89c59c-142b-44cc-9b94-b53bb4480eb2,CQ,C3714514,completely PREVENT (product) in,CQ,Infection,1,X,????,[patf],????,C01.539
043ffa5a-07c5-4510-9ab6-b1cd72b6b809,CQ,C3463820,Starting ,CQ,Inhibition,1,X,????,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405
043ffa5a-07c5-4510-9ab6-b1cd72b6b809,CQ,C3463820,was effective in ,CQ,Inhibition,2,X,????,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405
55035c0a-8952-4398-88ef-fede636857db,CQ,C0032285,was effective in ,CQ,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
55035c0a-8952-4398-88ef-fede636857db,CQ,C0032285,could Theoretically could thus effectively used in treatment of ,CQ,Pneumonia,1,X,????,[dsyn],????,C08.381.677;C08.730.610
af41ab73-e67b-4221-9605-44bb03ac9889,CQ,C1175743,is in ,CQ,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
d5849e0c-70b9-48f1-9c47-921f2a51da4c,C0020336,CQ,is more potent than CQ ,Hydroxychloroquine,CQ,1,X,[orch/phsu],????,D03.633.100.810.050.180.350,????
33bc86af-d391-4884-9ff1-02084de6e67d,C0087111,C0042776,are based on previous experience with ,Therapeutic procedure,Virus,1,X,[topp],[virs],E02,B04
a9765eb6-3522-46dd-b85b-9344e2981e2f,C0310367,C0042776,are based on previous experience with ,Today,Virus,1,X,[antb/orch],[virs],,B04
2a2e929c-1653-4b18-8b85-ae5a2ca522e4,C0310367,C1175743,are based on previous experience with ,Today,SARS coronavirus,2,X,[antb/orch],[virs],,B04.820.504.540.150.113.937
d2504fd7-bb95-40c4-9d59-1fc4a9dc0c3c,C0054871,C1537068,is required for ,Cathepsin L,Virus Internalization,1,X,[aapp/enzy],[biof],D08.811.277.656.224.407;D08.811.277.656.262.500.157;D08.811.277.656.300.200.157,G06.920.881
fe8b041c-8c14-42e4-9827-a039a25d36ae,C0054871,C0221284,is required for ,Cathepsin L,Leptocyte,1,X,[aapp/enzy],[cell],D08.811.277.656.224.407;D08.811.277.656.262.500.157;D08.811.277.656.300.200.157,
f15d6fea-b570-4601-9c77-dd752b00c388,C0221284,C0042774,inhibits ,Leptocyte,Virus Replication,1,X,[cell],[celf],,G06.920.925
f7f6e44a-8150-4a23-86c1-445171cbbf10,C0145106,C0042774,inhibits ,Teicoplanin,Virus Replication,1,X,[aapp/antb],[celf],D09.400.420.405.500;D12.644.233.352.500;x.x.x.x,G06.920.925
a3eba2cd-ba10-4f09-bd11-ad878a80da2f,C0038164,C1167622,restricting ,Staphylococcal Protein A,Binding (Molecular Function),2,X,[aapp/imft/irda],[moft],D12.776.097.820;D23.050.161.821,
481019f0-1480-4cf5-b8e6-ed05d4ee6618,C1514798,C1167622,restricting ,Recombinants,Binding (Molecular Function),1,X,[orgm],[moft],,
b9e55120-3dc2-49cd-a426-81bd3119d78c,C0038164,C0206750,spread of ,Staphylococcal Protein A,Coronavirus Infections,4,X,[aapp/imft/irda],[dsyn],D12.776.097.820;D23.050.161.821,C02.782.600.550.200
9ef2186d-93e5-46c1-943b-d6de3576d85a,C0020336,C1155266,decreases ,Hydroxychloroquine,inflammatory response,1,X,[orch/phsu],[patf],D03.633.100.810.050.180.350,
47c99ca1-7bf4-46a1-a0e5-ea73f6105254,C2266933,C0874161, includes ,Neuraminidase Inhibitors [MoA],Oseltamivir,6,X,[moft],[orch/phsu],,D02.065.064.525;D02.455.426.392.368.367.379.500
15de0a37-09e2-4067-bcc9-1d12db5df86c,C2266933,C1675326, includes ,Neuraminidase Inhibitors [MoA],peramivir,6,X,[moft],[orch/phsu],,x.x.x.x
7e91ca88-38d5-48b8-8a05-38baa0ec045c,C2266933,C0216660, includes ,Neuraminidase Inhibitors [MoA],Zanamivir,6,X,[moft],[orch/phsu],,D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775
36b534a3-5262-4f0a-9ef4-4b4dd6c9ef58,C2266933,C0254211,has Antiviral Agents effect in combination with,Neuraminidase Inhibitors [MoA],arbidol,1,X,[moft],[orch/phsu],,x.x.x.x
64e27315-b5df-4b05-9bf8-ca08172a2a79,C0874161,C0254211,has Antiviral Agents effect in combination with,Oseltamivir,arbidol,1,X,[orch/phsu],[orch/phsu],D02.065.064.525;D02.455.426.392.368.367.379.500,x.x.x.x
37b79d53-895d-4db4-b84e-82f3f5fa52d2,C1675326,C0254211,has Antiviral Agents effect in combination with,peramivir,arbidol,1,X,[orch/phsu],[orch/phsu],x.x.x.x,x.x.x.x
a9024b2c-85bf-4fb0-9fa3-e422a9f601c1,C0216660,C0254211,has Antiviral Agents effect in combination with,Zanamivir,arbidol,1,X,[orch/phsu],[orch/phsu],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,x.x.x.x
6f82b1d0-29d3-4b2d-abb9-01b436a171e6,C2266933,C0003451,has direct ,Neuraminidase Inhibitors [MoA],Antiviral Agents,1,X,[moft],[phsu],,D27.505.954.122.388
0f9354ad-f489-4711-82a4-a57d4aa4c98d,C0874161,C0003451,has direct ,Oseltamivir,Antiviral Agents,1,X,[orch/phsu],[phsu],D02.065.064.525;D02.455.426.392.368.367.379.500,D27.505.954.122.388
c26e1275-76fb-49e9-993b-b68873e18c99,C1675326,C0003451,has direct ,peramivir,Antiviral Agents,1,X,[orch/phsu],[phsu],x.x.x.x,D27.505.954.122.388
647169b3-5847-49b9-9276-345d30b49a77,C0216660,C0003451,has direct ,Zanamivir,Antiviral Agents,1,X,[orch/phsu],[phsu],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,D27.505.954.122.388
212f2e67-6474-4d34-b147-88c1a6d6dd31,C2266933,C0206750,be can useful for patients of ,Neuraminidase Inhibitors [MoA],Coronavirus Infections,1,X,[moft],[dsyn],,C02.782.600.550.200
9d296c6f-43b0-402f-8989-4c520086a5f6,C0874161,C0206750,be can useful for patients of ,Oseltamivir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.065.064.525;D02.455.426.392.368.367.379.500,C02.782.600.550.200
83a0dbb1-409d-439c-8fa6-e9b666bf0c0d,C1675326,C0206750,be can useful for patients of ,peramivir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
4090fc6e-de23-4b5f-beb7-e4f92d1900ee,C0216660,C0206750,be can useful for patients of ,Zanamivir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,C02.782.600.550.200
cbb4fe51-108b-45f0-afac-0cc690a56c3f,C2266933,C0598312,has Antiviral Agents effect on early,Neuraminidase Inhibitors [MoA],DNA Replication,1,X,[moft],[genf],,G02.111.225;G05.226
a86e05be-0eb0-4d34-9f34-1ee841aa8d00,C2266933,C1175743,has Antiviral Agents effect on early,Neuraminidase Inhibitors [MoA],SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
100ccb4f-49e5-4692-9a2a-4c354c95b6d7,C0874161,C0598312,has Antiviral Agents effect on early,Oseltamivir,DNA Replication,1,X,[orch/phsu],[genf],D02.065.064.525;D02.455.426.392.368.367.379.500,G02.111.225;G05.226
b1e13a1d-a950-435a-b0db-2d6828c877b1,C1675326,C0598312,has Antiviral Agents effect on early,peramivir,DNA Replication,1,X,[orch/phsu],[genf],x.x.x.x,G02.111.225;G05.226
1c9096ef-42a0-4b2e-8744-70638258ba67,C0216660,C0598312,has Antiviral Agents effect on early,Zanamivir,DNA Replication,1,X,[orch/phsu],[genf],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,G02.111.225;G05.226
47fde4d1-5efb-44ff-867d-a1198c97fbd2,C0874161,C1175743,has Antiviral Agents effect on early,Oseltamivir,SARS coronavirus,1,X,[orch/phsu],[virs],D02.065.064.525;D02.455.426.392.368.367.379.500,B04.820.504.540.150.113.937
a535a8dc-787c-4934-9f85-95247099eefb,C1675326,C1175743,has Antiviral Agents effect on early,peramivir,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
bb429910-cf59-4aa9-a421-4d2cc9e6e70d,C0216660,C1175743,has Antiviral Agents effect on early,Zanamivir,SARS coronavirus,1,X,[orch/phsu],[virs],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,B04.820.504.540.150.113.937
32af047a-6785-4c01-b3f9-e75dbbbc71d0,remdesivir,C0037090,improves ,remdesivir,Signs and Symptoms Respiratory,1,X,[clnd],[sosy],,C23.888.852
d309f2d6-09c5-4dec-b43b-239eb47f5c14,C0939237,C1175743,is in patients with ,lopinavir / Ritonavir,SARS coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150.113.937
38ae77f2-a64b-41d6-8c1c-5774d4f53f0d,C1138226,C0237820,increases clinical ,favipiravir,Recovery - action,1,X,[orch/phsu],[acty],x.x.x.x,
e47ee680-efbe-4d13-8b57-fc57dbf7ca9d,C1138226,C0003451,has stronger ,favipiravir,Antiviral Agents,1,X,[orch/phsu],[phsu],x.x.x.x,D27.505.954.122.388
103b13ec-1a13-4329-9740-d3287313b0ce,C1138226,C0939237,has stronger ,favipiravir,lopinavir / Ritonavir,1,X,[orch/phsu],[phsu],x.x.x.x,
07c86293-9f9d-4e52-ab7f-984142d3920d,C3640049,C1138226,reducing ,Appropriate Treatment,favipiravir,1,X,[clna],[orch/phsu],,x.x.x.x
d1dc64f4-ef89-4040-9ad8-1252c4869607,C3640049,C0003015,is currently ,Appropriate Treatment,Angiotensin-Converting Enzyme Inhibitors,1,X,[clna],[phsu],,D27.505.519.389.745.085
48cc1fae-4747-4a4c-b211-d61335cc1790,C1422064,C1167395,is ,ACE2 gene,Host (organism),1,X,[gngm],[orgm],,
19edf0c5-df91-4616-8c2d-0316888a2a1b,C1422064,C0011334,is highest within sinonasal ,ACE2 gene,Dental caries,1,X,[gngm],[dsyn],,C07.793.720.210
ec6ea8e5-feb5-4648-85f3-d0c4835732ab,C1422064,C0819757,was found In ,ACE2 gene,Structure of parenchyma of lung,2,X,[gngm],[tisu],,
b9f1d6f1-23d0-415d-82ae-a33c73d4797b,C1422064,C0699040,was found on apical ,ACE2 gene,Cell surface,2,X,[gngm],[celc],,
a3834b7f-1eaf-4d8f-922a-15ba5e448238,C0270724,C0034991,consider specific ,Infantile Neuroaxonal Dystrophy,Rehabilitation therapy,1,X,[dsyn],[topp],C10.228.140.744,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
29aa19ed-8d4b-4734-8b3e-1fddd8a8928f,RT-PCR,C0439056,is in ,RT-PCR,Throat swab sample,1,X,????,[bdsu],????,
a8d26423-62b6-4dee-bc3b-c69d5c148fa4,C1511790,C0439056,is in ,Detection,Throat swab sample,1,X,[topp],[bdsu],,
c5da054d-6928-469b-a685-4394e9c54c54,LDH,C0277562,are potential predictors of fatality in ,LDH,Adult disease,2,X,????,[dsyn],????,
053494da-2be6-45e7-b834-1c736a15fa73,C0024264,C1707455,was significantly lower ,Lymphocyte,Comparison,1,X,[cell],[acty],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
79582c58-7ec8-4c46-885b-6cafe5853494,C0474166,C0237820,are critical to ,Medical counseling,Recovery - action,2,X,[topp],[acty],,
1fbba0ef-2f76-4d49-a8da-e61133480cbf,C1704532,C0237820,are critical to ,Active Method,Recovery - action,1,X,[topp],[acty],,
d16865f6-bbbc-489e-bd84-aaee07b26cca,C0330941,C0206750,treating ,Melia azedarach,Coronavirus Infections,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.715.500.500,C02.782.600.550.200
5c25b872-99c8-4828-ae59-60d807bfb6d3,C1414371,C0206750,treating ,ELAVL1 gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
99edd56a-81fe-4980-81b1-754487c3e489,C0010837,C0206750,treating ,Cytoplasmic Granules,Coronavirus Infections,1,X,[celc],[dsyn],A11.284.430.214.190.500;A11.284.430.214.190.875.190.190,C02.782.600.550.200
7f776231-6ae5-4d47-a3f3-7ac7d91647ba,C5,C0039082,is with unrecognized respiratory ,C5,Syndrome,1,X,????,[dsyn],????,C23.550.288.500
880c98b9-fe9a-415b-8983-da840b140e27,C5,C0206750,is with unrecognized respiratory ,C5,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
95e1dfcb-327f-406e-9270-b67f2c2a9f2a,C0034991,C0242656,should consider effect on ,Rehabilitation therapy,Disease Progression,3,X,[topp],[patf],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C23.550.291.656
0cbf0de6-702c-4286-9766-84c260b1cebe,C0369768,C0019134,treatment with ,Molecular oxygen saturation,heparin,1,X,[moft],[bacs/orch/phsu],,D09.698.373.400
4b29ce97-c457-435c-b781-9ded21e040c1,C0184633,C0019134,of age gender temperature and is treatment with,Oxygen Therapy Care,heparin,1,X,[topp],[bacs/orch/phsu],E02.880.690,D09.698.373.400
fcaa1d8c-8bbd-406a-b3b1-a4ce11dabac3,C0674432,C0292818,is with ,lopinavir,Ritonavir,1,X,[orch/phsu],[orch/phsu],D03.383.742.698.553,D02.886.675.653;D03.383.129.708.653
53036206-3160-4f1d-af1f-21b9095204c7,C2745965,C0027765,should During pandemic should acquainted with ,Emergencies [Disease/Finding],nervous system disorder,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C10
9e29ea13-ac7c-4608-9dfd-661d53478d04,C0039082,CoV2,following CoV2 ,Syndrome,CoV2,1,X,[dsyn],????,C23.550.288.500,????
e226f416-064a-4022-96eb-8cc7ee41333b,C0039082,C0009450,following CoV2 ,Syndrome,Communicable Diseases,1,X,[dsyn],[dsyn],C23.550.288.500,C01.539.221
ed7d5265-657b-463f-a9ea-846c843e7ba2,C1704259,C0087111,be targeted as ,Biochemical Pathway,Therapeutic procedure,1,X,[moft],[topp],,E02
51e80042-a9cc-4b9f-bea8-edecd5d3c166,C1175175,C0030755,is in ,Severe Acute Respiratory Syndrome,Pediatrics,1,X,[dsyn],[bmod],C02.782.600.550.200.750;C08.730.730,H02.403.670
46733f89-7d2c-403c-83e5-c74201caaa44,C1706202,4th,were conducted in PubMed 4th,Search - action,4th,1,X,[acty],????,,????
eef6ccfc-caf9-4ded-bb41-caa2ddc74de0,C0220781,C0281169,suggested severe ,Anabolism,pulmonary complications,1,X,[biof],[patf],G03,
715eb139-b14d-4daf-b2dc-e80e00c8f2cb,PPE,COVID-19,could ,PPE,COVID-19,1,X,????,[virs],????,C000657245
18d40f48-f58b-40a9-bbf4-77b5a8ee9ebb,PPE,C0184661,could ,PPE,Interventional procedure,1,X,????,[topp],????,
95b479fb-b351-4349-bc29-1f6167531f28,TRPV4,C0034063,is protective in various preclinical models of ,TRPV4,Pulmonary Edema,1,X,????,[dsyn],????,C08.381.742
86e7a47a-183d-46f3-ac48-3f8370f58063,C0029892,C0034019,are recommending higher level for aerosol-generating procedures than ,Otolaryngology specialty,public health medicine (field),1,X,[bmod],[bmod],H02.403.810.526,H02.403.720;N01.400.550;N06.850
f4299264-3e6b-4b7f-b961-90028ee162c2,C0013804,C0038638,advanced energy devices open ,Electrocoagulation,Suction drainage,1,X,[topp],[topp],E02.154.402;E04.014.170.402,E04.237.890
311c2ebb-551e-4346-9b5e-0c1e8c392c19,C0013804,C0337279,advanced energy devices open ,Electrocoagulation,Drilling - action,1,X,[topp],[topp],E02.154.402;E04.014.170.402,
99c1492d-884d-4dbf-a99f-35dc3b8122db,hACE2,C1175743,enables Deploy for in-depth analysis following,hACE2,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
05a9fa59-ecd1-40b2-a1d0-5c426049b50d,C1564874,C1175743,enables Deploy for in-depth analysis following,Adeno-Associated Virus,SARS coronavirus,1,X,[virs],[virs],B04.280.580.650.170,B04.820.504.540.150.113.937
2642c8c9-3ad8-401d-be93-81fd566d5960,C2986594,C1175743,enables Deploy for in-depth analysis following,Mouse Model,SARS coronavirus,1,X,[emod],[virs],,B04.820.504.540.150.113.937
14ddf0aa-a90e-411e-b90d-e9b35fddce14,hACE2,C0206750,enables Deploy for in-depth analysis following,hACE2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
c5159dd2-a4ba-49f8-9d38-c023a9a8970d,C1564874,C0206750,enables Deploy for in-depth analysis following,Adeno-Associated Virus,Coronavirus Infections,1,X,[virs],[dsyn],B04.280.580.650.170,C02.782.600.550.200
4a5c517a-ccd3-4ffb-83a7-56347c806279,C2986594,C0206750,enables Deploy for in-depth analysis following,Mouse Model,Coronavirus Infections,1,X,[emod],[dsyn],,C02.782.600.550.200
9121c736-d299-47a1-8e73-8e357e5c8be9,C1175743,C0026809,is in ,SARS coronavirus,Mus,2,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.992.635.505.500
95eb7449-ac30-478e-9ed5-7a878e81a294,C0007590,C0225336,is in ,Cell division,Endothelial Cells,2,X,[celf],[cell],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,A11.436.275
8d602aca-aee9-47e4-910f-1bea61052f1e,C0870883,C0019169,prevents ,Metabolite,Hepatitis B Virus,1,X,[bacs],[virs],,B04.280.375.650.425;B04.450.390.650.425
f7204acf-b103-4a09-9e16-d5357a00182c,C0870883,C0598312,prevents ,Metabolite,DNA Replication,2,X,[bacs],[genf],,G02.111.225;G05.226
61066383-d7d1-4d99-ac2a-4f3867d94b1d,C0870883,C0029347,prevents ,Metabolite,Influenza A virus,1,X,[bacs],[virs],,B04.820.545.405.400
f0c29898-0e26-494e-a4cf-e895e9a23827,C0073177,C1175743,suggesting rhein as potential therapeutic agent for treatment of,rhein,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
f0c29898-0e26-494e-a4cf-e895e9a23827,C0073177,C1175743,inhibits ,rhein,SARS coronavirus,2,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
f9fc8fa5-e688-4609-aef1-5a7238b43083,C0073177,C4281807,inhibits ,rhein,Vitronectin human,4,X,[orch/phsu],[aapp/bacs],x.x.x.x,
fa049b18-7544-4ce9-ac37-06c39f181fe9,C0206750,C0018787, includes ,Coronavirus Infections,Heart,1,X,[dsyn],[bpoc],C02.782.600.550.200,A07.541
de63fb07-dc98-44a3-8a02-ce6c8d949ddd,C0206750,C0023884, includes ,Coronavirus Infections,Liver,1,X,[dsyn],[bpoc],C02.782.600.550.200,A03.620
4e269fc9-6e3e-4b49-b3e8-1912fac37ad1,C0206750,C0006104, includes ,Coronavirus Infections,Brain,1,X,[dsyn],[bpoc],C02.782.600.550.200,A08.186.211
5ea47d64-8476-43fc-ad5f-3538ddb87a6a,C0684336,C0206750,have have reported in ,Impaired health,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
0ebad2a6-3254-486c-96ee-e99ec6885d16,COVID-19,C0015733,is with positive long-term ,COVID-19,Feces,1,X,[virs],[bdsu],C000657245,A12.459
9e87fb2b-3dea-48d4-9f4a-73e814cd9b06,COVID-19,C0028606,is with positive long-term ,COVID-19,Nucleic Acids,1,X,[virs],[bacs/nnon],C000657245,D13.444
e5d9ca63-454d-4bc8-bf72-8139bc5a34d7,C1856053,C0035242,patients with negative ,Hydranencephaly with Renal Aplasia-Dysplasia,Respiratory Tract Diseases,1,X,[dsyn],[dsyn],x.x.x.x,C08
6a4d3c41-c03f-44c0-a92f-eeeda7b21ed7,C1856053,C0028606,patients with negative ,Hydranencephaly with Renal Aplasia-Dysplasia,Nucleic Acids,1,X,[dsyn],[bacs/nnon],x.x.x.x,D13.444
c0c84514-0121-4c8a-a6c3-f597362ae901,C0206750,C0035242,is with negative ,Coronavirus Infections,Respiratory Tract Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08
e5551cd5-cd59-49b0-aa35-cec2d9b8c7fe,RT-PCR,C0015733,continuously detect ,RT-PCR,Feces,1,X,????,[bdsu],????,A12.459
e5551cd5-cd59-49b0-aa35-cec2d9b8c7fe,RT-PCR,C0015733,had results in their ,RT-PCR,Feces,1,X,????,[bdsu],????,A12.459
3ab64302-83b2-49e2-ab4b-b277a54e8a99,RT-PCR,C0028606,detect ,RT-PCR,Nucleic Acids,2,X,????,[bacs/nnon],????,D13.444
6931af17-3c8b-4de9-8f1d-1c9feacea855,C2754997,7th,was detected on 7th ,IgM immunoglobulin complex circulating,7th,1,X,[celc],????,,????
e7709bdc-7f3a-4a9e-91f4-e77db0021f8a,C0206750,C0229671,have higher ,Coronavirus Infections,Serum,1,X,[dsyn],[bdsu],C02.782.600.550.200,A12.207.152.846;A15.145.846
e7709bdc-7f3a-4a9e-91f4-e77db0021f8a,C0206750,C0229671,are characterized by ,Coronavirus Infections,Serum,1,X,[dsyn],[bdsu],C02.782.600.550.200,A12.207.152.846;A15.145.846
ad601015-eb5e-4444-acb5-c595591f10b1,C0085295,C0012634,can Among them can used as predictors for fast diagnosis of patients with higher risk of ,Interleukin-10,Disease,1,X,[aapp/imft],[dsyn],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,C23.550.288
847e3493-57e6-413d-a09c-e2eae4f6d435,C0940933,C0206750,is with ,infection as a complication,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
bad504eb-9dbb-40b1-ae27-9b8380ba2e4f,C0032326,C0206750,is in patient with ,Pneumothorax,Coronavirus Infections,1,X,[dsyn],[dsyn],C08.528.778,C02.782.600.550.200
07ce50f8-1005-4e68-a0d0-278e2dcb6d21,C0206750,C0184661,reassessed infection risks involved in ,Coronavirus Infections,Interventional procedure,1,X,[dsyn],[topp],C02.782.600.550.200,
07ce50f8-1005-4e68-a0d0-278e2dcb6d21,C0206750,C0184661,affect operations of ,Coronavirus Infections,Interventional procedure,1,X,[dsyn],[topp],C02.782.600.550.200,
dba3f3a5-7d46-4580-bf24-6f74f2aecce9,C0060520,C0233929,demonstrate reduction in aerosol ,Fluorescein,Emission - Male genitalia finding,1,X,[irda/orch/phsu],[bdsu],D02.455.426.779.347.390;D03.633.300.953.275.390;D04.711.347.390,
e92cee7b-5f15-4655-a487-45d4e5aa863d,C1175175,C4284302,were In ,Severe Acute Respiratory Syndrome,EHD1 wt Allele,1,X,[dsyn],[gngm],C02.782.600.550.200.750;C08.730.730,
050ccf66-05d7-44a9-8270-11098aa589e4,C1175175,C0206419,were In ,Severe Acute Respiratory Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150
3faa82bf-3f06-4e34-9a36-5e7ed2bd6c54,C0272178,C0206750,may favour ,Drug-induced neutropenia,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
12e80124-001f-4cd8-93d2-954986eb422c,C1334043,C0020538,have have mostly associated with ,Homologous Gene,Hypertensive disease,1,X,[gngm],[dsyn],,C14.907.489
e8f70abb-ef0f-4b88-bb9c-0a955a12dce8,C0042776,C0033684,exploit ,Virus,Proteins,1,X,[virs],[aapp/bacs],B04,D12.776
3fd84287-0f42-4765-8a19-162e47ecd3ad,C1175743,C0683278,has caused tremendous ,SARS coronavirus,Mental Suffering,1,X,[virs],[mobd],B04.820.504.540.150.113.937,F01.145.126.990;F02.830.900
f3a62dcf-a762-4e3d-ba07-ea42224f7c02,C0012634,C0683278,has caused tremendous ,Disease,Mental Suffering,1,X,[dsyn],[mobd],C23.550.288,F01.145.126.990;F02.830.900
cf0505c9-bf5e-4cd5-8093-a56102617f74,C0042798,C0206750,is in major hotspots of ,Low Vision,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.597.751.941.905;C11.966.905;C23.888.592.763.941.848,C02.782.600.550.200
04e6902f-7f1d-44e2-b45c-c98b39c395e8,C1856053,C1096155,may may attributed to ,Hydranencephaly with Renal Aplasia-Dysplasia,Macrophage Activation Syndrome,1,X,[dsyn],[dsyn],x.x.x.x,C20.683.515.800
261d96ad-5a8c-4923-b225-cf9356587f8e,C0035685,C1268456,Viral Components in,RNA-Directed RNA Polymerase,Viral Components,1,X,[aapp/enzy],[celc],D08.811.913.696.445.735.780,A21
815ee74f-6ebd-4031-87a7-5d500eb7a0a6,C0035685,C0598312,Viral Components in,RNA-Directed RNA Polymerase,DNA Replication,1,X,[aapp/enzy],[genf],D08.811.913.696.445.735.780,G02.111.225;G05.226
49b83ce7-72ef-4527-af5c-462059b2de69,C1268456,C0598312,is in ,Viral Components,DNA Replication,1,X,[celc],[genf],A21,G02.111.225;G05.226
92ae69b6-969c-4927-bd2e-fa97c0961fe1,C1167622,C1152412,poses of three viral ,Binding (Molecular Function),RNA-directed RNA polymerase activity,1,X,[moft],[genf],,
c4834aea-6459-44e1-8a40-29726fd7b48c,C1167622,C0243077,poses of three viral ,Binding (Molecular Function),inhibitors,1,X,[moft],[chvf],,
8919c0bd-8842-45ec-9c5e-d28486c200ed,C1167622,C4519187,poses of ,Binding (Molecular Function),Galidesivir,1,X,[moft],[orch/phsu],,
6dcffbc9-2e2c-4f81-be12-6b5686b7685c,C1167622,C1138226,poses of ,Binding (Molecular Function),favipiravir,1,X,[moft],[orch/phsu],,x.x.x.x
10daa805-6186-4a5a-b0cb-ec3308704275,C1167622,C0164815,poses of ,Binding (Molecular Function),penciclovir,1,X,[moft],[nnon/phsu],,x.x.x.x
69745f02-e194-4fad-accf-4b2caa5872a8,C1405301,C0032374,can can caused by ,Poliomyelitis paralytic,Poliovirus Vaccines,2,X,[dsyn],[imft/orch/phsu],,D20.215.894.899.623
1f158d88-86de-4817-a8cf-73db84c4077a,C0032375,C0005775,reverts following prolonged ,Oral Poliovirus Vaccine,Blood Circulation,1,X,[imft/orch/phsu],[phsf],D20.215.894.899.623.750,G09.330.100
0ac12f25-7db9-48da-b817-812c70467283,C0042776,C0005775,reverts following prolonged ,Virus,Blood Circulation,1,X,[virs],[phsf],B04,G09.330.100
98b7f0a2-523a-44e6-aed8-131ec8a5d1f1,C2349954,C1706374,is in ,Withdraw (activity),Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
358b7f83-3ced-4f1d-b586-c58b3614ed37,C0206750,C0032371,resume ,Coronavirus Infections,Poliomyelitis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.687.359.764;C10.228.228.618.750;C10.228.854.525.850;C10.668.864
e918c119-9a93-4f33-abc1-f760343ae8a8,C2745965,C0032371,resume ,Emergencies [Disease/Finding],Poliomyelitis,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.687.359.764;C10.228.228.618.750;C10.228.854.525.850;C10.668.864
4ef90c76-85f3-4c0a-a15d-72baccf22e31,C2745965,C0441655,resume ,Emergencies [Disease/Finding],Activities,1,X,[patf],[acty],C23.550.291.781;N06.230.100.083;N06.850.376,
6a9046ed-5de2-43ed-bcc1-b19551690fb3,C0026882,C2806453,improved expression of ,Mutation,Betacoronavirus,1,X,[genf],[virs],G05.365.590,B04.820.504.540.150.113
327cc4eb-0621-4de6-93a5-b92f3d57bca5,C0026882,C0700271,improved expression of ,Mutation,M Protein multiple myeloma,1,X,[genf],[aapp/imft],G05.365.590,x.x.x.x
fe4e891f-d6e4-4d77-bf19-d9bd8e0f0186,C1175175,C1518420,is in ,Severe Acute Respiratory Syndrome,Mouse Nose,1,X,[dsyn],[tisu],C02.782.600.550.200.750;C08.730.730,
2f5bb831-76cd-4c53-acbf-3d822f60a331,C0035696,C1175175,protects against ,RNA Messenger,Severe Acute Respiratory Syndrome,1,X,[bacs/nnon],[dsyn],D13.444.735.544,C02.782.600.550.200.750;C08.730.730
07ab19f6-c7b2-4d59-8ba7-3863e066053a,C1516048,C1510711,provide answers about safety of ,Assessed,Abdominal Surgical Procedure,1,X,[acty],[topp],,
c51d29be-ba71-4baf-b62b-488fafa58019,C0459914,C0206750,dedicate reusable laparoscopic instrumentation to ,Conservative Treatment,Coronavirus Infections,1,X,[topp],[dsyn],E02.197,C02.782.600.550.200
e7a0cba7-4523-44fd-94be-09e96511b18e,C0459914,C1185738,dedicate ,Conservative Treatment,Column (anatomic),1,X,[topp],[bpoc],E02.197,
7add00f2-99aa-45a3-a89b-f9bb7c078280,C1185738,C0206750,reusable instrumentation to ,Column (anatomic),Coronavirus Infections,1,X,[bpoc],[dsyn],,C02.782.600.550.200
02719c7d-b435-4fba-90db-1584a684241e,C2349954,C0010076,is feasible In certain ,Withdraw (activity),Coronaviridae,2,X,[acty],[virs],,B04.820.504.540
82f6e8c1-7040-4c3f-b08e-7429442f16fc,C2349954,C0012634,is feasible In certain ,Withdraw (activity),Disease,2,X,[acty],[dsyn],,C23.550.288
5ebc2738-85d3-4799-b502-3e785c585427,C0700781,C1175175,be effective in therapy of ,Panavir,Severe Acute Respiratory Syndrome,1,X,[orch/phsu],[dsyn],D02.455.426.559.389.657.746,C02.782.600.550.200.750;C08.730.730
f030992f-47cd-4d8d-9df1-2f41ca46435e,C1101610,C3272452,are evolutionally conserved ,MicroRNAs,Single-Stranded RNA,1,X,[bacs/nnon],[nnon],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,
999f677d-fe84-4e4a-9d17-f3924966fb64,C1101610,C0017337,regulate ,MicroRNAs,Genes,1,X,[bacs/nnon],[gngm],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.360.340.024.340
83f0107e-9a88-4e39-b63e-aee7cee68a47,C1101610,C3714634,are key players in variety of ,MicroRNAs,Biological Processes,1,X,[bacs/nnon],[biof],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G16
d2ca51fb-1ecb-4a6f-9365-b0b5484fed39,C3714634,C0007589,regulate ,Biological Processes,Cell Differentiation process,1,X,[biof],[celf],G16,G04.152
cc3900a6-1ac1-4b15-8013-d0619c80ccb8,C3714634,C1155000,regulate ,Biological Processes,Immune Cell Activation Process,1,X,[biof],[celf],G16,
ca08736a-0d1d-4f21-b590-1f767fa5af96,C0206750,C0022661,significant threat to immunocompromised patients with ,Coronavirus Infections,Kidney Failure Chronic,2,X,[dsyn],[dsyn],C02.782.600.550.200,C12.777.419.780.750.500;C13.351.968.419.780.750.500
41354e76-8887-41c6-a6df-5c4c3402016a,C0015967,C0159028,are most prevalent ,Fever,General symptom,1,X,[sosy],[sosy],C23.888.119.344,
269d2be8-9080-4ce4-b9fe-44d2a58676c6,C0017102,C1175743,is suggested as beneficial preventive measure infected with ,Allium sativum,SARS coronavirus,2,X,[plnt],[virs],B01.650.940.800.575.912.250.618.100.050.060.300,B04.820.504.540.150.113.937
53e740eb-da3e-4ef4-b652-abe6952d8c12,C0017102,C2717755,is ,Allium sativum,Functional Food,1,X,[plnt],[food],B01.650.940.800.575.912.250.618.100.050.060.300,G07.203.300.572;J02.500.572
1b246287-49ae-44c1-8af8-487391626bb8,C0206750,C0598197,is including highly ,Coronavirus Infections,contagion,1,X,[dsyn],[npop],C02.782.600.550.200,
09d7b754-3dfd-465a-ade5-ea5e7bdfa2c5,C0030858,C0598197,were summarized including highly ,Pentaerythritol Tetranitrate,contagion,2,X,[orch/phsu],[npop],D02.033.455.706.690,
12ed6e6e-bf3d-414a-bde7-e6b7c3886420,C0206750,C0679247,is in ,Coronavirus Infections,Terminal illness,1,X,[dsyn],[dsyn],C02.782.600.550.200,
ee5c0fe8-7f35-4ed1-bbe6-3477ef6e75b3,livedo,C0027540,urticarial lesions ,livedo,Necrosis,1,X,????,[ortf],????,C23.550.717;G04.146.638
ee5c0fe8-7f35-4ed1-bbe6-3477ef6e75b3,livedo,C0027540,maculopapular eruptions ,livedo,Necrosis,1,X,????,[ortf],????,C23.550.717;G04.146.638
65ff1bb1-0d5a-4b1d-9ab4-9600db9576f0,C2948600,C2366913,is ,Aim,condition assessments,1,X,[inch/phsu],[topp],,
bdef6ab6-308d-483c-a0f6-ef664849d52b,C0012634,C0242656,has heterogenous ,Disease,Disease Progression,1,X,[dsyn],[patf],C23.550.288,C23.550.291.656
8e4c213a-62e9-46ea-bb88-ac05e7b536ec,C1096155,C4054044,also known as ,Macrophage Activation Syndrome,Secondary Hemophagocytic Lymphohistiocytosis,1,X,[dsyn],[dsyn],C20.683.515.800,
5ef15f58-a891-48a6-a09f-73eea593047c,C1096155,C0079189,resulting in ,Macrophage Activation Syndrome,cytokine,2,X,[dsyn],[aapp/imft],C20.683.515.800,D12.644.276.374;D12.776.467.374;D23.529.374
a3eda2f1-5820-4906-b165-1d2d521be7a8,C1096155,C1861452,resulting in ,Macrophage Activation Syndrome,Storm Syndrome,2,X,[dsyn],[dsyn],C20.683.515.800,x.x.x.x
73b767aa-0d6f-45eb-95ea-170f924d19d4,C0026882,C0960756,may also constitute ,Mutation,factor A,2,X,[genf],[orch],G05.365.590,x.x.x.x
42f96d4e-1b5f-4fa3-8228-0df2813adaa1,C0026882,C0206750,may constitute factor A risk factor A in,Mutation,Coronavirus Infections,1,X,[genf],[dsyn],G05.365.590,C02.782.600.550.200
24ad7ee5-8da6-486b-add0-79fa11dc6bf3,C0003191,C0008269,will will also discussed including ,Antirheumatic Agents,Chloroquine,1,X,[phsu],[orch/phsu],D27.505.954.329,D03.633.100.810.050.180
318a17f7-b520-4a25-86ff-4cdd352fc938,C0003191,C0544688,managing immunologic ,Antirheumatic Agents,complication of disease,1,X,[phsu],[patf],D27.505.954.329,
ec23f0fc-72bb-4db2-836d-659620919740,C0003191,C0206750,managing immunologic ,Antirheumatic Agents,Coronavirus Infections,1,X,[phsu],[dsyn],D27.505.954.329,C02.782.600.550.200
d7ee8b74-8d1a-4d35-9809-6630bbd064db,C0003191,C0009450,managing immunologic ,Antirheumatic Agents,Communicable Diseases,1,X,[phsu],[dsyn],D27.505.954.329,C01.539.221
70cf0d00-a277-4402-af09-bf4d4d2e87dc,C0679861,C0206750,will decrease morbidity in ,Complications of treatment,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
d65dab7e-8932-4b2a-ad9f-34f54cf38e88,C0679861,C0009450,will decrease morbidity in ,Complications of treatment,Communicable Diseases,2,X,[patf],[dsyn],,C01.539.221
0a7da88e-1fa0-4f5c-a8c2-715de748e705,CHAS,C2728259,implement telehospice ,CHAS,Program,1,X,????,[orch/phsu],????,V02.355.750
1dab4e7a-1e41-4ee9-81af-f5329fe0c639,C0034019,C1856053,began investigation on ,public health medicine (field),Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,x.x.x.x
1eab40f7-20ab-434b-920c-fc68a20b853e,C0939237,abidol,combined with abidol,lopinavir / Ritonavir,abidol,1,X,[phsu],????,,????
44fe76ef-ba74-4fdb-8649-a3ad0648ef20,C0036974,C0079189,were usually caused by ,Shock,cytokine,1,X,[patf],[aapp/imft],C23.550.835,D12.644.276.374;D12.776.467.374;D23.529.374
310501aa-e25c-4d85-89f4-ab1a129f65a1,C0525033,C0022938, includes ,Probiotics,Lactobacillus,2,X,[bact],[bact],G07.203.300.456.500;J02.500.456.500,B03.353.750.450.475;B03.510.460.400.410.475.475;B03.510.550.450.475
e7382d00-639a-406a-8eb9-453387b432a9,C4287543,C0525033,is with decreased ,Intestinal dysbiosis,Probiotics,2,X,[sosy],[bact],,G07.203.300.456.500;J02.500.456.500
6210dbae-9597-4ce6-9e84-eb83a72a35e6,C4287543,C0022938,is with decreased ,Intestinal dysbiosis,Lactobacillus,2,X,[sosy],[bact],,B03.353.750.450.475;B03.510.460.400.410.475.475;B03.510.550.450.475
df860fc1-674e-49d4-9828-f21dc468d2e4,C0027950,C0024109,patients with severe critical ,neutrophil,Lung,2,X,[cell],[bpoc],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,A04.411
26b6947d-228d-4999-98d1-841ebc6ba567,C3665444,C0221423,emerged ,Neutrophilia (disorder),Illness (finding),1,X,[dsyn],[sosy],,
7764f085-1560-4f7f-9560-a90efb927254,C0009830,C0024109,is in damaged ,Consumption of goods,Lung,2,X,[acty],[bpoc],,A04.411
8e35d5ce-feaa-4a3b-8180-19453407096b,C0040034,C0009830,was resulting from ,Thrombocytopenia,Consumption of goods,2,X,[dsyn],[acty],C15.378.140.855,
c27d50dd-4b6f-4653-ad0e-04df89e0bb81,C0040034,C0024109,was resulting from ,Thrombocytopenia,Lung,2,X,[dsyn],[bpoc],C15.378.140.855,A04.411
a3866f93-a334-4adf-bc7d-55b5fc1f8dde,C1155075,C0024109,aggravates immune damage of ,monocyte activation,Lung,2,X,[celf],[bpoc],,A04.411
f3394b3b-8e9d-4e6a-8575-f663bfa96d38,C0040300,C0596448,leads to increase of D ,Body tissue,dimer,2,X,[tisu],[chvs],A10,
d6f47dda-9bfc-46d9-8c2f-610639f234a3,C0024312,C0035222,followed by ,Lymphopenia,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C08.381.840;C08.618.840
89a91568-d020-4022-8074-2bd287eefd2d,C0021368,C0035222,followed by ,Inflammation,Respiratory Distress Syndrome Adult,1,X,[patf],[dsyn],C23.550.470,C08.381.840;C08.618.840
1e64729c-ca76-44aa-8689-8d1d98b8c9c1,C0155765,C0206750,been has reported in patients with severe ,Disease of capillaries,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
e7b72d97-4f74-4d02-98b7-a5f0215f183a,C0206750,C0751571,is impacting ,Coronavirus Infections,Cancer of Urinary Tract,2,X,[dsyn],[neop],C02.782.600.550.200,C04.588.945.947;C12.758.820;C13.351.937.820
61180b5f-66c4-467d-afb2-e0d7026ad0f4,C1880022,C0034019,further understand ,Characterization,public health medicine (field),1,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
1c5ed2d3-ddc2-4875-aa69-418b1f12714d,C1880022,C0699748,further understand its ,Characterization,Pathogenesis,1,X,[acty],[patf],,
23b3ffc4-a0ec-4aea-908d-56348b7d88b9,C1880022,C0242781,further understand ,Characterization,disease transmission,1,X,[acty],[patf],,N06.850.310
8c8f0778-118c-4bb4-b653-cf356459e334,C0458827,C1262020,is with ,Airway structure,diffuse alveolar damage,1,X,[bpoc],[dsyn],,
1a84c1cf-7256-436f-8a47-a1bd0cc07ab6,C0458827,C0214743,are modulated by ,Airway structure,Interleukin-13,1,X,[bpoc],[aapp/imft],,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
0f3efabe-93c6-4f71-8fd8-97f265774185,C0014597,C0214743,are modulated by ,Epithelial Cells,Interleukin-13,1,X,[cell],[aapp/imft],A11.436,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
17e7e02d-0229-4361-8a65-a1ebc767d078,C0185117,C0214743,are modulated by ,Expression procedure,Interleukin-13,1,X,[topp],[aapp/imft],,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
5caf1f4d-a9cd-4ec7-99f2-a62c1a609752,C2948600,C0214743,extend our work in ,Aim,Interleukin-13,1,X,[inch/phsu],[aapp/imft],,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
c2654c1f-e34b-4c9e-8f87-832ea99c3b1d,C2948600,C0005532,extend our work in ,Aim,biology (field),1,X,[inch/phsu],[bmod],,H01.158.273
d059f62e-94aa-4267-8ba9-c9751d14231c,C0022709,C0458827,is in primary ,Peptidyl-Dipeptidase A,Airway structure,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
0e270875-1e50-4c4b-bef5-d7f9c5ca8a33,C1742865,C0458827,is in ,TMPRSS2 protein human,Airway structure,1,X,[aapp/enzy],[bpoc],x.x.x.x,
df92e843-80bf-4a21-aeb5-eb85b527ebcb,C0185117,C0458827,is in ,Expression procedure,Airway structure,1,X,[topp],[bpoc],,
1f00217d-9feb-48c4-bc33-43578d939ca5,exvivo,C0458827,is in ,exvivo,Airway structure,1,X,????,[bpoc],????,
3acdbb36-0bc3-474a-9d19-d37ca3bcae6b,C1742865,C0014597,was increased in nasal ,TMPRSS2 protein human,Epithelial Cells,3,X,[aapp/enzy],[cell],x.x.x.x,A11.436
ffdd38b5-2321-45d4-ae3f-25c44dafa02c,C0185117,C0014597,was increased in nasal ,Expression procedure,Epithelial Cells,3,X,[topp],[cell],,A11.436
48f42bce-5a0d-4b37-bcf6-a59a36308d24,exvivo,C0014597,is in ,exvivo,Epithelial Cells,1,X,????,[cell],????,A11.436
7bc8f0fb-84dd-4dcd-9f15-c1912efbf576,C1742865,C0004096,was increased in nasal ,TMPRSS2 protein human,Asthma,1,X,[aapp/enzy],[dsyn],x.x.x.x,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
3d866d91-97e3-4d54-9d27-41998d91191f,C0185117,C0004096,was increased in nasal ,Expression procedure,Asthma,1,X,[topp],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
1b6e1460-b978-4986-b3ba-6746b5cef7f0,C0014597,C0004096,is in ,Epithelial Cells,Asthma,2,X,[cell],[dsyn],A11.436,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
4a845861-0fd7-4090-8108-db1592d0f6d2,C1742865,C0079189,was positively associated with type ,TMPRSS2 protein human,cytokine,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,D12.644.276.374;D12.776.467.374;D23.529.374
73d46232-de6c-43fe-8527-2421a04253f8,C0185117,C0079189,was positively associated with type ,Expression procedure,cytokine,1,X,[topp],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
73d46232-de6c-43fe-8527-2421a04253f8,C0185117,C0079189,was significantly negatively associated with type ,Expression procedure,cytokine,1,X,[topp],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
56072e79-4116-486f-b090-86d53a597342,C0214743,C0458827,modulates Peptidyl-Dipeptidase A Expression procedure in,Interleukin-13,Airway structure,1,X,[aapp/imft],[bpoc],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,
e2554edf-9841-4ff2-b568-79fb4562ef52,C0214743,C0014597,modulates Peptidyl-Dipeptidase A Expression procedure in,Interleukin-13,Epithelial Cells,1,X,[aapp/imft],[cell],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,A11.436
9ca10fc8-51b1-4e11-8fb5-82fc440c3c0b,C0214743,C0004096,modulates Peptidyl-Dipeptidase A Expression procedure in,Interleukin-13,Asthma,1,X,[aapp/imft],[dsyn],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
0cb14e42-215e-42b0-b222-26ae1d801700,C0214743,C0022709,modulates ,Interleukin-13,Peptidyl-Dipeptidase A,1,X,[aapp/imft],[aapp/enzy/imft],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,D08.811.277.656.350.350.687
6468b606-e2fa-4ec9-92b6-8d47c3d5a18a,C0214743,C0185117,modulates ,Interleukin-13,Expression procedure,1,X,[aapp/imft],[topp],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,
87247680-38b4-41cd-b812-05c69792e8cd,C0458827,C0004096,is in ,Airway structure,Asthma,1,X,[bpoc],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
5c0ca606-a1ce-48da-8971-f5888f41ef04,C0016452,C0206750,is in ,Food,Coronavirus Infections,1,X,[food],[dsyn],G07.203.300;J02.500,C02.782.600.550.200
1fb2ae6e-8482-4f62-89dd-588d30f2f00e,C0016452,C0242781,is in ,Food,disease transmission,1,X,[food],[patf],G07.203.300;J02.500,N06.850.310
b7c30f3e-2a7a-48b0-b48c-cbb6553fc26f,C0015967,C1948029,can facilitate ,Fever,Destruction (action),1,X,[sosy],[acty],C23.888.119.344,
2762f817-b355-4230-be61-cfc8837e454b,C0038817,C1948029,can facilitate ,Sunlight,Destruction (action),1,X,[npop],[acty],G01.358.500.505.650.836;G01.750.250.650.836;G01.750.770.578.836;G16.500.275.063.725.525;G16.500.750.775.525;N06.230.300.100.725.525,
219b8892-a829-4893-8df9-8832bc471a9d,C0038817,C1175743,can facilitate ,Sunlight,SARS coronavirus,1,X,[npop],[virs],G01.358.500.505.650.836;G01.750.250.650.836;G01.750.770.578.836;G16.500.275.063.725.525;G16.500.750.775.525;N06.230.300.100.725.525,B04.820.504.540.150.113.937
3e450efe-a1a2-496c-ad3c-c8945352eea2,C0185117,C0040300,is in ,Expression procedure,Body tissue,1,X,[topp],[tisu],,A10
71024d94-e2c9-4443-b9b9-9a96a6a03a28,COVID-19,C0030755,presented to tertiary ,COVID-19,Pediatrics,2,X,[virs],[bmod],C000657245,H02.403.670
9f730272-fb67-40b0-90f9-31763ce2c747,C0011071,C0014544,is in ,Sudden death,Epilepsy,1,X,[patf],[dsyn],C23.550.260.322,C10.228.140.490
678f40b5-9eea-4116-a4b0-33fc2feaba5e,C1515884,COVID-19,can cure ,Acupuncture and Oriental Medicine,COVID-19,1,X,[topp],[virs],,C000657245
8a6ac4cb-40ab-4e3c-af5a-9c1eb44f1dba,C1515884,C0032285,can cure ,Acupuncture and Oriental Medicine,Pneumonia,1,X,[topp],[dsyn],,C08.381.677;C08.730.610
0b42819e-c96e-49a4-9ead-173d48179186,C1145670,C1175743,is with ,Respiratory Failure,SARS coronavirus,1,X,[dsyn],[virs],C08.618.846,B04.820.504.540.150.113.937
54d499b0-cee5-4601-a333-46aee69cdc4b,C0003451,C0012634,are are given empirically to patients with ,Antiviral Agents,Disease,1,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288
0b6730c7-3f79-4451-801e-b4cea04bc328,C0278996,COVID-19,is in ,Malignant Head and Neck Neoplasm,COVID-19,1,X,[neop],[virs],,C000657245
0266a16a-8e1a-4099-88f3-a7da77e3ad13,C0020336,C0598312,have shown in activity on ,Hydroxychloroquine,DNA Replication,1,X,[orch/phsu],[genf],D03.633.100.810.050.180.350,G02.111.225;G05.226
cc3c625d-3044-46ba-b1d0-dc61c60f374b,C0008269,C1708476,has yielded to ,Chloroquine,Implementation,1,X,[orch/phsu],[acty],D03.633.100.810.050.180,
530149b9-7329-483d-83b3-21e02565c78b,C2239453,C1708476,has yielded to ,FICD gene,Implementation,1,X,[gngm],[acty],,
ff91ee14-2574-4955-b108-8c9c25283763,C2699153,C1175743,is in context of high ,Cell Invasion,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
d0e46eb7-d624-4a6a-8009-201a0bf74772,C4283742,C0030755,representing ,Ceramide Glucosyltransferase human,Pediatrics,1,X,[aapp/enzy],[bmod],,H02.403.670
df47d476-d88e-4581-ba69-d204ed1abef6,C0005802,C0020205,using ,Blood Glucose,Hybrids,1,X,[orch],[orgm],D09.947.875.359.448.500,B05.200
217c1ec5-4b00-4f6f-9f9b-57a5ae4b21e3,C1135927,COVID-19,is in ,Immunity Herd,COVID-19,1,X,[phsf],[virs],G12.450.400,C000657245
61fde842-f744-4eb1-9a9c-2ec9c698acba,C0037633,C0032857, includes dilute ,Solutions,Povidone-Iodine,1,X,[sbst],[orch/phsu],D26.776,D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745
13ae1e10-2917-4226-9c30-08cd2a6bf322,C2926735,C1533734,was d in Jinhua Qinggan ,Duration,Administration procedure,1,X,[orch/phsu],[topp],,
3a0ff73b-5200-4ce1-90bb-353d111ed434,C0028606,C1533734,average Duration of was d in Jinhua Qinggan,Nucleic Acids,Administration procedure,1,X,[bacs/nnon],[topp],D13.444,
0bfdbb84-7fdd-4ea0-834e-af6a35633962,C0014442,C0075165,acts as ,Enzymes,Staph protein A receptor,1,X,[aapp/enzy],[aapp/rcpt],D08.811,x.x.x.x
ebf52e05-96b3-461a-82d0-2d9eab0761fe,C0022709,C0075165,acts as ,Peptidyl-Dipeptidase A,Staph protein A receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
9e043fa4-43ac-435f-84f4-a56c69791cad,C0014442,C1537068,acts as ,Enzymes,Virus Internalization,1,X,[aapp/enzy],[biof],D08.811,G06.920.881
7f4f8d46-9e84-4c6f-acbb-45ab186f20a3,C0014442,C0042196,acts Upon ,Enzymes,Vaccination,1,X,[aapp/enzy],[topp],D08.811,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
1c4a0119-b299-4011-803f-29b39b8b82f1,C0022709,C0042196,acts Upon ,Peptidyl-Dipeptidase A,Vaccination,1,X,[aapp/enzy/imft],[topp],D08.811.277.656.350.350.687,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
c21614c2-a245-4c26-b8ed-25d38b52a7c6,C0014507,C1175175,related to ,Epidemiology,Severe Acute Respiratory Syndrome,1,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200.750;C08.730.730
7be206d7-1fdb-43d2-a62c-45131017b1bd,C1276413,C0206750,is in ,Therapeutic regimen,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
69653825-507b-4cab-9624-806f4582865c,C2949735,C1706374,date of was 9 ,Recruitment,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
1e38b7e6-b861-4c55-a948-99004929cfd0,C0699949,C0206750,is in ,airway disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
8ed38ffb-316e-4376-9dce-9d26b0a3d9f0,C0023882,C0030664,is in children with underlying chronic renal ,Little's Disease,Pathology,2,X,[dsyn],[bmod],C10.228.140.140.254,H02.403.650
5fa39b14-672a-440c-ba2e-1732cf0840dc,C1706374,C0030664,children with chronic renal ,Tumor Necrosis Factor Ligand Superfamily Member 13,Pathology,2,X,[aapp/bacs],[bmod],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,H02.403.650
9c800e1b-ebde-4f15-9a46-49f25e13f7e3,C0237820,C0034997,was rapidly achieved with ,Recovery - action,Rehydration,2,X,[acty],[topp],,E02.319.360
20f2d921-1ad1-4a08-9f03-328cbfeea8aa,C0206750,C0403398,provoked Recurrent disease In patients diagnosed with,Coronavirus Infections,Steroid-dependent nephrotic syndrome,2,X,[dsyn],[dsyn],C02.782.600.550.200,
f4196041-d549-4760-9fd5-e7957fc9626b,C0206750,C0277556,provoked ,Coronavirus Infections,Recurrent disease,2,X,[dsyn],[dsyn],C02.782.600.550.200,
d82d85b4-54af-4c98-8381-64248f1292b3,C0206750,C0006008,is in ,Coronavirus Infections,Border Disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.350.675.100;C22.836.160
13b31628-01d2-4c6a-b9e0-0efcc11eea7f,C0020517,C2741673,were conducted to ,Hypersensitivity,Account number:Identifier:Point in time:^Patient:Nominal,2,X,[patf],[clna],C20.543,
cbc98508-c2cf-4c62-83b8-931e6fc43dad,C1705178,C1856053,went at 5:00 pm on ,Order (action),Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[acty],[dsyn],,x.x.x.x
47561941-3944-42bb-aa66-250aff319816,C1457887,C0036238,is with ,Symptoms,Satellite Viruses,1,X,[sosy],[virs],,B04.265.658
d20d9475-9b3c-48fc-a50b-ce4ec2f46fa3,C0376565,C0674432, includes ,Anti-HIV Agents,lopinavir,1,X,[phsu],[orch/phsu],D27.505.954.122.388.077.088,D03.383.742.698.553
d9a03103-7105-42f6-bc5d-ec8dd2f05321,C0243077,C1167622,of G is ,inhibitors,Binding (Molecular Function),1,X,[chvf],[moft],,
a7954eda-9ee4-4940-8d74-d63f5754072f,C0008058,C0206419,are associated with ,Chilblains,Genus: Coronavirus,1,X,[dsyn],[virs],C26.212.500.217;C26.417.217,B04.820.504.540.150
cf30da05-c3f7-49aa-a95d-785c214d1678,titers,C0206419,were negative for ,titers,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
e02add80-6494-451f-87e4-6f5dca0558a4,C1325583,C3652465,impede delayed ,central element,Interferon,1,X,[celc],[aapp/imft/phsu],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
421b6418-b53c-453e-be48-91e657c9cdb0,C0199176,onco,is in moderate-to-severe onco ,Prophylactic treatment,onco,1,X,[topp],????,,????
b99e5b1d-1025-4fea-b5bd-ad601411ed68,C0199176,C0018939,is in moderate-to-severe onco ,Prophylactic treatment,Hematological Disease,1,X,[topp],[dsyn],,C15.378
3bbc96de-da54-4943-b7eb-7b8a6362212f,C0199176,C0027651,is in moderate-to-severe onco ,Prophylactic treatment,Neoplasms,1,X,[topp],[neop],,C04
046dc590-1eb5-419c-857b-cc0a12f8f673,C0340194,C0206419,are hallmarks of severe ,Respiratory failure without hypercapnia,Genus: Coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150
feb2ac09-757b-441c-9ef9-eab67596ca85,C0740766,C0206419,are hallmarks of severe ,acute pneumonia,Genus: Coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150
9c873007-2a3a-4b2e-a325-5235d24b6625,C0206419,C1706374,has spread worldwide over 80 000 deaths reported by end of ,Genus: Coronavirus,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
2260c563-a910-48ea-b75c-c338ddee7eda,C0281178,C0206419,be useful in patients with ,anti-cytokine therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
e1a7c429-85d9-4c63-a84f-a4e317a90b5e,C1566558,C0243042,exhibited exceptional act on ,Natural Products,Inflammation Mediators,1,X,[bacs],[phsu],D20.215,D23.469
cdd582bd-921c-4652-b0b3-8e19fabd8654,C3873497,C0206419,is with ,Severe acute respiratory infection,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
a2f2afc1-27fa-4c85-98e3-bbea7e231304,C3873497,C0162633,is accompanied by ,Severe acute respiratory infection,Viral Shedding,2,X,[dsyn],[patf],,G07.925
55c1ff06-0703-42a2-947d-a1f4d8b1826a,C3873497,C0015733,is accompanied by ,Severe acute respiratory infection,Feces,1,X,[dsyn],[bdsu],,A12.459
6b2979c3-de92-484c-b1bd-2d6d557edf7f,CoV2,C0005775,can reach system from ,CoV2,Blood Circulation,1,X,????,[phsf],????,G09.330.100
2c3f5f97-50b7-4209-a0fe-450901443680,CoV2,C0700271,binding ,CoV2,M Protein multiple myeloma,1,X,????,[aapp/imft],????,x.x.x.x
a8fbc053-3acc-4326-bf77-d0ad6875fb61,C1175743,C0030946,binding ,SARS coronavirus,Endopeptidases,1,X,[virs],[aapp/enzy/phsu],B04.820.504.540.150.113.937,D08.811.277.656.300
8d03159b-6b24-486f-8e82-336b55cd3dfe,CoV2,C0030946,binding ,CoV2,Endopeptidases,1,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
04c31395-3fae-48ac-987b-fded2931b3bb,C1175743,C1742865,binding ,SARS coronavirus,TMPRSS2 protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,x.x.x.x
d3d591e5-cab2-4f9d-83e0-a23a1295532b,CoV2,C1742865,binding ,CoV2,TMPRSS2 protein human,1,X,????,[aapp/enzy],????,x.x.x.x
acc15522-139e-4ba0-9c85-83d088236303,CoV2,C1452534,binding ,CoV2,ACE protein human,1,X,????,[aapp/bacs],????,x.x.x.x
0b230a3c-9693-4092-96ef-89c16360d50a,C1175743,C1418029,binding ,SARS coronavirus,OR2H2 gene,1,X,[virs],[gngm],B04.820.504.540.150.113.937,
bb10e2e6-4b8b-4579-950a-03a1d499abdd,CoV2,C1418029,binding ,CoV2,OR2H2 gene,1,X,????,[gngm],????,
a2c82672-d279-48b0-ab32-a1891c2f350d,C0031117,C1175743,can can observed after uneventful CoV2,Peripheral Neuropathy,SARS coronavirus,1,X,[dsyn],[virs],C10.668.829,B04.820.504.540.150.113.937
9e82ed20-e584-476f-98bc-8f14fd12f30c,C0031117,CoV2,can can observed after uneventful CoV2,Peripheral Neuropathy,CoV2,1,X,[dsyn],????,C10.668.829,????
0a750bef-66ed-4ce7-b1ea-70f36f0c08a5,C0235031,C1175743,can In conclusion can observed during CoV2 ,Neurologic Symptoms,SARS coronavirus,1,X,[sosy],[virs],C10.597;C23.888.592,B04.820.504.540.150.113.937
95009740-8352-4e3f-bca0-9e8ad69e56d8,C0235031,CoV2,can In conclusion can observed during CoV2 ,Neurologic Symptoms,CoV2,1,X,[sosy],????,C10.597;C23.888.592,????
78e1aa04-9494-4f8b-ab07-9895ac988819,C0235031,C0009450,can In conclusion can observed during CoV2 ,Neurologic Symptoms,Communicable Diseases,1,X,[sosy],[dsyn],C10.597;C23.888.592,C01.539.221
38468aa7-f284-407d-bf1e-25cc88eecc8d,C0005889,C0206419,nature of ,Body Fluids,Genus: Coronavirus,1,X,[bdsu],[virs],A12.207,B04.820.504.540.150
5d392e1b-832b-4f51-9bda-94936b4cdd46,C0019240,C0031843,is with traditional ,Herb,physiological aspects,1,X,[plnt],[phsf],,x.x.x.x
ac1abd4e-46ba-477a-90da-7eb6245e7c23,C0019240,C0018837,is with traditional ,Herb,Heat (physical force),1,X,[plnt],[npop],,
f888cd85-74a2-426a-bae2-574ceecc9a0b,PDL,C0087111,might also have ,PDL,Therapeutic procedure,1,X,????,[topp],????,E02
b6d2c3bc-a033-494a-a2cd-589918456f86,PDL,C0206419,might have ,PDL,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
aa53fa9d-f11c-44a3-896b-000df834630b,PDL,C1175743,might prevent entrance of ,PDL,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
08e55d7c-8ab6-4805-95b0-eb2ef82a2bba,PDL,C0242656,shorten ,PDL,Disease Progression,1,X,????,[patf],????,C23.550.291.656
34066891-14fb-4c64-b120-72d2b2e82c4e,PDL,C1527144,might have ,PDL,Therapeutic Effect,1,X,????,[clna],????,
0f0aa972-6cf9-4167-8c64-2509ca1ce382,C1457887,C0231918,was ,Symptoms,Nose symptoms,1,X,[sosy],[sosy],,
431c3fa0-afd1-47ea-93a9-d2e7d51386e6,C1457887,C0011991,was ,Symptoms,Diarrhea,1,X,[sosy],[sosy],,C23.888.821.214
48a10dfa-ffd0-40f8-9ecd-92ac16904e8d,C1457887,C0027498,was ,Symptoms,Nausea and vomiting,1,X,[sosy],[sosy],,
68e0a7bb-b0bf-4a11-ac57-4060cb125d2a,C0015967,C0231918,followed by ,Fever,Nose symptoms,1,X,[sosy],[sosy],C23.888.119.344,
46274225-0f9b-44dd-a4e9-3ee3aac41f3b,C0015967,C0011991,followed by ,Fever,Diarrhea,1,X,[sosy],[sosy],C23.888.119.344,C23.888.821.214
05b7a1a8-bbd9-4342-a69b-cc9551f7eecc,C0015967,C0027498,followed by ,Fever,Nausea and vomiting,1,X,[sosy],[sosy],C23.888.119.344,
18a306dd-a01a-4ad8-a47c-e1e630ca3e3c,C0204514,C0920672,understand potential ,Structural analysis,virus pathogenesis,2,X,[topp],[comd],,
4f8837cb-d16a-46e2-b242-7cbea42f8ddd,C2362546,C1334164,Further belong to novel ,Alpha protein,Immunoglobulin Family Protein,3,X,[aapp],[aapp/imft],,
d93c31fd-6346-4dd0-8a82-55210219c780,C2806453,C1334164,Further belong to novel ,Betacoronavirus,Immunoglobulin Family Protein,3,X,[virs],[aapp/imft],B04.820.504.540.150.113,
458dc02b-955b-424c-a121-6ea405d3b288,ORF8,C1334164,Further belong to novel ,ORF8,Immunoglobulin Family Protein,3,X,????,[aapp/imft],????,
35f2564b-3d83-4ec1-809e-f0ca671c4b5a,ORF8,C1175743,having hypervariable position among ,ORF8,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
2455154e-2405-4f06-a5a8-c5ade7bce865,C0017428,C1517880,is in its predicted ,Genome,Ligand Binding,1,X,[gngm],[moft],G05.360.340,
d830f72d-4dbf-4e64-8c00-e4f9970e4534,C0042736,C1512665,share architectures to those of CoV ,Viral Proteins,Immunoglobulin Domains,1,X,[aapp/bacs],[amas],D12.776.964,G02.111.570.820.709.275.750.250
d55b65d4-5165-459b-b343-529ffc5b9aa5,C0042736,C0033684,share architectures to those of CoV ,Viral Proteins,Proteins,1,X,[aapp/bacs],[aapp/bacs],D12.776.964,D12.776
f23aca45-f2cf-4c17-8643-5d8d3c5b5af8,ORF8,C0003060,is in ,ORF8,Animal Viruses,1,X,????,[virs],????,B04
e3ce5fae-78b4-4099-b32a-da9747241f47,ORF8,C1136170,is in ,ORF8,Virulence Factors,1,X,????,[bacs/hops/orch],????,D23.946.896
5a2bf2b7-225c-4b9c-88a3-e89196fbf5c3,C0033684,C0017428,encoded by ,Proteins,Genome,1,X,[aapp/bacs],[gngm],D12.776,G05.360.340
499285f2-0d5f-471f-99ab-c8fe73befd2a,C0206419,C1334164,comprise novel ,Genus: Coronavirus,Immunoglobulin Family Protein,3,X,[virs],[aapp/imft],B04.820.504.540.150,
499285f2-0d5f-471f-99ab-c8fe73befd2a,C0206419,C1334164,novel Immunoglobulin Family Protein of,Genus: Coronavirus,Immunoglobulin Family Protein,2,X,[virs],[aapp/imft],B04.820.504.540.150,
b549b2f5-114c-4ece-8db9-00aee0e145a1,C0204514,C2362546,ORF8 from ,Structural analysis,Alpha protein,1,X,[topp],[aapp],,
0b4e32c2-18dd-4a75-94df-58db510e7f06,C1334164,C0005525,might physiological aspects as potential,Immunoglobulin Family Protein,Biological Response Modifiers,1,X,[aapp/imft],[imft/phsu],,D27.505.696.477
763563c2-654d-49f3-8bc0-a611b0be3d1a,C1334164,C0682447,attenuate virus by host Immune response against,Immunoglobulin Family Protein,virus by host,2,X,[aapp/imft],[virs],,
46fc6fd2-6c80-429f-8b9c-84ef0ff87bf1,C1334164,C0301872,attenuate ,Immunoglobulin Family Protein,Immune response,1,X,[aapp/imft],[ortf],,
29c5ec53-d9ed-46cb-825e-4b1d1abdf2ea,C0206419,C0206277,is challenging at enhanced high risk for ,Genus: Coronavirus,Fatal Outcome,2,X,[virs],[patf],B04.820.504.540.150,E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325
228a2823-0127-4a33-bf08-56e4d2a76070,C0005516,C0041199, includes ,Biological Markers,Troponin,2,X,[clna],[aapp/bacs],D23.101,D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825
bf5046ec-97a3-4499-9136-79d2f297cdc0,C0206419,C0005516,is challenging as patients with elevated ,Genus: Coronavirus,Biological Markers,1,X,[virs],[clna],B04.820.504.540.150,D23.101
4ad65d5a-4d1e-470e-911b-73fe841a9879,C0206419,C0041199,is challenging as patients with elevated ,Genus: Coronavirus,Troponin,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825
6f06f834-f1e9-4cfc-82fc-5fab5332c391,C0206419,C0748355,19 with ,Genus: Coronavirus,Acute respiratory distress,1,X,[virs],[dsyn],B04.820.504.540.150,
7b8aeb58-3638-4369-8b3e-66e22f18ddfb,C0206419,C0014442,is downregulating ,Genus: Coronavirus,Enzymes,1,X,[virs],[aapp/enzy],B04.820.504.540.150,D08.811
a637fe34-8797-419b-b1af-521922bc8562,C1829939,C0748355,those with ,{Non-patient},Acute respiratory distress,1,X,[clna],[dsyn],,
d035f781-0739-4c75-bf1e-d055291908a6,C0553741,C0748355,those with ,Fluid Management,Acute respiratory distress,1,X,[topp],[dsyn],,
304ab7f2-ada6-42f4-a710-76042ebef23a,C0024109,C0748355,can can used in patients with L phenotype ,Lung,Acute respiratory distress,1,X,[bpoc],[dsyn],A04.411,
9d2c40ac-ca36-4a93-b499-080a506cd54b,C0242781,C0036537,route of is ,disease transmission,Bodily secretions,1,X,[patf],[bdsu],N06.850.310,A12.200
e02d7094-8f5b-4a1b-bf06-f7fb03e8029f,C1175743,C0009429,would overcome limitations associated with ,SARS coronavirus,Combined Modality Therapy,1,X,[virs],[topp],B04.820.504.540.150.113.937,E02.186
06d60938-f577-4193-bd79-6bc1031c5918,C0443640,C0022709,shows potent S ,Specific antibody,Peptidyl-Dipeptidase A,2,X,[aapp/imft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
9a888b52-83f2-481c-be2d-5c5b1df63590,C3850079,C0018026,is ,Cytoreductive Surgery,Gold,1,X,[topp],[elii/phsu],E04.166,D01.268.556.322;D01.268.956.186;D01.552.544.322;x.x.x.x
2843f713-6a5a-46aa-8530-06a958e47649,C0220781,C1516048,reported on uro ,Anabolism,Assessed,1,X,[biof],[acty],G03,
66ca95ba-d03c-4599-95ca-5081242f71f1,C0220781,C0206058,reported on uro ,Anabolism,Elective Surgical Procedures,1,X,[biof],[topp],G03,E04.249
4148809e-65aa-41d4-a98b-c0c3ee091634,C0220781,uro,reported on uro ,Anabolism,uro,1,X,[biof],????,G03,????
79a3cbba-06b0-412c-9f82-5bc660f0a56a,C0220781,C0278627,reported on uro ,Anabolism,oncology field,1,X,[biof],[bmod],G03,
abe55249-0454-484e-b999-3e4d7a115937,C0012634,C1708476,has required worldwide ,Disease,Implementation,1,X,[dsyn],[acty],C23.550.288,
c05d4d84-d854-4465-a67b-262c15469947,TOS,C0014507,was negatively associated with LOS in patients without ,TOS,Epidemiology,2,X,????,[bmod],????,H02.403.720.500
f3ff724c-06a4-4019-bce3-8850310b9bf4,C1704259,C0012634,is in experimental ,Biochemical Pathway,Disease,1,X,[moft],[dsyn],,C23.550.288
0327e44f-6f30-46d8-89bd-8a5ea7487268,C0225385,C0301872,is in ,Structure of respiratory epithelium,Immune response,2,X,[tisu],[ortf],,
17d62c69-be97-42de-98da-a71c6d20fffe,C1537068,C1171362,Specifically decreased ,Virus Internalization,protein expression,1,X,[biof],[genf],G06.920.881,
cc089684-7bdd-418a-9ada-bc7b2c89276a,C1537068,C0458827,Specifically decreased ,Virus Internalization,Airway structure,1,X,[biof],[bpoc],G06.920.881,
21c10c84-285c-4a6d-8c60-b184f2782503,C1537068,C0014609,Specifically decreased ,Virus Internalization,Epithelium,1,X,[biof],[tisu],G06.920.881,A10.272
8a3156c4-2cf0-4149-8c71-6b546d8692c4,C0022709,C0014609,is in ,Peptidyl-Dipeptidase A,Epithelium,1,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,A10.272
1896eb98-b2e6-4696-a110-d36a46af61fd,C1371550,C1372273,Increased Cytokine Production of immunomodulatory,Decreased Cytokine Production,Increased Cytokine Production,1,X,[ortf],[moft],,
ba223144-bb13-4592-a5a4-1994c6d271c2,C3825816,C0042769,may have greater capacity recover after ,Pneumonia in children,Virus Diseases,1,X,[dsyn],[dsyn],,C02
b635ff07-a71b-4e27-828a-10661aba4783,C0275522,C0158644,may may associated with subclinical ,Asymptomatic Infections,Congenital anomaly of lung,1,X,[dsyn],[cgab],C23.550.291.187.500,
02df6aff-44ad-456f-8c28-3f2d397b94a3,C2348077,C1706374,was ,Date Fruit,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[food],[aapp/bacs],B01.650.940.800.575.912.250.093.615,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
8f4b5a35-4c5c-436f-8af2-ecb52b5f1ccc,C0042333,C0999626,was increased with addition of ,Variation (Genetics),Manidae,1,X,[npop],[mamm],G05.365,
000014cf-d61b-4c80-9de9-de9ec97dddc3,C1706202,COVID,using COVID,Search - action,COVID,1,X,[acty],????,,????
11f3a8cd-c7c3-45a2-8724-4f5ee9082358,C0206750,C0012222,has attracted worldwide attention for its ,Coronavirus Infections,Diffusion,1,X,[dsyn],[npop],C02.782.600.550.200,G01.202;G02.196
0a3635ea-1466-4120-94b4-a24684f4b72b,C0038436,C0206750,related to ,Post-Traumatic Stress Disorder,Coronavirus Infections,1,X,[mobd],[dsyn],F03.950.750.500,C02.782.600.550.200
d28dfd74-b72f-4c3a-9a69-76c98d2d5714,C0038436,C2745965,related to ,Post-Traumatic Stress Disorder,Emergencies [Disease/Finding],1,X,[mobd],[patf],F03.950.750.500,C23.550.291.781;N06.230.100.083;N06.850.376
a628009d-c9af-4eec-aa6e-ee2b77e6704e,C2347784,C0021403,tested for only ,Clinical Endpoint,Influenza virus vaccine,1,X,[clna],[imft/phsu],,D20.215.894.899.302
ae6dfac2-56ec-42e3-a095-5d502da6f1fc,C0037090,C0035222,especially development of severe ,Signs and Symptoms Respiratory,Respiratory Distress Syndrome Adult,1,X,[sosy],[dsyn],C23.888.852,C08.381.840;C08.618.840
0dd7a446-5735-46c3-95f0-3c68518b8173,C0037090,C1175175,especially development of severe ,Signs and Symptoms Respiratory,Severe Acute Respiratory Syndrome,1,X,[sosy],[dsyn],C23.888.852,C02.782.600.550.200.750;C08.730.730
df27db7f-a572-4a49-939e-7e84c9d10f4d,C0161816,C0012634,associated with ,Cardiac complication,Disease,1,X,[patf],[dsyn],,C23.550.288
64099677-96d3-4773-a0d4-3f8581c5d129,C0161816,C1175175,are similar to those produced by ,Cardiac complication,Severe Acute Respiratory Syndrome,1,X,[patf],[dsyn],,C02.782.600.550.200.750;C08.730.730
e524d8e3-8e43-4e57-a003-3e7f498c060a,C0036974,C0012634,decreasing chances of serious ,Shock,Disease,2,X,[patf],[dsyn],C23.550.835,C23.550.288
e7434993-18c3-4ae8-8569-ad1fd3f78ec6,C0206750,C0597357,acts through ,Coronavirus Infections,receptor,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,
2725cc68-9ec4-40c9-b459-d5655f795fdc,C0085580,C0206750,is in ,Essential Hypertension,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907.489.165,C02.782.600.550.200
eed2e798-a7bf-4533-a369-677e750c8bdc,C0815017,C0085580,are Essential Hypertension in,Angiotensin Receptor Antagonists,Essential Hypertension,2,X,[phsu],[dsyn],D27.505.519.162,C14.907.489.165
1aa139a7-4286-4025-abf8-150b0365325d,C0030755,C0003615,is with ,Pediatrics,Appendicitis,1,X,[bmod],[dsyn],H02.403.670,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
839b2ec7-18cd-4fb2-9a35-947a41ee21a7,C1632842,C0206750,is in ,Complicated appendicitis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
035b2881-104c-4c3f-8062-3ddcba5704d9,C1632842,C1521863,is in ,Complicated appendicitis,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],,x.x.x.x
ae716bf5-ca36-4fef-9035-47e4a8c0070f,C0009566,C1521863,were found during ,Complication,estrogen receptor alpha human,2,X,[patf],[aapp/rcpt],,x.x.x.x
fb3cce21-5e14-4fac-8f81-3aaff1f1ddae,C0009566,C1707455,were found during ,Complication,Comparison,2,X,[patf],[acty],,
1b2119ba-3f97-4a97-be51-1e3979c2957d,C1175743,C3697872,belonging to ,SARS coronavirus,Genus Betacoronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
4affc199-44be-4dd0-a652-812439c830f5,C0030946,C0010813,recognizes specific ,Endopeptidases,Cytokinesis,1,X,[aapp/enzy/phsu],[celf],D08.811.277.656.300,G04.144.220.250
0e22d8c7-262e-4aa7-a414-8c3aba06e6ad,C0042774,C0014442,targeting ,Virus Replication,Enzymes,1,X,[celf],[aapp/enzy],G06.920.925,D08.811
37f26530-98d4-459c-b7dc-aad892e0325c,C0042774,C1328819,targeting SARS coronavirus M Enzymes with,Virus Replication,Small Molecule,1,X,[celf],[orch],G06.920.925,
3d7bcbb7-4f67-4dd8-8d77-5ca670a06243,C1167622,C0020276,was stabilized through four Glu166,Binding (Molecular Function),Hydrogen Bonding,1,X,[moft],[npop],,G02.282
36c35117-d289-4583-a18c-9875e9771612,C1167622,Glu166,was stabilized through four Glu166,Binding (Molecular Function),Glu166,1,X,[moft],????,,????
748c17df-dc3f-4dbf-a59b-44cc9bf2bb08,C0020276,Glu166,is with Glu166,Hydrogen Bonding,Glu166,1,X,[npop],????,G02.282,????
8ab93f1a-5c7b-4443-8a4c-c6937c029072,C0329155,C1175743,is in ,Leiostomus xanthurus,SARS coronavirus,1,X,[fish],[virs],,B04.820.504.540.150.113.937
65e210c0-f0f5-4afa-85cc-b2c47efe7338,C0329155,C0206750,is in ,Leiostomus xanthurus,Coronavirus Infections,1,X,[fish],[dsyn],,C02.782.600.550.200
12c10155-6c03-4b96-b6df-2da3fb887e5a,C1253910,C1510464,presenting CoV-2 ,Biological Community,Protein Structure,2,X,[npop],[aapp],G16.500.275.157.049.100;N06.230.124.049.100,
2e96b4d9-65c4-49e9-a627-a0a7c311bae8,C1253910,CoV-2,presenting CoV-2 ,Biological Community,CoV-2,1,X,[npop],????,G16.500.275.157.049.100;N06.230.124.049.100,????
c03af7de-6add-46f9-83cb-897286461361,C0206419,C0282686,target ,Genus: Coronavirus,Respiratory System Agents,1,X,[virs],[phsu],B04.820.504.540.150,D27.505.954.796
633955a9-d1ed-46b5-90a3-8c43e323d160,C0007820,COVID-19,simultaneously develop in ,Cerebrovascular Disorders,COVID-19,1,X,[dsyn],[virs],C10.228.140.300;C14.907.253,C000657245
ac02205e-6115-4d95-88b9-e6369bcdcfe7,C0007820,C0012634,simultaneously develop in ,Cerebrovascular Disorders,Disease,1,X,[dsyn],[dsyn],C10.228.140.300;C14.907.253,C23.550.288
a9cfa464-6b0d-4e45-a4b2-410b25a91248,C0021368,C0220781,may play role in ,Inflammation,Anabolism,1,X,[patf],[biof],C23.550.470,G03
02978e24-59af-4aaf-90e9-412aa74dfc61,C0021368,C0022116,may play role in ,Inflammation,Ischemia,1,X,[patf],[patf],C23.550.470,C23.550.513
71d3eccb-4023-4392-a2a2-d979cb2e55c1,C0021368,C0006560,predicted by ,Inflammation,C-reactive protein,1,X,[patf],[aapp/imft],C23.550.470,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
c1ce3b24-eb3f-408c-9377-9b962045c898,C0319157,C0015733,is shed via ,AS virus,Feces,2,X,[virs],[bdsu],,A12.459
ff42d3a5-cf78-4954-bd01-a45efbbbbf1c,C0002085,C0319157,may contribute to ,Alleles,AS virus,1,X,[gngm],[virs],G05.360.340.024.340.030,
1b40c9ef-13c8-470a-b309-909c8d7f2644,C0002085,C0042765,may contribute to ,Alleles,Virulence,1,X,[gngm],[biof],G05.360.340.024.340.030,G06.930
81d070ab-2c20-4f83-82ea-a61e2b92c34c,C0002085,C0086418,may contribute to ,Alleles,Homo sapiens,1,X,[gngm],[humn],G05.360.340.024.340.030,B01.050.150.900.649.313.988.400.112.400.400
9d7b7402-56c4-4c6e-916c-26a7f4936e0b,C0042765,C0086418,is in ,Virulence,Homo sapiens,1,X,[biof],[humn],G06.930,B01.050.150.900.649.313.988.400.112.400.400
a71997af-f130-4a93-b349-e8d4c0e988d1,C1707391,C0011627,available to ,Choose (action),Dermatology field,1,X,[acty],[bmod],,H02.403.225
95ac5288-d307-4e9d-b5fb-fe3671a65be6,C0206419,C0450442,is causative ,Genus: Coronavirus,Agent,1,X,[virs],[chvf],B04.820.504.540.150,
0deb017b-4db8-4fd8-95fd-761f40dcf9d2,C0035668,C2347609,can can used for ,RNA,Chemical Probe,1,X,[nnon],[chvf],D13.444.735,
4c5ff20d-f54e-443f-84e8-1c253498b7e6,COVID-19,C1704259,may lead to activated immune-inflammatory ,COVID-19,Biochemical Pathway,1,X,[virs],[moft],C000657245,
09e06094-51c2-4597-a66f-a453847023b8,C0009450,C1704259,may lead to activated immune-inflammatory ,Communicable Diseases,Biochemical Pathway,1,X,[dsyn],[moft],C01.539.221,
a4404897-e0a5-437c-be8b-5b82ba7e96b5,COVID-19,C0004936,is with prior ,COVID-19,Mental disorders,1,X,[virs],[mobd],C000657245,F03
764502b7-da4a-4826-9fef-ffd475cd63f2,C0282624,COVID-19,reconverted during ,Minimally Invasive Surgical Procedures,COVID-19,1,X,[topp],[virs],E04.502,C000657245
f3c04607-daa5-41e4-9356-454b785a81d2,C0199242,C1175743,is in patients infected with ,Anticoagulant prophylaxis,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
668473b3-2242-48f6-867e-6066c85fbc3d,C0032712,C0376520,results in displacement of ,Porphyrins,Dietary Iron,1,X,[bacs/orch],[inch],D03.383.129.578.840.500;D03.633.400.909.500;D04.345.783.500;D23.767.727,D01.490.600;D02.691.550.600
e08e69c3-c5ee-493d-a157-11ad35a3428d,C0032712,C0022023,results in displacement of ,Porphyrins,Ions,1,X,[bacs/orch],[elii],D03.383.129.578.840.500;D03.633.400.909.500;D04.345.783.500;D23.767.727,D01.248.497
4e7d20ff-a7a7-4720-8815-fbebe5a01ab3,C0019046,C0597157,loses capability for ,Hemoglobin,oxygen transport,2,X,[aapp/bacs],[ortf],D12.776.124.400;D12.776.422.316.762,
e061b263-6c72-4214-ab3d-a6662c2727c1,C0597157,C0003130,aggravates ,oxygen transport,Anoxia,1,X,[ortf],[patf],,C23.888.852.079
d50c5045-570a-4f57-8986-a906dc078670,C0020452,C0014583,increased ,Hyperemia,Episcleritis,1,X,[dsyn],[dsyn],C14.907.474,C11.790.500
98d4d46a-26e7-4e70-8ac1-29b239a8d5ff,C0020452,C0271298,increased ,Hyperemia,Chemosis of conjunctiva,1,X,[dsyn],[patf],C14.907.474,
78cf3102-d42b-42da-a331-4b66cc89ec4b,C0020452,C0036537,increased ,Hyperemia,Bodily secretions,1,X,[dsyn],[bdsu],C14.907.474,A12.200
19290d05-c8d9-482f-a333-bd4bb98d3121,C1457887,C0085636,was ,Symptoms,Photophobia,1,X,[sosy],[sosy],,C10.597.751.941.661;C11.966.741;C23.888.592.763.941.661
1f987aed-8e82-4a16-9d77-e9f1e0a4bb75,C0013227,C0872315,be Therefore may developed for future ,Pharmaceutical Preparations,Communicable Diseases Emerging,1,X,[phsu],[dsyn],D26,C01.539.221.500
6e83bb63-31b0-4f8e-ba8d-6555efab2fc4,C0013227,C0022709,targeting ,Pharmaceutical Preparations,Peptidyl-Dipeptidase A,1,X,[phsu],[aapp/enzy/imft],D26,D08.811.277.656.350.350.687
aa2ef1e1-65c5-41b7-a933-ffc83afe52ed,C0040408,C1707455,results of were ,Tongue,Comparison,1,X,[bpoc],[acty],A03.556.500.885;A14.549.885,
aed81373-00ae-4ff5-a59c-412f3d73bfa9,C1292527,C3687742, includes nasopharyngeal swab ,Body fluid sample,Oropharyngeal swab,2,X,[bdsu],[bdsu],,
4fb13f44-6d39-4991-8f23-640caa7641e4,C1292527,C0036087, includes nasopharyngeal swab ,Body fluid sample,saliva,2,X,[bdsu],[bdsu],,A12.200.666
b8182903-7709-47c6-93e8-f2022fcae7d8,C1292527,C0038056, includes nasopharyngeal swab ,Body fluid sample,Sputum,2,X,[bdsu],[bdsu],,A12.200.808
87d14e00-7b72-4c96-9c44-44d378109133,C0370003,C0038056, includes nasopharyngeal swab ,Specimen,Sputum,2,X,[sbst],[bdsu],,A12.200.808
0b137175-6102-44ee-a766-96ff72015722,C1292527,C1610733, includes nasopharyngeal swab ,Body fluid sample,Urine - SpecimenType,2,X,[bdsu],[bdsu],,
5b010888-9b44-4994-9d96-a8618a080f27,C0370003,C1610733, includes nasopharyngeal swab ,Specimen,Urine - SpecimenType,2,X,[sbst],[bdsu],,
6313486e-fc59-41a1-9c24-875170ef71a2,C2936194,C1292527,is in various ,Hydrodynamics,Body fluid sample,1,X,[npop],[bdsu],G01.342,
562afef8-9333-47e0-9d44-d9f4e5bea0d0,C2936194,C0370003,is in various ,Hydrodynamics,Specimen,1,X,[npop],[sbst],G01.342,
44244eb1-5720-4fc8-a59a-326a34b957dc,C2936194,C3687742,is in various nasopharyngeal swab ,Hydrodynamics,Oropharyngeal swab,1,X,[npop],[bdsu],G01.342,
2d357399-a53e-4ad2-be7e-02c92c0db094,C2936194,C0036087,is in various nasopharyngeal swab ,Hydrodynamics,saliva,1,X,[npop],[bdsu],G01.342,A12.200.666
9c59d0b7-0818-4415-a4d4-bee82da4bc5d,C2936194,C0038056,is in various nasopharyngeal swab ,Hydrodynamics,Sputum,1,X,[npop],[bdsu],G01.342,A12.200.808
c1955ad0-6735-43c4-9ccd-614d5a0b7370,C2936194,C1610733,is in various nasopharyngeal swab ,Hydrodynamics,Urine - SpecimenType,1,X,[npop],[bdsu],G01.342,
f8f2003a-7a7e-4286-a6ad-5f1d55d83e56,C0370003,C0352155,using ,Specimen,Chlorhexidine Mouthwash,1,X,[sbst],[clnd],,
86447722-4ebf-4912-9dfc-9ecc58446813,C1175743,C0206074,was determined by PCR,SARS coronavirus,Renal Replacement Therapy,1,X,[virs],[topp],B04.820.504.540.150.113.937,E02.870
4c14f6b3-7c73-44e6-94a3-513460fcc7be,C0352155,C1175743,reducing ,Chlorhexidine Mouthwash,SARS coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150.113.937
1e99f810-1c05-48a2-b6ae-fa0f0f7e1de9,C2349975,C0029341,similar to ,Enhance (action),Orthomyxoviridae,1,X,[acty],[virs],,B04.820.545
b1c4d449-5cfc-4358-becc-f8979e0a27f4,C0012634,C0029341,similar to ,Disease,Orthomyxoviridae,1,X,[dsyn],[virs],C23.550.288,B04.820.545
9bc80cbb-8eef-4877-ae27-88acc617464e,C0009450,C0018801,can result in myocardial injury ,Communicable Diseases,Heart failure,1,X,[dsyn],[dsyn],C01.539.221,C14.280.434
050307e3-3297-47e6-8d76-d86220569224,C0009450,C0003811,can result in myocardial injury ,Communicable Diseases,Cardiac Arrhythmia,1,X,[dsyn],[dsyn],C01.539.221,C14.280.067;C23.550.073
1eaeb671-1998-4f78-83c8-cca52a76903a,C0949266,C0042769,can interact In addition to ,Therapies Investigational,Virus Diseases,1,X,[topp],[dsyn],E02.931,C02
2c6712e9-5590-4b15-8b72-ea747f7e92ae,C0206419,C1516295,affects ,Genus: Coronavirus,Cardiopulmonary Physiology,1,X,[virs],[bmod],B04.820.504.540.150,
a21a9bd7-50b8-40d5-898f-d1b0241995da,C0012634,C1516295,affects ,Disease,Cardiopulmonary Physiology,1,X,[dsyn],[bmod],C23.550.288,
0c3c3f3e-c570-43cf-bcb9-75b18c050214,COVID-19,C0013227,was performed in First Affiliated Hospital of Zhejiang University School of ,COVID-19,Pharmaceutical Preparations,1,X,[virs],[phsu],C000657245,D26
b0e48f44-c8dc-4eda-82ef-9cc4cd7b924f,C0002930,C0007876,is preferred in ,Anesthesiology,Cesarean section,2,X,[bmod],[topp],H02.403.066,E04.520.252.500
03c63661-22b0-4a2c-a552-f175ab83bdb5,C0002915,C0021932,is with ,General Anesthesia,Intubation Intratracheal,1,X,[topp],[topp],E03.155.197,E02.041.500;E02.585.578;E05.497.578
86612b73-149b-47f1-bf35-c7bd58df4e1e,C0002930,C0035203,reduce its influence in ,Anesthesiology,Respiration,1,X,[bmod],[phsf],H02.403.066,G09.772.705
9c8cd2ed-1b08-4d0c-831a-1ffab85714e9,C0319157,C0035243,is mainly responsible for ,AS virus,Respiratory Tract Infections,1,X,[virs],[dsyn],,C01.539.739;C08.730
11261481-0010-4c54-8e59-f94a7bb2b45f,C0206750,C1861452,are characterized with ,Coronavirus Infections,Storm Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
98989fd9-2593-4efe-b6af-61b7795a3963,C1285338,C0206750,is in ,Inflammatory disorder of immune system,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
79a47526-7ab4-4106-bb87-a8a54cb3899a,C2827774,C0003451,is with ,Current Therapy,Antiviral Agents,1,X,[topp],[phsu],,D27.505.954.122.388
00c4fd74-533b-4c61-a521-7ca861d9c591,C0280274,C0441636,were ineffective for ,Antiviral Therapy,Surgical shortening - action,1,X,[topp],[topp],,
3e6a31a3-1e0b-4297-9f9e-67c3d06e05e1,C2827774,C0441636,were ineffective for ,Current Therapy,Surgical shortening - action,1,X,[topp],[topp],,
8e733017-4bfa-402c-a853-e2f5fb74c836,C0678222,C1511300,are concerned with ,Breast Carcinoma,Breast Cancer Therapeutic Procedure,1,X,[neop],[topp],C04.588.180;C17.800.090.500,
2d76e3ce-38a0-4fca-b7d6-cad494cc6770,C0678222,PRE,were divided into PRE ,Breast Carcinoma,PRE,1,X,[neop],????,C04.588.180;C17.800.090.500,????
b1f8fcdf-ed5f-4d89-9f5e-952f14001c76,C0678222,C0206750,were divided into PRE ,Breast Carcinoma,Coronavirus Infections,1,X,[neop],[dsyn],C04.588.180;C17.800.090.500,C02.782.600.550.200
6bcc6ba8-d436-41a6-aacb-ddaca62aaf15,C0280274,C0206750,is most important treatment for ,Antiviral Therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
d88ec8b1-85b2-4261-b383-29f067dc099c,C0008269,C0174990,prevent coronavirus receptor recognition by,Chloroquine,coronavirus receptor,2,X,[orch/phsu],[aapp/rcpt],D03.633.100.810.050.180,x.x.x.x
95791cd7-7b94-4b14-b833-902bbe1d2d0b,C0020336,C0174990,prevent coronavirus receptor recognition by,Hydroxychloroquine,coronavirus receptor,2,X,[orch/phsu],[aapp/rcpt],D03.633.100.810.050.180.350,x.x.x.x
6b19bc97-57f8-4d63-b6a9-c8342a380732,C0008269,C0018790,prevent coronavirus receptor recognition by,Chloroquine,Cardiac Arrest,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C14.280.383
bcd9f842-46f8-4665-a30f-6da7785a172c,C0020336,C0018790,prevent coronavirus receptor recognition by,Hydroxychloroquine,Cardiac Arrest,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C14.280.383
902bf52c-d064-48cf-9737-5c1d953bf9e1,C0806140,C0035203,six with invasive ,Flow,Respiration,1,X,[npop],[phsf],,G09.772.705
cde4429b-d3a2-4002-8a99-6b8aa2943a85,C0030054,C0035203,six with invasive ,Oxygen,Respiration,1,X,[bacs/elii/phsu],[phsf],D01.268.185.550;D01.362.670;x.x.x.x,G09.772.705
038adba9-1b4f-4aad-a7c2-2c6c2ce5fa35,C0242297,C0035203,six with invasive ,Dietary Supplementation,Respiration,1,X,[topp],[phsf],,G09.772.705
cdd75ceb-9cbc-47b5-bf78-30d2d0b1b155,C1609165,C0015967,rapidly beneficial effect on ,tocilizumab,Fever,1,X,[aapp/imft/phsu],[sosy],x.x.x.x,C23.888.119.344
5591acb7-d261-4240-bf52-143b302b49b6,C0042776,C0520510,track disease transmission through,Virus,Materials,1,X,[virs],[sbst],B04,
f6585d2e-b857-4573-bde4-6655b2c05817,C0520510,C0016248,thus avoiding artifacts ,Materials,Floods,2,X,[sbst],[npop],,G16.500.175.812;N06.230.100.230.250
609fdfa7-d6dd-452c-b69f-c56f9e8f3d1a,C0520510,C1325742,thus avoiding ,Materials,Pore,1,X,[sbst],[celc],,
5a73ba00-cfa2-4634-8856-5e3404ab77b1,C0520510,C1511790,greatly assist accuracy of ,Materials,Detection,1,X,[sbst],[topp],,
9acf9b92-c9d3-464f-9003-e48a3eba69e2,C0520510,C0596539,avoiding loss due to ,Materials,evaporation,1,X,[sbst],[npop],,
df533059-53c1-4cfb-acb7-b726aa75ded8,C0520510,C0934502,comprise absorbent hydrophilic ,Materials,anatomical layer,1,X,[sbst],[bpoc],,
df533059-53c1-4cfb-acb7-b726aa75ded8,C0520510,C0934502,comprise hydrophobic ,Materials,anatomical layer,1,X,[sbst],[bpoc],,
6bdf1c6f-1b9c-4370-8dd6-7bdde3cccb81,C0934502,C0042776,can adhere ,anatomical layer,Virus,1,X,[bpoc],[virs],,B04
8af73417-8058-4d6c-82d6-189521117b3a,C0934502,C0032582,comprising nonwoven ,anatomical layer,Polypropylenes,1,X,[bpoc],[bodm/orch],,D02.455.326.271.665.590;D05.750.716.550;D25.720.716.550;J01.637.051.720.716.550
5707ca7c-3a37-41da-b176-f50aca2c4a03,C0934502,C0032474,comprising nonwoven ,anatomical layer,Polyesters,1,X,[bpoc],[bodm/orch],,D05.750.728;D25.720.728;J01.637.051.720.728
128d1d4e-25a9-490e-9903-4dc6ff36a085,C0087111,C0597039,prevent such dangerous ,Therapeutic procedure,Infectious disease of nervous system,1,X,[topp],[dsyn],E02,
aeea9cde-8092-4781-9dd0-f0b11a3c9f68,C3652465,C1707814,was For adults with ,Interferon,Dose Reduced,2,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
aeea9cde-8092-4781-9dd0-f0b11a3c9f68,C3652465,C1707814,was associated with ,Interferon,Dose Reduced,2,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
8bb00e0f-a0bf-4279-966d-2525c0643d68,C3652465,C0001617,was For adults with ,Interferon,Adrenal Cortex Hormones,1,X,[aapp/imft/phsu],[horm/orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D06.472.040
8bb00e0f-a0bf-4279-966d-2525c0643d68,C3652465,C0001617,was associated with ,Interferon,Adrenal Cortex Hormones,1,X,[aapp/imft/phsu],[horm/orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D06.472.040
77ef77f7-a536-4b1c-98a2-32e34c72eef5,C0035525,C0559546,was associated with high risk of severe ,Ribavirin,Adverse reactions,2,X,[nnon/phsu],[patf],D13.570.800.790,
160c1967-04bc-4c94-bf83-32e4e902029a,COVID-19,C0281169,develop severe ,COVID-19,pulmonary complications,1,X,[virs],[patf],C000657245,
c148079f-50bb-4d03-b165-9ccc619facaf,COVID-19,C0264556,develop severe acute ,COVID-19,Acute pneumothorax,2,X,[virs],[dsyn],C000657245,
c3f24f55-516f-4588-8d56-d8e549e6dadf,COVID-19,C0233494,develop severe acute ,COVID-19,Tension,1,X,[virs],[mobd],C000657245,
a6275a8c-7d63-45b4-aff8-1b51d078782d,C0319157,C1704259,entered Cells through different,AS virus,Biochemical Pathway,1,X,[virs],[moft],,
2ce307a3-3b85-4043-ae6b-12a613bbdbc2,C3687832,C1704259,inhibit ,Drugs - dental services,Biochemical Pathway,1,X,[topp],[moft],,
abfde6db-fc2c-46b7-ba26-edec4cc5839a,C3687832,C0597360,significantly increase ,Drugs - dental services,receptor expression,1,X,[topp],[genf],,
abfde6db-fc2c-46b7-ba26-edec4cc5839a,C3687832,C0597360,receptor expression of,Drugs - dental services,receptor expression,1,X,[topp],[genf],,
9470fad7-c214-440e-b109-757966cff09b,C3687832,C0024109,significantly increase ,Drugs - dental services,Lung,1,X,[topp],[bpoc],,A04.411
9470fad7-c214-440e-b109-757966cff09b,C3687832,C0024109,receptor expression in,Drugs - dental services,Lung,1,X,[topp],[bpoc],,A04.411
da136d0b-e499-4071-85ed-e88d8ca3586f,C0597360,C0024109,is in ,receptor expression,Lung,1,X,[genf],[bpoc],,A04.411
450913da-3ab6-43f3-b563-d9550b8e8ebe,C3687832,C0003018,receptor expression for,Drugs - dental services,Angiotensins,1,X,[topp],[aapp/bacs/phsu],,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
71a99575-6a9a-4b27-81af-7bd4230044e5,C3687832,C0014442,receptor expression for,Drugs - dental services,Enzymes,1,X,[topp],[aapp/enzy],,D08.811
d4300a3a-90d2-4889-8c5d-ad7f1c9de09e,C0599878,C0012634,ranging from asymptomatic to critical ,disease characteristic,Disease,1,X,[patf],[dsyn],,C23.550.288
a0c5f30d-ae8b-421c-8755-34a8d23caad8,C1517281,C0206419,is in patients with ,Focused Ultrasound Therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
ce2569b7-5eb8-4050-ab3b-45645e6a2816,C0018801,C0302148,is with ,Heart failure,Blood Clot,1,X,[dsyn],[patf],C14.280.434,C14.907.355.830
df9c67b6-2747-48e3-942b-d5532f40ab7e,C0034065,C0302148,is with ,Pulmonary Embolism,Blood Clot,1,X,[patf],[patf],C08.381.746;C14.907.355.350.700,C14.907.355.830
650ea149-446a-4559-be1b-51b74a4d05fa,C0027059,C0302148,is with ,Myocarditis,Blood Clot,1,X,[dsyn],[patf],C14.280.238.625,C14.907.355.830
aa89f923-ab1f-4150-8286-524eb5bb3d97,C3526617,COVID-19,is with ,Outpatient Dialysis,COVID-19,1,X,[topp],[virs],,C000657245
f1f5e459-779a-489c-bcea-fe2ef6a666e2,C3526617,C0009450,is with ,Outpatient Dialysis,Communicable Diseases,1,X,[topp],[dsyn],,C01.539.221
6bfaf269-a2b0-479d-9cf6-a25ad9c49207,C0018563,C0281902,predicted lower psychological ,Hand,maladjustment,1,X,[bpoc],[mobd],A01.378.800.667,
55ebfc09-ffab-4ef9-b8d3-0a4d6eadbd3f,C1947933,C0034019,may become first choice in ,care activity,public health medicine (field),4,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
765ef20a-dc8d-4734-9d24-53dcb6af44e2,C0037633,C0034019,may become first choice in ,Solutions,public health medicine (field),2,X,[sbst],[bmod],D26.776,H02.403.720;N01.400.550;N06.850
c30fa961-60c1-4186-9813-85d0ee82e2e4,C0037633,C2745965,may become first choice in ,Solutions,Emergencies [Disease/Finding],2,X,[sbst],[patf],D26.776,C23.550.291.781;N06.230.100.083;N06.850.376
9a449d3c-75d3-4b08-a2e0-dca1a99f5840,C0206419,RTPCR,was In case report found by realtime RTPCR,Genus: Coronavirus,RTPCR,1,X,[virs],????,B04.820.504.540.150,????
9a449d3c-75d3-4b08-a2e0-dca1a99f5840,C0206419,RTPCR,was found by realtime fluorescent RTPCR,Genus: Coronavirus,RTPCR,1,X,[virs],????,B04.820.504.540.150,????
3763c3dd-a1e4-4b3a-9a1f-ab05c618e74d,C0206419,C1608239,was found in COVID19,Genus: Coronavirus,Specimen Type - Bile fluid,1,X,[virs],[bdsu],B04.820.504.540.150,
681cd591-e1fb-483d-9103-9c7a054301bd,C0206419,COVID19,was found in COVID19,Genus: Coronavirus,COVID19,1,X,[virs],????,B04.820.504.540.150,????
5e0b6497-ea31-41e3-864d-23d273bdd43b,C1516048,C1707391,were done in standard format from ,Assessed,Choose (action),1,X,[acty],[acty],,
9b44d6fa-43df-49ab-847c-c3f19d621952,C2948600,C1527144,investigate ,Aim,Therapeutic Effect,1,X,[inch/phsu],[clna],,
a96706b7-fa97-4f18-9e1c-7affecf7c1ff,C2948600,C0683465,investigate ,Aim,novel AODU treatment method,2,X,[inch/phsu],[topp],,
c2485590-2813-441a-a5cf-e66c8e73d4f9,C2948600,C0018787,investigate ,Aim,Heart,1,X,[inch/phsu],[bpoc],,A07.541
14bb8d7b-7a2e-4638-8762-fb68814f62fd,C1999230,C0008964,support for clinical ,Providing (action),Clinical Medicine,1,X,[acty],[bmod],,H02.403.200
1f27672d-778a-4de2-97c3-c57352fee160,C0543829,C0206419,is in ,pneumonia clinical,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
585ccde1-9ce2-48c7-932a-8d875d15ca8f,C0085295,C0032285,reduced ,Interleukin-10,Pneumonia,2,X,[aapp/imft],[dsyn],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,C08.381.677;C08.730.610
798c41e9-4707-42fb-9a7f-e1fed2e33f0b,C0085295,C0040300,reduced ,Interleukin-10,Body tissue,1,X,[aapp/imft],[tisu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,A10
3f228eb0-7c48-4885-a1eb-a2e765bbef31,C0085295,C0024109,levels in ,Interleukin-10,Lung,1,X,[aapp/imft],[bpoc],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,A04.411
668a8aeb-f29c-41f3-964d-d0717400de47,C2986594,C0439962,evaluate effectiveness of ,Mouse Model,Mixture,1,X,[emod],[sbst],,
18b6d0c3-553f-4403-b53c-c5a40d89ba1b,C2986594,C1999230,evaluate effectiveness to ,Mouse Model,Providing (action),1,X,[emod],[acty],,
094ae893-645f-4d3a-bf3e-61d17375412b,C2986594,C0003064,evaluate effectiveness to ,Mouse Model,Animals Laboratory,1,X,[emod],[anim],,B01.050.050.199
942a056a-4d24-4494-9448-cc18c4216764,C0819757,C0024109,calculate ,Structure of parenchyma of lung,Lung,1,X,[tisu],[bpoc],,A04.411
998c4f1d-eb7a-4f94-884a-a03b63cf1ac4,RT-PCR,C0819757,detect Nucleic Acids virus load in,RT-PCR,Structure of parenchyma of lung,1,X,????,[tisu],????,
c40268c7-04dd-4c5a-8762-3e60ac572a8b,C0085295,C0819757,is in ,Interleukin-10,Structure of parenchyma of lung,1,X,[aapp/imft],[tisu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
c109cf96-66ad-4cd2-8694-0c719c0bf79e,C0085295,C0033684,is in ,Interleukin-10,Proteins,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D12.776
30726a9a-16df-4a3f-9687-47b3cf07faeb,C0819757,C3463820,calculate ,Structure of parenchyma of lung,Inhibition,1,X,[tisu],[acty],,F01.145.544;F02.463.425.475;F02.739.794.405
e09d72ed-4b73-494a-8713-be00aa8fcd53,C0439962,C0024109,could reduce ,Mixture,Lung,1,X,[sbst],[bpoc],,A04.411
68eec93e-5482-486e-91cf-0889549fbe43,C0439962,C0206419,could reduce ,Mixture,Genus: Coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150
c7c7031c-ef45-4ba9-850c-e1becf599d37,C0439962,C1518039,could reduce ,Mixture,Mouse Lung,1,X,[sbst],[tisu],,
241fc13e-c1ec-49a6-bc09-080b1fe44eaa,C0085295,C0229671,content in ,Interleukin-10,Serum,1,X,[aapp/imft],[bdsu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,A12.207.152.846;A15.145.846
4015b2a4-5ac5-4390-965b-5c3e2427f740,C0085295,C2986594,content in ,Interleukin-10,Mouse Model,1,X,[aapp/imft],[emod],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
dd04a312-7c79-4a1e-9626-97c9830d2d23,C0085295,C0026594,content of ,Interleukin-10,motilin,1,X,[aapp/imft],[aapp/horm/phsu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D06.472.317.525;D06.472.699.500;D12.644.400.470;D12.644.548.500;D12.776.631.650.463
1b14959a-d72e-48ea-a554-808fafb3b749,C0085295,C1518039,is in ,Interleukin-10,Mouse Lung,2,X,[aapp/imft],[tisu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
8b4ff0c2-e79e-42d3-9ce9-f2c0b478a76e,C0085295,C1519523,is in ,Interleukin-10,Tissue Model,2,X,[aapp/imft],[emod],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
3f5837f5-83eb-4f81-88cf-277da9b7aec8,C2936405,C0242656,could Providing (action) pause in,Drug Repositioning,Disease Progression,1,X,[topp],[patf],E05.290.875,C23.550.291.656
8ff31b24-240f-4bae-8fb4-48f575dae9b9,C0023779,C1167395,encounter endosomal/lysosomal ,Lipids,Host (organism),1,X,[orch],[orgm],D10,
6ad86649-4693-4518-aa53-ffdcc81453ad,C0023779,C0009450,encounter Host (organism) compartment in critical step of,Lipids,Communicable Diseases,1,X,[orch],[dsyn],D10,C01.539.221
216d439b-34c4-49df-8c96-20777d62f057,C0220756,C0678236,is ,Niemann-Pick Disease Type C,Rare Diseases,4,X,[dsyn],[dsyn],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,C23.550.291.906
1e1eef61-2378-4f25-85f1-4ca23700fb80,C0220756,C1166848,is ,Niemann-Pick Disease Type C,late endosome,2,X,[dsyn],[celc],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,
b5d1018a-6911-4236-b435-b769cad81a28,C0220756,C0024369,is ,Niemann-Pick Disease Type C,Lysosomes,2,X,[dsyn],[celc],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,A11.284.430.214.190.875.190.550
e22f995b-c1c7-4b15-9d43-12a45b85fd63,C0220756,C0042769,been has associated with LE/L ,Niemann-Pick Disease Type C,Virus Diseases,1,X,[dsyn],[dsyn],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,C02
d3f94c78-283b-4419-ba6b-d87423652a60,C0017337,C0042769,been has associated with LE/L ,Genes,Virus Diseases,1,X,[gngm],[dsyn],G05.360.340.024.340,C02
50f5a920-5cc4-4dae-b11f-3c650763f5c4,C0220756,LE/L,been has associated with LE/L ,Niemann-Pick Disease Type C,LE/L,1,X,[dsyn],????,C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,????
c4083ad9-4faf-4a63-ae2b-020158e30ea9,C0017337,LE/L,been has associated with LE/L ,Genes,LE/L,1,X,[gngm],????,G05.360.340.024.340,????
4b9642b2-16f7-4047-8ce8-f03be66b1b78,C0220756,C0023779,been has associated with LE/L ,Niemann-Pick Disease Type C,Lipids,1,X,[dsyn],[orch],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,D10
6413f565-650d-40d6-8bc5-4f31caa68743,C0017337,C0023779,been has associated with LE/L ,Genes,Lipids,1,X,[gngm],[orch],G05.360.340.024.340,D10
9c8ee7a8-cb34-4ea6-b066-81b337127b13,C0220756,C0040616,could serve as ,Niemann-Pick Disease Type C,Anti-Anxiety Agents,1,X,[dsyn],[phsu],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
c1eb74c2-3bb2-4eca-9742-654d9dd7d4c1,C0920591,C0040616,could serve as ,mimetics,Anti-Anxiety Agents,1,X,[bmod],[phsu],,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
a1c85af9-0921-4c93-a808-b6d9b8cc7ffd,C0220756,C1175743,could serve as ,Niemann-Pick Disease Type C,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,B04.820.504.540.150.113.937
bc846755-daf7-4d3e-872b-bc7b8365b3be,C0920591,C1175743,could serve as ,mimetics,SARS coronavirus,1,X,[bmod],[virs],,B04.820.504.540.150.113.937
87fa2ddc-46c2-4991-a772-6309395687bf,C3179455,C0040616,could serve as ,Niemann-Pick Disease Type C1,Anti-Anxiety Agents,1,X,[dsyn],[phsu],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
30064aae-27b8-4006-98a8-74a53e598048,C0243077,C0040616,could serve as ,inhibitors,Anti-Anxiety Agents,1,X,[chvf],[phsu],,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
583b3b59-ef64-45d5-ba04-38297c1d63d1,C3179455,C1175743,could serve as ,Niemann-Pick Disease Type C1,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,B04.820.504.540.150.113.937
056772a2-5bd1-411e-9e81-adf35b5bdae3,C0567416,C0220756,causing ,Molecule,Niemann-Pick Disease Type C,1,X,[sbst],[dsyn],,C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875
64670af6-7758-4157-82ef-8ab90e0796df,C3463820,C0023779,may impair SARS coronavirus via several,Inhibition,Lipids,1,X,[acty],[orch],F01.145.544;F02.463.425.475;F02.739.794.405,D10
abe17b53-6fee-4419-bb7b-b25c51d9ccfb,C0035668,C1856053,was detected in During ,RNA,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[nnon],[dsyn],D13.444.735,x.x.x.x
6d934386-0996-4630-9c2a-5f628c1034c4,C0035668,C0019004,was detected in within overall population of ,RNA,Hemodialysis,1,X,[nnon],[topp],D13.444.735,E02.870.300;E02.912.800
f9f8c871-91c1-4850-ae66-668c22aef6ee,C0019004,C1175175,is with ,Hemodialysis,Severe Acute Respiratory Syndrome,1,X,[topp],[dsyn],E02.870.300;E02.912.800,C02.782.600.550.200.750;C08.730.730
f4edc18d-89eb-41c9-923a-c0894efac85f,C0042776,C0086022,acting as inanimate ,Virus,Cloning Vectors,1,X,[virs],[nnon],B04,G05.360.337
10ab015e-033b-4559-afcf-d48b92fe66b0,C0042776,C1533724,acting as ,Virus,Fomes,1,X,[virs],[fngs],B04,B01.300.179.120.174
6983bfa8-c276-472c-9ed5-a852ed0dce5d,C3826466,C0206419,may how may impacted by ,Dentistry--Practice,Genus: Coronavirus,1,X,[bmod],[virs],,B04.820.504.540.150
19888eef-f33a-4b5a-9f04-f21a7e7390ef,C0012634,C0206422,caused by novel ,Disease,Human coronavirus,1,X,[dsyn],[virs],C23.550.288,
c62bfd59-9b3e-45f7-827f-b7964550f36d,C0042736,C1167395,binds ,Viral Proteins,Host (organism),2,X,[aapp/bacs],[orgm],D12.776.964,
ee4e0f51-b111-46b0-9735-37e28aab8c28,C0042736,C0597358,binds ,Viral Proteins,receptor binding,2,X,[aapp/bacs],[moft],D12.776.964,
25cc1abe-9d17-40f0-9da3-6eaa1dde6c03,RBD,C0086418,may interact with ,RBD,Homo sapiens,1,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
a9b89588-0985-47c4-a8b8-510fb3689543,RBD,C0022709,may interact with ,RBD,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
795512a8-3cbb-47c5-b967-cbf20df6ff41,C0042196,C0475463,induce strong ,Vaccination,Antibodies Neutralizing,1,X,[topp],[aapp/imft],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
6a3f3221-be1d-4fca-899e-3270aabcd62a,C0042196,C0026809,induce Antibodies Neutralizing in,Vaccination,Mus,1,X,[topp],[mamm],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,B01.050.150.900.649.313.992.635.505.500
97a43aba-0d41-4e9c-b72d-95aeb718e385,C0042196,C0597358,is with ,Vaccination,receptor binding,1,X,[topp],[moft],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,
d55ce112-aaf2-4086-90dd-f3456fcbe335,C0003342,C1522002,are in ,Antigens Viral,RNA Recognition Motif,1,X,[imft],[aapp/bacs],D23.050.327,G02.111.570.820.709.275.500.869.500
e78d680b-7b47-4639-af86-5c9ef6800fe7,C0037088,C0475463,was confirmed with available ,Signs and Symptoms,Antibodies Neutralizing,2,X,[sosy],[aapp/imft],C23.888,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
effa0a2c-07c1-4e3d-8710-0977d01ed946,C0037088,C1175743,was confirmed with available ,Signs and Symptoms,SARS coronavirus,1,X,[sosy],[virs],C23.888,B04.820.504.540.150.113.937
172e077e-168a-4f6f-b301-e3fc43620a4b,C0003316,A475,were identified as A475 ,Epitopes,A475,1,X,[imft],????,D23.050.550,????
0abea432-9acc-447e-9b82-9420923b6907,C0003316,C1175743,were identified as A475 ,Epitopes,SARS coronavirus,2,X,[imft],[virs],D23.050.550,B04.820.504.540.150.113.937
f06e2e29-f2c8-4180-a17f-5a2424361b7d,A475,C1175743,is in ,A475,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
1c173a3f-1a15-4ab8-b13e-01ede5ead8e0,C0206419,C0349410,can cause multiple ,Genus: Coronavirus,Single organ dysfunction,1,X,[virs],[sosy],B04.820.504.540.150,
aa94d6c4-18ef-4036-bc36-2b32fe4c07b3,C0178784,C0206419,is important for patients with ,Organ,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
aa94d6c4-18ef-4036-bc36-2b32fe4c07b3,C0178784,C0206419,is Given lack of ,Organ,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
aa94d6c4-18ef-4036-bc36-2b32fe4c07b3,C0178784,C0206419,is in patients with severe ,Organ,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
5be47fb7-5d48-4dbb-9be3-e60903994455,C1562632,C0206419,is important for patients with ,Hoover technique,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
5be47fb7-5d48-4dbb-9be3-e60903994455,C1562632,C0206419,is Given lack of ,Hoover technique,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
6a71701a-05e6-4b20-a44c-9f9a324375c3,C0178784,C0003451,is important Given lack of ,Organ,Antiviral Agents,2,X,[bpoc],[phsu],,D27.505.954.122.388
2567be71-99f3-473f-90d8-fc5ce2ccdf35,C1562632,C0003451,is important Given lack of ,Hoover technique,Antiviral Agents,4,X,[topp],[phsu],,D27.505.954.122.388
844caac8-95d7-4686-bbc8-6f9fc71b45ce,C0042776,C1520005,insights into ,Virus,Viral Pathogenesis,1,X,[virs],[patf],B04,
b3def047-4bf4-43b9-93d9-f4aac52d6e19,C0042776,C0014507,insights into ,Virus,Epidemiology,1,X,[virs],[bmod],B04,H02.403.720.500
0481bf92-f31d-421b-bd0d-3f1fde9fb2d7,C2806453,C0450442,is ,Betacoronavirus,Agent,2,X,[virs],[chvf],B04.820.504.540.150.113,
4e5955b8-0ac6-4142-b136-ce70bc1648ae,C2806453,C0012634,is ,Betacoronavirus,Disease,2,X,[virs],[dsyn],B04.820.504.540.150.113,C23.550.288
abdf39a6-5ce0-49cc-a20d-2ae0733d5b6a,C2745965,C0563597,has generated unprecedented ,Emergencies [Disease/Finding],Momentum,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,
4cb924ec-49af-4fd0-b0fe-81f72011fa7b,C1880019,C1705178,is in ,Cessation,Order (action),1,X,[acty],[acty],,
8669060d-3a3c-47be-8eab-1983540a716a,C1511790,C0086312,using random ,Detection,Forests,2,X,[topp],[npop],,G16.500.275.157.437;N06.230.124.343
c9c1e26d-0004-4b16-ab89-464f55a87236,C1511790,C1856053,is with random ,Detection,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[topp],[dsyn],,x.x.x.x
ce113d24-0ec8-4d5c-be46-2ab17fbb8188,C0018563,C0242781,was commonly identified ,Hand,disease transmission,1,X,[bpoc],[patf],A01.378.800.667,N06.850.310
79df6be0-c47b-41f2-8f10-4e028419fb0e,C0018581,C0319157,was identified by of respondents as preventive measure against ,Handwashing,AS virus,2,X,[acty],[virs],N06.850.670.150.500,
da7527b7-0d88-46dd-8f94-76c0b04aa022,C0450254,C0221423,spectrum of ,Pathogenic organism,Illness (finding),1,X,[orgm],[sosy],,
e181c1c5-f3e6-41c2-9666-aefcf5bfcdd9,C0012634,C0184661,affect operations of ,Disease,Interventional procedure,1,X,[dsyn],[topp],C23.550.288,
7bfa41a6-926c-4617-8d61-497c44995442,C0079600,C0019693,is in ,Immunodominant Epitopes,HIV Infections,1,X,[imft],[dsyn],D23.050.550.500,C02.782.815.616.400;C02.800.801.400;C20.673.480
3356375b-017d-4199-b0fe-a6b1db2a245b,FMW,C0851578,had higher prevalence of ,FMW,Sleep Disorders,1,X,????,[mobd],????,C10.886;C23.888.592.796;F03.870
4fb69c27-ee1f-41e0-99ad-918516031203,FMW,PSQI,had significantly higher scores of PSQI,FMW,PSQI,1,X,????,????,????,????
bc9b42c6-21db-42bc-8e43-c4c95eaffdc4,C0015392,C0206750,is reeling under ,Eye,Coronavirus Infections,1,X,[bpoc],[dsyn],A01.456.505.420;A09.371,C02.782.600.550.200
703ff0eb-d891-462e-82c1-73b6f5098f5a,C1947933,E/M,be adjunct to to face-to-face E/M ,care activity,E/M,1,X,[acty],????,,????
d89e7e7c-f85c-4ba8-9c28-9d871c7c4d41,C0025124,C1527144,have shown ,Traditional Chinese Medicine,Therapeutic Effect,1,X,[bmod],[clna],E02.190.488.585.520;I01.076.201.450.654.558.520,
9095afe5-dd12-45d1-a307-ea9891b7fb7f,C0032594,C1550600,are important ,Polysaccharides,Ingredient,1,X,[orch/phsu],[chvf],D09.698,
a2d76b33-78fd-49fc-8326-cf7e778978ee,C0022646,C0243077,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,inhibitors,1,X,[bpoc],[chvf],A05.810.453,
793fab3d-e209-4eeb-bdb6-0528297d30b2,C0022646,C0020538,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,Hypertensive disease,1,X,[bpoc],[dsyn],A05.810.453,C14.907.489
9fa3f1d6-d8b9-4869-9311-7fb0d209e595,C0022646,C0011849,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,Diabetes Mellitus,1,X,[bpoc],[dsyn],A05.810.453,C18.452.394.750;C19.246
2d4e0c5d-a130-44be-a420-79c95930755a,C0022646,C0007222,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,Cardiovascular Diseases,1,X,[bpoc],[dsyn],A05.810.453,C14
b305f19d-709a-4e46-b15d-8d9205744548,C0079189,C0079633, includes IP10 ,cytokine,Interleukin-8,1,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312
66a0c03a-8bf5-4ce0-845a-dd428b063aa4,C0079189,C1448177, includes IP10 ,cytokine,TNF protein human,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374;D12.776.467.374;D23.529.374,x.x.x.x
605ddb4b-adb1-4d56-9f7e-60f6c929edce,C0079189,IP10, includes IP10 ,cytokine,IP10,1,X,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374,????
f28272da-17fa-47ad-9478-4084d1f8cffc,C0079189,C1449159, includes IP10 ,cytokine,CCL2 protein human,1,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,x.x.x.x
6216d51b-85a9-4410-b94c-da86f1a90bbc,C0079189,C0072978, includes IP10 ,cytokine,RANTES,1,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.200.110.250;D12.776.467.374.200.110.250;D23.125.300.110.250;D23.469.200.110.250;D23.529.374.200.110.250
fa1f2643-ceb0-485a-83a1-f90a5bb768b9,C0079633,C0206750,were elevated in patients with ,Interleukin-8,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312,C02.782.600.550.200
a0a0bb55-ff1a-4a7b-8244-acfa2521f8ed,C1448177,C0206750,were elevated in patients with ,TNF protein human,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
fcf052fb-590e-46d7-9acc-3a087bcd3896,IP10,C0206750,were elevated in patients with ,IP10,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
0d1aac85-671f-4ef8-9793-9d97e7369a85,C1449159,C0206750,were elevated in patients with ,CCL2 protein human,Coronavirus Infections,1,X,[aapp/imft],[dsyn],x.x.x.x,C02.782.600.550.200
5ca79f3d-34c5-45b7-b69c-cb849945df0a,C0072978,C0206750,were elevated in patients with ,RANTES,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.644.276.374.200.110.250;D12.776.467.374.200.110.250;D23.125.300.110.250;D23.469.200.110.250;D23.529.374.200.110.250,C02.782.600.550.200
944381b8-f9cf-4b37-8cf0-dec48d9d45eb,C1175743,C0225699,infect ,SARS coronavirus,Type-I Pneumocytes,1,X,[virs],[cell],B04.820.504.540.150.113.937,A04.411.715.100;A11.436.081
7e214149-8db3-41c8-9348-a99ebaa507fd,C0270942,C0544688,is potentially severe ,Myasthenic crisis,complication of disease,1,X,[dsyn],[patf],,
2d15e28b-6289-4e81-ac23-201f8ae58505,C0270942,C0206750,is potentially severe ,Myasthenic crisis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
f525d2d0-1ce5-42a0-ba55-3f8ec858fded,C0020336,C0270942,can aggravate ,Hydroxychloroquine,Myasthenic crisis,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,
1b967968-163e-4b37-b4b8-47819ac3459d,C0085297,C0270942,is potential treatment for ,Immunoglobulins Intravenous,Myasthenic crisis,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632,
876d00a6-c41d-4793-84c3-cdc28437653e,C0085297,C0302148,may cause ,Immunoglobulins Intravenous,Blood Clot,1,X,[aapp/imft/phsu],[patf],D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632,C14.907.355.830
78c0011a-1bcc-4f16-ac5b-970ba331331e,C1817756,C0012634,in improvements is particularly those specific for ,Immune System Processes,Disease,1,X,[ortf],[dsyn],G12,C23.550.288
1eb42983-d5b9-490f-8d26-5c7c231ff9ec,C0015259,C0003451,promote ,Exercise,Antiviral Agents,1,X,[dora],[phsu],G11.427.410.698.277;I03.350,D27.505.954.122.388
b9aba10b-94a2-4acc-bc06-bbc84624e57b,C0015259,C0020964,promote ,Exercise,Immunity,1,X,[dora],[phsf],G11.427.410.698.277;I03.350,G12.450
27c82760-7430-4212-b204-b73454c75411,C2745965,C3826426,understand preliminary data behind ,Emergencies [Disease/Finding],Dynamics,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,
0e165ff9-6376-48bb-b4ce-513a8eab7b35,C2745965,C0012634,understand preliminary data behind ,Emergencies [Disease/Finding],Disease,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C23.550.288
fabd3445-2308-4bc9-86f7-76135527b001,C1710276,C0229671,are characterized by ,Systemic Reaction,Serum,2,X,[biof],[bdsu],,A12.207.152.846;A15.145.846
1f95cc60-2ab6-47d5-b549-1e3b04e3a2b3,C0021368,C0229671,are characterized by ,Inflammation,Serum,1,X,[patf],[bdsu],C23.550.470,A12.207.152.846;A15.145.846
adf8ef8a-ab7d-471f-bfad-1a2ffab6e1cd,C0852312,C0206750,is in ,gender disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
182dd9d0-26b8-4e41-887e-b375fbdd8a8c,C1552133,C0206750,screening for fear of ,19s,Coronavirus Infections,2,X,[bpoc],[dsyn],,C02.782.600.550.200
7fe8ca49-080d-4d24-b1b6-7a5c49ad69c6,C0206750,C0018801,consisting of ,Coronavirus Infections,Heart failure,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.280.434
29fe2817-fa53-4b5a-81c0-efb64dae35cd,C1301700,C0206750,observed mild ,Cardiovascular morbidity,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
397272ad-db34-40ff-ac68-d22d9988f4eb,C1301700,C0152021,observed mild ,Cardiovascular morbidity,Congenital heart disease,1,X,[dsyn],[cgab],,
a090d977-3c09-41a8-bc9d-cae894aaa2f0,C0206750,C0152021,is in our cohort of ,Coronavirus Infections,Congenital heart disease,1,X,[dsyn],[cgab],C02.782.600.550.200,
dbfce18b-2ccb-4376-b7d0-d32c145d3893,C0008679,C0035435, includes ,Chronic disease,Rheumatism,1,X,[dsyn],[dsyn],C23.550.291.500,C05.799;C17.300.775
7cbfc83f-0367-4260-854e-e75f14be4f00,C1439284,C1175175,be ideal candidate for treatment of ,AGTR1 gene,Severe Acute Respiratory Syndrome,2,X,[gngm],[dsyn],,C02.782.600.550.200.750;C08.730.730
4f6853f7-5362-4d39-ab70-bdb1719daa34,C0243076,C1175175,be ideal candidate for treatment of ,antagonists,Severe Acute Respiratory Syndrome,2,X,[chvf],[dsyn],,C02.782.600.550.200.750;C08.730.730
a9e38a46-645c-467e-96c4-df26cc2b45f0,C0013227,C0441655,is with anti ,Pharmaceutical Preparations,Activities,1,X,[phsu],[acty],D26,
a9e38a46-645c-467e-96c4-df26cc2b45f0,C0013227,C0441655,were then tested for invitro ,Pharmaceutical Preparations,Activities,2,X,[phsu],[acty],D26,
a9e38a46-645c-467e-96c4-df26cc2b45f0,C0013227,C0441655,showed invitro ,Pharmaceutical Preparations,Activities,1,X,[phsu],[acty],D26,
d38773f6-3f8c-4516-8f11-ff3e7d843e77,C0013227,C0936087,were then tested for invitro ,Pharmaceutical Preparations,Coronavirus Feline,2,X,[phsu],[virs],D26,B04.820.504.540.150.075.500.375
6cc75059-4638-465b-b83a-7a6e98bed4fd,C0013227,invitro,were then tested for invitro ,Pharmaceutical Preparations,invitro,2,X,[phsu],????,D26,????
6cc75059-4638-465b-b83a-7a6e98bed4fd,C0013227,invitro,showed invitro ,Pharmaceutical Preparations,invitro,1,X,[phsu],????,D26,????
aec883c2-9658-480d-88d7-496d62164b10,C0013227,C0007634,were then tested for invitro ,Pharmaceutical Preparations,Cells,2,X,[phsu],[cell],D26,A11
7bc4d679-6801-4125-b31e-041da6f9ffd5,C0936087,invitro,is in invitro ,Coronavirus Feline,invitro,1,X,[virs],????,B04.820.504.540.150.075.500.375,????
1f34823a-249d-458e-90d2-ff3d72f868e8,C0936087,C0007634,is in invitro ,Coronavirus Feline,Cells,1,X,[virs],[cell],B04.820.504.540.150.075.500.375,A11
51951b37-77a8-4f56-879d-71d75bda16e6,C0013227,C0085305,showed invitro ,Pharmaceutical Preparations,Feline infectious peritonitis virus,2,X,[phsu],[virs],D26,B04.820.504.540.150.075.500.375
802f7e83-b4b4-4f43-a28e-c98ea9b56fcd,C0013227,C0336917,were found Active physical exercise during,Pharmaceutical Preparations,Active physical exercise,2,X,[phsu],[dora],D26,
245a28e6-b045-4a3f-b70b-1d4e35acbdfe,C0015967,C0282686,manifestations of ,Fever,Respiratory System Agents,1,X,[sosy],[phsu],C23.888.119.344,D27.505.954.796
06d94be8-440c-4fdc-bb9f-bb9ceb96f44d,C0031350,C0282686,manifestations of ,Pharyngitis,Respiratory System Agents,1,X,[dsyn],[phsu],C07.550.781;C08.730.561;C09.775.649,D27.505.954.796
4ee8d45d-5be9-4245-95de-1915e323db0f,C0010200,C0282686,manifestations of ,Coughing,Respiratory System Agents,1,X,[sosy],[phsu],C08.618.248;C23.888.852.293,D27.505.954.796
524b08b4-c17b-43f5-9ff1-e1b5650c2596,C0013404,C0282686,manifestations of ,Dyspnea,Respiratory System Agents,1,X,[sosy],[phsu],C08.618.326;C23.888.852.371,D27.505.954.796
2d96888e-2d58-4af6-9320-e9b25616cbf3,C0206750,C0031350,was After emergence of novel ,Coronavirus Infections,Pharyngitis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C07.550.781;C08.730.561;C09.775.649
2d96888e-2d58-4af6-9320-e9b25616cbf3,C0206750,C0031350,was initially characterized by ,Coronavirus Infections,Pharyngitis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C07.550.781;C08.730.561;C09.775.649
f6ef2abc-f160-4e78-ac0c-cd6d57464283,C0012634,C0031350,was After emergence of novel ,Disease,Pharyngitis,1,X,[dsyn],[dsyn],C23.550.288,C07.550.781;C08.730.561;C09.775.649
f6ef2abc-f160-4e78-ac0c-cd6d57464283,C0012634,C0031350,was initially characterized by ,Disease,Pharyngitis,1,X,[dsyn],[dsyn],C23.550.288,C07.550.781;C08.730.561;C09.775.649
ae5a23a9-386a-4d7c-857c-53b031072ef0,C0012634,C0010200,was After emergence of novel ,Disease,Coughing,1,X,[dsyn],[sosy],C23.550.288,C08.618.248;C23.888.852.293
ae5a23a9-386a-4d7c-857c-53b031072ef0,C0012634,C0010200,was initially characterized by ,Disease,Coughing,1,X,[dsyn],[sosy],C23.550.288,C08.618.248;C23.888.852.293
5ab0e434-dda6-4528-854c-5eb09cdc4fa9,C0012634,C0013404,was After emergence of novel ,Disease,Dyspnea,1,X,[dsyn],[sosy],C23.550.288,C08.618.326;C23.888.852.371
5ab0e434-dda6-4528-854c-5eb09cdc4fa9,C0012634,C0013404,was initially characterized by ,Disease,Dyspnea,1,X,[dsyn],[sosy],C23.550.288,C08.618.326;C23.888.852.371
09504162-4bc4-45ac-819f-5b95acd1275f,C0029237,C0206750,have have proactive in fight against ,Physiologic Organization,Coronavirus Infections,1,X,[phsf],[dsyn],,C02.782.600.550.200
50e1342c-2068-4515-8f36-b1b1243ebb90,C0005802,C1707455,improved as ,Blood Glucose,Comparison,1,X,[orch],[acty],D09.947.875.359.448.500,
0b9e8ff7-f606-4704-8d4e-a9fdbe37b7b6,C0005802,C1175743,improved before spread ,Blood Glucose,SARS coronavirus,1,X,[orch],[virs],D09.947.875.359.448.500,B04.820.504.540.150.113.937
5c8bffc9-5d07-4ed7-8356-584dcb1e2989,C0005802,7days,improved during first 7days ,Blood Glucose,7days,1,X,[orch],????,D09.947.875.359.448.500,????
f561a52b-f8da-4b89-9f07-259dd50e1caf,C0037090,C0034386,ultimately led to ,Signs and Symptoms Respiratory,Quarantine,1,X,[sosy],[topp],C23.888.852,N06.850.780.200.450.700
3d14c62f-19c0-4339-b376-375cf1481c73,C0242781,C3694279, includes ,disease transmission,Middle East Respiratory Syndrome,1,X,[patf],[dsyn],N06.850.310,C02.782.600.550.200
c829097e-db32-494b-827a-5ccbef6b5ccc,C0009450,C0043085,be influenced by ,Communicable Diseases,Weather,1,X,[dsyn],[npop],C01.539.221,G16.500.275.063.725;G16.500.750.775;N06.230.300.100.725
4867eb68-9300-44bd-9ef4-1e3b9e2b3654,C0018681,COVID-19,is in ,Headache,COVID-19,2,X,[sosy],[virs],C23.888.592.612.441,C000657245
24aeed8e-c483-43c5-b01f-a08140f392ea,C0018681,C1521863,is in ,Headache,estrogen receptor alpha human,1,X,[sosy],[aapp/rcpt],C23.888.592.612.441,x.x.x.x
c2949745-0b5f-44a8-a23c-11c90103da4c,C1947933,C1521863,is in ,care activity,estrogen receptor alpha human,1,X,[acty],[aapp/rcpt],,x.x.x.x
77d3109e-2a98-448f-8118-0734918fa424,C0042776,C0026882,is with ,Virus,Mutation,1,X,[virs],[genf],B04,G05.365.590
c95dd6d5-323f-44cf-b798-bf3899ba71ca,C0314620,COVID-19,was expressed in ,Non structural gene,COVID-19,2,X,[gngm],[virs],,C000657245
b423bee9-5e68-48f9-93e3-a3536df4ff8e,C0314620,C0206415,Using sequence-independent single ,Non structural gene,Oligonucleotide Primers,2,X,[gngm],[nnon],,D13.695.578.424.450.275;D27.720.470.530.600.223.600
28f69213-a512-4854-8e77-83e233590add,C0033684,C0020517,has ,Proteins,Hypersensitivity,1,X,[aapp/bacs],[patf],D12.776,C20.543
a24245c6-ef3e-44d3-82b9-718049117155,RT-PCR,C0020517,has ,RT-PCR,Hypersensitivity,1,X,????,[patf],????,C20.543
cb8d067f-4ee1-41fb-9719-3fb7964a99da,C1690518,C0230425,using real-time PCR ,Environmental swab,Structure of right thigh,1,X,[sbst],[bpoc],,
6f644d07-7029-4887-8b29-ab15eb41a763,C1690518,PCR,using real-time PCR ,Environmental swab,PCR,1,X,[sbst],????,,????
3f682c7b-9f44-4efc-81f7-3fdc2d2d7ea0,C1690518,C1511790,using real-time PCR ,Environmental swab,Detection,1,X,[sbst],[topp],,
4c42a809-4cb9-41aa-bc82-adbaef377f69,C0012634,C0162574,causes Respiration Disorders in,Disease,Glycation End Products Advanced,1,X,[dsyn],[bacs/orch],C23.550.288,D12.776.643.500
40272131-521e-40ff-b780-670e2327db11,L.,C0016452,may provide promising ,L.,Food,1,X,????,[food],????,G07.203.300;J02.500
9332dbdb-b5f7-4890-9134-d0579313e203,L.,C0042210,may provide promising ,L.,Vaccines,1,X,????,[aapp/imft/phsu],????,D20.215.894
25d84f32-af2b-47e7-9dfc-c6553e37506f,L.,C1175175,may provide promising ,L.,Severe Acute Respiratory Syndrome,1,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
74b2bb1f-ad5f-464b-8417-f9dc09f77e0b,C1707455,C1947933,is with standard ,Comparison,care activity,1,X,[acty],[acty],,
be11244c-4af2-453f-8c87-07d5d40eb3a7,C0939237,C1947933,is with standard ,lopinavir / Ritonavir,care activity,1,X,[phsu],[acty],,
aa97fdf6-9f77-4a81-92e2-9b669b308b0b,C0012634,C0872315,is ,Disease,Communicable Diseases Emerging,1,X,[dsyn],[dsyn],C23.550.288,C01.539.221.500
e0ee28f3-ba09-4108-80c8-cea3bf1aa0b7,C0301872,C0035222,can lead to ,Immune response,Respiratory Distress Syndrome Adult,2,X,[ortf],[dsyn],,C08.381.840;C08.618.840
365fa160-3e18-43b6-b0f9-32a481bfe8fe,C0242129,C0003281,occurred during ongoing ,Thrombotic stroke,Anticoagulation Therapy,1,X,[dsyn],[topp],,
185b18e4-4be0-4910-a8c8-01b465d1ca50,C0242129,C0004238,occurred during ongoing ,Thrombotic stroke,Atrial Fibrillation,1,X,[dsyn],[dsyn],,C14.280.067.198;C23.550.073.198
eec3238e-751c-45d2-b80c-23b6c2ee949f,C0242129,C1277289,occurred during ongoing ,Thrombotic stroke,Stroke prevention,1,X,[dsyn],[topp],,
4fbb7964-bf2d-4d89-897f-2a46fe79917e,C4552744,C0034019,provide reference deal with ,Daily Living,public health medicine (field),1,X,[dora],[bmod],,H02.403.720;N01.400.550;N06.850
a15796d6-540c-48e3-97f0-a4b2cba7ba5d,C4552744,C2745965,provide reference deal with ,Daily Living,Emergencies [Disease/Finding],1,X,[dora],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
70722b69-c616-49b0-95ab-f1171b0a4537,C0026691,C1621271,Macrophage Activation Syndrome by,Mucocutaneous Lymph Node Syndrome,Pediatric rheumatology,1,X,[dsyn],[bmod],C14.907.940.560;C15.604.560;C17.800.862.560,
c626cd40-d46f-41da-8171-cc47a75abeee,C0036974,C1621271,Macrophage Activation Syndrome by,Shock,Pediatric rheumatology,1,X,[patf],[bmod],C23.550.835,
62bc40c7-f9ff-4a44-a69c-cefc4f823789,C0009450,PCR,was sought by reverse-transcriptase PCR,Communicable Diseases,PCR,2,X,[dsyn],????,C01.539.221,????
528cc805-03e0-4f3e-8745-71c4cdfa3e12,C0009450,C1706005,detecting ,Communicable Diseases,CD40LG wt Allele,1,X,[dsyn],[gngm],C01.539.221,
7b1cdd46-5cb7-4ad5-9ac1-7296b355de7a,C0597404,C0020268,sampled by ,Respiratory viruses,Hydrocortisone,1,X,[virs],[horm/orch/phsu],,D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392
e0cadee1-3a32-4a21-9f2f-4ecc0fe5fa15,C0597404,C1175743,had ,Respiratory viruses,SARS coronavirus,1,X,[virs],[virs],,B04.820.504.540.150.113.937
de73c3c3-264e-44bf-9367-fbdbf1ccf35f,C0149931,C1521863,is in current ,Migraine Disorders,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C10.228.140.546.399.750,x.x.x.x
3fe134d1-524f-4cce-9469-584a50afc5a1,C0149931,C0206750,is in current ,Migraine Disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.546.399.750,C02.782.600.550.200
0a9c709f-7b62-471b-81e2-184c01d13993,C0037083,C1175175,are different in case of ,Signal Transduction,Severe Acute Respiratory Syndrome,1,X,[celf],[dsyn],G02.111.820;G04.835,C02.782.600.550.200.750;C08.730.730
a58e5bc2-2760-4a01-b491-214f67920e30,C0112081,C0206750,is in severe ,D-D mixture,Coronavirus Infections,1,X,[hops/orch],[dsyn],,C02.782.600.550.200
a58e5bc2-2760-4a01-b491-214f67920e30,C0112081,C0206750,may serve as useful ,D-D mixture,Coronavirus Infections,1,X,[hops/orch],[dsyn],,C02.782.600.550.200
4c9fb0a2-8251-4d61-a39a-2fa43f65be5f,NLR,C1514474,may serve as useful ,NLR,Prognostic Factors,1,X,????,[clna],????,E01.789
a9b1be21-0a83-4a0d-a659-64a01d93c41b,C0112081,C1514474,may serve as useful ,D-D mixture,Prognostic Factors,1,X,[hops/orch],[clna],,E01.789
c042ea6c-b97e-432b-bd99-8b8582f91357,C0079189,C1514474,may serve as useful ,cytokine,Prognostic Factors,1,X,[aapp/imft],[clna],D12.644.276.374;D12.776.467.374;D23.529.374,E01.789
c7d2b670-eb4c-492c-ad12-0e7303a113b9,NLR,C0814435,may serve as useful ,NLR,early identification,1,X,????,[topp],????,
3ac1a2ba-0f83-4a81-bf2a-679dabf6d3f0,C0112081,C0814435,may serve as useful ,D-D mixture,early identification,1,X,[hops/orch],[topp],,
2bea5c50-5409-4c80-b93b-570b2f2c346c,C0079189,C0814435,may serve as useful ,cytokine,early identification,1,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,
3abede90-08f1-4f7d-8451-203bce285e9d,C0178913,C0206750,were collected from confirmed ,Blood specimen,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
0b85b393-33e2-4df1-8a50-6842f5a6e34f,C0013227,remdesivir, includes ,Pharmaceutical Preparations,remdesivir,1,X,[phsu],[clnd],D26,
5d847b94-d79a-468f-b8fc-2ce05f946d9c,C0013227,C0207683, includes ,Pharmaceutical Preparations,nafamostat,1,X,[phsu],[orch/phsu],D26,x.x.x.x
b5a69374-23c6-4faa-9346-1e73715ff782,C0013227,C0129975, includes ,Pharmaceutical Preparations,camostat,1,X,[phsu],[orch/phsu],D26,x.x.x.x
ef8f146e-27e7-45a4-91df-cf830efe744c,C0013227,C0022322, includes ,Pharmaceutical Preparations,Ivermectin,1,X,[phsu],[orch/phsu],D26,D02.540.576.500.997;x.x.x.x
62a6725c-eb09-444e-9a02-0cf5fffde991,C0008269,C1175743,exhibited anti ,Chloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180,B04.820.504.540.150.113.937
9b0da62a-0474-4978-9e15-6053bd12fd7c,C0207683,C1175743,exhibited anti ,nafamostat,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
eabe24a2-91e7-42bf-8b35-649067f8c2d6,C0129975,C1175743,exhibited anti ,camostat,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
3c5aa6b4-e338-4b9d-9eab-1ef2e066de5e,C0022322,C1175743,exhibited anti ,Ivermectin,SARS coronavirus,1,X,[orch/phsu],[virs],D02.540.576.500.997;x.x.x.x,B04.820.504.540.150.113.937
6ea58139-1f75-4289-8e3f-5e609df97b61,C1948030,C0229671,exceeded their achievable peak ,EC Regimen (Etoposide-Carboplatin),Serum,1,X,[topp],[bdsu],,A12.207.152.846;A15.145.846
30366374-2b20-46e5-adcc-172391f1f489,C0021853,C0021852,is shared in ,Intestines,Intestines Small,1,X,[bpoc],[bpoc],A03.556.124,A03.556.124.684
b84efa38-5038-4c14-bbcf-8703e430a0e6,C0021853,C0682610,is shared in ,Intestines,Enterocytes,1,X,[bpoc],[cell],A03.556.124,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
9d97b1f6-c14b-41d1-9d76-c97d7ec61a35,C0021853,C0174990,is shared in ,Intestines,coronavirus receptor,1,X,[bpoc],[aapp/rcpt],A03.556.124,x.x.x.x
a6cbf426-4bf5-4769-a415-dca253c6058f,C1825598,C0003467,Moreover was associated with health ,IMPACT gene,Anxiety,1,X,[gngm],[mobd],,F01.470.132
e24f247c-bf58-47c1-8508-482b7de93c99,C2926735,C0206750,is in patients with ,Duration,Coronavirus Infections,2,X,[orch/phsu],[dsyn],,C02.782.600.550.200
896843d2-abf6-41a8-8d96-a5aa9f99d434,C0015967,C2926735,were risk factors for prolonged ,Fever,Duration,1,X,[sosy],[orch/phsu],C23.888.119.344,
d440eb46-785b-44f2-95bd-ef0923357c8a,C0015967,C0162633,were risk factors for prolonged ,Fever,Viral Shedding,1,X,[sosy],[patf],C23.888.119.344,G07.925
dda78dd2-ef62-4e4d-bb1c-4d9a6e251208,C0012634,C0018581,amplify pro ,Disease,Handwashing,1,X,[dsyn],[acty],C23.550.288,N06.850.670.150.500
40eef1bd-25a5-4d17-87c8-ff146c244a83,C0021376,C0004153,is associated with development of ,Chronic inflammation,Atherosclerosis,2,X,[patf],[dsyn],,C14.907.137.126.307
a2789dd8-fe78-4ecf-8015-e454896d3c34,C0021760,C0006560,showed positive correlation with ,Interleukin-6,C-reactive protein,1,X,[aapp/imft],[aapp/imft],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
fd352a27-f781-4a68-9e29-ea6c018d206b,C0042769,C0301872,preventing aberrant ,Virus Diseases,Immune response,1,X,[dsyn],[ortf],C02,
1f3cdbc0-8c32-442f-ae9a-352edbd9d0e7,C0003015,C0042776,reduce ,Angiotensin-Converting Enzyme Inhibitors,Virus,1,X,[phsu],[virs],D27.505.519.389.745.085,B04
a9768fa0-f680-4345-bae8-f5e25df99b8b,C0003015,C0024109,reduce ,Angiotensin-Converting Enzyme Inhibitors,Lung,1,X,[phsu],[bpoc],D27.505.519.389.745.085,A04.411
d8cb6bec-57a1-4c0f-b84d-1a3e3e9f4481,C0003015,C0018787,reduce ,Angiotensin-Converting Enzyme Inhibitors,Heart,1,X,[phsu],[bpoc],D27.505.519.389.745.085,A07.541
f59e1b0b-44a3-4af4-8395-be3508976d3c,C0009429,C0597721,affect ,Combined Modality Therapy,Janus kinase,1,X,[topp],[aapp/enzy],E02.186,D08.811.913.696.620.682.725.124;D12.776.476.393
3f2cca72-2a30-4124-8fe1-a33c8fcd2aec,C0683465,C0597721,affect ,novel AODU treatment method,Janus kinase,1,X,[topp],[aapp/enzy],,D08.811.913.696.620.682.725.124;D12.776.476.393
d72bc229-6ba9-4f67-aec8-b95cb2f3d3f8,C0683465,C0206750,affect ,novel AODU treatment method,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
09e742b2-bb78-45be-b772-41a524b1d2cd,C0597721,C0206750,is in patients with ,Janus kinase,Coronavirus Infections,1,X,[aapp/enzy],[dsyn],D08.811.913.696.620.682.725.124;D12.776.476.393,C02.782.600.550.200
4956d7fd-b4b9-4e43-933e-34902608a8ce,C0206750,C1880019,has seen ,Coronavirus Infections,Cessation,1,X,[dsyn],[acty],C02.782.600.550.200,
3ff98ce6-2f7f-4ed6-938d-a3028caf97ac,C1422064,C3266262,using large-scale omics ,ACE2 gene,Multiple Chronic Conditions,1,X,[gngm],[dsyn],,C23.550.291.500.500
fa9d7d90-b3fc-4aa9-8bca-70321e4c3dcc,C1422064,omics,using large-scale omics ,ACE2 gene,omics,1,X,[gngm],????,,????
9aa6a998-8a0c-4ea4-a3a7-194818e34770,C1422064,C1175743,Receptor Cell for,ACE2 gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
0d502d10-eedb-424d-8a11-3721985aa588,C0012634,C0178784,could lead to multi ,Disease,Organ,1,X,[dsyn],[bpoc],C23.550.288,
1b5a8b1e-cbad-4254-afbd-3152a57ed399,C0012634,C1175175,could lead to multi ,Disease,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C23.550.288,C02.782.600.550.200.750;C08.730.730
f04fa6f0-6590-4a2b-9e5e-31505dda6f32,C0206750,C1825598,had great ,Coronavirus Infections,IMPACT gene,1,X,[dsyn],[gngm],C02.782.600.550.200,
f3095ecb-414c-4a7c-96a6-9bd8c3a895fd,non-at,C0021053,is with ,non-at,Immune System Diseases,1,X,????,[dsyn],????,C20
c9d821f7-130c-4f75-b716-9d564b385885,non-at,C0037274,is with ,non-at,Dermatologic disorders,1,X,????,[dsyn],????,C17.800
7c4603e2-3279-41ca-8e9e-a5bf04725cfe,non-at,C0021053,is with ,non-at,Immune System Diseases,1,X,????,[dsyn],????,C20
8bb0fbb6-5950-4e00-8d47-d7e4d97830ec,C1609165,C0206750,is under Given its approval investigation in ,tocilizumab,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
8f95ce6b-e000-467a-a2ad-bd3b6a669136,C0301872,C0009450,probably plays role in pathophysiology of ,Immune response,Communicable Diseases,1,X,[ortf],[dsyn],,C01.539.221
e9c674ad-7407-49e7-aa2e-63e0037a4f17,C0301872,C0009450,plays role in pathophysiology of ,Immune response,Communicable Diseases,1,X,[ortf],[dsyn],,C01.539.221
96946194-592b-49d2-b397-f27c47139b49,C0589104,C1947933,is in ,Process training,care activity,1,X,[topp],[acty],,
b1da3ac1-ba39-4820-877c-363a287ef11a,C0018799,C0206750,is in context of ,Heart Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.280,C02.782.600.550.200
fbae3ae2-06e1-47eb-8520-7dec53733d89,C0018799,C0012634,is in context of ,Heart Diseases,Disease,1,X,[dsyn],[dsyn],C14.280,C23.550.288
1cefc36c-f944-4337-b4a3-740540962fb6,C0013964,C0007189,Society of ,emergency medicine (field),Cardiology discipline,1,X,[bmod],[bmod],H02.403.250,H02.403.429.163
559e07e2-e3e5-4413-b3e8-7d4aeb97e692,C0013964,C0013227,Association of Intensive Care ,emergency medicine (field),Pharmaceutical Preparations,1,X,[bmod],[phsu],H02.403.250,D26
ca697e8b-c76b-4ea0-8732-499a282d9014,C1947933,C0035273,should otherwise follow namely 2015 International Liaison Committee on ,care activity,Resuscitation procedure,1,X,[acty],[topp],,E02.365.647
8577298e-6a40-46e2-a405-566f83798979,C1947933,C0007189,should follow 2019 Update to Society of ,care activity,Cardiology discipline,1,X,[acty],[bmod],,H02.403.429.163
bd9f99f8-690a-4ce9-a3e5-501d2978f406,C1947933,C0007203,should follow 2019 Update to Society of ,care activity,Cardiopulmonary Resuscitation,1,X,[acty],[topp],,E02.365.647.110
9ec4440d-8e0f-45b4-9ece-4a0ad4113ddc,C0042769,C0960756,is ,Virus Diseases,factor A,1,X,[dsyn],[orch],C02,x.x.x.x
98d305cc-2051-480d-9c3f-57a421658a54,C0042769,C0032930,is ,Virus Diseases,Precipitating Factors,1,X,[dsyn],[clna],C02,N05.715.350.200.650;N06.850.490.625.500
4af49d4d-aa23-4140-a904-b401de087b77,C0042769,C0960756,is ,Virus Diseases,factor A,1,X,[dsyn],[orch],C02,x.x.x.x
a7f10205-61f8-4b4d-9352-d0fb0aa27847,C0042769,C0004096,is ,Virus Diseases,Asthma,1,X,[dsyn],[dsyn],C02,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
effd6ea3-0988-4e48-9b16-d067502b3344,HWC,C1706374,was launched on ,HWC,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
afea7ad2-1d82-4928-81c2-674257312ddf,HWC,C1706374,was launched on ,HWC,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
9768a745-508d-45a4-beaa-8c4cf74820af,HWC,C1856053,was launched on ,HWC,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,????,[dsyn],????,x.x.x.x
27c30fc3-46ef-47a6-8472-12714b8f676d,HWC,C1856053,was launched by ,HWC,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,????,[dsyn],????,x.x.x.x
70cf284c-55d5-4f8e-9e51-9e92c5102df6,C1175743,C0034019,has caused ,SARS coronavirus,public health medicine (field),1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.720;N01.400.550;N06.850
3af91ce3-fd60-4f65-b66d-3de1606d855e,C1175743,C2745965,has caused ,SARS coronavirus,Emergencies [Disease/Finding],1,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.291.781;N06.230.100.083;N06.850.376
db4db94d-c4ab-424d-9628-2adb91f93f63,C1175743,C0206750,etiologic agent for 2019,SARS coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
66577e07-6545-433e-a87a-3babdc9306ba,C1175743,C0012634,etiologic agent for 2019,SARS coronavirus,Disease,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C23.550.288
f69877a4-6043-4225-93fe-684cd051ce5b,C0319157,C0042765,be of increased ,AS virus,Virulence,1,X,[virs],[biof],,G06.930
03a96d3f-6d6f-410c-9809-b3dd534e9bb2,C0035736,C0370003,unexpectedly been detected ,RNA Viral,Specimen,1,X,[nnon],[sbst],D13.444.735.828,
ee8aac4d-0f83-42bf-b80c-069e213b7748,C0319157,C0007634,gains ,AS virus,Cells,1,X,[virs],[cell],,A11
d50886e7-0dbb-47a7-b09b-54322dd4c854,C0597357,C0009450,thereby potentiating its ,receptor,Communicable Diseases,1,X,[aapp/rcpt],[dsyn],,C01.539.221
33faac28-cd1e-48cd-a344-775634cc03a6,C0598312,C0021853,is in ,DNA Replication,Intestines,1,X,[genf],[bpoc],G02.111.225;G05.226,A03.556.124
7ea5f6fc-2e52-40c1-8f34-d1d28642c7bb,RT-PCR,C1292533,was performed on rectal ,RT-PCR,Tissue specimen,1,X,????,[tisu],????,
1ea9f74e-0c41-42e3-afe8-6c4267df8047,RT-PCR,C0015252,was performed on rectal ,RT-PCR,removal technique,1,X,????,[topp],????,
804b8693-7987-49c4-85f8-145a10ee0925,C0677043,C0018964,using ,Histopathology,Hematoxylin,1,X,[bmod],[irda/orch],,D03.383.663.283.600;D03.633.100.150.600
13d569bc-401c-4ed9-9e22-9a9d9df44da7,C0677043,C0014448,using ,Histopathology,Eosine Yellowish,1,X,[bmod],[chvf/orch],,D02.455.426.779.347.325;D03.633.300.953.275.325;D04.711.347.325
e8abc953-9eca-45fb-98ed-9990ee203938,C0677043,C0018964,using ,Histopathology,Hematoxylin,1,X,[bmod],[irda/orch],,D03.383.663.283.600;D03.633.100.150.600
b894348d-60f3-4ecc-9c43-7b636fcc56d5,C0010200,C0206750,was diagnosed with ,Coughing,Coronavirus Infections,1,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200
de6be3c9-047b-4f3e-b996-481d54256679,C0028606,C0206750,positive for typical ,Nucleic Acids,Coronavirus Infections,1,X,[bacs/nnon],[dsyn],D13.444,C02.782.600.550.200
1e7b098a-8a7b-4950-8ba8-78696a5d7f15,C0028606,C0042760,positive for typical ,Nucleic Acids,Virion,1,X,[bacs/nnon],[celc],D13.444,A21.249;B04.950
be0e7e83-982c-4c83-a765-5d5ab24cb6b8,C0028606,C0040300,positive for typical ,Nucleic Acids,Body tissue,1,X,[bacs/nnon],[tisu],D13.444,A10
9c068e54-7953-488c-ae71-10c116504f25,C0028606,C1175743,positive for ,Nucleic Acids,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.444,B04.820.504.540.150.113.937
079b1215-f469-4e4f-a4bc-b94d9f5fcdb2,C1175743,C0040300,Virion in rectal,SARS coronavirus,Body tissue,1,X,[virs],[tisu],B04.820.504.540.150.113.937,A10
f916e589-5610-4340-837c-391c503352ec,C0598312,C0034896,is in patients ,DNA Replication,Rectum,1,X,[genf],[bpoc],G02.111.225;G05.226,A03.556.124.526.767;A03.556.249.249.767
6eb715df-4524-4b71-a583-340d03bc2e5b,C1175743,C0007634,facilitate ,SARS coronavirus,Cells,1,X,[virs],[cell],B04.820.504.540.150.113.937,A11
ff9372c9-bcdf-4410-8c66-2014c9ec47e5,C0086418,C1422064,exhibits greater ,Homo sapiens,ACE2 gene,1,X,[humn],[gngm],B01.050.150.900.649.313.988.400.112.400.400,
c2d9ec23-e8f2-4c1f-b36f-03893bc4102d,C0018787,C1422064,exhibits greater ,Heart,ACE2 gene,1,X,[bpoc],[gngm],A07.541,
d7e3a06f-d9dc-45e9-93be-cf8235b7b685,C4082587,C1829939,is in ,HLA Class II Histocompatibility Antigen Gamma Chain human,{Non-patient},1,X,[aapp/imft],[clna],,
816db47f-d3bb-4526-9a55-39e8a7e4c180,sup2,C1829939,is in ,sup2,{Non-patient},1,X,????,[clna],????,
bdc09781-a685-48e4-a1ab-d7d5cdf696ea,C4082587,C1829939,is in ,HLA Class II Histocompatibility Antigen Gamma Chain human,{Non-patient},1,X,[aapp/imft],[clna],,
ce608656-d64d-48f7-b750-ecd3908862c5,sup2,C1829939,is in ,sup2,{Non-patient},1,X,????,[clna],????,
681b7f41-8986-4597-ab00-62795f8c1ab0,C1422064,C0024109,is With public single-cell sequence data analysis higher than that in ,ACE2 gene,Lung,1,X,[gngm],[bpoc],,A04.411
2d686abc-782d-4c64-ac34-e5091a4c19bf,C4281807,C0018787,is in ,Vitronectin human,Heart,1,X,[aapp/bacs],[bpoc],,A07.541
2abc66dc-2877-416e-bc9d-61e4d32f5c2d,C1422064,C0086418,is relatively highly expressed in ,ACE2 gene,Homo sapiens,1,X,[gngm],[humn],,B01.050.150.900.649.313.988.400.112.400.400
082010eb-e9af-4f76-bf58-90dcd02b3359,C1422064,C0018787,is relatively highly expressed in ,ACE2 gene,Heart,1,X,[gngm],[bpoc],,A07.541
138d24db-298d-4910-af9d-8bfef36bfccd,C0287990,C4281807,may Vitronectin human for S,paired basic amino acid cleaving enzyme,Vitronectin human,1,X,[aapp/enzy],[aapp/bacs],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
f236700c-9500-4bf6-aa44-45e854620838,C0054871,C4281807,may Vitronectin human for S,Cathepsin L,Vitronectin human,1,X,[aapp/enzy],[aapp/bacs],D08.811.277.656.224.407;D08.811.277.656.262.500.157;D08.811.277.656.300.200.157,
2e85e882-1c8c-4024-8e68-7057aef43052,C0034052,C0206750,are associated with injury in patients with ,Pulmonary artery structure,Coronavirus Infections,1,X,[bpoc],[dsyn],A07.015.114.715,C02.782.600.550.200
e8915056-5f4d-4961-9b3a-ff039cdfaf7e,C0741923,C0206750,is in ,cardiac event,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
f70b92c9-2cb3-41d4-9b9f-159db321b955,C0005775,C0741923,is pivotal ,Blood Circulation,cardiac event,1,X,[phsf],[dsyn],G09.330.100,
3550a648-aa87-41d6-8400-b7e9a8f4c758,C0741923,C0206750,is with ,cardiac event,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
dd84a125-c764-4fdd-8fa0-36b9a2a1e125,C0206750,C1856053,was established at National Hospital in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
b7605a4b-32bc-4d92-abeb-c25d4d42cb23,C0012634,C1856053,was established at National Hospital in ,Disease,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C23.550.288,x.x.x.x
c7a1c338-da05-4a29-a734-25a510b79b11,C0206750,C1705178,was established at National Hospital in ,Coronavirus Infections,Order (action),1,X,[dsyn],[acty],C02.782.600.550.200,
5b3d552c-1af0-413e-8737-855659f9dc72,C0012634,C1705178,was established at National Hospital in ,Disease,Order (action),1,X,[dsyn],[acty],C23.550.288,
d5cc8e36-0bb4-4376-b1ec-1a6a1191529a,C0206750,C1856053,was established in early ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
5a96ae2c-15dd-4abe-8d05-30500b2f736c,C0012634,C1856053,was established in early ,Disease,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C23.550.288,x.x.x.x
4465511e-a46c-4757-bc5d-a20988514f40,C0014038,C0019080,is with ,Encephalitis,Hemorrhage,1,X,[dsyn],[patf],C10.228.140.430,C23.550.414
287ad836-1373-4cdb-9ef0-b1e40098dac7,C0085584,C0011206,is with ,Encephalopathies,Delirium,1,X,[dsyn],[mobd],C10.228.140,C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350
4b49118b-ff4f-41e9-8a44-5bd07379d596,C0085584,C0033975,is with ,Encephalopathies,Psychotic Disorders,1,X,[dsyn],[mobd],C10.228.140,F03.700.675
1fe4ac7e-b93f-4189-b756-29b9c157f85f,C0948008,C0087086,associated with pro ,Ischemic stroke,Thrombus,1,X,[dsyn],[patf],,C14.907.355.830
5f9e2581-b587-4222-93fe-9623a7a45ccd,C1175743,C0206750,is etiological driver of ,SARS coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
71c3a9dc-4ca3-48fc-98c3-453e63530ed0,C1175743,C0206750,is etiological driver of ,SARS coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
ae733389-a3d4-4c10-aa6b-af2ad42661fb,C0030054,C0206750,play role in severity in ,Oxygen,Coronavirus Infections,1,X,[bacs/elii/phsu],[dsyn],D01.268.185.550;D01.362.670;x.x.x.x,C02.782.600.550.200
2812de47-8c80-49b8-abf5-d1b046a97d4d,C0598783,C0522534,was also observed especially short ,Lipid Metabolism,Saturated,1,X,[moft],[npop],G03.458,
90411de5-f597-4ed5-be96-1676b2f19805,C0598783,C0522094,was also observed especially short ,Lipid Metabolism,Medium chain fatty acid,1,X,[moft],[bacs/orch],G03.458,
4b0beb59-ed67-44a2-a2bb-d0a9c35b1af3,C0598783,C0368608,was also observed especially short ,Lipid Metabolism,acylcarnitine,1,X,[moft],[orch],G03.458,x.x.x.x
24b7e407-db91-4511-a6f5-8077185c2442,C0598783,C0037900,was also observed especially short ,Lipid Metabolism,Sphingolipids,1,X,[moft],[orch],G03.458,D10.570.877
3072c956-48e4-42ab-8dca-8221e26363f7,C1175175,C0086418,is in ,Severe Acute Respiratory Syndrome,Homo sapiens,1,X,[dsyn],[humn],C02.782.600.550.200.750;C08.730.730,B01.050.150.900.649.313.988.400.112.400.400
2e8104df-9aca-452c-97eb-4f185d7d138b,C1175175,C1185740,using respiratory ,Severe Acute Respiratory Syndrome,Tract,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,
5548765a-88bc-4183-a522-3ac061a06193,C1175175,C0370003,using respiratory ,Severe Acute Respiratory Syndrome,Specimen,1,X,[dsyn],[sbst],C02.782.600.550.200.750;C08.730.730,
